PMID,Terms,Numbers
30901624,Neuroimaging;Schizophrenia,E01.370.350.578;E01.370.376.537;E05.629;F03.700.750
30901543,,
30901535,,
30901053,,
30901051,,
30900849,,
30900464,Autistic Disorder,F03.625.164.113.500
30900367,"Hemoglobinuria, Paroxysmal",C15.378.071.141.560;C15.378.190.625.460
30900329,"Magnetic Resonance Imaging;Depressive Disorder, Major;Suicidal Ideation;Suicide",E01.370.350.825.500;F03.600.300.375;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.980.875;I01.880.735.856
30900001,Kidney Calculi;Nephrolithiasis;Sex;Temperature;Urolithiasis,C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;G08.686.810;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;C12.777.967;C13.351.968.967
30899874,"Anemia;Renal Insufficiency, Chronic;Erythropoietin;Inflammation",C15.378.071;C12.777.419.780.750;C13.351.968.419.780.750;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;C23.550.470
30899599,,
30899131,,
30899130,,
30899005,,
30898877,Clustered Regularly Interspaced Short Palindromic Repeats;RNA Polymerase III;Myelin Sheath;Oligodendroglia;Proteomics,G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D08.811.913.696.445.735.270.775;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;A08.637.600;A11.650.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
30898839,,
30898599,,
30898342,Edema;Quality of Life,C23.888.277;I01.800;K01.752.400.750;N06.850.505.400.425.837
30898240,"Cardiomyopathy, Hypertrophic;Atrial Fibrillation",C14.280.238.100;C14.280.484.150.070.160;C14.280.067.198;C23.550.073.198
30896912,,
30897605,,
30897056,,
30896998,,
30896674,,
30896507,,
30895926,Genetics;Genomics;Humans,H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400
30895865,Apoptosis,G04.146.160
30895807,,
30895380,Ventriculostomy;Pediatrics;Infratentorial Neoplasms;Ventriculoperitoneal Shunt,E04.035.188.957;E04.525.170.860;H02.403.670;C04.588.614.250.195.411;C10.228.140.211.500;C10.551.240.250.400;E04.035.188.850;E04.525.170.850
30894703,"Cytochrome P-450 CYP2D6;Antidepressive Agents;Analgesics, Opioid;Pharmacogenetics",D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368;D27.505.954.427.700.122;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;H01.158.273.343.750;H01.158.703.052;H02.628.479
30894353,,
30894101,"Hernias, Diaphragmatic, Congenital;Hypertension, Pulmonary;Sildenafil Citrate",C16.131.433;C23.300.707.500.116;C08.381.423;D02.065.884.675;D02.886.590.700.675;D03.383.606.854;D03.633.100.759.824
30893893,Glucagon-Like Peptide 1;Appetite;Exercise;Ghrelin;Leptin,D06.472.317.680.500.500;F02.830.071;G07.203.650.390.070;G10.261.390.070;G11.427.410.698.277;I03.350;D06.472.699.301;D12.644.548.322;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500
30893602,Ubiquitin-Protein Ligases;Axon Guidance;Spinal Cord,D08.811.464.938.750;G04.152.912.750.500;G07.345.500.325.377.687.750.750;G08.686.784.170.450.500.750.750;G11.561.620.750.500;A08.186.854
30893327,,
30893240,,
30893225,,
30893093,,
30893014,,
30893007,,
30892837,"Antigens, Fungal;Mycetoma",D23.050.202;C01.252.410.040.692.606;C01.252.825.557;C01.539.800.200.500;C01.539.800.720.557;C01.703.295.522;C17.800.838.208.557;C17.800.838.765.557
30892814,Rubinstein-Taybi Syndrome,C05.116.099.370.797;C05.660.207.850;C10.597.606.360.700;C16.131.077.804;C16.131.260.790;C16.131.621.207.850;C16.320.180.790
30891938,"Arthritis, Rheumatoid",C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199
30890783,,
30890717,,
30890710,,
30890709,,
30890618,,
30890493,,
30890492,,
30890491,,
30890490,,
30890489,,
30890488,,
30890487,,
30890486,,
30890485,,
30890484,,
30890483,,
30890482,"Dermatitis, Phototoxic",C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225
30889321,,
30889585,"Education, Medical;Infant, Newborn",I02.358.399;M01.060.703.520
30889418,Child;Heart;Liver,M01.060.406;A07.541;A03.620
30889026,,
30889007,,
30888988,,
30888933,,
30888632,Obesity;Primary Health Care,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;N04.590.233.727
30888021,Essential Tremor,C10.228.662.350
30887623,Medicaid;Patient Care,N03.219.521.346.506.564.655;N03.706.615.693;E02.760;N02.421.585
30887581,Granulocyte Colony-Stimulating Factor;Leukopenia;Filgrastim;Granulocyte Colony-Stimulating Factor;Kidney Transplantation,D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350;C15.378.553.546;D12.644.276.374.410.240.350.500;D12.776.395.240.200.500;D12.776.467.374.410.240.350.500;D23.529.374.410.240.350.500;D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350;E02.870.500;E04.936.450.485;E04.950.774.400
30887527,,
30887210,Lymphatic System;Magnetic Resonance Imaging;Protein-Losing Enteropathies,A15.382.520;E01.370.350.825.500;C06.405.469.818
30887152,"Carcinoma, Hepatocellular;Liver Neoplasms;Carcinoma, Hepatocellular",C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;C04.588.274.623;C06.301.623;C06.552.697;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160
30886401,,
30886182,,
30886120,Accreditation;Ambulatory Care;Attitude,N03.706.110.070;N05.700.200.100;E02.760.106;N02.421.585.106;F01.100
30885869,Fluorescence,G01.358.500.505.650.665.500;G01.590.540.665.500
30885769,Meningomyelocele;Spinal Dysraphism;Uterine Rupture,C10.500.680.610;C16.131.666.680.610;C10.500.680.800;C16.131.666.680.800;C13.351.500.852.904;C13.703.420.904;C26.761.853
30885716,,
30885715,,
30885714,,
30885704,Pediatrics;Adolescent;Caregivers;Child;Dialysis;Qualitative Research;Transplant Recipients;Young Adult,H02.403.670;M01.060.057;M01.085;M01.526.485.200;N02.360.200;M01.060.406;E05.196.353;G02.186;H01.770.644.241.850;M01.925;M01.060.116.815
30885693,,
30885692,,
30885359,Neoplasms;DNA Methylation,C04;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206
30884770,Lymphedema;Virtual Reality,C15.604.496;L01.224.160.875;L01.296.555
30884211,,
30883936,Autophagy;Colorectal Neoplasms;Hypoxia,G04.146.399;G04.417.350.091;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;C23.888.852.079
30882995,Recurrence,C23.550.291.937
30882883,,
30882879,,
30882855,,
30882766,,
30882730,,
30882565,,
30882514,,
30882134,,
30881859,"Optic Atrophy, Hereditary, Leber",C10.292.700.225.500.400;C10.574.500.662.400;C11.270.564.400;C11.640.451.451.400;C16.320.290.564.400;C16.320.400.630.400;C18.452.660.670
30881832,,
30881565,,
30881546,,
30881536,,
30880817,"Immunotherapy, Adoptive;Pediatrics;Survivorship",E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;H02.403.670;F01.058.144.500
30880632,,
30880577,,
30880467,Breath Tests;Men,E01.370.100;M01.390
30880361,Therapeutics;Therapeutics,E02;E02
30880359,Recurrence;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Therapeutics,C23.550.291.937;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;E02
30880163,,
30880065,Child Abuse;Critical Pathways,I01.198.240.856.350.250;I01.880.735.900.350.250;N04.590.233.624.625;N04.590.275
30880047,Algorithms,G17.035;L01.224.050
30879943,Grounded Theory;Mentors;Professionalism,H01.770.644.241.424;M01.395;K01.752.566.479.171.566;N05.350.340.581
30879919,"Genomics;Adolescent;Child;Disclosure;Ethics;Genetic Diseases, Inborn;Incidental Findings;Informed Consent;Review",H01.158.273.180.350;H01.158.273.343.350;M01.060.057;M01.060.406;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;K01.752.566.479;N05.350;C16.320;E01.410;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;V02.600.500;V02.912
30879729,Methicillin-Resistant Staphylococcus aureus;Staphylococcus aureus;Bacteremia;Child,B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;M01.060.406
30879724,,
30879640,"Intellectual Disability;Memory, Long-Term;Neurodevelopmental Disorders",C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F02.463.425.540.305;F03.625
30878790,Anorexia Nervosa,F03.400.125
30878608,Family;Delivery of Health Care;Pediatrics,F01.829.263;I01.880.853.150;N04.590.374;N05.300;H02.403.670
30878281,Dentistry;Oral Health,E06;H02.163;N01.400.535
30878206,Cholestasis;Biomarkers;Therapeutics,C06.130.120.135;D23.101;E02
30877338,,
30877337,"Child Abuse;Child;Ribs;Printing, Three-Dimensional",I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406;A02.835.232.570.500;J01.897.564;L01.224.108.150.500;L01.296.110.150.500
30877256,Transforming Growth Factor beta2,D12.644.276.374.687.200;D12.644.276.954.775.200;D12.776.467.374.687.200;D12.776.467.942.775.200;D23.529.374.687.200;D23.529.942.775.200
30877197,Citrate (si)-Synthase;Metabolism,D08.811.913.050.368;G03
30877103,,
30877075,,
30877032,Dystonia;Endoplasmic Reticulum;Nuclear Envelope;Neuronal Plasticity,C10.597.350.300;C23.888.592.350.300;A11.284.430.214.190.875.248;A11.284.149.165.630;A11.284.149.450.700;A11.284.430.106.279.692;A11.284.835.514.700;G11.561.638
30876957,,
30875463,Hemorrhage;Blood Coagulation;Hemostasis;Thrombosis,C23.550.414;G09.188.390.150;G09.188.390;C14.907.355.830
30875461,"Arthritis, Rheumatoid;Sex",C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;G08.686.810
30874803,Brain Neoplasms,C04.588.614.250.195;C10.228.140.211;C10.551.240.250
30874753,Research;Suicide,H01.770.644;F01.145.126.980.875;I01.880.735.856
30874482,Anti-Bacterial Agents;Antimicrobial Stewardship;Appendicitis,D27.505.954.122.085;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;C01.539.463.099;C06.405.205.099;C06.405.469.110.207
30874362,Behavior;De Lange Syndrome,F01.145;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210
30874357,B-Lymphocytes;Antibodies;Cell Differentiation;Germinal Center;Memory;Plasma Cells,A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;G04.152;A10.549.400.500;A15.382.520.604.412.500;F02.463.425.540;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725
30873794,,
30873612,Clinical Trial;Homocystinuria;Inflammation;Oxidative Stress;Taurine,V03.175.250;C10.228.140.163.100.365;C16.320.565.100.480.500;C16.320.565.189.365;C17.300.428;C18.452.132.100.365;C18.452.648.100.480.500;C18.452.648.189.365;C23.550.470;G03.673;G07.775.750;D02.455.326.146.100.850;D02.886.645.600.055.850
30873127,Genomics;Methicillin-Resistant Staphylococcus aureus,H01.158.273.180.350;H01.158.273.343.350;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500
30872988,Biosensing Techniques,E05.601.043
30872985,Cognition;Functional Neuroimaging,F02.463.188;E01.370.350.578.875;E01.370.376.537.625;E05.629.875
30872456,Drosophila melanogaster,B01.050.500.131.617.720.500.500.750.310.250.500
30872405,"Phosphotransferases;Acetylation;Chromatin;Histones;Mass Spectrometry;Muscle Development;Muscle Fibers, Skeletal",D08.811.913.696;G02.111.012.052;G02.607.063.052;G03.040.052;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G07.345.500.325.377.625.590;G11.427.578.590;A10.690.552.500.500;A11.620.249
30872387,"Decision Support Systems, Clinical;Electronic Health Records;Sepsis",L01.313.500.750.300.190;E05.318.308.940.968.625.500;C01.539.757;C23.550.470.790.500
30872376,,
30872156,"Hidradenitis Suppurativa;Adalimumab;Biomarkers;Lasers, Gas;Clindamycin;Ertapenem;Finasteride;Hidradenitis Suppurativa;Infliximab;Lasers;Microbiota;Rifampin;Spironolactone",C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;D23.101;E07.632.490.367;E07.710.520.367;D03.383.773.532.500.125;D09.408.471.500.125;D02.065.589.099.124.225;D03.633.100.300.124.225;D04.210.500.054.079.500;D04.210.500.925.100.250;C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E07.632.490;E07.710.520;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;D03.633.400.811.700;D04.345.295.750.700;D02.540.679;D04.210.500.745.745.855
30872149,"Hidradenitis Suppurativa;Adalimumab;Biomarkers;Lasers, Gas;Clindamycin;Ertapenem;Finasteride;Hidradenitis Suppurativa;Infliximab;Lasers;Microbiota;Rifampin;Spironolactone",C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;D23.101;E07.632.490.367;E07.710.520.367;D03.383.773.532.500.125;D09.408.471.500.125;D02.065.589.099.124.225;D03.633.100.300.124.225;D04.210.500.054.079.500;D04.210.500.925.100.250;C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E07.632.490;E07.710.520;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;D03.633.400.811.700;D04.345.295.750.700;D02.540.679;D04.210.500.745.745.855
30872105,Inflammatory Bowel Diseases,C06.405.205.731;C06.405.469.432
30871995,Intercellular Adhesion Molecule-1,D12.776.395.550.200.450;D12.776.543.550.200.450;D23.050.301.350.450
30871963,Calcium;Fatty Liver;Mitochondria,D01.268.552.100;D01.552.539.288;D23.119.100;C06.552.241;A11.284.430.214.190.875.564;A11.284.835.626
30871792,,
30871662,,
30871375,Healthcare Disparities;Myocardial Infarction;Quality of Health Care,N04.590.374.380;N05.300.493;C14.280.647.500;C14.907.585.500;N04.761;N05.715
30871343,,
30870574,Pyruvate Carboxylase;Pyruvate Carboxylase Deficiency Disease,D08.811.464.257.500;C10.228.140.163.100.725;C16.320.565.189.725;C16.320.565.202.810.666;C18.452.132.100.725;C18.452.648.189.725;C18.452.648.202.810.666;C18.452.660.705
30870091,,
30868720,"Hepatitis B;Immunoglobulins, Intravenous",C02.256.430.400;C02.440.435;C06.552.380.705.437;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632
30868557,Alzheimer Disease;Medicare;Aging;Dementia;Health Care Costs,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;G07.345.124;C10.228.140.380;F03.615.400;N03.219.151.400;N05.300.375
30868284,,
30867594,,
30867324,,
30867005,"Breast Neoplasms;Diet, High-Fat;Obesity;Recurrence",C04.588.180;C17.800.090.500;G07.203.650.240.267;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.550.291.937
30866011,,
30865787,,
30865489,,
30865486,Atherosclerosis;Chemokines;Coronary Artery Disease;Genome-Wide Association Study;Inflammation,C14.907.137.126.307;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;C23.550.470
30865309,"Dermatitis, Allergic Contact;Hypersensitivity;Eczema",C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;C20.543;C17.800.174.620;C17.800.815.620
30865161,,
30864881,Child;Thoracoscopy,M01.060.406;E01.370.388.250.840;E04.502.250.840;E04.928.752
30864759,Africa;Sports;Adolescent;Wounds and Injuries,Z01.058;I03.450.642.845;M01.060.057;C26
30864673,,
30864346,,
30864329,,
30864056,,
30863163,Pancreatic Stellate Cells;Primary Cell Culture,A11.700;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500
30862775,,
30862686,,
30862634,Cardiovascular Diseases;Food Supply;Social Class,C14;J01.576.423.750;I01.880.853.996.755;N01.824.782
30862454,Parkinson Disease,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
30861547,,
30861524,Fetus;Mitochondria;Oxygen Consumption;Respiration,A16.378;A11.284.430.214.190.875.564;A11.284.835.626;G03.680;G09.772.705
30861463,,
30861462,,
30861173,,
30861105,Circulating Tumor DNA;Precision Medicine,D13.444.154.500;D13.444.308.425.500;E02.574;H02.403.200.700
30860939,,
30859669,Coronary Artery Disease;Heart Failure;Hypertension;Prognosis;Pulse Wave Analysis;Therapeutics;Heart Valve Diseases,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C14.280.434;C14.907.489;E01.789;E01.370.370.680;E02;C14.280.484
30859648,,
30859514,Autism Spectrum Disorder,F03.625.164.113
30859050,,
30859016,"Biofilms;Immunity, Innate;Staphylococcus aureus",A20.593;G06.120;G12.450.564;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100
30858511,,
30858502,,
30858377,,
30858151,,
30858009,Bariatric Surgery;Depression;Impulsive Behavior;Substance-Related Disorders,E02.570.500.062;E04.062;F01.145.126.350;F01.145.527;C25.775;F03.900
30855741,,
30855740,,
30855392,,
30855282,,
30854934,,
30854742,Lewy Bodies;Parkinson Disease;Synucleins,A08.675.460;A11.284.420.460;A11.671.460;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.776.631.860
30853615,Azathioprine;Skin Neoplasms,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111;C04.588.805;C17.800.882
30853592,,
30853264,,
30853201,,
30853040,"Beckwith-Wiedemann Syndrome;Macroglossia;Sleep Apnea, Obstructive",C16.131.077.133;C16.131.260.080;C16.320.180.080;C07.465.910.460;C08.618.085.852.850;C10.886.425.800.750.850
30852663,Dent Disease;Proteinuria,C12.777.419.815.364;C13.351.968.419.815.364;C16.320.322.100;C16.320.565.861.271;C18.452.648.861.271;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
30852585,Immunoglobulins,D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
30852574,"Anemia;Renal Insufficiency, Chronic;Safety",C15.378.071;C12.777.419.780.750;C13.351.968.419.780.750;N06.850.135.060.075
30852090,Aortic Valve Stenosis;Transcatheter Aortic Valve Replacement;Heart Valve Diseases,C14.280.484.150;C14.280.955.249;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;C14.280.484
30851899,"Mastectomy, Segmental;Breast Carcinoma In Situ",E04.466.701;C04.557.470.200.240.187;C04.588.180.130;C17.800.090.500.130
30851883,Colonic Neoplasms,C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180
30851750,,
30851300,Interleukin-23;Pharmacokinetics;Psoriasis;Safety,D12.644.276.374.465.759;D12.776.467.374.465.759;D23.529.374.465.550;G03.787;G07.690.725;C17.800.859.675;N06.850.135.060.075
30851133,,
30850887,Autistic Disorder;Autism Spectrum Disorder,F03.625.164.113.500;F03.625.164.113
30850438,DNA Methylation;DNA Transposable Elements;Podocytes,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D13.444.308.520;G02.111.570.080.708.330.200;G05.360.080.708.330.200;G05.360.340.024.425.200;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720
30850379,Environmental Health;Premature Birth,H02.229;C13.703.420.491.500
30850039,Adolescent;Self-Injurious Behavior;Social Media;Child,M01.060.057;F01.145.126.980;L01.178.751;L01.224.230.110.500.750;M01.060.406
30849955,"Biliary Atresia;Cholestasis;Parenteral Nutrition, Total",C06.130.120.123;C06.198.125;C16.131.314.125;C06.130.120.135;E02.421.505.575;E02.642.500.505.750
30849353,,
30849341,,
30849280,Insulin Secretion,G03.442;G07.475
30848949,"Dopamine Agonists;Disruptive, Impulse Control, and Conduct Disorders;Parkinson Disease",D27.505.519.625.150.151;D27.505.696.577.150.151;F03.250;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
30848490,,
30848098,Executive Function;Fantasy,F02.463.217;F01.393.351;F02.463.188.634.507
30848084,,
30848065,Daunorubicin;Doxorubicin;Leukemia;Pharmacogenetics,D02.455.426.559.847.562.050.200;D04.615.562.050.200;D09.408.051.059.200;D02.455.426.559.847.562.050.200.175;D04.615.562.050.200.175;D09.408.051.059.200.175;C04.557.337;H01.158.273.343.750;H01.158.703.052;H02.628.479
30847414,Cardiovascular Diseases;Neutrophils;Blood Platelets;Psoriasis,C14;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;A11.118.188;A15.145.229.188;C17.800.859.675
30846987,Hydroxychloroquine;Interferons;Dendritic Cells,D03.633.100.810.050.180.350;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260
30846584,,
30846402,Neoplasms;Carbonic Anhydrases;Protein Isoforms,C04;D08.811.520.241.300.150;D12.776.800
30846386,Alzheimer Disease;Biomarkers;Cerebrospinal Fluid;Dementia,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A12.207.270.210;C10.228.140.380;F03.615.400
30846328,,
30846063,,
30845937,Awareness;Cues;Urinary Incontinence;Urination,F02.463.188.150;F02.463.425.234;C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800;G08.852.880
30845032,,
30844930,,
30844424,,
30844306,,
30844028,,
30843872,Cell Biology;Allergy and Immunology;Macrophages,H01.158.100.433;H01.158.273.160;H02.403.044;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
30843720,,
30843307,Mitochondria;Uniparental Disomy,A11.284.430.214.190.875.564;A11.284.835.626;C23.550.210.645.890;G05.365.590.175.935
30843005,,
30843002,,
30842678,,
30842658,,
30842258,,
30842105,,
30842058,,
30841788,,
30840905,gamma-Aminobutyric Acid,D02.241.081.114.500.350;D12.125.190.350
30840891,Autophagy;Inositol;Liver;Regeneration,G04.146.399;G04.417.350.091;D02.033.800.519;D09.853.519;A03.620;G16.762
30840531,Breast Milk Expression;Lactation,F01.145.407.199.500;G07.203.650.220.500.500.500;G07.203.650.353.199.500;G08.686.523;G08.686.702.500
30840050,,
30839154,Anesthesiology;Echocardiography;Education;Nerve Block;Patient Safety;Ultrasonography,H02.403.066;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;I02;E03.155.086.711;E04.525.210.550;N06.850.135.060.075.399;E01.370.350.850
30838479,,
30838315,Dystonia,C10.597.350.300;C23.888.592.350.300
30838129,Geography;Influenza A virus;Phylogeography,H01.277.500;B04.820.545.405.400;H01.158.273.343.335.500;H01.277.500.589
30838093,Metabolism;Mitochondria,G03;A11.284.430.214.190.875.564;A11.284.835.626
30837603,,
30837454,,
30837116,,
30837014,,
30836358,,
30836172,,
30835968,,
30835848,Acetic Acid,D02.241.081.018.165;D10.251.400.045.500
30835629,Erectile Dysfunction;Hypogonadism;Infertility;Quality of Life,C12.294.644.486;F03.835.400;C19.391.482;C12.294.365;C13.351.500.365;I01.800;K01.752.400.750;N06.850.505.400.425.837
30834994,"Carcinoma, Intraductal, Noninfiltrating;Carcinoma, Intraductal, Noninfiltrating;Mastectomy, Segmental;Radiotherapy",C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E04.466.701;E02.815
30834823,,
30834792,Aging;Accidental Falls,G07.345.124;N06.850.135.122
30833814,Obesity;Body Composition;Cohort Studies;Inflammation;Insulin Resistance,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G02.111.130;G03.180;G07.100.049;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.470;C18.452.394.968.500;G07.690.773.984.617
30833676,,
30833489,Cholangiocarcinoma;Colorectal Neoplasms,C04.557.470.200.025.450;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
30833466,,
30833414,,
30833375,,
30833087,,
30832952,Mental Health;Music,F02.418;N01.400.500;K01.602
30832741,Alzheimer Disease;Frontotemporal Lobar Degeneration;Tauopathies,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;C10.574.945
30832690,Policy;Substance-Related Disorders,I01.655;N03.623;C25.775;F03.900
30832541,Heart;Transplantation,A07.541;E04.936
30832204,Peroxiredoxins,D08.811.682.732.850
30831194,,
30831102,Ethinyl Estradiol,D04.210.500.668.651.568.291;D06.472.334.851.437.968.500
30830167,,
30830021,,
30829949,,
30829672,,
30829669,,
30829622,Hemoglobins,D12.776.124.400;D12.776.422.316.762
30829328,,
30828859,,
30828434,"Bile Ducts;Bilirubin;Portoenterostomy, Hepatic",A03.159.183;D03.383.129.578.840.249.184;D03.633.400.909.249.184;D04.345.783.249.184;D23.767.193.184;E04.035.775;E04.210.120.775
30828257,Bias;Phase Transition,N05.715.350.150;N06.850.490.500;G01.645;G02.734
30828204,Obesity;Continental Population Groups,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;M01.686.508
30827863,"Agouti-Related Protein;Sequence Analysis, RNA;Metabolism;Suprachiasmatic Nucleus",D12.644.276.074;D12.776.467.074;D23.529.074;E05.393.760.710;G03;A08.186.211.180.497.342.625;A08.186.211.200.317.357.342.625
30827783,,
30827673,,
30827501,Alternative Splicing;Computational Biology;Genetic Variation,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;H01.158.273.180;L01.313.124;G05.365
30827496,Autism Spectrum Disorder;Intellectual Disability;Neurodevelopmental Disorders,F03.625.164.113;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F03.625
30827039,,
30826793,,
30826459,"Electroencephalography;N-Methylaspartate;Schizophrenia;Interpersonal Relations;Memory, Short-Term",E01.370.376.300;E01.370.405.245;D12.125.067.500.400;D12.125.119.170.400;F03.700.750;F01.829.401;F02.463.425.540.407
30826274,,
30826226,Echocardiography;Heart Valve Diseases,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.280.484
30826182,RNA-Binding Proteins,D12.776.157.725;D12.776.664.962
30825909,"Hypertension, Pregnancy-Induced;Pre-Eclampsia",C13.703.395;C14.907.489.480;C13.703.395.249
30825839,Cell Biology;Molecular Biology,H01.158.100.433;H01.158.273.160;H01.158.201.636;H01.158.273.343.595;H01.181.122.650
30825539,,
30825406,,
30824866,,
30824653,,
30824649,,
30824630,,
30824258,Anxiety;Cognitive Behavioral Therapy;Depression,F01.470.132;F04.754.137.350;F01.145.126.350
30823506,Genetics;Subarachnoid Hemorrhage,H01.158.273.343;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
30822798,,
30822716,Epilepsy;Glioma;Glutamic Acid;Seizures,C10.228.140.490;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;C10.597.742;C23.888.592.742
30822219,Autism Spectrum Disorder;Heart Rate,F03.625.164.113;E01.370.600.875.500;G09.330.380.500
30821626,Neuropsychology;Personal Satisfaction,F04.096.795.600;H01.158.782.795.110;F01.145.677
30821428,Mental Disorders;Mental Health,F03;F02.418;N01.400.500
30821426,,
30821420,Amyloid;Memory,D05.500.049;D12.776.049;F02.463.425.540
30821010,,
30820939,,
30820047,,
30819909,Hematopoiesis;Hemoglobinopathies;Thalassemia,G04.152.825;G09.188.343;C15.378.420;C16.320.365;C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826
30819900,"Microscopy, Atomic Force;Galectins",E01.370.350.515.666.400;E05.595.666.400;D12.776.503.307
30819613,Blood-Brain Barrier;Genetic Therapy,A07.035;A08.186.211.035;E02.095.301;E05.393.420.301
30819612,RNA;Immunotherapy,D13.444.735;E02.095.465.425
30819546,Drosophila;Ion Channels;Nitric Oxide Synthase,B01.050.500.131.617.720.500.500.750.310.250;D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400;D08.811.682.664.500.772
30819472,,
30819328,,
30819041,"Models, Animal;Cartilage;Central Nervous System;Inflammation;Joint Diseases;Pain",E05.598;A02.165;A10.165.382;A08.186;C23.550.470;C05.550;C23.888.592.612;F02.830.816.444;G11.561.790.444
30818990,Child Psychiatry;Genetics;Genome-Wide Association Study;Tic Disorders;Tourette Syndrome,F04.096.544.193;H02.403.690.130;H01.158.273.343;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;C10.228.662.825;F03.625.992;C10.228.140.079.898;C10.228.662.825.800;C10.574.500.850;C16.320.400.820;F03.625.992.850
30818016,,
30817920,,
30817854,,
30817338,,
30817058,Neoplasms;Sleep,C04;F02.830.855;G11.561.803
30817056,"Immunity, Innate",G12.450.564
30816931,,
30816637,Clinical Trial;Hypoxia;Liver;Clinical Trial;Hepatopulmonary Syndrome;Lung;Sorafenib,V03.175.250;C23.888.852.079;A03.620;V03.175.250;C06.552.455;C08.381.385;A04.411;D02.455.426.559.389.703.757;D02.948.681.757;D03.066.515.530.750;D03.383.725.547.530.750
30816403,,
30816350,,
30815797,Body Mass Index;Night Eating Syndrome;Obesity;Overweight,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;F03.400.844;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699
30815453,Electrophysiology;Recurrence;Neuronal Plasticity;Tobacco,H01.158.344.528;H01.158.782.236;C23.550.291.937;G11.561.638;B01.650.940.800.575.912.250.908.500.900
30815200,,
30815147,,
30815060,,
30814575,,
30814326,,
30814317,"Genomics;Simplexvirus;Herpesvirus 2, Human",H01.158.273.180.350;H01.158.273.343.350;B04.280.382.100.750;B04.280.382.100.750.440
30814299,,
30814222,"Azacitidine;Immunity, Innate",D02.145.150;D03.383.742.680.245.217;D13.570.685.245.217;D13.570.800.286.300;G12.450.564
30813973,"Adolescent;Cognition;Cognitive Reserve;Executive Function;Multiple Sclerosis;Neuroimaging;Memory, Short-Term;Young Adult",M01.060.057;F02.463.188;F02.463.188.331;F02.463.217;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E01.370.350.578;E01.370.376.537;E05.629;F02.463.425.540.407;M01.060.116.815
30813933,"Hypoxia-Ischemia, Brain",C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716
30813859,Cell Biology;Prevalence,H01.158.100.433;H01.158.273.160;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
30811896,,
30811802,,
30811792,"Ductus Arteriosus, Patent;Stents",C14.240.400.340;C14.280.400.340;C16.131.240.400.340;E07.695.750
30811669,"Dermatitis, Atopic",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343
30811542,,
30811318,,
30811103,,
30811014,"Breast;Infant, Newborn;Organ Size;Ovary;Testis;Thyroid Gland;Uterus",A01.236;M01.060.703.520;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;A05.360.444.849;A05.360.576.782;A06.300.312.782;A06.300.900;A05.360.319.679
30810741,Self-Help Devices;Pediatrics;Rehabilitation;Wearable Electronic Devices,E07.796;H02.403.670;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784;E07.305.906
30810713,,
30810485,Comment,V01.205;V02.267
30810118,,
30810061,"Cardiovascular Diseases;Endothelium, Vascular;Exercise Therapy;Renal Insufficiency, Chronic",C14;A07.015.700.500;A10.272.491.355;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;C12.777.419.780.750;C13.351.968.419.780.750
30809045,,
30808770,,
30808755,Autism Spectrum Disorder;Intellectual Disability;Ubiquitination,F03.625.164.113;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
30808409,,
30807822,,
30807535,,
30807415,,
30807412,,
30807358,,
30807330,,
30807326,,
30807315,,
30807219,Child,M01.060.406
30805984,Arteries;Veins,A07.015.114;A07.015.908
30805965,,
30804938,,
30804563,,
30804517,,
30804515,,
30804004,Drosophila;Histidine;Metabolism,B01.050.500.131.617.720.500.500.750.310.250;D12.125.072.329;D12.125.142.308;G03
30803880,Body Image;Motivation;Obesity;General Surgery,F01.752.747.792.110;F02.463.593.112;F01.658;F01.752.543.500.750;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;H02.403.810.300
30803850,"Buprenorphine;Emergency Service, Hospital;Health Services Research",D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;H01.770.644.145.360;N03.349.380;N05.425
30802618,"Carcinoma, Non-Small-Cell Lung;Proton Therapy;Radiation;Re-Irradiation;Small Cell Lung Carcinoma",C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;E02.815.250.500;G01.750;E02.815.791;E02.887.500;C04.588.894.797.520.109.220.624;C08.381.540.140.750;C08.785.520.100.220.750
30801696,Botswana;Uterine Cervical Neoplasms;Chemoradiotherapy,Z01.058.290.175.230;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;E02.186.079;E02.319.164;E02.815.160
30801523,,
30801030,Microbiota,G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
30800930,"Arrhythmias, Cardiac;Cardiology;Hospital Medicine;Telemetry",C14.280.067;C23.550.073;H02.403.429.163;H02.403.377;E01.370.520.750;E05.925;L01.178.847.675
30800929,Emergency Medicine;Warfarin,H02.403.250;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
30800906,Hypoplastic Left Heart Syndrome;Hypoxia;Hypoxia;Tetralogy of Fallot;Transposition of Great Vessels;Transposition of Great Vessels,C14.240.400.625;C14.280.400.625;C16.131.240.400.625;C23.888.852.079;C23.888.852.079;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;C14.240.400.915;C14.280.400.915;C16.131.240.400.915;C14.240.400.915;C14.280.400.915;C16.131.240.400.915
30800901,Beneficence;Ethics;Social Justice;Beneficence,K01.752.566.479.830.500;N05.350.958.500;K01.752.566.479;N05.350;I01.880.604.473.700;K01.752.566.479.830.750;N03.706.437.700;N05.350.958.750;K01.752.566.479.830.500;N05.350.958.500
30800128,Autoimmunity;Breast Neoplasms,G12.450.192;C04.588.180;C17.800.090.500
30799872,,
30799855,,
30799751,,
30799265,Staphylococcus aureus;Endothelial Cells;Leukocidins,B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;A11.436.275;D12.776.543.695.750
30798778,"Child;Sleep Apnea, Obstructive;Polysomnography;Sleep Apnea Syndromes;Tonsillectomy;Tonsillitis",M01.060.406;C08.618.085.852.850;C10.886.425.800.750.850;E01.370.520.625;C08.618.085.852;C10.886.425.800.750;E04.580.848;C07.550.781.750;C08.730.561.750;C09.775.649.750
30798701,,
30798291,,
30797723,,
30797613,,
30797539,,
30797320,,
30797036,Anxiety;Autistic Disorder,F01.470.132;F03.625.164.113.500
30797034,Autistic Disorder;Circadian Rhythm;Sex Characteristics,F03.625.164.113.500;G07.180.562.190;G08.686.815
30796989,Nephrolithiasis;Pediatrics,C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;H02.403.670
30796894,Cocaine;Dopamine;Mesencephalon;Reward;Ventral Tegmental Area,D02.145.074.722.388;D03.132.889.354;D03.605.084.500.722.388;D03.605.869.388;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;A08.186.211.132.659;F02.463.425.770.836;A08.186.211.132.659.413.875.820
30796845,Patient Transfer,E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624
30796251,,
30796059,,
30795982,"Genes, Immunoglobulin;Influenza Vaccines;Antibodies, Monoclonal",G05.360.340.024.340.335;G12.500.299;D20.215.894.899.302;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
30795592,Sin Nombre virus;Peromyscus;Hantavirus,B04.820.087.440.700;B01.050.150.900.649.313.992.635.075.500.510;B04.820.087.440
30794725,,
30794638,,
30794314,,
30794303,,
30794288,,
30794053,,
30793808,Heart Diseases,C14.280
30793240,Bone Marrow,A15.382.216
30793167,Lyme Disease;Immunoenzyme Techniques;Serology,C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;E05.478.566.350;E05.478.583.400;E05.601.470.350;H02.781
30793090,Artifacts;Motion,E05.047;G01.482
30792873,"Renal Insufficiency, Chronic;Kidney Failure, Chronic",C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750.500;C13.351.968.419.780.750.500
30792817,,
30792620,Pliability;Mice,G01.374.705;B01.050.150.900.649.313.992.635.505.500
30792344,"Cognitive Science;Complicity;Ethics, Medical;Psychiatry;Psychology;Torture",F04.096.628.255;K01.752.566.479.090;N05.350.219;K01.752.566.479.171.132.750;N05.350.340.162.500;F04.096.544;H02.403.690;F04.096.628;I01.198.240.856.825;I01.880.735.900.825
30792287,,
30791645,Electronic Nicotine Delivery Systems;Nicotine;Tobacco,J01.637.767.500;D03.132.760.570;D03.383.725.518;B01.650.940.800.575.912.250.908.500.900
30791643,Athletes;Sleep Initiation and Maintenance Disorders;Students,M01.072;C10.886.425.800.800;F03.870.400.800.800;M01.848
30790721,"Fellowships and Scholarships;Education, Medical, Graduate;Hospices;Palliative Care",N03.219.483.838.276;I02.358.337.350;I02.358.399.350;N02.278.421.556.185;N02.421.143.550;E02.760.666;N02.421.585.666
30790714,,
30790587,,
30790466,"Vascular Endothelial Growth Factor A;Bevacizumab;Carcinoma, Hepatocellular;Liver Neoplasms",D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;C04.588.274.623;C06.301.623;C06.552.697
30790426,"Ductus Arteriosus, Patent;Stents",C14.240.400.340;C14.280.400.340;C16.131.240.400.340;E07.695.750
30790351,Obesity;Vitamin D,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D04.210.500.812.768
30790268,"Electroencephalography;Epilepsy;Hypoxia-Ischemia, Brain;Seizures",E01.370.376.300;E01.370.405.245;C10.228.140.490;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;C10.597.742;C23.888.592.742
30789764,,
30789490,,
30789401,,
30789007,,
30788845,Genotype;Phenotype,G05.380;G05.695
30788692,African Americans;Exercise;Mobile Applications;Social Support;Wearable Electronic Devices;Women,M01.686.508.100.100;M01.686.754.100;G11.427.410.698.277;I03.350;L01.224.900.685;I01.880.853.500.600;E07.305.906;M01.975
30788452,Inflammation;Obesity,C23.550.470;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30786864,"Cardiovascular Diseases;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Insulin Resistance;Mortality",C14;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;C18.452.394.968.500;G07.690.773.984.617;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
30785711,Attention Deficit Disorder with Hyperactivity;Humans;Students,F03.625.094.150;B01.050.150.900.649.313.988.400.112.400.400;M01.848
30785641,"Intensive Care, Neonatal;Observational Study",E02.760.190.405;N02.421.585.190.500;V03.175.500
30785603,,
30785381,Obesity;Thoracic Surgery,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;H02.403.810.803
30784550,,
30784237,"Renal Insufficiency, Chronic;Obesity;Sarcopenia",C12.777.419.780.750;C13.351.968.419.780.750;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C10.597.613.612.500;C23.300.070.500.500;C23.888.592.608.612.500
30784099,,
30783970,In Situ Hybridization,E01.370.225.500.620.670.325;E01.370.225.750.600.670.325;E05.200.500.620.670.325;E05.200.750.600.670.325;E05.393.661.475
30783897,"Autism Spectrum Disorder;Congenital Abnormalities;Genetic Diseases, Inborn;Continental Population Groups",F03.625.164.113;C16.131;C16.320;M01.686.508
30783727,"Polycystic Kidney, Autosomal Recessive;Diffusion Tensor Imaging;Kidney;Magnetic Resonance Imaging;Urology",C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A05.810.453;E01.370.350.825.500;H02.403.810.860
30783700,,
30783698,,
30783022,,
30782938,Mental Health,F02.418;N01.400.500
30782860,,
30782849,,
30782824,,
30782816,,
30782802,,
30782801,"Selection, Genetic;Genetics, Population",G05.783;H01.158.273.343.335
30782624,,
30782410,,
30780184,,
30780151,,
30779977,"Heart Arrest;Resuscitation;Echocardiography, Transesophageal",C14.280.383;E02.365.647;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
30779964,Adolescent;Communication;Condoms;Contraception;Parent-Child Relations;Risk-Taking;Sex Education;Sexual Behavior,M01.060.057;F01.145.209;L01.143;E07.190.270.150;E02.875.194;F01.829.263.370.290;F01.145.722;F04.096.837.500;I02.233.332.749;F01.145.802
30779950,Decision Theory;Evidence-Based Medicine,G17.162;H02.249.750;H02.403.200.400
30779743,,
30779720,,
30779519,,
30779299,,
30779252,,
30778904,Latin America,Z01.107.424
30778524,,
30778401,,
30778396,,
30778226,,
30778219,,
30778173,,
30777875,,
30777633,Kidney;Angiography;Nuclear Medicine;Urography;Radiation;Radiology;Renal Artery Obstruction;Review;Urography,A05.810.453;E01.370.350.700.060;E01.370.370.050;H02.403.740.500;E01.370.350.700.830;E01.370.390.830;G01.750;H02.403.740;C12.777.419.775;C13.351.968.419.775;C14.907.137.727;V02.600.500;V02.912;E01.370.350.700.830;E01.370.390.830
30777604,Gyrus Cinguli;Comorbidity,A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;N05.715.350.225;N06.850.490.687
30777198,Corpus Callosum;Diffusion Tensor Imaging;Glioblastoma;Prognosis;Survival,A08.186.211.200.885.800.750;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;E01.789;I03.784
30777113,Early Intervention (Education),N02.421.143.130.320;N02.421.726.320
30776791,,
30776453,,
30776077,,
30775386,,
30775051,Wolman Disease;Failure to Thrive,C16.320.565.398.641.201.500;C16.320.565.595.201.500;C16.614.947;C18.452.584.687.201.500;C18.452.648.398.641.201.500;C18.452.648.595.201.500;C23.888.338
30774764,MicroRNAs;Ovarian Neoplasms,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
30774629,"Killer Cells, Natural;Autophagy",A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;G04.146.399;G04.417.350.091
30774391,Asthma,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
30773828,"Microscopy, Atomic Force;Blood;Blood Coagulation Factors;Factor XIII;Transglutaminases",E01.370.350.515.666.400;E05.595.666.400;A12.207.152;A15.145;D12.776.124.125;D23.119;D12.776.124.125.475;D23.119.475;D08.811.913.050.200.800
30773688,,
30773687,,
30773672,Beckwith-Wiedemann Syndrome,C16.131.077.133;C16.131.260.080;C16.320.180.080
30773298,Chromatin;Epigenomics;Aging,A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;G07.345.124
30773289,,
30773196,"Adult;Anesthesiology;Education, Medical, Graduate;Fellowships and Scholarships;Health Resources;Humans;Internship and Residency",M01.060.116;H02.403.066;I02.358.337.350;I02.358.399.350;N03.219.483.838.276;N03.349.340;N05.300.420;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750
30772945,Genetics,H01.158.273.343
30772656,,
30772443,Benchmarking;Quality Improvement;Wounds and Injuries;Venous Thromboembolism,N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;J01.293.754;N04.761.744;C26;C14.907.355.590.700
30771559,African Americans,M01.686.508.100.100;M01.686.754.100
30771231,"Anorexia Nervosa;Body Composition;Bone Density;Absorptiometry, Photon;Feeding and Eating Disorders;Obesity;Overweight",F03.400.125;G02.111.130;G03.180;G07.100.049;G11.427.100;E01.370.350.700.024;E05.196.712.224.187;F03.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699
30770882,,
30770573,"Hypertension, Pulmonary",C08.381.423
30770546,Antibodies;Allergy and Immunology;Immunotherapy,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;H02.403.044;E02.095.465.425
30770500,,
30770499,,
30770376,,
30770193,Critical Care;Immunosuppression;Liver Transplantation;Therapeutics,E02.760.190;N02.421.585.190;E02.095.465.425.450;E05.478.610;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E02
30770048,,
30769947,,
30769086,,
30768838,Heart Failure;Heart Transplantation,C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475
30768528,,
30768518,,
30768455,,
30768416,Depression;Parenting,F01.145.126.350;F01.829.263.370.310
30768396,Neuroimaging;Schizophrenia,E01.370.350.578;E01.370.376.537;E05.629;F03.700.750
30767943,,
30767942,,
30767809,,
30767650,Exposure to Violence,I01.880.735.900.869
30767382,Carboplatin,D02.691.800.338
30767226,,
30767215,"Receptor, Cannabinoid, CB1;Receptor, Cannabinoid, CB2;Reward",D12.776.543.750.695.125.100;D12.776.543.750.695.125.200;F02.463.425.770.836
30767183,,
30767070,Central Amygdaloid Nucleus;Corticotropin-Releasing Hormone;Enkephalins;Locus Coeruleus,A08.186.211.180.090.750;A08.186.211.200.885.287.249.152.750;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;D12.644.400.575.281;D12.776.631.650.575.281;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437
30766736,,
30766451,Curriculum;Education;Teaching;Social Work;Substance-Related Disorders,I02.158;I02;I02.903;I01.880.792;N02.421.849;C25.775;F03.900
30765536,,
30765496,,
30765207,Critical Care;Mentors,E02.760.190;N02.421.585.190;M01.395
30764770,Enterobacteriaceae;Urinary Tract Infections,B03.440.450.425;B03.660.250.150;C01.539.895;C12.777.892;C13.351.968.892
30764698,,
30763733,,
30763471,Infant;Pharmacists,M01.060.703;M01.526.485.780;N02.360.780
30763462,Leigh Disease;Genetic Association Studies;Mitochondria,C10.228.140.163.100.412;C16.320.565.189.412;C16.320.565.202.810.444;C18.452.132.100.412;C18.452.648.189.412;C18.452.648.202.810.444;C18.452.660.520;E05.393.385;A11.284.430.214.190.875.564;A11.284.835.626
30763429,,
30762829,,
30762705,,
30762686,,
30762683,,
30762586,Cardiology;Therapeutics,H02.403.429.163;E02
30762245,,
30762080,,
30761771,Mosaicism,G05.365.590.175.595
30760892,Telangiectasis,C14.907.823
30760877,,
30760870,,
30760864,,
30760579,,
30760498,Kidney,A05.810.453
30760479,,
30760451,,
30760118,,
30759962,Vitamin D,D04.210.500.812.768
30759372,,
30759186,"Multiple Sclerosis;T-Lymphocytes, Regulatory",C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
30758852,,
30758703,Breast Neoplasms;Flavin-Adenine Dinucleotide;NAD,C04.588.180;C17.800.090.500;D03.633.100.733.315.650.249;D03.633.100.759.646.138.506;D03.633.300.507.650.249;D08.211.474.650.249;D13.695.667.138.506;D13.695.827.068.506;D23.767.405.650.249;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694
30758656,"Bone Density;Absorptiometry, Photon;Multidetector Computed Tomography;Osteoporosis;Spine",G11.427.100;E01.370.350.700.024;E05.196.712.224.187;E01.370.350.350.810.800.500;E01.370.350.600.350.700.810.800.500;E01.370.350.700.700.810.800.500;E01.370.350.700.810.810.800.249;E01.370.350.825.810.810.800.249;C05.116.198.579;C18.452.104.579;A02.835.232.834
30758128,Turner Syndrome;Registries;Research,C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;H01.770.644
30755712,,
30755616,,
30755420,,
30755224,Glutathione;Neuroblastoma,D12.644.456.448;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
30755220,Autistic Disorder;Organizational Culture;Schools,F03.625.164.113.500;N04.452.606;I02.783;J03.832
30755054,Norwood Procedures;Child;Diastole;Echocardiography;Humans,E04.100.376.724;E04.928.220.560;M01.060.406;G09.330.580.295;G11.427.494.554.250;G11.427.494.570.295;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400
30753705,,
30753348,,
30753175,,
30748099,,
30747815,,
30747812,,
30747771,,
30747719,"Economics, Behavioral;Implementation Science;Mental Health",F04.096.628.286;N03.219.215;L01.143.320.400;F02.418;N01.400.500
30747357,Blood Pressure;Hypertension;Obesity;Weight Loss,E01.370.600.875.249;G09.330.380.076;C14.907.489;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963
30747011,Heart Failure;Hospitalization;Mortality,C14.280.434;E02.760.400;N02.421.585.400;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
30746705,,
30746141,"Anemia;Renal Insufficiency, Chronic;Renal Dialysis",C15.378.071;C12.777.419.780.750;C13.351.968.419.780.750;E02.870.300;E02.912.800
30746140,"Renal Insufficiency, Chronic",C12.777.419.780.750;C13.351.968.419.780.750
30745813,"Sepsis;Shock, Septic",C01.539.757;C23.550.470.790.500;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712
30745570,,
30745433,,
30745294,,
30745124,Patient Comfort;Hospices;Wounds and Injuries;Palliative Care;Wounds and Injuries,N02.421.585.683;N02.278.421.556.185;N02.421.143.550;C26;E02.760.666;N02.421.585.666;C26
30745086,Breast Neoplasms;Lymphoma,C04.588.180;C17.800.090.500;C04.557.386;C15.604.515.569;C20.683.515.761
30745071,Breast Neoplasms;Cardiovascular Diseases;Drug Therapy;Trastuzumab,C04.588.180;C17.800.090.500;C14;E02.319;D12.776.124.486.485.114.224.060.875;D12.776.124.790.651.114.224.060.875;D12.776.377.715.548.114.224.200.875
30745051,Fetal Hypoxia,C13.703.277.390;C16.300.420;C23.888.852.079.594
30744878,,
30743089,,
30743065,"Enoxaparin;Hospitals, Pediatric;Venous Thromboembolism",D09.698.373.400.300.200;N02.278.421.556.437;C14.907.355.590.700
30742630,,
30742559,,
30742357,Renal Dialysis,E02.870.300;E02.912.800
30742264,Organoids,A10.802
30741886,,
30741229,"Education, Medical, Continuing;Education;Medicine;Otolaryngology;Patient Safety",I02.358.212.350;I02.358.399.250;I02;H02.403;H02.403.810.526;N06.850.135.060.075.399
30740938,,
30740813,Oligodendroglia,A08.637.600;A11.650.600
30740738,,
30740726,,
30740695,,
30740408,Congenital Disorders of Glycosylation;Congenital Disorders of Glycosylation,C16.320.565.202.125;C18.452.648.202.125;C16.320.565.202.125;C18.452.648.202.125
30740406,"Mitochondria;Energy Metabolism;DNA, Mitochondrial",A11.284.430.214.190.875.564;A11.284.835.626;G03.295;D13.444.308.283.225
30739869,Metabolism,G03
30739709,"Financing, Organized",N03.219.521
30739536,Adrenal Glands;Adrenocortical Adenoma;Aldosterone;Hyperaldosteronism;Mutation,A06.300.071;C04.588.322.078.265.500;C19.053.098.265.500;C19.053.347.500.500;C19.344.078.265.500;D04.210.500.745.745.654.062;D06.472.040.585.353.118;C19.053.800.604;G05.365.590
30739459,Thinking;Medical Errors;Patient Safety,F02.463.785;N02.421.450;N06.850.135.060.075.399
30739388,"Curriculum;Education, Medical;Professionalism;Education, Medical, Undergraduate",I02.158;I02.358.399;K01.752.566.479.171.566;N05.350.340.581;I02.358.399.450
30739222,,
30739198,Immunity,G12.450
30738983,,
30738606,Mohs Surgery;Education;Technology,E04.494.575;E04.680.275.580;I02;J01.897
30738593,,
30738554,"Factor Analysis, Statistical",E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400
30738278,Fabry Disease;Magnetic Resonance Imaging;Multiple Sclerosis;Paresthesia,C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200;E01.370.350.825.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C10.597.751.791.875;C23.888.592.763.770.875
30738054,,
30737732,Lung Neoplasms;Mass Screening;Smoking Cessation,C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F01.145.488.732
30737698,Oocytes;Proteomics,A05.360.490.690.680;A11.497.497.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
30737605,Depression;ROC Curve;Translational Medical Research,F01.145.126.350;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;H01.770.644.145.675
30737477,,
30737408,,
30737373,,
30737342,,
30737191,Anaphylaxis;Epinephrine;Food Hypersensitivity,C20.543.480.099;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;C20.543.480.370
30737076,Teaching,I02.903
30736889,,
30736855,"Animals;Cell Line;Enhancer of Zeste Homolog 2 Protein;Epigenesis, Genetic;Epithelial-Mesenchymal Transition;Histone Code;MAP Kinase Signaling System;Mice;Transforming Growth Factor beta",B01.050;A11.251.210;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;G05.308.203;G04.356.500;G02.111.570.060.360;G05.360.360;G02.111.820.560;G03.493.560;G04.835.560;B01.050.150.900.649.313.992.635.505.500;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775
30736800,"Clinical Competence;Education, Medical, Graduate;Educational Measurement;Fellowships and Scholarships;Humans;Patient Simulation;Program Evaluation;Reproducibility of Results;Rheumatology;United States;Education, Medical;Program Evaluation",I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;I02.399;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;I02.903.847.500;E05.337.820;N04.761.685;N05.715.360.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;H02.403.429.730;Z01.107.567.875;I02.358.399;E05.337.820;N04.761.685;N05.715.360.650
30735754,,
30735463,Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing,G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270
30735234,,
30734897,,
30734517,,
30733438,,
30733224,"Cross-Sectional Studies;Diet;Linear Models;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Creatinine;Glomerular Filtration Rate;Hypertension;Metabolism;Proteinuria;Risk Factors",E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G07.203.650.240;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;D03.383.129.308.207;E01.370.390.400.300;G08.852.357;C14.907.489;G03;C12.777.934.734;C13.351.968.934.734;C23.888.942.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30733096,Nerve Transfer;Accessory Nerve,E04.525.550;A08.800.800.120.060
30733033,,
30732973,,
30732608,Primary Health Care;Vulnerable Populations,N04.590.233.727;M01.965
30732497,Leukemia;Outcome Assessment (Health Care);Continental Population Groups,C04.557.337;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;M01.686.508
30731172,Consensus,F01.829.316.068;F02.463.785.373.433
30731168,Resuscitation Orders;Palliative Care;Palliative Care,E02.365.647.740;E02.760.905.700;I01.880.604.583.789;N02.421.585.905.700;N03.706.535.704;E02.760.666;N02.421.585.666;E02.760.666;N02.421.585.666
30730897,"Adoptive Transfer;Animals;Cell Survival;Cercopithecus aethiops;Communicable Diseases, Emerging;Genetic Engineering;HEK293 Cells;Humans;Macrophages;Mice;Mice, Inbred C57BL;Mice, Knockout;Receptor, Interferon alpha-beta;Spleen;Togaviridae;Togaviridae Infections;Vaccines, DNA;Vero Cells;Viral Vaccines",E02.095.465.425.400.330.050;E05.478.550.520.050;B01.050;G04.346;B01.050.150.900.649.313.988.400.112.199.120.126.110;C01.539.221.500;E05.393.420;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.543.750.705.852.400.500;A10.549.700;A15.382.520.604.700;B04.820.850;C02.782.930;D12.776.828.868.910;D20.215.894.865.910;D23.050.865.910;A11.251.210.955;A11.436.955;D20.215.894.899
30730554,,
30730414,,
30730354,,
30729982,Minimally Invasive Surgical Procedures;Thoracoscopy;Thymectomy,E04.502;E01.370.388.250.840;E04.502.250.840;E04.928.752;E04.928.770
30729789,,
30729681,Pregnancy,G08.686.784.769
30729654,Drug Therapy;Vomiting,E02.319;C23.888.821.937
30729166,Decision Support Techniques;Mammography;Decision Making,E05.245;L01.313.500.750.190;E01.370.350.700.500;F02.463.785.373
30728768,Neuropeptides,D12.644.400;D12.776.631.650
30728207,,
30727811,Adolescent;Cannabis;Tobacco,M01.060.057;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.908.500.900
30726738,,
30726215,,
30726122,,
30725536,Epidemiology;Kidney Transplantation,H02.403.720.500;E02.870.500;E04.936.450.485;E04.950.774.400
30725455,Acetyl Coenzyme A;Histones;Mass Spectrometry;Metabolism;Proteomics,D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G03;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
30725384,Genetics;Immunotherapy;Continental Population Groups;Triple Negative Breast Neoplasms,H01.158.273.343;E02.095.465.425;M01.686.508;C04.588.180.788;C17.800.090.500.788
30725088,,
30725081,,
30724333,"Cognitive Dysfunction;Sleep Apnea, Obstructive",F03.615.250.700;C08.618.085.852.850;C10.886.425.800.750.850
30723995,Health Services Research,H01.770.644.145.360;N03.349.380;N05.425
30723713,Cost-Benefit Analysis;Implementation Science,N03.219.151.125;L01.143.320.400
30723647,Radiotherapy,E02.815
30723287,,
30723106,,
30723017,,
30723013,"Insemination, Artificial, Homologous;Azathioprine;Liver Diseases;Prednisone",E02.875.800.937.525;E05.820.800.937.525;G08.686.784.363.492.750;D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111;C06.552;D04.210.500.745.432.719.702
30722709,Eosinophilic Esophagitis;Hypersensitivity;Diagnosis,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C20.543;E01
30721887,,
30721400,Narrative Medicine,F01.145.209.459.500;N04.590.233.727.407.250;N05.715.520
30721163,,
30721158,Fibrosis;Pulmonary Medicine,C23.550.355;H02.403.429.675
30720659,,
30720645,,
30720556,,
30719967,,
30719879,"Hematoma;Equipment and Supplies;Spectroscopy, Near-Infrared;Brain Injuries, Traumatic",C23.550.414.838;E07;E01.370.350.750;E05.196.867.851;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
30719864,Sotos Syndrome;Hyperinsulinism;Hypoglycemia,C16.131.077.889;C16.131.260.905;C16.320.180.905;C18.452.394.968;C18.452.394.984
30719842,"Myasthenic Syndromes, Congenital;Vocal Cord Paralysis",C10.668.758.800;C16.320.590;C08.360.931;C09.400.931;C10.292.887.800;C10.597.622.943;C23.888.592.636.943
30719840,Beckwith-Wiedemann Syndrome;Methylation;Continental Population Groups,C16.131.077.133;C16.131.260.080;C16.320.180.080;G02.111.035.538;G02.607.094.538;G03.059.538;M01.686.508
30719730,,
30719479,,
30718512,,
30718506,,
30718247,,
30717852,Cardiac Resynchronization Therapy,E02.331.200.500
30716596,Child Abuse;Psychopathology,I01.198.240.856.350.250;I01.880.735.900.350.250;F04.096.670
30716459,,
30716353,,
30715746,,
30715540,,
30715364,,
30714976,"Infant, Premature",M01.060.703.520.520
30714308,Evidence-Based Nursing;Evidence-Based Practice;Quality Improvement,H02.249.875;H02.478.197;H02.249;J01.293.754;N04.761.744
30714219,,
30714212,Cognition;Dementia;Healthy Aging;Cognitive Dysfunction,F02.463.188;C10.228.140.380;F03.615.400;F01.829.458.205.250;F03.615.250.700
30713341,,
30713110,"Diabetes Mellitus, Type 1",C18.452.394.750.124;C19.246.267;C20.111.327
30712512,,
30712508,,
30712121,"Arthritis, Juvenile;Magnetic Resonance Imaging",C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;E01.370.350.825.500
30711719,,
30711660,Cartilage;Osteoarthritis,A02.165;A10.165.382;C05.550.114.606;C05.799.613
30711642,Collagen Type I;Bone Development;Bone Density;Longitudinal Studies;Puberty,D05.750.078.280.300.100;D12.776.860.300.250.300.100;G07.345.500.325.377.625.050.500;G11.427.578.050.500;G11.427.100;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;G08.686.760;G08.686.841.374
30711529,,
30711487,,
30711237,,
30711235,"Analgesics, Opioid;Pain Management",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E02.745;N04.590.607.500
30711227,"Stress Disorders, Post-Traumatic;Wounds and Injuries",F03.950.750.500;C26
30711054,,
30711033,,
30710598,,
30710425,"Education;Anesthesia, General;Research",I02;E03.155.197;H01.770.644
30710036,,
30710035,,
30709951,,
30709931,,
30709878,,
30709843,,
30709713,,
30707941,,
30707892,,
30707849,,
30707766,Subacute Care,E02.760.850;N02.421.585.850
30707217,"Certification;Clinical Competence;Education, Medical, Continuing;Educational Measurement;Humans;Specialty Boards;United States",N03.706.110.120;N05.700.200.190;I02.399.630.210;N04.761.210;N05.715.175;I02.358.212.350;I02.358.399.250;I02.399;B01.050.150.900.649.313.988.400.112.400.400;N03.706.110.120.580;N05.700.200.190.750;Z01.107.567.875
30707210,,
30707123,,
30707063,,
30706743,,
30706531,,
30706149,Adult;Autistic Disorder;Review;Social Behavior,M01.060.116;F03.625.164.113.500;V02.600.500;V02.912;F01.145.813
30706049,Depression,F01.145.126.350
30706022,,
30706016,,
30705923,Hemophilia A;Bioengineering;Factor IX;Factor VIII;Genetic Therapy;Hemophilia B;Protein Engineering,C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;J01.293.069;D08.622.355;D12.776.124.125.375;D23.119.375;D12.776.124.125.350;D23.119.350;E02.095.301;E05.393.420.301;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;E05.393.420.601
30705403,,
30705375,,
30705188,,
30705032,,
30704882,Dialysis;Kidney Transplantation,E05.196.353;G02.186;E02.870.500;E04.936.450.485;E04.950.774.400
30704827,"Anxiety;Burnout, Psychological;Depersonalization;Depression",F01.470.132;F01.145.126.990.367;F02.830.900.333;F01.145.126.300;F01.145.126.350
30704576,Learning Curve,F02.784.629.529.274
30704510,,
30703769,Anemia;Erythropoietin;Fetus;Sheep,C15.378.071;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;A16.378;B01.050.150.900.649.313.500.380.791
30703745,"Animals;Chemistry, Pharmaceutical;Drug Design;Humans;Neoplasms;Parasitic Diseases;Pyrimidines;Structure-Activity Relationship;Triazoles;Chemistry, Pharmaceutical",B01.050;H01.158.703.007;H01.181.466;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;B01.050.150.900.649.313.988.400.112.400.400;C04;C03;D03.383.742;G02.111.830;G07.690.773.997;D03.383.129.799;H01.158.703.007;H01.181.466
30703743,"Phosphatidylserines;Lupus Erythematosus, Systemic",D10.570.755.375.760.400.971;C17.300.480;C20.111.590
30703392,,
30703275,"Antidepressive Agents;Cohort Studies;Colonic Neoplasms;Recurrence;Serotonin Uptake Inhibitors;Antidepressive Agents, Tricyclic",D27.505.954.427.700.122;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;C23.550.291.937;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900;D27.505.954.427.700.122.055
30703213,,
30702444,,
30702344,Endothelial Cells,A11.436.275
30701409,,
30701273,"Myopathies, Nemaline",C05.651.575.290;C10.668.491.550.290
30701090,,
30700988,"Immunity, Innate;Tuberculosis",G12.450.564;C01.252.410.040.552.846
30700610,,
30700590,,
30700572,,
30700563,Neisseria meningitidis;Neisseria meningitidis,B03.440.400.425.550.550.641;B03.660.075.525.520.500;B03.440.400.425.550.550.641;B03.660.075.525.520.500
30700562,Neisseria meningitidis;Sepsis,B03.440.400.425.550.550.641;B03.660.075.525.520.500;C01.539.757;C23.550.470.790.500
30700525,,
30700280,,
30699851,Adolescent;Diffusion Tensor Imaging;Frontal Lobe;Magnetic Resonance Imaging;Suicide;Young Adult,M01.060.057;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A08.186.211.200.885.287.500.270;E01.370.350.825.500;F01.145.126.980.875;I01.880.735.856;M01.060.116.815
30699326,"Accountable Care Organizations;Conflict of Interest;Delivery of Health Care, Integrated;Health Facility Merger;Humans;Medicare;Patient Care Management;Patient Protection and Affordable Care Act;United States",N05.300.380.500;K01.752.566.479.095;N05.350.225;N04.590.374.142;N05.300.262;N02.278.235;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.590;N03.219.521.576.343.918;N03.706.615.806;Z01.107.567.875
30698672,,
30698414,,
30698365,Epidemiology;Obesity,H02.403.720.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30698141,Medicine;Mice,H02.403;B01.050.150.900.649.313.992.635.505.500
30698133,,
30698116,Anxiety;Depression;Quality of Life,F01.470.132;F01.145.126.350;I01.800;K01.752.400.750;N06.850.505.400.425.837
30697907,,
30697460,Positron-Emission Tomography;Radioimmunotherapy,E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E02.095.465.425.750;E02.186.750;E02.815.520
30696825,,
30696823,,
30696821,,
30696723,Oxaliplatin;Rectal Neoplasms,D02.691.214.500;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500
30696253,Advance Care Planning;Advance Directives;Privacy;Trust,N04.590.233.624.124;I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050;I01.880.604.473.352.500;N03.706.437.352.500;N03.706.615.862;F01.829.401.825
20301382,,
30694819,,
30692206,"Cell Line, Tumor;DNA Breaks, Double-Stranded;Gene Knockout Techniques;Genomic Instability;HEK293 Cells;HeLa Cells;Humans;Interphase;Rad52 DNA Repair and Recombination Protein;Recombinases;Telomere Homeostasis;Homologous Recombination;Telomere",A11.251.210.190;A11.251.860.180;G05.200.210.220;E05.393.335.750;C23.550.362;G05.365.590.335;G05.370;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;G04.144.500;D12.776.260.696;D08.811.739;G04.144.220.625;G04.161.750.500.500;G05.113.610;G07.345.249.410.750.500.750;G05.728.615;A11.284.430.106.279.345.190.160.845;G05.360.160.845
30692132,,
30692100,,
30691215,HIV;Lymphocytic choriomeningitis virus;Immunotherapy,B04.820.650.589.650.350;B04.820.057.070.100.550;E02.095.465.425
30690647,,
30690618,,
30690316,Anesthesiology;Faculty,H02.403.066;M01.526.702.250
30690168,,
30690127,,
30689769,,
30689592,Huntington Disease;Clinical Trial;Genetic Therapy,C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;V03.175.250;E02.095.301;E05.393.420.301
30688988,,
30688750,,
30688513,,
30687477,Botswana;Craniocerebral Trauma;Wounds and Injuries,Z01.058.290.175.230;C10.900.300;C26.915.300;C26
30687409,"Blood Gas Analysis;Carbon Dioxide;Cardiopulmonary Resuscitation;Humans;Lung;Models, Biological;Models, Statistical;Oxygen;Respiration;Respiratory Transport;Treatment Outcome",E01.370.225.124.100.100;E01.370.386.700.100;E05.200.124.100.100;D01.200.200;D01.362.150;D01.650.550.200;E02.365.647.110;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E05.599.395;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;D01.268.185.550;D01.362.670;G09.772.705;G03.143.775;G09.772.705.760;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30686745,Dendrimers;Hypoxia;Stroke,D05.750.327;E02.319.300.380.200;J01.637.512.600.200;C23.888.852.079;C10.228.140.300.775;C14.907.253.855
30686529,Lipids;Apolipoproteins,D10;D10.532.091;D12.776.070.400;D12.776.521.120
30686307,Craniosynostoses;Risk Assessment,C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30685762,Deep Learning;Genomics;Machine Learning,G17.035.250.500.250;G17.485.500;L01.224.050.375.530.250;L01.224.050.375.605.500;H01.158.273.180.350;H01.158.273.343.350;G17.035.250.500;L01.224.050.375.530
30685496,Culture;Family;Palliative Care;Continental Population Groups;Religion,I01.076.201.450;I01.880.853.100;F01.829.263;I01.880.853.150;E02.760.666;N02.421.585.666;M01.686.508;K01.844
30685329,Infant,M01.060.703
30685272,Bipolar Disorder;Dopamine;Schizophrenia,F03.084.500;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;F03.700.750
30685229,,
30685158,,
30685136,Parturition,G08.686.784.769.490
30685112,Contracts;Fellowships and Scholarships;Job Application;Negotiating,I01.880.604.583.090;N03.706.535.241;N03.219.483.838.276;N04.452.677.400;F01.145.209.520;F01.829.401.520;F02.463.785.373.520;L01.143.620;N04.452.677.430
30684933,,
30684414,Cell Phone;Exercise;Veterans;Wearable Electronic Devices,L01.178.847.698.300;G11.427.410.698.277;I03.350;M01.930;E07.305.906
30684121,Anastomotic Leak;Colorectal Surgery;General Surgery;Microbiota;Microbiota;Surgical Wound Infection,C23.550.767.071;H02.403.810.208;H02.403.810.300;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C01.539.947.692;C23.550.767.925
30684082,Child;Stents,M01.060.406;E07.695.750
30684015,,
30683979,Magnetic Resonance Imaging;Pancreas,E01.370.350.825.500;A03.734
30683962,Bronchi;Child;Trachea;Tracheobronchomalacia,A04.411.125;M01.060.406;A04.889;C05.182.895;C08.127.719;C08.907.796;C16.131.621.953;C17.300.182.895
30683880,"Breast Neoplasms;Case-Control Studies;Colorectal Neoplasms;European Continental Ancestry Group;Genetic Predisposition to Disease;Genome-Wide Association Study;Head and Neck Neoplasms;Humans;Inheritance Patterns;Lung Neoplasms;Mental Disorders;Neoplasm Proteins;Ovarian Neoplasms;Phenotype;Polymorphism, Single Nucleotide;Prostatic Neoplasms;Smoking",C04.588.180;C17.800.090.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;M01.686.508.400;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;G05.420;C04.588.894.797.520;C08.381.540;C08.785.520;F03;D12.776.624;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G05.695;G05.365.795.598;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;F01.145.805
30683875,"Animals;Animals, Newborn;Dependovirus;Disease Models, Animal;Gene Expression;Genes, Reporter;Genetic Therapy;Genetic Vectors;Green Fluorescent Proteins;Hair Cells, Auditory, Inner;Hair Cells, Auditory, Outer;Hearing;Hearing Loss, Sensorineural;Mice;Myosins",B01.050;B01.050.050.282;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;G05.297;G05.360.340.024.340.435;E02.095.301;E05.393.420.301;G05.360.337;D12.776.532.265;A08.675.650.250.250;A08.675.650.915.750.600.350.350;A08.800.950.750.600.350.350;A09.246.300.246.577.325.315;A11.671.650.250.250;A11.671.650.915.750.600.350.350;A08.675.650.250.315;A08.675.650.915.750.600.350.365;A08.800.950.750.600.350.365;A09.246.300.246.577.325.380;A11.671.650.250.315;A11.671.650.915.750.600.350.365;F02.830.816.263;G11.561.790.263;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887;B01.050.150.900.649.313.992.635.505.500;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475
30683676,Diagnosis;Evidence-Based Practice,E01;H02.249
30683211,,
30682185,,
30681752,Blood Vessels;Cartilage,A07.015;A02.165;A10.165.382
30681717,,
30681707,,
30681449,,
30681447,,
30680780,,
30680653,Granuloma,C15.604.515.292;C23.550.382
30680222,"Bronchitis, Chronic;Pulmonary Disease, Chronic Obstructive;Emphysema;Obesity;Sinusitis",C08.127.446.567;C08.381.495.146.567;C08.381.495.389.500;C08.730.099.567;C08.381.495.389;C23.550.325;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C08.460.692.752;C08.730.749;C09.603.692.752
30679821,Language Development Disorders,C10.597.606.150.500.550;C23.888.592.604.150.500.550
30679745,,
30679390,,
30679234,,
30679070,Bias;Feedback,N05.715.350.150;N06.850.490.500;L01.906.394.211
30678683,,
30677646,,
30677461,,
30677148,"Outcome Assessment (Health Care);Muscular Atrophy, Spinal;Upper Extremity",H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C10.228.854.468;C10.574.562.500;C10.668.467.500;A01.378.800
30676822,,
30676620,,
30676557,"Child;Critical Illness;Humans;Intensive Care Units, Pediatric;Nutritional Support;Practice Guidelines as Topic",M01.060.406;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E02.642.500;N04.761.700.350.650;N05.700.350.650
30676535,,
30676492,,
30676479,Hydronephrosis;Prenatal Diagnosis;Reproducibility of Results,C12.777.419.307;C13.351.968.419.307;E01.370.378.630;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
30676062,Health Promotion;Students;Student Health Services;Work-Life Balance,I02.233.332.445;N02.421.726.407.579;M01.848;N02.421.897;I01.940;I03.946.225.438;N04.452.677.650.438
30675340,Antimicrobial Stewardship;Critical Pathways,N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;N04.590.233.624.625;N04.590.275
30675035,,
30674670,Hemostasis;Blood Platelets;Thrombin,G09.188.390;A11.118.188;A15.145.229.188;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
30674609,,
30674417,RNA;Alternative Splicing;Chromosomes;Gene Expression;Meiosis;Mice;Spermatogenesis,D13.444.735;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;G05.297;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;G04.152.650.624;G08.686.784.310.760
30674049,,
30673542,"Brain;Cerebral Angiography;Humans;Infant;Osteogenesis, Distraction;Reconstructive Surgical Procedures;Skull;Superior Sagittal Sinus;Tomography, X-Ray Computed;Twins, Conjoined",A08.186.211;E01.370.350.578.937.180;E01.370.350.700.060.180;E01.370.350.700.560.180;E01.370.370.050.180;E01.370.376.537.750.180;E05.629.937.180;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E04.555.120.690;E04.680;A02.835.232.781;A07.015.908.224.667;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C16.131.085.806
30673538,Endometrium;Fertilization in Vitro;Humans,A05.360.319.679.490;E02.875.800.750;E05.820.800.750;B01.050.150.900.649.313.988.400.112.400.400
30673084,,
30673079,,
30673067,,
30672903,,
30672841,,
30672747,,
30671648,Autoantibodies,D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323
30670881,,
30670880,,
30670848,,
30670684,,
30670162,Health,N01.400
30669967,"Computer Simulation;Genetic Association Studies;Humans;Models, Genetic;Research Design;Sample Size",L01.224.160;E05.393.385;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;E05.581.500;H01.770.644.728;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762
30669625,Gene Editing,E05.393.420.270
30668888,Dimerization;Glycosylation,G02.206;G03.230;G02.111.158.812;G02.607.299;G03.191.812
30668832,,
30668749,,
30668679,,
30668551,Cardiology;Heart Failure;Metabolism;Mitochondria,H02.403.429.163;C14.280.434;G03;A11.284.430.214.190.875.564;A11.284.835.626
30667487,"Anemia, Sickle Cell;Child;Hematopoietic Stem Cell Transplantation;Humans;Siblings;Stroke;Tissue Donors",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;M01.060.406;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;C10.228.140.300.775;C14.907.253.855;M01.898
30667477,,
30667412,,
30667411,,
30667332,,
30666753,"Epilepsy, Temporal Lobe",C10.228.140.490.360.290;C10.228.140.490.493.375
30666677,Melanoma,C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
30666631,Poly(ADP-ribose) Polymerase Inhibitors;Meta-Analysis,D27.505.519.389.739;D27.505.954.248.692;V03.600
30666307,"Neoplasms;Receptors, Chimeric Antigen;Immunotherapy",C04;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;E02.095.465.425
30665575,,
30665461,"Adolescent;Adult;Aged;Aged, 80 and over;Agriculture;Animals;Bacteroidaceae;Botswana;Cattle;Clostridiales;Cohort Studies;Diet, Paleolithic;Gastrointestinal Microbiome;Humans;Metagenome;Middle Aged;Philadelphia;Population Groups;Rural Population;Tanzania;Young Adult;Diet;Genetics;Gastrointestinal Microbiome;Industrial Development;Rural Population;Africa South of the Sahara",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;J01.040;B01.050;B03.140.094;B03.440.425.410.194;Z01.058.290.175.230;B01.050.150.900.649.313.500.380.271;B03.353.625;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.642.249.275;G07.203.650.240.275;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.550;M01.060.116.630;Z01.107.567.875.500.550.525;Z01.433.820;M01.686;N01.224.708;N01.600.725;Z01.058.290.120.840;M01.060.116.815;G07.203.650.240;H01.158.273.343;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;I01.261.262.500;J01.576.519;N01.600.725;Z01.058.290
30664738,,
30664693,,
30664683,,
30664590,,
30664569,,
30664565,,
30664564,,
30664323,Electroencephalography,E01.370.376.300;E01.370.405.245
30664276,Dexmedetomidine;Pediatrics;Pharmacokinetics,D03.383.129.308.245;H02.403.670;G03.787;G07.690.725
30664273,,
30664098,,
30664092,,
30664048,,
30663792,,
30663401,Logistic Models,E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450
30663113,Calibration;Discrimination (Psychology),E05.978.155;F02.463.593.257
30661772,,
30661501,Child;Diagnosis;Infarction;Pediatrics;Stroke,M01.060.406;E01;C23.550.513.355;C23.550.717.489;H02.403.670;C10.228.140.300.775;C14.907.253.855
30661280,Adolescent;Child;Family Relations;Graft Rejection;Humans;Immunosuppressive Agents;Internal-External Control;Kidney Transplantation;Longitudinal Studies;Medication Adherence;Parents;Young Adult;Adolescent;Parents;Kidney Transplantation,M01.060.057;M01.060.406;F01.829.263.370;I01.880.853.150.439;G12.875.545.328;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;F01.829.379;E02.870.500;E04.936.450.485;E04.950.774.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;M01.060.116.815;M01.060.057;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E02.870.500;E04.936.450.485;E04.950.774.400
30661196,Mass Screening,E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30661128,Adolescent;Bipolar Disorder;Depression;Obesity;Schizophrenia,M01.060.057;F03.084.500;F01.145.126.350;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F03.700.750
30661073,Fetoscopy,E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280
30660783,Evidence-Based Medicine,H02.249.750;H02.403.200.400
30660752,Heme;Iron;Mitochondria;Yeasts,D03.383.129.578.840.500.640.587;D03.633.400.909.500.640.587;D04.345.783.500.640.587;D23.767.727.640.587;D01.268.556.412;D01.268.956.287;D01.552.544.412;A11.284.430.214.190.875.564;A11.284.835.626;B01.300.930
30660727,Immunity;Immunotherapy;Pancreatic Neoplasms,G12.450;E02.095.465.425;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
30660643,CD40 Ligand;Hematopoietic Stem Cell Transplantation,D12.644.276.374.750.124;D12.776.395.550.185;D12.776.467.374.750.124;D12.776.543.550.198;D23.529.374.750.124;E02.095.147.500.500.500;E04.936.225.687.500
30660594,,
30660504,Amyotrophic Lateral Sclerosis;Phase Transition,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;G01.645;G02.734
30660382,"Case-Control Studies;Eye;Scleroderma, Systemic",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A01.456.505.420;A09.371;C17.300.799;C17.800.784
30660240,,
30660226,Cerebral Palsy,C10.228.140.140.254
30660216,Safety,N06.850.135.060.075
30659934,,
30659852,Biological Products,D20.215
30659819,Critical Care;Politics,E02.760.190;N02.421.585.190;I01.738
30659559,Fluoxetine;Tachyphylaxis,D02.092.831.280;G07.690.773.992.910;G12.535.425.910
30659522,Photochemotherapy,E02.186.500;E02.319.685;E02.774.722
30659461,Androgens;Estrogens;Pregnancy,D27.505.696.399.472.161;D27.505.696.399.472.277;G08.686.784.769
30659380,"Child;Respiration, Artificial",M01.060.406;E02.041.625;E02.365.647.729;E02.880.820
30659230,,
30657976,,
30657810,,
30657535,,
30657439,Obesity;Weight Loss,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963
30656717,"Catheter Ablation;Cicatrix;Tachycardia, Ventricular",E02.808.750.500;E04.014.760.500;A10.165.450.300;C23.550.355.274;G16.762.891.249;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30656282,Clinical Competence;Nurse-Patient Relations;Nursing Care;von Willebrand Diseases,I02.399.630.210;N04.761.210;N05.715.175;F01.829.401.650.600;N05.300.660.560;E02.760.611;N02.421.533;C15.378.100.100.900;C15.378.100.141.900;C15.378.140.900;C15.378.463.920;C16.320.099.920
30656180,,
30655433,,
30655338,RNA Stability;Interferons,G02.111.780;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
30655334,,
30655328,Precision Medicine,E02.574;H02.403.200.700
30655315,,
30655120,,
30654827,Clustered Regularly Interspaced Short Palindromic Repeats;Genetic Engineering;Software,G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420;L01.224.900
30654773,Humans;Irritable Bowel Syndrome;Plant Oils;Treatment Outcome;Abdominal Pain;Irritable Bowel Syndrome;Meta-Analysis,B01.050.150.900.649.313.988.400.112.400.400;C06.405.469.158.272.608;D10.627.700;D20.215.784.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.592.612.054;C23.888.821.030;C06.405.469.158.272.608;V03.600
30653964,African Americans;Glaucoma,M01.686.508.100.100;M01.686.754.100;C11.525.381
30653816,"Tooth Eruption;Tooth, Unerupted",G10.549.810;A14.549.167.860.715;C07.793.915
30653506,"African Americans;Alleles;Asian Americans;European Continental Ancestry Group;Genetic Predisposition to Disease;Genome-Wide Association Study;HLA-A3 Antigen;HLA-B7 Antigen;HLA-DRB1 Chains;Haplotypes;Hispanic Americans;Humans;Multiple Sclerosis;Polymorphism, Single Nucleotide;Transcription Factors",M01.686.508.100.100;M01.686.754.100;G05.360.340.024.340.030;M01.686.508.200.100;M01.686.754.225;M01.686.508.400;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.776.395.550.489.400.030;D12.776.543.550.439.400.030;D23.050.301.500.100.400.030;D23.050.301.500.450.370.030;D23.050.705.552.100.400.030;D23.050.705.552.450.370.376;D12.776.395.550.489.500.070;D12.776.543.550.439.500.070;D23.050.301.500.100.500.070;D23.050.301.500.450.380.070;D23.050.705.552.100.500.070;D23.050.705.552.450.380.070;D12.776.395.550.509.400.440.200.010;D12.776.543.550.440.400.440.200.010;D23.050.301.500.400.400.440.200.010;D23.050.301.500.450.400.440.333.500;D23.050.705.552.410.400.440.200.010;D23.050.705.552.450.400.440.333.500;G05.380.360;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;G05.365.795.598;D12.776.930
30653248,Parkinson Disease;Dementia;Cognitive Dysfunction;Neuropsychological Tests;Survival Analysis,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.380;F03.615.400;F03.615.250.700;F04.711.513;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
30653247,Parkinson Disease;Evidence-Based Medicine;Randomized Controlled Trial,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;H02.249.750;H02.403.200.400;V03.175.250.500.500
30653061,,
30653041,,
30652196,Adolescent;Child;Degloving Injuries;Knee;Magnetic Resonance Imaging;Wounds and Injuries,M01.060.057;M01.060.406;C26.808.500;A01.378.610.450;E01.370.350.825.500;C26
30651165,Adult;Demography;Extracorporeal Membrane Oxygenation;Forecasting;Humans;Patient Discharge;Rain;Retrospective Studies,M01.060.116;I01.240;N01.224;N06.850.505.400;E02.880.301;E04.292.451;I01.320;B01.050.150.900.649.313.988.400.112.400.400;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;G16.500.175.859;G16.500.275.063.725.395;G16.500.750.775.450;N06.230.300.100.725.450;N06.230.520;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29276893,,
30649961,Central Pattern Generators,A08.511.500
30649087,,
30649042,,
30649041,,
30647182,,
30647179,,
30647113,"Animals;Cartilage;Cattle;Cell Communication;Cell Differentiation;Cells, Cultured;Chondrocytes;Chondrogenesis;Coculture Techniques;Extracellular Matrix;Extracellular Vesicles;Mesenchymal Stem Cells;Tissue Engineering;Tissue Scaffolds;Chondrocytes;Extracellular Vesicles",B01.050;A02.165;A10.165.382;B01.050.150.900.649.313.500.380.271;G04.085;G04.152;A11.251;A11.329.171;G07.345.500.325.377.625.180;G11.427.578.180;E05.481.500.374;A11.284.295.310;A11.284.295.588;A11.329.830.500;A11.872.590.500;E05.481.500.311.500;J01.293.069.249.500;E07.206.627;E07.695.825;A11.329.171;A11.284.295.588
30646549,Beckwith-Wiedemann Syndrome;alpha-Fetoproteins;Hepatoblastoma;Mass Screening,C16.131.077.133;C16.131.260.080;C16.320.180.080;D12.776.124.790.106.092;D12.776.320.525.500;D12.776.377.228.500;D12.776.377.715.085.092;D23.101.140.050;C04.557.435.380;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30646398,,
30646321,,
30646284,,
30646244,,
30646207,,
30646162,,
30646152,,
30646151,,
30646094,,
30646054,,
30646043,,
30646039,,
30646029,,
30645975,Exosomes;Extracellular Vesicles;Interferons;Melanoma;Neoplasm Metastasis;Reserpine,A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;A11.284.295.588;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.697.650;C23.550.727.650;D03.132.436.681.933.500;D03.633.100.473.402.681.933.500
30645203,Dendritic Cells;Allergy and Immunology;Pharmacology,A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;H02.403.044;H01.158.703;H02.628
30645040,Survival,I03.784
30644433,,
30643944,"Diastole;Extracellular Matrix;Fibrosis;Macaca mulatta;Diabetes Mellitus, Type 2",G09.330.580.295;G11.427.494.554.250;G11.427.494.570.295;A11.284.295.310;C23.550.355;B01.050.150.900.649.313.988.400.112.199.120.510.550;C18.452.394.750.149;C19.246.300
30643785,Chondroma,C04.557.450.565.265
30643595,"Education, Medical;Educational Measurement;Humans;Quality Improvement",I02.358.399;I02.399;B01.050.150.900.649.313.988.400.112.400.400;J01.293.754;N04.761.744
30643249,,
30642950,,
30642878,,
30642798,,
30642781,Neuronal Plasticity;Neurofeedback,G11.561.638;E02.190.525.123.500;F02.830.131.500;F04.754.137.301.750;F04.754.308.500.750
30642740,,
30642722,Lyme Disease;Meta-Analysis,C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;V03.600
30642688,Adolescent;Epilepsy;Intellectual Disability,M01.060.057;C10.228.140.490;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
30642571,,
30642457,"Carcinoma, Non-Small-Cell Lung",C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500
30642396,,
30642208,Alzheimer Disease;Blinking;Dementia;Electric Stimulation,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G11.561.731.127;G14.152;C10.228.140.380;F03.615.400;E05.723.402
30641443,,
30641225,,
30640889,,
30640679,,
30640370,,
30640271,,
30640191,,
30639929,Gene Editing;Genetic Therapy;Precision Medicine,E05.393.420.270;E02.095.301;E05.393.420.301;E02.574;H02.403.200.700
30639791,Heart Arrest;Heart Arrest;Critical Care;Resuscitation;Ventricular Fibrillation,C14.280.383;C14.280.383;E02.760.190;N02.421.585.190;E02.365.647;C14.280.067.922;C23.550.073.922
30639763,Food Supply;Social Determinants of Health,J01.576.423.750;N01.224.425.762;N01.400.675
30639612,,
30639346,"Asthma;Dermatitis, Atopic;Biomarkers;Food Hypersensitivity",C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D23.101;C20.543.480.370
30639037,PPAR gamma;Adipocytes;Genetic Variation;Rosiglitazone,D12.776.826.239.588;A11.329.114;G05.365;D02.886.675.933.500;D03.383.129.708.933.500
30639035,DNA Methylation;Adenosylhomocysteinase;Hematopoietic Stem Cells,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D08.811.277.063;A11.148.378;A11.872.378;A15.378.316.378
30638962,,
30638541,,
30638537,Magnetic Resonance Spectroscopy,E05.196.867.519
30638531,,
30638527,Molecular Dynamics Simulation,E05.599.595.500;G02.111.570.895;L01.224.160.500
30637500,Alzheimer Disease;Cognitive Dysfunction,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F03.615.250.700
30637488,Adolescent;Anorexia Nervosa;Bulimia Nervosa;Feeding and Eating Disorders;Gonadal Hormones;Neurobiology;Sex Characteristics,M01.060.057;F03.400.125;F03.400.250;F03.400;D06.472.334;H01.158.273.610;H01.158.610.080;G08.686.815
30636740,Alzheimer Disease;Anesthesia;Autophagy;Calcium;Presenilins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E03.155;G04.146.399;G04.417.350.091;D01.268.552.100;D01.552.539.288;D23.119.100;D12.776.543.696
30636013,Appetite;Eating,F02.830.071;G07.203.650.390.070;G10.261.390.070;G07.203.650.283;G10.261.330
30635693,"Hernias, Diaphragmatic, Congenital;Magnetic Resonance Imaging;Infant, Newborn",C16.131.433;C23.300.707.500.116;E01.370.350.825.500;M01.060.703.520
30635586,Centromere;Centromere Protein A;Gene Editing;HeLa Cells;Humans;Phosphorylation,A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;E05.393.420.270;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;G02.111.665;G02.607.780;G03.796
30635474,,
30635448,,
30635416,"Animals;Anti-Bacterial Agents;Child;Chlorhexidine;Community-Acquired Infections;Genome, Bacterial;Humans;Methicillin-Resistant Staphylococcus aureus;Mice;Microbial Sensitivity Tests;Mupirocin;Phylogeny;Plasmids;Staphylococcal Infections;Virulence;Methicillin-Resistant Staphylococcus aureus;Virulence",B01.050;D27.505.954.122.085;M01.060.406;D02.078.370.141.100;C01.539.234;G05.360.340.358.207;B01.050.150.900.649.313.988.400.112.400.400;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B01.050.150.900.649.313.992.635.505.500;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;D02.355.291.411.658;D03.383.663.555;D10.251.536;G05.697;G16.075.605;L01.100.697;G05.360.600;C01.252.410.868;G06.930;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;G06.930
30635337,,
30635336,,
30635225,,
30635107,Agriculture;Climate Change;Environment,J01.040;G16.500.175.374;G16.500.275;N06.230
30634618,Electronic Nicotine Delivery Systems;Health Communication,J01.637.767.500;L01.143.350;N02.208
30634375,"Humans;Hypospadias;Polymorphism, Single Nucleotide;Risk Factors",B01.050.150.900.649.313.988.400.112.400.400;C12.294.494.400;C12.706.516;C13.351.875.466;C16.131.939.516;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30633980,Intrauterine Devices;Adolescent;Ambulatory Surgical Procedures;Gynecologic Surgical Procedures;Long-Acting Reversible Contraception;Young Adult,E07.190.250.510;M01.060.057;E04.030;E04.950.300;E02.875.194.589;M01.060.116.815
30633942,,
30633941,Alopecia Areata;Alopecia;Quality of Life,C17.800.329.937.122.147;C17.800.329.937.122;C23.300.035;I01.800;K01.752.400.750;N06.850.505.400.425.837
30633814,Parkinson Disease;alpha-Synuclein;Dopamine,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.776.631.860.500;D12.776.637.500;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342
30633129,,
30633034,,
30631825,,
30631061,"Adaptor Proteins, Signal Transducing;Animals;Cancer-Associated Fibroblasts;Cell Line;Cells, Cultured;Gene Expression Profiling;Heat Shock Transcription Factors;Humans;Intercellular Signaling Peptides and Proteins;Intracellular Signaling Peptides and Proteins;Low Density Lipoprotein Receptor-Related Protein-6;Membrane Proteins;Mice, Nude;Mice, Transgenic;Neoplasms;Phosphoproteins;Transcription Factors;Wnt Signaling Pathway;beta Catenin",D12.644.360.024;D12.776.157.057;D12.776.476.024;B01.050;A11.329.228.105;A11.251.210;A11.251;E05.393.332;D12.776.157.687.450;D12.776.260.260;D12.776.660.720.462;D12.776.930.317;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276;D12.776.467;D23.529;D12.644.360;D12.776.476;D12.776.526.600;D12.776.543.750.710.450.500.600;D12.776.543.750.850.781;D12.776.543;B01.050.150.900.649.313.992.635.505.500.550.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C04;D12.776.744;D12.776.930;G02.111.820.925;G04.835.925;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
30630982,"Hemoglobinopathies;Anemia, Sickle Cell",C15.378.420;C16.320.365;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
30630868,,
30630850,,
30630732,Laparoscopy;Nephrectomy;Kidney Neoplasms;Robotics,E01.370.388.250.520;E04.502.250.520;E04.950.774.435;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;H01.671.293.643;J01.897.104.834;L01.224.050.375.630
30630532,Alzheimer Disease;Biomarkers;Microglia,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A08.637.400;A11.650.400
30630261,"Endoscopy;Esthetics, Dental;Head and Neck Neoplasms;Humans;Neck Dissection;Robotic Surgical Procedures;Head and Neck Neoplasms;Neck Dissection;Oral Surgical Procedures;Robotics",E01.370.388.250;E04.502.250;E06.420;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;E04.446.318;E04.580.411;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;C04.588.443;E04.446.318;E04.580.411;E04.545;E06.645;H01.671.293.643;J01.897.104.834;L01.224.050.375.630
30629937,Ovarian Neoplasms,C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
30629920,"Amino Acid Sequence;Animals;Antibodies, Neutralizing;Antibody Formation;Disease Models, Animal;Epitopes;Guinea Pigs;HEK293 Cells;HIV Antibodies;HIV Envelope Protein gp120;HIV Infections;HIV-1;Humans;Immunization;Inhibitory Concentration 50;Models, Molecular;Mutation;Peptide Fragments;Protein Binding;Vaccination;Vaccines;env Gene Products, Human Immunodeficiency Virus;HIV-1;Machine Learning",G02.111.570.060;L01.453.245.667.060;B01.050;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;G12.070;C22.232;E05.598.500;E05.599.395.080;D23.050.550;B01.050.150.900.649.313.992.550;A11.251.210.172.750;A11.436.334;D12.776.124.486.485.114.254.150.440;D12.776.124.790.651.114.254.150.440;D12.776.377.715.548.114.254.150.440;D12.776.964.775.325.164.249;D12.776.964.775.562.500.500;D12.776.964.970.880.325.164.249;D23.050.327.520.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;E05.940.350;G07.690.936.563;E05.599.595;G05.365.590;D12.644.541;G02.111.679;G03.808;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;D20.215.894;D12.776.964.775.325.164;D12.776.964.775.562.500;D12.776.964.970.880.325.164;B04.820.650.589.650.350.400;G17.035.250.500;L01.224.050.375.530
30629845,Infant Formula,G07.203.100.712.249;G07.203.300.525.350.500;G07.203.300.525.500.500;J02.200.712.249;J02.500.525.350.500;J02.500.525.500.500
30629768,,
30628923,,
30627858,Kidney Transplantation;Pediatrics,E02.870.500;E04.936.450.485;E04.950.774.400;H02.403.670
30627706,,
30627660,"Adjuvants, Immunologic;Animals;Animals, Genetically Modified;Biomechanical Phenomena;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Cholinesterase Inhibitors;Disease Models, Animal;Forkhead Transcription Factors;Gait Disorders, Neurologic;Levamisole;Longevity;Muscular Atrophy, Spinal;Neuromuscular Junction;Pyridostigmine Bromide;RNA Interference;Signal Transduction;Survival Analysis;Survival of Motor Neuron 1 Protein;gamma-Aminobutyric Acid;Aging;Neuromuscular Junction",D27.505.696.477.067;B01.050;B01.050.050.136;B05.620.136;G01.154.090;G01.374.089;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;D27.505.519.389.275;D27.505.519.625.120.300;D27.505.696.577.120.300;C22.232;E05.598.500;E05.599.395.080;D12.776.260.950.249;D12.776.930.977.249;C10.597.404;C23.888.592.413;D02.886.675.346;D03.383.129.308.480;D03.383.129.708.346;G07.345.124.519;G07.540;C10.228.854.468;C10.574.562.500;C10.668.467.500;A08.800.550.550.550;A08.850.550.550;A11.284.149.165.420.780.550.550;D03.383.725.762.740;G05.308.203.374.790;G02.111.820;G04.835;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;D12.776.157.725.875.500;D12.776.580.922.500;D12.776.664.962.875.500;D02.241.081.114.500.350;D12.125.190.350;G07.345.124;A08.800.550.550.550;A08.850.550.550;A11.284.149.165.420.780.550.550
30627492,Radiotherapy,E02.815
30626929,,
30626755,Dermatology;Allergy and Immunology;Lymphoma,H02.403.225;H02.403.044;C04.557.386;C15.604.515.569;C20.683.515.761
30626747,"Inflammation;Immunity, Innate;Monocytes",C23.550.470;G12.450.564;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
30626744,Atherosclerosis;Cell Biology,C14.907.137.126.307;H01.158.100.433;H01.158.273.160
30626590,,
30626516,Humans;Motor Neuron Disease;Muscle Spasticity;Orthopedic Procedures;Contracture;Congenital Abnormalities;Motor Neuron Disease,B01.050.150.900.649.313.988.400.112.400.400;C10.574.562;C10.668.467;C05.651.512;C10.597.613.550.550;C23.888.592.608.550.550;E02.718;E04.555;C05.550.323;C05.651.197;C16.131;C10.574.562;C10.668.467
30626515,Humans;Muscle Spasticity;Neurosurgical Procedures;Deep Brain Stimulation;Dystonia;Neurosurgery;Rhizotomy,B01.050.150.900.649.313.988.400.112.400.400;C05.651.512;C10.597.613.550.550;C23.888.592.608.550.550;E04.525;E02.331.300;E04.190;C10.597.350.300;C23.888.592.350.300;H02.403.810.425;E04.525.210.815
30626437,,
30626253,"Leukemia, Lymphoid;Asparaginase;Pharmacokinetics",C04.557.337.428;C15.604.515.560;C20.683.515.528;D08.811.277.087.116;G03.787;G07.690.725
30626206,"Receptors, Calcium-Sensing;Endothelium;Hypertension, Pulmonary;Smoking;Spermine",D12.776.543.750.695.115;A10.272.491;C08.381.423;F01.145.805;D02.092.211.415.701.801.821;D02.092.782.802
30625502,,
30625486,,
30625463,"African Americans;Cardiovascular Diseases;Renal Insufficiency, Chronic;Sex;Sickle Cell Trait",M01.686.508.100.100;M01.686.754.100;C14;C12.777.419.780.750;C13.351.968.419.780.750;G08.686.810;C15.378.071.141.150.150.670;C15.378.420.155.668;C16.320.070.150.670;C16.320.365.155.668
30625409,,
30625390,Fertility Preservation;Survivorship,E02.875.800.625;E04.936.537.562;E05.820.800.625;F01.058.144.500
30625149,"Alleles;Allelic Imbalance;Animals;Gene Expression Regulation, Developmental;In Situ Hybridization, Fluorescence;Kidney;Mice;Organ Specificity;RNA, Long Noncoding",G05.360.340.024.340.030;G05.365.590.029;B01.050;G05.308.310;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;A05.810.453;B01.050.150.900.649.313.992.635.505.500;G07.650;D13.444.735.790.375
30625041,,
30624876,Rwanda,Z01.058.290.120.680
30624576,"Blood Pressure;Diabetes, Gestational;Hypertension;Hypertension",E01.370.600.875.249;G09.330.380.076;C13.703.170;C18.452.394.750.448;C19.246.200;C14.907.489;C14.907.489
30624416,,
30623823,"Suicide, Attempted;Bipolar Disorder;Depression;Bipolar Disorder;Suicidal Ideation",F01.145.126.980.875.600;I01.880.735.856.600;F03.084.500;F01.145.126.350;F03.084.500;F01.145.126.980.875.149;I01.880.735.856.149
30623581,Histocompatibility;Immunogenetics,G12.875.519;H01.158.273.343.420
30623517,Cerebrovascular Circulation;Machine Learning;Methamphetamine,G09.330.100.159;G17.035.250.500;L01.224.050.375.530;D02.092.471.683.152.619
30623210,Child;Magnetic Resonance Imaging;Osteomyelitis,M01.060.406;E01.370.350.825.500;C01.539.160.495;C05.116.165.495
30623164,"Disorders of Sex Development;Adrenal Hyperplasia, Congenital;Hypospadias",C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119;C12.706.316.090.500;C13.351.875.253.090.500;C16.131.939.316.129.500;C16.320.033;C16.320.565.925.249;C18.452.648.925.249;C19.053.440;C19.391.119.090.500;C12.294.494.400;C12.706.516;C13.351.875.466;C16.131.939.516
30622700,"Hypertension, Pulmonary;Heart Ventricles",C08.381.423;A07.541.560
30622344,,
30621825,"Electrocardiography;Electrocardiography;Sleep Apnea, Obstructive;Mass Screening",E01.370.370.380.240;E01.370.405.240;E01.370.370.380.240;E01.370.405.240;C08.618.085.852.850;C10.886.425.800.750.850;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30621634,Dialysis,E05.196.353;G02.186
30621445,Goldenhar Syndrome;Goldenhar Syndrome;Methods;Goldenhar Syndrome,C05.116.099.370.231.576.410;C05.660.207.231.576.410;C16.131.621.207.231.576.410;C05.116.099.370.231.576.410;C05.660.207.231.576.410;C16.131.621.207.231.576.410;E05.581;C05.116.099.370.231.576.410;C05.660.207.231.576.410;C16.131.621.207.231.576.410
30620916,,
30619294,Dendritic Cells,A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260
30618992,Depression;Obesity,F01.145.126.350;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30618563,Central Amygdaloid Nucleus,A08.186.211.180.090.750;A08.186.211.200.885.287.249.152.750
30618475,"Antipsychotic Agents;Clinical Trial;Depressive Disorder;Depressive Disorder, Major",D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;V03.175.250;F03.600.300;F03.600.300.375
30618147,,
30617275,,
30617273,,
30617166,,
30616938,Costs and Cost Analysis,N03.219.151
30616777,,
30616620,,
30616593,Career Mobility;Humans;Research;Universities;Work Performance,N01.824.245.175;N01.824.547.330;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644;I02.783.830;J03.832.830;I03.946.675
30615685,"Antigens, Viral;Apoptosis;B-Lymphocytes;Cell Line, Tumor;Cell Proliferation;Cell Transformation, Viral;DNA Methylation;Down-Regulation;Epigenesis, Genetic;Epstein-Barr Virus Infections;Epstein-Barr Virus Nuclear Antigens;Gene Expression Regulation;HEK293 Cells;Herpesvirus 4, Human;Humans;Lymphocyte Activation;Promoter Regions, Genetic;Tumor Suppressor Proteins",D23.050.327;G04.146.160;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;C04.697.098.500.160;C23.550.727.098.500.160;G06.920.143;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G02.111.240;G05.308.200;G07.690.773.937;G05.308.203;C02.256.466.313;C02.928.313;D23.050.290.249;D23.050.327.300;G05.308;A11.251.210.172.750;A11.436.334;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.624.776
30615518,,
30615211,,
30615093,,
30614950,,
30614194,De Lange Syndrome,C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210
30613845,Child;Lymphography;Magnetic Resonance Imaging;Noonan Syndrome;Thoracic Duct,M01.060.406;E01.370.350.700.475;E01.370.350.825.500;C05.660.207.690;C14.240.400.787;C14.280.400.787;C16.131.240.400.784;C16.131.621.207.690;C17.300.690;A15.382.520.301.750
30613471,"Rare Diseases;Hyperammonemia;Metabolism, Inborn Errors;Propionic Acidemia;Urea Cycle Disorders, Inborn",C23.550.291.906;C23.550.421;C16.320.565;C18.452.648;C16.320.565.100.823;C18.452.648.100.823;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937
30613425,,
30613341,,
30612907,Axonal Transport;Dyneins;Kinesin;Synaptic Vesicles,G03.143.355.040;G04.392.040;G11.561.050;D08.811.277.040.013.500.063;D08.811.277.040.025.024.063;D08.811.277.040.025.193.249;D12.776.157.025.750.063;D12.776.220.600.200;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A08.850.840;A11.284.430.214.190.875.190.880.830
30612906,Aging;Cytokinesis,G07.345.124;G04.144.220.250
30612739,"B-Lymphocytes;Immunoglobulin A;Encephalomyelitis, Autoimmune, Experimental;Microbiota;Multiple Sclerosis;Plasma Cells",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D12.776.124.486.485.114.619.026;D12.776.124.790.651.114.619.026;D12.776.377.715.548.114.619.026;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725
30612667,Asthma,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
30612044,Acetylcholine;Parkinson Disease;Smell,D02.092.211.111;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F02.830.816.643;G11.561.790.643
30611340,,
30611021,,
30610702,Autophagosomes;Autophagy;Axons;Dendrites,A11.284.430.214.190.875.190.700.500;G04.146.399;G04.417.350.091;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.675.256;A11.284.180.225;A11.671.240
30610015,,
30609103,Research Design,E05.581.500;H01.770.644.728
30608896,,
30608524,Civil Rights;Compensation and Redress;Humans;National Health Programs;United States;Vaccination;Vaccines,I01.880.604.473.352;N03.706.437.352;I01.880.604.583.050;N03.219.075;N03.706.535.125;B01.050.150.900.649.313.988.400.112.400.400;N03.349.550;Z01.107.567.875;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;D20.215.894
30608521,Heart Rate;Hypertension,E01.370.600.875.500;G09.330.380.500;C14.907.489
30608328,"Appendicitis;Cost-Benefit Analysis;Diagnosis, Differential;Humans;Magnetic Resonance Imaging;Sensitivity and Specificity;Tomography, X-Ray Computed;Ultrasonography",C01.539.463.099;C06.405.205.099;C06.405.469.110.207;N03.219.151.125;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850
30608303,,
30608270,,
30607663,Nijmegen Breakage Syndrome;Ataxia Telangiectasia,C18.452.284.600;C10.228.140.252.190.530.060;C10.562.100;C10.597.350.090.500.530.060;C14.907.823.213;C16.320.080;C18.452.284.060;C20.673.290
30607454,Baseball;Child;Shoulder,I03.450.642.845.110;M01.060.406;A01.378.800.750
30607435,"Child;Liver;Elasticity Imaging Techniques;Magnetic Resonance Imaging;Hypertension, Portal",M01.060.406;A03.620;E01.370.350.850.270;E01.370.350.825.500;C06.552.494
30607024,,
30606829,,
30606806,,
30606795,Drosophila,B01.050.500.131.617.720.500.500.750.310.250
30606774,,
30605766,,
30605731,Stem Cell Transplantation,E02.095.147.500.500;E04.936.225.687
30605701,,
30605226,T-Lymphocytes;Immunosuppression,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02.095.465.425.450;E05.478.610
30605130,,
30604764,"Adolescent;Adult;Anti-Inflammatory Agents, Non-Steroidal;Child;Colitis, Ulcerative;Feces;Gene Expression Profiling;Genes, Mitochondrial;Glucocorticoids;Humans;Integrins;Intestinal Mucosa;Mesalamine;Microbiota;Mitochondria;Mitochondrial Diseases;Precision Medicine;Prospective Studies;Rectum;Remission Induction;Sequence Analysis, RNA;Severity of Illness Index;Transcriptome;Treatment Outcome;Tumor Necrosis Factor-alpha",M01.060.057;M01.060.116;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;M01.060.406;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;A12.459;E05.393.332;G05.360.340.024.340.365;G05.420.275.500;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.408;A03.556.124.369;A10.615.550.444;D02.241.223.100.050.300.500;D02.241.223.100.300.595.100.540;D02.241.511.390.595.100.540;D02.455.426.559.389.127.020.452.750;D02.455.426.559.389.127.281.595.100.540;D02.455.426.559.389.657.410.595.100.540;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.284.430.214.190.875.564;A11.284.835.626;C18.452.660;E02.574;H02.403.200.700;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A03.556.124.526.767;A03.556.249.249.767;E02.860;E05.393.760.710;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G02.111.873.750;G05.297.700.750;G05.360.920;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
30604125,,
30604117,,
30602936,Alzheimer Disease;Axons;Neurons;tau Proteins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.675;A11.671;D12.776.220.600.450.510;D12.776.631.560.510
30602758,,
30602465,,
30602436,Animals;DNA Methylation;DNA-Binding Proteins;Epigenomics;Genomic Imprinting;Humans;Mice;Zinc Fingers,B01.050;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.308.203.500;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;G02.111.570.820.709.275.500.985
30602292,Orthodontics;Orthognathic Surgery,E06.658;H02.163.876.439;E06.892.500;H02.163.876.886.500;H02.403.810.481
30602070,Growth Plate,A02.835.232.251.352
30602062,Fibrosis,C23.550.355
30601983,,
30601875,,
30601421,,
30601233,,
30601216,,
30601148,,
30601062,,
30600386,Fibrosis;Liver;Magnetic Resonance Imaging,C23.550.355;A03.620;E01.370.350.825.500
30599297,Coxa Vara;Fibronectins;Mutation,C05.116.214.500.500;C23.300.970.249.500;D12.776.377.715.390;D12.776.395.550.350;D12.776.543.550.350;D12.776.860.300.450;G05.365.590
30599264,Adult;Autism Spectrum Disorder;Magnetoencephalography,M01.060.116;F03.625.164.113;E01.370.376.500;E01.370.405.440;E05.540.500
30599149,,
30599148,,
30599104,,
30598226,,
30598179,,
30598174,,
30597751,,
30597724,Carcinogenesis;Squamous Cell Carcinoma of Head and Neck,C04.697.098;C23.550.727.098;C04.557.470.200.400.565;C04.588.443.177
30597621,NF-kappa B,D12.776.260.600;D12.776.660.600;D12.776.930.600
30597605,Parkinson Disease;Epidemiology;Heptachlor Epoxide,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;H02.403.720.500;D02.455.526.439.516.350
30597184,,
30596901,,
30596887,,
30596171,"Kidney Failure, Chronic;Renal Insufficiency, Chronic;Health Behavior;Self-Management",C12.777.419.780.750.500;C13.351.968.419.780.750.500;C12.777.419.780.750;C13.351.968.419.780.750;F01.145.488;N02.421.784.760
30595457,,
30595424,Emergency Medicine;National Institutes of Health (U.S.),H02.403.250;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496
30594168,"Global Health;Global Health;Education, Medical;Ethics, Medical;Medical Missions",H02.403.371;N01.400.337;H02.403.371;N01.400.337;I02.358.399;K01.752.566.479.171.132.750;N05.350.340.162.500;I01.615.500.750
30593975,Cognitive Behavioral Therapy;Depression,F04.754.137.350;F01.145.126.350
30593623,,
30592986,"Immunotherapy, Adoptive",E02.095.465.425.400.330.050.400;E05.478.550.520.050.400
30592491,,
30591030,"Area Under Curve;Databases, Genetic;Deep Learning;Genetic Predisposition to Disease;Genome, Human;Humans;Mental Disorders;Neural Networks (Computer);Polymorphism, Single Nucleotide;Software;Machine Learning;Mental Disorders",E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;L01.313.500.750.300.188.400.325;L01.470.750.750.325;G17.035.250.500.250;G17.485.500;L01.224.050.375.530.250;L01.224.050.375.605.500;C23.550.291.687.500;G05.380.355;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;F03;G17.485;L01.224.050.375.605;G05.365.795.598;L01.224.900;G17.035.250.500;L01.224.050.375.530;F03
30591012,Computational Biology;Electronic Health Records;Humans;Internationality;MCF-7 Cells;Medicine;Pharmacogenetics;Translational Medical Research,H01.158.273.180;L01.313.124;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;I01.615;A11.251.210.190.630;H02.403;H01.158.273.343.750;H01.158.703.052;H02.628.479;H01.770.644.145.675
30590688,,
30590615,,
30589748,,
30589438,,
30588822,,
30588760,Cardiomyopathies,C14.280.238
30588714,"Memory, Episodic;Cognitive Dysfunction;Perirhinal Cortex",F02.463.425.540.254;F03.615.250.700;A08.186.211.200.885.287.500.863.574
30588639,General Surgery;Endoscopy;Sleep Apnea Syndromes,H02.403.810.300;E01.370.388.250;E04.502.250;C08.618.085.852;C10.886.425.800.750
30587996,Antidepressive Agents;Antipsychotic Agents;Depression;Double-Blind Method;Random Allocation,D27.505.954.427.700.122;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;F01.145.126.350;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700
30587607,Connective Tissue Growth Factor,D12.644.276.200.100;D12.776.467.200.100;D12.776.860.300.200.100;D23.529.237.100
30587321,,
30587303,Cerebral Palsy;Intensive Care Units;Postoperative Care;Spinal Fusion,C10.228.140.140.254;N02.278.388.493;E02.760.731.700;E04.604.500;N02.421.585.722.700;E04.555.100.700
30587255,,
30586708,Endothelial Cells;Lung,A11.436.275;A04.411
30586699,"Coronary Artery Disease;Coronary Circulation;Fractional Flow Reserve, Myocardial",C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;G09.330.100.324;G09.330.100.324.500
30586517,"Analgesics, Opioid;Cancer Survivors;Graft vs Host Disease;Humans;Medical Oncology;Opioid-Related Disorders",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;M01.860.350;C20.452;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C25.775.675;F03.900.675
30586411,"Alleles;Breast Neoplasms;Databases, Genetic;Gene Frequency;Genes, BRCA1;Genes, BRCA2;Genetic Predisposition to Disease;Genetic Variation;Humans;Information Dissemination;Mutation;Ovarian Neoplasms;Penetrance;Phenotype;Risk Factors",G05.360.340.024.340.030;C04.588.180;C17.800.090.500;L01.313.500.750.300.188.400.325;L01.470.750.750.325;G05.330;G05.360.340.024.340.375.249.100;G05.360.340.024.340.415.400.100;G05.360.340.024.340.375.249.105;G05.360.340.024.340.415.400.105;C23.550.291.687.500;G05.380.355;G05.365;B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;G05.365.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G05.420.655;G05.695.650;G05.695;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30586066,,
30586037,,
30585876,,
30585685,Drug Therapy;Critical Care;Mortality;Outcome Assessment (Health Care);Continental Population Groups,E02.319;E02.760.190;N02.421.585.190;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;M01.686.508
30585574,,
30584639,,
30584165,alpha-Synuclein;Parkinson Disease;Biomarkers,D12.776.631.860.500;D12.776.637.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D23.101
30584020,Antibiotic Prophylaxis,E02.319.162.150;E02.319.703.150
30583957,,
30583930,,
30583064,Brain,A08.186.211
30582995,,
30582496,,
30582430,,
30582277,DiGeorge Syndrome;DiGeorge Syndrome;Pediatrics;Urology,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;H02.403.670;H02.403.810.860
30582250,Epilepsy,C10.228.140.490
30581120,,
30580808,Genetic Association Studies;Intellectual Disability;Neurodevelopmental Disorders;Language Development Disorders;Transcriptome,E05.393.385;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F03.625;C10.597.606.150.500.550;C23.888.592.604.150.500.550;G02.111.873.750;G05.297.700.750;G05.360.920
30580681,,
30580604,Alzheimer Disease;Neurons;tau Proteins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.675;A11.671;D12.776.220.600.450.510;D12.776.631.560.510
30580561,Aorta;Fibrin;Mice;Thrombosis,A07.015.114.056;D12.776.124.270;B01.050.150.900.649.313.992.635.505.500;C14.907.355.830
30580237,"Cognition;Depression;Fluorodeoxyglucose F18;Learning;Depressive Disorder, Major;Positron-Emission Tomography;Retention (Psychology)",F02.463.188;F01.145.126.350;D09.254.229.500;F02.463.425;F02.784.629.529;F03.600.300.375;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;F02.463.425.540.772
30580198,Anxiety Disorders;Bipolar Disorder;Comparative Effectiveness Research;Mood Disorders,F03.080;F03.084.500;H01.770.644.145.360.500;N05.425.157;F03.600
30580062,,
30579977,,
30579694,"Echocardiography;Echocardiography, Transesophageal",E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
30579583,Failure to Thrive,C23.888.338
30579471,,
30578874,Eosinophilic Esophagitis;Transforming Growth Factor beta;Tumor Necrosis Factor-alpha;Coculture Techniques;Fibrosis;Protein-Lysine 6-Oxidase,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;E05.481.500.374;C23.550.355;D08.811.682.664.500.848
30578797,Drug Design,E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500
30578590,Hepacivirus;HIV;Kidney Transplantation,B04.450.380;B04.820.250.475;B04.820.650.589.650.350;E02.870.500;E04.936.450.485;E04.950.774.400
30578420,"Ethics, Medical",K01.752.566.479.171.132.750;N05.350.340.162.500
30578418,,
30578417,,
30578373,,
30578370,,
30578302,Blood Coagulation;Blood Coagulation Factors;Factor V;Hemostasis;Proteolysis;Thromboplastin;Serine Proteases;Thrombin,G09.188.390.150;D12.776.124.125;D23.119;D12.776.124.125.300;D23.119.300;G09.188.390;G02.111.720;G03.812;D12.776.124.125.900;D23.119.965;D08.811.277.656.959;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
30578222,Cardiovascular Diseases;Diabetes Mellitus;Hypertension;Language;Metaphor;Social Media,C14;C18.452.394.750;C19.246;C14.907.489;F01.145.209.399;L01.559;K01.400.899.500;K01.752.798.500;L01.178.751;L01.224.230.110.500.750
30578114,,
30578049,Epidemiology;Health Services Research;Migraine Disorders;Neurology,H02.403.720.500;H01.770.644.145.360;N03.349.380;N05.425;C10.228.140.546.399.750;H02.403.600
30577935,,
30577886,,
30577731,,
30576834,Leukemia,C04.557.337
30576525,,
30576432,,
30576410,,
30576389,,
30576374,,
30575856,,
30575721,"Animals;Cell Line, Tumor;Humans;Hypoxia-Inducible Factor-Proline Dioxygenases;Melanocytes;Melanoma;Mice, Transgenic;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins c-akt;TOR Serine-Threonine Kinases",B01.050;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.690.416.617.500;D08.811.682.690.708.694.500;A11.409.750;A11.436.613;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168;D08.811.913.696.620.682.700.931;D12.776.476.925
30575699,,
30575468,"Centers for Medicare and Medicaid Services (U.S.);Clinical Coding;Government Regulation;Humans;Medicare;Physician-Patient Relations;Reimbursement Mechanisms;Reimbursement, Incentive;United States;Value-Based Health Insurance",I01.409.418.750.600.310;N03.540.348.500.500.600.550;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;I01.880.604.394;N03.706.358;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;F01.829.401.650.675;N05.300.660.625;N03.219.521.710.305;N03.219.521.710.305.380;Z01.107.567.875;N03.219.521.576.343.972;N04.761.744.750
30575327,Autistic Disorder;Autism Spectrum Disorder;Epidemiology;Gestational Weight Gain;Obesity,F03.625.164.113.500;F03.625.164.113;H02.403.720.500;C23.888.144.243.926.500;G07.345.249.314.120.200.926.500;G08.686.330;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30575168,"Arrhythmogenic Right Ventricular Dysplasia;Catheter Ablation;Magnetic Resonance Imaging;Tachycardia, Ventricular",C14.240.400.145;C14.280.238.028;C14.280.400.145;C16.131.240.400.145;E02.808.750.500;E04.014.760.500;E01.370.350.825.500;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30573905,,
30573797,Marfan Syndrome;Natural History,C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;H01.158.273.602;H01.770.552;K01.400.703
30573768,,
30573751,,
30573736,,
30573658,"Epidermal Growth Factor;Molecular Weight;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Glomerular Filtration Rate;Humans;Metabolomics;Proteinuria",D06.472.317.350;D12.644.276.382.500;D12.776.467.382.500;D23.529.382.500;G02.494;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
30573213,,
30572799,Cytokines;Heat-Shock Proteins;Interleukin-8;Tumor Necrosis Factor-alpha,D12.644.276.374;D12.776.467.374;D23.529.374;D12.776.580.216;D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
30572203,"Chromatography, High Pressure Liquid;Humans;Limit of Detection;Linear Models;Oxides;Reproducibility of Results;Tandem Mass Spectrometry;Voriconazole;Voriconazole",E05.196.181.400.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.872.374;N05.715.360.750.725.500;N06.850.520.830.872.500;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;D01.248.497.158.685;D01.650.550;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.196.566.880;D03.383.129.799.950;D03.383.129.799.950
30572071,,
30571999,,
30571596,Adipokines;Child;Metabolic Syndrome;Metabolism;Obesity;Osteonectin,D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024;M01.060.406;C18.452.394.968.500.570;C18.452.625;G03;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D12.776.157.125.715;D12.776.395.600
30571459,Cardiovascular Diseases;Coronary Artery Disease;Inflammation;Lipoproteins;Oxidative Stress;Psoriasis,C14;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C23.550.470;D10.532;D12.776.521;G03.673;G07.775.750;C17.800.859.675
30571390,Wolff-Parkinson-White Syndrome;Cell Transplantation;Hypertension;Transplants,C14.280.067.780.977;C14.280.123.750.977;C16.131.240.400.980;E02.095.147.500;E04.936.225;C14.907.489;A01.941
30571367,,
30571353,,
30571344,Atherosclerosis;Biomarkers;Electronic Health Records;Proteomics,C14.907.137.126.307;D23.101;E05.318.308.940.968.625.500;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
30571300,,
30571185,Cardiac Catheterization;Coronary Angiography;Coronary Artery Disease;Human Genetics;Myocardial Infarction;Risk,E01.370.370.380.140;E02.148.442;E05.157.250;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;H01.158.273.343.385;C14.280.647.500;C14.907.585.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
30571171,Aspirin;Blood Pressure;Circadian Clocks;Mice,D02.455.426.559.389.657.410.595.176;E01.370.600.875.249;G09.330.380.076;G07.180.562.094.500;B01.050.150.900.649.313.992.635.505.500
30570419,Latent Class Analysis,E05.318.740.250.338;G17.035.625;L01.224.050.687;N05.715.360.750.200.375;N06.850.520.830.250.338
30569788,Physical Fitness;Conditioning (Psychology),G11.427.685;I03.450.642.845.054.800;N01.400.545;F02.463.425.179
30569639,,
30569407,Comorbidity;Executive Function;Inhibition (Psychology);Neurodevelopmental Disorders,N05.715.350.225;N06.850.490.687;F02.463.217;F01.145.544;F02.463.425.475;F02.739.794.405;F03.625
30569313,Haptoglobins;Thrombotic Microangiopathies,D12.776.124.050.300;D12.776.124.790.106.394;D12.776.377.715.085.394;D12.776.395.560.373;C15.378.140.855.925
30568308,Leukoencephalopathies;White Matter,C10.228.140.695;A08.186.211.204;A08.186.854.880
30568288,,
30568044,Cardiovascular Diseases;Fertility;Therapeutics;Hypoxia,C14;G08.686.210;E02;C23.888.852.079
30567979,"Herpesvirus 4, Human;Herpesvirus 4, Human;Herpesvirus 8, Human;Lymphocryptovirus;Rhadinovirus",B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;B04.280.210.400.500;B04.280.382.400.500;B04.613.204.500.500;B04.280.210.400.700;B04.280.382.400.700;B04.613.204.500.700
30567713,,
30567579,Asbestos;Case-Control Studies;Cohort Studies;Environmental Exposure;Humans;Mesothelioma;Risk Factors;Asbestos;Mesothelioma;Meta-Analysis;Systematic Review,D01.578.725.050;D01.837.725.700.760.070;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.470.035.510;C04.557.470.660.510;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D01.578.725.050;D01.837.725.700.760.070;C04.557.470.035.510;C04.557.470.660.510;V03.600;V03.850
30567460,"Ethics, Research;Coercion",K01.752.566.479.173;N05.350.670;I01.880.604.316;I01.880.630.200
30566963,,
30566934,Anxiety;Disorders of Sex Development,F01.470.132;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119
30566616,,
30566195,,
30565988,"Myocytes, Cardiac;Cardiomyopathies;Genetics;Gene Editing;Stem Cells",A07.541.704.570;A10.690.552.750.570;A11.620.500;C14.280.238;H01.158.273.343;E05.393.420.270;A11.872
30565761,Epigenomics,H01.158.273.180.350.074;H01.158.273.343.350.042
30565669,DNA Methylation;Rhabdomyosarcoma;Heterografts,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C04.557.450.590.550.660;C04.557.450.795.550.660;A01.941.875
30565286,,
30565249,DiGeorge Syndrome;Agammaglobulinemia;DiGeorge Syndrome,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C15.378.147.142;C15.604.515.032;C20.673.088;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
30564981,,
30564618,,
30564495,,
30564286,,
30563979,,
30563935,,
30563896,Cryptococcus neoformans,B01.300.381.258.366;B01.300.930.316.366
30563893,,
30563836,Adipocytes;Lipid Peroxidation;Obesity;Oxidative Stress,A11.329.114;G02.111.515;G03.295.531.587;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G03.673;G07.775.750
30563406,Cell Survival,G04.346
30563163,Conotoxins;Salivary Glands;Transcriptome,D20.888.590.162;D23.946.580.590.162;D23.946.833.590.162;A03.556.500.760;A10.336.779;A14.549.760;G02.111.873.750;G05.297.700.750;G05.360.920
30562310,,
30562104,"Cardiomyopathies;Catheter Ablation;Mortality;Risk Assessment;Tachycardia, Ventricular",C14.280.238;E02.808.750.500;E04.014.760.500;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30562050,Survival;Transplants,I03.784;A01.941
30561888,HIV;Adolescent,B04.820.650.589.650.350;M01.060.057
30561847,,
30561770,,
30561766,,
30561757,Optical Imaging;General Surgery;Thymoma,E01.370.350.589;E05.642;H02.403.810.300;C04.557.435.850;C04.588.894.949.500;C15.604.861.800
30561251,"Heart Arrest;Pediatrics;Quality Improvement;Death, Sudden, Cardiac",C14.280.383;H02.403.670;J01.293.754;N04.761.744;C14.280.383.220;C23.550.260.322.250
30561064,,
30560936,,
30560782,"Adult;Electroencephalography;Humans;Magnetic Resonance Imaging;Memory Consolidation;Odorants;Olfactory Perception;Prefrontal Cortex;Sleep;Young Adult;Electroencephalography;Magnetic Resonance Imaging;Humans;Memory Consolidation;Neurosciences;Sleep, Slow-Wave;Prefrontal Cortex",M01.060.116;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F02.463.425.540.305.500;G16.500.275.640;N06.230.480;F02.463.593.485;A08.186.211.200.885.287.500.270.700;F02.830.855;G11.561.803;M01.060.116.815;E01.370.376.300;E01.370.405.245;E01.370.350.825.500;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425.540.305.500;H01.158.610;F02.830.855.796.835;G11.561.803.754.835;A08.186.211.200.885.287.500.270.700
30560564,Animals;Brain;Contrast Media;Membranes;Microbubbles;Oxygenators,B01.050;A08.186.211;D27.505.259.500;D27.720.259;A10.615;E07.553;E07.652
30560547,"Brain;Hypoxia-Ischemia, Brain;Infant;Infant, Newborn",A08.186.211;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703;M01.060.703.520
30560299,Cystitis;Hematuria;Therapeutics;Urinary Bladder,C12.777.829.495;C13.351.968.829.495;C12.777.934.442;C13.351.968.934.442;C23.550.414.849;E02;A05.810.890
30559740,Neoplasms;Immunotherapy,C04;E02.095.465.425
30559481,,
30559420,,
30559364,,
30559338,"Adaptor Proteins, Signal Transducing;Apoptosis Regulatory Proteins;Cell Line, Tumor;HEK293 Cells;HSP70 Heat-Shock Proteins;HeLa Cells;Humans;Muscle Contraction;Muscle, Skeletal;Muscular Diseases;Myocardium;Protein Aggregation, Pathological;Protein Binding",D12.644.360.024;D12.776.157.057;D12.776.476.024;D12.644.360.075;D12.776.476.075;A11.251.210.190;A11.251.860.180;A11.251.210.172.750;A11.436.334;D12.776.580.216.375;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;G11.427.494;A02.633.567;A10.690.552.500;C05.651;C10.668.491;A02.633.580;A07.541.704;A10.690.552.750;C23.550.770;G02.111.675;G02.111.679;G03.808
30559220,Vibrio cholerae;Citric Acid;Fermentation,B03.440.450.900.859.225;B03.660.250.830.830.100;D02.241.081.901.434.249;G02.111.158.249;G03.191.249
30559105,"Darbepoetin alfa;Epoetin Alfa;Humans;Prolyl Hydroxylases;Prolyl-Hydroxylase Inhibitors;Pyrazoles;Renal Insufficiency, Chronic;Triazoles;Anemia;Renal Insufficiency, Chronic;Erythropoietin;Hemoglobins;Humans;Hypoxia;Renal Dialysis",D12.776.395.240.150.500;D12.644.276.374.410.240.150.500;D12.776.395.240.150.750;D12.776.467.374.410.240.150.500;D23.529.374.410.240.150.750;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.690.416.617;D08.811.682.690.708.694;D27.505.519.389.740;D03.383.129.539;C12.777.419.780.750;C13.351.968.419.780.750;D03.383.129.799;C15.378.071;C12.777.419.780.750;C13.351.968.419.780.750;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;E02.870.300;E02.912.800
30559071,Frontotemporal Dementia;Neuronal Ceroid-Lipofuscinoses;Progranulins,C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;C10.574.500.550;C16.320.400.600;C16.320.565.398.641.509;C18.452.584.687.509;C18.452.648.398.641.509;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917
30559033,Ergonomics;Diagnostic Imaging;Perception;Radiology,F02.784.412;J01.293.556;E01.370.350;F02.463.593;H02.403.740
30559025,"Hernias, Diaphragmatic, Congenital;Hypertension, Pulmonary",C16.131.433;C23.300.707.500.116;C08.381.423
30559002,"Hypoxia-Ischemia, Brain;Hypothermia, Induced",C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;E02.258.750
30558828,Liver Failure;Whole Genome Sequencing,C06.552.308.500;E05.393.760.700.825
30558721,,
30558653,Algorithms;Pilot Projects,G17.035;L01.224.050;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720
30558171,Exercise;Qualitative Research,G11.427.410.698.277;I03.350;H01.770.644.241.850
30557941,,
30557683,Attitude of Health Personnel;Critical Care;Electronic Health Records;Forecasting;Natural Language Processing,F01.100.050;N05.300.100;E02.760.190;N02.421.585.190;E05.318.308.940.968.625.500;I01.320;L01.224.050.375.580
30557583,,
30557537,,
30557217,,
30557199,,
30556932,Glioblastoma,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335
30556827,,
30556824,,
30556452,Cognitive Dysfunction;Multiple Sclerosis,F03.615.250.700;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
30556428,"Depression, Postpartum;Parenting;Technology",C13.703.844.253;F03.600.300.350;F01.829.263.370.310;J01.897
30556153,Hodgkin Disease,C04.557.386.355;C15.604.515.569.355;C20.683.515.761.355
30555730,Domestic Violence;Intimate Partner Violence,I01.198.240.856.350;I01.880.735.900.350;I01.198.240.856.575;I01.880.735.900.688
30554946,,
30554706,"Child;Child, Preschool;Cleft Palate;DiGeorge Syndrome;Humans;Infant;Postoperative Complications;Practice Patterns, Physicians';Reconstructive Surgical Procedures;Self Report;Surgeons;Surveys and Questionnaires;Velopharyngeal Insufficiency;Surveys and Questionnaires",M01.060.406;M01.060.406.448;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C23.550.767;N04.590.374.577;N05.300.625;E04.680;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;M01.526.485.810.910;N02.360.810.910;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C07.465.525.955;C07.550.966;C07.650.525.955;C09.775.955;C16.131.850.525.955;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
30554619,"Congresses as Topic;Dermatology;Education, Medical, Continuing;Humans;Interdisciplinary Communication;International Cooperation;Medicine;Societies, Medical;Travel",N03.540.199;H02.403.225;I02.358.212.350;I02.358.399.250;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;I01.615.500;H02.403;N03.540.828.589;I03.883
30554539,"Enterocolitis, Necrotizing;Neonatology;Observational Study;Infant, Premature",C06.405.205.596.700;C06.405.469.363.700;H02.403.670.400;V03.175.500;M01.060.703.520.520
30553808,,
30553654,,
30553053,,
30552906,Magnetic Resonance Imaging,E01.370.350.825.500
30552700,Melanoma;Mutation;Vemurafenib,C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;G05.365.590;D02.065.884.919;D02.886.590.700.919;D03.633.100.473.936
30552567,,
30552390,,
30552317,,
30552228,Autophagy;Mechanistic Target of Rapamycin Complex 1;Phosphorylation,G04.146.399;G04.417.350.091;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;G02.111.665;G02.607.780;G03.796
30552106,,
30551986,Complement C3b;Herpes Genitalis;Simplexvirus;Immune Evasion,D12.776.124.486.274.250.260;C02.256.466.382.290;C02.800.801.350;C12.294.329;C13.351.500.342;B04.280.382.100.750;G06.462.400;G12.413;G16.527.200.700
30551156,,
30551128,,
30550859,"Coma;Persistent Vegetative State;Swine;Brain Injuries, Traumatic;Persistent Vegetative State",C10.597.606.358.800.200;C23.888.592.604.359.800.200;C10.228.140.140.627;C10.597.606.358.800.400;C23.888.592.604.359.800.400;B01.050.150.900.649.313.500.880;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;C10.228.140.140.627;C10.597.606.358.800.400;C23.888.592.604.359.800.400
30549495,,
30549451,"High-Frequency Ventilation;Infant, Premature",E02.041.625.508;E02.880.820.508;M01.060.703.520.520
30549400,,
30549363,Fetus;Heart,A16.378;A07.541
30549331,,
30549289,,
30548628,,
30548577,"Administration, Oral;Adolescent;Humans;Keratoderma, Palmoplantar;Protein Kinase Inhibitors;Pyridones;Pyrimidinones;Keratoderma, Palmoplantar",E02.319.267.100;M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;C16.320.850.475;C17.800.428.435;C17.800.827.475;D27.505.519.389.755;D03.383.725.791;D03.383.742.698;C16.320.850.475;C17.800.428.435;C17.800.827.475
30548576,"Antineoplastic Agents;Dexamethasone;Etoposide;Humans;Infant;Lymphohistiocytosis, Hemophagocytic;Nail Diseases;Pigmentation Disorders",D27.505.954.248;D04.210.500.745.432.769.344;D04.210.500.908.238;D02.455.426.559.847.638.960.675.250;D04.615.638.960.675.250;D09.408.348.275;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C15.604.250.410.575;C17.800.529;C17.800.621;C23.550.755
30547229,Humans;Islets of Langerhans;Islets of Langerhans Transplantation;Humans;Insulin;Pancreas;Research;Health Resources,B01.050.150.900.649.313.988.400.112.400.400;A03.734.414;A06.300.414;E02.095.147.500.250;E04.270.550;E04.936.225.375;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A03.734;H01.770.644;N03.349.340;N05.300.420
30547227,Alzheimer Disease;Cerebrospinal Fluid;Immunohistochemistry;Mass Spectrometry,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A12.207.270.210;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E05.196.566
30547050,Genetic Therapy;Liver,E02.095.301;E05.393.420.301;A03.620
30545976,,
30545851,"Brain;Cells, Cultured;Chromatin;Chromatin Assembly and Disassembly;Chromosomes, Human;Connectome;Epigenesis, Genetic;Gene Expression Regulation, Developmental;Genetic Predisposition to Disease;Genome, Human;Genome-Wide Association Study;Humans;Neural Stem Cells;Neurogenesis;Neuroglia;Neurons;Nucleic Acid Conformation;Protein Interaction Maps;Proteomics;Risk;Schizophrenia;Transcription, Genetic;Transcriptome",A08.186.211;A11.251;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;A11.284.187.520.300;G05.360.162.520.300;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;G05.308.203;G05.308.310;C23.550.291.687.500;G05.380.355;G05.360.340.350;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;A11.872.653;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.637;A11.650;A08.675;A11.671;G02.111.570.820.486;G05.360.580;G03.493.750;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;F03.700.750;G02.111.873;G05.297.700;G02.111.873.750;G05.297.700.750;G05.360.920
30545834,,
30545708,Albuminuria;Atherosclerosis;Cytokines;Stroke,C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;C14.907.137.126.307;D12.644.276.374;D12.776.467.374;D23.529.374;C10.228.140.300.775;C14.907.253.855
30545707,Patient-Centered Care,N04.590.233.727.407
30545282,Dementia;Caregivers;Disease Management;Patient-Centered Care;Psychosocial Support Systems,C10.228.140.380;F03.615.400;M01.085;M01.526.485.200;N02.360.200;N04.590.607;N04.590.233.727.407;I01.880.853.500.600.500
30543845,,
30543838,Lung Neoplasms;Thrombosis,C04.588.894.797.520;C08.381.540;C08.785.520;C14.907.355.830
30543595,"Child;Humans;Immunotherapy, Adoptive;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell",M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D12.776.543.750.705.816.824
30543564,,
30543367,"Clinical Coding;Delivery of Health Care, Integrated;Fee-for-Service Plans;Humans;Medicare;Reimbursement Mechanisms;United States",N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;N04.590.374.142;N05.300.262;N03.219.442.195;N03.219.521.710.305.090;N04.452.758.745.225;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N03.219.521.710.305;Z01.107.567.875
30542367,Fertility;Primary Ovarian Insufficiency,G08.686.210;C13.351.500.056.630.750;C19.391.630.750
30542108,,
30541827,,
30541784,,
30541425,Autistic Disorder;Face;Social Perception,F03.625.164.113.500;A01.456.505;F02.463.593.752
30524407,Clinical Trial;Radiography;Therapeutics,V03.175.250;E01.370.350.700;E02
30523622,"Herpesvirus 4, Human;HIV;Lymphoma;Carcinogenesis",B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B04.820.650.589.650.350;C04.557.386;C15.604.515.569;C20.683.515.761;C04.697.098;C23.550.727.098
30523479,Autism Spectrum Disorder;Gestures;Motor Skills;Nonverbal Communication,F03.625.164.113;F01.145.209.530.538.445;F02.808.260;F01.145.209.530;L01.143.649
30523202,,
30523048,,
30523024,,
30522890,"Drug Development;Drug Discovery;Antibodies, Monoclonal;Pharmacokinetics",E05.290;H01.158.703.007.338;H01.181.466.338;E05.295;H01.158.703.007.675;H01.181.466.675;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;G03.787;G07.690.725
30522729,"Brain Injuries;Heart Defects, Congenital;Humans;Hypoxia-Ischemia, Brain;Infant, Newborn;Infant, Newborn, Diseases;Neuroimaging;Neurophysiological Monitoring;Preoperative Period;Stroke;White Matter",C10.228.140.199;C10.900.300.087;C26.915.300.200;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703.520;C16.614;E01.370.350.578;E01.370.376.537;E05.629;E01.370.520.596;E04.614.937;N02.421.585.753.937;C10.228.140.300.775;C14.907.253.855;A08.186.211.204;A08.186.854.880
30540928,,
30540613,,
30540352,,
30538699,Area Under Curve,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200
30538201,"Active Transport, Cell Nucleus;Cell Nucleus;Crystallography, X-Ray;Dimerization;Heterogeneous-Nuclear Ribonucleoproteins;Humans;Influenza A virus;Influenza, Human;Nuclear Proteins;Polypyrimidine Tract-Binding Protein;Protein Binding;Protein Domains;RNA Splicing;RNA, Messenger;Transcription Factors;Viral Nonstructural Proteins;Orthomyxoviridae",G03.143.310.100;G03.143.700.100;A11.284.430.106;A11.284.430.214.190.875.117;E05.196.309.742.225;G02.206;G03.230;D12.776.157.725.813.750;D12.776.664.962.813.750;B01.050.150.900.649.313.988.400.112.400.400;B04.820.545.405.400;C02.782.620.365;C08.730.310;D12.776.660;D12.776.157.725.829.250;D12.776.664.962.829.250;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.760.700;G03.839.700;G05.308.700.700;D13.444.735.544;D12.776.930;D12.776.964.900;B04.820.545
30538176,,
30538147,,
30538026,,
30537526,,
30537364,"Adult;African Americans;Aged;Aged, 80 and over;Breast Neoplasms;Ethnic Groups;European Continental Ancestry Group;Health Status Disparities;Healthcare Disparities;Hispanic Americans;Humans;Medicaid;Medicare;Middle Aged;Social Class;Socioeconomic Factors;Survival Rate;United States;Medicare;Breast Neoplasms;Social Class",M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;M01.060.116.100.080;C04.588.180;C17.800.090.500;M01.686.754;N01.224.317;M01.686.508.400;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;N04.590.374.380;N05.300.493;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.630;I01.880.853.996.755;N01.824.782;I01.880.853.996;N01.824;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;Z01.107.567.875;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C04.588.180;C17.800.090.500;I01.880.853.996.755;N01.824.782
30536995,,
30536762,Rett Syndrome;Brain Diseases;Genetics;Neurodevelopmental Disorders,C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937;C10.228.140;H01.158.273.343;F03.625
30535315,,
30534969,,
30534949,,
30534643,,
30534637,,
30533817,,
30532138,"Carrier Proteins;Cell Line;Herpesviridae Infections;Herpesvirus 8, Human;Humans;STAT6 Transcription Factor;Ubiquitination;Virus Activation;Virus Latency",D12.776.157;A11.251.210;C02.256.466;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360.024.342.600;D12.776.157.057.186.600;D12.776.476.024.430.600;D12.776.930.840.600;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831;G06.920.925.940;G06.920.900
30532003,,
30531617,,
30531561,,
30531545,,
30531458,Adolescent;Athletes;Child;Child Abuse;Humans;Sports Medicine;Youth Sports,M01.060.057;M01.072;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;B01.050.150.900.649.313.988.400.112.400.400;H02.403.830;I03.450.642.845.987
30531327,,
30530505,,
30529772,Beds;Infant Equipment,E07.325.220;E07.490
30529384,Hypoxia;Neuropeptides,C23.888.852.079;D12.644.400;D12.776.631.650
30529133,Congenital Hypothyroidism,C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281
30528281,"Body Weight;Glucagon-Like Peptide 1;Hypothalamic Area, Lateral;Conditioning, Operant",C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D06.472.317.680.500.500;A08.186.211.180.497.300;A08.186.211.200.317.357.300;F02.463.425.179.509
30528098,Electroencephalography;Seizures,E01.370.376.300;E01.370.405.245;C10.597.742;C23.888.592.742
30527750,Analgesia;Cognitive Dysfunction;Critical Care,E03.091;F03.615.250.700;E02.760.190;N02.421.585.190
30526888,,
30526882,Inflammation;Stem Cells,C23.550.470;A11.872
30526856,DNA-Directed RNA Polymerases;Biochemistry;Chromosomes;Gene Expression;Humans;Metabolism;Mitochondria,D08.811.913.696.445.735.270;H01.158.201;H01.181.122;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;G05.297;B01.050.150.900.649.313.988.400.112.400.400;G03;A11.284.430.214.190.875.564;A11.284.835.626
30526617,Cerebral Palsy,C10.228.140.140.254
30526557,Aged;Alzheimer Disease;Atrophy;Biomarkers;Brain;Brain Ischemia;GAP-43 Protein;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Middle Aged;Prospective Studies;Stroke;Biomarkers;Cerebrospinal Fluid;GAP-43 Protein;Stroke,M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C23.300.070;D23.101;A08.186.211;C10.228.140.300.150;C14.907.253.092;D12.776.395.550.400;D12.776.543.550.400;D12.776.631.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.228.140.300.775;C14.907.253.855;D23.101;A12.207.270.210;D12.776.395.550.400;D12.776.543.550.400;D12.776.631.400;C10.228.140.300.775;C14.907.253.855
30526278,"Active Transport, Cell Nucleus",G03.143.310.100;G03.143.700.100
30526160,,
30525989,Coronary Artery Disease;Genomics;Heart Diseases;Lipids;Triglycerides,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;H01.158.273.180.350;H01.158.273.343.350;C14.280;D10;D10.351.801
30521876,,
30521819,Epilepsy;Folic Acid;Lamotrigine;Levetiracetam,C10.228.140.490;D03.633.100.733.631.400;D03.383.931.480;D02.065.064.432;D02.241.081.018.110.463;D03.383.773.812.362
30520744,,
30520692,,
30520529,,
30520033,Cerebrospinal Fluid Leak;Craniopharyngioma,C10.597.114;C10.900.300.109;C23.888.592.114;C26.915.300.225;C04.557.465.625.200;C04.557.580.625.200
30518799,,
30518797,,
30518757,"Algorithms;Computational Biology;Databases, Genetic;Genetic Variation;Genome-Wide Association Study;Humans;Organ Specificity;Polymorphism, Single Nucleotide;Quantitative Trait Loci;RNA, Untranslated",G17.035;L01.224.050;H01.158.273.180;L01.313.124;L01.313.500.750.300.188.400.325;L01.470.750.750.325;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G07.650;G05.365.795.598;G05.360.340.024.380.937;D13.444.735.790
30518699,Genetics,H01.158.273.343
30518696,,
30518456,"Sleep Apnea, Obstructive",C08.618.085.852.850;C10.886.425.800.750.850
30508681,"Diffusion Tensor Imaging;Executive Function;Sex Characteristics;Memory, Short-Term",E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;F02.463.217;G08.686.815;F02.463.425.540.407
30508600,Evidence-Based Practice,H02.249
30508597,Aneurysm;Subarachnoid Hemorrhage,C14.907.055;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
30508563,,
30508419,,
30508027,,
30507839,,
30507702,,
30507687,,
30507591,Electronic Health Records;Medical Informatics;Urodynamics,E05.318.308.940.968.625.500;L01.313.500;G08.852.898
30507587,"Meningomyelocele;Ethics, Clinical;Prenatal Diagnosis",C10.500.680.610;C16.131.666.680.610;K01.752.566.479.045.500;K01.752.566.479.171.132;N05.350.200.500;N05.350.340.162;E01.370.378.630
30507261,Wolfram Syndrome;Diabetes Insipidus;Diabetes Mellitus;Electroretinography;Optic Atrophy;Retinal Degeneration,C09.218.458.341.186.500.750;C10.292.700.225.500.980;C10.574.500.662.980;C10.597.751.418.341.186.500.750;C10.597.751.941.162.625.750;C11.270.564.980;C11.640.451.451.980;C11.966.075.375.750;C12.777.419.135.875;C13.351.968.419.135.875;C16.131.077.299.750;C16.320.290.564.980;C16.320.400.630.980;C18.452.394.750.124.960;C19.246.267.960;C19.700.159.875;C12.777.419.135;C13.351.968.419.135;C19.700.159;C18.452.394.750;C19.246;E01.370.380.225;E01.370.405.270;C10.292.700.225;C11.640.451;C11.270.612;C11.768.585
30506667,Primary Health Care;Qualitative Research,N04.590.233.727;H01.770.644.241.850
30506626,Editorial;Epidemiology;Graft Survival;Kidney Transplantation,V01.250;V02.335;H02.403.720.500;G12.875.545.340;E02.870.500;E04.936.450.485;E04.950.774.400
30506328,Biopsy;Child;Fibrosis;Fontan Procedure;Liver,E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;C23.550.355;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;A03.620
30506144,"Renal Insufficiency, Chronic;Cinacalcet;Parathyroid Hormone;Hyperparathyroidism, Secondary",C12.777.419.780.750;C13.351.968.419.780.750;D02.455.426.559.847.638.183;D04.615.638.183;D06.472.699.590;D12.644.548.587;C19.642.355.480
30506052,"Immunity, Innate",G12.450.564
30505979,"Optic Atrophy, Hereditary, Leber",C10.292.700.225.500.400;C10.574.500.662.400;C11.270.564.400;C11.640.451.451.400;C16.320.290.564.400;C16.320.400.630.400;C18.452.660.670
30505575,,
30504887,,
30504841,,
30504441,"Education, Medical;Neonatology;Qualitative Research;Resuscitation",I02.358.399;H02.403.670.400;H01.770.644.241.850;E02.365.647
30504354,"ADAMTS13 Protein;Clinical Laboratory Techniques;Humans;Purpura, Thrombotic Thrombocytopenic",D08.811.277.656.675.374.102.500.813;D09.400.430.500.500.813;D12.776.395.033.500.813;D12.776.860.300.085.813;E01.370.225;E05.200;B01.050.150.900.649.313.988.400.112.400.400;C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680
30504346,"Anemia, Aplastic;Genes, MHC Class I;Hematopoiesis;Humans;Membrane Proteins;Mutation;Myelodysplastic Syndromes;Proto-Oncogene Proteins;Repressor Proteins;Risk Factors",C15.378.071.085;C15.378.190.196;G05.360.340.024.340.610.595;G05.360.340.024.380.500.595;G12.500.500.595;G04.152.825;G09.188.343;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;G05.365.590;C15.378.190.625;D12.776.624.664.700;D12.776.260.703;D12.776.930.780;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30504327,"Antibodies, Monoclonal;Castleman Disease;Herpesviridae Infections;Herpesvirus 8, Human;Humans;Interleukin-6;Practice Guidelines as Topic;Signal Transduction",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;C15.604.515.245;C20.683.515.250;C02.256.466;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;N04.761.700.350.650;N05.700.350.650;G02.111.820;G04.835
30504191,,
30503798,,
30503783,Linkage Disequilibrium,G05.348.500
30503724,,
30503381,,
30502280,Needs Assessment,I02.594;N03.349.380.565;N05.300.537
30502007,,
30501891,,
30501502,Hearing Loss;Primary Health Care;Tinnitus,C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;N04.590.233.727;C09.218.458.670;C10.597.751.418.670;C23.888.592.763.393.670
30501500,Alzheimer Disease;Aging;Immunohistochemistry;Smell;Olfaction Disorders;Olfactory Mucosa,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G07.345.124;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;F02.830.816.643;G11.561.790.643;C10.597.751.600;C23.888.592.763.550;A04.531.520.573;A04.760.600.640;A09.531.623;A10.615.550.760.600.640
30501469,,
30517931,"Renal Insufficiency, Chronic;Pediatrics;Anemia, Sickle Cell;Anemia, Sickle Cell",C12.777.419.780.750;C13.351.968.419.780.750;H02.403.670;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
30517739,,
30517112,,
30516820,,
30516691,"Brain;Brain Diseases;Child;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging",A08.186.211;C10.228.140;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500
30516623,,
30516472,"Animals;CLOCK Proteins;Circadian Clocks;Circadian Rhythm;Drosophila Proteins;Drosophila melanogaster;Exons;Feedback, Physiological;Introns;Nuclear Proteins;Period Circadian Proteins;Protein-Serine-Threonine Kinases;RNA Splicing;RNA, Messenger;Ribonucleoproteins, Small Nuclear;Sequence Analysis, RNA;Signal Transduction;Spliceosomes;Drosophila melanogaster;Drosophila;Circadian Rhythm;Genetics;Genomics",B01.050;D08.811.913.050.134.415.500.049;D12.644.360.138.100;D12.776.260.103.562;D12.776.476.156.200;D12.776.930.125.562;G07.180.562.094.500;G07.180.562.190;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;G05.360.340.024.340.137.232;G07.410.732;G05.360.340.024.220.400;G05.360.340.024.340.137.515;D12.776.660;D12.644.360.138.575;D12.776.157.530.750.687;D12.776.476.156.625;D12.776.543.585.750.687;D08.811.913.696.620.682.700;G02.111.760.700;G03.839.700;G05.308.700.700;D13.444.735.544;D12.776.157.725.500.875;D12.776.664.962.500.875;E05.393.760.710;G02.111.820;G04.835;A11.284.430.106.279.345.850;B01.050.500.131.617.720.500.500.750.310.250.500;B01.050.500.131.617.720.500.500.750.310.250;G07.180.562.190;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350
30516240,,
30515992,,
30515865,Pediatrics;Radiation,H02.403.670;G01.750
30515787,Chromatin Assembly and Disassembly,G04.400.095;G05.213.095;G05.308.095
30515155,"Lymphocytic choriomeningitis virus;Lymphohistiocytosis, Hemophagocytic;Interleukin-33;Perforin",B04.820.057.070.100.550;C15.604.250.410.575;D12.644.276.374.465.850;D12.776.467.374.465.850;D23.529.374.465.850;D12.776.543.695.875
30514968,,
30514386,Leukemia;Lymphoma,C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761
30514154,Resource Allocation,I01.261.750
30513300,"3' Untranslated Regions;Animals;Endoplasmic Reticulum;Humans;Protein Transport;RNA, Messenger",D13.444.735.544.875.880;D13.444.735.790.878.880;G05.360.340.024.220.880.880;G05.360.340.024.340.137.910.880;B01.050;A11.284.430.214.190.875.248;B01.050.150.900.649.313.988.400.112.400.400;G03.143.700;D13.444.735.544
30513084,,
30512094,Child;Hospital Mortality;Humans;New York;Sepsis,M01.060.406;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.075.437;Z01.107.567.875.350.530;Z01.107.567.875.500.530;C01.539.757;C23.550.470.790.500
30511982,"Adolescent;Bone Transplantation;Child;Follow-Up Studies;Goldenhar Syndrome;Humans;Mandibular Reconstruction;Osteogenesis, Distraction;Postoperative Complications;Prospective Studies;Reoperation;Ribs;Treatment Outcome",M01.060.057;E02.095.147.725.052;E04.555.130;E04.936.580.052;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C05.116.099.370.231.576.410;C05.660.207.231.576.410;C16.131.621.207.231.576.410;B01.050.150.900.649.313.988.400.112.400.400;E06.645.562.500;E04.555.120.690;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E04.690;A02.835.232.570.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30511498,"Ductus Arteriosus, Patent",C14.240.400.340;C14.280.400.340;C16.131.240.400.340
30510992,Fluorouracil;Autophagy,D03.383.742.698.875.404;G04.146.399;G04.417.350.091
30510609,"Polycystic Kidney, Autosomal Recessive;Caroli Disease",C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;C06.130.120.127.500;C06.198.184.500;C16.131.077.245.250;C16.131.314.184.500;C16.320.184.250
30510516,Cardiovascular Deconditioning;Hemodynamics;Posture,G09.330.175;G09.330.380;G11.427.695
30510265,,
30510257,,
30510173,,
30510108,DNA Damage,G05.200
30510082,,
30510032,,
30510013,,
30509979,"Color;DNA;Fluorescence;Fluorescent Dyes;Humans;Image Processing, Computer-Assisted;Imaging, Three-Dimensional;Microscopy, Fluorescence;Single Molecule Imaging",G01.590.540.199;D13.444.308;G01.358.500.505.650.665.500;G01.590.540.665.500;D27.720.233.348;D27.720.470.410.505.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.400;L01.224.308.410;E01.370.350.515.458;E05.595.458;E01.370.350.515.899;E01.370.350.557.750;E05.595.899;E05.601.555.500
30500988,Activities of Daily Living;Cognitive Dysfunction;Critical Care;Home Care Services;Mental Health;Sepsis,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;F03.615.250.700;E02.760.190;N02.421.585.190;N02.421.143.524;N02.421.539.089;F02.418;N01.400.500;C01.539.757;C23.550.470.790.500
30500532,,
30500437,,
30500341,,
30500057,,
30500054,,
30499797,,
30499645,"Anesthesia;Anesthesia, General;Humans;Mediastinal Neoplasms",E03.155;E03.155.197;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.479;C08.846.187.580
30499597,Breast Neoplasms;Data Mining;Decision Trees;Electronic Health Records;Humans;Machine Learning;Middle Aged;Predictive Value of Tests;Radiotherapy Dosage;Treatment Outcome;Machine Learning,C04.588.180;C17.800.090.500;L01.313.500.750.280.199;L01.470.625;G17.162.500;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E02.815.639;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G17.035.250.500;L01.224.050.375.530
30499112,,
30498789,,
30496869,Depression;Postpartum Period;Mass Screening,F01.145.126.350;G08.686.702;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30496829,,
30496332,,
30496330,,
30495995,,
30495989,,
30489697,"Animals;Centrifugation, Density Gradient;Contrast Media;Dependovirus;Disease Models, Animal;HEK293 Cells;Humans;Mice;Polyethyleneimine;Transfection;Triiodobenzoic Acids;Virus Cultivation;Dependovirus",B01.050;E05.181.724.336;E05.196.941.336;D27.505.259.500;D27.720.259;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D02.455.326.271.665.550.600;D02.491.650;D05.750.716.507.600;D25.720.716.507.600;J01.637.051.720.716.507.600;E05.393.350.810;G05.728.860;D02.241.223.100.400.880;D02.455.426.559.389.127.375.880;E01.370.225.875.970;E05.200.875.970;B04.280.580.650.170
30489616,,
30489488,,
30489280,,
30489095,,
30488462,"Models, Theoretical;Radiography;Selenium;X-Rays",E05.599;E01.370.350.700;D01.268.185.850;D01.578.700;G01.358.500.505.970;G01.750.250.970;G01.750.750.918
30488455,"Models, Theoretical;Radiography;Selenium;X-Rays",E05.599;E01.370.350.700;D01.268.185.850;D01.578.700;G01.358.500.505.970;G01.750.250.970;G01.750.750.918
30488277,Alzheimer Disease;Amyloid;Blood;Cerebrospinal Fluid,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;A12.207.152;A15.145;A12.207.270.210
30488168,,
30488038,"HIV;Amphotericin B;Meningitis, Cryptococcal;Africa South of the Sahara",B04.820.650.589.650.350;D02.540.576.500.500;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;Z01.058.290
30487575,"Animals;Humans;Killer Cells, Natural;Mice;Myeloid Cells;Transcriptome;Vaccines, Attenuated;Yellow Fever Vaccine;Yellow fever virus",B01.050;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;B01.050.150.900.649.313.992.635.505.500;A11.627;G02.111.873.750;G05.297.700.750;G05.360.920;D20.215.894.811;D20.215.894.899.970;B04.820.250.350.990
30487248,,
30487143,,
30487137,,
30487129,,
30487072,,
30487070,Diuretics;Ambulatory Care,D27.505.696.560.500;E02.760.106;N02.421.585.106
30485824,Gene Fusion;Ovarian Neoplasms,G05.728.385;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
30485810,Epidermis,A10.272.497;A17.815.250
30485789,,
30485770,Adolescent;Child;Electronic Health Records;Humans;Medical History Taking;Physician-Patient Relations;Refugees;Sudan;Trauma and Stressor Related Disorders,M01.060.057;M01.060.406;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.510;F01.829.401.650.675;N05.300.660.625;M01.755;Z01.058.290.120.760;F03.950
30485760,Neoplasms;Metabolism;Heart Diseases,C04;G03;C14.280
30485696,"Animals;Dependovirus;Disease Models, Animal;Genetic Therapy;Genetic Vectors;Mice;Dependovirus;Genetic Therapy;Lentivirus;Retroviridae",B01.050;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.992.635.505.500;B04.280.580.650.170;E02.095.301;E05.393.420.301;B04.820.650.589;B04.613.807;B04.820.650
30485442,,
30484907,Hidradenitis Suppurativa,C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320
30484776,,
30482868,Alzheimer Disease;Microglia;Progranulins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.637.400;A11.650.400;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917
30482831,"Carrier Proteins;Escherichia coli;Escherichia coli Proteins;Gene Deletion;Gene Expression Regulation, Bacterial;Membrane Proteins;Metabolic Networks and Pathways;Phosphoprotein Phosphatases;Phosphotransferases (Nitrogenous Group Acceptor);Protein Kinases",D12.776.157;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;G05.365.590.762.320;G05.558.800.320;G05.308.300;D12.776.543;G03.493;D08.811.277.352.650.625;D08.811.913.696.640;D08.811.913.696.620.682
30482768,,
30482766,,
30482463,"Demyelinating Diseases;Multiple Sclerosis;Killer Cells, Natural;Oligodendroglia",C10.314;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;A08.637.600;A11.650.600
30482069,Neoplasms;Chromatin;Epigenomics;Histones,C04;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469
20301398,,
30481777,Precursor Cell Lymphoblastic Leukemia-Lymphoma;Drug Therapy;Hematopoietic Stem Cell Transplantation;Osteochondroma;Osteonecrosis;Radiotherapy;Retinoids,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E02.319;E02.095.147.500.500.500;E04.936.225.687.500;C04.557.450.565.575.610;C05.116.099.708.670;C05.116.852;C23.550.717.732;E02.815;D02.455.326.271.665.202.495;D02.455.426.392.368.367.379.249.700;D02.455.849.131.495;D23.767.261.700
30481595,Bacteremia;Central Venous Catheters;Hematopoietic Stem Cells;Levofloxacin;Transplantation,C01.252.100;C01.539.757.100;C23.550.470.790.500.100;E07.132.750.500;A11.148.378;A11.872.378;A15.378.316.378;D03.633.100.810.835.322.500.500;E04.936
30481572,,
30481571,,
30481479,Methicillin-Resistant Staphylococcus aureus;Microbiology,B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;H01.158.273.540
30481278,,
30481216,,
30481214,,
30480869,Editorial;Ethics;Liver Diseases;Liver Transplantation,V01.250;V02.335;K01.752.566.479;N05.350;C06.552;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
30480830,Feeding Behavior;Public Policy,F01.145.113.547;F01.145.407;G07.203.650.353;I01.655.500.608;I01.880.604.825.608;N03.623.500.608
30480702,,
30480586,,
30480556,,
30480485,,
30480368,,
30480039,,
30480025,Anterior Cruciate Ligament Injuries;Collateral Ligaments;Obesity,C26.558.554.213;A02.513.514.162;A02.835.583.512.162;A10.165.669.514.162;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30479831,,
30479064,Biomarkers;Neuroblastoma,D23.101;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
30479020,Asthma;Community-Based Participatory Research;Motivational Interviewing;Nursing;Qualitative Research,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;H01.770.644.193;N05.425.104;F02.784.176.279.500;F04.408.413.349.500;N02.421.461.363.349.500;H02.478;N04.452.758.377;H01.770.644.241.850
30478448,,
30478444,,
30478409,,
30478300,,
30478238,,
30477741,Epilepsy,C10.228.140.490
30477554,DNA Copy Number Variations;Genomics;High-Throughput Nucleotide Sequencing;Humans;Melanoma,G05.365.795.297.500;H01.158.273.180.350;H01.158.273.343.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
30477459,"Adolescent;Adult;Aged;Aged, 80 and over;Chromosomes, Human, Pair 3;DNA Copy Number Variations;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Kaplan-Meier Estimate;Melanoma;Middle Aged;Mutation;Neoplasm Metastasis;Proportional Hazards Models;Tumor Suppressor Proteins;Ubiquitin Thiolesterase;Uveal Neoplasms;Young Adult;Germ-Line Mutation",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;A11.284.187.520.300.235.250;G05.360.162.520.300.235.250;G05.365.795.297.500;C23.550.291.687.500;G05.380.355;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;G05.365.590;C04.697.650;C23.550.727.650;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;D12.776.624.776;D08.811.037.500;D08.811.277.352.897.850;D12.776.637.937;C04.588.364.978;C11.319.494;C11.941.855;M01.060.116.815;G05.365.590.350
30476985,,
30476974,,
30476966,,
30476587,Esophagus;Index,A03.556.875.500;V02.550
30476213,,
30476191,,
30476186,,
30476135,,
30476010,,
30475454,Autism Spectrum Disorder;Technology,F03.625.164.113;J01.897
30475425,,
30475283,,
30475209,Animals;Blood-Brain Barrier;Drosophila;Drosophila Proteins;Dynamins;Endocytosis;Neuroglia;Sleep;rab GTP-Binding Proteins;Drosophila melanogaster;Blood-Brain Barrier;Endocytosis;Neuroglia;Neurosciences;Sleep,B01.050;A07.035;A08.186.211.035;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;D08.811.277.040.330.200;D12.776.220.600.450.200;D12.776.543.990.400;G04.417;A08.637;A11.650;F02.830.855;G11.561.803;D08.811.277.040.330.300.400.400;D12.644.360.525.400;D12.776.157.325.515.400;D12.776.476.525.400;B01.050.500.131.617.720.500.500.750.310.250.500;A07.035;A08.186.211.035;G04.417;A08.637;A11.650;H01.158.610;F02.830.855;G11.561.803
30475207,Humans;Lung Neoplasms;Mice,B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500
30475182,,
30475033,,
30474875,Child;Drug Eruptions;Humans;Photosensitivity Disorders;Protein Kinase Inhibitors;Sunburn;Vemurafenib,M01.060.406;C17.800.174.600;C20.543.206.380;C25.100.468.380;B01.050.150.900.649.313.988.400.112.400.400;C17.800.600;D27.505.519.389.755;C17.800.600.725;C26.200.855;D02.065.884.919;D02.886.590.700.919;D03.633.100.473.936
30474429,Fertility Preservation;Reproductive Health,E02.875.800.625;E04.936.537.562;E05.820.800.625;N01.400.625
30474422,Cardiac Surgical Procedures;Cardiac Volume;Economics;Heart Diseases;Mortality;Pediatrics,E04.100.376;E04.928.220;G09.330.380.249;I01.261;N03.219;C14.280;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;H02.403.670
30473945,Patient Satisfaction;Radiation Oncologists;Radiation Oncology,F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;M01.526.485.810.699.500;M01.526.485.810.877.500;N02.360.810.699.500;N02.360.810.877.500;H02.403.429.515.500;H02.403.740.650
30473474,Kidney,A05.810.453
30473419,,
30473139,Renal Dialysis;Randomized Controlled Trial,E02.870.300;E02.912.800;V03.175.250.500.500
30473058,"Carcinoma, Non-Small-Cell Lung;Unsupervised Machine Learning",C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;G17.035.250.500.750;L01.224.050.375.530.750
30473042,Big Data;Biomedical Research;Child;Data Science;Delivery of Health Care;Electronic Health Records;Evidence-Based Medicine;Humans;Pediatrics;Physician-Patient Relations;Quality Improvement;United States;Electronic Health Records;Pediatrics,L01.313.500.750.300.092;H01.770.644.145;M01.060.406;L01.305;N04.590.374;N05.300;E05.318.308.940.968.625.500;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;F01.829.401.650.675;N05.300.660.625;J01.293.754;N04.761.744;Z01.107.567.875;E05.318.308.940.968.625.500;H02.403.670
30472661,Neonatology;Resuscitation,H02.403.670.400;E02.365.647
30472267,Complement C3;Renal Dialysis,D12.776.124.050.140;D12.776.124.486.274.250;E02.870.300;E02.912.800
30472138,,
30472017,"Anesthesia;Cardiac Surgical Procedures;Humans;Practice Guidelines as Topic;Vascular Surgical Procedures;Atrial Fibrillation;Shock, Cardiogenic;Electrophysiology;Sirolimus",E03.155;E04.100.376;E04.928.220;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;E04.100.814;C14.280.067.198;C23.550.073.198;C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550;H01.158.344.528;H01.158.782.236;D02.540.505.760
30471752,,
30471750,,
30471718,Ciliary Motility Disorders;Situs Inversus,C08.200;C09.150;C16.131.077.245.500;C16.320.184.500;C16.131.810
30471370,,
30471242,,
30471046,,
30470924,Adolescent;Contraception;Counseling;Postpartum Period,M01.060.057;E02.875.194;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;G08.686.702
30470556,Disclosure;Medical Errors;Patient Safety,F01.829.401.046;I01.880.604.583.080.134;L01.143.335;N02.421.450;N06.850.135.060.075.399
30470382,"Adolescent;Body Height;Calcinosis;Calcium;Child;Creatinine;DNA Mutational Analysis;Homeostasis;Hormone Replacement Therapy;Humans;Hypoparathyroidism;Kidney Function Tests;Linear Models;Nephrocalcinosis;Parathyroid Hormone;Phosphorus;Polyendocrinopathies, Autoimmune;Receptors, Calcium-Sensing;Treatment Outcome;Vitamin D;Polyendocrinopathies, Autoimmune;Vitamin D;Hypocalcemia;Teriparatide",M01.060.057;E01.370.600.115.100.160.100;E05.041.124.160.500;G07.100.100.160.100;G07.345.249.314.100;C18.452.174.130;D01.268.552.100;D01.552.539.288;D23.119.100;M01.060.406;D03.383.129.308.207;E05.393.760.700.300;G07.410;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;C19.642.482;E01.370.390.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;C12.777.419.590;C13.351.968.419.590;C18.452.174.130.560;D06.472.699.590;D12.644.548.587;D01.268.666;C19.787;C20.111.750;D12.776.543.750.695.115;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D04.210.500.812.768;C19.787;C20.111.750;D04.210.500.812.768;C18.452.174.509;C18.452.950.509;D06.472.699.590.850;D12.644.548.587.850
30470300,Alternative Splicing;Neoplasms;Leukemia,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;C04;C04.557.337
30469094,"Gray Matter;Depressive Disorder, Major",A08.186.211.168;A08.186.854.348;F03.600.300.375
30468772,Continuity of Patient Care;Critical Care;Intensive Care Units;Decision Making,E02.760.169;N02.421.585.169;N04.590.233.727.210;E02.760.190;N02.421.585.190;N02.278.388.493;F02.463.785.373
30468769,Drosophila melanogaster;Wolbachia,B01.050.500.131.617.720.500.500.750.310.250.500;B03.440.647.825;B03.660.050.765.825
30467542,T-Lymphocytes;Doxycycline;Rituximab,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D02.455.426.559.847.562.900.200;D04.615.562.900.200;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
30467402,Electronic Health Records;Genomics,E05.318.308.940.968.625.500;H01.158.273.180.350;H01.158.273.343.350
30467372,,
30467170,,
30467161,,
30466795,,
30466773,Inflammation,C23.550.470
30466769,Gene Editing;Genetic Therapy;Whole Exome Sequencing;Whole Genome Sequencing,E05.393.420.270;E02.095.301;E05.393.420.301;E05.393.760.700.825.500;E05.393.760.700.825
30466684,"Botulinum Toxins;Cosmetic Techniques;Dermatologic Surgical Procedures;Humans;Lasers, Gas;Rejuvenation;Silicone Gels;Surgical Wound;Vagina;Botulinum Toxins",D08.811.277.656.300.480.153;D08.811.277.656.675.374.153;D12.776.097.156;D23.946.123.179;E02.218;E04.680.275;B01.050.150.900.649.313.988.400.112.400.400;E07.632.490.367;E07.710.520.367;E02.849;D02.715.650.700.755;D05.750.900.850.905;D25.720.900.850.905;J01.637.051.720.900.850.905;C26.859;A05.360.319.779;D08.811.277.656.300.480.153;D08.811.277.656.675.374.153;D12.776.097.156;D23.946.123.179
30466635,"Child;Ear;Hearing Loss;Humans;Magnetic Resonance Imaging;Tomography, X-Ray Computed;Cholesteatoma",M01.060.406;A01.456.313;A09.246;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C17.800.428.260
30465899,,
30465896,,
30464263,,
30464171,"Animals;Carcinoma, Basal Cell;Cicatrix;Collagen;Dermis;Fibroblasts;Hair Follicle;Hedgehog Proteins;Mice;Skin Neoplasms;Wnt Signaling Pathway;Wound Healing",B01.050;C04.557.470.200.165;C04.557.470.565.165;A10.165.450.300;C23.550.355.274;G16.762.891.249;D05.750.078.280;D12.776.860.300.250;A17.815.180;A11.329.228;A10.272.497.500;A17.360.710;A17.815.250.500;D12.644.276.671;D12.776.467.671;D23.529.671;B01.050.150.900.649.313.992.635.505.500;C04.588.805;C17.800.882;G02.111.820.925;G04.835.925;G16.762.891
30463917,,
30463915,,
30463885,"Decision Support Systems, Clinical;Critical Pathways;Evidence-Based Medicine;Quality Improvement",L01.313.500.750.300.190;N04.590.233.624.625;N04.590.275;H02.249.750;H02.403.200.400;J01.293.754;N04.761.744
30463884,"Behavior;Computational Biology;Drosophila melanogaster;Memory, Long-Term",F01.145;H01.158.273.180;L01.313.124;B01.050.500.131.617.720.500.500.750.310.250.500;F02.463.425.540.305
30463762,Nursing;Pain;Patient Satisfaction;Quality Improvement;Safety,H02.478;N04.452.758.377;C23.888.592.612;F02.830.816.444;G11.561.790.444;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;J01.293.754;N04.761.744;N06.850.135.060.075
30463757,Bariatric Surgery;Hypoalbuminemia;Malnutrition,E02.570.500.062;E04.062;C15.378.147.607.500;C18.654.521
30463756,Surgical Wound Infection;Wounds and Injuries,C01.539.947.692;C23.550.767.925;C26
30463495,Brain Injuries;Pregnancy,C10.228.140.199;C10.900.300.087;C26.915.300.200;G08.686.784.769
30463416,Interleukin-12;Interleukin-17;Interleukin-23;Acitretin;Biological Products;Cyclosporine;Methotrexate;Phototherapy;Psoriasis,D12.644.276.374.465.512;D12.776.467.374.465.512;D23.529.374.465.512;D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517;D12.644.276.374.465.759;D12.776.467.374.465.759;D23.529.374.465.550;D02.455.326.271.665.202.495.050;D02.455.849.131.495.050;D23.767.261.700.050;D20.215;D04.345.566.235.300;D12.644.641.235.300;D03.633.100.733.631.192.500;E02.774;C17.800.859.675
30462942,Centers for Medicare and Medicaid Services (U.S.);Eligibility Determination;Health Policy;Humans;Medicaid;State Health Plans;United States,I01.409.418.750.600.310;N03.540.348.500.500.600.550;N04.452.264;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;N03.349.650.480;Z01.107.567.875
30461593,,
30460985,,
30460219,Child;Critical Illness;Enteral Nutrition;Parenteral Nutrition,M01.060.406;C23.550.291.625;E02.421.360;E02.642.500.360;E02.421.505;E02.642.500.505
30460178,Quality Improvement;Patient Safety,J01.293.754;N04.761.744;N06.850.135.060.075.399
30459394,"Amino Acid Metabolism, Inborn Errors;Amino Acids;Chromatography, Liquid;Genetics, Medical;Genomics;Humans;Infant, Newborn;Metabolism, Inborn Errors;Neonatal Screening;Tandem Mass Spectrometry;United States;Amino Acids",C16.320.565.100;C18.452.648.100;D12.125;E05.196.181.400;H01.158.273.343.385.500;H02.403.350;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C16.320.565;C18.452.648;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;E05.196.566.880;Z01.107.567.875;D12.125
30459343,,
30459244,"Diabetes Mellitus, Type 1;Diabetes Mellitus, Type 2;Humans;T Cell Transcription Factor 1;Transcription Factor 7-Like 2 Protein",C18.452.394.750.124;C19.246.267;C20.111.327;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.730.750;D12.776.660.235.400.800.750;D12.776.664.235.400.800.750;D12.776.930.875.750;D12.776.260.730.875;D12.776.660.235.400.800.875;D12.776.664.235.400.800.875;D12.776.930.875.875
30459208,,
30458779,"Communication;Education, Medical, Graduate;Patient Safety;Qualitative Research",F01.145.209;L01.143;I02.358.337.350;I02.358.399.350;N06.850.135.060.075.399;H01.770.644.241.850
30458271,,
30458270,,
30458267,,
30458206,"Carcinoma, Basal Cell;Transplants;Melanoma;Carcinoma, Squamous Cell",C04.557.470.200.165;C04.557.470.565.165;A01.941;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.557.470.200.400;C04.557.470.700.400
30458183,"Dermatitis, Atopic;Rhinitis, Allergic;Asthma;Food Hypersensitivity",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C20.543.480.370
30458158,,
30458152,,
30457440,Adolescent;Mice;Nicotine,M01.060.057;B01.050.150.900.649.313.992.635.505.500;D03.132.760.570;D03.383.725.518
30457181,Adolescent;Peer Influence,M01.060.057;F01.829.316.483.750
30456907,,
30456903,Vascular Stiffness;Cardiovascular Diseases;Meta-Analysis,G09.330.940;C14;V03.600
30456866,Liraglutide;Neuropharmacology,D06.472.317.680.500.500.500;H01.158.610.208;H01.158.703.030;H02.628.280
30456816,Chordoma,C04.557.465.220
30456600,Actin Cytoskeleton;rho GTP-Binding Proteins,A11.284.430.214.190.750.050;D08.811.277.040.330.300.400.700;D12.644.360.525.700;D12.776.157.325.515.700;D12.776.476.525.700
30456387,,
30456157,,
30455703,Colitis;Hypoxia;Inflammation;Macrophages;Neutrophils;Serum Amyloid A Protein,C06.405.205.265;C06.405.469.158.188;C23.888.852.079;C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;D12.776.049.407.750;D12.776.124.050.725
30455611,Aging;Health;Income;Multimorbidity,G07.345.124;N01.400;N01.824.417;N05.715.350.225.500;N06.850.490.687.500
30455465,,
30455034,Adolescent,M01.060.057
30454815,"Acute Coronary Syndrome;Acute Disease;Aortic Diseases;Cardiac-Gated Imaging Techniques;Chest Pain;Contrast Media;Coronary Angiography;Emergency Service, Hospital;Humans;Risk Assessment;Sensitivity and Specificity;Syndrome;Tomography, X-Ray Computed;Triage;Dissection;Myocardial Ischemia",C14.280.647.124;C14.907.585.124;C23.550.291.125;C14.907.109;E01.370.350.130.500;C23.888.592.612.233;D27.505.259.500;D27.720.259;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C23.550.288.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;N02.421.297.900;E01.370.225.998.221;E04.221;E05.200.998.221;C14.280.647;C14.907.585
30454742,"Child;Dent Disease;Diagnosis, Differential;Disease Progression;Humans;Renal Insufficiency, Chronic;Dent Disease;Nephrolithiasis",M01.060.406;C12.777.419.815.364;C13.351.968.419.815.364;C16.320.322.100;C16.320.565.861.271;C18.452.648.861.271;E01.171;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.815.364;C13.351.968.419.815.364;C16.320.322.100;C16.320.565.861.271;C18.452.648.861.271;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249
30454725,,
30454645,DNA Methylation;Drug Development;Gene Silencing,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;E05.290;H01.158.703.007.338;H01.181.466.338;G05.308.203.374
30453946,"Adolescent;Adult;Aged;Aged, 80 and over;Antitubercular Agents;Child;Child, Preschool;Humans;Incidence;Isoniazid;Latent Tuberculosis;Medication Adherence;Middle Aged;Norway;Prospective Studies;Rifampin;Young Adult;Chemoprevention;Compliance;Isoniazid;Latent Tuberculosis;Rifampin;Mass Screening",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.085.255;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D02.442.436;D03.066.349.410;D03.383.725.394.582;C01.252.410.040.552.846.122;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;Z01.542.816.374;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D03.633.400.811.700;D04.345.295.750.700;M01.060.116.815;E02.319.162;G01.374.590.210;D02.442.436;D03.066.349.410;D03.383.725.394.582;C01.252.410.040.552.846.122;D03.633.400.811.700;D04.345.295.750.700;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30453380,,
30453004,,
30453002,,
30453000,,
30452999,,
30452998,,
30452997,,
30452923,,
30452917,,
30452739,,
30452500,,
30452422,"Muscular Dystrophy, Duchenne;NF-kappa B",C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;D12.776.260.600;D12.776.660.600;D12.776.930.600
30451920,,
30451811,,
30451738,,
30451702,"Adolescent;Blood Pressure;Blood Pressure Monitoring, Ambulatory;Humans;Hypertension;Prevalence",M01.060.057;E01.370.600.875.249;G09.330.380.076;E01.370.370.140.100;E01.370.520.500.100;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
30451029,,
30450772,Anophthalmos;Microphthalmos,C11.250.080;C16.131.384.159;C11.250.566;C16.131.384.666
30450661,Dysphonia;Pediatricians;Pediatrics;Primary Health Care;Referral and Consultation;Voice Disorders,C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325;M01.526.485.810.758;N02.360.810.758;H02.403.670;N04.590.233.727;N04.452.758.849;C08.360.940;C09.400.940;C10.597.975;C23.888.592.979
30450075,"Stress Disorders, Post-Traumatic;Anxiety;Depression;Stroke",F03.950.750.500;F01.470.132;F01.145.126.350;C10.228.140.300.775;C14.907.253.855
30449983,Stem Cells,A11.872
30449737,,
30449684,Insulin Resistance;Obesity,C18.452.394.968.500;G07.690.773.984.617;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30449662,Cardiovascular Diseases;Genetic Therapy,C14;E02.095.301;E05.393.420.301
30449418,,
30449318,Neurosciences,H01.158.610
30448874,"Academic Success;Renal Insufficiency, Chronic",I02.399.136.500;C12.777.419.780.750;C13.351.968.419.780.750
30448424,,
30448214,,
30448004,,
30447236,,
30446903,Glioblastoma;Neuropathology;Radiation Effects;Radiotherapy;Survival,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;H01.158.610.184;H02.403.600.250;H02.403.650.375;G01.750.745;N06.850.810.300;E02.815;I03.784
30446646,"Animals;Animals, Newborn;Bone Morphogenetic Protein 1;Bone Morphogenetic Protein 2;Bone Morphogenetic Protein Receptors, Type I;Bone and Bones;Cartilage;Cell Differentiation;Cell Proliferation;Chondrocytes;Chondrogenesis;Embryo, Mammalian;Gene Expression Regulation, Developmental;Glucose;Glucose Transporter Type 1;Hypoxia-Inducible Factor 1, alpha Subunit;Mechanistic Target of Rapamycin Complex 1;Mice;Mice, Knockout;Osteoblasts;Osteogenesis;Primary Cell Culture;Signal Transduction",B01.050;B01.050.050.282;D08.811.277.656.300.480.525.700.049;D08.811.277.656.675.374.525.700.900.500;D12.644.276.848.049;D12.644.276.948.500;D12.644.276.954.200.100;D12.776.467.836.049;D12.776.467.942.200.100;D12.776.467.948.500;D23.529.942.200.100;D23.529.948.500;D12.644.276.954.200.200;D12.776.467.942.200.200;D23.529.942.200.200;D08.811.913.696.620.682.700.109.500;D12.776.543.750.750.400.049.500;A02.835.232;A10.165.265;A02.165;A10.165.382;G04.152;G04.161.750;G07.345.249.410.750;A11.329.171;G07.345.500.325.377.625.180;G11.427.578.180;A16.254;G05.308.310;D09.947.875.359.448;D12.776.157.530.500.500.500;D12.776.157.530.937.563.500;D12.776.543.585.500.500.500;D12.776.543.585.937.625.500;D12.776.260.103.625.750;D12.776.930.125.625.750;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.329.629;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;G02.111.820;G04.835
30446589,,
30446475,,
30446435,Autism Spectrum Disorder;Magnetic Resonance Imaging;Infant,F03.625.164.113;E01.370.350.825.500;M01.060.703
30446374,Clustered Regularly Interspaced Short Palindromic Repeats;DNA Repair,G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G02.111.222;G05.219
30446328,,
30446062,"Child;Emergency Service, Hospital;Humans;Patient Safety;Pediatric Emergency Medicine;Quality Improvement;Quality of Health Care;Benchmarking;Pediatric Emergency Medicine;Quality Improvement;Safety",M01.060.406;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;N06.850.135.060.075.399;H02.403.250.500;H02.403.670.450;J01.293.754;N04.761.744;N04.761;N05.715;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;H02.403.250.500;H02.403.670.450;J01.293.754;N04.761.744;N06.850.135.060.075
30446059,"Biomedical Technology;Child;Education, Medical;Emergency Medical Services;Humans;Pediatric Emergency Medicine;Point-of-Care Systems;Clinical Competence;Decision Support Systems, Clinical;Electronic Health Records;Pediatric Emergency Medicine;Ultrasonography",J01.897.115;M01.060.406;I02.358.399;N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;H02.403.250.500;H02.403.670.450;N04.452.442.452.680;N04.452.515.360.652;N04.590.874;I02.399.630.210;N04.761.210;N05.715.175;L01.313.500.750.300.190;E05.318.308.940.968.625.500;H02.403.250.500;H02.403.670.450;E01.370.350.850
30445615,,
30445549,,
30445220,Data Science;Natural Language Processing;Social Media;Data Mining,L01.305;L01.224.050.375.580;L01.178.751;L01.224.230.110.500.750;L01.313.500.750.280.199;L01.470.625
30445173,,
30445008,Clinical Trial;Osteoporosis,V03.175.250;C05.116.198.579;C18.452.104.579
30444928,,
30444861,,
30444833,,
30444758,,
30444686,,
30444552,"Diffuse Axonal Injury;Brain Injuries, Traumatic",C10.228.140.199.388.500;C10.900.300.087.219.500;C26.915.300.200.188.500;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
30444495,Cadaver;Checklist;Clinical Competence;Cold Ischemia;Hand Transplantation;Humans;Transplantation,C23.550.260.224;N05.715.360.300.179;I02.399.630.210;N04.761.210;N05.715.175;E04.936.337;E05.760.833.445;E04.936.450.825.500;B01.050.150.900.649.313.988.400.112.400.400;E04.936
30444066,Pitch Discrimination,F02.463.593.071.700.408
30444053,Magnetic Resonance Imaging;Tetralogy of Fallot,E01.370.350.825.500;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30443738,Extracorporeal Membrane Oxygenation;Gastroschisis;Meconium Aspiration Syndrome;Respiratory Insufficiency,E02.880.301;E04.292.451;C05.660.417;C16.131.621.417;C23.300.707.374.500;C08.381.520.687;C08.618.580;C13.703.277.785;C16.300.580;C16.614.580;C08.618.846
30443719,"Bariatric Surgery;Renal Insufficiency, Chronic;Kidney Failure, Chronic;Obesity",E02.570.500.062;E04.062;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30443667,Child;Congenital Abnormalities;Radiography;Ulna,M01.060.406;C16.131;E01.370.350.700;A02.835.232.087.090.850
30442924,,
30442863,"Kidney Failure, Chronic;Kidney Diseases;Paraproteinemias;Paraproteinemias;Renal Insufficiency, Chronic;Kidney Failure, Chronic",C12.777.419.780.750.500;C13.351.968.419.780.750.500;C12.777.419;C13.351.968.419;C15.378.147.780;C20.683.780;C15.378.147.780;C20.683.780;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750.500;C13.351.968.419.780.750.500
30442701,,
30442667,CD8-Positive T-Lymphocytes;Fetus;Gene Expression Regulation;Humans;Nucleic Acid Amplification Techniques;Pregnancy;RNA;T-Lymphocyte Subsets;Uterus;Mucosal-Associated Invariant T Cells;Apoptosis,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;A16.378;G05.308;B01.050.150.900.649.313.988.400.112.400.400;E05.393.620;G08.686.784.769;D13.444.735;A11.118.637.555.567.550.500;A11.118.637.555.567.569.500;A15.145.229.637.555.567.550.500;A15.145.229.637.555.567.569.500;A15.382.490.555.567.550.500;A15.382.490.555.567.569.500;A05.360.319.679;A11.118.637.555.567.550.500.100;A11.118.637.555.567.569.500.100;A15.145.229.637.555.567.550.500.100;A15.145.229.637.555.567.569.500.100;A15.382.490.555.567.550.500.100;A15.382.490.555.567.569.500.100;G04.146.160
30442643,,
30442461,"Alprostadil;Echocardiography;Hernias, Diaphragmatic, Congenital;Humans;Hypertension, Pulmonary;Infant, Newborn;Natriuretic Peptide, Brain;Philadelphia;Registries;Retrospective Studies;Treatment Outcome;Vasodilator Agents;Hernias, Diaphragmatic, Congenital;Alprostadil;Hypertension, Pulmonary",D10.251.355.255.550.250.100;D10.251.355.325.050;D23.469.050.175.725.250.100;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;M01.060.703.520;D06.472.699.584.625;D12.644.548.585.625;D12.776.631.590;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D27.505.954.411.918;C16.131.433;C23.300.707.500.116;D10.251.355.255.550.250.100;D10.251.355.325.050;D23.469.050.175.725.250.100;C08.381.423
30442286,"Epidemiology;Continental Population Groups;Risk Factors;Death, Sudden, Cardiac",H02.403.720.500;M01.686.508;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.383.220;C23.550.260.322.250
30442240,"Accidents, Traffic;Anesthetics;Humans;Medication Errors;Self Report",N06.850.135.392;D27.505.696.277.100;D27.505.954.427.210.100;B01.050.150.900.649.313.988.400.112.400.400;E02.319.529;N02.421.450.500;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500
30439517,"Carcinoma, Hepatocellular;Research Design",C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;E05.581.500;H01.770.644.728
30431557,,
30431541,,
30431433,"Biochemistry;Humans;Sarcoma, Synovial",H01.158.201;H01.181.122;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.565.835;C04.557.450.795.875
30430034,"Wolf-Hirschhorn Syndrome;Hernias, Diaphragmatic, Congenital",C16.131.077.944;C16.131.260.985;C16.320.180.985;C16.131.433;C23.300.707.500.116
30428424,Inflammation;Obesity,C23.550.470;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30428151,Brain;Dexmedetomidine;Remifentanil,A08.186.211;D03.383.129.308.245;D02.241.081.751.756;D03.383.621.828
30428023,,
30427929,,
30427907,,
30427736,,
30427701,,
30426927,Cytoskeleton,A11.284.430.214.190.750
30426816,Research,H01.770.644
30426110,Healthcare Disparities;Workforce,N04.590.374.380;N05.300.493;N04.452.525
30426066,Alzheimer Disease;Biomarkers;Cerebrospinal Fluid;Immunoassay;Patient Selection,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A12.207.270.210;E05.478.566;E05.601.470;E05.581.500.653;N04.590.731
30425188,Aging;Drug Discovery,G07.345.124;E05.295;H01.158.703.007.675;H01.181.466.675
30425130,,
30425110,"Antimicrobial Stewardship;Infant, Very Low Birth Weight",N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;M01.060.703.520.460.600
30425056,,
30424803,,
30423480,Stem Cell Transplantation,E02.095.147.500.500;E04.936.225.687
30423312,Endoplasmic Reticulum;National Institutes of Health (U.S.);Neuroaxonal Dystrophies;N-Acetylneuraminic Acid;Uridine Diphosphate,A11.284.430.214.190.875.248;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;C10.228.140.744;D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030;D03.383.742.686.850.600;D13.695.740.850.600;D13.695.827.919.600
30423101,,
30423035,,
30422863,,
30422861,,
30422774,,
30422278,Chronic Disease;Humans;Motivation;Physician Incentive Plans;United States;Value-Based Health Insurance,C23.550.291.500;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;N04.452.677.740;Z01.107.567.875;N03.219.521.576.343.972;N04.761.744.750
30422224,,
30422157,,
30421856,,
30421851,,
30421678,Diagnosis;Emphysema;Respiratory Function Tests;Systematic Review,E01;C23.550.325;E01.370.386.700;V03.850
30420736,,
30420687,,
30420471,,
30420215,Bone Marrow;Bone Neoplasms;Fluorodeoxyglucose F18;Humans;Positron Emission Tomography Computed Tomography;Radiopharmaceuticals;Bone Marrow;Neoplasms;Positron Emission Tomography Computed Tomography,A15.382.216;C04.588.149;C05.116.231;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;A15.382.216;C04;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500
30420158,"Purpura, Schoenlein-Henoch;Adult",C14.907.940.777;C15.378.100.802.375;C15.378.463.515.580;C20.543.520.600;C23.550.414.950.375;C23.888.885.687.375;M01.060.116
30420061,MicroRNAs,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
30419952,Brain Neoplasms;Epigenomics;Glioma;Histones,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;H01.158.273.180.350.074;H01.158.273.343.350.042;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469
30419210,Enteric Nervous System;Hirschsprung Disease;Humans;Learning;Organogenesis;Sequence Analysis,A08.800.050.150;C06.198.439;C06.405.469.158.701.439;C16.131.314.439;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;G07.345.500.325.377;G08.686.784.170.450;E05.393.760
30419141,,
30419129,,
30418507,,
30418491,,
30418432,,
30418413,,
30417460,Neoplasms;Neoplasm Metastasis;Ependymoma;Necrosis;Recurrence,C04;C04.697.650;C23.550.727.650;C04.557.465.625.600.380.290;C04.557.470.670.380.290;C04.557.580.625.600.380.290;C23.550.717;G04.146.638;C23.550.291.937
30417091,,
30416506,"Receptors, Chimeric Antigen;Immunotherapy",D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;E02.095.465.425
30416076,,
30416003,Radiology;Research,H02.403.740;H01.770.644
30415593,Multiple Sclerosis;Disease Progression,C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C23.550.291.656
30415577,Malnutrition;Serum Albumin,C18.654.521;D12.776.034.841;D12.776.124.727
30415424,Bipolar Disorder;Data Mining,F03.084.500;L01.313.500.750.280.199;L01.470.625
30415078,"Adaptation, Psychological;Hospitalization;Parents",F01.058;E02.760.400;N02.421.585.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620
30414987,"Adult;Brain;Brain Mapping;Depression;Depressive Disorder, Major;Emotions;Humans;Magnetic Resonance Imaging;Middle Aged;Social Perception;Depression;Parietal Lobe;Magnetic Resonance Imaging",M01.060.116;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F01.145.126.350;F03.600.300.375;F01.470;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;F02.463.593.752;F01.145.126.350;A08.186.211.200.885.287.500.670;E01.370.350.825.500
30414961,,
30414865,"Economics, Behavioral;Ethics;Motivation",F04.096.628.286;N03.219.215;K01.752.566.479;N05.350;F01.658;F01.752.543.500.750
30414857,,
30414759,Pediatrics;Proton Therapy;Surveys and Questionnaires,H02.403.670;E02.815.250.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
30414739,"Animals;Cell Cycle;Cell Line, Tumor;Cyclin D1;DNA Breaks, Double-Stranded;DNA Repair;Genes, BRCA1;Humans;Mice;Mice, Inbred BALB C;Ovarian Neoplasms;Phthalazines;Piperazines;Rad51 Recombinase;Cyclin D1;Homologous Recombination;Ovarian Neoplasms",B01.050;G04.144;A11.251.210.190;A11.251.860.180;D12.644.360.262.150.100;D12.776.167.218.150.100;D12.776.476.262.150.100;D12.776.624.664.700.100;G05.200.210.220;G02.111.222;G05.219;G05.360.340.024.340.375.249.100;G05.360.340.024.340.415.400.100;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D03.383.710.605;D03.383.606;D08.811.739.650.500;D12.776.260.695;D12.776.313.968;D12.644.360.262.150.100;D12.776.167.218.150.100;D12.776.476.262.150.100;D12.776.624.664.700.100;G05.728.615;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
30414631,"Heart Defects, Congenital",C14.240.400;C14.280.400;C16.131.240.400
30414523,Adult;Biomarkers;Cervical Vertebrae;Cohort Studies;Humans;Interleukin-6;Lumbar Vertebrae;Middle Aged;Nerve Growth Factor;Prospective Studies;Spinal Cord Injuries;Thoracic Vertebrae;Treatment Outcome;Young Adult;Glial Cell Line-Derived Neurotrophic Factor;Interleukin-6;Nerve Growth Factor;Spinal Cord Injuries,M01.060.116;D23.101;A02.835.232.834.151;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;A02.835.232.834.519;M01.060.116.630;D12.644.276.860.437;D12.776.467.860.437;D12.776.631.600.437;D23.529.850.437;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.228.854.763;C10.900.850;C26.819;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;D12.644.276.860.381.500;D12.776.467.860.381.500;D12.776.631.600.381.500;D23.529.850.381.500;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;D12.644.276.860.437;D12.776.467.860.437;D12.776.631.600.437;D23.529.850.437;C10.228.854.763;C10.900.850;C26.819
30414468,,
30414466,,
30414379,Culture;Flow Cytometry;Microglia,I01.076.201.450;I01.880.853.100;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;A08.637.400;A11.650.400
30414138,"Myositis Ossificans;Ossification, Heterotopic",C05.651.594.638;C23.550.751
30413993,Fluoroscopy,E01.370.350.700.225
30413934,Alzheimer Disease;Genetic Pleiotropy;Lipids,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G05.420.556;G05.695.550;D10
30413631,,
30413629,,
30413401,,
30413352,"Muscular Dystrophy, Duchenne;Muscle Strength",C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.600.425;G11.427.560
30413235,,
30411905,,
30411459,"Adenosine Monophosphate;Animals;Autoantibodies;Biomarkers, Tumor;C-Reactive Protein;Cyclic AMP-Dependent Protein Kinases;Dog Diseases;Dogs;Neoplasms;C-Reactive Protein;Neoplasms",D03.633.100.759.646.138.180;D13.695.667.138.180;D13.695.827.068.180;B01.050;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;D23.101.140;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;D08.811.913.696.620.682.700.150.125;D12.644.360.200.125;D12.776.476.200.125;C22.268;B01.050.150.900.649.313.750.250.216.200;C04;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;C04
30411382,,
30410666,Colorectal Neoplasms;Neuroendocrine Cells;Tretinoin;Stem Cells,C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;A11.382.944;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780;A11.872
30410443,Ganoderma;Bibliometrics;Reishi,B01.300.179.120.379;L01.178.682.099.325;L01.453.183.291;B01.300.179.120.379.700
30410033,,
30409970,,
30409548,Mentoring,I02.358.859;I02.588
30409376,Chagas Disease,C03.752.300.900.200
30408542,,
30408541,,
30408538,,
30408536,,
30408436,,
30408015,,
30408006,,
30407953,,
30407516,,
30407106,,
30406366,Blood Pressure;Hypertension;Pediatrics,E01.370.600.875.249;G09.330.380.076;C14.907.489;H02.403.670
30405584,Uterine Cervical Neoplasms;Fungi,C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;B01.300
30404834,"Fatigue;Mitochondria;Muscle, Skeletal",C23.888.369;A11.284.430.214.190.875.564;A11.284.835.626;A02.633.567;A10.690.552.500
30404791,,
30404775,,
30404737,,
30404654,Alzheimer Disease;Microtubules;Tauopathies;Therapeutics,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A11.284.430.214.190.750.602;C10.574.945;E02
30404548,Autism Spectrum Disorder;Qualitative Research,F03.625.164.113;H01.770.644.241.850
30404207,Adult;Dietary Fats;Eating;Food Analysis;Humans;Mobile Applications;Overweight;Poland;Smartphone;Young Adult;Ecological Momentary Assessment,M01.060.116;D10.212.302;G07.203.300.375;J02.500.375;G07.203.650.283;G10.261.330;E05.362;J01.576.423.850.100;B01.050.150.900.649.313.988.400.112.400.400;L01.224.900.685;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;Z01.542.248.679;L01.224.230.260.550.500.500;M01.060.116.815;F04.711.336
30404033,,
30404006,"Clustered Regularly Interspaced Short Palindromic Repeats;Cyclooxygenase 2;Inflammation;Immunity, Innate",G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D08.811.600.720.750;C23.550.470;G12.450.564
30403402,Alcoholism,C25.775.100.250;F03.900.100.350
30401835,,
30401707,,
30401549,Antidepressive Agents;Cognitive Behavioral Therapy;Depression;Gene-Environment Interaction;Gonadal Steroid Hormones;Hormone Replacement Therapy;Humans;Longitudinal Studies;Perimenopause;Psychotherapy;Depression;Genetics;Hormones;Perimenopause,D27.505.954.427.700.122;F04.754.137.350;F01.145.126.350;G05.695.337;D06.472.334.851;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;G08.686.157.500.562;G08.686.841.249.500.562;F04.754;F01.145.126.350;H01.158.273.343;D06.472;D27.505.696.399.472;G08.686.157.500.562;G08.686.841.249.500.562
30401544,"Affect;Aging;Depression;Evidence-Based Medicine;Hot Flashes;Humans;Menopause;Reproductive Health;Sexual Dysfunction, Physiological;Sleep Wake Disorders;Women's Health;Anxiety;Depression;Libido;Menopause",F01.470.047;G07.345.124;F01.145.126.350;H02.249.750;H02.403.200.400;C23.888.475;B01.050.150.900.649.313.988.400.112.400.400;G08.686.157.500;G08.686.841.249.500;N01.400.625;C12.294.644;C13.351.500.665;C10.886;C23.888.592.796;F03.870;N01.400.900;F01.470.132;F01.145.126.350;F02.739.794.511;G08.686.157.500;G08.686.841.249.500
30401511,Diabetic Ketoacidosis;Intensive Care Units;Length of Stay;Medication Adherence;Resuscitation,C18.452.076.176.652.500;C18.452.394.750.535;C19.246.099.812;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E02.365.647
30400859,"Adult;Aged;Blood Glucose;Diabetes Mellitus, Type 2;Glycated Hemoglobin A;Health Knowledge, Attitudes, Practice;Healthy Lifestyle;Humans;Medication Adherence;Middle Aged;Patient Participation;Self Care;Self Report;Qualitative Research",M01.060.116;M01.060.116.100;D09.947.875.359.448.500;C18.452.394.750.149;C19.246.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;F01.100.150.500;N05.300.150.410;F01.829.458.205;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;E02.900;I03.050.563;N02.421.784.680;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;H01.770.644.241.850
30400099,Alzheimer Disease;Hypertension,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C14.907.489
30399415,,
30399404,"Gastrointestinal Microbiome;Interleukin-6;Microbiota;Fatty Acids, Omega-3;Pregnancy",G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;D10.212.302.380.410;D10.251.355.337;D10.627.430.450;G08.686.784.769
30399039,,
30398897,Epidemiology;Craniocerebral Trauma,H02.403.720.500;C10.900.300;C26.915.300
30398602,"Administration, Inhalation;Aged;Cross-Over Studies;Double-Blind Method;Exercise Test;Exercise Tolerance;Heart Failure;Humans;Inorganic Chemicals;Middle Aged;Nitrites;Oxygen Consumption;Stroke Volume;Treatment Failure",E02.319.267.050;M01.060.116.100;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;G11.427.680.270;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;D01;M01.060.116.630;D01.248.497.158.635;D01.625.600.600;D02.633;G03.680;E01.370.370.380.150.700;G09.330.380.124.882;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
30398470,,
30397898,"Histones;Infertility, Male;Protein Processing, Post-Translational;Spermatozoa",D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;C12.294.365.700;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;A05.360.490.890;A11.497.760
30397595,"Diffusion Magnetic Resonance Imaging;Diffusion Tensor Imaging;Neuroimaging;Stress Disorders, Post-Traumatic;Veterans",E01.370.350.825.500.150;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;E01.370.350.578;E01.370.376.537;E05.629;F03.950.750.500;M01.930
30397497,"Autoimmune Diseases;Autoimmunity;Lupus Erythematosus, Systemic",C20.111;G12.450.192;C17.300.480;C20.111.590
30397339,,
30396408,,
30395992,African Americans;Asthma;Health Status Disparities;Implementation Science;Medication Adherence,M01.686.508.100.100;M01.686.754.100;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;L01.143.320.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500
30395517,Electronic Health Records;Information Technology;Safety,E05.318.308.940.968.625.500;L01.479;N06.850.135.060.075
30395418,"Animals;Brain;Dependovirus;Disease Models, Animal;Genetic Vectors;Injections;Mice;Stereotaxic Techniques;Transgenes;Dependovirus;Central Nervous System;Injections",B01.050;A08.186.211;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;G05.360.337;E02.319.267.530;B01.050.150.900.649.313.992.635.505.500;E04.525.800;E05.873;G05.360.340.024.340.825;B04.280.580.650.170;A08.186;E02.319.267.530
30395209,,
30395028,,
30395025,,
30395024,,
30394917,,
30394521,Axitinib;Axitinib,D02.065.277.051;D02.241.223.100.100.115;D02.455.426.559.389.127.085.093;D03.383.129.539.487.065;D03.633.100.449.065;D02.065.277.051;D02.241.223.100.100.115;D02.455.426.559.389.127.085.093;D03.383.129.539.487.065;D03.633.100.449.065
30394335,Adolescent;Adult;Chlamydia Infections;Chlamydia trachomatis;Cohort Studies;Delivery of Health Care;Humans;Mass Screening;Preventive Health Services;Primary Health Care;Quality Improvement;Sexual Behavior;Young Adult;Adolescent;Chlamydia trachomatis;Primary Health Care;Mass Screening;Sexually Transmitted Diseases,M01.060.057;M01.060.116;C01.252.400.210.210;C01.252.810.301;C01.539.778.281.301;C12.294.668.281.301;C13.351.500.711.281.301;B03.440.190.190.190.750;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N02.421.726;N04.590.233.727;J01.293.754;N04.761.744;F01.145.802;M01.060.116.815;M01.060.057;B03.440.190.190.190.750;N04.590.233.727;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C01.539.778;C02.800;C12.294.668;C13.351.500.711
30394323,"Adult;Brain;Brain Mapping;Deception;Games, Experimental;Humans;Individuality;Machine Learning;Magnetic Resonance Imaging;Nerve Net;Young Adult;Deception;Individuality;Machine Learning",M01.060.116;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F01.145.813.157;E05.385;B01.050.150.900.649.313.988.400.112.400.400;F01.752.488;G17.035.250.500;L01.224.050.375.530;E01.370.350.825.500;A08.511;M01.060.116.815;F01.145.813.157;F01.752.488;G17.035.250.500;L01.224.050.375.530
30394139,Eosinophilic Esophagitis;Biological Products;Diagnosis;Diet Therapy;Therapeutics,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;D20.215;E01;E02.642.249;E02
30393588,Diagnosis;Mitochondrial Diseases;Therapeutics,E01;C18.452.660;E02
30393446,Social Environment,I01.880.853.500
30393163,Analgesia;Prostaglandin-Endoperoxide Synthases;Pain;Prostaglandins,E03.091;D08.811.600.720;D08.811.682.690.708.715;C23.888.592.612;F02.830.816.444;G11.561.790.444;D10.251.355.255.550;D23.469.050.175.725
30392958,T-Lymphocytes;Chromatin;Glutaminase;Glutamine;Metabolism,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D08.811.277.087.483;D12.125.068.330;D12.125.095.461;D12.125.154.424;G03
30392625,Autism Spectrum Disorder,F03.625.164.113
30392605,Area Under Curve;Menopause;Pelvic Inflammatory Disease;Pelvic Pain;Vulvodynia,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;G08.686.157.500;G08.686.841.249.500;C01.539.635.500;C13.351.500.056.750;C23.888.592.612.944;C13.351.500.944.951
30392600,"Area Under Curve;Mammography;Gynecomastia;Breast Neoplasms, Male;Mammography",E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E01.370.350.700.500;C17.800.090.875;C04.588.180.260;C17.800.090.500.260;E01.370.350.700.500
30392596,Area Under Curve;Mastodynia;Mammography;Mammography,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C23.888.592.612.530;F02.830.816.308;G11.561.790.308;E01.370.350.700.500;E01.370.350.700.500
30392595,Area Under Curve;Breast Neoplasms;Breast Feeding;Lactation;Nipple Discharge;Pregnancy,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C04.588.180;C17.800.090.500;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;G08.686.523;G08.686.702.500;A12.207.824;G08.686.784.769
30392594,"Area Under Curve;Osteomyelitis;Arthritis, Infectious;Tibial Fractures",E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C01.539.160.495;C05.116.165.495;C01.539.100;C05.550.114.099;C26.404.875;C26.558.857
30392592,Area Under Curve;Diagnostic Imaging;Pyelonephritis,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E01.370.350;C12.777.419.570.643.790;C12.777.419.570.821.717;C13.351.968.419.570.643.790;C13.351.968.419.570.821.717
30391859,"Adult;Algorithms;Brain;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Middle Aged;Multiple Sclerosis;Sensitivity and Specificity",M01.060.116;G17.035;L01.224.050;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872
30391552,,
30391476,"Morphine;Receptors, Opioid, mu",D03.132.577.249.562.571;D03.605.497.607.587;D03.633.400.686.607.587;D04.615.723.795.576.571;D12.776.543.750.695.620.550;D12.776.543.750.720.600.610.550;D12.776.543.750.750.555.610.550
30391350,,
30391323,,
30391277,Ankyrin Repeat;NF-KappaB Inhibitor alpha,G02.111.570.060.720.030;G02.111.570.820.709.275.500.030;G02.111.570.820.709.275.750.500.080;G02.111.570.820.709.275.875.030;D12.644.360.365.500;D12.776.260.420.500;D12.776.476.381.500;D12.776.930.326.500
30391249,,
30391197,Heart-Assist Devices,E04.050.430;E07.695.300.300;E07.858.082.374.300
30391195,Protein-Losing Enteropathies,C06.405.469.818
30391194,,
30390823,Endocrinology;Humans;Hypoparathyroidism,H01.158.782.323;H02.403.429.323;B01.050.150.900.649.313.988.400.112.400.400;C19.642.482
30390819,Adult;Bone Diseases;Child;Drug Resistance;Humans;Parathyroid Hormone;Pseudohypoparathyroidism;Brachydactyly;Pseudohypoparathyroidism,M01.060.116;C05.116;M01.060.406;G07.690.773.984;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.590;D12.644.548.587;C05.116.198.709;C16.320.565.618.815;C18.452.104.709;C18.452.174.766;C18.452.648.618.815;C05.660.585.262;C16.131.621.585.262;C05.116.198.709;C16.320.565.618.815;C18.452.104.709;C18.452.174.766;C18.452.648.618.815
30390815,Humans;Hypoparathyroidism;Parathyroid Diseases;Parathyroid Glands;Parathyroid Hormone;Genetics;Hypoparathyroidism;Parathyroid Hormone,B01.050.150.900.649.313.988.400.112.400.400;C19.642.482;C19.642;A06.300.560;D06.472.699.590;D12.644.548.587;H01.158.273.343;C19.642.482;D06.472.699.590;D12.644.548.587
30390790,,
30390789,Anemia;Blood Transfusion;Humans;Iron;Length of Stay;Postoperative Complications;Preoperative Care;Anemia;Hemoglobins,C15.378.071;E02.095.135;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.412;D01.268.956.287;D01.552.544.412;E02.760.400.480;N02.421.585.400.480;C23.550.767;E02.760.795;E04.604.750;N02.421.585.795;C15.378.071;D12.776.124.400;D12.776.422.316.762
30390383,Breast Neoplasms,C04.588.180;C17.800.090.500
30389972,,
30389954,,
30389908,,
30389798,,
30389748,,
30389331,,
30389060,Knowledge;Parenting;Perception,K01.468;F01.829.263.370.310;F02.463.593
30388402,Haploinsufficiency;Intellectual Disability;Megalencephaly;Megalencephaly;NFI Transcription Factors,G05.365.590.029.530.587;G05.380.350.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C05.660.207.536;C10.500.507.400.249;C16.131.621.207.532;C16.131.666.507.400.249;C05.660.207.536;C10.500.507.400.249;C16.131.621.207.532;C16.131.666.507.400.249;D12.776.260.605;D12.776.930.612
30387908,Biopsy;Pathologists;Transplants,E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.526.485.810.746;N02.360.810.746;A01.941
30387904,Cholinesterase Inhibitors;Cognitive Dysfunction;Memantine,D27.505.519.389.275;D27.505.519.625.120.300;D27.505.696.577.120.300;F03.615.250.700;D02.455.426.100.050.035.500
30387024,Africa,Z01.058
30386863,Body Composition;Down Syndrome,G02.111.130;G03.180;G07.100.049;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260
30386685,Database;Genomics;Mitochondrial Diseases,V02.300;H01.158.273.180.350;H01.158.273.343.350;C18.452.660
30386039,,
30385850,,
30385625,,
30385622,,
30385620,,
30385619,,
30385618,,
30385490,,
30385043,Immunotherapy;Lymphoma,E02.095.465.425;C04.557.386;C15.604.515.569;C20.683.515.761
30384971,Comorbidity;Headache;Mental Disorders;Migraine Disorders,N05.715.350.225;N06.850.490.687;C23.888.592.612.441;F03;C10.228.140.546.399.750
30383719,,
30383571,,
30383187,,
30383109,,
30382827,Infant Care;Parenting;Social Media,N02.421.088.120;F01.829.263.370.310;L01.178.751;L01.224.230.110.500.750
30382786,Critical Care;Telemedicine,E02.760.190;N02.421.585.190;H02.403.840;L01.178.847.652;N04.590.374.800
30382734,"Adolescent;Adolescent Behavior;Adult;Aggression;Anger;Anger Management Therapy;Humans;Juvenile Delinquency;Models, Psychological;Outcome Assessment (Health Care);Young Adult",M01.060.057;F01.145.022;M01.060.116;F01.145.126.125;F01.145.813.045;F01.470.093;F04.754.137.087;B01.050.150.900.649.313.988.400.112.400.400;I01.880.735.479;E05.599.695;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;M01.060.116.815
30381778,Aging;Mental Health;Africa South of the Sahara,G07.345.124;F02.418;N01.400.500;Z01.058.290
30381474,,
30381434,Corticosterone;Corticotropin-Releasing Hormone;Microglia,D04.210.500.745.745.654.237;D06.472.040.585.353.237;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;A08.637.400;A11.650.400
30381428,Autophagy;Endosomes;Lysosomes;Neurons,G04.146.399;G04.417.350.091;A11.284.430.214.190.875.190.880.337;A11.284.430.214.190.875.190.550;A08.675;A11.671
30381394,Glioblastoma;Isocitrate Dehydrogenase;Systems Biology,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;D08.811.682.047.820.475;H01.158.273.180.800
30381349,"Animals;Antibodies, Viral;Disease Models, Animal;Disease Transmission, Infectious;Ferrets;Hemorrhagic Fever, Ebola;Immunoglobulin G;Immunoglobulin M;Survival Analysis;Ebolavirus;Models, Animal;Ferrets;Filoviridae",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;C22.232;E05.598.500;E05.599.395.080;N06.850.310;B01.050.150.900.649.313.750.250.575.350;C02.782.417.415;C02.782.580.250.400;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;D12.776.124.486.485.114.619.574;D12.776.124.790.651.114.619.574;D12.776.377.715.548.114.619.574;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;B04.820.455.300.200;E05.598;B01.050.150.900.649.313.750.250.575.350;B04.820.455.300
30380416,Mi-2 Nucleosome Remodeling and Deacetylase Complex;Breast Neoplasms;Mitosis,D08.811.277.040.025.176;D08.811.277.087.520.500;D08.811.600.620;C04.588.180;C17.800.090.500;G04.144.220.220.781;G05.113.220.781
30380395,Cocaine;Cocaine-Related Disorders;Drug Overdose;Fentanyl;Humans;Middle Aged;Pennsylvania;Substance Abuse Detection,D02.145.074.722.388;D03.132.889.354;D03.605.084.500.722.388;D03.605.869.388;C25.775.300;F03.900.300;C25.775.383;E02.319.306.500.500;D03.383.621.265;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.885;N06.850.780.500.765
30380195,,
30380194,DiGeorge Syndrome;DiGeorge Syndrome;DiGeorge Syndrome,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
30380191,Syndrome,C23.550.288.500
30380189,DiGeorge Syndrome;DiGeorge Syndrome;Clubfoot;Orthopedics,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.330.488.655.063;C05.330.495.681.063;C05.660.585.512.380.813.063;C16.131.621.585.512.500.681.063;H02.403.810.494
30380188,DiGeorge Syndrome;DiGeorge Syndrome;Hypocalcemia;Intellectual Disability,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C18.452.174.509;C18.452.950.509;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
30380020,,
30379671,,
30379624,,
30379617,"Enteric Nervous System;Interstitial Cells of Cajal;Muscle, Smooth",A08.800.050.150;A11.620.124;A02.633.570;A10.690.467
30379592,,
30379395,Association;Cognition;Genetics,F02.463.425.069;F04.754.720.346;F02.463.188;H01.158.273.343
30379138,,
30378526,Extracorporeal Membrane Oxygenation;Mortality,E02.880.301;E04.292.451;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
30378461,Bipolar Disorder;Diagnostic and Statistical Manual of Mental Disorders;Diagnosis;Bipolar Disorder,F03.084.500;L01.453.245.945.200;E01;F03.084.500
30378256,Osteosarcoma,C04.557.450.565.575.650;C04.557.450.795.620
30377930,,
30377791,"Artificial Intelligence;Image Processing, Computer-Assisted;Tomography, X-Ray",G17.035.250;L01.224.050.375;L01.224.308;E01.370.350.700.810;E01.370.350.825.810
30377383,Retinitis Pigmentosa,C11.270.684;C11.768.585.658.500;C16.320.290.684
30377334,,
30377266,Biomarkers,D23.101
30376898,"Adult;Bacteria;DNA, Bacterial;Humans;Microbiota;Placenta;Pregnancy;Premature Birth;RNA, Ribosomal, 16S;Sequence Analysis, DNA;Term Birth;Uterus;Microbiota;Placenta;Premature Birth",M01.060.116;B03;D13.444.308.212;B01.050.150.900.649.313.988.400.112.400.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A16.710;G08.686.784.769;C13.703.420.491.500;D13.444.735.686.670;E05.393.760.700;G08.686.784.769.490.500;A05.360.319.679;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A16.710;C13.703.420.491.500
30376893,Child;Tranexamic Acid;Wounds and Injuries,M01.060.406;D02.241.223.268.860;C26
30376582,"Adaptation, Physiological;Animals;Biofilms;Catalase;Cholera;Host-Pathogen Interactions;Intestines;Mice;Mutation;Oxidative Stress;Reactive Oxygen Species;Vibrio cholerae;Virulence",G07.025;G16.012.500;B01.050;A20.593;G06.120;D08.811.682.732.332;C01.252.400.959.347;G06.462;G16.527.200;A03.556.124;B01.050.150.900.649.313.992.635.505.500;G05.365.590;G03.673;G07.775.750;D01.339.431;D01.650.775;B03.440.450.900.859.225;B03.660.250.830.830.100;G06.930
30376508,,
30376505,"Adolescent;Adult;Child;Child, Preschool;Clinical Protocols;Craniosynostoses;Critical Pathways;Health Resources;Humans;Infant;Infant, Newborn;Intensive Care Units;Length of Stay;Middle Aged;Perioperative Care;Reconstructive Surgical Procedures;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E02.183;N05.715.360.330.125;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;N04.590.233.624.625;N04.590.275;N03.349.340;N05.300.420;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;E02.760.731;E04.604;N02.421.585.722;E04.680;M01.060.116.815
30376496,"Adolescent;Bone Nails;Bone Screws;Child;Fracture Fixation, Internal;Fracture Healing;Fractures, Avulsion;Humans;Open Fracture Reduction;Postoperative Complications;Retrospective Studies;Tibial Fractures;Trauma Centers",M01.060.057;E07.695.370.249;E07.858.442.660.460.249;E07.858.690.725.460.249;E07.695.370.437;E07.858.442.660.460.437;E07.858.690.725.460.437;M01.060.406;E04.555.300.300;G16.762.891.500;C26.404.038;B01.050.150.900.649.313.988.400.112.400.400;E04.555.300.690;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C26.404.875;C26.558.857;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400
30376374,,
30375931,,
30375917,Cardiopulmonary Bypass,E04.292.413
30375723,"Circadian Rhythm;Hypertension;Sleep Apnea, Obstructive;Sleep Deprivation;Sleep Wake Disorders",G07.180.562.190;C14.907.489;C08.618.085.852.850;C10.886.425.800.750.850;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;C10.886;C23.888.592.796;F03.870
30375692,,
30375498,,
30375122,Electronic Health Records;Pharmacoepidemiology;Phenotype,E05.318.308.940.968.625.500;H01.158.703.045;H02.403.720.500.650;H02.628.413;G05.695
30374655,Curriculum;Education;Fellowships and Scholarships,I02.158;I02;N03.219.483.838.276
30374084,,
30374071,,
30373910,,
30373907,,
30373887,,
30373700,,
30373495,,
30372751,,
30372600,,
30372552,Precursor Cell Lymphoblastic Leukemia-Lymphoma;Bone Density;Crohn Disease;Cystic Fibrosis;Growth;Puberty,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;G11.427.100;C06.405.205.731.500;C06.405.469.432.500;C06.689.202;C08.381.187;C16.320.190;C16.614.213;G07.345.249;G08.686.760;G08.686.841.374
30371821,,
30371759,,
30371676,,
30371305,Outcome Assessment (Health Care);Risk Factors,H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30371255,Aortic Valve Stenosis;Extracellular Matrix;Reactive Oxygen Species,C14.280.484.150;C14.280.955.249;A11.284.295.310;D01.339.431;D01.650.775
30370879,,
30370425,,
30370210,Colorectal Neoplasms,C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
30370172,,
30368871,,
30368460,,
30368400,"Adolescent;Child;Child, Preschool;Debridement;Endoscopy;Follow-Up Studies;Humans;Invasive Fungal Infections;Magnetic Resonance Imaging;Nose;Paranasal Sinuses;Philadelphia;Retrospective Studies;Sinusitis;Tomography, X-Ray Computed;Young Adult;Fungi;Immunocompromised Host",M01.060.057;M01.060.406;M01.060.406.448;E04.176;E01.370.388.250;E04.502.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C01.703.492;E01.370.350.825.500;A01.456.505.733;A04.531;A09.531;A04.531.621;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C08.460.692.752;C08.730.749;C09.603.692.752;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;M01.060.116.815;B01.300;G12.470
30368044,"Chromatography, High Pressure Liquid;Gangliosides;Humans;Limit of Detection;Linear Models;Reproducibility of Results;Tandem Mass Spectrometry",E05.196.181.400.300;D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.872.374;N05.715.360.750.725.500;N06.850.520.830.872.500;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.196.566.880
30367518,Glutamate Dehydrogenase;Insulin,D08.811.682.664.500.398;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
30367311,"Interdisciplinary Communication;Psoriasis;Arthritis, Psoriatic;Quality of Health Care",F01.829.401.205.249;L01.143.865.500;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;N04.761;N05.715
30367059,"2-Aminoadipate Transaminase;Animals;Biological Transport;COS Cells;Cercopithecus aethiops;European Continental Ancestry Group;Gene Expression Regulation;Genome-Wide Association Study;Humans;Hyperthyroidism;Hypothyroidism;Polymorphism, Single Nucleotide;Risk Factors;Sodium-Phosphate Cotransporter Proteins, Type I;Thyroid Gland;Thyroid Hormones;Thyrotropin",D08.811.913.477.700.120;B01.050;G03.143;A11.251.210.172.500;A11.329.228.220;B01.050.150.900.649.313.988.400.112.199.120.126.110;M01.686.508.400;G05.308;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C19.874.397;C19.874.482;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.157.530.450.074.750.750.500;D12.776.157.530.450.625.625.500;D12.776.157.648.500.750.500;D12.776.543.585.450.074.750.750.500;D12.776.543.585.450.625.625.500;A06.300.900;D06.472.931;D06.472.699.631.525.883;D12.644.548.691.525.883
30366745,Hydrocephalus,C10.228.140.602
30366567,,
30366552,"JC Virus;Opportunistic Infections;Leukoencephalopathy, Progressive Multifocal",B04.280.210.700.615.400;B04.613.204.670.615.400;C01.539.597;C02.597;C03.684;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450
30366111,,
30366018,Dystonia;RNA Interference,C10.597.350.300;C23.888.592.350.300;G05.308.203.374.790
30365996,,
30365873,Polymicrogyria,C10.500.507.500.500;C16.131.666.507.500.500
30365426,,
30365390,Haplorhini;Motion,B01.050.150.900.649.313.988.400;G01.482
30365354,Actigraphy;Exercise,E01.370.520.049;E05.003.500;G11.427.410.698.277;I03.350
30364843,,
30364328,"Stress Disorders, Post-Traumatic;Veterans;Magnetic Resonance Imaging",F03.950.750.500;M01.930;E01.370.350.825.500
30364123,Hippocampus,A08.186.211.180.405;A08.186.211.200.885.287.500.345
30363975,,
30363491,Epidemiology;Huntington Disease,H02.403.720.500;C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390
30363045,"Certification;Databases, Factual;Fellowships and Scholarships;Humans;Orthopedics;Pediatrics;Specialization;Specialty Boards;Sports Medicine;United States",N03.706.110.120;N05.700.200.190;L01.313.500.750.300.188.400;L01.470.750.750;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;H02.403.810.494;H02.403.670;H02.811;N03.706.110.120.580;N05.700.200.190.750;H02.403.830;Z01.107.567.875
30362824,Anti-Bacterial Agents;Obesity;Primary Health Care,D27.505.954.122.085;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;N04.590.233.727
30362448,Endocrine Disruptors;Inflammation;Insulin Secretion,D27.505.696.353;D27.888.141;C23.550.470;G03.442;G07.475
30362249,,
30362247,Inosine Triphosphate;Hemophilia A,D03.633.100.759.646.616.800;D13.695.667.616.800;D13.695.827.519.800;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500
30361699,,
30361432,,
30361325,"Angiotensin II;Endothelins;Glomerulosclerosis, Focal Segmental;Proteinuria",D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;D12.644.276.400;D12.776.467.400;D23.529.400;C12.777.419.570.363.660;C13.351.968.419.570.363.640;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
30361206,,
30360383,Iron;Retina,D01.268.556.412;D01.268.956.287;D01.552.544.412;A09.371.729
30359683,"Dermatitis, Atopic;Biological Products;Eczema;Microbiota;Transcriptome",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D20.215;C17.800.174.620;C17.800.815.620;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G02.111.873.750;G05.297.700.750;G05.360.920
30358739,,
30358719,,
30358690,,
30358689,,
30358241,,
30358158,Gene Editing,E05.393.420.270
30357853,,
30357777,,
30357359,,
30357297,"Cerebral Intraventricular Hemorrhage;Double-Blind Method;Follow-Up Studies;Gestational Age;Humans;Infant, Extremely Premature;Infant, Newborn;Infant, Newborn, Diseases;Inositol;Intensive Care, Neonatal;Retinopathy of Prematurity;Treatment Failure",C10.228.140.300.535.200.600;C14.907.253.573.200.600;C23.550.414.913.100.600;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;M01.060.703.520;C16.614;D02.033.800.519;D09.853.519;E02.760.190.405;N02.421.585.190.500;C11.768.836;C16.614.521.731;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
30357278,Mass Screening;Spouse Abuse,E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;I01.198.240.856.350.750;I01.198.240.856.575.500;I01.880.735.900.350.750;I01.880.735.900.688.500
30356771,Parietal Lobe;Speech Perception,A08.186.211.200.885.287.500.670;F02.463.593.071.875
30355956,,
30355686,HIV Infections,C02.782.815.616.400;C02.800.801.400;C20.673.480
30355623,,
30355496,"Antibodies, Neutralizing",D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
30355261,Learning Curve,F02.784.629.529.274
30355212,Brain Ischemia;Cerebrovascular Disorders;Child;Follow-Up Studies;Humans,C10.228.140.300.150;C14.907.253.092;C10.228.140.300;C14.907.253;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400
30354783,Hemodynamics;Prostheses and Implants;Pulmonary Valve;Stents;Tetralogy of Fallot,G09.330.380;E07.695;A07.541.510.738;E07.695.750;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30354718,"Adolescent;Blood Pressure;Hypertension;Monitoring, Ambulatory;Pediatrics;Prevalence",M01.060.057;E01.370.600.875.249;G09.330.380.076;C14.907.489;E01.370.520.500;H02.403.670;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
30354589,"Certification;Education, Medical;Outcome Assessment (Health Care);Percutaneous Coronary Intervention;Quality of Health Care",N03.706.110.120;N05.700.200.190;I02.358.399;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E04.100.814.529.968;E04.502.382.968;N04.761;N05.715
30354544,"Atherosclerosis;Cholesterol Esters;Cholesterol, HDL;Cholesterol, LDL;Lecithin Cholesterol Acyltransferase Deficiency",C14.907.137.126.307;D04.210.500.247.222.284.200;D04.210.500.247.808.197.200;D10.570.938.208.250;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;C16.320.565.398.500.330.500;C18.452.584.500.875.330.500;C18.452.648.398.500.330.500
30354518,"Blood Pressure;Blood Pressure Monitoring, Ambulatory",E01.370.600.875.249;G09.330.380.076;E01.370.370.140.100;E01.370.520.500.100
30354458,"Ethics Committees, Research;Multicenter Study",K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;V03.650
30354304,Endothelial Cells;Gene Expression;Genome-Wide Association Study;Genomics;Stem Cells,A11.436.275;G05.297;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;A11.872
30354303,"Actins;Cardiomyopathies;Family;Genes;Genetic Testing;Mutation;Tachycardia, Ventricular",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;C14.280.238;F01.829.263;I01.880.853.150;G05.360.340.024.340;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30354298,Takayasu Arteritis;Aortitis;Autophagy;Genetics,C14.907.109.239.650;C14.907.940.090.800;C17.800.862.875;C14.907.109.320;C14.907.940.080;G04.146.399;G04.417.350.091;H01.158.273.343
30354233,"Megakaryocytes;Purpura;Purpura, Thrombotic Thrombocytopenic;von Willebrand Factor",A11.148.479;A15.378.316.479;C15.378.100.802;C23.550.414.950;C23.888.885.687;C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680;D12.776.124.125.920;D23.119.985
30354222,Arteriosclerosis;Humans;Mice;Rats;Thrombosis,C14.907.137.126;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.700;C14.907.355.830
30353829,,
30353806,"Obesity;Sleep Apnea, Obstructive;Exercise",C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C08.618.085.852.850;C10.886.425.800.750.850;G11.427.410.698.277;I03.350
30353273,"Brain;Clinical Protocols;Infant, Newborn;Perfusion",A08.186.211;E02.183;N05.715.360.330.125;M01.060.703.520;E05.680
30353265,Glioblastoma;Immunotherapy;T-Lymphocytes,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;E02.095.465.425;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
30353082,,
30353015,,
30353006,"Animals;DNA-Binding Proteins;Drosophila Proteins;Drosophila melanogaster;Genetic Loci;HEK293 Cells;Humans;Models, Biological;Nuclear Proteins;Polytene Chromosomes;Protein Binding;RNA, Small Nuclear;RNA, Untranslated;Transcription Elongation, Genetic;Transcription Factors;Transcriptional Elongation Factors",B01.050;D12.776.260;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;G05.360.340.024.380;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;D12.776.660;A11.284.187.440.500;A11.284.430.106.279.345.190.580;G05.360.162.440.500;G02.111.679;G03.808;D13.444.735.628.818;D13.444.735.790.552.937;D13.444.735.790;G02.111.873.562;G05.297.700.562;D12.776.930;D12.776.930.955
30352544,Anterior Cruciate Ligament Reconstruction;Obesity,E04.555.110.026;E04.680.101.026;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30352434,Delivery Rooms;Neonatology;Resuscitation,N02.278.388.150;H02.403.670.400;E02.365.647
30352365,Complement System Proteins;Epigenomics,D12.776.124.486.274;H01.158.273.180.350.074;H01.158.273.343.350.042
30352289,,
30352204,Glucocorticoids;Dermatomyositis;Vasculitis,D06.472.040.543;D27.505.696.399.472.488;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;C14.907.940
30352048,Endocrinology;Epigenomics,H01.158.782.323;H02.403.429.323;H01.158.273.180.350.074;H01.158.273.343.350.042
30351409,,
30351394,,
30350774,,
30350439,Histone Chaperones;Chromatin Assembly and Disassembly;Histones,D12.776.580.219;G04.400.095;G05.213.095;G05.308.095;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469
30350406,Art;HIV,K01.093;B04.820.650.589.650.350
30350375,,
30350026,,
30349857,,
30349849,,
30349770,,
30349508,Gardnerella vaginalis;Lactobacillus crispatus;Cervix Uteri;Inflammation;MicroRNAs;Premature Birth,B03.510.024.400.800;B03.353.750.450.475.238;B03.510.460.400.410.475.475.238;B03.510.550.450.475.238;A05.360.319.679.256;C23.550.470;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;C13.703.420.491.500
30349290,Medicaid;Transportation;Social Determinants of Health,N03.219.521.346.506.564.655;N03.706.615.693;J01.937;N01.224.425.762;N01.400.675
30349096,,
30348976,Animals;Apoptosis;Cell Line;Cell Proliferation;Endothelial Cells;Fertility Preservation;Germ Cells;Glial Cell Line-Derived Neurotrophic Factor;Humans;Mice;Spermatogenesis;Stem Cell Niche;Testis,B01.050;G04.146.160;A11.251.210;G04.161.750;G07.345.249.410.750;A11.436.275;E02.875.800.625;E04.936.537.562;E05.820.800.625;A05.360.490;A11.497;D12.644.276.860.381.500;D12.776.467.860.381.500;D12.776.631.600.381.500;D23.529.850.381.500;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;G04.152.650.624;G08.686.784.310.760;G04.366.249;A05.360.444.849;A05.360.576.782;A06.300.312.782
30348778,Sirtuin 1,D08.811.277.087.520.200.650.100;D12.776.476.900.100
30348619,Fluorouracil;Acute Coronary Syndrome;Capecitabine;Chest Pain,D03.383.742.698.875.404;C14.280.647.124;C14.907.585.124;D03.383.742.680.245.500.425;D03.383.742.698.875.404.425;D13.570.230.329.313;D13.570.685.245.500.425;C23.888.592.612.233
30348343,Adolescent;Humans;Prospective Studies;Quality of Life;Retrospective Studies;Scheuermann Disease;Scoliosis;Quality of Life;Pain;Scheuermann Disease,M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.821.500.500;C05.116.900.800.500.500;C05.116.900.808.500;C05.116.900.800.875;I01.800;K01.752.400.750;N06.850.505.400.425.837;C23.888.592.612;F02.830.816.444;G11.561.790.444;C05.116.821.500.500;C05.116.900.800.500.500;C05.116.900.808.500
30348338,"Adolescent;Child;Cross-Sectional Studies;Humans;Image Processing, Computer-Assisted;Observer Variation;Radiography;Rotation;Scoliosis",M01.060.057;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.350.700;G01.482.703;C05.116.900.800.875
30348335,,
30348077,Autism Spectrum Disorder;Endophenotypes;Language,F03.625.164.113;G05.695.224;F01.145.209.399;L01.559
30347621,Cognition Disorders;Delirium;Neurocognitive Disorders;Postoperative Complications,F03.615.250;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;F03.615;C23.550.767
30347572,"Neurosurgery;Neurosurgical Procedures;Reflex, Trigeminocardiac",H02.403.810.425;E04.525;G11.561.731.781
30347042,,
30347020,,
30346801,Pregnancy;Viral Load,G08.686.784.769;E01.370.225.875.950;E05.200.875.950;G06.920.850
30346472,,
30346358,,
30346242,Aged;Antipsychotic Agents;Critical Illness;Delirium;Dopamine Antagonists;Double-Blind Method;Haloperidol;Humans;Kaplan-Meier Estimate;Middle Aged;Piperazines;Respiratory Insufficiency;Shock;Thiazoles;Treatment Failure,M01.060.116.100;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;C23.550.291.625;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;D27.505.519.625.150.175;D27.505.696.577.150.175;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D02.522.352.506;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;D03.383.606;C08.618.846;C23.550.835;D02.886.675;D03.383.129.708;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
30345565,"Africa;Urinary Bladder Neoplasms;Carcinoma, Squamous Cell;Carcinoma, Transitional Cell",Z01.058;C04.588.945.947.960;C12.758.820.968;C12.777.829.813;C13.351.937.820.945;C13.351.968.829.707;C04.557.470.200.400;C04.557.470.700.400;C04.557.470.200.430
30345432,,
30344046,Drosophila;Glioblastoma;Glioma;Ion Channels;Mice,B01.050.500.131.617.720.500.500.750.310.250;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400;B01.050.150.900.649.313.992.635.505.500
30344038,,
30343978,"Adolescent;Adult;Child;Child, Preschool;Congenital Hyperinsulinism;Follow-Up Studies;Humans;Infant;Infant, Newborn;Insulinoma;Laparoscopy;Pancreas;Pancreatectomy;Pancreatic Neoplasms;Positron Emission Tomography Computed Tomography;Retrospective Studies;Young Adult;Beckwith-Wiedemann Syndrome;Congenital Hyperinsulinism;Insulinoma;Pancreatectomy",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04.557.470.035.100.852;C04.588.274.761.249.500;C04.588.322.475.249.500;C06.301.761.249.500;C06.689.667.249.500;C19.344.421.249.500;E01.370.388.250.520;E04.502.250.520;A03.734;E04.210.752;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;C16.131.077.133;C16.131.260.080;C16.320.180.080;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;C04.557.470.035.100.852;C04.588.274.761.249.500;C04.588.322.475.249.500;C06.301.761.249.500;C06.689.667.249.500;C19.344.421.249.500;E04.210.752
30343955,"Asphyxia Neonatorum;Humans;Hypothermia;Hypothermia, Induced;Hypoxia-Ischemia, Brain;Infant;Infant, Newborn;Infant, Premature;Asphyxia;Evidence-Based Medicine;Clinical Decision-Making",C16.614.092;B01.050.150.900.649.313.988.400.112.400.400;C23.888.119.565;E02.258.750;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703;M01.060.703.520;M01.060.703.520.520;C23.550.260.095;C26.103;H02.249.750;H02.403.200.400;E01.055
30343943,Arthrogryposis;Calcium Channels;Epilepsy,C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;C10.228.140.490
30343890,"Dependovirus;Bioengineering;Genetic Therapy;Protein Processing, Post-Translational;Viral Structures",B04.280.580.650.170;J01.293.069;E02.095.301;E05.393.420.301;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;A21
30343507,,
30342588,Biomarkers;Genetics;Microbiota;Polyps,D23.101;H01.158.273.343;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C23.300.825
30341983,Cetuximab;Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Propensity Score,D12.776.124.486.485.114.224.060.750;D12.776.124.790.651.114.224.060.750;D12.776.377.715.548.114.224.200.750;E02.186.079;E02.319.164;E02.815.160;D01.210.375;D01.625.125;D01.710.100;C04.588.443;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650
30341588,Prenatal Diagnosis,E01.370.378.630
30340044,Embryonic Development,G07.345.500.325.180;G08.686.784.170.104
30339959,,
30339958,,
30339729,Fibrosis;Hepatitis C;Hormones;Liver Diseases;Women,C23.550.355;C02.440.440;C02.782.350.350;C06.552.380.705.440;D06.472;D27.505.696.399.472;C06.552;M01.975
30339583,,
30339549,,
30339522,,
30338538,,
30338489,,
30338267,Pediatrics,H02.403.670
30337873,PPAR gamma;Pioglitazone,D12.776.826.239.588;D02.886.675.933.250;D03.383.129.708.933.250
30337651,,
30337566,,
30337451,"Ethics, Research",K01.752.566.479.173;N05.350.670
30337335,,
30337189,Incubators;Randomized Controlled Trial;Temperature;Weaning,E07.461;V03.175.250.500.500;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;G07.203.650.220.500.750;G07.203.650.915
30337151,Alzheimer Disease;Gastrointestinal Microbiome;Immunity;Inflammation;Metabolome;Metabolomics,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G12.450;C23.550.470;G03.500;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
30336876,"Ebstein Anomaly;Catheter Ablation;Death, Sudden, Cardiac;Tachycardia, Ventricular",C14.240.400.395;C14.280.400.395;C16.131.240.400.395;E02.808.750.500;E04.014.760.500;C14.280.383.220;C23.550.260.322.250;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30336844,Anesthesia;Cognition Disorders;Diagnostic and Statistical Manual of Mental Disorders;Emergence Delirium;Humans;Incidence;Neuropsychological Tests;Postoperative Complications;Preexisting Condition Coverage;Research Design;Terminology as Topic;Cognition Disorders;Delirium;Neurocognitive Disorders;Postoperative Complications,E03.155;F03.615.250;L01.453.245.945.200;C10.597.606.337.500.500;C23.550.767.181;C23.888.592.604.339.500.500;F01.700.250.500.500;F03.615.350.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;F04.711.513;C23.550.767;N03.219.521.576.585.500;E05.581.500;H01.770.644.728;L01.559.598.400;F03.615.250;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;F03.615;C23.550.767
30336416,,
30336264,,
30336260,,
30336259,,
30336257,,
30336228,"Diagnostic Tests, Routine;Humans;Income;Odorants;Smell;Socioeconomic Factors",E01.370.395;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;G16.500.275.640;N06.230.480;F02.830.816.643;G11.561.790.643;I01.880.853.996;N01.824
30336167,Inflammation,C23.550.470
30335920,Child;Contrast Media;Urinary Tract Infections;Vesico-Ureteral Reflux,M01.060.406;D27.505.259.500;D27.720.259;C01.539.895;C12.777.892;C13.351.968.892;C12.777.829.920;C13.351.968.829.920
30335698,,
30335555,Brain-Derived Neurotrophic Factor;Extracellular Vesicles;Regenerative Medicine,D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;A11.284.295.588;H02.403.750
30335514,Adolescent,M01.060.057
30334910,,
30334904,,
30333998,,
30333982,,
30333217,,
30333155,Cholesterol;Cytoskeleton;Iron;Lipoproteins;Retina,D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;A11.284.430.214.190.750;D01.268.556.412;D01.268.956.287;D01.552.544.412;D10.532;D12.776.521;A09.371.729
30333130,,
30332401,"Adult;Brain;Computational Biology;Humans;Language;Models, Neurological;Nerve Net;Speech Perception;Task Performance and Analysis;Young Adult",M01.060.116;A08.186.211;H01.158.273.180;L01.313.124;B01.050.150.900.649.313.988.400.112.400.400;F01.145.209.399;L01.559;E05.599.395.642;A08.511;F02.463.593.071.875;F02.784.412.846;F02.784.692.746;F02.808.600;M01.060.116.815
30329153,,
30328405,"Communication;Education, Medical;Africa South of the Sahara",F01.145.209;L01.143;I02.358.399;Z01.058.290
30327536,,
30327483,"Asthma;Cohort Studies;Databases, Factual;Drug Discovery;Genetic Association Studies;Genetic Pleiotropy;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Interferon-Induced Helicase, IFIH1;Lipase;Membrane Proteins;Molecular Targeted Therapy;Phenotype;Polymorphism, Single Nucleotide;Reproducibility of Results;Thromboembolism;United Kingdom",C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;E05.295;H01.158.703.007.675;H01.181.466.675;E05.393.385;G05.420.556;G05.695.550;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.445.735.720.249.875;D08.811.277.352.100.400;D12.776.543;E02.319.574;G05.695;G05.365.795.598;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C14.907.355.590;Z01.542.363
30327441,"Animals;Anti-Bacterial Agents;Biological Transport, Active;Copper;Drug Tolerance;Interspersed Repetitive Sequences;Membrane Transport Proteins;Methicillin-Resistant Staphylococcus aureus;Mice;Microbial Viability;Operon;Oxidation-Reduction;Oxidoreductases;Phagocytes;Plasmids;RAW 264.7 Cells;Methicillin-Resistant Staphylococcus aureus;Staphylococcus aureus;Macrophages;Metals;Interspersed Repetitive Sequences",B01.050;D27.505.954.122.085;G03.143.310;D01.268.556.195;D01.268.956.170;D01.552.544.195;G07.690.773.992;G02.111.570.080.708.330;G05.360.080.708.330;G05.360.340.024.425;D12.776.157.530;D12.776.543.585;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B01.050.150.900.649.313.992.635.505.500;G06.580;G05.360.340.024.686;G05.360.340.358.207.500;G02.700;G03.295.531;D08.811.682;A11.733;A15.382.680;G05.360.600;A11.251.210.172.875;A11.733.397.815;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;D01.552;G02.111.570.080.708.330;G05.360.080.708.330;G05.360.340.024.425
30326976,"Atrioventricular Block;Cardiac Conduction System Disease;Child;Disease Progression;Electrocardiography;Humans;Kearns-Sayre Syndrome;Pacemaker, Artificial;Prophylactic Surgical Procedures;Kearns-Sayre Syndrome;Pediatrics",C14.280.067.558.230;C14.280.123.500.230;C23.550.073.425.062;C14.280.123;M01.060.406;C23.550.291.656;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;C05.651.460.700.500;C10.292.562.750.250.500;C10.597.622.447.511.500;C10.668.491.500.700.500;C11.590.472.250.500;C11.768.585.658.500.627;C14.280.238.510;C18.452.660.410;C18.452.660.560.700.500;C23.888.592.636.447.511.500;E07.305.250.750;E04.625;C05.651.460.700.500;C10.292.562.750.250.500;C10.597.622.447.511.500;C10.668.491.500.700.500;C11.590.472.250.500;C11.768.585.658.500.627;C14.280.238.510;C18.452.660.410;C18.452.660.560.700.500;C23.888.592.636.447.511.500;H02.403.670
30326883,Cerebral Palsy;Child;Rehabilitation,C10.228.140.140.254;M01.060.406;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
30326321,,
30326316,"Humans;Skull Fracture, Depressed;Skull Fracture, Depressed",B01.050.150.900.649.313.988.400.112.400.400;C10.900.300.918.300;C26.404.750.890;C26.915.300.745.350;C10.900.300.918.300;C26.404.750.890;C26.915.300.745.350
30326046,,
30326026,Direct-To-Consumer Screening and Testing;Humans;Paternalism;Personal Autonomy;Physician's Role;Physician-Patient Relations;Referral and Consultation,E01.370.398;N02.421.726.233.166;B01.050.150.900.649.313.988.400.112.400.400;F01.829.547;F02.600;I01.880.604.473.380.500;K01.752.566.479.830.650;N03.706.437.380.500;N05.350.958.650;F01.829.316.616.625.600;F01.829.401.650.675;N05.300.660.625;N04.452.758.849
30326008,,
30325878,,
30325861,"Acute Disease;Biomedical Research;Child;Child, Preschool;Cohort Studies;Diabetes Mellitus;Humans;International Agencies;Multicenter Studies as Topic;Observational Studies as Topic;Pancreatic Neoplasms;Pancreatitis;Pancreatitis, Chronic;Research Design;Surveys and Questionnaires",C23.550.291.125;H01.770.644.145;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C18.452.394.750;C19.246;B01.050.150.900.649.313.988.400.112.400.400;N03.540.514;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;E05.318.372.250.500;N05.715.360.330.250.500;N06.850.520.450.250.500;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;C06.689.750;C06.689.750.830;E05.581.500;H01.770.644.728;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
30325806,,
30325748,,
30325747,,
30325647,Femoracetabular Impingement,C05.550.384;C23.550.347
30325587,"C-Reactive Protein;Crohn Disease;Tourette Syndrome;Hypersensitivity;Anorexia Nervosa;Attention Deficit Disorder with Hyperactivity;Bipolar Disorder;Celiac Disease;Hypothyroidism;Neuroticism;Liver Cirrhosis, Biliary;Arthritis, Rheumatoid;Smoking;Lupus Erythematosus, Systemic;Diabetes Mellitus, Type 1;Colitis, Ulcerative",D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;C06.405.205.731.500;C06.405.469.432.500;C10.228.140.079.898;C10.228.662.825.800;C10.574.500.850;C16.320.400.820;F03.625.992.850;C20.543;F03.400.125;F03.625.094.150;F03.084.500;C06.405.469.637.250;C18.452.603.250;C19.874.482;F01.752.723;C06.130.120.135.250.250;C06.552.150.250;C06.552.630.400;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;F01.145.805;C17.300.480;C20.111.590;C18.452.394.750.124;C19.246.267;C20.111.327;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
30325306,"5-Methylcytosine;Animals;DNA Methylation;DNA-Binding Proteins;Dioxygenases;Epigenomics;Gene Expression Regulation, Developmental;Hematopoiesis;Humans;Mice;Mouse Embryonic Stem Cells;Mutation;N-Acetylglucosaminyltransferases;Protein Binding;Protein Domains;Proto-Oncogene Proteins;Zebrafish;Zebrafish Proteins;Biochemistry;Cell Biology;Chromatin;Epigenomics;Mice;Stem Cells",D03.383.742.698.421.500;B01.050;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;D08.811.682.690.416;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.308.310;G04.152.825;G09.188.343;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.872.700.250.875;G05.365.590;D08.811.913.400.100.250;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.624.664.700;B01.050.150.900.493.200.244.828;D12.776.325.500;H01.158.201;H01.181.122;H01.158.100.433;H01.158.273.160;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;B01.050.150.900.649.313.992.635.505.500;A11.872
30325016,Cognition Disorders;Delirium;Neurocognitive Disorders;Postoperative Complications,F03.615.250;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;F03.615;C23.550.767
30324723,Adolescent;Calcitonin Gene-Related Peptide;Migraine Disorders,M01.060.057;D12.644.400.097;D12.776.631.650.097;C10.228.140.546.399.750
30324338,Cognition Disorders;Delirium;Neurocognitive Disorders;Postoperative Complications,F03.615.250;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;F03.615;C23.550.767
30324301,Acute Coronary Syndrome;Clopidogrel;Drug Utilization;Medical Records;Proton Pump Inhibitors,C14.280.647.124;C14.907.585.124;D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500;N04.452.706.477;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;D27.505.519.389.848
30324289,,
30324048,Disclosure,F01.829.401.046;I01.880.604.583.080.134;L01.143.335
30323833,Gene Regulatory Networks;Schizophrenia,G05.360.080.689.360;F03.700.750
30323345,,
30322910,Adult;Depression;Depressive Disorder;Electronic Health Records;Humans;Language;Social Media;Surveys and Questionnaires;Big Data;Depression;Mass Screening;Social Media,M01.060.116;F01.145.126.350;F03.600.300;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;F01.145.209.399;L01.559;L01.178.751;L01.224.230.110.500.750;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;L01.313.500.750.300.092;F01.145.126.350;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;L01.178.751;L01.224.230.110.500.750
30322903,Locus Coeruleus;Sleep Deprivation;Tauopathies,A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;C10.574.945
30322880,,
30322798,,
30322413,"Argentina;Attitude of Health Personnel;Canada;Cardiology Service, Hospital;Glasgow Coma Scale;Heart Defects, Congenital;Humans;Intensive Care Units, Pediatric;Kuwait;Mexico;Nervous System Diseases;Neurodevelopmental Disorders;Neurologic Examination;Physicians;Surveys and Questionnaires;United States;Glasgow Coma Scale;Brain Injuries",Z01.107.757.077;F01.100.050;N05.300.100;Z01.107.567.176;N02.278.216.500.968.215;N04.452.442.422.215;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;Z01.252.245.500.425;Z01.107.567.589;C10;F03.625;E01.370.376.550;E01.370.600.550;M01.526.485.810;N02.360.810;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;C10.228.140.199;C10.900.300.087;C26.915.300.200
30321739,Adult;Alcoholism;Ambulatory Care Facilities;Diagnostic and Statistical Manual of Mental Disorders;Humans;Patient Satisfaction;Primary Health Care;Surveys and Questionnaires;Tobacco Use Disorder;Virtual Reality;Tobacco;Virtual Reality,M01.060.116;C25.775.100.250;F03.900.100.350;N02.278.035;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;N04.590.233.727;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C25.775.912;F03.900.912;L01.224.160.875;L01.296.555;B01.650.940.800.575.912.250.908.500.900;L01.224.160.875;L01.296.555
30321505,Alzheimer Disease;Amyloid;Disease Progression;Cognitive Dysfunction,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;C23.550.291.656;F03.615.250.700
30321501,"Alzheimer Disease;Diagnosis, Differential;Enzyme-Linked Immunosorbent Assay;GAP-43 Protein",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E01.171;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;D12.776.395.550.400;D12.776.543.550.400;D12.776.631.400
30320311,,
30320310,,
30320308,,
30320083,Adenocarcinoma;Carcinoma;Eyelids;Lacrimal Apparatus,C04.557.470.200.025;C04.557.470.200;A01.456.505.420.504;A09.371.337;A09.371.463;A10.336.422
30319709,Autism Spectrum Disorder;Adult;Anxiety;Depression;Therapeutics;Therapeutics,F03.625.164.113;M01.060.116;F01.470.132;F01.145.126.350;E02;E02
30319473,Attention;Drawing;Executive Function,F02.830.104.214;V01.185.625;V02.700.300;F02.463.217
30318995,"Adolescent;Adult;Age of Onset;Child;Child, Preschool;Echocardiography;Endocarditis;Heart Valve Diseases;Humans;Incidence;Lupus Erythematosus, Systemic;Middle Aged;Myocarditis;Pericarditis;Prevalence;Regression Analysis;Retrospective Studies;Risk Factors;United States;Young Adult;Cardiovascular Diseases;Lupus Erythematosus, Systemic",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.280.282;C14.280.484;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C17.300.480;C20.111.590;M01.060.116.630;C14.280.238.625;C14.280.720;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;M01.060.116.815;C14;C17.300.480;C20.111.590
30318516,,
30318138,"Adolescent;Alopecia;Alopecia Areata;Child;Cohort Studies;Databases, Factual;Disease Progression;Hospitals, Pediatric;Hospitals, University;Humans;Philadelphia;Prevalence;Prognosis;Retrospective Studies;Seasons;Severity of Illness Index",M01.060.057;C17.800.329.937.122;C23.300.035;C17.800.329.937.122.147;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;C23.550.291.656;N02.278.421.556.437;N02.278.020.300.310;N02.278.421.639.725;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
30317541,,
30317433,"Renal Insufficiency, Chronic;Kidney Failure, Chronic",C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750.500;C13.351.968.419.780.750.500
30317410,"Immunotherapy;Lymphoma, T-Cell;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma",E02.095.465.425;C04.557.386.480.750;C15.604.515.569.480.750;C20.683.515.761.480.750;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620
30316959,Disabled Persons;Government Programs;Medicare;Patient Satisfaction;Rehabilitation,M01.150;I01.451;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
30316807,,
30316776,Area Under Curve,E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200
30316411,"Fertility;Health Status;Humans;Infertility, Female;Infertility, Male;Longevity;Reproduction;Infertility, Female;Longevity;Infertility, Male",G08.686.210;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;C13.351.500.365.700;C12.294.365.700;G07.345.124.519;G07.540;G08.686.784;C13.351.500.365.700;G07.345.124.519;G07.540;C12.294.365.700
30316320,,
30316316,Child;Global Health;Humans;Morbidity;Program Development;Urologic Diseases;Urology;Bladder Exstrophy,M01.060.406;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;N04.452.760;C12.777;C13.351.968;H02.403.810.860;C12.706.132;C12.777.829.132;C13.351.875.132;C13.351.968.829.132;C16.131.939.132
30316315,Child;Humans;Minimally Invasive Surgical Procedures;Urologic Diseases;Urology;Laparoscopy;Minimally Invasive Surgical Procedures,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E04.502;C12.777;C13.351.968;H02.403.810.860;E01.370.388.250.520;E04.502.250.520;E04.502
30316314,Humans;Pediatrics;Transition to Adult Care;Urologic Diseases;Urology;Disorders of Sex Development;Hypospadias;Prune Belly Syndrome;Spinal Dysraphism,B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;C12.777;C13.351.968;H02.403.810.860;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119;C12.294.494.400;C12.706.516;C13.351.875.466;C16.131.939.516;C16.131.077.745;C10.500.680.800;C16.131.666.680.800
30316309,"Child;Diagnostic Techniques, Urological;Global Health;Humans;Incidence;Kidney Calculi;Risk Factors;Diagnostic Imaging;Nephrolithiasis;Pediatrics;Urology",M01.060.406;E01.370.390;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;H02.403.670;H02.403.810.860
30315947,Hispanic Americans;Language,M01.686.754.441;F01.145.209.399;L01.559
30315941,Graft vs Host Disease,C20.452
30315831,Eosinophilic Esophagitis,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356
30315772,"Hepatitis, Alcoholic;Humans;Liver Transplantation;Patient Selection",C06.552.380.290;C06.552.645.490;C25.775.100.087.645.490;B01.050.150.900.649.313.988.400.112.400.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E05.581.500.653;N04.590.731
30315340,Catheter Ablation;Fluoroscopy,E02.808.750.500;E04.014.760.500;E01.370.350.700.225
30315151,,
30314802,"Apolipoprotein A-I;Apolipoprotein C-III;Lipoproteins, HDL",D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;D10.532.091.400.875;D12.776.070.400.400.875;D12.776.521.120.400.875;D10.532.432;D12.776.521.479
30314662,Autistic Disorder;Obesity,F03.625.164.113.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30314641,Cytokines;Pregnancy,D12.644.276.374;D12.776.467.374;D23.529.374;G08.686.784.769
30312755,,
30312721,Biocompatible Materials;Immunotherapy;Nanomedicine;Translational Medical Research,D25.130;D27.720.102.130;J01.637.051.130;E02.095.465.425;H01.603.600;J01.897.115.625;J01.897.520.600.600;H01.770.644.145.675
30312705,Neutropenia;Severe Combined Immunodeficiency,C15.378.553.546.184.564;C16.614.815;C18.452.284.800;C20.673.815
30312551,Cystic Fibrosis;Lung Transplantation,C06.689.202;C08.381.187;C16.320.190;C16.614.213;E04.928.600.495;E04.936.450.495
30312457,,
30312226,,
30312223,"Aged;Databases, Factual;Humans;Lymphatic Metastasis;Middle Aged;Neoplasm Grading;Neuroendocrine Tumors;Rectal Neoplasms;Retrospective Studies;Risk Factors;Survival Rate;Tumor Burden;United States",M01.060.116.100;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;M01.060.116.630;E01.789.612;C04.557.465.625.650;C04.557.580.625.650;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E05.041.124.892;Z01.107.567.875
30312013,Copepoda;Muscles;Sarcomeres,B01.050.500.131.365.160;A02.633;A10.690;A10.690.552.875.700;A11.284.430.214.190.875.820;A11.620.249.850.700;A11.620.500.500.700
30311853,Extracellular Vesicles;Peripheral Nerve Injuries,A11.284.295.588;C10.668.829.712;C10.900.575;C26.915.650
30311386,Deafness;Hearing Loss,C09.218.458.341.186;C10.597.751.418.341.186;C23.888.592.763.393.341.186;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341
30311378,Information Dissemination,L01.143.443
30311377,Epilepsy,C10.228.140.490
30311369,,
30311139,"Glucose;Hypoglycemia;Insulin;Infant, Newborn;Pancreas",D09.947.875.359.448;C18.452.394.984;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;M01.060.703.520;A03.734
30311096,,
30310141,Animals;Brain;Cytoplasm;DNA-Binding Proteins;Frontotemporal Lobar Degeneration;Hippocampus;Humans;Mice;Neurons;Tissue Extracts,B01.050;A08.186.211;A11.284.430.214;D12.776.260;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A08.675;A11.671;D20.777
30309898,Ultrasonography;Arteriovenous Fistula;Clinical Trial;Renal Dialysis,E01.370.350.850;C14.240.850.750.147;C14.240.850.984.750;C14.907.150.125;C14.907.933.555;C16.131.240.850.750.125;C23.300.575.950.250;V03.175.250;E02.870.300;E02.912.800
30309891,,
30309762,,
30309675,Advisory Committees;Electric Power Supplies;Esophagus;Foreign Bodies;Humans;Pediatrics;Product Labeling;Foreign Bodies,N03.706.742.500;E07.305.124;A03.556.875.500;C26.392;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;J01.576.761.700;C26.392
30309358,"Abortion, Spontaneous;Adult;Chorionic Gonadotropin;Estradiol;Humans;Placental Lactogen;Pregnancy;Pregnancy Outcome;Pregnancy Trimester, First;Progesterone;Prospective Studies;Risk Assessment;Risk Factors;Abortion, Spontaneous;Estradiol;Progesterone",C13.703.039;G08.686.784.769.496.125;M01.060.116;D06.472.699.322.326;D06.472.699.649.367;D12.644.548.726.367;D12.776.780.400;D04.210.500.365.415.248;D06.472.334.851.437.500;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.649.692;D12.644.548.726.692;D12.776.780.650;G08.686.784.769;E01.789.700;G08.686.784.769.496;G08.686.707.408;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C13.703.039;G08.686.784.769.496.125;D04.210.500.365.415.248;D06.472.334.851.437.500;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750
30309259,Cleft Palate,C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185
30308214,Reinforcement (Psychology);Substance-Related Disorders,F02.463.425.770;C25.775;F03.900
30308200,,
30308161,"Adolescent;Adrenal Cortex Hormones;Anti-Inflammatory Agents, Non-Steroidal;Child;Child, Preschool;Clostridiales;Cohort Studies;Colectomy;Colitis, Ulcerative;Disease Progression;Feces;Gastrointestinal Microbiome;Humans;Leukocyte L1 Antigen Complex;Longitudinal Studies;Mesalamine;Time Factors;Colectomy;Adrenal Cortex Hormones;Gastrointestinal Microbiome",M01.060.057;D06.472.040;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;M01.060.406;M01.060.406.448;B03.353.625;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.210.219;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;C23.550.291.656;A12.459;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.125.750.500;D12.776.631.655.500;D23.050.301.562;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;D02.241.223.100.050.300.500;D02.241.223.100.300.595.100.540;D02.241.511.390.595.100.540;D02.455.426.559.389.127.020.452.750;D02.455.426.559.389.127.281.595.100.540;D02.455.426.559.389.657.410.595.100.540;G01.910.857;E04.210.219;D06.472.040;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
30307589,,
30306618,Parkinson Disease;Dementia;Cognitive Dysfunction;Outcome Assessment (Health Care),C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.380;F03.615.400;F03.615.250.700;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
30306437,HIV;Indonesia;Ukraine;Vietnam,B04.820.650.589.650.350;Z01.252.145.380;Z01.639.580;Z01.542.248.960;Z01.542.931.960;Z01.586.950.960;Z01.252.145.945
30306351,Cognition;Gender Identity;Affect;Sex;Transgender Persons,F02.463.188;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;F01.470.047;G08.686.810;M01.777.500
30306125,Glioblastoma,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335
30305909,Genetics;Hispanic Americans;Obesity,H01.158.273.343;M01.686.754.441;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30305626,"Animals;Calmodulin;Ion Channel Gating;Models, Biological;Models, Molecular;Phosphatidylinositol 4,5-Diphosphate;Rabbits;Structure-Activity Relationship;TRPV Cation Channels",B01.050;D12.644.360.372.249;D12.776.157.125.412.249;D12.776.476.387.249;G02.111.820.400;G04.835.400;G07.265.625;E05.599.395;E05.599.595;D10.570.755.375.760.400.942.625.900;B01.050.150.900.649.313.968.700;G02.111.830;G07.690.773.997;D12.776.157.530.400.901.888
30305427,,
30305309,Dialysis,E05.196.353;G02.186
30305089,Autoimmunity;Cell- and Tissue-Based Therapy;Genetic Therapy;Hematology;Precision Medicine;Stem Cells,G12.450.192;E02.095.147;E02.095.301;E05.393.420.301;H02.403.429.445;E02.574;H02.403.200.700;A11.872
30304778,Animals;Biomarkers;Carbon Isotopes;Cell Count;Cell Proliferation;Cell Survival;Dentate Gyrus;Immunohistochemistry;Ki-67 Antigen;Mice;Neurogenesis;Pyramidal Cells;Whole-Body Irradiation;Carbon;Hippocampus;Neurogenesis,B01.050;D23.101;D01.268.150.075;D01.496.123;E01.370.225.500.195;E05.200.500.195;E05.242.195;G04.140;G04.161.750;G07.345.249.410.750;G04.346;A08.186.211.180.405.200;A08.186.211.200.885.287.500.345.200;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;D12.776.660.625.500;D23.050.290.500;D23.101.140.400;B01.050.150.900.649.313.992.635.505.500;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.675.790;A11.671.790;E02.815.814;E05.980;D01.268.150;A08.186.211.180.405;A08.186.211.200.885.287.500.345;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620
30304758,"Adhesives;Dermatitis, Allergic Contact;Child;Adhesives;Patch Tests",D27.720.013;J01.637.016;C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;M01.060.406;D27.720.013;J01.637.016;E01.370.225.812.871.610;E05.200.812.871.610;E05.478.594.890.610
30304425,"Adult;Analgesia, Epidural;Analgesia, Obstetrical;Cesarean Section;Delivery, Obstetric;Humans;Labor Stage, Second;Parity;Pregnancy;Time Factors",M01.060.116;E03.091.080;E03.091.110;E04.520.252.500;E04.520.252;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769.326.500.090;G08.686.677;G08.686.784.769.472;N06.850.490.812.600;G08.686.784.769;G01.910.857
30304419,Clinical Laboratory Techniques;Precision Medicine;Reference Values;Statistics as Topic,E01.370.225;E05.200;E02.574;H02.403.200.700;E05.978.810;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830
30304382,,
30304325,,
30303895,,
30303868,,
30303782,,
30303608,"T-Lymphocytes, Regulatory",A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
30303113,,
30302900,Diploidy,G05.700.264
30302744,Colonoscopy;Colorectal Neoplasms;Hispanic Americans,E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;M01.686.754.441
30302335,,
30302228,Safety;Hepatic Veno-Occlusive Disease;Therapeutics,N06.850.135.060.075;C06.552.360;C14.907.460;E02
30301784,Cardiolipins;Fatigue;Interleukin-15;Interleukins;Microscopy;Mitochondria,D10.570.755.375.760.400.885.185;D23.050.550.480.330;C23.888.369;D12.644.276.374.465.515;D12.776.467.374.465.515;D23.529.374.465.515;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;E01.370.350.515;E05.595;H01.671.617.562;A11.284.430.214.190.875.564;A11.284.835.626
30301677,Adolescent;BRCA1 Protein;Breast Neoplasms;Breast Self-Examination;Healthy Lifestyle;Maternal Behavior;Mothers;Risk-Taking,M01.060.057;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;C04.588.180;C17.800.090.500;E01.370.600.750.100;F01.145.488.700.100;F01.829.458.205;F01.829.263.370.215;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.145.722
30300730,,
30300729,,
30300727,,
30300725,"Aquatic Organisms;Databases, Chemical;Dermatitis, Phototoxic;Endpoint Determination;Mutagenicity Tests;Perfume;Reproduction;Respiration;Risk Assessment;Skin;Spectrophotometry, Ultraviolet;Toxicity Tests",B05.080;G16.500.275.725.500.650.075;L01.313.500.750.300.188.400.300;L01.470.750.750.300;C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225;E05.315;E05.393.560;E05.940.560;D27.720.269.700;G08.686.784;G09.772.705;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;A17.815;E05.196.712.726.802;E05.196.867.826.802;E05.940
30300724,,
30300723,,
30300576,,
30300172,,
30300003,Liver,A03.620
30299996,Child;Knee,M01.060.406;A01.378.610.450
30299579,Onychomycosis,C01.539.800.200.720.550;C01.703.295.872.458;C17.800.529.550;C17.800.838.208.883.458
30299395,,
30298970,"Airway Management;Anesthesia, General;Laryngeal Masks;Magnetic Resonance Imaging;Pediatrics;Radiology",E02.041;E03.155.197;E02.041.500.475;E02.585.578.475;E05.497.578.475;E07.700.500.450;J01.637.708.560.782.450;E01.370.350.825.500;H02.403.670;H02.403.740
30298529,"African Continental Ancestry Group;Algorithms;Chromosomes, Human;Electronic Health Records;European Continental Ancestry Group;Genetic Predisposition to Disease;Genome-Wide Association Study;Haplotypes;Herpes Zoster;Homozygote;Humans;Phenotype;Polymorphism, Single Nucleotide;Principal Component Analysis;Electronic Health Records;Genotype;Herpes Zoster",M01.686.508.100;G17.035;L01.224.050;A11.284.187.520.300;G05.360.162.520.300;E05.318.308.940.968.625.500;M01.686.508.400;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380.360;C02.256.466.930.750;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;G05.695;G05.365.795.598;E05.318.740.562;E05.318.308.940.968.625.500;G05.380;C02.256.466.930.750
30298211,Child;Diffusion Tensor Imaging;Magnetic Resonance Imaging;Urinary Tract,M01.060.406;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;E01.370.350.825.500;A05.810
30298210,"Acoustics;Fetus;Hearing Loss, Noise-Induced;Hearing Tests;Humans;Infant;Infant, Newborn;Magnetic Resonance Imaging;Neonatal Screening;Pregnancy;Fetus;Hearing Tests;Magnetic Resonance Imaging;Infant, Newborn;Safety",H01.671.031;A16.378;C09.218.458.341.887.460;C10.597.751.418.341.887.460;C23.888.592.763.393.341.887.460;E01.370.382.375;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.350.825.500;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;G08.686.784.769;A16.378;E01.370.382.375;E01.370.350.825.500;M01.060.703.520;N06.850.135.060.075
30298188,"Brain Mapping;Case-Control Studies;Child;Gaucher Disease;Humans;Image Interpretation, Computer-Assisted;Longitudinal Studies;Magnetic Resonance Imaging;Nerve Net;Child;Gaucher Disease",E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;A08.511;M01.060.406;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400
30298069,Computational Biology;Database,H01.158.273.180;L01.313.124;V02.300
30298065,Food Hypersensitivity,C20.543.480.370
30297970,,
30297903,,
30297850,,
30297699,,
30297518,Frontotemporal Lobar Degeneration,C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380
30297459,DNA Repair;Acetylation;Homologous Recombination,G02.111.222;G05.219;G02.111.012.052;G02.607.063.052;G03.040.052;G05.728.615
30297293,Birth Weight;Gestational Age,C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;G07.345.500.325.235.968;G08.686.320
30297292,"Bacteremia;Meningitis, Bacterial",C01.252.100;C01.539.757.100;C23.550.470.790.500.100;C01.252.200.500;C10.228.228.180.500;C10.228.614.280
30297093,"Education, Medical;Sex Education;Sexual Health",I02.358.399;F04.096.837.500;I02.233.332.749;N01.400.663
30296739,Hepatitis;Hepatocytes,C06.552.380;A11.436.348
30296695,Air Pollution;Environmental Exposure;Socioeconomic Factors,N06.850.460.100;N06.850.460.350;I01.880.853.996;N01.824
30296517,,
30296516,,
30296515,,
30296513,,
30296512,,
30296511,,
30296510,,
30296509,,
30296478,,
30295700,,
30294750,,
30294746,Dopamine;Pets,D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;B01.050.050.116.600
30294518,Hepatitis C,C02.440.440;C02.782.350.350;C06.552.380.705.440
30293898,"Adrenal Cortex Hormones;Age Factors;Child;Child, Preschool;Cohort Studies;Disease Progression;Follow-Up Studies;Hemangioma, Capillary;Humans;Laser Therapy;Propranolol;Retrospective Studies;Risk Assessment;Severity of Illness Index;Skin Neoplasms;Time Factors;Treatment Outcome;United States;Growth Hormone",D06.472.040;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C04.557.645.375.380;B01.050.150.900.649.313.988.400.112.400.400;E02.594;E04.014.520;D02.033.100.624.698.711;D02.033.755.624.698.711;D02.092.063.624.698.711;D02.455.426.559.847.638.945;D04.615.638.945;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C04.588.805;C17.800.882;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;D06.472.699.631.525.425;D12.644.548.691.525.425
30293866,Enteric Nervous System;Gastrointestinal Motility;Virus Diseases,A08.800.050.150;G10.261.360;C02
30293838,"Centromere;Centromere Protein A;Chromatin;Chromatin Assembly and Disassembly;Chromosomal Proteins, Non-Histone;Chromosome Segregation;DNA Replication;DNA-Binding Proteins;Epigenomics;HEK293 Cells;HeLa Cells;Histones;Humans;Kinetochores;Mitosis;Nucleosomes;S Phase;DNA Replication;Centromere;Chromatin;Chromosomes;Epigenomics;Mitosis;Nucleosomes",A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;D12.776.660.235;D12.776.664.235;G04.144.220.220.625;G05.113.220.625;G02.111.225;G05.226;D12.776.260;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.106.279.345.190.160.165.500;G05.360.160.165.500;G04.144.220.220.781;G05.113.220.781;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;G02.111.225.880;G04.144.500.800;G05.226.880;G02.111.225;G05.226;A11.284.430.106.279.345.190.160.165;G05.360.160.165;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;H01.158.273.180.350.074;H01.158.273.343.350.042;G04.144.220.220.781;G05.113.220.781;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625
30293810,Histones;Mass Spectrometry,D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566
30293786,DNA Damage;Microsatellite Repeats;Microsatellite Repeats,G05.200;G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500;G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500
30293637,"Access to Information;Data Collection;Databases, Factual;Humans;Infant, Newborn;Infant, Newborn, Diseases;Information Dissemination;Intensive Care Units, Neonatal;Interinstitutional Relations;Pediatrics;Program Development;Vulnerable Populations;Morbidity;Reference Standards",I01.880.604.473.352.500.030;L01.143.024;L01.737.030;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C16.614;L01.143.443;N02.278.388.493.390.380;N04.452.822.400;H02.403.670;N04.452.760;M01.965;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;E05.978.808
30292855,Congenital Abnormalities;Epidemiology;Natural Language Processing,C16.131;H02.403.720.500;L01.224.050.375.580
30292786,Cleft Palate;Enteric Nervous System;Heart,C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;A08.800.050.150;A07.541
30292623,,
30292621,,
30292386,"Thoracic Surgery;Cognitive Dysfunction;Spectroscopy, Near-Infrared",H02.403.810.803;F03.615.250.700;E01.370.350.750;E05.196.867.851
30291883,"Hypothermia, Induced;Hypothermia, Induced",E02.258.750;E02.258.750
30291811,Fatigue;Palliative Care,C23.888.369;E02.760.666;N02.421.585.666
30291807,"Informed Consent;Ethics, Research;Selection Bias",I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;K01.752.566.479.173;N05.350.670;N05.715.350.150.775;N06.850.490.500.500
30291672,,
30291479,Meta-Analysis;Magnetic Resonance Imaging,V03.600;E01.370.350.825.500
30291340,,
30291321,,
30291194,Radiopharmaceuticals;Neuroendocrine Tumors;Paraganglioma;Pheochromocytoma,D27.505.259.843;D27.505.519.871;D27.720.470.410.650;C04.557.465.625.650;C04.557.580.625.650;C04.557.465.625.650.700;C04.557.580.625.650.700;C04.557.465.625.650.700.725;C04.557.580.625.650.700.725
30291164,Dimenhydrinate,D02.092.471.320.250;D02.455.426.559.389.115.250.250;D03.633.100.759.758.824.751.162;D26.310.368
30290980,HIV;Primary Health Care,B04.820.650.589.650.350;N04.590.233.727
30290174,,
30290171,,
30289932,,
30289733,,
30289625,"DiGeorge Syndrome;Intellectual Disability;Segmental Duplications, Genomic",C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G02.111.570.080.708.565;G05.360.080.708.565
30289601,Mosaicism;Polyhydramnios;Prenatal Diagnosis,G05.365.590.175.595;C13.703.610;E01.370.378.630
30289405,"Anemia, Sickle Cell;Antisickling Agents;Benzaldehydes;Crystallography, X-Ray;Hemoglobin, Sickle;Humans;Ligands;Polymerization;Protein Binding;Protein Stability;Hemoglobins;Polymerization;Anemia, Sickle Cell",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.502.135;D02.047.222;E05.196.309.742.225;D12.776.124.400.463.588;D12.776.422.316.762.426.588;B01.050.150.900.649.313.988.400.112.400.400;D27.720.470.480;G02.750;G02.111.679;G03.808;G02.111.700;D12.776.124.400;D12.776.422.316.762;G02.750;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
30288777,,
30288681,,
30288474,,
30288436,Advance Directives,I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050
30288340,Melanoma,C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
30287922,,
30287906,,
30287468,,
30287337,,
30287336,,
30287335,"Animals;Aquatic Organisms;Databases, Chemical;Endpoint Determination;Humans;Perfume;Reproduction;Risk Assessment;Skin;Spectrophotometry, Ultraviolet;Teratogens;Toxicity Tests",B01.050;B05.080;G16.500.275.725.500.650.075;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E05.315;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;G08.686.784;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;A17.815;E05.196.712.726.802;E05.196.867.826.802;D27.888.569.864;E05.940
30287334,"Acetals;Consumer Product Safety;Databases, Chemical;Endpoint Determination;Food Analysis;Humans;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E05.315;E05.362;J01.576.423.850.100;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
30287333,,
30287332,,
30287316,Costs and Cost Analysis;Dermatology;Telemedicine,N03.219.151;H02.403.225;H02.403.840;L01.178.847.652;N04.590.374.800
30286926,Mortality,E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
30286853,Stents,E07.695.750
30286684,Eating;Environment;Food Preferences;School Nursing;Students;Urban Health,G07.203.650.283;G10.261.330;G16.500.275;N06.230;F01.145.407.516;G07.203.650.353.516;H02.478.676.824;N02.421.726.809.742;M01.848;N01.400.548.875
30286299,Crime;Humans;Income;New Orleans;Poverty;Residence Characteristics;Unemployment;Urban Renewal;Violence;Crime;Violence,I01.198.240;I01.880.735.191;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;Z01.107.567.875.750.480.500;Z01.433.697;I01.880.735.634;I01.880.853.996.535;N01.824.600;N01.224.791;N06.850.505.400.800;N01.824.245.850;I01.880.709.876;I01.198.240.856;I01.880.735.900;I01.198.240;I01.880.735.191;I01.198.240.856;I01.880.735.900
30286223,"Clinical Trials as Topic;Health Services Research;Humans;Suicide;Suicide, Attempted",E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;F01.145.126.980.875;I01.880.735.856;F01.145.126.980.875.600;I01.880.735.856.600
30285110,,
30285047,,
30285033,,
30284281,,
30284262,Erythrocytes;Erythroid Precursor Cells;Humans;Indicators and Reagents;Isoantibodies;Serologic Tests,A11.118.290;A11.443.240;A15.145.229.334;A11.148.378.590.837.250;A11.443.240.497;A11.872.378.590.817.250;A15.378.316.378.590.837.250;B01.050.150.900.649.313.988.400.112.400.400;D27.720.470.410;D12.776.124.486.485.114.664;D12.776.124.790.651.114.664;D12.776.377.715.548.114.664;E01.370.225.812.735;E05.200.812.735;E05.478.594.760
30284214,,
30283846,Faculty;Healthcare Disparities;Minority Groups;Program Evaluation,M01.526.702.250;N04.590.374.380;N05.300.493;I01.880.853.300;E05.337.820;N04.761.685;N05.715.360.650
30283780,Actins;Immunological Synapses,D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;A11.284.149.165.420.548;A15.382.370
30283164,Anesthesiology;Bias;Ethics;Gastroenterology,H02.403.066;N05.715.350.150;N06.850.490.500;K01.752.566.479;N05.350;H02.403.429.405
30283157,,
30283095,,
30282738,"Action Potentials;Entorhinal Cortex;Grid Cells;Humans;Models, Neurological;Neurons;Space Perception;Spatial Memory;Spatial Navigation;Theta Rhythm;Grid Cells;Spatial Memory",G04.580.100;G07.265.675.100;G11.561.570.100;A08.186.211.180.590.750.225;A08.186.211.180.710.225;A08.186.211.200.885.287.500.382.750.225;A08.186.211.200.885.287.500.620.562;A08.186.211.200.885.287.500.814.695.374;A08.186.211.200.885.287.750.562;A08.675.324;A11.671.322;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.642;A08.675;A11.671;F02.463.593.778;F02.463.425.540.886;F01.145.875.797;F02.463.641;E01.370.376.300.150.937;E01.370.405.245.287.937;G07.265.087.937;G11.561.127.937;A08.675.324;A11.671.322;F02.463.425.540.886
30282537,"Adolescent;Arthroscopy;Debridement;Fistula;Ganglionectomy;Humans;Joint Capsule;Ligaments, Articular;Magnetic Resonance Imaging;Reconstructive Surgical Procedures;Recurrence;Wrist;Wrist Joint;Ganglion Cysts;Ganglion Cysts;Wrist",M01.060.057;E01.370.388.250.070;E04.502.250.070;E04.555.113;E04.176;C23.300.575;E04.525.210.105.800.380;B01.050.150.900.649.313.988.400.112.400.400;A02.835.583.443;A02.513.514;A02.835.583.512;A10.165.669.514;E01.370.350.825.500;E04.680;C23.550.291.937;A01.378.800.667.715;A02.835.583.405.930;C04.182.347;C17.300.550.274;C04.182.347;C17.300.550.274;A01.378.800.667.715
30282375,"Adolescent;Antioxidants;Child;Humans;Muscular Dystrophy, Duchenne;Peak Expiratory Flow Rate;Respiratory Function Tests;Self Care;Ubiquinone;Muscular Dystrophy, Duchenne;Respiration",M01.060.057;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.386.700.660.225.600;G09.772.650.300.790;E01.370.386.700;E02.900;I03.050.563;N02.421.784.680;D02.806.250.900;D08.211.935;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;G09.772.705
30281936,"Animals;Cysteine;Humans;Organomercury Compounds;Protein Processing, Post-Translational;Resins, Synthetic;Cysteine;Proteomics",B01.050;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;B01.050.150.900.649.313.988.400.112.400.400;D02.691.750;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D05.750.716.822;D25.339.816;D25.720.716.822;J01.637.051.339.816;J01.637.051.720.716.822;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
30281842,Patient Safety,N06.850.135.060.075.399
30281777,Multimorbidity,N05.715.350.225.500;N06.850.490.687.500
30281145,Biomarkers;Chemoprevention;Melanoma;Biological Products,D23.101;E02.319.162;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D20.215
30280910,Informed Consent;Presumed Consent,I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;I01.880.604.583.659;N03.706.535.664
30279644,Alleles;Child;DNA Mutational Analysis;Exome;Exons;Glucose-6-Phosphatase;Heterozygote;Humans;Pedigree;Pregnancy;Preimplantation Diagnosis;Sequence Deletion;Prostaglandins D,G05.360.340.024.340.030;M01.060.406;E05.393.760.700.300;G05.360.340.011;G05.360.340.024.340.137.232;D08.811.277.352.650.225;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;E05.393.673;G08.686.784.769;E01.370.378.625;G05.365.590.762;G05.558.800;D10.251.355.255.550.200;D23.469.050.175.725.200
30279592,,
30279470,,
30279348,Hyponatremia;Pediatrics,C18.452.950.620;H02.403.670
30279226,,
30279172,,
30278957,Colonic Neoplasms;General Surgery,C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;H02.403.810.300
30278284,,
30278272,,
30277808,Health Personnel;Health Promotion;Lactation;Return to Work;Work-Life Balance;Workplace,M01.526.485;N02.360;I02.233.332.445;N02.421.726.407.579;G08.686.523;G08.686.702.500;I03.946.449;N01.824.245.725;I01.940;I03.946.225.438;N04.452.677.650.438;N01.824.245.925;N04.452.677.975
30277015,,
30276676,Glioma;Microvessels;Molecular Typing,C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;A07.015.461;E01.370.225.875.150.125.457;E05.200.875.150.125.457;E05.393.542
30276391,,
30275901,,
30275886,,
30275569,,
30275568,,
30275566,,
30275531,,
30275510,,
30275469,,
30274857,,
30274480,Dermatology;Telemedicine;Telemedicine;Skin Diseases;Technology;Telepathology,H02.403.225;H02.403.840;L01.178.847.652;N04.590.374.800;H02.403.840;L01.178.847.652;N04.590.374.800;C17.800;J01.897;H02.403.650.600;H02.403.840.600;L01.178.847.652.600;N04.590.374.800.600
30273268,,
30272673,,
30272613,"Confounding Factors (Epidemiology);Data Interpretation, Statistical;Records",N05.715.350.240;N06.850.490.718;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;E05.318.308.940;L01.399.250.900;N04.452.859;N05.715.360.300.715;N06.850.520.308.940
30272495,,
30272281,"Animals;Apoptosis;Basigin;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Gene Expression Regulation, Neoplastic;Humans;Insulin-Like Growth Factor Binding Protein 2;Melanoma;Mice;Neoplasm Transplantation;PTEN Phosphohydrolase;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Signal Transduction",B01.050;G04.146.160;D12.776.395.550.045;D12.776.543.550.187;D23.050.285.040;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G02.111.240;G05.308.200;G07.690.773.937;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.420.260;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;E05.624;D08.811.277.352.650.850;D12.776.476.590;D12.776.624.776.695;D08.811.913.696.620.500;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168;G02.111.820;G04.835
30272210,,
30272184,,
30270691,,
30270492,alpha-Fetoproteins;Early Detection of Cancer;Hepatoblastoma,D12.776.124.790.106.092;D12.776.320.525.500;D12.776.377.228.500;D12.776.377.715.085.092;D23.101.140.050;E01.390.500;C04.557.435.380
30270167,Neurodevelopmental Disorders,F03.625
30270009,Neoplasms;Radiation;Trauma Centers,C04;G01.750;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400
30269912,Sprains and Strains;Tetralogy of Fallot,C26.844;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30269332,,
30268864,,
30268788,"Adenocarcinoma;Aged;Aged, 80 and over;California;Cause of Death;Colorectal Neoplasms;Early Detection of Cancer;Humans;Middle Aged;Patient Acceptance of Health Care;Predictive Value of Tests;Protective Factors;Reproducibility of Results;Retrospective Studies;Risk Factors;Time Factors;Adenoma;Colonic Neoplasms",C04.557.470.200.025;M01.060.116.100;M01.060.116.100.080;Z01.107.567.875.580.200;Z01.107.567.875.760.200;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.600.800.582;N05.715.350.200.675;N05.715.360.750.625.700.570;N06.850.490.625.625;N06.850.520.830.600.800.582;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;C04.557.470.035;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180
30268397,Adiposity;Infant;Obesity,E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.060.703;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30267985,Depression;Intelligence;Affect;Neuropsychology;Vocabulary,F01.145.126.350;F01.752.543;F01.470.047;F04.096.795.600;H01.158.782.795.110;L01.559.598.901
30267061,,
30266756,Genetics;Neurology,H01.158.273.343;H02.403.600
30266222,"Muscular Dystrophy, Duchenne;Natural History;Respiration",C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;H01.158.273.602;H01.770.552;K01.400.703;G09.772.705
30266153,Cholestasis,C06.130.120.135
30265817,Brain Concussion,C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200
30265347,,
30265344,,
30265325,,
30264395,,
30264215,Arteriovenous Fistula,C14.240.850.750.147;C14.240.850.984.750;C14.907.150.125;C14.907.933.555;C16.131.240.850.750.125;C23.300.575.950.250
30264131,,
30264127,,
30263042,,
30262472,"Animals;Carcinogenesis;DNA;Extracellular Traps;Humans;Inflammation;Integrin alpha3beta1;Lamins;Leukocyte Elastase;Lipopolysaccharides;Lung;Lung Neoplasms;MCF-7 Cells;Matrix Metalloproteinase 9;Mice;Mice, Inbred BALB C;Neoplasms, Experimental;Neutrophils;Pneumonia;Pneumonia, Bacterial;Protein-Arginine Deiminases;Proteolysis;Rats;Signal Transduction;Smoking;Tobacco",B01.050;C04.697.098;C23.550.727.098;D13.444.308;A11.284.295.495;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.776.543.750.685.300;D12.776.543.750.705.408.850.249;D12.776.543.750.705.876.311;D12.776.660.650.875;D08.811.277.656.300.760.560.500;D08.811.277.656.959.350.560.500;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;A04.411;C04.588.894.797.520;C08.381.540;C08.785.520;A11.251.210.190.630;D08.811.277.656.300.480.205.360;D08.811.277.656.300.480.252.445;D08.811.277.656.300.480.525.700.350;D08.811.277.656.675.374.205.360;D08.811.277.656.675.374.252.445;D08.811.277.656.675.374.525.700.350;D12.644.276.848.350;D12.776.467.836.350;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;C04.619;E05.598.500.496;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C08.381.677;C08.730.610;C01.252.620;C08.381.677.540;C08.730.610.540;D08.811.277.721;G02.111.720;G03.812;B01.050.150.900.649.313.992.635.505.700;G02.111.820;G04.835;F01.145.805;B01.650.940.800.575.912.250.908.500.900
30262200,"Gender Dysphoria;Puberty, Precocious",F03.835.550;C19.391.693
30261933,"Consensus;Consensus Development Conferences as Topic;Ethics Committees, Research;Ethics, Research;Humans;Interdisciplinary Communication;Multicenter Studies as Topic;Practice Guidelines as Topic;Pragmatic Clinical Trials as Topic;Research Design;Review Literature as Topic;Stakeholder Participation;Comparative Effectiveness Research;Informed Consent;Ethics, Research",F01.829.316.068;F02.463.785.373.433;L01.178.682.759.150;N03.540.199.205;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;K01.752.566.479.173;N05.350.670;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;N04.761.700.350.650;N05.700.350.650;E05.318.372.250.250.365.500.750;N05.715.360.330.250.250.365.500.750;N06.850.520.450.250.250.365.500.750;E05.581.500;H01.770.644.728;L01.178.682.759;I01.738.805;I03.743;H01.770.644.145.360.500;N05.425.157;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;K01.752.566.479.173;N05.350.670
30261899,"Cell Division;Child, Preschool;Complementarity Determining Regions;Genetic Therapy;Humans;Microbiota;Receptors, Antigen, T-Cell, alpha-beta;T-Lymphocytes;X-Linked Combined Immunodeficiency Diseases",G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500;M01.060.406.448;D12.644.541.500.650.500.180;D12.776.124.486.485.680.650.500.180;D12.776.124.486.485.797.180;D12.776.124.790.651.680.650.500.180;D12.776.124.790.651.797.180;D12.776.377.715.548.680.650.500.180;D12.776.377.715.548.797.180;D12.776.543.750.705.816.824.300;G02.111.570.060.425.160;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;D12.776.543.750.705.816.824.825;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C16.320.322.968;C16.614.815.500;C20.673.815.500
30261451,,
30261385,"Aged;Aged, 80 and over;Antineoplastic Agents;Brain Neoplasms;Follow-Up Studies;Glioma;Humans;Middle Aged;Neoplasm Grading;Drug Therapy;Radiotherapy",M01.060.116.100;M01.060.116.100.080;D27.505.954.248;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789.612;E02.319;E02.815
30261308,"Adolescent;Adult;Aged;Aged, 80 and over;Aging;Brain;Child;Child, Preschool;Connectome;Humans;Longevity;Magnetic Resonance Imaging;Middle Aged;Young Adult;Aging;Connectome;Diffusion;Longevity;Perfusion",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;G07.345.124;A08.186.211;M01.060.406;M01.060.406.448;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;B01.050.150.900.649.313.988.400.112.400.400;G07.345.124.519;G07.540;E01.370.350.825.500;M01.060.116.630;M01.060.116.815;G07.345.124;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;G01.202;G02.196;G07.345.124.519;G07.540;E05.680
30261219,Heart Arrest;Cardiopulmonary Resuscitation;Critical Care,C14.280.383;E02.365.647.110;E02.760.190;N02.421.585.190
30260930,,
30260921,"Adolescent;Blood Loss, Surgical;Body Mass Index;Humans;Kyphosis;Lordosis;Radiography;Retrospective Studies;Scoliosis;Severity of Illness Index;Sex Factors;Spinal Fusion;Thoracic Vertebrae",M01.060.057;C23.550.414.300;C23.550.505.300;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;B01.050.150.900.649.313.988.400.112.400.400;C05.116.900.800.500;C05.116.900.800.750;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N05.715.350.675;N06.850.490.875;E04.555.100.700;A02.835.232.834.892
30260864,,
30260580,"Interleukin-13;Immunity, Mucosal",D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513;G12.450.573
30258022,,
30257798,Aortic Valve Stenosis;Transcatheter Aortic Valve Replacement,C14.280.484.150;C14.280.955.249;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
30257200,Aging;Epigenomics;Cicatrix;Skin,G07.345.124;H01.158.273.180.350.074;H01.158.273.343.350.042;A10.165.450.300;C23.550.355.274;G16.762.891.249;A17.815
30256954,,
30256911,,
30256548,,
30256514,Humans;Inpatients;Liver Transplantation;Patient Readmission,B01.050.150.900.649.313.988.400.112.400.400;M01.643.470;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E02.760.400.620;N02.421.585.400.620
30255815,Alternative Splicing;Alzheimer Disease;Whole Genome Sequencing,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E05.393.760.700.825
30255125,,
30254368,"Animals;Bone Marrow Transplantation;Cell Proliferation;Cells, Cultured;DNA Repair;DNA Replication;Fanconi Anemia;Fanconi Anemia Complementation Group D2 Protein;Genomic Instability;Hematopoietic Stem Cells;Humans;Intracellular Signaling Peptides and Proteins;Mice, Inbred C57BL;Mice, Inbred Strains;Mice, Knockout",B01.050;E02.095.147.725.040;E04.936.580.040;G04.161.750;G07.345.249.410.750;A11.251;G02.111.222;G05.219;G02.111.225;G05.226;C15.378.071.085.080.280;C15.378.190.196.080.280;C16.320.077.280;C18.452.284.280;D12.776.313.812;D12.776.660.285;D12.776.744.484;C23.550.362;G05.365.590.335;G05.370;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360;D12.776.476;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.199.520.520;B01.050.150.900.649.313.992.635.505.500.400;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500
30254108,"Animals;Cardiomyopathies;Cell Nucleus;Gene Expression Profiling;Gene Regulatory Networks;Growth Differentiation Factor 15;Heart;High-Throughput Nucleotide Sequencing;Mice;Mitochondrial Diseases;Myocardium;Myocytes, Cardiac;Sequence Analysis, RNA;Transcriptional Activation;Transcriptome",B01.050;C14.280.238;A11.284.430.106;A11.284.430.214.190.875.117;E05.393.332;G05.360.080.689.360;D12.644.276.374.305;D12.644.276.954.300.915;D12.776.467.374.305;D12.776.467.942.300.915;D23.529.374.305;D23.529.942.300.915;A07.541;E05.393.760.319;B01.050.150.900.649.313.992.635.505.500;C18.452.660;A02.633.580;A07.541.704;A10.690.552.750;A07.541.704.570;A10.690.552.750.570;A11.620.500;E05.393.760.710;G05.308.800;G02.111.873.750;G05.297.700.750;G05.360.920
30253916,"Adult;Clinical Competence;Computer-Assisted Instruction;Delivery of Health Care;Education, Nursing, Baccalaureate;Humans;Infection Control;Learning;Middle Aged;Nursing Staff, Hospital;Simulation Training;Surveys and Questionnaires;United States;Urinary Catheterization;Young Adult",M01.060.116;I02.399.630.210;N04.761.210;N05.715.175;I02.903.771.500.208;N04.590.374;N05.300;I02.358.462.316;B01.050.150.900.649.313.988.400.112.400.400;N06.850.780.200.450;F02.463.425;F02.784.629.529;M01.060.116.630;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;I02.903.847;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;E01.370.390.820;E02.148.947;E05.157.500;M01.060.116.815
30253221,Epidemiology,H02.403.720.500
30253213,Animals;Heparin;Immunosuppressive Agents;Lipopolysaccharides;Luciferases;Mice;Molecular Dynamics Simulation;NF-kappa B;Nanoparticles;RAW 264.7 Cells;Sphingosine;Structure-Activity Relationship;Toll-Like Receptor 4;Molecular Dynamics Simulation;NF-kappa B;Surface Plasmon Resonance;Toll-Like Receptor 4,B01.050;D09.698.373.400;D27.505.696.477.656;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;D08.811.682.517;D12.776.532.510;B01.050.150.900.649.313.992.635.505.500;E05.599.595.500;G02.111.570.895;L01.224.160.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;J01.637.512.600;A11.251.210.172.875;A11.733.397.815;D02.033.100.700;D02.033.455.843;D02.092.063.700;G02.111.830;G07.690.773.997;D12.776.543.750.705.910.500.400;E05.599.595.500;G02.111.570.895;L01.224.160.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;E05.196.890;E05.601.043.700;D12.776.543.750.705.910.500.400
30252971,,
30252935,Genome-Wide Association Study;Human Genetics,E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.343.385
30252808,Adult;Aggression;Beauty;Controlled Before-After Studies;Esthetics;Face;Facial Expression;Humans;Perception;Personality;Photography;Postoperative Period;Preoperative Period;Rhinoplasty,M01.060.116;F01.145.126.125;F01.145.813.045;F02.463.785.477.304;K01.752.210.304;E05.318.372.500.812;N05.715.360.330.500.812;N06.850.520.450.500.812;F02.463.785.477;K01.752.210;A01.456.505;E01.370.600.225;F01.145.209.530.385;B01.050.150.900.649.313.988.400.112.400.400;F02.463.593;F01.752;E01.370.350.600;E05.712;E04.614.750;N02.421.585.753.750;E04.614.937;N02.421.585.753.937;E02.218.755;E04.580.392.500;E04.680.650
30252790,,
30252712,,
30252589,Cerebral Palsy,C10.228.140.140.254
30252575,,
30252172,Cohort Studies;Hypertension;Incidence;Sleep Apnea Syndromes,E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C14.907.489;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C08.618.085.852;C10.886.425.800.750
30252148,Electronic Health Records;Phenotype,E05.318.308.940.968.625.500;G05.695
30252044,,
30251826,Animals;Hippocampus;Microtechnology;Nerve Net;Neurites;Rats;Silicon Compounds;Neurons,B01.050;A08.186.211.180.405;A08.186.211.200.885.287.500.345;H01.570;J01.897.520.500;A08.511;A08.675.256.500;A08.675.542.145.500;A11.284.180.610;A11.671.501.145.500;A11.671.543;B01.050.150.900.649.313.992.635.505.700;D01.837;A08.675;A11.671
30251764,,
30251352,,
30251308,Child;Developing Countries;Humans;Pain Management;Poverty;Nursing;Pain;Pain Management,M01.060.406;I01.615.500.300;B01.050.150.900.649.313.988.400.112.400.400;E02.745;N04.590.607.500;I01.880.735.634;I01.880.853.996.535;N01.824.600;H02.478;N04.452.758.377;C23.888.592.612;F02.830.816.444;G11.561.790.444;E02.745;N04.590.607.500
30250226,,
30249524,Genetic Therapy,E02.095.301;E05.393.420.301
30249416,"Depression;Depressive Disorder, Major;Pregnancy;Transcranial Magnetic Stimulation",F01.145.126.350;F03.600.300.375;G08.686.784.769;E02.621.820
30248309,,
30247666,,
30247581,,
30247579,,
30247555,,
30247517,,
30247459,,
30247284,,
30247181,,
30247160,,
30246903,,
30246132,Necrobiosis Lipoidica,C17.300.200.495.545;C17.800.550.545;C17.800.849.495;C18.452.880.495
30246042,Anterior Cruciate Ligament Reconstruction,E04.555.110.026;E04.680.101.026
30245972,,
30245513,,
30245509,Epilepsy,C10.228.140.490
30245009,Oxidoreductases;Glycolysis;Lipogenesis;Metabolomics;Mitochondria;Pyruvic Acid;Reactive Oxygen Species;Thiamine,D08.811.682;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;G02.111.528;G03.458.249;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;A11.284.430.214.190.875.564;A11.284.835.626;D02.241.755.812.800;D01.339.431;D01.650.775;D02.886.675.900;D03.383.129.708.900;D03.383.742.795
30244988,"Adrenal Cortex Hormones;Biliary Atresia;Body Weight;Cephalometry;Child Development;Child, Preschool;Double-Blind Method;Failure to Thrive;Follow-Up Studies;Humans;Infant;Monitoring, Physiologic;Portoenterostomy, Hepatic;Postoperative Care;Prospective Studies;Reference Values;Risk Assessment;Sarcopenia;Time Factors;Treatment Outcome;Failure to Thrive;Sarcopenia",D06.472.040;C06.130.120.123;C06.198.125;C16.131.314.125;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;F01.525.200;G07.345.374.750;M01.060.406.448;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;C23.888.338;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.520;E04.035.775;E04.210.120.775;E02.760.731.700;E04.604.500;N02.421.585.722.700;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.978.810;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C10.597.613.612.500;C23.300.070.500.500;C23.888.592.608.612.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.338;C10.597.613.612.500;C23.300.070.500.500;C23.888.592.608.612.500
30244983,"Cerebral Palsy;Child, Preschool;Cohort Studies;Developmental Disabilities;Early Diagnosis;Humans;Infant;Infant, Newborn;Intensive Care Units, Neonatal;Logistic Models;Magnetic Resonance Imaging;Neuroimaging;Outcome Assessment (Health Care);Parents;Patient Care Team;Prognosis;Retrospective Studies;Time Factors;Motivation;Hypoxia-Ischemia, Brain;Infant, Newborn;Uncertainty",C10.228.140.140.254;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F03.625.421;E01.390;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390.380;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;N04.590.715;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;F01.658;F01.752.543.500.750;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703.520;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900
30244528,"DiGeorge Syndrome;CHARGE Syndrome;DiGeorge Syndrome;Glucosephosphate Dehydrogenase Deficiency;Cystic Fibrosis;Diagnosis, Dual (Psychiatry);DiGeorge Syndrome;von Willebrand Diseases",C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C11.270.147.500;C16.131.077.239;C16.320.165;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402;C06.689.202;C08.381.187;C16.320.190;C16.614.213;E01.190;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C15.378.100.100.900;C15.378.100.141.900;C15.378.140.900;C15.378.463.920;C16.320.099.920
30244484,"Hernias, Diaphragmatic, Congenital;Gallbladder;Obstetrics",C16.131.433;C23.300.707.500.116;A03.159.439;H02.403.810.450
30244297,"Adenocarcinoma;Aged;Aged, 80 and over;Cohort Studies;Colonic Neoplasms;Colorectal Neoplasms;Diabetes Complications;Diabetes Mellitus;Humans;Middle Aged;Neoplasm Recurrence, Local;Neoplasms, Second Primary;Proportional Hazards Models;Registries;Risk Factors;United States;Colonic Neoplasms;Recurrence;Survivorship",C04.557.470.200.025;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;C19.246.099;C18.452.394.750;C19.246;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.697.655;C23.550.727.655;C04.692;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;C23.550.291.937;F01.058.144.500
30244209,,
30244066,Adult;Child;Dermatologic Agents;Dermatology;Drug Approval;Health Services Accessibility;Humans;Needs Assessment;Off-Label Use;Skin Diseases;United States;United States Food and Drug Administration,M01.060.116;M01.060.406;D27.505.954.444;H02.403.225;E05.290.250;E05.337.300;I01.880.604.605.250.250;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;I02.594;N03.349.380.565;N05.300.537;E02.319.307.500;C17.800;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
30243967,,
30243966,,
30243880,Diarrhea;Food Hypersensitivity;Vomiting,C23.888.821.214;C20.543.480.370;C23.888.821.937
30243810,"Biomarkers;Pregnancy, Ectopic;Methotrexate",D23.101;C13.703.733;D03.633.100.733.631.192.500
30243746,,
30243745,,
30243744,,
30243743,,
30243742,,
30243657,,
30243648,"Aged;Animals;Antineoplastic Agents;Apoptosis;Arsenic Trioxide;Cell Proliferation;Gene Expression Regulation, Neoplastic;Head and Neck Neoplasms;Humans;Mice;Mice, Inbred BALB C;Mice, Nude;Mice, SCID;Middle Aged;Papillomaviridae;Papillomavirus Infections;Tumor Cells, Cultured;Xenograft Model Antitumor Assays;Apoptosis;Arsenic Trioxide;Cell Proliferation",M01.060.116.100;B01.050;D27.505.954.248;G04.146.160;D01.075.038;D01.650.550.125;G04.161.750;G07.345.249.410.750;G05.308.370;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.150.900.649.313.992.635.505.500.550.500;B01.050.150.900.649.313.992.635.505.500.550.780;M01.060.116.630;B04.280.210.655;B04.613.204.655;C02.256.650;C02.928.725;A11.251.860;E05.337.550.200.900;E05.624.850;G04.146.160;D01.075.038;D01.650.550.125;G04.161.750;G07.345.249.410.750
30243621,"Adolescent;Adult;Age of Onset;Colorectal Neoplasms;Databases, Factual;Early Detection of Cancer;Genetic Predisposition to Disease;Humans;Incidence;Li-Fraumeni Syndrome;Middle Aged;Mutation;Phenotype;Philadelphia;Predictive Value of Tests;Retrospective Studies;Risk Factors;Time Factors;Tumor Suppressor Protein p53;Young Adult",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;L01.313.500.750.300.188.400;L01.470.750.750;E01.390.500;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C04.700.600;C16.320.700.600;C18.452.284.520;M01.060.116.630;G05.365.590;G05.695;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;M01.060.116.815
30243559,,
30243425,Pharmaceutical Preparations;HIV;Yoga,D26;B04.820.650.589.650.350;E02.190.525.937;E02.190.901.984;E02.779.474.937;K01.844.799.867
30243353,,
30243342,,
30243319,"Child;Glomerular Filtration Rate;Humans;Renal Insufficiency, Chronic;Young Adult",M01.060.406;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750;C13.351.968.419.780.750;M01.060.116.815
30243012,NADH Dehydrogenase;Electron Transport,D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500;G02.111.248;G03.295.531.403;G03.493.350
30242447,"Adolescent;Age Factors;Child;Child, Preschool;Humans;Infant;Magnetic Resonance Imaging;Menisci, Tibial;Reference Values;Retrospective Studies;Child;Growth;Meniscus;Meniscus",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;A02.165.308.538.500;A02.835.583.475.590;A10.165.382.350.163.500;E05.978.810;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.406;G07.345.249;A02.165.308.538;A10.165.382.350.163;A02.165.308.538;A10.165.382.350.163
30242377,,
30242360,,
30242354,,
30242219,"Adenosine Triphosphate;Animals;Cardiotonic Agents;Cell Line;Drug Evaluation, Preclinical;Mice;Monte Carlo Method;Myosins;Optical Tweezers;Swine;Urea",D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;B01.050;D27.505.954.411.222;D27.720.799.080;A11.251.210;E05.290.750;E05.337.550;B01.050.150.900.649.313.992.635.505.500;E05.318.740.525;L01.906.394.422;N05.715.360.750.540;N06.850.520.830.525;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475;E05.650;B01.050.150.900.649.313.500.880;D02.948
30242160,,
30242075,,
30242026,BK Virus;Kidney Diseases;Polyomavirus Infections;Kidney Transplantation,B04.280.210.700.615.100;B04.613.204.670.615.100;C12.777.419;C13.351.968.419;C02.256.721;E02.870.500;E04.936.450.485;E04.950.774.400
30242022,,
30241956,Bipolar Disorder;Body Mass Index;Body Weight;Lithium;Quetiapine Fumarate;Weight Gain,F03.084.500;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;D02.886.680.702.500.500;D03.633.300.276.500;C23.888.144.243.926;G07.345.249.314.120.200.926
30240779,Diagnosis;Disease Management;Erythema;Ethnic Groups;Flushing;Continental Population Groups;Rhinophyma;Telangiectasis,E01;N04.590.607;C17.800.229;C23.888.885.328;M01.686.754;N01.224.317;C23.888.885.344;M01.686.508;C17.800.716.500;C17.800.794.650;C14.907.823
30240732,,
30240730,,
30240293,Child;Health Literacy,M01.060.406;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500
30240185,,
30240032,,
30239887,,
30239724,,
30239389,,
30239371,,
30238627,"Cardiac Surgical Procedures;Decompression, Surgical;Echocardiography;Follow-Up Studies;Heart Septum;Heart Ventricles;Humans;Infant, Newborn;Pulmonary Atresia;Retrospective Studies;Treatment Outcome;Ventricular Function",E04.100.376;E04.928.220;E04.188;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A07.541.459;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.955
30238403,Medicaid,N03.219.521.346.506.564.655;N03.706.615.693
30238166,Adolescent;Adult;Autistic Disorder,M01.060.057;M01.060.116;F03.625.164.113.500
30237017,,
30236997,Immunization;Universities;Vaccines,E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;I02.783.830;J03.832.830;D20.215.894
30236636,,
30236482,Adolescent;Metabolic Syndrome;Vitamin D;Young Adult,M01.060.057;C18.452.394.968.500.570;C18.452.625;D04.210.500.812.768;M01.060.116.815
30234675,,
30234621,,
30234591,,
30234532,,
30234506,,
30234399,"Leukemia, Myeloid, Acute",C04.557.337.539.275
30233412,"Acceleration;Lower Body Negative Pressure;Hypotension, Orthostatic;Skin Temperature",G01.482.107;E02.278.500;C10.177.575.600.450;C14.907.514.482;G07.110.753;G13.750.844
30233045,,
30232636,Anesthesia;Endoscopy;Etomidate;Propofol;Sleep,E03.155;E01.370.388.250;E04.502.250;D03.383.129.308.265;D02.455.426.559.389.657.773;F02.830.855;G11.561.803
30232532,"Adolescent;Child;Child, Preschool;Contrast Media;Humans;Infant;Magnetic Resonance Imaging;Musculoskeletal Diseases;Retrospective Studies;Unnecessary Procedures;Child;Contrast Media;Magnetic Resonance Imaging;Mass Screening",M01.060.057;M01.060.406;M01.060.406.448;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;C05;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N02.421.380.450.500;N05.300.150.395.450.500;M01.060.406;D27.505.259.500;D27.720.259;E01.370.350.825.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30232425,,
30232279,Autoimmune Diseases;Hematology;Inflammation;Neutrophils;Thrombosis,C20.111;H02.403.429.445;C23.550.470;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C14.907.355.830
30232217,,
30232115,Health Communication;Heart Failure;Primary Health Care;Qualitative Research,L01.143.350;N02.208;C14.280.434;N04.590.233.727;H01.770.644.241.850
30231844,"Adult;Anxiety;Emotions;Facial Expression;Facial Recognition;Heart Rate;Humans;Odorants;Olfactory Perception;Parasympathetic Nervous System;Social Perception;Stress, Psychological;Young Adult;Smell",M01.060.116;F01.470.132;F01.470;E01.370.600.225;F01.145.209.530.385;F02.463.593.524.500.500;F02.463.593.932.622.500;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;G16.500.275.640;N06.230.480;F02.463.593.485;A08.800.050.600;F02.463.593.752;F01.145.126.990;F02.830.900;M01.060.116.815;F02.830.816.643;G11.561.790.643
30231229,"46, XX Disorders of Sex Development;Adult;Androgen-Insensitivity Syndrome;Congenital Abnormalities;Diagnosis, Differential;Humans;Infertility, Female;Mullerian Ducts;Uterus",C12.706.316.064;C13.351.875.253.064;C16.131.939.316.064;C19.391.119.064;M01.060.116;C12.706.316.096.500;C13.351.875.253.096.500;C16.131.939.316.096.500;C16.320.322.061;C19.391.119.096.500;C16.131;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C13.351.500.365.700;A16.623;A05.360.319.679
30230692,Aged;Attitude;Robotics;Young Adult,M01.060.116.100;F01.100;H01.671.293.643;J01.897.104.834;L01.224.050.375.630;M01.060.116.815
30230593,"Animals;Anti-Bacterial Agents;Child;Child, Preschool;Glucocorticoids;Humans;Spider Bites;Spiders;Superinfection;Arachnida;Arthropods;Infection;Spider Bites",B01.050;D27.505.954.122.085;M01.060.406;M01.060.406.448;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C25.723.127.723;C26.176.790;B01.050.500.131.166.803;C01.539.597.880;C02.597.880;C03.684.880;B01.050.500.131.166;B01.050.500.131;C01.539;C25.723.127.723;C26.176.790
30230537,Rhabdoid Tumor,C04.557.435.710
30229541,Fingolimod Hydrochloride;Review,D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;V02.600.500;V02.912
30229186,,
30228863,Enterobacteriaceae,B03.440.450.425;B03.660.250.150
30227950,,
30227762,,
30227341,"Brain;Electroencephalography;Follow-Up Studies;Humans;Hypothermia, Induced;Hypoxia-Ischemia, Brain;Infant;Neurodevelopmental Disorders;Retrospective Studies;Seizures;Electroencephalography;Hypothermia, Induced",A08.186.211;E01.370.376.300;E01.370.405.245;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703;F03.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.597.742;C23.888.592.742;E01.370.376.300;E01.370.405.245;E02.258.750
30227197,Linkage Disequilibrium;MicroRNAs,G05.348.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
30227134,"Integrases;Recombination, Genetic;Sensitivity and Specificity",D08.811.739.500;G05.728;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872
30227128,,
30227127,,
30226884,"Animals;Blotting, Western;Cytokines;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;Killer Cells, Natural;Lectins, C-Type;MAP Kinase Signaling System;Membrane Potential, Mitochondrial;Mice;Mice, Knockout;Mitochondrial Degradation;Monosaccharide Transport Proteins;Spleen",B01.050;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;D12.644.276.374;D12.776.467.374;D23.529.374;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;D12.776.503.280;G02.111.820.560;G03.493.560;G04.835.560;G03.295.770.500;G04.580.550;G07.265.675.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G04.599.500;D12.776.157.530.500;D12.776.543.585.500;A10.549.700;A15.382.520.604.700
30226866,,
30225912,Nociceptors;Spinal Cord Dorsal Horn,A08.675.650.915.875;A08.800.950.875;A11.671.650.915.875;A08.186.854.697
30225140,,
30224458,Dihydroxyphenylalanine;Escherichia coli;Escherichia coli Proteins;Free Radicals;Ribonucleotide Reductases;Tyrosine;Dihydroxyphenylalanine,D02.092.311.200;D02.455.426.559.389.657.166.175.200;D12.125.072.050.685.400;D12.125.072.050.875.130;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;D01.339;D02.389;D08.811.682.810;D12.125.072.050.875;D02.092.311.200;D02.455.426.559.389.657.166.175.200;D12.125.072.050.685.400;D12.125.072.050.875.130
30224297,Adolescent;Bariatric Surgery;Obesity;Systematic Review,M01.060.057;E02.570.500.062;E04.062;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;V03.850
30223915,"Child, Preschool;Fontan Procedure;Global Health;Humans;Hypoplastic Left Heart Syndrome;Infant;Infant, Newborn;Morbidity;Palliative Care;Pregnancy;Prenatal Diagnosis;Survival Rate;Hypoplastic Left Heart Syndrome;Review",M01.060.406.448;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703;M01.060.703.520;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;E02.760.666;N02.421.585.666;G08.686.784.769;E01.370.378.630;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;V02.600.500;V02.912
30223114,,
30222916,"Adult;Appetite;Behavior Therapy;Benzazepines;Bulimia;Counseling;Craving;Eating;Emotions;Humans;Life Style;Middle Aged;Obesity;Placebos;Stress, Psychological;Treatment Outcome;Weight Loss;Appetite;Craving;Obesity",M01.060.116;F02.830.071;G07.203.650.390.070;G10.261.390.070;F04.754.137;D03.633.100.079;C23.888.821.645.500;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;F01.658.293.195;G07.203.650.283;G10.261.330;F01.470;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D26.660;E02.785;F01.145.126.990;F02.830.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963;F02.830.071;G07.203.650.390.070;G10.261.390.070;F01.658.293.195;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30222655,,
30222183,Patient Care,E02.760;N02.421.585
30221226,,
30220563,,
30220554,,
30220219,Depression;Psychotherapy,F01.145.126.350;F04.754
30219631,"Interferons;Hypertension, Pulmonary",D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;C08.381.423
30218840,"Medicaid;Patient Protection and Affordable Care Act;Health Services Accessibility;Child;Insurance, Health",N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.576.343.918;N03.706.615.806;N04.590.374.350;N05.300.430;M01.060.406;N03.219.521.576.343
30217796,"Animals;Biocatalysis;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Embryonic Development;Epigenesis, Genetic;Histones;Lysine;Methylation;Oocytes;Spermatozoa;Temperature;X Chromosome;Chromatin;Epigenomics;Germ Cells",B01.050;G02.111.086;G02.130.500;G03.105;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;G07.345.500.325.180;G08.686.784.170.104;G05.308.203;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D12.125.068.555;D12.125.095.647;D12.125.142.497;G02.111.035.538;G02.607.094.538;G03.059.538;A05.360.490.690.680;A11.497.497.600;A05.360.490.890;A11.497.760;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;A11.284.187.865.982;G05.360.162.865.982;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;A05.360.490;A11.497
30217791,Complement System Proteins;Infection;Inflammation,D12.776.124.486.274;C01.539;C23.550.470
30217721,"Child;Infant;Pharmacokinetics;Urea Cycle Disorders, Inborn",M01.060.406;M01.060.703;G03.787;G07.690.725;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937
30217691,"Anti-Bacterial Agents;Apgar Score;Bacteremia;Catheterization, Central Venous;Congenital Abnormalities;Databases, Factual;Drug Utilization;Extracorporeal Membrane Oxygenation;Hernias, Diaphragmatic, Congenital;Humans;Hydrogen-Ion Concentration;Infant, Low Birth Weight;Infant, Newborn;Intensive Care Units, Neonatal;Kidney;Retrospective Studies;Risk Assessment;Surgical Mesh;United States;Urinary Tract Infections;Hernias, Diaphragmatic, Congenital;Intensive Care, Neonatal;Hypertension, Pulmonary",D27.505.954.122.085;E01.370.600.050;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;C16.131;L01.313.500.750.300.188.400;L01.470.750.750;N04.452.706.477;E02.880.301;E04.292.451;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;G02.300;M01.060.703.520.460;M01.060.703.520;N02.278.388.493.390.380;A05.810.453;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E07.858.708;Z01.107.567.875;C01.539.895;C12.777.892;C13.351.968.892;C16.131.433;C23.300.707.500.116;E02.760.190.405;N02.421.585.190.500;C08.381.423
30217588,Anesthesia;Anesthetics;Echocardiography;Heart Valve Prosthesis;Transcatheter Aortic Valve Replacement,E03.155;D27.505.696.277.100;D27.505.954.427.210.100;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E07.695.310;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
30217528,"Adolescent;Adult;Age Factors;Cardiac Surgical Procedures;Continuity of Patient Care;Heart Defects, Congenital;Humans;Middle Aged;Prognosis;Quality of Life;Risk Factors;Survivors;Time Factors;Transition to Adult Care;Young Adult;Outcome Assessment (Health Care)",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;E04.100.376;E04.928.220;E02.760.169;N02.421.585.169;N04.590.233.727.210;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.860;G01.910.857;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
30217352,"Child Abuse, Sexual;Technology;Telemedicine",I01.198.240.748.300;I01.198.240.856.350.250.255;I01.880.735.900.350.250.255;J01.897;H02.403.840;L01.178.847.652;N04.590.374.800
30217304,Humans;Laparoscopy;Pancreatectomy;Pancreatic Neoplasms;Pancreaticoduodenectomy;Postoperative Complications;Robotic Surgical Procedures;Safety;Treatment Outcome;Pancreaticoduodenectomy,B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;E04.210.752;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E04.210.760;C23.550.767;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;N06.850.135.060.075;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E04.210.760
30217292,"Aged;Breast Neoplasms;Community Health Centers;Databases, Factual;Follow-Up Studies;Health Services Accessibility;Humans;Middle Aged;Neoplasm Staging;Survival Rate;Breast Neoplasms",M01.060.116.100;C04.588.180;C17.800.090.500;N02.278.035.128;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789.625;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C04.588.180;C17.800.090.500
30217281,"Dermatitis, Atopic;Emollients;Histamine Antagonists;Humans;Primary Prevention;Probiotics;Secondary Prevention",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D27.505.954.444.200;D27.505.519.625.375.425;D27.505.696.577.375.425;B01.050.150.900.649.313.988.400.112.400.400;N02.421.726.758;N06.850.780.680;G07.203.300.456.500;J02.500.456.500;E02.897;N02.421.726.825;N06.850.780.750
30217027,"Models, Animal;Flavivirus;Vaccines;Zika Virus",E05.598;B04.820.250.350;D20.215.894;B04.820.250.350.995
30216751,,
30216732,Humans;Hypertension,B01.050.150.900.649.313.988.400.112.400.400;C14.907.489
30216541,Parkinson Disease;Cognition;Cognitive Dysfunction,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F02.463.188;F03.615.250.700
30216416,,
30216311,,
30216207,"Adult;Aging;Brain Waves;Coma;Electroencephalography;Heart Arrest;Humans;International Cooperation;North America;Physical Endurance;Practice Patterns, Physicians';Prognosis;Retrospective Studies;Surveys and Questionnaires",M01.060.116;G07.345.124;E01.370.376.300.150;E01.370.405.245.287;G07.265.087;G11.561.127;C10.597.606.358.800.200;C23.888.592.604.359.800.200;E01.370.376.300;E01.370.405.245;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;Z01.107.567;G11.427.680;I03.450.642.845.054.600;N04.590.374.577;N05.300.625;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
30216124,,
30215822,,
30215584,Cerebrospinal Fluid Leak;Spine;Surgical Wound Infection,C10.597.114;C10.900.300.109;C23.888.592.114;C26.915.300.225;A02.835.232.834;C01.539.947.692;C23.550.767.925
30215381,"Amikacin;Antitubercular Agents;Capreomycin;Carbapenems;Clofazimine;Diarylquinolines;Drug Therapy, Combination;Fluoroquinolones;Humans;Kanamycin;Levofloxacin;Linezolid;Moxifloxacin;Recurrence;Treatment Failure;Tuberculosis, Multidrug-Resistant;Tuberculosis, Pulmonary",D09.408.051.476.060;D27.505.954.122.085.255;D04.345.566.142;D12.644.641.142;D02.065.589.099.124;D03.633.100.300.124;D03.633.300.704.353;D03.633.100.810.087;E02.319.310;D03.633.100.810.835.322;B01.050.150.900.649.313.988.400.112.400.400;D09.408.051.476;D03.633.100.810.835.322.500.500;D02.065.064.463;D02.241.081.018.110.525;D03.383.129.462.600.550;D03.633.100.810.835.322.327;C23.550.291.937;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;C01.252.410.040.552.846.775;C01.252.410.040.552.846.899;C08.381.922;C08.730.939
30214040,,
30213831,,
30213803,,
30213728,"Chromatin;Chromosomes, Human;Disease;Gene Expression Regulation;Genome, Human;Humans;Neoplasms",A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.284.187.520.300;G05.360.162.520.300;C23.550.288;G05.308;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;C04
30213625,"Asthma;B-Lymphocytes;Allergens;Biological Therapy;Environment;Eosinophils;Genetics;T-Lymphocytes, Helper-Inducer;Microbiota;Neutrophils",C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D23.050.063;E02.095;G16.500.275;N06.230;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;H01.158.273.343;A11.118.637.555.567.550.500.400;A11.118.637.555.567.569.200.400;A11.118.637.555.567.569.500.400;A15.145.229.637.555.567.550.500.400;A15.145.229.637.555.567.569.200.400;A15.145.229.637.555.567.569.500.400;A15.382.490.555.567.550.500.400;A15.382.490.555.567.569.200.400;A15.382.490.555.567.569.500.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
30213581,Fibrosis,C23.550.355
30212861,,
30212568,"Aneuploidy;Antigens, Viral;Cdc20 Proteins;Cell Cycle Checkpoints;Cell Cycle Proteins;Cell Line;Centromere;Chromosomal Instability;Cyclin B1;Herpesvirus 8, Human;Histones;Humans;Mitosis;Models, Biological;Nuclear Localization Signals;Nuclear Proteins;Phosphorylation;Protein Interaction Domains and Motifs;Protein-Serine-Threonine Kinases;Proteolysis;Securin",C23.550.210.050;G05.365.590.175.050;G05.700.131;D23.050.327;D08.811.464.938.750.092.998;D12.776.167.024.998;G04.144.109;D12.776.167;A11.251.210;A11.284.430.106.279.345.190.160.165;G05.360.160.165;C23.550.210.110;C23.550.362.180;G05.365.590.175.165;G05.370.180;D12.644.360.262.120.100;D12.776.167.218.120.100;D12.776.476.262.120.100;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;G04.144.220.220.781;G05.113.220.781;E05.599.395;D12.644.770.610;G02.111.570.060.670.610;D12.776.660;G02.111.665;G02.607.780;G03.796;G02.111.570.820.709.275.750.500;D08.811.913.696.620.682.700;G02.111.720;G03.812;D12.776.167.504
30212476,Adult;Aged;Brain;Disease Progression;Follow-Up Studies;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Middle Aged;Multiple Sclerosis,M01.060.116;M01.060.116.100;A08.186.211;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
30211755,,
30211722,,
30211252,,
30210756,Dependovirus;Genetic Therapy;Hemophilia A;Lentivirus,B04.280.580.650.170;E02.095.301;E05.393.420.301;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;B04.820.650.589
30210404,Adolescent;Risk-Taking,M01.060.057;F01.145.722
30210282,Perception;Auditory Cortex;Macaca mulatta,F02.463.593;A08.186.211.200.885.287.500.814.249;A08.186.211.200.885.287.500.863.297;B01.050.150.900.649.313.988.400.112.199.120.510.550
30209976,"Proteolysis;Phosphorylation;Protein Processing, Post-Translational",G02.111.720;G03.812;G02.111.665;G02.607.780;G03.796;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
30209881,"Celiac Disease;Epidemiology;Incidence;Mass Screening;Diabetes Mellitus, Type 1",C06.405.469.637.250;C18.452.603.250;H02.403.720.500;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C18.452.394.750.124;C19.246.267;C20.111.327
30209392,,
30209036,Extracellular Fluid;Macrophages;Massage,A11.284.295.260;A12.207.270;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750
30208894,"Adolescent;Adult;Biomechanical Phenomena;Child;Databases, Factual;Humans;Image Interpretation, Computer-Assisted;Kentucky;Magnetic Resonance Imaging, Cine;Myocardial Contraction;Philadelphia;Predictive Value of Tests;Reference Standards;Reproducibility of Results;Retrospective Studies;Torsion, Mechanical;Ventricular Dysfunction, Left;Ventricular Function, Left;Young Adult;Sprains and Strains",M01.060.057;M01.060.116;G01.154.090;G01.374.089;M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;Z01.107.567.875.075.400;Z01.107.567.875.510.400;E01.370.350.825.500.510;G09.330.580;G11.427.494.570;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.978.808;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.374.860;C14.280.945.900;G09.330.955.800;M01.060.116.815;C26.844
30208496,,
30208456,"Adolescent;Anti-Bacterial Agents;Antibiotic Prophylaxis;Antineoplastic Agents;Bacteremia;Child;Child, Preschool;Hematopoietic Stem Cell Transplantation;Humans;Infant;Leukemia, Myeloid, Acute;Levofloxacin;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Young Adult",M01.060.057;D27.505.954.122.085;E02.319.162.150;E02.319.703.150;D27.505.954.248;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;M01.060.406;M01.060.406.448;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.337.539.275;D03.633.100.810.835.322.500.500;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;M01.060.116.815
30208424,,
30208418,,
30208384,,
30208317,"Calcium-Calmodulin-Dependent Protein Kinase Type 2;Organelle Biogenesis;Muscle, Skeletal",D08.811.913.696.620.682.700.125.200;D12.644.360.100.200;D12.776.476.100.200;G04.618;G16.645;A02.633.567;A10.690.552.500
30208226,Prenatal Diagnosis,E01.370.378.630
30207920,"Administration, Oral;Adolescent;Brain;Child;Fingolimod Hydrochloride;Headache;Humans;Immunologic Factors;Infection;Injections, Intramuscular;Interferon-beta;Leukopenia;Magnetic Resonance Imaging;Multiple Sclerosis, Relapsing-Remitting;Secondary Prevention",E02.319.267.100;M01.060.057;A08.186.211;M01.060.406;D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;C23.888.592.612.441;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;C01.539;E02.319.267.530.460;D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275;C15.378.553.546;E01.370.350.825.500;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;E02.897;N02.421.726.825;N06.850.780.750
30207821,Critical Pathways;Emergency Medicine;Metered Dose Inhalers;Quality Improvement,N04.590.233.624.625;N04.590.275;H02.403.250;E07.605.750;J01.293.754;N04.761.744
30207780,,
30207430,Bronchoalveolar Lavage,E05.927.100
30207055,Precursor Cell Lymphoblastic Leukemia-Lymphoma;Recurrence,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;C23.550.291.937
30206936,Continuity of Patient Care;Patient-Centered Care;Primary Health Care,E02.760.169;N02.421.585.169;N04.590.233.727.210;N04.590.233.727.407;N04.590.233.727
30206500,Mesothelioma,C04.557.470.035.510;C04.557.470.660.510
30206421,"Genes, X-Linked;Epilepsy;Intellectual Disability;Protein Isoforms",G05.360.340.024.340.500;G05.420.457;C10.228.140.490;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;D12.776.800
30206307,,
30205147,"Aorta;Coronary Vessels;Humans;Infant;Infant, Newborn",A07.015.114.056;A07.015.114.269;A07.015.908.194;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520
30204546,,
30203926,"Adenoidectomy;Adenoids;Diagnostic Tests, Routine;Olfaction Disorders;Olfactory Perception;Sex;Smell",E04.580.068;A04.623.557.500;A10.549.100;A14.724.557.500;A15.382.520.604.100;E01.370.395;C10.597.751.600;C23.888.592.763.550;F02.463.593.485;G08.686.810;F02.830.816.643;G11.561.790.643
30203839,Interleukin-6,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
30203149,Hypertension;Radiofrequency Ablation,C14.907.489;E02.808.750;E04.014.760
30203094,,
30202886,,
30201937,"Adult;Amniotic Fluid;Arachidonic Acid;Case-Control Studies;Chromatography, Liquid;Diabetes, Gestational;Docosahexaenoic Acids;Gas Chromatography-Mass Spectrometry;Humans;Infant, Newborn;Mass Spectrometry;Metabolomics;Pregnancy;Pregnancy Trimester, Second;Sex Factors;Amniotic Fluid;Fetal Development;Diabetes, Gestational;Metabolomics",M01.060.116;A12.098;A16.378.149;D10.251.355.255.100.100;D10.251.355.310.166.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.196.181.400;C13.703.170;C18.452.394.750.448;C19.246.200;D10.212.302.380.410.210;D10.251.355.337.250;D10.627.430.450.375;E05.196.181.349.500;E05.196.566.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E05.196.566;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;G08.686.784.769;G08.686.707.490;N05.715.350.675;N06.850.490.875;A12.098;A16.378.149;G07.345.500.325.235;G08.686.784.170.157;C13.703.170;C18.452.394.750.448;C19.246.200;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
30201664,"Electronic Health Records;Emergency Service, Hospital;Grounded Theory;Hospitalization;Patient Satisfaction;Primary Health Care",E05.318.308.940.968.625.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;H01.770.644.241.424;E02.760.400;N02.421.585.400;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;N04.590.233.727
30201389,,
30199744,Actigraphy;Adult;Aged;Chronotherapy;Circadian Rhythm;Cognitive Behavioral Therapy;Comorbidity;Depression;Humans;Middle Aged;Pilot Projects;Reward;Self Report;Sleep;Sleep Initiation and Maintenance Disorders;Veterans;Depression;Sleep Initiation and Maintenance Disorders,E01.370.520.049;E05.003.500;M01.060.116;M01.060.116.100;E02.168;G07.180.562.190;F04.754.137.350;N05.715.350.225;N06.850.490.687;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;F02.463.425.770.836;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;F02.830.855;G11.561.803;C10.886.425.800.800;F03.870.400.800.800;M01.930;F01.145.126.350;C10.886.425.800.800;F03.870.400.800.800
30199665,,
30199403,,
30199384,,
30199337,"Clinical Competence;Humans;Internship and Residency;Psychiatry;Psychotherapy, Psychodynamic;Surveys and Questionnaires;Teaching;Psychoanalysis;Psychotherapy, Psychodynamic;Psychotherapy",I02.399.630.210;N04.761.210;N05.715.175;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F04.096.544;H02.403.690;F04.754.775;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.903;F04.096.544.779;F04.754.775;F04.754
30199018,"Animals;Blotting, Western;Electrophoresis, Polyacrylamide Gel;Hematopoietic Stem Cells;Mice",B01.050;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;E05.196.401.402;E05.301.300.319;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.992.635.505.500
30198955,,
30198448,"Adolescent;Adrenergic Uptake Inhibitors;Atomoxetine Hydrochloride;Central Nervous System Stimulants;Child;Cognitive Dysfunction;Databases, Factual;Drug Therapy, Combination;Drug Utilization;Fatigue;Hospitals, Pediatric;Humans;Methylphenidate;Philadelphia;Postural Orthostatic Tachycardia Syndrome;Retrospective Studies;Treatment Outcome;Primary Dysautonomias;Adolescent",M01.060.057;D27.505.519.562.437.050;D27.505.519.625.050.601;D27.505.519.625.600.050;D27.505.696.577.050.601;D27.505.696.577.600.050;D02.092.831.085;D27.505.696.282;D27.505.954.427.220;M01.060.406;F03.615.250.700;L01.313.500.750.300.188.400;L01.470.750.750;E02.319.310;N04.452.706.477;C23.888.369;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;D02.241.223.601.600;D03.383.621.460;Z01.107.567.875.500.550.525;Z01.433.820;C10.177.575.600.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C10.177.575;M01.060.057
30198004,,
30197992,,
30197422,Chemokines;Chemokine CCL24;Interleukin-8,D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;D12.644.276.374.200.110.910;D12.776.467.374.200.110.910;D23.125.300.110.910;D23.469.200.110.910;D23.529.374.200.110.910;D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312
30197257,,
30197233,Brain Concussion,C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200
30197073,,
30196853,Retinoschisis;Clinical Trial;Genetic Therapy;Retinal Diseases,C11.768.585.865;V03.175.250;E02.095.301;E05.393.420.301;C11.768
30196072,Cardiovascular Diseases;Heart Failure,C14;C14.280.434
30195768,"RNA Editing;Models, Animal;Genetic Therapy;Molecular Biology;Trans-Splicing",G02.111.760.250;G03.839.250;G05.308.700.250;E05.598;E02.095.301;E05.393.420.301;H01.158.201.636;H01.158.273.343.595;H01.181.122.650;G02.111.760.700.750;G03.839.700.750;G05.308.700.700.750
30195579,Body Surface Potential Mapping;Patient-Specific Modeling,E01.370.370.380.240.850.100;E01.370.405.240.850.100;E05.599.395.821;L01.224.160.750
30195449,"Anti-Inflammatory Agents;Azathioprine;Biological Products;Clinical Decision-Making;Colitis, Ulcerative;Crohn Disease;Drug Therapy, Combination;Gastrointestinal Agents;Humans;Mercaptopurine;Methotrexate;Purines;Risk Factors;Thioguanine;Treatment Outcome;Immunologic Factors;Inflammatory Bowel Diseases;Colitis, Ulcerative",D27.505.954.158;D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111;D20.215;E01.055;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;C06.405.205.731.500;C06.405.469.432.500;E02.319.310;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;D02.886.489.534;D03.633.100.759.570;D03.633.100.733.631.192.500;D03.633.100.759;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D03.633.100.759.854;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D27.505.696.477;C06.405.205.731;C06.405.469.432;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
30195054,Bibliometrics;Humans;Neuroimaging;Periodicals as Topic;Neuroimaging,L01.178.682.099.325;L01.453.183.291;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;L01.178.682.829.678;E01.370.350.578;E01.370.376.537;E05.629
30194996,,
30194971,,
30194902,,
30194647,Accidental Falls,N06.850.135.122
30194461,Arteriovenous Malformations;Hemangioma;Infant;Liver,C14.240.850.750;C14.907.150;C16.131.240.850.750;C04.557.645.375;M01.060.703;A03.620
30194459,Child;Humans;Magnetic Resonance Imaging;Whole Body Imaging,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.925;E05.979
30194392,,
30194242,,
30194086,,
30193380,,
30193347,,
30193328,,
30193325,,
30193310,,
30193298,,
30193294,,
30193284,,
30193276,"Aged;Aged, 80 and over;Arthroplasty, Replacement, Hip;Arthroplasty, Replacement, Knee;Diagnosis-Related Groups;Economics, Hospital;Episode of Care;Hospitals, High-Volume;Hospitals, Low-Volume;Humans;Long-Term Care;Medicare;Rehabilitation Centers;Reimbursement Mechanisms;Skilled Nursing Facilities;United States",M01.060.116.100;M01.060.116.100.080;E04.555.110.110.110;E04.650.110.110;E04.680.101.110.110;E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;N03.219.521.710.305.200.080;N03.219.262;E02.760.300;N02.421.585.300;N02.278.421.414;N02.278.421.434;B01.050.150.900.649.313.988.400.112.400.400;E02.760.476;N02.421.585.476;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N02.278.808;N03.219.521.710.305;N02.278.825.610.770;Z01.107.567.875
30192949,,
30192240,,
30192170,,
30192042,,
30191502,Obesity,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30190612,"Autistic Disorder;Biological Variation, Population",F03.625.164.113.500;G16.117
30190611,Genetic Association Studies;Neurofibroma,E05.393.385;C04.557.580.600.580;C10.551.775.500.750;C10.668.829.725.500.600
30190529,,
30190371,,
30190287,,
30189812,"Brain Death;Cerebrovascular Circulation;Contrast Media;Humans;Infant;Ultrasonography;Brain Death;Infant, Newborn",C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;G09.330.100.159;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.850;C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;M01.060.703.520
30189336,Factor IX;Factor IXa;Humans;Protein S;Factor IXa;Factor Xa;Protein S;Thrombophilia,D08.622.355;D12.776.124.125.375;D23.119.375;D08.811.277.656.300.760.310;D08.811.277.656.959.350.310;D12.776.124.125.375.310;D23.119.375.310;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.670;D12.776.395.642;D23.113.725;D08.811.277.656.300.760.310;D08.811.277.656.959.350.310;D12.776.124.125.375.310;D23.119.375.310;D08.811.277.656.300.760.315;D08.811.277.656.959.350.315;D12.776.124.125.400.315;D23.119.400.315;D12.776.124.670;D12.776.395.642;D23.113.725;C15.378.925
30189318,,
30189317,,
30188405,,
30187517,"Child;Consensus;Delivery of Health Care;Enteral Nutrition;Gastrointestinal Contents;Humans;Hydrogen-Ion Concentration;Intubation, Gastrointestinal;Patient Safety;Pediatrics;Practice Guidelines as Topic;Radiography;Risk;Societies, Medical;X-Rays;Enteral Nutrition",M01.060.406;F01.829.316.068;F02.463.785.373.433;N04.590.374;N05.300;E02.421.360;E02.642.500.360;A12.519;B01.050.150.900.649.313.988.400.112.400.400;G02.300;E02.585.412;E05.497.412;N06.850.135.060.075.399;H02.403.670;N04.761.700.350.650;N05.700.350.650;E01.370.350.700;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;N03.540.828.589;G01.358.500.505.970;G01.750.250.970;G01.750.750.918;E02.421.360;E02.642.500.360
30187369,"Hyperammonemia;Metabolism;Urea Cycle Disorders, Inborn",C23.550.421;G03;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937
30187238,Chordae Tendineae;Finite Element Analysis;Mitral Valve,A07.541.510.240;E05.355;A07.541.510.507
30186359,"Influenza Vaccines;Metformin;Anti-Inflammatory Agents, Non-Steroidal",D20.215.894.899.302;D02.078.370.141.450;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030
30186248,Methicillin-Resistant Staphylococcus aureus;Methicillin-Resistant Staphylococcus aureus;Phylogeny,B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;G05.697;G16.075.605;L01.100.697
30185934,,
30185676,Energy Metabolism;Inflammation;Metabolism;Mitochondria;General Surgery,G03.295;C23.550.470;G03;A11.284.430.214.190.875.564;A11.284.835.626;H02.403.810.300
30185503,"Adaptation, Psychological;Adult;Attitude to Death;Bereavement;Critical Care;Grief;Humans;Middle Aged;Nursing Staff, Hospital;Psychological Theory",F01.058;M01.060.116;F01.100.125;N05.300.125;F01.470.142;E02.760.190;N02.421.585.190;F01.470.142.110;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;F02.739
30184773,"Apoptosis;Cell Line, Tumor;DNA Fragmentation;Flavones;Humans;Hydrogen-Ion Concentration;Lung Neoplasms;Neoplasm Metastasis;Quantum Dots;Zinc Oxide;Apoptosis;Lung Neoplasms;Quantum Dots;Zinc Oxide",G04.146.160;A11.251.210.190;A11.251.860.180;G05.200.230;D03.383.663.283.266.450.260;D03.633.100.150.266.450.260;B01.050.150.900.649.313.988.400.112.400.400;G02.300;C04.588.894.797.520;C08.381.540;C08.785.520;C04.697.650;C23.550.727.650;E07.705;J01.637.512.600.650;D01.650.550.975;D01.975.975;G04.146.160;C04.588.894.797.520;C08.381.540;C08.785.520;E07.705;J01.637.512.600.650;D01.650.550.975;D01.975.975
30182442,Holoprosencephaly,C05.660.207.410;C10.500.034.875;C16.131.077.410;C16.131.260.380;C16.131.621.207.410;C16.131.666.034.875;C16.320.180.380
30182150,Cancer Survivors;Pain;Exercise,M01.860.350;C23.888.592.612;F02.830.816.444;G11.561.790.444;G11.427.410.698.277;I03.350
30181580,,
30181386,,
30181236,,
30181172,,
30181083,Marfan Syndrome;Adolescent,C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;M01.060.057
30180999,"Elasticity Imaging Techniques;Hydrocephalus;Infant, Newborn",E01.370.350.850.270;C10.228.140.602;M01.060.703.520
30180976,,
30180137,,
30179955,,
30179942,,
30179913,Fluorodeoxyglucose F18;Humans;Infant;Penile Neoplasms;Positron Emission Tomography Computed Tomography;Radiopharmaceuticals;Rhabdomyosarcoma,D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.588.945.440.715;C12.294.260.500;C12.294.494.591;C12.758.409.500;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;C04.557.450.590.550.660;C04.557.450.795.550.660
30179860,Carbohydrate Metabolism;Microcirculation,G02.111.158;G03.191;G09.330.100.645
30178481,,
30178342,"Animals;Biomarkers, Tumor;Breast Neoplasms;Flavin-Adenine Dinucleotide;Heterografts;Humans;Image Processing, Computer-Assisted;Mice;NAD;Optical Imaging;Oxidation-Reduction;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha",B01.050;D23.101.140;C04.588.180;C17.800.090.500;D03.633.100.733.315.650.249;D03.633.100.759.646.138.506;D03.633.300.507.650.249;D08.211.474.650.249;D13.695.667.138.506;D13.695.827.068.506;D23.767.405.650.249;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;B01.050.150.900.649.313.992.635.505.500;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;E01.370.350.589;E05.642;G02.700;G03.295.531;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650
30178187,"Adolescent;Adult;Catheter Ablation;Child;Child, Preschool;Humans;Positive-Pressure Respiration;Prospective Studies;Tachycardia, Supraventricular;Tidal Volume;Young Adult;Catheter Ablation;Electrophysiology;Ventilation",M01.060.057;M01.060.116;E02.808.750.500;E04.014.760.500;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E02.041.625.790;E02.880.820.790;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C14.280.067.845.880;C14.280.123.875.880;C23.550.073.845.880;E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700;M01.060.116.815;E02.808.750.500;E04.014.760.500;H01.158.344.528;H01.158.782.236;N06.230.150.520
30177518,,
30177484,"Renal Insufficiency, Chronic;Prediabetic State",C12.777.419.780.750;C13.351.968.419.780.750;C18.452.394.750.774;C19.246.774
30177475,Hemorrhage;Coronary Artery Bypass;Factor IX;Hemophilia B,C23.550.414;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;D08.622.355;D12.776.124.125.375;D23.119.375;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235
30177242,"Accelerometry;Calibration;Calorimetry, Indirect;Self-Assessment",E05.003;E05.978.155;E05.196.131.655;F01.752.747.792.537
30177236,"Adult;Depression, Postpartum;Double-Blind Method;Drug Combinations;GABA Agonists;Humans;Injections, Intravenous;Pregnancy;Pregnancy Trimester, Third;Pregnanolone;Psychiatric Status Rating Scales;Receptors, GABA;Severity of Illness Index;Treatment Outcome;Young Adult;beta-Cyclodextrins",M01.060.116;C13.703.844.253;F03.600.300.350;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D26.310;D27.505.519.625.240.200;D27.505.696.577.240.200;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.082.750;E02.319.267.530.540;G08.686.784.769;G08.686.707.520;D04.210.500.745.640;F04.711.513.653;D12.776.543.750.720.200.300;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;D04.345.103.333;D09.301.915.400.375.333;D09.698.365.855.400.375.333
30176494,"Adult;Antidepressive Agents, Second-Generation;Cognitive Behavioral Therapy;Comorbidity;Depressive Disorder, Major;Fluoxetine;Humans;Middle Aged;Phobia, Social;Recurrence;Risk Assessment;Social Behavior;Anxiety Disorders;Cognitive Behavioral Therapy;Comorbidity;Fluoxetine;Depressive Disorder, Major;Phobia, Social",M01.060.116;D27.505.954.427.700.122.050;F04.754.137.350;N05.715.350.225;N06.850.490.687;F03.600.300.375;D02.092.831.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F03.080.725.500;C23.550.291.937;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;F01.145.813;F03.080;F04.754.137.350;N05.715.350.225;N06.850.490.687;D02.092.831.280;F03.600.300.375;F03.080.725.500
30176396,"Adolescent;Athletic Injuries;Baseball;Humans;Humerus;Range of Motion, Articular;Rotation;Shoulder Injuries;Torque;Shoulder Pain",M01.060.057;C26.115;I03.450.642.845.110;B01.050.150.900.649.313.988.400.112.400.400;A02.835.232.087.090.400;E01.370.600.700;G11.427.760;G01.482.703;C26.803;G01.374.860.500;C05.550.091.700;C23.888.592.612.094.700;F02.830.816.444.350.500;G11.561.790.444.350.500
30176310,,
30176308,,
30176306,,
30176005,Adult;Humans;Taste;Taste Buds;Tongue;Young Adult,M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;F02.830.816.724;G11.561.790.724;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779;A03.556.500.885;A14.549.885;M01.060.116.815
30175440,Diabetes Mellitus;Pediatrics;Research Design,C18.452.394.750;C19.246;H02.403.670;E05.581.500;H01.770.644.728
30175228,Alzheimer Disease;Memantine;Vitamin E,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D02.455.426.100.050.035.500;D03.383.663.283.909;D03.633.100.150.909
30175221,Acne Vulgaris;Amoxicillin;Pregnancy,C17.800.030.150;C17.800.794.111;D02.065.589.099.750.750.050.050;D02.886.108.750.750.050.050;D03.633.100.300.750.750.050.050;G08.686.784.769
30174930,,
30174314,Neurogenesis;Lateral Ventricles,G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.186.211.140.650
30174309,"Aging;Cardiomyopathies;DNA, Mitochondrial",G07.345.124;C14.280.238;D13.444.308.283.225
30174295,Hippocampus;Neurogenesis,A08.186.211.180.405;A08.186.211.200.885.287.500.345;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620
30174265,"Aged;Cardiac Surgical Procedures;Echocardiography, Transesophageal;Follow-Up Studies;Guideline Adherence;Heart Valve Diseases;Heart Valve Prosthesis;Heart Valves;Humans;Monitoring, Intraoperative;Practice Patterns, Physicians';Reproducibility of Results;Retrospective Studies;Health Services;Echocardiography, Transesophageal",M01.060.116.100;E04.100.376;E04.928.220;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;N04.761.337;N05.715.360.395;C14.280.484;E07.695.310;A07.541.510;B01.050.150.900.649.313.988.400.112.400.400;E01.370.520.510;E04.510;N04.590.374.577;N05.300.625;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N02.421;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
30174261,,
30174244,"Spasms, Infantile;Epilepsy;Spasms, Infantile;Seizures",C10.228.140.490.375.760;C10.228.140.490.493.875;C10.228.140.490;C10.228.140.490.375.760;C10.228.140.490.493.875;C10.597.742;C23.888.592.742
30174228,Apoptosis;Pancreas,G04.146.160;A03.734
30174180,"Alpha-Globulins;Animals;Body Patterning;Cell Adhesion Molecules;Chick Embryo;Chickens;Digestive System;Embryo, Mammalian;Functional Laterality;Hyaluronic Acid;Mice;Mice, Inbred BALB C;Mice, Knockout;Congenital Abnormalities;Embryonic Development;Extracellular Matrix;Hyaluronic Acid",D12.776.124.790.106;D12.776.377.715.085;B01.050;G07.345.500.100;D12.776.395.550.200;D12.776.543.550.200;D23.050.301.350;A13.350.150;A16.331.200;B01.050.150.900.248.350.150;B01.050.150.900.248.690.192;A03;A16.254;F02.830.297.425;G11.561.225.425;D09.698.373.475;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C16.131;G07.345.500.325.180;G08.686.784.170.104;A11.284.295.310;D09.698.373.475
30174166,Transplants,A01.941
30174144,Risk Management;Patient Safety,N03.219.463.800;N04.452.871;N06.850.135.060.075.399
30173918,Fragile X Syndrome;Genomic Instability;Microsatellite Repeats,C10.597.606.360.455.500;C16.131.260.830.300;C16.320.180.830.300;C16.320.322.500.500;C16.320.400.525.500;C23.550.362;G05.365.590.335;G05.370;G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500
30173720,,
30172918,"Economics, Behavioral",F04.096.628.286;N03.219.215
30172830,Adult;Aged;Body Image;Brain;Fingers;Hand Strength;Humans;Lenses;Middle Aged;Motor Activity;Movement Disorders;Random Allocation;Stroke;Stroke Rehabilitation;Visual Perception;Body Image;Therapeutics,M01.060.116;M01.060.116.100;F01.752.747.792.110;F02.463.593.112;A08.186.211;A01.378.800.667.430;E01.370.600.425.500;G11.427.560.500;B01.050.150.900.649.313.988.400.112.400.400;E07.632.500;M01.060.116.630;F01.145.632;G11.427.410.698;C10.228.662;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;C10.228.140.300.775;C14.907.253.855;E02.760.169.063.500.477.500;E02.831.477.500;H02.403.680.600.750.500;N02.421.784.511.500;F02.463.593.932;F01.752.747.792.110;F02.463.593.112;E02
30172426,"Bronchopulmonary Dysplasia;Cohort Studies;Comorbidity;Echocardiography, Doppler;Gestational Age;Hospital Mortality;Humans;Hypertension, Pulmonary;Infant;Infant, Newborn;Infant, Premature;Intensive Care, Neonatal;Multivariate Analysis;Patient Readmission;Pregnancy;Prevalence;Prognosis;Regression Analysis;Retrospective Studies;Severity of Illness Index;Survival Rate;Bronchopulmonary Dysplasia;Epidemiology;Hypertension, Pulmonary",C08.381.520.750.500;C16.614.521.125;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;G07.345.500.325.235.968;G08.686.320;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;M01.060.703;M01.060.703.520;M01.060.703.520.520;E02.760.190.405;N02.421.585.190.500;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.760.400.620;N02.421.585.400.620;G08.686.784.769;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C08.381.520.750.500;C16.614.521.125;H02.403.720.500;C08.381.423
30172191,"Blood Pressure;Child;Renal Insufficiency, Chronic;Glomerular Filtration Rate",E01.370.600.875.249;G09.330.380.076;M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;E01.370.390.400.300;G08.852.357
30171876,"Attitude;Education, Medical;Psoriasis",F01.100;I02.358.399;C17.800.859.675
30171078,,
30171045,,
30171044,,
30170988,,
30170123,"Dermatitis, Atopic",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343
30170085,"Amygdala;Animals;Down-Regulation;Extinction, Psychological;Fear;Glutamate Decarboxylase;Hippocampus;Immobility Response, Tonic;Mice;Microinjections;Nicotine;Prefrontal Cortex;Proto-Oncogene Proteins c-fos;gamma-Aminobutyric Acid;Hippocampus;Receptors, Nicotinic;Stress Disorders, Post-Traumatic",A08.186.211.180.090;A08.186.211.200.885.287.249.152;B01.050;G02.111.240;G05.308.200;G07.690.773.937;F02.463.425.770.232;F01.470.361;D08.811.520.224.125.250;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F01.145.113.680;F01.145.632.680;G11.427.410.698.680;B01.050.150.900.649.313.992.635.505.500;E02.319.267.530.690;E05.591.570;D03.132.760.570;D03.383.725.518;A08.186.211.200.885.287.500.270.700;D12.776.260.108.765;D12.776.624.664.700.179;D12.776.660.760;D12.776.930.127.765;D02.241.081.114.500.350;D12.125.190.350;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D12.776.157.530.400.400.100.500;D12.776.543.550.450.500.100.500;D12.776.543.585.400.500.100.500;D12.776.543.750.130.687;D12.776.543.750.720.360.550;F03.950.750.500
30170026,,
30169481,,
30169476,"Adult;Aged;Aged, 80 and over;Autonomic Nerve Block;Cadaver;Carbon;Humans;Intercostal Muscles;Intercostal Nerves;Methylcellulose;Middle Aged;Retrospective Studies;Superficial Back Muscles;Thoracic Wall;Ultrasonography, Interventional",M01.060.116;M01.060.116.100;M01.060.116.100.080;E03.155.086.711.299;E04.525.210.550.500;C23.550.260.224;D01.268.150;B01.050.150.900.649.313.988.400.112.400.400;A02.633.567.900.500;A08.800.800.720.800.350;D09.698.365.180.663;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.633.567.175.875;A01.923.761.850;E01.370.350.850.855;E04.502.890
30169378,,
30169322,,
30169300,,
30169275,"Adaptation, Psychological;Child;Europe;Humans;Prospective Studies;Quality of Life",F01.058;M01.060.406;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837
30169254,,
30169239,Anticonvulsants;Child;Humans;Prognosis;Prospective Studies;Status Epilepticus,D27.505.954.427.080;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.597.742.785;C23.888.592.742.785
30169225,,
30169189,,
30168847,Adolescent;Adult;Aged;Ambulatory Care Facilities;Autoimmune Diseases;Botswana;Dermatology;Humans;Incidence;Middle Aged;Retrospective Studies;Skin Diseases;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;N02.278.035;C20.111;Z01.058.290.175.230;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C17.800;M01.060.116.815
30168660,Malignant Hyperthermia,C23.550.505.700;C23.550.767.600
30168188,"Brain;Child;Facial Hemiatrophy;Humans;Immunosuppressive Agents;Magnetic Resonance Imaging;Methotrexate;Remission Induction;Scleroderma, Localized;Seizures;Skin",A08.186.211;M01.060.406;C07.465.284;C07.465.299.375;C10.292.319.375;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;E01.370.350.825.500;D03.633.100.733.631.192.500;E02.860;C17.300.787;C17.800.767;C10.597.742;C23.888.592.742;A17.815
30168024,Dyskeratosis Congenita;Telomere,C16.131.831.150;C16.320.322.108;C16.320.850.235;C17.800.804.150;C17.800.827.235;A11.284.430.106.279.345.190.160.845;G05.360.160.845
30168000,,
30167992,"Adalimumab;Adverse Drug Reaction Reporting Systems;Anti-Inflammatory Agents;Databases, Pharmaceutical;Humans;Proof of Concept Study;Social Media;Systematic Reviews as Topic;United States;United States Food and Drug Administration",D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;E05.337.800.120;N02.421.668.320.120;D27.505.954.158;L01.313.500.750.300.188.400.400;L01.470.750.750.400;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.578;L01.178.751;L01.224.230.110.500.750;L01.178.682.759.575;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
30167880,Humans;Huntington Disease;Risk Factors;Suicidal Ideation;Depression;Huntington Disease;Risk Factors;Suicidal Ideation,B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.350;C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.980.875.149;I01.880.735.856.149
30167814,"Arthritis, Psoriatic;Consensus;Delphi Technique;Humans;Outcome Assessment (Health Care);Psoriasis;Quality Assurance, Health Care;Randomized Controlled Trials as Topic;Arthritis, Psoriatic;Psychometrics;Mass Screening",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;F01.829.316.068;F02.463.785.373.433;L01.906.197;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C17.800.859.675;N04.761.700;N05.700;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;F04.711.780;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30167444,"Abatacept;Lupus Erythematosus, Systemic",D12.776.124.790.651.114.580.225;D12.776.377.715.548.114.580.225;C17.300.480;C20.111.590
30166629,,
30166620,,
30166224,,
30165701,,
30165168,,
30165136,,
30165135,,
30165134,,
30165133,,
30165132,,
30165131,,
30165129,,
30161067,,
30161055,Adult;Aged;Autoantibodies;Autoimmune Diseases;Biomarkers;Carbonic Anhydrases;Case-Control Studies;Humans;Middle Aged;Prevalence;Prospective Studies;Salivary Proteins and Peptides;Sjogren's Syndrome;Young Adult,M01.060.116;M01.060.116.100;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;C20.111;D23.101;D08.811.520.241.300.150;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.644.848;D12.776.850;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774;M01.060.116.815
30160986,Osteochondroma,C04.557.450.565.575.610;C05.116.099.708.670
30160208,Demyelinating Diseases;Quality of Life;Multiple Sclerosis;Quality of Life,C10.314;I01.800;K01.752.400.750;N06.850.505.400.425.837;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;I01.800;K01.752.400.750;N06.850.505.400.425.837
30159811,Muscular Diseases,C05.651;C10.668.491
30159592,"Adolescent;Catheterization, Central Venous;Catheters, Indwelling;Child;Equipment Failure;Fibrin;Humans;Retrospective Studies;Thrombolytic Therapy;Treatment Outcome;Vascular Patency;Young Adult;Central Venous Catheters;Child;Radiology, Interventional",M01.060.057;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;E07.132.500;M01.060.406;E05.325;D12.776.124.270;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.319.913;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.920;M01.060.116.815;E07.132.750.500;M01.060.406;H02.403.740.675
30159585,"Child;Child, Preschool;Critical Pathways;Fontan Procedure;Heart Defects, Congenital;Heart Ventricles;Humans;Outcome and Process Assessment (Health Care);Program Evaluation;Surveys and Questionnaires",M01.060.406;M01.060.406.448;N04.590.233.624.625;N04.590.275;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;N04.761.559;N05.715.360.575;E05.337.820;N04.761.685;N05.715.360.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
30158954,Chromatin,A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180
30157956,Poly ADP Ribosylation;Poly Adenosine Diphosphate Ribose,G02.111.660.871.790.600.200.500;G02.111.691.600.200.500;G03.734.871.790.600.200.500;G05.308.670.600.200.500;D09.408.620.569.070.125.600;D13.695.578.550.530;D13.695.827.708.070.125.600
30157950,Biomarkers;Breast;Breast Neoplasms;DNA Methylation;Epigenomics;Epigenomics;Genome;Humans;Multivariate Analysis;Smoking,D23.101;A01.236;C04.588.180;C17.800.090.500;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;H01.158.273.180.350.074;H01.158.273.343.350.042;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;F01.145.805
30157590,"Arthroplasty;Knee;Obesity;Microscopy, Electron, Scanning Transmission",E04.555.110;E04.680.101;A01.378.610.450;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E01.370.350.515.402.580.480;E05.595.402.580.480
30157500,,
30157284,,
30157115,,
30156583,,
30156182,,
30155787,Parkinson Disease;REM Sleep Behavior Disorder,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.886.659.633.700;F03.870.664.633.700
30155581,,
30155509,Blood Proteins;Platelet Factor 4,D12.776.124;D12.644.276.374.200.120.900;D12.776.124.125.720;D12.776.467.374.200.120.900;D23.119.940;D23.125.300.120.900;D23.469.200.120.900;D23.529.374.200.120.900
30154560,,
30154500,,
30154145,,
30154114,,
30153231,,
30152559,"Acute Disease;Child;Dermatitis, Allergic Contact;Humans;Irritants;Play and Playthings;Skin;Dermatitis, Contact;Dermatitis, Irritant",C23.550.291.125;M01.060.406;C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;B01.050.150.900.649.313.988.400.112.400.400;D27.720.400;D27.888.569.300;I03.450.642.693;A17.815;C17.800.174.255;C17.800.815.255;C17.800.174.255.400;C17.800.815.255.400
30152166,"Consensus;Larynx;Constriction, Pathologic;Trachea",F01.829.316.068;F02.463.785.373.433;A04.329;C23.300.287;A04.889
30152016,"Craniosynostoses;Neurodevelopmental Disorders;Hearing Loss, Sensorineural",C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;F03.625;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887
30151689,"Child;Computer Simulation;Dyspnea;Humans;Proportional Hazards Models;Respiratory Distress Syndrome, Adult",M01.060.406;L01.224.160;C08.618.326;C23.888.852.371;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C08.381.840;C08.618.840
30151646,Dimethyl Sulfoxide;Flavin-Adenine Dinucleotide;Flavoproteins;Mitochondria;NAD;Optical Imaging,D02.886.640.150;D03.633.100.733.315.650.249;D03.633.100.759.646.138.506;D03.633.300.507.650.249;D08.211.474.650.249;D13.695.667.138.506;D13.695.827.068.506;D23.767.405.650.249;D12.776.331;A11.284.430.214.190.875.564;A11.284.835.626;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;E01.370.350.589;E05.642
30151434,,
30150688,,
30150366,Cytokines;Systemic Vasculitis,D12.644.276.374;D12.776.467.374;D23.529.374;C14.907.940.897
30150297,,
30150158,Aged;Evidence-Based Medicine;Frail Elderly;Geriatric Assessment;Humans;Patient Selection;Precision Medicine;Prevalence;Recovery of Function;Rectal Neoplasms;Frailty;Rectal Neoplasms,M01.060.116.100;H02.249.750;H02.403.200.400;M01.060.116.100.540;E05.318.308.225;I01.240.425.350;N01.224.425.350;N05.715.360.300.360;N06.850.505.400.425.350;N06.850.520.308.225;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500.653;N04.590.731;E02.574;H02.403.200.700;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;G16.757;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;C23.550.359;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500
30149950,"Adnexal Diseases;Consensus;Data Systems;Diagnosis, Differential;Humans;Image Interpretation, Computer-Assisted;Practice Guidelines as Topic;Radiology Information Systems;Risk Assessment;Societies, Medical;Ultrasonography;United States;Ovarian Neoplasms",C13.351.500.056;F01.829.316.068;F02.463.785.373.433;L01.224.068.500;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;N04.761.700.350.650;N05.700.350.650;N04.452.515.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N03.540.828.589;E01.370.350.850;Z01.107.567.875;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
30149885,Drug Delivery Systems;Inflammation;Nanoparticles,E02.319.300;C23.550.470;J01.637.512.600
30149500,Autistic Disorder;Electroencephalography,F03.625.164.113.500;E01.370.376.300;E01.370.405.245
30149120,Epigenomics;Heat-Shock Response;Histone Deacetylase Inhibitors,H01.158.273.180.350.074;H01.158.273.343.350.042;G07.775.500;D27.505.519.389.360
30149117,,
30149116,,
30149115,,
30149114,,
30149113,,
30149112,,
30149111,,
30149110,,
30149108,,
30149107,,
30149106,,
30148751,Adolescent;Allografts;Anterior Cruciate Ligament Injuries;Anterior Cruciate Ligament Reconstruction;Athletic Injuries;Autografts;Body Mass Index;Case-Control Studies;Fibrosis;Humans;Joint Diseases;Postoperative Complications;Retrospective Studies;Risk Factors;Time Factors,M01.060.057;A01.941.500;C26.558.554.213;E04.555.110.026;E04.680.101.026;C26.115;A01.941.750;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.550.355;B01.050.150.900.649.313.988.400.112.400.400;C05.550;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857
30148750,,
30148678,,
30148164,"Adolescent;Adult;Aged;Aged, 80 and over;Asia;Cross-Sectional Studies;Europe;Humans;Lupus Erythematosus, Cutaneous;Middle Aged;North America;Prevalence;Prospective Studies;Pruritus;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;Z01.252;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;C17.300.475;C17.800.480;M01.060.116.630;Z01.107.567;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C17.800.685;C23.888.885.625;M01.060.116.815
30148005,Analgesia;Anterior Cruciate Ligament;Meniscus,E03.091;A02.513.514.100;A02.835.583.512.100;A10.165.669.514.100;A02.165.308.538;A10.165.382.350.163
30147251,,
30146301,Polymicrogyria;Speech,C10.500.507.500.500;C16.131.666.507.500.500;F01.145.209.908.677;G11.561.812;L01.559.423.676
30146193,"Animals;CRISPR-Associated Proteins;CRISPR-Cas Systems;Clustered Regularly Interspaced Short Palindromic Repeats;DNA Damage;Diffusion of Innovation;Forecasting;Gene Editing;Gene Expression Regulation;Humans;Radiography, Interventional;Translational Medical Research",B01.050;D12.776.212;G05.308.203.374.394;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G05.200;L01.143.320;I01.320;E05.393.420.270;G05.308;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.725;E04.502.780;H01.770.644.145.675
30146011,"Academies and Institutes;Animals;Databases, Chemical;Fatty Alcohols;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.033.415;D10.289;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30146010,"Academies and Institutes;Acetates;Animals;Databases, Chemical;Dioxoles;Humans;Perfume;Propanols;Registries;Risk Assessment",N03.540.052;D02.241.081.018;D10.251.400.045;B01.050;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D03.383.246;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;D02.033.755;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30146001,Cognitive Dysfunction;Neurocognitive Disorders,F03.615.250.700;F03.615
30145627,,
30145310,"Adolescent;Adult;Blood Pressure;Child;Child, Preschool;Cohort Studies;Environmental Pollutants;Gestational Age;Humans;Hypertension;Infant, Newborn;Lead;Maternal-Fetal Exchange;Mexico;Pregnancy;Prenatal Exposure Delayed Effects;Prospective Studies;Young Adult;Blood Pressure;Gestational Age;Lead;Premature Birth",M01.060.057;M01.060.116;E01.370.600.875.249;G09.330.380.076;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D27.888.284;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;M01.060.703.520;D01.268.556.435;D01.552.544.435;G08.686.784.769.455;Z01.107.567.589;G08.686.784.769;C13.703.824.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;M01.060.116.815;E01.370.600.875.249;G09.330.380.076;G07.345.500.325.235.968;G08.686.320;D01.268.556.435;D01.552.544.435;C13.703.420.491.500
30145146,,
30145145,,
30145144,,
30145142,,
30145141,,
30145140,,
30144859,,
30144848,Bronchopulmonary Dysplasia,C08.381.520.750.500;C16.614.521.125
30144429,"Adult;Animals;Bile Acids and Salts;Chenodeoxycholic Acid;Gastrointestinal Microbiome;Healthy Volunteers;Humans;Intestine, Small;Mice;Mice, Inbred C57BL;Receptors, Cytoplasmic and Nuclear;Genetics;Metabolism",M01.060.116;B01.050;D04.210.500.105;D04.210.500.105.225.272.150;D04.210.500.221.430.342.300;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;M01.774.500;M01.955.236;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.684;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.826;H01.158.273.343;G03
30144423,"Animals;DNA, Mitochondrial;Humans;Immunotherapy;Mitochondria;Mitochondrial Dynamics;Neoplasms;T-Lymphocytes",B01.050;D13.444.308.283.225;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;A11.284.430.214.190.875.564;A11.284.835.626;G04.599.750;C04;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
30144415,,
30144077,Child;Adolescent;Evidence-Based Practice;Implementation Science,M01.060.406;M01.060.057;H02.249;L01.143.320.400
30143896,Cerebral Palsy,C10.228.140.140.254
30143749,,
30143619,"Animals;CCCTC-Binding Factor;Calcium;Cells, Cultured;Chromatin Assembly and Disassembly;Histone Deacetylase 1;Mice;Mice, Inbred mdx;Muscular Dystrophy, Duchenne;Myocytes, Cardiac;NF-kappa B;Repressor Proteins;Signal Transduction;Sodium-Calcium Exchanger",B01.050;D12.776.157.687.157;D12.776.260.120;D12.776.660.235.050;D12.776.660.720.157;D12.776.664.235.050;D12.776.930.780.563;D01.268.552.100;D01.552.539.288;D23.119.100;A11.251;G04.400.095;G05.213.095;G05.308.095;D08.811.277.087.520.500.100;D08.811.277.087.520.750.100;D08.811.600.620.100;D08.811.600.795.100;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420.500;B01.050.150.900.649.313.992.635.505.500.400.420.500;B01.050.150.900.649.313.992.635.505.500.550.265;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;A07.541.704.570;A10.690.552.750.570;A11.620.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;D12.776.260.703;D12.776.930.780;G02.111.820;G04.835;D12.776.157.530.450.162.442;D12.776.543.585.450.162.442
30143323,Genomics,H01.158.273.180.350;H01.158.273.343.350
30142707,"Academic Medical Centers;Ambulatory Care Facilities;Appointments and Schedules;Dermatology;Health Services Accessibility;Humans;Outpatient Clinics, Hospital;Patient Satisfaction;Pennsylvania;Retrospective Studies",N02.278.020;N02.278.035;N04.452.095;H02.403.225;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N02.278.035.380;N02.278.216.500.968.527;N04.452.442.422.527;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
30142610,"Adolescent;Aorta;Cardiac-Gated Imaging Techniques;Child;Child, Preschool;Computed Tomography Angiography;Coronary Vessels;Electrocardiography;Heart Rate;Humans;Infant;Infant, Newborn;Prospective Studies;Radiographic Image Interpretation, Computer-Assisted;Signal-To-Noise Ratio;Child;Coronary Vessels",M01.060.057;A07.015.114.056;E01.370.350.130.500;M01.060.406;M01.060.406.448;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;A07.015.114.269;A07.015.908.194;E01.370.370.380.240;E01.370.405.240;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.158.600.680;E01.370.350.350.700;E01.370.350.700.705;L01.313.500.750.100.158.600.680;E05.318.370.800.875;E05.318.740.872.875;G17.800.500;N05.715.360.325.700.840;N05.715.360.750.725.750;N06.850.520.445.800.875;N06.850.520.830.872.750;M01.060.406;A07.015.114.269;A07.015.908.194
30140866,"Bradycardia;Humans;Hypoxia;Infant;Infant, Newborn;Monitoring, Physiologic;Oximetry;Oxygen;Sensitivity and Specificity;United States;United States Food and Drug Administration",C14.280.067.319;C23.550.073.300;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;M01.060.703;M01.060.703.520;E01.370.520;E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;D01.268.185.550;D01.362.670;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
30140567,Posterior Cruciate Ligament;Rehabilitation,A02.513.514.600;A02.835.583.512.600;A10.165.669.514.600;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
30140199,"Arrhythmias, Cardiac;Heart Neoplasms;Basal Cell Nevus Syndrome;Basal Cell Nevus Syndrome;Tachycardia, Ventricular",C14.280.067;C23.550.073;C04.588.894.309;C14.280.459;C04.182.089.530.690.150;C04.557.470.200.165.150;C04.557.470.565.165.150;C04.700.175;C05.116.099.105;C05.500.470.690.150;C07.320.450.670.130;C16.131.077.130;C16.320.700.175;C04.182.089.530.690.150;C04.557.470.200.165.150;C04.557.470.565.165.150;C04.700.175;C05.116.099.105;C05.500.470.690.150;C07.320.450.670.130;C16.131.077.130;C16.320.700.175;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
30140068,,
30140067,,
30139910,Antitubercular Agents;Humans;Time Factors;Tuberculosis,D27.505.954.122.085.255;B01.050.150.900.649.313.988.400.112.400.400;G01.910.857;C01.252.410.040.552.846
30139724,Substance-Related Disorders,C25.775;F03.900
30139565,,
30139484,Atrial Fibrillation,C14.280.067.198;C23.550.073.198
30139374,"Animals;Cells, Cultured;Green Fluorescent Proteins;Mice;Mice, Inbred C57BL;Microscopy, Fluorescence;Muscle Fibers, Skeletal;Myoblasts;Optical Imaging;PAX7 Transcription Factor;Flow Cytometry;Muscle Development;Muscle, Skeletal",B01.050;A11.251;D12.776.532.265;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E01.370.350.515.458;E05.595.458;A10.690.552.500.500;A11.620.249;A11.872.620;E01.370.350.589;E05.642;D12.776.260.400.812;D12.776.260.645.875;D12.776.930.700.875;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G07.345.500.325.377.625.590;G11.427.578.590;A02.633.567;A10.690.552.500
30138781,Intimate Partner Violence;Domestic Violence,I01.198.240.856.575;I01.880.735.900.688;I01.198.240.856.350;I01.880.735.900.350
30138726,,
30138292,Femoral Neck Fractures;Hemiarthroplasty;Humans;Joint Instability;Leg Length Inequality;Pain;Patient Care Planning;Patient Selection;Periprosthetic Fractures;Postoperative Complications;Prosthesis Design;Prosthesis Failure;Prosthesis-Related Infections;Reoperation;Treatment Failure,C26.404.061.425.500;C26.531.750.500;C26.558.276.425.500;E04.555.110.110.482;E04.650.110.482;E04.680.101.110.482;B01.050.150.900.649.313.988.400.112.400.400;C05.550.521;C05.116.099.655;C23.300.808;C23.888.592.612;F02.830.816.444;G11.561.790.444;N04.590.233.624;E05.581.500.653;N04.590.731;C26.404.550;C23.550.767;E05.320.550;E07.695.680;C23.550.767.865;E05.325.771;C01.539.685;C23.550.767.868;E04.690;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
30138085,,
30138064,,
30138015,Adolescent;Adult;Alcoholism;Combined Modality Therapy;Counseling;Double-Blind Method;Goals;Humans;Naltrexone;Narcotic Antagonists;Treatment Outcome;Young Adult,M01.060.057;M01.060.116;C25.775.100.250;F03.900.100.350;E02.186;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;F01.658.500;B01.050.150.900.649.313.988.400.112.400.400;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;D27.505.696.543;D27.505.696.663.850.512;D27.505.954.427.550;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
30137653,Child;Headache;Pseudotumor Cerebri;Migraine Disorders;Pseudotumor Cerebri,M01.060.406;C23.888.592.612.441;C10.228.140.631.750;C10.228.140.546.399.750;C10.228.140.631.750
30137463,,
30137364,,
30137348,,
30137266,,
30137251,,
30136299,Women;Lower Urinary Tract Symptoms;Social Environment;Women,M01.975;C23.888.942.343;I01.880.853.500;M01.975
30136097,Cerebrospinal Fluid;Creutzfeldt-Jakob Syndrome;Parkinson Disease,A12.207.270.210;C10.228.140.380.165;C10.228.228.800.230;F03.615.400.300;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
30135863,Tobacco Use Disorder,C25.775.912;F03.900.912
30135763,Adolescent;Anxiety;Child;Cognitive Behavioral Therapy,M01.060.057;F01.470.132;M01.060.406;F04.754.137.350
30135514,"Animals;Antibodies, Viral;Cells, Cultured;Dogs;Enzyme-Linked Immunosorbent Assay;Ferrets;Flow Cytometry;Hemagglutinins;Influenza A Virus, H5N1 Subtype;Madin Darby Canine Kidney Cells;Mice;Mice, Inbred BALB C;Orthomyxoviridae;Phylogeny;RNA, Messenger;Rabbits",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;A11.251;B01.050.150.900.649.313.750.250.216.200;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.750.250.575.350;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;D27.505.696.477.136.377;B04.820.545.405.400.500;A11.251.210.827;A11.436.589;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B04.820.545;G05.697;G16.075.605;L01.100.697;D13.444.735.544;B01.050.150.900.649.313.968.700
30135485,,
30135317,Metabolism;Nitric Oxide;Therapeutics,G03;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E02
30134920,"Adult;Aged;Animals;Endoplasmic Reticulum Stress;Humans;Lung;Middle Aged;Pulmonary Stretch Receptors;Rats;Rats, Sprague-Dawley;Respiratory Mucosa;Swine;Ventilator-Induced Lung Injury;eIF-2 Kinase;Ventilator-Induced Lung Injury",M01.060.116;M01.060.116.100;B01.050;G04.434;B01.050.150.900.649.313.988.400.112.400.400;A04.411;M01.060.116.630;A08.675.650.915.750.780;A08.800.950.750.780;A11.671.650.915.750.780;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;A04.760;A10.615.550.760;B01.050.150.900.649.313.500.880;C08.381.520.750;D08.811.913.696.620.682.700.300;D12.644.360.275;D12.776.476.275;C08.381.520.750
30134862,Hypothalamus,A08.186.211.180.497;A08.186.211.200.317.357
30134365,,
30134085,Wisconsin Card Sorting Test;Genome-Wide Association Study,F04.711.513.919;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
30133917,"Humans;Infant;Intubation, Intratracheal;Tidal Volume",B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.041.500;E02.585.578;E05.497.578;E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700
30133785,Nocturia;Therapeutics,C23.888.942.343.550;E02
30133378,Haplorhini;Motion,B01.050.150.900.649.313.988.400;G01.482
30133189,Disclosure;Facilities and Services Utilization;Genetic Carrier Screening;Genetic Counseling;Humans;Translational Medical Research;Whole Genome Sequencing;Exome;Genome,F01.829.401.046;I01.880.604.583.080.134;L01.143.335;E05.318.740.388;H01.548.832.625;N04.452.289;N05.715.360.750.344;N06.850.520.830.375;E01.370.225.562.250;E05.200.562.250;E05.393.435.250;N02.421.308.200;N02.421.726.233.221.250;H01.158.273.343.385.500.384;N02.421.308.400;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.675;E05.393.760.700.825;G05.360.340.011;G05.360.340
30133180,Echocardiography;Mitral Valve,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A07.541.510.507
30132986,Waiting Lists,N04.452.095.738
30132831,"Alleles;Case-Control Studies;Cell Line, Tumor;Cell Proliferation;Genes, Tumor Suppressor;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;HEK293 Cells;Humans;Infant;Neoplasm Invasiveness;Neuroblastoma;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;RNA, Messenger;Tumor Suppressor Proteins;Ubiquitin-Protein Ligases;Neuroblastoma",G05.360.340.024.340.030;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G05.360.340.024.340.375.249;G05.360.340.024.340.415.400;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.697.645;C23.550.727.645;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.365.795.598;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D13.444.735.544;D12.776.624.776;D08.811.464.938.750;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
30131881,,
30131449,,
30131062,"Child;Insurance, Health",M01.060.406;N03.219.521.576.343
30130977,Power (Psychology),F01.658.780
30130795,"Adolescent;Adult;Child;Child, Preschool;Ethnic Groups;Growth Disorders;Healthcare Disparities;Hormone Replacement Therapy;Human Growth Hormone;Humans;Pediatrics;Practice Patterns, Physicians';United States;Young Adult;Growth Hormone;Continental Population Groups;Therapeutics",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;M01.686.754;N01.224.317;C23.550.393;N04.590.374.380;N05.300.493;E02.319.452;D06.472.699.631.525.425.875;D12.644.548.691.525.425.875;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;N04.590.374.577;N05.300.625;Z01.107.567.875;M01.060.116.815;D06.472.699.631.525.425;D12.644.548.691.525.425;M01.686.508;E02
30130617,,
30130597,"Adult;Aged;Anesthesia, Local;Anesthetics, Local;Humans;Injections;Lidocaine;Middle Aged;Pain;Vibration",M01.060.116;M01.060.116.100;E03.155.086.231;D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530;D02.065.199.092.500;D02.092.146.113.092.500;M01.060.116.630;C23.888.592.612;F02.830.816.444;G11.561.790.444;G01.374.930
30130581,Zebrafish,B01.050.150.900.493.200.244.828
30130412,Cystic Fibrosis;Insulin,C06.689.202;C08.381.187;C16.320.190;C16.614.213;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
30130151,Dietary Fiber;Microbiota,D09.301.416;G07.203.300.400;J02.500.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
30130029,,
30128718,Anxiety;Autistic Disorder;Depression;Phenotype,F01.470.132;F03.625.164.113.500;F01.145.126.350;G05.695
30127291,"Accidents, Traffic;Automobile Driving;Caregivers;Child;Child Restraint Systems;Child, Preschool;Cross-Sectional Studies;Humans;Infant;Parents;Social Values;United States;Utilization Review;Child Restraint Systems;Child;Parents;Seat Belts",N06.850.135.392;I03.125;M01.085;M01.526.485.200;N02.360.200;M01.060.406;E07.490.249;E07.700.175;J01.637.708.175;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.829.873;Z01.107.567.875;N04.761.879;N05.700.900;E07.490.249;E07.700.175;J01.637.708.175;M01.060.406;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E07.700.800
30127064,,
30126551,,
30125461,Editorial;Kidney Transplantation;Tissue and Organ Procurement,V01.250;V02.335;E02.870.500;E04.936.450.485;E04.950.774.400;N02.421.911
30125297,"Adult;Aged;Aged, 80 and over;Biomarkers;Cognition;Cohort Studies;Disease Susceptibility;Humans;Middle Aged;Mutation;Neuropsychological Tests;Parkinson Disease;Risk Assessment;Risk Factors",M01.060.116;M01.060.116.100;M01.060.116.100.080;D23.101;F02.463.188;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30124981,,
30124884,"Granulocyte-Macrophage Colony-Stimulating Factor;Sequence Analysis, RNA;Neutrophils",D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375;E05.393.760.710;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
30124757,,
30124487,"Biopsy, Needle;Child;Combined Modality Therapy;Diagnosis, Differential;Erythema;Facial Neoplasms;Humans;Immunohistochemistry;Prognosis;Rare Diseases;Rhabdomyosarcoma, Alveolar;Skin Neoplasms",E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;M01.060.406;E02.186;E01.171;C17.800.229;C23.888.885.328;C04.588.443.392;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E01.789;C23.550.291.906;C04.557.450.590.550.660.665;C04.557.450.795.550.660.665;C04.588.805;C17.800.882
30124055,HIV;Depression;Maternal Health;Retention in Care,B04.820.650.589.650.350;F01.145.126.350;N01.400.900.500;E02.760.169.671;N02.421.585.169.671
30122652,,
30122549,Clinical Alarms;Critical Care Nursing;Electrocardiography;Intensive Care Units;Clinical Alarms,E07.230.200;H02.478.676.175;N02.421.533.149;E01.370.370.380.240;E01.370.405.240;N02.278.388.493;E07.230.200
30122135,Psychotic Disorders;Psychotherapy;Rehabilitation;Schizophrenia,F03.700.675;F04.754;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784;F03.700.750
30121962,Obstetrics;Placenta,H02.403.810.450;A16.710
30121867,"Adolescent;Age Factors;Child;Cross-Sectional Studies;Echocardiography;Echocardiography, Stress;Exercise;Exercise Test;Humans;Prospective Studies;Pulmonary Valve Insufficiency;Tetralogy of Fallot;Ultrasonography, Doppler;Ventricular Function, Right;Young Adult;Echocardiography, Stress;Tetralogy of Fallot",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.350.130.750.228;E01.370.350.850.220.228;E01.370.370.380.220.228;G11.427.410.698.277;I03.350;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C14.280.484.660;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;E01.370.350.850.850;G09.330.955.900;M01.060.116.815;E01.370.350.130.750.228;E01.370.350.850.220.228;E01.370.370.380.220.228;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30121865,"Adult;Delivery of Health Care;Electronic Health Records;Guideline Adherence;Humans;Quality Indicators, Health Care;Tetralogy of Fallot;Quality Improvement;Tetralogy of Fallot",M01.060.116;N04.590.374;N05.300;E05.318.308.940.968.625.500;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;N04.761.789;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;J01.293.754;N04.761.744;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30121796,"Education, Medical;History, 19th Century;History, 20th Century;History, 21st Century;History, Ancient;Humans;Learning;Models, Educational;Pediatrics;Radiology;Teaching;Education;History;Learning;Education, Medical;Teaching",I02.358.399;K01.400.504.937;K01.400.504.968;K01.400.504.984;K01.400.470;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;E05.599.545;I02.903.302;H02.403.670;H02.403.740;I02.903;I02;K01.400;F02.463.425;F02.784.629.529;I02.358.399;I02.903
30121795,"Bibliography as Topic;Database Management Systems;Databases, Bibliographic;Humans;Internet;Learning;Pediatrics;Radiology;Software;Teaching;Writing;Publications;Research;Teaching",L01.178.682.099;L01.453.183;L01.224.068;L01.224.900.280;N04.452.515.110;L01.313.500.750.300.188.300;L01.470.750.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;F02.463.425;F02.784.629.529;H02.403.670;H02.403.740;L01.224.900;I02.903;L01.559.423.906;L01.178.682;H01.770.644;I02.903
30121792,"Diffusion of Innovation;Education, Medical;Educational Measurement;Focus Groups;Humans;Models, Educational;Models, Statistical;Needs Assessment;Pediatrics;Radiology;Teaching;Education;Needs Assessment;Radiology",L01.143.320;I02.358.399;I02.399;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;B01.050.150.900.649.313.988.400.112.400.400;E05.599.545;I02.903.302;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;I02.594;N03.349.380.565;N05.300.537;H02.403.670;H02.403.740;I02.903;I02;I02.594;N03.349.380.565;N05.300.537;H02.403.740
30121791,"Curriculum;Faculty, Medical;Humans;Mentoring;Models, Educational;Pediatrics;Radiology;Teaching;Teaching Materials;Education;Learning;Mentors;Radiology;Teaching;Education",I02.158;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;I02.358.859;I02.588;E05.599.545;I02.903.302;H02.403.670;H02.403.740;I02.903;L01.178.820;I02;F02.463.425;F02.784.629.529;M01.395;H02.403.740;I02.903;I02
30121449,"Adult;Case-Control Studies;Cognition;Cognitive Dysfunction;Depressive Disorder, Major;Factor Analysis, Statistical;Humans;Mental Status and Dementia Tests;Middle Aged;Psychiatric Status Rating Scales;Severity of Illness Index;Task Performance and Analysis;Young Adult",M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F02.463.188;F03.615.250.700;F03.600.300.375;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.603;M01.060.116.630;F04.711.513.653;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F02.784.412.846;F02.784.692.746;F02.808.600;M01.060.116.815
30121351,,
30121350,,
30121349,,
30121318,Child Abuse;Child Abuse,I01.198.240.856.350.250;I01.880.735.900.350.250;I01.198.240.856.350.250;I01.880.735.900.350.250
30121317,Program Evaluation,E05.337.820;N04.761.685;N05.715.360.650
30121097,,
30120948,,
30120947,,
30120812,"Aged;Body Weight;Double-Blind Method;Drug Administration Schedule;Follow-Up Studies;Heart Failure;Humans;Hypoglycemic Agents;Injections, Subcutaneous;Liraglutide;Middle Aged;Obesity;Stroke Volume;Treatment Outcome;Weight Loss;Heart Failure;Liraglutide;Weight Loss",M01.060.116.100;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.283;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;E02.319.267.530.620;D06.472.317.680.500.500.500;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E01.370.370.380.150.700;G09.330.380.124.882;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963;C14.280.434;D06.472.317.680.500.500.500;C23.888.144.243.963;G07.345.249.314.120.200.963
30120108,"Renal Insufficiency, Chronic;Kidney Failure, Chronic;Nephrology",C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750.500;C13.351.968.419.780.750.500;H02.403.429.580
30119871,Alopecia Areata;Child;Humans;Vitamin D;Vitamin D Deficiency;Vitamins,C17.800.329.937.122.147;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.812.768;C18.654.521.500.133.770;D27.505.696.377.683.500.600;G07.203.300.681.500.600;J02.500.681.500.600
30119137,,
30119103,"Biopsy, Needle;Child;Combined Modality Therapy;Diagnosis, Differential;Erythema;Facial Neoplasms;Humans;Immunohistochemistry;Rare Diseases;Rhabdomyosarcoma, Alveolar;Risk Assessment;Skin Neoplasms;Treatment Outcome",E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;M01.060.406;E02.186;E01.171;C17.800.229;C23.888.885.328;C04.588.443.392;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;C23.550.291.906;C04.557.450.590.550.660.665;C04.557.450.795.550.660.665;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04.588.805;C17.800.882;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30118821,,
30118819,,
30118818,,
30118814,Brain Death;Heart Arrest;Shock,C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;C14.280.383;C23.550.835
30118812,Heart Arrest;Survival,C14.280.383;I03.784
30118183,Alternative Splicing;Animals;Glycogen Synthase Kinase 3;Humans;Mutation;Neoplasms;Leukemia,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;D05.500.117.875;D08.811.913.696.620.682.700.429.500;D08.811.913.696.620.682.700.646.625;D12.644.360.300.500;D12.776.476.081.875;D12.776.476.300.500;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04;C04.557.337
30117228,Anesthesia;Anesthetics;Animals;Brain;Child;Child Development;Humans;Neurotoxicity Syndromes;Anesthesia;Clinical Trial;Pediatrics;Research,E03.155;D27.505.696.277.100;D27.505.954.427.210.100;B01.050;A08.186.211;M01.060.406;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;C10.720;C25.723.705;E03.155;V03.175.250;H02.403.670;H01.770.644
30116926,"Adolescent;Age Factors;Atrial Function, Left;Biomechanical Phenomena;Child;Child, Preschool;Echocardiography, Doppler;Heart Atria;Heart Diseases;Humans;Image Interpretation, Computer-Assisted;Infant;Observer Variation;Pilot Projects;Predictive Value of Tests;Reproducibility of Results;Retrospective Studies;Ventricular Function, Left;Ventricular Pressure;Young Adult;Heart Atria",M01.060.057;N05.715.350.075;N06.850.490.250;G09.330.040.100;G01.154.090;G01.374.089;M01.060.406;M01.060.406.448;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;A07.541.358;C14.280;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;M01.060.703;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G09.330.955.800;G09.330.380.937;G09.330.955.950;M01.060.116.815;A07.541.358
30116905,"Algorithms;Cardiac Surgical Procedures;Humans;Infant, Newborn;Leukomalacia, Periventricular;Machine Learning;Pregnancy;Reproducibility of Results;Retrospective Studies;Decision Support Systems, Clinical;Heart Defects, Congenital;Leukomalacia, Periventricular;Machine Learning;Support Vector Machine;Wavelet Analysis",G17.035;L01.224.050;E04.100.376;E04.928.220;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C10.228.140.300.700;C10.228.140.461.550;C14.907.253.612;C16.614.521.450;G17.035.250.500;L01.224.050.375.530;G08.686.784.769;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;L01.313.500.750.300.190;C14.240.400;C14.280.400;C16.131.240.400;C10.228.140.300.700;C10.228.140.461.550;C14.907.253.612;C16.614.521.450;G17.035.250.500;L01.224.050.375.530;G17.035.250.500.500.500;L01.224.050.375.530.500.500;E05.959;G17.915;L01.224.800.750
30116862,Checklist;Consensus;Humans;Perioperative Care;Research Design;Research Report,N05.715.360.300.179;F01.829.316.068;F02.463.785.373.433;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731;E04.604;N02.421.585.722;E05.581.500;H01.770.644.728;H01.770.644.864;L01.559.423.906.769
30116834,"Global Health;Humans;Medical Missions;Organizational Objectives;Pediatrics;Radiology;Societies, Medical",H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500.750;N04.452.615;H02.403.670;H02.403.740;N03.540.828.589
30116212,Behavior Therapy;Obesity;Weight Loss,F04.754.137;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963
30115697,,
30115668,,
30115432,"Barium Sulfate;Deglutition Disorders;Diagnostic Techniques, Digestive System;Esophagus;Humans;Deglutition Disorders",D01.103.075;D01.875.800.800.850.075;C06.405.117.119;C09.775.174;E01.370.372;A03.556.875.500;B01.050.150.900.649.313.988.400.112.400.400;C06.405.117.119;C09.775.174
30115424,,
30115365,,
30115121,"Adolescent;Adult;Aged;Alcohol Abstinence;Alcohol Drinking;Alcoholism;Clinical Protocols;Double-Blind Method;Excitatory Amino Acid Antagonists;Gene Frequency;Homozygote;Humans;Middle Aged;Naltrexone;Narcotic Antagonists;New South Wales;Pharmacogenomic Variants;Prospective Studies;Receptors, Kainic Acid;Receptors, Opioid, mu;Recurrence;Research Design;Time Factors;Topiramate;Treatment Outcome;Young Adult;Alcoholism;Alcoholism;Naltrexone;Pharmacogenetics;Topiramate",M01.060.057;M01.060.116;M01.060.116.100;F01.145.317.134;F01.145.317.269;C25.775.100.250;F03.900.100.350;E02.183;N05.715.360.330.125;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D27.505.519.625.190.300;D27.505.696.577.190.300;G05.330;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;D27.505.696.543;D27.505.696.663.850.512;D27.505.954.427.550;Z01.639.100.750;Z01.678.100.373.750;G05.365.795.446;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.157.530.400.400.500.200;D12.776.543.550.450.500.200.200;D12.776.543.585.400.500.200.200;D12.776.543.750.720.200.450.400.200;D12.776.543.750.695.620.550;D12.776.543.750.720.600.610.550;D12.776.543.750.750.555.610.550;C23.550.291.937;E05.581.500;H01.770.644.728;G01.910.857;D09.947.875.359.250.500;D09.947.875.465.354.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C25.775.100.250;F03.900.100.350;C25.775.100.250;F03.900.100.350;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;H01.158.273.343.750;H01.158.703.052;H02.628.479;D09.947.875.359.250.500;D09.947.875.465.354.500
30114447,,
30114445,,
30113973,,
30113865,Sepsis,C01.539.757;C23.550.470.790.500
30113687,,
30113685,,
30113667,,
30113658,,
30113518,,
30113373,,
30112615,Metabolism;Insulin Resistance,G03;C18.452.394.968.500;G07.690.773.984.617
30112420,Crigler-Najjar Syndrome;Dependovirus;Bilirubin;Liver,C16.320.565.300.281;C18.452.648.300.281;B04.280.580.650.170;D03.383.129.578.840.249.184;D03.633.400.909.249.184;D04.345.783.249.184;D23.767.193.184;A03.620
30112253,"Osteosarcoma;Fractures, Spontaneous;Sarcoma",C04.557.450.565.575.650;C04.557.450.795.620;C26.404.374;C04.557.450.795
30112102,Diphosphonates;Pseudoxanthoma Elasticum,D02.705.429.500;C14.907.454.530;C15.378.463.515.530;C16.131.831.766;C16.320.850.750;C17.300.766;C17.800.804.766;C17.800.827.750
30111645,,
30111633,,
30111608,,
30111196,"Child;Humans;Immunotherapy;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;Recurrence;Survival Rate;Young Adult;Immunotherapy;Precursor Cell Lymphoblastic Leukemia-Lymphoma",M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D12.776.543.750.705.816.824;C23.550.291.937;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;M01.060.116.815;E02.095.465.425;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
30111112,"Complement Pathway, Alternative;Complement System Proteins;Gingival Crevicular Fluid;Periodontitis;Primates;Proteome",G12.274.695;D12.776.124.486.274;A12.383.500;C07.465.714.533;B01.050.150.900.649.313.988;D12.776.817
30110561,Decompression Sickness;Microscopy;Mitochondria;Respiration,C26.120.248;E01.370.350.515;E05.595;H01.671.617.562;A11.284.430.214.190.875.564;A11.284.835.626;G09.772.705
30110123,Adult;Anti-HIV Agents;Bariatric Surgery;HIV Infections;Humans;Interdisciplinary Communication;Obesity;Postoperative Care;HIV;Bariatric Surgery;Obesity,M01.060.116;D27.505.954.122.388.077.088;E02.570.500.062;E04.062;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02.760.731.700;E04.604.500;N02.421.585.722.700;B04.820.650.589.650.350;E02.570.500.062;E04.062;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30109821,"Animals;Birth Weight;Diabetes Mellitus, Type 2;Fetal Growth Retardation;Humans;Oxidative Stress",B01.050;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;C18.452.394.750.149;C19.246.300;C13.703.277.370;C16.300.390;C23.550.393.450;B01.050.150.900.649.313.988.400.112.400.400;G03.673;G07.775.750
30108290,,
30108257,,
30108168,"Animals;Anti-Bacterial Agents;Homeostasis;Macrophages;Mice;Microbial Viability;Nitric Oxide;RAW 264.7 Cells;Salmonella Infections, Animal;Salmonella typhimurium;Zinc;Salmonella;Nitric Oxide",B01.050;D27.505.954.122.085;G07.410;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;G06.580;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;A11.251.210.172.875;A11.733.397.815;C01.252.400.310.821.706;C22.812;B03.440.450.425.800.200.825;B03.660.250.150.710.160.760;D01.268.556.940;D01.268.956.906;D01.552.544.940;B03.440.450.425.800;B03.660.250.150.710;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
30108143,,
30108141,,
30108137,,
30107849,Developing Countries;HIV;Neurological Rehabilitation;Robotics;Stroke,I01.615.500.300;B04.820.650.589.650.350;E02.760.169.063.500.477;E02.831.477;H02.403.680.600.750;N02.421.784.511;H01.671.293.643;J01.897.104.834;L01.224.050.375.630;C10.228.140.300.775;C14.907.253.855
30106767,,
30106213,Catheter Ablation;Cryosurgery;Papillary Muscles;Ventricular Premature Complexes;Ventricular Premature Complexes,E02.808.750.500;E04.014.760.500;E04.014.180;A02.633.580.680;A07.541.510.619;A07.541.704.750;C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800;C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800
30106034,Astrocytes;Brain Injuries;Tissue Engineering,A08.637.200;A11.650.200;C10.228.140.199;C10.900.300.087;C26.915.300.200;E05.481.500.311.500;J01.293.069.249.500
30105916,HIV;Microbiota,B04.820.650.589.650.350;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
30105757,"Cardiac Catheterization;Cohort Studies;Diastole;Echocardiography;Heart Ventricles;Humans;Infant;Infant, Newborn;Reproducibility of Results;Retrospective Studies;Tetralogy of Fallot;Ventricular Dysfunction, Right;Echocardiography, Doppler;Tetralogy of Fallot",E01.370.370.380.140;E02.148.442;E05.157.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G09.330.580.295;G11.427.494.554.250;G11.427.494.570.295;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;C14.280.945.910;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
30105394,"Compassionate Use Trials;Drug Evaluation;Drugs, Investigational;Government Regulation;Health Services Accessibility;Humans;Informed Consent;Legislation, Drug;Therapies, Investigational;United States;United States Food and Drug Administration",E02.931.500;E05.290.250.199;E05.337.300.199;E05.290.625;E05.337.425;D26.371;I01.880.604.394;N03.706.358;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;I01.880.604.605;N03.706.615.402;E02.931;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
30105367,,
30104567,"Adolescent;Adult;Aged;Child;Child, Preschool;Chromosomes, Human, Pair 15;Cohort Studies;Gene Ontology;Gene Regulatory Networks;Genetic Predisposition to Disease;Humans;Infant;Infant, Newborn;Lung Neoplasms;Middle Aged;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Reproducibility of Results;Risk Factors;Smoking;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;M01.060.406.448;A11.284.187.520.300.370.385;G05.360.162.520.300.370.385;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;G05.360.080.689.360;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;G05.365.795.598;G05.360.340.024.380.937;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.805;M01.060.116.815
30104422,,
30104343,"Epilepsies, Myoclonic;Epilepsy;Interneurons",C10.228.140.490.375.130;C10.228.140.490.493.063;C10.228.140.490;A08.675.358;A11.671.358
30104252,RNA Splicing;Immunotherapy;Membrane Proteins;Protein Folding,G02.111.760.700;G03.839.700;G05.308.700.700;E02.095.465.425;D12.776.543;G01.154.651;G02.111.688
30104250,"Myocytes, Cardiac;Heart Diseases",A07.541.704.570;A10.690.552.750.570;A11.620.500;C14.280
30103043,,
30102696,"Animals;Biliary Atresia;Child;Chromosomes, Human, Pair 2;Ethnic Groups;Extracellular Matrix Proteins;Gene Expression Regulation;Genetic Loci;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotyping Techniques;Humans;Liver;Logistic Models;Muscle, Smooth, Vascular;Organogenesis;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Rats",B01.050;C06.130.120.123;C06.198.125;C16.131.314.125;M01.060.406;A11.284.187.520.300.235.245;G05.360.162.520.300.235.245;M01.686.754;N01.224.317;D12.776.860.300;G05.308;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;E05.393.442;B01.050.150.900.649.313.988.400.112.400.400;A03.620;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;A02.633.570.491;A07.015.733.500;A10.690.467.491;G07.345.500.325.377;G08.686.784.170.450;G05.365.795.598;G05.360.340.024.380.937;B01.050.150.900.649.313.992.635.505.700
30102568,Inflammation;Microbiota,C23.550.470;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
30102368,,
30102290,Blood;Cell Adhesion Molecules;Humans;Lipid Bilayers;Lymphoid Tissue;T-Lymphocytes,A12.207.152;A15.145;D12.776.395.550.200;D12.776.543.550.200;D23.050.301.350;B01.050.150.900.649.313.988.400.112.400.400;D10.570.510;J01.637.087.500.510;A10.549;A15.382.520.604;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
30102218,,
30102191,,
30102071,Autism Spectrum Disorder;Gestational Weight Gain;Obesity,F03.625.164.113;C23.888.144.243.926.500;G07.345.249.314.120.200.926.500;G08.686.330;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
30101408,Eosinophilic Esophagitis;Fibrosis;Interleukin-13,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C23.550.355;D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
30101221,"Arthrogryposis;Intubation, Intratracheal;Malignant Hyperthermia",C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;E02.041.500;E02.585.578;E05.497.578;C23.550.505.700;C23.550.767.600
30101205,Machine Learning;Medication Adherence,G17.035.250.500;L01.224.050.375.530;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500
30100709,,
30100264,Poly ADP Ribosylation;Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Phosphorylation;Poly Adenosine Diphosphate Ribose,G02.111.660.871.790.600.200.500;G02.111.691.600.200.500;G03.734.871.790.600.200.500;G05.308.670.600.200.500;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;C10.574.562;C10.668.467;G02.111.665;G02.607.780;G03.796;D09.408.620.569.070.125.600;D13.695.578.550.530;D13.695.827.708.070.125.600
30100193,,
30100082,"Biomarkers, Tumor;Breast Neoplasms;Cell Proliferation;Humans;Positron-Emission Tomography;Predictive Value of Tests;Radiopharmaceuticals;Breast Neoplasms",D23.101.140;C04.588.180;C17.800.090.500;G04.161.750;G07.345.249.410.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;C04.588.180;C17.800.090.500
30100075,Breast;Breast Neoplasms;Fluorodeoxyglucose F18;Humans;Positron-Emission Tomography;Radiopharmaceuticals;Breast Neoplasms;Pets,A01.236;C04.588.180;C17.800.090.500;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;C04.588.180;C17.800.090.500;B01.050.050.116.600
30100043,Aspirin;Breast Neoplasms,D02.455.426.559.389.657.410.595.176;C04.588.180;C17.800.090.500
30099988,tau Proteins;Serine,D12.776.220.600.450.510;D12.776.631.560.510;D12.125.154.800
30099660,"Arthrography;Humans;Injections, Intra-Articular;Magnetic Resonance Imaging;Phantoms, Imaging;Robotics;Shoulder",E01.370.350.700.070;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.380;E01.370.350.825.500;E07.671;H01.671.293.643;J01.897.104.834;L01.224.050.375.630;A01.378.800.750
30099543,,
30098989,Animals;Biomarkers;Brain Concussion;Child;Humans;Meta-Analysis as Topic;Electrophysiology;Brain Concussion;Neuroimaging,B01.050;D23.101;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;H01.158.344.528;H01.158.782.236;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;E01.370.350.578;E01.370.376.537;E05.629
30098871,Marfan Syndrome;Mitral Valve Insufficiency;Mitral Valve,C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;C14.280.484.461;A07.541.510.507
30098420,"Acute Lung Injury;Fibrosis;Hyaluronic Acid;Inflammation;Mice, Transgenic",C08.381.520.500;C23.550.355;D09.698.373.475;C23.550.470;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
30098353,,
30098293,"Adenocarcinoma;Adenocarcinoma of Lung;Clinical Trials as Topic;Fluorescent Dyes;Humans;Lung Neoplasms;Mediastinal Neoplasms;Mesothelioma;Monitoring, Intraoperative;Optical Imaging;Solitary Pulmonary Nodule;Surgery, Computer-Assisted;Thoracic Neoplasms;Thoracic Surgical Procedures;Thoracic Surgery",C04.557.470.200.025;C04.557.470.200.025.022;C04.588.894.797.520.055;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;D27.720.233.348;D27.720.470.410.505.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;C04.588.894.479;C08.846.187.580;C04.557.470.035.510;C04.557.470.660.510;E01.370.520.510;E04.510;E01.370.350.589;E05.642;C08.381.884;E02.950.875;E04.749;L01.313.500.750.100.710.800;C04.588.894;E04.928;H02.403.810.803
30097611,,
30097527,,
30097135,Depression;Migraine Disorders,F01.145.126.350;C10.228.140.546.399.750
30096712,,
30096423,"Acute Coronary Syndrome;African Americans;Aged;Amino Acid Substitution;Epoxide Hydrolases;European Continental Ancestry Group;Gene Frequency;Genotype;Humans;Kaplan-Meier Estimate;Middle Aged;Polymorphism, Single Nucleotide;Prognosis;Survival Rate;Cardiovascular Diseases;Eicosanoids;Humans;Prognosis",C14.280.647.124;C14.907.585.124;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;E05.393.420.601.035;G05.558.109;D08.811.277.340;M01.686.508.400;G05.330;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;G05.365.795.598;E01.789;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C14;D10.251.355.255;D23.469.050.175;B01.050.150.900.649.313.988.400.112.400.400;E01.789
30096381,,
30096084,,
30096025,Dermatology;Propranolol,H02.403.225;D02.033.100.624.698.711;D02.033.755.624.698.711;D02.092.063.624.698.711;D02.455.426.559.847.638.945;D04.615.638.945
30095747,,
30095720,,
30095503,,
30095502,,
30095498,,
30095495,,
30095394,Adolescent;Child;Humans;Hypergammaglobulinemia;Immunoglobulin E;Omalizumab;Treatment Outcome,M01.060.057;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C15.378.147.542;C20.683.460;C23.888.512;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;D12.776.124.486.485.114.071.500;D12.776.124.486.485.114.224.060.844;D12.776.124.790.651.114.071.500;D12.776.124.790.651.114.224.060.844;D12.776.377.715.548.114.071.500;D12.776.377.715.548.114.224.200.844;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30095276,Breast Feeding;Employment;Legislation;Workplace,F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;N01.824.245;V02.620;N01.824.245.925;N04.452.677.975
30095028,Program Evaluation,E05.337.820;N04.761.685;N05.715.360.650
30094515,"Child;Critical Pathways;Fluoroscopy;Humans;Nephrolithotomy, Percutaneous;Radiation Exposure;Tomography, X-Ray Computed;Ultrasonography;Ureteroscopy;Urolithiasis;Fluoroscopy;Nephrolithotomy, Percutaneous;Radiation Exposure;Ureteroscopy",M01.060.406;N04.590.233.624.625;N04.590.275;E01.370.350.700.225;B01.050.150.900.649.313.988.400.112.400.400;E04.502.250.520.790;E04.950.774.638;G01.750.748;N06.850.460.350.850;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850;E01.370.388.250.920;E01.370.390.800;E04.502.250.920;E04.950.774.840;C12.777.967;C13.351.968.967;E01.370.350.700.225;E04.502.250.520.790;E04.950.774.638;G01.750.748;N06.850.460.350.850;E01.370.388.250.920;E01.370.390.800;E04.502.250.920;E04.950.774.840
30093730,,
30093668,,
30093589,"Animal Experimentation;Drug Evaluation, Preclinical;Human Experimentation;Humans;Phenotype;Precision Medicine",E05.017;H01.770.644.053;E05.290.750;E05.337.550;E05.445;H01.770.644.145.365;B01.050.150.900.649.313.988.400.112.400.400;G05.695;E02.574;H02.403.200.700
30093511,Adolescent;Metabolic Syndrome,M01.060.057;C18.452.394.968.500.570;C18.452.625
30093449,,
30093352,DiGeorge Syndrome,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
30093214,,
30093145,,
30092943,"Acute Pain;Anesthesia, Conduction;Anesthesiology;Humans",C23.888.592.612.081;E03.155.086;H02.403.066;B01.050.150.900.649.313.988.400.112.400.400
30092942,,
30092940,"Anesthetics, Local;Catheters;Child;Humans;Nerve Block;Peripheral Nerves;Postoperative Care;Ultrasonography, Interventional",D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;E07.132;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E03.155.086.711;E04.525.210.550;A08.800.800;E02.760.731.700;E04.604.500;N02.421.585.722.700;E01.370.350.850.855;E04.502.890
30092938,"Anesthesia, Conduction;Arthroplasty;Humans;Length of Stay;Postoperative Complications;Recovery of Function;Shoulder;Anesthesia, Conduction",E03.155.086;E04.555.110;E04.680.101;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;C23.550.767;G16.757;A01.378.800.750;E03.155.086
30092897,,
30092870,,
30092478,Craniosynostoses;Hydrocephalus;Intracranial Hypertension,C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;C10.228.140.602;C10.228.140.631
30092382,"Autism Spectrum Disorder;Child;Depression;Family Health;Family Relations;Humans;Intelligence Tests;Interpersonal Relations;Outcome Assessment (Health Care);Parenting;Parents;Quality of Life;Reproducibility of Results;Stress, Psychological;Autism Spectrum Disorder;Quality of Life",F03.625.164.113;M01.060.406;F01.145.126.350;N01.400.300;F01.829.263.370;I01.880.853.150.439;B01.050.150.900.649.313.988.400.112.400.400;F04.711.141.493;F01.829.401;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F01.829.263.370.310;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;F01.145.126.990;F02.830.900;F03.625.164.113;I01.800;K01.752.400.750;N06.850.505.400.425.837
30092277,Animals;Arterial Pressure;Cardiopulmonary Resuscitation;Cerebrovascular Circulation;Heart Arrest;Heart Massage;Hemodynamics;Linear Models;Swine;Cardiopulmonary Resuscitation;Resuscitation,B01.050;G09.330.380.076.347;E02.365.647.110;G09.330.100.159;C14.280.383;E02.365.647.375;E04.100.376.458;E04.928.220.380;G09.330.380;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;B01.050.150.900.649.313.500.880;E02.365.647.110;E02.365.647
30092011,"Aged;Algorithms;Biomarkers, Tumor;Carcinoma, Pancreatic Ductal;Cohort Studies;DNA Methylation;Gene Expression Regulation, Neoplastic;Humans;Immunohistochemistry;Microarray Analysis;Middle Aged;Models, Biological;Pancreas;Pancreatic Neoplasms;Prognosis;Sequence Analysis, RNA;Survival Analysis",M01.060.116.100;G17.035;L01.224.050;D23.101.140;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E05.588.570;M01.060.116.630;E05.599.395;A03.734;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E01.789;E05.393.760.710;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
30091713,"Diagnosis, Differential;Humans;Magnetic Resonance Imaging;Reproducibility of Results;Scrotum;Testicular Diseases;Ultrasonography",E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;A05.360.444.661;C12.294.829;C19.391.829;E01.370.350.850
30091290,Precision Medicine;Pluripotent Stem Cells,E02.574;H02.403.200.700;A11.872.700
30089911,"Animals;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological;B7-H1 Antigen;CD8-Positive T-Lymphocytes;Case-Control Studies;Cell Line, Tumor;Disease Progression;Exosomes;Humans;Immune Tolerance;Interferon-gamma;Melanoma;Mice;Mice, Nude;Neoplasm Metastasis;Prognosis;Programmed Cell Death 1 Receptor;Tumor Escape;Xenograft Model Antitumor Assays",B01.050;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D27.505.954.248.384;D12.776.467.150.300;D12.776.543.095.300;D23.050.301.285.400;D23.529.168.300;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251.210.190;A11.251.860.180;C23.550.291.656;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.500;C04.697.650;C23.550.727.650;E01.789;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;G12.900;E05.337.550.200.900;E05.624.850
30089657,,
30089447,Health Communication,L01.143.350;N02.208
30089240,,
30089064,"Acute Pain;Analgesics, Opioid;Drug Prescriptions;Health Policy;Humans;Legislation, Drug;Opioid-Related Disorders;Pain Management;Patient-Centered Care;United States",C23.888.592.612.081;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E02.319.307;N02.421.668.778.500;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.605;N03.706.615.402;C25.775.675;F03.900.675;E02.745;N04.590.607.500;N04.590.233.727.407;Z01.107.567.875
30089031,Urinary Bladder,A05.810.890
30088802,Oximetry;Respiratory Function Tests;Respiratory Sounds,E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;E01.370.386.700;C23.888.852.779;E01.370.386.720;G09.772.775
30088436,"Adolescent;Brain Concussion;Vision, Ocular",M01.060.057;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
30087679,Inflammation,C23.550.470
30087455,,
30087441,,
30087419,,
30086540,Congenital Hyperinsulinism;Hypoglycemia;Obesity;Octreotide,C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;C18.452.394.984;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D04.345.566.650;D12.644.641.650
30086109,Brain;Humans;Kearns-Sayre Syndrome;Magnetic Resonance Imaging;Mitochondrial Myopathies;Neuroimaging,A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;C05.651.460.700.500;C10.292.562.750.250.500;C10.597.622.447.511.500;C10.668.491.500.700.500;C11.590.472.250.500;C11.768.585.658.500.627;C14.280.238.510;C18.452.660.410;C18.452.660.560.700.500;C23.888.592.636.447.511.500;E01.370.350.825.500;C05.651.460;C10.668.491.500;C18.452.660.560;E01.370.350.578;E01.370.376.537;E05.629
30086077,"Adult;Aged;Fluorine Radioisotopes;Humans;Image Processing, Computer-Assisted;Middle Aged;Positron Emission Tomography Computed Tomography;Sodium Fluoride;Spine;Young Adult",M01.060.116;M01.060.116.100;D01.496.749.340;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.116.630;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;D01.303.350.300.875;D01.857.725;D25.223.716;J01.637.051.223.716;A02.835.232.834;M01.060.116.815
30085932,,
30085438,,
30085400,Dermatology;Genetics;Genomics;Kidney Transplantation;Risk Assessment,H02.403.225;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350;E02.870.500;E04.936.450.485;E04.950.774.400;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30085281,,
30085177,,
30085176,,
30085153,,
30084913,,
30084538,Cell Movement,G04.198;G07.568.500.180
30084368,,
30084155,DNA Repair;Genomic Instability,G02.111.222;G05.219;C23.550.362;G05.365.590.335;G05.370
30084105,"Atherosclerosis;Cardiovascular Diseases;Diet;Dietary Fats;Nutrition Policy;Fatty Acids;Cholesterol, LDL;Triglycerides",C14.907.137.126.307;C14;G07.203.650.240;D10.212.302;G07.203.300.375;J02.500.375;I01.655.500.608.400.650;I01.880.604.825.608.400.650;N03.623.500.608.428.650;D10.251;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;D10.351.801
30084035,Pets;Pulmonary Embolism,B01.050.050.116.600;C08.381.746;C14.907.355.350.700
30083772,,
30083748,,
30083649,,
30082906,,
30082891,,
30082887,Brain;Estradiol;Humans;Sex Characteristics;Testosterone;Transgender Persons;Transsexualism,A08.186.211;D04.210.500.365.415.248;D06.472.334.851.437.500;B01.050.150.900.649.313.988.400.112.400.400;G08.686.815;D04.210.500.054.079.429.824;D06.472.334.851.968.984;M01.777.500;F01.145.802.975.750
30082790,"Adaptor Proteins, Signal Transducing;Binding Sites;Cell Cycle Proteins;Cell Line, Tumor;Chromatin;Crystallography, X-Ray;DNA;DNA Damage;Databases, Protein;Green Fluorescent Proteins;HeLa Cells;Histone Chaperones;Histones;Humans;Molecular Chaperones;Nuclear Proteins;Plasmids;Protein Binding;Protein Conformation;Transcription Factors;Ultraviolet Rays",D12.644.360.024;D12.776.157.057;D12.776.476.024;G02.111.570.120;D12.776.167;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;E05.196.309.742.225;D13.444.308;G05.200;L01.313.500.750.300.188.400.300.750;L01.313.500.750.300.188.400.325.710;L01.470.750.750.300.750;L01.470.750.750.325.710;D12.776.532.265;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;D12.776.580.219;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;D12.776.580;D12.776.660;G05.360.600;G02.111.679;G03.808;G02.111.570.820.709;D12.776.930;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
30082450,,
30082319,Chondrogenesis;Heparitin Sulfate;Hyaluronic Acid,G07.345.500.325.377.625.180;G11.427.578.180;D09.698.373.425;D09.698.373.475
30082128,Critical Illness;Hemorrhage;Hypoxia;Shock,C23.550.291.625;C23.550.414;C23.888.852.079;C23.550.835
30081036,Orexins;Orexins;Sex Characteristics,D12.644.400.360;D12.776.631.650.363;D12.644.400.360;D12.776.631.650.363;G08.686.815
30080950,Color Vision Defects,C10.597.751.941.256;C11.270.151.500;C11.966.256;C23.888.592.763.941.256
30080816,,
30080791,"Anti-Bacterial Agents;Borrelia burgdorferi;Diagnosis, Differential;Humans;Lyme Disease;Polymerase Chain Reaction;Synovial Fluid",D27.505.954.122.085;B03.440.425.410.711.193.150.125;B03.851.595.193.150.125;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;E05.393.620.500;A02.835.583.443.800.800;A12.207.270.847
30080777,,
30080770,"Child;Child, Preschool;Closed Fracture Reduction;Compartment Syndromes;Fracture Fixation, Internal;Fracture Healing;Humans;Humeral Fractures;Median Nerve;Median Neuropathy;Open Fracture Reduction;Postoperative Complications;Recovery of Function;Reoperation;Retrospective Studies;Time-to-Treatment;Vascular Surgical Procedures",M01.060.406;M01.060.406.448;E04.555.300.150;C05.651.180;C14.907.303;E04.555.300.300;G16.762.891.500;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;A08.800.800.720.050.500;C10.668.829.500.500;E04.555.300.690;C23.550.767;G16.757;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.928;N02.421.585.928;E04.100.814
30080754,,
30080470,Primary Health Care,N04.590.233.727
30080089,Adolescent;Child;Chronic Pain;Depression;Humans;Retrospective Studies;Risk Assessment;Suicidal Ideation;Time Factors,M01.060.057;M01.060.406;C23.888.592.612.274;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;F01.145.126.980.875.149;I01.880.735.856.149;G01.910.857
30079848,"Adolescent;Child;Constipation;Databases, Factual;Dizziness;Drug Therapy, Combination;Drug Utilization;Headache;Humans;Nausea;Pain;Pain Management;Philadelphia;Postural Orthostatic Tachycardia Syndrome;Sleep Initiation and Maintenance Disorders;Primary Dysautonomias;Headache;Sleep Initiation and Maintenance Disorders;Dizziness",M01.060.057;M01.060.406;C23.888.821.150;L01.313.500.750.300.188.400;L01.470.750.750;C23.888.592.763.237;E02.319.310;N04.452.706.477;C23.888.592.612.441;B01.050.150.900.649.313.988.400.112.400.400;C23.888.821.712;C23.888.592.612;F02.830.816.444;G11.561.790.444;E02.745;N04.590.607.500;Z01.107.567.875.500.550.525;Z01.433.820;C10.177.575.600.625;C10.886.425.800.800;F03.870.400.800.800;C10.177.575;C23.888.592.612.441;C10.886.425.800.800;F03.870.400.800.800;C23.888.592.763.237
30079274,,
30079172,HIV;Cough;Diagnosis;Sputum,B04.820.650.589.650.350;C08.618.248;C23.888.852.293;E01;A12.200.808
30079128,"Renal Insufficiency, Chronic;Ultrasonography",C12.777.419.780.750;C13.351.968.419.780.750;E01.370.350.850
30079127,,
30079126,Hippocampus,A08.186.211.180.405;A08.186.211.200.885.287.500.345
30079125,,
30078439,,
30078432,,
30078046,"Child;Contrast Media;Diagnosis, Differential;Gastrointestinal Diseases;Humans;Inflammatory Bowel Diseases;Magnetic Resonance Imaging;Child;Graft vs Host Disease;Infection;Neurofibroma;Polyps",M01.060.406;D27.505.259.500;D27.720.259;E01.171;C06.405;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;E01.370.350.825.500;M01.060.406;C20.452;C01.539;C04.557.580.600.580;C10.551.775.500.750;C10.668.829.725.500.600;C23.300.825
30078038,"Child;Diagnosis, Differential;Elasticity Imaging Techniques;Humans;Liver Cirrhosis;Magnetic Resonance Imaging;Child;Fibrosis;Liver;Elasticity Imaging Techniques;Magnetic Resonance Imaging",M01.060.406;E01.171;E01.370.350.850.270;B01.050.150.900.649.313.988.400.112.400.400;C06.552.630;E01.370.350.825.500;M01.060.406;C23.550.355;A03.620;E01.370.350.850.270;E01.370.350.825.500
30077719,"Adolescent;Adult;Amygdala;Gene Expression Profiling;Humans;Infant;Middle Aged;RNA, Long Noncoding;Schizophrenia;Sequence Analysis, RNA;Transcriptome;Young Adult;Schizophrenia;Systems Biology;Transcriptome",M01.060.057;M01.060.116;A08.186.211.180.090;A08.186.211.200.885.287.249.152;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;D13.444.735.790.375;F03.700.750;E05.393.760.710;G02.111.873.750;G05.297.700.750;G05.360.920;M01.060.116.815;F03.700.750;H01.158.273.180.800;G02.111.873.750;G05.297.700.750;G05.360.920
30077685,Pulmonary Valve,A07.541.510.738
30077623,,
30076905,,
30076206,"Macular Degeneration;Lipoproteins, HDL",C11.768.585.439;D10.532.432;D12.776.521.479
30075875,Epilepsy;Status Epilepticus,C10.228.140.490;C10.597.742.785;C23.888.592.742.785
30075198,"Acute Kidney Injury;Adolescent;Cardiopulmonary Resuscitation;Child;Child, Preschool;Coma;Humans;Hypothermia, Induced;Infant;Intensive Care Units, Pediatric;Out-of-Hospital Cardiac Arrest;Risk Factors;Severity of Illness Index;Time Factors;Acute Kidney Injury;Hypothermia, Induced",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.057;E02.365.647.110;M01.060.406;M01.060.406.448;C10.597.606.358.800.200;C23.888.592.604.359.800.200;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;M01.060.703;N02.278.388.493.390;C14.280.383.610;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;C12.777.419.780.050;C13.351.968.419.780.050;E02.258.750
30075141,"Acetylation;Animals;Carcinogenesis;Cell Nucleus;Epigenesis, Genetic;Epigenomics;Gene Expression Regulation, Neoplastic;Histones;Humans;Metabolic Networks and Pathways;Methylation;Neoplasms;Nutrients;Nutrigenomics;Protein Processing, Post-Translational;Signal Transduction",G02.111.012.052;G02.607.063.052;G03.040.052;B01.050;C04.697.098;C23.550.727.098;A11.284.430.106;A11.284.430.214.190.875.117;G05.308.203;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.308.370;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;G03.493;G02.111.035.538;G02.607.094.538;G03.059.538;C04;D27.505.696.377.683;G07.203.300.681;J02.500.681;H01.158.273.180.350.349;H01.158.273.343.350.349;H02.533.468;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;G02.111.820;G04.835
30074591,"Blood Loss, Surgical;Casts, Surgical;Child;Humans;Orthopedic Procedures;Orthopedics;Patient Care Bundles;Perioperative Care;Quality Improvement;Radiography;Surgical Wound Infection;Venous Thromboembolism",C23.550.414.300;C23.550.505.300;E07.858.442.660.430.500;E07.858.690.725.430.500;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;H02.403.810.494;E02.765;E02.760.731;E04.604;N02.421.585.722;J01.293.754;N04.761.744;E01.370.350.700;C01.539.947.692;C23.550.767.925;C14.907.355.590.700
30074450,Craniosynostoses,C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364
30073799,,
30073401,,
30073369,,
30073320,,
30073271,,
30073179,,
30073178,,
30072394,,
30071997,Hyperlipoproteinemia Type II;Genetic Counseling;Genetic Testing,C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;H01.158.273.343.385.500.384;N02.421.308.400;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221
30071516,,
30071237,,
30071236,,
30070761,,
30070726,"Antiviral Agents;Benzimidazoles;Child;Drug Resistance, Viral;Drug Therapy, Combination;Fluorenes;Hepatitis C, Chronic;Humans;Ribavirin;Sustained Virologic Response;Uridine Monophosphate",D27.505.954.122.388;D03.633.100.103;M01.060.406;G06.225.420;G06.920.225;G07.690.773.984.269.420;E02.319.310;D02.455.426.559.847.389;D04.615.389;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;D13.570.800.790;E01.789.800.570;N04.761.559.590.800.665;N05.715.360.575.575.800.665;D03.383.742.686.850.877;D13.695.740.850.877;D13.695.827.919.877
30070715,,
30070014,Neuroblastoma,C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
30069585,"Adolescent;Age Determination by Skeleton;Algorithms;Artificial Intelligence;Bone Diseases, Metabolic;Child;Child, Preschool;Deep Learning;Humans;Radiographic Image Interpretation, Computer-Assisted;Retrospective Studies;Machine Learning",M01.060.057;E01.370.049;E01.370.350.700.050;G17.035;L01.224.050;G17.035.250;L01.224.050.375;C05.116.198;C18.452.104;M01.060.406;M01.060.406.448;G17.035.250.500.250;G17.485.500;L01.224.050.375.530.250;L01.224.050.375.605.500;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600.680;E01.370.350.350.700;E01.370.350.700.705;L01.313.500.750.100.158.600.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G17.035.250.500;L01.224.050.375.530
30068943,Adolescent;Adult;Brain;Child;Cohort Studies;Humans;Multivariate Analysis;Nerve Net;Psychopathology;Reproducibility of Results;Sex Characteristics;Young Adult,M01.060.057;M01.060.116;A08.186.211;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;A08.511;F04.096.670;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;G08.686.815;M01.060.116.815
30068703,"Animals;Carcinogenesis;Cell Line, Tumor;Colorectal Neoplasms;Gene Expression Regulation;Humans;Intestinal Mucosa;Mice;Mice, Transgenic;Oncogenes;Protein Biosynthesis;RNA-Binding Proteins;Regeneration;Regulon;Stem Cells;Wnt Signaling Pathway",B01.050;C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;G05.308;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.369;A10.615.550.444;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.360.340.024.340.375.500;G02.111.660.871;G03.734.871;G05.297.670;D12.776.157.725;D12.776.664.962;G16.762;G05.360.340.024.742;A11.872;G02.111.820.925;G04.835.925
30068701,"Sarcoma, Ewing;Epigenomics",C04.557.450.565.575.650.800;C04.557.450.795.620.800;H01.158.273.180.350.074;H01.158.273.343.350.042
30068477,,
30068013,,
30067595,,
30067485,"Hypoglycemia;Death, Sudden, Cardiac;Syndactyly;Ventricular Fibrillation",C18.452.394.984;C14.280.383.220;C23.550.260.322.250;C05.116.099.370.894.819;C05.660.585.800;C05.660.906.819;C16.131.621.585.800;C16.131.621.906.819;C14.280.067.922;C23.550.073.922
30067389,Acute Lung Injury;Air Pollution;Epidemiology;Wounds and Injuries,C08.381.520.500;N06.850.460.100;H02.403.720.500;C26
30066654,Crowdsourcing;Emotions;Semantic Web,L01.399.250.179;F01.470;L01.224.740
30066420,"Accountable Care Organizations;Aged, 80 and over;Fee-for-Service Plans;Health Expenditures;Hospitals;Humans;Length of Stay;Medicare;Outcome Assessment (Health Care);Patient Discharge;Patient Readmission;Skilled Nursing Facilities;Subacute Care;United States;Medicare;Subacute Care;Accountable Care Organizations;Hospitals",N05.300.380.500;M01.060.116.100.080;N03.219.442.195;N03.219.521.710.305.090;N04.452.758.745.225;N03.219.151.450;N05.300.385;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E02.760.400.620;N02.421.585.400.620;N02.278.825.610.770;E02.760.850;N02.421.585.850;Z01.107.567.875;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E02.760.850;N02.421.585.850;N05.300.380.500;N02.278.421
30066291,"Atrial Fibrillation;Cardiac Output, Low;Catheter Ablation;Conservative Treatment;Heart Failure;Humans;Prognosis;Randomized Controlled Trials as Topic;Recurrence;Risk Assessment;Stroke Volume;Survival Rate;Treatment Outcome;Atrial Fibrillation;Catheter Ablation;Meta-Analysis;Randomized Controlled Trial;Heart Failure, Systolic",C14.280.067.198;C23.550.073.198;C14.280.148;C23.888.192;E02.808.750.500;E04.014.760.500;E02.197;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E01.789;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C23.550.291.937;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.370.370.380.150.700;G09.330.380.124.882;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.067.198;C23.550.073.198;E02.808.750.500;E04.014.760.500;V03.600;V03.175.250.500.500;C14.280.434.676
30066187,Craving;Food Addiction;Obesity;Therapeutics;Weight Loss,F01.658.293.195;F01.145.527.100.120.500;F03.400.813;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02;C23.888.144.243.963;G07.345.249.314.120.200.963
30066167,Iron Overload;Liver Cirrhosis,C18.452.565.500;C06.552.630
30066156,"Adolescent;Child;Child, Preschool;Contrast Media;Diffusion Magnetic Resonance Imaging;Humans;Jejunum;Reference Values;Reproducibility of Results;Retrospective Studies;Young Adult;Child;Crohn Disease;Jejunum",M01.060.057;M01.060.406;M01.060.406.448;D27.505.259.500;D27.720.259;E01.370.350.825.500.150;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.684.500;A03.556.249.750;E05.978.810;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;M01.060.406;C06.405.205.731.500;C06.405.469.432.500;A03.556.124.684.500;A03.556.249.750
30066140,Longevity;Morphogenesis;Saccharomyces cerevisiae,G07.345.124.519;G07.540;G07.345.500;B01.300.107.795.785.800;B01.300.930.705.655
30066068,"Body Mass Index;Obesity;Hernia, Hiatal;Thinness",E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.300.707.500.467;C23.888.144.828;E01.370.600.115.100.160.120.828;G07.100.100.160.120.828
30066065,Esophagectomy,E04.210.346
30065952,,
30065293,Biofilms;Catalysis;Dental Caries;Ferrosoferric Oxide;Humans;Hydrogen Peroxide;Nanoparticles,A20.593;G06.120;G02.130;C07.793.720.210;D01.490.100.375;D01.490.200.350;D01.578.285;B01.050.150.900.649.313.988.400.112.400.400;D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253;J01.637.512.600
30065108,Disease Progression;Disease Susceptibility;Humans;Neoplasms;Signal Transduction;rac GTP-Binding Proteins;rho GTP-Binding Proteins,C23.550.291.656;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;C04;G02.111.820;G04.835;D08.811.277.040.330.300.400.700.100;D12.644.360.525.700.100;D12.776.157.325.515.700.100;D12.776.476.525.700.100;D08.811.277.040.330.300.400.700;D12.644.360.525.700;D12.776.157.325.515.700;D12.776.476.525.700
30065002,,
30063611,,
30063371,,
30063333,,
30063078,,
30062831,"Infant, Extremely Low Birth Weight;Infant, Newborn",M01.060.703.520.460.600.500;M01.060.703.520
30062738,,
30062632,,
30062590,Cytochrome P-450 CYP3A;Absorption;Liver;Pediatrics,D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500;G01.015;G02.010;G03.015;G03.787.024;G07.690.725.015;A03.620;H02.403.670
30062319,Echocardiography,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
30062212,Apoptosis;Cardiotoxicity;Sunitinib;Tissue Engineering;Toxicology,G04.146.160;C23.550.161;C25.100.389;C26.733.266;G01.750.748.500.266;D03.383.129.578.823;D03.633.100.473.877;E05.481.500.311.500;J01.293.069.249.500;H01.158.891;H02.884
30062156,Cardiovascular Diseases;Diabetes Mellitus,C14;C18.452.394.750;C19.246
30060684,Vascularized Composite Allotransplantation;Hand Transplantation;Vascularized Composite Allotransplantation,E04.936.450.825;E04.936.450.825.500;E04.936.450.825
30060177,"Base Pairing;Cholera;Chromosomes, Bacterial;Culture Media;DNA Replication Timing;Gene Deletion;Gene Duplication;Genomic Islands;Humans;Mutation Rate;Pandemics;Reproducibility of Results;Rifampin;Vibrio cholerae",G02.111.570.820.486.100;G02.111.611.500;G05.360.580.100;C01.252.400.959.347;A11.284.187.190;A20.812;G05.360.162.190;D27.720.470.305;E07.206;G02.111.225.760;G05.226.760;G05.365.590.762.320;G05.558.800.320;G05.365.590.320;G05.558.320;G02.111.570.080.708.330.330;G05.360.080.708.330.330;G05.360.340.024.425.500;B01.050.150.900.649.313.988.400.112.400.400;G05.045.250.750;G05.365.590.612;G16.075.250.750;N06.850.290.200.600;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;D03.633.400.811.700;D04.345.295.750.700;B03.440.450.900.859.225;B03.660.250.830.830.100
30059747,"Adolescent;Benchmarking;Catheter-Related Infections;Catheterization, Central Venous;Child;Child, Preschool;Epidemiological Monitoring;Fungi;Gram-Negative Bacteria;Gram-Positive Bacteria;Greece;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Intensive Care Units;Sepsis;Benchmarking;Infection;Infection Control",M01.060.057;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;C01.539.195;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;M01.060.406;M01.060.406.448;E05.318.375;N06.850.520.460;B01.300;B03.440;B03.510;Z01.542.383;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493;C01.539.757;C23.550.470.790.500;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;C01.539;N06.850.780.200.450
30059394,Carcinoma;Eye Neoplasms;Humans;Lacrimal Apparatus Diseases;Middle Aged,C04.557.470.200;C04.588.364;C11.319;B01.050.150.900.649.313.988.400.112.400.400;C11.496;M01.060.116.630
30059181,Circadian Rhythm;Neuropeptides,G07.180.562.190;D12.644.400;D12.776.631.650
30058263,Adult;Blood Glucose;Diabetes Mellitus;Fasting;Health Surveys;Humans;Logistic Models;Middle Aged;Multilevel Analysis;Multivariate Analysis;Namibia;Prediabetic State;Prevalence;Namibia;Multilevel Analysis;Social Class,M01.060.116;D09.947.875.359.448.500;C18.452.394.750;C19.246;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;N06.850.520.830.562;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;Z01.058.290.175.580;C18.452.394.750.774;C19.246.774;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;Z01.058.290.175.580;N06.850.520.830.562;I01.880.853.996.755;N01.824.782
30058218,Economics;Kidney Diseases;Kidney Transplantation,I01.261;N03.219;C12.777.419;C13.351.968.419;E02.870.500;E04.936.450.485;E04.950.774.400
30058145,,
30057363,Malaria;Metabolism;Metabolomics,C03.752.530;G03;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
30057115,Peroxisome Proliferator-Activated Receptors;Chronotherapy;Circadian Rhythm;Fatty Liver;Lipogenesis,D12.776.826.239;D12.776.930.705;E02.168;G07.180.562.190;C06.552.241;G02.111.528;G03.458.249
30057097,,
30057067,Islets of Langerhans;Glucagon-Secreting Cells;Insulin-Secreting Cells,A03.734.414;A06.300.414;A03.734.414.065;A06.300.414.043;A06.390.087;A11.382.625.064;A11.436.294.064;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092
30057029,Intellectual Disability;Neurodevelopmental Disorders,C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F03.625
30056785,"Adult;Aged;Aged, 80 and over;Anticoagulants;Computed Tomography Angiography;Diagnosis, Differential;Echocardiography;Electrocardiography;Humans;Middle Aged;Predictive Value of Tests;Pulmonary Artery;Pulmonary Embolism;ST Elevation Myocardial Infarction;Thrombolytic Therapy;Treatment Outcome;Pulmonary Embolism;Meta-Analysis",M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.502.119;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.171;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;A07.015.114.715;C08.381.746;C14.907.355.350.700;C14.280.647.500.875;C14.907.585.500.875;E02.319.913;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.381.746;C14.907.355.350.700;V03.600
30056562,Hemoglobins;Inflammatory Bowel Diseases;Iron,D12.776.124.400;D12.776.422.316.762;C06.405.205.731;C06.405.469.432;D01.268.556.412;D01.268.956.287;D01.552.544.412
30056157,,
30056095,"Adult;Aged;Aged, 80 and over;Anticoagulants;Diverticulum;Gastrointestinal Hemorrhage;Humans;Incidence;Middle Aged;Recurrence;Retrospective Studies;Risk Factors;Fibrinolytic Agents;Diverticular Diseases;Clinical Decision-Making;Pharmacoepidemiology",M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.502.119;C01.539.463.199.750;C06.405.205.282.750;C23.300.415;C06.405.227;C23.550.414.788;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;C01.539.463.199;C06.405.205.282;E01.055;H01.158.703.045;H02.403.720.500.650;H02.628.413
30055634,"Adolescent;Blood Preservation;Canada;Child;Child, Preschool;Critical Illness;Double-Blind Method;Erythrocyte Transfusion;Europe;Hospital Mortality;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Israel;Multicenter Studies as Topic;Multiple Organ Failure;Randomized Controlled Trials as Topic;Risk Assessment;Risk Factors;Time Factors;Treatment Outcome;United States;Blood;Child;Critical Care;Erythrocytes;Critical Care;Mortality;Randomized Controlled Trial",M01.060.057;E02.792.833.230;E05.760.833.230;Z01.107.567.176;M01.060.406;M01.060.406.448;C23.550.291.625;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.095.135.140.275;Z01.542;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;Z01.252.245.500.375;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;C23.550.835.525;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;A12.207.152;A15.145;M01.060.406;E02.760.190;N02.421.585.190;A11.118.290;A11.443.240;A15.145.229.334;E02.760.190;N02.421.585.190;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;V03.175.250.500.500
30055615,"Drugs, Chinese Herbal;Humans;Infant, Newborn;Jaundice, Neonatal;Phototherapy;Randomized Controlled Trials as Topic;Meta-Analysis;Jaundice, Neonatal;Systematic Review",D20.215.784.500.350;D26.335;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C16.614.451.500;C23.550.429.249.500;E02.774;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;V03.600;C16.614.451.500;C23.550.429.249.500;V03.850
30055317,"Academies and Institutes;Animals;Databases, Chemical;Fatty Alcohols;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.033.415;D10.289;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30055316,"Academies and Institutes;Acetophenones;Animals;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;D02.522.120;B01.050;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30055086,"Cleft Palate;Heart Defects, Congenital",C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;C14.240.400;C14.280.400;C16.131.240.400
30055079,Bloom Syndrome;DNA Repair;Chromosomal Instability,C16.131.077.137;C18.452.284.100;G02.111.222;G05.219;C23.550.210.110;C23.550.362.180;G05.365.590.175.165;G05.370.180
30055034,22q11 Deletion Syndrome;DiGeorge Syndrome;Prenatal Diagnosis,C05.660.207.103;C14.240.400.021;C14.280.400.044;C15.604.451.249;C16.131.077.019;C16.131.240.400.021;C16.131.260.019;C16.131.482.249;C16.131.621.207.103;C16.320.180.019;C19.642.482.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E01.370.378.630
30055033,"Calcium;Costello Syndrome;Noonan Syndrome;LEOPARD Syndrome;Tachycardia, Ectopic Atrial",D01.268.552.100;D01.552.539.288;D23.119.100;C05.660.207.219;C16.131.077.256;C16.320.185;C05.660.207.690;C14.240.400.787;C14.280.400.787;C16.131.240.400.784;C16.131.621.207.690;C17.300.690;C05.660.207.525;C14.240.400.695;C14.280.400.695;C14.280.484.716.525;C16.131.077.525;C16.131.240.400.685;C16.131.621.207.525;C17.800.621.430.530.550.525;C14.280.067.845.880.315;C14.280.123.875.880.315;C23.550.073.845.880.315
30054622,,
30054336,,
30054193,Lung Transplantation,E04.928.600.495;E04.936.450.495
30054152,,
30054012,"Cell Line;Killer Cells, Natural",A11.251.210;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537
30053902,"Animals;Diabetes Complications;Diabetes Mellitus, Experimental;Diabetes Mellitus, Type 1;Erectile Dysfunction;Fibrosis;Islets of Langerhans Transplantation;Penile Diseases;Penis;Rats;Rats, Wistar;Streptozocin;Diabetes Mellitus;Erectile Dysfunction;Transforming Growth Factor beta1",B01.050;C19.246.099;C18.452.394.750.074;C19.246.240;E05.598.500.374;C18.452.394.750.124;C19.246.267;C20.111.327;C12.294.644.486;F03.835.400;C23.550.355;E02.095.147.500.250;E04.270.550;E04.936.225.375;C12.294.494;A05.360.444.492;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.900;D02.654.692.768;D02.948.594.768;D09.408.051.900;C18.452.394.750;C19.246;C12.294.644.486;F03.835.400;D12.644.276.374.687.100;D12.644.276.954.775.100;D12.776.467.374.687.100;D12.776.467.942.775.100;D23.529.374.687.100;D23.529.942.775.100
30053632,Autism Spectrum Disorder;Child,F03.625.164.113;M01.060.406
30053631,Hospitalization,E02.760.400;N02.421.585.400
30053536,"Academies and Institutes;Animals;Benzene Derivatives;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.455.426.559.389;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30053535,"Academies and Institutes;Animals;Benzyl Compounds;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.455.426.559.389.140;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30053522,Fibrosis;Liver Diseases;Mortality,C23.550.355;C06.552;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
30053014,,
30051733,"Animals;Dependovirus;High-Throughput Nucleotide Sequencing;Humans;Plasmids;Reproducibility of Results;Sequence Analysis, DNA",B01.050;B04.280.580.650.170;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.360.600;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.393.760.700
30051202,"Aging;Contraception;Delivery of Health Care;Fertility;Fertility Preservation;Humans;Menopause;Neoplasms;Pregnancy;Quality of Life;Reproductive Health;Sexual Dysfunction, Physiological;Reproductive Health",G07.345.124;E02.875.194;N04.590.374;N05.300;G08.686.210;E02.875.800.625;E04.936.537.562;E05.820.800.625;B01.050.150.900.649.313.988.400.112.400.400;G08.686.157.500;G08.686.841.249.500;C04;G08.686.784.769;I01.800;K01.752.400.750;N06.850.505.400.425.837;N01.400.625;C12.294.644;C13.351.500.665;N01.400.625
30051063,,
30050797,Prostatic Neoplasms;Radiotherapy,C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;E02.815
30050117,,
30049686,Neonatology,H02.403.670.400
30049656,Adult;Cardiopulmonary Resuscitation;Feedback;Health Personnel;Heart Arrest;Humans;Patient Care Team;Pediatrics;Quality Improvement;Quality of Health Care;Workload;Cardiopulmonary Resuscitation;Resuscitation;Workload,M01.060.116;E02.365.647.110;L01.906.394.211;M01.526.485;N02.360;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;H02.403.670;J01.293.754;N04.761.744;N04.761;N05.715;I03.946.225.500;N04.452.677.650.500;E02.365.647.110;E02.365.647;I03.946.225.500;N04.452.677.650.500
30049547,,
30049521,"Acute Disease;Adult;Extracorporeal Membrane Oxygenation;Follow-Up Studies;Humans;Middle Aged;Quality of Life;Respiratory Distress Syndrome, Adult;Retrospective Studies;Survival Rate;Time Factors;Treatment Outcome;United States;Respiratory Distress Syndrome, Adult;Extracorporeal Membrane Oxygenation;Extracorporeal Membrane Oxygenation;Quality of Life;Outcome Assessment (Health Care)",C23.550.291.125;M01.060.116;E02.880.301;E04.292.451;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;I01.800;K01.752.400.750;N06.850.505.400.425.837;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C08.381.840;C08.618.840;E02.880.301;E04.292.451;E02.880.301;E04.292.451;I01.800;K01.752.400.750;N06.850.505.400.425.837;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
30048789,"Databases, Bibliographic;Humans;Hydrocephalus;Incidence;Subarachnoid Hemorrhage;Ventriculoperitoneal Shunt;Hydrocephalus;Subarachnoid Hemorrhage",L01.313.500.750.300.188.300;L01.470.750.500;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850;E04.035.188.850;E04.525.170.850;C10.228.140.602;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
30048645,"Academies and Institutes;Animals;Caproates;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.241.081.193;D10.251.400.326;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30048610,Behavior;Gene Expression,F01.145;G05.297
30048247,,
30047430,"Autoantibodies;Calcinosis;Fingers;Humans;Pigmentation Disorders;Pruritus;Raynaud Disease;Scleroderma, Localized;Scleroderma, Systemic;Skin Ulcer;Telangiectasis;Terminology as Topic",D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;C18.452.174.130;A01.378.800.667.430;B01.050.150.900.649.313.988.400.112.400.400;C17.800.621;C23.550.755;C17.800.685;C23.888.885.625;C14.907.617.812;C17.300.787;C17.800.767;C17.300.799;C17.800.784;C17.800.893;C14.907.823;L01.559.598.400
30046821,,
30046766,Hemophilia A;Hemophilia B;Precision Medicine;Pharmacokinetics,C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;E02.574;H02.403.200.700;G03.787;G07.690.725
30046746,,
30046662,,
30046640,"Diagnosis;Education, Medical;Tuberculosis",E01;I02.358.399;C01.252.410.040.552.846
30046297,Cytokines;Immunotherapy;Neuroblastoma;Safety,D12.644.276.374;D12.776.467.374;D23.529.374;E02.095.465.425;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;N06.850.135.060.075
30046149,,
30045982,"Animals;Antibodies, Neutralizing;Antibodies, Viral;Antigenic Variation;Antigens, Viral;Chick Embryo;Epitopes;Gene Expression;Hemagglutination Inhibition Tests;Hemagglutinin Glycoproteins, Influenza Virus;Humans;Immune Evasion;Immune Sera;Influenza A Virus, H1N1 Subtype;Influenza, Human;Models, Molecular;Mutation;Neutralization Tests;Zygote;Influenza, Human;Mutation",B01.050;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;G05.365.073;G12.500.249;D23.050.327;A13.350.150;A16.331.200;D23.050.550;G05.297;E01.370.225.812.735.370;E05.200.812.735.370;E05.478.594.760.370;D12.776.964.970.880.345.500;B01.050.150.900.649.313.988.400.112.400.400;G06.462.400;G12.413;G16.527.200.700;A12.207.152.846.500;D12.776.124.486.485.114.573;D12.776.124.790.651.114.573;D12.776.377.715.548.114.573;D20.215.401;B04.820.545.405.400.214;C02.782.620.365;C08.730.310;E05.599.595;G05.365.590;E01.370.225.812.735.550;E05.200.812.735.550;E05.478.594.760.550;A05.360.490.690.970;A11.497.497.950;A16.950;C02.782.620.365;C08.730.310;G05.365.590
30045669,"Adult;Cervix Uteri;Gestational Age;Humans;Pregnancy;Pregnancy Outcome;RNA, Long Noncoding;RNA, Long Noncoding;Cervix Uteri;RNA, Long Noncoding;Pregnancy;Premature Birth",M01.060.116;A05.360.319.679.256;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;E01.789.700;G08.686.784.769.496;D13.444.735.790.375;D13.444.735.790.375;A05.360.319.679.256;D13.444.735.790.375;G08.686.784.769;C13.703.420.491.500
30045159,,
30045144,Aged;Anxiety;Cross-Sectional Studies;Depression;Diagnostic Self Evaluation;Humans;Quality of Life;Skin Neoplasms,M01.060.116.100;F01.470.132;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.126.350;E01.370.360;F01.752.747.792.220;B01.050.150.900.649.313.988.400.112.400.400;I01.800;K01.752.400.750;N06.850.505.400.425.837;C04.588.805;C17.800.882
30044978,,
30044930,"Emergency Medical Services;Humans;Resuscitation;Shock, Hemorrhagic",N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;E02.365.647;C23.550.414.980;C23.550.835.650
30044289,,
30044247,,
30044155,Endometriosis;Infertility,C13.351.500.163;C12.294.365;C13.351.500.365
30043658,Clinical Trial;Multiple Sclerosis,V03.175.250;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
30043460,Global Health,H02.403.371;N01.400.337
30043271,Granuloma;United States,C15.604.515.292;C23.550.382;Z01.107.567.875
30043064,"Adolescent;Child;Child, Preschool;Cohort Studies;Emergency Service, Hospital;Emergency Treatment;Guideline Adherence;Hospital Mortality;Humans;Infant;Infant, Newborn;Mandatory Programs;New York;Odds Ratio;Patient Care Bundles;Practice Guidelines as Topic;Risk Adjustment;Sepsis;Time Factors",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.365;N04.761.337;N05.715.360.395;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;I01.880.604.622;N03.706.657;N04.452.521;Z01.107.567.875.075.437;Z01.107.567.875.350.530;Z01.107.567.875.500.530;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E02.765;N04.761.700.350.650;N05.700.350.650;N04.452.871.715.800;N04.761.789.800;N05.715.360.750.625.700.690.800;C01.539.757;C23.550.470.790.500;G01.910.857
30042517,,
30042225,"Angioplasty, Balloon;Angioplasty, Balloon, Coronary;Constriction, Pathologic;Paclitaxel",E02.148.050.060;E04.100.814.529.124.060;E04.502.382.124.060;E05.157.016.060;E02.148.050.060.100;E04.100.376.719.100;E04.100.814.529.124.060.100;E04.100.814.529.968.050;E04.502.382.124.060.100;E04.502.382.968.050;E04.928.220.520.100;E05.157.016.060.100;C23.300.287;D02.455.426.392.368.242.888.777;D02.455.849.291.850.777
30042146,,
30042096,,
30042057,Brain;Magnetic Resonance Imaging,A08.186.211;E01.370.350.825.500
30041938,"Age Factors;Body Mass Index;Cardiovascular Diseases;Child;Cohort Studies;Comorbidity;Disease Progression;Glomerular Filtration Rate;Humans;Metabolic Syndrome;Obesity;Prevalence;Prognosis;Renal Insufficiency, Chronic;Risk Assessment;Sex Factors;Statistics, Nonparametric;United States;Child;Renal Insufficiency, Chronic;Metabolic Syndrome",N05.715.350.075;N06.850.490.250;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C14;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;C23.550.291.656;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500.570;C18.452.625;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N05.715.350.675;N06.850.490.875;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;Z01.107.567.875;M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;C18.452.394.968.500.570;C18.452.625
30041892,Sex Characteristics,G08.686.815
30041834,Adult;Autoantibodies;Diabetes Mellitus,M01.060.116;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;C18.452.394.750;C19.246
30041576,Adolescent;Adolescent Health;Public Health;Health Promotion,M01.060.057;N01.400.075;H02.403.720;N01.400.550;N06.850;I02.233.332.445;N02.421.726.407.579
30041280,Disease Progression;Humans;Liver Diseases;Predictive Value of Tests;Risk Factors;Sarcoidosis;Treatment Outcome,C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C06.552;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C15.604.515.827;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30040859,,
30040148,Osteoporosis,C05.116.198.579;C18.452.104.579
30039859,Metagenomics,H01.158.273.343.350.261
30039776,"Cardiac Catheterization;Follow-Up Studies;Fontan Procedure;Heart Ventricles;Humans;Hypoplastic Left Heart Syndrome;Infant;Infant, Newborn;Length of Stay;Palliative Care;Retrospective Studies;Risk Factors;Time Factors;Treatment Outcome;Classification;Hypoplastic Left Heart Syndrome;Perioperative Care",E01.370.370.380.140;E02.148.442;E05.157.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E02.760.666;N02.421.585.666;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;L01.100;L01.453.245.275;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E02.760.731;E04.604;N02.421.585.722
30039360,"Animals;Gene Dosage;Humans;Markov Chains;Oligonucleotide Array Sequence Analysis;Polymorphism, Single Nucleotide;Sequence Analysis, DNA",B01.050;G05.380.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.500;E05.318.740.996.500;G17.830.500;N05.715.360.750.625.500;N05.715.360.750.770.500;N06.850.520.830.600.500;N06.850.520.830.996.500;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;G05.365.795.598;E05.393.760.700
30039164,,
30038931,,
30038384,,
30037788,Academic Success;Leadership;Social Media,I02.399.136.500;F01.752.609;L01.178.751;L01.224.230.110.500.750
30037727,,
30036581,,
30036290,"Arthritis, Infectious;Biomarkers;Biopsy, Needle;Case-Control Studies;Child;Child, Preschool;Gentian Violet;Humans;Leukocyte Count;Neutrophils;Phenazines;Predictive Value of Tests;Staining and Labeling;Synovial Fluid",C01.539.100;C05.550.114.099;D23.101;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;D02.092.146.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;D03.633.300.704;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670;A02.835.583.443.800.800;A12.207.270.847
30036237,,
30036223,,
30035274,Machine Learning;Quality Control,G17.035.250.500;L01.224.050.375.530;J01.897.608
30035265,Ageusia;Ageusia;Taste;Tonsillectomy,C10.597.751.861.184;C23.888.592.763.861.184;C10.597.751.861.184;C23.888.592.763.861.184;F02.830.816.724;G11.561.790.724;E04.580.848
30035264,"Cilia;Taste;Immunity, Innate;Nose Diseases;Nitric Oxide",A11.284.180.165;F02.830.816.724;G11.561.790.724;G12.450.564;C08.460;C09.603;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
30035259,Anti-Bacterial Agents;Bacteria;Smell;Viruses,D27.505.954.122.085;B03;F02.830.816.643;G11.561.790.643;B04
30035257,Ageusia;Olfaction Disorders;Ageusia;Identification (Psychology);Smell;Psychophysics;Smell;Taste,C10.597.751.861.184;C23.888.592.763.861.184;C10.597.751.600;C23.888.592.763.550;C10.597.751.861.184;C23.888.592.763.861.184;F01.393.446;F01.752.747.385;F02.830.816.643;G11.561.790.643;E01.370.685;F04.096.753;F02.830.816.643;G11.561.790.643;F02.830.816.724;G11.561.790.724
30033560,,
30032754,Hemolysis,C23.550.403;G12.122.545
30032644,"Animals;Cisterna Magna;Dependovirus;Fluoroscopy;Gene Transfer Techniques;Genetic Therapy;Injections, Spinal;Primates;Central Nervous System;Genetic Therapy",B01.050;A08.186.566.166.686.351;B04.280.580.650.170;E01.370.350.700.225;E05.393.350;E02.095.301;E05.393.420.301;E02.319.267.530.580;B01.050.150.900.649.313.988;A08.186;E02.095.301;E05.393.420.301
30032277,,
30032172,,
30031903,United States;Child,Z01.107.567.875;M01.060.406
30031844,,
30031768,Aged;Colonoscopy;Colorectal Neoplasms;Early Detection of Cancer;Humans;Incidence;Middle Aged;Occult Blood;Colonic Neoplasms;Neoplasms,M01.060.116.100;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E01.370.225.925;E05.200.925;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;C04
30031514,,
30031493,"Adolescent;Arthritis, Juvenile;Child;Diagnosis, Differential;Humans;Remission Induction;Sex Distribution;Spondylarthritis;Spondylitis, Ankylosing;Arthritis, Juvenile;Arthritis, Psoriatic",M01.060.057;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E02.860;I01.240.800;N01.224.803;N06.850.505.400.850;C05.116.900.853.625;C05.550.114.865;C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
30031491,"Autoimmune Diseases;Child;Diagnosis, Differential;Humans;Inflammation;Rheumatic Diseases;Autoimmunity;Inflammation;Rheumatic Diseases",C20.111;M01.060.406;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C05.799;C17.300.775;G12.450.192;C23.550.470;C05.799;C17.300.775
30031055,"Adolescent;Blood Pressure Determination;Child;Child, Preschool;Guideline Adherence;Heart Arrest;Heart Massage;Hospital Mortality;Hospitals, Pediatric;Humans;Infant;Intensive Care Units, Pediatric;Nervous System Diseases;Outcome and Process Assessment (Health Care);Practice Guidelines as Topic;Pressure;Quality Improvement;United States;Heart Arrest;Cardiopulmonary Resuscitation;Intensive Care Units",M01.060.057;E01.370.370.140;E01.370.600.100;M01.060.406;M01.060.406.448;N04.761.337;N05.715.360.395;C14.280.383;E02.365.647.375;E04.100.376.458;E04.928.220.380;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;C10;N04.761.559;N05.715.360.575;N04.761.700.350.650;N05.700.350.650;G01.374.715;J01.293.754;N04.761.744;Z01.107.567.875;C14.280.383;E02.365.647.110;N02.278.388.493
30031009,,
30030295,,
30030146,,
30029989,,
30029858,"Bronchopulmonary Dysplasia;Ethnic Groups;Humans;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Nitric Oxide",C08.381.520.750.500;C16.614.521.125;M01.686.754;N01.224.317;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;C16.614.521;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
30029855,"Adolescent;Adult;Aminophenols;Child;Child, Preschool;Chloride Channel Agonists;Cystic Fibrosis;Cystic Fibrosis Transmembrane Conductance Regulator;DNA;DNA Mutational Analysis;Energy Metabolism;Humans;Middle Aged;Mutation;Quality of Life;Quinolones;Treatment Outcome;Weight Gain;Young Adult;Cystic Fibrosis;Energy Metabolism",M01.060.057;M01.060.116;D02.092.146.100;D02.455.426.559.389.657.050;M01.060.406;M01.060.406.448;D27.505.519.562.311;C06.689.202;C08.381.187;C16.320.190;C16.614.213;D12.776.157.530.100.304.500;D12.776.157.530.400.175.125;D12.776.157.530.450.074.500.500.500.500;D12.776.543.550.450.175.125;D12.776.543.585.100.304.500;D12.776.543.585.400.175.125;D12.776.543.585.450.074.500.500.500.500;D13.444.308;E05.393.760.700.300;G03.295;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;I01.800;K01.752.400.750;N06.850.505.400.425.837;D03.633.100.810.835;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.926;G07.345.249.314.120.200.926;M01.060.116.815;C06.689.202;C08.381.187;C16.320.190;C16.614.213;G03.295
30029732,"Antineoplastic Agents;Dehydroepiandrosterone Sulfate;Delayed-Action Preparations;Gene Expression Regulation, Neoplastic;Humans;Prostatic Neoplasms, Castration-Resistant;Steroid 17-alpha-Hydroxylase;Androgens;Prostatic Neoplasms;Steryl-Sulfatase",D27.505.954.248;D04.210.500.054.079.429.625.300;D04.210.500.578.502.400.300;D06.472.040.502.400.300;D06.472.334.851.968.952.300;D26.255.210;E02.319.300.253;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.440.770.500;C12.294.260.750.500;C12.294.565.625.500;C12.758.409.750.500;D08.244.453.487.500;D08.244.453.915.748;D08.811.682.690.708.170.444.500;D08.811.682.690.708.170.915.748;D12.776.422.220.453.487.500;D12.776.422.220.453.915.748;D27.505.696.399.472.161;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;D08.811.277.352.827.070.625
30028985,,
30028363,,
30028344,,
30027857,,
30027278,,
30027232,Hospice Care;Humans;Terminal Care;United States,E02.760.905.400;N02.421.585.905.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.905;N02.421.585.905;Z01.107.567.875
30027223,,
30026227,"Anemia, Sickle Cell;CRISPR-Cas Systems;Carrier Proteins;Cell Line;Erythroid Cells;Fetal Hemoglobin;Gene Expression Regulation;Genetic Testing;Humans;Molecular Targeted Therapy;Nuclear Proteins;RNA, Guide;eIF-2 Kinase",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;G05.308.203.374.394;D12.776.157;A11.251.210;A11.443;D12.776.124.400.303;D12.776.422.316.762.320;G05.308;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;E02.319.574;D12.776.660;D13.444.735.790.552.625;D08.811.913.696.620.682.700.300;D12.644.360.275;D12.776.476.275
30026212,"Gene Expression Regulation;Humans;Kidney;Kidney Neoplasms;Transcription, Genetic",G05.308;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;G02.111.873;G05.297.700
30026182,,
30026006,"Academic Medical Centers;Adolescent;Adult;Aged;Aged, 80 and over;Anti-Bacterial Agents;Cross Infection;Disease Transmission, Infectious;Drug Utilization;Gram-Positive Bacterial Infections;Humans;Intensive Care Units;Middle Aged;Prevalence;Rectum;Retrospective Studies;United States;Vancomycin;Vancomycin-Resistant Enterococci;Young Adult;Environment;Hospitals",N02.278.020;M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.085;C01.539.248;C23.550.291.875.500;N06.850.310;N04.452.706.477;C01.252.410;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;A03.556.124.526.767;A03.556.249.249.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;D09.400.420.925;D12.644.233.925;B03.353.750.250.250.650;B03.510.550.250.250.650;M01.060.116.815;G16.500.275;N06.230;N02.278.421
30025822,"Animals;Antineoplastic Agents;Apoptosis;Cell Line, Tumor;Cell Proliferation;DNA Damage;DNA Repair;Genes, BRCA1;Humans;Mice;Neoplasm Grading;Neoplasm Transplantation;Neoplasms, Cystic, Mucinous, and Serous;Ovarian Neoplasms;Phthalazines;Piperazines;Poly (ADP-Ribose) Polymerase-1;Radiation Tolerance;Radiotherapy",B01.050;D27.505.954.248;G04.146.160;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G05.200;G02.111.222;G05.219;G05.360.340.024.340.375.249.100;G05.360.340.024.340.415.400.100;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;E01.789.612;E05.624;C04.557.470.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D03.383.710.605;D03.383.606;D08.811.913.400.725.115.690.420;G04.712;G07.738;E02.815
30025101,"Animals;Aqueous Humor;Biological Transport;Blotting, Western;Cells, Cultured;Ciliary Body;Connexins;Gap Junctions;Gene Expression Regulation;Gene Knockdown Techniques;Pigment Epithelium of Eye;Protein Isoforms;RNA, Messenger;RNA, Small Interfering;Real-Time Polymerase Chain Reaction;Swine",B01.050;A09.371.060.067.070;A12.207.270.040;G03.143;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;A11.251;A09.371.060.160;A09.371.894.280;D12.776.543.585.250;A11.284.149.165.420.471;G05.308;E05.393.335.500;A09.371.670;A10.272.640;D12.776.800;D13.444.735.544;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;E05.393.620.500.706;B01.050.150.900.649.313.500.880
30025090,"Animals;Bruch Membrane;Complement Factor H;Disease Models, Animal;Electroretinography;Enzyme-Linked Immunosorbent Assay;Glomerulonephritis, Membranoproliferative;Immunohistochemistry;Mice;Mice, Inbred C57BL;Microscopy, Electron;Properdin;Retinal Diseases;Retinal Pigment Epithelium",B01.050;A09.371.894.223.250;A10.272.220.250;A10.615.179.250;D12.776.124.486.274.920.325.200;D12.776.124.790.223.200;D12.776.377.715.182.200;C22.232;E05.598.500;E05.599.395.080;E01.370.380.225;E01.370.405.270;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;C12.777.419.570.363.615;C13.351.968.419.570.363.615;C20.425;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E01.370.350.515.402;E05.595.402;D12.776.124.486.274.965;D12.776.124.790.223.624;D12.776.377.715.182.624;C11.768;A09.371.670.500;A09.371.729.887
30024926,"Animals;Cytokines;Ligands;Mice;Mice, Inbred C57BL;Mice, Knockout;Mutagenesis, Site-Directed;Mutation;Phosphorylation;Protein Stability;Signal Transduction;Toll-Like Receptor 9;Tyrosine",B01.050;D12.644.276.374;D12.776.467.374;D23.529.374;D27.720.470.480;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.393.420.601.575;G05.365.590;G02.111.665;G02.607.780;G03.796;G02.111.700;G02.111.820;G04.835;D12.776.260.750;D12.776.543.750.705.910.500.900;D12.125.072.050.875
30024428,,
30024272,RNA;Immunotherapy,D13.444.735;E02.095.465.425
30023034,Disorders of Sex Development,C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119
30022410,Crowding;Patients' Rooms;Workload,F01.145.875.281;N02.278.220.640;I03.946.225.500;N04.452.677.650.500
30022340,,
30022113,,
30021871,Harm Reduction;Nicotine;Public Policy,F01.145.477;D03.132.760.570;D03.383.725.518;I01.655.500.608;I01.880.604.825.608;N03.623.500.608
30021770,,
30021496,Clinical Trial;Treatment Outcome,V03.175.250;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
30021451,Medicaid;Weight Loss,N03.219.521.346.506.564.655;N03.706.615.693;C23.888.144.243.963;G07.345.249.314.120.200.963
30021151,Amyotrophic Lateral Sclerosis;Frontotemporal Lobar Degeneration;Phase Transition,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;G01.645;G02.734
30021145,Friends;Intestines;Microbiota;Phagocytes;T-Lymphocytes,M01.252;A03.556.124;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.733;A15.382.680;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
30020458,,
30020440,,
30020250,"Adolescent;Anemia, Sickle Cell;Anti-Bacterial Agents;Blood Cell Count;Blood Culture;Child;Child, Preschool;Electrolytes;Emergency Service, Hospital;Fever;Hospitalization;Humans;Infant;Practice Patterns, Physicians';Retrospective Studies;Urinalysis;Young Adult",M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.122.085;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E01.370.225.875.185;E05.200.875.185;M01.060.406;M01.060.406.448;D01.248;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C23.888.119.344;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.225.124.810;E01.370.390.810;E05.200.124.810;M01.060.116.815
30020238,"Bone Diseases, Developmental;Bone Transplantation;Child;Child, Preschool;Humans;Infant;Neurofibromatosis 1;Reconstructive Surgical Procedures;Retrospective Studies;Skull;Sphenoid Bone;Surgical Mesh;Vision Disorders",C05.116.099;E02.095.147.725.052;E04.555.130;E04.936.580.052;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;E04.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.781;A02.835.232.781.802;E07.858.708;C10.597.751.941;C11.966;C23.888.592.763.941
30020234,"Adolescent;Adult;Aged;Aged, 80 and over;Attitude to Health;Cleft Lip;Cleft Palate;Controlled Before-After Studies;Emotions;Facial Expression;Humans;Middle Aged;Orthognathic Surgical Procedures;Photography;Postoperative Care;Preoperative Care;Social Perception;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;F01.100.150;N05.300.150;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;E05.318.372.500.812;N05.715.360.330.500.812;N06.850.520.450.500.812;F01.470;E01.370.600.225;F01.145.209.530.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.545.562;E04.555.580.289;E06.645.562;E01.370.350.600;E05.712;E02.760.731.700;E04.604.500;N02.421.585.722.700;E02.760.795;E04.604.750;N02.421.585.795;F02.463.593.752;M01.060.116.815
30019795,,
30019234,"Adult;Analysis of Variance;Brain;Case-Control Studies;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Middle Aged;Motor Activity;Multiple Sclerosis;Postural Balance;Reaction Time;Sensation Disorders;Sex Factors;Multiple Sclerosis;Proprioception;Vision, Ocular",M01.060.116;E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;M01.060.116.630;F01.145.632;G11.427.410.698;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;G11.427.690;G11.561.790.541.595;E05.796.817;F02.830.650;F04.669.817;G11.561.677;C10.597.751;C23.888.592.763;N05.715.350.675;N06.850.490.875;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;F02.830.816.541;G11.561.790.541;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
30019219,Cluster Analysis;Ependymoma,E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;C04.557.465.625.600.380.290;C04.557.470.670.380.290;C04.557.580.625.600.380.290
30018976,Adult;Brain;Electroencephalography;Humans;Neurological Rehabilitation;Transcranial Direct Current Stimulation;Wearable Electronic Devices,M01.060.116;A08.186.211;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;E02.760.169.063.500.477;E02.831.477;H02.403.680.600.750;N02.421.784.511;E02.331.750;F04.570.200.791;F04.669.224.650;E07.305.906
30018328,Adolescent;Attention Deficit Disorder with Hyperactivity;Autism Spectrum Disorder;Bayes Theorem;Brain;Child;Humans;Magnetic Resonance Imaging;Neural Pathways;Neuroimaging;Phenotype;Psychiatric Status Rating Scales;Young Adult,M01.060.057;F03.625.094.150;F03.625.164.113;E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;A08.186.211;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A08.612;E01.370.350.578;E01.370.376.537;E05.629;G05.695;F04.711.513.653;M01.060.116.815
30018038,,
30017963,Chronic Pain;Cystitis;Nociceptive Pain;Patient Reported Outcome Measures;Urinary Bladder,C23.888.592.612.274;C12.777.829.495;C13.351.968.829.495;C23.888.592.612.720;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;A05.810.890
30017801,,
30017732,Aged;Glioblastoma;Radiation,M01.060.116.100;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;G01.750
30017628,Humans;Intensive Care Units;Pediatrics;Radiology;Radiology Information Systems;Remote Consultation;Teaching Rounds,B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;H02.403.670;H02.403.740;N04.452.515.825;L01.178.847.652.550;N04.452.758.849.550;N04.590.374.800.550;I02.358.399.822
30017583,"Neoplasms;Genome, Human;Methylation",C04;G05.360.340.350;G02.111.035.538;G02.607.094.538;G03.059.538
30017553,Aspirin;Cardiovascular Diseases;Platelet Aggregation Inhibitors;Primary Prevention,D02.455.426.559.389.657.410.595.176;C14;D27.505.954.502.780;N02.421.726.758;N06.850.780.680
30017492,"Alcohol Drinking;Humans;Oxygen;Randomized Controlled Trials as Topic;Sleep Apnea, Obstructive;Sleep Apnea Syndromes",F01.145.317.269;B01.050.150.900.649.313.988.400.112.400.400;D01.268.185.550;D01.362.670;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C08.618.085.852.850;C10.886.425.800.750.850;C08.618.085.852;C10.886.425.800.750
30017339,"Blood Donors;Bronchopulmonary Dysplasia;Humans;Infant;Infant, Newborn;Infant, Premature;Infant, Very Low Birth Weight;Transfusion-Related Acute Lung Injury",M01.898.313;C08.381.520.750.500;C16.614.521.125;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;M01.060.703.520.460.600;C08.381.520.500.500;C15.378.962.500;C20.920.500
30017337,"Accidents, Traffic;Adolescent;Adult;Automobile Driving;Caregivers;Cell Phone;Cell Phone Use;Child;Child Restraint Systems;Child, Preschool;Cross-Sectional Studies;Humans;Middle Aged;Parents;Seat Belts;Self Report;Surveys and Questionnaires;United States;Young Adult;Cell Phone;Child Restraint Systems;Distracted Driving;Seat Belts",N06.850.135.392;M01.060.057;M01.060.116;I03.125;M01.085;M01.526.485.200;N02.360.200;L01.178.847.698.300;F01.145.209.186;F01.145.813.537;M01.060.406;E07.490.249;E07.700.175;J01.637.708.175;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E07.700.800;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;M01.060.116.815;L01.178.847.698.300;E07.490.249;E07.700.175;J01.637.708.175;I03.125.474;E07.700.800
30016992,Autism Spectrum Disorder;Brain;Carrier Proteins;Gene Regulatory Networks;Humans;Phosphoprotein Phosphatases;Transcriptome;Autism Spectrum Disorder;Gene Expression,F03.625.164.113;A08.186.211;D12.776.157;G05.360.080.689.360;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.352.650.625;G02.111.873.750;G05.297.700.750;G05.360.920;F03.625.164.113;G05.297
30016425,,
30016326,"Bacteroidaceae;Batch Cell Culture Techniques;Bioreactors;Colon;Computational Biology;Fatty Acids, Volatile;Feces;Firmicutes;Gastrointestinal Microbiome;Humans;Intestinal Mucosa;Microbial Consortia;Models, Biological;RNA, Ribosomal, 16S;Sequence Analysis, DNA",B03.140.094;B03.440.425.410.194;E05.481.500.249.124;E07.115;J01.897.120.115;A03.556.124.526.356;A03.556.249.249.356;H01.158.273.180;L01.313.124;D10.251.400;A12.459;B03.353;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.369;A10.615.550.444;G06.591.750;G16.500.275.157.049.100.500.750;N06.230.124.049.100.500.500;E05.599.395;D13.444.735.686.670;E05.393.760.700
30015704,,
30015008,alpha-Amylases;Circadian Rhythm;Sexual Behavior;Sympathetic Nervous System;Young Adult,D08.811.277.450.066.050;G07.180.562.190;F01.145.802;A08.800.050.800;M01.060.116.815
30014599,"Animals;Clustered Regularly Interspaced Short Palindromic Repeats;Food Microbiology;Genetic Variation;Humans;Livestock;Pennsylvania;Salmonella Infections;Salmonella Infections, Animal;Salmonella enterica;Zoonoses;Clustered Regularly Interspaced Short Palindromic Repeats;Cattle;Poultry",B01.050;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;H01.158.273.540.274.332;J01.576.423.850.730.500.249.300;N06.850.425.200;N06.850.460.400.300;N06.850.601.500.249.300;G05.365;B01.050.150.900.649.313.988.400.112.400.400;B01.050.050.116.500;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C01.252.400.310.821;C01.252.400.310.821.706;C22.812;B03.440.450.425.800.200;B03.660.250.150.710.160;C01.908;C02.968;C03.908;C22.969;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;B01.050.150.900.649.313.500.380.271;B01.050.050.116.625;B01.050.150.900.248.690;G07.203.300.600.750;J02.500.600.750
30014584,"Adolescent;Antifungal Agents;Child;Combined Modality Therapy;Debridement;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Immunocompromised Host;Immunosuppressive Agents;Lung Diseases, Fungal;Mucormycosis;Opportunistic Infections;Mucormycosis;Stem Cell Transplantation",M01.060.057;D27.505.954.122.136;M01.060.406;E02.186;E04.176;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;G12.470;D27.505.696.477.656;C01.703.534;C08.381.472;C08.730.435;C01.703.980.600;C01.539.597;C02.597;C03.684;C01.703.980.600;E02.095.147.500.500;E04.936.225.687
30014376,"Adult;Clinical Competence;Competency-Based Education;Education, Medical;Education, Medical, Graduate;Educational Measurement;Feasibility Studies;Humans;Interdisciplinary Communication;Maternal-Child Health Centers;Middle Aged;Program Evaluation;Quality Improvement;Reproducibility of Results",M01.060.116;I02.399.630.210;N04.761.210;N05.715.175;I02.158.210;I02.358.399;I02.358.337.350;I02.358.399.350;I02.399;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;N02.278.035.310;M01.060.116.630;E05.337.820;N04.761.685;N05.715.360.650;J01.293.754;N04.761.744;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
30014112,,
30012828,Echocardiography;Hypoplastic Left Heart Syndrome;Mortality;Risk Factors,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
30012350,"Academies and Institutes;Animals;Databases, Chemical;Haptens;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D23.050.550.480;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
30012349,"Leukemia, Myeloid, Acute;Ketosteroids;Polycystic Ovary Syndrome;Prostaglandins",C04.557.337.539.275;D04.210.500.578;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;D10.251.355.255.550;D23.469.050.175.725
30011878,Genomics;Reference Standards,H01.158.273.180.350;H01.158.273.343.350;E05.978.808
30011249,Alzheimer Disease;Longitudinal Studies,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500
30011058,Peer Review;Publications,F01.829.316.549;I01.880.604.640;N03.706.700;L01.178.682
30010897,,
30010318,Molecular Dynamics Simulation,E05.599.595.500;G02.111.570.895;L01.224.160.500
30009926,Education;Positive-Pressure Respiration,I02;E02.041.625.790;E02.880.820.790
30009819,"Algorithms;Consensus;Diagnostic Techniques, Digestive System;Eosinophilic Esophagitis;Gastroenterology;Humans;Predictive Value of Tests;Prognosis;Proton Pump Inhibitors;Diagnosis;Eosinophilic Esophagitis",G17.035;L01.224.050;F01.829.316.068;F02.463.785.373.433;E01.370.372;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;H02.403.429.405;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;D27.505.519.389.848;E01;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356
30009615,Immunization;Measles,E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;C02.782.580.600.500.500
30009566,Li-Fraumeni Syndrome;Communication;Genetic Testing,C04.700.600;C16.320.700.600;C18.452.284.520;F01.145.209;L01.143;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221
30008715,Clone Cells;Immunoglobulins,A11.251.353;D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
30008316,"Cell Differentiation;Cell Line;Early Growth Response Protein 1;Early Growth Response Protein 2;Enhancer Elements, Genetic;Humans;Monocytes;Myeloid Progenitor Cells;Repressor Proteins;Myelopoiesis",G04.152;A11.251.210;D12.776.260.158.500;D12.776.460.525.500;D12.776.930.213.500;D12.776.260.158.750;D12.776.460.525.750;D12.776.930.213.750;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A11.148.378.590;A11.627.635;A11.872.378.590;A15.378.316.378.590;D12.776.260.703;D12.776.930.780;G04.152.825.597.750;G09.188.343.597.750
30008129,"Anemia;Renal Insufficiency, Chronic;Hemoglobins;Vitamin D",C15.378.071;C12.777.419.780.750;C13.351.968.419.780.750;D12.776.124.400;D12.776.422.316.762;D04.210.500.812.768
30008034,Fetus;Lung;Magnetic Resonance Imaging,A16.378;A04.411;E01.370.350.825.500
30007916,,
30007867,DiGeorge Syndrome;Smell;Psychotic Disorders;Schizophrenia,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F02.830.816.643;G11.561.790.643;F03.700.675;F03.700.750
30006913,Hyper-IgM Immunodeficiency Syndrome;Common Variable Immunodeficiency,C15.378.147.333.249;C16.320.413;C20.673.430.249;C20.673.330
30006586,"Genetic Testing;Genetics, Medical;Genomics;Humans;Neurofibromatosis 1;Neurofibromin 1;United States",E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.343.385.500;H02.403.350;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;D12.644.360.325.150.500.460;D12.776.476.325.150.500.460;D12.776.624.776.610;Z01.107.567.875
30006480,"Animals;Cell Respiration;Cells, Cultured;Fatty Acids;Gene Expression;Glucose;Glutamine;Interleukin-4;Macrophage Activation;Macrophages;Mice, Inbred C57BL;Mice, Knockout;PPAR gamma;Rosiglitazone;Thiazolidinediones;PPAR gamma;Glutamine;Macrophages;Metabolism;Rosiglitazone",B01.050;G03.197;G04.270;A11.251;D10.251;G05.297;D09.947.875.359.448;D12.125.068.330;D12.125.095.461;D12.125.154.424;D12.644.276.374.465.186;D12.776.467.374.465.178;D23.529.374.465.186;G12.287.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.826.239.588;D02.886.675.933.500;D03.383.129.708.933.500;D02.886.675.933;D03.383.129.708.933;D12.776.826.239.588;D12.125.068.330;D12.125.095.461;D12.125.154.424;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;G03;D02.886.675.933.500;D03.383.129.708.933.500
30006470,"Fetoscopy;Fetus;Humans;Infant, Newborn;Postoperative Complications;Pregnancy;Spina Bifida Cystica;Treatment Outcome;Fetoscopy;Meningomyelocele;Spina Bifida Cystica",E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;A16.378;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C23.550.767;G08.686.784.769;C10.500.680.800.730;C16.131.666.680.800.730;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;C10.500.680.610;C16.131.666.680.610;C10.500.680.800.730;C16.131.666.680.800.730
30003986,"Adolescent;Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Biopsy;Cross-Sectional Studies;Diagnostic Errors;Epidermis;Follow-Up Studies;Humans;Hutchinson's Melanotic Freckle;MART-1 Antigen;Melanocytes;Melanoma;Middle Aged;Mohs Surgery;Neoplasm Invasiveness;Neoplasm Recurrence, Local;Neoplasm Staging;Precancerous Conditions;Retrospective Studies;Skin Neoplasms;T-Lymphocytes;Young Adult;Mohs Surgery;Melanoma",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D23.050.285;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.354;N02.421.450.280;A10.272.497;A17.815.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510.385;C04.557.580.625.650.510.385;C04.557.665.510.385;D12.776.624.301.750;D23.050.285.439.750;A11.409.750;A11.436.613;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;E04.494.575;E04.680.275.580;C04.697.645;C23.550.727.645;C04.697.655;C23.550.727.655;E01.789.625;C04.834;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.805;C17.800.882;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;M01.060.116.815;E04.494.575;E04.680.275.580;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
30003873,"Amyotrophic Lateral Sclerosis;Brain;C9orf72 Protein;DNA-Binding Proteins;Frontotemporal Dementia;Heterogeneous-Nuclear Ribonucleoproteins;Humans;Mutagenesis, Insertional;Polypyrimidine Tract-Binding Protein;RNA Splicing;RNA-Binding Proteins;Biochemistry;Frontotemporal Dementia;Humans;Medicine",C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;A08.186.211;D12.776.141;D12.776.260;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;D12.776.157.725.813.750;D12.776.664.962.813.750;B01.050.150.900.649.313.988.400.112.400.400;E05.393.420.601.550;G05.365.590.575;G05.558.550;D12.776.157.725.829.250;D12.776.664.962.829.250;G02.111.760.700;G03.839.700;G05.308.700.700;D12.776.157.725;D12.776.664.962;H01.158.201;H01.181.122;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;B01.050.150.900.649.313.988.400.112.400.400;H02.403
30003572,"Adenomyoepithelioma;Biomarkers, Tumor;Breast;Breast Neoplasms;Carcinoma, Adenoid Cystic;Gene Rearrangement;Humans;Middle Aged;Proto-Oncogene Proteins c-myb;Retrospective Studies;Adenomyoepithelioma;Carcinoma, Adenoid Cystic;Breast",C04.557.435.108;D23.101.140;A01.236;C04.588.180;C17.800.090.500;C04.557.470.200.025.220;G05.344;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D12.776.260.675;D12.776.624.664.700.188;D12.776.930.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.435.108;C04.557.470.200.025.220;A01.236
30003481,"Economics, Behavioral;Clinical Trial;Exercise;Smartphone;Weight Loss",F04.096.628.286;N03.219.215;V03.175.250;G11.427.410.698.277;I03.350;L01.224.230.260.550.500.500;C23.888.144.243.963;G07.345.249.314.120.200.963
30003374,Prostatic Neoplasms;Mass Screening,C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
30003216,,
30003126,Bowen's Disease;HIV;Epidermodysplasia Verruciformis;Papillomaviridae,C04.557.470.200.400.130;C04.557.470.700.400.130;B04.820.650.589.650.350;C02.256.650.810.345;C02.825.810.260;C02.928.914.345;C17.800.838.790.810.260;B04.280.210.655;B04.613.204.655
30001793,"Aged;Aged, 80 and over;Aging;Humans;Olfaction Disorders;Severity of Illness Index;Smell;Taste;Taste Disorders;Geriatrics;Taste;Smell;Psychophysics;Smell;Taste",M01.060.116.100;M01.060.116.100.080;G07.345.124;B01.050.150.900.649.313.988.400.112.400.400;C10.597.751.600;C23.888.592.763.550;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F02.830.816.643;G11.561.790.643;F02.830.816.724;G11.561.790.724;C10.597.751.861;C23.888.592.763.861;H02.403.355;F02.830.816.724;G11.561.790.724;F02.830.816.643;G11.561.790.643;E01.370.685;F04.096.753;F02.830.816.643;G11.561.790.643;F02.830.816.724;G11.561.790.724
30001534,"Dermatitis, Atopic;Food Hypersensitivity;Humans;Hydrolysis;Infant;Infant Formula;Infant, Newborn;Risk Factors;Whey Proteins;Dermatitis, Atopic;Growth;Infant",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C20.543.480.370;B01.050.150.900.649.313.988.400.112.400.400;G02.380;M01.060.703;G07.203.100.712.249;G07.203.300.525.350.500;G07.203.300.525.500.500;J02.200.712.249;J02.500.525.350.500;J02.500.525.500.500;M01.060.703.520;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.256.626.816;G07.203.300.350.525.520.500;G07.203.300.350.525.760.500;G07.203.300.428.626.500;J02.500.350.525.520.500;J02.500.350.525.760.500;J02.500.428.626.500;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;G07.345.249;M01.060.703
30001329,"Adenosine Triphosphatases;Animals;Cell Cycle Proteins;Cell Line;Cell Nucleus;Chromosomal Proteins, Non-Histone;Chromosomes;DNA-Binding Proteins;Drosophila;Drosophila Proteins;Genomic Instability;Interphase;Multiprotein Complexes",D08.811.277.040.025;B01.050;D12.776.167;A11.251.210;A11.284.430.106;A11.284.430.214.190.875.117;D12.776.660.235;D12.776.664.235;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;D12.776.260;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;C23.550.362;G05.365.590.335;G05.370;G04.144.500;D05.500
30001157,Adenosine Monophosphate;Energy Metabolism;Oxygen,D03.633.100.759.646.138.180;D13.695.667.138.180;D13.695.827.068.180;G03.295;D01.268.185.550;D01.362.670
29998307,,
29998299,,
29998286,,
29998189,Smoking Cessation;Tobacco Use Disorder;Varenicline,F01.145.488.732;C25.775.912;F03.900.912;D03.633.100.079.900;D03.633.100.857.942
29998181,Dermatomyositis;Lacosamide,C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;D02.065.064.416;D02.241.081.018.110.432
29998102,Glomus Tumor,C04.557.645.350
29997963,"Aortic Valve Stenosis;Hypertension, Pulmonary",C14.280.484.150;C14.280.955.249;C08.381.423
29997599,Adsorption;Bacteria;Fungi;Yeasts,G01.030;G02.020;B03;B01.300;B01.300.930
29997569,Biomarkers;Thoracic Surgery;Cardiopulmonary Bypass;Brain Ischemia;Neuroprotection;Systems Biology,D23.101;H02.403.810.803;E04.292.413;C10.228.140.300.150;C14.907.253.092;G11.561.645;H01.158.273.180.800
29997224,,
29997218,"B-Lymphocytes;Cell Cycle Proteins;Cell Nucleus;Cell Proliferation;Cell Transformation, Viral;Cyclin D2;Epstein-Barr Virus Nuclear Antigens;Gene Expression Regulation;Herpesvirus 4, Human;Humans;Herpesvirus 4, Human;Cell Proliferation;Cyclin D2",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D12.776.167;A11.284.430.106;A11.284.430.214.190.875.117;G04.161.750;G07.345.249.410.750;C04.697.098.500.160;C23.550.727.098.500.160;G06.920.143;D12.644.360.262.150.200;D12.776.167.218.150.200;D12.776.476.262.150.200;D23.050.290.249;D23.050.327.300;G05.308;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;G04.161.750;G07.345.249.410.750;D12.644.360.262.150.200;D12.776.167.218.150.200;D12.776.476.262.150.200
29997120,"Adult;Aged;Aged, 80 and over;Asymptomatic Diseases;Humans;Middle Aged;Multiplex Polymerase Chain Reaction;Nasopharynx;New York City;Prevalence;Respiratory Tract Infections;Seasons;Virus Diseases;Virus Shedding;Viruses;Young Adult;Asymptomatic Infections;Population Health",M01.060.116;M01.060.116.100;M01.060.116.100.080;C23.550.291.187;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.393.620.500.487;A04.623.557;A14.724.557;Z01.107.567.875.350.530.530;Z01.107.567.875.500.530.530;Z01.433.741;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C01.539.739;C08.730;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525;C02;G07.925;B04;M01.060.116.815;C23.550.291.187.500;N01.400.548
29997110,Granulomatosis with Polyangiitis;Infection,C08.381.483.950;C14.907.940.897.249.750;C20.111.193.875;C01.539
29997041,"Adult;Asian Continental Ancestry Group;Case-Control Studies;DNA, Mitochondrial;Diabetes Mellitus, Type 2;Far East;Haplotypes;Humans;Metabolic Syndrome;Middle Aged;Mitochondria;Pedigree;Phenotype;Polymorphism, Single Nucleotide;Mitochondria;Obesity;DNA, Mitochondrial",M01.060.116;M01.686.508.200;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D13.444.308.283.225;C18.452.394.750.149;C19.246.300;Z01.252.474;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500.570;C18.452.625;M01.060.116.630;A11.284.430.214.190.875.564;A11.284.835.626;E05.393.673;G05.695;G05.365.795.598;A11.284.430.214.190.875.564;A11.284.835.626;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D13.444.308.283.225
29996925,Magnetic Resonance Imaging;Sacroiliitis,E01.370.350.825.500;C05.550.114.854
29996066,"Genome, Viral;Virus Replication",G05.360.340.358.840;G06.920.925
29995861,"Animals;Autoimmunity;CRISPR-Cas Systems;Cells, Cultured;Cellular Reprogramming;Gene Editing;Genome, Human;Humans;Interleukin-2 Receptor alpha Subunit;Mice;Neoplasm Transplantation;Protein Engineering;Receptors, Antigen, T-Cell;T-Lymphocytes",B01.050;G12.450.192;G05.308.203.374.394;A11.251;G04.152.262;G05.135;E05.393.420.270;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.852.420.320.500;B01.050.150.900.649.313.992.635.505.500;E05.624;E05.393.420.601;D12.776.543.750.705.816.824;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29995837,,
29995695,"Aged;Aged, 80 and over;Chronic Disease;General Surgery;Humans;Medicare;Multimorbidity;United States",M01.060.116.100;M01.060.116.100.080;C23.550.291.500;H02.403.810.300;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N05.715.350.225.500;N06.850.490.687.500;Z01.107.567.875
29995484,,
29994983,,
29993286,,
29992966,"Adsorption;Animals;Drug Carriers;Drug Delivery Systems;Erythrocytes;Humans;Lung;Lung Diseases;Mice, Inbred C57BL;Nanoparticles;Rats;Swine",G01.030;G02.020;B01.050;D26.255.260;E02.319.300.380;E02.319.300;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.381;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;J01.637.512.600;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.500.880
29992946,"Animals;Cell Differentiation;Cell Line;Diabetes Mellitus;Drug Discovery;Gene Expression Profiling;Human Embryonic Stem Cells;Humans;Hypoglycemic Agents;Insulin Secretion;Insulin-Secreting Cells;Mice, SCID;Mutation;Pyrazoles;Quinolines;Transcription Factors;Transplantation, Heterologous",B01.050;G04.152;A11.251.210;C18.452.394.750;C19.246;E05.295;H01.158.703.007.675;H01.181.466.675;E05.393.332;A11.872.700.250.750;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;B01.050.150.900.649.313.992.635.505.500.550.780;G05.365.590;D03.383.129.539;D03.633.100.810;D12.776.930;E04.936.764
29992710,Neoplasms;Enzymes;Proteins,C04;D08.811;D12.776
29992429,Patient Transfer;Heart Failure;Patient Outcome Assessment;Qualitative Research,E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624;C14.280.434;N04.761.559.590.399;N05.715.360.575.575.399;H01.770.644.241.850
29992271,"Amino Acid Sequence;Cell Membrane;Computer-Aided Design;Drug Design;Humans;Integrin alpha5beta1;Micelles;Peptides;Protein Conformation, alpha-Helical;Protein Domains",G02.111.570.060;L01.453.245.667.060;A11.284.149;L01.224.108.150;L01.296.110.150;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550.625.379;D12.776.543.550.625.379;D12.776.543.750.705.408.530.750;D12.776.543.750.705.408.850.349;D12.776.543.750.705.675.460;D12.776.543.750.705.876.374;D05.374;D26.255.560;D12.644;G02.111.570.820.709.600.020;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500
29992253,,
29992095,"DNA;Sequence Analysis, DNA;Polymorphism, Restriction Fragment Length",D13.444.308;E05.393.760.700;G05.365.795.595
29991493,"Animals;Cell Nucleus;Enzyme Therapy;Enzymes;Gene Expression Regulation;Humans;Mitochondria;Models, Biological;Multiprotein Complexes",B01.050;A11.284.430.106;A11.284.430.214.190.875.117;E02.319.353;D08.811;G05.308;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;E05.599.395;D05.500
29991439,"Sleep Apnea, Obstructive;Polysomnography",C08.618.085.852.850;C10.886.425.800.750.850;E01.370.520.625
29990593,Bundle-Branch Block;Cardiac Resynchronization Therapy;Cardiac Resynchronization Therapy Devices;Feasibility Studies;Hemodynamics;Humans,C14.280.067.558.323;C14.280.123.500.323;C23.550.073.425.100;E02.331.200.500;E07.305.250.750.500;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400
29990560,Brain;Emotions;Happiness;Humans;Magnetic Resonance Imaging;Photic Stimulation;Sadness;Young Adult;Cerebellum;Emotions;Parietal Lobe;Magnetic Resonance Imaging,A08.186.211;F01.470;F01.470.516;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.723.729;F01.470.933;M01.060.116.815;A08.186.211.132.810.428.200;F01.470;A08.186.211.200.885.287.500.670;E01.370.350.825.500
29990498,Glioblastoma;Glioma;Survival,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;I03.784
29989842,"Animals;Forkhead Transcription Factors;Humans;Neoplasms;Species Specificity;T-Lymphocytes, Regulatory;Medical Oncology;Immunotherapy",B01.050;D12.776.260.950.249;D12.776.930.977.249;B01.050.150.900.649.313.988.400.112.400.400;C04;G16.824;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;H02.403.429.515;E02.095.465.425
29989040,Renal Dialysis,E02.870.300;E02.912.800
29988980,"Renal Insufficiency, Chronic;Renal Dialysis;Inflammation",C12.777.419.780.750;C13.351.968.419.780.750;E02.870.300;E02.912.800;C23.550.470
29988648,Uniparental Disomy,C23.550.210.645.890;G05.365.590.175.935
29987620,Glucose-6-Phosphatase;Hexokinase;Ovarian Neoplasms,D08.811.277.352.650.225;D08.811.913.696.620.300;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
29987318,,
29987113,Genetic Techniques;Genetic Variation;Genetics;Genome-Wide Association Study;Humans,E05.393;G05.365;H01.158.273.343;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400
29987102,Adolescent;Blood Pressure;Cardiovascular Diseases;Hypertension;Vascular Stiffness,M01.060.057;E01.370.600.875.249;G09.330.380.076;C14;C14.907.489;G09.330.940
29986742,"Aged;Aged, 80 and over;Dual-Specificity Phosphatases;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Mitogen-Activated Protein Kinase Phosphatases;Organic Anion Transporters;Polymorphism, Single Nucleotide;Supranuclear Palsy, Progressive",M01.060.116.100;M01.060.116.100.080;D08.811.277.352.650.625.225;D08.811.277.352.650.775.250;D08.811.641.755;D12.644.360.268;D12.776.476.268;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D08.811.277.352.650.587;D12.644.360.445;D12.776.476.445;D12.776.157.530.450.074.500;D12.776.543.585.450.074.500;G05.365.795.598;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690
29986726,Autophagy;Pancreatic Neoplasms,G04.146.399;G04.417.350.091;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29985836,"Adolescent;Child;Child, Preschool;Decompression, Surgical;Follow-Up Studies;Graves Ophthalmopathy;Humans;Neuroimaging;Neurosurgical Procedures;Ophthalmologic Surgical Procedures;Orbit;Retrospective Studies;Time Factors;Treatment Outcome",M01.060.057;M01.060.406;M01.060.406.448;E04.188;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C11.270.240;C11.675.349.500.500;C16.320.347;C19.874.283.605.500;C19.874.397.370.500;C20.111.555.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;E04.525;E04.540;A02.835.232.781.324.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29985697,Medicare;Physicians,N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.526.485.810;N02.360.810
29985478,,
29985301,,
29985255,,
29984864,,
29984114,Biofilms;Fungi;Microbiota,A20.593;G06.120;B01.300;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29983992,Adolescent;Anorexia Nervosa,M01.060.057;F03.400.125
29983884,,
29983355,Cystic Fibrosis;Diet,C06.689.202;C08.381.187;C16.320.190;C16.614.213;G07.203.650.240
29983323,Hydrocephalus;Hydrocephalus;Genetic Association Studies;Neural Stem Cells,C10.228.140.602;C10.228.140.602;E05.393.385;A11.872.653
29982694,,
29982606,,
29982511,,
29981842,Autophagy;Mitochondrial Degradation;Motor Neuron Disease,G04.146.399;G04.417.350.091;G04.599.500;C10.574.562;C10.668.467
29981179,Liver Transplantation,E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
29980957,Adolescent;Adolescent Behavior;Adolescent Development;Child;Delay Discounting;Humans;Impulsive Behavior;Risk-Taking;Sensation;Substance-Related Disorders;Thinking;Adolescent;Impulsive Behavior;Risk-Taking,M01.060.057;F01.145.022;F01.525.049;G07.345.374.500;M01.060.406;F02.463.785.373.346.700;B01.050.150.900.649.313.988.400.112.400.400;F01.145.527;F01.145.722;F02.830.816;G11.561.790;C25.775;F03.900;F02.463.785;M01.060.057;F01.145.527;F01.145.722
29980896,"Apoptosis;Endoplasmic Reticulum Stress;Myocardial Ischemia;Ischemic Preconditioning, Myocardial",G04.146.160;G04.434;C14.280.647;C14.907.585;E02.592.325;E05.516.325
29980641,,
29980612,,
29980451,"Abdominal Muscles;Abdominal Wall;Adult;Aged;Cohort Studies;Elasticity Imaging Techniques;Feasibility Studies;Humans;Image Interpretation, Computer-Assisted;Middle Aged;Pilot Projects;Prospective Studies;Reproducibility of Results;Sensitivity and Specificity;Young Adult;Elasticity Imaging Techniques",A02.633.567.050;A01.923.047.050;M01.060.116;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.350.850.270;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116.815;E01.370.350.850.270
29980396,Echocardiography;Hypoplastic Left Heart Syndrome;Norwood Procedures,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E04.100.376.724;E04.928.220.560
29980375,Adolescent;Chronic Disease;Communication;Dialysis;Focus Groups;Pediatrics;Qualitative Research;Transplants,M01.060.057;C23.550.291.500;F01.145.209;L01.143;E05.196.353;G02.186;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;H02.403.670;H01.770.644.241.850;A01.941
29980290,"Follow-Up Studies;Humans;Infant;Infant, Newborn;Intensive Care Units, Neonatal;Intubation, Intratracheal;Laryngoscopy;Retrospective Studies;Video Recording",E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390.380;E02.041.500;E02.585.578;E05.497.578;E01.370.386.460;E01.370.388.250.525;E04.502.250.525;E04.580.373;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;L01.280.960
29980277,"Esophagitis;Rhinitis, Allergic;Antigens;Food Hypersensitivity",C06.405.117.620;C06.405.205.663;C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443;D23.050;C20.543.480.370
29980239,Immunotherapy;T-Lymphocytes;Triple Negative Breast Neoplasms,E02.095.465.425;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C04.588.180.788;C17.800.090.500.788
29980156,,
29979882,,
29979831,"Cytokinesis;Protein Processing, Post-Translational",G04.144.220.250;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
29979673,Adult;Brain;Brain Mapping;Cognition;Humans;Machine Learning;Magnetic Resonance Imaging;Nerve Net;Perception;Stroop Test;Task Performance and Analysis;Young Adult,M01.060.116;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;E01.370.350.825.500;A08.511;F02.463.593;F04.711.513.703;F02.784.412.846;F02.784.692.746;F02.808.600;M01.060.116.815
29978755,"Adolescent;Analgesics, Opioid;Commerce;Humans;Incidence;Narcotics;Opioid-Related Disorders;Oxycodone;Pain;Street Drugs;United States;Young Adult;Incidence;Abuse-Deterrent Formulations",M01.060.057;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;J01.219;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D27.505.696.277.600;D27.505.696.663.850.014.760;D27.505.954.427.040.550;D27.505.954.427.210.600;C25.775.675;F03.900.675;D03.132.577.249.562.149.575;D03.605.497.607.204.650;D03.633.400.686.607.204.650;D04.615.723.795.576.149.575;C23.888.592.612;F02.830.816.444;G11.561.790.444;D26.878;Z01.107.567.875;M01.060.116.815;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D26.255.075;D27.505.696.034;D27.505.696.663.850.007;D27.505.954.427.005;E02.319.300.127;E05.916.250.500
29978272,,
29977955,Hepacivirus;Insurance,B04.450.380;B04.820.250.475;N03.219.521.576
29977663,Apolipoproteins E;Alzheimer Disease;Frontotemporal Lobar Degeneration;Parkinson Disease,D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29977061,,
29976600,"Antihypertensive Agents;Blood Pressure Monitoring, Ambulatory;Cohort Studies;Comorbidity;Masked Hypertension;Prevalence;Renal Insufficiency, Chronic;White Coat Hypertension;Blood Pressure;Renal Insufficiency, Chronic;Diabetes Mellitus;Ethnic Groups;Hypertension;Kidney;Proteinuria",D27.505.954.411.162;E01.370.370.140.100;E01.370.520.500.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;C14.907.489.861;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C12.777.419.780.750;C13.351.968.419.780.750;C14.907.489.907;E01.370.600.875.249;G09.330.380.076;C12.777.419.780.750;C13.351.968.419.780.750;C18.452.394.750;C19.246;M01.686.754;N01.224.317;C14.907.489;A05.810.453;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
29976387,,
29975748,"Health Services Accessibility;Hospitals, Teaching;Hospitals, Veterans;Humans;Travel;United States;United States Department of Veterans Affairs",N04.590.374.350;N05.300.430;N02.278.020.300;N02.278.421.639;N02.278.421.510.180.400;B01.050.150.900.649.313.988.400.112.400.400;I03.883;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700
29975622,Benzodiazepines;Fentanyl;Olanzapine;Pharmacokinetics,D03.633.100.079.080;D03.383.621.265;D03.633.100.079.080.738;G03.787;G07.690.725
29974518,,
29974501,"Emergency Service, Hospital;Exanthema;Fever;Hospitalization;Humans;Infant;Infant, Newborn;Practice Patterns, Physicians';Retrospective Studies",N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C17.800.257;C23.888.119.344;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29974044,Eosinophilic Esophagitis,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356
29973348,Child;Pneumonia;Ultrasonography,M01.060.406;C08.381.677;C08.730.610;E01.370.350.850
29972754,"Adoptive Transfer;Antigens, CD19;Genetic Engineering;Humans;Neoplasms;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Remission Induction;T-Lymphocytes",E02.095.465.425.400.330.050;E05.478.550.520.050;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;E05.393.420;B01.050.150.900.649.313.988.400.112.400.400;C04;D12.776.543.750.705.816.824;D12.776.828.300;E02.860;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29972635,Bronchopulmonary Dysplasia;Growth and Development;Tracheostomy,C08.381.520.750.500;C16.614.521.125;G07.345;E02.041.750;E04.579.935;E04.580.900;E04.928.780
29972246,"Adult;Health Surveys;Hepatitis C;Humans;Infectious Disease Transmission, Vertical;Ohio;Practice Guidelines as Topic;Pregnancy;Pregnancy Complications, Infectious;Pregnant Women;Prenatal Diagnosis;Prevalence;Public Health Surveillance;Risk Factors;Information Storage and Retrieval;Hepatitis C;Pregnancy",M01.060.116;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;N06.850.310.425;Z01.107.567.875.075.512;Z01.107.567.875.350.540;Z01.107.567.875.510.540;N04.761.700.350.650;N05.700.350.650;G08.686.784.769;C01.539.674;C13.703.700;M01.975.807;E01.370.378.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.980.438.700.324;N05.715.360.300.800.438.625.324;N06.850.520.308.980.438.700.324;N06.850.780.675.487;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;L01.313.500.750.280;L01.470;C02.440.440;C02.782.350.350;C06.552.380.705.440;G08.686.784.769
29971940,Brain;Connectome;Executive Function;Humans;Nerve Net;Neurosciences;Magnetic Resonance Imaging,A08.186.211;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;A08.511;H01.158.610;E01.370.350.825.500
29971646,"Algorithms;Alzheimer Disease;Frontotemporal Dementia;Genetic Association Studies;Genetic Counseling;Genetic Predisposition to Disease;Genetic Testing;Genomics;Humans;Practice Patterns, Physicians'",G17.035;L01.224.050;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;E05.393.385;H01.158.273.343.385.500.384;N02.421.308.400;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;N04.590.374.577;N05.300.625
29971591,Berlin;Blood Gas Analysis;Child;Humans;Lung;Prospective Studies;Respiratory Insufficiency;Child,Z01.433.128;Z01.542.315.182;E01.370.225.124.100.100;E01.370.386.700.100;E05.200.124.100.100;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C08.618.846;M01.060.406
29971555,"Abdomen;Child;Child, Preschool;Contrast Media;Humans;Infant;Infant, Newborn;Liver;Magnetic Resonance Imaging;Neck;Pelvis;Spleen;Tomography, X-Ray Computed;Ultrasonography;Urogenital System;Vascular Neoplasms",A01.923.047;M01.060.406;M01.060.406.448;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A03.620;E01.370.350.825.500;A01.598;A01.923.600;A10.549.700;A15.382.520.604.700;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850;A05;C04.588.839.750;C14.907.936
29971438,"Adolescent;Adult;Aged;Child;Color Vision Defects;Cone Opsins;Cross-Sectional Studies;Electroretinography;Eye Diseases, Hereditary;Follow-Up Studies;Humans;Middle Aged;Mutation;Orphan Nuclear Receptors;Retinal Cone Photoreceptor Cells;Retinal Degeneration;Retrospective Studies;Vision Disorders;Visual Acuity;Visual Field Tests;Visual Fields;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;C10.597.751.941.256;C11.270.151.500;C11.966.256;C23.888.592.763.941.256;D12.776.306.466.249;D23.767.930.750.249;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.380.225;E01.370.405.270;C11.270;C16.320.290;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;D12.776.260.643;D12.776.826.209;D12.776.930.645;A08.675.650.850.625.670.100;A08.675.650.915.937.670.100;A08.800.950.937.670.100;A09.371.729.831.625.670.100;A11.671.650.850.625.670.100;A11.671.650.915.937.670.100;C11.270.612;C11.768.585;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.597.751.941;C11.966;C23.888.592.763.941;E01.370.380.850.950;F02.463.593.932.901;G14.940;E01.370.380.850.962;F02.463.593.932.934;G14.950;M01.060.116.815
29971425,,
29971329,,
29971090,Proteomics,H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
29970972,,
29970385,,
29969889,"Animal Experimentation;Apoptosis;Brain Injuries;Cognitive Dysfunction;Infant;Infant, Newborn;Anesthesia",E05.017;H01.770.644.053;G04.146.160;C10.228.140.199;C10.900.300.087;C26.915.300.200;F03.615.250.700;M01.060.703;M01.060.703.520;E03.155
29969537,Trypanosoma brucei brucei;Microtubules,B01.268.475.868.887.080;A11.284.430.214.190.750.602
29969439,,
29968802,,
29968489,"Art;Alleles;DNA, Mitochondrial",K01.093;G05.360.340.024.340.030;D13.444.308.283.225
29968368,"China;Hearing Loss;Meta-Analysis;Infant, Newborn",Z01.252.474.164;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;V03.600;M01.060.703.520
29967939,Apolipoproteins E;Alzheimer Disease;Amyloid;Neuropathology;Sex Characteristics,D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;H01.158.610.184;H02.403.600.250;H02.403.650.375;G08.686.815
29967758,Genotype;Mitochondria,G05.380;A11.284.430.214.190.875.564;A11.284.835.626
29967609,Cytokines;Immunotherapy;Neuroblastoma;Safety,D12.644.276.374;D12.776.467.374;D23.529.374;E02.095.465.425;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;N06.850.135.060.075
29967039,"Adult;Blood Pressure;Case-Control Studies;DNA;Europe;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Incidence;Odds Ratio;Phenotype;Polymorphism, Single Nucleotide;Pre-Eclampsia;Pregnancy;United States;Genetic Association Studies;Hypertension;Population Control;Pre-Eclampsia;Pregnancy",M01.060.116;E01.370.600.875.249;G09.330.380.076;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D13.444.308;Z01.542;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G05.695;G05.365.795.598;C13.703.395.249;G08.686.784.769;Z01.107.567.875;E05.393.385;C14.907.489;I01.240.600.650;N01.224.625.650;N06.850.505.400.700.650;C13.703.395.249;G08.686.784.769
29966789,"Aged;Craniotomy;Databases, Factual;Elective Surgical Procedures;Humans;Middle Aged;Mortality;Perioperative Period;Population Surveillance;Postoperative Complications;Predictive Value of Tests;Mortality",M01.060.116.100;E04.525.190;L01.313.500.750.300.188.400;L01.470.750.750;E04.249;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E04.614;N02.421.585.753;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;C23.550.767;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
29966477,Alzheimer Disease,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
29965835,,
29964274,,
29964043,"Adult;Aged;Anti-Inflammatory Agents;Colitis, Ulcerative;Double-Blind Method;Drug Administration Schedule;Drug Therapy, Combination;Gastrointestinal Agents;Humans;Kaplan-Meier Estimate;Methotrexate;Middle Aged;Prospective Studies;Recurrence;Remission Induction;Steroids;Time Factors;Treatment Outcome;United States;Inflammatory Bowel Diseases",M01.060.116;M01.060.116.100;D27.505.954.158;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.283;E02.319.310;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;D03.633.100.733.631.192.500;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C23.550.291.937;E02.860;D04.210.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C06.405.205.731;C06.405.469.432
29962049,Aging;Atlas;Magnetic Resonance Imaging,G07.345.124;V02.150;E01.370.350.825.500
29961584,Lactation;Puberty;Reproduction;Sex Characteristics,G08.686.523;G08.686.702.500;G08.686.760;G08.686.841.374;G08.686.784;G08.686.815
29961570,Diagnosis;Electronic Health Records;Exome;Genome;Natural Language Processing;Precision Medicine,E01;E05.318.308.940.968.625.500;G05.360.340.011;G05.360.340;L01.224.050.375.580;E02.574;H02.403.200.700
29961080,"Humans;Immunotherapy, Adoptive;Receptors, Antigen, T-Cell",B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.776.543.750.705.816.824
29960636,Folklore,I01.076.201.450.515
29960633,Sexual Behavior,F01.145.802
29960275,,
29959988,Neoplasms;Genetics;Lipid Metabolism;Therapeutics,C04;H01.158.273.343;G03.458;E02
29959933,Glyburide;Metformin,D02.886.590.795.575;D02.948.828.575;D02.078.370.141.450
29959613,"Age Factors;Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Breast Neoplasms;Chemotherapy, Adjuvant;Follow-Up Studies;Gene Expression Profiling;Humans;Middle Aged;Neoplasm Recurrence, Local;Nomograms;Practice Patterns, Physicians';Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Tumor Burden",N05.715.350.075;N06.850.490.250;M01.060.116.100;E02.183.750.500;E02.319.077.500;E02.319.310.037;D23.101.140;C04.588.180;C17.800.090.500;E02.186.170;E02.319.170;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.697.655;C23.550.727.655;E01.789.650;E05.318.740.500.625;E05.599.835.895;G17.582;N05.715.360.750.530.530;N06.850.520.830.500.625;N04.590.374.577;N05.300.625;E01.789;D08.811.913.696.620.682.725.400.009.400;D12.776.543.750.630.009.400;D12.776.543.750.750.400.074.400;D12.776.624.664.700.642;D23.050.301.500.600.700;D23.050.705.552.600.550;D23.101.140.642;D12.776.826.750.350;D12.776.930.778.350;D12.776.826.750.765;E05.041.124.892
29959430,,
29959046,"Atlases as Topic;Brain;Datasets as Topic;Diffusion Tensor Imaging;Gestational Age;Gray Matter;Humans;Image Processing, Computer-Assisted;Infant, Newborn;Infant, Premature;Neural Pathways;White Matter;Atlas;Infant, Newborn",L01.178.682.192.836.147;A08.186.211;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;G07.345.500.325.235.968;G08.686.320;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.703.520;M01.060.703.520.520;A08.612;A08.186.211.204;A08.186.854.880;V02.150;M01.060.703.520
29959025,,
29958749,,
29958676,,
29958645,Herniorrhaphy;Laparoscopy,E04.680.325;E01.370.388.250.520;E04.502.250.520
29958387,Feeding and Eating Disorders,F03.400
29958300,"Amphetamine-Related Disorders;Animals;Dependovirus;Genetic Vectors;Methamphetamine;Mice;Mice, Inbred BALB C;Single-Chain Antibodies",C25.775.225;F03.900.225;B01.050;B04.280.580.650.170;G05.360.337;D02.092.471.683.152.619;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795
29958227,,
29958208,,
29957617,Adolescent;Child;Cohort Studies;Fracture Fixation;Humans;Open Fracture Reduction;Retrospective Studies;Tibial Fractures,M01.060.057;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.555.300;B01.050.150.900.649.313.988.400.112.400.400;E04.555.300.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C26.404.875;C26.558.857
29957270,"African Americans;Aged;Aged, 80 and over;Asian Americans;Biomarkers;Collagen Type I;Cross-Sectional Studies;Hispanic Americans;Humans;Lung;Lung Diseases, Interstitial;Middle Aged;Peptide Fragments;Peptides;Procollagen;Prospective Studies;Sex Factors;Smoking;Tomography, X-Ray Computed;United States;Extracellular Matrix",M01.686.508.100.100;M01.686.754.100;M01.060.116.100;M01.060.116.100.080;M01.686.508.200.100;M01.686.754.225;D23.101;D05.750.078.280.300.100;D12.776.860.300.250.300.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.381.483;M01.060.116.630;D12.644.541;D12.644;D12.776.811.690;D12.776.860.300.250.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N05.715.350.675;N06.850.490.875;F01.145.805;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875;A11.284.295.310
29957178,"Adaptation, Physiological;Allostasis;Biological Evolution;Brain;Cardiovascular Diseases;Energy Metabolism;Energy-Generating Resources;Humans;Industrial Development;Obesity;Origin of Life;Substance-Related Disorders;Allostasis;Economics;Medicine;Neurosciences",G07.025;G16.012.500;G16.012.500.274;G05.045;G16.075;A08.186.211;C14;G03.295;N06.230.132;B01.050.150.900.649.313.988.400.112.400.400;I01.261.262.500;J01.576.519;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G16.650;I01.076.368.584.542;C25.775;F03.900;G16.012.500.274;I01.261;N03.219;H02.403;H01.158.610
29957094,Palliative Care;Population Health,E02.760.666;N02.421.585.666;N01.400.548
29956597,Neurology;Risk Factors;Seizures,H02.403.600;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.597.742;C23.888.592.742
29956381,Animals;Drug Carriers;Drug Delivery Systems;Mice;Nanoparticles;Polyethylene Glycols;Polyethyleneimine;Cell Biology;Nanomedicine,B01.050;D26.255.260;E02.319.300.380;E02.319.300;B01.050.150.900.649.313.992.635.505.500;J01.637.512.600;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;D02.455.326.271.665.550.600;D02.491.650;D05.750.716.507.600;D25.720.716.507.600;J01.637.051.720.716.507.600;H01.158.100.433;H01.158.273.160;H01.603.600;J01.897.115.625;J01.897.520.600.600
29956283,"Animals;Blastocyst;Bromodeoxyuridine;Cell Adhesion;Culture Media, Conditioned;Ectoderm;Embryo, Mammalian;Embryonic Development;Fluorescent Antibody Technique;Mice;Molecular Biology;Progranulins;RNA, Messenger;Embryonic Development;Progranulins",B01.050;A16.254.500;D03.383.742.680.852.300.150;D13.570.230.430.196;D13.570.685.852.300.150;G04.022;D27.720.470.305.250;E07.206.250;A16.504.273;A16.254;G07.345.500.325.180;G08.686.784.170.104;E01.370.225.500.607.512.240;E01.370.225.750.551.512.240;E05.200.500.607.512.240;E05.200.750.551.512.240;E05.478.583.375;B01.050.150.900.649.313.992.635.505.500;H01.158.201.636;H01.158.273.343.595;H01.181.122.650;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917;D13.444.735.544;G07.345.500.325.180;G08.686.784.170.104;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917
29955929,Athletes;Athletic Injuries;Humans;Lower Extremity;Patient Reported Outcome Measures;Return to Sport;Soccer;Treatment Outcome;Return to Sport,M01.072;C26.115;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;I03.450.642.845.605;I03.450.642.845.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;I03.450.642.845.605
29955863,"Aging;Animals;Cholecalciferol;Cholestanetriol 26-Monooxygenase;Cytochrome P-450 CYP3A;Gene Expression;Kidney;Liver;Low Density Lipoprotein Receptor-Related Protein-2;Membrane Proteins;Mice;RNA, Messenger;Receptors, Cell Surface;Vitamin D;Vitamin D Deficiency;Vitamin D3 24-Hydroxylase",G07.345.124;B01.050;D04.210.500.247.222.159;D04.210.500.247.808.146;D04.210.500.812.768.196;D10.570.938.146;D08.244.453.499.750;D08.244.453.915.149;D08.811.682.690.708.170.493.750;D08.811.682.690.708.170.915.150;D12.776.422.220.453.499.750;D12.776.422.220.453.915.150;D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500;G05.297;A05.810.453;A03.620;D12.776.526.200;D12.776.543.750.710.450.500.200;D23.050.422.500.500;D12.776.543;B01.050.150.900.649.313.992.635.505.500;D13.444.735.544;D12.776.543.750;D04.210.500.812.768;C18.654.521.500.133.770;D08.244.453.496.500;D08.811.682.690.708.170.469.500;D12.776.422.220.453.496.500
29955824,,
29955637,Finite Element Analysis;Magnetic Resonance Imaging,E05.355;E01.370.350.825.500
29955586,,
29955165,,
29955163,,
29955151,"Adult;Cerebral Cortex;Depressive Disorder, Major;Double-Blind Method;Humans;Machine Learning;Middle Aged;Organ Size;Serotonin Uptake Inhibitors;Treatment Outcome;Young Adult",M01.060.116;A08.186.211.200.885.287.500;F03.600.300.375;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;M01.060.116.630;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
29954925,,
29954839,,
29954692,"Rhinitis, Allergic;Asthma;Dermatitis, Atopic;Eosinophilic Esophagitis;Food Hypersensitivity",C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C20.543.480.370
29954664,Urinary Retention,C12.777.934.880;C13.351.968.934.880
29953849,,
29953741,"Adolescent;Arthritis, Juvenile;Dermatomyositis;Mental Health;Young Adult",M01.060.057;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;F02.418;N01.400.500;M01.060.116.815
29953390,,
29953287,Knee;Meniscus;Tissue Engineering,A01.378.610.450;A02.165.308.538;A10.165.382.350.163;E05.481.500.311.500;J01.293.069.249.500
29953257,"Animals;Cerebellum;Convection;Dependovirus;Gadolinium;Gene Transfer Techniques;Genetic Therapy;Green Fluorescent Proteins;Heterocyclic Compounds;Infusions, Intraventricular;Macaca fascicularis;Magnetic Resonance Imaging;Organometallic Compounds;Cerebellum",B01.050;A08.186.211.132.810.428.200;G01.906.230;B04.280.580.650.170;D01.268.558.362.484;D01.552.550.399.484;E05.393.350;E02.095.301;E05.393.420.301;D12.776.532.265;D03;E02.319.267.510.692;B01.050.150.900.649.313.988.400.112.199.120.510.520;E01.370.350.825.500;D02.691;A08.186.211.132.810.428.200
29953253,,
29952644,Carticaine;Calcium;Lidocaine;Neurons;Paresthesia;Sodium Channels,D02.886.778.150;D03.383.903.150;D01.268.552.100;D01.552.539.288;D23.119.100;D02.065.199.092.500;D02.092.146.113.092.500;A08.675;A11.671;C10.597.751.791.875;C23.888.592.763.770.875;D12.776.157.530.400.875;D12.776.543.550.450.875;D12.776.543.585.400.875
29952278,"Cardiology;Cooperative Behavior;Critical Care;Humans;Intensive Care Units, Pediatric;Pediatrics;Quality Improvement;Registries;United States;Quality Improvement",H02.403.429.163;F01.145.813.115;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;H02.403.670;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;Z01.107.567.875;J01.293.754;N04.761.744
29950165,"Algorithms;Cluster Analysis;Computational Biology;High-Throughput Nucleotide Sequencing;Microbiota;Phylogeny;RNA, Ribosomal, 16S;Sequence Analysis, DNA;Microbiota",G17.035;L01.224.050;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;H01.158.273.180;L01.313.124;E05.393.760.319;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G05.697;G16.075.605;L01.100.697;D13.444.735.686.670;E05.393.760.700;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29950020,,
29949775,,
29949761,,
29949604,Animals;Cell Differentiation;Epithelial Cells;Gene Expression Regulation;Mice;MicroRNAs;Thymus Gland,B01.050;G04.152;A11.436;G05.308;B01.050.150.900.649.313.992.635.505.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A10.549.750;A15.382.520.604.750
29949234,Biomarkers;Magnetic Resonance Imaging;Machine Learning;Nicotine;Support Vector Machine,D23.101;E01.370.350.825.500;G17.035.250.500;L01.224.050.375.530;D03.132.760.570;D03.383.725.518;G17.035.250.500.500.500;L01.224.050.375.530.500.500
29949128,"Body Composition;Bone Density;Absorptiometry, Photon;Feeding and Eating Disorders;Exercise;Sports",G02.111.130;G03.180;G07.100.049;G11.427.100;E01.370.350.700.024;E05.196.712.224.187;F03.400;G11.427.410.698.277;I03.350;I03.450.642.845
29948339,Adolescent;Adult;Cell Phone;HIV Infections;Humans;Medication Adherence;Pain Management;Patient Compliance;Pilot Projects;Reminder Systems;Self Efficacy;Substance-Related Disorders;Telemedicine;Treatment Outcome;Young Adult;Adolescent;Depression;HIV;Technology,M01.060.057;M01.060.116;L01.178.847.698.300;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E02.745;N04.590.607.500;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;L01.143.820;L01.313.500.750.300.790;F01.752.747.792.700;C25.775;F03.900;H02.403.840;L01.178.847.652;N04.590.374.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;M01.060.057;F01.145.126.350;B04.820.650.589.650.350;J01.897
29948310,"Child;Renal Insufficiency, Chronic;Health Literacy",M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500
29948309,"Acute Kidney Injury;Child;Intensive Care Units, Pediatric;Risk Factors;Sepsis",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.406;N02.278.388.493.390;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.757;C23.550.470.790.500
29948025,"Adolescent;Adult;Angiotensin II Type 1 Receptor Blockers;Antihypertensive Agents;Aorta;Aortic Diseases;Atenolol;Child;Child, Preschool;Dilatation;Echocardiography;Humans;Infant;Losartan;Marfan Syndrome;ROC Curve;Referral and Consultation;Risk Assessment;Risk Factors;Vascular Surgical Procedures;Young Adult;Marfan Syndrome",M01.060.057;M01.060.116;D27.505.519.162.500;D27.505.954.411.162;A07.015.114.056;C14.907.109;D02.033.100.624.698.070;D02.033.755.624.698.070;D02.092.063.624.698.070;M01.060.406;M01.060.406.448;E05.284;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D02.455.426.559.389.185.475;D03.383.129.308.507;D03.383.129.617.467;C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;N04.452.758.849;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.100.814;M01.060.116.815;C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500
29947971,Noise;Oxygen,G01.750.770.776.567;G16.500.275.600;N06.230.400;N06.850.460.610;D01.268.185.550;D01.362.670
29947746,,
29947574,United States;Immunization;Primary Health Care,Z01.107.567.875;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;N04.590.233.727
29947018,Anorexia Nervosa;Binge-Eating Disorder;Bulimia Nervosa;Feeding and Eating Disorders;Polycystic Ovary Syndrome,F03.400.125;F03.400.188;F03.400.250;F03.400;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765
29946679,,
29946495,,
29946105,,
29946040,,
29945345,"Adult;Breast Neoplasms;Breast Neoplasms, Male;CD4-Positive T-Lymphocytes;Clonal Evolution;Humans;Lymph Nodes;Receptors, Antigen, T-Cell, alpha-beta;T-Lymphocyte Subsets;Breast Neoplasms;T-Lymphocytes, Helper-Inducer",M01.060.116;C04.588.180;C17.800.090.500;C04.588.180.260;C17.800.090.500.260;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;G04.375;G05.158;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;D12.776.543.750.705.816.824.825;A11.118.637.555.567.550.500;A11.118.637.555.567.569.500;A15.145.229.637.555.567.550.500;A15.145.229.637.555.567.569.500;A15.382.490.555.567.550.500;A15.382.490.555.567.569.500;C04.588.180;C17.800.090.500;A11.118.637.555.567.550.500.400;A11.118.637.555.567.569.200.400;A11.118.637.555.567.569.500.400;A15.145.229.637.555.567.550.500.400;A15.145.229.637.555.567.569.200.400;A15.145.229.637.555.567.569.500.400;A15.382.490.555.567.550.500.400;A15.382.490.555.567.569.200.400;A15.382.490.555.567.569.500.400
29945252,,
29944862,"Alcohol Drinking;Animals;Anxiety;Central Nervous System Depressants;Choice Behavior;Conditioning (Psychology);Ethanol;Hypnotics and Sedatives;Hypothermia;Mice, Inbred C57BL;Mice, Knockout;Motor Activity;Receptors, Nicotinic;Reflex;Reward;Spatial Behavior;Ethanol;Mice;Receptors, Nicotinic;Reward",F01.145.317.269;B01.050;F01.470.132;D27.505.696.277;D27.505.954.427.210;F02.463.785.373.346;F02.463.425.179;D02.033.375;D27.505.696.277.350;D27.505.954.427.210.350;C23.888.119.565;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;F01.145.632;G11.427.410.698;D12.776.157.530.400.400.100.500;D12.776.543.550.450.500.100.500;D12.776.543.585.400.500.100.500;D12.776.543.750.130.687;D12.776.543.750.720.360.550;E01.370.376.550.650;E01.370.600.550.650;F02.830.702;G11.561.731;F02.463.425.770.836;F01.145.875;D02.033.375;B01.050.150.900.649.313.992.635.505.500;D12.776.157.530.400.400.100.500;D12.776.543.550.450.500.100.500;D12.776.543.585.400.500.100.500;D12.776.543.750.130.687;D12.776.543.750.720.360.550;F02.463.425.770.836
29944707,"Adolescent;Adult;Aging;Child;Child, Preschool;Disease Progression;Follow-Up Studies;Humans;Middle Aged;Muscular Atrophy, Spinal;Prospective Studies;Walk Test;Walking;Young Adult",M01.060.057;M01.060.116;G07.345.124;M01.060.406;M01.060.406.448;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.228.854.468;C10.574.562.500;C10.668.467.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.370.370.380.250.500;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940;M01.060.116.815
29944678,Adult;Anti-HIV Agents;CD4 Lymphocyte Count;Employment;HIV Infections;Humans;Kenya;Patient Acceptance of Health Care;Public Health;Socioeconomic Factors;Uganda;Viral Load,M01.060.116;D27.505.954.122.388.077.088;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;N01.824.245;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;Z01.058.290.120.400;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;H02.403.720;N01.400.550;N06.850;I01.880.853.996;N01.824;Z01.058.290.120.880;E01.370.225.875.950;E05.200.875.950;G06.920.850
29944540,,
29944147,,
29943505,,
29943494,"Adult;Aged;Biomarkers, Tumor;Carcinoma in Situ;Carcinoma, Squamous Cell;Diagnostic Errors;Humans;Keratinocytes;Keratosis, Actinic;MART-1 Antigen;Melanocytes;Melanoma;Middle Aged;Skin Neoplasms;Melanocytes",M01.060.116;M01.060.116.100;D23.101.140;C04.557.470.200.240;C04.557.470.200.400;C04.557.470.700.400;E01.354;N02.421.450.280;B01.050.150.900.649.313.988.400.112.400.400;A11.409.500;A11.436.397;C04.834.450;C17.800.428.570;D12.776.624.301.750;D23.050.285.439.750;A11.409.750;A11.436.613;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;C04.588.805;C17.800.882;A11.409.750;A11.436.613
29943262,"Adaptation, Psychological;Adult;Child;Curriculum;Family;Family Health;Homeless Persons;Homeless Youth;Housing;Humans;Object Attachment;Parent-Child Relations;Parenting;Parents;Program Development;Program Evaluation;Resilience, Psychological;Social Work;Stress, Psychological;Homeless Persons;Parent-Child Relations",F01.058;M01.060.116;M01.060.406;I02.158;F01.829.263;I01.880.853.150;N01.400.300;M01.325;M01.325.400;J03.340;N01.224.791.400;N06.230.150.360;N06.850.505.400.800.400;B01.050.150.900.649.313.988.400.112.400.400;F02.739.794.624;F01.829.263.370.290;F01.829.263.370.310;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;N04.452.760;E05.337.820;N04.761.685;N05.715.360.650;F02.940;I01.880.792;N02.421.849;F01.145.126.990;F02.830.900;M01.325;F01.829.263.370.290
29943106,,
29942082,,
29941873,,
29941593,"Amyloid;Ebolavirus;Glycoproteins;HeLa Cells;Hemorrhagic Fever, Ebola;Humans;Seminal Plasma Proteins;Viral Proteins;Ebolavirus;Amyloid;Semen",D05.500.049;D12.776.049;B04.820.455.300.200;D09.400.430;D12.776.395;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;C02.782.417.415;C02.782.580.250.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.866;D12.776.964;B04.820.455.300.200;D05.500.049;D12.776.049;A12.200.732
29941095,,
29940877,"Kidney Failure, Chronic;Epidemiology;Hematuria;Mortality;Risk Factors",C12.777.419.780.750.500;C13.351.968.419.780.750.500;H02.403.720.500;C12.777.934.442;C13.351.968.934.442;C23.550.414.849;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29940281,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment;Spiro Compounds",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.455.426.779;D04.711
29940279,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Octanols;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D02.033.415.600;D10.289.600;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29940246,Anti-Bacterial Agents;Recurrence;Urinary Tract Infections;Women,D27.505.954.122.085;C23.550.291.937;C01.539.895;C12.777.892;C13.351.968.892;M01.975
29940161,Biomarkers;Cerebrospinal Fluid,D23.101;A12.207.270.210
29940160,"Animals;Charcot-Marie-Tooth Disease;Disease Models, Animal;Intermediate Filaments;Mice;Mice, Inbred C57BL;Mice, Mutant Strains;Mutation;Nerve Fibers, Myelinated;Neurofilament Proteins;Neural Conduction;Intermediate Filaments",B01.050;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;C22.232;E05.598.500;E05.599.395.080;A11.284.430.214.190.750.410;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.150.900.649.313.992.635.505.500.550;G05.365.590;A08.675.542.512;A11.671.501.512;A11.671.514;D05.750.078.593.630;D12.776.220.475.630;D12.776.631.630;G07.265.753;G11.561.601;A11.284.430.214.190.750.410
29939414,,
29939055,,
29939050,Adolescent;Attention Deficit Disorder with Hyperactivity;Child;Diagnostic and Statistical Manual of Mental Disorders;Humans;Impulsive Behavior;Parents;School Teachers;Sex Factors,M01.060.057;F03.625.094.150;M01.060.406;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;F01.145.527;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;M01.526.702.500;N05.715.350.675;N06.850.490.875
29938877,,
29938586,Cerebral Palsy;Spinal Fusion;Weight Gain,C10.228.140.140.254;E04.555.100.700;C23.888.144.243.926;G07.345.249.314.120.200.926
29938396,Fluorodeoxyglucose F18;Humans;Neoplasms;Positron-Emission Tomography;Radiopharmaceuticals;Pets;Neoplasms,D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;C04;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;B01.050.050.116.600;C04
29938247,,
29937326,Emotions;Evoked Potentials;Schizophrenia,F01.470;G07.265.216.500;G11.561.200.500;F03.700.750
29937256,"Adaptation, Psychological;Adolescent;Child;Child, Preschool;Cluster Analysis;Cognitive Behavioral Therapy;Humans;Mental Health Services;Neurodevelopmental Disorders;Referral and Consultation;School Health Services;Schools;Students;Treatment Outcome;Urban Population;Evidence-Based Practice",F01.058;M01.060.057;M01.060.406;M01.060.406.448;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;F04.754.137.350;B01.050.150.900.649.313.988.400.112.400.400;F04.408;N02.421.461;F03.625;N04.452.758.849;N02.421.726.809;I02.783;J03.832;M01.848;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N01.600.900;H02.249
29937251,,
29937193,"Adolescent;Adult;African Americans;Aged;Behavioral Risk Factor Surveillance System;Homicide;Humans;Interview, Psychological;Mental Health;Middle Aged;Non-Randomized Controlled Trials as Topic;Police;Racism;United States;Young Adult",M01.060.057;M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;E05.318.308.980.438.149;N05.715.360.300.800.438.149;N06.850.520.308.980.438.149;I01.198.240.470;I01.880.735.344;B01.050.150.900.649.313.988.400.112.400.400;F04.669.599;F02.418;N01.400.500;M01.060.116.630;E05.318.372.250.250.365.250;N05.715.360.330.250.250.365.250;N06.850.520.450.250.250.365.250;M01.526.373.750;M01.526.760;F01.145.813.550.500;F01.145.813.629.625;F01.829.595.500;I01.880.735.820.500.500;Z01.107.567.875;M01.060.116.815
29936972,Adolescent;Adult;Cell Phone;Child;Communication;Humans;Parent-Child Relations;Parents;Physician-Patient Relations;Professional-Family Relations;Social Media,M01.060.057;M01.060.116;L01.178.847.698.300;M01.060.406;F01.145.209;L01.143;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.290;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.829.401.650.675;N05.300.660.625;F01.829.401.550;L01.178.751;L01.224.230.110.500.750
29936282,"Academies and Institutes;Acetates;Animals;Consumer Product Safety;Cyclohexanols;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;D02.241.081.018;D10.251.400.045;B01.050;N06.850.210;D02.033.415.510.500;D02.455.426.392.368.367.318;D10.289.510.500;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29936281,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment;Spiro Compounds",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.455.426.779;D04.711
29936280,"Academies and Institutes;Acetates;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;D02.241.081.018;D10.251.400.045;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29936279,"Academies and Institutes;Acetophenones;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;D02.522.120;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29936278,"Academies and Institutes;Animals;Butyric Acid;Consumer Product Safety;Databases, Chemical;Esters;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.241.081.114.750;D10.251.400.143.500;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.241.400;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29936260,,
29936229,,
29936143,"Alternative Splicing;Animals;Cells, Cultured;E2F1 Transcription Factor;Hippocampus;Neuroglia;Neurons;Rats;Rats, Sprague-Dawley;Alternative Splicing",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;A11.251;D12.644.360.024.328.049;D12.776.157.057.158.049;D12.776.476.024.420.049;D12.776.660.769.049;D12.776.930.211.500;A08.186.211.180.405;A08.186.211.200.885.287.500.345;A08.637;A11.650;A08.675;A11.671;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100
29936086,"Vascular Stiffness;Pediatrics;Diabetes Mellitus, Type 2;Vascular Diseases",G09.330.940;H02.403.670;C18.452.394.750.149;C19.246.300;C14.907
29935969,Education;Internship and Residency;Licensure;Students,I02;I02.358.337.350.500;I02.358.399.350.750;N03.706.110.510;N05.700.200.450;M01.848
29935788,"Adolescent;Adult;Angiography, Digital Subtraction;Arteriovenous Malformations;Blood Vessel Prosthesis;Blood Vessel Prosthesis Implantation;Computed Tomography Angiography;Endovascular Procedures;Humans;Middle Aged;Polytetrafluoroethylene;Prosthesis Design;Pulmonary Artery;Pulmonary Circulation;Pulmonary Veins;Stents;Time Factors;Treatment Outcome;Vascular Patency",M01.060.057;M01.060.116;E01.370.350.600.350.700.060;E01.370.350.700.060.060;E01.370.350.700.700.060;E01.370.350.760.060;E01.370.370.050.060;C14.240.850.750;C14.907.150;C16.131.240.850.750;E07.695.110;E04.100.814.868.500;E04.650.200;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D05.750.395.616;D25.720.395.616;J01.637.051.720.395.616;E05.320.550;E07.695.680;A07.015.114.715;G09.330.100.770;G09.772.593;A07.015.908.713;E07.695.750;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.920
29935658,Ascorbic Acid;Diet;Embryo Culture Techniques;Evidence-Based Medicine;Humans;Pregnancy;Randomized Controlled Trials as Topic;Rationalization;Research Design;Scurvy,D02.241.081.844.107;D02.241.511.902.107;D09.811.100;G07.203.650.240;E05.481.500.468;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;F01.393.746;E05.581.500;H01.770.644.728;C14.907.454.800;C15.378.463.515.800;C18.654.521.500.133.115.661
29935448,"Apolipoprotein E4;Air Pollution;alpha-Synuclein;Plaque, Amyloid;Child;Olfactory Bulb;Suicide;Tauopathies;Young Adult",D10.532.091.500.750;D12.776.070.400.500.750;D12.776.521.120.500.750;N06.850.460.100;D12.776.631.860.500;D12.776.637.500;C23.300.821;M01.060.406;A08.186.211.200.885.388;F01.145.126.980.875;I01.880.735.856;C10.574.945;M01.060.116.815
29935251,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Isobutyrates;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D02.241.081.114.968;D10.251.400.143.875;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29935249,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Fatty Alcohols;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.033.415;D10.289;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29935246,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment;Sesquiterpenes",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.455.849.765
29935244,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Pentanoic Acids;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D02.241.081.944.509;D10.251.400.895.593;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29935219,Common Variable Immunodeficiency,C20.673.330
29935119,"Hydrocortisone;Dynorphins;Receptors, Opioid, kappa;Mood Disorders",D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;D12.644.400.575.180;D12.776.631.650.575.180;D12.776.543.750.695.620.400;D12.776.543.750.720.600.610.400;D12.776.543.750.750.555.610.400;F03.600
29934536,,
29934408,,
29933926,,
29933844,,
29933826,Alcoholism;Apnea;Cocaine-Related Disorders;Cognitive Behavioral Therapy;Humans;Marijuana Abuse;Opioid-Related Disorders;Referral and Consultation;Sleep Wake Disorders;Substance-Related Disorders;Alcoholism;Cocaine-Related Disorders;Marijuana Abuse;Opioid-Related Disorders;Sleep Initiation and Maintenance Disorders;Substance-Related Disorders,C25.775.100.250;F03.900.100.350;C08.618.085;C23.888.852.130;C25.775.300;F03.900.300;F04.754.137.350;B01.050.150.900.649.313.988.400.112.400.400;C25.775.635;F03.900.635;C25.775.675;F03.900.675;N04.452.758.849;C10.886;C23.888.592.796;F03.870;C25.775;F03.900;C25.775.100.250;F03.900.100.350;C25.775.300;F03.900.300;C25.775.635;F03.900.635;C25.775.675;F03.900.675;C10.886.425.800.800;F03.870.400.800.800;C25.775;F03.900
29933282,,
29933280,,
29933145,"Epilepsy;Klinefelter Syndrome;Pathology, Molecular",C10.228.140.490;C12.706.316.795.500;C13.351.875.253.795.500;C16.131.260.830.835.500;C16.131.939.316.795.500;C16.320.180.830.835.500;C19.391.119.795.500;C19.391.482.629;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505
29933010,"Acute Disease;Animals;Brain Injuries, Traumatic;Child;Chronic Disease;Humans;Cognition;Erythropoietin;Infant, Newborn;Progesterone;Brain Injuries, Traumatic",C23.550.291.125;B01.050;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;C23.550.291.500;B01.050.150.900.649.313.988.400.112.400.400;F02.463.188;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;M01.060.703.520;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29932997,"Academies and Institutes;Animals;Butyrates;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment;Safety;Terpenes",N03.540.052;B01.050;D02.241.081.114;D10.251.400.143;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N06.850.135.060.075;D02.455.849
29932996,"Academies and Institutes;Animals;Butyrophenones;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.522.352;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29932995,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Phenylacetates;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;D02.241.223.601;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29932994,"Academies and Institutes;Animals;Consumer Product Safety;Databases, Chemical;Hexanols;Humans;Perfume;Registries;Risk Assessment;Safety",N03.540.052;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.033.415.510;D10.289.510;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N06.850.135.060.075
29932993,"Academies and Institutes;Animals;Consumer Product Safety;Cyclopentanes;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;D02.455.426.392.368.450;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29932958,"Animals;Anxiety Disorders;Depressive Disorder, Major;Humans;Hypothalamo-Hypophyseal System;Orexins;Pituitary-Adrenal System;Stress, Psychological;Appetite;Cognition;Orexins;Orexins;Sleep",B01.050;F03.080;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;A06.688.357;A08.186.211.180.497.352.435;A08.186.211.200.317.357.352.435;A08.713.357;D12.644.400.360;D12.776.631.650.363;A06.300.691;F01.145.126.990;F02.830.900;F02.830.071;G07.203.650.390.070;G10.261.390.070;F02.463.188;D12.644.400.360;D12.776.631.650.363;D12.644.400.360;D12.776.631.650.363;F02.830.855;G11.561.803
29932905,"Animals;Chromatin;Gene Silencing;Histone Code;Histones;Lysine;Methylation;Mice;Mice, Inbred C57BL;Mouse Embryonic Stem Cells;Polycomb Repressive Complex 2;Polycomb-Group Proteins;Protein Binding;Protein Processing, Post-Translational;Epigenomics",B01.050;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.308.203.374;G02.111.570.060.360;G05.360.360;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D12.125.068.555;D12.125.095.647;D12.125.142.497;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.872.700.250.875;D05.500.781.750;D08.811.913.555.500.800.200.500.500;D12.776.660.235.600.200;D12.776.664.235.800.200;D12.776.930.780.890.200;D05.500.781;D12.776.660.235.600;D12.776.664.235.800;D12.776.930.780.890;G02.111.679;G03.808;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.273.180.350.074;H01.158.273.343.350.042
29932516,,
29932341,Multiple Sclerosis;Pediatrics;Surveys and Questionnaires;Risk Factors;Sunlight;Tobacco Smoke Pollution;Vitamin D,C10.114.375.500;C10.314.350.500;C20.111.258.250.500;H02.403.670;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525;D20.633.937.680;N06.850.460.100.555;D04.210.500.812.768
29932284,Beckwith-Wiedemann Syndrome;Wilms Tumor,C16.131.077.133;C16.131.260.080;C16.320.180.080;C04.557.435.595;C04.588.945.947.535.585;C04.700.900;C12.758.820.750.585;C12.777.419.473.585;C13.351.937.820.535.585;C13.351.968.419.473.585;C16.320.700.900
29932002,,
29931777,"Genetics, Behavioral;Oxytocin;Macaca mulatta;Social Behavior;Vasopressins",F04.096.276;H01.158.273.343.290;D06.472.699.631.692.433;D12.644.548.691.692.433;B01.050.150.900.649.313.988.400.112.199.120.510.550;F01.145.813;D06.472.699.631.692.781;D12.644.400.900;D12.644.456.925;D12.644.548.691.692.781;D12.776.631.650.937
29931738,"Lassa virus;Communicable Diseases, Emerging;Hantavirus;Zoonoses",B04.820.057.070.100.500;C01.539.221.500;B04.820.087.440;C01.908;C02.968;C03.908;C22.969
29931690,Vasopressins,D06.472.699.631.692.781;D12.644.400.900;D12.644.456.925;D12.644.548.691.692.781;D12.776.631.650.937
29931102,,
29931068,,
29930512,Inflammation;Vascular Diseases,C23.550.470;C14.907
29930385,Adolescent;Brain;Child;Humans;Mental Disorders;Multimodal Imaging;Neuroimaging;Sex Characteristics,M01.060.057;A08.186.211;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;F03;E01.370.350.567;E01.370.350.578;E01.370.376.537;E05.629;G08.686.815
29930175,Blood Coagulation Factors,D12.776.124.125;D23.119
29930156,"Electrocardiography;Hypertrophy, Left Ventricular;Pediatrics;Reference Values",E01.370.370.380.240;E01.370.405.240;C14.280.195.400;C23.300.775.250.400;H02.403.670;E05.978.810
29930129,Clinical Trials as Topic;Humans;United States;United States Food and Drug Administration,E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
29930110,"Brain Diseases;Genetic Variation;Genome-Wide Association Study;Humans;Mental Disorders;Phenotype;Quantitative Trait, Heritable;Risk Factors",C10.228.140;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;F03;G05.695;G05.420.720;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29930022,Endothelium;Kidney;Nitric Oxide;Pharmacology;Prostaglandins,A10.272.491;A05.810.453;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;H01.158.703;H02.628;D10.251.355.255.550;D23.469.050.175.725
29929999,"Adult;Ethnic Groups;European Continental Ancestry Group;Hispanic Americans;Humans;Insurance, Health;Logistic Models;Medicaid;Patient Protection and Affordable Care Act;Renal Insufficiency, Chronic;Retrospective Studies;United States;Kidney Transplantation;Renal Dialysis",M01.060.116;M01.686.754;N01.224.317;M01.686.508.400;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.576.343.918;N03.706.615.806;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;E02.870.500;E04.936.450.485;E04.950.774.400;E02.870.300;E02.912.800
29929646,,
29929438,Magnetic Resonance Imaging,E01.370.350.825.500
29929421,"DNA;DNA Repair;DNA Replication;DNA-Directed RNA Polymerases;Epigenesis, Genetic;Escherichia coli;Escherichia coli Proteins;Genome, Bacterial;Single-Cell Analysis;Transcription Factors;Transcription, Genetic;Transcriptional Elongation Factors",D13.444.308;G02.111.222;G05.219;G02.111.225;G05.226;D08.811.913.696.445.735.270;G05.308.203;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;G05.360.340.358.207;E05.242.900;D12.776.930;G02.111.873;G05.297.700;D12.776.930.955
29929376,,
29928914,"Academies and Institutes;Animals;Benzoates;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;D02.241.223.100;D02.455.426.559.389.127;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29927859,,
29927793,,
29927761,,
29927655,,
29927623,Achilles Tendon;Biology;Metabolism,A02.880.176;H01.158.273;G03
29926146,Hydronephrosis;Infant,C12.777.419.307;C13.351.968.419.307;M01.060.703
29926099,,
29925992,,
29925924,,
29925915,,
29925666,"Animals;CCR5 Receptor Antagonists;Cyclohexanes;Humans;Infant;Infectious Disease Transmission, Vertical;Macaca mulatta;Maraviroc;Palatine Tonsil;Serum;Simian Acquired Immunodeficiency Syndrome;Treatment Outcome;Triazoles;Viral Load;Maraviroc;Macaca mulatta;Simian Immunodeficiency Virus",B01.050;D27.505.519.275;D27.505.954.122.388.077.088.104;D02.455.426.392.368.367;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N06.850.310.425;B01.050.150.900.649.313.988.400.112.199.120.510.550;D02.455.426.392.368.367.726;D03.383.129.799.682;A04.623.603.925;A10.549.580;A14.724.603.925;A15.382.520.604.580;A12.207.152.846;A15.145.846;C02.782.815.616.850;C02.839.850;C22.735.500.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D03.383.129.799;E01.370.225.875.950;E05.200.875.950;G06.920.850;D02.455.426.392.368.367.726;D03.383.129.799.682;B01.050.150.900.649.313.988.400.112.199.120.510.550;B04.820.650.589.650.800;B04.820.650.805.700
29925640,,
29925637,,
29925512,Genetics;Retina,H01.158.273.343;A09.371.729
29925499,,
29924990,B-Lymphocytes;Hypoxia;Inflammation;Wounds and Injuries;Pancreatitis;Regeneration,A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;C23.888.852.079;C23.550.470;C26;C06.689.750;G16.762
29924950,"Delegation, Professional;Ethics, Medical;Humans;Informed Consent;Patient Care Team;Pennsylvania;Physician's Role;State Government;United States",N04.590.374.070;K01.752.566.479.171.132.750;N05.350.340.162.500;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;N04.590.715;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;F01.829.316.616.625.600;I01.409.775;N03.540.348.875;Z01.107.567.875
29924070,"Adult;Contracture;Hip Joint;Humans;Knee Joint;Lower Extremity;Motor Disorders;Muscular Atrophy, Spinal;Range of Motion, Articular",M01.060.116;C05.550.323;C05.651.197;A02.835.583.411;B01.050.150.900.649.313.988.400.112.400.400;A02.835.583.475;A01.378.610;F03.608;C10.228.854.468;C10.574.562.500;C10.668.467.500;E01.370.600.700;G11.427.760
29923891,,
29923053,,
29922984,DiGeorge Syndrome;Meta-Analysis;Neuropsychology;DiGeorge Syndrome,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;V03.600;F04.096.795.600;H01.158.782.795.110;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
29922822,"Alcohol Drinking;Motivation;Research;Stress Disorders, Post-Traumatic",F01.145.317.269;F01.658;F01.752.543.500.750;H01.770.644;F03.950.750.500
29922140,Electroencephalography;Connectome,E01.370.376.300;E01.370.405.245;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500
29921878,"Heterogeneous-Nuclear Ribonucleoprotein K;Humans;Influenza A virus;Influenza, Human;Mutation;Nuclear Proteins;RNA Precursors;RNA Splicing;RNA, Messenger;RNA, Viral;Ribonucleoprotein, U1 Small Nuclear;Transcription Factors;Virus Replication",D12.776.157.725.813.750.500;D12.776.260.268;D12.776.664.962.813.750.500;B01.050.150.900.649.313.988.400.112.400.400;B04.820.545.405.400;C02.782.620.365;C08.730.310;G05.365.590;D12.776.660;D13.400.730;D13.444.735.640;G02.111.760.700;G03.839.700;G05.308.700.700;D13.444.735.544;D13.444.735.828;D12.776.157.725.500.875.600;D12.776.157.725.829.313;D12.776.664.962.500.875.600;D12.776.664.962.829.313;D12.776.930;G06.920.925
29921864,"Animals;Animals, Genetically Modified;Axons;LDL-Receptor Related Proteins;Microscopy, Confocal;Mutation;Nerve Regeneration;Neuroglia;Peripheral Nerve Injuries;Receptor Protein-Tyrosine Kinases;Schwann Cells;Time-Lapse Imaging;Zebrafish;Zebrafish Proteins",B01.050;B01.050.050.136;B05.620.136;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;D12.776.526;D12.776.543.750.710.450.500;E01.370.350.515.395;E05.595.395;G05.365.590;G11.561.585;G16.762.611;A08.637;A11.650;C10.668.829.712;C10.900.575;C26.915.650;D08.811.913.696.620.682.725.400;D12.776.543.750.630;A08.637.800;A08.800.800.690;A11.650.800;E01.370.350.600.817;E05.712.657;L01.280.960.399;B01.050.150.900.493.200.244.828;D12.776.325.500
29921582,"Chromatin Assembly and Disassembly;Epigenesis, Genetic;Glioma;Histones;Humans;Methylation;Mutation;Nucleosomes;Ribonucleases;Ribonucleoproteins;Transcription, Genetic;Tumor Cells, Cultured;Ribonuclease P;RNA, Antisense;Epigenomics;Glioblastoma;Histones",G04.400.095;G05.213.095;G05.308.095;G05.308.203;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;G02.111.035.538;G02.607.094.538;G03.059.538;G05.365.590;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;D08.811.277.352.700;D12.776.157.725.500;D12.776.664.962.500;G02.111.873;G05.297.700;A11.251.860;D08.811.277.352.700.350.711;D08.811.797.500;D12.776.157.725.500.625;D12.776.664.962.500.625;D13.150.650;D13.444.600.150.760;D13.444.735.150;D27.720.470.530.600.150.760;H01.158.273.180.350.074;H01.158.273.343.350.042;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469
29921452,,
29921212,Amyloid;Calcium;Dantrolene;Ryanodine Receptor Calcium Release Channel;Therapeutics,D05.500.049;D12.776.049;D01.268.552.100;D01.552.539.288;D23.119.100;D03.383.129.308.432.555.287;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800;E02
29920872,"Osteotomy, Le Fort;Craniofacial Abnormalities;Craniosynostoses;Pediatrics;Registries",E04.545.575;E04.555.580.580;E06.645.575;C05.660.207;C16.131.621.207;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;H02.403.670;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
29920452,,
29920275,"Animals;Cadherins;Catenins;Cell Adhesion;Cell Line, Tumor;Cell Plasticity;Epithelial Cells;Epithelial-Mesenchymal Transition;Gene Expression Regulation, Neoplastic;Humans;Liver Neoplasms;Lung Neoplasms;Mice;Neoplasm Metastasis;Pancreatic Ducts;Pancreatic Neoplasms;Phosphoproteins;Protein Isoforms;Cadherins;Neoplasm Metastasis;Pancreatic Neoplasms",B01.050;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;D12.776.220.145;G04.022;A11.251.210.190;A11.251.860.180;G04.356.250;A11.436;G04.356.500;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;C04.697.650;C23.550.727.650;A03.734.667;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;D12.776.744;D12.776.800;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;C04.697.650;C23.550.727.650;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29920274,"Animals;Cadherins;Cell Line, Tumor;Cell Movement;Cell Plasticity;Epithelial Cells;Epithelial-Mesenchymal Transition;Gene Expression Regulation, Neoplastic;Humans;Mice;Neoplasm Invasiveness;Pancreatic Neoplasms;Signal Transduction;Transcription Factors;Cadherins;Neoplastic Cells, Circulating;Epithelial-Mesenchymal Transition;Neoplasm Metastasis;Pancreatic Neoplasms",B01.050;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;G04.356.250;A11.436;G04.356.500;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;C04.697.645;C23.550.727.645;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;G02.111.820;G04.835;D12.776.930;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;A11.642;C04.697.650.900;C23.550.727.650.900;G04.356.500;C04.697.650;C23.550.727.650;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29920215,Bone and Bones;Osteogenesis;Growth Plate,A02.835.232;A10.165.265;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;A02.835.232.251.352
29920187,Fibrosis;Pulmonary Surfactants;Pulmonary Medicine,C23.550.355;D27.505.954.796.600;H02.403.429.675
29920144,Body Mass Index;Gestational Weight Gain;Obesity;Pregnancy,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C23.888.144.243.926.500;G07.345.249.314.120.200.926.500;G08.686.330;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G08.686.784.769
29920116,Antipsychotic Agents;Child;Clinical Trial;Obesity;Schizophrenia,D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;M01.060.406;V03.175.250;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F03.700.750
29920096,,
29917125,,
29917077,,
29917007,"Child;Databases, Factual;Fellowships and Scholarships;Humans;Orthopedic Procedures;Orthopedic Surgeons;Orthopedics;Pediatrics;United States",M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;M01.526.485.810.910.875;N02.360.810.910.875;H02.403.810.494;H02.403.670;Z01.107.567.875
29917006,"Acetabulum;Femur Head;Hip Dislocation, Congenital;Humans;Infant;Magnetic Resonance Imaging;Postoperative Period;Retrospective Studies",A02.835.232.043.825.108;A02.835.232.043.650.247.343;C05.660.449;C16.131.621.449;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;E04.614.750;N02.421.585.753.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29916733,Blood Substitutes,D27.505.954.502.140;J01.637.087.249
29915816,Genetic Techniques;Genetic Variation;Genetics;Genomics,E05.393;G05.365;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350
29915428,,
29915380,"Chromosome Aberrations;Chromosomes;Congenital Abnormalities;Genetic Testing;Genetics, Medical;Genomics;Humans;Intellectual Disability;Karyotyping;Microarray Analysis;Neurodevelopmental Disorders;Genetic Testing;Mosaicism",C23.550.210;G05.365.590.175;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;C16.131;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.343.385.500;H02.403.350;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;E01.370.225.500.385.315;E05.200.500.385.315;E05.242.385.315;E05.393.285.475;E05.588.570;F03.625;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590.175.595
29915281,,
29915025,,
29914979,,
29913282,"Brain;Brain Mapping;Diffusion Magnetic Resonance Imaging;Humans;Infant, Newborn;Infant, Premature;Nerve Net;Diffusion Magnetic Resonance Imaging",A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E01.370.350.825.500.150;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;A08.511;E01.370.350.825.500.150
29913007,,
29912749,,
29912095,,
29912056,,
29912034,,
29911891,Adolescent;Age of Onset;Amygdala;Brain;Case-Control Studies;Child;Cognition;Humans;Magnetic Resonance Imaging;Memory;Memory Disorders;Multiple Sclerosis;Neuropsychological Tests;Reaction Time,M01.060.057;N05.715.350.075.100;N06.850.490.250.100;A08.186.211.180.090;A08.186.211.200.885.287.249.152;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F02.463.425.540;C10.597.606.525;C23.888.592.604.529;F01.700.625;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;F04.711.513;E05.796.817;F02.830.650;F04.669.817;G11.561.677
29911684,Evidence-Based Medicine,H02.249.750;H02.403.200.400
29911538,,
29910700,Magnetic Resonance Imaging;Photochemotherapy,E01.370.350.825.500;E02.186.500;E02.319.685;E02.774.722
29910047,,
29910032,Aorta;Ductus Arteriosus,A07.015.114.056;A07.541.278.395;A16.378.303.395
29909964,Diarrhea,C23.888.821.214
29909929,"Animals;Diagnosis, Differential;Humans;Radiology, Interventional;Radiology, Interventional;Constriction, Pathologic",B01.050;E01.171;B01.050.150.900.649.313.988.400.112.400.400;H02.403.740.675;H02.403.740.675;C23.300.287
29909817,"Arrhythmias, Cardiac;Balloon Valvuloplasty;Decompression, Surgical;Heart Defects, Congenital;Heart Ventricles;Hemodynamics;Humans;Infant, Newborn;Kaplan-Meier Estimate;Logistic Models;Postoperative Complications;Pulmonary Atresia;Pulmonary Valve;Reoperation;Retrospective Studies;Treatment Outcome;United States;Ventricular Septum;Pulmonary Atresia",C14.280.067;C23.550.073;E02.148.108;E05.157.125;E04.188;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C23.550.767;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;A07.541.510.738;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;A07.541.459.750;C14.240.850.937;C14.280.484.640;C16.131.240.850.906
29909594,"Adolescent;Adolescent Health Services;Neoplasms;Genetic Testing;Genetics;Neoplastic Syndromes, Hereditary;Li-Fraumeni Syndrome;Parents;Genes, p53",M01.060.057;N02.421.044;C04;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.343;C04.700;C16.320.700;C04.700.600;C16.320.700.600;C18.452.284.520;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385
29909593,"Arthritis, Infectious;Child, Preschool;Diagnosis, Differential;Discitis;Humans;Infant;Kingella kingae;Myositis;Neisseriaceae Infections;Osteomyelitis;Retrospective Studies;Child;Infection",C01.539.100;C05.550.114.099;M01.060.406.448;E01.171;C01.539.160.762.301;C05.116.165.762.301;C05.116.900.853.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;B03.440.400.425.550.400.375;B03.660.075.525.410.410;C05.651.594;C10.668.491.562;C01.252.400.625;C01.539.160.495;C05.116.165.495;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.406;C01.539
29909556,Lactobacillus,B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475
29909190,Minimally Invasive Surgical Procedures,E04.502
29908979,Intracranial Aneurysm;Meta-Analysis;Subarachnoid Hemorrhage,C10.228.140.300.510.600;C14.907.055.635;C14.907.253.560.300;V03.600;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
29908771,"Adult;Affect;Anxiety;Cognitive Behavioral Therapy;Comorbidity;Depressive Disorder, Major;Humans;Obesity;Philadelphia;Pilot Projects;Polycystic Ovary Syndrome;Quality of Life;Risk Factors;Risk Reduction Behavior;Time Factors;Treatment Outcome;Weight Loss;Depression;Weight Loss",M01.060.116;F01.470.047;F01.470.132;F04.754.137.350;N05.715.350.225;N06.850.490.687;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.699;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963;F01.145.126.350;C23.888.144.243.963;G07.345.249.314.120.200.963
29908694,Vascular Stiffness;Hypertension;Mortality;Review,G09.330.940;C14.907.489;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;V02.600.500;V02.912
29908583,"History, 18th Century;History, 19th Century;History, 20th Century;Hospitals, Chronic Disease;Humans;Leprosy;Louisiana;Museums",K01.400.504.875;K01.400.504.937;K01.400.504.968;N02.278.421.556.200;B01.050.150.900.649.313.988.400.112.400.400;C01.252.410.040.552.386;Z01.107.567.875.750.480;J03.570;K01.400.152.552
29908360,Endoscopy;Esophagus;Histology;Inflammation,E01.370.388.250;E04.502.250;A03.556.875.500;H01.158.100.656;C23.550.470
29907892,"Alzheimer Disease;Brain;Databases, Factual;Humans;Magnetic Resonance Imaging;Neuroimaging;Polymorphism, Single Nucleotide;Regression Analysis",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;G05.365.795.598;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750
29907874,"Animals;Genes, Neoplasm;Humans;Neoplasms",B01.050;G05.360.340.024.340.375;B01.050.150.900.649.313.988.400.112.400.400;C04
29907799,,
29907798,"Abnormalities, Multiple;Child, Preschool;Congenital Hyperinsulinism;DNA-Binding Proteins;Face;Genetic Predisposition to Disease;Hematologic Diseases;Histone Demethylases;Humans;Infant;Intellectual Disability;Mutation;Neoplasm Proteins;Nuclear Proteins;Pathology, Molecular;Retrospective Studies;Vestibular Diseases;Hypoglycemia;Hyperinsulinism",C16.131.077;M01.060.406.448;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;D12.776.260;A01.456.505;C23.550.291.687.500;G05.380.355;C15.378;D08.811.682.662.582.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590;D12.776.624;D12.776.660;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C09.218.568.900;C18.452.394.984;C18.452.394.968
29907669,Calibration;Disease Progression;Magnetic Resonance Imaging;Sacroiliac Joint,E05.978.155;C23.550.291.656;E01.370.350.825.500;A02.835.583.707
29907618,Accreditation;Attitude;Biopsy;Consensus;Education;Fellowships and Scholarships;Internal Medicine;Surveys and Questionnaires;Nephrology;Peritoneal Dialysis;Renal Dialysis,N03.706.110.070;N05.700.200.100;F01.100;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;F01.829.316.068;F02.463.785.373.433;I02;N03.219.483.838.276;H02.403.429;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;H02.403.429.580;E02.870.300.650;E02.912.800.650;E02.870.300;E02.912.800
29907543,Multiple Myeloma,C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650
29907397,"Bronchopulmonary Dysplasia;Meta-Analysis;Ductus Arteriosus, Patent;Infant, Premature",C08.381.520.750.500;C16.614.521.125;V03.600;C14.240.400.340;C14.280.400.340;C16.131.240.400.340;M01.060.703.520.520
29907334,,
29905864,"Animals;Disease Models, Animal;HEK293 Cells;Heterozygote;Humans;Lymphatic Abnormalities;Lymphatic Vessels;Mechanistic Target of Rapamycin Complex 1;Pedigree;Phosphorylation;Receptor Protein-Tyrosine Kinases;Receptor, EphB4;Signal Transduction;Whole Exome Sequencing;Zebrafish",B01.050;C22.232;E05.598.500;E05.599.395.080;A11.251.210.172.750;A11.436.334;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;C15.604.451;C16.131.482;A15.382.520.301;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;E05.393.673;G02.111.665;G02.607.780;G03.796;D08.811.913.696.620.682.725.400;D12.776.543.750.630;D08.811.913.696.620.682.725.400.850.750;D12.776.543.750.630.500.781;G02.111.820;G04.835;E05.393.760.700.825.500;B01.050.150.900.493.200.244.828
29905842,"Chronic Pain;Fibromyalgia;Analgesics, Opioid",C23.888.592.612.274;C05.651.324;C05.799.321;C10.668.491.425;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
29905839,,
29905672,,
29905593,,
29905414,"Angiography;Catheterization, Peripheral;Clinical Decision-Making;Diabetic Foot;Endovascular Procedures;Humans;Ischemia;Lower Extremity;Peripheral Arterial Disease;Predictive Value of Tests;Time Factors;Treatment Outcome;Ultrasonography",E01.370.350.700.060;E01.370.370.050;E02.148.224;E04.100.814.529.937;E04.502.382.937;E05.157.375;E01.055;C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;C23.550.513;A01.378.610;C14.907.137.126.307.500;C14.907.617.671;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850
29903905,Headache;Neurosurgery,C23.888.592.612.441;H02.403.810.425
29903894,,
29903721,Neonatology;Resuscitation;Technology,H02.403.670.400;E02.365.647;J01.897
29903569,Adolescent;Adult;Cadherins;Cardiovascular Diseases;Genetic Association Studies;Heart Ventricles;Humans;Metabolic Syndrome;Risk Factors;Sleep;Young Adult;Adiponectin,M01.060.057;M01.060.116;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;C14;E05.393.385;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500.570;C18.452.625;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F02.830.855;G11.561.803;M01.060.116.815;D06.472.699.042.249;D12.644.276.024.249;D12.644.548.011.249;D12.776.467.024.249;D23.529.024.249
29903567,,
29903541,,
29903504,,
29903404,,
29902804,"Animals;Congenital Hyperinsulinism;Haploinsufficiency;Histone Demethylases;Humans;Infant;Infant, Newborn;Mice;Nuclear Proteins;Retrospective Studies;Turner Syndrome;Congenital Hyperinsulinism;Diazoxide;Genetics;Hypoglycemia;Pancreatectomy;Turner Syndrome;X Chromosome",B01.050;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;G05.365.590.029.530.587;G05.380.350.500;D08.811.682.662.582.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;B01.050.150.900.649.313.992.635.505.500;D12.776.660;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;D02.886.590.700.135.300;D02.886.655.500.300;D03.633.100.174.300;H01.158.273.343;C18.452.394.984;E04.210.752;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;A11.284.187.865.982;G05.360.162.865.982
29902794,Biomarkers;C-Reactive Protein;Inflammation;Bipolar Disorder;Mood Disorders,D23.101;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;C23.550.470;F03.084.500;F03.600
29902478,,
29902328,,
29902314,,
29902293,,
29902219,Community Health Workers;Decision Making;Health Services Accessibility;Humans;Surveys and Questionnaires;Tanzania;Treatment Refusal;Trichiasis,M01.526.485.067.080;N02.360.067.080;F02.463.785.373;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.058.290.120.840;F01.100.150.750.750;F01.145.488.887.750;I01.880.604.473.650.968;N03.706.437.650.875;N05.300.150.800.750;C11.338.912
29900567,,
29899889,"Leukemia, Myeloid, Acute;Clinical Trial;Immunotherapy",C04.557.337.539.275;V03.175.250;E02.095.465.425
29899820,Multiple Myeloma,C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650
29899519,"Amino Acid Substitution;Angiopoietin-like 4 Protein;Animals;Blood Glucose;Case-Control Studies;Diabetes Mellitus, Type 2;Gene Silencing;Genetic Association Studies;Genetic Variation;Heterozygote;Homeostasis;Humans;Insulin Resistance;Lipoprotein Lipase;Mice;Mice, Inbred C57BL;Mice, Knockout;Risk Factors;Whole Exome Sequencing",E05.393.420.601.035;G05.558.109;D12.644.276.100.050.500;D12.776.467.100.050.500;D23.529.100.050.500;B01.050;D09.947.875.359.448.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C18.452.394.750.149;C19.246.300;G05.308.203.374;E05.393.385;G05.365;G05.380.383;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500;G07.690.773.984.617;D08.811.277.352.100.430;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.393.760.700.825.500
29899015,"Economics, Behavioral;Myocardial Ischemia;Exercise;Wearable Electronic Devices",F04.096.628.286;N03.219.215;C14.280.647;C14.907.585;G11.427.410.698.277;I03.350;E07.305.906
29898995,,
29898993,,
29898960,,
29898866,Hypospadias;Wounds and Injuries,C12.294.494.400;C12.706.516;C13.351.875.466;C16.131.939.516;C26
29898407,DNA Methylation;Seminoma,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C04.557.465.330.800
29898209,,
29897851,"Adolescent;Brain Edema;Brain Injuries;Child;Child, Preschool;Diabetic Ketoacidosis;Drug Administration Schedule;Fluid Therapy;Glasgow Coma Scale;Humans;Infant;Infusions, Intravenous;Prospective Studies;Rehydration Solutions;Sodium Chloride",M01.060.057;C10.228.140.187;C10.228.140.199;C10.900.300.087;C26.915.300.200;M01.060.406;M01.060.406.448;C18.452.076.176.652.500;C18.452.394.750.535;C19.246.099.812;E02.319.283;E02.319.360;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.319.267.082.500;E02.319.267.510.590;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D26.776.741;D01.210.450.150.875;D01.857.650
29896789,Amygdala;Wills;Transcriptome,A08.186.211.180.090;A08.186.211.200.885.287.249.152;I01.880.604.583.927;G02.111.873.750;G05.297.700.750;G05.360.920
29895965,,
29895892,,
29895835,,
29895740,"Adult;Child;Child Health;Child, Preschool;Counseling;Follow-Up Studies;Health Behavior;Health Promotion;Humans;Infant;Parents;Pediatrics;Single-Blind Method;Smoking Cessation;Telemedicine;Tobacco Smoke Pollution;Treatment Outcome;Tobacco Smoke Pollution;Smoking Cessation",M01.060.116;M01.060.406;N01.400.225;M01.060.406.448;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;F01.145.488;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;H02.403.670;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;F01.145.488.732;H02.403.840;L01.178.847.652;N04.590.374.800;D20.633.937.680;N06.850.460.100.555;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D20.633.937.680;N06.850.460.100.555;F01.145.488.732
29895552,Complement System Proteins,D12.776.124.486.274
29895534,Brain;Central Nervous System Vascular Malformations;Cerebral Hemorrhage;Neuroimaging;Pediatrics,A08.186.211;C10.500.190;C14.240.850.875;C16.131.240.850.875;C16.131.666.190;C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100;E01.370.350.578;E01.370.376.537;E05.629;H02.403.670
29895316,,
29894689,"Immune Tolerance;T-Lymphocytes, Regulatory",G12.535.425;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
29894546,Child;Dietary Supplements;Humans;Palm Oil;Pigmentation Disorders;beta Carotene,M01.060.406;G07.203.300.456;J02.500.456;B01.050.150.900.649.313.988.400.112.400.400;D10.627.700.798;D20.215.784.750.728;C17.800.621;C23.550.755;D02.455.326.271.665.202.123;D02.455.426.392.368.367.379.249.050;D02.455.849.131.123;D23.767.261.050
29894313,,
29893957,,
29893805,,
29893687,NAD;NAD;Cell Biology;Mitochondria;Mice;Niacin;Niacinamide,D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;H01.158.100.433;H01.158.273.160;A11.284.430.214.190.875.564;A11.284.835.626;B01.050.150.900.649.313.992.635.505.500;D03.066.515.475;D03.383.725.547.475;D03.066.515.530;D03.383.725.547.530
29893643,"Adolescent;Adult;Brain;Cerebrovascular Circulation;Child;Humans;Magnetic Resonance Imaging;Prospective Studies;Renal Insufficiency, Chronic;Spin Labels;Young Adult",M01.060.057;M01.060.116;A08.186.211;G09.330.100.159;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C12.777.419.780.750;C13.351.968.419.780.750;D02.389.678;M01.060.116.815
29893265,,
29892560,,
29892203,Patient Reported Outcome Measures;Trigeminal Neuralgia,E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;C07.465.299.625.500.700;C10.292.319.625.700.700
29892015,,
29891732,Aggression;Motivation;Nucleus Accumbens,F01.145.126.125;F01.145.813.045;F01.658;F01.752.543.500.750;A08.186.211.200.885.287.249.487.775.500
29891714,"Adipocytes;Adipose Tissue;Animals;Cell Line;Gene Expression Regulation;Leptin;Mice;Mice, Obese;PPAR gamma;Response Elements;Retinoid X Receptor alpha;PPAR gamma;Adipose Tissue;Leptin",A11.329.114;A10.165.114;B01.050;A11.251.210;G05.308;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.530;D12.776.826.239.588;G02.111.570.080.689.330.700;G02.111.570.080.689.675.700;G05.360.080.689.330.700;G05.360.080.689.675.700;G05.360.340.024.340.137.750.249.765;G05.360.340.024.340.137.750.680.765;D12.776.826.701.500.500;D12.776.826.239.588;A10.165.114;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500
29891538,,
29891491,,
29891443,Education;Patient Safety,I02;N06.850.135.060.075.399
29891216,Adipokines;Obesity;Adolescent,D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;M01.060.057
29891013,Tauopathies,C10.574.945
29890914,Kidney Calculi,C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550
29890779,,
29890318,Anti-Arrhythmia Agents;Electrocardiography;Flecainide;Humans;Propafenone;Ventricular Premature Complexes,D27.505.954.411.097;E01.370.370.380.240;E01.370.405.240;D03.383.621.270;B01.050.150.900.649.313.988.400.112.400.400;D02.522.818.830;C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800
29889799,,
29889605,,
29889306,Foreign Bodies,C26.392
29889129,,
29889101,Embryonic Stem Cells;Pulmonary Medicine;Induced Pluripotent Stem Cells,A11.872.700.250;H02.403.429.675;A11.872.040.500;A11.872.700.500
29888053,,
29887609,,
29887486,Adolescent;Communication;Confidentiality;Health Services;Parents;Primary Health Care,M01.060.057;F01.145.209;L01.143;F04.096.544.335.240;I01.880.604.473.650.500;I01.880.604.583.080;N03.706.437.650.124;N03.706.535.230;N02.421;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;N04.590.233.727
29887262,,
29887227,"Renal Insufficiency, Chronic;Epidemiologic Methods;Fibroblast Growth Factors;Glomerular Filtration Rate;Pediatrics;Proteinuria",C12.777.419.780.750;C13.351.968.419.780.750;E05.318;N06.850.520;D12.644.276.624;D12.776.467.624;D23.529.624;E01.370.390.400.300;G08.852.357;H02.403.670;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
29886922,Humans;Orthopedic Procedures;Prostheses and Implants;Ribs;Scoliosis;Surveys and Questionnaires,B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;E07.695;A02.835.232.570.500;C05.116.900.800.875;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29886909,Age Determination by Skeleton;Humans;Observer Variation;Patient Positioning;Spine,E01.370.049;E01.370.350.700.050;B01.050.150.900.649.313.988.400.112.400.400;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E02.760.670;N02.421.585.700;A02.835.232.834
29886044,"Renal Insufficiency, Chronic;Genetics",C12.777.419.780.750;C13.351.968.419.780.750;H01.158.273.343
29885523,"Adolescent;Adult;Aggrecans;Child;Child, Preschool;Epilepsy;Extracellular Matrix;Frontal Lobe;Hippocampus;Humans;Infant;Infant, Newborn;Young Adult;Epilepsy;Interneurons",M01.060.057;M01.060.116;D09.698.735.200.500;D12.776.395.650.750.687.100;D12.776.503.280.437.100;D12.776.860.300.140;M01.060.406;M01.060.406.448;C10.228.140.490;A11.284.295.310;A08.186.211.200.885.287.500.270;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.116.815;C10.228.140.490;A08.675.358;A11.671.358
29885305,,
29885251,,
29885044,Insulin Secretion,G03.442;G07.475
29884986,"Adult;Amphotericin B;Antifungal Agents;Dermatomycoses;Fluconazole;Hand Dermatoses;Humans;Immunocompetence;Meningitis, Cryptococcal;Neck",M01.060.116;D02.540.576.500.500;D27.505.954.122.136;C01.539.800.200;C01.703.295;C17.800.838.208;D03.383.129.799.450;C17.800.338;B01.050.150.900.649.313.988.400.112.400.400;G12.460;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;A01.598
29884903,,
29884735,,
29884677,,
29883819,"Animals;Humans;Intraoperative Complications;Neurosurgical Procedures;Postoperative Complications;Reflex, Trigeminocardiac;Heart Arrest;Bradycardia;Cerebellopontine Angle;Hypotension;Neurosurgery;Trigeminal Nerve;Reflex, Trigeminocardiac",B01.050;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505;E04.525;C23.550.767;G11.561.731.781;C14.280.383;C14.280.067.319;C23.550.073.300;A08.186.211.132.810.428.200.462;C14.907.514;H02.403.810.425;A08.800.800.120.760;G11.561.731.781
29883738,,
29883535,Clinical Alarms;Infusion Pumps;Review,E07.230.200;E07.505;E07.858.082.505;V02.600.500;V02.912
29882698,Gender Identity,F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200
29882456,Myelin Sheath;Pathology;Whole Exome Sequencing,A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;H02.403.650;E05.393.760.700.825.500
29881733,,
29881132,"Clinical Trials as Topic;Consent Forms;Ethics Committees, Research;Ethics, Research;Humans;Informed Consent;Prospective Studies",E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;I01.880.604.583.427.134;N03.706.535.489.134;N04.452.859.198;N05.715.360.300.715.245;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;K01.752.566.479.173;N05.350.670;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650
29880908,"Genetic Therapy;Humans;Immunotherapy, Adoptive;Neoplasms;Receptors, Antigen, T-Cell;T-Lymphocytes",E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04;D12.776.543.750.705.816.824;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29880876,"Animals;Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Cell Differentiation;Cell Line, Tumor;Cell Proliferation;Gene Expression Regulation, Neoplastic;Gene Silencing;Humans;Mice;N-Myc Proto-Oncogene Protein;Neuroblastoma",B01.050;D12.776.260.103.500;D12.776.260.108.092;D12.776.930.125.500;D12.776.930.127.092;G04.152;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G05.308.370;G05.308.203.374;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
29880692,Adult;Blood Chemical Analysis;Cell-Free Nucleic Acids;Fetal Development;Fetal Monitoring;Gestational Age;Humans;Pilot Projects;Pregnancy;Premature Birth;Prenatal Care;Young Adult,M01.060.116;E01.370.225.124.100;E05.200.124.100;D13.444.154;G07.345.500.325.235;G08.686.784.170.157;E01.370.378.230;E01.370.520.230;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G08.686.784.769;C13.703.420.491.500;E02.760.786;N02.421.143.620.704;N02.421.585.786;M01.060.116.815
29880614,,
29880296,"Contrast Media;Feasibility Studies;Groin;Humans;Lymph Nodes;Lymphatic Vessels;Lymphography;Magnetic Resonance Imaging;Microbubbles;Middle Aged;Needles;Predictive Value of Tests;Reproducibility of Results;Retrospective Studies;Ultrasonography, Interventional",D27.505.259.500;D27.720.259;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;A01.923.047.365;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;A15.382.520.301;E01.370.350.700.475;E01.370.350.825.500;E07.553;M01.060.116.630;E07.612;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.850.855;E04.502.890
29879431,"Animals;Biomarkers, Tumor;Cardiovascular Diseases;Cholesterol, HDL;Humans;Hypolipidemic Agents;Lipid Metabolism;Neoplasms;Risk Assessment;Risk Factors;Neoplasms;Cholesterol;Hypoalphalipoproteinemias;Mortality",B01.050;D23.101.140;C14;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071;D27.505.954.557.500;G03.458;C04;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C04;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;C16.320.565.398.500.330;C18.452.584.500.875.330;C18.452.648.398.500.330;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
29879430,,
29878075,,
29877946,"Child;Fracture Fixation;Fractures, Bone;Humans;Postoperative Care;Preoperative Care;Tomography, X-Ray Computed",M01.060.406;E04.555.300;C26.404;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.700;E04.604.500;N02.421.585.722.700;E02.760.795;E04.604.750;N02.421.585.795;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29877918,"Acetabulum;Adolescent;Adult;Child;Femur;Hip Dislocation;Humans;Longitudinal Studies;Middle Aged;Osteotomy;Range of Motion, Articular;Retrospective Studies;Young Adult",A02.835.232.043.825.108;M01.060.057;M01.060.116;M01.060.406;A02.835.232.043.650.247;C05.550.518.384;C26.289.384;C26.531.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;E04.555.580;E01.370.600.700;G11.427.760;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
29877714,Bronchoalveolar Lavage;Child;Microbiota,E05.927.100;M01.060.406;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29876905,Encephalitis;Hashimoto Disease;Humans,C10.228.140.430;C19.874.871.102.500;B01.050.150.900.649.313.988.400.112.400.400
29876711,Abscess;Methicillin-Resistant Staphylococcus aureus,C01.539.830.025;C23.550.470.756.100;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500
29876584,"Respiration, Artificial;Tetralogy of Fallot",E02.041.625;E02.365.647.729;E02.880.820;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29876368,Enterobacteriaceae,B03.440.450.425;B03.660.250.150
29875405,,
29875258,,
29874614,,
29874592,Ants;Epigenomics;Genome,B01.050.500.131.617.720.500.500.875.205;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.360.340
29874515,,
29874381,,
29874142,,
29873895,,
29873505,Vena Cava Filters,E07.695.207.500
29873395,Artificial Intelligence;Attitude of Health Personnel;Dermatology;Humans;Physician-Patient Relations,G17.035.250;L01.224.050.375;F01.100.050;N05.300.100;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.650.675;N05.300.660.625
29872963,Body Mass Index;Dyslipidemias;Hypertension;Obesity,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C18.452.584.500;C14.907.489;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29872913,"Angiography, Digital Subtraction;Gadolinium;Intracranial Aneurysm;Magnetic Resonance Imaging;Risk Factors",E01.370.350.600.350.700.060;E01.370.350.700.060.060;E01.370.350.700.700.060;E01.370.350.760.060;E01.370.370.050.060;D01.268.558.362.484;D01.552.550.399.484;C10.228.140.300.510.600;C14.907.055.635;C14.907.253.560.300;E01.370.350.825.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29872881,Pulmonary Veins;Risk Factors;General Surgery,A07.015.908.713;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H02.403.810.300
29872359,,
29871919,"Animals;DEAD-box RNA Helicases;DNA, Viral;Dendritic Cells;Host-Pathogen Interactions;Humans;Leukemia Virus, Murine;Macrophages;Mice;Mice, Inbred C57BL;Nucleotidyltransferases;RNA, Viral;Retroviridae Infections",B01.050;D08.811.913.696.445.735.720.249;D13.444.308.568;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;B04.613.807.375.525;B04.820.650.375.525;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D08.811.913.696.445;D13.444.735.828;C02.782.815
29871822,Esophagus;Lung;Regeneration,A03.556.875.500;A04.411;G16.762
29871506,,
29870817,Adult;Algorithms;Behavior;Brain;Cognition;Connectome;Datasets as Topic;Humans;Machine Learning;Magnetic Resonance Imaging;Sample Size;Young Adult;Machine Learning;Sample Size,M01.060.116;G17.035;L01.224.050;F01.145;A08.186.211;F02.463.188;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;E01.370.350.825.500;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;M01.060.116.815;G17.035.250.500;L01.224.050.375.530;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762
29870737,"Intrauterine Devices, Copper;Intrauterine Devices;Intrauterine Device Expulsion;Long-Acting Reversible Contraception",E07.190.250.510.520.300;E07.190.250.510;E05.325.578.500;E02.875.194.589
29870674,Breast Feeding;Maternal Health,F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;N01.400.900.500
29870511,"Humans;Lip;Mandible;Osteogenesis, Distraction;Pierre Robin Syndrome;Reconstructive Surgical Procedures;Tongue;Treatment Outcome",B01.050.150.900.649.313.988.400.112.400.400;A01.456.505.631.515;A14.549.336;A02.835.232.781.324.502.632;A14.521.632;E04.555.120.690;C05.500.460.606;C05.660.207.540.460.606;C07.320.440.606;C07.650.500.460.606;C16.131.621.207.540.460.606;C16.131.850.500.460.606;E04.680;A03.556.500.885;A14.549.885;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29870136,Global Health,H02.403.371;N01.400.337
29870024,,
29869139,,
29869115,Angiography;Fibromuscular Dysplasia;Hypertension,E01.370.350.700.060;E01.370.370.050;C14.907.137.372;C14.907.489
29868987,Glucose Tolerance Test,E01.370.225.124.100.355;E01.370.374.355;E05.200.124.100.355
29868751,,
29868540,United States;Heart Failure;Mortality;Risk Factors,Z01.107.567.875;C14.280.434;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29867923,"Th17 Cells;Multiple Sclerosis;Killer Cells, Natural",A11.118.637.555.567.550.500.400.915;A11.118.637.555.567.569.200.400.915;A11.118.637.555.567.569.500.400.915;A15.145.229.637.555.567.550.500.400.770;A15.145.229.637.555.567.569.200.400.770;A15.145.229.637.555.567.569.500.400.770;A15.382.490.555.567.550.500.400.915;A15.382.490.555.567.569.200.400.915;A15.382.490.555.567.569.500.400.915;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537
29867857,Microbiota;Triple Negative Breast Neoplasms,G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C04.588.180.788;C17.800.090.500.788
29867673,Creativity;Paranoid Disorders,F01.752.264;F02.463.785.302;F03.700.450
29867220,,
29866654,Alternative Splicing;Erythropoiesis;Hematopoiesis;Myeloid Progenitor Cells,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;G04.152.825.414;G09.188.343.414;G04.152.825;G09.188.343;A11.148.378.590;A11.627.635;A11.872.378.590;A15.378.316.378.590
29866625,"Adult;Benchmarking;Emergency Service, Hospital;Humans;Middle Aged;Resuscitation;Retrospective Studies;Survival Rate;Thoracic Injuries;Thoracotomy;Video Recording;Emergency Service, Hospital;Quality Improvement;Resuscitation;Thoracotomy",M01.060.116;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.365.647;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C26.891;E04.928.760;L01.280.960;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;J01.293.754;N04.761.744;E02.365.647;E04.928.760
29866095,"Cohort Studies;Cross-Sectional Studies;Health Knowledge, Attitudes, Practice;Humans;Surveys and Questionnaires;Urinary Bladder, Overactive;Urinary Bladder, Overactive;Women",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780;C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780;M01.975
29865090,"Clinical Competence;Clinical Trials as Topic;Humans;Infant;Observer Variation;Oligonucleotides;Oligonucleotides, Antisense;Physical Therapists;Reproducibility of Results;Spinal Muscular Atrophies of Childhood;Teaching;Outcome Assessment (Health Care);Reproducibility of Results;Muscular Atrophy, Spinal",I02.399.630.210;N04.761.210;N05.715.175;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;D13.695.578.424;D13.150.480;D13.444.600.150.640;D13.695.578.424.480;D27.720.470.530.600.150.640;M01.526.485.790;N02.360.790;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C10.228.854.468.800;C10.574.500.812;C10.574.562.500.750;C10.668.467.500.750;C16.320.400.765;I02.903;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C10.228.854.468;C10.574.562.500;C10.668.467.500
29864629,"Adolescent;Child;Child, Preschool;Decision Support Techniques;Humans;Pulmonary Embolism;Child;Decision Support Techniques;Pulmonary Embolism",M01.060.057;M01.060.406;M01.060.406.448;E05.245;L01.313.500.750.190;B01.050.150.900.649.313.988.400.112.400.400;C08.381.746;C14.907.355.350.700;M01.060.406;E05.245;L01.313.500.750.190;C08.381.746;C14.907.355.350.700
29864479,"Academies and Institutes;Animals;Consumer Product Safety;Cyclooctanes;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment;Safety",N03.540.052;B01.050;N06.850.210;D02.455.426.392.368.408;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N06.850.135.060.075
29864098,,
29864067,,
29864047,,
29864040,,
29864037,,
29863929,"Arthroplasty, Replacement;Databases, Factual;Episode of Care;Health Expenditures;Humans;Insurance, Health;Mandatory Programs;Medicare;Orthopedics;Outcome Assessment (Health Care);Patient Care Bundles;Retrospective Studies;Statistics, Nonparametric;United States;Hospitals;Medicare",E04.555.110.110;E04.650.110;E04.680.101.110;L01.313.500.750.300.188.400;L01.470.750.750;E02.760.300;N02.421.585.300;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;I01.880.604.622;N03.706.657;N04.452.521;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;H02.403.810.494;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E02.765;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;Z01.107.567.875;N02.278.421;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696
29863927,"Adolescent;Child;Child Health Services;Child, Preschool;Databases, Factual;Health Services Accessibility;Hospitals, Pediatric;Humans;Infant;Insurance Coverage;Insurance, Health;Medicaid;Outcome Assessment (Health Care);Poverty;United States;Child Health",M01.060.057;M01.060.406;N02.421.143.130;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;N04.590.374.350;N05.300.430;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N03.219.521.576.265;N03.219.521.576.343;N03.219.521.346.506.564.655;N03.706.615.693;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;I01.880.735.634;I01.880.853.996.535;N01.824.600;Z01.107.567.875;N01.400.225
29863725,"Anticoagulants;Aptamers, Nucleotide;Cardiopulmonary Bypass;Crystallography, X-Ray;Drug Combinations;Factor Xa;Factor Xa Inhibitors;Heparin;Humans;Postoperative Hemorrhage;Protein Conformation",D27.505.954.502.119;D13.695.578.424.224;E04.292.413;E05.196.309.742.225;D26.310;D08.811.277.656.300.760.315;D08.811.277.656.959.350.315;D12.776.124.125.400.315;D23.119.400.315;D27.505.519.389.745.800.449.500;D27.505.954.502.119.500.500;D09.698.373.400;B01.050.150.900.649.313.988.400.112.400.400;C23.550.414.941;C23.550.767.850;G02.111.570.820.709
29863638,,
29863637,,
29863636,,
29862484,Adolescent;Body Composition;Bone Density;Child;Child Nutritional Physiological Phenomena;Crohn Disease;Diet;Food Additives;Food Analysis;Humans;Patient Acuity;Retrospective Studies;Risk Factors;Statistics as Topic;United States;Crohn Disease;Food Additives,M01.060.057;G02.111.130;G03.180;G07.100.049;G11.427.100;M01.060.406;G07.203.650.220;C06.405.205.731.500;C06.405.469.432.500;G07.203.650.240;D27.720.372.300;G07.203.300.514.500;J02.500.514.500;E05.362;J01.576.423.850.100;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980.438.475.456;N05.715.360.300.800.438.375.364;N06.850.520.308.980.438.475.364;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;Z01.107.567.875;C06.405.205.731.500;C06.405.469.432.500;D27.720.372.300;G07.203.300.514.500;J02.500.514.500
29862416,Inflammation;Serotonin Uptake Inhibitors,C23.550.470;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900
29862374,Neonatal Screening;Public Health Surveillance,E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;E05.318.308.980.438.700.324;N05.715.360.300.800.438.625.324;N06.850.520.308.980.438.700.324;N06.850.780.675.487
29861178,"Adolescent;Adult;Aged;Antibodies;Antibodies, Viral;Cohort Studies;Hemagglutination Inhibition Tests;Hemagglutinin Glycoproteins, Influenza Virus;Humans;Influenza A Virus, H1N1 Subtype;Influenza Vaccines;Middle Aged;Young Adult;Hemagglutinins;Influenza, Human;Vaccines",M01.060.057;M01.060.116;M01.060.116.100;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.225.812.735.370;E05.200.812.735.370;E05.478.594.760.370;D12.776.964.970.880.345.500;B01.050.150.900.649.313.988.400.112.400.400;B04.820.545.405.400.214;D20.215.894.899.302;M01.060.116.630;M01.060.116.815;D27.505.696.477.136.377;C02.782.620.365;C08.730.310;D20.215.894
29861175,"Amino Acids, Dicarboxylic;Animals;CLOCK Proteins;Carrier Proteins;Cell Hypoxia;Cells, Cultured;Circadian Clocks;Culture Media;Hydrogen-Ion Concentration;Hypoxia-Inducible Factor 1, alpha Subunit;Lysosomes;Mechanistic Target of Rapamycin Complex 1;Mice;Phosphoproteins;RNA Interference;RNA, Small Interfering;Ras Homolog Enriched in Brain Protein;Signal Transduction;T-Lymphocytes;Transcriptome;Tuberous Sclerosis Complex 2 Protein;Neoplasms;Hypoxia;Lysosomes;Hydrogen-Ion Concentration",D12.125.119;B01.050;D08.811.913.050.134.415.500.049;D12.644.360.138.100;D12.776.260.103.562;D12.776.476.156.200;D12.776.930.125.562;D12.776.157;G03.197.300;G04.270.300;A11.251;G07.180.562.094.500;D27.720.470.305;E07.206;G02.300;D12.776.260.103.625.750;D12.776.930.125.625.750;A11.284.430.214.190.875.190.550;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;B01.050.150.900.649.313.992.635.505.500;D12.776.744;G05.308.203.374.790;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D08.811.277.040.330.300.400.488;D12.644.360.525.488;D12.776.157.325.515.488;D12.776.476.525.488;D12.776.631.650.665;G02.111.820;G04.835;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;G02.111.873.750;G05.297.700.750;G05.360.920;D12.644.360.938;D12.776.476.935;D12.776.624.776.769;C04;C23.888.852.079;A11.284.430.214.190.875.190.550;G02.300
29861165,,
29861107,"Adult;Base Sequence;Calcium;Calcium Channels;Fetus;HEK293 Cells;Humans;Hyperparathyroidism;Infant, Newborn;Ion Transport;Maternal-Fetal Exchange;Mutation;Pedigree;Placenta;Pregnancy;TRPV Cation Channels;Calcium;Hyperparathyroidism;Placenta;Transients and Migrants",M01.060.116;G02.111.570.080;G05.360.080;L01.453.245.667.080;D01.268.552.100;D01.552.539.288;D23.119.100;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;A16.378;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;C19.642.355;M01.060.703.520;G03.143.500;G08.686.784.769.455;G05.365.590;E05.393.673;A16.710;G08.686.784.769;D12.776.157.530.400.901.888;D01.268.552.100;D01.552.539.288;D23.119.100;C19.642.355;A16.710;M01.920
29861105,"Alleles;Animals;Axons;COS Cells;Cercopithecus aethiops;Child;Child, Preschool;HEK293 Cells;Humans;Infant;Intellectual Disability;Lipids;Mice, Knockout;Motor Neuron Disease;Muscle Hypotonia;Mutant Proteins;Mutation;Nerve Tissue Proteins;Rats, Sprague-Dawley;Spectrin;Axon Initial Segment;Cytoskeleton",G05.360.340.024.340.030;B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A11.251.210.172.500;A11.329.228.220;B01.050.150.900.649.313.988.400.112.199.120.126.110;M01.060.406;M01.060.406.448;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;D10;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C10.574.562;C10.668.467;C10.597.613.575;C23.888.592.608.575;D12.776.602;G05.365.590;D12.776.631;B01.050.150.900.649.313.992.635.505.700.750;D12.776.220.980;D12.776.543.850;A08.675.542.145.250;A11.284.180.075.125;A11.671.137.170;A11.671.501.145.250;A11.284.430.214.190.750
29860986,Cancer Vaccines;Humans;Immunotherapy;Pancreatic Neoplasms;Immunotherapy;Pancreatic Neoplasms,D20.215.894.200;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E02.095.465.425;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29860705,Cardiopulmonary Resuscitation;Caregivers;Critical Care;Emergency Medical Services;Humans;Out-of-Hospital Cardiac Arrest;Heart Arrest;Cardiopulmonary Resuscitation,E02.365.647.110;M01.085;M01.526.485.200;N02.360.200;E02.760.190;N02.421.585.190;N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;C14.280.383.610;C14.280.383;E02.365.647.110
29860671,,
29860495,"Animals;Antioxidants;Biomarkers;Cell Cycle Proteins;Chromosomal Proteins, Non-Histone;De Lange Syndrome;Gene Expression Profiling;Gene Expression Regulation;Genomic Instability;Humans;In Vitro Techniques;Mutation;Oxidative Stress;Zebrafish",B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;D23.101;D12.776.167;D12.776.660.235;D12.776.664.235;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;E05.393.332;G05.308;C23.550.362;G05.365.590.335;G05.370;B01.050.150.900.649.313.988.400.112.400.400;E05.481;G05.365.590;G03.673;G07.775.750;B01.050.150.900.493.200.244.828
29860493,,
29860405,,
29860294,,
29860082,"Brain;Brain Mapping;Humans;Image Processing, Computer-Assisted;Models, Neurological;Neural Pathways",A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E05.599.395.642;A08.612
29860018,"Academies and Institutes;Alkanes;Animals;Consumer Product Safety;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;D02.455.326.146;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29859719,Quality of Life,I01.800;K01.752.400.750;N06.850.505.400.425.837
29859676,"Cerebrovascular Circulation;Infant, Newborn",G09.330.100.159;M01.060.703.520
29859269,Brain Injuries;Child Abuse;Craniocerebral Trauma;Magnetic Resonance Imaging;Shaken Baby Syndrome;Spinal Injuries,C10.228.140.199;C10.900.300.087;C26.915.300.200;I01.198.240.856.350.250;I01.880.735.900.350.250;C10.900.300;C26.915.300;E01.370.350.825.500;C10.900.300.087.850;C26.915.300.200.825;C26.117.500
29858391,"Animals;Cytochromes c;Humans;Hydrolases;Lipids;Mitochondria, Heart;Oxidation-Reduction;Oxidative Stress;Plasmalogens;Vinyl Compounds",B01.050;D08.244.286.100;D12.776.422.220.286.100;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277;D10;A11.284.430.214.190.875.564.627.603;A11.284.835.626.627.603;G02.700;G03.295.531;G03.673;G07.775.750;D10.570.755.375.760.400.985.820;D02.455.326.271.884
29858364,Costs and Cost Analysis;Heart-Assist Devices,N03.219.151;E04.050.430;E07.695.300.300;E07.858.082.374.300
29858357,"Arthritis, Psoriatic;Humans;Intersectoral Collaboration;Psoriasis;Research;Biomarkers;Outcome Assessment (Health Care);Psoriasis;Arthritis, Psoriatic;Research",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;B01.050.150.900.649.313.988.400.112.400.400;N04.226;C17.800.859.675;H01.770.644;D23.101;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H01.770.644
29858355,"Arthritis, Psoriatic;Dermatology;Humans;Psoriasis;Research;Rheumatology;Education;Psoriasis;Arthritis, Psoriatic;Research",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;C17.800.859.675;H01.770.644;H02.403.429.730;I02;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H01.770.644
29858286,,
29858280,Complement System Proteins;Hemolytic-Uremic Syndrome,D12.776.124.486.274;C12.777.419.936.463;C13.351.968.419.936.463;C15.378.071.141.610;C15.378.140.855.925.500
29857333,Biocompatible Materials;Cartilage;Dermal Fillers;Durapatite;Humans;Hyaluronic Acid;Nose;Reoperation;Rhinoplasty;Surgical Flaps,D25.130;D27.720.102.130;J01.637.051.130;A02.165;A10.165.382;D27.720.102.461;D01.029.260.700.675.374.075.025.300.150;D01.146.360.050.300.200;D01.578.122.477.300;D01.695.625.675.650.075.025.300.150;B01.050.150.900.649.313.988.400.112.400.400;D09.698.373.475;A01.456.505.733;A04.531;A09.531;E04.690;E02.218.755;E04.580.392.500;E04.680.650;A10.850.710;E07.862.710
29857119,Atlas;Quality Control;Whole Genome Sequencing,V02.150;J01.897.608;E05.393.760.700.825
29856956,"Animals;Cell Differentiation;Cell Line, Tumor;Cell Lineage;Electroporation;Hematopoiesis;Hematopoietic Stem Cells;Humans;Immunotherapy;Leukemia, Myeloid, Acute;Macaca mulatta;Mice;Mice, Inbred NOD;Mice, Knockout;Mice, SCID;Neoplasm Transplantation;RNA, Guide;Reactive Oxygen Species;Sialic Acid Binding Ig-like Lectin 3;T-Lymphocytes;Clustered Regularly Interspaced Short Palindromic Repeats;Leukemia, Myeloid, Acute;Hematopoiesis;Immunotherapy",B01.050;G04.152;A11.251.210.190;A11.251.860.180;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;E05.200.500.454;E05.242.448;E05.301.500;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.337.539.275;B01.050.150.900.649.313.988.400.112.199.120.510.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.150.900.649.313.992.635.505.500.550.780;E05.624;D13.444.735.790.552.625;D01.339.431;D01.650.775;D12.776.503.921.400;D23.050.301.264.900.565;D23.101.100.900.565;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C04.557.337.539.275;G04.152.825;G09.188.343;E02.095.465.425
29856734,"Bacterial Proteins;DNA Damage;Escherichia coli;Gene Expression Regulation, Bacterial;Gene Regulatory Networks;Genes, Bacterial;Kinetics;Models, Genetic;Promoter Regions, Genetic;Repressor Proteins;SOS Response (Genetics);Serine Endopeptidases;Time Factors",D12.776.097;G05.200;B03.440.450.425.325.300;B03.660.250.150.180.100;G05.308.300;G05.360.080.689.360;G05.360.340.024.340.364.249;G05.360.340.358.024.249;G05.360.340.358.207.249;G01.374.661;G02.111.490;E05.599.395.397;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.260.703;D12.776.930.780;G02.111.222.830;G05.219.830;D08.811.277.656.300.760;D08.811.277.656.959.350;G01.910.857
29856625,,
29856520,Nasal Polyps,C08.460.572;C09.603.557;C23.300.825.557
29855864,Gender Identity;Sexual Behavior,F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;F01.145.802
29855837,"Adult;Allied Health Personnel;Child;Child Abuse;Child, Preschool;Family;Home Care Services;House Calls;Humans;Maternal Behavior;Parenting;Parents;Pennsylvania;Program Evaluation;Qualitative Research;Retrospective Studies;Young Adult;Child Abuse",M01.060.116;M01.526.485.067;N02.360.067;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406.448;F01.829.263;I01.880.853.150;N02.421.143.524;N02.421.539.089;N04.452.758.307;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.215;F01.829.263.370.310;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.337.820;N04.761.685;N05.715.360.650;H01.770.644.241.850;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;I01.198.240.856.350.250;I01.880.735.900.350.250
29855606,"Adult;Alleles;Benzoxazines;Botswana;Central Nervous System;Cohort Studies;Cytochrome P-450 Enzyme System;Genotype;HIV Infections;Humans;Polymorphism, Single Nucleotide;Reverse Transcriptase Inhibitors",M01.060.116;G05.360.340.024.340.030;D03.383.533.249;D03.633.100.209;Z01.058.290.175.230;A08.186;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.244.453;D08.811.682.690.708.170;D12.776.422.220.453;G05.380;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;D27.505.519.389.675.850;D27.505.954.122.388.077.750
29855356,Synucleins,D12.776.631.860
29852896,Forecasting,I01.320
29852831,Multiple Sclerosis,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29852509,,
29852258,Eosinophils;Eosinophilic Esophagitis;Quality of Life,A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;I01.800;K01.752.400.750;N06.850.505.400.425.837
29852051,,
29851928,"Animals;Antineoplastic Combined Chemotherapy Protocols;BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;Capecitabine;Furans;Gene Expression Regulation, Neoplastic;Humans;Indazoles;Indoles;Ketones;Mutation;Phthalazines;Piperazines;Piperidines;Poly(ADP-ribose) Polymerase Inhibitors;Poly(ADP-ribose) Polymerases;Prognosis;Randomized Controlled Trials as Topic;Survival Analysis;Vinblastine;Vinorelbine",B01.050;E02.183.750.500;E02.319.077.500;E02.319.310.037;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;D12.776.313.249;D12.776.624.776.101;D12.776.660.105;C04.588.180;C17.800.090.500;D03.383.742.680.245.500.425;D03.383.742.698.875.404.425;D13.570.230.329.313;D13.570.685.245.500.425;D03.383.312;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.539.487;D03.633.100.449;D03.633.100.473;D02.522;G05.365.590;D03.383.710.605;D03.383.606;D03.383.621;D27.505.519.389.739;D27.505.954.248.692;D08.811.913.400.725.115.690;E01.789;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;D03.132.436.681.827.650;D03.633.100.473.402.681.827.650;D03.132.436.681.827.915;D03.633.100.473.402.681.827.915
29851842,"Adult;Biomarkers;Cohort Studies;Disease Progression;HIV Infections;Humans;Lipoproteins, HDL;Middle Aged;Prospective Studies;Receptor for Advanced Glycation End Products;Retrospective Studies;Risk Factors",M01.060.116;D23.101;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.656;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;D10.532.432;D12.776.521.479;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.543.750.615;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29851731,,
29851702,,
29851669,,
29851207,,
29850229,,
29849948,Analgesia;Dexmedetomidine,E03.091;D03.383.129.308.245
29849141,"5-Methylcytosine;Adoptive Transfer;Aged;Alleles;Antigens, CD19;Cell Differentiation;Clinical Trials as Topic;Clone Cells;Dioxygenases;Epigenesis, Genetic;HEK293 Cells;Humans;Immunotherapy;Leukemia, Lymphocytic, Chronic, B-Cell;Mutation;Recombinant Fusion Proteins;T-Lymphocytes;Transgenes",D03.383.742.698.421.500;E02.095.465.425.400.330.050;E05.478.550.520.050;M01.060.116.100;G05.360.340.024.340.030;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;G04.152;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;A11.251.353;D08.811.682.690.416;G05.308.203;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.337.428.080.125;C15.604.515.560.080.125;C20.683.515.528.080.125;G05.365.590;D12.776.828.300;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;G05.360.340.024.340.825
29848492,"Animals;Autism Spectrum Disorder;Autistic Disorder;Chromatin;Humans;Mice;Mice, Inbred C57BL;Mutation;Neurogenesis;RNA Polymerase II;Regulatory Sequences, Nucleic Acid;Transcription, Genetic",B01.050;F03.625.164.113;F03.625.164.113.500;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G05.365.590;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;D08.811.913.696.445.735.270.762;G02.111.570.080.689;G05.360.080.689;G02.111.873;G05.297.700
29848400,"Adult;Communication;Heart Defects, Congenital;Home Care Services;Humans;Infant;Infant, Newborn;Parents;Patient Discharge;Quality of Life;Stress, Psychological;Telemedicine;United States;Weight Gain;Infant;Telemedicine;Telemedicine",M01.060.116;F01.145.209;L01.143;C14.240.400;C14.280.400;C16.131.240.400;N02.421.143.524;N02.421.539.089;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;I01.800;K01.752.400.750;N06.850.505.400.425.837;F01.145.126.990;F02.830.900;H02.403.840;L01.178.847.652;N04.590.374.800;Z01.107.567.875;C23.888.144.243.926;G07.345.249.314.120.200.926;M01.060.703;H02.403.840;L01.178.847.652;N04.590.374.800;H02.403.840;L01.178.847.652;N04.590.374.800
29848071,Animals;Gene Transfer Techniques;Genetic Therapy;Histocytological Preparation Techniques;Macaca fascicularis;Macaca mulatta;Retina;Histology;Immunohistochemistry;Retina,B01.050;E05.393.350;E02.095.301;E05.393.420.301;E01.370.225.500.620;E01.370.225.750.600;E05.200.500.620;E05.200.750.600;B01.050.150.900.649.313.988.400.112.199.120.510.520;B01.050.150.900.649.313.988.400.112.199.120.510.550;A09.371.729;H01.158.100.656;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;A09.371.729
29847785,"Receptors, AMPA;Auditory Cortex;Autistic Disorder;Epilepsy;Neurodevelopmental Disorders",D12.776.157.530.400.400.500.100;D12.776.543.550.450.500.200.100;D12.776.543.585.400.500.200.100;D12.776.543.750.720.200.450.400.100;A08.186.211.200.885.287.500.814.249;A08.186.211.200.885.287.500.863.297;F03.625.164.113.500;C10.228.140.490;F03.625
29847652,"Administration, Intranasal;Amnion;Animals;Axons;Cell Survival;Cytokines;Disease Models, Animal;Mice;Mice, Inbred C57BL;Myelin Sheath;Nerve Crush;Neuroprotection;Neuroprotective Agents;Nystagmus, Optokinetic;Optic Nerve Injuries;Retinal Ganglion Cells",E02.319.267.120.655.500;A10.615.284.277;A16.254.750.277;B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;G04.346;D12.644.276.374;D12.776.467.374;D23.529.374;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;E04.525.210.560;G11.561.645;D27.505.696.706.548;D27.505.954.427.575;G14.350.378.500;C10.292.200.750;C10.292.700.475;C10.900.300.218.550;C11.640.530;C26.915.300.400.650;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875
29847639,"Adult;DNA;DNA Copy Number Variations;DNA Mutational Analysis;Eye Proteins;Genes, Dominant;Genes, X-Linked;High-Throughput Nucleotide Sequencing;Humans;Incidence;Mutation;Pedigree;Prevalence;Retinitis Pigmentosa;Retrospective Studies;Spain",M01.060.116;D13.444.308;G05.365.795.297.500;E05.393.760.700.300;D12.776.306;G05.360.340.024.340.240;G05.420.320;G05.360.340.024.340.500;G05.420.457;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;G05.365.590;E05.393.673;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C11.270.684;C11.768.585.658.500;C16.320.290.684;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.542.846
29847549,Biomedical Research;Causality;Communication;Communications Media;Humans;Internet;Language;Social Media,H01.770.644.145;N05.715.350.200;N06.850.490.625;F01.145.209;L01.143;L01.178;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;F01.145.209.399;L01.559;L01.178.751;L01.224.230.110.500.750
29847509,"Adult;Benzoxazines;Central Nervous System Diseases;Genomics;Genotype;HIV;HIV Infections;Humans;Middle Aged;Neurotransmitter Transport Proteins;Pharmacogenomic Testing;Polymorphism, Single Nucleotide;Receptors, Neurotransmitter;Reverse Transcriptase Inhibitors",M01.060.116;D03.383.533.249;D03.633.100.209;C10.228;H01.158.273.180.350;H01.158.273.343.350;G05.380;B04.820.650.589.650.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D12.776.157.530.562;D12.776.543.585.562;E01.370.225.562.500;E05.200.562.500;E05.393.435.500;N02.421.308.430.500;N02.421.726.233.221.500;G05.365.795.598;D12.776.543.750.720;D27.505.519.389.675.850;D27.505.954.122.388.077.750
29847366,"Anesthesia;Apnea;Capnography;Endoscopy;Humans;Monitoring, Physiologic;Photoplethysmography;Respiratory Rate;Treatment Outcome",E03.155;C08.618.085;C23.888.852.130;E01.370.386.700.150;E01.370.388.250;E04.502.250;B01.050.150.900.649.313.988.400.112.400.400;E01.370.520;E01.370.370.610.600;E01.370.600.875.875;G09.772.705.730;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29847143,Knee;Meniscus;Tissue Engineering,A01.378.610.450;A02.165.308.538;A10.165.382.350.163;E05.481.500.311.500;J01.293.069.249.500
29845767,,
29845420,"Adult;Aged;Aged, 80 and over;California;Cancer Survivors;Humans;Middle Aged;Oregon;Ostomy;Quality of Life;Rectal Neoplasms;Self Care;Self Report;Surveys and Questionnaires;Washington;Quality of Life;Rectal Neoplasms;Survivorship",M01.060.116;M01.060.116.100;M01.060.116.100.080;Z01.107.567.875.580.200;Z01.107.567.875.760.200;M01.860.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.560.550;Z01.107.567.875.580.550;E04.579;I01.800;K01.752.400.750;N06.850.505.400.425.837;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;E02.900;I03.050.563;N02.421.784.680;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875.560.900;Z01.107.567.875.580.900;I01.800;K01.752.400.750;N06.850.505.400.425.837;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;F01.058.144.500
29845213,"Animals;Cell Line, Tumor;Cell Proliferation;Coculture Techniques;Endothelial Cells;Gene Expression Regulation, Neoplastic;Lung Neoplasms;Mammary Neoplasms, Experimental;Melanoma, Experimental;Mice;Platelet Endothelial Cell Adhesion Molecule-1;Signal Transduction;Tissue Inhibitor of Metalloproteinase-1;Tumor Microenvironment",B01.050;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;E05.481.500.374;A11.436.275;G05.308.370;C04.588.894.797.520;C08.381.540;C08.785.520;C04.588.531.500;C04.619.590;E05.598.500.496.843;C04.557.465.625.650.510.525;C04.557.580.625.650.510.525;C04.557.665.510.525;C04.619.600;E05.598.500.496.937;B01.050.150.900.649.313.992.635.505.500;D12.776.395.550.200.131;D12.776.543.550.200.131;D23.050.301.264.900.131;D23.050.301.350.131;D23.101.100.900.131;G02.111.820;G04.835;D12.776.645.875.450;G04.366.500
29844336,,
29844205,"Adolescent;Adult;Allografts;Busulfan;Child;Child, Preschool;Cyclophosphamide;Disease-Free Survival;Hematopoietic Stem Cell Transplantation;Humans;Infant;Myeloablative Agonists;Retrospective Studies;Survival Rate;Transplantation Conditioning;Vidarabine",M01.060.057;M01.060.116;A01.941.500;D02.033.455.125.125;D02.455.326.146.100.050.500.100;D02.886.645.600.055.050.510.100;M01.060.406;M01.060.406.448;D02.455.526.728.650.730.243;D02.705.672.500.243;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D27.505.696.477.656.750;D27.505.954.248.589;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E02.095.465.425.450.800;E05.478.610.800;D03.633.100.759.590.138.900;D13.570.065.950;D13.570.583.138.900
29844136,,
29844122,,
29844014,"Allosteric Site;Amino Acid Sequence;Anesthetics, Intravenous;Binding Sites;Crystallography, X-Ray;Humans;Kinesin;Microtubules;Molecular Docking Simulation;Propofol;Anesthesia;Kinesin;Microtubules;Propofol;Tubulin",G02.111.570.120.147;G02.111.570.060;L01.453.245.667.060;D27.505.696.277.100.035.075;D27.505.954.427.210.100.035.075;G02.111.570.120;E05.196.309.742.225;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A11.284.430.214.190.750.602;E05.599.595.249;L01.224.160.249;D02.455.426.559.389.657.773;E03.155;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A11.284.430.214.190.750.602;D02.455.426.559.389.657.773;D05.750.078.734.800;D12.776.220.600.800;D12.776.631.920
29843248,Huntington Disease;HIV,C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;B04.820.650.589.650.350
29843109,Adult;Alcohol Drinking;Alcoholism;Cross-Sectional Studies;Family;Humans;Medical History Taking;Middle Aged;Mood Disorders;Risk Factors;Sleep Wake Disorders;Alcohol Drinking;Sleep;Sleep Initiation and Maintenance Disorders,M01.060.116;F01.145.317.269;C25.775.100.250;F03.900.100.350;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;E01.370.510;M01.060.116.630;F03.600;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.886;C23.888.592.796;F03.870;F01.145.317.269;F02.830.855;G11.561.803;C10.886.425.800.800;F03.870.400.800.800
29843048,Aging;Sleep;Unfolded Protein Response,G07.345.124;F02.830.855;G11.561.803;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850
29813154,,
29812996,,
29809295,Cytokines,D12.644.276.374;D12.776.467.374;D23.529.374
29809203,,
29809149,"Cell Biology;Computational Biology;Gene Expression;Mice;Rats;Muscle, Skeletal;Systems Biology;Tissue Engineering",H01.158.100.433;H01.158.273.160;H01.158.273.180;L01.313.124;G05.297;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.700;A02.633.567;A10.690.552.500;H01.158.273.180.800;E05.481.500.311.500;J01.293.069.249.500
29808010,,
29807781,Transforming Growth Factor beta;Prostatic Neoplasms,D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
29807216,"Adult;Analgesics, Opioid;Drug Prescriptions;Drug Utilization;Geography, Medical;Humans;Maternal Health;Patient Safety;Postpartum Period;Pregnancy;United States;Young Adult;Postpartum Period;Prescriptions",M01.060.116;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E02.319.307;N02.421.668.778.500;N04.452.706.477;H01.277.500.097;H02.403.352;B01.050.150.900.649.313.988.400.112.400.400;N01.400.900.500;N06.850.135.060.075.399;G08.686.702;G08.686.784.769;Z01.107.567.875;M01.060.116.815;G08.686.702;N02.421.668.778
29807065,Reinforcement (Psychology);Substance-Related Disorders,F02.463.425.770;C25.775;F03.900
29806733,,
29806580,Data Collection;Humans;Libraries;Pennsylvania;Public Health,E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;B01.050.150.900.649.313.988.400.112.400.400;J03.400.596;L01.346.596;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;H02.403.720;N01.400.550;N06.850
29806185,"Arrhythmias, Cardiac;Asthma;Child;Pharmacoepidemiology",C14.280.067;C23.550.073;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;H01.158.703.045;H02.403.720.500.650;H02.628.413
29806158,Accidental Falls;Therapeutics,N06.850.135.122;E02
29805107,Keratin-15;Radiation Injuries;Stem Cells;Neoplasms,D12.776.220.475.450.300.500;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;A11.872;C04
29805042,"Alleles;Amino Acid Sequence;Animals;Biotinylation;Cadherins;Catenins;Cleft Lip;Cleft Palate;Epithelium;Gene Deletion;Genetic Predisposition to Disease;Humans;Infant;Infant, Newborn;Mice;Mutation;Palate;Pedigree;Syndrome;Whole Exome Sequencing;Adherens Junctions;Cell Adhesion;Cleft Lip;Cleft Lip;Cleft Palate",G05.360.340.024.340.030;G02.111.570.060;L01.453.245.667.060;B01.050;E05.601.085;G02.111.109;G03.162;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;D12.776.220.145;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;A10.272;G05.365.590.762.320;G05.558.800.320;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;B01.050.150.900.649.313.992.635.505.500;G05.365.590;A14.521.658;A14.549.617;E05.393.673;C23.550.288.500;E05.393.760.700.825.500;A11.284.149.165.420.020;G04.022;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185
29804674,"Animals;Biological Assay;Cattle;Kinesin;Kinetochores;Microtubule-Associated Proteins;Microtubules;Sus scrofa;Microscopy, Fluorescence;Microtubule-Associated Proteins",B01.050;E05.091;B01.050.150.900.649.313.500.380.271;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A11.284.430.106.279.345.190.160.165.500;G05.360.160.165.500;D12.776.220.600.450;D12.776.631.560;A11.284.430.214.190.750.602;B01.050.150.900.649.313.500.880.399;E01.370.350.515.458;E05.595.458;D12.776.220.600.450;D12.776.631.560
29804288,,
29804122,"Congenital Hypothyroidism;Humans;Infant, Newborn;Ireland;Mass Screening;Retrospective Studies;Thyrotropin;Congenital Hypothyroidism;Thyrotropin",C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;Z01.542.467;Z01.639.587;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D06.472.699.631.525.883;D12.644.548.691.525.883;C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;D06.472.699.631.525.883;D12.644.548.691.525.883
29803797,Eosinophilic Esophagitis;Diagnosis;Food Hypersensitivity;Therapeutics,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;E01;C20.543.480.370;E02
29803589,"Angiography;Antihypertensive Agents;Blood Pressure;Blood Pressure Monitoring, Ambulatory;Denervation;Humans;Hypertension;Kidney;Medication Adherence;Middle Aged;Renal Artery;Single-Blind Method;Treatment Outcome",E01.370.350.700.060;E01.370.370.050;D27.505.954.411.162;E01.370.600.875.249;G09.330.380.076;E01.370.370.140.100;E01.370.520.500.100;E04.525.210;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;A05.810.453;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;A07.015.114.745;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29802901,Graft vs Host Disease,C20.452
29802752,"Adult;Aged;Bacteria;Colony Count, Microbial;Fractures, Open;Humans;Longitudinal Studies;Microbiota;Middle Aged;Pennsylvania;Prospective Studies;RNA, Ribosomal, 16S;Skin;Wound Healing;Wound Infection;Young Adult",M01.060.116;M01.060.116.100;B03;E01.370.225.875.220;E05.200.875.220;C26.404.311;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D13.444.735.686.670;A17.815;G16.762.891;C01.539.947;M01.060.116.815
29802147,Atherosclerosis;Percutaneous Coronary Intervention,C14.907.137.126.307;E04.100.814.529.968;E04.502.382.968
29801978,"Contrast Media;Image Enhancement;Microbubbles;Phantoms, Imaging;Ultrasonography;Urinary Bladder",D27.505.259.500;D27.720.259;E01.370.350.600.350;L01.224.308.380;E07.553;E07.671;E01.370.350.850;A05.810.890
29801771,,
29801192,,
29801097,Adult;Centers for Medicare and Medicaid Services (U.S.);Disabled Persons;Eligibility Determination;Employment;Health Policy;Humans;Medicaid;State Health Plans;United States,M01.060.116;I01.409.418.750.600.310;N03.540.348.500.500.600.550;M01.150;N04.452.264;N01.824.245;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;N03.349.650.480;Z01.107.567.875
29801032,,
29801024,,
29800306,,
29800080,,
29800040,,
29800030,,
29799989,,
29799911,,
29799829,Academic Medical Centers;Adolescent;Adult;Aged;Body Mass Index;Cross-Sectional Studies;Dermis;Epidermis;Face;Humans;Middle Aged;Neck;Predictive Value of Tests;Sensitivity and Specificity;Skin Aging;Ultrasonography,N02.278.020;M01.060.057;M01.060.116;M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;A17.815.180;A10.272.497;A17.815.250;A01.456.505;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;A01.598;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;G13.750.804;E01.370.350.850
29799508,Neuroblastoma;Polyamines,C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D02.092.782
29799130,Interleukin-6;Inflammation;Photochemotherapy;General Surgery,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;C23.550.470;E02.186.500;E02.319.685;E02.774.722;H02.403.810.300
29799024,,
29798794,Body Mass Index;Obesity,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29798762,"Angiography;Gastrointestinal Hemorrhage;History, 20th Century;History, 21st Century;Humans",E01.370.350.700.060;E01.370.370.050;C06.405.227;C23.550.414.788;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400
29797748,"Alopecia Areata;Celiac Disease;Child;Diet, Gluten-Free;Humans;Mass Screening;Parents;Alopecia",C17.800.329.937.122.147;C06.405.469.637.250;C18.452.603.250;M01.060.406;E02.642.249.265;G07.203.650.240.265;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;C17.800.329.937.122;C23.300.035
29797644,"Natural History;Anemia, Sickle Cell",H01.158.273.602;H01.770.552;K01.400.703;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
29797557,,
29797456,Adolescent;Complex Regional Pain Syndromes;Exercise Therapy;Face;Humans;Occupational Therapy,M01.060.057;C10.177.195;C10.668.829.250;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;A01.456.505;B01.050.150.900.649.313.988.400.112.400.400;E02.760.169.063.500.489;E02.831.489;H02.010.500
29797095,,
29796797,"Child;Child Abuse;Child, Preschool;Consensus;Craniocerebral Trauma;Hematoma, Subdural;Humans;Infant;Infant, Newborn;Retinal Hemorrhage;Rib Fractures;Societies, Medical;Spinal Injuries;Child Abuse;Child;Infant;Magnetic Resonance Imaging",M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;C10.900.300;C26.915.300;C10.228.140.300.535.450.400;C10.900.300.837.600;C14.907.253.573.400.450;C23.550.414.838.700;C23.550.414.913.700;C26.915.300.490.450;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C11.290.807;C11.768.710;C23.550.414.756.775;C26.404.593;C26.891.733;N03.540.828.589;C26.117.500;I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406;M01.060.703;E01.370.350.825.500
29796794,Calculi;Child;Contrast Media;Gadolinium;Gastrointestinal Diseases;Humans;Magnetic Resonance Imaging;Testicular Diseases;Ultrasonography;Abdomen;Adolescent;Child;Gadolinium;Magnetic Resonance Imaging,C23.300.175;M01.060.406;D27.505.259.500;D27.720.259;D01.268.558.362.484;D01.552.550.399.484;C06.405;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C12.294.829;C19.391.829;E01.370.350.850;A01.923.047;M01.060.057;M01.060.406;D01.268.558.362.484;D01.552.550.399.484;E01.370.350.825.500
29795796,,
29795429,,
29795426,,
29795408,,
29795365,,
29795209,,
29795194,"5-Methylcytosine;Animals;Animals, Newborn;Cells, Cultured;DNA Demethylation;DNA-Binding Proteins;Epigenesis, Genetic;Gene Expression Regulation, Developmental;Hepatocytes;High-Throughput Nucleotide Sequencing;Liver;Mice;Mice, Inbred C57BL;Mice, Knockout;Primary Cell Culture;Proto-Oncogene Proteins;Sequence Analysis, RNA;Signal Transduction",D03.383.742.698.421.500;B01.050;B01.050.050.282;A11.251;G02.111.188.500.500;G02.607.141.500.500;G03.219.500.500;D12.776.260;G05.308.203;G05.308.310;A11.436.348;E05.393.760.319;A03.620;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;D12.776.624.664.700;E05.393.760.710;G02.111.820;G04.835
29794923,Case-Control Studies;Early Ambulation;Humans;Length of Stay;Neurosurgical Procedures;Patient-Centered Care;Postoperative Care;Postoperative Period;Quality Improvement;Retrospective Studies;Spinal Cord,E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E02.760.169.063.500.335;E02.831.335;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E04.525;N04.590.233.727.407;E02.760.731.700;E04.604.500;N02.421.585.722.700;E04.614.750;N02.421.585.753.750;J01.293.754;N04.761.744;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A08.186.854
29794861,,
29794714,"Adipose Tissue;Genioplasty;Humans;Informed Consent;Mandible;Maxilla;Orthognathic Surgical Procedures;Patient Care Planning;Postoperative Complications;Preoperative Care;Sleep Apnea, Obstructive;Treatment Outcome",A10.165.114;E06.645.562.249;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;A02.835.232.781.324.502.632;A14.521.632;A02.835.232.781.324.502.645;A14.521.645;E04.545.562;E04.555.580.289;E06.645.562;N04.590.233.624;C23.550.767;E02.760.795;E04.604.750;N02.421.585.795;C08.618.085.852.850;C10.886.425.800.750.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29794709,"Anastomosis, Surgical;Chylothorax;Humans;Infant;Microsurgery;Postoperative Care;Thoracic Duct;Veins;Venules",E04.035;C08.528.142;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E04.494;E05.591.580;E02.760.731.700;E04.604.500;N02.421.585.722.700;A15.382.520.301.750;A07.015.908;A07.015.461.920;A07.015.908.952
29794518,,
29794236,,
29793996,,
29793837,"Child;Diagnostic Imaging;Genetic Predisposition to Disease;Humans;Neoplasms, Radiation-Induced;Radiation, Ionizing;Syndrome",M01.060.406;E01.370.350;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;C04.682;C26.733.476;G01.750.748.500.476;G01.750.750;C23.550.288.500
29793747,Checklist;Humans;Pregnancy;Referral and Consultation,N05.715.360.300.179;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;N04.452.758.849
29792564,"Adolescent;Bisexuality;Cognition;HIV Infections;Homosexuality, Male;Humans;Resilience, Psychological;Young Adult;HIV;Adolescent",M01.060.057;F01.145.802.975.200;G08.686.867.200;F02.463.188;C02.782.815.616.400;C02.800.801.400;C20.673.480;F01.145.802.975.500.600;G08.686.867.500.600;B01.050.150.900.649.313.988.400.112.400.400;F02.940;M01.060.116.815;B04.820.650.589.650.350;M01.060.057
29792542,"Adolescent;Adult;Child;Health Knowledge, Attitudes, Practice;Health Promotion;Humans;Urinary Bladder;Young Adult;Urinary Bladder;Health;Urinary Tract",M01.060.057;M01.060.116;M01.060.406;F01.100.150.500;N05.300.150.410;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;A05.810.890;M01.060.116.815;A05.810.890;N01.400;A05.810
29792383,Chondrogenesis,G07.345.500.325.377.625.180;G11.427.578.180
29792160,,
29791930,,
29791870,,
29791602,"Adenocarcinoma, Follicular;Carcinoma, Papillary;Diagnosis, Differential;Humans;Lymphatic Metastasis;Neoplasm Invasiveness;Thyroid Neoplasms",C04.557.470.200.025.060;C04.557.470.200.360;C04.557.470.700.360;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;C04.697.645;C23.550.727.645;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
29791513,"Animals;Antibodies, Viral;Cercopithecus aethiops;Epitopes;Guinea Pigs;Herpes Genitalis;Herpes Simplex Virus Vaccines;Immunization, Passive;Immunoglobulin G;Mice;Mice, Inbred BALB C;Simplexvirus;Vero Cells;Viral Envelope Proteins;Virus Internalization",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;B01.050.150.900.649.313.988.400.112.199.120.126.110;D23.050.550;B01.050.150.900.649.313.992.550;C02.256.466.382.290;C02.800.801.350;C12.294.329;C13.351.500.342;D20.215.894.899.290.400;E02.095.465.425.400.330;E05.478.550.520;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B04.280.382.100.750;A11.251.210.955;A11.436.955;D12.776.964.970.880;G06.920.881
29791137,,
29790959,Adult;Biomarkers;Case-Control Studies;Friedreich Ataxia;Gene Expression Profiling;Gene Expression Regulation;Gene Regulatory Networks;High-Throughput Nucleotide Sequencing;Humans;Inflammation;Inflammation Mediators;Middle Aged;Transcriptome,M01.060.116;D23.101;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;E05.393.332;G05.308;G05.360.080.689.360;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D23.469;M01.060.116.630;G02.111.873.750;G05.297.700.750;G05.360.920
29790754,"Acylation;Epigenomics;Histones;Mutation;Protein Processing, Post-Translational",G02.111.012;G02.607.063;G03.040;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G05.365.590;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
29789970,"Actin Cytoskeleton;Animals;Biomechanical Phenomena;Cell Adhesion;Cell Movement;Dendritic Cells;Dimethylpolysiloxanes;Integrins;Mice, Inbred C57BL;Myosins;Actins;Dendritic Cells",A11.284.430.214.190.750.050;B01.050;G01.154.090;G01.374.089;G04.022;G04.198;G07.568.500.180;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;D02.715.650.700.150;D05.750.900.850.150;D25.720.900.850.150;J01.637.051.720.900.850.150;D12.776.543.750.705.408;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260
29789718,"Adaptor Proteins, Signal Transducing;Cadherins;Cell Line, Tumor;Cellular Senescence;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cytoskeletal Proteins;Disease-Free Survival;Humans;LIM Domain Proteins;Liposarcoma;Piperazines;Progression-Free Survival;Proto-Oncogene Proteins c-mdm2;Pyridines",D12.644.360.024;D12.776.157.057;D12.776.476.024;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;A11.251.210.190;A11.251.860.180;G04.043;D08.811.913.696.620.682.700.646.500.875;D12.644.360.250.451;D12.776.167.200.451;D12.776.476.250.451;D08.811.913.696.620.682.700.646.500.937;D12.644.360.250.515;D12.776.167.200.515;D12.776.476.250.515;D12.776.220;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;D12.776.512;C04.557.450.550.420;C04.557.450.795.465;D03.383.606;E01.789.800.285;E05.318.740.998.738;N04.761.559.590.800.474;N05.715.360.575.575.800.474;N05.715.360.750.795.738;N06.850.520.830.998.825;D08.811.464.938.750.562;D12.776.624.664.700.185;D12.776.660.764;D03.383.725
29789559,,
29789393,Brain Edema;Glyburide;Infarction,C10.228.140.187;D02.886.590.795.575;D02.948.828.575;C23.550.513.355;C23.550.717.489
29789300,,
29789281,Adolescent;Health;Homeless Youth;Internet;Smartphone;Social Media,M01.060.057;N01.400;M01.325.400;L01.224.230.110.500;L01.224.230.260.550.500.500;L01.178.751;L01.224.230.110.500.750
29789017,Anxiety Disorders;Cognitive Behavioral Therapy;Health Plan Implementation;Humans;Psychotherapy;Reproducibility of Results;Retrospective Studies;Treatment Outcome,F03.080;F04.754.137.350;N03.349.300;B01.050.150.900.649.313.988.400.112.400.400;F04.754;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29788533,Health;Obesity,N01.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29788441,,
29788207,,
29788090,,
29787979,"Animals;Cell Line;Genome-Wide Association Study;Humans;Inflammation;Intracellular Signaling Peptides and Proteins;Macrophages;Mice;Mice, Inbred C57BL;Mitochondria;Myeloid Cells;Neoplasms;Cardiovascular Diseases;Inflammation;Lipid Metabolism",B01.050;A11.251.210;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.644.360;D12.776.476;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.284.430.214.190.875.564;A11.284.835.626;A11.627;C04;C14;C23.550.470;G03.458
29787850,"Academies and Institutes;Animals;Consumer Product Safety;Crotonates;Databases, Chemical;Humans;Perfume;Registries;Risk Assessment",N03.540.052;B01.050;N06.850.210;D02.241.081.114.875;D10.251.400.143.687;L01.313.500.750.300.188.400.300;L01.470.750.750.300;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29786874,Adolescent;Meta-Analysis;Social Media;Underage Drinking;Young Adult,M01.060.057;V03.600;L01.178.751;L01.224.230.110.500.750;F01.145.022.750;F01.145.317.269.875;I01.880.735.878;M01.060.116.815
29784877,"3-Hydroxyanthranilic Acid;Amino Acid Sequence;Bacterial Proteins;Catalysis;Catalytic Domain;Crystallography, X-Ray;Cupriavidus;Dioxygenases;Ligands;Models, Molecular;Mutagenesis, Site-Directed;Mutation;Oxygen;Protein Conformation;Sequence Homology;Substrate Specificity;Hydrophobic and Hydrophilic Interactions;Iron",D02.241.223.100.050.400.400;D02.241.223.100.300.300;D02.241.511.390.300;D02.455.426.559.389.127.020.906.249;G02.111.570.060;L01.453.245.667.060;D12.776.097;G02.130;G02.111.570.120.704;G02.111.570.820.709.275.750.188;E05.196.309.742.225;B03.440.400.425.251.200;B03.660.075.090.688.200;D08.811.682.690.416;D27.720.470.480;E05.599.595;E05.393.420.601.575;G05.365.590;D01.268.185.550;D01.362.670;G02.111.570.820.709;G02.111.810;G05.810;G02.111.835;G02.409;D01.268.556.412;D01.268.956.287;D01.552.544.412
29784674,,
29784587,"Animals;Antigens, CD19;B-Lymphocytes;Humans;Mice;Mice, Transgenic;T-Lymphocytes",B01.050;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29784517,"Antihypertensive Agents;Dose-Response Relationship, Drug;Epoprostenol;Follow-Up Studies;Hernias, Diaphragmatic, Congenital;Humans;Hypertension, Pulmonary;Infant;Infant, Newborn;Pulmonary Wedge Pressure;Registries;Retrospective Studies;Treatment Outcome;Epoprostenol",D27.505.954.411.162;G07.690.773.875;G07.690.936.500;D10.251.355.255.550.550.500;D23.469.050.175.725.550.500;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;M01.060.703;M01.060.703.520;G09.330.380.076.695;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D10.251.355.255.550.550.500;D23.469.050.175.725.550.500
29784512,"Anti-Bacterial Agents;Bacteria;Bacterial Infections;Cross-Sectional Studies;Emergency Service, Hospital;Humans;Incidence;Infant;Infant, Newborn;Retrospective Studies;United States;Bacteremia;Meningitis",D27.505.954.122.085;B03;C01.252;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;C10.228.614
29784498,"Anesthesia;Critical Care;Disease Management;Humans;Periodicals as Topic;Respiratory Distress Syndrome, Adult;Angiotensin II;Blood Culture;Thoracic Surgery;Cognitive Dysfunction;Adrenal Cortex Hormones;Critical Care;Delirium;Fever;Stroke",E03.155;E02.760.190;N02.421.585.190;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;L01.178.682.829.678;C08.381.840;C08.618.840;D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;E01.370.225.875.185;E05.200.875.185;H02.403.810.803;F03.615.250.700;D06.472.040;E02.760.190;N02.421.585.190;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;C23.888.119.344;C10.228.140.300.775;C14.907.253.855
29784122,"Adolescent;Child, Preschool;Cryosurgery;Humans;Middle Aged;Sclerosing Solutions;Sclerotherapy;Treatment Outcome;Vascular Malformations;Vascular Surgical Procedures;Veins;Bleomycin;Cryosurgery;Sclerotherapy;Vascular Malformations",M01.060.057;M01.060.406.448;E04.014.180;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D26.776.708.822;D27.505.954.411.700;D27.505.954.578.822;D27.720.752.822;E02.319.805;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.240.850;C16.131.240.850;E04.100.814;A07.015.908;D09.400.420.110;D12.644.233.110;E04.014.180;E02.319.805;C14.240.850;C16.131.240.850
29784119,Absorbable Implants;Chronic Disease;Endovascular Procedures;Humans;Prosthesis Design;Stents;Treatment Outcome;Veins;Venous Insufficiency,E07.695.025;C23.550.291.500;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;E05.320.550;E07.695.680;E07.695.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A07.015.908;C14.907.952
29783161,Molecular Epidemiology;Sleep;Sleepiness,E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;F02.830.855;G11.561.803;C23.888.900
29782879,Heart Arrest;Humans;Oxygen,C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;D01.268.185.550;D01.362.670
29782625,Neuromyelitis Optica;Rituximab,C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
29782404,,
29782360,,
29781994,"Animals;Central Nervous System;Disease Models, Animal;Drosophila;Drosophila melanogaster;Nerve Regeneration;Peripheral Nervous System",B01.050;A08.186;C22.232;E05.598.500;E05.599.395.080;B01.050.500.131.617.720.500.500.750.310.250;B01.050.500.131.617.720.500.500.750.310.250.500;G11.561.585;G16.762.611;A08.800
29781906,Attitude of Health Personnel;Clinical Competence;Curriculum;Dermatology;Humans;Internship and Residency;Self-Assessment;Surveys and Questionnaires,F01.100.050;N05.300.100;I02.399.630.210;N04.761.210;N05.715.175;I02.158;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F01.752.747.792.537;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29781864,,
29781862,Exanthema;Humans;Sarcoma;Skin Neoplasms;Young Adult,C17.800.257;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.795;C04.588.805;C17.800.882;M01.060.116.815
29781065,,
29780874,Alzheimer Disease;Cognitive Dysfunction,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F03.615.250.700
29780873,Alzheimer Disease;Early Diagnosis,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E01.390
29779517,"Breast Feeding;Goals;Humans;Maternal-Child Health Services;Mothers;Postnatal Care;Pregnancy;Social Support;Workplace;Anatomy;Milk, Human;Physiology",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;F01.658.500;B01.050.150.900.649.313.988.400.112.400.400;N02.421.143.130.660;N02.421.143.620.275;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;E02.760.703.500;N02.421.143.620.550.500;N02.421.585.703.500;G08.686.784.769;I01.880.853.500.600;N01.824.245.925;N04.452.677.975;H01.158.100;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;H01.158.782
29778504,Interleukin-13,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
29778420,Aortic Valve;Aortic Valve Stenosis;Heart Valve Prosthesis;Private Practice;Risk Factors;Transcatheter Aortic Valve Replacement;Treatment Outcome,A07.541.510.110;C14.280.484.150;C14.280.955.249;E07.695.310;N04.452.758.745;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29778388,"Androgens;Anxiety;Depression;Feeding and Eating Disorders;Humans;Polycystic Ovary Syndrome;Quality of Life;Societies, Medical;Anxiety;Depression;Quality of Life",D27.505.696.399.472.161;F01.470.132;F01.145.126.350;F03.400;B01.050.150.900.649.313.988.400.112.400.400;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;I01.800;K01.752.400.750;N06.850.505.400.425.837;N03.540.828.589;F01.470.132;F01.145.126.350;I01.800;K01.752.400.750;N06.850.505.400.425.837
29778387,"Adolescent;Adult;Antidepressive Agents;Cohort Studies;Depressive Disorder, Major;Fertility;Humans;Infertility, Female;Infertility, Male;Young Adult;Infertility;Depression",M01.060.057;M01.060.116;D27.505.954.427.700.122;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F03.600.300.375;G08.686.210;B01.050.150.900.649.313.988.400.112.400.400;C13.351.500.365.700;C12.294.365.700;M01.060.116.815;C12.294.365;C13.351.500.365;F01.145.126.350
29778304,,
29778231,"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Exome;Genetic Predisposition to Disease;Genetic Testing;Humans;Infant;Middle Aged;Neoplasms;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.060.406;M01.060.406.448;G05.360.340.011;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;C04;M01.060.116.815
29777584,DiGeorge Syndrome;DiGeorge Syndrome;Catatonia;Psychotic Disorders;Schizophrenia,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C10.597.606.115;C23.888.592.604.115;F01.145.126.156;F01.700.165;F03.700.675;F03.700.750
29777410,Affect;Electromyography;Psychophysiology;Sex,F01.470.047;E01.370.405.255;E01.370.530.255;E02.190.525.812;F02.830;F04.096.795;H01.158.782.795;G08.686.810
29777319,Gonadal Hormones;Neurobiology,D06.472.334;H01.158.273.610;H01.158.610.080
29777014,Monoclonal Gammopathy of Undetermined Significance;Paraproteinemias;Glomerulonephritis;Kidney;Multiple Myeloma,C15.378.147.542.640;C15.378.147.780.570;C20.683.460.640;C20.683.780.640;C15.378.147.780;C20.683.780;C12.777.419.570.363;C13.351.968.419.570.363;A05.810.453;C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650
29776990,Adalimumab;Biomarkers;Inflammation;Psoriasis,D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;D23.101;C23.550.470;C17.800.859.675
29776869,,
29776653,,
29776422,Animals;Cell Cycle;Cell Proliferation;Humans;Mammals;Myocardium;Regeneration;Cyclins;Muscle Cells;Regeneration,B01.050;G04.144;G04.161.750;G07.345.249.410.750;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649;A02.633.580;A07.541.704;A10.690.552.750;G16.762;D12.644.360.262;D12.776.167.218;D12.776.476.262;A11.620;G16.762
29775556,Child;Death;Family;Palliative Care;Siblings,M01.060.406;C23.550.260;F01.829.263;I01.880.853.150;E02.760.666;N02.421.585.666;F01.829.263.500.490;I01.880.853.150.500.505;M01.781
29774783,"Hippocampus;Amnesia;Fentanyl;Memory;Analgesics, Opioid",A08.186.211.180.405;A08.186.211.200.885.287.500.345;C10.597.606.525.100;C23.888.592.604.529.100;F01.700.625.100;F03.615.200;D03.383.621.265;F02.463.425.540;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
29774776,"Spatial Memory;Brain Injuries, Traumatic",F02.463.425.540.886;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29774481,"Adolescent;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Renal Insufficiency;Risk Factors;Ultrasonography;Urethra;Urethral Obstruction;Renal Insufficiency",M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C12.777.419.780;C13.351.968.419.780;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350.850;A05.360.444.492.726;A05.810.876;C12.777.767.700;C13.351.968.767.700;C12.777.419.780;C13.351.968.419.780
29773810,,
29773603,,
29773588,Wounds and Injuries,C26
29773447,"Advisory Committees;Curriculum;Education, Medical, Graduate;Educational Measurement;Faculty, Medical;Guidelines as Topic;Humans;Internship and Residency;Radiology;United States",N03.706.742.500;I02.158;I02.358.337.350;I02.358.399.350;I02.399;M01.526.485.375;M01.526.702.250.373;N02.360.375;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.740;Z01.107.567.875
29772483,Military Personnel;Veterans,M01.526.625;M01.930
29772353,,
29772275,"Animals;Cell Culture Techniques;Cells, Cultured;Chromosome Mapping;Chromosomes;DNA Primers;Genome;Mice;Mice, Inbred C57BL;Mouse Embryonic Stem Cells;Nucleic Acid Conformation;Polymerase Chain Reaction;Sequence Analysis, DNA;Embryonic Stem Cells",B01.050;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.251;E05.393.183;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;D13.695.578.424.450.275;D27.720.470.530.600.223.600;G05.360.340;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.872.700.250.875;G02.111.570.820.486;G05.360.580;E05.393.620.500;E05.393.760.700;A11.872.700.250
29771953,"Adolescent;Adult;Aged;Attitude to Health;Child;Child, Preschool;Clinical Trials as Topic;Cohort Studies;Developmental Disabilities;Epilepsy;Health Expenditures;Humans;Infant;Informed Consent;Middle Aged;Mitochondrial Diseases;Motivation;Muscle Weakness;Patient Acceptance of Health Care;Phlebotomy;Research Design;Severity of Illness Index;Surveys and Questionnaires;Symptom Assessment;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;F01.100.150;N05.300.150;M01.060.406;M01.060.406.448;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F03.625.421;C10.228.140.490;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;M01.060.116.630;C18.452.660;F01.658;F01.752.543.500.750;C05.651.515;C10.597.613.593;C23.550.695;C23.888.592.608.593;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E01.370.225.998.110.625;E02.800.558;E04.665.150.625;E05.200.998.110.625;E05.581.500;H01.770.644.728;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.872;M01.060.116.815
29771787,,
29771609,Achilles Tendon;Running;Tendinopathy,A02.880.176;G11.427.410.568.610;G11.427.410.698.277.750;I03.350.750;I03.450.642.845.610;C05.651.869;C26.874.800
29771551,,
29770945,Colorectal Neoplasms;Community Health Centers;Mass Screening,C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;N02.278.035.128;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
29770913,Cardiomyopathies,C14.280.238
29770202,Neoplasms;Vaccination,C04;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
29770199,Genetic Therapy;Hemophilia A,E02.095.301;E05.393.420.301;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500
29769713,,
29769628,Aphakia;Forkhead Transcription Factors;Genetic Testing;Humans;Mutation;Phenotype,C11.510.103;D12.776.260.950.249;D12.776.930.977.249;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G05.695
29769243,"Adolescent;Age Distribution;Child;Continental Population Groups;Hospitalization;Hospitals, Pediatric;Humans;Retrospective Studies;Seasons;Sex Distribution;Suicidal Ideation;Suicide, Attempted;United States",M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.406;M01.686.508;E02.760.400;N02.421.585.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525;I01.240.800;N01.224.803;N06.850.505.400.850;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.980.875.600;I01.880.735.856.600;Z01.107.567.875
29769202,Length of Stay;General Surgery;Tetralogy of Fallot,E02.760.400.480;N02.421.585.400.480;H02.403.810.300;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29768181,"Cardiopulmonary Resuscitation;Child;Child, Preschool;Clinical Competence;Cooperative Behavior;Guideline Adherence;Heart Arrest;Humans;Infant;Interprofessional Relations;Outcome and Process Assessment (Health Care);Patient Care Team;Prospective Studies;Qualitative Research;Quality Improvement;Time Factors",E02.365.647.110;M01.060.406;M01.060.406.448;I02.399.630.210;N04.761.210;N05.715.175;F01.145.813.115;N04.761.337;N05.715.360.395;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.401.205;N04.761.559;N05.715.360.575;N04.590.715;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H01.770.644.241.850;J01.293.754;N04.761.744;G01.910.857
29768011,"Biosensing Techniques;DNA;DNA Probes;Equipment Design;Graphite;Nucleic Acid Hybridization;Transistors, Electronic",E05.601.043;D13.444.308;D13.444.600.223;D27.505.259.750.600.223;D27.720.470.530.600.223;E05.320;D01.268.150.300;D01.578.300;E05.393.661;G02.111.611;E07.305.625.714
29767845,Hepatic Veno-Occlusive Disease,C06.552.360;C14.907.460
29767641,,
29767381,,
29767353,Olfaction Disorders;Epilepsy;Smell;Temporal Lobe,C10.597.751.600;C23.888.592.763.550;C10.228.140.490;F02.830.816.643;G11.561.790.643;A08.186.211.200.885.287.500.863
29766664,Parkinson Disease;Dopaminergic Neurons;Regenerative Medicine;Tissue Engineering,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;A08.675.278;A11.671.270;H02.403.750;E05.481.500.311.500;J01.293.069.249.500
29766542,"Adolescent;Cyberbullying;Parents;Primary Health Care;Stress, Psychological",M01.060.057;F01.145.126.125.550.500;F01.145.813.213.500.500;I01.880.735.070.500;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;N04.590.233.727;F01.145.126.990;F02.830.900
29766439,"Adolescent;Child;Cross-Cultural Comparison;Exercise;Hispanic Americans;Humans;Information Systems;Outcome Assessment (Health Care);Patient Reported Outcome Measures;Quality of Life;Reproducibility of Results;Stress, Psychological;Surveys and Questionnaires;Translating;Translations;Family;Exercise",M01.060.057;M01.060.406;I01.076.201.450.281;I01.880.853.100.257;G11.427.410.698.277;I03.350;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;L01.313.500.750.300;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;F01.145.126.990;F02.830.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;L01.559.423.796;L01.178.682.920;F01.829.263;I01.880.853.150;G11.427.410.698.277;I03.350
29765153,"Adenocarcinoma;Animals;Carcinogenesis;Cell Line, Tumor;Cyclooxygenase 2;Humans;Mice;NF-kappa B;Prostate;Prostatic Neoplasms;Protein Kinase C-epsilon;Signal Transduction",C04.557.470.200.025;B01.050;C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;D08.811.600.720.750;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;A05.360.444.575;A10.336.707;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;D08.811.913.696.620.682.700.725.750;G02.111.820;G04.835
29764955,"CRISPR-Cas Systems;Gene Editing;Genome, Human;Humans;Proteins;Structure-Activity Relationship;Clustered Regularly Interspaced Short Palindromic Repeats;Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Synthetic Biology",G05.308.203.374.394;E05.393.420.270;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;D12.776;G02.111.830;G07.690.773.997;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;H01.158.273.904;J01.293.069.500
29764680,"Adjuvants, Immunologic;Aging;Animals;Antibodies, Viral;Antigens, Helminth;Gene Expression Regulation;Helminth Proteins;Histocompatibility Antigens Class II;Immunization;Influenza Vaccines;Macrophages;Mice;Mice, Knockout;Monocytes;Muscle, Skeletal;Myeloid Differentiation Factor 88;Neutrophils;Orthomyxoviridae Infections;Receptors, CCR2;Receptors, CXCR3;Survival Analysis;T-Lymphocytes, Helper-Inducer;Viral Load;Chemokines",D27.505.696.477.067;G07.345.124;B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;D23.050.223;G05.308;D12.776.419;D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;D20.215.894.899.302;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A02.633.567;A10.690.552.500;D12.644.360.024.311;D12.776.157.057.074;D12.776.476.024.390;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C02.782.620;D12.776.543.750.695.160.150.200;D12.776.543.750.705.852.125.150.200;D12.776.543.750.695.160.500.300;D12.776.543.750.705.852.125.500.300;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;A11.118.637.555.567.550.500.400;A11.118.637.555.567.569.200.400;A11.118.637.555.567.569.500.400;A15.145.229.637.555.567.550.500.400;A15.145.229.637.555.567.569.200.400;A15.145.229.637.555.567.569.500.400;A15.382.490.555.567.550.500.400;A15.382.490.555.567.569.200.400;A15.382.490.555.567.569.500.400;E01.370.225.875.950;E05.200.875.950;G06.920.850;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200
29763623,"Adolescent;Bevacizumab;CD8-Positive T-Lymphocytes;Chemoradiotherapy;Child;Child, Preschool;DNA Polymerase III;Glioma;Humans;Mutation;Neoplasm Grading;Neurofibromin 1;Proto-Oncogene Proteins B-raf;Survival Analysis;Temozolomide",M01.060.057;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;E02.186.079;E02.319.164;E02.815.160;M01.060.406;M01.060.406.448;D08.811.913.696.445.308.300.235;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;E01.789.612;D12.644.360.325.150.500.460;D12.776.476.325.150.500.460;D12.776.624.776.610;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;D02.925.200.500;D03.383.129.308.240.500
29763587,"Behavior;Dehydroepiandrosterone;Hippocampus;Sequence Analysis, RNA;Serotonin",F01.145;D04.210.500.054.079.429.625;D04.210.500.578.502.400;D06.472.040.502.400;D06.472.334.851.968.952;A08.186.211.180.405;A08.186.211.200.885.287.500.345;E05.393.760.710;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650
29763481,Artificial Intelligence;Biomedical Technology;Dermatology;Humans;Virtual Reality,G17.035.250;L01.224.050.375;J01.897.115;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;L01.224.160.875;L01.296.555
29763457,"3T3-L1 Cells;Adipogenesis;Alkaline Phosphatase;Animals;Cell Differentiation;Cell Line;GTP-Binding Protein alpha Subunits, G12-G13;Mice;Morpholines;Purines;Signal Transduction",A11.251.210.100.775.800;A11.329.228.100.775.800;G04.152.149;D08.811.277.352.650.035;B01.050;G04.152;A11.251.210;D08.811.277.040.330.300.200.100.100;D12.644.360.360.100.100;D12.776.157.325.332.100.100;D12.776.476.375.100.100;D12.776.543.325.100.100;B01.050.150.900.649.313.992.635.505.500;D03.383.533.640;D03.633.100.759;G02.111.820;G04.835
29762868,Antifungal Agents;Candidemia,D27.505.954.122.136;C01.539.757.360.150;C01.703.160.175.150;C01.703.492.500.150;C01.703.492.625.150;C23.550.470.790.500.360.150
29762864,"Pulmonary Disease, Chronic Obstructive",C08.381.495.389
29762799,"Curriculum;Delivery of Health Care, Integrated;Education, Medical, Graduate;Family Practice;Humans;Internship and Residency;Mental Health Services;Physicians;Psychiatry;Surveys and Questionnaires;United States",I02.158;N04.590.374.142;N05.300.262;I02.358.337.350;I02.358.399.350;H02.403.340.500;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F04.408;N02.421.461;M01.526.485.810;N02.360.810;F04.096.544;H02.403.690;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875
29762282,,
29762217,,
29761549,,
29761140,Botswana;Audiology;Child;Hearing Loss;Hearing Loss,Z01.058.290.175.230;H02.010.150;M01.060.406;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341
29760867,,
29760839,"Adolescent;Blood Pressure;Brain Injuries, Traumatic;Child;Child, Preschool;Humans;Hypertension;Infant;Infant, Newborn;Injury Severity Score;Registries;Retrospective Studies",M01.060.057;E01.370.600.875.249;G09.330.380.076;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;M01.060.703;M01.060.703.520;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29760621,"Lupus Erythematosus, Cutaneous;Lupus Erythematosus, Discoid",C17.300.475;C17.800.480;C17.300.475.479;C17.800.480.479
29760283,,
29760084,"Adipose Tissue;Animals;Exosomes;Humans;Inflammation;Macrophages;Mice;Mice, Inbred C57BL;Obesity;Tetraspanin 29;Transcriptome;Adipose Tissue;Inflammation;Macrophages;Obesity",A10.165.114;B01.050;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D12.776.395.550.018;D12.776.543.550.090;D12.776.543.900.109;G02.111.873.750;G05.297.700.750;G05.360.920;A10.165.114;C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29760046,,
29759607,"Amiodarone;Cardiomyopathies;Catheter Ablation;Tachycardia, Ventricular",D03.633.100.127.075;C14.280.238;E02.808.750.500;E04.014.760.500;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
29759483,"Animals;Disease Models, Animal;Mice;Mice, Knockout;Parkinson Disease;Proteasome Endopeptidase Complex;Protein Aggregation, Pathological;Proteostasis;alpha-Synuclein;Dopaminergic Neurons;Parkinson Disease;Proteostasis",B01.050;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D05.500.562.500;D08.811.277.656.918;D08.811.600.730;C23.550.770;G02.111.675;G02.111.730;G03.816;D12.776.631.860.500;D12.776.637.500;A08.675.278;A11.671.270;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;G02.111.730;G03.816
29759418,Glomerulonephritis;Lymphoma;Multiple Myeloma,C12.777.419.570.363;C13.351.968.419.570.363;C04.557.386;C15.604.515.569;C20.683.515.761;C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650
29759068,"Adolescent;Age Factors;Biomarkers;Child;China;Cross-Sectional Studies;Decision Support Techniques;Humans;Incidence;Insulin Resistance;Longitudinal Studies;Metabolic Syndrome;Predictive Value of Tests;Prospective Studies;Retinol-Binding Proteins, Plasma;Risk Assessment;Risk Factors;Time Factors;Child;Insulin Resistance;Metabolic Syndrome;Adolescent",M01.060.057;N05.715.350.075;N06.850.490.250;D23.101;M01.060.406;Z01.252.474.164;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.245;L01.313.500.750.190;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C18.452.394.968.500;G07.690.773.984.617;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C18.452.394.968.500.570;C18.452.625;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.124.698;D12.776.124.790.106.745;D12.776.157.469.550;D12.776.157.700.500;D12.776.377.715.085.745;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.060.406;C18.452.394.968.500;G07.690.773.984.617;C18.452.394.968.500.570;C18.452.625;M01.060.057
29758342,Clinical Trials as Topic;Drug Development;Genotype;High-Throughput Nucleotide Sequencing;Humans;Molecular Targeted Therapy;Phenotype;Precision Medicine,E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E05.290;H01.158.703.007.338;H01.181.466.338;G05.380;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E02.319.574;G05.695;E02.574;H02.403.200.700
29758070,"Animals;Cell Line, Tumor;Embryo, Mammalian;Fibroblasts;Gene Expression Regulation, Neoplastic;Humans;Insulin-Like Growth Factor II;Lung Neoplasms;Lymphangioleiomyomatosis;Mice;Mice, Knockout;Signal Transduction;Sirolimus;Tuberous Sclerosis Complex 2 Protein;Tumor Suppressor Proteins",B01.050;A11.251.210.190;A11.251.860.180;A16.254;A11.329.228;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.937.420;D12.776.124.862.425;D12.776.467.937.420;D23.529.937.420;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.375.460.465;C04.557.450.692.500;C15.604.515.562.465;C20.683.515.710.465;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G02.111.820;G04.835;D02.540.505.760;D12.644.360.938;D12.776.476.935;D12.776.624.776.769;D12.776.624.776
29757891,,
29757793,,
29756403,,
29756079,,
29755639,Electronic Nicotine Delivery Systems;Vaping,J01.637.767.500;F01.145.805.500
29755313,Amygdala,A08.186.211.180.090;A08.186.211.200.885.287.249.152
29755268,Melanoma,C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
29754953,Amino Acids;Metabolism;Polyamines;Pyridoxal Phosphate;Kidney Neoplasms,D12.125;G03;D02.092.782;D03.383.725.676.925.500.500;D08.211.740;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473
29754888,"Administration, Topical;Adolescent;Alopecia;Alopecia Areata;Child;Child, Preschool;Cohort Studies;Dose-Response Relationship, Drug;Drug Administration Schedule;Follow-Up Studies;Hair;Humans;Pediatrics;Piperidines;Pyrimidines;Pyrroles;Sampling Studies;Treatment Outcome",E02.319.267.120;M01.060.057;C17.800.329.937.122;C23.300.035;C17.800.329.937.122.147;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G07.690.773.875;G07.690.936.500;E02.319.283;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A17.360;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;D03.383.621;D03.383.742;D03.383.129.578;E05.318.372.875;N05.715.360.330.875;N06.850.520.450.875;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29754875,"Adolescent;Age Factors;Anticonvulsants;Brain;Child;Electroencephalography;Epilepsy, Rolandic;Follow-Up Studies;Humans;Remission Induction;Retrospective Studies;Time-to-Treatment;Epilepsy, Rolandic;Epilepsy",M01.060.057;N05.715.350.075;N06.850.490.250;D27.505.954.427.080;A08.186.211;M01.060.406;E01.370.376.300;E01.370.405.245;C10.228.140.490.360.280;C10.228.140.490.493.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.860;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.928;N02.421.585.928;C10.228.140.490.360.280;C10.228.140.490.493.250;C10.228.140.490
29754869,Adolescent;Adolescent Health;Child;Communication;Confidentiality;Humans;Parents;Sexual Behavior,M01.060.057;N01.400.075;M01.060.406;F01.145.209;L01.143;F04.096.544.335.240;I01.880.604.473.650.500;I01.880.604.583.080;N03.706.437.650.124;N03.706.535.230;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.145.802
29754865,"California;Cerebral Hemorrhage;Follow-Up Studies;Gestational Age;Humans;Incidence;Infant, Newborn;Infant, Premature, Diseases;Infant, Very Low Birth Weight;Intensive Care Units, Neonatal;Population Surveillance;Retrospective Studies;Severity of Illness Index",Z01.107.567.875.580.200;Z01.107.567.875.760.200;C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703.520;C16.614.521;M01.060.703.520.460.600;N02.278.388.493.390.380;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
29754827,"Crystallography, X-Ray;Fibrin;Microscopy, Atomic Force;Models, Molecular;Protein Conformation;Protein Multimerization;Fibrin;Fibrinogen",E05.196.309.742.225;D12.776.124.270;E01.370.350.515.666.400;E05.595.666.400;E05.599.595;G02.111.570.820.709;G02.111.694;D12.776.124.270;D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490
29754825,"Crystallography, X-Ray",E05.196.309.742.225
29754159,"Anticoagulants;Child;Contrast Media;Humans;Kidney;Leg;Magnetic Resonance Imaging;Syndrome;Vascular Malformations;Vena Cava, Inferior;Venous Thrombosis;Child;Vena Cava, Inferior;Kidney;Magnetic Resonance Imaging;Venous Thrombosis",D27.505.954.502.119;M01.060.406;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;A01.378.610.500;E01.370.350.825.500;C23.550.288.500;C14.240.850;C16.131.240.850;A07.015.908.949.648;C14.907.355.830.925;M01.060.406;A07.015.908.949.648;A05.810.453;E01.370.350.825.500;C14.907.355.830.925
29753993,Adolescent;Amygdala;Anger;Bayes Theorem;Child;Emotions;Facial Expression;Facial Recognition;Fear;Gyrus Cinguli;Happiness;Humans;Magnetic Resonance Imaging;Oxygen;Prefrontal Cortex;Reproducibility of Results;Magnetic Resonance Imaging,M01.060.057;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F01.470.093;E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;M01.060.406;F01.470;E01.370.600.225;F01.145.209.530.385;F02.463.593.524.500.500;F02.463.593.932.622.500;F01.470.361;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;F01.470.516;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;D01.268.185.550;D01.362.670;A08.186.211.200.885.287.500.270.700;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E01.370.350.825.500
29753572,Child;Headache;Pseudotumor Cerebri;Papilledema;Pseudotumor Cerebri,M01.060.406;C23.888.592.612.441;C10.228.140.631.750;C10.292.700.900;C11.640.710;C10.228.140.631.750
29753539,"Adult;Behavior Therapy;Child Development;Child, Preschool;Humans;Infant;Infant, Newborn;Parents;Retrospective Studies;Sleep;Sleep Deprivation;Surveys and Questionnaires;Young Adult",M01.060.116;F04.754.137;F01.525.200;G07.345.374.750;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;F02.830.855;G11.561.803;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815
29753368,Alcohol Drinking;Cardiovascular Diseases;Humans;Risk Factors,F01.145.317.269;C14;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29753073,Glycine;Oxidative Stress,D12.125.481;G03.673;G07.775.750
29753031,,
29752934,,
29752399,Atrial Fibrillation;Electrocardiography;Genetics;Haplotypes;Population,C14.280.067.198;C23.550.073.198;E01.370.370.380.240;E01.370.405.240;H01.158.273.343;G05.380.360;N01.600
29752136,"Efficiency, Organizational;Humans;Physician Assistants;Professional Competence;Quality Improvement;Radiology Department, Hospital",N04.452.209.500;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.067.740;N02.360.067.740;I02.399.630;J01.293.754;N04.761.744;N02.278.216.500.968.695;N04.452.442.422.695
29751192,"Adolescent;Eating;Food Preferences;Fruit;Humans;Students;Surveys and Questionnaires;Universities;Vegetables;Young Adult;Feeding Behavior;Factor Analysis, Statistical",M01.060.057;G07.203.650.283;G10.261.330;F01.145.407.516;G07.203.650.353.516;A18.024.500;G07.203.300.562;J02.500.562;B01.050.150.900.649.313.988.400.112.400.400;M01.848;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.783.830;J03.832.830;B01.650.160.956;B01.650.510.956;G07.203.300.850;J02.500.850;M01.060.116.815;F01.145.113.547;F01.145.407;G07.203.650.353;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400
29751019,Animals;Blood Glucose;Circadian Rhythm;Energy Metabolism;Fatty Liver;Light;Lipogenesis;Liver;Mice;MicroRNAs;Motor Activity;MicroRNAs,B01.050;D09.947.875.359.448.500;G07.180.562.190;G03.295;C06.552.241;G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578;G02.111.528;G03.458.249;A03.620;B01.050.150.900.649.313.992.635.505.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;F01.145.632;G11.427.410.698;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29750906,,
29750770,,
29750689,,
29750579,,
29750572,Algorithms;Facial Asymmetry;Genetics;Pediatrics,G17.035;L01.224.050;C23.300.505;H01.158.273.343;H02.403.670
29750499,alpha-Synuclein;Lewy Bodies;Parkinson Disease,D12.776.631.860.500;D12.776.637.500;A08.675.460;A11.284.420.460;A11.671.460;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29750331,"Adoptive Transfer;Animals;Mice;Mice, Inbred NOD;Salivary Glands;Sialadenitis;Sjogren's Syndrome;T-Lymphocyte Subsets;T-Lymphocytes, Regulatory;Sjogren's Syndrome;Autoimmunity;T-Lymphocytes, Regulatory;Salivary Glands;Sialadenitis",E02.095.465.425.400.330.050;E05.478.550.520.050;B01.050;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;A03.556.500.760;A10.336.779;A14.549.760;C07.465.815.793;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774;A11.118.637.555.567.550.500;A11.118.637.555.567.569.500;A15.145.229.637.555.567.550.500;A15.145.229.637.555.567.569.500;A15.382.490.555.567.550.500;A15.382.490.555.567.569.500;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774;G12.450.192;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;A03.556.500.760;A10.336.779;A14.549.760;C07.465.815.793
29750142,,
29749933,Cardiac Resynchronization Therapy;Cardiac Resynchronization Therapy;Heart Failure,E02.331.200.500;E02.331.200.500;C14.280.434
29748706,Craniosynostoses;Equipment and Supplies;Infection;General Surgery,C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E07;C01.539;H02.403.810.300
29748329,Anti-Bacterial Agents;Kidney Calculi;Microbiota,D27.505.954.122.085;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29748321,"Cardiomyopathies;Genetic Testing;Glycogen;Heart Failure;Tachycardia, Ventricular",C14.280.238;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;D05.750.078.562.388;D09.698.365.388;C14.280.434;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
29748271,Cell Differentiation,G04.152
29748191,Adolescent;Emotions;Humans;Risk-Taking;Sexual Behavior,M01.060.057;F01.470;B01.050.150.900.649.313.988.400.112.400.400;F01.145.722;F01.145.802
29747965,Equipment Design;Heart Valves,E05.320;A07.541.510
29746857,Central Nervous System Sensitization;Patient Reported Outcome Measures;Postsynaptic Potential Summation;Urinary Bladder;Urinary Incontinence,G11.561.148;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;G02.111.820.850.500;G04.580.887.750;G04.835.850.500;G07.265.675.887.750;G07.265.880.750.780;G11.561.570.918.750;G11.561.830.750.780;A05.810.890;C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
29746793,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Hypoxia;Leukemia,C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;C23.888.852.079;C04.557.337
29746679,"Autoimmune Diseases;Diagnosis, Differential;Granuloma;Granulomatous Disease, Chronic;Humans;Inflammatory Bowel Diseases;Lung Diseases",C20.111;E01.171;C15.604.515.292;C23.550.382;C15.378.553.774.535;C16.320.322.233;C20.673.774.535;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;C08.381
29746663,,
29746604,"Adult;Fetal Development;Humans;Pregnancy;Pregnancy Trimester, Third;Sound;Uterus",M01.060.116;G07.345.500.325.235;G08.686.784.170.157;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;G08.686.707.520;G01.750.770.776;A05.360.319.679
29746587,"B-Lymphocytes;Blotting, Western;Gene Expression Regulation, Viral;Glucose;Herpesvirus 8, Human;Humans;Hypoxia;Hypoxia-Inducible Factor 1, alpha Subunit;Lactic Acid;Leukocytes, Mononuclear;Metabolome;Microscopy, Confocal;Phenotype;Promoter Regions, Genetic;RNA, Viral;Reactive Oxygen Species;Receptors, G-Protein-Coupled;Sequence Analysis, RNA;Transcriptional Activation",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;G05.308.385;D09.947.875.359.448;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;D12.776.260.103.625.750;D12.776.930.125.625.750;D02.241.511.459.450;A11.118.637.555;A15.145.229.637.555;A15.382.490.555;G03.500;E01.370.350.515.395;E05.595.395;G05.695;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D13.444.735.828;D01.339.431;D01.650.775;D12.776.543.750.695;E05.393.760.710;G05.308.800
29746501,"Agouti-Related Protein;Animals;Behavior, Animal;Biomarkers;Body Weight;Circadian Rhythm;Diet;Energy Intake;Energy Metabolism;Gene Expression;Hypothalamus;Leptin;Mice;Mice, Inbred C57BL;Neuropeptide Y;Obesity;Sleep;Wakefulness",D12.644.276.074;D12.776.467.074;D23.529.074;B01.050;F01.145.113;D23.101;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;G07.180.562.190;G07.203.650.240;G07.203.650.240.340;G03.295;G05.297;A08.186.211.180.497;A08.186.211.200.317.357;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.644.400.500;D12.776.631.650.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.830.855;G11.561.803;F02.830.104.821;G11.561.035.738
29746405,,
29746403,,
29746340,,
29746225,,
29745061,"Neoplasms;Chromatin;Histones;Mass Spectrometry;Protein Processing, Post-Translational",C04;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
29744923,Phosphorus,D01.268.666
29744577,Colon;Endoscopic Mucosal Resection,A03.556.124.526.356;A03.556.249.249.356;E01.370.372.250.250.250;E01.370.388.250.250.250.230;E04.210.240.250.230;E04.502.250.250.250.230
29743675,"Asia;Asian Continental Ancestry Group;Europe;European Continental Ancestry Group;Farmers;Genome, Human;Grassland;History, Ancient;Human Migration;Humans;Phylogeny",Z01.252;M01.686.508.200;Z01.542;M01.686.508.400;M01.526.390;G05.360.340.350;G16.500.275.157.531;N06.230.124.390;K01.400.470;I01.240.600.525;N01.224.625.525;N06.850.505.400.700.525;B01.050.150.900.649.313.988.400.112.400.400;G05.697;G16.075.605;L01.100.697
29743672,"Animals;Cytoplasm;Humans;Lewy Bodies;Lewy Body Disease;Mice;Mice, Inbred C57BL;Neurons;Oligodendroglia;Organ Specificity;Protein Folding;alpha-Synuclein",B01.050;A11.284.430.214;B01.050.150.900.649.313.988.400.112.400.400;A08.675.460;A11.284.420.460;A11.671.460;C10.228.140.079.862.400;C10.228.140.380.422;C10.228.662.600.200;C10.574.531;F03.615.400.512;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A08.675;A11.671;A08.637.600;A11.650.600;G07.650;G01.154.651;G02.111.688;D12.776.631.860.500;D12.776.637.500
29743629,,
29742798,"Walk Test;Muscular Dystrophy, Duchenne;Outcome Assessment (Health Care)",E01.370.370.380.250.500;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
29742717,"Aged;Aged, 80 and over;Ambulatory Care;Disabled Persons;Health Services Accessibility;Hospital Costs;Hospitalization;Humans;Medicare;Quality Indicators, Health Care;United States",M01.060.116.100;M01.060.116.100.080;E02.760.106;N02.421.585.106;M01.150;N04.590.374.350;N05.300.430;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.761.789;Z01.107.567.875
29742656,,
29742382,"Cost-Benefit Analysis;Health Expenditures;Humans;Insurance Coverage;Insurance, Health;Medication Adherence;Preventive Medicine",N03.219.151.125;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;H02.403.720.750
29742379,"Blood Pressure;Humans;Shock, Hemorrhagic",E01.370.600.875.249;G09.330.380.076;B01.050.150.900.649.313.988.400.112.400.400;C23.550.414.980;C23.550.835.650
29742330,,
29742315,"Interleukin-13;Immunity, Mucosal",D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513;G12.450.573
29742017,"Ataxia Telangiectasia Mutated Proteins;Cell Cycle;Cell Line, Tumor;Cell Movement;Cell Nucleus;Cell Proliferation;DNA Damage;DNA Repair;Gene Knockdown Techniques;Histones;Humans",D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;G04.144;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;A11.284.430.106;A11.284.430.214.190.875.117;G04.161.750;G07.345.249.410.750;G05.200;G02.111.222;G05.219;E05.393.335.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400
29741952,,
29741766,,
29741727,Sleep;United States,F02.830.855;G11.561.803;Z01.107.567.875
29741715,,
29741288,"Databases, Genetic;Exome;Genetic Testing;Genetic Variation;Humans;Infant;Spasms, Infantile;Epilepsy;Genetics;Genomics;Seizures;Twins",L01.313.500.750.300.188.400.325;L01.470.750.750.325;G05.360.340.011;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.228.140.490.375.760;C10.228.140.490.493.875;C10.228.140.490;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350;C10.597.742;C23.888.592.742;M01.438.873
29741232,,
29741129,"Adolescent;Antibodies, Viral;Case-Control Studies;Child;Humans;Lupus Erythematosus, Systemic;Prospective Studies;Rubella;Rubella Vaccine;Rubella virus;Vaccination",M01.060.057;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C17.300.480;C20.111.590;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C02.782.930.700.700;D20.215.894.899.779;B04.820.850.700.700;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
29740948,Animals;Astrocytes;Autoimmune Diseases of the Nervous System;Encephalitis;Homeostasis;Humans;Inflammation;Interferon-alpha;Mutation;Nervous System Malformations;Signal Transduction;Astrocytes;Interferons,B01.050;A08.637.200;A11.650.200;C10.114;C20.111.258;C10.228.140.430;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.644.276.374.440.890.250;D12.776.467.374.440.890.250;D23.529.374.440.890.250;G05.365.590;C10.500;C16.131.666;G02.111.820;G04.835;A08.637.200;A11.650.200;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
29740856,,
29740699,"Adult;Amino Acid Sequence;Child;Child, Preschool;Cyclin-Dependent Kinase 8;Humans;Mediator Complex;Mutation, Missense;Neurodevelopmental Disorders;Sequence Deletion;Transcription Initiation, Genetic;Ubiquitination;United Kingdom",M01.060.116;G02.111.570.060;L01.453.245.667.060;M01.060.406;M01.060.406.448;D05.500.374.500;D08.811.913.696.620.682.700.646.500.968;D12.644.360.024.309.500;D12.644.360.250.547;D12.776.157.057.072.500;D12.776.167.200.548;D12.776.476.024.388.500;D12.776.476.250.548;D12.776.660.551.500;B01.050.150.900.649.313.988.400.112.400.400;D05.500.374;D12.644.360.024.309;D12.776.157.057.072;D12.776.476.024.388;D12.776.660.551;G05.365.590.650;F03.625;G05.365.590.762;G05.558.800;G02.111.873.625;G05.297.700.625;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831;Z01.542.363
29740578,Sodium,D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725
29740502,Africa;Breast Neoplasms;Humans;Incidence;Registries,Z01.058;C04.588.180;C17.800.090.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
29739889,"Animals;Gene Expression Regulation;Kidney Concentrating Ability;Kidney Medulla;Kidney Tubules, Collecting;Mice;Mice, Inbred C57BL;Mice, Knockout;Osmotic Pressure;Receptors, Cytoplasmic and Nuclear;Stress, Physiological;Transcription Factors;Cell Survival",B01.050;G05.308;G08.852.536;A05.810.453.466;A05.810.453.736.560.510;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G01.374.715.578;G02.640.249;G02.723.661;D12.776.826;G07.775;D12.776.930;G04.346
29739835,,
29739773,Adult;Allografts;Disease-Free Survival;Donor Selection;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Middle Aged;Myelodysplastic Syndromes;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Registries;Sex Factors;Siblings;Survival Rate;Unrelated Donors,M01.060.116;A01.941.500;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E04.936.537.500;N02.421.911.600;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C15.378.190.625;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;N05.715.350.675;N06.850.490.875;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;M01.898.828
29739461,Genetic Counseling,H01.158.273.343.385.500.384;N02.421.308.400
29738885,Autism Spectrum Disorder;Rett Syndrome;Seizures,F03.625.164.113;C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937;C10.597.742;C23.888.592.742
29738327,,
29737912,"Adolescent;Child;Child, Preschool;Congresses as Topic;Delivery of Health Care;Humans;Infant;Infant, Newborn;Neoplasms;Risk Factors;Texas;Health Policy",M01.060.057;M01.060.406;M01.060.406.448;N03.540.199;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875.760.750;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428
29736754,,
29736741,DNA Damage;Triple Negative Breast Neoplasms,G05.200;C04.588.180.788;C17.800.090.500.788
29735694,"Animals;Cysts;Energy Metabolism;Epigenomics;Gene Expression Regulation;Hepatocyte Nuclear Factor 1-beta;Humans;Kidney;Mice;Mice, Knockout;Mitochondria;Promoter Regions, Genetic;Receptors, Estrogen;Renal Insufficiency, Chronic;Kidney;Mitochondria;Renal Reabsorption",B01.050;C04.182;C23.300.306;G03.295;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.308;D12.776.260.262.500.750;D12.776.260.400.218.750;D12.776.660.352.500.750;D12.776.930.318.500.750;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.826.750.350;D12.776.930.778.350;C12.777.419.780.750;C13.351.968.419.780.750;A05.810.453;A11.284.430.214.190.875.564;A11.284.835.626;G03.015.500.679;G03.787.024.500.679;G07.690.725.015.500.679;G08.852.536.500
29735554,,
29735307,"Renal Insufficiency, Chronic;Glomerular Filtration Rate;Young Adult",C12.777.419.780.750;C13.351.968.419.780.750;E01.370.390.400.300;G08.852.357;M01.060.116.815
29735220,Aortic Valve;Heart Valve Prosthesis;Humans;Longitudinal Studies;Transcatheter Aortic Valve Replacement,A07.541.510.110;E07.695.310;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
29735117,Ataxia;Child;Humans,C10.597.350.090;C23.888.592.350.090;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400
29735025,"Adult;Cohort Studies;Graft Rejection;Graft Survival;Humans;Liver Diseases;Liver Regeneration;Liver Transplantation;Living Donors;Multicenter Studies as Topic;Postoperative Complications;Survival Rate;Tissue and Organ Harvesting;United States;Liver Failure, Acute;Cohort Studies",M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G12.875.545.328;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;C06.552;G10.261.475;G16.762.468;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.898.656;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;C23.550.767;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E04.936.537;Z01.107.567.875;C06.552.308.500.750;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750
29734997,Polysomnography,E01.370.520.625
29734957,,
29734234,,
29733832,"Awards and Prizes;Biomedical Research;Gastroenterology;History, 20th Century;History, 21st Century;Humans;Mexico",K01.150;H01.770.644.145;H02.403.429.405;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.589
29733454,Cytokines;Microbiota;Nursing,D12.644.276.374;D12.776.467.374;D23.529.374;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;H02.478;N04.452.758.377
29733421,,
29733087,Glioblastoma,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335
29732477,Adult;Antineoplastic Combined Chemotherapy Protocols;Castleman Disease;China;Humans;Middle Aged;Retrospective Studies;Rituximab;Survival Analysis;Treatment Outcome;Rituximab,M01.060.116;E02.183.750.500;E02.319.077.500;E02.319.310.037;C15.604.515.245;C20.683.515.250;Z01.252.474.164;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
29732382,HIV;Genetic Variation;Mortality;Tuberculosis,B04.820.650.589.650.350;G05.365;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C01.252.410.040.552.846
29732168,Bone and Bones;Epigenomics;Estrogens,A02.835.232;A10.165.265;H01.158.273.180.350.074;H01.158.273.343.350.042;D27.505.696.399.472.277
29731334,"Adult;Anesthesia, Cardiac Procedures;Anesthesiology;Education, Medical, Graduate;Humans;Internship and Residency;Mentoring;Mentors;Surveys and Questionnaires;United States;Burnout, Psychological;Change Management;Mentors",M01.060.116;E03.155.403;H02.403.066;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;I02.358.859;I02.588;M01.395;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;F01.145.126.990.367;F02.830.900.333;N04.452.610.125;M01.395
29731013,"Adult;Antihypertensive Agents;Blood Pressure Determination;Blood Pressure Monitoring, Ambulatory;Canada;Cardiovascular Diseases;Child;Evidence-Based Practice;Health Promotion;Humans;Hypertension;Preventive Health Services;Risk Assessment",M01.060.116;D27.505.954.411.162;E01.370.370.140;E01.370.600.100;E01.370.370.140.100;E01.370.520.500.100;Z01.107.567.176;C14;M01.060.406;H02.249;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;N02.421.726;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29730594,"Bronchopulmonary Dysplasia;Cerebral Intraventricular Hemorrhage;Gestational Age;Humans;Infant;Infant Mortality;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Infant, Small for Gestational Age;Retrospective Studies;Risk Assessment;Bronchopulmonary Dysplasia;Infant, Premature;Retinopathy of Prematurity",C08.381.520.750.500;C16.614.521.125;C10.228.140.300.535.200.600;C14.907.253.573.200.600;C23.550.414.913.100.600;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;M01.060.703.520.520;C16.614.521;M01.060.703.520.460.560;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C08.381.520.750.500;C16.614.521.125;M01.060.703.520.520;C11.768.836;C16.614.521.731
29730494,"Brain;Humans;Image Processing, Computer-Assisted;Imaging, Three-Dimensional;Magnetic Resonance Imaging;Models, Theoretical;Neuroimaging;Principal Component Analysis;Passive Cutaneous Anaphylaxis;Pathology",A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.400;L01.224.308.410;E01.370.350.825.500;E05.599;E01.370.350.578;E01.370.376.537;E05.629;E05.318.740.562;E01.370.225.812.871.600;E05.200.812.871.600;E05.478.594.890.600;G12.122.754;H02.403.650
29730491,"Adult;Cerebral Cortex;Connectome;Diffusion Magnetic Resonance Imaging;Humans;Nerve Net;Prefrontal Cortex;Stress Disorders, Post-Traumatic;Veterans;Diffusion Magnetic Resonance Imaging;Magnetic Resonance Imaging;Stress Disorders, Post-Traumatic;Veterans",M01.060.116;A08.186.211.200.885.287.500;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;E01.370.350.825.500.150;B01.050.150.900.649.313.988.400.112.400.400;A08.511;A08.186.211.200.885.287.500.270.700;F03.950.750.500;M01.930;E01.370.350.825.500.150;E01.370.350.825.500;F03.950.750.500;M01.930
29730081,"Adolescent;Adult;Aged;Biopsy;Child;Child, Preschool;Cross-Sectional Studies;Eosinophilic Esophagitis;Esophagoscopy;Gene Expression Profiling;Humans;Hyperplasia;Leukocyte Count;Machine Learning;Middle Aged;Phenotype;Prospective Studies;Severity of Illness Index;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;E01.370.372.250.250.275;E01.370.388.250.250.250.260;E04.210.240.250.260;E04.502.250.250.250.260;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;C23.550.444;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;G17.035.250.500;L01.224.050.375.530;M01.060.116.630;G05.695;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815
29729943,CTLA-4 Antigen;Abatacept;Autoimmunity;Common Variable Immunodeficiency;Hematopoietic Stem Cell Transplantation;Agammaglobulinemia;Sirolimus,D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;D12.776.124.790.651.114.580.225;D12.776.377.715.548.114.580.225;G12.450.192;C20.673.330;E02.095.147.500.500.500;E04.936.225.687.500;C15.378.147.142;C15.604.515.032;C20.673.088;D02.540.505.760
29729659,Cooperative Behavior;Critical Illness;Evidence-Based Practice;Humans;Intensive Care Units;Patient Care Bundles;Prospective Studies;Quality Improvement;Surveys and Questionnaires;Delirium;Critical Care,F01.145.813.115;C23.550.291.625;H02.249;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E02.765;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;J01.293.754;N04.761.744;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;E02.760.190;N02.421.585.190
29728721,"Cohort Studies;Fetal Development;Fetus;Gestational Age;Heart Defects, Congenital;Humans;Infant, Newborn;Placenta;Placenta Diseases;Pregnancy;Ultrasonography, Prenatal;Placenta",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G07.345.500.325.235;G08.686.784.170.157;A16.378;G07.345.500.325.235.968;G08.686.320;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;A16.710;C13.703.590;G08.686.784.769;E01.370.350.850.865;E01.370.378.630.865;A16.710
29728694,,
29728599,Administrative Personnel;Baltimore;Child;Computer Simulation;Humans;Pediatric Obesity;Qualitative Research;Pediatric Obesity;Qualitative Research,M01.526.070;Z01.107.567.875.500.500.100;Z01.433.100;M01.060.406;L01.224.160;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;H01.770.644.241.850;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;H01.770.644.241.850
29728427,"Biomedical Research;Herpesvirus 4, Human;Vaccines",H01.770.644.145;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;D20.215.894
29728413,"Humans;Intubation, Intratracheal;Laryngoscopes;Laryngoscopy;Video Recording",B01.050.150.900.649.313.988.400.112.400.400;E02.041.500;E02.585.578;E05.497.578;E07.230.220.525;E07.858.240.525;E01.370.386.460;E01.370.388.250.525;E04.502.250.525;E04.580.373;L01.280.960
29728407,,
29728321,"Accreditation;Humans;Magnetic Resonance Imaging;Pediatrics;Quality Assurance, Health Care;Radiology Department, Hospital;Specialty Boards;United States;Accreditation",N03.706.110.070;N05.700.200.100;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;H02.403.670;N04.761.700;N05.700;N02.278.216.500.968.695;N04.452.442.422.695;N03.706.110.120.580;N05.700.200.190.750;Z01.107.567.875;N03.706.110.070;N05.700.200.100
29728316,Cognitive Dysfunction;Dementia;Executive Function;Memory,F03.615.250.700;C10.228.140.380;F03.615.400;F02.463.217;F02.463.425.540
29728304,Child;Child Development;Critical Care;Critical Illness;Humans;Quality of Life;Recovery of Function;Syndrome;Quality of Life,M01.060.406;F01.525.200;G07.345.374.750;E02.760.190;N02.421.585.190;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;I01.800;K01.752.400.750;N06.850.505.400.425.837;G16.757;C23.550.288.500;I01.800;K01.752.400.750;N06.850.505.400.425.837
29727686,Gene Expression Regulation;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Molecular Sequence Annotation;Quantitative Trait Loci;Risk Factors,G05.308;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;E05.393.760.479;L01.453.245.667.580;G05.360.340.024.380.937;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29727635,"Adaptor Proteins, Signal Transducing;Animals;DNA-Binding Proteins;Endocardium;Fibroblasts;Heart;Human Umbilical Vein Endothelial Cells;Humans;Mice;Myocardium;Neuregulin-1;Organogenesis;Phosphoproteins;Protein-Serine-Threonine Kinases;Signal Transduction;Transcription Factors",D12.644.360.024;D12.776.157.057;D12.776.476.024;B01.050;D12.776.260;A07.541.207;A11.329.228;A07.541;A11.436.275.682;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A02.633.580;A07.541.704;A10.690.552.750;D12.644.276.860.550.750;D12.776.467.860.550.750;D12.776.631.600.550.750;D23.529.850.550.750;G07.345.500.325.377;G08.686.784.170.450;D12.776.744;D08.811.913.696.620.682.700;G02.111.820;G04.835;D12.776.930
29727562,,
29727427,,
29727423,,
29727416,,
29727412,"Child;Clinical Decision-Making;Consensus;Evidence-Based Medicine;Humans;North America;Orthopedic Surgeons;Orthopedics;Practice Guidelines as Topic;Societies, Medical",M01.060.406;E01.055;F01.829.316.068;F02.463.785.373.433;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567;M01.526.485.810.910.875;N02.360.810.910.875;H02.403.810.494;N04.761.700.350.650;N05.700.350.650;N03.540.828.589
29727409,Access to Information;Child;Closed Fracture Reduction;Hospital Charges;Humans;Orthopedic Procedures;Prospective Studies;Radius Fractures;Telephone;United States,I01.880.604.473.352.500.030;L01.143.024;L01.737.030;M01.060.406;E04.555.300.150;N03.219.262.300;N03.219.442.613;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C26.088.268.556;C26.404.562;L01.178.847.698;Z01.107.567.875
29727408,"Adolescent;African Americans;Age Distribution;Child;Child, Preschool;Databases, Factual;European Continental Ancestry Group;Fractures, Bone;Hispanic Americans;Hospitalization;Humans;Incidence;Infant;Infant, Newborn;Injury Severity Score;Retrospective Studies;United States;Wounds, Gunshot;Young Adult",M01.060.057;M01.686.508.100.100;M01.686.754.100;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;M01.686.508.400;C26.404;M01.686.754.441;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C26.986.900;M01.060.116.815
29727248,Premature Birth,C13.703.420.491.500
29726993,,
29725966,,
29725841,"Acoustic Impedance Tests;Acoustic Stimulation;Adolescent;Adult;Auditory Diseases, Central;Auditory Pathways;Child;Child, Preschool;Electroencephalography;Evoked Potentials, Auditory, Brain Stem;Humans;Infant;Otoacoustic Emissions, Spontaneous;Otoscopy;Pelizaeus-Merzbacher Disease;Young Adult;Evoked Potentials, Auditory, Brain Stem;Hearing;Pelizaeus-Merzbacher Disease",E01.370.382.375.050;E02.037;E02.190.888.030;E05.723.136;M01.060.057;M01.060.116;C09.218.807.186;C10.228.140.068;A08.612.220.110;M01.060.406;M01.060.406.448;E01.370.376.300;E01.370.405.245;G07.265.216.500.370.300;G11.561.200.500.370.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G11.561.790.263.570;E01.370.382.637;C10.228.140.163.100.362.775;C10.228.140.695.625.775;C10.314.400.775;C16.320.322.906;C16.320.565.189.362.775;C18.452.132.100.362.775;C18.452.648.189.362.775;M01.060.116.815;G07.265.216.500.370.300;G11.561.200.500.370.300;F02.830.816.263;G11.561.790.263;C10.228.140.163.100.362.775;C10.228.140.695.625.775;C10.314.400.775;C16.320.322.906;C16.320.565.189.362.775;C18.452.132.100.362.775;C18.452.648.189.362.775
29724730,Granulomatosis with Polyangiitis;Lupus Nephritis;Systemic Vasculitis,C08.381.483.950;C14.907.940.897.249.750;C20.111.193.875;C12.777.419.570.363.680;C13.351.968.419.570.363.680;C17.300.480.680;C20.111.590.560;C14.907.940.897
29724592,"Age of Onset;Aged;Case-Control Studies;Cerebellum;Frontotemporal Lobar Degeneration;Genetic Predisposition to Disease;Genome-Wide Association Study;Glial Cell Line-Derived Neurotrophic Factor Receptors;Humans;Middle Aged;Mutation;Progranulins;RNA, Messenger",N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A08.186.211.132.810.428.200;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.776.395.550.448.400;D12.776.543.484.500.400;D12.776.543.550.418.400;D12.776.543.750.750.400.550.124;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917;D13.444.735.544
29724430,"Child;Contrast Media;Evidence-Based Medicine;Hematuria;Humans;Societies, Medical;United States;Area Under Curve;Child;Hematuria;Nephrolithiasis;Wounds and Injuries;Urolithiasis",M01.060.406;D27.505.259.500;D27.720.259;H02.249.750;H02.403.200.400;C12.777.934.442;C13.351.968.934.442;C23.550.414.849;B01.050.150.900.649.313.988.400.112.400.400;N03.540.828.589;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;M01.060.406;C12.777.934.442;C13.351.968.934.442;C23.550.414.849;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C26;C12.777.967;C13.351.968.967
29724416,"Age Factors;Breast Implants;Diagnostic Imaging;Evidence-Based Medicine;Humans;Postoperative Complications;Societies, Medical;United States;Area Under Curve;Breast Implants",N05.715.350.075;N06.850.490.250;E07.695.140;E01.370.350;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;C23.550.767;N03.540.828.589;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E07.695.140
29724057,"Animals;Antigens, Viral;CRISPR-Cas Systems;Herpes Simplex;Herpesvirus 1, Human;Herpesvirus Vaccines;Immunogenicity, Vaccine;Macaca mulatta;Mutation;Neutralization Tests;Phenotype;Trigeminal Ganglion;Vaccines, Attenuated;Viral Matrix Proteins;Viral Proteins;Virus Replication;Herpesvirus 1, Human;Macaca mulatta",B01.050;D23.050.327;G05.308.203.374.394;C02.256.466.382;C02.825.320;C17.800.838.790.320;B04.280.382.100.750.390;D20.215.894.899.290;G12.070.500;G12.450.050.370.500;G12.450.050.460;G12.513;B01.050.150.900.649.313.988.400.112.199.120.510.550;G05.365.590;E01.370.225.812.735.550;E05.200.812.735.550;E05.478.594.760.550;G05.695;A08.340.390.850;A08.800.350.850;A08.800.800.120.760.825;D20.215.894.811;D12.776.964.970.880.940;D12.776.964;G06.920.925;B04.280.382.100.750.390;B01.050.150.900.649.313.988.400.112.199.120.510.550
29723692,"Genetic Diseases, Inborn",C16.320
29722917,Ischemia;Pseudoxanthoma Elasticum;Stroke,C23.550.513;C14.907.454.530;C15.378.463.515.530;C16.131.831.766;C16.320.850.750;C17.300.766;C17.800.804.766;C17.800.827.750;C10.228.140.300.775;C14.907.253.855
29722473,,
29722467,Ebstein Anomaly,C14.240.400.395;C14.280.400.395;C16.131.240.400.395
29722029,Dyskeratosis Congenita;Lithium;Pulmonary Fibrosis;Telomerase;Telomere,C16.131.831.150;C16.320.322.108;C16.320.850.235;C17.800.804.150;C17.800.827.235;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;C08.381.765;D08.811.913.696.445.308.300.750.750;D12.776.157.687.613;D12.776.157.725.500.921;D12.776.660.720.613;D12.776.664.962.500.921;A11.284.430.106.279.345.190.160.845;G05.360.160.845
29721850,"Docetaxel;Carcinoma, Non-Small-Cell Lung;Pharmacokinetics",D02.455.426.392.368.242.888.389;D02.455.849.291.850.389;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;G03.787;G07.690.725
29721585,,
29721192,Brain Neoplasms;Medulloblastoma,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500
29720649,"Acyltransferases;Animals;Cell Proliferation;Cell Self Renewal;Forkhead Transcription Factors;Intestinal Mucosa;Ligands;Membrane Proteins;Mice;Mice, Inbred C57BL;RNA, Messenger;Receptor, Platelet-Derived Growth Factor alpha;Telocytes;Wnt Proteins;Wnt Signaling Pathway",D08.811.913.050;B01.050;G04.161.750;G07.345.249.410.750;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;D12.776.260.950.249;D12.776.930.977.249;A03.556.124.369;A10.615.550.444;D27.720.470.480;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D13.444.735.544;D08.811.913.696.620.682.725.400.900.500;D12.776.543.750.630.625.300;D12.776.543.750.750.400.630.300;A11.329.830.750;D12.776.467.984;D23.529.984;G02.111.820.925;G04.835.925
29720475,"Adult;Aged;Area Under Curve;Biomarkers;Cohort Studies;Communicable Diseases;Critical Illness;Emergency Service, Hospital;Hospital Mortality;Humans;Lactic Acid;Mass Screening;Middle Aged;Organ Dysfunction Scores;ROC Curve;Reproducibility of Results;Retrospective Studies;Sepsis;Severity of Illness Index;United States;Mass Screening;Critical Illness;Emergency Service, Hospital;Sepsis;Sepsis",M01.060.116;M01.060.116.100;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;D23.101;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C01.539.221;C23.550.291.625;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;D02.241.511.459.450;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;E05.318.308.980.438.475.456.500.625;N05.715.360.300.800.438.375.364.500.625;N06.850.520.308.980.438.475.364.500.625;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.539.757;C23.550.470.790.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;Z01.107.567.875;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C23.550.291.625;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C01.539.757;C23.550.470.790.500;C01.539.757;C23.550.470.790.500
29720449,,
29719113,Child;Pharmacokinetics,M01.060.406;G03.787;G07.690.725
29718792,,
29718599,,
29718391,,
29718327,,
29718310,,
29718237,,
29718224,,
29718188,,
29717110,"Adult;Aged;Aged, 80 and over;B-Lymphocyte Subsets;B-Lymphocytes;CD11c Antigen;Cell Differentiation;Cohort Studies;Humans;Interleukins;Lupus Erythematosus, Systemic;Middle Aged;Plasma Cells;T-Box Domain Proteins;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;A11.063.438.450;A11.118.637.555.567.550.450;A11.118.637.555.567.562.200;A15.145.229.637.555.567.550.450;A15.145.229.637.555.567.562.200;A15.382.032.438.450;A15.382.490.555.567.550.300;A15.382.490.555.567.562.450;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D12.776.395.550.200.074.875;D12.776.395.550.200.275.500;D12.776.543.550.200.093.875;D12.776.543.550.200.275.500;D12.776.543.750.705.408.100.200;D12.776.543.750.705.408.600.100.500;D12.776.543.750.705.833.249.500;D23.050.301.350.074.074;D23.050.301.350.275.500;G04.152;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;C17.300.480;C20.111.590;M01.060.116.630;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;D12.776.260.725;D12.776.930.850;M01.060.116.815
29716949,,
29715212,"Child;Clinical Competence;Hospitals, Pediatric;Humans;Inservice Training;Nursing Staff, Hospital;Personnel Selection;Preceptorship",M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;I02.574;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;N04.452.677.500;I02.358.968
29715118,"Humans;Neoadjuvant Therapy;Radiotherapy, Adjuvant;Radiotherapy, Intensity-Modulated;Rectal Neoplasms;Retrospective Studies;United States;Rectal Neoplasms;Radiotherapy",B01.050.150.900.649.313.988.400.112.400.400;E02.186.450;E02.186.775;E02.815.600;E02.815.635.700.700;L01.313.500.750.100.710.600.550.700;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;E02.815
29714123,Animals;CRISPR-Cas Systems;Cardiovascular Diseases;Gene Editing;Humans;Clustered Regularly Interspaced Short Palindromic Repeats;Cardiomyopathies;Cardiovascular Diseases;Coronary Disease;Embryonic Structures;Genetic Therapy;Genetics;Gene Editing;Lipids,B01.050;G05.308.203.374.394;C14;E05.393.420.270;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C14.280.238;C14;C14.280.647.250;C14.907.585.250;A16;E02.095.301;E05.393.420.301;H01.158.273.343;E05.393.420.270;D10
29713660,Esophageal Diseases;Organoids,C06.405.117;A10.802
29713384,Machine Learning,G17.035.250.500;L01.224.050.375.530
29713383,Obesity,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29713182,Neoplasms;Cell Proliferation;Glycolysis,C04;G04.161.750;G07.345.249.410.750;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360
29713085,,
29712736,"Adult;Aged;Blood Flow Velocity;Blood Pressure;Carotid Arteries;Cause of Death;Disease Progression;Glomerular Filtration Rate;Humans;Hypertension;Middle Aged;Pulse Wave Analysis;Renal Insufficiency, Chronic;Retrospective Studies;Survival Rate;United States;Young Adult;Follow-Up Studies;Humans;Kidney Failure, Chronic;Renal Insufficiency, Chronic;Vascular Stiffness",M01.060.116;M01.060.116.100;E01.370.370.130;G09.330.380.630.080;E01.370.600.875.249;G09.330.380.076;A07.015.114.186;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;C23.550.291.656;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;M01.060.116.630;E01.370.370.680;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;Z01.107.567.875;M01.060.116.815;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C12.777.419.780.750;C13.351.968.419.780.750;G09.330.940
29712498,Asthma;Child;Health Status;Quality of Life,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;I01.240.425;N01.224.425;N06.850.505.400.425;I01.800;K01.752.400.750;N06.850.505.400.425.837
29710244,Health Behavior;Health Promotion;Humans;Motivation;Occupational Health;Occupational Health Services;Weight Loss,F01.145.488;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;N01.400.525;N02.421.143.740;C23.888.144.243.963;G07.345.249.314.120.200.963
29710235,,
29710219,,
29710216,,
29710211,,
29710074,,
29710063,,
29709553,Narcotics,D27.505.696.277.600;D27.505.696.663.850.014.760;D27.505.954.427.040.550;D27.505.954.427.210.600
29709528,,
29709204,"DNA, Ancient",D13.444.308.065
29707164,Heart Arrest;Bradycardia;Heart Arrest;Defibrillators,C14.280.383;C14.280.067.319;C23.550.073.300;C14.280.383;E07.305.250.159
29706592,Cytosol;Mitochondria;Yeasts,A11.284.430.214.200;A11.284.430.429.200;A11.284.835.450.200;A11.284.430.214.190.875.564;A11.284.835.626;B01.300.930
29706505,"Animals;Bacterial Proteins;Bacterial Toxins;Cell Communication;Cysteine;Cytokines;Gene Expression Profiling;Gene Expression Regulation, Bacterial;Hemolysin Proteins;Host-Pathogen Interactions;Immunity, Innate;Mice;Mice, Inbred C57BL;Mice, Knockout;Nitric Oxide;Nitric Oxide Synthase Type II;Operon;Pneumonia, Staphylococcal;Promoter Regions, Genetic;Quorum Sensing;Staphylococcal Infections;Staphylococcus;Staphylococcus aureus;Trans-Activators;Transcription Factors;Virulence;Immunity, Innate;Nitric Oxide;Quorum Sensing;Virulence",B01.050;D12.776.097;D23.946.123;G04.085;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;D12.644.276.374;D12.776.467.374;D23.529.374;E05.393.332;G05.308.300;D12.776.543.695.444;G06.462;G16.527.200;G12.450.564;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D08.811.682.664.500.772.500;D12.776.157.687.575;D12.776.660.720.575;G05.360.340.024.686;G05.360.340.358.207.500;C01.252.410.868.675;C01.252.620.620;C08.381.677.540.620;C08.730.610.540.620;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G04.085.700;G06.550.700;C01.252.410.868;B03.300.390.400.800.750;B03.353.500.750.750;B03.510.100.750.750;B03.510.400.790.750;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;D12.776.260.755;D12.776.930.900;D12.776.964.925.984;D12.776.930;G06.930;G12.450.564;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;G04.085.700;G06.550.700;G06.930
29706060,Cardiopulmonary Resuscitation;Heart Arrest;Extracorporeal Membrane Oxygenation,E02.365.647.110;C14.280.383;E02.880.301;E04.292.451
29705908,Aging;Nervous System Diseases,G07.345.124;C10
29705089,"Delivery Rooms;Humans;Infant, Newborn;Intermittent Positive-Pressure Ventilation;Pregnancy;Respiration;Resuscitation;Infant, Newborn;Resuscitation;Ventilation",N02.278.388.150;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.041.625.790.550;E02.880.820.790.550;G08.686.784.769;G09.772.705;E02.365.647;M01.060.703.520;E02.365.647;N06.230.150.520
29704683,Quality of Health Care,N04.761;N05.715
29704588,Humans;Infant;Kidney Neoplasms;Nephrectomy;Nephrons;Organ Sparing Treatments;Wilms Tumor,B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;E04.950.774.435;A05.810.453.736;E02.674;C04.557.435.595;C04.588.945.947.535.585;C04.700.900;C12.758.820.750.585;C12.777.419.473.585;C13.351.937.820.535.585;C13.351.968.419.473.585;C16.320.700.900
29703948,,
29702754,,
29702721,"Absorbable Implants;Edema;Humans;Inflammation;Middle Aged;Nasal Septum;Nose Deformities, Acquired;Polydioxanone;Reoperation;Rhinoplasty;Young Adult",E07.695.025;C23.888.277;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;M01.060.116.630;A04.531.591;C08.460.619;C09.603.619;D05.750.728.700;D25.130.650;D25.720.728.700;J01.637.051.130.650;J01.637.051.720.728.700;E04.690;E02.218.755;E04.580.392.500;E04.680.650;M01.060.116.815
29702710,,
29702461,"Receptor, Serotonin, 5-HT1A;Endophenotypes;Machine Learning;Depressive Disorder, Major;Molecular Imaging;Positron-Emission Tomography",D12.776.543.750.670.800.100.100;D12.776.543.750.695.800.100.100;D12.776.543.750.720.850.100.100;G05.695.224;G17.035.250.500;L01.224.050.375.530;F03.600.300.375;E01.370.350.557;E05.601.555;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399
29702411,Anticonvulsants;Child;Disease Management;Humans;Patient Care Team;Quality Improvement;Status Epilepticus;Time-to-Treatment;Quality Improvement,D27.505.954.427.080;M01.060.406;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;J01.293.754;N04.761.744;C10.597.742.785;C23.888.592.742.785;E02.760.928;N02.421.585.928;J01.293.754;N04.761.744
29701796,,
29701615,Adolescent;Attention Deficit and Disruptive Behavior Disorders;Automobile Driving;Humans;Linear Models;Pennsylvania;Psychomotor Performance;Risk-Taking;Sampling Studies;Self Report;Simulation Training;Surveys and Questionnaires,M01.060.057;F03.625.094;I03.125;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;F02.808;G11.427.700;G11.561.660;F01.145.722;E05.318.372.875;N05.715.360.330.875;N06.850.520.450.875;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;I02.903.847;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29701145,RNA-Binding Proteins;Inflammation,D12.776.157.725;D12.776.664.962;C23.550.470
29700679,,
29700597,Alzheimer Disease;Cerebrospinal Fluid;Neurogranin;Neuropathology,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A12.207.270.210;D12.776.157.142.500;D12.776.631.640;H01.158.610.184;H02.403.600.250;H02.403.650.375
29700475,,
29700345,,
29698932,"Age Factors;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Capecitabine;Chemotherapy, Adjuvant;Clinical Decision-Making;Colonic Neoplasms;Databases, Factual;Drug Administration Schedule;Fluorouracil;Humans;Neoplasm Staging;Oxaliplatin;Risk Factors;Time Factors;Treatment Outcome;Colonic Neoplasms;Oxaliplatin",N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;E02.183.750.500;E02.319.077.500;E02.319.310.037;D03.383.742.680.245.500.425;D03.383.742.698.875.404.425;D13.570.230.329.313;D13.570.685.245.500.425;E02.186.170;E02.319.170;E01.055;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;L01.313.500.750.300.188.400;L01.470.750.750;E02.319.283;D03.383.742.698.875.404;B01.050.150.900.649.313.988.400.112.400.400;E01.789.625;D02.691.214.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;D02.691.214.500
29698814,"Eye Infections, Viral;Humans;Microcephaly;Pregnancy;Pregnancy Complications, Infectious;Zika Virus;Zika Virus Infection",C02.325;C11.294.800;B01.050.150.900.649.313.988.400.112.400.400;C05.660.207.620;C10.500.507.400.500;C16.131.621.207.620;C16.131.666.507.400.500;G08.686.784.769;C01.539.674;C13.703.700;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
29698113,Cleft Lip;Cleft Palate;Nasal Obstruction,C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;C08.460.525;C08.618.846.185.525;C09.603.525
29698006,,
29697830,"Adolescent;Androgens;Aspartate Aminotransferases;Body Mass Index;Diabetes Mellitus, Type 2;Drug Therapy, Combination;Estradiol;Glycated Hemoglobin A;Humans;Hypoglycemic Agents;Insulin Resistance;Life Style;Menstruation Disturbances;Metformin;Rosiglitazone;Sex Hormone-Binding Globulin;Testosterone",M01.060.057;D27.505.696.399.472.161;D08.811.913.477.700.225;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C18.452.394.750.149;C19.246.300;E02.319.310;D04.210.500.365.415.248;D06.472.334.851.437.500;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;C18.452.394.968.500;G07.690.773.984.617;F01.829.458;C23.550.568;D02.078.370.141.450;D02.886.675.933.500;D03.383.129.708.933.500;D12.776.124.790.223.800;D12.776.157.762;D12.776.377.715.182.800;D04.210.500.054.079.429.824;D06.472.334.851.968.984
29697594,,
29697425,,
29697146,"Anemia, Sickle Cell;Erythrocyte Transfusion;Hemoglobinopathies;Humans;Isoantibodies;Isoantigens;beta-Thalassemia",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;E02.095.135.140.275;C15.378.420;C16.320.365;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.664;D12.776.124.790.651.114.664;D12.776.377.715.548.114.664;D23.050.705;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150
29696817,,
29696782,Leukoencephalopathies;Whole Exome Sequencing,C10.228.140.695;E05.393.760.700.825.500
29696780,,
29696775,Morphogenesis;Natural History,G07.345.500;H01.158.273.602;H01.770.552;K01.400.703
29696635,"Stress Disorders, Post-Traumatic;Anger;Military Personnel;Rage;Veterans",F03.950.750.500;F01.470.093;M01.526.625;F01.470.093.640;M01.930
29696326,Delivery of Health Care;Geography;Global Health;Health Care Costs;Health Expenditures;Health Services Accessibility;Hospitals;Humans;Musculoskeletal Diseases;Orthopedic Procedures;Patient Safety;Probability;Sensitivity and Specificity;Tanzania;Uncertainty,N04.590.374;N05.300;H01.277.500;H02.403.371;N01.400.337;N03.219.151.400;N05.300.375;N03.219.151.450;N05.300.385;N04.590.374.350;N05.300.430;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;C05;E02.718;E04.555;N06.850.135.060.075.399;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;Z01.058.290.120.840;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900
29695998,Apoptosis;Metabolism,G04.146.160;G03
29695840,,
29695833,"Animals;Breast Neoplasms;Cell Line, Tumor;Humans;MCF-7 Cells;Mammary Glands, Human;Mammary Neoplasms, Animal;Mice;Mice, Transgenic;Proto-Oncogene Proteins c-ret;Receptors, Progesterone",B01.050;C04.588.180;C17.800.090.500;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.630;A01.236.249;A10.336.532;C04.588.531;C22.520;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D08.811.913.696.620.682.725.400.087;D12.776.395.550.200.188.500;D12.776.543.131.500;D12.776.543.750.630.217;D12.776.624.664.700.194;D12.776.826.750.765
29695787,,
29695594,,
29695585,"Brain Ischemia;Child;Child, Preschool;Heart Defects, Congenital;Hispanic Americans;Hospital Mortality;Hospitalization;Humans;Infant;Infant, Newborn;Multivariate Analysis;Registries;Risk Factors;Stroke;United States",C10.228.140.300.150;C14.907.253.092;M01.060.406;M01.060.406.448;C14.240.400;C14.280.400;C16.131.240.400;M01.686.754.441;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.228.140.300.775;C14.907.253.855;Z01.107.567.875
29695498,Adrenal Cortex Hormones;Granulomatosis with Polyangiitis;Outcome Assessment (Health Care);Systemic Vasculitis,D06.472.040;C08.381.483.950;C14.907.940.897.249.750;C20.111.193.875;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C14.907.940.897
29694882,Huntington Disease;Heart,C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;A07.541
29694462,,
29694455,,
29693796,Pediatrics,H02.403.670
29693445,,
29693043,,
29691928,"Circadian Rhythm;Disease Progression;Eye;Humans;Myopia;Refraction, Ocular;Circadian Rhythm;Dopamine;Myopia",G07.180.562.190;C23.550.291.656;A01.456.505.420;A09.371;B01.050.150.900.649.313.988.400.112.400.400;C11.744.636;E01.370.380.850.700;G01.590.775;G14.760;G07.180.562.190;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;C11.744.636
29691798,"Algorithms;Alzheimer Disease;Brain;Data Mining;Genomics;Humans;Neuroimaging;Polymorphism, Single Nucleotide;Web Browser;Alzheimer Disease;Data Mining;Genomics",G17.035;L01.224.050;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;L01.313.500.750.280.199;L01.470.625;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;G05.365.795.598;L01.224.900.940;L01.470.937;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;L01.313.500.750.280.199;L01.470.625;H01.158.273.180.350;H01.158.273.343.350
29691613,Classification;Osteonecrosis,L01.100;L01.453.245.275;C05.116.852;C23.550.717.732
29691419,,
29691411,"Databases, Genetic;Diabetes Mellitus, Type 2;Disease;Gene Frequency;Genetic Testing;Genetic Variation;Humans;Obesity;Phenotype;Proteins;Respiratory Hypersensitivity;United Kingdom",L01.313.500.750.300.188.400.325;L01.470.750.750.325;C18.452.394.750.149;C19.246.300;C23.550.288;G05.330;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G05.695;D12.776;C08.674;C20.543.480.680;Z01.542.363
29691365,"Aged;Biomarkers;Carcinoma, Pancreatic Ductal;Cytokines;Disease Progression;Humans;Inflammation;Middle Aged;Pancreatic Neoplasms;Prospective Studies;Risk Factors",M01.060.116.100;D23.101;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;D12.644.276.374;D12.776.467.374;D23.529.374;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;M01.060.116.630;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29691341,"Cell Line;Cell Proliferation;Cell Transformation, Neoplastic;Coinfection;Epigenesis, Genetic;Epithelial Cells;Epstein-Barr Virus Infections;Gene Expression Profiling;Helicobacter Infections;Helicobacter pylori;Herpesvirus 4, Human;Humans;Models, Biological;Herpesvirus 4, Human;Helicobacter pylori;Epigenomics",A11.251.210;G04.161.750;G07.345.249.410.750;C04.697.098.500;C23.550.727.098.500;C01.539.218;C02.219;C03.202;G05.308.203;A11.436;C02.256.466.313;C02.928.313;E05.393.332;C01.252.400.466;B03.440.500.550;B03.660.150.235.500.250.550;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B03.440.500.550;B03.660.150.235.500.250.550;H01.158.273.180.350.074;H01.158.273.343.350.042
29691264,"Acetaminophen;Adult;Aged;Analgesics, Non-Narcotic;Cross-Sectional Studies;Drug Labeling;Drug Misuse;Health Literacy;Humans;Medication Errors;Middle Aged;Risk Factors;Self Administration;Vision Disorders;Visual Acuity;Acetaminophen;Medication Errors;Vision, Ocular;Visual Acuity",D02.065.199.092.040;D02.092.146.113.092.040;M01.060.116;M01.060.116.100;D27.505.696.663.850.014.040;D27.505.954.427.040.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.916.310;J01.576.655.750.321.400;J01.576.761.300.400;E02.319.306;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500;B01.050.150.900.649.313.988.400.112.400.400;E02.319.529;N02.421.450.500;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E02.319.890;E02.900.890;C10.597.751.941;C11.966;C23.888.592.763.941;E01.370.380.850.950;F02.463.593.932.901;G14.940;D02.065.199.092.040;D02.092.146.113.092.040;E02.319.529;N02.421.450.500;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935;E01.370.380.850.950;F02.463.593.932.901;G14.940
29691200,"Immunotherapy, Adoptive;Clustered Regularly Interspaced Short Palindromic Repeats",E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069
29690950,"Child;Child, Preschool;Heart Arrest;Humans;Incidence;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Intubation, Intratracheal;Logistic Models;Quality Improvement;Registries;Retrospective Studies;Risk Factors;Heart Arrest;Heart Diseases;Quality Improvement;Safety",M01.060.406;M01.060.406.448;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.383;C14.280;J01.293.754;N04.761.744;N06.850.135.060.075
29689018,"Breast Feeding;Humans;Infant Health;Infant, Newborn;Milk, Human;Mother-Child Relations;Nursing Process;Postnatal Care;Program Evaluation;Quality Improvement",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;B01.050.150.900.649.313.988.400.112.400.400;N01.400.388;M01.060.703.520;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;F01.829.263.370.290.170;N04.590.233.508;E02.760.703.500;N02.421.143.620.550.500;N02.421.585.703.500;E05.337.820;N04.761.685;N05.715.360.650;J01.293.754;N04.761.744
29689016,"Adult;Breast Feeding;Education;Education, Nursing;Educational Measurement;Humans;Prenatal Education;Program Evaluation;Surveys and Questionnaires;Teaching",M01.060.116;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;I02;I02.358.462;I02.399;B01.050.150.900.649.313.988.400.112.400.400;I02.233.332.500.500;N02.421.726.407.680.500;E05.337.820;N04.761.685;N05.715.360.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.903
29689004,Adolescent;Child;Follow-Up Studies;Humans;Pedicle Screws;Postural Balance;Prospective Studies;Retrospective Studies;Scoliosis;Shoulder;Spinal Fusion;Surgical Instruments;Young Adult,M01.060.057;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E07.695.370.437.500;E07.858.442.660.460.437.500;E07.858.690.725.460.437.500;G11.427.690;G11.561.790.541.595;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;A01.378.800.750;E04.555.100.700;E07.858.700;M01.060.116.815
29688897,,
29688290,,
29688233,Gynecology;Humans;Internship and Residency;Mobile Applications;Obstetrics;Physicians,H02.403.763.750;H02.403.810.310;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;L01.224.900.685;H02.403.810.450;M01.526.485.810;N02.360.810
29688227,,
29688160,"Hip Dislocation;Hip Joint;Humans;Imaging, Three-Dimensional;Reproducibility of Results;Retrospective Studies;Ultrasonography",C05.550.518.384;C26.289.384;C26.531.500;A02.835.583.411;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.850
29688145,"Acute Disease;Adolescent;Child;Child, Preschool;Echocardiography;Electrocardiography;Heart Diseases;Humans;Logistic Models;Lupus Erythematosus, Systemic;Multivariate Analysis;Retrospective Studies;Young Adult;Cardiovascular Diseases;Diagnostic Imaging;Echocardiography;Lupus Erythematosus, Systemic",C23.550.291.125;M01.060.057;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.370.380.240;E01.370.405.240;C14.280;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C17.300.480;C20.111.590;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;C14;E01.370.350;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C17.300.480;C20.111.590
29688108,,
29687961,Histocompatibility;Lung Transplantation,G12.875.519;E04.928.600.495;E04.936.450.495
29687529,"Adolescent;Anesthesia;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Lymph Nodes;Lymphatic Diseases;Lymphography;Magnetic Resonance Imaging;Chylothorax;Chylous Ascites;Lymphography;Lymphedema",M01.060.057;E03.155;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A10.549.400;A15.382.520.604.412;C15.604;E01.370.350.700.475;E01.370.350.825.500;C08.528.142;C06.844.200;E01.370.350.700.475;C15.604.496
29687490,Magnetic Resonance Imaging,E01.370.350.825.500
29685800,"Aorta, Thoracic;Aortic Diseases;Coronary Artery Bypass;Coronary Artery Disease;Echocardiography, Transesophageal;Electrocardiography;Humans;Intra-Aortic Balloon Pumping;Middle Aged;Mitral Valve;Mitral Valve Insufficiency;Plaque, Atherosclerotic;Cardiopulmonary Bypass;Coronary Artery Bypass;Embolism;Intensive Care Units;Cardiac Output, Low;Spectroscopy, Near-Infrared;Aorta, Thoracic;Echocardiography, Transesophageal",A07.015.114.056.372;C14.907.109;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;E04.050.215.400;M01.060.116.630;A07.541.510.507;C14.280.484.461;C23.300.823;E04.292.413;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;C14.907.355.350;N02.278.388.493;C14.280.148;C23.888.192;E01.370.350.750;E05.196.867.851;A07.015.114.056.372;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
29685734,NAD;NAD;Mass Spectrometry;Niacin;Niacinamide,D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;E05.196.566;D03.066.515.475;D03.383.725.547.475;D03.066.515.530;D03.383.725.547.530
29685618,Case-Control Studies;Child Development;Goldenhar Syndrome;Hearing Loss;Humans;Infant;Neurodevelopmental Disorders;Socioeconomic Factors,E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F01.525.200;G07.345.374.750;C05.116.099.370.231.576.410;C05.660.207.231.576.410;C16.131.621.207.231.576.410;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F03.625;I01.880.853.996;N01.824
29685539,Adolescent;Anisotropy;Case-Control Studies;Child;Diffusion Tensor Imaging;Gaucher Disease;Humans;Internal Capsule;Magnetic Resonance Imaging;Middle Cerebellar Peduncle;Nerve Net;White Matter;Child;Diffusion Tensor Imaging;Gaucher Disease;White Matter,M01.060.057;G01.590.040;G02.050;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;B01.050.150.900.649.313.988.400.112.400.400;A08.186.211.200.885.385;A08.612.435;E01.370.350.825.500;A08.186.211.132.810.428.600.521;A08.511;A08.186.211.204;A08.186.854.880;M01.060.406;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;A08.186.211.204;A08.186.854.880
29685489,"Child;Chondroma;Contrast Media;Gastrointestinal Stromal Tumors;Humans;Leiomyosarcoma;Lung Neoplasms;Magnetic Resonance Imaging;Multimodal Imaging;Paraganglioma, Extra-Adrenal;Positron Emission Tomography Computed Tomography;Stomach Neoplasms;Tomography, X-Ray Computed;Gastrointestinal Stromal Tumors;Positron Emission Tomography Computed Tomography",M01.060.406;C04.557.450.565.265;D27.505.259.500;D27.720.259;C04.557.450.565.370;C06.301.371.308;C06.405.249.308;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.590.455;C04.557.450.795.455;C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.350.825.500;E01.370.350.567;C04.557.465.625.650.700.705;C04.557.580.625.650.700.705;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C04.557.450.565.370;C06.301.371.308;C06.405.249.308;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500
29685369,,
29684375,,
29684313,"International Classification of Diseases;Clinical Coding;Hypertension, Pulmonary",L01.453.245.945.400;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;C08.381.423
29684213,,
29684039,"Anesthetics, Intravenous;Animals;Brain;Central Venous Catheters;Drug Delivery Systems;Infusion Pumps;Infusions, Intravenous;Jugular Veins;Mice;Mice, Inbred C57BL;Models, Biological;Propofol",D27.505.696.277.100.035.075;D27.505.954.427.210.100.035.075;B01.050;A08.186.211;E07.132.750.500;E02.319.300;E07.505;E07.858.082.505;E02.319.267.082.500;E02.319.267.510.590;A07.015.908.498;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.599.395;D02.455.426.559.389.657.773
29684005,,
29683451,Baculoviridae;Genetic Therapy;Recombinant Proteins;Transfection,B04.280.065;B04.525.100;E02.095.301;E05.393.420.301;D12.776.828;E05.393.350.810;G05.728.860
29683437,"Animals;Hepatectomy;Hepatic Veins;Liver;Liver Transplantation;Rats;Rats, Inbred Lew",B01.050;E04.210.556;A07.015.908.380;A03.620;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;B01.050.150.900.649.313.992.635.505.700;B01.050.050.199.520.760.280;B01.050.150.900.649.313.992.635.505.700.400.280
29682426,Docetaxel,D02.455.426.392.368.242.888.389;D02.455.849.291.850.389
29681531,Mice;Taste Buds,B01.050.150.900.649.313.992.635.505.500;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779
29681510,"Animals;Child;Frameshift Mutation;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Ikaros Transcription Factor;Mice;Neoplasm Transplantation;Pedigree;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Sequence Analysis, DNA;Precursor Cell Lymphoblastic Leukemia-Lymphoma",B01.050;M01.060.406;G05.365.590.265;C23.550.291.687.500;G05.380.355;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.522.500;D12.776.930.375.500;B01.050.150.900.649.313.992.635.505.500;E05.624;E05.393.673;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;E05.393.760.700;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
29681499,"Abnormalities, Multiple;Allosteric Regulation;Cell Line, Tumor;Chromatin;Congenital Hypothyroidism;Craniofacial Abnormalities;Enhancer of Zeste Homolog 2 Protein;Hand Deformities, Congenital;Histones;Humans;Neoplasms;Polycomb Repressive Complex 2",C16.131.077;G02.111.044;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;C05.660.207;C16.131.621.207;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;C05.390.408;C05.660.585.988.425;C16.131.621.585.988.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;C04;D05.500.781.750;D08.811.913.555.500.800.200.500.500;D12.776.660.235.600.200;D12.776.664.235.800.200;D12.776.930.780.890.200
29681497,"DNA-Directed RNA Polymerases;Endoribonucleases;Escherichia coli;Gene Expression;High-Throughput Nucleotide Sequencing;NAD;Nucleotides;Promoter Regions, Genetic;RNA Caps;Transcription Initiation Site;Transcription, Genetic;Transcriptome;DNA-Directed RNA Polymerases;NAD;Transcription Initiation Site",D08.811.913.696.445.735.270;D08.811.277.352.355.350;D08.811.277.352.700.350;B03.440.450.425.325.300;B03.660.250.150.180.100;G05.297;E05.393.760.319;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D09.408.620;D13.695;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D03.633.100.759.646.454.700;D13.444.735.544.500;D13.695.667.454.700;D13.695.827.426.700;G05.360.340.024.340.137.750.840;G02.111.873;G05.297.700;G02.111.873.750;G05.297.700.750;G05.360.920;D08.811.913.696.445.735.270;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;G05.360.340.024.340.137.750.840
29681477,"Receptors, Calcium-Sensing;Decision Making;Reflex, Startle;Zebrafish",D12.776.543.750.695.115;F02.463.785.373;E01.370.376.550.650.800;E01.370.600.550.650.800;F02.830.702.807;G11.561.731.869;B01.050.150.900.493.200.244.828
29681100,Exome,G05.360.340.011
29681099,Autistic Disorder;Ependymoma;Glioma;Neurofibrosarcoma;Meningioma;Neurofibromin 2;Neurofibroma;Neurofibromatoses;Neurofibromin 1;Pseudarthrosis;Neurilemmoma,F03.625.164.113.500;C04.557.465.625.600.380.290;C04.557.470.670.380.290;C04.557.580.625.600.380.290;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;C04.557.450.565.590.350.590;C04.557.450.795.350.590;C04.557.580.600.580.795;C10.551.775.500.750.750;C10.668.829.725.500.600.600;C04.557.580.520;C04.557.645.520;C04.588.614.250.580.500;C10.551.240.500.500;D12.776.543.685;D12.776.624.776.612;C04.557.580.600.580;C10.551.775.500.750;C10.668.829.725.500.600;C04.557.580.600.580.590;C04.700.631;C10.562.600;C10.574.500.549;C16.320.400.560;C16.320.700.633;D12.644.360.325.150.500.460;D12.776.476.325.150.500.460;D12.776.624.776.610;C26.404.468.627;C04.557.465.625.650.595;C04.557.580.600.610.595;C04.557.580.625.650.595
29680637,Animals;Heart Failure;Randomized Controlled Trials as Topic;Risk Assessment;Survival Analysis;Time Factors;Veterinary Medicine;Biostatistics;Epidemiology;Survival Analysis,B01.050;C14.280.434;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G01.910.857;H02.956;E05.318.740.237;H02.403.720.500;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
29679731,"Precursor Cell Lymphoblastic Leukemia-Lymphoma;Bone Density;Bone Density;Absorptiometry, Photon",C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;G11.427.100;G11.427.100;E01.370.350.700.024;E05.196.712.224.187
29679697,Adult;Cardiopulmonary Resuscitation;Child;Global Health;Health Promotion;Humans;Out-of-Hospital Cardiac Arrest;Time-to-Treatment;Heart Arrest;Cardiopulmonary Resuscitation,M01.060.116;E02.365.647.110;M01.060.406;H02.403.371;N01.400.337;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;C14.280.383.610;E02.760.928;N02.421.585.928;C14.280.383;E02.365.647.110
29678754,Adolescent;Sex Characteristics,M01.060.057;G08.686.815
29678398,Humans;Hydrocortisone;Hypothalamo-Hypophyseal System;Pituitary-Adrenal System;Sleep Initiation and Maintenance Disorders;Ultradian Rhythm;Circadian Rhythm;Hydrocortisone;Sleep Initiation and Maintenance Disorders;Ultradian Rhythm,B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;A06.688.357;A08.186.211.180.497.352.435;A08.186.211.200.317.357.352.435;A08.713.357;A06.300.691;C10.886.425.800.800;F03.870.400.800.800;G07.180.562.797;G07.180.562.190;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;C10.886.425.800.800;F03.870.400.800.800;G07.180.562.797
29677645,,
29677512,"Active Transport, Cell Nucleus;Adult;Aged;Animals;Cytoplasm;DNA-Binding Proteins;Drosophila melanogaster;Green Fluorescent Proteins;HEK293 Cells;HeLa Cells;Homeostasis;Humans;Karyopherins;Middle Aged;Molecular Chaperones;Mutation;Neurodegenerative Diseases;Prions;Protein Domains;RNA-Binding Protein EWS;RNA-Binding Proteins;Receptors, Cytoplasmic and Nuclear;TATA-Binding Protein Associated Factors;beta Karyopherins;Phase Transition",G03.143.310.100;G03.143.700.100;M01.060.116;M01.060.116.100;B01.050;A11.284.430.214;D12.776.260;B01.050.500.131.617.720.500.500.750.310.250.500;D12.776.532.265;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;G07.410;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530.750.500;D12.776.543.585.750.500;D12.776.660.502;M01.060.116.630;D12.776.580;G05.365.590;C10.574;D12.776.785;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.644.360.650;D12.776.157.142.750;D12.776.157.725.813.750.900;D12.776.476.650;D12.776.624.664.700.913;D12.776.664.962.813.750.900;D12.776.157.725;D12.776.664.962;D12.776.826;D12.776.260.775.186;D12.776.930.930.186;D12.776.157.530.750.500.249;D12.776.543.585.750.500.249;D12.776.660.502.500;G01.645;G02.734
29677395,,
29677235,,
29677028,,
29676957,Health Education;Information Dissemination,I02.233.332;N02.421.726.407;L01.143.443
29676940,Gene Targeting,E05.393.335
29676844,Diffusion Tensor Imaging,E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750
29676783,Epilepsy;Genetic Testing;Humans;Neurodevelopmental Disorders,C10.228.140.490;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;F03.625
29676782,Veterans,M01.930
29676530,,
29675737,Genetic Testing,E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221
29675680,"Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;C-Reactive Protein;Capecitabine;Humans;Inflammation Mediators;Kaplan-Meier Estimate;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Proportional Hazards Models;Pyrazoles;Receptor, ErbB-2;Treatment Outcome;Young Adult;Breast Neoplasms;Capecitabine",M01.060.116;M01.060.116.100;M01.060.116.100.080;E02.183.750.500;E02.319.077.500;E02.319.310.037;C04.588.180;C17.800.090.500;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;D03.383.742.680.245.500.425;D03.383.742.698.875.404.425;D13.570.230.329.313;D13.570.685.245.500.425;B01.050.150.900.649.313.988.400.112.400.400;D23.469;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;C04.697.650;C23.550.727.650;E01.789.625;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;D03.383.129.539;D08.811.913.696.620.682.725.400.009.400;D12.776.543.750.630.009.400;D12.776.543.750.750.400.074.400;D12.776.624.664.700.642;D23.050.301.500.600.700;D23.050.705.552.600.550;D23.101.140.642;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C04.588.180;C17.800.090.500;D03.383.742.680.245.500.425;D03.383.742.698.875.404.425;D13.570.230.329.313;D13.570.685.245.500.425
29675547,"Adult;Aged;Aged, 80 and over;Cross-Sectional Studies;Exercise;Fatigue;Humans;Middle Aged;Neoplasms;Pain;Surveys and Questionnaires;Young Adult;Neoplasms;Fatigue;Pain;Exercise",M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G11.427.410.698.277;I03.350;C23.888.369;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04;C23.888.592.612;F02.830.816.444;G11.561.790.444;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;C04;C23.888.369;C23.888.592.612;F02.830.816.444;G11.561.790.444;G11.427.410.698.277;I03.350
29674640,,
29674358,"Adolescent;Brain Injuries, Traumatic;Child;Education, Special;Health Services Needs and Demand;Hospitalization;Humans;Longitudinal Studies;Mental Health Services;Occupational Therapy;Physical Therapy Modalities;Retrospective Studies;Speech Therapy;Trauma Severity Indices",M01.060.057;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;I02.233.213;N03.349.380.420;N05.300.450;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F04.408;N02.421.461;E02.760.169.063.500.489;E02.831.489;H02.010.500;E02.779;E02.831.535;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.169.063.500.727.552;E02.831.727.552;E05.318.308.940.968.875;E05.944;N04.452.859.564.800;N05.715.360.300.715.500.800;N06.850.520.308.940.968.875
29674166,Computational Biology;Gene Expression Regulation;Humans;Metabolic Networks and Pathways;MicroRNAs;Organelle Biogenesis;Mitochondria;Organelle Biogenesis;MicroRNAs,H01.158.273.180;L01.313.124;G05.308;B01.050.150.900.649.313.988.400.112.400.400;G03.493;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;G04.618;G16.645;A11.284.430.214.190.875.564;A11.284.835.626;G04.618;G16.645;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29673727,,
29673641,,
29673530,"Anesthesia, General;Anesthetics, Inhalation;Anesthetics, Intravenous;Artifacts;Brain;Data Interpretation, Statistical;Electrodes;Electroencephalography;Halothane;Humans;Propofol;Software;Wakefulness;Electroencephalography",E03.155.197;D27.505.696.277.100.035.060;D27.505.954.427.210.100.035.060;D27.505.696.277.100.035.075;D27.505.954.427.210.100.035.075;E05.047;A08.186.211;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;E07.305.250;E01.370.376.300;E01.370.405.245;D02.455.526.340;B01.050.150.900.649.313.988.400.112.400.400;D02.455.426.559.389.657.773;L01.224.900;F02.830.104.821;G11.561.035.738;E01.370.376.300;E01.370.405.245
29673520,"Anesthetics, Inhalation;Buffers;Calorimetry;Dimethyl Sulfoxide;Halothane;Humans;Hydrogen-Ion Concentration;Hydrophobic and Hydrophilic Interactions;Isoflurane;Kinetics;Methoxyflurane;Protein Binding;Serum Albumin, Human;Solutions;Solvents;Thermodynamics;Anesthesia;Serum Albumin, Human;Isoflurane",D27.505.696.277.100.035.060;D27.505.954.427.210.100.035.060;D27.720.470.280;E05.196.131;D02.886.640.150;D02.455.526.340;B01.050.150.900.649.313.988.400.112.400.400;G02.300;G02.409;D02.355.601.570;G01.374.661;G02.111.490;D02.355.417.600;D02.355.601.620;G02.111.679;G03.808;D12.776.034.841.603;D12.776.124.727.906;D26.776;D27.720.844;G01.906;E03.155;D12.776.034.841.603;D12.776.124.727.906;D02.355.601.570
29673365,Multiple Sclerosis,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29673079,Hypersensitivity;Anti-Bacterial Agents;Clinical Decision-Making;Immunosuppression;Kidney Transplantation;Pharmacology,C20.543;D27.505.954.122.085;E01.055;E02.095.465.425.450;E05.478.610;E02.870.500;E04.936.450.485;E04.950.774.400;H01.158.703;H02.628
29673058,Heart Transplantation;Pediatrics,E04.100.376.475;E04.928.220.390;E04.936.450.475;H02.403.670
29673056,Editorial;Kidney Transplantation;Jurisprudence;Pediatrics,V01.250;V02.335;E02.870.500;E04.936.450.485;E04.950.774.400;I01.880.604.583;N03.706.535;H02.403.670
29672917,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
29672440,,
29672366,,
29671249,"Fatigue;Pain;Stress, Psychological",C23.888.369;C23.888.592.612;F02.830.816.444;G11.561.790.444;F01.145.126.990;F02.830.900
29669947,Hematology,H02.403.429.445
29669908,,
29669853,,
29669818,Adult;Behavior Therapy;Calcineurin Inhibitors;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Proportional Hazards Models;Survivors;Washington;Albuminuria;Creatinine;Diabetes Mellitus;Glomerular Filtration Rate;Hypertension;Kidney;Mortality;Risk Factors,M01.060.116;F04.754.137;D27.505.519.389.174;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;M01.860;Z01.107.567.875.560.900;Z01.107.567.875.580.900;C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;D03.383.129.308.207;C18.452.394.750;C19.246;E01.370.390.400.300;G08.852.357;C14.907.489;A05.810.453;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29669777,,
29669587,Breast Neoplasms;Puberty,C04.588.180;C17.800.090.500;G08.686.760;G08.686.841.374
29669516,"Bacterial Proteins;Cell Membrane;Cell Membrane Permeability;Drug Tolerance;Escherichia coli;Escherichia coli Proteins;Ethanol;Gene Expression Regulation, Bacterial;Genetic Loci;Membrane Proteins;Microbial Sensitivity Tests;Microbial Viability;Receptors, Cell Surface;Silent Mutation;Temperature;Whole Genome Sequencing;Escherichia coli",D12.776.097;A11.284.149;G03.143.335;G04.175;G07.690.773.992;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;D02.033.375;G05.308.300;G05.360.340.024.380;D12.776.543;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;G06.580;D12.776.543.750;G05.365.590.803;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;E05.393.760.700.825;B03.440.450.425.325.300;B03.660.250.150.180.100
29669400,Gastroenterology;Humans;Liver Diseases,H02.403.429.405;B01.050.150.900.649.313.988.400.112.400.400;C06.552
29669389,,
29669291,Zebrafish,B01.050.150.900.493.200.244.828
29669281,"Glycolysis;Lipid Droplets;Oxidative Phosphorylation;Culture Media, Serum-Free",G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;A11.284.430.214.190.875.393;G02.111.665.550;G03.295.631;G03.796.550;D27.720.470.305.255;E07.206.255
29669226,"Adolescent;Adult;Antigens, CD34;Child;Erythrocyte Transfusion;Gene Transfer Techniques;Genetic Therapy;Genetic Vectors;Hemoglobins;Humans;Lentivirus;Mutation;Transplantation, Autologous;Young Adult;beta-Globins;beta-Thalassemia",M01.060.057;M01.060.116;D23.050.301.264.035.134;D23.101.100.110.134;M01.060.406;E02.095.135.140.275;E05.393.350;E02.095.301;E05.393.420.301;G05.360.337;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589;G05.365.590;E04.936.664;M01.060.116.815;D12.776.124.400.434.325;D12.776.422.316.762.403.325;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150
29669185,,
29668967,"Argentina;Blindness;Child Advocacy;Cooperative Behavior;Focus Groups;Health Plan Implementation;Health Policy;Humans;Infant;Infant, Newborn;Retinopathy of Prematurity;Retrospective Studies",Z01.107.757.077;C10.597.751.941.162;C11.966.075;C23.888.592.763.941.162;I01.880.604.473.300;I01.880.787.293.350;N03.706.437.300;F01.145.813.115;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;N03.349.300;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C11.768.836;C16.614.521.731;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29668521,,
29668393,,
29668327,"Animals;Antibodies;B-Lymphocytes;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Dependovirus;Enzyme-Linked Immunosorbent Assay;Enzyme-Linked Immunospot Assay;Epitope Mapping;Genetic Therapy;Genetic Vectors;Humans;Immunity, Cellular;Immunity, Humoral;Immunity, Innate;Interferons;Interleukins;Primary Cell Culture;Transduction, Genetic;Transgenes;Cytokines;Immunity, Innate;Antibodies, Neutralizing",B01.050;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;B04.280.580.650.170;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E01.370.225.500.508;E05.200.500.508;E05.242.551;E05.478.566.350.170.500;E05.478.566.380.360.500;E05.478.583.400.170.500;E05.601.470.350.170.500;E05.601.470.380.360.500;E05.478.274;E05.601.690.300;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;G12.450.050.420;G12.450.564;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;E05.393.350.800;G05.728.850;G05.360.340.024.340.825;D12.644.276.374;D12.776.467.374;D23.529.374;G12.450.564;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
29667786,Lung Transplantation,E04.928.600.495;E04.936.450.495
29667065,Child;Humans;Laparoscopy;Robotic Surgical Procedures;Urologic Diseases;Urologic Surgical Procedures,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;C12.777;C13.351.968;E04.950.774
29666764,,
29666241,"Animals;Cell Communication;Enteric Nervous System;Fetus;Intestines;Macrophage Colony-Stimulating Factor;Macrophages;Mice;Mice, Knockout;Neurons;Hirschsprung Disease;Enteric Nervous System",B01.050;G04.085;A08.800.050.150;A16.378;A03.556.124;D12.644.276.374.410.240.500;D12.776.395.240.500;D12.776.467.374.410.240.500;D23.529.374.410.240.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A08.675;A11.671;C06.198.439;C06.405.469.158.701.439;C16.131.314.439;A08.800.050.150
29666165,"Adolescent;Aggression;Continuity of Patient Care;Crisis Intervention;Emergency Service, Hospital;Humans;Mental Disorders;Mental Health Services;Patient Care Team;Referral and Consultation;United States",M01.060.057;F01.145.126.125;F01.145.813.045;E02.760.169;N02.421.585.169;N04.590.233.727.210;F04.754.252;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;F03;F04.408;N02.421.461;N04.590.715;N04.452.758.849;Z01.107.567.875
29666163,"Cerebral Palsy;Cognitive Dysfunction;Developmental Disabilities;Gestational Age;Humans;Infant, Extremely Premature;Infant, Newborn;Motor Disorders;Neurologic Examination;Retrospective Studies;Risk Factors;Sensation Disorders;Severity of Illness Index;Socioeconomic Factors",C10.228.140.140.254;F03.615.250.700;F03.625.421;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;M01.060.703.520;F03.608;E01.370.376.550;E01.370.600.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.597.751;C23.888.592.763;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;I01.880.853.996;N01.824
29666161,,
29666117,,
29665793,"Renal Insufficiency, Chronic",C12.777.419.780.750;C13.351.968.419.780.750
29665038,Animals;Antilymphocyte Serum;Feasibility Studies;Immunosuppressive Agents;Kidney Transplantation;Length of Stay;Outpatients;Patient Readmission;Rabbits;Retrospective Studies;Patient Readmission;Patient Safety;Transplants,B01.050;A12.207.152.846.500.203;D12.776.124.486.485.114.573.203;D12.776.124.790.651.114.573.203;D12.776.377.715.548.114.573.203;D20.215.401.203;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;D27.505.696.477.656;E02.870.500;E04.936.450.485;E04.950.774.400;E02.760.400.480;N02.421.585.400.480;M01.643.630;E02.760.400.620;N02.421.585.400.620;B01.050.150.900.649.313.968.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.400.620;N02.421.585.400.620;N06.850.135.060.075.399;A01.941
29664879,"Ambulatory Surgical Procedures;Bone Nails;Bone Wires;Child, Preschool;Closed Fracture Reduction;Cost-Benefit Analysis;Health Care Costs;Hospitals, Pediatric;Humans;Humeral Fractures;Operative Time;Radiography;Retrospective Studies;Surgicenters;Treatment Outcome",E04.030;E07.695.370.249;E07.858.442.660.460.249;E07.858.690.725.460.249;E07.695.370.468;E07.858.442.660.460.468;E07.858.690.725.460.468;M01.060.406.448;E04.555.300.150;N03.219.151.125;N03.219.151.400;N05.300.375;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;E04.614.374.500;N02.421.585.753.374.500;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N02.278.035.652;N02.278.421.556.868;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29664872,,
29664818,,
29663914,"Candidiasis, Oral;Child, Preschool;Dental Caries;Humans;Infant;Retrospective Studies;Risk Factors",C01.703.160.180;C07.465.130;M01.060.406.448;C07.793.720.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29663641,"DiGeorge Syndrome;Thoracic Surgery;Cardiovascular Abnormalities;MicroRNAs;Polymorphism, Single Nucleotide",C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;H02.403.810.803;C14.240;C16.131.240;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;G05.365.795.598
29663593,"Adolescent;Cell Line;Chemokine CCL5;Child;Cytokines;Eosinophilic Esophagitis;Eosinophils;Esophagus;Humans;Intestinal Mucosa;Neoplasm Proteins;Nuclear Proteins;RNA, Small Interfering;Repressor Proteins;Up-Regulation",M01.060.057;A11.251.210;D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250;M01.060.406;D12.644.276.374;D12.776.467.374;D23.529.374;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;A03.556.875.500;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.369;A10.615.550.444;D12.776.624;D12.776.660;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D12.776.260.703;D12.776.930.780;G02.111.905;G05.308.850;G07.690.773.998
29663554,Biofilms;Quorum Sensing,A20.593;G06.120;G04.085.700;G06.550.700
29663285,"Animals;Exosomes;Humans;Models, Biological;Nervous System Diseases;Exosomes;Extracellular Vesicles;Stroke",B01.050;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;C10;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;A11.284.295.588;C10.228.140.300.775;C14.907.253.855
29663091,"Achilles Tendon;Adolescent;Adult;Aged;Aged, 80 and over;Anatomic Variation;Ankle Joint;Arthroscopy;Cadaver;Embalming;Feasibility Studies;Humans;Middle Aged;Muscle, Skeletal;Rupture;Tendinopathy;Tendon Transfer;Tendons;Tibia;Young Adult;Achilles Tendon",A02.880.176;M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;G07.049;G16.117.500;A02.835.583.378.062;E01.370.388.250.070;E04.502.250.070;E04.555.113;C23.550.260.224;I01.076.201.450.550.250;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;A02.633.567;A10.690.552.500;C26.761;C05.651.869;C26.874.800;E04.555.700;A02.880;A02.835.232.043.650.883;M01.060.116.815;A02.880.176
29662948,"Adaptation, Psychological;Animals;Behavior, Animal;Disease Models, Animal;Orexins;Rats;Rats, Sprague-Dawley;Resilience, Psychological;Social Behavior;Stress, Psychological",F01.058;B01.050;F01.145.113;C22.232;E05.598.500;E05.599.395.080;D12.644.400.360;D12.776.631.650.363;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;F02.940;F01.145.813;F01.145.126.990;F02.830.900
29662748,Arthroplasty,E04.555.110;E04.680.101
29662202,,
29661830,,
29661809,,
29661525,Cardiomyopathies;Mechanics;Pediatrics,C14.280.238;H01.671.515;H02.403.670
29661383,"Administration, Intranasal;Anesthesia;Child, Preschool;Dexmedetomidine;Dose-Response Relationship, Drug;Humans;Hypnotics and Sedatives;Infant;Prospective Studies;Dexmedetomidine;Pharmacokinetics",E02.319.267.120.655.500;E03.155;M01.060.406.448;D03.383.129.308.245;G07.690.773.875;G07.690.936.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.277.350;D27.505.954.427.210.350;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D03.383.129.308.245;G03.787;G07.690.725
29660499,Blood-Brain Barrier;Carbenoxolone;Membrane Fluidity;Neuronal Ceroid-Lipofuscinoses,A07.035;A08.186.211.035;D02.455.849.919.530.444.250;G01.154.500;G02.111.550;G04.570;C10.574.500.550;C16.320.400.600;C16.320.565.398.641.509;C18.452.584.687.509;C18.452.648.398.641.509
29659623,"Amino Acid Sequence;Animals;CD4-Positive T-Lymphocytes;Cercocebus atys;Macaca mulatta;Phylogeny;Receptors, CCR5;Receptors, CXCR6;Sequence Homology;Simian Acquired Immunodeficiency Syndrome;Simian Immunodeficiency Virus;Viral Load;Virus Internalization",G02.111.570.060;L01.453.245.667.060;B01.050;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;B01.050.150.900.649.313.988.400.112.199.120.120.110;B01.050.150.900.649.313.988.400.112.199.120.510.550;G05.697;G16.075.605;L01.100.697;D12.776.543.750.695.160.150.500;D12.776.543.750.705.852.125.150.500;D12.776.543.750.830.700.605;D12.776.543.750.695.160.500.625;D12.776.543.750.705.852.125.500.625;D12.776.543.750.830.475;G02.111.810;G05.810;C02.782.815.616.850;C02.839.850;C22.735.500.850;B04.820.650.589.650.800;B04.820.650.805.700;E01.370.225.875.950;E05.200.875.950;G06.920.850;G06.920.881
29659391,"Brain Neoplasms;Carcinoma, Papillary;Child;Humans;Thyroid Cancer, Papillary;Thyroid Neoplasms",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.557.470.200.360;C04.557.470.700.360;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.557.470.200.025.085.612;C04.588.322.894.400;C04.588.443.915.400;C19.344.894.400;C19.874.788.400;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
29659320,"Crime;Analgesics, Opioid;Social Media",I01.198.240;I01.880.735.191;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;L01.178.751;L01.224.230.110.500.750
29659098,,
29659047,,
29659042,,
29659001,Apathy,F01.470.137
29658186,"Child Nutritional Physiological Phenomena;Child, Preschool;Cystic Fibrosis;Digestion;Enteral Nutrition;Enzymes, Immobilized;Exocrine Pancreatic Insufficiency;Growth Charts;Humans;Lipolysis;Malabsorption Syndromes;Malnutrition;Microspheres;Neuroblastoma;Pancrelipase;Severity of Illness Index;Steatorrhea;Treatment Outcome;Weight Gain;Cystic Fibrosis;Enteral Nutrition;Exocrine Pancreatic Insufficiency;Growth;Pancrelipase;Pediatrics;Steatorrhea",G07.203.650.220;M01.060.406.448;C06.689.202;C08.381.187;C16.320.190;C16.614.213;G07.203.650.250;G10.261.190;E02.421.360;E02.642.500.360;D08.811.180;D12.776.463.500;C06.689.276;E05.978.808.500;B01.050.150.900.649.313.988.400.112.400.400;G02.111.534;G03.458.500;C06.405.469.637;C18.452.603;C18.654.521;E07.565;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D08.811.277.352.100.400.745;D20.777.500.745;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C06.405.469.637.887;C18.452.603.887;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.926;G07.345.249.314.120.200.926;C06.689.202;C08.381.187;C16.320.190;C16.614.213;E02.421.360;E02.642.500.360;C06.689.276;G07.345.249;D08.811.277.352.100.400.745;D20.777.500.745;H02.403.670;C06.405.469.637.887;C18.452.603.887
29657904,Breast Neoplasms;Cancer Vaccines;Immunotherapy;Oncolytic Viruses,C04.588.180;C17.800.090.500;D20.215.894.200;E02.095.465.425;B04.700
29657674,Melanoma;Skin Neoplasms,C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.588.805;C17.800.882
29657087,,
29656949,,
29656931,"Animals;Biological Transport;Calcium;Cell Differentiation;Gene Expression Regulation;Glucose;Humans;Hypoglycemic Agents;Insulin;Insulin Secretion;Insulin-Secreting Cells;Mice;Mice, Knockout;Sweetening Agents;Synaptotagmins;Insulin;Membrane Fusion;Bodily Secretions",B01.050;G03.143;D01.268.552.100;D01.552.539.288;D23.119.100;G04.152;G05.308;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D27.720.372.300.353.609;G07.203.300.514.500.400.700;J02.500.514.500.400.700;D12.776.157.125.825;D12.776.543.990.850;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G04.575;A12.200
29656858,"Age of Onset;Cerebellar Diseases;Child, Preschool;Epilepsy, Generalized;Facies;Heterozygote;Humans;Infant;Infant, Newborn;Mutation, Missense;Phenotype;Vesicular Transport Proteins;Epilepsy;Intellectual Disability",N05.715.350.075.100;N06.850.490.250.100;C10.228.140.252;M01.060.406.448;C10.228.140.490.375;C23.550.291.812;E01.370.600.230;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G05.365.590.650;G05.695;D12.776.543.990;C10.228.140.490;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
29656848,Epidemiology;Precision Medicine;Translational Medical Research,H02.403.720.500;E02.574;H02.403.200.700;H01.770.644.145.675
29656405,Early Intervention (Education);Parenting;Quality of Life,N02.421.143.130.320;N02.421.726.320;F01.829.263.370.310;I01.800;K01.752.400.750;N06.850.505.400.425.837
29656398,"Dialysis;Kidney Failure, Chronic;Graft Survival;Kidney Transplantation",E05.196.353;G02.186;C12.777.419.780.750.500;C13.351.968.419.780.750.500;G12.875.545.340;E02.870.500;E04.936.450.485;E04.950.774.400
29656285,,
29655938,Diffusion Magnetic Resonance Imaging,E01.370.350.825.500.150
29655837,"Adult;Age Factors;Alcohol Abstinence;Alcohol Drinking;Follow-Up Studies;Humans;Incidence;Liver Diseases, Alcoholic;Liver Transplantation;Middle Aged;Patient Selection;Recurrence;Retrospective Studies;Risk Factors;Survival Analysis;Time Factors;Treatment Outcome;United States;Recidivism;Recurrence",M01.060.116;N05.715.350.075;N06.850.490.250;F01.145.317.134;F01.145.317.269;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C06.552.645;C25.775.100.087.645;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;E05.581.500.653;N04.590.731;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;I01.198.240.679;C23.550.291.937
29655608,"Anemia, Sickle Cell;Antisickling Agents;Benzaldehydes;Blood;Crystallography, X-Ray;Drug Design;Hemoglobin, Sickle;Humans;Protein Binding;Protein Conformation;Protein Subunits;Pyridines;Structure-Activity Relationship;Hemoglobins;Polymerization;Anemia, Sickle Cell",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.502.135;D02.047.222;A12.207.152;A15.145;E05.196.309.742.225;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;D12.776.124.400.463.588;D12.776.422.316.762.426.588;B01.050.150.900.649.313.988.400.112.400.400;G02.111.679;G03.808;G02.111.570.820.709;D12.776.813;D03.383.725;G02.111.830;G07.690.773.997;D12.776.124.400;D12.776.422.316.762;G02.750;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
29655541,,
29655537,,
29655498,,
29655375,Child Psychiatry;Cognition,F04.096.544.193;H02.403.690.130;F02.463.188
29655171,Electrocorticography,E01.370.376.300.294;E01.370.405.245.431
29654549,Leukoencephalopathies;Mitochondrial Diseases,C10.228.140.695;C18.452.660
29654450,"Adolescent;Biomarkers;Child;Databases, Factual;Extracorporeal Membrane Oxygenation;Heart Transplantation;Heart-Assist Devices;Hospitalization;Humans;Immunoglobulins, Intravenous;Infant;Myocarditis;Prognosis;Respiration, Artificial;Retrospective Studies;Troponin;Mortality;Myocarditis;Troponin",M01.060.057;D23.101;M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;E02.880.301;E04.292.451;E04.100.376.475;E04.928.220.390;E04.936.450.475;E04.050.430;E07.695.300.300;E07.858.082.374.300;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;M01.060.703;C14.280.238.625;E01.789;E02.041.625;E02.365.647.729;E02.880.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C14.280.238.625;D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
29654266,,
29654263,,
29654215,"Kidney Diseases, Cystic;Kidney Failure, Chronic;Human Genetics;Transplantation",C12.777.419.403;C13.351.968.419.403;C12.777.419.780.750.500;C13.351.968.419.780.750.500;H01.158.273.343.385;E04.936
29654206,Meta-Analysis;Percutaneous Coronary Intervention,V03.600;E04.100.814.529.968;E04.502.382.968
29654159,Amyloid;Autophagy,D05.500.049;D12.776.049;G04.146.399;G04.417.350.091
29654146,"Animals;CD8-Positive T-Lymphocytes;Cell Differentiation;Lymphocyte Activation;Lymphocytic Choriomeningitis;Lymphocytic choriomeningitis virus;Mice;Programmed Cell Death 1 Receptor;Receptors, Antigen, T-Cell;Virus Diseases",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;G04.152;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;C02.182.550.500;C02.782.082.580;C10.228.228.245.500.500;C10.228.614.400.500;B04.820.057.070.100.550;B01.050.150.900.649.313.992.635.505.500;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;D12.776.543.750.705.816.824;C02
29654098,Exome;Gene Expression;Genetic Techniques;Genome-Wide Association Study;Human Genetics,G05.360.340.011;G05.297;E05.393;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.343.385
29653906,,
29653875,Immunotherapy,E02.095.465.425
29653788,Health Services Research;Public Health;Violence,H01.770.644.145.360;N03.349.380;N05.425;H02.403.720;N01.400.550;N06.850;I01.198.240.856;I01.880.735.900
29653769,Child;Disease Progression;Proteinuria,M01.060.406;C23.550.291.656;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
29653437,Adolescent;Age of Onset;Case-Control Studies;Communicable Diseases;Environmental Exposure;Humans;Logistic Models;Multiple Sclerosis;Multivariate Analysis;Risk Factors;United States;Epidemiology;Multiple Sclerosis,M01.060.057;N05.715.350.075.100;N06.850.490.250.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C01.539.221;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;H02.403.720.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29653244,,
29653213,"Anti-Inflammatory Agents;Arthritis;Arthritis, Rheumatoid;Diagnosis, Differential;Digestive System Surgical Procedures;Disease Management;Humans;Immunosuppressive Agents;Inflammation;Inflammatory Bowel Diseases;Neutrophils;Postoperative Complications;Pyoderma Gangrenosum;Reoperation;Skin Ulcer;Still's Disease, Adult-Onset;Wound Healing;Neutrophils;Pyoderma Gangrenosum",D27.505.954.158;C05.550.114;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;E01.171;E04.210;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;C23.550.470;C06.405.205.731;C06.405.469.432;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C23.550.767;C17.800.695.675;C17.800.862.675;C17.800.893.675;E04.690;C17.800.893;C05.550.114.154.870;C05.799.114.870;C17.300.775.099.870;C20.111.199.870;G16.762.891;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C17.800.695.675;C17.800.862.675;C17.800.893.675
29653210,"Adrenal Cortex Hormones;Antineoplastic Agents;Autoimmune Diseases;Behcet Syndrome;Chemotaxis, Leukocyte;Cytokines;Dermis;Diagnosis, Differential;Drug Eruptions;Epidermis;Ethnic Groups;Genetic Predisposition to Disease;Hidradenitis;Humans;Immunity, Innate;Immunosuppressive Agents;Inflammation;Neoplasms;Neutrophils;Sweet Syndrome;Vasculitis;Behcet Syndrome;Sweet Syndrome;Sweet Syndrome;Neutrophils;Hidradenitis",D06.472.040;D27.505.954.248;C20.111;C07.465.075;C11.941.879.780.880.200;C14.907.940.100;C16.320.382.250;C17.800.827.368.250;C17.800.862.150;G04.198.424.233;D12.644.276.374;D12.776.467.374;D23.529.374;A17.815.180;E01.171;C17.800.174.600;C20.543.206.380;C25.100.468.380;A10.272.497;A17.815.250;M01.686.754;N01.224.317;C23.550.291.687.500;G05.380.355;C17.800.946.315;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;D27.505.696.477.656;C23.550.470;C04;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C17.800.229.800;C14.907.940;C07.465.075;C11.941.879.780.880.200;C14.907.940.100;C16.320.382.250;C17.800.827.368.250;C17.800.862.150;C17.800.229.800;C17.800.229.800;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C17.800.946.315
29652923,CD4-Positive T-Lymphocytes;Case-Control Studies;HIV Infections;HIV-1;Humans;Immunologic Surveillance;Lymph Nodes;Lymphoid Tissue;Viral Load,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400.412;G12.525;A10.549.400;A15.382.520.604.412;A10.549;A15.382.520.604;E01.370.225.875.950;E05.200.875.950;G06.920.850
29652922,"2',5'-Oligoadenylate Synthetase;Adenine Nucleotides;Animals;Antiviral Agents;Endoribonucleases;HeLa Cells;Hepatitis, Viral, Animal;Host-Pathogen Interactions;Humans;Mice;Murine hepatitis virus;Oligoribonucleotides;Theilovirus;Viral Proteins",D08.811.913.696.445.625;D03.633.100.759.646.138;D13.695.667.138;D13.695.827.068;B01.050;D27.505.954.122.388;D08.811.277.352.355.350;D08.811.277.352.700.350;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;C02.407;C06.552.380.315.430;C22.467.435;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B04.450.580;B04.820.504.540.150.113.875;D13.695.578.424.500;B04.820.565.170.800;D12.776.964
29652549,"Child;Child, Preschool;Glycogen Storage Disease Type I;Granulocyte Colony-Stimulating Factor;Humans;Infant;Leukemia, Myeloid, Acute;Telomere Homeostasis;Time Factors;Leukemia, Myeloid, Acute;Glycogen Storage Disease;Granulocyte Colony-Stimulating Factor;Telomere",M01.060.406;M01.060.406.448;C16.320.565.202.449.448;C18.452.648.202.449.448;D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.337.539.275;G04.144.220.625;G04.161.750.500.500;G05.113.610;G07.345.249.410.750.500.750;G01.910.857;C04.557.337.539.275;C16.320.565.202.449;C18.452.648.202.449;D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350;A11.284.430.106.279.345.190.160.845;G05.360.160.845
29652523,"Economics, Behavioral;Distracted Driving",F04.096.628.286;N03.219.215;I03.125.474
29651121,,
29651054,,
29650772,"Amino Acids, Branched-Chain;Blood Glucose;Cardiovascular Diseases;Diabetes Mellitus, Type 2;Humans;Prospective Studies;Cardiovascular Diseases;Humans;Metabolomics;Risk Factors",D12.125.070;D09.947.875.359.448.500;C14;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C14;B01.050.150.900.649.313.988.400.112.400.400;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29650685,"ErbB Receptors;Carcinoma, Non-Small-Cell Lung",D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500
29650663,"Aedes;Animals;Ethics Committees, Research;Human Experimentation;Humans;Risk;Social Values;Zika Virus;Zika Virus Infection",B01.050.500.131.617.720.500.500.750.712.500.875.100;B01.050;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;E05.445;H01.770.644.145.365;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;F01.829.873;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
29650550,"Dyspnea;Humans;Pulmonary Disease, Chronic Obstructive;Thinking",C08.618.326;C23.888.852.371;B01.050.150.900.649.313.988.400.112.400.400;C08.381.495.389;F02.463.785
29650351,,
29650350,Adipose Tissue;Hypothalamus;Neuropeptides;Obesity,A10.165.114;A08.186.211.180.497;A08.186.211.200.317.357;D12.644.400;D12.776.631.650;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29649820,Acidosis;Alkalosis,C18.452.076.176;C18.452.076.354
29649255,"Gene Silencing;Histone-Lysine N-Methyltransferase;Mutation;Nuclear Proteins;RNA, Fungal;RNA, Untranslated;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Telomere",G05.308.203.374;D08.811.913.555.500.800.200.500;G05.365.590;D12.776.660;D13.444.735.500;D13.444.735.790;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;A11.284.430.106.279.345.190.160.845;G05.360.160.845
29648538,Cell Biology;Cell Line;Humans;Melanoma;Lipoylation,H01.158.100.433;H01.158.273.160;A11.251.210;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;G02.111.540;G03.458.875
29648519,Glutamate Dehydrogenase;Insulin,D08.811.682.664.500.398;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
29644793,,
29644496,"Animals;Cerebellum;Glucose-6-Phosphate;Models, Neurological;Nerve Net;Positron-Emission Tomography;Rats;Visual Cortex;Brain",B01.050;A08.186.211.132.810.428.200;D09.894.417.448.500;E05.599.395.642;A08.511;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;B01.050.150.900.649.313.992.635.505.700;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.186.211
29644336,,
29644055,"Kidney Failure, Chronic;Hyperkalemia;Pediatrics",C12.777.419.780.750.500;C13.351.968.419.780.750.500;C18.452.950.396;H02.403.670
29643747,,
29643746,,
29643745,,
29643390,"Amino Acid Sequence;Binding Sites;Chromatin Assembly and Disassembly;Cloning, Molecular;Gene Expression;HEK293 Cells;Histones;Humans;Kinetics;Models, Molecular;Nucleosomes;Protein Binding;Protein Conformation, alpha-Helical;Protein Conformation, beta-Strand;Protein Interaction Domains and Motifs;Protein Isoforms;Protein Processing, Post-Translational;Recombinant Proteins;Sequence Alignment;Sequence Homology, Amino Acid;Substrate Specificity;Transcriptional Activation;Ubiquitination",G02.111.570.060;L01.453.245.667.060;G02.111.570.120;G04.400.095;G05.213.095;G05.308.095;E05.393.220;G05.297;A11.251.210.172.750;A11.436.334;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;G01.374.661;G02.111.490;E05.599.595;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;G02.111.679;G03.808;G02.111.570.820.709.600.020;G02.111.570.820.709.600.750;G02.111.570.820.709.275.750.500;D12.776.800;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D12.776.828;E05.393.751;G02.111.810.200;G05.810.200;G02.111.835;G05.308.800;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
29643231,,
29643084,,
29643070,"Apnea;Caffeine;Central Nervous System Stimulants;Child;Child Development;Double-Blind Method;Follow-Up Studies;Humans;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Infant, Very Low Birth Weight;Motor Skills;Psychomotor Performance;Spatial Processing;Visual Perception",C08.618.085;C23.888.852.130;D03.132.960.175;D03.633.100.759.758.824.175;D27.505.696.282;D27.505.954.427.220;M01.060.406;F01.525.200;G07.345.374.750;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;C16.614.521;M01.060.703.520.460.600;F02.808.260;F02.808;G11.427.700;G11.561.660;F01.145.875.830;F02.463.593.932
29642972,"Adult;Behavior;Birth Weight;Child, Preschool;Emotions;Humans;Infant;Twins, Dizygotic;Twins, Monozygotic;Problem Behavior;Twins",M01.060.116;F01.145;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;M01.060.406.448;F01.470;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.438.873.920;M01.438.873.940;F01.145.126.972;F01.145.179.750;M01.438.873
29642537,Aging;Chromatin;Epigenomics;Histones;Telomere,G07.345.124;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;A11.284.430.106.279.345.190.160.845;G05.360.160.845
29641951,Breast Neoplasms;Cancer Survivors;Cardiovascular Diseases;Humans;Survivors;United States,C04.588.180;C17.800.090.500;M01.860.350;C14;B01.050.150.900.649.313.988.400.112.400.400;M01.860;Z01.107.567.875
29641834,,
29641811,,
29641804,,
29638203,"Adolescent;Bacterial Infections;Child;Child, Preschool;Extracorporeal Membrane Oxygenation;Hospital Mortality;Humans;Infant;Infant, Newborn;Mycoses;Prospective Studies;Risk Factors;Virus Diseases;Extracorporeal Membrane Oxygenation;Infection;Mortality;Pediatrics",M01.060.057;C01.252;M01.060.406;M01.060.406.448;E02.880.301;E04.292.451;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C01.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C02;E02.880.301;E04.292.451;C01.539;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;H02.403.670
29637688,United States;Epidemiology,Z01.107.567.875;H02.403.720.500
29637431,Accidental Falls;Pediatrics,N06.850.135.122;H02.403.670
29637430,,
29637420,Suicide;Young Adult,F01.145.126.980.875;I01.880.735.856;M01.060.116.815
29637417,Chicago,Z01.107.567.875.350.350.200;Z01.107.567.875.510.350.200;Z01.433.305
29637338,"Adolescent;Age of Onset;Arthritis, Juvenile;Case-Control Studies;Child;Child, Preschool;Cultural Characteristics;Disability Evaluation;Health Status;Humans;Parents;Patient Reported Outcome Measures;Patients;Predictive Value of Tests;Prognosis;Psychometrics;Quality of Life;Reproducibility of Results;Rheumatology;Translating;United States;Quality of Life;Arthritis, Juvenile",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;I01.076.201.450.324;I01.880.853.100.329;E01.370.400;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;M01.643;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;H02.403.429.730;L01.559.423.796;Z01.107.567.875;I01.800;K01.752.400.750;N06.850.505.400.425.837;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198
29636862,Intervertebral Disc;Prostaglandin-Endoperoxide Synthases;Osteogenesis,A02.165.308.410;A02.835.232.834.432;A10.165.382.350.050;D08.811.600.720;D08.811.682.690.708.715;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729
29636415,"A549 Cells;Binding, Competitive;Diglycerides;HeLa Cells;Humans;Lactones;Ligands;Protein Binding;Protein Kinase C-alpha;Protein Kinase C-delta;Protein Kinase C-epsilon;Protein Transport;Substrate Specificity;Cytoskeleton;Second Messenger Systems",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;E05.196.080;G02.111.084;G02.111.570.120.309;D10.351.303;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;D02.540;D27.720.470.480;G02.111.679;G03.808;D08.811.913.696.620.682.700.725.100;D08.811.913.696.620.682.700.725.400;D08.811.913.696.620.682.700.725.750;G03.143.700;G02.111.835;A11.284.430.214.190.750;G02.111.820.800;G04.835.800
29636150,Cosmetic Techniques;Humans;Lip;Reconstructive Surgical Procedures,E02.218;B01.050.150.900.649.313.988.400.112.400.400;A01.456.505.631.515;A14.549.336;E04.680
29635813,"Adolescent;Child;Child, Preschool;Databases, Factual;Follow-Up Studies;Health Information Systems;Heart Transplantation;Humans;Infant;Infant, Newborn;Information Storage and Retrieval;United States;Young Adult;Heart Transplantation;Hospitals;Mortality;Research",M01.060.057;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;L01.313.500.750.300.361;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;L01.313.500.750.280;L01.470;Z01.107.567.875;M01.060.116.815;E04.100.376.475;E04.928.220.390;E04.936.450.475;N02.278.421;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;H01.770.644
29635300,,
29635260,"Adolescent;Bone and Bones;Child;Elbow;Fractures, Ununited;Humans;Humeral Fractures;Incidence;Orthopedic Procedures;Range of Motion, Articular;Reoperation;Retrospective Studies;Risk Factors;Treatment Outcome;United States",M01.060.057;A02.835.232;A10.165.265;M01.060.406;A01.378.800.420;C26.404.468;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E02.718;E04.555;E01.370.600.700;G11.427.760;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
29635139,"Anterior Cruciate Ligament;Arthritis, Juvenile;Child;Femur;Humans;Knee;Knee Joint;Magnetic Resonance Imaging;Menisci, Tibial;Meniscus;Posterior Cruciate Ligament;Radiography;Arthritis, Juvenile",A02.513.514.100;A02.835.583.512.100;A10.165.669.514.100;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;A02.835.232.043.650.247;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.450;A02.835.583.475;E01.370.350.825.500;A02.165.308.538.500;A02.835.583.475.590;A10.165.382.350.163.500;A02.165.308.538;A10.165.382.350.163;A02.513.514.600;A02.835.583.512.600;A10.165.669.514.600;E01.370.350.700;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198
29634905,"Anemia, Sickle Cell;Animals;Antisickling Agents;Disulfides;Erythrocytes;Hemoglobin, Sickle;Hemoglobins;Humans;Hypoxia;Mice;Mice, Inbred C57BL;Oxygen;Polymerization;Protein Binding;Triazoles;Hemoglobins;Erythrocytes;Anemia, Sickle Cell;Hemoglobin, Sickle",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;B01.050;D27.505.954.502.135;D01.248.497.158.874.390;D01.875.350.850.150;D02.886.520.150;A11.118.290;A11.443.240;A15.145.229.334;D12.776.124.400.463.588;D12.776.422.316.762.426.588;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D01.268.185.550;D01.362.670;G02.750;G02.111.679;G03.808;D03.383.129.799;D12.776.124.400;D12.776.422.316.762;A11.118.290;A11.443.240;A15.145.229.334;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D12.776.124.400.463.588;D12.776.422.316.762.426.588
29634614,,
29634445,Health Promotion;Humans;Lower Urinary Tract Symptoms;Prevalence;Quality of Life;Research;Urinary Bladder;Women's Health;Urinary Bladder;Health Promotion;Lower Urinary Tract Symptoms;Social Environment;Urinary Tract Infections;Urination;Women's Health,I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;C23.888.942.343;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;H01.770.644;A05.810.890;N01.400.900;A05.810.890;I02.233.332.445;N02.421.726.407.579;C23.888.942.343;I01.880.853.500;C01.539.895;C12.777.892;C13.351.968.892;G08.852.880;N01.400.900
29634382,Retinal Degeneration;Retinoschisis,C11.270.612;C11.768.585;C11.768.585.865
29634279,,
29633297,"Consensus;Curriculum;Health Personnel;Humans;Optical Imaging;Patient Safety;Practice Guidelines as Topic;Societies, Medical;Surgery, Computer-Assisted;Molecular Probes",F01.829.316.068;F02.463.785.373.433;I02.158;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.589;E05.642;N06.850.135.060.075.399;N04.761.700.350.650;N05.700.350.650;N03.540.828.589;E02.950.875;E04.749;L01.313.500.750.100.710.800;D27.505.259.750;D27.720.470.530
29633002,"Aged;Basilar Artery;Contrast Media;Gadolinium;Humans;Intracranial Arteriosclerosis;Magnetic Resonance Imaging;Middle Aged;Plaque, Atherosclerotic;Plaque, Atherosclerotic;Basilar Artery;Intracranial Arteriosclerosis;Magnetic Resonance Imaging;Stroke",M01.060.116.100;A07.015.114.106;D27.505.259.500;D27.720.259;D01.268.558.362.484;D01.552.550.399.484;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.510.800;C14.907.137.126.372;C14.907.253.560.350;E01.370.350.825.500;M01.060.116.630;C23.300.823;C23.300.823;A07.015.114.106;C10.228.140.300.510.800;C14.907.137.126.372;C14.907.253.560.350;E01.370.350.825.500;C10.228.140.300.775;C14.907.253.855
29632742,Host-Pathogen Interactions;Infection;Inflammation;Serine Proteases,G06.462;G16.527.200;C01.539;C23.550.470;D08.811.277.656.959
29632381,,
29632379,,
29632235,"Blood Platelets;Case-Control Studies;Cells, Cultured;Child;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Endoplasmic Reticulum;Golgi Apparatus;Humans;Leukemia, Erythroblastic, Acute;Megakaryocytes;Promoter Regions, Genetic;Protein Binding;Protein Transport;rab1 GTP-Binding Proteins;von Willebrand Factor",A11.118.188;A15.145.229.188;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251;M01.060.406;M01.060.406.448;D12.776.930.155.200.200;A11.284.430.214.190.875.248;A11.284.430.214.190.875.336;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275.325;C15.378.190.636.276;A11.148.479;A15.378.316.479;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;G03.143.700;D08.811.277.040.330.300.400.400.025;D12.644.360.525.400.025;D12.776.157.325.515.400.025;D12.776.476.525.400.025;D12.776.124.125.920;D23.119.985
29632166,Alzheimer Disease;N-Methylaspartate,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.125.067.500.400;D12.125.119.170.400
29631804,,
29630979,Brain Mapping;Implantable Neurostimulators;Lower Urinary Tract Symptoms;Magnetic Resonance Imaging;Urinary Bladder,E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E07.305.250.319.381;E07.695.202.381;C23.888.942.343;E01.370.350.825.500;A05.810.890
29630712,,
29630691,,
29630654,"Adolescent;Anti-HIV Agents;Botswana;Child;Delayed Diagnosis;HIV Infections;Health Services Accessibility;Hospitalization;Humans;Infectious Disease Transmission, Vertical;Medication Adherence;Pregnancy;Young Adult",M01.060.057;D27.505.954.122.388.077.088;Z01.058.290.175.230;M01.060.406;E01.110;E02.288;E02.760.273;N02.421.585.273;C02.782.815.616.400;C02.800.801.400;C20.673.480;N04.590.374.350;N05.300.430;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N06.850.310.425;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;G08.686.784.769;M01.060.116.815
29630563,Rehabilitation;Stroke,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784;C10.228.140.300.775;C14.907.253.855
29629986,,
29629927,,
29629923,Humans;Outcome and Process Assessment (Health Care);Patient Satisfaction;Patient-Centered Care;Primary Health Care;Quality of Health Care;Residence Characteristics;Socioeconomic Factors;Surveys and Questionnaires;United States,B01.050.150.900.649.313.988.400.112.400.400;N04.761.559;N05.715.360.575;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;N04.590.233.727.407;N04.590.233.727;N04.761;N05.715;N01.224.791;N06.850.505.400.800;I01.880.853.996;N01.824;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875
29629797,Thyroid Neoplasms;Thyroid Nodule,C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800
29629785,"Adolescent;Grief;Humans;Psychiatric Status Rating Scales;Psychological Trauma;Referral and Consultation;Schools;Stress Disorders, Post-Traumatic;Students",M01.060.057;F01.470.142.110;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.653;F03.950.750.375;N04.452.758.849;I02.783;J03.832;F03.950.750.500;M01.848
29629396,,
29628412,"Echocardiography;Fetus;Heart Ventricles;Hernias, Diaphragmatic, Congenital;Humans;Hypertension, Pulmonary;Infant, Newborn;Ventricular Dysfunction, Left;Hernias, Diaphragmatic, Congenital;Extracorporeal Membrane Oxygenation;Milrinone;Nitric Oxide;Ductus Arteriosus, Patent",E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A16.378;A07.541.560;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;M01.060.703.520;C14.280.945.900;C16.131.433;C23.300.707.500.116;E02.880.301;E04.292.451;D02.092.080.085.543;D03.383.725.050.085.543;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;C14.240.400.340;C14.280.400.340;C16.131.240.400.340
29628365,,
29628285,Electronic Health Records;Environmental Exposure;Geographic Information Systems;Residence Characteristics,E05.318.308.940.968.625.500;N06.850.460.350;L01.313.500.750.300.314;L01.470.750.750.462;N01.224.791;N06.850.505.400.800
29628208,"Gastroschisis;Humans;Infant, Newborn;Length of Stay;Parenteral Nutrition;Referral and Consultation;Retrospective Studies;Treatment Outcome;Gastroschisis;Intestinal Atresia;Enterocolitis, Necrotizing",C05.660.417;C16.131.621.417;C23.300.707.374.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E02.421.505;E02.642.500.505;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C05.660.417;C16.131.621.417;C23.300.707.374.500;C06.198.719;C06.405.469.445;C16.131.314.466;C06.405.205.596.700;C06.405.469.363.700
29628186,Amygdala,A08.186.211.180.090;A08.186.211.200.885.287.249.152
29628068,"Memory, Episodic;Emotions;Hippocampus;Depressive Disorder, Major;Magnetic Resonance Imaging",F02.463.425.540.254;F01.470;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F03.600.300.375;E01.370.350.825.500
29627932,Autistic Disorder;Intellectual Disability;Medicaid,F03.625.164.113.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;N03.219.521.346.506.564.655;N03.706.615.693
29627863,Communication;Uncertainty,F01.145.209;L01.143;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900
29627765,DiGeorge Syndrome;DiGeorge Syndrome;Scoliosis;Spine,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.116.900.800.875;A02.835.232.834
29627433,Animals;Cell Proliferation;Colorectal Neoplasms;Gene Expression Regulation;Humans;Intestinal Mucosa;Protein Binding;RNA;RNA-Binding Proteins;Stem Cells;RNA-Binding Proteins;Colorectal Neoplasms,B01.050;G04.161.750;G07.345.249.410.750;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;G05.308;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.369;A10.615.550.444;G02.111.679;G03.808;D13.444.735;D12.776.157.725;D12.776.664.962;A11.872;D12.776.157.725;D12.776.664.962;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
29627189,"Adolescent;Athletic Injuries;Brain Concussion;Child;Child, Preschool;Databases, Factual;Humans;Infant;Infant, Newborn;Philadelphia;Risk Factors;Pediatrics;Brain Injuries, Traumatic",M01.060.057;C26.115;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H02.403.670;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29627138,Heart Ventricles;Sprains and Strains;Tetralogy of Fallot,A07.541.560;C26.844;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29626746,"Adult;Humans;Middle Aged;Needle-Exchange Programs;Patient Acceptance of Health Care;Philadelphia;Qualitative Research;Skin Diseases, Infectious;Social Stigma;Soft Tissue Infections;Substance Abuse, Intravenous;Abscess",M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N02.421.726.708;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;Z01.107.567.875.500.550.525;Z01.433.820;H01.770.644.241.850;C01.539.800;C17.800.838;F01.145.813.840;C01.539.820;C25.775.793;F03.900.793;C01.539.830.025;C23.550.470.756.100
29626619,Lung Neoplasms;Molecular Imaging;General Surgery,C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.350.557;E05.601.555;H02.403.810.300
29626575,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Sesquiterpenes;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.455.849.765;E05.940
29626380,,
29626337,Cognitive Neuroscience;Depression;Schizophrenia,F04.096.628.255.500;H01.158.610.030;F01.145.126.350;F03.700.750
29626170,"Adolescent;Adult;Amino Acid Sequence;Animals;B-Lymphocytes;HIV Infections;Humans;Interleukins;Lymph Nodes;Lymphocyte Activation;Middle Aged;Receptors, Antigen, T-Cell;T-Lymphocytes, Helper-Inducer;Young Adult",M01.060.057;M01.060.116;G02.111.570.060;L01.453.245.667.060;B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;A10.549.400;A15.382.520.604.412;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;M01.060.116.630;D12.776.543.750.705.816.824;A11.118.637.555.567.550.500.400;A11.118.637.555.567.569.200.400;A11.118.637.555.567.569.500.400;A15.145.229.637.555.567.550.500.400;A15.145.229.637.555.567.569.200.400;A15.145.229.637.555.567.569.500.400;A15.382.490.555.567.550.500.400;A15.382.490.555.567.569.200.400;A15.382.490.555.567.569.500.400;M01.060.116.815
29626010,,
29625786,"Adolescent;Adult;Cohort Studies;Diagnosis, Computer-Assisted;Humans;Personality Inventory;Reproducibility of Results;Schizotypal Personality Disorder;Self Report;Surveys and Questionnaires;Psychotic Disorders",M01.060.057;M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.158;L01.313.500.750.100.158;B01.050.150.900.649.313.988.400.112.400.400;F04.711.647.513;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;F03.675.725;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F03.700.675
29625429,,
29625308,"Brain Neoplasms;Craniotomy;Databases, Factual;Humans;Liver Diseases;Middle Aged;Perioperative Care;Postoperative Complications;Program Evaluation;Quality Improvement;Surgeons;Survival Rate;Treatment Outcome;United States;Craniotomy;Liver Diseases",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E04.525.190;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C06.552;M01.060.116.630;E02.760.731;E04.604;N02.421.585.722;C23.550.767;E05.337.820;N04.761.685;N05.715.360.650;J01.293.754;N04.761.744;M01.526.485.810.910;N02.360.810.910;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;E04.525.190;C06.552
29625234,"Infant;Infant, Newborn;Premature Birth",M01.060.703;M01.060.703.520;C13.703.420.491.500
29625131,Incidence;Mortality;Residence Characteristics;Prostatic Neoplasms,E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;N01.224.791;N06.850.505.400.800;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
29624752,Parkinson Disease;Biomarkers;Cognitive Dysfunction,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D23.101;F03.615.250.700
29624527,,
29624526,,
29623639,,
29623450,"Child;Diagnostic Techniques, Urological;Electromyography;Humans;Kidney;Lower Urinary Tract Symptoms;Pelvis;Rheology;Ultrasonography;Urinary Bladder;Urodynamics;Urologic Diseases;Pediatrics",M01.060.406;E01.370.390;E01.370.405.255;E01.370.530.255;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C23.888.942.343;A01.923.600;E05.830;H01.671.808;E01.370.350.850;A05.810.890;G08.852.898;C12.777;C13.351.968;H02.403.670
29623289,Health Behavior;Delivery of Health Care;Pediatrics;Preconception Care,F01.145.488;N04.590.374;N05.300;H02.403.670;E02.760.775;N02.421.143.620.620;N02.421.585.775;N02.421.920.660
29623284,"Chromatography, Liquid;Liquid-Liquid Extraction;Metabolomics;Tandem Mass Spectrometry",E05.196.181.400;E05.196.155.650;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;E05.196.566.880
29622677,"Animals;Bone Morphogenetic Protein 2;Bone Morphogenetic Protein Receptors, Type II;Cells, Cultured;Chondrogenesis;Exostoses, Multiple Hereditary;Gene Expression Regulation;Heparitin Sulfate;Humans;Mice;Mice, Inbred C3H;Phosphorylation;Signal Transduction;Urea;Cell Biology;Heparitin Sulfate;Exostoses, Multiple Hereditary",B01.050;D12.644.276.954.200.200;D12.776.467.942.200.200;D23.529.942.200.200;D08.811.913.696.620.682.700.109.750;D12.776.543.750.750.400.049.750;A11.251;G07.345.500.325.377.625.180;G11.427.578.180;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;G05.308;D09.698.373.425;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.388;B01.050.150.900.649.313.992.635.505.500.400.388;G02.111.665;G02.607.780;G03.796;G02.111.820;G04.835;D02.948;H01.158.100.433;H01.158.273.160;D09.698.373.425;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330
29622589,Electrocardiography;Electrocardiography;Genome-Wide Association Study,E01.370.370.380.240;E01.370.405.240;E01.370.370.380.240;E01.370.405.240;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
29622331,Child;Humans;Pain Management;Pediatrics;Postoperative Hemorrhage;Risk Factors;Tonsillectomy;Hemorrhage;Emergency Medicine;Hemorrhage;Tonsillectomy,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.745;N04.590.607.500;H02.403.670;C23.550.414.941;C23.550.767.850;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.580.848;C23.550.414;H02.403.250;C23.550.414;E04.580.848
29622279,,
29621930,"Adolescent;Aggression;Humans;Pennsylvania;Rural Population;Schools;Students;Urban Population;Violence;Factor Analysis, Statistical",M01.060.057;F01.145.126.125;F01.145.813.045;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;N01.600.725;I02.783;J03.832;M01.848;N01.600.900;I01.198.240.856;I01.880.735.900;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400
29621377,,
29621064,"Adolescent;Age Factors;Anemia, Sickle Cell;Body Weight;Calcium;Child;Child, Preschool;Hand Strength;Humans;Nutritional Status",M01.060.057;N05.715.350.075;N06.850.490.250;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D01.268.552.100;D01.552.539.288;D23.119.100;M01.060.406;M01.060.406.448;E01.370.600.425.500;G11.427.560.500;B01.050.150.900.649.313.988.400.112.400.400;G07.203.650.650;N01.224.425.525
29620997,,
29620972,Thyroid (USP);Hypothyroidism;Thyroxine,D06.472.931.669;C19.874.482;D06.472.931.812;D12.125.072.050.767
29620616,"Austria;Congresses as Topic;Graft Rejection;Graft Survival;Humans;Immunosuppression;Immunosuppressive Agents;Penis;Reconstructive Surgical Procedures;Transplantation, Homologous;Uterus;Vascularized Composite Allotransplantation",Z01.542.088;N03.540.199;G12.875.545.328;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.450;E05.478.610;D27.505.696.477.656;A05.360.444.492;E04.680;E04.936.864;A05.360.319.679;E04.936.450.825
29620599,,
29619965,Adult;Age Factors;Anti-HIV Agents;Botswana;Chemoradiotherapy;Confidence Intervals;HIV Infections;HIV Seronegativity;Humans;Kaplan-Meier Estimate;Middle Aged;Multivariate Analysis;Prospective Studies;Radiotherapy Dosage;Survival Rate;Uterine Cervical Neoplasms,M01.060.116;N05.715.350.075;N06.850.490.250;D27.505.954.122.388.077.088;Z01.058.290.175.230;E02.186.079;E02.319.164;E02.815.160;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;C02.782.815.616.400;C02.800.801.400;C20.673.480;G12.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.815.639;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850
29619844,Arthrodesis,E04.555.100
29619656,Common Variable Immunodeficiency;Failure to Thrive;Obesity;Thinness,C20.673.330;C23.888.338;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.828;E01.370.600.115.100.160.120.828;G07.100.100.160.120.828
29619645,Gender Identity;Parents;Occupations,F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;N01.824.547
29619565,Aged;Alzheimer Disease;Biomechanical Phenomena;Cognitive Dysfunction;Fingers;Humans;Logistic Models;Motor Skills;Neuropsychological Tests;Parkinson Disease;Sensitivity and Specificity;Time Factors;Alzheimer Disease;Cognitive Dysfunction;Parkinson Disease,M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G01.154.090;G01.374.089;F03.615.250.700;A01.378.800.667.430;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;F02.808.260;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;G01.910.857;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F03.615.250.700;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29618662,"Cell Movement;Immunity, Cellular;Allergy and Immunology;Lymph",G04.198;G07.568.500.180;G12.450.050.400;H02.403.044;A12.207.270.606;A15.382.520.150
29618658,Neoplasms;T-Lymphocytes;Therapeutics,C04;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02
29618526,Deep Learning;Genomics;Machine Learning;Precision Medicine,G17.035.250.500.250;G17.485.500;L01.224.050.375.530.250;L01.224.050.375.605.500;H01.158.273.180.350;H01.158.273.343.350;G17.035.250.500;L01.224.050.375.530;E02.574;H02.403.200.700
29618318,"Algorithms;Computer Simulation;Disease;Genetic Association Studies;Genome-Wide Association Study;Humans;Phenotype;Polymorphism, Single Nucleotide;Quantitative Trait Loci",G17.035;L01.224.050;L01.224.160;C23.550.288;E05.393.385;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.695;G05.365.795.598;G05.360.340.024.380.937
29618007,"Alleles;Antigens, Nuclear;Case-Control Studies;Cryptorchidism;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Nerve Tissue Proteins;Polymorphism, Single Nucleotide;RNA Splicing Factors;Repressor Proteins;Testicular Neoplasms",G05.360.340.024.340.030;D12.776.660.625;D23.050.290;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C12.294.829.258;C12.706.258;C16.131.939.258;C19.391.829.258;E05.393.385;C23.550.291.687.500;G05.380.355;G05.380;B01.050.150.900.649.313.988.400.112.400.400;D12.776.631;G05.365.795.598;D12.776.157.725.829;D12.776.664.962.829;D12.776.260.703;D12.776.930.780;C04.588.322.762;C04.588.945.440.915;C12.294.260.937;C12.758.409.937;C19.344.762;C19.391.829.782
29617862,,
29617843,,
29617738,,
29617664,,
29617658,Gene Expression;Machine Learning,G05.297;G17.035.250.500;L01.224.050.375.530
29617638,,
29617573,,
29617408,Alcohol Drinking;Cross-Sectional Studies;Humans;Public Health;Social Media;United States,F01.145.317.269;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;H02.403.720;N01.400.550;N06.850;L01.178.751;L01.224.230.110.500.750;Z01.107.567.875
29617376,"Animals;Animals, Genetically Modified;Axons;Central Nervous System;Cytoskeletal Proteins;DNA-Binding Proteins;Drosophila Proteins;Drosophila melanogaster;Embryo, Nonmammalian;Gene Expression Regulation, Developmental;In Situ Hybridization, Fluorescence;Microtubules;Netrin Receptors;Protein Binding;Signal Transduction",B01.050;B01.050.050.136;B05.620.136;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.186;D12.776.220;D12.776.260;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;A13.350;A16.331;G05.308.310;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;A11.284.430.214.190.750.602;D12.776.543.750.003;G02.111.679;G03.808;G02.111.820;G04.835
29616485,Autistic Disorder,F03.625.164.113.500
29615480,"Anaphylaxis;Bronchodilator Agents;Child;Critical Pathways;Emergency Service, Hospital;Epinephrine;Hospitalization;Hospitals, Pediatric;Hospitals, Teaching;Humans;Injections, Intramuscular;Inservice Training;Medical Staff, Hospital;Patient Care Team;Patient Education as Topic;Philadelphia;Quality Improvement;Referral and Consultation;Time Factors;Time-to-Treatment",C20.543.480.099;D27.505.696.663.050.110;D27.505.954.796.050.100;M01.060.406;N04.590.233.624.625;N04.590.275;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;E02.760.400;N02.421.585.400;N02.278.421.556.437;N02.278.020.300;N02.278.421.639;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.460;I02.574;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;N04.590.715;I02.233.332.500;N02.421.726.407.680;Z01.107.567.875.500.550.525;Z01.433.820;J01.293.754;N04.761.744;N04.452.758.849;G01.910.857;E02.760.928;N02.421.585.928
29615329,Eosinophilic Esophagitis;Health Promotion;Health Services Research;Rare Diseases;Surveys and Questionnaires,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;I02.233.332.445;N02.421.726.407.579;H01.770.644.145.360;N03.349.380;N05.425;C23.550.291.906;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29615134,Heart Arrest;Chimera;Survival,C14.280.383;B05.200;I03.784
29614433,,
29614076,"Adult;Aged;Biopsy;Databases, Factual;Heart Failure;Humans;Image Interpretation, Computer-Assisted;Middle Aged;Neural Networks (Computer)",M01.060.116;M01.060.116.100;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;L01.313.500.750.300.188.400;L01.470.750.750;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;M01.060.116.630;G17.485;L01.224.050.375.605
29613858,"Dermatitis, Allergic Contact;Humans;Patch Tests",C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.871.610;E05.200.812.871.610;E05.478.594.890.610
29611850,Bibliometrics;Biomedical Research;Efficiency;Humans;Journal Impact Factor;Orthopedics;Prevalence;Publishing,L01.178.682.099.325;L01.453.183.291;H01.770.644.145;F02.784.692.351;N04.452.209;B01.050.150.900.649.313.988.400.112.400.400;L01.178.682.099.325.500;L01.453.183.291.500;H02.403.810.494;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;L01.737
29611348,Immune System Diseases;Pediatrics;Respiratory Tract Diseases;Stem Cell Transplantation,C20;H02.403.670;C08;E02.095.147.500.500;E04.936.225.687
29611176,,
29611105,"Aged;Aged, 80 and over;Anticoagulants;Atrial Fibrillation;Factor Xa Inhibitors;Humans;Practice Guidelines as Topic;Practice Patterns, Physicians';Pyrazoles;Pyridones;Retrospective Studies;Rivaroxaban;Atrial Fibrillation;Dabigatran;Aged;Rivaroxaban",M01.060.116.100;M01.060.116.100.080;D27.505.954.502.119;C14.280.067.198;C23.550.073.198;D27.505.519.389.745.800.449.500;D27.505.954.502.119.500.500;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;D03.383.129.539;D03.383.725.791;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D02.886.778.727;D03.383.533.640.713;D03.383.903.727;C14.280.067.198;C23.550.073.198;D03.383.725.192;D03.633.100.103.280;M01.060.116.100;D02.886.778.727;D03.383.533.640.713;D03.383.903.727
29610834,,
29610508,,
29610424,"Encephalitis;Gangliosides;Humans;Neuroblastoma;Receptors, Antigen, T-Cell;T-Lymphocytes",C10.228.140.430;D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D12.776.543.750.705.816.824;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29610348,"AMP-Activated Protein Kinases;Aminoimidazole Carboxamide;Animals;Anxiety Disorders;Drug Evaluation, Preclinical;Enzyme Activation;Feeding Behavior;Gene Knockdown Techniques;Hippocampus;Metformin;Mice;Mice, 129 Strain;Mice, Inbred C57BL;Nerve Tissue Proteins;Nicotine;Ribonucleotides;Signal Transduction;Substance Withdrawal Syndrome;Tobacco Use Disorder;Metformin;Nicotine",D08.811.913.696.620.682.700.085;D12.644.360.062;D12.776.476.062;D03.383.129.308.030;B01.050;F03.080;E05.290.750;E05.337.550;G02.111.263;G03.328;F01.145.113.547;F01.145.407;G07.203.650.353;E05.393.335.500;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D02.078.370.141.450;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.400.025;B01.050.150.900.649.313.992.635.505.500.550.025;B01.050.150.900.649.313.992.635.505.500.800.500.025;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.631;D03.132.760.570;D03.383.725.518;D13.695.827;G02.111.820;G04.835;C25.775.835;F03.900.825;C25.775.912;F03.900.912;D02.078.370.141.450;D03.132.760.570;D03.383.725.518
29610310,"Anaerobiosis;Animals;Bacteria, Anaerobic;Computer Systems;Gastric Mucosa;Gastrointestinal Contents;Gastrointestinal Microbiome;Germ-Free Life;Intestinal Mucosa;Lipids;Luminescent Measurements;Metalloporphyrins;Mice;Mice, Inbred C57BL;Oxidation-Reduction;Oxygen;Oxygen Consumption;Proteins;Gastrointestinal Microbiome",G02.111.062;G03.078;B01.050;B03.130;L01.224.230;A03.556.875.875.440;A10.615.550.291;A12.519;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G06.320;A03.556.124.369;A10.615.550.444;D10;E05.196.712.516;D03.383.129.578.840.500.640;D03.633.400.909.500.640;D04.345.783.500.640;D23.767.727.640;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.700;G03.295.531;D01.268.185.550;D01.362.670;G03.680;D12.776;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
29609888,"Heart Defects, Congenital;Fibrosis;Hemodynamics",C14.240.400;C14.280.400;C16.131.240.400;C23.550.355;G09.330.380
29609728,Fatigue;Sleepiness,C23.888.369;C23.888.900
29609727,"Time;Medical Marijuana;Sleep Apnea, Obstructive",G01.910;D26.528;C08.618.085.852.850;C10.886.425.800.750.850
29608635,,
29608535,,
29608525,Emotions;Facial Expression;Orthognathic Surgery;Perception;Personality,F01.470;E01.370.600.225;F01.145.209.530.385;E06.892.500;H02.163.876.886.500;H02.403.810.481;F02.463.593;F01.752
29608524,Free Tissue Flaps;Lower Extremity;Reconstructive Surgical Procedures,A10.850.710.500;E07.862.710.500;A01.378.610;E04.680
29608343,Child;Child Mortality;Humans;Infant Mortality;Mortality,M01.060.406;E05.318.308.985.550.287;N01.224.935.698.150;N06.850.505.400.975.550.287;N06.850.520.308.985.550.287;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
29608081,"Clinical Competence;Communication;Education, Medical;Education, Medical, Graduate;Humans;Students, Medical",I02.399.630.210;N04.761.210;N05.715.175;F01.145.209;L01.143;I02.358.399;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;M01.848.769.602
29607705,Ataxia;Neurodegenerative Diseases;Quality of Life,C10.597.350.090;C23.888.592.350.090;C10.574;I01.800;K01.752.400.750;N06.850.505.400.425.837
29607525,Adolescent;Feeding and Eating Disorders;Humans;Metabolic Syndrome;Adolescent;Metabolic Syndrome;Obesity;Overweight,M01.060.057;F03.400;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500.570;C18.452.625;M01.060.057;C18.452.394.968.500.570;C18.452.625;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699
29607465,"Leukemia, Myeloid, Acute;Mechanistic Target of Rapamycin Complex 1",C04.557.337.539.275;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500
29607445,Bipolar Disorder;Dementia;Depressive Disorder;Latent Class Analysis;Mood Disorders,F03.084.500;C10.228.140.380;F03.615.400;F03.600.300;E05.318.740.250.338;G17.035.625;L01.224.050.687;N05.715.360.750.200.375;N06.850.520.830.250.338;F03.600
29605619,Nasal Polyps,C08.460.572;C09.603.557;C23.300.825.557
29605442,"Administration, Intranasal;Animals;Corpus Striatum;Dimethyldithiocarbamate;Dopamine;Hypothermia;Mice;Motor Activity;Olfactory Bulb;Oxidative Stress;Parkinson Disease, Secondary;Reactive Oxygen Species;Tyrosine 3-Monooxygenase;Dimethyldithiocarbamate;Mice;Olfactory Pathways;Parkinson Disease",E02.319.267.120.655.500;B01.050;A08.186.211.200.885.287.249.487;D02.241.081.251.869.210;D02.886.706.175;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;C23.888.119.565;B01.050.150.900.649.313.992.635.505.500;F01.145.632;G11.427.410.698;A08.186.211.200.885.388;G03.673;G07.775.750;C10.228.140.079.862.800;C10.228.662.600.700;D01.339.431;D01.650.775;D08.811.682.690.708.923;D12.776.556.579.374.925;D02.241.081.251.869.210;D02.886.706.175;B01.050.150.900.649.313.992.635.505.500;A08.186.211.180.699;A08.612.220.640;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29605396,"Bronchopulmonary Dysplasia;Humans;Infant, Newborn;Infant, Premature;Longitudinal Studies",C08.381.520.750.500;C16.614.521.125;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500
29605270,"Animals;Animals, Newborn;Extracorporeal Membrane Oxygenation;Hernias, Diaphragmatic, Congenital;Herniorrhaphy;Humans;Models, Animal;Respiratory Insufficiency;Retrospective Studies;Sheep;Hernias, Diaphragmatic, Congenital;Extracorporeal Membrane Oxygenation",B01.050;B01.050.050.282;E02.880.301;E04.292.451;C16.131.433;C23.300.707.500.116;E04.680.325;B01.050.150.900.649.313.988.400.112.400.400;E05.598;C08.618.846;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;B01.050.150.900.649.313.500.380.791;C16.131.433;C23.300.707.500.116;E02.880.301;E04.292.451
29604981,"AIDS-Related Opportunistic Infections;Animals;Antiretroviral Therapy, Highly Active;Central Nervous System Infections;Global Health;HIV Infections;Humans;HIV;Aging;Cerebrovascular Disorders;Dementia;Epilepsy;Cognitive Dysfunction;Neurology",C01.539.597.050;C02.597.050;C02.782.815.616.400.100;C03.684.050;C20.673.480.100;B01.050;E02.319.310.075;C01.395;C10.228.228;H02.403.371;N01.400.337;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589.650.350;G07.345.124;C10.228.140.300;C14.907.253;C10.228.140.380;F03.615.400;C10.228.140.490;F03.615.250.700;H02.403.600
29604546,,
29604324,"Adolescent;Adult;Anemia;Case-Control Studies;Cerebrovascular Circulation;Child;Hematocrit;Humans;Image Interpretation, Computer-Assisted;Kidney Failure, Chronic;Magnetic Resonance Imaging;Spin Labels;Young Adult;Anemia;Cerebrovascular Circulation;Renal Insufficiency, Chronic",M01.060.057;M01.060.116;C15.378.071;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G09.330.100.159;M01.060.406;E01.370.225.625.400;E05.200.625.400;G09.188.370.374;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E01.370.350.825.500;D02.389.678;M01.060.116.815;C15.378.071;G09.330.100.159;C12.777.419.780.750;C13.351.968.419.780.750
29604263,"Alzheimer Disease;Biomarkers;Cerebrospinal Fluid;Diagnosis, Differential;alpha-Synuclein",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A12.207.270.210;E01.171;D12.776.631.860.500;D12.776.637.500
29604222,Liver;Bile;Child;Cholestasis,A03.620;A12.200.087;M01.060.406;C06.130.120.135
29603626,"Adult;Heart Defects, Congenital;Heart Failure;Heart Transplantation;Hemodynamics;Humans;Hypertension, Pulmonary;Lung Transplantation;Hypertension, Pulmonary;Transplantation",M01.060.116;C14.240.400;C14.280.400;C16.131.240.400;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;E04.928.600.495;E04.936.450.495;C08.381.423;E04.936
29603600,Cell Biology;Immunosuppression;Translational Medical Research,H01.158.100.433;H01.158.273.160;E02.095.465.425.450;E05.478.610;H01.770.644.145.675
29603342,"Adolescent;Antigens, CD;CD8-Positive T-Lymphocytes;Child;Child, Preschool;Humans;Immunologic Memory;Infant;Integrin alpha Chains;Liver Failure, Acute;Prospective Studies;Retrospective Studies",M01.060.057;D23.050.301.264.035;D23.101.100.110;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.500;M01.060.703;D12.776.543.750.705.408.100;C06.552.308.500.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29603147,Breast;Cervix Uteri;Colon;Early Detection of Cancer;Early Diagnosis;Lung;Mass Screening;Neoplasms,A01.236;A05.360.319.679.256;A03.556.124.526.356;A03.556.249.249.356;E01.390.500;E01.390;A04.411;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C04
29603087,Disabled Children;Emigrants and Immigrants,M01.150.200;M01.189
29602697,Cell Biology;Cell Compartmentation;Organelles;Phase Transition;Protein Domains;Proteins,H01.158.100.433;H01.158.273.160;G04.128;A11.284.430.214.190.875;G01.645;G02.734;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776
29602631,Adolescent;Compliance;Graft Survival;Kidney Transplantation;Adolescent;Young Adult,M01.060.057;G01.374.590.210;G12.875.545.340;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.057;M01.060.116.815
29602395,"Acute Kidney Injury;Animals;Endothelial Cells;Epithelial Cells;Fibrosis;Gene Expression Regulation;Glomerulonephritis;Humans;Kidney;Kidney Tubules;Mitochondria;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;Podocytes;Renal Insufficiency, Chronic;Mitochondria;Podocytes",C12.777.419.780.050;C13.351.968.419.780.050;B01.050;A11.436.275;A11.436;C23.550.355;G05.308;C12.777.419.570.363;C13.351.968.419.570.363;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;A05.810.453.736.560;A11.284.430.214.190.875.564;A11.284.835.626;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720;C12.777.419.780.750;C13.351.968.419.780.750;A11.284.430.214.190.875.564;A11.284.835.626;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720
29602068,"Animals;Cell Line;Ectromelia virus;Ectromelia, Infectious;Gene Knockout Techniques;Humans;Mice, Inbred BALB C;RNA-Binding Proteins;Vaccines, Attenuated;Viral Proteins;Viral Vaccines;Virus Replication;RNA, Double-Stranded;Ectromelia virus;Ectromelia virus",B01.050;A11.251.210;B04.280.650.160.650.200;C02.256.743.239;C22.795.239;E05.393.335.750;B01.050.150.900.649.313.988.400.112.400.400;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;D12.776.157.725;D12.776.664.962;D20.215.894.811;D12.776.964;D20.215.894.899;G06.920.925;D13.444.735.490;G02.111.570.820.486.775;G05.360.580.775;B04.280.650.160.650.200;B04.280.650.160.650.200
29601806,,
29601463,"Cholestasis;Diagnosis, Differential;Humans;Infant;Infant, Newborn;Jaundice, Neonatal",C06.130.120.135;E01.171;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C16.614.451.500;C23.550.429.249.500
29601091,Anaphylaxis;Food Hypersensitivity;Pediatrics,C20.543.480.099;C20.543.480.370;H02.403.670
29600551,Body Image;Touch,F01.752.747.792.110;F02.463.593.112;F02.830.816.850;G11.561.790.850
29600108,Cardiomyopathies;Twins,C14.280.238;M01.438.873
29600010,,
29599513,,
29599299,"Acute Kidney Injury;Adult;Algorithms;Decision Support Systems, Clinical;Humans;Precision Medicine;Precision Medicine;Probability;Prognosis;Random Allocation;Creatinine",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.116;G17.035;L01.224.050;L01.313.500.750.300.190;B01.050.150.900.649.313.988.400.112.400.400;E02.574;H02.403.200.700;E02.574;H02.403.200.700;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;E01.789;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;D03.383.129.308.207
29599195,"Animals;Cell Proliferation;Cells, Cultured;Heparin;Humans;Megakaryocytes;Mice;Platelet Count;Platelet Factor 4;Thrombocytopenia;Thrombopoiesis",B01.050;G04.161.750;G07.345.249.410.750;A11.251;D09.698.373.400;B01.050.150.900.649.313.988.400.112.400.400;A11.148.479;A15.378.316.479;B01.050.150.900.649.313.992.635.505.500;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;D12.644.276.374.200.120.900;D12.776.124.125.720;D12.776.467.374.200.120.900;D23.119.940;D23.125.300.120.900;D23.469.200.120.900;D23.529.374.200.120.900;C15.378.140.855;G04.152.825.798;G09.188.343.798
29599180,Epidemiology,H02.403.720.500
29599139,"Endothelium;Prostaglandin-E Synthases;Receptors, Prostaglandin;Vascular Remodeling",A10.272.491;D08.811.399.475.600;D12.776.543.750.695.200.700;C23.300.977;C23.550.918;G09.330.930
29599028,"Adolescent;Adult;Aged;Aged, 80 and over;Autoimmunity;Child;Child, Preschool;Common Variable Immunodeficiency;Humans;Middle Aged;Phenotype;Registries;Retrospective Studies;Sex Factors;Symptom Assessment;Young Adult;Autoimmunity",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;G12.450.192;M01.060.406;M01.060.406.448;C20.673.330;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.695;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N05.715.350.675;N06.850.490.875;E01.370.872;M01.060.116.815;G12.450.192
29596725,,
29596659,,
29596416,Cloud Computing;Computational Biology;Computer Security;Humans;Workflow,L01.224.097;H01.158.273.180;L01.313.124;L01.224.134;N04.452.910.200;B01.050.150.900.649.313.988.400.112.400.400;L01.906.893
29596042,Conservative Treatment;Dialysis;Kidney Diseases;Nephrology;Renal Insufficiency,E02.197;E05.196.353;G02.186;C12.777.419;C13.351.968.419;H02.403.429.580;C12.777.419.780;C13.351.968.419.780
29595809,Hearing Loss;Reflex,C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;E01.370.376.550.650;E01.370.600.550.650;F02.830.702;G11.561.731
29595734,"Case-Control Studies;Cranial Sutures;Craniosynostoses;Humans;Infant;Logistic Models;Odds Ratio;Tomography, X-Ray Computed",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A02.835.232.781.200;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29595225,Hidradenitis Suppurativa;Humans;Incidence;Retrospective Studies;Risk Factors;Smokers;Tobacco Smoking,C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.808;F01.145.805.375;F01.145.958.875
29594260,Diabetes Mellitus;Growth;Hypothyroidism;Mitochondrial Diseases,C18.452.394.750;C19.246;G07.345.249;C19.874.482;C18.452.660
29593737,Epigenomics;Gene Expression;Genome-Wide Association Study,H01.158.273.180.350.074;H01.158.273.343.350.042;G05.297;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
29593342,,
29593034,"Animals;Cell Line;Cytidine Deaminase;Deamination;HEK293 Cells;Humans;Leukemia Virus, Murine;Mice;Mice, Inbred C57BL;Mice, Transgenic;RNA, Viral;RNA-Directed DNA Polymerase;Retroviridae Infections;Reverse Transcriptase Inhibitors;Reverse Transcription;Retroviridae;Mice, Transgenic",B01.050;A11.251.210;D08.811.277.151.486.250;G02.111.192;G02.607.157;G03.222;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B04.613.807.375.525;B04.820.650.375.525;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D13.444.735.828;D08.811.913.696.445.308.300.750;D12.776.964.775.375.750;D12.776.964.970.600.850.375.750;C02.782.815;D27.505.519.389.675.850;D27.505.954.122.388.077.750;G02.111.873.500;G05.297.700.500;B04.613.807;B04.820.650;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
29590671,Acute Lung Injury;Bronchiolitis Obliterans;Humans;Lung;Lung Transplantation;Primary Graft Dysfunction;Quality of Life;Risk Assessment;Risk Factors;Time Factors,C08.381.520.500;C08.127.446.135.140;C08.381.495.146.135.140;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E04.928.600.495;E04.936.450.495;C14.907.725.675;C23.550.767.877.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857
29590612,Drosophila;Circadian Rhythm;Neurofibromatosis 1,B01.050.500.131.617.720.500.500.750.310.250;G07.180.562.190;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650
29590597,,
29590461,,
29590345,"Adult;Colitis, Ulcerative;Crohn Disease;Drug Monitoring;Gastrointestinal Agents;Hospitalization;Humans;Infliximab;Kaplan-Meier Estimate;Middle Aged;Retrospective Studies;Treatment Failure",M01.060.116;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;C06.405.205.731.500;C06.405.469.432.500;E01.370.520.200;D27.505.954.483;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
29590323,,
29589989,"Animals;Antibodies, Monoclonal;Blood Glucose;Disease Models, Animal;Fasting;Humans;Hyperinsulinism;Hypoglycemia;Insulin;KATP Channels;Mice, Inbred C57BL;Mice, Knockout;Receptor, Insulin;Hyperinsulinism;Hypoglycemia;Insulin;Pancreas",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D09.947.875.359.448.500;C22.232;E05.598.500;E05.599.395.080;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968;C18.452.394.984;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;D12.776.157.530.400.600.450.550;D12.776.543.550.450.750.450.550;D12.776.543.585.400.750.450.550;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.913.696.620.682.725.400.200;D12.776.543.750.630.484;D12.776.543.750.750.580.300;C18.452.394.968;C18.452.394.984;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A03.734
29589910,Human Embryonic Stem Cells;Microfluidics;Transcriptome,A11.872.700.250.750;E05.830.666;H01.671.808.500;J01.897.520.500.500;G02.111.873.750;G05.297.700.750;G05.360.920
29589818,Patients,M01.643
29589152,Neurology;Whole Exome Sequencing,H02.403.600;E05.393.760.700.825.500
29589127,Anxiety Disorders;Parenting,F03.080;F01.829.263.370.310
29589100,Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Mutation;Neoplasm Proteins;Neuroblastoma;Genome-Wide Association Study,C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.624;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
29588511,,
29588463,,
29588401,"Animals;Ecology;Gastrointestinal Microbiome;Gastrointestinal Tract;RNA, Ribosomal, 16S;Bacteria;Microbiota;Microbiota",B01.050;H01.158.273.248;H01.277.249;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;A03.556;D13.444.735.686.670;B03;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29588319,,
29588041,Molecular Dynamics Simulation,E05.599.595.500;G02.111.570.895;L01.224.160.500
29588030,Electroencephalography;Electromyography;Hypnosis,E01.370.376.300;E01.370.405.245;E01.370.405.255;E01.370.530.255;E02.190.525.217;F04.754.424
29588029,Anesthesia;Behavior;Gene Editing;Propofol;Zebrafish,E03.155;F01.145;E05.393.420.270;D02.455.426.559.389.657.773;B01.050.150.900.493.200.244.828
29587805,,
29587735,,
29587698,"Autism Spectrum Disorder;Child;Child, Preschool;Comparative Effectiveness Research;Connecticut;Ethnic Groups;Health Services Accessibility;Healthcare Disparities;Humans;Massachusetts;Patient Navigation;Pennsylvania;Primary Health Care;Research Design;Autism Spectrum Disorder",F03.625.164.113;M01.060.406;M01.060.406.448;H01.770.644.145.360.500;N05.425.157;Z01.107.567.875.550.200;M01.686.754;N01.224.317;N04.590.374.350;N05.300.430;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.550.510;N04.590.233.727.407.500;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;N04.590.233.727;E05.581.500;H01.770.644.728;F03.625.164.113
29587165,"Adult;Cerebral Cortex;Depressive Disorder, Major;Gyrus Cinguli;Humans;Magnetic Resonance Imaging;Middle Aged;Neural Pathways;Neuroimaging;Parietal Lobe;Thalamus;Depressive Disorder, Major;Thalamus",M01.060.116;A08.186.211.200.885.287.500;F03.600.300.375;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;A08.612;E01.370.350.578;E01.370.376.537;E05.629;A08.186.211.200.885.287.500.670;A08.186.211.200.317.826;F03.600.300.375;A08.186.211.200.317.826
29584498,"Accidents, Traffic;Biomechanical Phenomena;Child;Child Restraint Systems;Craniocerebral Trauma;Equipment Design;Head;Humans;Manikins;Neck;Neck Injuries;Posture;Thoracic Injuries;Thorax;Weight-Bearing",N06.850.135.392;G01.154.090;G01.374.089;M01.060.406;E07.490.249;E07.700.175;J01.637.708.175;C10.900.300;C26.915.300;E05.320;A01.456;B01.050.150.900.649.313.988.400.112.400.400;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;A01.598;C26.700;G11.427.695;C26.891;A01.923.761;G01.374.965
29584494,"Accidents, Traffic;Biomechanical Phenomena;Child;Child Restraint Systems;Child, Preschool;Humans;Manikins;Models, Biological;Posture",N06.850.135.392;G01.154.090;G01.374.089;M01.060.406;E07.490.249;E07.700.175;J01.637.708.175;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;E05.599.395;G11.427.695
29584476,"Accidents, Traffic;Adolescent;Adolescent Behavior;Attitude;Automobile Driving;Distracted Driving;Focus Groups;Humans;Middle Aged;Parents;Perception;Protective Devices;Risk Factors;Risk-Taking;Young Adult",N06.850.135.392;M01.060.057;F01.145.022;F01.100;I03.125;I03.125.474;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F02.463.593;E07.700;J01.637.708;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.722;M01.060.116.815
29584473,"Accidents, Traffic;Adolescent;Adult;Age Factors;Automobile Driving;Databases, Factual;Humans;Middle Aged;Videotape Recording;Young Adult",N06.850.135.392;M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;I03.125;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;J01.897.280.500.846.734;J01.897.280.500.898.840;L01.178.590.875.840;L01.178.820.090.846.734;L01.178.820.090.898.840;L01.280.940.840;L01.280.960.880;M01.060.116.815
29584455,,
29582459,"Adolescent;Diagnosis, Differential;Humans;Keloid;Nevus, Epithelioid and Spindle Cell;Skin;Skin Neoplasms",M01.060.057;E01.171;B01.050.150.900.649.313.988.400.112.400.400;A10.165.450.300.425;C17.300.200.425;C23.550.355.274.510;C04.557.665.560.615.625.585;A17.815;C04.588.805;C17.800.882
29582451,"Acetylcysteine;Administration, Topical;Adolescent;Child;Child, Preschool;Free Radical Scavengers;Humans;Ichthyosis;Infant;Retrospective Studies;Treatment Outcome;Ichthyosis",D02.886.030.230.259;D12.125.166.230.259;E02.319.267.120;M01.060.057;M01.060.406;M01.060.406.448;D27.505.519.217.500;B01.050.150.900.649.313.988.400.112.400.400;C16.131.831.512;C16.614.492;C17.800.428.333;C17.800.804.512;M01.060.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C16.131.831.512;C16.614.492;C17.800.428.333;C17.800.804.512
29582213,"Adult;Anticoagulants;Fibrinolytic Agents;Hematology;Humans;Medication Therapy Management;Middle Aged;Oklahoma;Oncologists;Platelet Aggregation Inhibitors;Platelet Count;Practice Patterns, Physicians';Purpura, Thrombocytopenic, Idiopathic;Specialization;Surveys and Questionnaires;Inosine Triphosphate;Purpura, Thrombocytopenic, Idiopathic",M01.060.116;D27.505.954.502.119;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;H02.403.429.445;B01.050.150.900.649.313.988.400.112.400.400;N02.421.668.438;N03.219.521.576.343.575.500.500;N03.219.521.576.343.840.938.500;N04.590.661;M01.060.116.630;Z01.107.567.875.510.550;M01.526.485.810.699;N02.360.810.699;D27.505.954.502.780;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;N04.590.374.577;N05.300.625;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;H02.811;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;D03.633.100.759.646.616.800;D13.695.667.616.800;D13.695.827.519.800;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600
29581924,"Child;Lyme Disease;Arthritis, Infectious",M01.060.406;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;C01.539.100;C05.550.114.099
29581427,"Animals;Carcinogenesis;Cell Line;Cell Line, Tumor;Cell Proliferation;Cell Survival;Cells, Cultured;Deubiquitinating Enzymes;Enzyme Activation;Homeostasis;Humans;Mice;Proteasome Endopeptidase Complex;Protein Binding;Protein Conformation;Protein Folding;Proteolysis;Tripartite Motif Proteins;Ubiquitin Thiolesterase;Ubiquitin-Protein Ligases;Up-Regulation",B01.050;C04.697.098;C23.550.727.098;A11.251.210;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G04.346;A11.251;D08.811.037;G02.111.263;G03.328;G07.410;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D05.500.562.500;D08.811.277.656.918;D08.811.600.730;G02.111.679;G03.808;G02.111.570.820.709;G01.154.651;G02.111.688;G02.111.720;G03.812;D12.776.934;D08.811.037.500;D08.811.277.352.897.850;D12.776.637.937;D08.811.464.938.750;G02.111.905;G05.308.850;G07.690.773.998
29581318,"Neisseria gonorrhoeae;Arthritis, Infectious",B03.440.400.425.550.550.474;B03.660.075.525.520.400;C01.539.100;C05.550.114.099
29581317,"Adolescent;Anti-Bacterial Agents;Arthritis, Infectious;Arthrocentesis;Blood Cell Count;Blood Sedimentation;C-Reactive Protein;Ceftriaxone;Gonorrhea;Humans;Knee;Neisseria gonorrhoeae;Synovial Fluid;Neisseria gonorrhoeae;Arthritis, Infectious",M01.060.057;D27.505.954.122.085;C01.539.100;C05.550.114.099;E01.370.225.998.329.465;E02.800.550.310;E04.665.600.465;E05.200.998.329.465;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E01.370.225.625.125;E05.200.625.125;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;D02.065.589.099.249.190.190.155;D02.886.665.074.190.190.155;D03.633.100.300.249.190.190.155;C01.252.400.625.391;C01.252.810.401;C01.539.778.281.401;C12.294.668.281.401;C13.351.500.711.281.401;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.450;B03.440.400.425.550.550.474;B03.660.075.525.520.400;A02.835.583.443.800.800;A12.207.270.847;B03.440.400.425.550.550.474;B03.660.075.525.520.400;C01.539.100;C05.550.114.099
29581307,"Acetyltransferases;Actins;Crystallography, X-Ray;Enzyme Inhibitors;Humans;N-Terminal Acetyltransferases;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Structure-Activity Relationship;Actins",D08.811.913.050.134;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;E05.196.309.742.225;D27.505.519.389;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.050.134.423;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;G02.111.830;G07.690.773.997;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255
29581253,Acetylation;Acetyltransferases;Actin Cytoskeleton;Actin-Related Protein 2-3 Complex;Cell Movement;HEK293 Cells;Humans;N-Terminal Acetyltransferases;Pseudopodia;Actins;Cell Movement,G02.111.012.052;G02.607.063.052;G03.040.052;D08.811.913.050.134;A11.284.430.214.190.750.050;D05.750.078.730.246;D12.776.220.525.246;G04.198;G07.568.500.180;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.050.134.423;A11.284.180.700;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;G04.198;G07.568.500.180
29581191,"Animals;Bacterial Capsules;Blood Bactericidal Activity;Complement System Proteins;Humans;Kingella kingae;Neisseriaceae Infections;Polysaccharides, Bacterial;Rats;Rats, Sprague-Dawley;Virulence;Kingella kingae",B01.050;A20.186;G09.188.100;G12.450.564.204;D12.776.124.486.274;B01.050.150.900.649.313.988.400.112.400.400;B03.440.400.425.550.400.375;B03.660.075.525.410.410;C01.252.400.625;D09.698.718;D23.050.161.616;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;G06.930;B03.440.400.425.550.400.375;B03.660.075.525.410.410
29581181,,
29581042,Medicaid,N03.219.521.346.506.564.655;N03.706.615.693
29580790,,
29580661,,
29579687,"Alzheimer Disease;Amyloid beta-Peptides;Animals;Depression, Chemical;Deuterium;Dietary Supplements;Disease Models, Animal;Fatty Acids, Unsaturated;Hippocampus;Lipid Peroxidation;Memory;Mice, Transgenic;Spatial Learning;Amyloid;Hippocampus;Lipid Peroxidation",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;B01.050;G07.690.773.750;D01.268.406.500;D01.362.340.500;D01.496.289;G07.203.300.456;J02.500.456;C22.232;E05.598.500;E05.599.395.080;D10.251.355;A08.186.211.180.405;A08.186.211.200.885.287.500.345;G02.111.515;G03.295.531.587;F02.463.425.540;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;F01.145.875.730;F02.463.425.874;F02.784.629.529.775;D05.500.049;D12.776.049;A08.186.211.180.405;A08.186.211.200.885.287.500.345;G02.111.515;G03.295.531.587
29579618,"Animals;Fluorescence;Fluorescent Dyes;Humans;Models, Molecular;Neoplasms;Optical Imaging;Surgery, Computer-Assisted",B01.050;G01.358.500.505.650.665.500;G01.590.540.665.500;D27.720.233.348;D27.720.470.410.505.500;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595;C04;E01.370.350.589;E05.642;E02.950.875;E04.749;L01.313.500.750.100.710.800
29579341,,
29579251,,
29579020,Adolescent;Adult;Case-Control Studies;Craniosynostoses;Humans;Middle Aged;Prospective Studies;Quality of Life;Registries;Reoperation;Surveys and Questionnaires;Young Adult,M01.060.057;M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E04.690;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815
29578952,Cardiac Surgical Procedures;Hospital Mortality;Humans;Myocardial Infarction;Outcome Assessment (Health Care);Postoperative Complications;Quality of Health Care;United States,E04.100.376;E04.928.220;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;C14.280.647.500;C14.907.585.500;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C23.550.767;N04.761;N05.715;Z01.107.567.875
29578883,Ambulatory Surgical Procedures;Cross-Sectional Studies;Dermatologic Surgical Procedures;Humans;Medicare;Operating Rooms;Skin Neoplasms;Soft Tissue Neoplasms;United States,E04.030;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E04.680.275;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N02.278.388.700;C04.588.805;C17.800.882;C04.588.839;Z01.107.567.875
29578539,,
29577986,,
29577947,"Animals;Consumer Product Safety;Cyclohexanecarboxylic Acids;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;D02.241.223.268;D02.455.426.392.368.367.218;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29577513,"Gestational Age;Immune Tolerance;Parturition;Placenta;Population Dynamics;T-Lymphocytes, Regulatory",G07.345.500.325.235.968;G08.686.320;G12.535.425;G08.686.784.769.490;A16.710;I01.240.600;N01.224.625;N06.850.505.400.700;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
29577493,Long-Term Care,E02.760.476;N02.421.585.476
29577488,,
29577272,"Animals;Apoptosis;Carcinogens;Cell Proliferation;Drug Therapy, Combination;Estrogen Replacement Therapy;Estrogens;Estrogens, Conjugated (USP);Indoles;Mammary Neoplasms, Animal;Methylnitrosourea;Progestins;Rats;Rats, Inbred ACI;Rats, Sprague-Dawley;Selective Estrogen Receptor Modulators;Breast Neoplasms;Estrogens, Conjugated (USP);Estradiol",B01.050;G04.146.160;D27.888.569.100;G04.161.750;G07.345.249.410.750;E02.319.310;E02.319.452.150;D27.505.696.399.472.277;D06.472.334.851.437.988;D03.633.100.473;C04.588.531;C22.520;D02.654.692.480;D02.948.594.490;D27.505.696.399.472.858;B01.050.150.900.649.313.992.635.505.700;B01.050.050.199.520.760.080;B01.050.150.900.649.313.992.635.505.700.400.080;B01.050.150.900.649.313.992.635.505.700.750;D06.347.360.827;D27.505.696.399.450.360.827;C04.588.180;C17.800.090.500;D06.472.334.851.437.988;D04.210.500.365.415.248;D06.472.334.851.437.500
29576916,Radiography,E01.370.350.700
29576505,"Adolescent;Adult;Azetidines;Benzyl Compounds;Cohort Studies;Disease Progression;Dose-Response Relationship, Drug;Double-Blind Method;Humans;Middle Aged;Multiple Sclerosis, Chronic Progressive;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;D03.383.082.301;D02.455.426.559.389.140;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.656;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.114.375.500.200;C10.314.350.500.200;C20.111.258.250.500.200;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
29576330,"Child, Preschool;Dacryocystorhinostomy;Foreign-Body Migration;Humans;Infant;Lacrimal Apparatus;Lacrimal Duct Obstruction;Nasal Cavity;Nasolacrimal Duct;Stents;Lacrimal Apparatus Diseases;Intubation;Lacrimal Apparatus",M01.060.406.448;E04.540.255;E04.579.255;C26.392.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A09.371.463;A10.336.422;C11.496.456;A04.531.449;A09.371.463.640;E07.695.750;C11.496;E02.585;E05.497;A09.371.463;A10.336.422
29576218,"Catalytic Domain;Child;Child, Preschool;Dermis;Electron Transport;Fibroblasts;Humans;Induced Pluripotent Stem Cells;Iron-Sulfur Proteins;Magnetic Resonance Imaging;Metalloendopeptidases;Mitochondria;Mutation;Nerve Degeneration;Pedigree;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Mitochondrial Diseases",G02.111.570.120.704;G02.111.570.820.709.275.750.188;M01.060.406;M01.060.406.448;A17.815.180;G02.111.248;G03.295.531.403;G03.493.350;A11.329.228;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;D12.776.157.427.374.375;D12.776.556.579.374.375;E01.370.350.825.500;D08.811.277.656.300.480;D08.811.277.656.675.374;A11.284.430.214.190.875.564;A11.284.835.626;G05.365.590;C23.550.737;E05.393.673;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;C18.452.660
29575622,"Adolescent;Adult;Child;Child, Preschool;Chromosome Deletion;DiGeorge Syndrome;Genetic Testing;Humans;Infant;Infant, Newborn;Kaplan-Meier Estimate;Middle Aged;Phenotype;Young Adult;DiGeorge Syndrome;Neurology;Scoliosis;Seizures;DiGeorge Syndrome",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;G05.695;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;H02.403.600;C05.116.900.800.875;C10.597.742;C23.888.592.742;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
29575457,"Adolescent;Anesthesia;Anesthesiology;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Pediatrics;Perioperative Care;Research Design;Treatment Outcome",M01.060.057;E03.155;H02.403.066;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;H02.403.670;E02.760.731;E04.604;N02.421.585.722;E05.581.500;H01.770.644.728;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29575076,,
29574922,,
29574055,Allosteric Regulation,G02.111.044
29573938,"Education;Fellowships and Scholarships;Students, Medical;Internship and Residency;Technology",I02;N03.219.483.838.276;M01.848.769.602;I02.358.337.350.500;I02.358.399.350.750;J01.897
29573656,Adolescent;Adult;Aged;Depression;Humans;Middle Aged;Motivation;Psychiatric Status Rating Scales;Psychometrics;Reproducibility of Results;Schizophrenia;Schizophrenic Psychology;Self Concept;Self Report;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.658;F01.752.543.500.750;F04.711.513.653;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;F03.700.750;F04.824;F01.752.747.792;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;M01.060.116.815
29573456,Adolescent;Child;Glucocorticoids;Humans;Hypertrophy;Reconstructive Surgical Procedures;Vulva;Hypertrophy,M01.060.057;M01.060.406;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C23.300.775;E04.680;A05.360.319.887;C23.300.775
29572492,,
29571997,"Histology;Carcinoma, Non-Small-Cell Lung;Carcinoma, Squamous Cell",H01.158.100.656;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;C04.557.470.200.400;C04.557.470.700.400
29571696,,
29571602,"Norwood Procedures;Thoracic Surgery;Heart Defects, Congenital",E04.100.376.724;E04.928.220.560;H02.403.810.803;C14.240.400;C14.280.400;C16.131.240.400
29571547,,
29571546,,
29571545,,
29571543,,
29571542,,
29570999,"Aging;Animals;Endothelial Cells;Humans;Hydrogen Sulfide;Mice;Mice, Knockout;Microvessels;Mitochondria;Muscle, Skeletal;NAD;Neovascularization, Physiologic;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;Physical Conditioning, Animal;RNA Interference;RNA, Small Interfering;Receptors, Notch;Signal Transduction;Sirtuin 1;Vascular Endothelial Growth Factor A;Aging;Exercise;Hydrogen Sulfide;Ischemia;Nicotinamide Mononucleotide;Sirtuins",G07.345.124;B01.050;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;D01.029.260.340;D01.362.350;D01.875.350;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A07.015.461;A11.284.430.214.190.875.564;A11.284.835.626;A02.633.567;A10.690.552.500;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;G09.330.630;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650;G11.427.410.698.277.280;G05.308.203.374.790;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;D08.811.277.087.520.200.650.100;D12.776.476.900.100;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;G07.345.124;G11.427.410.698.277;I03.350;D01.029.260.340;D01.362.350;D01.875.350;C23.550.513;D13.695.827.648;D08.811.277.087.520.200.650;D08.811.913.400.725.115.961;D12.776.476.900
29570983,Internet;Survivorship,L01.224.230.110.500;F01.058.144.500
29570963,"Cognitive Behavioral Therapy;Depressive Disorder;Humans;Primary Health Care;Randomized Controlled Trials as Topic;Therapy, Computer-Assisted",F04.754.137.350;F03.600.300;B01.050.150.900.649.313.988.400.112.400.400;N04.590.233.727;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E02.950;L01.313.500.750.100.710
29570815,Electroencephalography;Magnetoencephalography;Schizophrenia;Temporal Lobe,E01.370.376.300;E01.370.405.245;E01.370.376.500;E01.370.405.440;E05.540.500;F03.700.750;A08.186.211.200.885.287.500.863
29570371,Erectile Dysfunction;Penile Prosthesis,C12.294.644.486;F03.835.400;E07.695.610
29568374,"Molecular Imaging;Carcinoma, Squamous Cell;General Surgery",E01.370.350.557;E05.601.555;C04.557.470.200.400;C04.557.470.700.400;H02.403.810.300
29568081,,
29568068,,
29567837,"Acetylation;Amino Acid Motifs;Amino Acid Sequence;Biophysical Phenomena;Chromatin Assembly and Disassembly;DNA Helicases;DNA-Binding Proteins;Gene Expression Regulation;Gene Regulatory Networks;HEK293 Cells;Humans;Mi-2 Nucleosome Remodeling and Deacetylase Complex;Nuclear Proteins;Peptides;Protein Binding;Protein Domains;RNA-Binding Proteins;Sequence Homology, Amino Acid;Trans-Activators;Acetylation",G02.111.012.052;G02.607.063.052;G03.040.052;G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;G02.111.570.060;L01.453.245.667.060;G01.154;G04.400.095;G05.213.095;G05.308.095;D08.811.277.040.025.159;D08.811.399.340;D12.776.260;G05.308;G05.360.080.689.360;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.040.025.176;D08.811.277.087.520.500;D08.811.600.620;D12.776.660;D12.644;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.157.725;D12.776.664.962;G02.111.810.200;G05.810.200;D12.776.260.755;D12.776.930.900;D12.776.964.925.984;G02.111.012.052;G02.607.063.052;G03.040.052
29567813,,
29567456,,
29567209,"Bone Diseases, Metabolic;Humans;Myositis Ossificans;Ossification, Heterotopic;Skin Diseases, Genetic;Ossification, Heterotopic",C05.116.198;C18.452.104;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;C23.550.751;C16.320.850;C17.800.827;C23.550.751
29567127,"Adolescent;Algorithms;Antigens, Bacterial;Bacterial Toxins;Child;Child, Preschool;Clostridium Infections;Clostridium difficile;Glutamate Dehydrogenase;Humans;Immunoenzyme Techniques;Infant;Molecular Diagnostic Techniques;Predictive Value of Tests;Prospective Studies;Sensitivity and Specificity;Clostridium difficile",M01.060.057;G17.035;L01.224.050;D23.050.161;D23.946.123;M01.060.406;M01.060.406.448;C01.252.410.222;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;D08.811.682.664.500.398;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566.350;E05.478.583.400;E05.601.470.350;M01.060.703;E01.370.225.880;E05.200.880;E05.393.520;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250
29567081,"Aged;Carcinoma, Pancreatic Ductal;Disease-Free Survival;Fluorodeoxyglucose F18;GPI-Linked Proteins;Humans;Immunotherapy, Adoptive;Middle Aged;Neoplasm Metastasis;Pancreatic Neoplasms;Positron Emission Tomography Computed Tomography;RNA, Messenger;Radiopharmaceuticals;Receptors, Antigen, T-Cell;Survival Rate;T-Lymphocytes;Transplantation, Autologous",M01.060.116.100;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;D09.254.229.500;D12.776.395.550.448;D12.776.543.484.500;D12.776.543.550.418;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;M01.060.116.630;C04.697.650;C23.550.727.650;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;D13.444.735.544;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;D12.776.543.750.705.816.824;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E04.936.664
29567045,Biomedical Research;Child;Child Health;Environmental Exposure;Environmental Health;Health Promotion;Humans;National Institutes of Health (U.S.);United States,H01.770.644.145;M01.060.406;N01.400.225;N06.850.460.350;H02.229;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;Z01.107.567.875
29567042,Child;Critical Care;Infant;Critical Care;Surveys and Questionnaires,M01.060.406;E02.760.190;N02.421.585.190;M01.060.703;E02.760.190;N02.421.585.190;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29566989,,
29566899,,
29566799,Tetralogy of Fallot,C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29566797,Cardiac Catheterization;Health Services Research;Outcome Assessment (Health Care),E01.370.370.380.140;E02.148.442;E05.157.250;H01.770.644.145.360;N03.349.380;N05.425;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
29566735,"Spondylitis, Ankylosing;Arthritis, Juvenile",C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198
29566124,,
29566096,"Adult;Anti-HIV Agents;Antiretroviral Therapy, Highly Active;Cohort Studies;Drug Administration Schedule;HIV Infections;HIV-1;Humans;Medication Adherence;Models, Statistical;Probability;Prognosis;Time Factors;Uganda;Withholding Treatment",M01.060.116;D27.505.954.122.388.077.088;E02.319.310.075;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.319.283;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;E01.789;G01.910.857;Z01.058.290.120.880;E02.760.952;N02.421.585.952
29565197,"Adolescent;Adult;Aged;Blood Glucose;Blood Glucose Self-Monitoring;Child;Diabetes Mellitus, Type 1;Glycated Hemoglobin A;Humans;Hypoglycemic Agents;Middle Aged;Time Factors;Young Adult;Diabetes Mellitus, Type 1",M01.060.057;M01.060.116;M01.060.116.100;D09.947.875.359.448.500;E01.370.225.124.100.105;E01.370.374.100;E01.370.520.100;E02.900.100;E05.200.124.100.105;M01.060.406;C18.452.394.750.124;C19.246.267;C20.111.327;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;M01.060.116.630;G01.910.857;M01.060.116.815;C18.452.394.750.124;C19.246.267;C20.111.327
29564609,,
29564608,Professionalism;Workforce,K01.752.566.479.171.566;N05.350.340.581;N04.452.525
29564178,Colonic Neoplasms,C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180
29564165,,
29563139,,
29563066,Circadian Rhythm;Homeostasis;Humans;Psychomotor Performance;Sleep;Sleep Deprivation;Wakefulness;Genetics;Individuality;Neuroimaging;Phenotype;Sleep Deprivation,G07.180.562.190;G07.410;B01.050.150.900.649.313.988.400.112.400.400;F02.808;G11.427.700;G11.561.660;F02.830.855;G11.561.803;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F02.830.104.821;G11.561.035.738;H01.158.273.343;F01.752.488;E01.370.350.578;E01.370.376.537;E05.629;G05.695;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
29563054,"Adrenal Cortex Hormones;Antineoplastic Combined Chemotherapy Protocols;Bacterial Infections;Chromosomes, Human, Pair 11;Chromosomes, Human, Pair 4;Exanthema;Humans;Immunoglobulins, Intravenous;Immunologic Deficiency Syndromes;Infant, Newborn;Methotrexate;Opportunistic Infections;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Remission Induction;Translocation, Genetic;Treatment Outcome",D06.472.040;E02.183.750.500;E02.319.077.500;E02.319.310.037;C01.252;A11.284.187.520.300.325.355;G05.360.162.520.300.325.355;A11.284.187.520.300.280.285;G05.360.162.520.300.280.285;C17.800.257;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;C20.673;M01.060.703.520;D03.633.100.733.631.192.500;C01.539.597;C02.597;C03.684;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E02.860;C23.550.210.870;G05.365.590.175.870;G05.558.860;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29562982,,
29562794,,
29562364,"Aged;Aged, 80 and over;Aging;Blood Chemical Analysis;Consensus;Diagnostic Techniques, Endocrine;Endocrinology;Evidence-Based Medicine;Hormone Replacement Therapy;Humans;Hypogonadism;Middle Aged;Societies, Medical;Testosterone",M01.060.116.100;M01.060.116.100.080;G07.345.124;E01.370.225.124.100;E05.200.124.100;F01.829.316.068;F02.463.785.373.433;E01.370.374;H01.158.782.323;H02.403.429.323;H02.249.750;H02.403.200.400;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;C19.391.482;M01.060.116.630;N03.540.828.589;D04.210.500.054.079.429.824;D06.472.334.851.968.984
29562266,,
29562193,"Animals;Antineoplastic Agents, Immunological;Biomarkers, Tumor;Combined Modality Therapy;Humans;Immune System;Immunomodulation;Immunotherapy;Molecular Targeted Therapy;Neoplasms;Receptors, Pattern Recognition;Signal Transduction;Tumor Microenvironment",B01.050;D27.505.954.248.384;D23.101.140;E02.186;B01.050.150.900.649.313.988.400.112.400.400;A15.382;E02.095.465;G12.535;E02.095.465.425;E02.319.574;C04;D12.776.543.750.705.910;G02.111.820;G04.835;G04.366.500
29562168,"Insulin-Like Growth Factor I;RNA Interference;Mitochondrial Diseases;Genome, Mitochondrial;Mitochondrial Degradation;Mutation",D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;G05.308.203.374.790;C18.452.660;G05.360.340.360;G04.599.500;G05.365.590
29562163,"17-Hydroxysteroid Dehydrogenases;Alanine Transaminase;Aspartate Aminotransferases;Biomarkers;Chronic Disease;Disease Progression;Fatty Liver;Genetic Predisposition to Disease;Genetic Variation;Genotype;Humans;Linear Models;Liver;Liver Diseases;Loss of Function Mutation;Sequence Analysis, RNA;Whole Exome Sequencing",D08.811.682.047.436.375;D08.811.913.477.700.100;D08.811.913.477.700.225;D23.101;C23.550.291.500;C23.550.291.656;C06.552.241;C23.550.291.687.500;G05.380.355;G05.365;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;A03.620;C06.552;G05.365.590.538;E05.393.760.710;E05.393.760.700.825.500
29562074,,
29561517,,
29561158,Astatine;Boron;Boronic Acids;Catalysis;Copper;Esters;Halogenation;Iodine Radioisotopes;Molecular Structure;Temperature;Time Factors,D01.268.271.110;D01.268.380.075;D01.496.749.305.110;D01.268.513.500;D01.029.260.110;D01.132.285;D02.203.200;G02.130;D01.268.556.195;D01.268.956.170;D01.552.544.195;D02.241.400;G02.111.323;G03.360;D01.268.380.400.500.496;D01.496.448.496;D01.496.749.474;G02.111.570;G02.466;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;G01.910.857
29560900,"Autism Spectrum Disorder;Brain;Child, Preschool;Humans;Language Development;Language Development Disorders;Magnetic Resonance Imaging;Phenotype;Risk Factors;Brain;Language Development Disorders",F03.625.164.113;A08.186.211;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;F01.525.200.310;C10.597.606.150.500.550;C23.888.592.604.150.500.550;E01.370.350.825.500;G05.695;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A08.186.211;C10.597.606.150.500.550;C23.888.592.604.150.500.550
29560315,,
29559904,Diffusion Tensor Imaging;Frontotemporal Lobar Degeneration;Neuropathology,E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;H01.158.610.184;H02.403.600.250;H02.403.650.375
29559809,Dopamine;alpha-Synuclein,D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;D12.776.631.860.500;D12.776.637.500
29559695,,
29559570,"Antibodies, Neutralizing;Antibody-Dependent Cell Cytotoxicity;CD4-Positive T-Lymphocytes;Flow Cytometry;Granzymes;HEK293 Cells;HIV Envelope Protein gp120;HIV-1;Humans;Antibody-Dependent Cell Cytotoxicity;HIV-1",D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;G12.287.070;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;D08.811.277.656.300.760.397;D08.811.277.656.959.350.397;A11.251.210.172.750;A11.436.334;D12.776.964.775.325.164.249;D12.776.964.775.562.500.500;D12.776.964.970.880.325.164.249;D23.050.327.520.350;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;G12.287.070;B04.820.650.589.650.350.400
29559409,,
29559344,,
29559174,"Aged;Aged, 80 and over;Carcinoma, Mucoepidermoid;Cohort Studies;Databases, Factual;Disease-Free Survival;Humans;Incidence;Kaplan-Meier Estimate;Lymphatic Metastasis;Middle Aged;Multivariate Analysis;Neoplasm Invasiveness;Neoplasm Staging;Parotid Gland;Parotid Neoplasms;Prognosis;Proportional Hazards Models;Retrospective Studies;Risk Assessment;Survival Analysis;United States;Demography;Carcinoma, Mucoepidermoid;Parotid Gland;Prognosis;Survival",M01.060.116.100;M01.060.116.100.080;C04.557.470.200.025.340;C04.557.470.590.340;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.697.650.560;C23.550.727.650.560;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;C04.697.645;C23.550.727.645;E01.789.625;A03.556.500.760.464;A10.336.779.464;A14.549.760.464;C04.588.443.591.824.695;C07.465.530.824.695;C07.465.815.470.770;C07.465.815.718.589;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;Z01.107.567.875;I01.240;N01.224;N06.850.505.400;C04.557.470.200.025.340;C04.557.470.590.340;A03.556.500.760.464;A10.336.779.464;A14.549.760.464;E01.789;I03.784
29558714,,
29557873,,
29557857,,
29557842,,
29557719,"Attitude of Health Personnel;Burnout, Professional;Clinical Competence;Continuity of Patient Care;Faculty, Medical;Hospital Administrators;Humans;Internal Medicine;Internship and Residency;Job Satisfaction;Medical Staff, Hospital;Personnel Staffing and Scheduling;Surveys and Questionnaires;Time and Motion Studies;United States;Work Schedule Tolerance;Workload",F01.100.050;N05.300.100;C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;I02.399.630.210;N04.761.210;N05.715.175;E02.760.169;N02.421.585.169;N04.590.233.727.210;M01.526.485.375;M01.526.702.250.373;N02.360.375;M01.526.070.490.490;M01.526.485.430.490;M01.526.485.740.380;N02.360.430.490;N02.360.740.380;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;F02.784.692.425;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;I03.946.225;N04.452.677.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F02.784.412.846.707;F02.784.692.746.707;Z01.107.567.875;I03.946.225.375;N04.452.677.650.375;I03.946.225.500;N04.452.677.650.500
29557490,"Athletic Injuries;Child;Cumulative Trauma Disorders;Humans;Ligaments, Articular;Risk Assessment;Wrist Injuries;Wrist Joint;Child;Wounds and Injuries;Magnetic Resonance Imaging;Wrist",C26.115;M01.060.406;C26.844.150;B01.050.150.900.649.313.988.400.112.400.400;A02.513.514;A02.835.583.512;A10.165.669.514;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C26.088.906;A02.835.583.405.930;M01.060.406;C26;E01.370.350.825.500;A01.378.800.667.715
29556827,"Certification;History, 20th Century;Humans;Pelvic Floor Disorders;Quality of Life;Reconstructive Surgical Procedures;Urology",N03.706.110.120;N05.700.200.190;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;C12.483;C13.351.625;C13.703.565;I01.800;K01.752.400.750;N06.850.505.400.425.837;E04.680;H02.403.810.860
29556027,,
29555623,Adolescent;Internet;Obesity;Social Media,M01.060.057;L01.224.230.110.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;L01.178.751;L01.224.230.110.500.750
29555345,"Animals;Clinical Trials as Topic;Communicable Diseases, Emerging;Disease Models, Animal;Flavivirus;Humans;Vaccines, DNA;Viral Vaccines;Zika Virus;Zika Virus Infection;Models, Animal;Vaccines, DNA;Flavivirus;Immunity",B01.050;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;C01.539.221.500;C22.232;E05.598.500;E05.599.395.080;B04.820.250.350;B01.050.150.900.649.313.988.400.112.400.400;D12.776.828.868.910;D20.215.894.865.910;D23.050.865.910;D20.215.894.899;B04.820.250.350.995;C02.081.990;C02.782.350.250.990;E05.598;D12.776.828.868.910;D20.215.894.865.910;D23.050.865.910;B04.820.250.350;G12.450
29555231,,
29555187,Diet,G07.203.650.240
29555076,"Animals;Cattle;Extracellular Matrix;Fetus;Fibrillar Collagens;Meniscus;Microscopy, Atomic Force;Extracellular Matrix;Meniscus",B01.050;B01.050.150.900.649.313.500.380.271;A11.284.295.310;A16.378;D05.750.078.280.300;D12.776.860.300.250.300;A02.165.308.538;A10.165.382.350.163;E01.370.350.515.666.400;E05.595.666.400;A11.284.295.310;A02.165.308.538;A10.165.382.350.163
29554444,Cleft Palate;Risk Assessment,C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29554335,,
29554176,,
29554116,"Biomarkers;Child;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Muscle, Skeletal;Muscular Dystrophy, Duchenne",D23.101;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;E05.196.867.519;A02.633.567;A10.690.552.500;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300
29554046,,
29554020,"Arthritis, Infectious;Drainage;Femur;Hip Dislocation, Congenital;Hip Joint;Humans;Legg-Calve-Perthes Disease;North America;Orthopedic Procedures;Orthopedics;Osteoarthritis;Slipped Capital Femoral Epiphyses;Societies, Medical",C01.539.100;C05.550.114.099;E02.309;E04.237;A02.835.232.043.650.247;C05.660.449;C16.131.621.449;A02.835.583.411;B01.050.150.900.649.313.988.400.112.400.400;C05.116.852.175.570;Z01.107.567;E02.718;E04.555;H02.403.810.494;C05.550.114.606;C05.799.613;C05.116.099.708.928;C05.116.425.500;N03.540.828.589
29553972,,
29553459,Air Pollutants;Aldehydes;Autism Spectrum Disorder;Autistic Disorder;Benzidines;Chlorobenzenes;Dioxanes;Environmental Exposure;Humans;Methyl Ethers;Trihalomethanes;Urethane,D27.888.284.101;D02.047;F03.625.164.113;F03.625.164.113.500;D02.455.426.559.389.185.100;D02.455.426.559.389.261;D02.455.526.439.202;D03.383.188;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;D02.355.601;D02.455.526.913;D02.241.081.251.944
29552748,"Echocardiography, Doppler, Color;Fetal Heart;Humans;Mediastinal Cyst;Pericardium;Pregnancy;Ultrasonography, Prenatal;Ultrasonography, Doppler, Color;Echocardiography;Fetus;Infant, Newborn;Mediastinal Cyst",E01.370.350.130.750.220.220;E01.370.350.850.220.220.220;E01.370.350.850.850.220.220;E01.370.350.850.850.850.850.220;E01.370.370.380.220.220.220;A07.541.278;A16.378.303;B01.050.150.900.649.313.988.400.112.400.400;C04.182.444;C08.846.187.145;A07.541.795;A10.615.789.470;G08.686.784.769;E01.370.350.850.865;E01.370.378.630.865;E01.370.350.850.850.850.850;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A16.378;M01.060.703.520;C04.182.444;C08.846.187.145
29552707,"Clinical Coding;Current Procedural Terminology;Diagnostic Imaging;Documentation;Forms and Records Control;Humans;Insurance Claim Reporting;Insurance, Health, Reimbursement;International Classification of Diseases;Pediatrics;Radiologists;Reimbursement Mechanisms;United States;Clinical Coding;Current Procedural Terminology;Insurance, Health",N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;L01.453.245.945.160;E01.370.350;L01.453.245;N04.452.758.708.200.400;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.210;N03.219.521.576.343.480;N03.219.521.710;L01.453.245.945.400;H02.403.670;M01.526.485.810.877;N02.360.810.877;N03.219.521.710.305;Z01.107.567.875;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;L01.453.245.945.160;N03.219.521.576.343
29552622,Eosinophilic Esophagitis;Keratinocytes,C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A11.409.500;A11.436.397
29552577,Genetic Therapy;Immunotherapy,E02.095.301;E05.393.420.301;E02.095.465.425
29552508,,
29551360,"Animals;Carcinogenesis;Colonic Neoplasms;Complement C5a;Cytokines;Humans;Liver Neoplasms;Macrophage Activation;Macrophages;Mice;Mice, Inbred C57BL;Mice, Knockout;Receptor, Anaphylatoxin C5a;Signal Transduction;Tumor Cells, Cultured;Tumor Microenvironment;Macrophages;Neoplasm Metastasis;Tumor Microenvironment",B01.050;C04.697.098;C23.550.727.098;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;D12.776.124.486.274.024.270;D12.776.124.486.274.450.250;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;G12.287.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.543.750.695.024;D12.776.543.750.705.833.550;G02.111.820;G04.835;A11.251.860;G04.366.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;C04.697.650;C23.550.727.650;G04.366.500
29551316,"Adolescent;Attention;Child;Child, Preschool;Cognition;Cognitive Dysfunction;Cross-Sectional Studies;Depression;Executive Function;Fatigue;Humans;Infant;Infant, Newborn;Intelligence Tests;Liver Failure, Acute;Longitudinal Studies;Mental Status and Dementia Tests;Motor Skills;Prospective Studies;Quality of Life;Stress Disorders, Post-Traumatic;Treatment Outcome;Young Adult;Cognition Disorders",M01.060.057;F02.830.104.214;M01.060.406;M01.060.406.448;F02.463.188;F03.615.250.700;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.126.350;F02.463.217;C23.888.369;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F04.711.141.493;C06.552.308.500.750;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F04.711.513.603;F02.808.260;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;F03.950.750.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;F03.615.250
29551315,"Canada;Cohort Studies;Humans;Infant, Newborn;Infant, Premature;Parturition;Pregnancy;Outcome Assessment (Health Care)",Z01.107.567.176;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;G08.686.784.769.490;G08.686.784.769;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
29550966,"Antiviral Agents;Drug Therapy, Combination;Hepacivirus;Hepatitis C;Hepatitis C, Chronic;Humans;Interferon-alpha;Polyethylene Glycols;Ribavirin",D27.505.954.122.388;E02.319.310;B04.450.380;B04.820.250.475;C02.440.440;C02.782.350.350;C06.552.380.705.440;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.440.890.250;D12.776.467.374.440.890.250;D23.529.374.440.890.250;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;D13.570.800.790
29550866,"Abdominal Wall;Diagnosis, Differential;Digestive System Abnormalities;Gastroschisis;Humans;Magnetic Resonance Imaging;Pregnancy;Prenatal Diagnosis;Urogenital Abnormalities;Urinary Bladder;Cloaca;Fetus;Magnetic Resonance Imaging",A01.923.047.050;E01.171;C06.198;C16.131.314;C05.660.417;C16.131.621.417;C23.300.707.374.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;G08.686.784.769;E01.370.378.630;C12.706;C13.351.875;C16.131.939;A05.810.890;A13.223;A16.178;A16.378;E01.370.350.825.500
29550865,"Central Nervous System Infections;Cytomegalovirus Infections;Diagnosis, Differential;HIV Infections;Herpes Simplex;Humans;Infant, Newborn;Toxoplasmosis;Zika Virus Infection;Brain;Central Nervous System;Fetus;Infant;Infection;Magnetic Resonance Imaging;Viruses",C01.395;C10.228.228;C02.256.466.245;E01.171;C02.782.815.616.400;C02.800.801.400;C20.673.480;C02.256.466.382;C02.825.320;C17.800.838.790.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C03.752.250.800;C02.081.990;C02.782.350.250.990;A08.186.211;A08.186;A16.378;M01.060.703;C01.539;E01.370.350.825.500;B04
29550840,"Adult;Aged;Aging;Axis, Cervical Vertebra;Body Weight;Fluorodeoxyglucose F18;Healthy Volunteers;Humans;Lumbar Vertebrae;Middle Aged;Pain;Positron-Emission Tomography;Spine;Thoracic Vertebrae;Young Adult",M01.060.116;M01.060.116.100;G07.345.124;A02.835.232.834.151.383;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D09.254.229.500;M01.774.500;M01.955.236;B01.050.150.900.649.313.988.400.112.400.400;A02.835.232.834.519;M01.060.116.630;C23.888.592.612;F02.830.816.444;G11.561.790.444;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;A02.835.232.834;A02.835.232.834.892;M01.060.116.815
29550739,"Biosensing Techniques;Cerebrospinal Fluid;Colorimetry;Humans;Limit of Detection;Malaria, Falciparum;Meningococcal Infections;Microfluidics;Neisseria meningitidis;Nucleic Acids;Pathology, Molecular;Plasmodium falciparum;Point-of-Care Systems;Printing, Three-Dimensional;Printing, Three-Dimensional",E05.601.043;A12.207.270.210;E05.196.922.250;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.872.374;N05.715.360.750.725.500;N06.850.520.830.872.500;C03.752.530.650;C01.252.400.625.549;E05.830.666;H01.671.808.500;J01.897.520.500.500;B03.440.400.425.550.550.641;B03.660.075.525.520.500;D13.444;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;B01.043.075.380.611.561;N04.452.442.452.680;N04.452.515.360.652;N04.590.874;J01.897.564;L01.224.108.150.500;L01.296.110.150.500;J01.897.564;L01.224.108.150.500;L01.296.110.150.500
29550505,Adult;Aged;Attention;Body Weight;Food Preferences;Humans;Impulsive Behavior;Middle Aged;Neuropsychological Tests;Obesity;Reward;Aging,M01.060.116;M01.060.116.100;F02.830.104.214;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;F01.145.407.516;G07.203.650.353.516;B01.050.150.900.649.313.988.400.112.400.400;F01.145.527;M01.060.116.630;F04.711.513;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.463.425.770.836;G07.345.124
29550343,Walking;Patient Reported Outcome Measures;Exercise;Survival,G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;G11.427.410.698.277;I03.350;I03.784
29550306,"Echocardiography, Three-Dimensional;Anthracyclines",E01.370.350.130.750.230;E01.370.350.400.200;E01.370.350.850.220.230;E01.370.370.380.220.230;D02.455.426.559.847.562.050;D04.615.562.050;D09.408.051.059
29550266,"Adipocytes;Adipokines;Bone Density;Mesenchymal Stem Cells;Adipose Tissue, White",A11.329.114;D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024;G11.427.100;A11.329.830.500;A11.872.590.500;A10.165.114.830
29550087,Atrial Fibrillation,C14.280.067.198;C23.550.073.198
29549330,,
29549329,,
29549319,,
29548840,,
29548837,,
29548670,Angiopoietin-like 4 Protein;Cholesterol;Lipid Metabolism;Lipids,D12.644.276.100.050.500;D12.776.467.100.050.500;D23.529.100.050.500;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;G03.458;D10
29548520,,
29547960,"Analgesics, Opioid;Chronic Pain;Humans;Opioid-Related Disorders;Prescriptions;Risk Assessment",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;C23.888.592.612.274;B01.050.150.900.649.313.988.400.112.400.400;C25.775.675;F03.900.675;N02.421.668.778;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
29547809,"Adenoviruses, Human;Cell Cycle Proteins;Cell Line;DNA Repair Enzymes;DNA-Binding Proteins;Host-Pathogen Interactions;Humans;MRE11 Homologue Protein;Nuclear Proteins;Serogroup;Virus Replication;Adenoviridae;Serogroup",B04.280.030.500.350;D12.776.167;A11.251.210;D08.811.074;D12.776.260;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.352.335.350.650;D08.811.277.352.335.375.813;D08.811.277.352.355.325.600;D08.811.277.352.365.290.250;D12.776.157.687.495;D12.776.260.539;D12.776.660.720.495;D12.776.660;G05.695.825;G06.920.925;B04.280.030;G05.695.825
29547719,Amyotrophic Lateral Sclerosis;Cell Cycle Proteins;Humans;Transcription Factors;Ubiquitin;Ubiquitins,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;D12.776.167;B01.050.150.900.649.313.988.400.112.400.400;D12.776.930;D12.776.947.500;D12.776.947
29546331,,
29546286,,
29546281,"Adolescent;Child;Diagnosis, Differential;Humans;Reproducibility of Results;Retrospective Studies;Sensitivity and Specificity;Thyroid Neoplasms;Thyroid Nodule;Ultrasonography, Doppler, Color",M01.060.057;M01.060.406;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;E01.370.350.850.850.850.850
29545597,,
29545564,"Antigens, Neoplasm;CD8-Positive T-Lymphocytes;Epitopes, T-Lymphocyte;Humans;Immunotherapy;Lymphocytes, Tumor-Infiltrating;Ovarian Neoplasms;Receptors, Antigen, T-Cell",D23.050.285;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D23.050.550.402;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D12.776.543.750.705.816.824
29545362,Atrial Fibrillation;Catheter Ablation;Meta-Analysis,C14.280.067.198;C23.550.073.198;E02.808.750.500;E04.014.760.500;V03.600
29545344,,
29545255,Animals;Biomarkers;Blood Platelets;Hematopoietic Stem Cells;Humans;Immunohistochemistry;Megakaryocytes;Mice;Platelet Aggregation Inhibitors;Protein Kinase Inhibitors;Thrombopoiesis,B01.050;D23.101;A11.118.188;A15.145.229.188;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;A11.148.479;A15.378.316.479;B01.050.150.900.649.313.992.635.505.500;D27.505.954.502.780;D27.505.519.389.755;G04.152.825.798;G09.188.343.798
29545254,,
29544708,"Endometrial Neoplasms;Gynecologic Surgical Procedures;Health Care Reform;Humans;Models, Economic;Physicians;Reimbursement Mechanisms;Societies, Medical;United States;Endometrial Neoplasms",C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200;E04.950.300;I01.655.500.608.400.285;I01.880.604.825.608.400.285;N03.349.285;N03.623.500.608.428.285;N04.590.374.285;N05.300.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.600;E05.599.835.890;N05.715.360.750.530.500;N06.850.520.830.500.600;M01.526.485.810;N02.360.810;N03.219.521.710.305;N03.540.828.589;Z01.107.567.875;C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200
29544424,Adolescent;Body Mass Index;Child;Cross-Sectional Studies;Exercise;Fontan Procedure;Health Behavior;Humans;Pediatric Obesity;Postoperative Complications;Retrospective Studies;Risk Factors;Surveys and Questionnaires;Tetralogy of Fallot;Transposition of Great Vessels;Hypoplastic Left Heart Syndrome;Outcome Assessment (Health Care),M01.060.057;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G11.427.410.698.277;I03.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;F01.145.488;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;C14.240.400.915;C14.280.400.915;C16.131.240.400.915;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
29543944,,
29543653,,
29543342,Parkinson Disease;Dementia;Cognitive Dysfunction,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.380;F03.615.400;F03.615.250.700
29542319,,
29542053,Cognitive Reserve;Occupations,F02.463.188.331;N01.824.547
29541842,"Adolescent;Child;Computer Simulation;Humans;Imaging, Three-Dimensional;Kyphosis;Lordosis;Pelvic Bones;Radiostereometric Analysis;Regression Analysis;Retrospective Studies;Scoliosis;Spine",M01.060.057;M01.060.406;L01.224.160;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;C05.116.900.800.500;C05.116.900.800.750;A02.835.232.043.825;E01.370.350.600.630.750;E01.370.350.700.750;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;A02.835.232.834
29541764,,
29541755,,
29541750,,
29540833,"Alleles;Animals;CRISPR-Cas Systems;Floxuridine;Gene Expression Regulation, Neoplastic;Genes, Tumor Suppressor;Genetic Engineering;Genetic Vectors;Humans;Mice;Mice, Transgenic;Neoplasms, Experimental;RNA Interference;Recombinases",G05.360.340.024.340.030;B01.050;G05.308.203.374.394;D03.383.742.680.852.300.350;D13.570.230.430.432;D13.570.685.852.300.350;G05.308.370;G05.360.340.024.340.375.249;G05.360.340.024.340.415.400;E05.393.420;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C04.619;E05.598.500.496;G05.308.203.374.790;D08.811.739
29540618,,
29540468,"Adult;Aged;Alleles;Animals;Genes, Reporter;Genetic Predisposition to Disease;Genotype;Haplotypes;Heart Ventricles;Homozygote;Humans;Introns;Linkage Disequilibrium;Middle Aged;Protein Kinase C-alpha;Quantitative Trait Loci;Ventricular Remodeling;Zebrafish;Gene Expression Regulation;Genetics;Heart Failure;Protein Kinase C;Ventricular Remodeling",M01.060.116;M01.060.116.100;G05.360.340.024.340.030;B01.050;G05.360.340.024.340.435;C23.550.291.687.500;G05.380.355;G05.380;G05.380.360;A07.541.560;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.220.400;G05.360.340.024.340.137.515;G05.348.500;M01.060.116.630;D08.811.913.696.620.682.700.725.100;G05.360.340.024.380.937;C23.300.985;G09.330.955.975;B01.050.150.900.493.200.244.828;G05.308;H01.158.273.343;C14.280.434;D08.811.913.696.620.682.700.725;C23.300.985;G09.330.955.975
29539613,"Guideline Adherence;Guidelines as Topic;Humans;Intestinal Neoplasms;Neuroendocrine Tumors;Pancreatic Neoplasms;Practice Patterns, Physicians';Stomach Neoplasms;Surveys and Questionnaires;Surveys and Questionnaires",N04.761.337;N05.715.360.395;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.476.411;C06.301.371.411;C06.405.249.411;C06.405.469.491;C04.557.465.625.650;C04.557.580.625.650;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;N04.590.374.577;N05.300.625;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29539190,"Bees;Genome, Mitochondrial",B01.050.500.131.617.720.500.500.875.387;G05.360.340.360
29538700,,
29538674,,
29538621,"Animals;Autophagy;CD47 Antigen;CD8-Positive T-Lymphocytes;Cell Line, Tumor;Glioblastoma;Humans;Immunotherapy;Macrophages;Mice;Phagocytosis;Receptors, Immunologic;TOR Serine-Threonine Kinases",B01.050;G04.146.399;G04.417.350.091;D12.776.395.550.014;D12.776.543.550.147;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;A11.251.210.190;A11.251.860.180;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;G04.417.350;G09.188.665;G12.450.564.809;G12.688;D12.776.543.750.705;D08.811.913.696.620.682.700.931;D12.776.476.925
29538470,,
29538453,"Adolescent;Adult;Aged;Aged, 80 and over;Anti-Inflammatory Agents, Non-Steroidal;Brain Ischemia;Clopidogrel;Drug Interactions;Follow-Up Studies;Gastrointestinal Hemorrhage;Humans;Incidence;Intracranial Hemorrhages;Medicaid;Middle Aged;Mortality;Myocardial Infarction;Platelet Aggregation Inhibitors;Retrospective Studies;Stroke;Ticlopidine;United States;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;C10.228.140.300.150;C14.907.253.092;D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500;G07.690.773.968;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C06.405.227;C23.550.414.788;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C10.228.140.300.535;C14.907.253.573;C23.550.414.913;N03.219.521.346.506.564.655;N03.706.615.693;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C14.280.647.500;C14.907.585.500;D27.505.954.502.780;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.300.775;C14.907.253.855;D02.886.778.823.500;D03.383.725.849.500;D03.383.903.830.500;D03.633.100.928.500;Z01.107.567.875;M01.060.116.815
29538344,"Adult;Data Accuracy;Environmental Exposure;Humans;Noise, Transportation;Odds Ratio;Probability;Self Report;Sleep;Sleep Wake Disorders;Surveys and Questionnaires;Sleep;Noise, Transportation",M01.060.116;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;N06.230.400.550;N06.850.460.610.680;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;F02.830.855;G11.561.803;C10.886;C23.888.592.796;F03.870;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F02.830.855;G11.561.803;N06.230.400.550;N06.850.460.610.680
29538107,,
29537983,,
29536431,Carbon Monoxide;Mitochondria;Poisoning;Respiration;Toxicology,D01.200.250;D01.362.200;D01.650.550.250;A11.284.430.214.190.875.564;A11.284.835.626;C25.723;G09.772.705;H01.158.891;H02.884
29536133,Adult;Animals;Cardiomyopathies;Carrier Proteins;Heart Ventricles;Humans;Mice;Mutation;Signal Transduction;Zinc;Endocardium;Myocardium;Zinc,M01.060.116;B01.050;C14.280.238;D12.776.157;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;G05.365.590;G02.111.820;G04.835;D01.268.556.940;D01.268.956.906;D01.552.544.940;A07.541.207;A02.633.580;A07.541.704;A10.690.552.750;D01.268.556.940;D01.268.956.906;D01.552.544.940
29536081,Cost-Benefit Analysis;Costs and Cost Analysis;Delivery of Health Care;Health Care Costs,N03.219.151.125;N03.219.151;N04.590.374;N05.300;N03.219.151.400;N05.300.375
29535906,Adolescent;Cannabis;Cannabis,M01.060.057;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.859.937.055.500
29535260,"Adult;Aerosols;Cannula;Child, Preschool;Humans;Humidifiers;Infant;Infant, Newborn;Nebulizers and Vaporizers;Pediatrics;Practice Patterns, Physicians';Child;Pediatrics",M01.060.116;D20.280.055;D26.255.165.055;E07.132.125;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E07.451;J01.494.650;M01.060.703;M01.060.703.520;E07.605;H02.403.670;N04.590.374.577;N05.300.625;M01.060.406;H02.403.670
29533701,Safety,N06.850.135.060.075
29533355,,
29533352,,
29533083,Heart Failure;Self Care;Social Support,C14.280.434;E02.900;I03.050.563;N02.421.784.680;I01.880.853.500.600
29532564,"Acinar Cells;Animals;Cell Differentiation;Cells, Cultured;DNA-Binding Proteins;Mice;Mice, Knockout;Pancreas;Pancreatic Ducts;Pancreatitis;SOX9 Transcription Factor;Signal Transduction;Transcription Factors;Pancreatitis",A11.031;B01.050;G04.152;A11.251;D12.776.260;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A03.734;A03.734.667;C06.689.750;D12.776.260.719.500.500;D12.776.660.235.400.750.500.500;D12.776.664.235.400.750.500.500;D12.776.930.823.500.500;G02.111.820;G04.835;D12.776.930;C06.689.750
29532090,,
29532087,,
29531967,Glioblastoma;Machine Learning,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;G17.035.250.500;L01.224.050.375.530
29531506,,
29531354,,
29530960,,
29530881,"Animals;DNA Methylation;DNA-Binding Proteins;Epigenomics;Genomic Imprinting;Germ Cells;Mice;Mice, Inbred C57BL;Mice, Inbred ICR;Mice, Knockout;Proto-Oncogene Proteins;Real-Time Polymerase Chain Reaction;DNA Methylation;Genomic Imprinting;Mice",B01.050;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.308.203.500;A05.360.490;A11.497;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.199.520.520.510;B01.050.150.900.649.313.992.635.505.500.400.510;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.624.664.700;E05.393.620.500.706;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G05.308.203.500;B01.050.150.900.649.313.992.635.505.500
29530675,Conscience;Ethics;Morals;Religion,F01.829.500.359;K01.752.566.359;K01.752.566.479;N05.350;F01.829.500;K01.752.566;K01.844
29530304,"Longitudinal Studies;Sleep Apnea, Obstructive",E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C08.618.085.852.850;C10.886.425.800.750.850
29529621,Knee;Knee Joint,A01.378.610.450;A02.835.583.475
29529415,Animals;Autophagy;Brain;Extracellular Fluid;Homeostasis;Humans;Neurons,B01.050;G04.146.399;G04.417.350.091;A08.186.211;A11.284.295.260;A12.207.270;G07.410;B01.050.150.900.649.313.988.400.112.400.400;A08.675;A11.671
29529219,"Anti-Bacterial Agents;Bacterial Infections;Biomarkers;Calcitonin;Child;Critical Illness;Hospitals, Pediatric;Humans;Intensive Care Units, Pediatric;Medical Overuse;Pennsylvania;Practice Patterns, Physicians';Retrospective Studies",D27.505.954.122.085;C01.252;D23.101;D06.472.699.150;D06.472.931.052;D12.644.400.095;D12.644.548.150;D12.776.631.650.095;M01.060.406;C23.550.291.625;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;N02.421.380.450;N05.300.150.395.450;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29528977,,
29528712,Penile Prosthesis,E07.695.610
29528710,,
29528181,"Leukemia, Myelomonocytic, Juvenile",C04.557.337.539.525;C15.378.190.615.520
29528178,Infarction,C23.550.513.355;C23.550.717.489
29528131,Adolescent;High-Frequency Ventilation;Humans;Lung;Respiratory Insufficiency;Thoracic Diseases;Ultrasonography;Thorax;Pediatrics;Pneumothorax,M01.060.057;E02.041.625.508;E02.880.820.508;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.618.846;C08.846;E01.370.350.850;A01.923.761;H02.403.670;C08.528.778
29527824,Whole Exome Sequencing;Whole Genome Sequencing,E05.393.760.700.825.500;E05.393.760.700.825
29527339,Fever;Health Services Accessibility;Social Determinants of Health,C23.888.119.344;N04.590.374.350;N05.300.430;N01.224.425.762;N01.400.675
29526763,,
29526616,Mitochondria;Zebrafish,A11.284.430.214.190.875.564;A11.284.835.626;B01.050.150.900.493.200.244.828
29526502,"Aged;Antibodies, Monoclonal;Anticholesteremic Agents;Biomarkers;Cholesterol, LDL;Clinical Trials, Phase III as Topic;Down-Regulation;Drug Therapy, Combination;Glomerular Filtration Rate;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Hypercholesterolemia;Kidney;Middle Aged;Proprotein Convertase 9;Randomized Controlled Trials as Topic;Renal Insufficiency, Chronic;Risk Factors;Treatment Outcome;Renal Insufficiency, Chronic;Safety",M01.060.116.100;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D27.505.519.186.071.202;D27.505.954.557.500.202;D23.101;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;E05.318.372.250.250.220;N05.715.360.330.250.250.220;N06.850.520.450.250.250.220;G02.111.240;G05.308.200;G07.690.773.937;E02.319.310;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;C18.452.584.500.500.396;A05.810.453;M01.060.116.630;D08.811.277.656.300.760.718;D08.811.277.656.837.688;D08.811.277.656.959.350.718;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C12.777.419.780.750;C13.351.968.419.780.750;N06.850.135.060.075
29526461,"ATP Binding Cassette Transporter, Subfamily B, Member 1;Animals;Blood-Brain Barrier;Brain;Circadian Clocks;Connexins;Drosophila;Drosophila Proteins;Gap Junctions;Magnesium;Neuroglia;Phenytoin;Rhodamines;Seizures;Xenobiotics;Drosophila;Blood-Brain Barrier;Circadian Rhythm;Gap Junctions",D12.776.157.530.100.075.063;D12.776.157.530.450.074.500.500.250.125;D12.776.395.550.020.400.153;D12.776.543.550.192.400.153;D12.776.543.585.100.200.125;D12.776.543.585.450.074.500.500.250.125;B01.050;A07.035;A08.186.211.035;A08.186.211;G07.180.562.094.500;D12.776.543.585.250;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;A11.284.149.165.420.471;D01.268.552.437;D01.268.557.500;D01.552.547.500;A08.637;A11.650;D03.383.129.308.432.555.730;D03.633.300.953.600;C10.597.742;C23.888.592.742;D26.969;B01.050.500.131.617.720.500.500.750.310.250;A07.035;A08.186.211.035;G07.180.562.190;A11.284.149.165.420.471
29525193,"End Stage Liver Disease;Heart Arrest;Hemodynamics;Humans;Liver Transplantation;Middle Aged;Perioperative Care;Pulmonary Embolism;Resuscitation;Anticoagulants;Antifibrinolytic Agents;Heart Arrest;Liver Transplantation;Pulmonary Embolism;Heart Ventricles;Echocardiography, Transesophageal;von Willebrand Factor",C06.552.308.500.177;C14.280.383;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;E02.760.731;E04.604;N02.421.585.722;C08.381.746;C14.907.355.350.700;E02.365.647;D27.505.954.502.119;D27.505.519.421.500;D27.505.954.502.270.463.091;C14.280.383;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;C08.381.746;C14.907.355.350.700;A07.541.560;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;D12.776.124.125.920;D23.119.985
29525103,,
29524935,"Adult;Conflict of Interest;Databases, Factual;Disclosure;Drug Industry;Health Knowledge, Attitudes, Practice;Health Policy;Humans;Physicians;Practice Patterns, Physicians';United States;Conflict of Interest;Informed Consent",M01.060.116;K01.752.566.479.095;N05.350.225;L01.313.500.750.300.188.400;L01.470.750.750;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;J01.576.655.750;F01.100.150.500;N05.300.150.410;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;N04.590.374.577;N05.300.625;Z01.107.567.875;K01.752.566.479.095;N05.350.225;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489
29524874,Adult;Behavior Therapy;Central Nervous System Stimulants;Humans;Patient Compliance;Substance-Related Disorders;United States;United States Department of Veterans Affairs;Veterans,M01.060.116;F04.754.137;D27.505.696.282;D27.505.954.427.220;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;C25.775;F03.900;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;M01.930
29524590,Biomarkers;Cytokines;Endometriosis;MicroRNAs,D23.101;D12.644.276.374;D12.776.467.374;D23.529.374;C13.351.500.163;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29524478,Child;Humans;Hypoxia,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079
29523680,"Acute Kidney Injury;Acute Kidney Injury;Health Care Costs;Models, Animal;National Institute of Diabetes and Digestive and Kidney Diseases (U.S.);Primary Prevention;Rodentia;Secondary Prevention;Translational Medical Research;Acute Kidney Injury;Models, Animal;Delayed Graft Function",C12.777.419.780.050;C13.351.968.419.780.050;C12.777.419.780.050;C13.351.968.419.780.050;N03.219.151.400;N05.300.375;E05.598;I01.409.418.750.600.650.496.450;N03.540.052.750.450;N03.540.348.500.500.600.650.496.450;N02.421.726.758;N06.850.780.680;B01.050.150.900.649.313.992;E02.897;N02.421.726.825;N06.850.780.750;H01.770.644.145.675;C12.777.419.780.050;C13.351.968.419.780.050;E05.598;C23.550.277
29523504,,
29523228,,
29522939,"Adolescent;Adolescent Development;Anxiety Disorders;Anxiety, Separation;Child;Comorbidity;Depression;Depressive Disorder;Humans;Longitudinal Studies;Prospective Studies;Self Report;Syndrome",M01.060.057;F01.525.049;G07.345.374.500;F03.080;F03.080.300;F03.625.047;M01.060.406;N05.715.350.225;N06.850.490.687;F01.145.126.350;F03.600.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;C23.550.288.500
29522833,,
29522375,Actins;Actomyosin;Adenosine Triphosphatases;Anesthetics;Animals;Calcium;Heart;Muscle Contraction;Myocardial Contraction;Myocardium;Myosins;Propofol;Rats;Excitation Contraction Coupling,D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D12.776.210.500.154;D08.811.277.040.025;D27.505.696.277.100;D27.505.954.427.210.100;B01.050;D01.268.552.100;D01.552.539.288;D23.119.100;A07.541;G11.427.494;G09.330.580;G11.427.494.570;A02.633.580;A07.541.704;A10.690.552.750;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475;D02.455.426.559.389.657.773;B01.050.150.900.649.313.992.635.505.700;G02.111.820.800.100.500;G04.835.199;G11.427.494.235
29522222,,
29522134,,
29522088,Aged;Aging;Androgens;Controlled Clinical Trials as Topic;Hormone Replacement Therapy;Humans;Outcome Assessment (Health Care);Testosterone,M01.060.116.100;G07.345.124;D27.505.696.399.472.161;E05.318.372.250.250.365;N05.715.360.330.250.250.365;N06.850.520.450.250.250.365;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;D04.210.500.054.079.429.824;D06.472.334.851.968.984
29521937,Adolescent;Adult;Cerebral Palsy;Child;Follow-Up Studies;Humans;Postoperative Period;Quality of Life;Radiography;Retrospective Studies;Scoliosis;Spinal Fusion;Thoracic Vertebrae;Traction;Treatment Outcome,M01.060.057;M01.060.116;C10.228.140.140.254;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E04.614.750;N02.421.585.753.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;E04.555.100.700;A02.835.232.834.892;E04.555.720;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29521800,Animal Assisted Therapy;Animals;Humans;Intensive Care Units;Terminal Care,E02.760.169.063.500.083;E02.779.124;F04.754.017;B01.050;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E02.760.905;N02.421.585.905
29521782,"Adult;Attitude of Health Personnel;Clinical Competence;Cross-Sectional Studies;Health Knowledge, Attitudes, Practice;Health Personnel;Humans;Logistic Models;Patient Care Team;Trauma Centers;Wounds and Injuries",M01.060.116;F01.100.050;N05.300.100;I02.399.630.210;N04.761.210;N05.715.175;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.100.150.500;N05.300.150.410;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N04.590.715;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;C26
29521768,"Cephalometry;Child;Child, Preschool;Craniosynostoses;Humans;Infant;Infant, Newborn;Organ Size;Osteogenesis, Distraction;Retrospective Studies;Skull;Tomography, X-Ray Computed",E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E04.555.120.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.781;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29521441,,
29521004,"Adolescent;Anthropometry;Child;Cross-Sectional Studies;Fontan Procedure;Health Status;Humans;Hypoplastic Left Heart Syndrome;Puberty, Delayed;Quality of Life;Surveys and Questionnaires;Survivors;Puberty, Delayed;Quality of Life",M01.060.057;E01.370.600.024;E05.041;N06.850.505.200.100;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;C19.391.690;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.860;C19.391.690;I01.800;K01.752.400.750;N06.850.505.400.425.837
29520794,Bibliometrics;Transfusion Medicine,L01.178.682.099.325;L01.453.183.291;H02.403.429.445.500
29520748,Medicare;Accountable Care Organizations;Health Policy;Subacute Care;Skilled Nursing Facilities,N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N05.300.380.500;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;E02.760.850;N02.421.585.850;N02.278.825.610.770
29520463,"Case-Control Studies;Collateral Circulation;DiGeorge Syndrome;Gestational Age;Heart Septal Defects, Ventricular;Humans;Infant, Newborn;Pulmonary Atresia;Pulmonary Valve Stenosis;Retrospective Studies;Tetralogy of Fallot;Treatment Outcome;DiGeorge Syndrome;Tetralogy of Fallot",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G09.330.100.248;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;G07.345.500.325.235.968;G08.686.320;C14.240.400.560.540;C14.280.400.560.540;C16.131.240.400.560.540;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;C14.280.484.716;C14.280.955.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29520449,"Chest Pain;Coronary Angiography;Coronary Artery Disease;Emergency Service, Hospital;Humans;Randomized Controlled Trials as Topic;Registries;Tomography, X-Ray Computed;Triage;Emergency Service, Hospital;Standard of Care",C23.888.592.612.233;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;N02.421.297.900;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;N04.761.789.900;N05.715.840
29519869,,
29519602,"Adult;Aneurysm, Dissecting;Aortic Aneurysm, Thoracic;Fetal Monitoring;Humans;Patient Care Team;Pregnancy;Pregnancy Complications, Cardiovascular;Cesarean Section;Cardiopulmonary Bypass;Estrogens;Fetal Viability;Magnetic Resonance Imaging;Postpartum Hemorrhage;Pregnancy;Pulsatile Flow;Echocardiography, Transesophageal",M01.060.116;C14.907.055.050;C14.907.055.239.125;C14.907.109.139.125;E01.370.378.230;E01.370.520.230;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;G08.686.784.769;C13.703.634;C14.583;E04.520.252.500;E04.292.413;D27.505.696.399.472.277;G07.280;G07.345.500.325.235.875;G08.686.220;E01.370.350.825.500;C13.703.420.725;C13.703.844.700;C23.550.414.993.850;G08.686.784.769;G01.482.620;G09.330.380.630.555;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
29519540,"Biliary Atresia;Child, Preschool;Cognition;Developmental Disabilities;Humans;Infant;Liver;Longitudinal Studies;Motor Skills;Multivariate Analysis;Neuropsychological Tests;Observational Studies as Topic;Prospective Studies;Randomized Controlled Trials as Topic;Regression Analysis;Risk;Treatment Outcome;Vulnerable Populations",C06.130.120.123;C06.198.125;C16.131.314.125;M01.060.406.448;F02.463.188;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A03.620;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F02.808.260;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;F04.711.513;E05.318.372.250.500;N05.715.360.330.250.500;N06.850.520.450.250.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.965
29519469,Humans;Language;Parietal Lobe;Language;Parietal Lobe;Semantics,B01.050.150.900.649.313.988.400.112.400.400;F01.145.209.399;L01.559;A08.186.211.200.885.287.500.670;F01.145.209.399;L01.559;A08.186.211.200.885.287.500.670;L01.559.598.745
29518538,Dopamine,D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342
29518120,"Age of Onset;Child, Preschool;Follow-Up Studies;Gene Ontology;Gestational Age;Humans;Infant;Multivariate Analysis;Prospective Studies;Spasms, Infantile",N05.715.350.075.100;N06.850.490.250.100;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.228.140.490.375.760;C10.228.140.490.493.875
29518005,"Animals;Cyclooxygenase 2;Humans;Microglia;Molecular Imaging;Positron-Emission Tomography;Reactive Oxygen Species;Receptor, Cannabinoid, CB2;Receptors, GABA;Receptors, Purinergic P2X7;Microglia;Positron-Emission Tomography",B01.050;D08.811.600.720.750;B01.050.150.900.649.313.988.400.112.400.400;A08.637.400;A11.650.400;E01.370.350.557;E05.601.555;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D01.339.431;D01.650.775;D12.776.543.750.695.125.200;D12.776.543.750.720.200.300;D12.776.157.530.400.400.750.700;D12.776.543.550.450.500.600.700;D12.776.543.585.400.500.600.700;D12.776.543.750.695.700.720.250.700;D12.776.543.750.720.700.720.500.700;A08.637.400;A11.650.400;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399
29517938,,
29517580,,
29517551,,
29517533,,
29517156,Quality of Life,I01.800;K01.752.400.750;N06.850.505.400.425.837
29516669,Logistic Models;Multiple Sclerosis,E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29516535,,
29516387,Breast Neoplasms;Positron-Emission Tomography,C04.588.180;C17.800.090.500;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399
29516304,"Adult;Humans;Kidney Calculi;Minimally Invasive Surgical Procedures;Nephrolithotomy, Percutaneous;Nephrolithotomy, Percutaneous;Uridine Monophosphate",M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;E04.502;E04.502.250.520.790;E04.950.774.638;E04.502.250.520.790;E04.950.774.638;D03.383.742.686.850.877;D13.695.740.850.877;D13.695.827.919.877
29516272,"Adolescent;Female Urogenital Diseases;Humans;Male Urogenital Diseases;Public Policy;Spinal Dysraphism;Transitional Care;Urinary Bladder, Neurogenic;Young Adult;Patient Transfer;Meningomyelocele;Spinal Dysraphism",M01.060.057;C13.351;B01.050.150.900.649.313.988.400.112.400.400;C12;I01.655.500.608;I01.880.604.825.608;N03.623.500.608;C10.500.680.800;C16.131.666.680.800;E02.760.169.812;E02.760.940;N02.421.585.169.812;N02.421.585.940;N04.590.233.727.210.812;C10.597.900;C12.777.829.839;C13.351.968.829.760;C23.888.592.900;M01.060.116.815;E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624;C10.500.680.610;C16.131.666.680.610;C10.500.680.800;C16.131.666.680.800
29516190,Dyslipidemias;Ezetimibe,C18.452.584.500;D03.383.082.301.550
29516100,,
29516095,,
29516089,,
29516064,Adenoidectomy;Tonsillectomy,E04.580.068;E04.580.848
29515513,Amputees;Phantom Limb;Phantom Limb;Virtual Reality,M01.150.100;C10.597.606.762.700;C23.550.767.700.500;C23.888.592.604.764.700;C23.888.592.612.832.500;F01.700.750.700;C10.597.606.762.700;C23.550.767.700.500;C23.888.592.604.764.700;C23.888.592.612.832.500;F01.700.750.700;L01.224.160.875;L01.296.555
29515126,Amino Acid Sequence;Cytoplasmic Dyneins;Dynactin Complex;HeLa Cells;Humans;Movement;Protein Conformation,G02.111.570.060;L01.453.245.667.060;D08.811.277.040.025.193.249.750;D05.500.142;D12.776.220.600.450.150;D12.776.631.560.225;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;G07.568;G11.427.410;G02.111.570.820.709
29514852,,
29514842,,
29514805,,
29514551,Aggression;Bullying,F01.145.126.125;F01.145.813.045;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070
29514486,"Adult;Aged;Art Therapy;Humans;Mental Health;Middle Aged;Mindfulness;Neoplasms;Pilot Projects;Quality of Life;Sleep;Spirituality;Stress, Psychological;Art Therapy;Neoplasms;Mindfulness;Quality of Life;Spirituality",M01.060.116;M01.060.116.100;E02.190.888.124;E02.760.169.063.500.100;E02.831.100;F04.754.070;B01.050.150.900.649.313.988.400.112.400.400;F02.418;N01.400.500;M01.060.116.630;F02.463.551;F04.754.137.350.500;C04;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;I01.800;K01.752.400.750;N06.850.505.400.425.837;F02.830.855;G11.561.803;F02.880.705;K01.844.664.500;F01.145.126.990;F02.830.900;E02.190.888.124;E02.760.169.063.500.100;E02.831.100;F04.754.070;C04;F02.463.551;F04.754.137.350.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;F02.880.705;K01.844.664.500
29514374,Age Factors;Arthroscopy;Child;Fracture Fixation;Humans;Patient Selection;Tibial Fractures,N05.715.350.075;N06.850.490.250;E01.370.388.250.070;E04.502.250.070;E04.555.113;M01.060.406;E04.555.300;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500.653;N04.590.731;C26.404.875;C26.558.857
29514301,,
29514225,,
29513919,"Stress Disorders, Post-Traumatic",F03.950.750.500
29513203,"Adolescent;Cardiomyopathy, Hypertrophic;Child;Child, Preschool;Disopyramide;Dose-Response Relationship, Drug;Echocardiography, Doppler;Electrocardiography;Heart Ventricles;Humans;Infant;Infant, Newborn;Prognosis;Retrospective Studies;Ventricular Function, Left;Voltage-Gated Sodium Channel Blockers;Young Adult;Cardiomyopathy, Hypertrophic;Child;Disopyramide",M01.060.057;C14.280.238.100;C14.280.484.150.070.160;M01.060.406;M01.060.406.448;D03.383.725.227;G07.690.773.875;G07.690.936.500;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;E01.370.370.380.240;E01.370.405.240;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G09.330.955.800;D27.505.519.562.750.500;D27.505.954.411.720.500;M01.060.116.815;C14.280.238.100;C14.280.484.150.070.160;M01.060.406;D03.383.725.227
29512899,"Acetyl Coenzyme A;Epigenomics;Histones;Metabolism;Protein Processing, Post-Translational",D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G03;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
29512259,"Adolescent;Adult;Age Distribution;Aged;Aged, 80 and over;Australia;Child;Child, Preschool;Diabetes Mellitus, Type 1;Diabetes Mellitus, Type 2;Health Surveys;Humans;Infant;Infant, Newborn;Latent Autoimmune Diabetes in Adults;Middle Aged;Prevalence;Sex Distribution;Young Adult;Australia;Prevalence",M01.060.057;M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.116.100;M01.060.116.100.080;Z01.639.100;Z01.678.100.373;M01.060.406;M01.060.406.448;C18.452.394.750.124;C19.246.267;C20.111.327;C18.452.394.750.149;C19.246.300;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C18.452.394.750.714;C19.246.656;C20.111.576;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;I01.240.800;N01.224.803;N06.850.505.400.850;M01.060.116.815;Z01.639.100;Z01.678.100.373;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
29512196,"Adalimumab;Adult;Antibodies, Monoclonal;Dermatologic Agents;Double-Blind Method;Humans;Middle Aged;Psoriasis;Self Report;Severity of Illness Index;Symptom Assessment",D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;M01.060.116;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D27.505.954.444;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C17.800.859.675;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.370.872
29511999,Intellectual Disability;Mediator Complex,C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;D05.500.374;D12.644.360.024.309;D12.776.157.057.072;D12.776.476.024.388;D12.776.660.551
29511882,Heart Diseases;Metabolic Syndrome;Obesity,C14.280;C18.452.394.968.500.570;C18.452.625;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29511165,,
29510988,,
29510960,"Accountable Care Organizations;Aged;Aged, 80 and over;Community Health Services;Humans;Medical Oncology;Models, Organizational;Neoplasms;New Mexico",N05.300.380.500;M01.060.116.100;M01.060.116.100.080;N02.421.143;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;E05.599.670;N04.452.534;C04;Z01.107.567.875.760.560
29510793,"Sleep Initiation and Maintenance Disorders;Sleep Apnea, Obstructive;Sleepiness",C10.886.425.800.800;F03.870.400.800.800;C08.618.085.852.850;C10.886.425.800.750.850;C23.888.900
29510721,Hand;Heme Oxygenase-1;Interferons,A01.378.800.667;D08.811.682.690.708.410.500;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
29510112,,
29509936,,
29509908,,
29509905,"Abnormalities, Multiple;Animals;Aorta;Chromosome Duplication;Chromosomes, Human, Pair 22;DiGeorge Syndrome;Disease Models, Animal;Embryonic Development;Gene Expression Regulation, Developmental;Heart;Heart Defects, Congenital;Homologous Recombination;Humans;Meiosis;Mice;Mutation;T-Box Domain Proteins;Truncus Arteriosus, Persistent",C16.131.077;B01.050;A07.015.114.056;C23.550.210.182;G05.365.590.175.183;G05.558.164;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C22.232;E05.598.500;E05.599.395.080;G07.345.500.325.180;G08.686.784.170.104;G05.308.310;A07.541;C14.240.400;C14.280.400;C16.131.240.400;G05.728.615;B01.050.150.900.649.313.988.400.112.400.400;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;G05.365.590;D12.776.260.725;D12.776.930.850;C14.240.400.560.098.500;C14.280.400.560.098.500;C16.131.240.400.560.098.500
29509871,Biomarkers;Biopsy;Calcitonin;Humans;Thyroglobulin;Thyroid Hormones;Thyroid Nodule;Thyroidectomy;Ultrasonography;Watchful Waiting,D23.101;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;D06.472.699.150;D06.472.931.052;D12.644.400.095;D12.644.548.150;D12.776.631.650.095;B01.050.150.900.649.313.988.400.112.400.400;D12.776.377.856;D12.776.395.768;D12.776.486.706;D06.472.931;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;E04.270.856;E01.370.350.850;N04.761.559.590.900
29509754,,
29509741,Environmental Exposure;Epigenomics;Genome;Humans;National Institute of Environmental Health Sciences (U.S.);United States,N06.850.460.350;H01.158.273.180.350.074;H01.158.273.343.350.042;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496.455;N03.540.052.750.455;N03.540.348.500.500.600.650.496.455;Z01.107.567.875
29509625,,
29509607,"Databases, Factual;Education;Education, Medical, Continuing;Fellowships and Scholarships;Humans;Orthopedics;Pediatrics;United States",L01.313.500.750.300.188.400;L01.470.750.750;I02;I02.358.212.350;I02.358.399.250;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;H02.403.810.494;H02.403.670;Z01.107.567.875
29509546,Diagnostic Imaging;Molecular Biology;Pharmacology;Therapeutics,E01.370.350;H01.158.201.636;H01.158.273.343.595;H01.181.122.650;H01.158.703;H02.628;E02
29509491,Hispanic Americans;Albuterol;Asthma,M01.686.754.441;D02.033.100.291.057;D02.092.063.291.057;D02.092.471.683.061;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
29509061,Adolescent,M01.060.057
29508763,"Angiogenesis Inhibitors;Animals;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Humans;Lung Neoplasms;Mesothelioma;Molecular Targeted Therapy;Pleural Neoplasms;Signal Transduction;Treatment Outcome",D27.505.696.377.077.099;D27.505.696.377.450.100;D27.505.954.248.025;B01.050;D27.505.954.248.384;E02.183.750.500;E02.319.077.500;E02.319.310.037;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.470.035.510;C04.557.470.660.510;E02.319.574;C04.588.894.797.640;C08.528.694;C08.785.640;G02.111.820;G04.835;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29508305,"Granulomatosis with Polyangiitis;Microscopic Polyangiitis;Leukoencephalopathy, Progressive Multifocal;Arthritis, Rheumatoid;Rituximab",C08.381.483.950;C14.907.940.897.249.750;C20.111.193.875;C10.228.140.300.275.600;C14.907.253.329.600;C14.907.940.897.249.500;C20.111.193.750;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
29508081,Humans;Patient-Centered Care;Quality of Life;Surveys and Questionnaires;Urolithiasis;Nephrolithiasis;Patient-Centered Care;Quality of Life;Urolithiasis,B01.050.150.900.649.313.988.400.112.400.400;N04.590.233.727.407;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C12.777.967;C13.351.968.967;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;N04.590.233.727.407;I01.800;K01.752.400.750;N06.850.505.400.425.837;C12.777.967;C13.351.968.967
29507935,,
29507520,Alzheimer Disease;Axons;Neurons;tau Proteins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.675;A11.671;D12.776.220.600.450.510;D12.776.631.560.510
29507413,,
29507394,,
29507356,,
29507338,,
29507238,"3T3 Cells;Animals;Cell Adhesion;Cell Culture Techniques;Extracellular Matrix;Focal Adhesions;Humans;Hydrogels;Integrins;Mesenchymal Stem Cells;Mice;Models, Biological;Monte Carlo Method;Rheology;Surface Properties;Viscosity;Focal Adhesions",A11.251.210.100;A11.329.228.100;B01.050;G04.022;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.284.295.310;A11.284.149.165.165.285;B01.050.150.900.649.313.988.400.112.400.400;D20.280.320.375;D26.255.165.320.375;D12.776.543.750.705.408;A11.329.830.500;A11.872.590.500;B01.050.150.900.649.313.992.635.505.500;E05.599.395;E05.318.740.525;L01.906.394.422;N05.715.360.750.540;N06.850.520.830.525;E05.830;H01.671.808;G02.860;G02.930;A11.284.149.165.165.285
29507198,"Animals;Bestrophins;Dog Diseases;Dogs;Eye Diseases, Hereditary;Genetic Therapy;Genetic Vectors;Humans;Light;Mutation;Retinal Detachment;Retinal Diseases;Retinal Pigment Epithelium;Tomography, Optical Coherence;Microvilli",B01.050;D12.776.157.530.400.175.063;D12.776.306.228;D12.776.543.550.450.175.063;D12.776.543.585.400.175.063;C22.268;B01.050.150.900.649.313.750.250.216.200;C11.270;C16.320.290;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578;G05.365.590;C11.768.648;C11.768;A09.371.670.500;A09.371.729.887;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;A11.284.180.565
29506951,,
29506895,Bipolar Disorder;Cardiac Surgical Procedures;Humans;Tulipa,F03.084.500;E04.100.376;E04.928.220;B01.050.150.900.649.313.988.400.112.400.400;B01.650.940.800.575.912.250.618.875.500.786
29506894,Anesthesia;Aortic Valve;Aortic Valve Stenosis;Heart Valve Prosthesis;Risk Factors;Transcatheter Aortic Valve Replacement;Treatment Outcome,E03.155;A07.541.510.110;C14.280.484.150;C14.280.955.249;E07.695.310;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29506323,"Allografts;Child;Child, Preschool;End Stage Liver Disease;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Liver;Liver Transplantation;Practice Patterns, Physicians';Resource Allocation;Risk Assessment;Risk Factors;Severity of Illness Index;Time Factors;Tissue Donors;Tissue and Organ Procurement;Transplant Recipients;United States;Waiting Lists",A01.941.500;M01.060.406;M01.060.406.448;C06.552.308.500.177;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A03.620;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;N04.590.374.577;N05.300.625;I01.261.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;M01.898;N02.421.911;M01.925;Z01.107.567.875;N04.452.095.738
29506195,,
29506126,"Animals;Breast;Cattle;Child Development;Estrogens;Humans;Infant;Infant Formula;Infant Nutritional Physiological Phenomena;Infant, Newborn;Isoflavones;Longitudinal Studies;Milk;Milk, Human;Phytoestrogens;Urethra;Uterus",B01.050;A01.236;B01.050.150.900.649.313.500.380.271;F01.525.200;G07.345.374.750;D27.505.696.399.472.277;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G07.203.100.712.249;G07.203.300.525.350.500;G07.203.300.525.500.500;J02.200.712.249;J02.500.525.350.500;J02.500.525.500.500;G07.203.650.220.500;M01.060.703.520;D03.383.663.283.266.450.400;D03.633.100.150.266.450.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;D27.505.696.399.472.277.540.500;A05.360.444.492.726;A05.810.876;A05.360.319.679
29505959,"Anesthetics, Local;Humans;Medical Errors;Nerve Block;Patient Safety;Time Factors;Anesthesia;Nerve Block;Safety",D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;B01.050.150.900.649.313.988.400.112.400.400;N02.421.450;E03.155.086.711;E04.525.210.550;N06.850.135.060.075.399;G01.910.857;E03.155;E03.155.086.711;E04.525.210.550;N06.850.135.060.075
29505861,"Adult;Aged;Aged, 80 and over;Choice Behavior;Decision Making;Facial Neoplasms;Health Expenditures;Humans;Informed Consent;Margins of Excision;Melanoma;Middle Aged;Mohs Surgery;Neoplasm Recurrence, Local;Office Visits;Patient Preference;Prospective Studies;Reoperation;Risk Factors;Skin Neoplasms;Time Factors;Young Adult;Mohs Surgery;Margins of Excision;Melanoma;Patient Preference",M01.060.116;M01.060.116.100;M01.060.116.100.080;F02.463.785.373.346;F02.463.785.373;C04.588.443.392;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;A10.830;C23.149.625;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;E04.494.575;E04.680.275.580;C04.697.655;C23.550.727.655;N04.452.758.635;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E04.690;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C04.588.805;C17.800.882;G01.910.857;M01.060.116.815;E04.494.575;E04.680.275.580;A10.830;C23.149.625;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500
29505610,Aged;Alzheimer Disease;Biomarkers;Clinical Chemistry Tests;Humans;Reproducibility of Results;Time Factors,M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;E01.370.225.124;E05.200.124;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;G01.910.857
29505303,"Anesthetics;Animals;Binding Sites;Cell Line;Humans;Isoflurane;Membrane Proteins;Oocytes;Receptors, GABA-A;Sevoflurane;Xenopus laevis;Isoflurane;Sevoflurane",D27.505.696.277.100;D27.505.954.427.210.100;B01.050;G02.111.570.120;A11.251.210;B01.050.150.900.649.313.988.400.112.400.400;D02.355.601.570;D12.776.543;A05.360.490.690.680;A11.497.497.600;D12.776.157.530.400.175.562;D12.776.157.530.400.400.100.100;D12.776.543.550.450.175.562;D12.776.543.550.450.500.100.100;D12.776.543.585.400.175.562;D12.776.543.585.400.500.100.100;D12.776.543.750.130.500;D12.776.543.750.720.200.300.300;D02.355.601.810;D02.455.526.510.717;B01.050.150.900.090.180.610.500.562;D02.355.601.570;D02.355.601.810;D02.455.526.510.717
29504951,,
29504047,Autistic Disorder;Neurodevelopmental Disorders;Sex Characteristics,F03.625.164.113.500;F03.625;G08.686.815
29503220,Minimally Invasive Surgical Procedures;Replantation;Robotic Surgical Procedures;Ureter;Vesico-Ureteral Reflux,E04.502;E04.936.494;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;A05.810.776;C12.777.829.920;C13.351.968.829.920
29503215,"Adult;Age Factors;Aged;Anxiety;Breast Neoplasms;Cross-Sectional Studies;Humans;Mastectomy;Middle Aged;Pain Measurement;Pain, Postoperative;Postoperative Nausea and Vomiting;Prospective Studies;Psychometrics",M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;F01.470.132;C04.588.180;C17.800.090.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E04.466;M01.060.116.630;E01.370.600.550.324;C23.550.767.700;C23.888.592.612.832;C23.550.767.859;C23.888.821.712.700;C23.888.821.937.059;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.711.780
29503202,Genetic Therapy;Lysosomal Storage Diseases;Protein Engineering,E02.095.301;E05.393.420.301;C16.320.565.595;C18.452.648.595;E05.393.420.601
29503121,,
29502970,"Aerobiosis;Anaerobiosis;Base Sequence;Binding Sites;Escherichia coli;Escherichia coli Proteins;Methylamines;Oxygen;Periplasmic Proteins;Phosphotransferases;Promoter Regions, Genetic;Protein Binding;Signal Transduction;Transcription Factors;Transcription, Genetic;Up-Regulation;Oxygen",G02.111.017;G03.049;G02.111.062;G03.078;G02.111.570.080;G05.360.080;L01.453.245.667.080;G02.111.570.120;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;D02.092.668;D01.268.185.550;D01.362.670;D12.776.090.650;D12.776.097.577;D12.776.765.537;D08.811.913.696;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;G02.111.820;G04.835;D12.776.930;G02.111.873;G05.297.700;G02.111.905;G05.308.850;G07.690.773.998;D01.268.185.550;D01.362.670
29502770,Combined Modality Therapy;Femoral Vein;Fibrinolytic Agents;Humans;Iliac Vein;Mechanical Thrombolysis;Patient Selection;Thrombolytic Therapy;Treatment Outcome;Venous Thrombosis;Venous Thrombosis;May-Thurner Syndrome;Postthrombotic Syndrome;Pulmonary Embolism,E02.186;A07.015.908.314;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;B01.050.150.900.649.313.988.400.112.400.400;A07.015.908.427;E02.631;E04.100.814.842.500;E05.581.500.653;N04.590.731;E02.319.913;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.907.355.830.925;C14.907.355.830.925;C14.240.850.906;C14.907.617.648;C16.131.240.850.890;C14.907.355.830.925.462;C14.907.952.880;C08.381.746;C14.907.355.350.700
29502035,"Aged;Aged, 80 and over;Biomarkers, Tumor;Carcinoembryonic Antigen;Colonic Neoplasms;Humans;Middle Aged;Prognosis;Proportional Hazards Models;Colonic Neoplasms",M01.060.116.100;M01.060.116.100.080;D23.101.140;D12.776.395.550.200.210;D12.776.543.550.200.210;D23.050.285.329;D23.050.301.350.210;D23.101.140.300;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180
29501599,C-Reactive Protein;Colonoscopy;Inflammatory Bowel Diseases,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C06.405.205.731;C06.405.469.432
29501362,,
29500915,"Animals;Cells, Cultured;Frizzled Receptors;HEK293 Cells;Humans;Mice;Neoplasms;Protein Domains;Receptors, Cell Surface;Single-Chain Antibodies;Antibodies;Neoplasms",B01.050;A11.251;D12.776.543.750.695.017;D12.776.543.750.850.500;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;C04;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.543.750;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;C04
29500813,Parkinson Disease;alpha-Synuclein,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.776.631.860.500;D12.776.637.500
29500650,,
29500649,Liver Cirrhosis;Magnetic Resonance Imaging;Tetralogy of Fallot,C06.552.630;E01.370.350.825.500;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29500218,"Animals;Dependovirus;Disease Models, Animal;Dogs;Factor IX;Genetic Therapy;Hemophilia B;Immune Tolerance;Muscle, Skeletal;Phenotype;Recombinant Proteins",B01.050;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.750.250.216.200;D08.622.355;D12.776.124.125.375;D23.119.375;E02.095.301;E05.393.420.301;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;G12.535.425;A02.633.567;A10.690.552.500;G05.695;D12.776.828
29499750,"Immunotherapy, Adoptive;Safety",E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;N06.850.135.060.075
29499291,Climate Change;Conservation of Natural Resources;Dermatology;Expert Testimony;Humans;International Cooperation;Physician's Role;Politics;United States;Climate Change;Environment;Politics,G16.500.175.374;J01.256;N06.230.080;H02.403.225;I01.880.604.583.232;N03.706.535.253;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;F01.829.316.616.625.600;I01.738;Z01.107.567.875;G16.500.175.374;G16.500.275;N06.230;I01.738
29499223,,
29499213,Arousal;Dopamine;Drosophila melanogaster;Sleep;Wolbachia,F02.830.104;G11.561.035;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;B01.050.500.131.617.720.500.500.750.310.250.500;F02.830.855;G11.561.803;B03.440.647.825;B03.660.050.765.825
29499171,,
29499166,"Adult;Aged;Aged, 80 and over;Amino Acid Sequence;Charcot-Marie-Tooth Disease;Child;Family;Genes, Dominant;Humans;Middle Aged;Mutation;Pedigree;Sodium-Potassium-Exchanging ATPase;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;G02.111.570.060;L01.453.245.667.060;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;M01.060.406;F01.829.263;I01.880.853.150;G05.360.340.024.340.240;G05.420.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;E05.393.673;D08.811.277.040.025.314.750;D12.776.157.530.450.162.780;D12.776.157.530.450.250.880;D12.776.157.530.813.750;D12.776.543.585.450.162.800;D12.776.543.585.450.250.890;D12.776.543.585.813.750;M01.060.116.815
29499134,"Amyotrophic Lateral Sclerosis;Animals;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Gene Silencing;HEK293 Cells;Humans;Mice;MicroRNAs;RNA, Helminth;RNA-Binding Protein FUS;RNA;Gene Silencing;MicroRNAs",C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;G05.308.203.374;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D13.444.735.520;D12.776.157.725.813.750.905;D12.776.624.664.700.915;D12.776.664.962.813.750.902;D13.444.735;G05.308.203.374;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29498774,"Aged;Aged, 80 and over;Anxiety Disorders;Case-Control Studies;Chronic Pain;Delivery of Health Care, Integrated;Depressive Disorder;Humans;Middle Aged;Patient Care Management;Psychotropic Drugs;Quality of Life;Telephone;Chronic Pain;Aged;Pain Management",M01.060.116.100;M01.060.116.100.080;F03.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.888.592.612.274;N04.590.374.142;N05.300.262;F03.600.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.590;D27.505.954.427.700;I01.800;K01.752.400.750;N06.850.505.400.425.837;L01.178.847.698;C23.888.592.612.274;M01.060.116.100;E02.745;N04.590.607.500
29498593,"Adult;Aged;Aged, 80 and over;Biopsy;Cohort Studies;Humans;Middle Aged;Radiology Information Systems;Reproducibility of Results;Sensitivity and Specificity;Societies, Medical;Thyroid Gland;Thyroid Nodule;Ultrasonography;United States;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.452.515.825;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;N03.540.828.589;A06.300.900;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;E01.370.350.850;Z01.107.567.875;M01.060.116.815
29498057,Policy;Public Health,I01.655;N03.623;H02.403.720;N01.400.550;N06.850
29497922,,
29497166,"Animals;Anti-Obesity Agents;Astrocytes;Brain;Cocaine-Related Disorders;Conditioning, Operant;Dose-Response Relationship, Drug;Drug-Seeking Behavior;Exenatide;Glucagon-Like Peptide-1 Receptor;Neurons;Proglucagon;Rats;Rats, Sprague-Dawley;Recurrence;Solitary Nucleus;Ventral Tegmental Area",B01.050;D27.505.954.203;A08.637.200;A11.650.200;A08.186.211;C25.775.300;F03.900.300;F02.463.425.179.509;G07.690.773.875;G07.690.936.500;F01.145.342;D12.644.187;D20.888.300;D23.946.833.300;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;A08.675;A11.671;D06.472.317.680;D06.472.699.587.730;D12.644.548.586.730;D12.776.811.700;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;C23.550.291.937;A08.186.211.132.810.591.500.750;A08.186.211.132.659.413.875.820
29497078,,
29496976,,
29496794,"Lipid Metabolism;Lipoproteins;Oligonucleotides, Antisense",G03.458;D10.532;D12.776.521;D13.150.480;D13.444.600.150.640;D13.695.578.424.480;D27.720.470.530.600.150.640
29496499,Diagnosis;Lung Neoplasms;Proteomics,E01;C04.588.894.797.520;C08.381.540;C08.785.520;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
29495981,,
29495896,Alzheimer Disease;Hippocampus;Memory,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F02.463.425.540
29495384,,
29495013,,
29494763,,
29494741,"Animals;Cell Survival;Disease Models, Animal;Encephalomyelitis, Autoimmune, Experimental;Gene Transfer Techniques;Genetic Therapy;Genetic Vectors;Intravitreal Injections;Mice;Mice, Inbred C57BL;Multiple Sclerosis;NF-E2-Related Factor 2;Neuroprotective Agents;Optic Neuritis;Retinal Ganglion Cells;Sirtuin 1;Visual Acuity",B01.050;G04.346;C22.232;E05.598.500;E05.599.395.080;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;E05.393.350;E02.095.301;E05.393.420.301;G05.360.337;E02.319.267.530.475.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.260.108.737;D12.776.930.127.737;D27.505.696.706.548;D27.505.954.427.575;C10.292.700.550;C11.640.576;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;D08.811.277.087.520.200.650.100;D12.776.476.900.100;E01.370.380.850.950;F02.463.593.932.901;G14.940
29494662,"Age of Onset;Alanine;Binding Sites;Cohort Studies;Cyprus;Diabetes Mellitus, Type 1;Epitope Mapping;Gene Frequency;Genetic Predisposition to Disease;Glutamine;HLA-DQ beta-Chains;HLA-DRB1 Chains;Haplotypes;Humans;Linkage Disequilibrium",N05.715.350.075.100;N06.850.490.250.100;D12.125.042;G02.111.570.120;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;Z01.542.580.500.300;Z01.639.640.300;C18.452.394.750.124;C19.246.267;C20.111.327;E05.478.274;E05.601.690.300;G05.330;C23.550.291.687.500;G05.380.355;D12.125.068.330;D12.125.095.461;D12.125.154.424;D12.776.395.550.509.400.430.750;D12.776.543.550.440.400.430.750;D23.050.301.500.400.400.430.750;D23.050.301.500.450.400.430.750;D23.050.705.552.410.400.430.750;D23.050.705.552.450.400.430.750;D12.776.395.550.509.400.440.200.010;D12.776.543.550.440.400.440.200.010;D23.050.301.500.400.400.440.200.010;D23.050.301.500.450.400.440.333.500;D23.050.705.552.410.400.440.200.010;D23.050.705.552.450.400.440.333.500;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;G05.348.500
29494397,"Dermatitis, Allergic Contact;Dermatology;Humans;Societies, Medical;United States",C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;N03.540.828.589;Z01.107.567.875
29493733,"Cosmetic Techniques;Granuloma, Foreign-Body;Humans;Middle Aged;Silicones",E02.218;C23.550.382.437;C26.392.560.325;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850
29493732,"Cosmetic Techniques;Dermal Fillers;Face;Granuloma, Foreign-Body;Humans;Injections, Subcutaneous;Silicones",E02.218;D27.720.102.461;A01.456.505;C23.550.382.437;C26.392.560.325;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.620;D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850
29493440,"G-Quadruplexes;DNA, Mitochondrial",G02.111.570.820.486.550;G05.360.580.550;D13.444.308.283.225
29493412,Motivation,F01.658;F01.752.543.500.750
29493090,"Diabetes Mellitus, Type 2;Hypoglycemia;Insulin",C18.452.394.750.149;C19.246.300;C18.452.394.984;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
29492905,Osteoporosis;Tenofovir;Veterans,C05.116.198.579;C18.452.104.579;D02.705.429.906;D03.633.100.759.138.881;M01.930
29492747,"Adalimumab;Biosimilar Pharmaceuticals;Crohn Disease;Inflammatory Bowel Diseases;Infliximab;Colitis, Ulcerative",D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;D20.215.261;C06.405.205.731.500;C06.405.469.432.500;C06.405.205.731;C06.405.469.432;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
29491402,,
29491034,"Airway Remodeling;Genetic Predisposition to Disease;Host-Pathogen Interactions;Humans;Lung;Lung Injury;Mycobacterium tuberculosis;Prognosis;Respiration;Risk Factors;Tuberculosis, Pulmonary",C23.300.017;G09.772.029;C23.550.291.687.500;G05.380.355;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.381.520;C26.891.554;B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702;E01.789;G09.772.705;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.252.410.040.552.846.899;C08.381.922;C08.730.939
29490973,"Catheterization;Outcome Assessment (Health Care);Hypertension, Pulmonary",E02.148;E05.157;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C08.381.423
29490888,"Angiogenesis Inhibitors;Animals;Antineoplastic Agents;Cell Transformation, Neoplastic;Endothelial Cells;Humans;Neoplasms;Neovascularization, Pathologic;Tumor Microenvironment",D27.505.696.377.077.099;D27.505.696.377.450.100;D27.505.954.248.025;B01.050;D27.505.954.248;C04.697.098.500;C23.550.727.098.500;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;C04;C23.550.589.500;G04.366.500
29490358,,
29490263,DNA Damage;Poly(ADP-ribose) Polymerase Inhibitors;Chromatin;Prostatic Neoplasms,G05.200;D27.505.519.389.739;D27.505.954.248.692;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
29490050,,
29489921,,
29489898,"Adolescent;Anti-Bacterial Agents;Child;Child, Preschool;Community-Acquired Infections;Critical Pathways;Drug Prescriptions;Humans;Infant;Inpatients;Length of Stay;Outpatients;Pneumonia;Treatment Failure",M01.060.057;D27.505.954.122.085;M01.060.406;M01.060.406.448;C01.539.234;N04.590.233.624.625;N04.590.275;E02.319.307;N02.421.668.778.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.643.470;E02.760.400.480;N02.421.585.400.480;M01.643.630;C08.381.677;C08.730.610;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
29489755,"Alleles;Aneuploidy;Child;DNA Copy Number Variations;Exome;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genome, Human;Humans;Leukemia;Mutation;Mutation Rate;Neoplasms;Oncogenes;Precision Medicine;Ultraviolet Rays",G05.360.340.024.340.030;C23.550.210.050;G05.365.590.175.050;G05.700.131;M01.060.406;G05.365.795.297.500;G05.360.340.011;E05.393.332;G05.308.370;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337;G05.365.590;G05.045.250.750;G05.365.590.612;G16.075.250.750;C04;G05.360.340.024.340.375.500;E02.574;H02.403.200.700;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
29489754,"Adolescent;Adult;Child;Chromothripsis;Cohort Studies;DNA Copy Number Variations;Diploidy;Genetic Predisposition to Disease;Genome, Human;Genomics;Germ-Line Mutation;Humans;Molecular Targeted Therapy;Mutation;Mutation Rate;Neoplasms;Tumor Suppressor Protein p53;Young Adult",M01.060.057;M01.060.116;M01.060.406;C23.550.210.310;G05.365.590.175.310;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.365.795.297.500;G05.700.264;C23.550.291.687.500;G05.380.355;G05.360.340.350;H01.158.273.180.350;H01.158.273.343.350;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;E02.319.574;G05.365.590;G05.045.250.750;G05.365.590.612;G16.075.250.750;C04;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;M01.060.116.815
29489752,"Acute Lung Injury;Animals;Antigens, Surface;Axin Protein;Biomarkers;Cell Cycle;Cell Lineage;Chromatin;Epigenomics;Epithelial Cells;Evolution, Molecular;Fibroblast Growth Factors;Humans;Mice;Neoplasm Proteins;Organoids;Pulmonary Alveoli;Regeneration;Stem Cells;Transcriptome;Wnt Signaling Pathway",C08.381.520.500;B01.050;D23.050.301;D05.500.117.500;D12.776.476.081.500;D23.101;G04.144;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.436;G05.045.250;G16.075.250;D12.644.276.624;D12.776.467.624;D23.529.624;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.624;A10.802;A04.411.715;G16.762;A11.872;G02.111.873.750;G05.297.700.750;G05.360.920;G02.111.820.925;G04.835.925
29488848,,
29488838,Drug Resistant Epilepsy,C10.228.140.490.125
29488126,"Adult;Age Factors;Aged;Aged, 80 and over;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Combined Modality Therapy;Humans;Mastectomy, Segmental;Middle Aged;Neoplasm Staging;Neoplasms, Second Primary;Prognosis;Risk;Risk Assessment;SEER Program;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Carcinoma, Intraductal, Noninfiltrating;Radiotherapy",M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;C04.588.180;C17.800.090.500;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E02.186;B01.050.150.900.649.313.988.400.112.400.400;E04.466.701;M01.060.116.630;E01.789.625;C04.692;E01.789;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.970.725;N04.452.859.819.725;N05.715.360.300.715.700.725;N06.850.520.308.970.725;C04.588.180;C17.800.090.500;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E02.815
29487798,"Aged;Aged, 80 and over;Aniline Compounds;Biomarkers;Cognitive Dysfunction;Cross-Sectional Studies;Ethylene Glycols;Hippocampus;Humans;Image Processing, Computer-Assisted;Longitudinal Studies;Magnetic Resonance Imaging;Mental Status Schedule;Middle Aged;Neurodegenerative Diseases;Neuropsychological Tests;Cognitive Dysfunction",M01.060.116.100;M01.060.116.100.080;D02.092.146;D23.101;F03.615.250.700;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D02.033.455.250;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;F04.711.513.603.500;F04.711.513.653.574;M01.060.116.630;C10.574;F04.711.513;F03.615.250.700
29487712,,
29487695,Breast Neoplasms;Genetic Testing;Mutation;Ovarian Neoplasms,C04.588.180;C17.800.090.500;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
29487413,,
29487303,,
29487285,Adenine Nucleotides;Allosteric Regulation;Benzamides;DNA Repair;Humans;NAD;Poly (ADP-Ribose) Polymerase-1;Protein Conformation,D03.633.100.759.646.138;D13.695.667.138;D13.695.827.068;G02.111.044;D02.065.277;D02.241.223.100.100;D02.455.426.559.389.127.085;G02.111.222;G05.219;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D08.811.913.400.725.115.690.420;G02.111.570.820.709
29487164,"Biomedical Technology;Financing, Organized;Health Policy;Humans;Insurance, Health, Reimbursement;Internet Access;Pediatrics;Program Evaluation;Telemedicine;United States;Workforce",J01.897.115;N03.219.521;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343.480;N03.219.521.710;L01.143.539;L01.224.230.110.500.625;H02.403.670;E05.337.820;N04.761.685;N05.715.360.650;H02.403.840;L01.178.847.652;N04.590.374.800;Z01.107.567.875;N04.452.525
29487060,"Benzoates;Child;Hemorrhage;Humans;Hydrazines;Platelet Count;Purpura, Thrombocytopenic, Idiopathic;Pyrazoles;Receptors, Thrombopoietin",D02.241.223.100;D02.455.426.559.389.127;M01.060.406;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;D02.442;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;D03.383.129.539;D12.776.543.750.705.852.610
29486675,"Aneurysm;Child;Computed Tomography Angiography;Humans;Phlebography;Popliteal Vein;Pulmonary Embolism;Recurrence;Saphenous Vein;Thrombolytic Therapy;Treatment Outcome;Ultrasonography, Doppler, Color;Vascular Grafting;Venous Thrombosis;Aneurysm",C14.907.055;M01.060.406;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.060.600;E01.370.370.050.600;A07.015.908.641;C08.381.746;C14.907.355.350.700;C23.550.291.937;A07.015.908.819;E02.319.913;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850.850.850.850;E04.100.814.868;C14.907.355.830.925;C14.907.055
29486673,Tumor Microenvironment;Neoplastic Stem Cells;Epigenomics;Epithelial-Mesenchymal Transition;Hypoxia;Neoplasm Metastasis,G04.366.500;A11.872.650;H01.158.273.180.350.074;H01.158.273.343.350.042;G04.356.500;C23.888.852.079;C04.697.650;C23.550.727.650
29486493,"Child;Child Mortality;Decision Support Techniques;Heart Arrest;Hospital Mortality;Hospitalization;Humans;Intensive Care Units, Pediatric;Severity of Illness Index;Time Factors",M01.060.406;E05.318.308.985.550.287;N01.224.935.698.150;N06.850.505.400.975.550.287;N06.850.520.308.985.550.287;E05.245;L01.313.500.750.190;C14.280.383;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857
29486253,Risk Factors;Therapeutics,E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E02
29486230,"Anticoagulants;Central America;Computed Tomography Angiography;Endovascular Procedures;Health Care Surveys;Healthcare Disparities;Humans;Iliac Vein;Phlebography;Practice Patterns, Physicians';Punctures;South America;Stents;Time Factors;Treatment Outcome;Ultrasonography, Interventional;United States;Vascular Patency;Vena Cava Filters;Vena Cava, Inferior;Venous Thrombosis",D27.505.954.502.119;Z01.107.169;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E04.100.814.529;E04.502.382;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;A07.015.908.427;E01.370.350.700.060.600;E01.370.370.050.600;N04.590.374.577;N05.300.625;E02.800;E04.665;Z01.107.757;E07.695.750;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850.855;E04.502.890;Z01.107.567.875;G09.330.920;E07.695.207.500;A07.015.908.949.648;C14.907.355.830.925
29485500,,
29485484,,
29485483,,
29485482,,
29485480,,
29484800,Heterochromatin;Lipid Metabolism;Liver;Nuclear Lamina,A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;G03.458;A03.620;A11.284.149.165.630.500;A11.284.430.106.279.345.700.700;A11.284.430.106.279.692.314;A11.284.835.514.700.500
29483313,,
29483246,"Cities;Cluster Analysis;Crime;Environmental Restoration and Remediation;Fear;Humans;Recreation;Residence Characteristics;United States;Urban Renewal;Violence;Criminology;Environment;Epidemiology;Anthropology, Cultural;Geography",G16.500.275.069;N06.230.069;Z01.433;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;I01.198.240;I01.880.735.191;J01.256.282;N06.230.080.600;N06.850.460.375;F01.470.361;B01.050.150.900.649.313.988.400.112.400.400;I03.450.642;N01.224.791;N06.850.505.400.800;Z01.107.567.875;I01.880.709.876;I01.198.240.856;I01.880.735.900;I01.198;G16.500.275;N06.230;H02.403.720.500;I01.076.201;H01.277.500
29483174,Clustered Regularly Interspaced Short Palindromic Repeats;Coronary Disease;Lipids,G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C14.280.647.250;C14.907.585.250;D10
29482941,"Dose-Response Relationship, Drug;Drug Design;Molecular Structure;Protein Aggregates;Quinolines;Structure-Activity Relationship;alpha-Synuclein;Parkinson Disease",G07.690.773.875;G07.690.936.500;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;G02.111.570;G02.466;D05.875;D03.633.100.810;G02.111.830;G07.690.773.997;D12.776.631.860.500;D12.776.637.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29482255,,
29482217,,
29482026,"Acute Disease;Aged;Aged, 80 and over;Biomarkers;Cystatin C;Dose-Response Relationship, Drug;Furosemide;Heart Failure;Hospitalization;Humans;Middle Aged;National Heart, Lung, and Blood Institute (U.S.);Prognosis;Sodium Potassium Chloride Symporter Inhibitors;United States;Cystatin C;Renal Insufficiency",C23.550.291.125;M01.060.116.100;M01.060.116.100.080;D23.101;D12.776.215.300;G07.690.773.875;G07.690.936.500;D02.065.884.725.300;D02.092.146.807.300;D02.886.590.700.725.300;C14.280.434;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;I01.409.418.750.600.650.496.300;N03.540.052.750.300;N03.540.348.500.500.600.650.496.300;E01.789;D27.505.519.562.906;D27.505.696.560.500.931;Z01.107.567.875;D12.776.215.300;C12.777.419.780;C13.351.968.419.780
29481721,,
29481408,Free Tissue Flaps;Humans;Leg Injuries;Lower Extremity;Patient Reported Outcome Measures;Reconstructive Surgical Procedures;Retrospective Studies;Soft Tissue Injuries;Treatment Outcome,A10.850.710.500;E07.862.710.500;B01.050.150.900.649.313.988.400.112.400.400;C26.558;A01.378.610;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;E04.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C26.808;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29481308,"Anemia, Iron-Deficiency;Animals;Apoptosis;Cells, Cultured;Erythroid Cells;Ferritins;Fibroblast Growth Factors;Iron;Mice;Mice, Inbred C57BL;Oligopeptides;Renal Insufficiency, Chronic;Signal Transduction;Renal Insufficiency, Chronic;Erythropoietin;Iron",C15.378.071.196.300;C18.452.565.100;B01.050;G04.146.160;A11.251;A11.443;D12.776.157.427.249;D12.776.556.579.249;D12.644.276.624;D12.776.467.624;D23.529.624;D01.268.556.412;D01.268.956.287;D01.552.544.412;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.644.456;C12.777.419.780.750;C13.351.968.419.780.750;G02.111.820;G04.835;C12.777.419.780.750;C13.351.968.419.780.750;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;D01.268.556.412;D01.268.956.287;D01.552.544.412
29480540,,
29480089,"Epoprostenol;Hypertension, Pulmonary;Ventricular Function, Right",D10.251.355.255.550.550.500;D23.469.050.175.725.550.500;C08.381.423;G09.330.955.900
29479868,Drug Therapy;Radiation;Survival,E02.319;G01.750;I03.784
29478893,"Animals;Cell Proliferation;DNA Damage;Homeostasis;Intestinal Mucosa;Intestines;Mechanistic Target of Rapamycin Complex 1;Mice;Mice, Inbred C57BL;Regeneration;Stem Cells;Intestines;Radiation Injuries;Radiation Tolerance;Regeneration;Stem Cells",B01.050;G04.161.750;G07.345.249.410.750;G05.200;G07.410;A03.556.124.369;A10.615.550.444;A03.556.124;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G16.762;A11.872;A03.556.124;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;G04.712;G07.738;G16.762;A11.872
29478774,"Animals;Antigens, Bacterial;B-Lymphocytes;Bacteria;Bone Marrow;Gastrointestinal Microbiome;Immunoglobulin A;Intestinal Mucosa;Intestines;Mice;Mice, Inbred C57BL;Microbiota;Plasma Cells;Proteobacteria;RNA, Ribosomal, 16S;Sepsis;Symbiosis;T-Lymphocytes;Immunoglobulin A;Antibodies;Microbiota;Plasma Cells;Sepsis;Serum",B01.050;D23.050.161;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;B03;A15.382.216;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;D12.776.124.486.485.114.619.026;D12.776.124.790.651.114.619.026;D12.776.377.715.548.114.619.026;A03.556.124.369;A10.615.550.444;A03.556.124;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;B03.660;D13.444.735.686.670;C01.539.757;C23.550.470.790.500;G06.550.800;G16.840;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.124.486.485.114.619.026;D12.776.124.790.651.114.619.026;D12.776.377.715.548.114.619.026;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;C01.539.757;C23.550.470.790.500;A12.207.152.846;A15.145.846
29478607,"Adult;Brain;Humans;Image Processing, Computer-Assisted;Leukoencephalopathies;Magnetic Resonance Imaging;Demyelinating Diseases;Magnetic Resonance Imaging;Myelin Sheath;Oligodendroglia",M01.060.116;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;C10.228.140.695;E01.370.350.825.500;C10.314;E01.370.350.825.500;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;A08.637.600;A11.650.600
29478492,"Adolescent;Body Composition;Child;Child, Preschool;Chronic Disease;Cross-Sectional Studies;Frailty;Gait;Hand Strength;Humans;Liver Diseases;Prospective Studies;Sensitivity and Specificity;Frailty",M01.060.057;G02.111.130;G03.180;G07.100.049;M01.060.406;M01.060.406.448;C23.550.291.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.359;E01.370.600.250;G11.427.410.568.900.750;E01.370.600.425.500;G11.427.560.500;B01.050.150.900.649.313.988.400.112.400.400;C06.552;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C23.550.359
29478021,Anterior Cruciate Ligament Injuries;Athletic Injuries;Child;Consensus;Delphi Technique;Humans;Pediatrics;Societies;Sports,C26.558.554.213;C26.115;M01.060.406;F01.829.316.068;F02.463.785.373.433;L01.906.197;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;N03.540.828;I03.450.642.845
29477728,,
29477624,"Adult;Aged;Arteries;Computed Tomography Angiography;Device Removal;Endovascular Procedures;Humans;Middle Aged;Radiography, Interventional;Vascular System Injuries;Vena Cava Filters;Vena Cava, Inferior",M01.060.116;M01.060.116.100;A07.015.114;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E04.199;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.350.700.725;E04.502.780;C14.907.937;C26.940;E07.695.207.500;A07.015.908.949.648
29477481,Anti-Bacterial Agents;Body Mass Index;Pediatric Obesity;Electronic Health Records,D27.505.954.122.085;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;E05.318.308.940.968.625.500
29477456,Benzodiazepines;Delirium;Lung Transplantation;Phosphopyruvate Hydratase;Postoperative Complications;Primary Graft Dysfunction,D03.633.100.079.080;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;E04.928.600.495;E04.936.450.495;D08.811.520.241.300.500;C23.550.767;C14.907.725.675;C23.550.767.877.750
29477193,"Humans;Melanoma;Mutation;Neoplasms, Radiation-Induced;Proto-Oncogene Proteins B-raf;Skin Neoplasms;Ultraviolet Rays",B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;G05.365.590;C04.682;C26.733.476;G01.750.748.500.476;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;C04.588.805;C17.800.882;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
29477191,Epidermal Cells;Humans;Keratinocytes;Melanins;Melanocytes;Melanosomes;Skin Pigmentation,A11.409;B01.050.150.900.649.313.988.400.112.400.400;A11.409.500;A11.436.397;D12.125.072.050.875.379;D23.767.620;A11.409.750;A11.436.613;A11.284.430.214.190.500.560;A11.284.430.214.190.875.190.190.560;A11.409.750.560;A11.436.265.531.560;A11.436.613.560;E01.370.600.115.450.500;E01.370.600.620.750;G07.100.175.500;G13.750.837;G16.690.890
29476978,"Animals;Apoptosis;Blotting, Western;Bone Morphogenetic Proteins;Cancellous Bone;Genetic Markers;Immunohistochemistry;In Situ Nick-End Labeling;Osteocytes;RANK Ligand;Rats;Rats, Sprague-Dawley;X-Ray Microtomography;Osteoprotegerin;Cumulative Trauma Disorders",B01.050;G04.146.160;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;A10.165.265.414;D23.101.387;G05.695.450;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E05.393.475;A11.329.629.500;D12.644.276.374.750.562;D12.776.467.374.750.562;D23.529.374.750.562;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900;D12.776.543.750.705.852.760.949.249;C26.844.150
29476920,Alzheimer Disease;Brain;Eicosanoids;Lipid Peroxidation;Mass Spectrometry,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;D10.251.355.255;D23.469.050.175;G02.111.515;G03.295.531.587;E05.196.566
29476866,,
29476112,,
29475990,Chest Pain;Dyspnea;Headache;Muscle Cramp;Office Visits;Street Drugs;Blood Pressure;Fibromuscular Dysplasia;Hypertension;Renal Artery Obstruction,C23.888.592.612.233;C08.618.326;C23.888.852.371;C23.888.592.612.441;C05.651.475;C10.597.613.500;C23.888.592.608.500;N04.452.758.635;D26.878;E01.370.600.875.249;G09.330.380.076;C14.907.137.372;C14.907.489;C12.777.419.775;C13.351.968.419.775;C14.907.137.727
29475951,Adenovirus E1A Proteins;Animals;COS Cells;Caco-2 Cells;Cell Nucleus;Cell Proliferation;Cercopithecus aethiops;Dogs;Gene Expression Regulation;HEK293 Cells;HeLa Cells;Humans;Madin Darby Canine Kidney Cells;Protein Binding;Proto-Oncogene Proteins;Qa-SNARE Proteins;Signal Transduction;Solubility;beta Karyopherins;SNARE Proteins;Alternative Splicing;Membrane Fusion;Signal Transduction,D12.776.460.050.100;D12.776.624.664.520.045.050.100;D12.776.930.100;D12.776.964.700.045.050.100;D23.050.285.062.045;D23.050.327.062.045;B01.050;A11.251.210.172.500;A11.329.228.220;A11.251.210.190.160;A11.251.860.180.160;A11.436.140;A11.284.430.106;A11.284.430.214.190.875.117;G04.161.750;G07.345.249.410.750;B01.050.150.900.649.313.988.400.112.199.120.126.110;B01.050.150.900.649.313.750.250.216.200;G05.308;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.827;A11.436.589;G02.111.679;G03.808;D12.776.624.664.700;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500;G02.111.820;G04.835;G02.805;D12.776.157.530.750.500.249;D12.776.543.585.750.500.249;D12.776.660.502.500;D12.776.543.512.249;D12.776.543.990.775;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;G04.575;G02.111.820;G04.835
29475888,,
29475831,"Animals;Bariatric Surgery;Biomarkers;Diabetes Mellitus, Type 2;Gastrectomy;Gene Expression Profiling;Gene Expression Regulation;Glucose Clamp Technique;Humans;Hyperglycemia;Insulin;Insulin Resistance;Insulin Secretion;Leptin;Lipid Droplets;Liver;Matched-Pair Analysis;Mice, Mutant Strains;Muscle, Skeletal;Obesity, Morbid;Pancreas;Weight Gain;Weight Loss",B01.050;E02.570.500.062;E04.062;D23.101;C18.452.394.750.149;C19.246.300;E04.210.419;E05.393.332;G05.308;E01.370.225.124.100.350;E05.196.500;E05.200.124.100.350;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;C18.452.394.968.500;G07.690.773.984.617;G03.442;G07.475;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;A11.284.430.214.190.875.393;A03.620;E05.318.370.485;E05.318.740.475;N05.715.360.325.500;N05.715.360.750.500;N06.850.520.445.485;N06.850.520.830.475;B01.050.150.900.649.313.992.635.505.500.550;A02.633.567;A10.690.552.500;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;A03.734;C23.888.144.243.926;G07.345.249.314.120.200.926;C23.888.144.243.963;G07.345.249.314.120.200.963
29475824,Electronic Health Records,E05.318.308.940.968.625.500
29475795,Atrial Fibrillation;Continental Population Groups;Follow-Up Studies;Humans;Incidence;Middle Aged;Registries;Retrospective Studies;Risk Assessment;Stroke;United States;Atrial Fibrillation;Ethnic Groups;Population;Continental Population Groups;Risk Factors;Stroke,C14.280.067.198;C23.550.073.198;M01.686.508;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C10.228.140.300.775;C14.907.253.855;Z01.107.567.875;C14.280.067.198;C23.550.073.198;M01.686.754;N01.224.317;N01.600;M01.686.508;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.228.140.300.775;C14.907.253.855
29474920,"Adolescent;Adult;Age of Onset;Aged, 80 and over;Animals;Base Sequence;Child;Child, Preschool;Developmental Disabilities;Evolution, Molecular;Gene Deletion;Genetic Predisposition to Disease;HEK293 Cells;Haploinsufficiency;Humans;Infant;Mice;Middle Aged;Mutation;Mutation, Missense;Neurons;Pedigree;Protein Stability;RNA-Binding Proteins;Seizures;Ataxin-1;RNA-Binding Proteins;Ataxia;Intellectual Disability;Seizures",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100.080;B01.050;G02.111.570.080;G05.360.080;L01.453.245.667.080;M01.060.406;M01.060.406.448;F03.625.421;G05.045.250;G16.075.250;G05.365.590.762.320;G05.558.800.320;C23.550.291.687.500;G05.380.355;A11.251.210.172.750;A11.436.334;G05.365.590.029.530.587;G05.380.350.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;B01.050.150.900.649.313.992.635.505.500;M01.060.116.630;G05.365.590;G05.365.590.650;A08.675;A11.671;E05.393.673;G02.111.700;D12.776.157.725;D12.776.664.962;C10.597.742;C23.888.592.742;D12.776.631.069.500;D12.776.660.075.500;D12.776.157.725;D12.776.664.962;C10.597.350.090;C23.888.592.350.090;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C10.597.742;C23.888.592.742
29474848,"Adolescent;Child;Child, Preschool;Emergency Service, Hospital;Facilities and Services Utilization;Hospitalization;Humans;Infant;Infant, Newborn;Referral and Consultation;Retrospective Studies;South Carolina;Tomography, X-Ray Computed;Urinary Calculi;Hospitals;Nephrolithiasis;Patient Readmission;Pediatrics;Urinary Calculi",M01.060.057;M01.060.406;M01.060.406.448;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.740.388;H01.548.832.625;N04.452.289;N05.715.360.750.344;N06.850.520.830.375;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875.075.662;Z01.107.567.875.750.700;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C12.777.967.500;C13.351.968.967.500;C23.300.175.850;N02.278.421;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;E02.760.400.620;N02.421.585.400.620;H02.403.670;C12.777.967.500;C13.351.968.967.500;C23.300.175.850
29474320,,
29473945,Policy,I01.655;N03.623
29472949,Autism Spectrum Disorder;Motor Skills,F03.625.164.113;F02.808.260
29472723,,
29472540,Animals;Cell Line;Chromatin;Chromatin Immunoprecipitation;Genetic Variation;Mice;Protein Binding;Transcription Factors,B01.050;A11.251.210;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;E05.393.170;E05.478.605.160;G05.365;B01.050.150.900.649.313.992.635.505.500;G02.111.679;G03.808;D12.776.930
29472494,"Adolescent;Cardiac Surgical Procedures;Child;Child, Preschool;Healthcare Disparities;Hospital Costs;Hospitalization;Humans;Income;Infant;Infant, Newborn;Insurance, Health;Length of Stay;Outcome Assessment (Health Care);Race Factors;Residence Characteristics;Retrospective Studies",M01.060.057;E04.100.376;E04.928.220;M01.060.406;M01.060.406.448;N04.590.374.380;N05.300.493;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;M01.060.703;M01.060.703.520;N03.219.521.576.343;E02.760.400.480;N02.421.585.400.480;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;N05.715.350.463;N01.224.791;N06.850.505.400.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29472300,,
29472146,"Lung Transplantation;Image Processing, Computer-Assisted",E04.928.600.495;E04.936.450.495;L01.224.308
29472003,Academic Success;Academies and Institutes;General Surgery;Humans;Job Satisfaction;Leadership;Lymphoma;Leadership,I02.399.136.500;N03.540.052;H02.403.810.300;B01.050.150.900.649.313.988.400.112.400.400;F02.784.692.425;F01.752.609;C04.557.386;C15.604.515.569;C20.683.515.761;F01.752.609
29471856,"Adult;Aged;Blood Flow Velocity;Case-Control Studies;Computed Tomography Angiography;Coronary Angiography;Coronary Artery Disease;Coronary Circulation;Coronary Vessels;Fractional Flow Reserve, Myocardial;Humans;Magnetic Resonance Imaging, Cine;Microcirculation;Middle Aged;Myocardial Perfusion Imaging;Predictive Value of Tests;Purines;Pyrazoles;Vasodilator Agents;Metabolic Syndrome;Women",M01.060.116;M01.060.116.100;E01.370.370.130;G09.330.380.630.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;G09.330.100.324;A07.015.114.269;A07.015.908.194;G09.330.100.324.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.510;G09.330.100.645;M01.060.116.630;E01.370.350.130.875;E01.370.350.710.600.500;E01.370.370.380.500;E01.370.384.730.354.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;D03.633.100.759;D03.383.129.539;D27.505.954.411.918;C18.452.394.968.500.570;C18.452.625;M01.975
29471464,,
29470624,,
29470513,"Adult;Case-Control Studies;CpG Islands;DNA Methylation;Diabetes Mellitus, Type 2;Gene Expression;Humans;Infant, Newborn;Obesity;Placenta;Pregnancy;Pregnancy in Diabetics;Prenatal Exposure Delayed Effects;RNA, Messenger;Sex Factors;Young Adult",M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G02.111.570.080.380.160;G05.360.080.380.160;G05.360.340.024.159;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C18.452.394.750.149;C19.246.300;G05.297;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;A16.710;G08.686.784.769;C13.703.726;C13.703.824.500;D13.444.735.544;N05.715.350.675;N06.850.490.875;M01.060.116.815
29470501,"Animals;Cells, Cultured;Genomic Imprinting;Growth Disorders;Humans;Insulin-Like Growth Factor II;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Transgenic;Mosaicism;Mouse Embryonic Stem Cells;Mutation;Organ Specificity;Phenotype;Pregnancy;RNA, Long Noncoding",B01.050;A11.251;G05.308.203.500;C23.550.393;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.937.420;D12.776.124.862.425;D12.776.467.937.420;D23.529.937.420;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.365.590.175.595;A11.872.700.250.875;G05.365.590;G07.650;G05.695;G08.686.784.769;D13.444.735.790.375
29470464,,
29470319,,
29470283,,
29470270,,
29470255,"Carcinogenesis;Histiocytosis, Langerhans-Cell;Humans;MAP Kinase Signaling System;Mitogen-Activated Protein Kinases;Mutation;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf",C04.697.098;C23.550.727.098;C08.381.483.375;C15.604.250.400;B01.050.150.900.649.313.988.400.112.400.400;G02.111.820.560;G03.493.560;G04.835.560;D08.811.913.696.620.682.700.567;D12.644.360.450;D12.776.476.450;G05.365.590;D27.505.519.389.755;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200
29470247,,
29470098,Datasets as Topic;Diagnostic Imaging;Early Detection of Cancer;Humans;Information Dissemination;Mass Screening;Registries;Workflow,E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;E01.370.350;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;L01.906.893
29469925,"Age Factors;Child;Child, Preschool;Cochlear Implantation;Cochlear Implants;Hearing Loss, Bilateral;Hearing Loss, Sensorineural;Humans;Infant;Speech Perception;Treatment Outcome",N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;E04.580.450.220;E04.650.220;E07.305.250.319.381.500.500;E07.695.150;E07.695.202.381.500.500;E07.814.458.150;C09.218.458.341.374;C10.597.751.418.341.374;C23.888.592.763.393.341.374;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F02.463.593.071.875;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29469900,Ambulatory Care Facilities;Clinical Competence;Continuity of Patient Care;Humans;Internship and Residency;Personal Satisfaction,N02.278.035;I02.399.630.210;N04.761.210;N05.715.175;E02.760.169;N02.421.585.169;N04.590.233.727.210;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F01.145.677
29469822,"Adolescent;Child;Child, Preschool;Exome;Genetic Linkage;Genetic Predisposition to Disease;Genotype;Heterozygote;Humans;Infant;Mutation;Noonan Syndrome;Pedigree;Protein Isoforms;RNA Splicing;Siblings;Transcription Factors;Noonan Syndrome;Cardiomyopathies;Leukemia",M01.060.057;M01.060.406;M01.060.406.448;G05.360.340.011;G05.348;C23.550.291.687.500;G05.380.355;G05.380;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.365.590;C05.660.207.690;C14.240.400.787;C14.280.400.787;C16.131.240.400.784;C16.131.621.207.690;C17.300.690;E05.393.673;D12.776.800;G02.111.760.700;G03.839.700;G05.308.700.700;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;D12.776.930;C05.660.207.690;C14.240.400.787;C14.280.400.787;C16.131.240.400.784;C16.131.621.207.690;C17.300.690;C14.280.238;C04.557.337
29467987,"Databases as Topic;Education, Medical, Graduate;Educational Measurement;Feedback;Humans;Internship and Residency",L01.313.500.750.300.188;L01.470.750;I02.358.337.350;I02.358.399.350;I02.399;L01.906.394.211;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750
29467584,,
29467322,Allergy and Immunology;Microbiology,H02.403.044;H01.158.273.540
29466837,,
29466756,"Animals;Cell Lineage;Chromatin;Chromatin Assembly and Disassembly;Epigenomics;Fibroblasts;Hepatocyte Nuclear Factor 1-alpha;Mice;NIH 3T3 Cells;T Cell Transcription Factor 1;T-Lymphocytes;Transcription, Genetic;Epigenomics;Nucleosomes",B01.050;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.329.228;D12.776.260.262.500.500;D12.776.260.400.218.500;D12.776.660.352.500.500;D12.776.930.318.500.500;B01.050.150.900.649.313.992.635.505.500;A11.251.210.100.550;A11.329.228.100.550;D12.776.260.730.750;D12.776.660.235.400.800.750;D12.776.664.235.400.800.750;D12.776.930.875.750;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;G02.111.873;G05.297.700;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625
29466292,Bone Marrow;Immunotherapy;Prognosis,A15.382.216;E02.095.465.425;E01.789
29466260,"Deglutition Disorders;Humans;Mass Screening;Patient Care Team;Pneumonia, Aspiration;Quality Improvement",C06.405.117.119;C09.775.174;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N04.590.715;C08.381.677.529;C08.730.610.529;J01.293.754;N04.761.744
29466138,,
29466131,Child;Clinical Decision-Making;Decision Making;Humans;Patient Participation,M01.060.406;E01.055;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620
29465588,"Databases, Factual;Electronic Health Records;Hospitalization;Humans;Immunoglobulins, Intravenous;International Classification of Diseases;Medical Records;Middle Aged;Predictive Value of Tests;Pulmonary Embolism;Reproducibility of Results;Risk Assessment;United States;Venous Thromboembolism;Venous Thrombosis",L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.940.968.625.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;L01.453.245.945.400;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;C08.381.746;C14.907.355.350.700;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;Z01.107.567.875;C14.907.355.590.700;C14.907.355.830.925
29465475,"Adolescent;Alleles;Bone Density;Bone and Bones;Child;Child, Preschool;Exercise;Humans;Models, Theoretical;Wnt Signaling Pathway",M01.060.057;G05.360.340.024.340.030;G11.427.100;A02.835.232;A10.165.265;M01.060.406;M01.060.406.448;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;E05.599;G02.111.820.925;G04.835.925
29465451,,
29465261,Endoplasmic Reticulum Stress;Pulmonary Fibrosis;Unfolded Protein Response,G04.434;C08.381.765;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850
29464511,Hypoplastic Left Heart Syndrome;Vascular Resistance,C14.240.400.625;C14.280.400.625;C16.131.240.400.625;G09.330.380.921
29464130,,
29464092,"Models, Animal",E05.598
29464082,Amino Acyl-tRNA Synthetases;Protein Biosynthesis,D08.811.464.263.200;G02.111.660.871;G03.734.871;G05.297.670
29463858,"AMP Deaminase;Cerebellar Diseases;Cerebral Cortex;Child;Child, Preschool;Homozygote;Humans;Infant;Microcephaly;Mutation;Paraplegia;Pedigree;Pregnancy",D08.811.277.151.653.060;C10.228.140.252;A08.186.211.200.885.287.500;M01.060.406;M01.060.406.448;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C05.660.207.620;C10.500.507.400.500;C16.131.621.207.620;C16.131.666.507.400.500;G05.365.590;C10.597.622.669;C23.888.592.636.637;E05.393.673;G08.686.784.769
29463850,,
29463566,,
29462670,Biomarkers;Cardiovascular Diseases;Cell Communication;Cell-Derived Microparticles;Humans;Metabolic Diseases,D23.101;C14;G04.085;A11.284.295.588.500;B01.050.150.900.649.313.988.400.112.400.400;C18.452
29462489,,
29462395,,
29462384,,
29462280,,
29462189,"Advertising as Topic;Animals;Choice Behavior;Conditioning (Psychology);Humans;Macaca mulatta;Models, Animal;Models, Psychological;Photic Stimulation;Reward;Sexual Behavior, Animal;Social Behavior",J01.219.687.274;L01.143.050;B01.050;F02.463.785.373.346;F02.463.425.179;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.988.400.112.199.120.510.550;E05.598;E05.599.695;E05.723.729;F02.463.425.770.836;F01.145.113.252.748;F01.145.813
29462120,"Adolescent;Child;Child, Preschool;Elbow Joint;Emergency Service, Hospital;Fractures, Open;Hospitalization;Humans;Humeral Fractures;Incidence;Retrospective Studies;Risk Factors;United States",M01.060.057;M01.060.406;M01.060.406.448;A02.835.583.290;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C26.404.311;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
29461981,"Bone Diseases;Genetic Diseases, Inborn;Genetics",C05.116;C16.320;H01.158.273.343
29460975,Cognition;Cognition Disorders;Humans;Mass Screening;Neuropsychological Tests;Parkinson Disease;Parkinson Disease;Dementia,F02.463.188;F03.615.250;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.380;F03.615.400
29460440,Adult;Cocaine-Related Disorders;Continuity of Patient Care;Counseling;Criminal Law;Humans;Middle Aged;Treatment Outcome,M01.060.116;C25.775.300;F03.900.300;E02.760.169;N02.421.585.169;N04.590.233.727.210;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;I01.198.290;I01.880.604.583.100;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29460415,,
29460158,"Acidosis, Renal Tubular;Hypercalcemia;Nephrocalcinosis",C12.777.419.815.093;C13.351.968.419.815.093;C16.320.565.861.093;C18.452.076.176.210;C18.452.648.861.093;C18.452.174.451;C18.452.950.340;C12.777.419.590;C13.351.968.419.590;C18.452.174.130.560
29460157,"Acidosis, Renal Tubular;Hypercalcemia;Nephrocalcinosis",C12.777.419.815.093;C13.351.968.419.815.093;C16.320.565.861.093;C18.452.076.176.210;C18.452.648.861.093;C18.452.174.451;C18.452.950.340;C12.777.419.590;C13.351.968.419.590;C18.452.174.130.560
29460110,Genetic Counseling;Genomics;Precision Medicine,H01.158.273.343.385.500.384;N02.421.308.400;H01.158.273.180.350;H01.158.273.343.350;E02.574;H02.403.200.700
29460006,Blood-Brain Barrier;Fibrinogen;Gliosis;Brain Concussion,A07.035;A08.186.211.035;D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490;C23.550.369;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200
29459708,,
29459687,,
29458805,"Abdominal Pain;Diagnosis, Differential;Humans;Tomography, X-Ray Computed;Wandering Spleen;Young Adult",C23.888.592.612.054;C23.888.821.030;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C15.604.744.954;M01.060.116.815
29458755,"Cell Culture Techniques;Cell Line, Tumor;Click Chemistry;DNA;DNA Breaks, Double-Stranded;DNA Replication;Deoxyuridine;Humans;Intravital Microscopy;Microscopy, Fluorescence;Recombinational DNA Repair;Single Molecule Imaging;Telomere;Neoplasms;Homologous Recombination;Telomere",E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.251.210.190;A11.251.860.180;E05.197.124;J01.897.836.249.124;D13.444.308;G05.200.210.220;G02.111.225;G05.226;D03.383.742.680.852.300;D13.570.230.430;D13.570.685.852.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.277;E05.595.185;E01.370.350.515.458;E05.595.458;G02.111.222.700;G05.219.700;G05.728.615.612;E01.370.350.515.899;E01.370.350.557.750;E05.595.899;E05.601.555.500;A11.284.430.106.279.345.190.160.845;G05.360.160.845;C04;G05.728.615;A11.284.430.106.279.345.190.160.845;G05.360.160.845
29458736,"Animals;Clinical Trials as Topic;Combined Modality Therapy;Disease Management;Drug Discovery;Drug Evaluation, Preclinical;Erythropoiesis;Humans;beta-Globins;beta-Thalassemia;beta-Globins;beta-Thalassemia",B01.050;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E02.186;N04.590.607;E05.295;H01.158.703.007.675;H01.181.466.675;E05.290.750;E05.337.550;G04.152.825.414;G09.188.343.414;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.400.434.325;D12.776.422.316.762.403.325;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150;D12.776.124.400.434.325;D12.776.422.316.762.403.325;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150
29458727,"Anemia;Animals;Biomarkers;Cell Differentiation;Erythroid Precursor Cells;Erythropoiesis;Gene Expression Regulation;Humans;Iron Overload;Signal Transduction;Stress, Physiological;Iron Overload",C15.378.071;B01.050;D23.101;G04.152;A11.148.378.590.837.250;A11.443.240.497;A11.872.378.590.817.250;A15.378.316.378.590.837.250;G04.152.825.414;G09.188.343.414;G05.308;B01.050.150.900.649.313.988.400.112.400.400;C18.452.565.500;G02.111.820;G04.835;G07.775;C18.452.565.500
29458689,Yersinia pestis;Plague,B03.440.450.425.900.600;B03.660.250.150.950.580;C01.252.400.310.980.745
29458688,"Antiviral Agents;Child;Child Health;Child, Preschool;Emergency Service, Hospital;Humans;Influenza A virus;Influenza B virus;Influenza, Human;Molecular Diagnostic Techniques;Nasopharynx;Oseltamivir;Reagent Kits, Diagnostic;Real-Time Polymerase Chain Reaction;Respiratory Syncytial Virus Infections;Respiratory Syncytial Viruses;Sensitivity and Specificity;Treatment Outcome;Virus Diseases;Emergency Service, Hospital;Orthomyxoviridae;Oseltamivir",D27.505.954.122.388;M01.060.406;N01.400.225;M01.060.406.448;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;B04.820.545.405.400;B04.820.545.407.410;C02.782.620.365;C08.730.310;E01.370.225.880;E05.200.880;E05.393.520;A04.623.557;A14.724.557;D02.065.064.525;D02.455.426.392.368.367.379.500;D27.505.259.875;D27.720.470.410.680;E07.720;E05.393.620.500.706;C02.782.580.600.550.750;B04.820.455.600.670.600.750;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C02;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B04.820.545;D02.065.064.525;D02.455.426.392.368.367.379.500
29458216,,
29457790,Atherosclerosis;Macrophages,C14.907.137.126.307;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
29457688,,
29456047,Atrial Fibrillation;Cardiac Surgical Procedures;Catheter Ablation;Heart Conduction System;Heart Rate;Humans;Treatment Outcome;Atrial Fibrillation;Catheter Ablation,C14.280.067.198;C23.550.073.198;E04.100.376;E04.928.220;E02.808.750.500;E04.014.760.500;A07.541.409;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.067.198;C23.550.073.198;E02.808.750.500;E04.014.760.500
29456038,"Child;Child, Preschool;Food Hypersensitivity;Humans;Immunocompromised Host;Immunosuppression;Immunosuppressive Agents;Infant;Killer Cells, Natural;Liver Transplantation;Mycophenolic Acid;Tacrolimus;Child;Food Hypersensitivity;Kidney Transplantation;Liver Transplantation",M01.060.406;M01.060.406.448;C20.543.480.370;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E02.095.465.425.450;E05.478.610;D27.505.696.477.656;M01.060.703;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;D02.241.081.193.678;D10.251.618;D02.540.505.810;M01.060.406;C20.543.480.370;E02.870.500;E04.936.450.485;E04.950.774.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
29455243,Advisory Committees;Anterior Cruciate Ligament Injuries;Anterior Cruciate Ligament Reconstruction;Athletic Injuries;Biomedical Research;Clinical Decision-Making;Delphi Technique;Diagnostic Imaging;Epiphyses;Humans;Informed Consent;Knee Joint;Patient Reported Outcome Measures;Pediatrics;Physical Examination;Physical Therapy Modalities;Return to Sport;Secondary Prevention;Sports Medicine;Anterior Cruciate Ligament;Child;Consensus;Knee,N03.706.742.500;C26.558.554.213;E04.555.110.026;E04.680.101.026;C26.115;H01.770.644.145;E01.055;L01.906.197;E01.370.350;A02.835.232.251;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;A02.835.583.475;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;H02.403.670;E01.370.600;E02.779;E02.831.535;I03.450.642.845.605;E02.897;N02.421.726.825;N06.850.780.750;H02.403.830;A02.513.514.100;A02.835.583.512.100;A10.165.669.514.100;M01.060.406;F01.829.316.068;F02.463.785.373.433;A01.378.610.450
29454938,Single-Cell Analysis,E05.242.900
29454792,"Adolescent;Alleles;Child;Child, Preschool;Cohort Studies;Crohn Disease;Down-Regulation;Gene Expression Profiling;Glucose;Humans;Infant;Mutation, Missense;NADPH Oxidases;Neutrophils;Phenotype;Reactive Oxygen Species;Sequence Analysis, RNA;Up-Regulation;Whole Exome Sequencing",M01.060.057;G05.360.340.024.340.030;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C06.405.205.731.500;C06.405.469.432.500;G02.111.240;G05.308.200;G07.690.773.937;E05.393.332;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.365.590.650;D08.811.682.608.575;D12.776.331.894;D12.776.543.653;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;G05.695;D01.339.431;D01.650.775;E05.393.760.710;G02.111.905;G05.308.850;G07.690.773.998;E05.393.760.700.825.500
29454628,Spermatic Cord Torsion,C12.294.693
29453879,Blood Glucose;Diabetes Mellitus;Glycated Hemoglobin A;Humans;Islets of Langerhans Transplantation;Outcome Assessment (Health Care),D09.947.875.359.448.500;C18.452.394.750;C19.246;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;E02.095.147.500.250;E04.270.550;E04.936.225.375;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
29453744,Common Variable Immunodeficiency;Immunoglobulin E,C20.673.330;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312
29453533,Animals;Apoptosis;Autophagy;Drug Delivery Systems;Humans;Nanoparticles;Necrosis;Oxidative Stress;Autophagy;Mitochondrial Degradation;Nanoparticles;Oxidative Stress,B01.050;G04.146.160;G04.146.399;G04.417.350.091;E02.319.300;B01.050.150.900.649.313.988.400.112.400.400;J01.637.512.600;C23.550.717;G04.146.638;G03.673;G07.775.750;G04.146.399;G04.417.350.091;G04.599.500;J01.637.512.600;G03.673;G07.775.750
29453446,"Animals;Cocaine-Related Disorders;Epigenesis, Genetic;Genetic Predisposition to Disease;Humans;Molecular Targeted Therapy",B01.050;C25.775.300;F03.900.300;G05.308.203;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;E02.319.574
29453429,,
29453388,"Autoimmune Diseases;Gene Regulatory Networks;Genetic Predisposition to Disease;Genetic Techniques;Humans;Polymorphism, Single Nucleotide;Untranslated Regions",C20.111;G05.360.080.689.360;C23.550.291.687.500;G05.380.355;E05.393;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;D13.444.735.544.875;D13.444.735.790.878;G05.360.340.024.220.880;G05.360.340.024.340.137.910
29452938,"Adenine;Animals;DNA;DNA Methylation;DNA Modification Methylases;Epigenesis, Genetic;Gene Editing;Genome;Humans",D03.633.100.759.138;B01.050;D13.444.308;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D08.811.150.240;D08.811.913.555.500.350;G05.308.203;E05.393.420.270;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400
29452932,Child;Domestic Violence,M01.060.406;I01.198.240.856.350;I01.880.735.900.350
29452832,"Aged;Aorta, Thoracic;Blood Vessel Prosthesis Implantation;Chi-Square Distribution;Databases, Factual;Endovascular Procedures;Hospital Mortality;Humans;Injury Severity Score;Logistic Models;Middle Aged;Multivariate Analysis;Odds Ratio;Retrospective Studies;Risk Factors;Thoracic Injuries;Time Factors;Time-to-Treatment;Treatment Outcome;Vascular System Injuries;Wounds, Nonpenetrating",M01.060.116.100;A07.015.114.056.372;E04.100.814.868.500;E04.650.200;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;L01.313.500.750.300.188.400;L01.470.750.750;E04.100.814.529;E04.502.382;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26.891;G01.910.857;E02.760.928;N02.421.585.928;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.907.937;C26.940;C26.974
29452799,Anesthesia;Anesthesiology;Ergonomics;Humans;Medication Errors;Operating Rooms;Patient Safety,E03.155;H02.403.066;F02.784.412;J01.293.556;B01.050.150.900.649.313.988.400.112.400.400;E02.319.529;N02.421.450.500;N02.278.388.700;N06.850.135.060.075.399
29452795,"Anesthesia, General;Anesthetics;Brain;Consciousness;Humans",E03.155.197;D27.505.696.277.100;D27.505.954.427.210.100;A08.186.211;F02.463.188.409;F02.830.233;B01.050.150.900.649.313.988.400.112.400.400
29452609,Humans;Indenes;Kidney Diseases;Podocytes;Proto-Oncogene Proteins B-raf;Pyrazoles,B01.050.150.900.649.313.988.400.112.400.400;D02.455.426.559.847.486;D04.615.486;C12.777.419;C13.351.968.419;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D03.383.129.539
29452565,"Animals;Ascorbic Acid;Endoplasmic Reticulum Stress;Longevity;Loss of Function Mutation;Mice;Mice, Inbred C57BL;Werner Syndrome;Werner Syndrome Helicase;Werner Syndrome;Aging;Metabolomics",B01.050;D02.241.081.844.107;D02.241.511.902.107;D09.811.100;G04.434;G07.345.124.519;G07.540;G05.365.590.538;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;C16.320.925;C18.452.284.960;D08.811.277.040.025.159.249.500;D08.811.277.352.335.375.875;D08.811.277.352.365.290.500;D08.811.399.340.249.500;D12.776.157.687.750;D12.776.660.720.750;C16.320.925;C18.452.284.960;G07.345.124;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
29452463,Gene-Environment Interaction;Genetics;Mannose-Binding Lectin,G05.695.337;H01.158.273.343;D12.776.503.280.249.500;D12.776.503.311.500
29452202,Asthma;Allergens;Floors and Floorcoverings;Pyroglyphidae;Pets,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;D23.050.063;J01.086.339.140;B01.050.500.131.166.132.419.600;B01.050.050.116.600
29451418,"Analgesics, Opioid;Health Care Surveys;Hospitalization;Hospitals;Humans;Internet;Narration;Outcome Assessment (Health Care);Pain Management;Patient Satisfaction;Retrospective Studies;Surveys and Questionnaires;Pain Measurement;Pain Management;Social Media;Analgesics, Opioid",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;E02.760.400;N02.421.585.400;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;E05.318.308.502;F01.145.209.459;L01.399.250.660;N05.715.360.300.480;N06.850.520.308.502;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E02.745;N04.590.607.500;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.600.550.324;E02.745;N04.590.607.500;L01.178.751;L01.224.230.110.500.750;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
29450512,Humans;Randomized Controlled Trials as Topic;Research Design,B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.581.500;H01.770.644.728
29450484,"Adult;Brain;Brain Concussion;Cuba;Diagnosis, Differential;Government Employees;Headache;Hearing Loss, Sensorineural;Humans;Middle Aged;Nervous System Diseases;Neuroimaging;Neuropsychological Tests;Noise;Oculomotor Nerve Diseases;Postural Balance;Sensation Disorders;Somatoform Disorders;United States",M01.060.116;A08.186.211;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;Z01.107.084.900.225;Z01.639.880.225;E01.171;M01.526.446;C23.888.592.612.441;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10;E01.370.350.578;E01.370.376.537;E05.629;F04.711.513;G01.750.770.776.567;G16.500.275.600;N06.230.400;N06.850.460.610;C10.292.562.700;C11.590.436;G11.427.690;G11.561.790.541.595;C10.597.751;C23.888.592.763;F03.875;Z01.107.567.875
29450474,,
29450465,,
29450457,,
29450453,,
29450242,Substance-Related Disorders,C25.775;F03.900
29450207,Cartilage,A02.165;A10.165.382
29450007,Translational Medical Research,H01.770.644.145.675
29449760,Pediatrics;Practice (Psychology);Professional Practice,H02.403.670;F02.463.425.674;N04.452.758
29449575,"Adult;Aged;Animals;Ataxia Telangiectasia Mutated Proteins;Cell Line, Tumor;DNA Damage;Epigenesis, Genetic;Gene Expression Profiling;HEK293 Cells;Humans;Kaplan-Meier Estimate;Leukemia, Prolymphocytic, T-Cell;Mice, Transgenic;Middle Aged;Mutation;Proto-Oncogene Proteins",M01.060.116;M01.060.116.100;B01.050;D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;A11.251.210.190;A11.251.860.180;G05.200;G05.308.203;E05.393.332;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.557.337.428.565.750;C04.557.337.428.580.075;C15.604.515.560.550.750;C15.604.515.560.575.125;C20.683.515.528.565.750;C20.683.515.528.582.125;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;M01.060.116.630;G05.365.590;D12.776.624.664.700
29449495,"Arthritis, Psoriatic;Social Media",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;L01.178.751;L01.224.230.110.500.750
29449434,,
29449357,Blood Platelets;Cell Membrane;Epoprostenol;Prostaglandins;Thromboxane A2,A11.118.188;A15.145.229.188;A11.284.149;D10.251.355.255.550.550.500;D23.469.050.175.725.550.500;D10.251.355.255.550;D23.469.050.175.725;D10.251.355.255.100.825.800;D10.251.355.310.166.971.800
29449144,,
29449075,DiGeorge Syndrome;Down Syndrome;Turner Syndrome,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750
29448179,Adolescent;Antipsychotic Agents;Biomarkers;Humans;Inflammation;Inpatients;Leukocyte Count;Lymphocytes;Neutrophils;Psychotic Disorders;Child Psychiatry;Inflammation;Psychotic Disorders;Schizophrenia,M01.060.057;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;D23.101;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;M01.643.470;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;F03.700.675;F04.096.544.193;H02.403.690.130;C23.550.470;F03.700.675;F03.700.750
29448014,Astrocytes;Microglia,A08.637.200;A11.650.200;A08.637.400;A11.650.400
29447948,"Animals;Animals, Newborn;Cartilage, Articular;Cell Differentiation;Cell Proliferation;Cells, Cultured;Chondrocytes;Chondrogenesis;Hedgehog Proteins;Mice;SOX9 Transcription Factor;Signal Transduction;Temporomandibular Joint;Tenascin;Fibrocartilage;Mandibular Condyle;Stem Cells;Temporomandibular Joint",B01.050;B01.050.050.282;A02.165.407.150;A02.835.583.192;G04.152;G04.161.750;G07.345.249.410.750;A11.251;A11.329.171;G07.345.500.325.377.625.180;G11.427.578.180;D12.644.276.671;D12.776.467.671;D23.529.671;B01.050.150.900.649.313.992.635.505.500;D12.776.260.719.500.500;D12.776.660.235.400.750.500.500;D12.776.664.235.400.750.500.500;D12.776.930.823.500.500;G02.111.820;G04.835;A02.835.583.861;A14.907;D12.776.860.300.850;A02.165.308;A10.165.382.350;A02.835.232.781.324.502.632.600;A14.521.632.600;A11.872;A02.835.583.861;A14.907
29447908,Adult;DiGeorge Syndrome;Humans;Infant;Lymphedema;DiGeorge Syndrome,M01.060.116;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C15.604.496;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
29447694,Clostridium difficile;Disease Outbreaks;Humans;Sugars,B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;N06.850.290;B01.050.150.900.649.313.988.400.112.400.400;D09.947
29447332,,
29447225,"Adolescent;Adult;Apolipoprotein A-I;Child;Chromatography, Liquid;Friedreich Ataxia;HEK293 Cells;Hep G2 Cells;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Iron-Binding Proteins;Mass Spectrometry;Simvastatin;Young Adult",M01.060.057;M01.060.116;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;M01.060.406;E05.196.181.400;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;A11.251.210.172.750;A11.436.334;A11.251.860.180.432;A11.436.348.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;D12.776.157.427;D12.776.556.579;E05.196.566;D02.455.426.559.847.638.400.900;D04.615.638.400.900;M01.060.116.815
29447210,"Adolescent;Adult;Anti-Bacterial Agents;Bacterial Load;Colon;Fatty Acids, Volatile;Fluorodeoxyglucose F18;Gastrointestinal Microbiome;Glucose;Glycolysis;Humans;Middle Aged;Positron Emission Tomography Computed Tomography;Prospective Studies;Young Adult",M01.060.057;M01.060.116;D27.505.954.122.085;E01.370.225.875.150.115;E01.370.225.875.220.115;E05.200.875.150.115;E05.200.875.220.115;G06.099.100;A03.556.124.526.356;A03.556.249.249.356;D10.251.400;D09.254.229.500;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;D09.947.875.359.448;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;M01.060.116.815
29446570,"Adaptation, Psychological;Adolescent;Adult;Child;Cognitive Dissonance;Disclosure;Fear;Frustration;Genetic Counseling;Genetic Testing;Genome, Human;Humans;Middle Aged;Motivation;Parents;Surveys and Questionnaires;Uncertainty;Whole Exome Sequencing;Young Adult;Adolescent;Genetic Counseling;Parents;Qualitative Research",F01.058;M01.060.057;M01.060.116;M01.060.406;F02.463.188.305;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;F01.470.361;F01.470.405;H01.158.273.343.385.500.384;N02.421.308.400;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.658;F01.752.543.500.750;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900;E05.393.760.700.825.500;M01.060.116.815;M01.060.057;H01.158.273.343.385.500.384;N02.421.308.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;H01.770.644.241.850
29446546,"Alleles;Child, Preschool;Gene Frequency;Genetic Association Studies;Genetic Predisposition to Disease;Genetic Variation;Genotype;Heart Defects, Congenital;Humans;Membrane Proteins;Mutation;Phenotype;Syndrome;Transcription Factors;Urogenital Abnormalities;Scimitar Syndrome",G05.360.340.024.340.030;M01.060.406.448;G05.330;E05.393.385;C23.550.291.687.500;G05.380.355;G05.365;G05.380;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;G05.365.590;G05.695;C23.550.288.500;D12.776.930;C12.706;C13.351.875;C16.131.939;C08.381.844;C08.695.815;C14.240.850.968;C14.907.780;C16.131.240.850.937;C16.131.740.815
29446208,Heart Transplantation;Pediatrics,E04.100.376.475;E04.928.220.390;E04.936.450.475;H02.403.670
29446198,Breast Neoplasms;Ethnic Groups;Geography;Mutation;Ovarian Neoplasms,C04.588.180;C17.800.090.500;M01.686.754;N01.224.317;H01.277.500;G05.365.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
29446185,Diagnosis;Medical Records;Myocardial Infarction;Pharmacoepidemiology;Predictive Value of Tests;Validation Studies,E01;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;C14.280.647.500;C14.907.585.500;H01.158.703.045;H02.403.720.500.650;H02.628.413;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;V03.950
29445517,Global Health;Inventions;Neurology;Wounds and Injuries,H02.403.371;N01.400.337;J01.897.400;H02.403.600;C26
29445516,Global Health,H02.403.371;N01.400.337
29445097,,
29445029,,
29444941,"B-Lymphocytes;Cell Adhesion;Cell Line, Transformed;Cell Proliferation;Cell Survival;Collagen Type I;Epstein-Barr Virus Infections;Herpesvirus 4, Human;Humans;Isoenzymes;L-Lactate Dehydrogenase;Lactic Acid;MAP Kinase Kinase 4;MicroRNAs;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Smad3 Protein;Tumor Microenvironment;Virus Latency;Herpesvirus 4, Human;Lactic Acid;MicroRNAs",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.022;A11.251.210.172;G04.161.750;G07.345.249.410.750;G04.346;D05.750.078.280.300.100;D12.776.860.300.250.300.100;C02.256.466.313;C02.928.313;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;D08.811.348;D12.776.800.300;D08.811.682.047.551.400;D08.811.682.047.820.493;D02.241.511.459.450;D08.811.913.696.620.682.700.565.400;D08.811.913.696.620.682.725.200.400;D12.644.360.440.400;D12.776.476.440.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.644.360.024.334.500.300;D12.776.157.057.170.500.300;D12.776.260.713.500.300;D12.776.476.024.428.500.300;D12.776.744.741.875;D12.776.930.806.500.300;G04.366.500;G06.920.900;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;D02.241.511.459.450;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29444724,"Cardiac Surgical Procedures;Conscious Sedation;Follow-Up Studies;Heart Ventricles;Humans;Infant;Magnetic Resonance Imaging, Cine;Pilot Projects;Postoperative Period;Retrospective Studies;Tetralogy of Fallot;Time Factors;Ventricular Function, Right;Ventricular Remodeling;Tetralogy of Fallot;Heart Ventricles",E04.100.376;E04.928.220;E03.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500.510;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E04.614.750;N02.421.585.753.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;G01.910.857;G09.330.955.900;C23.300.985;G09.330.955.975;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;A07.541.560
29444292,Cytokines;Sleepiness,D12.644.276.374;D12.776.467.374;D23.529.374;C23.888.900
29444268,,
29443976,,
29443901,Animals;Chemical Engineering;Dendrimers;Humans;Nanoparticles;Polyamines;Toxicity Tests;Nanomedicine;Toxicology,B01.050;J01.293.257;D05.750.327;E02.319.300.380.200;J01.637.512.600.200;B01.050.150.900.649.313.988.400.112.400.400;J01.637.512.600;D02.092.782;E05.940;H01.603.600;J01.897.115.625;J01.897.520.600.600;H01.158.891;H02.884
29443864,,
29443794,"Acute Disease;Brain;Child;Child, Preschool;Disease Progression;Electroencephalography;Heart Arrest;Humans;Infant;Prospective Studies;Resuscitation;Time Factors",C23.550.291.125;A08.186.211;M01.060.406;M01.060.406.448;C23.550.291.656;E01.370.376.300;E01.370.405.245;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.365.647;G01.910.857
29442424,Heart Transplantation;Pediatrics,E04.100.376.475;E04.928.220.390;E04.936.450.475;H02.403.670
29442392,Parkinson Disease;Neuropsychology,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F04.096.795.600;H01.158.782.795.110
29442367,"Animals;Antibodies;Antibody Formation;Bone Marrow;Bone Marrow Cells;Eosinophils;GATA1 Transcription Factor;Mice;Mice, Inbred C57BL;Mice, Knockout;Plasma Cells;T-Lymphocytes;Tumor Necrosis Factor Ligand Superfamily Member 13;Antibodies;B-Lymphocytes;Eosinophils;Memory;Plasma Cells",B01.050;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;G12.070;A15.382.216;A11.148;A15.378.316;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;D12.776.260.235.500;D12.776.260.257.100;D12.776.930.216.500;D12.776.930.314.100;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;F02.463.425.540;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725
29442152,"Advisory Committees;Child;Contrast Media;Humans;Pediatrics;Practice Patterns, Physicians';Societies, Medical;Ultrasonography;United States;Child;Surveys and Questionnaires",N03.706.742.500;M01.060.406;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;N04.590.374.577;N05.300.625;N03.540.828.589;E01.370.350.850;Z01.107.567.875;M01.060.406;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29441070,"Alleles;Amino Acid Sequence;Anaplastic Lymphoma Kinase;Antigens, Neoplasm;CD8-Positive T-Lymphocytes;Computational Biology;Epitopes;Epitopes, T-Lymphocyte;Histocompatibility Antigens Class I;Humans;Models, Molecular;Mutation;Peptides;Protein Conformation;Protein Multimerization;Structure-Activity Relationship;Receptors, Antigen, T-Cell;Neoplasms;Computational Biology;HLA Antigens",G05.360.340.024.340.030;G02.111.570.060;L01.453.245.667.060;D08.811.913.696.620.682.725.400.002;D12.776.543.750.630.002;D23.050.285;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;H01.158.273.180;L01.313.124;D23.050.550;D23.050.550.402;D12.776.395.550.489;D12.776.543.550.439;D23.050.301.500.100;D23.050.705.552.100;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595;G05.365.590;D12.644;G02.111.570.820.709;G02.111.694;G02.111.830;G07.690.773.997;D12.776.543.750.705.816.824;C04;H01.158.273.180;L01.313.124;D23.050.301.500.450;D23.050.705.552.450
29440753,,
29440750,,
29440567,,
29440536,,
29440447,"Genome, Human;Humans;RNA Interference;Transfection;X-Box Binding Protein 1",G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;G05.308.203.374.790;E05.393.350.810;G05.728.860;D12.776.260.108.937;D12.776.930.127.937
29440278,"Animals;Animals, Newborn;Calcium;Congenital Hyperinsulinism;Disease Models, Animal;Histidine;Hyperinsulinism;Hypoglycemia;Insulin-Secreting Cells;KATP Channels;Mice;Mice, Knockout;Patch-Clamp Techniques;Phosphoric Monoester Hydrolases;Phosphorylation;Protein Transport;TRPC Cation Channels",B01.050;B01.050.050.282;D01.268.552.100;D01.552.539.288;D23.119.100;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;C22.232;E05.598.500;E05.599.395.080;D12.125.072.329;D12.125.142.308;C18.452.394.968;C18.452.394.984;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;D12.776.157.530.400.600.450.550;D12.776.543.550.450.750.450.550;D12.776.543.585.400.750.450.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.200.500.905;E05.242.800;D08.811.277.352.650;G02.111.665;G02.607.780;G03.796;G03.143.700;D12.776.157.530.400.901.500;D12.776.543.585.400.901.500
29440224,"Animals;Cell Lineage;Chromatin;Gene Expression Regulation, Developmental;Heart;Humans;Myocardium;Nuclear Pore Complex Proteins;Stem Cells;Transcription Factors",B01.050;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.308.310;A07.541;B01.050.150.900.649.313.988.400.112.400.400;A02.633.580;A07.541.704;A10.690.552.750;D12.776.157.530.750.625;D12.776.543.585.750.625;A11.872;D12.776.930
29440205,,
29440119,"Blood Pressure Determination;Blood Pressure Monitoring, Ambulatory;Child;Cross-Sectional Studies;Follow-Up Studies;Humans;Hypertrophy, Left Ventricular;Kidney Failure, Chronic;Renal Insufficiency, Chronic;Systole;Blood Pressure;Hypertension",E01.370.370.140;E01.370.600.100;E01.370.370.140.100;E01.370.520.500.100;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C14.280.195.400;C23.300.775.250.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C12.777.419.780.750;C13.351.968.419.780.750;G09.330.580.880;G11.427.494.570.880;E01.370.600.875.249;G09.330.380.076;C14.907.489
29439465,"Amino Acid Substitution;Cell Line, Tumor;Cell Survival;Collagen Type II;HEK293 Cells;Humans;Osteochondrodysplasias;Protein Denaturation;Protein Domains;Protein Stability;Protein Transport;Unfolded Protein Response;Mutation;Unfolded Protein Response",E05.393.420.601.035;G05.558.109;A11.251.210.190;A11.251.860.180;G04.346;D05.750.078.280.300.200;D12.776.860.300.250.300.200;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;C05.116.099.708;C16.320.728;G01.154.651.750.500;G02.111.688.750.500;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.700;G03.143.700;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850;G05.365.590;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850
29438760,"Adolescent;Adult;Aged;Humans;Learning Curve;Melanoma;Middle Aged;Mobile Applications;Nevus, Pigmented;Photography;Self-Examination;Skin Neoplasms;Skin Pigmentation;Smartphone;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;B01.050.150.900.649.313.988.400.112.400.400;F02.784.629.529.274;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;L01.224.900.685;C04.557.665.560.615;E01.370.350.600;E05.712;E01.370.600.750;F01.145.488.700;C04.588.805;C17.800.882;E01.370.600.115.450.500;E01.370.600.620.750;G07.100.175.500;G13.750.837;G16.690.890;L01.224.230.260.550.500.500;M01.060.116.815
29438697,"Animals;Core Binding Factor Alpha 2 Subunit;Enhancer of Zeste Homolog 2 Protein;Gene Expression Regulation, Leukemic;Leukemia, Myeloid, Acute;Mice, Knockout;Mutation;Myeloid Cells;Signal Transduction;Stem Cells",B01.050;D12.776.930.155.200.200;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;G05.308.370.500;C04.557.337.539.275;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;A11.627;G02.111.820;G04.835;A11.872
29438655,,
29438531,"Adolescent;Carcinoma, Papillary, Follicular;Child;Humans;Lymphatic Metastasis;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",M01.060.057;C04.557.470.200.025.060.225;C04.557.470.200.025.085.225;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;E04.270.856;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29438496,,
29438177,"Acute Disease;Brain;Child;Child, Preschool;Disease Progression;Electroencephalography;Factor Analysis, Statistical;Heart Arrest;Humans;Infant;Prospective Studies;Regression Analysis;Resuscitation;Time Factors",C23.550.291.125;A08.186.211;M01.060.406;M01.060.406.448;C23.550.291.656;E01.370.376.300;E01.370.405.245;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E02.365.647;G01.910.857
29437884,Beckwith-Wiedemann Syndrome;Child;Early Diagnosis;Humans;Infant;Parents;Patient Education as Topic;Physician-Patient Relations;Professional-Family Relations;Rare Diseases;Risk Factors,C16.131.077.133;C16.131.260.080;C16.320.180.080;M01.060.406;E01.390;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I02.233.332.500;N02.421.726.407.680;F01.829.401.650.675;N05.300.660.625;F01.829.401.550;C23.550.291.906;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29437883,"Age Factors;Cerebrospinal Fluid Proteins;Cross-Sectional Studies;Glucose;Humans;Infant;Infant, Newborn;Leukocyte Count;Reference Values;Retrospective Studies;Spinal Puncture",N05.715.350.075;N06.850.490.250;D12.776.178;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;E05.978.810;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.225.998.054.790;E01.370.376.700;E02.800.779;E04.074.790;E04.665.700;E05.200.998.054.790
29437862,Child;Delphi Technique;Gastrointestinal Diseases;Health Services Research;Humans;Interdisciplinary Research;Patient Care Team;Program Development;Respiratory Tract Diseases;Terminology as Topic;United States,M01.060.406;L01.906.197;C06.405;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.287;N04.590.715;N04.452.760;C08;L01.559.598.400;Z01.107.567.875
29437823,"Aged;Arrhythmias, Cardiac;Cause of Death;Death, Sudden, Cardiac;Diabetic Angiopathies;Glipizide;Glyburide;Humans;Hypoglycemia;Hypoglycemic Agents;Middle Aged;Retrospective Studies;Risk Factors;Sulfonylurea Compounds;United States;Ventricular Dysfunction",M01.060.116.100;C14.280.067;C23.550.073;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;C14.280.383.220;C23.550.260.322.250;C14.907.320;C19.246.099.500;D02.886.590.795.500;D02.886.590.795.575;D02.948.828.575;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.984;D27.505.696.422;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D02.886.590.795;D02.948.828;Z01.107.567.875;C14.280.945
29437594,,
29437489,Telemedicine;Medication Adherence,H02.403.840;L01.178.847.652;N04.590.374.800;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500
29437237,"Adolescent;Adult;Aortic Stenosis, Subvalvular;Aortic Valve;Cardiac Valve Annuloplasty;Child;Child, Preschool;Echocardiography, Doppler;Echocardiography, Transesophageal;Follow-Up Studies;Humans;Infant;Monitoring, Intraoperative;Predictive Value of Tests;Retrospective Studies;Risk Factors;Ventricular Outflow Obstruction;Young Adult;Echocardiography, Transesophageal",M01.060.057;M01.060.116;C14.280.484.150.070;C14.280.955.249.070;A07.541.510.110;E04.100.376.062;E04.928.220.109;M01.060.406;M01.060.406.448;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.520.510;E04.510;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.955;M01.060.116.815;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
29437119,"Norwood Procedures;Thoracic Surgery;Heart Defects, Congenital",E04.100.376.724;E04.928.220.560;H02.403.810.803;C14.240.400;C14.280.400;C16.131.240.400
29436922,"Adolescent;Alleles;Breast Neoplasms;Child;CpG Islands;DNA Methylation;DNA-Binding Proteins;Epigenesis, Genetic;Estrogen Receptor alpha;Genome-Wide Association Study;Haplotypes;Humans;Medical History Taking;Polymorphism, Single Nucleotide;Quantitative Trait Loci;DNA Methylation",M01.060.057;G05.360.340.024.340.030;C04.588.180;C17.800.090.500;M01.060.406;G02.111.570.080.380.160;G05.360.080.380.160;G05.360.340.024.159;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;G05.308.203;D12.776.826.750.350.174;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;E01.370.510;G05.365.795.598;G05.360.340.024.380.937;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206
29436146,"Abnormalities, Multiple;Adolescent;Adult;Child;Child, Preschool;Facies;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Infant;Inheritance Patterns;Matrix Attachment Region Binding Proteins;Phenotype;Polymorphism, Single Nucleotide;Syndrome;Transcription Factors;Young Adult;Genetic Association Studies;Natural History",C16.131.077;M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C23.550.291.812;E01.370.600.230;E05.393.385;C23.550.291.687.500;G05.380.355;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.420;D12.776.260.532;G05.695;G05.365.795.598;C23.550.288.500;D12.776.930;M01.060.116.815;E05.393.385;H01.158.273.602;H01.770.552;K01.400.703
29435807,"Adolescent;Adult;Arginine;Child;Child, Preschool;Creatine;Creatinine;Genotype;Glycine;Humans;Infant;Intellectual Disability;Membrane Transport Proteins;Phenotype;Seizures;Treatment Outcome;Young Adult;Epilepsy;Intellectual Disability",M01.060.057;M01.060.116;D12.125.068.050;D12.125.095.104;D12.125.142.087;M01.060.406;M01.060.406.448;D02.078.370.280;D12.125.373;D03.383.129.308.207;G05.380;D12.125.481;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;D12.776.157.530;D12.776.543.585;G05.695;C10.597.742;C23.888.592.742;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C10.228.140.490;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
29435695,"Adolescent;Age of Onset;Child;Child, Preschool;Cognitive Behavioral Therapy;Comorbidity;Family Health;Humans;Obsessive-Compulsive Disorder;Psychiatric Status Rating Scales;Relaxation Therapy;Treatment Outcome;Comorbidity;Therapeutics",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;M01.060.406;M01.060.406.448;F04.754.137.350;N05.715.350.225;N06.850.490.687;N01.400.300;B01.050.150.900.649.313.988.400.112.400.400;F03.080.600;F04.711.513.653;E02.190.525.875;F04.754.137.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N05.715.350.225;N06.850.490.687;E02
29435578,,
29435118,Folate Receptor 1;Folate Receptor 2;Lung Neoplasms;Pancreatic Neoplasms,D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;D12.776.157.530.450.074.500.299.500.750;D12.776.395.550.448.370.750;D12.776.543.484.500.370.750;D12.776.543.550.418.370.750;D12.776.543.585.450.074.500.224.500.750;D12.776.543.750.301.750;C04.588.894.797.520;C08.381.540;C08.785.520;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29434440,,
29434439,,
29434351,,
29434335,,
29434212,"Animals;Carcinoma, Ovarian Epithelial;Cell Line, Tumor;Enhancer of Zeste Homolog 2 Protein;Humans;Mice;Neoplasms, Glandular and Epithelial;Ovarian Neoplasms;Protein-Arginine N-Methyltransferases;Transcription Factors",B01.050;C04.557.470.200.295;C04.588.322.455.199;C13.351.500.056.630.705.350;C13.351.937.418.685.350;C19.344.410.199;C19.391.630.705.350;A11.251.210.190;A11.251.860.180;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;C04.557.470;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D08.811.913.555.500.800.750;D12.776.930
29434002,,
29433952,,
29433568,"Africa, Northern;Chromosomes, Human, Y;High-Throughput Nucleotide Sequencing;Humans;Phylogeny;Population Dynamics",Z01.058.266;A11.284.187.520.300.505.757;A11.284.187.865.983.500;G05.360.162.520.300.505.757;G05.360.162.865.983.500;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.697;G16.075.605;L01.100.697;I01.240.600;N01.224.625;N06.850.505.400.700
29433532,Gastrointestinal Hemorrhage;Heart Failure;Heart-Assist Devices;Humans;Length of Stay;Middle Aged;Postoperative Complications;Reproducibility of Results;Retrospective Studies;Stroke;Surgical Wound Infection,C06.405.227;C23.550.414.788;C14.280.434;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;C23.550.767;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.300.775;C14.907.253.855;C01.539.947.692;C23.550.767.925
29433464,Adult;Body Height;Body Mass Index;Body Weight;Child;Humans;Obesity;Overweight;Parents;Perception;Self Report;Surveys and Questionnaires;Body Mass Index;Body Weights and Measures;Obesity;Overweight;Parents,M01.060.116;E01.370.600.115.100.160.100;E05.041.124.160.500;G07.100.100.160.100;G07.345.249.314.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F02.463.593;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E01.370.600.115.100;E05.041.124;G07.100.100;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;F01.829.263.500.320;I01.880.853.150.500.340;M01.620
29433407,Bias;Efficiency,N05.715.350.150;N06.850.490.500;F02.784.692.351;N04.452.209
29433067,"Cells, Cultured;Chromatin;Chromatin Immunoprecipitation;Gene Expression Regulation;Humans;Lipopolysaccharides;Macrophages;Promoter Regions, Genetic;Protein Binding;Proto-Oncogene Proteins c-jun;Time Factors;Up-Regulation;Histone Code",A11.251;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;E05.393.170;E05.478.605.160;G05.308;B01.050.150.900.649.313.988.400.112.400.400;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;D12.776.260.108.820;D12.776.624.664.700.182;D12.776.660.763;D12.776.930.127.820;G01.910.857;G02.111.905;G05.308.850;G07.690.773.998;G02.111.570.060.360;G05.360.360
29432908,,
29432749,Anti-Inflammatory Agents;Biological Products;Drug Monitoring;Gastrointestinal Agents;Humans;Inflammatory Bowel Diseases;Predictive Value of Tests;Standard of Care;Treatment Outcome;Tumor Necrosis Factor-alpha,D27.505.954.158;D20.215;E01.370.520.200;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;N04.761.789.900;N05.715.840;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
29432572,,
29432556,,
29431517,Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Machine Learning;Phenotype;Cluster Analysis;Multifactorial Inheritance;Machine Learning;Phenotype,C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;G05.695;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;G05.420.590;G17.035.250.500;L01.224.050.375.530;G05.695
29431168,,
29429994,,
29429980,"Lymphocytes, Tumor-Infiltrating;Receptors, Antigen, T-Cell",A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;D12.776.543.750.705.816.824
29429135,Child;Child Health;Delivery of Health Care;Evidence-Based Medicine;Home Care Services;Humans;Interviews as Topic;Maternal-Child Health Services;Pennsylvania;Postnatal Care;Pregnancy;Qualitative Research,M01.060.406;N01.400.225;N04.590.374;N05.300;H02.249.750;H02.403.200.400;N02.421.143.524;N02.421.539.089;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;N02.421.143.130.660;N02.421.143.620.275;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E02.760.703.500;N02.421.143.620.550.500;N02.421.585.703.500;G08.686.784.769;H01.770.644.241.850
29428775,Adolescent;Adult;Anorexia Nervosa;Body Mass Index;Diagnostic and Statistical Manual of Mental Disorders;Humans;Severity of Illness Index;Young Adult,M01.060.057;M01.060.116;F03.400.125;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815
29428621,Echocardiography,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
29428506,"Adolescent;Adult;Arginine;Brain;Child;Child, Preschool;Citrulline;DNA, Mitochondrial;Humans;Infant;Infusions, Intravenous;Magnetic Resonance Imaging;Mitochondria;Mitochondrial Diseases;Nitric Oxide;Prospective Studies;Retrospective Studies;Stroke;Treatment Outcome;Young Adult;Brain Diseases;Leigh Disease;Mitochondrial Encephalomyopathies;Therapeutics",M01.060.057;M01.060.116;D12.125.068.050;D12.125.095.104;D12.125.142.087;A08.186.211;M01.060.406;M01.060.406.448;D12.125.095.226;D13.444.308.283.225;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.319.267.082.500;E02.319.267.510.590;E01.370.350.825.500;A11.284.430.214.190.875.564;A11.284.835.626;C18.452.660;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.300.775;C14.907.253.855;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C10.228.140;C10.228.140.163.100.412;C16.320.565.189.412;C16.320.565.202.810.444;C18.452.132.100.412;C18.452.648.189.412;C18.452.648.202.810.444;C18.452.660.520;C05.651.460.620;C10.228.140.163.540;C10.668.491.500.500;C18.452.132.540;C18.452.660.560.620;E02
29428438,"Cardiomyopathy, Dilated;Heart Failure;Pediatrics",C14.280.195.160;C14.280.238.070;C14.280.434;H02.403.670
29428355,,
29428354,,
29428330,Craving;Ecological Momentary Assessment;Affect,F01.658.293.195;F04.711.336;F01.470.047
29428298,"Animals;Biomarkers;Capsid Proteins;Dependovirus;Gene Expression;Gene Transfer Techniques;Genetic Engineering;Genetic Vectors;Mice;Mice, Inbred C57BL;Organ Specificity;Tissue Distribution;Transduction, Genetic",B01.050;D23.101;D12.776.964.970.600.550;B04.280.580.650.170;G05.297;E05.393.350;E05.393.420;G05.360.337;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G07.650;G03.787.917;G07.690.725.949;E05.393.350.800;G05.728.850
29428002,,
29427697,"Administration, Oral;Adolescent;Child;Chronic Disease;Communication Barriers;Diabetes Mellitus, Type 2;Follow-Up Studies;Humans;Hypoglycemic Agents;Medication Adherence;Reminder Systems",E02.319.267.100;M01.060.057;M01.060.406;C23.550.291.500;L01.143.230;C18.452.394.750.149;C19.246.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;L01.143.820;L01.313.500.750.300.790
29427562,"Delivery of Health Care;Directed Tissue Donation;Donor Selection;Humans;Informed Consent;Kidney Transplantation;Liver Transplantation;Models, Organizational;Program Evaluation;Tissue Donors;United States;Workflow",N04.590.374;N05.300;N02.421.911.200;E04.936.537.500;N02.421.911.600;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;E02.870.500;E04.936.450.485;E04.950.774.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E05.599.670;N04.452.534;E05.337.820;N04.761.685;N05.715.360.650;M01.898;Z01.107.567.875;L01.906.893
29427374,,
29427027,"Adolescent;Child;Child, Preschool;Foot Injuries;Fractures, Bone;Humans;Infant;Magnetic Resonance Imaging;Retrospective Studies;Tarsal Bones;Child;Foot;Wounds and Injuries;Magnetic Resonance Imaging;Radiography",M01.060.057;M01.060.406;M01.060.406.448;C26.558.300;C26.404;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.043.300.710;M01.060.406;A01.378.610.250;C26;E01.370.350.825.500;E01.370.350.700
29426836,Cellular Microenvironment;Chondrogenesis;Combinatorial Chemistry Techniques;Hyaluronic Acid;Hydrogels;Mesenchymal Stem Cells;Norbornanes;Peptides;Sulfhydryl Compounds,G04.366;G07.345.500.325.377.625.180;G11.427.578.180;E05.197.312;J01.897.836.249.249;D09.698.373.475;D20.280.320.375;D26.255.165.320.375;A11.329.830.500;A11.872.590.500;D02.455.849.575.781;D12.644;D02.886.489
29426391,,
29426276,Neuroblastoma,C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
29425881,Pediatrics,H02.403.670
29425600,Anesthesiology;Humans;Quality Improvement;Registries;Quality Improvement,H02.403.066;B01.050.150.900.649.313.988.400.112.400.400;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;J01.293.754;N04.761.744
29425597,Anesthesiology;Humans;Medical Audit;Quality Improvement;Quality Improvement,H02.403.066;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.250.500;N05.700.175.500;J01.293.754;N04.761.744;J01.293.754;N04.761.744
29425593,Evidence-Based Medicine;Humans;Perioperative Care;Evidence-Based Practice;Implementation Science,H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731;E04.604;N02.421.585.722;H02.249;L01.143.320.400
29425578,Infant;Massage;Sleep,M01.060.703;E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750;F02.830.855;G11.561.803
29424959,Demography;Mass Screening,I01.240;N01.224;N06.850.505.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
29424777,,
29424688,Drosophila melanogaster;Drosophila;Larva;Neurogenesis;Neurosciences;Sleep,B01.050.500.131.617.720.500.500.750.310.250.500;B01.050.500.131.617.720.500.500.750.310.250;B05.500.500;G07.345.500.550.500.500;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;H01.158.610;F02.830.855;G11.561.803
29424085,"Botswana;Clinical Competence;Early Detection of Cancer;Education, Nursing, Baccalaureate;Global Health;Humans;Learning;Nursing Education Research;Nursing Evaluation Research;Organizational Case Studies;Public Health Nursing;Students, Nursing;Uterine Cervical Neoplasms;Case Reports;Global Health;Public Health Nursing",Z01.058.290.175.230;I02.399.630.210;N04.761.210;N05.715.175;E01.390.500;I02.358.462.316;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;H01.770.644.145.390.413;H02.478.395.413;I02.358.462.612;N04.590.233.508.613.413;H01.770.644.145.390.432;H02.478.395.432;N04.590.233.508.613.432;N03.349.380.710;N05.715.360.455;H02.478.676.755;M01.848.769.685;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;V03.100;H02.403.371;N01.400.337;H02.478.676.755
29423909,"DNA Methylation;Diet, High-Fat",G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G07.203.650.240.267
29423681,"Acupuncture Therapy;Adult;Aged;Aged, 80 and over;Cognitive Behavioral Therapy;Humans;Middle Aged;Neoplasms;Patient Preference;Sleep Initiation and Maintenance Disorders;Acupuncture;Neoplasms;Cognitive Behavioral Therapy;Sleep Initiation and Maintenance Disorders",E02.190.044;M01.060.116;M01.060.116.100;M01.060.116.100.080;F04.754.137.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;C10.886.425.800.800;F03.870.400.800.800;H02.004;C04;F04.754.137.350;C10.886.425.800.800;F03.870.400.800.800
29423135,Adolescent;Autistic Disorder;Brain;Case-Control Studies;Child;Humans;Magnetic Resonance Imaging;Motivation;Reward;Social Behavior;Stereotyped Behavior;Autism Spectrum Disorder;Caudate Nucleus;Magnetic Resonance Imaging;Motivation;Reward,M01.060.057;F03.625.164.113.500;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F01.658;F01.752.543.500.750;F02.463.425.770.836;F01.145.813;F01.145.896;F03.625.164.113;A08.186.211.200.885.287.249.487.550.184;E01.370.350.825.500;F01.658;F01.752.543.500.750;F02.463.425.770.836
29423071,"Protein Processing, Post-Translational;Prostatic Neoplasms",G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
29421004,"Adult;Cardiac Catheterization;Cardiac Surgical Procedures;Child, Preschool;Cohort Studies;Ductus Arteriosus, Patent;Follow-Up Studies;Heart Defects, Congenital;Heart Septal Defects, Atrial;Humans;Minimally Invasive Surgical Procedures;Practice Patterns, Physicians';Registries;Retrospective Studies;Risk Assessment;Treatment Outcome;United States",M01.060.116;E01.370.370.380.140;E02.148.442;E05.157.250;E04.100.376;E04.928.220;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C14.240.400.340;C14.280.400.340;C16.131.240.400.340;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;C14.240.400.560.375;C14.280.400.560.375;C16.131.240.400.560.375;B01.050.150.900.649.313.988.400.112.400.400;E04.502;N04.590.374.577;N05.300.625;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
29420848,,
29420604,"Adolescent;Adult;Analgesics, Opioid;Child;Child, Preschool;Drug Utilization Review;Humans;Infant;Leukemia, Myeloid, Acute;Pain Management;Young Adult",M01.060.057;M01.060.116;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;M01.060.406;M01.060.406.448;N04.452.706.477.400;N04.761.879.300;N05.700.900.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.337.539.275;E02.745;N04.590.607.500;M01.060.116.815
29419939,Kidney Transplantation;Registries,E02.870.500;E04.936.450.485;E04.950.774.400;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
29419821,,
29419820,,
29419276,"Humans;Kidney Failure, Chronic;Renal Insufficiency, Chronic",B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C12.777.419.780.750;C13.351.968.419.780.750
29418018,,
29417369,"Adolescent;Anxiety;Bipolar Disorder;Depression;Humans;Infant, Newborn;Medicaid;Mothers;Neonatal Abstinence Syndrome;Pennsylvania;Pregnancy;Pregnancy Complications;Prenatal Exposure Delayed Effects;Prevalence;Retrospective Studies;Schizophrenia;Schizophrenic Psychology;United States;Young Adult;Mental Health;Neonatal Abstinence Syndrome",M01.060.057;F01.470.132;F03.084.500;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N03.219.521.346.506.564.655;N03.706.615.693;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;C16.614.610;C25.775.650;F03.900.650;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;G08.686.784.769;C13.703;C13.703.824.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;F03.700.750;F04.824;Z01.107.567.875;M01.060.116.815;F02.418;N01.400.500;C16.614.610;C25.775.650;F03.900.650
29417303,"Adult;Child;Chromogranins;Exons;Fertilization in Vitro;GTP-Binding Protein alpha Subunits, Gs;Gene Deletion;Genomic Imprinting;Genu Valgum;Humans;Prognosis;Pseudohypoparathyroidism;Slipped Capital Femoral Epiphyses;Slipped Capital Femoral Epiphyses",M01.060.116;M01.060.406;D12.776.631.199;D12.776.811.185;G05.360.340.024.340.137.232;E02.875.800.750;E05.820.800.750;D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400;G05.365.590.762.320;G05.558.800.320;G05.308.203.500;C05.116.482;B01.050.150.900.649.313.988.400.112.400.400;E01.789;C05.116.198.709;C16.320.565.618.815;C18.452.104.709;C18.452.174.766;C18.452.648.618.815;C05.116.099.708.928;C05.116.425.500;C05.116.099.708.928;C05.116.425.500
29417219,,
29417204,"Abdominal Wall;Cesarean Section;Digestive System Surgical Procedures;Gastroschisis;Gestational Age;Humans;Infant;Infant, Newborn;Infant, Premature;Length of Stay;Retrospective Studies;Treatment Outcome;Cesarean Section;Gastroschisis",A01.923.047.050;E04.520.252.500;E04.210;C05.660.417;C16.131.621.417;C23.300.707.374.500;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;E02.760.400.480;N02.421.585.400.480;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E04.520.252.500;C05.660.417;C16.131.621.417;C23.300.707.374.500
29415576,Binge Drinking,C25.775.100.437;F01.145.317.269.500;F03.900.100.550
29415231,Alzheimer Disease;Antibodies;Frontotemporal Lobar Degeneration;Tauopathies,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;C10.574.945
29415173,,
29414276,"Abdomen;Brain;Cataract;Deafness;Diagnosis, Differential;Hepatomegaly;Humans;Infant, Newborn;Nigeria;Radiography, Thoracic;Rubella Syndrome, Congenital;Splenomegaly;Thrombocytopenia;Ultrasonography",A01.923.047;A08.186.211;C11.510.245;C09.218.458.341.186;C10.597.751.418.341.186;C23.888.592.763.393.341.186;E01.171;C06.552.416;C23.300.775.525;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;Z01.058.290.190.565;E01.370.350.700.730;C02.782.930.700.700.700;C16.131.077.790;C23.300.775.750;C15.378.140.855;E01.370.350.850
29414257,,
29413741,Adolescent;Follow-Up Studies;Humans;Lordosis;Lumbar Vertebrae;Lumbosacral Region;Postoperative Complications;Postoperative Period;Preoperative Period;Prospective Studies;Quality of Life;Scheuermann Disease;Spinal Fusion;Thoracic Vertebrae;Young Adult,M01.060.057;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C05.116.900.800.750;A02.835.232.834.519;A01.923.176.519;C23.550.767;E04.614.750;N02.421.585.753.750;E04.614.937;N02.421.585.753.937;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;C05.116.821.500.500;C05.116.900.800.500.500;C05.116.900.808.500;E04.555.100.700;A02.835.232.834.892;M01.060.116.815
29413523,Encephalitis,C10.228.140.430
29413336,"Allergens;Animals;Asthma;Cross Reactions;Dermatitis, Atopic;Desensitization, Immunologic;Diet Therapy;Evidence-Based Medicine;Food Hypersensitivity;Humans;Immunization;Immunoglobulin E;Risk Factors;T-Lymphocytes",D23.050.063;B01.050;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;G12.122.281;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;E02.095.465.425.450.310;E05.478.610.310;E02.642.249;H02.249.750;H02.403.200.400;C20.543.480.370;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29413330,"Age of Onset;Allergens;Eosinophilic Esophagitis;Eosinophils;Humans;Hypersensitivity, Immediate;Particulate Matter;Risk Factors;United States",N05.715.350.075.100;N06.850.490.250.100;D23.050.063;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;B01.050.150.900.649.313.988.400.112.400.400;C20.543.480;D20.633;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
29413145,Autism Spectrum Disorder;Insurance Coverage,F03.625.164.113;N03.219.521.576.265
29412980,"Aged;Benzodiazepines;Cognitive Behavioral Therapy;Humans;Sleep;Sleep Aids, Pharmaceutical;Sleep Hygiene;Sleep Initiation and Maintenance Disorders;Treatment Outcome;Benzodiazepines;Drug Therapy",M01.060.116.100;D03.633.100.079.080;F04.754.137.350;B01.050.150.900.649.313.988.400.112.400.400;F02.830.855;G11.561.803;D27.505.696.277.350.500;D27.505.954.427.210.350.500;F01.145.488.725;F02.830.855.734;C10.886.425.800.800;F03.870.400.800.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D03.633.100.079.080;E02.319
29412976,Aged;Aging;Circadian Rhythm;Environment;Homeostasis;Humans;Life Style;Sleep;Sleep Stages;Sleep Wake Disorders;Social Participation;Wakefulness;Circadian Rhythm;Hormones,M01.060.116.100;G07.345.124;G07.180.562.190;G16.500.275;N06.230;G07.410;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;F02.830.855;G11.561.803;F02.830.855.796;G11.561.803.754;C10.886;C23.888.592.796;F03.870;I03.050.750;F02.830.104.821;G11.561.035.738;G07.180.562.190;D06.472;D27.505.696.399.472
29412059,Animals;Astrocytes;Brain;Brain Ischemia;Humans;Mitochondria;Neurons,B01.050;A08.637.200;A11.650.200;A08.186.211;C10.228.140.300.150;C14.907.253.092;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;A08.675;A11.671
29411862,Citrulline,D12.125.095.226
29411652,Adult;Age Factors;Anti-Obesity Agents;Child;Combined Modality Therapy;Drug Approval;Humans;Lactones;Life Style;Liraglutide;Orlistat;Pediatric Obesity;Weight Loss;Obesity;Pediatrics;Pharmacology;Safety;Therapeutics,M01.060.116;N05.715.350.075;N06.850.490.250;D27.505.954.203;M01.060.406;E02.186;E05.290.250;E05.337.300;I01.880.604.605.250.250;B01.050.150.900.649.313.988.400.112.400.400;D02.540;F01.829.458;D06.472.317.680.500.500.500;D02.540.529;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;C23.888.144.243.963;G07.345.249.314.120.200.963;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;H02.403.670;H01.158.703;H02.628;N06.850.135.060.075;E02
29411017,"Foramen Ovale, Patent;Humans;Risk Factors;Stroke",C14.240.400.560.375.258;C14.280.400.560.375.258;C16.131.240.400.560.375.258;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.228.140.300.775;C14.907.253.855
29410550,,
29410491,,
29410262,,
29409888,"Adult;Aged;Aged, 80 and over;Brain Neoplasms;Chemotherapy, Adjuvant;Databases, Factual;Glioma;Humans;Kaplan-Meier Estimate;Middle Aged;Neurosurgery;Propensity Score;Proportional Hazards Models;Radiotherapy, Adjuvant;Survival Analysis;Treatment Outcome;Drug Therapy;Radiotherapy;Survival",M01.060.116;M01.060.116.100;M01.060.116.100.080;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E02.186.170;E02.319.170;L01.313.500.750.300.188.400;L01.470.750.750;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;H02.403.810.425;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E02.186.775;E02.815.600;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02.319;E02.815;I03.784
29409834,Contraception;Estradiol;Pharmacokinetics,E02.875.194;D04.210.500.365.415.248;D06.472.334.851.437.500;G03.787;G07.690.725
29409812,"Adolescent;Bariatric Medicine;Behavior Therapy;Exercise;Humans;Obesity;Sleep;Sleep Apnea, Obstructive;Sleep Wake Disorders;Treatment Outcome;Weight Loss;Weight Reduction Programs;Sleep Apnea, Obstructive;Sleep;Weight Loss",M01.060.057;H02.403.074;F04.754.137;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.830.855;G11.561.803;C08.618.085.852.850;C10.886.425.800.750.850;C10.886;C23.888.592.796;F03.870;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963;I02.233.332.445.650;N02.421.726.407.579.650;C08.618.085.852.850;C10.886.425.800.750.850;F02.830.855;G11.561.803;C23.888.144.243.963;G07.345.249.314.120.200.963
29409619,"Animals;Drug Administration Schedule;Hernias, Diaphragmatic, Congenital;Imatinib Mesylate;Lung;Phenyl Ethers;Pregnancy;Prenatal Care;Protein Kinase Inhibitors;Pulmonary Alveoli;Pulmonary Artery;Random Allocation;Rats;Rats, Sprague-Dawley;Treatment Outcome;Tretinoin;Hernias, Diaphragmatic, Congenital;Imatinib Mesylate;Tretinoin",B01.050;E02.319.283;C16.131.433;C23.300.707.500.116;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;A04.411;D02.355.726;D02.455.426.559.389.657.654;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786;D27.505.519.389.755;A04.411.715;A07.015.114.715;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780;C16.131.433;C23.300.707.500.116;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780
23556151,,
29409077,"Adolescent;Ankle;Ankle Injuries;Athletic Injuries;Child;Foot Deformities, Congenital;Foot Injuries;Fractures, Bone;Humans",M01.060.057;A01.378.610.250.149;C26.558.100;C26.115;M01.060.406;C05.330.495;C05.660.585.512.380;C16.131.621.585.512.500;C26.558.300;C26.404;B01.050.150.900.649.313.988.400.112.400.400
29409070,"Artifacts;Child;Fracture Fixation, Internal;Fractures, Bone;Humans;Orthopedic Fixation Devices;Radiography",E05.047;M01.060.406;E04.555.300.300;C26.404;B01.050.150.900.649.313.988.400.112.400.400;E07.858.442.660;E07.858.690.725;E01.370.350.700
29408806,"Gastroenterology;Inflammatory Bowel Diseases;Immunity, Innate",H02.403.429.405;C06.405.205.731;C06.405.469.432;G12.450.564
29408617,"Dermatitis, Phototoxic;Ecotoxicology;Humans;Lung;No-Observed-Adverse-Effect Level;Odorants;Reproduction;Risk Assessment;Safety;Skin;Teratogens;Terpenes;Toxicity Tests;Dermatitis, Phototoxic",C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225;H01.158.273.248.500;H01.158.891.211;H01.277.249.500;H02.884.211;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E05.940.600;G07.690.936.750;G16.500.275.640;N06.230.480;G08.686.784;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N06.850.135.060.075;A17.815;D27.888.569.864;D02.455.849;E05.940;C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225
29408506,Blood Component Removal;Transplantation;Unrelated Donors,E02.120;E04.936;M01.898.828
29408494,"Bronchitis;Child;Embolization, Therapeutic;Ethiodized Oil;Humans;Intracranial Embolism;Middle Cerebral Artery;Tomography, X-Ray Computed",C08.127.446;C08.381.495.146;C08.730.099;M01.060.406;E02.520.360;E02.926.500;D10.627.700.550.300;D20.215.784.750.550.300;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.525.400;C14.907.253.566.300;C14.907.355.590.213.300;A07.015.114.228.550;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29408384,"Arachidonic Acid;Carbon Isotopes;Carbon Radioisotopes;Culture Techniques;Glucose;Mortierella;Arachidonic Acid;Fatty Acids, Unsaturated;Isotope Labeling",D10.251.355.255.100.100;D10.251.355.310.166.100;D01.268.150.075;D01.496.123;D01.268.150.075.328;D01.496.123.328;D01.496.749.154;E05.481.500;D09.947.875.359.448;B01.300.300.500.480;D10.251.355.255.100.100;D10.251.355.310.166.100;D10.251.355;E05.522
29408289,Survivorship,F01.058.144.500
29407544,"Adolescent;Adult;Aged;Case-Control Studies;Cross-Sectional Studies;Depressive Disorder, Major;Humans;Hydrocortisone;Hypothalamo-Hypophyseal System;Middle Aged;Pituitary-Adrenal System;Saliva;Stress, Physiological;Stress, Psychological;Suicidal Ideation;Young Adult;Hydrocortisone;Depressive Disorder, Major;Suicidal Ideation",M01.060.057;M01.060.116;M01.060.116.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;A06.688.357;A08.186.211.180.497.352.435;A08.186.211.200.317.357.352.435;A08.713.357;M01.060.116.630;A06.300.691;A12.200.666;G07.775;F01.145.126.990;F02.830.900;F01.145.126.980.875.149;I01.880.735.856.149;M01.060.116.815;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;F03.600.300.375;F01.145.126.980.875.149;I01.880.735.856.149
29406940,Child;Heart Diseases;Humans;Mass Screening;Chest Pain;Child;Cyanosis;Heart Murmurs;Endocarditis;Primary Health Care,M01.060.406;C14.280;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C23.888.592.612.233;M01.060.406;C23.888.248;C23.888.447;C14.280.282;N04.590.233.727
29406903,Ventriculostomy;Hydrocephalus,E04.035.188.957;E04.525.170.860;C10.228.140.602
29406781,DNA Methylation;Histone Code;Insulin Secretion;Insulin Resistance,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G02.111.570.060.360;G05.360.360;G03.442;G07.475;C18.452.394.968.500;G07.690.773.984.617
29406479,"Bacteremia;Blood Cell Count;Blood Culture;Cerebrospinal Fluid;Cohort Studies;Databases, Factual;Fever;Humans;Infant;Infant, Newborn;Meningitis, Bacterial;Retrospective Studies;Sensitivity and Specificity;Urinalysis;Urinary Tract Infections",C01.252.100;C01.539.757.100;C23.550.470.790.500.100;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E01.370.225.875.185;E05.200.875.185;A12.207.270.210;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;C23.888.119.344;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C01.252.200.500;C10.228.228.180.500;C10.228.614.280;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.225.124.810;E01.370.390.810;E05.200.124.810;C01.539.895;C12.777.892;C13.351.968.892
29406459,,
29406441,"Adolescent;Chronic Disease;Humans;Models, Organizational;Primary Health Care;Specialization;Transition to Adult Care;Young Adult",M01.060.057;C23.550.291.500;B01.050.150.900.649.313.988.400.112.400.400;E05.599.670;N04.452.534;N04.590.233.727;H02.811;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815
29406428,,
29406380,,
29406379,,
29406378,,
29406377,,
29406375,,
29406007,"Hyperinsulinism;Hypoglycemia;Insulin;Infant, Newborn;Pancreas;Pancreatectomy",C18.452.394.968;C18.452.394.984;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;M01.060.703.520;A03.734;E04.210.752
29406005,Graves Disease;Hyperthyroidism;Thyrotoxicosis,C11.675.349.500;C19.874.283.605;C19.874.397.370;C20.111.555;C19.874.397;C19.874.397.685
29405947,"Anti-Arrhythmia Agents;Cardiomyopathies;Echocardiography;Electrocardiography;Flecainide;Humans;Magnetic Resonance Imaging, Cine;Middle Aged;Myocardial Contraction;Pennsylvania;Propafenone;Retrospective Studies;Survival Rate;Ventricular Function, Left;Ventricular Premature Complexes;Cardiomyopathies;Flecainide;Ventricular Premature Complexes;Propafenone",D27.505.954.411.097;C14.280.238;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.370.380.240;E01.370.405.240;D03.383.621.270;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.510;M01.060.116.630;G09.330.580;G11.427.494.570;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;D02.522.818.830;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;G09.330.955.800;C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800;C14.280.238;D03.383.621.270;C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800;D02.522.818.830
29404619,,
29404572,,
29404425,Gastrointestinal Microbiome;Inflammatory Bowel Diseases,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;C06.405.205.731;C06.405.469.432
29404241,Cholesteatoma;Petrous Bone;Rhabdomyosarcoma;Skull Base;Temporal Bone,C17.800.428.260;A02.835.232.781.885.681;C04.557.450.590.550.660;C04.557.450.795.550.660;A01.456.830;A02.835.232.781.750;A02.835.232.781.885
29403502,"Actins;CD4-Positive T-Lymphocytes;Cell Line, Tumor;Humans;Immunological Synapses;Integrin alpha4beta1;Intercellular Adhesion Molecule-1;Jurkat Cells;Lymphocyte Activation;Lymphocyte Function-Associated Antigen-1;Paxillin;Phosphorylation;Receptors, Antigen, T-Cell;Signal Transduction;Talin;Tyrosine;Vascular Cell Adhesion Molecule-1;Vinculin;Actins;Immunological Synapses;Talin;Vinculin",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;A11.284.149.165.420.548;A15.382.370;D12.776.395.550.200.625.347;D12.776.543.550.200.625.347;D12.776.543.750.705.408.530.500;D12.776.543.750.705.408.850.299;D12.776.543.750.705.877.347;D23.050.301.350.625.347;D12.776.395.550.200.450;D12.776.543.550.200.450;D23.050.301.350.450;A11.251.210.190.495;A11.251.860.180.495;A15.382.490.555.567.569.440;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;D12.776.395.550.200.074.937;D12.776.395.550.200.625.550;D12.776.543.550.200.093.937;D12.776.543.550.200.625.550;D12.776.543.750.705.408.600.400;D12.776.543.750.705.877.550;D23.050.301.350.074.400;D23.050.301.350.625.550;D12.644.360.024.316;D12.776.157.057.092;D12.776.476.024.397;D12.776.512.374;D12.776.744.665;G02.111.665;G02.607.780;G03.796;D12.776.543.750.705.816.824;G02.111.820;G04.835;D12.776.220.985;D12.125.072.050.875;D12.776.395.550.200.920;D12.776.543.550.200.920;D23.050.301.350.920;D12.776.220.990;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;A11.284.149.165.420.548;A15.382.370;D12.776.220.985;D12.776.220.990
29403500,"ADP-ribosyl Cyclase 1;CD4 Lymphocyte Count;CD4-CD8 Ratio;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;CTLA-4 Antigen;Forkhead Transcription Factors;HIV-1;HLA-DR Antigens;Humans;Ikaros Transcription Factor;Immunologic Memory;Lymphocyte Activation;Membrane Glycoproteins;Programmed Cell Death 1 Receptor;Receptors, Immunologic;Viral Load;Virus Replication",D08.811.277.450.430.400.060.500;D12.776.543.550.045;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;E01.370.225.500.195.107.595.500.150.160;E01.370.225.625.107.595.500.150.160;E05.200.500.195.107.595.500.150.160;E05.200.625.107.595.500.150.160;E05.242.195.107.595.500.150.160;G04.140.107.595.500.150.160;G09.188.105.595.500.150.160;G12.248;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;D12.776.260.950.249;D12.776.930.977.249;B04.820.650.589.650.350.400;D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.522.500;D12.776.930.375.500;G12.450.050.500;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;D12.776.395.550;D12.776.543.550;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;D12.776.543.750.705;E01.370.225.875.950;E05.200.875.950;G06.920.850;G06.920.925
29403147,Pain,C23.888.592.612;F02.830.816.444;G11.561.790.444
29403030,,
29402777,"Birth Weight;Child Development;Fetal Blood;Humans;Infant;Infant, Newborn;Insulin-Like Growth Factor I;Insulin-Like Growth Factor II;Mass Spectrometry;Growth Hormone;Insulin-Like Growth Factor I;Insulin-Like Growth Factor II;Mass Spectrometry",C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;F01.525.200;G07.345.374.750;A12.207.152.200;A15.145.300;A16.378.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;D12.644.276.937.420;D12.776.124.862.425;D12.776.467.937.420;D23.529.937.420;E05.196.566;D06.472.699.631.525.425;D12.644.548.691.525.425;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;D12.644.276.937.420;D12.776.124.862.425;D12.776.467.937.420;D23.529.937.420;E05.196.566
29402210,"Algorithms;Animals;Animals, Newborn;CpG Islands;DNA Methylation;Databases, Genetic;Fetus;Hippocampus;Iron;Molecular Sequence Annotation;Rats, Sprague-Dawley;Software;Time Factors;DNA Methylation;Epigenomics",G17.035;L01.224.050;B01.050;B01.050.050.282;G02.111.570.080.380.160;G05.360.080.380.160;G05.360.340.024.159;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;L01.313.500.750.300.188.400.325;L01.470.750.750.325;A16.378;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D01.268.556.412;D01.268.956.287;D01.552.544.412;E05.393.760.479;L01.453.245.667.580;B01.050.150.900.649.313.992.635.505.700.750;L01.224.900;G01.910.857;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;H01.158.273.180.350.074;H01.158.273.343.350.042
29402152,"Neuropsychology;Signal Detection, Psychological;Brain Injuries, Traumatic",F04.096.795.600;H01.158.782.795.110;E01.370.685.814;E05.796.908;F02.463.593.257.800;F02.463.593.710.725;F04.096.753.814;F04.669.908;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29401442,"Animals;Biomechanical Phenomena;Collagen;Extracellular Matrix;Fibroblasts;Mechanical Phenomena;Mice;Models, Biological;NIH 3T3 Cells;Rats;Spheroids, Cellular;Stress, Mechanical",B01.050;G01.154.090;G01.374.089;D05.750.078.280;D12.776.860.300.250;A11.284.295.310;A11.329.228;G01.374;B01.050.150.900.649.313.992.635.505.500;E05.599.395;A11.251.210.100.550;A11.329.228.100.550;B01.050.150.900.649.313.992.635.505.700;A11.251.800;G01.374.835
29400400,Social Support,I01.880.853.500.600
29399839,Bullying;Mental Health;Public Health;Risk-Taking,F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;F02.418;N01.400.500;H02.403.720;N01.400.550;N06.850;F01.145.722
29399791,Consensus;Drug Resistant Epilepsy;Epileptic Syndromes;Humans;Status Epilepticus;Encephalitis,F01.829.316.068;F02.463.785.373.433;C10.228.140.490.125;C10.228.140.490.493;B01.050.150.900.649.313.988.400.112.400.400;C10.597.742.785;C23.888.592.742.785;C10.228.140.430
29399394,Cancer Vaccines;Chemokines;Immunotherapy;Lung Neoplasms;Mesothelioma;Vaccinia virus,D20.215.894.200;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;E02.095.465.425;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.470.035.510;C04.557.470.660.510;B04.280.650.160.650.900
29399288,Liver Cirrhosis;Meta-Analysis;Non-alcoholic Fatty Liver Disease;Vitamin D,C06.552.630;V03.600;C06.552.241.519;D04.210.500.812.768
29399206,"Renal Insufficiency, Chronic",C12.777.419.780.750;C13.351.968.419.780.750
29398626,"Adolescent;Child;Electroencephalography;Epilepsy;Hospital Units;Hospitalization;Humans;Length of Stay;Monitoring, Ambulatory;Monitoring, Physiologic;Preoperative Care;Preoperative Period;Retrospective Studies;Seizures;Status Epilepticus;Child;Length of Stay",M01.060.057;M01.060.406;E01.370.376.300;E01.370.405.245;C10.228.140.490;N02.278.388;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E01.370.520.500;E01.370.520;E02.760.795;E04.604.750;N02.421.585.795;E04.614.937;N02.421.585.753.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.597.742;C23.888.592.742;C10.597.742.785;C23.888.592.742.785;M01.060.406;E02.760.400.480;N02.421.585.400.480
29398588,"Adrenal Hyperplasia, Congenital;Disorders of Sex Development",C12.706.316.090.500;C13.351.875.253.090.500;C16.131.939.316.129.500;C16.320.033;C16.320.565.925.249;C18.452.648.925.249;C19.053.440;C19.391.119.090.500;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119
29398180,Adolescent;Child;Cognitive Dysfunction;Neuroanatomy,M01.060.057;M01.060.406;F03.615.250.700;H01.158.100.700;H01.158.610.060
29398178,"Catheterization;Kidney Failure, Chronic;Renal Dialysis",E02.148;E05.157;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.300;E02.912.800
29398050,"Adolescent;Blood Glucose;Child;Cholesterol, LDL;Diabetes Mellitus, Type 2;Disease Progression;Dyslipidemias;Glycated Hemoglobin A;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Inflammation;Insulin;Lipids;Adolescent;Insulin;Lipids;Diabetes Mellitus, Type 2",M01.060.057;D09.947.875.359.448.500;M01.060.406;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;C18.452.394.750.149;C19.246.300;C23.550.291.656;C18.452.584.500;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;C23.550.470;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;D10;M01.060.057;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;D10;C18.452.394.750.149;C19.246.300
29398047,Humans;Infant;Spinal Puncture,B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.225.998.054.790;E01.370.376.700;E02.800.779;E04.074.790;E04.665.700;E05.200.998.054.790
29398042,"Adult;Aged;Aged, 80 and over;Ambulatory Care;Appendectomy;Cholecystectomy;Feasibility Studies;Herniorrhaphy;Humans;Laparoscopy;Middle Aged;Patient Preference;Patient Satisfaction;Pilot Projects;Postoperative Care;Telemedicine;Telephone;Urban Health Services;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;E02.760.106;N02.421.585.106;E04.210.078;E04.210.120.172;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;E04.680.325;B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;M01.060.116.630;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E02.760.731.700;E04.604.500;N02.421.585.722.700;H02.403.840;L01.178.847.652;N04.590.374.800;L01.178.847.698;N02.421.914;M01.060.116.815
29397959,Cerebrovascular Circulation;Electroencephalography;Magnetic Resonance Imaging;Intracranial Hemorrhages;Stroke,G09.330.100.159;E01.370.376.300;E01.370.405.245;E01.370.350.825.500;C10.228.140.300.535;C14.907.253.573;C23.550.414.913;C10.228.140.300.775;C14.907.253.855
29397932,,
29397335,,
29397290,"Brain;Child, Preschool;Consensus;Humans;Multiple Sulfatase Deficiency Disease;Mutation;Protein Processing, Post-Translational;Rare Diseases;Sulfatases;Consensus;Mucopolysaccharidoses;Multiple Sulfatase Deficiency Disease;Therapeutics",A08.186.211;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.163.100.435.825.850.750;C16.320.565.189.435.825.850.750;C16.320.565.398.641.803.925.750;C16.320.565.595.554.825.850.750;C18.452.132.100.435.825.850.750;C18.452.584.687.803.925.750;C18.452.648.189.435.825.850.750;C18.452.648.398.641.803.925.750;C18.452.648.595.554.825.850.750;G05.365.590;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;C23.550.291.906;D08.811.277.352.827;F01.829.316.068;F02.463.785.373.433;C16.320.565.202.715;C16.320.565.595.600;C17.300.550.575;C18.452.648.202.715;C18.452.648.595.600;C10.228.140.163.100.435.825.850.750;C16.320.565.189.435.825.850.750;C16.320.565.398.641.803.925.750;C16.320.565.595.554.825.850.750;C18.452.132.100.435.825.850.750;C18.452.584.687.803.925.750;C18.452.648.189.435.825.850.750;C18.452.648.398.641.803.925.750;C18.452.648.595.554.825.850.750;E02
29397272,"Desensitization, Immunologic;Eosinophilic Esophagitis;Food Hypersensitivity;Humans",E02.095.465.425.450.310;E05.478.610.310;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C20.543.480.370;B01.050.150.900.649.313.988.400.112.400.400
29397132,Anesthesia;Anesthesiology;Evidence-Based Medicine;Goals;Humans;Patient Care;Quality Improvement,E03.155;H02.403.066;H02.249.750;H02.403.200.400;F01.658.500;B01.050.150.900.649.313.988.400.112.400.400;E02.760;N02.421.585;J01.293.754;N04.761.744
29397117,Activities of Daily Living;Aged;Arthritis;Body Mass Index;Disability Evaluation;Health Status;Humans;Incidence;Joints;Longitudinal Studies;Middle Aged;Obesity;Orthopedic Procedures;Postoperative Complications;Retirement;Surveys and Questionnaires;United States;Activities of Daily Living;Obesity,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;C05.550.114;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E01.370.400;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;A02.835.583;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02.718;E04.555;C23.550.767;I03.702;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29396792,"Carcinoma, Hepatocellular;Catheter Ablation;Child;Combined Modality Therapy;Embolization, Therapeutic;Endovascular Procedures;Hepatoblastoma;Humans;Image-Guided Biopsy;Liver Neoplasms;Radiography, Interventional;Biopsy;Child;Radiology, Interventional;Liver;Neoplasms",C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;E02.808.750.500;E04.014.760.500;M01.060.406;E02.186;E02.520.360;E02.926.500;E04.100.814.529;E04.502.382;C04.557.435.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.384.100.370;E01.370.225.998.054.370;E01.370.388.100.370;E04.074.370;E05.200.500.384.100.370;E05.200.998.054.370;E05.242.384.100.370;C04.588.274.623;C06.301.623;C06.552.697;E01.370.350.700.725;E04.502.780;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;H02.403.740.675;A03.620;C04
29396438,,
29396138,"Acetals;Aldehydes;Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;D02.047;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29395989,"Disease Management;Endocrine System;Gastrointestinal Tract;Humans;Muscular Dystrophy, Duchenne;Neuromuscular Junction;Nutrition Therapy",N04.590.607;A06;A03.556;B01.050.150.900.649.313.988.400.112.400.400;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;A08.800.550.550.550;A08.850.550.550;A11.284.149.165.420.780.550.550;E02.642
29395899,"Aged;Arteriovenous Shunt, Surgical;Graft Occlusion, Vascular;Humans;Middle Aged;Renal Dialysis;Retrospective Studies",M01.060.116.100;E04.035.087;E04.100.814.868.249;C23.550.767.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.870.300;E02.912.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29395798,Mammography,E01.370.350.700.500
29395626,Neoplasms;Cardiotoxicity;Echocardiography,C04;C23.550.161;C25.100.389;C26.733.266;G01.750.748.500.266;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
29395557,,
29395419,"Animals;Anisoles;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests;Dermatitis, Phototoxic",B01.050;D02.355.601.200;D02.355.726.158;D02.455.426.559.389.657.654.158;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940;C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225
29395418,"Animals;Butyrates;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;D02.241.081.114;D10.251.400.143;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29395273,"Adolescent;Adult;Anticonvulsants;Cannabidiol;Child;Child, Preschool;Double-Blind Method;Drug Therapy, Combination;Humans;Lennox Gastaut Syndrome;Middle Aged;Seizures;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;D27.505.954.427.080;D02.455.849.090.100;M01.060.406;M01.060.406.448;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.310;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.490.493.750;C16.320.495;M01.060.116.630;C10.597.742;C23.888.592.742;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
29395214,Pulmonary Valve Insufficiency,C14.280.484.660
29395170,"Adolescent;Asthma;Child;Child, Preschool;Follow-Up Studies;Hospitals, Pediatric;Humans;Patient Discharge;Patient Readmission;Retrospective Studies;United States;Asthma;Inpatients",M01.060.057;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E02.760.400.620;N02.421.585.400.620;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.643.470
29395062,"Animals;Cell Nucleus;Epigenesis, Genetic;Histone Demethylases;Inflammation;Methylation;Mice;Mice, Inbred C57BL;NF-kappa B;Phosphorylation;Protein Kinase C;Protein-Serine-Threonine Kinases;Signal Transduction;Transcription Factor RelA;Tumor Necrosis Factor-alpha;Inflammation;Sepsis",B01.050;A11.284.430.106;A11.284.430.214.190.875.117;G05.308.203;D08.811.682.662.582.475;C23.550.470;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.260.600;D12.776.660.600;D12.776.930.600;G02.111.665;G02.607.780;G03.796;D08.811.913.696.620.682.700.725;D08.811.913.696.620.682.700;G02.111.820;G04.835;D12.776.260.600.249;D12.776.660.600.249;D12.776.930.600.249;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;C23.550.470;C01.539.757;C23.550.470.790.500
29394903,Biological Products;Patient Selection,D20.215;E05.581.500.653;N04.590.731
29394465,Head and Neck Neoplasms;Head and Neck Neoplasms;Radiotherapy;General Surgery,C04.588.443;C04.588.443;E02.815;H02.403.810.300
29394248,"Biomarkers;Cytokines;Humans;Infant;Infant, Newborn;Interleukin-18;Interleukin-23;Meningitis, Bacterial;Prospective Studies;Receptor for Advanced Glycation End Products",D23.101;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;D12.644.276.374.465.759;D12.776.467.374.465.759;D23.529.374.465.550;C01.252.200.500;C10.228.228.180.500;C10.228.614.280;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.543.750.615
29394237,,
29394222,"Child;Child, Preschool;Chlorides;Critical Illness;Humans;Infant;Intensive Care Units, Pediatric;Prognosis;Retrospective Studies;Risk Factors;Shock, Septic;United States;Water-Electrolyte Imbalance",M01.060.406;M01.060.406.448;D01.210.450.150;D01.248.497.158.215;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;Z01.107.567.875;C18.452.950
29394127,"Adult;Age Factors;Humans;Middle Aged;Severity of Illness Index;Urinary Bladder, Overactive;Urinary Incontinence, Stress;Urinary Incontinence, Urge;Women, Working;Young Adult;Urinary Incontinence;Women, Working",M01.060.116;N05.715.350.075;N06.850.490.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780;C12.777.934.852.249;C13.351.968.934.814.500;C23.888.942.343.800.500;C12.777.934.852.500;C13.351.968.934.814.750;C23.888.942.343.800.750;M01.975.825;M01.060.116.815;C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800;M01.975.825
29394097,"Clustered Regularly Interspaced Short Palindromic Repeats;DNA, Bacterial;Drug Resistance, Multiple, Bacterial;Humans;Multilocus Sequence Typing;Pennsylvania;Salmonella enterica;Serogroup;Serotyping;Clustered Regularly Interspaced Short Palindromic Repeats;Drug Resistance, Microbial",G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D13.444.308.212;G06.099.225.812;G06.225.347.812;G07.690.773.984.269.347.812;G07.690.773.984.300.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.875.150.125.457.500;E05.200.875.150.125.457.500;E05.393.542.500;E05.393.760.700.650;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;B03.440.450.425.800.200;B03.660.250.150.710.160;G05.695.825;E01.370.225.812.742;E01.370.225.875.150.125.890;E05.200.812.742;E05.200.875.150.125.890;E05.478.594.780;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G06.225;G07.690.773.984.269
29393768,Multiple Sclerosis;Epidemiology,C10.114.375.500;C10.314.350.500;C20.111.258.250.500;H02.403.720.500
29393529,"Acetic Acid;Child;Cicatrix;Humans;Malus;Medicine, Traditional;Nevus, Pigmented;Skin Neoplasms;Medicine, Traditional;Nevus",D02.241.081.018.165;D10.251.400.045.500;M01.060.406;A10.165.450.300;C23.550.355.274;G16.762.891.249;B01.050.150.900.649.313.988.400.112.400.400;B01.650.940.800.575.912.250.859.937.500.444;E02.190.488;I01.076.201.450.654;C04.557.665.560.615;C04.588.805;C17.800.882;E02.190.488;I01.076.201.450.654;C04.557.665.560
29393340,"Animals;Cell Line, Tumor;Disease Models, Animal;Humans;Imidazoles;Indoles;Mice;Mice, Transgenic;Mutation;N-Myc Proto-Oncogene Protein;Neuroblastoma;Piperazines;Proto-Oncogene Proteins c-mdm2;Pyrrolidines;Radiation, Ionizing;Signal Transduction;Spiro Compounds;Tumor Suppressor Protein p53;para-Aminobenzoates",B01.050;A11.251.210.190;A11.251.860.180;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.308;D03.633.100.473;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.365.590;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D03.383.606;D08.811.464.938.750.562;D12.776.624.664.700.185;D12.776.660.764;D03.383.773;G01.750.750;G02.111.820;G04.835;D02.455.426.779;D04.711;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;D02.241.223.100.050.500;D02.455.426.559.389.127.020.937
29393227,Adolescent;Adult;Anti-Mullerian Hormone;Antineoplastic Combined Chemotherapy Protocols;Case-Control Studies;Headache;Hot Flashes;Humans;Libido;Mood Disorders;Neoplasms;Premenopause;Prevalence;Prospective Studies;Risk Factors;Sleep Wake Disorders;Sweating;Young Adult;Drug Therapy;Menopause;Survivorship,M01.060.057;M01.060.116;D06.472.334.984.500;D09.400.430.625;D12.776.395.089;E02.183.750.500;E02.319.077.500;E02.319.310.037;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.888.592.612.441;C23.888.475;B01.050.150.900.649.313.988.400.112.400.400;F02.739.794.511;F03.600;C04;G08.686.157.500.812;G08.686.841.249.500.812;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.886;C23.888.592.796;F03.870;G07.110.232.693;G07.410.421.693;G13.750.860;G16.012.500.535.693;M01.060.116.815;E02.319;G08.686.157.500;G08.686.841.249.500;F01.058.144.500
29392729,,
29392620,"Administration, Intravenous;Administration, Oral;Autoimmune Diseases;Dermatologic Agents;Humans;Immunosorbent Techniques;Incidence;Infertility, Male;Lactation;Paternal Exposure;Plasmapheresis;Pregnancy;Pregnancy Complications;Prenatal Injuries;Risk Assessment;Skin Diseases, Vesiculobullous",E02.319.267.082;E02.319.267.100;C20.111;D27.505.954.444;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566.380;E05.601.470.380;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C12.294.365.700;G08.686.523;G08.686.702.500;N06.850.460.350.700;E02.120.770;E02.912.715;G08.686.784.769;C13.703;C13.703.824;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C17.800.865
29392516,"Adolescent;Adult;Child;Child, Preschool;Cryopreservation;Decision Making;Humans;Infertility, Female;Middle Aged;Neoplasms;Ovary;Ovulation Induction;Parents;Tissue Preservation;Fertility Preservation",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E01.370.225.500.620.760.160;E01.370.225.750.600.760.160;E02.792.156;E05.200.500.620.760.160;E05.200.750.600.760.160;E05.760.156;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;C13.351.500.365.700;M01.060.116.630;C04;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;E02.875.800.984;E05.820.800.984;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E01.370.225.500.620.760;E01.370.225.750.600.760;E02.792.833;E05.200.500.620.760;E05.200.750.600.760;E05.760.833;E02.875.800.625;E04.936.537.562;E05.820.800.625
29392432,Ethiopia;Federal Government,Z01.058.290.120.310;I01.409.137;I01.409.418.625;N03.540.348.500;N03.540.400.750
29392304,Adult;Amyotrophic Lateral Sclerosis;Cause of Death;Follow-Up Studies;Football;Humans;Middle Aged;Mortality;Proportional Hazards Models;Retrospective Studies;United States;Young Adult,M01.060.116;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;I03.450.642.845.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;M01.060.116.815
29392078,Glucagon-Like Peptide 1;Glucose,D06.472.317.680.500.500;D09.947.875.359.448
29391602,"Animals;Carcinogenesis;Cell Proliferation;HEK293 Cells;Humans;Mice;Mice, Inbred BALB C;Mice, Nude;NIH 3T3 Cells;Oncogene Proteins, Fusion;STAT1 Transcription Factor;Signal Transduction",B01.050;C04.697.098;C23.550.727.098;G04.161.750;G07.345.249.410.750;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.150.900.649.313.992.635.505.500.550.500;A11.251.210.100.550;A11.329.228.100.550;D12.776.602.500.500;D12.776.624.664.500;D12.644.360.024.303.500.500;D12.644.360.024.342.100;D12.776.157.057.061.500.500;D12.776.157.057.186.100;D12.776.260.513.249.500;D12.776.476.024.386.500.500;D12.776.476.024.430.100;D12.776.930.354.249.500;D12.776.930.840.100;G02.111.820;G04.835
29391398,"Adult;Amygdala;High-Throughput Nucleotide Sequencing;Humans;MicroRNAs;Prefrontal Cortex;RNA, Long Noncoding;Schizophrenia;Sequence Analysis, RNA",M01.060.116;A08.186.211.180.090;A08.186.211.200.885.287.249.152;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A08.186.211.200.885.287.500.270.700;D13.444.735.790.375;F03.700.750;E05.393.760.710
29391017,"Consensus;Hematopoietic Stem Cell Transplantation;Humans;Infant;Infant, Newborn;Leukodystrophy, Globoid Cell;Neonatal Screening;United States;Galactosylceramidase;Leukodystrophy, Globoid Cell;Neonatal Screening;Psychosine",F01.829.316.068;F02.463.785.373.433;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C10.228.140.163.100.362.500;C10.228.140.163.100.435.825.590;C10.228.140.695.625.500;C10.314.400.500;C16.320.565.189.362.500;C16.320.565.189.435.825.590;C16.320.565.398.641.803.585;C16.320.565.595.554.825.590;C18.452.132.100.362.500;C18.452.132.100.435.825.590;C18.452.584.687.803.585;C18.452.648.189.362.500;C18.452.648.189.435.825.590;C18.452.648.398.641.803.585;C18.452.648.595.554.825.590;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;Z01.107.567.875;D08.811.277.450.410.120;C10.228.140.163.100.362.500;C10.228.140.163.100.435.825.590;C10.228.140.695.625.500;C10.314.400.500;C16.320.565.189.362.500;C16.320.565.189.435.825.590;C16.320.565.398.641.803.585;C16.320.565.595.554.825.590;C18.452.132.100.362.500;C18.452.132.100.435.825.590;C18.452.584.687.803.585;C18.452.648.189.362.500;C18.452.648.189.435.825.590;C18.452.648.398.641.803.585;C18.452.648.595.554.825.590;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;D02.033.100.700.700;D02.092.063.700.700;D09.400.410.420.806;D10.390.470.806;D10.570.877.360.806
29390862,Hypertension;Motivation;Medicaid;Motivation;Population Health,C14.907.489;F01.658;F01.752.543.500.750;N03.219.521.346.506.564.655;N03.706.615.693;F01.658;F01.752.543.500.750;N01.400.548
29389922,"Computational Biology;Data Accuracy;Exome;Genetic Association Studies;Genetic Predisposition to Disease;Genetic Testing;Genomics;High-Throughput Nucleotide Sequencing;Humans;INDEL Mutation;Polymorphism, Single Nucleotide;Reproducibility of Results;Sensitivity and Specificity;Sequence Analysis, DNA",H01.158.273.180;L01.313.124;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;G05.360.340.011;E05.393.385;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.180.350;H01.158.273.343.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.500;G05.558.370;G05.365.795.598;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.393.760.700
29389786,"Attitude of Health Personnel;Burnout, Professional;Emotions;Empathy;Forgiveness;Humans;Interpersonal Relations;Orthopedic Surgeons;Resilience, Psychological",F01.100.050;N05.300.100;C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;F01.470;F01.752.355;F01.752.543.500.500;F01.470.383;F01.829.401.166;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401;M01.526.485.810.910.875;N02.360.810.910.875;F02.940
29389383,,
29389115,"Binding Sites;Choline Kinase;Crystallography, X-Ray;Drug Design;Humans;Molecular Docking Simulation;Protein Binding;Protein Conformation;Protein Kinase Inhibitors",G02.111.570.120;D08.811.913.696.620.155;E05.196.309.742.225;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595.249;L01.224.160.249;G02.111.679;G03.808;G02.111.570.820.709;D27.505.519.389.755
29388940,"Attitude of Health Personnel;Disclosure;Education, Medical;Genetic Testing;Genomics;Health Knowledge, Attitudes, Practice;Health Personnel;Humans;Incidental Findings;Physicians;Sequence Analysis, DNA;Specialization;Surveys and Questionnaires;Attitude;Genetic Testing;Incidental Findings;Physicians",F01.100.050;N05.300.100;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;I02.358.399;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.180.350;H01.158.273.343.350;F01.100.150.500;N05.300.150.410;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;E01.410;M01.526.485.810;N02.360.810;E05.393.760.700;H02.811;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F01.100;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;E01.410;M01.526.485.810;N02.360.810
29388804,,
29388237,"Animals;Fetal Therapies;Models, Animal;Neurosurgical Procedures;Pregnancy;Sheep;Spinal Dysraphism",B01.050;E02.467;E05.598;E04.525;G08.686.784.769;B01.050.150.900.649.313.500.380.791;C10.500.680.800;C16.131.666.680.800
29387879,,
29387401,Sarcoma;General Surgery,C04.557.450.795;H02.403.810.300
29386514,3T3 Cells;Acrylic Resins;Animals;Cell Differentiation;Cell Shape;Elastic Modulus;Fibroblasts;Gels;Materials Testing;Mice;Paxillin;Viscoelastic Substances,A11.251.210.100;A11.329.228.100;D05.750.716.822.111;D25.720.716.822.111;J01.637.051.720.716.822.111;B01.050;G04.152;G04.320;G01.374.590.605;A11.329.228;D20.280.320;D26.255.165.320;E05.570;B01.050.150.900.649.313.992.635.505.500;D12.644.360.024.316;D12.776.157.057.092;D12.776.476.024.397;D12.776.512.374;D12.776.744.665;D27.720.944
29386276,,
29386112,NF-kappa B;TNF Receptor-Associated Factor 6;Hematopoietic Stem Cells;Toll-Like Receptors,D12.776.260.600;D12.776.660.600;D12.776.930.600;D12.644.360.024.500.968;D12.776.157.057.500.968;D12.776.476.024.500.968;A11.148.378;A11.872.378;A15.378.316.378;D12.776.543.750.705.910.500
29386064,"Animals;Biomedical Research;Cardiovascular Diseases;Congresses as Topic;Diffusion of Innovation;History, 21st Century;Humans;Magnetic Resonance Imaging;Predictive Value of Tests;Time Factors;Archives;Heart;History",B01.050;H01.770.644.145;C14;N03.540.199;L01.143.320;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;G01.910.857;J03.400.208;K01.400.152;L01.346.208;A07.541;K01.400
29386063,Animals;Brain;Humans;Mental Disorders;Synapses,B01.050;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;F03;A08.850;A11.284.149.165.420.780
29385863,"Carcinoma, Ovarian Epithelial;Cohort Studies;Cytoreduction Surgical Procedures;Humans;Middle Aged;Neoplasm Recurrence, Local;Neoplasms, Glandular and Epithelial;Ovarian Neoplasms;Retrospective Studies;Survival Analysis;Treatment Outcome",C04.557.470.200.295;C04.588.322.455.199;C13.351.500.056.630.705.350;C13.351.937.418.685.350;C19.344.410.199;C19.391.630.705.350;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.166;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.697.655;C23.550.727.655;C04.557.470;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29385828,"Accidents, Traffic;Adaptation, Psychological;Anxiety Disorders;Attention;Axons;Brain Concussion;Central Nervous System Stimulants;Cognitive Behavioral Therapy;Cognitive Dysfunction;Corpus Callosum;Depressive Disorder;Exercise Therapy;Fatigue;Headache;Humans;Magnetic Resonance Imaging;Methylphenidate;Neuropsychological Tests;Post-Concussion Syndrome;Stress, Psychological;Time Factors;Brain Concussion",N06.850.135.392;F01.058;F03.080;F02.830.104.214;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;D27.505.696.282;D27.505.954.427.220;F04.754.137.350;F03.615.250.700;A08.186.211.200.885.800.750;F03.600.300;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;C23.888.369;C23.888.592.612.441;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;D02.241.223.601.600;D03.383.621.460;F04.711.513;C10.900.300.350.300.500;C26.915.300.450.500.500;C26.974.382.200.500;F01.145.126.990;F02.830.900;G01.910.857;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200
29385551,"Behavioral Medicine;Chronic Pain;Humans;Pain Management;Practice Guidelines as Topic;Psychotherapy;Societies, Medical",F04.096.080;H02.403.090;C23.888.592.612.274;B01.050.150.900.649.313.988.400.112.400.400;E02.745;N04.590.607.500;N04.761.700.350.650;N05.700.350.650;F04.754;N03.540.828.589
29385370,"Adolescent;Antibodies, Monoclonal, Humanized;Antigens, CD19;Antineoplastic Combined Chemotherapy Protocols;Child;Child, Preschool;Humans;Infusions, Intravenous;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;Remission Induction;Survival Analysis;Young Adult",M01.060.057;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;E02.183.750.500;E02.319.077.500;E02.319.310.037;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.082.500;E02.319.267.510.590;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.705.816.824;E02.860;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;M01.060.116.815
29385178,"Adult;Asian Continental Ancestry Group;Blood Glucose;Cross-Over Studies;Diet, High-Fat;Diet, High-Protein;Dietary Carbohydrates;Dietary Fats;Dietary Proteins;Ghrelin;Glucagon-Like Peptide 1;Humans;Insulin;Insulin Resistance;Obesity;Peptide YY;Postprandial Period;Satiety Response;Singapore;Young Adult",M01.060.116;M01.686.508.200;D09.947.875.359.448.500;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;G07.203.650.240.267;E02.642.249.268;G07.203.650.240.269;D09.301;G07.203.300.362;J02.500.362;D10.212.302;G07.203.300.375;J02.500.375;D12.776.256;G07.203.300.428;J02.500.428;D06.472.699.301;D12.644.548.322;D06.472.317.680.500.500;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;C18.452.394.968.500;G07.690.773.984.617;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D06.472.317.662;D06.472.699.595;D12.644.548.595;G10.261.700;F02.830.749.658;Z01.252.145.774;M01.060.116.815
29385124,"Animals;Animals, Genetically Modified;Axons;Cell Differentiation;Embryo, Nonmammalian;Gene Expression Regulation, Developmental;Genes, Developmental;Nerve Net;Neurogenesis;Olfactory Bulb;Olfactory Marker Protein;Olfactory Mucosa;Olfactory Receptor Neurons;Receptors, Odorant;Sensory Receptor Cells;Transcriptome;Zebrafish",B01.050;B01.050.050.136;B05.620.136;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;G04.152;A13.350;A16.331;G05.308.310;G05.360.340.024.340.230;A08.511;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.186.211.200.885.388;D12.644.360.543;D12.776.476.543;D12.776.631.652;A04.531.520.573;A04.760.600.640;A09.531.623;A10.615.550.760.600.640;A04.531.520.573.580;A04.760.600.640.640;A08.675.650.915.500.540;A08.800.950.500.540;A09.531.623.580;A10.615.550.760.600.640.640;A11.671.650.915.500.540;D12.776.543.750.695.600;A08.675.650.915;A08.800.950;A11.671.650.915;G02.111.873.750;G05.297.700.750;G05.360.920;B01.050.150.900.493.200.244.828
29384925,"Adolescent;Adult;Aged;Aged, 80 and over;Brain Ischemia;Child;Child, Preschool;Databases, Factual;Electronic Health Records;Hospitalization;Humans;Immunoglobulins, Intravenous;Immunologic Factors;Infant;Infant, Newborn;International Classification of Diseases;Middle Aged;Predictive Value of Tests;Stroke;United States;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.140.300.150;C14.907.253.092;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.940.968.625.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;D27.505.696.477;M01.060.703;M01.060.703.520;L01.453.245.945.400;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;C10.228.140.300.775;C14.907.253.855;Z01.107.567.875;M01.060.116.815
29384525,,
29384264,,
29383650,"Autism Spectrum Disorder;Hernias, Diaphragmatic, Congenital;Hypertension, Pulmonary",F03.625.164.113;C16.131.433;C23.300.707.500.116;C08.381.423
29383459,Carbon Monoxide;Mitochondria;Reactive Oxygen Species,D01.200.250;D01.362.200;D01.650.550.250;A11.284.430.214.190.875.564;A11.284.835.626;D01.339.431;D01.650.775
29382722,"Acetylation;Amino Acid Sequence;Chromatin;DNA Replication;HEK293 Cells;Histone Acetyltransferases;Histones;Homeodomain Proteins;Humans;Protein Binding;Protein Processing, Post-Translational;Recombinant Proteins;Sequence Homology;Substrate Specificity;Tumor Suppressor Proteins;Epigenomics",G02.111.012.052;G02.607.063.052;G03.040.052;G02.111.570.060;L01.453.245.667.060;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G02.111.225;G05.226;A11.251.210.172.750;A11.436.334;D08.811.913.050.134.415.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D12.776.260.400;B01.050.150.900.649.313.988.400.112.400.400;G02.111.679;G03.808;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D12.776.828;G02.111.810;G05.810;G02.111.835;D12.776.624.776;H01.158.273.180.350.074;H01.158.273.343.350.042
29382695,,
29382688,,
29382559,"Animals;Benzyl Compounds;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Heptanes;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;D02.455.426.559.389.140;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;D02.455.326.146.485;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29382367,Adolescent;Adult;Aged;Alcohol Abstinence;Alcohol Drinking;Alcoholism;Automation;Continuity of Patient Care;Counseling;Health Services Accessibility;Humans;Interpersonal Relations;Middle Aged;Philadelphia;Prospective Studies;Randomized Controlled Trials as Topic;Recurrence;Smartphone;Telemedicine;Telephone;Time Factors;Treatment Outcome;Young Adult;Alcoholism;Telemedicine;Smartphone,M01.060.057;M01.060.116;M01.060.116.100;F01.145.317.134;F01.145.317.269;C25.775.100.250;F03.900.100.350;J01.897.104;E02.760.169;N02.421.585.169;N04.590.233.727.210;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401;M01.060.116.630;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C23.550.291.937;L01.224.230.260.550.500.500;H02.403.840;L01.178.847.652;N04.590.374.800;L01.178.847.698;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C25.775.100.250;F03.900.100.350;H02.403.840;L01.178.847.652;N04.590.374.800;L01.224.230.260.550.500.500
29382366,Bacteroides;Faecalibacterium;Microbiota,B03.140.094.152;B03.440.425.410.194.152;B03.353.625.766;B03.440.425.410.413;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29381616,Age Factors;Cephalometry;Craniosynostoses;Craniotomy;Humans;Infant;Postoperative Period;Preoperative Period;Reconstructive Surgical Procedures;Retrospective Studies,N05.715.350.075;N06.850.490.250;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E04.525.190;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E04.614.750;N02.421.585.753.750;E04.614.937;N02.421.585.753.937;E04.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29381615,"Acrocephalosyndactylia;Child;Child, Preschool;Craniosynostoses;Humans;Infant;Intracranial Hypertension;Osteogenesis, Distraction;Skull;Syndrome",C05.116.099.370.894.232.015;C05.116.099.370.894.819.100;C05.660.207.240.100;C05.660.585.800.100;C05.660.906.364.100;C05.660.906.819.100;C16.131.621.207.240.100;C16.131.621.585.800.100;C16.131.621.906.364.100;C16.131.621.906.819.100;M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.228.140.631;E04.555.120.690;A02.835.232.781;C23.550.288.500
29381545,Aged;Cicatrix;Facial Neoplasms;Humans;Middle Aged;Mohs Surgery;Observer Variation;Photography;Reproducibility of Results;Severity of Illness Index;Skin Neoplasms,M01.060.116.100;A10.165.450.300;C23.550.355.274;G16.762.891.249;C04.588.443.392;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.494.575;E04.680.275.580;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.350.600;E05.712;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C04.588.805;C17.800.882
29381485,Neoplasms;Drug Therapy;Therapeutics,C04;E02.319;E02
29381435,,
29380068,"Adult;Aged;Child;Electric Impedance;Humans;Oscillometry;Pulmonary Disease, Chronic Obstructive;Respiratory Function Tests;Asthma",M01.060.116;M01.060.116.100;M01.060.406;G01.358.500.249.277.350;B01.050.150.900.649.313.988.400.112.400.400;E05.654;C08.381.495.389;E01.370.386.700;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
29379958,"College Admission Test;Education, Medical, Undergraduate;Emotional Intelligence;Humans;Intelligence;Interpersonal Relations;Interviews as Topic;Physicians;School Admission Criteria",I02.399.272;I02.358.399.450;F01.752.543.500;B01.050.150.900.649.313.988.400.112.400.400;F01.752.543;F01.829.401;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.526.485.810;N02.360.810;I02.399.750
29379818,,
29379322,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;Microscopic Polyangiitis;Quality of Life,C14.907.940.897.249;C20.111.193;C10.228.140.300.275.600;C14.907.253.329.600;C14.907.940.897.249.500;C20.111.193.750;I01.800;K01.752.400.750;N06.850.505.400.425.837
29379029,"Animals;Antibodies, Monoclonal;Antigens;CRISPR-Cas Systems;Cell Line, Tumor;Clustered Regularly Interspaced Short Palindromic Repeats;Cysteine;Humans;Immunoconjugates;Mice;Rats;Reproducibility of Results",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D23.050;G05.308.203.374.394;A11.251.210.190;A11.251.860.180;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.790.651.114.580;D12.776.377.715.548.114.580;D27.888.569.257;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.700;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
29378931,,
29378231,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Octanes;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D02.455.326.146.720;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29378062,,
29377879,,
29377867,,
29377857,"Burnout, Professional;Burnout, Psychological;Humans;Internship and Residency;Physicians;Qualitative Research",C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;F01.145.126.990.367;F02.830.900.333;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.810;N02.360.810;H01.770.644.241.850
29377443,"Animals;Aquaporin 4;Basilar Artery;Diterpenes, Clerodane;Endothelin-1;Nitric Oxide;Nitric Oxide Synthase Type III;Rats;Subarachnoid Hemorrhage;Vasospasm, Intracranial;Vasospasm, Intracranial;Subarachnoid Hemorrhage",B01.050;D12.776.157.530.400.500.040.468;D12.776.543.550.450.730.040.468;D12.776.543.585.400.730.040.577;A07.015.114.106;D02.455.849.291.228;D12.644.276.400.225;D12.776.467.400.225;D23.529.400.225;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D08.811.682.664.500.772.750;B01.050.150.900.649.313.992.635.505.700;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850;C10.228.140.300.900;C14.907.253.951;C10.228.140.300.900;C14.907.253.951;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
29377258,"Adolescent;Adult;Age Distribution;Age of Onset;Analysis of Variance;Blood Glucose;Diabetes Mellitus, Type 2;Glycated Hemoglobin A;Humans;Insurance Coverage;Insurance, Health;Transition to Adult Care;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;N05.715.350.075.100;N06.850.490.250.100;E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;D09.947.875.359.448.500;C18.452.394.750.149;C19.246.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
29376878,"Aged;Aged, 80 and over;Alzheimer Disease;Biomarkers;Cognitive Dysfunction;Cross-Sectional Studies;Disease Progression;Executive Function;Humans;Linear Models;Longitudinal Studies;Memory Disorders;Multivariate Analysis;Neuropsychological Tests;Phosphorylation;alpha-Synuclein;tau Proteins;Alzheimer Disease;Biomarkers;Cerebrospinal Fluid;Cognitive Dysfunction;alpha-Synuclein",M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;F03.615.250.700;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.291.656;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C10.597.606.525;C23.888.592.604.529;F01.700.625;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;F04.711.513;G02.111.665;G02.607.780;G03.796;D12.776.631.860.500;D12.776.637.500;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A12.207.270.210;F03.615.250.700;D12.776.631.860.500;D12.776.637.500
29376397,Autism Spectrum Disorder;Endophenotypes,F03.625.164.113;G05.695.224
29376095,,
29375540,Autoimmunity;Common Variable Immunodeficiency,G12.450.192;C20.673.330
29375169,,
29374585,Thalassemia;Unrelated Donors,C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826;M01.898.828
29374252,,
29374082,,
29373982,,
29373847,Attention;Motivation,F02.830.104.214;F01.658;F01.752.543.500.750
29373802,"Acute Lung Injury;Respiratory Distress Syndrome, Adult;Pediatrics;Positive-Pressure Respiration",C08.381.520.500;C08.381.840;C08.618.840;H02.403.670;E02.041.625.790;E02.880.820.790
29373797,"Respiratory Distress Syndrome, Adult;Extracorporeal Membrane Oxygenation;Extracorporeal Membrane Oxygenation",C08.381.840;C08.618.840;E02.880.301;E04.292.451;E02.880.301;E04.292.451
29373385,Cardiopulmonary Resuscitation;Clinical Competence;Competitive Behavior;Humans;Internet;Manikins;Reaction Time;Self Report;Simulation Training;User-Computer Interface;Video Games,E02.365.647.110;I02.399.630.210;N04.761.210;N05.715.175;F01.145.813.105;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;E05.796.817;F02.830.650;F04.669.817;G11.561.677;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;I02.903.847;L01.224.900.910;I03.450.642.693.930;L01.224.900.930
29373346,"Aftercare;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Outcome and Process Assessment (Health Care);Patient Discharge;Pilot Projects;Postoperative Period;Quality Indicators, Health Care;Telemedicine",E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;N04.761.559;N05.715.360.575;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E04.614.750;N02.421.585.753.750;N04.761.789;H02.403.840;L01.178.847.652;N04.590.374.800
29373345,"Disease Management;Early Diagnosis;Esophageal Atresia;Humans;Infant, Newborn;Tracheoesophageal Fistula",N04.590.607;E01.390;C06.198.330;C06.405.117.260;C16.131.314.330;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C06.267.250.725;C06.405.117.367.725;C08.702.750;C08.907.863;C23.300.575.185.250.725
29372485,Breast Neoplasms;Lymphedema;Survivorship,C04.588.180;C17.800.090.500;C15.604.496;F01.058.144.500
29371620,Adsorption;Animals;Biological Phenomena;Chemical Phenomena;Dextrans;Drug Delivery Systems;Erythrocytes;Humans;Mice;Nanoparticles;Polystyrenes,G01.030;G02.020;B01.050;G16;G02;D05.750.078.562.272;D09.698.365.272;E02.319.300;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;J01.637.512.600;D02.455.426.559.389.150.750.800.830;D05.750.716.579;D25.720.716.579;J01.637.051.720.716.579
29371390,"Dyspnea;Humans;Pulmonary Disease, Chronic Obstructive",C08.618.326;C23.888.852.371;B01.050.150.900.649.313.988.400.112.400.400;C08.381.495.389
29371200,Myocardial Infarction,C14.280.647.500;C14.907.585.500
29370970,,
29370896,,
29370893,,
29370819,"Administration, Inhalation;Aged;Androstadienes;Benzyl Alcohols;Bronchodilator Agents;Chlorobenzenes;Double-Blind Method;Humans;Middle Aged;Nebulizers and Vaporizers;Pulmonary Disease, Chronic Obstructive;Quinuclidines;Pulmonary Disease, Chronic Obstructive;Randomized Controlled Trial",E02.319.267.050;M01.060.116.100;D04.210.500.054.079.129;D02.033.160;D02.455.426.559.389.140.200;D27.505.696.663.050.110;D27.505.954.796.050.100;D02.455.426.559.389.261;D02.455.526.439.202;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E07.605;C08.381.495.389;D03.605.687;C08.381.495.389;V03.175.250.500.500
29370379,"Animals;Humans;Immunotherapy;Neoplasms;Polysaccharides;Receptors, Antigen, T-Cell",B01.050;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04;D09.698;D12.776.543.750.705.816.824
29370075,Multifactorial Inheritance,G05.420.590
29370071,Anti-Bacterial Agents;Antimicrobial Stewardship;Quality Improvement,D27.505.954.122.085;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;J01.293.754;N04.761.744
29369091,,
29368955,,
29368331,"Id;Arrhythmias, Cardiac",F01.752.747.347;F02.739.794.371;C14.280.067;C23.550.073
29368207,Depression,F01.145.126.350
29367646,"Animals;Antibodies;Antigens, CD;Cadherins;Cells, Cultured;Cytokines;Endothelial Cells;Humans;Mice, Inbred C57BL;Permeability;Platelet Endothelial Cell Adhesion Molecule-1;Protein Binding",B01.050;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;D23.050.301.264.035;D23.101.100.110;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;A11.251;D12.644.276.374;D12.776.467.374;D23.529.374;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.723;D12.776.395.550.200.131;D12.776.543.550.200.131;D23.050.301.264.900.131;D23.050.301.350.131;D23.101.100.900.131;G02.111.679;G03.808
29367627,Algorithms;Animals;Brain;Cognition;Connectome;Diffusion Tensor Imaging;Drosophila;Gene Expression;Humans;Macaca;Mice;Nerve Net;Neural Pathways;Rats;White Matter,G17.035;L01.224.050;B01.050;A08.186.211;F02.463.188;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.500.131.617.720.500.500.750.310.250;G05.297;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.988.400.112.199.120.510;B01.050.150.900.649.313.992.635.505.500;A08.511;A08.612;B01.050.150.900.649.313.992.635.505.700;A08.186.211.204;A08.186.854.880
29367602,"Animals;Brain;Calcium;Electroencephalography;Electromyography;GABAergic Neurons;Mice;Neural Pathways;Periaqueductal Gray;Polysomnography;Pons;Sleep;Sleep, REM;Ultradian Rhythm",B01.050;A08.186.211;D01.268.552.100;D01.552.539.288;D23.119.100;E01.370.376.300;E01.370.405.245;E01.370.405.255;E01.370.530.255;A08.675.289;A11.671.285;B01.050.150.900.649.313.992.635.505.500;A08.612;A08.186.211.132.659.413.875.595;E01.370.520.625;A08.186.211.132.810.428.600;F02.830.855;G11.561.803;F02.830.855.796.671;G11.561.803.754.671;G07.180.562.797
29367601,Bacterial Toxins;Cell Membrane;Hydrogen-Ion Concentration;Lactobacillus;Pore Forming Cytotoxic Proteins;Protein Binding,D23.946.123;A11.284.149;G02.300;B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475;D12.776.543.695;G02.111.679;G03.808
29367464,Organ Transplantation;Pulmonary Medicine;Respiration;Transplantation;Endothelial Cells,E04.936.450;H02.403.429.675;G09.772.705;E04.936;A11.436.275
29367210,"Animals;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Inflammation;Interferon-gamma;Interleukin-12;Leishmania;Leishmaniasis, Cutaneous;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Skin;Th1 Cells",B01.050;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;C23.550.470;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.276.374.465.512;D12.776.467.374.465.512;D23.529.374.465.512;B01.268.475.868.488;C03.752.300.500.400;C03.858.560.400;C17.800.838.775.560.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A17.815;A11.118.637.555.567.550.500.400.900;A11.118.637.555.567.569.200.400.900;A11.118.637.555.567.569.500.400.900;A15.145.229.637.555.567.550.500.400.500;A15.145.229.637.555.567.569.200.400.500;A15.145.229.637.555.567.569.500.400.500;A15.382.490.555.567.550.500.400.900;A15.382.490.555.567.569.200.400.900;A15.382.490.555.567.569.500.400.900
29367209,"Anaphylatoxins;Aneurysm, Dissecting;Animals;Cells, Cultured;Complement Activation;Complement C3a;Complement C5a;Disease Models, Animal;Humans;Matrix Metalloproteinase 2;Mice;Mice, Inbred C57BL;Mice, Knockout;Myocytes, Smooth Muscle;Receptor, Anaphylatoxin C5a;Receptors, Complement;Signal Transduction",D12.776.124.486.274.024;C14.907.055.050;B01.050;A11.251;G12.274;D12.776.124.486.274.024.250;D12.776.124.486.274.250.250;D12.776.124.486.274.024.270;D12.776.124.486.274.450.250;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.656.300.480.205.352;D08.811.277.656.300.480.252.420;D08.811.277.656.300.480.525.700.150;D08.811.277.656.675.374.205.352;D08.811.277.656.675.374.252.420;D08.811.277.656.675.374.525.700.150;D12.644.276.848.150;D12.776.467.836.150;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.620.520;D12.776.543.750.695.024;D12.776.543.750.705.833.550;D12.776.543.750.705.833;G02.111.820;G04.835
29365320,Bone Marrow Diseases;Hematopoietic Stem Cell Transplantation;Humans;Infant;Mutation;Myelodysplastic Syndromes;Phenotype;Prognosis;Proteins;Syndrome;Thrombocytopenia;Treatment Outcome,C15.378.190;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.365.590;C15.378.190.625;G05.695;E01.789;D12.776;C23.550.288.500;C15.378.140.855;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29365311,"Animals;Anion Exchange Protein 1, Erythrocyte;Drug Delivery Systems;Erythrocytes;Humans;Inflammation;Macaca;Mice;Recombinant Fusion Proteins;Rh-Hr Blood-Group System;Single-Chain Antibodies;Thrombomodulin;Thrombosis",B01.050;D12.776.157.530.450.162.193.500;D12.776.157.530.450.437.249.500;D12.776.157.530.937.625.249.500;D12.776.543.550.190.276.500;D12.776.543.550.779.249.500;D12.776.543.585.450.162.193.500;D12.776.543.585.450.437.249.500;D12.776.543.585.937.750.249.500;E02.319.300;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;B01.050.150.900.649.313.988.400.112.199.120.510;B01.050.150.900.649.313.992.635.505.500;D12.776.828.300;D23.050.301.290.775;D23.050.705.230.775;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;D12.776.395.550.625.800.800;D12.776.543.550.625.800.800;D12.776.543.750.705.675.892.800;D12.776.543.750.750.850.800;C14.907.355.830
29365303,"Blood Transfusion;Emergency Medical Services;Humans;Resuscitation;Shock, Hemorrhagic",E02.095.135;N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;E02.365.647;C23.550.414.980;C23.550.835.650
29365160,"Clinical Competence;Education, Medical, Undergraduate;Educational Measurement;Humans;Licensure, Medical;Pain Management",I02.399.630.210;N04.761.210;N05.715.175;I02.358.399.450;I02.399;B01.050.150.900.649.313.988.400.112.400.400;N03.706.110.510.410;N05.700.200.450.500;E02.745;N04.590.607.500
29365075,,
29365063,,
29364887,"Animals;Animals, Newborn;Apoptosis Regulatory Proteins;Cells, Cultured;DNA-Binding Proteins;Dystonia;Humans;K562 Cells;Mice;Mice, Inbred C57BL;Mice, Knockout;Mutation;Nerve Net;Neuronal Plasticity;Neurons;Nuclear Proteins",B01.050;B01.050.050.282;D12.644.360.075;D12.776.476.075;A11.251;D12.776.260;C10.597.350.300;C23.888.592.350.300;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;A08.511;G11.561.638;A08.675;A11.671;D12.776.660
29364767,Aged;Brain Ischemia;Cerebral Angiography;Combined Modality Therapy;Endovascular Procedures;Fibrinolytic Agents;Humans;Middle Aged;Perfusion Imaging;Single-Blind Method;Stroke;Thrombectomy;Time-to-Treatment,M01.060.116.100;C10.228.140.300.150;C14.907.253.092;E01.370.350.578.937.180;E01.370.350.700.060.180;E01.370.350.700.560.180;E01.370.370.050.180;E01.370.376.537.750.180;E05.629.937.180;E02.186;E04.100.814.529;E04.502.382;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.350.710.600;E01.370.384.730.354;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;C10.228.140.300.775;C14.907.253.855;E04.100.814.842;E02.760.928;N02.421.585.928
29364557,Epidermolysis Bullosa,C16.131.831.493;C16.320.850.275;C17.800.804.493;C17.800.827.275;C17.800.865.410
29364269,"Animals;Astrocytes;Cell Movement;Cells, Cultured;Central Nervous System;Humans;Nerve Regeneration;Tissue Engineering;Tissue Scaffolds",B01.050;A08.637.200;A11.650.200;G04.198;G07.568.500.180;A11.251;A08.186;B01.050.150.900.649.313.988.400.112.400.400;G11.561.585;G16.762.611;E05.481.500.311.500;J01.293.069.249.500;E07.206.627;E07.695.825
29363562,Centers for Disease Control and Prevention (U.S.);Conflict of Interest;Disclosure;Drug Industry;Equipment and Supplies;Gift Giving;Interprofessional Relations;Patient Protection and Affordable Care Act;Physicians;United States,I01.409.418.750.600.650.200;N03.540.348.500.500.600.650.225;K01.752.566.479.095;N05.350.225;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;J01.576.655.750;E07;F01.145.813.208;F01.829.401.205;N03.219.521.576.343.918;N03.706.615.806;M01.526.485.810;N02.360.810;Z01.107.567.875
29363461,"Animals;Bedbugs;Chagas Disease;Guinea Pigs;Insect Vectors;Longevity;Mice;Mice, Inbred BALB C;Probability;Reproduction",B01.050;B01.050.500.131.617.412.420.150.100;C03.752.300.900.200;B01.050.150.900.649.313.992.550;N06.850.310.350.100.500;G07.345.124.519;G07.540;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;G08.686.784
29363220,"Biomarkers;Genome-Wide Association Study;Genomics;Heart Transplantation;Humans;Postoperative Complications;Genes;Genomics;Pathology, Molecular;Proteomics",D23.101;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;C23.550.767;G05.360.340.024.340;H01.158.273.180.350;H01.158.273.343.350;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
29362902,Albumin-Bound Paclitaxel;Pancreatic Neoplasms,D02.455.426.392.368.242.888.777.500;D02.455.849.291.850.777.500;D12.776.034.073;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29362840,"Carcinoma, Hepatocellular;Child;Combined Modality Therapy;Endovascular Procedures;Hepatoblastoma;Humans;Liver Neoplasms;Radiography, Interventional;Child;Hepatoblastoma;Carcinoma, Hepatocellular;Radiology, Interventional",C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;M01.060.406;E02.186;E04.100.814.529;E04.502.382;C04.557.435.380;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;E01.370.350.700.725;E04.502.780;M01.060.406;C04.557.435.380;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;H02.403.740.675
29362683,,
29361987,"Animals;Cell Differentiation;Cell Division;Cell Transformation, Neoplastic;DNA Methylation;DNA-Binding Proteins;Hematopoietic Stem Cells;Leukemia, Myeloid, Acute;MDS1 and EVI1 Complex Locus Protein;Mice;Mice, Inbred C57BL;Mice, Knockout;Proto-Oncogene Proteins;Time-Lapse Imaging;fms-Like Tyrosine Kinase 3",B01.050;G04.152;G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500;C04.697.098.500;C23.550.727.098.500;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;A11.148.378;A11.872.378;A15.378.316.378;C04.557.337.539.275;D12.776.260.534;D12.776.624.664.700.129;D12.776.930.419;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.624.664.700;E01.370.350.600.817;E05.712.657;L01.280.960.399;D08.811.913.696.620.682.725.400.020;D12.776.543.750.630.020;D12.776.624.664.700.114
29361566,"Animals;Cell Differentiation;Core Binding Factor Alpha 2 Subunit;Endothelial Cells;Gene Expression Regulation, Developmental;Gestational Age;Hematopoiesis;Hematopoietic Stem Cells;Mice;Mice, Transgenic;Organ Specificity;Pregnancy;Yolk Sac;Embryonic Structures;Hematopoiesis;Hemangioblasts",B01.050;G04.152;D12.776.930.155.200.200;A11.436.275;G05.308.310;G07.345.500.325.235.968;G08.686.320;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G07.650;G08.686.784.769;A10.615.284.981;A16.254.750.981;A16.331.800;A16;G04.152.825;G09.188.343;A11.436.275.365;A11.872.378.270
29361528,Endocytosis;Gap Junctions,G04.417;A11.284.149.165.420.471
29361522,Fibrosis;Myofibroblasts;Transforming Growth Factor beta1;Transforming Growth Factor beta1;Wound Healing,C23.550.355;A11.329.228.975;A11.620.520.500;D12.644.276.374.687.100;D12.644.276.954.775.100;D12.776.467.374.687.100;D12.776.467.942.775.100;D23.529.374.687.100;D23.529.942.775.100;D12.644.276.374.687.100;D12.644.276.954.775.100;D12.776.467.374.687.100;D12.776.467.942.775.100;D23.529.374.687.100;D23.529.942.775.100;G16.762.891
29361370,"Adolescent;Adult;Aged;Biomarkers;Child;Child, Preschool;Disease Progression;Elasticity Imaging Techniques;Gaucher Disease;Humans;Liver;Middle Aged;Reproducibility of Results;Retrospective Studies;Severity of Illness Index;Young Adult;Gaucher Disease;Liver Diseases",M01.060.057;M01.060.116;M01.060.116.100;D23.101;M01.060.406;M01.060.406.448;C23.550.291.656;E01.370.350.850.270;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;B01.050.150.900.649.313.988.400.112.400.400;A03.620;M01.060.116.630;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;C06.552
29361360,"Colony Count, Microbial;Disinfection;Equipment Contamination;Equipment Reuse;Humans;Surgical Instruments",E01.370.225.875.220;E05.200.875.220;N06.850.780.200.450.850.375;N06.850.540;E05.328;N06.850.585;B01.050.150.900.649.313.988.400.112.400.400;E07.858.700
29361189,"Humans;Polysomnography;Sleep Apnea, Obstructive",B01.050.150.900.649.313.988.400.112.400.400;E01.370.520.625;C08.618.085.852.850;C10.886.425.800.750.850
29361088,"Crohn Disease;RNA, Long Noncoding",C06.405.205.731.500;C06.405.469.432.500;D13.444.735.790.375
29361080,"Alleles;Chromosome Deletion;Chromosome Mapping;Chromosomes, Human, Pair 22;DiGeorge Syndrome;Humans;Meiosis",G05.360.340.024.340.030;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;E05.393.183;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;G04.144.220.220.687;G05.113.220.687
29360948,,
29360660,Adolescent;Follow-Up Studies;Humans;Kyphosis;Lumbar Vertebrae;Paraspinal Muscles;Radiography;Retrospective Studies;Rotation;Scoliosis;Spinal Fusion;Thoracic Vertebrae;Treatment Outcome,M01.060.057;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C05.116.900.800.500;A02.835.232.834.519;A02.633.567.175.750;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.482.703;C05.116.900.800.875;E04.555.100.700;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29360647,,
29360422,"Disease Management;Humans;Respiratory Insufficiency;Sepsis;Hypoxia;Sepsis;Shock, Septic;Work of Breathing",N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C08.618.846;C01.539.757;C23.550.470.790.500;C23.888.852.079;C01.539.757;C23.550.470.790.500;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;E01.370.386.700.975;G09.772.965
29360037,Ablation Techniques;Animals;Biological Clocks;Caenorhabditis elegans;Cholinergic Neurons;Locomotion;Motor Neurons;Optogenetics;Periodicity;Behavior;Locomotion;Neurosciences;Optogenetics,E04.014;B01.050;G07.180.562.094;B01.050.500.500.294.400.875.660.250.250;A08.675.127;A11.671.188;G07.568.500;G11.427.410.568;A08.675.655.500;A11.671.655.500;E05.393.667;G01.910.645;G07.180.562;F01.145;G07.568.500;G11.427.410.568;H01.158.610;E05.393.667
29359830,Electrophysiology;Interneurons;Rabies virus;Synapses,H01.158.344.528;H01.158.782.236;A08.675.358;A11.671.358;B04.820.455.750.500.700;A08.850;A11.284.149.165.420.780
29359353,Fetal Blood,A12.207.152.200;A15.145.300;A16.378.200
29359245,Animals;Cardiovascular Diseases;Drug Delivery Systems;Humans,B01.050;C14;E02.319.300;B01.050.150.900.649.313.988.400.112.400.400
29358465,Body Weight;Diabetes Mellitus;Humans,C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;C18.452.394.750;C19.246;B01.050.150.900.649.313.988.400.112.400.400
29358376,"Actins;Actomyosin;Adenosine Diphosphate;Binding Sites;Catalytic Domain;Cryoelectron Microscopy;Crystallography, X-Ray;Models, Molecular;Molecular Dynamics Simulation;Myosin Type I;Phalloidine;Protein Conformation;Cryoelectron Microscopy;Cytoskeleton",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D12.776.210.500.154;D03.633.100.759.646.138.124;D13.695.667.138.124;D13.695.827.068.124;G02.111.570.120;G02.111.570.120.704;G02.111.570.820.709.275.750.188;E01.370.350.515.402.150;E05.595.402.150;E05.196.309.742.225;E05.599.595;E05.599.595.500;G02.111.570.895;L01.224.160.500;D05.750.078.730.475.470;D08.811.277.040.025.193.750.500;D12.776.210.500.600.465;D12.776.220.525.475.470;D04.345.566.735;D12.644.456.735;D12.644.641.735;D23.946.587.755;G02.111.570.820.709;E01.370.350.515.402.150;E05.595.402.150;A11.284.430.214.190.750
29358031,"Adult;Aged;Aged, 80 and over;Brain Neoplasms;Cohort Studies;Cranial Irradiation;Disease-Free Survival;Humans;Kaplan-Meier Estimate;Lung Neoplasms;Middle Aged;Propensity Score;Small Cell Lung Carcinoma;Radiation;Small Cell Lung Carcinoma",M01.060.116;M01.060.116.100;M01.060.116.100.080;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.815.190;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;C04.588.894.797.520.109.220.624;C08.381.540.140.750;C08.785.520.100.220.750;G01.750;C04.588.894.797.520.109.220.624;C08.381.540.140.750;C08.785.520.100.220.750
29357955,Adolescent;Age Distribution;Child;Humans;Morbidity;Outpatients;Pennsylvania;Postural Orthostatic Tachycardia Syndrome;Retrospective Studies;Sex Distribution;Primary Dysautonomias;Joint Instability,M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;M01.643.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C10.177.575.600.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.240.800;N01.224.803;N06.850.505.400.850;C10.177.575;C05.550.521
29357516,Cognition;Weightlessness;Space Flight,F02.463.188;G01.060.350.369.400.900;J01.937.285.850
29357489,,
29357459,"Adaptation, Ocular;Retina;Retinal Ganglion Cells",G14.020;A09.371.729;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875
29356850,"Adult;Child;Humans;Infant;Shock, Septic",M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712
29356811,,
29356645,Breast Density;Breast Neoplasms;Cancer Care Facilities;Humans;Mammography;Observer Variation,E01.370.600.115.275;G07.100.138;C04.588.180;C17.800.090.500;N02.278.421.556.070;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.500;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250
29355366,"Adaptation, Psychological;Adolescent;Bullying;Crime Victims;Humans;Internal-External Control;Interpersonal Relations;Pediatric Obesity;Peer Group;Risk;Schools;Students",F01.058;M01.060.057;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;M01.135;B01.050.150.900.649.313.988.400.112.400.400;F01.829.379;F01.829.401;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;F01.829.316.483;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;I02.783;J03.832;M01.848
29355359,"Depression;Humans;Infant;Infant, Newborn;Maternal Behavior;Mother-Child Relations;Object Attachment;Parenting;Young Adult",F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F01.829.263.370.215;F01.829.263.370.290.170;F02.739.794.624;F01.829.263.370.310;M01.060.116.815
29355066,Drosophila;Circadian Clocks;Ultradian Rhythm,B01.050.500.131.617.720.500.500.750.310.250;G07.180.562.094.500;G07.180.562.797
29354684,,
29353257,"Ethics, Medical;Humans;Infant, Newborn;Infant, Premature;Intensive Care Units, Neonatal;Quality Assurance, Health Care;Resuscitation;Video Recording;Ethics;Neonatology;Resuscitation",K01.752.566.479.171.132.750;N05.350.340.162.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;N02.278.388.493.390.380;N04.761.700;N05.700;E02.365.647;L01.280.960;K01.752.566.479;N05.350;H02.403.670.400;E02.365.647
29353244,,
29352697,"Catheter-Related Infections;Catheterization, Central Venous;Catheters, Indwelling;Device Removal;Humans;Infant;Radiography, Interventional;Retrospective Studies;Treatment Outcome",C01.539.195;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;E07.132.500;E04.199;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.700.725;E04.502.780;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29352664,"Adrenal Cortex Hormones;Asthma;Child, Preschool;Humans;Infant;Length of Stay;Respiratory Sounds",D06.472.040;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.760.400.480;N02.421.585.400.480;C23.888.852.779;E01.370.386.720;G09.772.775
29352657,"Brain;Electroencephalography;Humans;Infant, Newborn;Prognosis;Seizures;Status Epilepticus;Electroencephalography;Infant, Newborn;Seizures;Status Epilepticus",A08.186.211;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.789;C10.597.742;C23.888.592.742;C10.597.742.785;C23.888.592.742.785;E01.370.376.300;E01.370.405.245;M01.060.703.520;C10.597.742;C23.888.592.742;C10.597.742.785;C23.888.592.742.785
29352073,"Heart Ventricles;Hypertension, Pulmonary;Myofibrils;Protein Kinases;Scleroderma, Systemic",A07.541.560;C08.381.423;A10.690.552.875;A11.284.430.214.190.750.620;A11.620.249.850;A11.620.500.500;D08.811.913.696.620.682;C17.300.799;C17.800.784
29351824,,
29351821,,
29351489,"Adaptation, Physiological;Animals;Animals, Newborn;Cell Differentiation;Cells, Cultured;Diet, High-Fat;Gene Expression Regulation, Developmental;Glucose;Hepatocyte Nuclear Factor 6;Homeodomain Proteins;Insulin-Secreting Cells;Islets of Langerhans;Mice;Mice, Transgenic;Multipotent Stem Cells;Organogenesis;Trans-Activators",G07.025;G16.012.500;B01.050;B01.050.050.282;G04.152;A11.251;G07.203.650.240.267;G05.308.310;D09.947.875.359.448;D12.776.260.262.984;D12.776.260.400.624.500;D12.776.660.352.984;D12.776.930.318.984;D12.776.930.640.500;D12.776.260.400;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;A03.734.414;A06.300.414;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.872.590;G07.345.500.325.377;G08.686.784.170.450;D12.776.260.755;D12.776.930.900;D12.776.964.925.984
29351487,Insulin Secretion;Olanzapine;Parasympathetic Nervous System,G03.442;G07.475;D03.633.100.079.080.738;A08.800.050.600
29351184,"Child;Child, Preschool;Cleft Palate;Cohort Studies;Hospital Charges;Hospitals, High-Volume;Hospitals, Low-Volume;Humans;Infant;Infant, Newborn;Length of Stay;Multivariate Analysis;Orthognathic Surgical Procedures;Postoperative Complications;Retrospective Studies;Treatment Outcome",M01.060.406;M01.060.406.448;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N03.219.262.300;N03.219.442.613;N02.278.421.414;N02.278.421.434;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E04.545.562;E04.555.580.289;E06.645.562;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29351036,Cementoma,C04.557.695.210
29350456,Brain Neoplasms;Quality of Life,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;I01.800;K01.752.400.750;N06.850.505.400.425.837
29349805,"Adolescent;Adult;Algorithms;Blood Flow Velocity;Child;Computer Simulation;Equipment Design;Heart Failure;Heart, Artificial;Humans;Infant;Models, Cardiovascular",M01.060.057;M01.060.116;G17.035;L01.224.050;E01.370.370.130;G09.330.380.630.080;M01.060.406;L01.224.160;E05.320;C14.280.434;E07.695.300;E07.858.082.374;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.599.395.161
29349113,Autoimmune Diseases;Desmoglein 1;Desmoglein 3;Pemphigus,C20.111;D12.776.395.550.200.200.500.500.500;D12.776.543.550.200.200.500.500.500;D23.050.301.350.200.500.500.500;D23.050.422.124;D12.776.395.550.200.200.500.500.750;D12.776.543.550.200.200.500.500.750;D23.050.301.350.200.500.500.750;D23.050.422.249;C17.800.865.716;C20.111.736
29348813,,
29348587,"Adult;Alcohol Drinking;Asian Continental Ancestry Group;Bacteroides;China;Diet;Ethnic Groups;Feces;Firmicutes;Gastrointestinal Microbiome;Humans;Middle Aged;Minority Groups;Prevotella;Principal Component Analysis;RNA, Ribosomal, 16S;Reproductive Isolation;Rural Population",M01.060.116;F01.145.317.269;M01.686.508.200;B03.140.094.152;B03.440.425.410.194.152;Z01.252.474.164;G07.203.650.240;M01.686.754;N01.224.317;A12.459;B03.353;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;I01.880.853.300;B03.140.094.640;B03.440.425.410.194.640;E05.318.740.562;D13.444.735.686.670;G05.045.675;G16.075.802;N01.600.725
29348560,,
29348408,"Biomarkers;Cell Differentiation;Computational Biology;De Lange Syndrome;Gene Expression Profiling;Gene Expression Regulation;Genetic Predisposition to Disease;Genotype;Haploinsufficiency;Heart Defects, Congenital;Humans;Induced Pluripotent Stem Cells;Myoblasts, Cardiac;Myocytes, Cardiac;Pluripotent Stem Cells;Proteins;Transcriptome",D23.101;G04.152;H01.158.273.180;L01.313.124;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;E05.393.332;G05.308;C23.550.291.687.500;G05.380.355;G05.380;G05.365.590.029.530.587;G05.380.350.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A07.541.704.500;A10.690.552.750.500;A11.872.620.470;A07.541.704.570;A10.690.552.750.570;A11.620.500;A11.872.700;D12.776;G02.111.873.750;G05.297.700.750;G05.360.920
29348334,,
29348325,,
29348229,France;Humans;Vaccines,Z01.542.286;B01.050.150.900.649.313.988.400.112.400.400;D20.215.894
29348127,,
29348040,Adult;Affect;Amygdala;Anxiety;Attention;Autism Spectrum Disorder;Brain Mapping;Facial Recognition;Humans;Magnetic Resonance Imaging;Social Behavior;Young Adult;Amygdala;Anxiety Disorders;Autism Spectrum Disorder,M01.060.116;F01.470.047;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F01.470.132;F02.830.104.214;F03.625.164.113;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F02.463.593.524.500.500;F02.463.593.932.622.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F01.145.813;M01.060.116.815;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F03.080;F03.625.164.113
29348039,Adolescent;Adult;Child;Cognition;Emotions;Facial Expression;Facial Recognition;Humans;Memory;Neurodevelopmental Disorders;Neuropsychological Tests;Problem Solving;Recognition (Psychology);Social Behavior;Young Adult;Psychopathology;Psychotic Disorders,M01.060.057;M01.060.116;M01.060.406;F02.463.188;F01.470;E01.370.600.225;F01.145.209.530.385;F02.463.593.524.500.500;F02.463.593.932.622.500;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425.540;F03.625;F04.711.513;F02.463.425.725;F02.463.785.810;F02.463.425.540.706;F01.145.813;M01.060.116.815;F04.096.670;F03.700.675
29346752,Diagnosis-Related Groups,N03.219.521.710.305.200.080
29346537,,
29346438,"Animals;Biomechanical Phenomena;Cervix Uteri;Cytokines;Enzyme-Linked Immunosorbent Assay;Gardnerella vaginalis;Inflammation;Mice;Pregnancy;Real-Time Polymerase Chain Reaction;Vagina;Vaginosis, Bacterial",B01.050;G01.154.090;G01.374.089;A05.360.319.679.256;D12.644.276.374;D12.776.467.374;D23.529.374;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B03.510.024.400.800;C23.550.470;B01.050.150.900.649.313.992.635.505.500;G08.686.784.769;E05.393.620.500.706;A05.360.319.779;C01.252.954;C13.351.500.894.906.800
29346370,"Bone and Bones;Databases, Factual;Gene Regulatory Networks;Humans;Knowledge;Models, Anatomic;Muscles;Musculoskeletal Physiological Phenomena;Nerve Net",A02.835.232;A10.165.265;L01.313.500.750.300.188.400;L01.470.750.750;G05.360.080.689.360;B01.050.150.900.649.313.988.400.112.400.400;K01.468;J01.897.280.500.545.129;L01.178.820.090.545.129;A02.633;A10.690;G11.427;A08.511
29346201,"Anesthesia, Dental;Anesthesiology;Humans;United States Department of Veterans Affairs;Veterans Health",E03.155.141;E06.045;H02.403.066;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.700;N03.540.348.500.500.700;N01.400.850
29345372,"Inflammation;Macrophages;Monocytes;Receptors, Neurokinin-1;Neurokinin-1 Receptor Antagonists;Substance P;Tachykinins",C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D12.776.543.750.695.862.500;D12.776.543.750.720.600.830.500;D12.776.543.750.750.555.830.500;D27.505.519.625.487;D27.505.696.577.487;D12.644.276.812.900.866;D12.644.400.800.750;D12.644.456.800.866;D12.776.467.812.900.866;D12.776.631.650.800.750;D23.469.050.375.850.890;D23.529.812.900.866;D12.644.276.812.900;D12.644.400.800;D12.644.456.800;D12.776.467.812.900;D12.776.631.650.800;D23.469.050.375.850;D23.529.812.900
29344549,Cadherins;Stomach Neoplasms;beta Catenin,D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
29343940,Leber Congenital Amaurosis;Cone-Rod Dystrophies;Retinal Degeneration;Retinitis Pigmentosa;Whole Exome Sequencing,C11.270.516;C11.768.364;C11.270.152;C11.768.585.658.250;C16.320.290.152;C11.270.612;C11.768.585;C11.270.684;C11.768.585.658.500;C16.320.290.684;E05.393.760.700.825.500
29343837,,
29343557,,
29343540,"Child;Child, Preschool;Diagnostic Equipment;Encephalitis;Humans;Meningitis;Molecular Diagnostic Techniques;Multiplex Polymerase Chain Reaction;Neisseria meningitidis;Simplexvirus;Streptococcus pneumoniae;Syndrome;United States;United States Food and Drug Administration;Neisseria meningitidis;Streptococcus pneumoniae;Encephalitis;Enterovirus;Simplexvirus",M01.060.406;M01.060.406.448;E07.230;C10.228.140.430;B01.050.150.900.649.313.988.400.112.400.400;C10.228.614;E01.370.225.880;E05.200.880;E05.393.520;E05.393.620.500.487;B03.440.400.425.550.550.641;B03.660.075.525.520.500;B04.280.382.100.750;B03.353.750.737.872.550;B03.510.400.800.872.550;B03.510.550.737.872.550;C23.550.288.500;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760;B03.440.400.425.550.550.641;B03.660.075.525.520.500;B03.353.750.737.872.550;B03.510.400.800.872.550;B03.510.550.737.872.550;C10.228.140.430;B04.820.565.284;B04.280.382.100.750
29343519,Thrombosis;Thromboplastin,C14.907.355.830;D12.776.124.125.900;D23.119.965
29342387,"Alert Fatigue, Health Personnel;Delivery of Health Care;Economics, Behavioral;Electronic Health Records;Humans;Quality of Health Care;Reminder Systems",C23.888.369.500.250;F01.100.050.500;F01.145.126.937.250;N04.761.700.075;N05.300.100.169;N05.700.075;N04.590.374;N05.300;F04.096.628.286;N03.219.215;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;N04.761;N05.715;L01.143.820;L01.313.500.750.300.790
29342233,,
29342066,,
29341497,Anxiety;Cognition;Motivation;Therapeutics,F01.470.132;F02.463.188;F01.658;F01.752.543.500.750;E02
29341423,Immunoglobulin G;T-Lymphocytes,D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29341354,Charcot-Marie-Tooth Disease,C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200
29340937,,
29340873,"Clinical Decision-Making;Fontan Procedure;Heart Defects, Congenital;Hemodynamics;Humans;Models, Cardiovascular;Patient Selection;Patient-Centered Care;Patient-Specific Modeling;Surgery, Computer-Assisted;Time-to-Treatment;Ventricular Function",E01.055;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.161;E05.581.500.653;N04.590.731;N04.590.233.727.407;E05.599.395.821;L01.224.160.750;E02.950.875;E04.749;L01.313.500.750.100.710.800;E02.760.928;N02.421.585.928;G09.330.955
29340807,"Adult;Dose-Response Relationship, Drug;Drug Administration Schedule;Drug Monitoring;Drug Tolerance;Gastrointestinal Agents;Humans;Inflammatory Bowel Diseases;Infliximab;Middle Aged;Remission Induction;Retrospective Studies;Tumor Necrosis Factor-alpha;Young Adult;Crohn Disease;Drug Monitoring;Colitis, Ulcerative",M01.060.116;G07.690.773.875;G07.690.936.500;E02.319.283;E01.370.520.200;G07.690.773.992;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;M01.060.116.630;E02.860;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;M01.060.116.815;C06.405.205.731.500;C06.405.469.432.500;E01.370.520.200;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
29340286,,
29340148,"Anti-Bacterial Agents;Emergency Service, Hospital;Inappropriate Prescribing;Intensive Care Units;Nursing;Urinalysis",D27.505.954.122.085;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.319.490;N02.421.450.500.249;N02.278.388.493;H02.478;N04.452.758.377;E01.370.225.124.810;E01.370.390.810;E05.200.124.810
29339723,"Adolescent;Area Under Curve;Attention Deficit Disorder with Hyperactivity;Child;Dose-Response Relationship, Drug;Double-Blind Method;Excitatory Amino Acid Agents;Half-Life;Humans;Mutation;Receptors, Metabotropic Glutamate;Single-Blind Method",M01.060.057;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;F03.625.094.150;M01.060.406;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D27.505.519.625.190;D27.505.696.577.190;G01.910.405;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.543.750.695.450;D12.776.543.750.720.200.450.500;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850
29339533,"Adolescent;Alternative Splicing;Animals;Autistic Disorder;Case-Control Studies;Child;Child, Preschool;Chromatin Assembly and Disassembly;Cohort Studies;Epigenesis, Genetic;Gene Expression Regulation;Hippocampus;Humans;Learning;Mice;Mice, Inbred C57BL;Nerve Tissue Proteins;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;RNA, Untranslated;Regulatory Sequences, Nucleic Acid",M01.060.057;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;F03.625.164.113.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;G04.400.095;G05.213.095;G05.308.095;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.308.203;G05.308;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.631;G05.365.795.598;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D13.444.735.790;G02.111.570.080.689;G05.360.080.689
29339441,,
29339376,,
29339073,"Adult;Animals;Brain;HEK293 Cells;Humans;Immunoprecipitation;Intermediate Filament Proteins;Mice;Nerve Tissue Proteins;Protein Binding;Protein Interaction Maps;Protein Subunits;RNA Polymerase II;Rats, Wistar;Receptors, N-Methyl-D-Aspartate;Two-Hybrid System Techniques",M01.060.116;B01.050;A08.186.211;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E05.196.150.639;E05.478.605;D05.750.078.593;D12.776.220.475;B01.050.150.900.649.313.992.635.505.500;D12.776.631;G02.111.679;G03.808;G03.493.750;D12.776.813;D08.811.913.696.445.735.270.762;B01.050.150.900.649.313.992.635.505.700.900;D12.776.157.530.400.400.500.500;D12.776.543.550.450.500.200.500;D12.776.543.585.400.500.200.500;D12.776.543.750.720.200.450.400.500;E05.393.220.870;E05.601.690.650;E05.601.870
29338954,,
29338875,"Computational Biology;MicroRNAs;RNA;Sequence Analysis, RNA;Transcriptome",H01.158.273.180;L01.313.124;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D13.444.735;E05.393.760.710;G02.111.873.750;G05.297.700.750;G05.360.920
29338874,"Hypertension, Pulmonary",C08.381.423
29338620,Dentate Gyrus;Perforant Pathway,A08.186.211.180.405.200;A08.186.211.200.885.287.500.345.200;A08.186.211.180.730;A08.612.600
29338081,"Menopause, Premature;Survivorship",C13.351.500.056.630.250;G08.686.157.500.500;G08.686.841.249.500.500;F01.058.144.500
29337845,"Confounding Factors (Epidemiology);Models, Statistical;Observational Studies as Topic;Research Design",N05.715.350.240;N06.850.490.718;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.372.250.500;N05.715.360.330.250.500;N06.850.520.450.250.500;E05.581.500;H01.770.644.728
29337306,"Cardiology;Extracellular Matrix;Genetic Diseases, Inborn",H02.403.429.163;A11.284.295.310;C16.320
29337076,Actin Cytoskeleton;Kinesin;Microtubules;Myosins,A11.284.430.214.190.750.050;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A11.284.430.214.190.750.602;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475
29336962,"Coronary Artery Bypass;Diastole;Echocardiography;Humans;Transcatheter Aortic Valve Replacement;Ventricular Dysfunction, Left",E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;G09.330.580.295;G11.427.494.554.250;G11.427.494.570.295;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;C14.280.945.900
29336833,Extracorporeal Membrane Oxygenation,E02.880.301;E04.292.451
29336832,Hemostasis;Heparin;Heparin,G09.188.390;D09.698.373.400;D09.698.373.400
29336795,"Gestational Age;Heart Rate;Humans;Infant, Newborn;Infant, Premature;Oxygen Consumption;Physical Exertion;Positive-Pressure Respiration;Respiratory Function Tests;Retrospective Studies;Tidal Volume;Parturition;Infant, Premature;Resuscitation",G07.345.500.325.235.968;G08.686.320;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;G03.680;G11.427.683;E02.041.625.790;E02.880.820.790;E01.370.386.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700;G08.686.784.769.490;M01.060.703.520.520;E02.365.647
29336491,,
29336307,"Animals;Antineoplastic Agents;Disease Models, Animal;Humans;Melanoma;Mice;Pigments, Biological;Receptors, Estrogen;Receptors, G-Protein-Coupled;Signal Transduction;Survival Analysis;Treatment Outcome;Tumor Cells, Cultured;Humans;Melanoma;Mice",B01.050;D27.505.954.248;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;D23.767;D12.776.826.750.350;D12.776.930.778.350;D12.776.543.750.695;G02.111.820;G04.835;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A11.251.860;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500
29336228,,
29336197,"Vision, Ocular",F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
29336064,"Clinical Competence;Curriculum;Education, Medical, Graduate;Fellowships and Scholarships;Hemodialysis, Home;Humans;Kidney Failure, Chronic;Nephrology;Quality Improvement;United States",I02.399.630.210;N04.761.210;N05.715.175;I02.158;I02.358.337.350;I02.358.399.350;N03.219.483.838.276;E02.870.300.300;E02.912.800.300;N02.421.143.524.337;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;H02.403.429.580;J01.293.754;N04.761.744;Z01.107.567.875
29335054,"Child, Preschool;Dental Care for Children;Face;Humans;Mediastinum;Neck;Orbit;Subcutaneous Emphysema",M01.060.406.448;E06.170.152;N02.421.240.190.215;A01.456.505;B01.050.150.900.649.313.988.400.112.400.400;A01.923.761.800.500;A01.598;A02.835.232.781.324.690;C23.550.325.500
29334587,,
29334377,,
29334374,,
29333924,Glioblastoma;Magnetic Resonance Imaging;Thromboplastin,C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;E01.370.350.825.500;D12.776.124.125.900;D23.119.965
29333880,Opioid-Related Disorders;Buprenorphine;Methadone;Pharmacogenetics,C25.775.675;F03.900.675;D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;D02.522.675;H01.158.273.343.750;H01.158.703.052;H02.628.479
29333701,,
29333363,Rare Diseases,C23.550.291.906
29332720,"Cultural Diversity;Ethics, Medical;Morals;Volunteers",I01.076.201.450.350;I01.880.853.100.450;K01.752.566.479.171.132.750;N05.350.340.162.500;F01.829.500;K01.752.566;M01.955
29332712,Advertising as Topic;Dermatology;Hospitals;Humans;Personnel Selection;Private Practice;Salaries and Fringe Benefits;Workforce,J01.219.687.274;L01.143.050;H02.403.225;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;N04.452.677.500;N04.452.758.745;N01.824.417.700;N04.452.677.800;N04.452.525
29332448,"Adult;Aged;Aged, 80 and over;Humans;Lung;Lung Neoplasms;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Radiation Pneumonitis;Radiosurgery;Radiotherapy Dosage;Radiotherapy Planning, Computer-Assisted;Radiotherapy, Intensity-Modulated;Radiation Pneumonitis",M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;C04.697.650;C23.550.727.650;E01.789.625;C08.381.483.675;C08.381.520.734;C26.733.762;G01.750.748.500.762;E02.815.530;E04.525.800.650;E05.873.500;E02.815.639;E02.950.825;L01.313.500.750.100.710.600.608;E02.815.635.700.700;L01.313.500.750.100.710.600.550.700;C08.381.483.675;C08.381.520.734;C26.733.762;G01.750.748.500.762
29332247,,
29332179,Autism Spectrum Disorder;Anxiety,F03.625.164.113;F01.470.132
29331727,"Individuality;Memory, Short-Term",F01.752.488;F02.463.425.540.407
29331574,"Brachytherapy;Conscious Sedation;Costs and Cost Analysis;Deep Sedation;Dose Fractionation, Radiation;Hospital Costs;Humans;Magnetic Resonance Imaging;Medicare;Physicians;Radiotherapy Planning, Computer-Assisted;Tomography, X-Ray Computed;United States;Uterine Cervical Neoplasms;Uterine Cervical Neoplasms;Cervix Uteri;Costs and Cost Analysis;Medicare",E02.815.150;E03.250;N03.219.151;E03.295;E02.815.639.200;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.526.485.810;N02.360.810;E02.950.825;L01.313.500.750.100.710.600.608;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;A05.360.319.679.256;N03.219.151;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696
29331346,Emergency Medicine;Pediatrics,H02.403.250;H02.403.670
29331209,"Bioethics;Terminal Care;Infant, Newborn;Palliative Care",K01.752.566.479.045;N05.350.200;E02.760.905;N02.421.585.905;M01.060.703.520;E02.760.666;N02.421.585.666
29331082,"Adult;Brain;Epilepsy, Temporal Lobe;Humans;Mechanistic Target of Rapamycin Complex 1;Mechanistic Target of Rapamycin Complex 2;Middle Aged;Signal Transduction;TOR Serine-Threonine Kinases;Young Adult",M01.060.116;A08.186.211;C10.228.140.490.360.290;C10.228.140.490.493.375;B01.050.150.900.649.313.988.400.112.400.400;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;D05.500.356;D08.811.913.696.620.682.700.931.750;D12.776.476.925.750;M01.060.116.630;G02.111.820;G04.835;D08.811.913.696.620.682.700.931;D12.776.476.925;M01.060.116.815
29331045,Hypersensitivity;Anaphylaxis;Drug Hypersensitivity;Food Hypersensitivity,C20.543;C20.543.480.099;C20.543.206;C25.100.468;C20.543.480.370
29330808,"Animals;Basic Helix-Loop-Helix Transcription Factors;Carcinoma, Pancreatic Ductal;Cell Hypoxia;Humans;Hypoxia-Inducible Factor 1, alpha Subunit;Immunohistochemistry;Mice;Pancreatic Neoplasms;Paraffin Embedding;Hypoxia;Immunohistochemistry",B01.050;D12.776.260.103;D12.776.930.125;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;G03.197.300;G04.270.300;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.103.625.750;D12.776.930.125.625.750;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;B01.050.150.900.649.313.992.635.505.500;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;E01.370.225.500.620.760.440.610;E01.370.225.750.600.760.440.610;E05.200.500.620.760.440.610;E05.200.750.600.760.440.610;C23.888.852.079;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512
29330293,"Caco-2 Cells;Cell Line, Tumor;Cisplatin;Colorectal Neoplasms;DNA-Binding Proteins;Drug Resistance, Neoplasm;Endonucleases;Extracellular Signal-Regulated MAP Kinases;Fluorouracil;HCT116 Cells;Hep G2 Cells;Humans;MicroRNAs;Protein Isoforms;RNA-Binding Proteins;Signal Transduction;ras Proteins",A11.251.210.190.160;A11.251.860.180.160;A11.436.140;A11.251.210.190;A11.251.860.180;D01.210.375;D01.625.125;D01.710.100;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;D12.776.260;G07.690.773.984.395;D08.811.277.352.355;D08.811.913.696.620.682.700.567.249;D12.644.360.450.169;D12.776.476.450.169;D03.383.742.698.875.404;A11.251.210.190.380;A11.251.860.180.380;A11.251.860.180.432;A11.436.348.500;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.800;D12.776.157.725;D12.776.664.962;G02.111.820;G04.835;D08.811.277.040.330.300.400.500;D12.644.360.525.500;D12.776.157.325.515.500;D12.776.476.525.500
29330117,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests;Valerates",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940;D02.241.081.944;D10.251.400.895
29329697,"Age Factors;Aged;Aging;Antineoplastic Agents, Hormonal;Aromatase Inhibitors;Arthralgia;Breast Neoplasms;Cancer Survivors;Chemotherapy, Adjuvant;Depression;Health Knowledge, Attitudes, Practice;Humans;Medication Adherence;Middle Aged;Multivariate Analysis;Neoplasm Staging;Perception;Proportional Hazards Models;Prospective Studies;Risk Factors;Severity of Illness Index;Time Factors;Treatment Outcome;Aging;Aromatase Inhibitors;Breast Neoplasms;Perception",N05.715.350.075;N06.850.490.250;M01.060.116.100;G07.345.124;D27.505.954.248.169;D27.505.519.389.870.300;D27.505.696.399.450.327.149;D27.505.696.399.450.855.300;C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350;C04.588.180;C17.800.090.500;M01.860.350;E02.186.170;E02.319.170;F01.145.126.350;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E01.789.625;F02.463.593;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G07.345.124;D27.505.519.389.870.300;D27.505.696.399.450.327.149;D27.505.696.399.450.855.300;C04.588.180;C17.800.090.500;F02.463.593
29329447,"Congenital Hyperinsulinism;Hepatocyte Nuclear Factor 3-beta;Humans;Hypopituitarism;Infant, Newborn;Mutation",C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;D12.776.260.262.875;D12.776.260.950.249.750;D12.776.660.352.875;D12.776.930.318.875;D12.776.930.977.249.750;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.617.738.300;C19.700.482;M01.060.703.520;G05.365.590
29329430,"Absorptiometry, Photon;Adolescent;Bone Density;Child;Child, Preschool;Crohn Disease;Estradiol;Femur Neck;Gastrointestinal Agents;Hip Joint;Humans;Infliximab;Insulin-Like Growth Factor I;Muscle, Skeletal;Organ Size;Severity of Illness Index;Tomography, X-Ray Computed;Tumor Necrosis Factor-alpha;Young Adult",E01.370.350.700.024;E05.196.712.224.187;M01.060.057;G11.427.100;M01.060.406;M01.060.406.448;C06.405.205.731.500;C06.405.469.432.500;D04.210.500.365.415.248;D06.472.334.851.437.500;A02.835.232.043.650.247.510;D27.505.954.483;A02.835.583.411;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;A02.633.567;A10.690.552.500;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;M01.060.116.815
29329183,"Hepatitis Antibodies;Hepatitis E;Hepatitis E virus;Host-Pathogen Interactions;Humans;Immunocompromised Host;Immunosuppressive Agents;Kidney Transplantation;Opportunistic Infections;Prevalence;Prospective Studies;RNA, Viral;Seroepidemiologic Studies;Treatment Outcome;United States;Viral Load",D12.776.124.486.485.114.254.450;D12.776.124.790.651.114.254.450;D12.776.377.715.548.114.254.450;C02.440.470;C02.782.455;C06.552.380.705.470;B04.450.412;B04.820.340.400;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G12.470;D27.505.696.477.656;E02.870.500;E04.936.450.485;E04.950.774.400;C01.539.597;C02.597;C03.684;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D13.444.735.828;E05.318.372.500.950;N05.715.360.330.500.950;N06.850.520.450.500.950;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;E01.370.225.875.950;E05.200.875.950;G06.920.850
29329164,,
29328874,Built Environment;Crime;Housing;Schools;Violence,N06.230.145.500;I01.198.240;I01.880.735.191;J03.340;N01.224.791.400;N06.230.150.360;N06.850.505.400.800.400;I02.783;J03.832;I01.198.240.856;I01.880.735.900
29328793,,
29327400,"Animals;Appetite Regulation;Behavior, Animal;Blood-Brain Barrier;Drug Stability;Energy Intake;Energy Metabolism;Exenatide;Glucagon-Like Peptide-1 Receptor;Glucose Intolerance;HEK293 Cells;Humans;Hypoglycemic Agents;Insulin-Secreting Cells;Mice, Inbred C57BL;Nausea;Rats, Sprague-Dawley;Recombinant Proteins;Tissue Distribution;Vitamin B 12;Drug Development;Exenatide",B01.050;G07.203.650.170;G07.203.650.390.070.290;G10.261.390.070.290;F01.145.113;A07.035;A08.186.211.035;E05.916.330;G07.203.650.240.340;G03.295;D12.644.187;D20.888.300;D23.946.833.300;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;C18.452.394.952.500;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;C23.888.821.712;B01.050.150.900.649.313.992.635.505.700.750;D12.776.828;G03.787.917;G07.690.725.949;D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777;E05.290;H01.158.703.007.338;H01.181.466.338;D12.644.187;D20.888.300;D23.946.833.300
29326930,Leukemia,C04.557.337
29326827,Ventricular Premature Complexes;Heart Failure,C14.280.067.325.500;C14.280.123.375.500;C23.550.073.325.800;C14.280.434
29326808,"Zollinger-Ellison Syndrome;Gastritis, Atrophic;Chromogranin A;Gastrinoma",C04.730.713.988;C06.301.371.883;C06.405.249.883;C06.405.469.275.800.924;C06.405.469.965;C06.405.748.586.924;C06.405.748.947;C06.405.205.697.394;C06.405.748.398.394;D12.776.631.199.249;C04.557.470.200.025.290.500;C04.588.274.761.500.124;C04.588.322.475.500.124;C06.301.761.500.124;C06.689.667.500.124;C19.344.421.500.124
29326717,Immune Reconstitution;Stem Cell Transplantation,G12.432;E02.095.147.500.500;E04.936.225.687
29326366,"Adolescent;Adult;Case-Control Studies;Cell Lineage;Cell Plasticity;Cell Proliferation;Child;Child, Preschool;Diabetes Mellitus, Type 1;Ghrelin;Glucagon;Glucagon-Secreting Cells;Homeodomain Proteins;Humans;Infant;Infant, Newborn;Islets of Langerhans;Ki-67 Antigen;Pancreatic Polypeptide;SOX9 Transcription Factor;Somatostatin;Transcription Factors;Young Adult",M01.060.057;M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.356.250;G04.161.750;G07.345.249.410.750;M01.060.406;M01.060.406.448;C18.452.394.750.124;C19.246.267;C20.111.327;D06.472.699.301;D12.644.548.322;D06.472.699.587.730.500;D12.644.548.586.730.500;A03.734.414.065;A06.300.414.043;A06.390.087;A11.382.625.064;A11.436.294.064;D12.776.260.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A03.734.414;A06.300.414;D12.776.660.625.500;D23.050.290.500;D23.101.140.400;D06.472.699.587.700;D12.644.400.600;D12.644.548.586.700;D12.776.631.650.600;D12.776.260.719.500.500;D12.776.660.235.400.750.500.500;D12.776.664.235.400.750.500.500;D12.776.930.823.500.500;D06.472.699.327.700.875;D06.472.699.587.780;D12.644.400.400.700.875;D12.644.548.365.700.875;D12.644.548.586.780;D12.776.631.650.405.700.875;D12.776.930;M01.060.116.815
29326146,"Medicaid;Cholesterol, LDL;Health Insurance Exchanges;Hyperlipoproteinemia Type II;Medical Records",N03.219.521.346.506.564.655;N03.706.615.693;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;N03.219.521.576.343.918.500;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968
29325913,Randomized Controlled Trial,V03.175.250.500.500
29325807,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;Nitriles;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;D02.626;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29325806,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Glutarates;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;D02.241.081.337.351;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29325642,Aortic Valve Stenosis;Cardiovascular Diseases;Lipoprotein(a);Metabolism;Therapeutics,C14.280.484.150;C14.280.955.249;C14;D10.532.350;D12.776.521.400;G03;E02
29325164,,
29325163,"Adolescent;Adult;African Americans;Aged;Body Mass Index;Child;European Continental Ancestry Group;Gene Frequency;Genetic Loci;Genome-Wide Association Study;Hispanic Americans;Humans;Middle Aged;Polymorphism, Single Nucleotide;United States;Vitamin D;Vitamin D Deficiency;Young Adult",M01.060.057;M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;M01.686.508.400;G05.330;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.795.598;Z01.107.567.875;D04.210.500.812.768;C18.654.521.500.133.770;M01.060.116.815
29325029,Computational Biology,H01.158.273.180;L01.313.124
29324592,,
29324529,"Child;Emergency Service, Hospital;Fractures, Bone;Humans;Musculoskeletal Diseases;Referral and Consultation;Retrospective Studies;Time Factors",M01.060.406;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C26.404;B01.050.150.900.649.313.988.400.112.400.400;C05;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857
29324481,,
29324477,,
29324391,"Animals;Arthritis, Experimental;Arthritis, Rheumatoid;Cell Differentiation;Cell Movement;Cells, Cultured;Cytokines;Dendritic Cells;Disease Models, Animal;Humans;Inflammation Mediators;Lymphocyte Activation;Macrophages;Mice;Mice, Inbred DBA;Proto-Oncogene Proteins c-rel;RNA, Small Interfering;Th1 Cells;Th17 Cells;Arthritis, Experimental;RNA, Small Interfering",B01.050;C05.550.114.015;E05.598.500.249;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;G04.152;G04.198;G07.568.500.180;A11.251;D12.644.276.374;D12.776.467.374;D23.529.374;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;D23.469;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.500;B01.050.150.900.649.313.992.635.505.500.400.500;D12.776.260.682;D12.776.624.664.700.192;D12.776.660.767;D12.776.930.730;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;A11.118.637.555.567.550.500.400.900;A11.118.637.555.567.569.200.400.900;A11.118.637.555.567.569.500.400.900;A15.145.229.637.555.567.550.500.400.500;A15.145.229.637.555.567.569.200.400.500;A15.145.229.637.555.567.569.500.400.500;A15.382.490.555.567.550.500.400.900;A15.382.490.555.567.569.200.400.900;A15.382.490.555.567.569.500.400.900;A11.118.637.555.567.550.500.400.915;A11.118.637.555.567.569.200.400.915;A11.118.637.555.567.569.500.400.915;A15.145.229.637.555.567.550.500.400.770;A15.145.229.637.555.567.569.200.400.770;A15.145.229.637.555.567.569.500.400.770;A15.382.490.555.567.550.500.400.915;A15.382.490.555.567.569.200.400.915;A15.382.490.555.567.569.500.400.915;C05.550.114.015;E05.598.500.249;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875
29323797,"Adult;Brain;Carbon Radioisotopes;Depressive Disorder, Major;Diffusion Tensor Imaging;Humans;Magnetic Resonance Imaging;Multimodal Imaging;Neural Pathways;Organ Size;Piperazines;Positron-Emission Tomography;Pyridines;Radiopharmaceuticals;Receptor, Serotonin, 5-HT1A",M01.060.116;A08.186.211;D01.268.150.075.328;D01.496.123.328;D01.496.749.154;F03.600.300.375;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.567;A08.612;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;D03.383.606;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D03.383.725;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;D12.776.543.750.670.800.100.100;D12.776.543.750.695.800.100.100;D12.776.543.750.720.850.100.100
29323666,"Diagnosis, Differential;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation",E01.171;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590.350
29323298,"Animals;Brain;Cell Line, Tumor;Cell Respiration;Cell Transformation, Neoplastic;Glioblastoma;Humans;Mice;Microtubule-Associated Proteins;Mitochondria;NIMA-Interacting Peptidylprolyl Isomerase;Neoplasms;Oncogene Proteins, Fusion;Organelle Biogenesis;Oxidative Phosphorylation;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;Peroxisomes;Phosphorylation;Protein Biosynthesis;Reactive Oxygen Species;Receptor, Fibroblast Growth Factor, Type 3;Receptors, Estrogen;Transcription, Genetic;Xenograft Model Antitumor Assays",B01.050;A08.186.211;A11.251.210.190;A11.251.860.180;G03.197;G04.270;C04.697.098.500;C23.550.727.098.500;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.220.600.450;D12.776.631.560;A11.284.430.214.190.875.564;A11.284.835.626;D08.811.399.325.500.700;C04;D12.776.602.500.500;D12.776.624.664.500;G04.618;G16.645;G02.111.665.550;G03.295.631;G03.796.550;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650;A11.284.430.214.190.500.585.600;A11.284.430.214.190.875.190.190.755.600;G02.111.665;G02.607.780;G03.796;G02.111.660.871;G03.734.871;G05.297.670;D01.339.431;D01.650.775;D08.811.913.696.620.682.725.400.179;D12.776.543.750.630.442;D12.776.543.750.750.400.370.875;D12.776.624.664.700.792;D12.776.826.750.350;D12.776.930.778.350;G02.111.873;G05.297.700;E05.337.550.200.900;E05.624.850
29323279,,
29322281,,
29322181,Clinical Decision-Making;Evidence-Based Medicine;Humans;Speech Therapy;Stuttering,E01.055;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.169.063.500.727.552;E02.831.727.552;C10.597.606.150.500.800.750;C23.888.592.604.150.500.800.750
29322063,Africa;HIV;Meningitis,Z01.058;B04.820.650.589.650.350;C10.228.614
29322050,,
29321517,"Adult;African Americans;Alleles;Atherosclerosis;Coronary Artery Disease;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Homocysteine;Humans;Longitudinal Studies;Middle Aged;Mississippi;Polymorphism, Single Nucleotide;Population Surveillance;Quantitative Trait Loci;Quantitative Trait, Heritable;Young Adult",M01.060.116;M01.686.508.100.100;M01.686.754.100;G05.360.340.024.340.030;C14.907.137.126.307;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;D02.886.030.498;D12.125.166.498;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;Z01.107.567.875.750.500;G05.365.795.598;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;G05.360.340.024.380.937;G05.420.720;M01.060.116.815
29321372,Atherosclerosis;Cardiology;Cardiovascular Diseases;Inflammation;Macrophages,C14.907.137.126.307;H02.403.429.163;C14;C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
29321369,Allergy and Immunology;Immunotherapy,H02.403.044;E02.095.465.425
29321002,Adult;Child;Humans;Meta-Analysis as Topic;Outcome Assessment (Health Care);Randomized Controlled Trials as Topic;Sample Size;Systematic Reviews as Topic,M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;L01.178.682.759.575
29320902,"Acute Disease;Alleles;Alternative Splicing;Child;Gene Expression Regulation;Gene Frequency;Genotype;HEK293 Cells;Humans;K562 Cells;Leukemia, Myeloid;Monocytes;Polymorphism, Single Nucleotide;Sialic Acid Binding Ig-like Lectin 3",C23.550.291.125;G05.360.340.024.340.030;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;M01.060.406;G05.308;G05.330;G05.380;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;C04.557.337.539;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;G05.365.795.598;D12.776.503.921.400;D23.050.301.264.900.565;D23.101.100.900.565
29320737,"Gene Expression;Influenza, Human;Rhinovirus",G05.297;C02.782.620.365;C08.730.310;B04.820.565.775
29320714,"Aged;Bone Diseases, Metabolic;Genetic Predisposition to Disease;Humans;Myositis Ossificans;Ossification, Heterotopic;Sequence Analysis, DNA;Skin Diseases, Genetic;Ossification, Heterotopic",M01.060.116.100;C05.116.198;C18.452.104;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;C23.550.751;E05.393.760.700;C16.320.850;C17.800.827;C23.550.751
29320710,"Adenosine;Apoptosis;Autoimmunity;Humans;Immune Tolerance;Neoplasms;Oxidative Stress;T-Lymphocytes, Regulatory",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;G04.146.160;G12.450.192;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;C04;G03.673;G07.775.750;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
29320302,"Clinical Trials, Phase I as Topic;Critical Illness;Drug Approval;Drug Evaluation;Drug Industry;Drug-Related Side Effects and Adverse Reactions;Drugs, Investigational;Government Regulation;Health Services Accessibility;Humans;Legislation, Drug;Liability, Legal;Patient Safety;United States;United States Food and Drug Administration",E05.318.372.250.250.200;N05.715.360.330.250.250.200;N06.850.520.450.250.250.200;C23.550.291.625;E05.290.250;E05.337.300;I01.880.604.605.250.250;E05.290.625;E05.337.425;J01.576.655.750;C25.100;D26.371;I01.880.604.394;N03.706.358;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.605;N03.706.615.402;I01.880.604.583.490;N03.706.535.547;N06.850.135.060.075.399;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
29319634,,
29318022,Bevacizumab;Blood Pressure;Hypertension,D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;E01.370.600.875.249;G09.330.380.076;C14.907.489
29317777,"A Kinase Anchor Proteins;Animals;Cocaine;Cocaine-Related Disorders;Dietary Sucrose;Disease Models, Animal;Dopamine Uptake Inhibitors;Drug-Seeking Behavior;Excitatory Postsynaptic Potentials;Genetic Vectors;Nucleus Accumbens;Rats, Sprague-Dawley;Receptors, AMPA;Receptors, Dopamine D1;Recurrence;Self Administration;Synaptic Transmission",D12.644.360.024.065;D12.776.157.057.003;D12.776.476.024.069;B01.050;D02.145.074.722.388;D03.132.889.354;D03.605.084.500.722.388;D03.605.869.388;C25.775.300;F03.900.300;D09.301.831.250;D09.698.629.305.770.200;D09.947.500.250;D09.947.750.770.200;D27.720.372.300.353.609.750.250;G07.203.300.362.831.250;G07.203.300.514.500.400.700.750.250;J02.500.362.831.250;J02.500.514.500.400.700.750.250;C22.232;E05.598.500;E05.599.395.080;D27.505.519.562.437.220;D27.505.519.625.150.800;D27.505.519.625.600.220;D27.505.696.577.150.800;D27.505.696.577.600.220;F01.145.342;G04.580.887.249;G07.265.675.887.249;G07.265.880.750.199;G11.561.570.918.249;G11.561.830.750.199;G05.360.337;A08.186.211.200.885.287.249.487.775.500;B01.050.150.900.649.313.992.635.505.700.750;D12.776.157.530.400.400.500.100;D12.776.543.550.450.500.200.100;D12.776.543.585.400.500.200.100;D12.776.543.750.720.200.450.400.100;D12.776.543.750.670.300.400.400;D12.776.543.750.695.150.400.400;D12.776.543.750.720.330.400.400;C23.550.291.937;E02.319.890;E02.900.890;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830
29317466,,
29317331,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Formates;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;D02.241.081.420;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29317329,"Animals;Benzopyrans;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;D03.383.663.283;D03.633.100.150;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29317058,"Acceleration;Animals;Animals, Newborn;Cardiac Surgical Procedures;Heart Defects, Congenital;Hippocampus;Humans;Infant, Newborn;Ischemic Preconditioning, Myocardial;Models, Cardiovascular;Myocardial Reperfusion Injury;Swine;Cardiopulmonary Bypass;Hypoxia;Neuroprotection;Nitric Oxide",G01.482.107;B01.050;B01.050.050.282;E04.100.376;E04.928.220;C14.240.400;C14.280.400;C16.131.240.400;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.592.325;E05.516.325;E05.599.395.161;C14.280.238.615;C14.280.647.625;C14.907.585.625;C14.907.725.600;C23.550.767.877.500;B01.050.150.900.649.313.500.880;E04.292.413;C23.888.852.079;G11.561.645;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
29316191,Dysbiosis;Gastrointestinal Microbiome;Graft Rejection;Humans;Immunosuppressive Agents;Liver;Liver Diseases;Liver Transplantation;Perioperative Period;Probiotics;Quality of Life,C23.550.308;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G12.875.545.328;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;A03.620;C06.552;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E04.614;N02.421.585.753;G07.203.300.456.500;J02.500.456.500;I01.800;K01.752.400.750;N06.850.505.400.425.837
29316006,"Airway Extubation;Child;Child, Preschool;Cohort Studies;Humans;Intensive Care Units, Pediatric;Length of Stay;Liver Transplantation;Operating Rooms;Philadelphia;Postoperative Care;Postoperative Complications;Retrospective Studies;Risk Factors;Time Factors;Treatment Outcome",E02.041.249;E05.008;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E02.760.400.480;N02.421.585.400.480;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;N02.278.388.700;Z01.107.567.875.500.550.525;Z01.433.820;E02.760.731.700;E04.604.500;N02.421.585.722.700;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29315614,"Adolescent;Adult;Anticonvulsants;Ataxia;Child;Child, Preschool;Cohort Studies;Electroencephalography;Epilepsies, Myoclonic;Epilepsies, Partial;Epilepsy, Generalized;GABA Plasma Membrane Transport Proteins;Genetic Association Studies;Humans;Intellectual Disability;Language Development Disorders;Mutation;Mutation, Missense;Neurodevelopmental Disorders;Phenotype;Treatment Outcome;Valproic Acid;Young Adult;Epilepsy",M01.060.057;M01.060.116;D27.505.954.427.080;C10.597.350.090;C23.888.592.350.090;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.376.300;E01.370.405.245;C10.228.140.490.375.130;C10.228.140.490.493.063;C10.228.140.490.360;C10.228.140.490.375;D12.776.157.530.450.625.139;D12.776.157.530.562.374.750;D12.776.543.585.450.625.139;D12.776.543.585.562.374.750;E05.393.385;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C10.597.606.150.500.550;C23.888.592.604.150.500.550;G05.365.590;G05.365.590.650;F03.625;G05.695;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.241.081.944.509.900;D10.251.400.895.593.900;M01.060.116.815;C10.228.140.490
29315422,"Animals;Brain Injuries, Traumatic;Diet Therapy;Glutamic Acid;Hypothalamic Area, Lateral;Hypothalamus;Mice;Mice, Inbred C57BL;Neurons;Orexins;Presynaptic Terminals;Sleep",B01.050;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;E02.642.249;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;A08.186.211.180.497.300;A08.186.211.200.317.357.300;A08.186.211.180.497;A08.186.211.200.317.357;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A08.675;A11.671;D12.644.400.360;D12.776.631.650.363;A08.675.542.145.750;A08.850.700;A11.284.149.165.420.780.700;A11.671.137.750;A11.671.501.145.750;F02.830.855;G11.561.803
29315414,,
29315334,"Aged;Frontotemporal Dementia;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Middle Aged;Polymorphism, Single Nucleotide",M01.060.116.100;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.795.598
29315137,,
29315104,Abducens Nerve Diseases;Athletic Injuries;Bicycling;Brain Concussion;Child;Humans,C10.292.150;C26.115;I03.450.642.845.140;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400
29314773,,
29314125,Herpes Zoster;Humans;Inflammatory Bowel Diseases;Tumor Necrosis Factor-alpha;Vaccination,C02.256.466.930.750;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
29313286,Budesonide,D04.210.500.745.745.654.105
29313031,"Blood Substitutes;Hemoglobins;Protein Stability;Chromatography, Gel",D27.505.954.502.140;J01.637.087.249;D12.776.124.400;D12.776.422.316.762;G02.111.700;E05.196.181.400.250
29312903,Diagnosis;Prognosis;Therapeutics,E01;E01.789;E02
29312893,"Animals;Bacterial Proteins;Binding Sites;Cholera;Crystallography, X-Ray;DNA, Bacterial;Disease Models, Animal;Electrophoretic Mobility Shift Assay;Mice;Models, Molecular;Palmitoyl Coenzyme A;Protein Binding;Protein Conformation;Repressor Proteins;Surface Plasmon Resonance;Vibrio alginolyticus;Vibrio cholerae;Virulence;Vibrio alginolyticus;Virulence",B01.050;D12.776.097;G02.111.570.120;C01.252.400.959.347;E05.196.309.742.225;D13.444.308.212;C22.232;E05.598.500;E05.599.395.080;E05.196.401.500;B01.050.150.900.649.313.992.635.505.500;E05.599.595;D03.633.100.759.646.138.382.300.700;D08.211.211.300.700;D10.251.694.600.500;D13.695.667.138.382.300.700;D13.695.827.068.382.300.700;G02.111.679;G03.808;G02.111.570.820.709;D12.776.260.703;D12.776.930.780;E05.196.890;E05.601.043.700;B03.440.450.900.859.030;B03.660.250.830.830.030;B03.440.450.900.859.225;B03.660.250.830.830.100;G06.930;B03.440.450.900.859.030;B03.660.250.830.830.030;G06.930
29312754,Lung Neoplasms,C04.588.894.797.520;C08.381.540;C08.785.520
29311649,"Animals;Axons;Cells, Cultured;Computational Biology;Gene Expression Profiling;Gene Expression Regulation;Gene Ontology;Mice;MicroRNAs;Mitochondria;Molecular Imaging;Motor Neurons;RNA Interference;Transcriptome;Vimentin",B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A11.251;H01.158.273.180;L01.313.124;E05.393.332;G05.308;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;B01.050.150.900.649.313.992.635.505.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A11.284.430.214.190.875.564;A11.284.835.626;E01.370.350.557;E05.601.555;A08.675.655.500;A11.671.655.500;G05.308.203.374.790;G02.111.873.750;G05.297.700.750;G05.360.920;D05.750.078.593.900;D12.776.220.475.900
29311282,"Biofilms;Cyclic GMP;Gene Expression Profiling;Gene Expression Regulation, Bacterial;Pseudomonas fluorescens;Signal Transduction;Two-Hybrid System Techniques;Biofilms",A20.593;G06.120;D03.633.100.759.646.454.160;D13.695.462.275;D13.695.667.454.160;D13.695.827.426.160;E05.393.332;G05.308.300;B03.440.400.425.625.625.325;B03.660.250.580.590.210;G02.111.820;G04.835;E05.393.220.870;E05.601.690.650;E05.601.870;A20.593;G06.120
29311051,Internet;Neoplasms;Incidence,L01.224.230.110.500;C04;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375
29310961,"Accidents, Traffic;Adult;Aorta;Flail Chest;Humans;Motor Vehicles;Rib Fractures;Seat Belts;Tomography, X-Ray Computed",N06.850.135.392;M01.060.116;A07.015.114.056;C26.891.315;B01.050.150.900.649.313.988.400.112.400.400;J01.937.500;C26.404.593;C26.891.733;E07.700.800;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29310717,"Abnormalities, Multiple;Automation;Biomarkers;Flow Cytometry;Glycosylphosphatidylinositols;Humans;Image Processing, Computer-Assisted;Intellectual Disability;Phenotype;Phosphorus Metabolism Disorders;Syndrome;Genes",C16.131.077;J01.897.104;D23.101;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;D09.400.410.475;D10.390.475;D10.570.755.375.760.400.942.250;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.695;C18.452.750;C23.550.288.500;G05.360.340.024.340
29310668,"Adolescent;Arthritis, Juvenile;Biomarkers;Cell Culture Techniques;Child;Child, Preschool;Disease Progression;Enzyme-Linked Immunosorbent Assay;Humans;Microarray Analysis;Real-Time Polymerase Chain Reaction;Synovial Fluid;Synoviocytes;Transcriptome;Arthritis, Juvenile",M01.060.057;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;D23.101;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;M01.060.406;M01.060.406.448;C23.550.291.656;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.988.400.112.400.400;E05.588.570;E05.393.620.500.706;A02.835.583.443.800.800;A12.207.270.847;A11.329.835;G02.111.873.750;G05.297.700.750;G05.360.920;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198
29310009,Sexual Health,N01.400.663
29309924,"Cell Line, Tumor;DNA, Mitochondrial;Humans;Mitochondria;Mitochondrial Proteins;Neoplasm Proteins;RNA-Binding Proteins;Triple Negative Breast Neoplasms;Triple Negative Breast Neoplasms",A11.251.210.190;A11.251.860.180;D13.444.308.283.225;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.575;D12.776.624;D12.776.157.725;D12.776.664.962;C04.588.180.788;C17.800.090.500.788;C04.588.180.788;C17.800.090.500.788
29309821,"Adult;Aged;Aged, 80 and over;Biopsy;Dermatomyositis;Diagnosis, Differential;Diagnostic Errors;Humans;Middle Aged;Retrospective Studies",M01.060.116;M01.060.116.100;M01.060.116.100.080;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;E01.171;E01.354;N02.421.450.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29309628,"Actins;Alleles;Birth Weight;Cytochrome P-450 CYP3A;DNA-Binding Proteins;Genetic Variation;Genome-Wide Association Study;Genotype;Gestational Age;HMGA2 Protein;Humans;Kv1.3 Potassium Channel;Polymorphism, Single Nucleotide;Protein-Serine-Threonine Kinases;Proteins;Receptor, Melatonin, MT2;Trans-Activators;Transcription Factor 7-Like 2 Protein",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;G05.360.340.024.340.030;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500;D12.776.260;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;G07.345.500.325.235.968;G08.686.320;D12.776.260.312.937;D12.776.660.235.400.500.600;D12.776.664.235.400.500.600;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530.400.600.900.500.217;D12.776.543.550.450.750.900.124.358;D12.776.543.585.400.750.900.624.217;G05.365.795.598;D08.811.913.696.620.682.700;D12.776;D12.776.543.750.695.440.750;D12.776.260.755;D12.776.930.900;D12.776.964.925.984;D12.776.260.730.875;D12.776.660.235.400.800.875;D12.776.664.235.400.800.875;D12.776.930.875.875
29309562,"Animals;Cells, Cultured;Diabetes Mellitus, Type 2;Fetal Growth Retardation;Gene Expression Profiling;Humans;Islets of Langerhans;Pancreatic Diseases;Pregnancy;Prenatal Exposure Delayed Effects;Rats;Rats, Sprague-Dawley;Risk Factors;Transcriptome",B01.050;A11.251;C18.452.394.750.149;C19.246.300;C13.703.277.370;C16.300.390;C23.550.393.450;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;A03.734.414;A06.300.414;C06.689;G08.686.784.769;C13.703.824.500;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G02.111.873.750;G05.297.700.750;G05.360.920
29309404,"Animals;Animals, Genetically Modified;Blood Vessels;Cells, Cultured;Drosophila Proteins;Drosophila melanogaster;Embryo, Nonmammalian;Extracellular Matrix;Gene Expression Regulation, Developmental;Lymphatic Vessels;Morphogenesis;Neovascularization, Physiologic;Nuclear Proteins;Organ Size;Tight Junctions;Trachea;Transcription Factors;Zinc Fingers",B01.050;B01.050.050.136;B05.620.136;A07.015;A11.251;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;A13.350;A16.331;A11.284.295.310;G05.308.310;A15.382.520.301;G07.345.500;G09.330.630;D12.776.660;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;A11.284.149.165.420.820;A04.889;D12.776.930;G02.111.570.820.709.275.500.985
29309380,,
29309221,"Adolescent;Child;Child Mortality;Child, Preschool;Cross-Sectional Studies;Databases, Factual;Global Health;Health Expenditures;Homicide;Humans;Infant;Infant Mortality;Infant, Newborn;Organisation for Economic Co-Operation and Development;Sex Factors;United States;Young Adult;Child Health;Demography;Epidemiology;Public Health",M01.060.057;M01.060.406;E05.318.308.985.550.287;N01.224.935.698.150;N06.850.505.400.975.550.287;N06.850.520.308.985.550.287;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;L01.313.500.750.300.188.400;L01.470.750.750;H02.403.371;N01.400.337;N03.219.151.450;N05.300.385;I01.198.240.470;I01.880.735.344;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;N03.540.514.481;N05.715.350.675;N06.850.490.875;Z01.107.567.875;M01.060.116.815;N01.400.225;I01.240;N01.224;N06.850.505.400;H02.403.720.500;H02.403.720;N01.400.550;N06.850
29308990,Home Care Services;Hospice Care;Humans;Length of Stay;Long-Term Care;Nursing Homes;Rehabilitation;United States;United States Department of Veterans Affairs;Veterans;Veterans;Long-Term Care,N02.421.143.524;N02.421.539.089;E02.760.905.400;N02.421.585.905.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E02.760.476;N02.421.585.476;N02.278.825.610;E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;M01.930;M01.930;E02.760.476;N02.421.585.476
29308704,"Natriuretic Peptide, Brain;Pediatrics",D06.472.699.584.625;D12.644.548.585.625;D12.776.631.590;H02.403.670
29308354,African Americans;Hepatitis B;Hispanic Americans,M01.686.508.100.100;M01.686.754.100;C02.256.430.400;C02.440.435;C06.552.380.705.437;M01.686.754.441
29308116,,
29307846,,
29307777,"Activin Receptors, Type I;Animals;Bone Morphogenetic Protein Receptors;Humans;Mutation;Myositis Ossificans;Protein Binding;Signal Transduction;Zebrafish;Zebrafish",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;B01.050;D08.811.913.696.620.682.700.109;D12.776.543.750.750.400.049;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C05.651.594.638;G02.111.679;G03.808;G02.111.820;G04.835;B01.050.150.900.493.200.244.828;B01.050.150.900.493.200.244.828
29307585,"Brain;Brain Mapping;Creativity;Diffusion Tensor Imaging;Humans;Image Processing, Computer-Assisted;Intelligence;Models, Neurological;Neural Pathways;Neuropsychological Tests;White Matter;Young Adult;Creativity;Intelligence",A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F01.752.264;F02.463.785.302;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;F01.752.543;E05.599.395.642;A08.612;F04.711.513;A08.186.211.204;A08.186.854.880;M01.060.116.815;F01.752.264;F02.463.785.302;F01.752.543
29307548,Behavior;Practice Guidelines as Topic;Research Design;Mice;Rats,F01.145;N04.761.700.350.650;N05.700.350.650;E05.581.500;H01.770.644.728;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.700
29307472,,
29307400,Authorship;Clinical Trials as Topic;Editorial Policies;Humans;Information Dissemination;Peer Review;Perception;Periodicals as Topic;Research Personnel,L01.559.423.906.215;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;L01.737.484;B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;F01.829.316.549;I01.880.604.640;N03.706.700;F02.463.593;L01.178.682.829.678;M01.526.839
29306616,"Anesthesia, Cardiac Procedures;Clinical Competence;Curriculum;Humans;Internship and Residency;Program Development;Education;Education, Distance;Echocardiography, Transesophageal",E03.155.403;I02.399.630.210;N04.761.210;N05.715.175;I02.158;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;N04.452.760;I02;I02.195;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
29305932,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Sesquiterpenes;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.455.849.765;E05.940
29305930,"Animals;Consumer Product Safety;Crotonates;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;D02.241.081.114.875;D10.251.400.143.687;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29305654,Early Detection of Cancer;Genomics;Humans;Immunotherapy;Neuroblastoma;Remission Induction;Neuroblastoma;Regression (Psychology);Telomerase,E01.390.500;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E02.860;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;F01.393.784;D08.811.913.696.445.308.300.750.750;D12.776.157.687.613;D12.776.157.725.500.921;D12.776.660.720.613;D12.776.664.962.500.921
29305553,"ADP-ribosyl Cyclase 1;Adolescent;Adult;Animals;Antibodies, Monoclonal;Child;Child, Preschool;Gene Expression Regulation, Leukemic;Humans;Membrane Glycoproteins;Mice;Mice, Inbred NOD;Mice, SCID;Neoplasm Proteins;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Xenograft Model Antitumor Assays",D08.811.277.450.430.400.060.500;D12.776.543.550.045;M01.060.057;M01.060.116;B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;M01.060.406;M01.060.406.448;G05.308.370.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550;D12.776.543.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.150.900.649.313.992.635.505.500.550.780;D12.776.624;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;E05.337.550.200.900;E05.624.850
29305383,Apolipoprotein A-I;Cholesterol,D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208
29305336,"Adult;Aged;Aged, 80 and over;Brain Injuries, Traumatic;Fluorescent Antibody Technique;Humans;Middle Aged;Ossification, Heterotopic;Osteogenesis;Spinal Cord Injuries;Stem Cells;Stroke;Young Adult;Stroke;Ossification, Heterotopic;Wounds and Injuries;Spinal Cord Injuries;Wounds and Injuries;Brain Injuries, Traumatic",M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;E01.370.225.500.607.512.240;E01.370.225.750.551.512.240;E05.200.500.607.512.240;E05.200.750.551.512.240;E05.478.583.375;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.751;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;C10.228.854.763;C10.900.850;C26.819;A11.872;C10.228.140.300.775;C14.907.253.855;M01.060.116.815;C10.228.140.300.775;C14.907.253.855;C23.550.751;C26;C10.228.854.763;C10.900.850;C26.819;C26;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29305137,"Muscular Atrophy, Spinal",C10.228.854.468;C10.574.562.500;C10.668.467.500
29304726,"Animals;Cell Transdifferentiation;Databases, Factual;Embryonic Stem Cells;Fibroblasts;Gene Expression Profiling;Internet;Transcription Factors;User-Computer Interface",B01.050;G04.356;L01.313.500.750.300.188.400;L01.470.750.750;A11.872.700.250;A11.329.228;E05.393.332;L01.224.230.110.500;D12.776.930;L01.224.900.910
29304474,"Animals;Antibody Specificity;Antigens, CD;Antigens, Neoplasm;Antineoplastic Agents, Phytogenic;Humans;Immunoconjugates;Immunotoxins;Mice;Molecular Targeted Therapy;Ribosome Inactivating Proteins, Type 1;Saporins;Sarcoma;Single-Chain Antibodies;Xenograft Model Antitumor Assays;Immunotoxins;Sarcoma",B01.050;G12.100;D23.050.301.264.035;D23.101.100.110;D23.050.285;D27.505.954.248.179;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.790.651.114.580;D12.776.377.715.548.114.580;D27.888.569.257;D12.776.124.790.651.114.580.450;D12.776.377.715.548.114.580.450;D27.888.569.257.500;B01.050.150.900.649.313.992.635.505.500;E02.319.574;D08.811.277.450.430.700.500;D12.776.765.710.500;D08.811.277.450.430.700.500.500;D12.776.765.710.500.250;C04.557.450.795;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;E05.337.550.200.900;E05.624.850;D12.776.124.790.651.114.580.450;D12.776.377.715.548.114.580.450;D27.888.569.257.500;C04.557.450.795
29304378,"Adolescent;Age Factors;Animals;Bone Density;Child;Child, Preschool;Genetic Loci;Genome-Wide Association Study;Humans;Infant;Infant, Newborn;Mice, Knockout;Polymorphism, Single Nucleotide;Quantitative Trait, Heritable;Regression Analysis;Bone Density;Genome-Wide Association Study",M01.060.057;N05.715.350.075;N06.850.490.250;B01.050;G11.427.100;M01.060.406;M01.060.406.448;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.795.598;G05.420.720;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;G11.427.100;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
29304347,Adult;Attention;Depression;Facial Expression;Humans;Infant;Infant Behavior;Mother-Child Relations;Mothers;Depression;Infant;Mother-Child Relations,M01.060.116;F02.830.104.214;F01.145.126.350;E01.370.600.225;F01.145.209.530.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.145.179.500;F01.829.263.370.290.170;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.145.126.350;M01.060.703;F01.829.263.370.290.170
29304336,Base Sequence;CRISPR-Cas Systems;Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Mutagenesis,G02.111.570.080;G05.360.080;L01.453.245.667.080;G05.308.203.374.394;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;G05.558
29303891,"Child Development;Child, Preschool;Extracorporeal Membrane Oxygenation;Follow-Up Studies;Hernias, Diaphragmatic, Congenital;Herniorrhaphy;Humans;Infant;Infant, Newborn;Neurodevelopmental Disorders;Retrospective Studies;Risk Factors;Tertiary Care Centers;Time Factors",F01.525.200;G07.345.374.750;M01.060.406.448;E02.880.301;E04.292.451;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C16.131.433;C23.300.707.500.116;E04.680.325;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F03.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N02.278.421.830;G01.910.857
29302953,Folate Receptor 1;Osteosarcoma;General Surgery,D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;C04.557.450.565.575.650;C04.557.450.795.620;H02.403.810.300
29302685,,
29302365,,
29302220,"Buprenorphine;Cytochrome P-450 CYP2B6;Genome-Wide Association Study;Humans;Narcotic Antagonists;Opioid-Related Disorders;Pharmacogenetics;Polymorphism, Single Nucleotide;Potassium Channels;Receptors, Opioid, mu;Genetics;Pharmacogenetics",D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;D08.244.453.005.575;D08.244.453.491.344;D08.811.682.690.708.170.010.575;D08.811.682.690.708.170.450.344;D12.776.422.220.453.010.575;D12.776.422.220.453.491.344;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.543;D27.505.696.663.850.512;D27.505.954.427.550;C25.775.675;F03.900.675;H01.158.273.343.750;H01.158.703.052;H02.628.479;G05.365.795.598;D12.776.157.530.400.600;D12.776.543.550.450.750;D12.776.543.585.400.750;D12.776.543.750.695.620.550;D12.776.543.750.720.600.610.550;D12.776.543.750.750.555.610.550;H01.158.273.343;H01.158.273.343.750;H01.158.703.052;H02.628.479
29302065,,
29302039,"Aged;Animals;Antineoplastic Agents;Benzamides;Cell Line, Tumor;Cell Proliferation;Co-Repressor Proteins;Drug Design;Drug Screening Assays, Antitumor;Histone Deacetylase Inhibitors;Histone Deacetylases;Humans;Melanoma;Mice;Mice, Inbred BALB C;Mice, Nude;Middle Aged;Nerve Tissue Proteins;Oligonucleotide Array Sequence Analysis;Pyridines;Repressor Proteins;Skin Neoplasms;Tranylcypromine;Xenograft Model Antitumor Assays",M01.060.116.100;B01.050;D27.505.954.248;D02.065.277;D02.241.223.100.100;D02.455.426.559.389.127.085;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;D12.776.930.780.625;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;E01.370.225.500.388;E05.200.500.388;E05.242.417;E05.337.550.200;D27.505.519.389.360;D08.811.277.087.520;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.150.900.649.313.992.635.505.500.550.500;M01.060.116.630;D12.776.631;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;D03.383.725;D12.776.260.703;D12.776.930.780;C04.588.805;C17.800.882;D02.092.831.845;E05.337.550.200.900;E05.624.850
29302025,"Alleles;Azacitidine;Base Sequence;Carrier Proteins;Enzyme Inhibitors;Epistasis, Genetic;Family Health;Fibroblasts;Heterozygote;Humans;Metabolism, Inborn Errors;Mutation;Pedigree;Peroxiredoxins;Vitamin B 12;Whole Genome Sequencing",G05.360.340.024.340.030;D02.145.150;D03.383.742.680.245.217;D13.570.685.245.217;D13.570.800.286.300;G02.111.570.080;G05.360.080;L01.453.245.667.080;D12.776.157;D27.505.519.389;G05.308.207;N01.400.300;A11.329.228;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;C16.320.565;C18.452.648;G05.365.590;E05.393.673;D08.811.682.732.850;D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777;E05.393.760.700.825
29301959,"Emulsions;Escherichia coli;Gene Knockout Techniques;Genes, Essential;Genes, Synthetic;Genetic Complementation Test;Oligonucleotides;Proteins;Synthetic Biology",D20.280.260;D26.255.165.260;B03.440.450.425.325.300;B03.660.250.150.180.100;E05.393.335.750;G05.360.340.024.340.270;G05.360.340.024.340.465;E05.393.281.526;D13.695.578.424;D12.776;H01.158.273.904;J01.293.069.500
29301893,,
29301865,Hydroxyeicosatetraenoic Acids,D10.251.355.255.100.300;D10.251.355.310.166.550
29301854,Autophagy;Liver,G04.146.399;G04.417.350.091;A03.620
29301385,"Ethics Committees, Research;Electronic Health Records;Informed Consent",K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;E05.318.308.940.968.625.500;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489
29301021,"Adult;Aged;Cluster Analysis;Cohort Studies;Continuous Positive Airway Pressure;Follow-Up Studies;Health Surveys;Humans;Iceland;Middle Aged;Sleep Apnea, Obstructive;Treatment Outcome;Wakefulness",M01.060.116;M01.060.116.100;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.041.625.790.259;E02.880.820.790.259;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;Z01.542.816.249;Z01.639.490;M01.060.116.630;C08.618.085.852.850;C10.886.425.800.750.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;F02.830.104.821;G11.561.035.738
29300926,,
29300620,,
29300374,"Actins;Adolescent;Adult;Aortic Aneurysm, Thoracic;Arginine;Child;Child, Preschool;Ductus Arteriosus, Patent;Eye Diseases, Hereditary;Genetic Predisposition to Disease;Genetic Testing;Humans;Infant;Medical Records;Muscle, Smooth;Mydriasis;Young Adult;Ductus Arteriosus, Patent;Aortic Aneurysm, Thoracic",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;M01.060.057;M01.060.116;C14.907.055.239.125;C14.907.109.139.125;D12.125.068.050;D12.125.095.104;D12.125.142.087;M01.060.406;M01.060.406.448;C14.240.400.340;C14.280.400.340;C16.131.240.400.340;C11.270;C16.320.290;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;A02.633.570;A10.690.467;C11.710.570;M01.060.116.815;C14.240.400.340;C14.280.400.340;C16.131.240.400.340;C14.907.055.239.125;C14.907.109.139.125
29300281,"Adult;Emergency Medical Services;Humans;Infusions, Intraosseous;Infusions, Intravenous;Prospective Studies;Resuscitation;Shock, Hemorrhagic;Survival Rate;United States;Vascular Access Devices;Video Recording",M01.060.116;N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.510.560;E02.319.267.082.500;E02.319.267.510.590;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.365.647;C23.550.414.980;C23.550.835.650;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;Z01.107.567.875;E07.132.750;L01.280.960
29300049,,
29300007,Acquired Immunodeficiency Syndrome;Amino Acid Sequence;Animals;Cell Adhesion Molecules;Cercocebus atys;Exons;Frameshift Mutation;Genetic Predisposition to Disease;Genetic Variation;Genome;Genomics;HIV;Host Specificity;Humans;Macaca;Sequence Deletion;Simian Acquired Immunodeficiency Syndrome;Simian Immunodeficiency Virus;Species Specificity;Toll-Like Receptor 4;Transcriptome;Whole Genome Sequencing,C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;G02.111.570.060;L01.453.245.667.060;B01.050;D12.776.395.550.200;D12.776.543.550.200;D23.050.301.350;B01.050.150.900.649.313.988.400.112.199.120.120.110;G05.360.340.024.340.137.232;G05.365.590.265;C23.550.291.687.500;G05.380.355;G05.365;G05.360.340;H01.158.273.180.350;H01.158.273.343.350;B04.820.650.589.650.350;G06.462.380;G16.527.200.380;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.988.400.112.199.120.510;G05.365.590.762;G05.558.800;C02.782.815.616.850;C02.839.850;C22.735.500.850;B04.820.650.589.650.800;B04.820.650.805.700;G16.824;D12.776.543.750.705.910.500.400;G02.111.873.750;G05.297.700.750;G05.360.920;E05.393.760.700.825
29298983,,
29298866,"Animals;Antagomirs;CD4-Positive T-Lymphocytes;Diabetes Mellitus, Type 1;Forkhead Transcription Factors;Humans;Immunogenetics;Mice;Mice, Mutant Strains;MicroRNAs;NFATC Transcription Factors",B01.050;D13.695.578.424.112;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;C18.452.394.750.124;C19.246.267;C20.111.327;D12.776.260.950.249;D12.776.930.977.249;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.343.420;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.930.608
29298827,"Cerebrospinal Fluid;Cross-Sectional Studies;Herpes Simplex;Humans;Infant;Infant, Newborn;Meningitis;Odds Ratio;Retrospective Studies;Simplexvirus",A12.207.270.210;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C02.256.466.382;C02.825.320;C17.800.838.790.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C10.228.614;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;B04.280.382.100.750
29298748,Data Mining;Decision Making;Mental Health;Cell Phone,L01.313.500.750.280.199;L01.470.625;F02.463.785.373;F02.418;N01.400.500;L01.178.847.698.300
29297988,Asian Continental Ancestry Group;Attitude to Health;Body Image;Body Mass Index;China;Feeding and Eating Disorders;Humans;Self Concept;Sex Factors;Students;Young Adult;Body Image;Feeding and Eating Disorders;Sex,M01.686.508.200;F01.100.150;N05.300.150;F01.752.747.792.110;F02.463.593.112;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;Z01.252.474.164;F03.400;B01.050.150.900.649.313.988.400.112.400.400;F01.752.747.792;N05.715.350.675;N06.850.490.875;M01.848;M01.060.116.815;F01.752.747.792.110;F02.463.593.112;F03.400;G08.686.810
29297619,Precursor Cell Lymphoblastic Leukemia-Lymphoma,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
29297051,,
29296928,,
29296920,,
29296912,,
29296814,,
29296813,,
29296786,,
29296782,,
29296762,,
29296743,,
29296732,,
29296706,,
29296192,Neoplasm Metastasis,C04.697.650;C23.550.727.650
29295957,,
29295923,Adenosine Triphosphate;Chaperonin 60;Escherichia coli;Escherichia coli Proteins;Kinetics;Maltose-Binding Proteins;Protein Binding;Protein Conformation;Protein Folding;Protein Folding,D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;D08.811.277.040.025.142.500.500;D12.776.580.216.210.590.750;B03.440.450.425.325.300;B03.660.250.150.180.100;D12.776.097.275;G01.374.661;G02.111.490;D12.776.097.577.500.500;G02.111.679;G03.808;G02.111.570.820.709;G01.154.651;G02.111.688;G01.154.651;G02.111.688
29295910,"Epidemics;Evolution, Molecular;Genetic Variation;Genome, Bacterial;Genotype;Humans;Methicillin-Resistant Staphylococcus aureus;Molecular Epidemiology;Phylogeography;Sequence Analysis, DNA;Staphylococcal Infections;United States;Epidemics;Fluoroquinolones;Founder Effect;Genetic Drift;Genetics, Population",N06.850.290.200;G05.045.250;G16.075.250;G05.365;G05.360.340.358.207;G05.380;B01.050.150.900.649.313.988.400.112.400.400;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;H01.158.273.343.335.500;H01.277.500.589;E05.393.760.700;C01.252.410.868;Z01.107.567.875;N06.850.290.200;D03.633.100.810.835.322;G05.285;G05.045.300;G05.330.320;H01.158.273.343.335
29295853,"Adolescent;Age Factors;Antihypertensive Agents;Blood Pressure Determination;Blood Pressure Monitoring, Ambulatory;Child;Child, Preschool;Comorbidity;Follow-Up Studies;Glomerular Filtration Rate;Humans;Hypertension;Longitudinal Studies;Masked Hypertension;Needs Assessment;Renal Insufficiency, Chronic;Retrospective Studies;Risk Assessment;Severity of Illness Index;Sex Factors;Statistics, Nonparametric;Treatment Outcome;Blood Pressure;Child;Hypertension;Kidney Diseases;Masked Hypertension",M01.060.057;N05.715.350.075;N06.850.490.250;D27.505.954.411.162;E01.370.370.140;E01.370.600.100;E01.370.370.140.100;E01.370.520.500.100;M01.060.406;M01.060.406.448;N05.715.350.225;N06.850.490.687;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C14.907.489.861;I02.594;N03.349.380.565;N05.300.537;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N05.715.350.675;N06.850.490.875;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.600.875.249;G09.330.380.076;M01.060.406;C14.907.489;C12.777.419;C13.351.968.419;C14.907.489.861
29294788,Caregivers;Family;Mental Health;Mental Health Services;Sex Offenses,M01.085;M01.526.485.200;N02.360.200;F01.829.263;I01.880.853.150;F02.418;N01.400.500;F04.408;N02.421.461;I01.198.240.748
29294098,,
29293904,"Adult;Diagnosis, Differential;Diagnostic Errors;Eosinophilic Esophagitis;Humans;Middle Aged;Patient Selection;Pennsylvania;Proton Pump Inhibitors;Retrospective Studies;Time-to-Treatment",M01.060.116;E01.171;E01.354;N02.421.450.280;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.581.500.653;N04.590.731;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;D27.505.519.389.848;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.928;N02.421.585.928
29293269,Communicable Diseases;Humans;Multiple System Atrophy;Prion Diseases;Proteostasis Deficiencies;alpha-Synuclein,C01.539.221;B01.050.150.900.649.313.988.400.112.400.400;C10.177.575.550;C10.228.140.079.612;C10.228.662.550;C10.574.625;C10.228.228.800;C10.574.843;C18.452.845;D12.776.631.860.500;D12.776.637.500
29293150,,
29292843,,
29292308,,
29292283,Anesthesia;Anxiety;Child;Fear;Humans;Operating Rooms;Pain Management;Parents;Patient Education as Topic;Perioperative Care;Physician-Patient Relations;Professional-Family Relations,E03.155;F01.470.132;M01.060.406;F01.470.361;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.700;E02.745;N04.590.607.500;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I02.233.332.500;N02.421.726.407.680;E02.760.731;E04.604;N02.421.585.722;F01.829.401.650.675;N05.300.660.625;F01.829.401.550
29292162,"Animals;Choroidal Neovascularization;Dependovirus;Disease Models, Animal;Gene Expression;Gene Order;Gene Transfer Techniques;Genetic Therapy;Genetic Vectors;Immunoglobulin Fab Fragments;Macular Degeneration;Mice;Retinal Neovascularization;Transduction, Genetic;Transgenes;Vascular Endothelial Growth Factor A;Choroidal Neovascularization;Genetic Therapy",B01.050;C11.941.160.244;C23.550.589.500.145;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;G05.297;G05.340;E05.393.350;E02.095.301;E05.393.420.301;G05.360.337;D12.644.541.500.650;D12.776.124.486.485.680.650;D12.776.124.790.651.680.650;D12.776.377.715.548.680.650;C11.768.585.439;B01.050.150.900.649.313.992.635.505.500;C11.768.725;C23.550.589.500.725;E05.393.350.800;G05.728.850;G05.360.340.024.340.825;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;C11.941.160.244;C23.550.589.500.145;E02.095.301;E05.393.420.301
29292025,Cardiopulmonary Resuscitation;Heart Arrest;Humans;Infant;Thumb,E02.365.647.110;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A01.378.800.667.430.705
29292022,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Succinates;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.241.081.337.759;E05.940
29291954,"Academic Medical Centers;Adult;Aged;Biopsy, Needle;Cohort Studies;Dermatomyositis;Diagnosis, Differential;Humans;Immunohistochemistry;Middle Aged;Retrospective Studies;Rheumatology;Sensitivity and Specificity;Severity of Illness Index;Societies, Medical;United States;Connective Tissue Diseases;Dermatomyositis",N02.278.020;M01.060.116;M01.060.116.100;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;H02.403.429.730;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N03.540.828.589;Z01.107.567.875;C17.300;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185
29291939,,
29291394,Angiotensins;Cardiovascular Diseases;Mitral Valve;Physiology;Serotonin;General Surgery,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050;C14;A07.541.510.507;H01.158.782;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650;H02.403.810.300
29290580,"Diagnosis;Orthopedics;Muscular Atrophy, Spinal",E01;H02.403.810.494;C10.228.854.468;C10.574.562.500;C10.668.467.500
29290519,Craniofacial Dysostosis;Carotid Arteries;Craniosynostoses;Skull Base,C05.116.099.370.231;C05.660.207.231;C16.131.621.207.231;A07.015.114.186;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;A01.456.830;A02.835.232.781.750
29290516,"Abscess;Antibodies, Monoclonal;Diagnosis, Differential;Gene Frequency;Genotype;Humans;Infant;Interleukin-1beta;Mevalonate Kinase Deficiency;Mevalonic Acid;Mutation;Pedigree;Phosphotransferases (Alcohol Group Acceptor);Rectal Fistula;Rectum;Remission Induction;Whole Exome Sequencing",C01.539.830.025;C23.550.470.756.100;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;E01.171;G05.330;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;C10.228.140.163.100.593;C15.378.147.542.319;C16.320.382.750;C16.320.565.189.593;C16.320.565.663.430;C18.452.132.100.593;C18.452.648.189.593;C18.452.648.663.430;C20.683.460.319;D02.241.511.579;G05.365.590;E05.393.673;D08.811.913.696.620;C06.267.550.600;C06.405.469.471.600;C06.405.469.860.752;C23.300.575.185.550.600;A03.556.124.526.767;A03.556.249.249.767;E02.860;E05.393.760.700.825.500
29290371,"Alzheimer Disease;Autistic Disorder;Mitochondria;Receptors, Cytoplasmic and Nuclear;DNA, Mitochondrial",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F03.625.164.113.500;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.826;D13.444.308.283.225
29290338,"Adolescent;Amino Acid Sequence;Child;Codon;Cohort Studies;Computer Simulation;Demography;Genetic Association Studies;Heterozygote;Humans;Mutation, Missense;Neurofibromatosis 1;Neurofibromin 1;Phenotype;Young Adult;Neurofibrosarcoma;Genetic Association Studies;Mutation, Missense;Neurofibromatosis 1;Neurofibroma, Plexiform",M01.060.057;G02.111.570.060;L01.453.245.667.060;M01.060.406;D13.444.735.544.355;G05.360.335.355;G05.360.340.024.340.137.190;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.224.160;I01.240;N01.224;N06.850.505.400;E05.393.385;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;D12.644.360.325.150.500.460;D12.776.476.325.150.500.460;D12.776.624.776.610;G05.695;M01.060.116.815;C04.557.450.565.590.350.590;C04.557.450.795.350.590;C04.557.580.600.580.795;C10.551.775.500.750.750;C10.668.829.725.500.600.600;E05.393.385;G05.365.590.650;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;C04.557.580.600.580.585;C10.551.775.500.750.500;C10.668.829.725.500.600.500
29290337,"Adolescent;Animals;Arthrogryposis;Brain;Child;Gene Knockdown Techniques;Humans;Infant;Infant, Newborn;Magnetic Resonance Imaging;Mutation;Pedigree;Proteins;Zebrafish;Zebrafish Proteins;Arthrogryposis;Clubfoot;Hydrocephalus",M01.060.057;B01.050;C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;A08.186.211;M01.060.406;E05.393.335.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.350.825.500;G05.365.590;E05.393.673;D12.776;B01.050.150.900.493.200.244.828;D12.776.325.500;C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;C05.330.488.655.063;C05.330.495.681.063;C05.660.585.512.380.813.063;C16.131.621.585.512.500.681.063;C10.228.140.602
29289860,Humidity;Nephrolithiasis;Temperature,G16.500.275.063.725.310;G16.500.750.775.310;N06.230.150.372;N06.230.300.100.725.310;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710
29289717,"Animals;Brain;Central Nervous System Agents;Dose-Response Relationship, Drug;Dystonia Musculorum Deformans;Endoplasmic Reticulum Stress;Eukaryotic Initiation Factor-2;Humans;Induced Pluripotent Stem Cells;Mice, Transgenic;Rats, Sprague-Dawley;Rats, Transgenic;Transcriptome;Tunicamycin;Unfolded Protein Response;Up-Regulation;Dystonia",B01.050;A08.186.211;D27.505.954.427;G07.690.773.875;G07.690.936.500;C10.228.140.079.357;C10.228.662.300.200;C10.574.500.393;C16.320.400.330;G04.434;D12.776.835.725.868.249;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;B01.050.150.900.649.313.992.635.505.700.750;B01.050.050.136.700;B01.050.150.900.649.313.992.635.505.700.825;G02.111.873.750;G05.297.700.750;G05.360.920;D03.383.742.680.725;D13.570.685.725;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850;G02.111.905;G05.308.850;G07.690.773.998;C10.597.350.300;C23.888.592.350.300
29289637,"Acetals;Aldehydes;Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;D02.047;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29289528,Adult;Aged;Clinical Decision-Making;Colonoscopy;Colorectal Neoplasms;Consensus;Cystic Fibrosis;Decision Support Techniques;Early Detection of Cancer;Gastroenterology;Humans;Middle Aged;Organ Transplantation;Predictive Value of Tests;Prognosis;Risk Assessment;Risk Factors;Neoplasms;Colon;Colonoscopy;Cost-Benefit Analysis;Cystic Fibrosis;Intestines;Rectum;Mass Screening,M01.060.116;M01.060.116.100;E01.055;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;F01.829.316.068;F02.463.785.373.433;C06.689.202;C08.381.187;C16.320.190;C16.614.213;E05.245;L01.313.500.750.190;E01.390.500;H02.403.429.405;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.936.450;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C04;A03.556.124.526.356;A03.556.249.249.356;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;N03.219.151.125;C06.689.202;C08.381.187;C16.320.190;C16.614.213;A03.556.124;A03.556.124.526.767;A03.556.249.249.767;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
29289463,"Anaphylaxis;Child;Child, Preschool;Cross Reactions;Desensitization, Immunologic;Diet Therapy;Food Labeling;Humans;Immunoglobulin E;Peanut Hypersensitivity;Practice Guidelines as Topic;Prevalence;Quality of Life;Risk;United States",C20.543.480.099;M01.060.406;M01.060.406.448;G12.122.281;E02.095.465.425.450.310;E05.478.610.310;E02.642.249;J01.576.423.850.600.400;J01.576.761.400.450;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;C20.543.480.370.572.750;N04.761.700.350.650;N05.700.350.650;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;Z01.107.567.875
29289462,"Adolescent;Allergens;Animals;Biopsy;Cattle;Child;Child, Preschool;Cytokines;Eosinophilic Esophagitis;Eosinophils;Esophagus;Humans;Immunophenotyping;Lymphocyte Activation;Milk;Milk Hypersensitivity;Milk Proteins;Th2 Cells",M01.060.057;D23.050.063;B01.050;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;B01.050.150.900.649.313.500.380.271;M01.060.406;M01.060.406.448;D12.644.276.374;D12.776.467.374;D23.529.374;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;A03.556.875.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525;C20.543.480.370.500;D12.776.256.626;G07.203.300.350.525.520;G07.203.300.428.626;J02.500.350.525.520;J02.500.428.626;A11.118.637.555.567.550.500.400.905;A11.118.637.555.567.569.200.400.905;A11.118.637.555.567.569.500.400.905;A15.145.229.637.555.567.550.500.400.750;A15.145.229.637.555.567.569.200.400.750;A15.145.229.637.555.567.569.500.400.750;A15.382.490.555.567.550.500.400.905;A15.382.490.555.567.569.200.400.905;A15.382.490.555.567.569.500.400.905
30841811,Piper,B01.650.940.800.575.912.250.812.666
29288952,Adolescent;Brain-Derived Neurotrophic Factor;Brain-Derived Neurotrophic Factor;Child,M01.060.057;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;M01.060.406
29288875,"Activin Receptors, Type I;Blotting, Western;Bone Morphogenetic Proteins;Cells, Cultured;Connective Tissue Cells;Enzyme-Linked Immunosorbent Assay;Humans;Myositis Ossificans;Real-Time Polymerase Chain Reaction;Signal Transduction;Stem Cells;Toll-Like Receptor 3;Ossification, Heterotopic",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;A11.251;A11.329;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;E05.393.620.500.706;G02.111.820;G04.835;A11.872;D12.776.543.750.705.910.500.300;C23.550.751
29288763,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Succinates;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.241.081.337.759;E05.940
29288762,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Propionates;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;D02.241.081.751;D10.251.400.706;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29288643,Cystitis;Prostatitis;Surveys and Questionnaires;Symptom Flare Up;Urinary Bladder,C12.777.829.495;C13.351.968.829.495;C12.294.565.750;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.550.291.937.500;A05.810.890
29288545,Adult;Aged;Benzazepines;Caloric Restriction;Counseling;Humans;Life Style;Middle Aged;Obesity;Weight Loss;Young Adult,M01.060.116;M01.060.116.100;D03.633.100.079;E02.642.249.200;G07.203.650.240.340.150;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963;M01.060.116.815
29287848,"Child;Child, Preschool;Humans;Larynx;Pneumonia, Aspiration;Recurrent Laryngeal Nerve;Recurrent Laryngeal Nerve Injuries;Vocal Cord Paralysis;Voice;Dysphonia;Synkinesis",M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;A04.329;C08.381.677.529;C08.730.610.529;A08.800.050.050.925.450.700;A08.800.050.600.825.450.700;A08.800.800.060.920.450.700;A08.800.800.120.900.450.700;C08.360.424.500;C09.400.424.500;C10.292.200.937.750.500;C10.900.300.218.887.750.500;C26.915.300.400.912.750.500;C08.360.931;C09.400.931;C10.292.887.800;C10.597.622.943;C23.888.592.636.943;G09.772.925;C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325;C10.597.350.675;C23.888.592.350.675
29287818,Adolescent;Adult;Cerebral Palsy;Clinical Competence;Follow-Up Studies;Humans;Learning Curve;Middle Aged;Operative Time;Orthopedic Surgeons;Prospective Studies;Scoliosis;Treatment Outcome;Cerebral Palsy,M01.060.057;M01.060.116;C10.228.140.140.254;I02.399.630.210;N04.761.210;N05.715.175;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;F02.784.629.529.274;M01.060.116.630;E04.614.374.500;N02.421.585.753.374.500;M01.526.485.810.910.875;N02.360.810.910.875;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C05.116.900.800.875;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C10.228.140.140.254
29287815,Adolescent;Humans;Kyphosis;Postoperative Complications;Radiography;Retrospective Studies;Sacrum;Scoliosis;Spinal Fusion;Thoracic Vertebrae;Treatment Outcome;Scoliosis,M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;C05.116.900.800.500;C23.550.767;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.834.717;C05.116.900.800.875;E04.555.100.700;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C05.116.900.800.875
29287814,Adolescent;Child;Disease Progression;Follow-Up Studies;Humans;Lumbar Vertebrae;Retrospective Studies;Scoliosis;Surgical Stapling;Thoracic Vertebrae;Treatment Outcome,M01.060.057;M01.060.406;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;A02.835.232.834.519;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;E04.987.775.800;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29287035,"Adolescent;Autism Spectrum Disorder;Child;Child, Preschool;Humans;Insurance Claim Review;Insurance Coverage;Insurance, Health;Mandatory Programs;United States",M01.060.057;F03.625.164.113;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.215;N03.219.521.576.265;N03.219.521.576.343;I01.880.604.622;N03.706.657;N04.452.521;Z01.107.567.875
29287012,,
29286980,,
29286977,Adolescent;Epidermal Cyst;Gardner Syndrome;Humans,M01.060.057;C04.182.254;C04.557.470.035.215.100.500;C04.588.274.476.411.307.089.393;C04.700.100.392;C06.301.371.411.307.090.500;C06.405.249.411.307.090.500;C06.405.469.158.356.090.500;C06.405.469.491.307.090.500;C06.405.469.578.249.393;C16.131.077.393;C16.320.700.100.393;B01.050.150.900.649.313.988.400.112.400.400
29286848,Adolescent;Humans;Qualitative Research,M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.241.850
29286846,Early Detection of Cancer;Humans;Lung Neoplasms;Mass Screening;Primary Health Care,E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N04.590.233.727
29286575,,
29286570,"Leukemia, Myeloid, Acute;Neutropenia",C04.557.337.539.275;C15.378.553.546.184.564
29286562,,
29286549,Hematopoietic Stem Cell Transplantation;Osteochondroma;Osteonecrosis;Slipped Capital Femoral Epiphyses;Whole-Body Irradiation,E02.095.147.500.500.500;E04.936.225.687.500;C04.557.450.565.575.610;C05.116.099.708.670;C05.116.852;C23.550.717.732;C05.116.099.708.928;C05.116.425.500;E02.815.814;E05.980
29286389,Animals;Cell Culture Techniques;Cell Differentiation;Humans;Interneurons;Mice;Mouse Embryonic Stem Cells,B01.050;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;G04.152;B01.050.150.900.649.313.988.400.112.400.400;A08.675.358;A11.671.358;B01.050.150.900.649.313.992.635.505.500;A11.872.700.250.875
29286183,Leiomyosarcoma,C04.557.450.590.455;C04.557.450.795.455
29285583,Child;Humans;Pediatrics,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670
29284596,"Adolescent;Child;Child, Preschool;Disease-Free Survival;High-Throughput Nucleotide Sequencing;Humans;Infant;Neoplasm, Residual;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Risk Assessment;Survival Rate",M01.060.057;M01.060.406;M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.697.700;C23.550.727.700;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
29284279,Oceanic Ancestry Group;Obesity,M01.686.508.600;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29284026,"Ambulatory Care Facilities;Education, Medical;Humans;Monte Carlo Method;Philadelphia;Preventive Health Services;Quality-Adjusted Life Years;Students, Medical",N02.278.035;I02.358.399;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.525;L01.906.394.422;N05.715.360.750.540;N06.850.520.830.525;Z01.107.567.875.500.550.525;Z01.433.820;N02.421.726;E05.318.740.100.500.700;N01.224.935.530.700;M01.848.769.602
29283699,Critical Care Outcomes;Critical Care;Physicians;Respiration,N04.761.559.590.399.250;N05.715.360.575.575.200;N05.715.360.575.575.399.250;E02.760.190;N02.421.585.190;M01.526.485.810;N02.360.810;G09.772.705
29283619,,
29283439,"Adolescent;Autophagy;Biomarkers;Child;Exome;Fibroblasts;Heredodegenerative Disorders, Nervous System;Humans;Intellectual Disability;Leucine;Mechanistic Target of Rapamycin Complex 1;Mutation;Oligosaccharides;Phagosomes;Phenotype;Protein-Serine-Threonine Kinases;Puerto Rico",M01.060.057;G04.146.399;G04.417.350.091;D23.101;M01.060.406;G05.360.340.011;A11.329.228;C10.574.500;C16.320.400;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;D12.125.070.637;D12.125.142.441;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;G05.365.590;D09.698.629;A11.284.430.214.190.875.190.700;G05.695;D08.811.913.696.620.682.700;Z01.107.084.900.750;Z01.639.880.750
29282873,"Bariatric Surgery;Humans;Obesity, Morbid;Pain Management",E02.570.500.062;E04.062;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;E02.745;N04.590.607.500
29282815,Adult;Cerebral Hemorrhage;Cross-Sectional Studies;Hemophilia A;Hemophilia B;Humans;Middle Aged;Prevalence;Risk Factors;Hemophilia B;Magnetic Resonance Imaging;Prevalence;Risk Factors,M01.060.116;C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;E01.370.350.825.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29282788,,
29282646,Animals;Antioxidants;Biological Products;Drug Delivery Systems;Endothelium;Humans;Antioxidants,B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;D20.215;E02.319.300;A10.272.491;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.217;D27.505.696.706.125;D27.720.799.047
29282469,,
29282253,,
29282086,"Adolescent;Child;Education, Medical;Health Education;Humans;Mass Screening;Mental Health Services;Neurodevelopmental Disorders;Rheumatic Diseases;Education, Medical;Mental Health;Pediatrics",M01.060.057;M01.060.406;I02.358.399;I02.233.332;N02.421.726.407;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F04.408;N02.421.461;F03.625;C05.799;C17.300.775;I02.358.399;F02.418;N01.400.500;H02.403.670
29280785,,
29280782,,
29280680,Immunohistochemistry,E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512
29280236,Elasticity Imaging Techniques,E01.370.350.850.270
29280227,Glymphatic System,A07.521;A08.186.211.150;A15.382.520.075
29280137,,
29279902,,
29279609,"Base Sequence;Child;Child, Preschool;Chromosome Breakpoints;Comparative Genomic Hybridization;DNA Copy Number Variations;De Lange Syndrome;Exons;Facies;Gene Duplication;Genetic Association Studies;Histone Deacetylases;Humans;Phenotype;Repressor Proteins;Sequence Analysis, DNA;Sequence Deletion;X Chromosome Inactivation",G02.111.570.080;G05.360.080;L01.453.245.667.080;M01.060.406;M01.060.406.448;G05.200.210.170.500;E05.393.285.240;E05.393.520.500;E05.393.661.187;G05.365.795.297.500;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;G05.360.340.024.340.137.232;C23.550.291.812;E01.370.600.230;G05.365.590.320;G05.558.320;E05.393.385;D08.811.277.087.520;B01.050.150.900.649.313.988.400.112.400.400;G05.695;D12.776.260.703;D12.776.930.780;E05.393.760.700;G05.365.590.762;G05.558.800;G05.308.203.249.970
29279413,Cardiopulmonary Resuscitation;Heart Arrest;Pediatrics;Survival,E02.365.647.110;C14.280.383;H02.403.670;I03.784
29279362,"Adolescent;Chest Wall Oscillation;Child;Child, Preschool;Databases, Factual;Hematopoietic Stem Cell Transplantation;Humans;Infant;Postoperative Complications;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Retrospective Studies;Survival Analysis;Treatment Outcome;Young Adult;Adult;Respiration, Artificial;Critical Care;Hematopoietic Stem Cell Transplantation;High-Frequency Ventilation;Mortality;Respiratory Insufficiency",M01.060.057;E02.880.130;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C23.550.767;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;M01.060.116;E02.041.625;E02.365.647.729;E02.880.820;E02.760.190;N02.421.585.190;E02.095.147.500.500.500;E04.936.225.687.500;E02.041.625.508;E02.880.820.508;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C08.618.846
29278965,Trial of Labor,G08.686.784.769.326.660
29278896,"Adolescent;Case-Control Studies;Child;Disease Progression;Double-Blind Method;Humans;Lung;Maximal Respiratory Pressures;Morpholinos;Muscular Dystrophy, Duchenne;Respiratory Function Tests;Vital Capacity;Dystrophin;Maximal Respiratory Pressures;Maximal Respiratory Pressures;Vital Capacity",M01.060.057;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;C23.550.291.656;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E01.370.386.700.550;D03.383.533.640.562;D13.695.578.424.337;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.386.700;E01.370.386.700.485.750.900;G09.772.850.970;D12.776.210.500.250;D12.776.220.250;D12.776.543.250;E01.370.386.700.550;E01.370.386.700.550;E01.370.386.700.485.750.900;G09.772.850.970
29278774,Adolescent;Adult;Cerebral Cortex;Cohort Studies;Data Accuracy;Datasets as Topic;Humans;Magnetic Resonance Imaging;Neuroimaging;Quality Control;Artifacts;Motion,M01.060.057;M01.060.116;A08.186.211.200.885.287.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;J01.897.608;E05.047;G01.482
29278618,,
29278591,"Clinical Competence;Documentation;Education, Medical, Undergraduate;Humans;Medical Records;Patient Simulation;Reproducibility of Results",I02.399.630.210;N04.761.210;N05.715.175;L01.453.245;I02.358.399.450;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;I02.903.847.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
29277722,"Heparitin Sulfate;Heparan Sulfate Proteoglycans;Exostoses, Multiple Hereditary",D09.698.373.425;D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330
29277463,Quality Improvement,J01.293.754;N04.761.744
29277125,"Patient Protection and Affordable Care Act;Economics, Behavioral;Motivation;Obesity;Weight Loss",N03.219.521.576.343.918;N03.706.615.806;F04.096.628.286;N03.219.215;F01.658;F01.752.543.500.750;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963
29277028,Adolescent;Cohort Studies;Humans;Incidence;Kyphosis;Lumbosacral Region;Pelvis;Postural Balance;Pressure;Radiography;Regression Analysis;Retrospective Studies;Rotation;Scoliosis;Postural Balance,M01.060.057;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C05.116.900.800.500;A01.923.176.519;A01.923.600;G11.427.690;G11.561.790.541.595;G01.374.715;E01.370.350.700;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.482.703;C05.116.900.800.875;G11.427.690;G11.561.790.541.595
29276092,"Anesthesia, Cardiac Procedures;Anesthesiology;Fellowships and Scholarships;Humans;Internship and Residency;Physician Executives;Program Development;United States;Education, Medical, Graduate",E03.155.403;H02.403.066;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.526.070.700;M01.526.485.800;N02.360.800;N04.452.760;Z01.107.567.875;I02.358.337.350;I02.358.399.350
29276004,"Adolescent;Amino Acid Sequence;Animals;Behavior, Animal;Child;Child, Preschool;Dendrites;Drosophila Proteins;Drosophila melanogaster;Epilepsy;GTP-Binding Proteins;Gene Dosage;HEK293 Cells;Humans;Mutation, Missense;Phenotype;Synapses;Tumor Suppressor Proteins;Drosophila melanogaster;Intellectual Disability;Ubiquitination",M01.060.057;G02.111.570.060;L01.453.245.667.060;B01.050;F01.145.113;M01.060.406;M01.060.406.448;A08.675.256;A11.284.180.225;A11.671.240;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;C10.228.140.490;D08.811.277.040.330.300;D12.776.157.325;G05.380.350;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;G05.695;A08.850;A11.284.149.165.420.780;D12.776.624.776;B01.050.500.131.617.720.500.500.750.310.250.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
29275977,"Adult;Aged;Cerebral Cortex;Demyelinating Diseases;Humans;Magnetic Resonance Imaging;Middle Aged;Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Neurologic Examination;Oligoclonal Bands;Spinal Cord",M01.060.116;M01.060.116.100;A08.186.211.200.885.287.500;C10.314;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;E01.370.376.550;E01.370.600.550;D12.776.124.486.485.114.715;D12.776.124.790.651.114.715;D12.776.377.715.548.114.715;D23.101.613;A08.186.854
29275926,"Cohort Studies;Humans;Infant, Extremely Low Birth Weight;Infant, Newborn;Infant, Premature;Positive-Pressure Respiration;Respiration, Artificial;Respiratory Distress Syndrome, Newborn;Bronchopulmonary Dysplasia;Infant, Premature;Respiration, Artificial;Respiratory Distress Syndrome, Newborn;Ventilator-Induced Lung Injury",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.460.600.500;M01.060.703.520;M01.060.703.520.520;E02.041.625.790;E02.880.820.790;E02.041.625;E02.365.647.729;E02.880.820;C08.381.842;C08.618.842;C16.614.521.563;C08.381.520.750.500;C16.614.521.125;M01.060.703.520.520;E02.041.625;E02.365.647.729;E02.880.820;C08.381.842;C08.618.842;C16.614.521.563;C08.381.520.750
29275827,"Animals;Animals, Newborn;Cardiac Surgical Procedures;Disease Models, Animal;Education, Medical, Graduate;Heart Defects, Congenital;Models, Educational;Surgeons;Swine;Thoracic Surgery",B01.050;B01.050.050.282;E04.100.376;E04.928.220;C22.232;E05.598.500;E05.599.395.080;I02.358.337.350;I02.358.399.350;C14.240.400;C14.280.400;C16.131.240.400;E05.599.545;I02.903.302;M01.526.485.810.910;N02.360.810.910;B01.050.150.900.649.313.500.880;H02.403.810.803
29275149,"Adult;Blood Cells;Cohort Studies;Humans;Microscopy, Fluorescence;Middle Aged;Mitochondria;Mitochondrial Dynamics;Sepsis;Microscopy;Mitochondria;Sepsis",M01.060.116;A11.118;A15.145.229;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.458;E05.595.458;M01.060.116.630;A11.284.430.214.190.875.564;A11.284.835.626;G04.599.750;C01.539.757;C23.550.470.790.500;E01.370.350.515;E05.595;H01.671.617.562;A11.284.430.214.190.875.564;A11.284.835.626;C01.539.757;C23.550.470.790.500
29275083,"Guidelines as Topic;Hospital Design and Construction;Humans;Leadership;Patient Satisfaction;Radiology Department, Hospital;Architecture",N04.761.700.350;N05.700.350;J01.086.339.250;N02.278.200.403;B01.050.150.900.649.313.988.400.112.400.400;F01.752.609;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;N02.278.216.500.968.695;N04.452.442.422.695;J01.086
29275055,"Coronary Artery Bypass;Disease Management;Humans;Intraoperative Complications;Middle Aged;Mitral Valve;Mitral Valve Insufficiency;Heart Septal Defects, Atrial;Cardiopulmonary Bypass;Coronary Artery Bypass;Mitral Valve Annuloplasty;Mitral Valve Insufficiency;Papillary Muscles;Pectinidae;Echocardiography, Transesophageal;Echocardiography",E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505;M01.060.116.630;A07.541.510.507;C14.280.484.461;C14.240.400.560.375;C14.280.400.560.375;C16.131.240.400.560.375;E04.292.413;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E04.100.376.062.500;E04.928.220.109.500;C14.280.484.461;A02.633.580.680;A07.541.510.619;A07.541.704.750;B01.050.500.644.080.660;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
29274372,"Humans;Image Processing, Computer-Assisted;Infant;Infant, Newborn;Infant, Very Low Birth Weight;Ophthalmoscopy;Retinopathy of Prematurity;Sensitivity and Specificity;Telemedicine",B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.703;M01.060.703.520;M01.060.703.520.460.600;E01.370.380.560;C11.768.836;C16.614.521.731;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;H02.403.840;L01.178.847.652;N04.590.374.800
29274118,Child;Clinical Trial;Costs and Cost Analysis;Leukemia,M01.060.406;V03.175.250;N03.219.151;C04.557.337
29274015,,
29273844,Adolescent;Attitude;Child;Habits;Humans;Knowledge;Marijuana Abuse;Marijuana Smoking;Multiple Sclerosis;Perception;Prevalence;Surveys and Questionnaires;Young Adult;Adolescent;Cannabis;Cannabis;Multiple Sclerosis,M01.060.057;F01.100;M01.060.406;F01.145.466;B01.050.150.900.649.313.988.400.112.400.400;K01.468;C25.775.635;F03.900.635;F01.145.610.875;F01.145.805.250.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;F02.463.593;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;M01.060.057;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.859.937.055.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29273807,,
29273434,Comorbidity;Epidemiology;Gender Identity;Health Services;Parkinson Disease,N05.715.350.225;N06.850.490.687;H02.403.720.500;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;N02.421;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29273393,Neoplasms;Drug Therapy;Immunotherapy;Macrophages;Neoplasms,C04;E02.319;E02.095.465.425;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;C04
29273104,"Algorithms;Alopecia Areata;Child;Diagnosis, Computer-Assisted;Hair;Humans;Image Processing, Computer-Assisted;Photography;Scalp;Severity of Illness Index",G17.035;L01.224.050;C17.800.329.937.122.147;M01.060.406;E01.158;L01.313.500.750.100.158;A17.360;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.600;E05.712;A01.456.810;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
29272703,"Amyotrophic Lateral Sclerosis;Biomarkers;Cells, Cultured;Cellular Reprogramming;Chromosomal Proteins, Non-Histone;Chromosome Mapping;Fibroblasts;Genomics;Heterochromatin;High-Throughput Nucleotide Sequencing;Histones;Humans;Proteomics;Heterochromatin;Proteomics",C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;D23.101;A11.251;G04.152.262;G05.135;D12.776.660.235;D12.776.664.235;E05.393.183;A11.329.228;H01.158.273.180.350;H01.158.273.343.350;A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;E05.393.760.319;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
29272532,,
29272484,"Adolescent;Adult;Antibodies, Antineutrophil Cytoplasmic;Antibodies, Bacterial;Antibodies, Fungal;Biomarkers;Child;Cohort Studies;Crohn Disease;Humans;Immunoglobulin A;Middle Aged;Postoperative Complications;Prognosis;Young Adult;African Americans;Crohn Disease;Inflammatory Bowel Diseases;Serology",M01.060.057;M01.060.116;D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050;D12.776.124.486.485.114.107;D12.776.124.790.651.114.125;D12.776.377.715.548.114.125;D12.776.124.486.485.114.179;D12.776.124.790.651.114.179;D12.776.377.715.548.114.179;D23.101;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C06.405.205.731.500;C06.405.469.432.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.026;D12.776.124.790.651.114.619.026;D12.776.377.715.548.114.619.026;M01.060.116.630;C23.550.767;E01.789;M01.060.116.815;M01.686.508.100.100;M01.686.754.100;C06.405.205.731.500;C06.405.469.432.500;C06.405.205.731;C06.405.469.432;H02.781
29272482,Aged;Case-Control Studies;Hospitalization;Humans;Inflammatory Bowel Diseases;Interferon-gamma;Latent Tuberculosis;Mass Screening;Middle Aged;Mycobacterium tuberculosis;Retrospective Studies;Time-to-Treatment;Tuberculin Test;Tumor Necrosis Factor-alpha;Tuberculosis,M01.060.116.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;C01.252.410.040.552.846.122;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.928;N02.421.585.928;E01.370.225.812.871.800;E05.200.812.871.800;E05.478.594.890.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;C01.252.410.040.552.846
29272255,"Animals;Composite Tissue Allografts;Forelimb;Graft Survival;Interleukin-2;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;T-Lymphocytes, Regulatory",B01.050;A01.941.843;A13.395;G12.875.545.340;D12.644.276.374.465.021;D12.644.276.374.480.372;D12.776.467.374.465.021;D12.776.467.374.480.372;D23.529.374.465.155;D23.529.374.480.372;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
29272104,"Adolescent;Adult;Biomarkers;Blood Platelets;Child;Chromatography, Liquid;Friedreich Ataxia;Humans;Iron-Binding Proteins;Mass Spectrometry;Middle Aged;Rare Diseases;Sensitivity and Specificity;Young Adult",M01.060.057;M01.060.116;D23.101;A11.118.188;A15.145.229.188;M01.060.406;E05.196.181.400;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.427;D12.776.556.579;E05.196.566;M01.060.116.630;C23.550.291.906;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116.815
29270984,"Animals;Blood Platelets;Breeding;DNA Mutational Analysis;Gene Expression;Mutation;Phenotype;Receptors, Lysophospholipid;Zebrafish;Genetics;Blood Platelets;Thrombosis;Zebrafish",B01.050;A11.118.188;A15.145.229.188;E05.820.150;G05.090;E05.393.760.700.300;G05.297;G05.365.590;G05.695;D12.776.543.750.695.420;B01.050.150.900.493.200.244.828;H01.158.273.343;A11.118.188;A15.145.229.188;C14.907.355.830;B01.050.150.900.493.200.244.828
29270611,"Delivery of Health Care;Diffusion of Innovation;Evidence-Based Practice;Financing, Government;Health Services Research;Humans;Organizational Innovation;Research Support as Topic",N04.590.374;N05.300;L01.143.320;H02.249;N03.219.521.346;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;N04.452.610;N03.219.483.645
29270464,,
29270371,Aortic Aneurysm;Transforming Growth Factor beta,C14.907.055.239;C14.907.109.139;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775
29270332,Alagille Syndrome;Genetic Therapy;Haploinsufficiency;Liver Diseases,C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051;E02.095.301;E05.393.420.301;G05.365.590.029.530.587;G05.380.350.500;C06.552
29270278,,
29269848,,
29269355,Heart Block,C14.280.067.558;C14.280.123.500;C23.550.073.425
29269198,"Apnea;Child Restraint Systems;Hospitalization;Humans;Infant, Newborn;Infant, Premature;Intensive Care Units, Neonatal;Mass Screening;Retrospective Studies;Risk Factors;Infant, Premature",C08.618.085;C23.888.852.130;E07.490.249;E07.700.175;J01.637.708.175;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;N02.278.388.493.390.380;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.703.520.520
29269196,"DNA Helicases;Ectodermal Dysplasia;Genotyping Techniques;Heterozygote;High-Throughput Nucleotide Sequencing;Humans;Infant, Newborn;Nails, Malformed;Pedigree;Sequence Deletion;Skin Diseases, Genetic;Whole Exome Sequencing;Dermatoglyphics;Whole Exome Sequencing",D08.811.277.040.025.159;D08.811.399.340;C16.131.077.350;C16.131.831.350;C16.320.850.250;C17.800.804.350;C17.800.827.250;E05.393.442;G05.380.383;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C23.300.820;E05.393.673;G05.365.590.762;G05.558.800;C16.320.850;C17.800.827;E05.393.760.700.825.500;E05.256;I01.198.780.937.343;E05.393.760.700.825.500
29268729,"Botswana;Clinical Competence;Humans;Internship and Residency;Personal Satisfaction;Personnel Loyalty;Pilot Projects;Program Development;Program Evaluation;Schools, Medical;Surveys and Questionnaires;Capacity Building;Global Health;Education, Medical, Graduate;Health Workforce;Africa South of the Sahara",Z01.058.290.175.230;I02.399.630.210;N04.761.210;N05.715.175;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F01.145.677;N04.452.677.460;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;N04.452.760;E05.337.820;N04.761.685;N05.715.360.650;I02.783.495.552;N02.278.020.578;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N02.138;N04.452.105;H02.403.371;N01.400.337;I02.358.337.350;I02.358.399.350;N02.350;N04.452.525.500;N05.300.420.400;Z01.058.290
29267955,,
29267876,,
29267283,"A549 Cells;Adenocarcinoma;Adenocarcinoma of Lung;Adenocarcinoma, Mucinous;Adenoma;Animals;Carcinoma, Non-Small-Cell Lung;Cell Line, Tumor;Disease Progression;Forkhead Box Protein M1;Heterografts;Humans;Lung Neoplasms;Mice;Mice, Inbred NOD;Mice, Transgenic;Promoter Regions, Genetic;Proteins",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;C04.557.470.200.025;C04.557.470.200.025.022;C04.588.894.797.520.055;C04.557.470.200.025.075;C04.557.470.590.075;C04.557.470.035;B01.050;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;A11.251.210.190;A11.251.860.180;C23.550.291.656;D12.776.260.950.249.063;D12.776.930.977.249.063;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776
29266831,Epidemiology;Gender Identity;Graft Survival;Kidney Transplantation;Pregnancy,H02.403.720.500;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;G12.875.545.340;E02.870.500;E04.936.450.485;E04.950.774.400;G08.686.784.769
29266824,Adult;Aged;Body Mass Index;Continental Population Groups;Discrimination (Psychology);Humans;Middle Aged;Obesity;Philadelphia;Prejudice;Young Adult;Discrimination (Psychology);Obesity;Continental Population Groups,M01.060.116;M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.686.508;F02.463.593.257;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;Z01.107.567.875.500.550.525;Z01.433.820;F01.145.813.550;F01.829.595;M01.060.116.815;F02.463.593.257;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;M01.686.508
29266786,"Emergency Nursing;Emergency Service, Hospital;Factor Analysis, Statistical;Humans;Nurses;Occupational Health;Perception;Psychometrics;Reproducibility of Results;Surveys and Questionnaires;United States;Workforce;Workplace;Workplace Violence;Emergencies;Nursing;Psychometrics;Safety;Surveys and Questionnaires;Workplace Violence",H02.478.676.200;N02.421.533.200;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.650;N02.360.650;N01.400.525;F02.463.593;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;N04.452.525;N01.824.245.925;N04.452.677.975;I01.198.240.856.912;I01.880.735.900.912;C23.550.291.781;N06.230.100.083;N06.850.376;H02.478;N04.452.758.377;F04.711.780;N06.850.135.060.075;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I01.198.240.856.912;I01.880.735.900.912
29266189,Clofarabine;Precursor Cell Lymphoblastic Leukemia-Lymphoma,D03.633.100.759.646.138.309;D13.570.065.195;D13.695.667.138.309;D13.695.827.068.309;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
29266024,,
29265955,"Animals;Disease Models, Animal;Drug Discovery;Drug Evaluation, Preclinical;Gastroenteritis;History, 20th Century;History, 21st Century;Humans;Rotavirus;Rotavirus Infections;Rotavirus Vaccines;United States;Gastroenteritis;Rotavirus",B01.050;C22.232;E05.598.500;E05.599.395.080;E05.295;H01.158.703.007.675;H01.181.466.675;E05.290.750;E05.337.550;C06.405.205;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;B04.820.630.790;C02.782.791.814;D20.215.894.899.760;Z01.107.567.875;C06.405.205;B04.820.630.790
29264556,Cold-Shock Response;Energy Metabolism;Hypothalamus;Obesity;Oxytocin,G07.775.249;G03.295;A08.186.211.180.497;A08.186.211.200.317.357;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D06.472.699.631.692.433;D12.644.548.691.692.433
29264382,Pets;Allergy and Immunology;Sarcoidosis,B01.050.050.116.600;H02.403.044;C15.604.515.827
29263859,,
29263752,Scoliosis;Surgical Wound Infection,C05.116.900.800.875;C01.539.947.692;C23.550.767.925
29263008,Cohort Studies;Genome-Wide Association Study;Humans;Lewy Body Disease,E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.400;C10.228.140.380.422;C10.228.662.600.200;C10.574.531;F03.615.400.512
29262722,Diagnostic Imaging;Ankle Injuries,E01.370.350;C26.558.100
29262326,"CD8-Positive T-Lymphocytes;Cells, Cultured;Cytotoxicity, Immunologic;HIV Infections;Humans;Immunologic Memory;Lymphoid Tissue;Receptors, CXCR5;HIV;Lymphoid Tissue",A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;A11.251;G12.287;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.500;A10.549;A15.382.520.604;D12.776.543.750.695.160.500.500;D12.776.543.750.705.852.125.500.500;B04.820.650.589.650.350;A10.549;A15.382.520.604
29261783,"Adolescent;Adult;Child;Child, Preschool;Fibroblasts;Friedreich Ataxia;Genomic Instability;Humans;Iron-Binding Proteins;Longitudinal Studies;Lymphocytes;Time Factors;Trinucleotide Repeat Expansion;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;A11.329.228;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;C23.550.362;G05.365.590.335;G05.370;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.427;D12.776.556.579;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;G01.910.857;G02.111.570.080.708.800.140.865;G02.111.570.080.708.800.500.850.200;G05.360.080.708.800.074.865;G05.360.080.708.800.500.850.200;G05.360.340.024.189.220.865;G05.360.340.024.850.500.850.200;G05.365.590.220.865;G05.558.220.865;M01.060.116.815
29261563,,
29261540,,
29261036,"Adult;Analgesics, Opioid;Feasibility Studies;Humans;Musculoskeletal System;Orthopedics;Pain Management;Pain Measurement;Pain, Postoperative;Prospective Studies;Robotics;Text Messaging;Trauma Centers;United States;Wounds and Injuries;Orthopedics;Telemedicine;Wounds and Injuries",M01.060.116;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;A02;H02.403.810.494;E02.745;N04.590.607.500;E01.370.600.550.324;C23.550.767.700;C23.888.592.612.832;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H01.671.293.643;J01.897.104.834;L01.224.050.375.630;L01.178.847.698.300.500;L01.559.423.906.377.666;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;Z01.107.567.875;C26;H02.403.810.494;H02.403.840;L01.178.847.652;N04.590.374.800;C26
29261028,Endothelium;Inflammation,A10.272.491;C23.550.470
29260263,"Adolescent;Child;Child, Preschool;Heart Failure;Humans;Incidence;Infant;Prevalence;Risk Factors;Epidemiology;Heart Failure;Incidence;Prevalence",M01.060.057;M01.060.406;M01.060.406.448;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H02.403.720.500;C14.280.434;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
29260224,"Acute Disease;Amoxicillin-Potassium Clavulanate Combination;Anti-Bacterial Agents;Cephalosporins;Child;Child, Preschool;Humans;Macrolides;Otitis Media;Pharyngitis;Primary Health Care;Quality of Life;Respiratory Tract Infections;Retrospective Studies;Sinusitis;Streptococcal Infections;Streptococcus pyogenes;Treatment Failure",C23.550.291.125;D02.065.589.099.374.160.060;D02.065.589.099.750.750.050.050.060;D02.886.108.750.750.050.050.060;D03.633.100.300.374.160.060;D03.633.100.300.750.750.050.050.500;D26.310.102;D27.505.954.122.085;D02.065.589.099.249;D02.886.665.074;D03.633.100.300.249;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;D02.540.505;D02.540.576.500;D04.345.674.500;C09.218.705.663;C07.550.781;C08.730.561;C09.775.649;N04.590.233.727;I01.800;K01.752.400.750;N06.850.505.400.425.837;C01.539.739;C08.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C08.460.692.752;C08.730.749;C09.603.692.752;C01.252.410.890;B03.353.750.737.872.575;B03.510.400.800.872.575;B03.510.550.737.872.575;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
29259794,Diet;Telemedicine;Obesity;Exercise;Weight Loss,G07.203.650.240;H02.403.840;L01.178.847.652;N04.590.374.800;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G11.427.410.698.277;I03.350;C23.888.144.243.963;G07.345.249.314.120.200.963
29259040,,
29259026,"Aging;Animals;Biomarkers;Cerebellum;Disease Models, Animal;Friedreich Ataxia;Iron-Binding Proteins;Mice, Inbred C57BL;Mice, Knockout;Mitochondria;Parvalbumins;Presynaptic Terminals;Purkinje Cells;Synapses;Vesicular Glutamate Transport Protein 1;Friedreich Ataxia",G07.345.124;B01.050;D23.101;A08.186.211.132.810.428.200;C22.232;E05.598.500;E05.599.395.080;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;D12.776.157.427;D12.776.556.579;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.034.700;D12.776.210.500.750;A08.675.542.145.750;A08.850.700;A11.284.149.165.420.780.700;A11.671.137.750;A11.671.501.145.750;A08.186.211.132.810.428.200.212.600;A08.675.784;A11.671.784;A08.850;A11.284.149.165.420.780;D12.776.157.530.450.162.887.625.500;D12.776.157.530.562.750.625.500;D12.776.543.585.450.162.887.625.500;D12.776.543.585.562.750.625.500;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300
29258993,"ARNTL Transcription Factors;Aging;Animals;CLOCK Proteins;Cell Differentiation;Circadian Clocks;Circadian Rhythm;Feedback, Physiological;Gene Expression Regulation;Homeostasis;Humans;Neoplasms;Organ Specificity;Regeneration;Signal Transduction;Sleep;Stem Cells;Aging;Circadian Rhythm;Regeneration;Stem Cells",D12.644.360.138.049;D12.776.260.103.249;D12.776.476.156.100;D12.776.930.125.249;G07.345.124;B01.050;D08.811.913.050.134.415.500.049;D12.644.360.138.100;D12.776.260.103.562;D12.776.476.156.200;D12.776.930.125.562;G04.152;G07.180.562.094.500;G07.180.562.190;G07.410.732;G05.308;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C04;G07.650;G16.762;G02.111.820;G04.835;F02.830.855;G11.561.803;A11.872;G07.345.124;G07.180.562.190;G16.762;A11.872
29258076,Brain Injuries;Indomethacin,C10.228.140.199;C10.900.300.087;C26.915.300.200;D03.633.100.473.420
29256268,"Administrative Claims, Healthcare;Adolescent;Adult;Aged;Data Collection;Databases, Factual;Drug Overdose;Emergency Service, Hospital;Humans;International Classification of Diseases;Lacerations;Middle Aged;Self-Injurious Behavior;Suicide, Attempted;United States;Wounds, Gunshot;Young Adult;Emergency Service, Hospital;Suicide",N04.452.859.564.137;M01.060.057;M01.060.116;M01.060.116.100;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;L01.313.500.750.300.188.400;L01.470.750.750;C25.775.383;E02.319.306.500.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;L01.453.245.945.400;C26.540;M01.060.116.630;F01.145.126.980;F01.145.126.980.875.600;I01.880.735.856.600;Z01.107.567.875;C26.986.900;M01.060.116.815;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;F01.145.126.980.875;I01.880.735.856
29256071,"Contrast Media;Embolization, Therapeutic;Humans;Image Enhancement;Lymphatic Diseases;Lymphatic System;Lymphatic Vessels;Lymphography;Magnetic Resonance Imaging;Thoracic Duct;Lymphography",D27.505.259.500;D27.720.259;E02.520.360;E02.926.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.600.350;L01.224.308.380;C15.604;A15.382.520;A15.382.520.301;E01.370.350.700.475;E01.370.350.825.500;A15.382.520.301.750;E01.370.350.700.475
29255892,,
29255881,,
29255880,,
29255879,,
29255877,,
29255845,,
29255284,"Animals;Bacteria;Bacterial Typing Techniques;Biodiversity;Gastrointestinal Microbiome;Gastrointestinal Tract;Humans;Metagenome;Metagenomics;RNA, Ribosomal, 16S",B01.050;B03;E01.370.225.875.150.125;E05.200.875.150.125;G16.500.275.157.049;N06.230.124.049;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;A03.556;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.550;H01.158.273.343.350.261;D13.444.735.686.670
29255238,,
29254108,Parkinson Disease,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29253868,"Adaptive Immunity;Adaptor Protein Complex 3;Animals;Autophagy;Dendritic Cells;Host-Pathogen Interactions;Humans;Inflammasomes;Interleukin-17;Interleukin-18;Interleukin-1beta;Mice;Mice, Inbred C57BL;Mice, Knockout;NLR Proteins;Phagocytosis;Salmonella Infections, Animal;Salmonella typhimurium;Transcriptional Activation",G12.450.050;D12.776.543.990.150.300;B01.050;G04.146.399;G04.417.350.091;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D05.500.224;D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.644.360.539;G04.417.350;G09.188.665;G12.450.564.809;G12.688;C01.252.400.310.821.706;C22.812;B03.440.450.425.800.200.825;B03.660.250.150.710.160.760;G05.308.800
29253711,"Adult;Botswana;Colorimetry;Cross-Over Studies;Dose-Response Relationship, Drug;Drug Monitoring;HIV Infections;Humans;Non-Randomized Controlled Trials as Topic;Pyrazinamide;Reproducibility of Results;Sensitivity and Specificity;Treatment Outcome;Tuberculosis;Young Adult;HIV;Pharmacokinetics;Point-of-Care Testing;Pyrazinamide;Tuberculosis",M01.060.116;Z01.058.290.175.230;E05.196.922.250;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;G07.690.773.875;G07.690.936.500;E01.370.520.200;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.250;N05.715.360.330.250.250.365.250;N06.850.520.450.250.250.365.250;D03.383.679.750;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C01.252.410.040.552.846;M01.060.116.815;B04.820.650.589.650.350;G03.787;G07.690.725;N04.590.874.500;D03.383.679.750;C01.252.410.040.552.846
29253531,"Acetals;Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29253178,,
29253154,"Aged;Aged, 80 and over;Aging;Biomarkers;Cardiovascular System;Double-Blind Method;Hormone Replacement Therapy;Humans;Hypogonadism;Testosterone;United States",M01.060.116.100;M01.060.116.100.080;G07.345.124;D23.101;A07;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;C19.391.482;D04.210.500.054.079.429.824;D06.472.334.851.968.984;Z01.107.567.875
29252955,Critical Care;Critical Illness;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Sepsis,E02.760.190;N02.421.585.190;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;C01.539.757;C23.550.470.790.500
29252940,"Adolescent;Anemia, Sickle Cell;Child;Child, Preschool;Critical Pathways;Delivery of Health Care;Emergency Medical Services;Emergency Service, Hospital;Fever;Hospitalization;Humans;Infant;Quality Improvement;Tertiary Care Centers;Young Adult",M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;M01.060.406;M01.060.406.448;N04.590.233.624.625;N04.590.275;N04.590.374;N05.300;N02.421.297;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C23.888.119.344;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;J01.293.754;N04.761.744;N02.278.421.830;M01.060.116.815
29252929,,
29252865,,
29252508,,
29250905,International Classification of Diseases;Diabetes Mellitus;Infection;Pharmacoepidemiology,L01.453.245.945.400;C18.452.394.750;C19.246;C01.539;H01.158.703.045;H02.403.720.500.650;H02.628.413
29250027,Machine Learning;Neurogranin;Phosphopyruvate Hydratase,G17.035.250.500;L01.224.050.375.530;D12.776.157.142.500;D12.776.631.640;D08.811.520.241.300.500
29249689,Aging;Metabolism;NAD;Nicotinamide Mononucleotide;Nicotinamide Phosphoribosyltransferase;Sirtuins,G07.345.124;G03;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D13.695.827.648;D08.811.913.400.725.575;D08.811.277.087.520.200.650;D08.811.913.400.725.115.961;D12.776.476.900
29249580,"Adult;Cardiopulmonary Bypass;Echocardiography;Echocardiography, Transesophageal;Endocarditis, Bacterial;Humans;American Heart Association;Cardiopulmonary Bypass;Fistula;Heart Failure;Endocarditis;Mitral Valve;Pneumonia;Echocardiography, Transesophageal;Echocardiography;Heart Septal Defects, Ventricular",M01.060.116;E04.292.413;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407;B01.050.150.900.649.313.988.400.112.400.400;N03.540.630.780.110;E04.292.413;C23.300.575;C14.280.434;C14.280.282;A07.541.510.507;C08.381.677;C08.730.610;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.240.400.560.540;C14.280.400.560.540;C16.131.240.400.560.540
29249244,"Germ-Line Mutation;Guidelines as Topic;Humans;Sequence Analysis, DNA",G05.365.590.350;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;E05.393.760.700
29249008,"Adolescent;Appendicitis;Child;Child, Preschool;Diagnosis, Differential;Humans;Magnetic Resonance Imaging;Predictive Value of Tests;Retrospective Studies;Sensitivity and Specificity;Tomography, X-Ray Computed;Ultrasonography;Appendicitis;Child",M01.060.057;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406;M01.060.406.448;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406
29248757,"Antibody-Dependent Cell Cytotoxicity;CD4 Antigens;HIV Antibodies;HIV Infections;HIV-1;Humans;Serum;env Gene Products, Human Immunodeficiency Virus;Antibody-Dependent Cell Cytotoxicity;HIV-1",G12.287.070;D12.776.543.750.705.852.420.810.500;D12.776.543.750.830.700.025;D23.050.301.264.894.100;D23.101.100.894.100;D12.776.124.486.485.114.254.150.440;D12.776.124.790.651.114.254.150.440;D12.776.377.715.548.114.254.150.440;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;A12.207.152.846;A15.145.846;D12.776.964.775.325.164;D12.776.964.775.562.500;D12.776.964.970.880.325.164;G12.287.070;B04.820.650.589.650.350.400
29248746,"Antiviral Agents;Hepatitis B virus;Hepatitis B, Chronic;Humans;Research;Hepatitis B;Hepatitis D;Carcinoma, Hepatocellular",D27.505.954.122.388;B04.280.375.650.425;B04.450.390.650.425;C02.256.430.400.100;C02.440.435.100;C06.552.380.350.100;C06.552.380.705.437.100;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644;C02.256.430.400;C02.440.435;C06.552.380.705.437;C02.440.450;C02.782.450;C06.552.380.705.450;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160
29248362,Cardiovascular Diseases;China;Data Collection;Documentation;Epidemiologic Studies;Humans;Morbidity;Quality Improvement;Risk Factors,C14;Z01.252.474.164;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;L01.453.245;E05.318.372.500;N05.715.360.330.500;N06.850.520.450.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;J01.293.754;N04.761.744;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29248186,"Accidents;Adult;African Americans;Aged;Aged, 80 and over;Emotions;Humans;Interviews as Topic;Mental Health;Middle Aged;Psychiatric Status Rating Scales;Qualitative Research;Social Environment;Survivors;United States;Urban Population;Violence;Wounds and Injuries;Young Adult;Mental Health",N06.850.135;M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;M01.060.116.100.080;F01.470;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;F02.418;N01.400.500;M01.060.116.630;F04.711.513.653;H01.770.644.241.850;I01.880.853.500;M01.860;Z01.107.567.875;N01.600.900;I01.198.240.856;I01.880.735.900;C26;M01.060.116.815;F02.418;N01.400.500
29247836,"Chromosome Deletion;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 11;Gene Amplification;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Gene Regulatory Networks;Humans;N-Myc Proto-Oncogene Protein;Neuroblastoma;Transcriptome;Neuroblastoma",C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.235.240;G05.360.162.520.300.235.240;A11.284.187.520.300.325.355;G05.360.162.520.300.325.355;G05.308.250;G05.365.590.310;G05.558.315;E05.393.332;G05.308.370;G05.360.080.689.360;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G02.111.873.750;G05.297.700.750;G05.360.920;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
29247076,,
29246577,"Adult;Child Development;Child, Preschool;Fetal Therapies;Follow-Up Studies;Humans;Infant;Infant, Newborn;Meningomyelocele;Neurodevelopmental Disorders;Pregnancy;Prospective Studies;Single-Blind Method;Treatment Outcome;Ankle;Knee;Meningomyelocele",M01.060.116;F01.525.200;G07.345.374.750;M01.060.406.448;E02.467;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C10.500.680.610;C16.131.666.680.610;F03.625;G08.686.784.769;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A01.378.610.250.149;A01.378.610.450;C10.500.680.610;C16.131.666.680.610
29246505,"Acetates;Animals;Benzyl Compounds;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.241.081.018;D10.251.400.045;B01.050;D02.455.426.559.389.140;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29246363,"Adolescent;Biomarkers;Cardiovascular Diseases;Child;Combined Modality Therapy;Diabetes Mellitus, Type 2;Diet Therapy;Drug Therapy, Combination;Echocardiography;Exercise Therapy;Follow-Up Studies;Heart Ventricles;Humans;Hypoglycemic Agents;Metformin;Risk Factors;Rosiglitazone;Thiazolidinediones;Treatment Outcome;Ventricular Function, Left;Adolescent;Diabetes Mellitus, Type 2",M01.060.057;D23.101;C14;M01.060.406;E02.186;C18.452.394.750.149;C19.246.300;E02.642.249;E02.319.310;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;D02.078.370.141.450;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D02.886.675.933.500;D03.383.129.708.933.500;D02.886.675.933;D03.383.129.708.933;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.955.800;M01.060.057;C18.452.394.750.149;C19.246.300
29246344,"Age Factors;Algorithms;Biomarkers;Congenital Hypothyroidism;Guideline Adherence;Healthcare Disparities;Humans;Infant, Newborn;Neonatal Screening;Practice Guidelines as Topic;Reference Standards;Thyroid Function Tests;Thyrotropin;United States;United States;Congenital Hypothyroidism;Infant, Newborn;Thyroid Gland",N05.715.350.075;N06.850.490.250;G17.035;L01.224.050;D23.101;C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;N04.761.337;N05.715.360.395;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;N04.761.700.350.650;N05.700.350.650;E05.978.808;E01.370.374.750;D06.472.699.631.525.883;D12.644.548.691.525.883;Z01.107.567.875;Z01.107.567.875;C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;M01.060.703.520;A06.300.900
29246340,"Adolescent;Area Under Curve;Bed Rest;Child;Child, Preschool;Decision Support Techniques;Equipment and Supplies;Hospitalization;Humans;Infant;Infant, Newborn;Pressure Ulcer;Prospective Studies;ROC Curve;Risk Assessment;Risk Factors;Sensitivity and Specificity;Child;Pressure Ulcer",M01.060.057;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E02.075;M01.060.406;M01.060.406.448;E05.245;L01.313.500.750.190;E07;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C17.800.893.665;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.406;C17.800.893.665
29246336,"Child Development;Child, Preschool;Follow-Up Studies;Hearing Loss;Heart Defects, Congenital;Humans;Infant;Infant, Newborn;Postoperative Complications;Prevalence;Prospective Studies;Risk Factors;Attention;Cognition;Language;Prevalence",F01.525.200;G07.345.374.750;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C23.550.767;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F02.830.104.214;F02.463.188;F01.145.209.399;L01.559;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
29246097,Animals;Clinical Trials as Topic;Cooperative Behavior;Humans;Neurofibromatoses;Brain Neoplasms;Cognition;Genetics;Neuroimaging;Ophthalmology;Therapeutics,B01.050;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;F01.145.813.115;B01.050.150.900.649.313.988.400.112.400.400;C04.557.580.600.580.590;C04.700.631;C10.562.600;C10.574.500.549;C16.320.400.560;C16.320.700.633;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;F02.463.188;H01.158.273.343;E01.370.350.578;E01.370.376.537;E05.629;H02.403.810.468;E02
29244522,Cardiopulmonary Resuscitation;Heart Arrest;Shock,E02.365.647.110;C14.280.383;C23.550.835
29244189,Humans;Microsporidia;Microsporidiosis;Molecular Diagnostic Techniques;Polymerase Chain Reaction;Encephalitozoon;Enterocytozoon;Microsporidia;Microsporidiosis;Polymerase Chain Reaction;Vittaforma,B01.050.150.900.649.313.988.400.112.400.400;B01.300.360;C01.703.617;E01.370.225.880;E05.200.880;E05.393.520;E05.393.620.500;B01.300.360.500.500.100.175;B01.300.360.500.500.100.200;B01.300.360;C01.703.617;E05.393.620.500;B01.300.360.500.500.100.900
29244021,Actins;Amino Acid Sequence;Animals;Base Sequence;Gene Editing;Mice;Protein Isoforms;Actins;Biochemistry;Cell Biology;Protein Isoforms;Mice,D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;G02.111.570.060;L01.453.245.667.060;B01.050;G02.111.570.080;G05.360.080;L01.453.245.667.080;E05.393.420.270;B01.050.150.900.649.313.992.635.505.500;D12.776.800;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;H01.158.201;H01.181.122;H01.158.100.433;H01.158.273.160;D12.776.800;B01.050.150.900.649.313.992.635.505.500
29243998,,
29243830,"Adult;Animals;Biological Products;Blood Preservation;Blood Safety;Child;Erythrocyte Transfusion;Erythrocytes;Humans;Models, Animal;Randomized Controlled Trials as Topic;Transfusion Reaction;United States;United States Food and Drug Administration",M01.060.116;B01.050;D20.215;E02.792.833.230;E05.760.833.230;E02.792.833.230.500;E05.760.833.230.500;N06.850.780.200.450.325;M01.060.406;E02.095.135.140.275;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;E05.598;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C15.378.962;C20.920;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
29243544,Neuropsychology;Writing,F04.096.795.600;H01.158.782.795.110;L01.559.423.906
29243457,"Appetite;Bariatric Surgery;Comorbidity;Diabetes Mellitus, Type 2;Digestive System Diseases;Energy Metabolism;Forecasting;Hormones;Humans;Kidney Diseases;Obesity;Organ Transplantation;Postgastrectomy Syndromes;Postoperative Complications;Pregnancy;Pregnancy Complications;Reoperation;Satiation;Sleep Apnea, Obstructive;Treatment Outcome;Weight Loss",F02.830.071;G07.203.650.390.070;G10.261.390.070;E02.570.500.062;E04.062;N05.715.350.225;N06.850.490.687;C18.452.394.750.149;C19.246.300;C06;G03.295;I01.320;D06.472;D27.505.696.399.472;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E04.936.450;C06.405.748.630;C23.550.767.812;C23.550.767;G08.686.784.769;C13.703;E04.690;F02.830.749;C08.618.085.852.850;C10.886.425.800.750.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963
29243304,"Abnormalities, Multiple;Aortic Coarctation;Eye Abnormalities;Heart;Humans;Infant;Infant, Newborn;Neurocutaneous Syndromes;Tetralogy of Fallot;Tetralogy of Fallot",C16.131.077;C14.240.400.090;C14.280.400.090;C16.131.240.400.090;C11.250;C16.131.384;A07.541;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C10.562;C16.131.077.350.712;C16.131.831.350.712;C16.320.850.250.712;C17.800.804.350.712;C17.800.827.250.712;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29242892,,
29242551,"Animals;CD8-Positive T-Lymphocytes;Cell Line, Tumor;Enhancer of Zeste Homolog 2 Protein;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Immunologic Memory;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;Neoplasms, Experimental;Phosphorylation;Proto-Oncogene Proteins c-akt",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;A11.251.210.190;A11.251.860.180;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;E05.393.332;G05.308.370;G12.450.050.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C04.619;E05.598.500.496;G02.111.665;G02.607.780;G03.796;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168
29242373,"Adult;Centers for Disease Control and Prevention (U.S.);Child;Confidence Intervals;Humans;Kidney Failure, Chronic;Renal Replacement Therapy;Risk;United States;Kidney;Kidney Transplantation;Renal Dialysis",M01.060.116;I01.409.418.750.600.650.200;N03.540.348.500.500.600.650.225;M01.060.406;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;Z01.107.567.875;A05.810.453;E02.870.500;E04.936.450.485;E04.950.774.400;E02.870.300;E02.912.800
29242363,,
29241970,"Adenocarcinoma;Animals;Contrast Media;Disease Models, Animal;Folate Receptor 1;Folate Receptors, GPI-Anchored;Gene Expression;Humans;Immunohistochemistry;Intraoperative Care;Lung Neoplasms;Mice;Molecular Imaging;Xenograft Model Antitumor Assays;Folate Receptor 1;General Surgery",C04.557.470.200.025;B01.050;D27.505.259.500;D27.720.259;C22.232;E05.598.500;E05.599.395.080;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;D12.776.157.530.450.074.500.299.500;D12.776.395.550.448.370;D12.776.543.484.500.370;D12.776.543.550.418.370;D12.776.543.585.450.074.500.224.500;D12.776.543.750.301;G05.297;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E02.760.731.400;E04.604.249;N02.421.585.722.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;E01.370.350.557;E05.601.555;E05.337.550.200.900;E05.624.850;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;H02.403.810.300
29241828,"Activin Receptors, Type I;Humans;Mechanistic Target of Rapamycin Complex 1;Myositis Ossificans;Ossification, Heterotopic;Sirolimus;Ossification, Heterotopic;Sirolimus",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;B01.050.150.900.649.313.988.400.112.400.400;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;C05.651.594.638;C23.550.751;D02.540.505.760;C23.550.751;D02.540.505.760
29241827,Adult;Age Factors;Humans;Kidney Calculi;Middle Aged;Myositis Ossificans;Nephrolithiasis;Prevalence;Risk Factors;Sex Factors;Surveys and Questionnaires;Young Adult;Myositis Ossificans;Kidney Calculi;Nephrolithiasis,M01.060.116;N05.715.350.075;N06.850.490.250;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;M01.060.116.630;C05.651.594.638;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;C05.651.594.638;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249
29241542,"Calcium;Calcium Channels;Calcium Signaling;Calcium-Binding Proteins;Cation Transport Proteins;Cations, Divalent;Gene Expression Regulation;HEK293 Cells;Humans;Inositol 1,4,5-Trisphosphate Receptors;Ion Transport;Membrane Potential, Mitochondrial;Mitochondria;Mitochondrial Membrane Transport Proteins;Protein Binding;Protein Multimerization;Signal Transduction;Calcium;Mitochondria",D01.268.552.100;D01.552.539.288;D23.119.100;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;G02.111.820.800.100;G03.143.500.100;G04.835.800.100;D12.776.157.125;D12.776.157.530.450.250;D12.776.543.585.450.250;D01.248.497.300.333;G05.308;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530.400.150.760;D12.776.543.550.450.150.760;D12.776.543.585.400.150.760;D12.776.826.179;G03.143.500;G03.295.770.500;G04.580.550;G07.265.675.550;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.543.585.475;D12.776.575.750;G02.111.679;G03.808;G02.111.694;G02.111.820;G04.835;D01.268.552.100;D01.552.539.288;D23.119.100;A11.284.430.214.190.875.564;A11.284.835.626
29241143,"Adult;Drug Overdose;Drug Users;Harm Reduction;Humans;Interviews as Topic;Middle Aged;Needle-Exchange Programs;Perception;Philadelphia;Public Health;Substance Abuse, Intravenous;Harm Reduction",M01.060.116;C25.775.383;E02.319.306.500.500;M01.169;F01.145.477;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;N02.421.726.708;F02.463.593;Z01.107.567.875.500.550.525;Z01.433.820;H02.403.720;N01.400.550;N06.850;C25.775.793;F03.900.793;F01.145.477
29240982,Bone Density;Child,G11.427.100;M01.060.406
29240889,,
29240774,"Animals;Behavior, Animal;GABA-A Receptor Agonists;Haplorhini;Humans;Muscimol;Parietal Lobe;Photic Stimulation;Vision, Ocular",B01.050;F01.145.113;D27.505.519.625.240.200.500;D27.505.696.577.240.200.500;B01.050.150.900.649.313.988.400;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.462.470;D23.946.587.587;A08.186.211.200.885.287.500.670;E05.723.729;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
29240034,"Aspirin;Child;Hemangioendothelioma;Humans;Kasabach-Merritt Syndrome;Sarcoma, Kaposi;Sirolimus",D02.455.426.559.389.657.410.595.176;M01.060.406;C04.557.645.375.370;B01.050.150.900.649.313.988.400.112.400.400;C04.557.645.375.617;C15.378.140.855.645;C02.256.466.860;C04.557.450.795.850;C04.557.645.750;D02.540.505.760
29240006,,
29240000,,
29239980,,
29239978,,
29239946,"Arthroplasty, Replacement, Knee;Humans;Nerve Block;Postoperative Period;Risk",E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;B01.050.150.900.649.313.988.400.112.400.400;E03.155.086.711;E04.525.210.550;E04.614.750;N02.421.585.753.750;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
29239903,,
29239869,Adolescent;Anterior Cruciate Ligament Injuries;Anterior Cruciate Ligament Reconstruction;Bone Development;Bone Transplantation;Child;Conservative Treatment;Directive Counseling;Humans;Ligaments;Return to Sport;Risk Factors;Rupture,M01.060.057;C26.558.554.213;E04.555.110.026;E04.680.101.026;G07.345.500.325.377.625.050.500;G11.427.578.050.500;E02.095.147.725.052;E04.555.130;E04.936.580.052;M01.060.406;E02.197;F02.784.176.279;F04.408.413.349;N02.421.461.363.349;B01.050.150.900.649.313.988.400.112.400.400;A02.513;A10.165.669;I03.450.642.845.605;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26.761
29239865,,
29239803,Diverticulum;Pediatrics;Radiation;Ultrasonography;Ureteroscopy;Urolithiasis,C01.539.463.199.750;C06.405.205.282.750;C23.300.415;H02.403.670;G01.750;E01.370.350.850;E01.370.388.250.920;E01.370.390.800;E04.502.250.920;E04.950.774.840;C12.777.967;C13.351.968.967
29239267,White Matter,A08.186.211.204;A08.186.854.880
29239042,Carcinoma;Humans;Thyroid Neoplasms;Thyroid Neoplasms,C04.557.470.200;B01.050.150.900.649.313.988.400.112.400.400;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
29238869,"Adolescent;Adult;Aged;Aged, 80 and over;Child;Chylous Ascites;Embolization, Therapeutic;Humans;Lymphatic Vessels;Lymphography;Magnetic Resonance Imaging;Middle Aged;Retrospective Studies;Treatment Outcome;Young Adult;Chylous Ascites;Lymphography",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.060.406;C06.844.200;E02.520.360;E02.926.500;B01.050.150.900.649.313.988.400.112.400.400;A15.382.520.301;E01.370.350.700.475;E01.370.350.825.500;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C06.844.200;E01.370.350.700.475
29238838,"Dermatology;Eponyms;History, 19th Century;History, 20th Century;Humans;Pigmentation Disorders;United States",H02.403.225;L01.559.598.400.556.536;K01.400.504.937;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;C17.800.621;C23.550.755;Z01.107.567.875
29238837,"Dermatology;History, 19th Century;History, 20th Century;Humans;Pellagra;Public Health;United States",H02.403.225;K01.400.504.937;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;C18.654.521.500.133.699.529;H02.403.720;N01.400.550;N06.850;Z01.107.567.875
29238800,,
29237794,,
29237594,"Animals;Binding Sites;Cation Transport Proteins;Cells, Cultured;Computer Simulation;Drug Resistance;Endocytosis;HEK293 Cells;Hepcidins;Humans;Iron;Mice;Mice, Inbred C57BL;Mutagenesis, Site-Directed;Mutation;Oocytes;Protein Binding;Protein Conformation;Protein Domains;Structure-Activity Relationship;Ubiquitination;Xenopus laevis",B01.050;G02.111.570.120;D12.776.157.530.450.250;D12.776.543.585.450.250;A11.251;L01.224.160;G07.690.773.984;G04.417;A11.251.210.172.750;A11.436.334;D12.776.494.249;D12.776.543.695.054.425;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.412;D01.268.956.287;D01.552.544.412;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.393.420.601.575;G05.365.590;A05.360.490.690.680;A11.497.497.600;G02.111.679;G03.808;G02.111.570.820.709;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.830;G07.690.773.997;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831;B01.050.150.900.090.180.610.500.562
29236961,"Algorithms;Alternative Splicing;Gene Expression Profiling;Sequence Analysis, RNA;Software",G17.035;L01.224.050;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;E05.393.332;E05.393.760.710;L01.224.900
29236775,"Catalytic Domain;Cell Line, Tumor;Drosophila Proteins;Forkhead Transcription Factors;Histone Acetyltransferases;Humans;Protease Inhibitors;T-Lymphocytes, Regulatory;Ubiquitin-Specific Peptidase 7;Ubiquitination",G02.111.570.120.704;G02.111.570.820.709.275.750.188;A11.251.210.190;A11.251.860.180;D12.776.093.500.462;D12.776.260.950.249;D12.776.930.977.249;D08.811.913.050.134.415.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.389.745;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;D08.811.037.500.500;D08.811.037.750.750;D08.811.277.352.897.850.500;D08.811.277.656.300.887.875;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
29236529,Electronic Nicotine Delivery Systems;Young Adult,J01.637.767.500;M01.060.116.815
29234145,,
29233958,"Animals;Bone Marrow Transplantation;Cardiotoxins;Cell Movement;Cells, Cultured;Chemokine CCL5;Chimera;Complement C3a;Complement Pathway, Alternative;Disease Models, Animal;Elapid Venoms;Humans;Inflammation;Macrophages;Mice;Mice, Knockout;Monocytes;Muscle, Skeletal;Receptors, Complement;Regeneration;Signal Transduction;Wound Healing",B01.050;E02.095.147.725.040;E04.936.580.040;D27.888.569.142;G04.198;G07.568.500.180;A11.251;D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250;B05.200;D12.776.124.486.274.024.250;D12.776.124.486.274.250.250;G12.274.695;C22.232;E05.598.500;E05.599.395.080;D20.888.850.325;D23.946.833.850.325;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A02.633.567;A10.690.552.500;D12.776.543.750.705.833;G16.762;G02.111.820;G04.835;G16.762.891
29233936,Consumer Product Safety;Electronic Nicotine Delivery Systems;Humans;Risk Assessment;Smoking Cessation;Tobacco Industry;Tobacco Products;Tobacco Smoke Pollution;Tobacco Use Disorder;United States;United States Food and Drug Administration,N06.850.210;J01.637.767.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;F01.145.488.732;J01.576.655.968;J01.637.767.844;D20.633.937.680;N06.850.460.100.555;C25.775.912;F03.900.912;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
29232645,Clinical Protocols;Elective Surgical Procedures;Humans;Neurosurgical Procedures;Postoperative Care;Postoperative Complications;Preoperative Care;Randomized Controlled Trials as Topic;Recovery of Function;Patient Reported Outcome Measures;Patient Satisfaction,E02.183;N05.715.360.330.125;E04.249;B01.050.150.900.649.313.988.400.112.400.400;E04.525;E02.760.731.700;E04.604.500;N02.421.585.722.700;C23.550.767;E02.760.795;E04.604.750;N02.421.585.795;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;G16.757;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600
29232593,Tobacco Use Disorder;Smoking Cessation;Varenicline,C25.775.912;F03.900.912;F01.145.488.732;D03.633.100.079.900;D03.633.100.857.942
29231258,"Adolescent;Biopsy;Child;Child, Preschool;Databases, Factual;Factor Analysis, Statistical;Fungi;Humans;Immunocompromised Host;Invasive Fungal Infections;Philadelphia;Retrospective Studies;Risk Factors;Skin",M01.060.057;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.300;B01.050.150.900.649.313.988.400.112.400.400;G12.470;C01.703.492;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A17.815
29230822,Blood Cell Count;Hematopoietic Stem Cell Mobilization;Heterocyclic Compounds;Humans;Peripheral Blood Stem Cells,E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E02.095.410;D03;B01.050.150.900.649.313.988.400.112.400.400;A11.872.378.795
29230810,Bipolar Disorder;Molecular Epidemiology;Wounds and Injuries,F03.084.500;E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;C26
29230198,Rifabutin;Rifampin;Tuberculosis,D03.633.400.811.650;D04.345.295.750.650;D03.633.400.811.700;D04.345.295.750.700;C01.252.410.040.552.846
29230015,,
29229815,"Calcium;Calcium Signaling;Caveolin 1;Cell Line;Humans;Muscle Proteins;Muscle, Skeletal;Ryanodine Receptor Calcium Release Channel;Ryanodine Receptor Calcium Release Channel;Calcium Signaling",D01.268.552.100;D01.552.539.288;D23.119.100;G02.111.820.800.100;G03.143.500.100;G04.835.800.100;D12.644.360.024.264;D12.776.157.057.010;D12.776.476.024.280;D12.776.543.990.100.500;D12.776.744.287;A11.251.210;B01.050.150.900.649.313.988.400.112.400.400;D12.776.210.500;A02.633.567;A10.690.552.500;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800;G02.111.820.800.100;G03.143.500.100;G04.835.800.100
29229508,"Aged, 80 and over;Aortic Aneurysm, Abdominal;Computed Tomography Angiography;Conversion to Open Surgery;Embolization, Therapeutic;Endoleak;Endovascular Procedures;Humans;Retrospective Studies;Aortic Aneurysm, Abdominal",M01.060.116.100.080;C14.907.055.239.075;C14.907.109.139.075;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E04.502.250.155;E02.520.360;E02.926.500;C14.907.055.501;C23.550.414.941.500;C23.550.767.850.500;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.907.055.239.075;C14.907.109.139.075
29229484,"Bronchopulmonary Sequestration;Fetal Therapies;Follow-Up Studies;Humans;Infant, Newborn;Perinatal Care;Pregnancy;Prenatal Diagnosis;Retrospective Studies;Treatment Outcome;Bronchopulmonary Sequestration;Edema;Hydrothorax;Laser Coagulation;Thoracentesis",C08.695.214;C16.131.740.214;E02.467;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.760.703;N02.421.088.120.180;N02.421.143.620.550;N02.421.585.703;G08.686.784.769;E01.370.378.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.695.214;C16.131.740.214;C23.888.277;C08.528.476;E02.520.745.410;E02.594.530;E04.014.520.530;E04.350.750.410;E04.540.630.410;E01.370.225.998.329.810;E02.800.550.810;E04.665.600.810;E05.200.998.329.810
29229255,"Carcinoma, Renal Cell;Catheterization, Swan-Ganz;Disease Management;Humans;Kidney Neoplasms;Neoplastic Cells, Circulating;Vena Cava, Inferior;Venous Thrombosis",C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160;E01.370.370.380.140.210;E02.148.224.165;E02.148.442.165;E04.100.814.529.937.165;E04.502.382.937.165;E05.157.250.165;E05.157.375.165;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;A11.642;C04.697.650.900;C23.550.727.650.900;A07.015.908.949.648;C14.907.355.830.925
29229182,Humans;Neoplasms;Signal Transduction;Tumor Microenvironment,B01.050.150.900.649.313.988.400.112.400.400;C04;G02.111.820;G04.835;G04.366.500
29228952,"Adolescent;Adult;Biomechanical Phenomena;Cardiac Surgical Procedures;Cross-Sectional Studies;Fibrosis;Humans;Magnetic Resonance Imaging, Cine;Myocardial Contraction;Myocardium;Risk Factors;Tetralogy of Fallot;Time Factors;Treatment Outcome;Ventricular Dysfunction, Left;Ventricular Function, Left;Ventricular Remodeling;Young Adult;Sprains and Strains;Tetralogy of Fallot",M01.060.057;M01.060.116;G01.154.090;G01.374.089;E04.100.376;E04.928.220;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.355;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.510;G09.330.580;G11.427.494.570;A02.633.580;A07.541.704;A10.690.552.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.945.900;G09.330.955.800;C23.300.985;G09.330.955.975;M01.060.116.815;C26.844;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29228768,"Biological Transport;Cation Transport Proteins;Cell Separation;Coordination Complexes;Culture Media;Electron Spin Resonance Spectroscopy;Electrons;Gene Deletion;Gene Knockdown Techniques;Iron;Mass Spectrometry;Mitochondrial Proteins;Nanoparticles;Phenotype;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Spectrophotometry;Spectroscopy, Mossbauer",G03.143;D12.776.157.530.450.250;D12.776.543.585.450.250;E01.370.225.500.363;E05.200.500.363;E05.242.363;D01.234;D02.691.214;D27.720.470.305;E07.206;E05.196.867.519.274;G01.249.335;G01.358.500.750;G05.365.590.762.320;G05.558.800.320;E05.393.335.500;D01.268.556.412;D01.268.956.287;D01.552.544.412;E05.196.566;D12.776.575;J01.637.512.600;G05.695;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;E05.196.712.726;E05.196.867.826;E05.196.867.776.751
29228211,TDP-43 Proteinopathies;Tauopathies,C10.574.950;C18.452.845.800;C10.574.945
29228163,,
29228153,,
29228147,,
29227991,"Mitochondria;Nucleic Acid Conformation;RNA, Transfer;Virulence",A11.284.430.214.190.875.564;A11.284.835.626;G02.111.570.820.486;G05.360.580;D13.444.735.757;G06.930
29227558,"Sequence Analysis, RNA;Annulus Fibrosus;Extracellular Matrix;Intervertebral Disc;Nucleus Pulposus",E05.393.760.710;A02.165.308.410.250;A02.835.232.834.432.250;A10.165.382.350.050.250;A11.284.295.310;A02.165.308.410;A02.835.232.834.432;A10.165.382.350.050;A02.165.308.410.500;A02.835.232.834.432.500;A10.165.382.350.050.500
29227373,"Adolescent;Anterior Cruciate Ligament Injuries;Cartilage, Articular;Child;Child, Preschool;Humans;Incidence;Intra-Articular Fractures;Knee Injuries;Magnetic Resonance Imaging;Retrospective Studies;Risk Factors;Tibial Fractures;Tibial Meniscus Injuries",M01.060.057;C26.558.554.213;A02.165.407.150;A02.835.583.192;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C26.404.505;C26.558.554;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26.404.875;C26.558.857;C26.558.781
29227305,"Humans;Lung Transplantation;Patient Selection;Pulmonary Disease, Chronic Obstructive;Quality of Life;Severity of Illness Index;Survival Rate;Treatment Outcome",B01.050.150.900.649.313.988.400.112.400.400;E04.928.600.495;E04.936.450.495;E05.581.500.653;N04.590.731;C08.381.495.389;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29226764,"Adult;Aged;Antigens, CD19;B-Lymphocytes;Biomarkers;Disease-Free Survival;Humans;Immunotherapy, Adoptive;Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse;Middle Aged;Receptors, Antigen, T-Cell;Remission Induction;Survival Analysis;T-Lymphocytes",M01.060.116;M01.060.116.100;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;D23.101;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.557.386.480.350;C15.604.515.569.480.350;C20.683.515.761.480.350;C04.557.386.480.150.585;C15.604.515.569.480.150.585;C20.683.515.761.480.150.585;M01.060.116.630;D12.776.543.750.705.816.824;E02.860;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29226740,"Infant, Newborn;Urinary Tract Infections;Vesico-Ureteral Reflux",M01.060.703.520;C01.539.895;C12.777.892;C13.351.968.892;C12.777.829.920;C13.351.968.829.920
29226617,Glucagon-Like Peptide 1;Nucleus Accumbens;Recurrence,D06.472.317.680.500.500;A08.186.211.200.885.287.249.487.775.500;C23.550.291.937
29226612,Animals;Antioxidants;Blood Substitutes;Glutaral;Hemoglobins;Molecular Weight;Oligochaeta;Oxidation-Reduction;Oxygen;Oligochaeta;Blood Substitutes;Glutaral,B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;D27.505.954.502.140;J01.637.087.249;D02.047.532;D12.776.124.400;D12.776.422.316.762;G02.494;B01.050.500.091.657;G02.700;G03.295.531;D01.268.185.550;D01.362.670;B01.050.500.091.657;D27.505.954.502.140;J01.637.087.249;D02.047.532
29226467,"Animals;Axon Guidance;Gene Expression Regulation;Humans;Ligands;Receptors, Cell Surface;Signal Transduction;Netrins;Axon Guidance;Semaphorins;Transcription Factors",B01.050;G04.152.912.750.500;G07.345.500.325.377.687.750.750;G08.686.784.170.450.500.750.750;G11.561.620.750.500;G05.308;B01.050.150.900.649.313.988.400.112.400.400;D27.720.470.480;D12.776.543.750;G02.111.820;G04.835;D12.644.276.860.494;D12.776.467.860.494;D12.776.631.600.494;D12.776.860.300.731;D23.125.842;D23.529.850.494;G04.152.912.750.500;G07.345.500.325.377.687.750.750;G08.686.784.170.450.500.750.750;G11.561.620.750.500;D12.644.276.923;D12.776.467.923;D23.529.923;D12.776.930
29226302,,
29226301,Classification,L01.100;L01.453.245.275
29226166,Cartilage;Osteochondritis Dissecans,A02.165;A10.165.382;C05.116.791.668
29226065,"Carcinoma, Ovarian Epithelial;Pathology;Survival",C04.557.470.200.295;C04.588.322.455.199;C13.351.500.056.630.705.350;C13.351.937.418.685.350;C19.344.410.199;C19.391.630.705.350;H02.403.650;I03.784
29225817,"Kidney Failure, Chronic;Iron",C12.777.419.780.750.500;C13.351.968.419.780.750.500;D01.268.556.412;D01.268.956.287;D01.552.544.412
29225159,"Adult;Aged;Brain Injuries, Traumatic;Cell Movement;Humans;Immunohistochemistry;Middle Aged;Ossification, Heterotopic;Osteogenesis;Spinal Cord Injuries;Stroke;Wounds and Injuries;Young Adult;Aging;Joint Diseases;Arthroplasty;Stroke;Ossification, Heterotopic;Wounds and Injuries;Spinal Cord Injuries;Wounds and Injuries;Brain Injuries, Traumatic",M01.060.116;M01.060.116.100;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;G04.198;G07.568.500.180;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.116.630;C23.550.751;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;C10.228.854.763;C10.900.850;C26.819;C10.228.140.300.775;C14.907.253.855;C26;M01.060.116.815;G07.345.124;C05.550;E04.555.110;E04.680.101;C10.228.140.300.775;C14.907.253.855;C23.550.751;C26;C10.228.854.763;C10.900.850;C26.819;C26;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29224845,Aging;Animals;B-Lymphocyte Subsets;Humans;Infection;T-Box Domain Proteins,G07.345.124;B01.050;A11.063.438.450;A11.118.637.555.567.550.450;A11.118.637.555.567.562.200;A15.145.229.637.555.567.550.450;A15.145.229.637.555.567.562.200;A15.382.032.438.450;A15.382.490.555.567.550.300;A15.382.490.555.567.562.450;B01.050.150.900.649.313.988.400.112.400.400;C01.539;D12.776.260.725;D12.776.930.850
29224739,,
29224135,Ferritins;Inflammation,D12.776.157.427.249;D12.776.556.579.249;C23.550.470
29223791,Early Detection of Cancer;Mammography;Preventive Health Services,E01.390.500;E01.370.350.700.500;N02.421.726
29223724,Angiotensin II;Cardiac Surgical Procedures;Cardiopulmonary Bypass;Humans;Methylene Blue;Risk Factors;Vascular Surgical Procedures;Vasoplegia;Angiotensin II;Cardiopulmonary Bypass;Hydroxocobalamin;Methylene Blue;Nitric Oxide;Vasopressins,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;E04.100.376;E04.928.220;E04.292.413;B01.050.150.900.649.313.988.400.112.400.400;D02.886.369.517;D03.633.300.783.517;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.100.814;C14.907.946;C23.550.767.962;D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;E04.292.413;D03.383.129.578.840.437.777.560;D03.633.400.909.437.777.560;D04.345.783.437.777.560;D02.886.369.517;D03.633.300.783.517;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D06.472.699.631.692.781;D12.644.400.900;D12.644.456.925;D12.644.548.691.692.781;D12.776.631.650.937
29223721,"Adult;Cardiac Surgical Procedures;Echocardiography, Transesophageal;Foramen Ovale, Patent;Humans;Perioperative Care;Eisenmenger Complex;Functional Residual Capacity;Hypoxia;Obesity, Morbid;Nitric Oxide;Sleep Apnea, Obstructive;Foramen Ovale, Patent;Hypertension, Pulmonary;Vascular Resistance;Vascular Resistance;Echocardiography, Transesophageal;Echocardiography",M01.060.116;E04.100.376;E04.928.220;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;C14.240.400.560.375.258;C14.280.400.560.375.258;C16.131.240.400.560.375.258;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731;E04.604;N02.421.585.722;C14.240.400.450;C14.280.400.450;C16.131.240.400.450;E01.370.386.700.485.750.275;G09.772.850.390;C23.888.852.079;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;C08.618.085.852.850;C10.886.425.800.750.850;C14.240.400.560.375.258;C14.280.400.560.375.258;C16.131.240.400.560.375.258;C08.381.423;G09.330.380.921;G09.330.380.921;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
29223682,Aged;Alzheimer Disease;Atrophy;Diffusion Magnetic Resonance Imaging;Disease Progression;Gray Matter;Hippocampus;Humans;Logistic Models;Middle Aged;Neocortex;Retrospective Studies;Alzheimer Disease;Atrophy;Disease Progression;Hippocampus;Magnetic Resonance Imaging,M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C23.300.070;E01.370.350.825.500.150;C23.550.291.656;A08.186.211.168;A08.186.854.348;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;A08.186.211.200.885.287.500.420;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C23.300.070;C23.550.291.656;A08.186.211.180.405;A08.186.211.200.885.287.500.345;E01.370.350.825.500
29223668,"Acute Disease;Adolescent;Appendectomy;Appendicitis;Child;Child, Preschool;Cost-Benefit Analysis;Hospital Costs;Humans;Laparoscopy;Length of Stay;Operative Time;Pennsylvania;Retrospective Studies;Treatment Outcome;Umbilicus;Young Adult;Appendicitis",C23.550.291.125;M01.060.057;E04.210.078;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406;M01.060.406.448;N03.219.151.125;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;E02.760.400.480;N02.421.585.400.480;E04.614.374.500;N02.421.585.753.374.500;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A01.923.047.849;M01.060.116.815;C01.539.463.099;C06.405.205.099;C06.405.469.110.207
29223665,"Checklist;Child;Global Health;Humans;Medical Missions;North America;Pediatrics;Perioperative Care;Specialties, Surgical;Surgical Procedures, Operative;Global Health",N05.715.360.300.179;M01.060.406;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500.750;Z01.107.567;H02.403.670;E02.760.731;E04.604;N02.421.585.722;H02.403.810;E04;H02.403.371;N01.400.337
29223562,Adolescent,M01.060.057
29222399,"Adolescent;Age Factors;Child;Humans;Hypotension, Orthostatic;Incidence;Orthostatic Intolerance;Pediatrics;Postural Balance;Postural Orthostatic Tachycardia Syndrome;Prognosis;Risk Assessment;Syncope, Vasovagal;Tilt-Table Test",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C10.177.575.600.450;C14.907.514.482;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C10.177.575.600;C23.888.592.610;H02.403.670;G11.427.690;G11.561.790.541.595;C10.177.575.600.625;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C10.177.575.600.800;C10.597.606.358.800.600.500;C23.888.592.604.359.800.600.500;E01.370.370.750
29222320,"Adolescent;Adult;Anticoagulants;Child;Child, Preschool;Extracorporeal Membrane Oxygenation;Heart-Assist Devices;Humans;Infant;Platelet Aggregation Inhibitors;Thrombosis",M01.060.057;M01.060.116;D27.505.954.502.119;M01.060.406;M01.060.406.448;E02.880.301;E04.292.451;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D27.505.954.502.780;C14.907.355.830
29222308,"Animals;Dependovirus;Factor IX;Factor VIII;Genetic Therapy;Hemophilia A;Humans;Transduction, Genetic",B01.050;B04.280.580.650.170;D08.622.355;D12.776.124.125.375;D23.119.375;D12.776.124.125.350;D23.119.350;E02.095.301;E05.393.420.301;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;B01.050.150.900.649.313.988.400.112.400.400;E05.393.350.800;G05.728.850
29222249,"ADAMTS13 Protein;Humans;Mycophenolic Acid;Postpartum Period;Pre-Eclampsia;Pregnancy;Pregnancy Complications, Hematologic;Purpura, Thrombotic Thrombocytopenic;Receptors, Thrombopoietin;Rituximab",D08.811.277.656.675.374.102.500.813;D09.400.430.500.500.813;D12.776.395.033.500.813;D12.776.860.300.085.813;B01.050.150.900.649.313.988.400.112.400.400;D02.241.081.193.678;D10.251.618;G08.686.702;C13.703.395.249;G08.686.784.769;C13.703.667;C15.378.785;C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680;D12.776.543.750.705.852.610;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
29222127,,
29221922,"Adolescent;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Nephrostomy, Percutaneous;Radiography, Interventional;Retrospective Studies;Treatment Outcome;Urologic Diseases",M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.390.550;E04.579.642;E04.950.774.739.500;E04.950.774.852.642;E01.370.350.700.725;E04.502.780;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C12.777;C13.351.968
29221750,Body Mass Index;Coronary Artery Bypass;Erythrocyte Transfusion;Surgical Wound Infection,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E02.095.135.140.275;C01.539.947.692;C23.550.767.925
29221691,"Adolescent;Child;Child, Preschool;Databases, Factual;Emergency Service, Hospital;Heart Failure;Hospitalization;Humans;Infant;Patient Acceptance of Health Care;Retrospective Studies;Risk Factors;United States;Heart Failure",M01.060.057;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C14.280.434;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C14.280.434
29221624,"Emigration and Immigration;Licensure, Medical;Internship and Residency",I01.240.600.525.500;N01.224.625.525.500;N06.850.505.400.700.525.500;N03.706.110.510.410;N05.700.200.450.500;I02.358.337.350.500;I02.358.399.350.750
29221533,"Adult;Age Factors;Attitude of Health Personnel;Career Choice;Cross-Sectional Studies;Global Health;Humans;Income;Logistic Models;Multivariate Analysis;Sex Factors;Students, Medical;Students, Nursing;Surveys and Questionnaires;Young Adult;Global Health;Education, Medical;Students, Medical;Students, Nursing",M01.060.116;N05.715.350.075;N06.850.490.250;F01.100.050;N05.300.100;F02.463.785.373.346.400;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;N05.715.350.675;N06.850.490.875;M01.848.769.602;M01.848.769.685;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;H02.403.371;N01.400.337;I02.358.399;M01.848.769.602;M01.848.769.685
29221528,"Ambulatory Care;Anemia;Anemia, Iron-Deficiency;Dietary Supplements;Dominican Republic;Erythrocyte Indices;Health Resources;Hemoglobins;Humans;Infant;Iron;Mass Screening;Practice Guidelines as Topic;Prevalence;Severity of Illness Index;Trace Elements;Caribbean Region;Quality Improvement",E02.760.106;N02.421.585.106;C15.378.071;C15.378.071.196.300;C18.452.565.100;G07.203.300.456;J02.500.456;Z01.107.084.900.300;Z01.639.880.300;E01.370.225.625.230;E05.200.625.230;G09.188.260;N03.349.340;N05.300.420;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D01.268.556.412;D01.268.956.287;D01.552.544.412;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N04.761.700.350.650;N05.700.350.650;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;D27.505.696.377.683.500.555;G07.203.300.681.500.555;J02.500.681.500.555;Z01.107.084;J01.293.754;N04.761.744
29221319,Aged;Lung Transplantation,M01.060.116.100;E04.928.600.495;E04.936.450.495
29220646,"Animals;Cell Nucleus;Centrifugation, Density Gradient;Cerebral Cortex;Disease Models, Animal;High-Throughput Nucleotide Sequencing;Human Embryonic Stem Cells;Humans;Kinetics;Mice;Mice, Inbred C57BL;Microfluidic Analytical Techniques;NIH 3T3 Cells;Neural Inhibition;Neurons;Pentylenetetrazole;RNA;Seizures;Sequence Analysis, RNA;Single-Cell Analysis;Synaptic Transmission;Transcription, Genetic;Transfection;Cerebral Cortex;Seizures",B01.050;A11.284.430.106;A11.284.430.214.190.875.117;E05.181.724.336;E05.196.941.336;A08.186.211.200.885.287.500;C22.232;E05.598.500;E05.599.395.080;E05.393.760.319;A11.872.700.250.750;B01.050.150.900.649.313.988.400.112.400.400;G01.374.661;G02.111.490;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.588.465;A11.251.210.100.550;A11.329.228.100.550;G07.265.755;G11.561.616;A08.675;A11.671;D03.383.066.600;D13.444.735;C10.597.742;C23.888.592.742;E05.393.760.710;E05.242.900;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830;G02.111.873;G05.297.700;E05.393.350.810;G05.728.860;A08.186.211.200.885.287.500;C10.597.742;C23.888.592.742
29219855,"Arthrography;Child;Epiphyses;Femur Head;Hip Joint;Humans;Legg-Calve-Perthes Disease;Observer Variation;Range of Motion, Articular;Reproducibility of Results",E01.370.350.700.070;M01.060.406;A02.835.232.251;A02.835.232.043.650.247.343;A02.835.583.411;B01.050.150.900.649.313.988.400.112.400.400;C05.116.852.175.570;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.600.700;G11.427.760;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
29218914,,
29218913,"Computational Biology;Databases, Genetic;Diabetes Mellitus, Type 2;Enhancer Elements, Genetic;Epistasis, Genetic;Genome-Wide Association Study;Genomics;Humans;Models, Genetic;Polymorphism, Single Nucleotide;Promoter Regions, Genetic",H01.158.273.180;L01.313.124;L01.313.500.750.300.188.400.325;L01.470.750.750.325;C18.452.394.750.149;C19.246.300;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.308.207;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;G05.365.795.598;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680
29218875,"Computational Biology;Critical Care;Databases, Factual;Electronic Health Records;Humans;Machine Learning;Supervised Machine Learning;Unsupervised Machine Learning",H01.158.273.180;L01.313.124;E02.760.190;N02.421.585.190;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;G17.035.250.500.500;L01.224.050.375.530.500;G17.035.250.500.750;L01.224.050.375.530.750
29218817,,
29218725,"Amacrine Cells;Animals;Dendrites;Gene Expression Profiling;Gene Expression Regulation, Developmental;Immunohistochemistry;Mice, Transgenic;Proto-Oncogene Proteins c-ret;Retinal Ganglion Cells;Retinal Horizontal Cells;Transcription Factor Brn-3A;Visual Pathways;Amacrine Cells;Geniculate Bodies;Retinal Ganglion Cells;Superior Colliculi",A08.675.358.050;A08.675.650.850.500;A09.371.729.831.500;A11.671.358.050;A11.671.650.850.500;B01.050;A08.675.256;A11.284.180.225;A11.671.240;E05.393.332;G05.308.310;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D08.811.913.696.620.682.725.400.087;D12.776.395.550.200.188.500;D12.776.543.131.500;D12.776.543.750.630.217;D12.776.624.664.700.194;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;A08.675.650.850.937;A09.371.729.831.937;A11.671.650.850.937;D12.776.260.655.625.124;D12.776.930.710.625.500;A08.612.220.860;A08.675.358.050;A08.675.650.850.500;A09.371.729.831.500;A11.671.358.050;A11.671.650.850.500;A08.186.211.200.317.826.701.444;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;A08.186.211.132.659.800.816
29218659,"Biliary Dyskinesia;Cholecystectomy;Cholecystectomy, Laparoscopic",C06.130.120.250.098;E04.210.120.172;E04.210.120.172.140;E04.502.250.520.160
29218323,"Adaptor Proteins, Signal Transducing;Animals;Caenorhabditis elegans;Dendrites;HEK293 Cells;Humans;Membrane Proteins;Neurogenesis;Rats;Spinal Cord;alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid;Dendrites",D12.644.360.024;D12.776.157.057;D12.776.476.024;B01.050;B01.050.500.500.294.400.875.660.250.250;A08.675.256;A11.284.180.225;A11.671.240;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;B01.050.150.900.649.313.992.635.505.700;A08.186.854;D03.383.129.385.025;A08.675.256;A11.284.180.225;A11.671.240
29218319,,
29218045,Atypical Hemolytic Uremic Syndrome;Complement System Proteins;Complement Factor H;Neutrophils;Blood Platelets,C12.777.419.936.463.500;C13.351.968.419.936.463.500;C15.378.071.141.610.500;C15.378.140.855.925.500.500;D12.776.124.486.274;D12.776.124.486.274.920.325.200;D12.776.124.790.223.200;D12.776.377.715.182.200;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;A11.118.188;A15.145.229.188
29217671,"Academic Medical Centers;Attitude of Health Personnel;Child;Clinical Competence;Education, Medical, Graduate;Feedback;Hospitals, Pediatric;Humans;Internship and Residency;Outcome Assessment (Health Care);Pediatrics;Perception;Philadelphia;Qualitative Research",N02.278.020;F01.100.050;N05.300.100;M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;L01.906.394.211;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;H02.403.670;F02.463.593;Z01.107.567.875.500.550.525;Z01.433.820;H01.770.644.241.850
29217611,"Aged;Air Pollution;Environmental Exposure;Ethnic Groups;European Continental Ancestry Group;Humans;Logistic Models;Lung Diseases, Interstitial;Middle Aged;Multivariate Analysis;Nitrogen Dioxide;Nitrogen Oxides;Ozone;Particulate Matter;Prospective Studies;Risk Assessment;Spatio-Temporal Analysis;Tomography, X-Ray Computed;United States",M01.060.116.100;N06.850.460.100;N06.850.460.350;M01.686.754;N01.224.317;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C08.381.483;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;D01.362.635.600;D01.625.550.525;D01.650.550.587.625;D01.362.635;D01.625.550;D01.650.550.587;D01.362.670.600;D20.633;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.933.500;N05.715.360.750.746.500;N06.850.520.830.933.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875
29215644,,
29215494,"Adult;Aged;Aged, 80 and over;Databases, Factual;Humans;Informed Consent;Jurisprudence;Malpractice;Middle Aged;Neurosurgeons;Orthopedic Surgeons;Retrospective Studies;Spinal Diseases;United States;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;I01.880.604.583;N03.706.535;I01.880.604.583.524;N03.706.535.606;M01.060.116.630;M01.526.485.810.910.750;N02.360.810.910.750;M01.526.485.810.910.875;N02.360.810.910.875;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900;Z01.107.567.875;M01.060.116.815
29215023,,
29214443,"Renal Insufficiency, Chronic",C12.777.419.780.750;C13.351.968.419.780.750
29214373,Breast Neoplasms;Early Detection of Cancer;Guideline Adherence;Magnetic Resonance Imaging;Risk Factors,C04.588.180;C17.800.090.500;E01.390.500;N04.761.337;N05.715.360.395;E01.370.350.825.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29214155,Pregnancy;Obesity;Overweight;Pregnancy;Technology,G08.686.784.769;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;G08.686.784.769;J01.897
29214114,Alzheimer Disease;Calcium;Dantrolene;Ryanodine Receptor Calcium Release Channel,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D01.268.552.100;D01.552.539.288;D23.119.100;D03.383.129.308.432.555.287;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800
29212175,Adipokines;Child;Leptin;Obesity,D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024;M01.060.406;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29212134,"Adolescent;Anxiety;Attentional Bias;Child;Fear;Humans;Phobic Disorders;Anxiety;Biomarkers;Child;Computers;Phobic Disorders;Anxiety, Separation",M01.060.057;F01.470.132;F02.830.104.214.500;M01.060.406;F01.470.361;B01.050.150.900.649.313.988.400.112.400.400;F03.080.725;F01.470.132;D23.101;M01.060.406;L01.224.230.260;F03.080.725;F03.080.300;F03.625.047
29212019,"Animals;DNA, Mitochondrial;High-Throughput Nucleotide Sequencing;Humans;Mice;Mitochondria;Mutation;Polymorphism, Single Nucleotide;Sequence Analysis, DNA",B01.050;D13.444.308.283.225;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.284.430.214.190.875.564;A11.284.835.626;G05.365.590;G05.365.795.598;E05.393.760.700
29211986,"Fluorescence Resonance Energy Transfer;Peptide Elongation Factor G;Protein Biosynthesis;RNA, Transfer;Ribosomal Proteins;Ribosomes",E05.196.712.516.600.676.500;G01.154.240.280;G02.111.255.280;D08.811.277.040.330.300.100.200;D12.776.157.325.150.200;D12.776.835.700.350.200;G02.111.660.871;G03.734.871;G05.297.670;D13.444.735.757;D12.776.835;A11.284.430.214.190.875.811
29211979,,
29211678,Adolescent;Adult;Dependovirus;Factor IX;Genetic Therapy;Genetic Vectors;Hemophilia B;Hemorrhage;Humans;Middle Aged;Transgenes;Young Adult,M01.060.057;M01.060.116;B04.280.580.650.170;D08.622.355;D12.776.124.125.375;D23.119.375;E02.095.301;E05.393.420.301;G05.360.337;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.360.340.024.340.825;M01.060.116.815
29211576,,
29210925,"Adolescent;Child;Child, Preschool;Cohort Studies;Critical Illness;Hemodynamics;Humans;Hypoxia;Infant;Intensive Care Units, Pediatric;Intubation, Intratracheal;Oxygen;Quality Improvement;Registries;Retrospective Studies",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.625;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;M01.060.703;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;D01.268.185.550;D01.362.670;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29210830,"Adolescent;Adult;Aged;Aged, 80 and over;Anti-HIV Agents;Antiretroviral Therapy, Highly Active;Cohort Studies;HIV Infections;Humans;Incidence;Middle Aged;Renal Insufficiency;Risk Assessment;Tenofovir;Veterans;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.388.077.088;E02.319.310.075;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;C12.777.419.780;C13.351.968.419.780;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D02.705.429.906;D03.633.100.759.138.881;M01.930;M01.060.116.815
29210737,,
29210515,"Adolescent;Age of Onset;Biological Variation, Individual;Child;Child, Preschool;Family;Humans;Mucopolysaccharidosis II;Phenotype;Registries;Siblings;Surveys and Questionnaires;Symptom Assessment;Mucopolysaccharidosis II;Lysosomal Storage Diseases;Siblings",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;G16.115;M01.060.406;M01.060.406.448;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360.455.750;C16.320.322.500.750;C16.320.400.525.750;C16.320.565.202.715.645;C16.320.565.595.600.645;C17.300.550.575.645;C18.452.648.202.715.645;C18.452.648.595.600.645;G05.695;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.872;C10.597.606.360.455.750;C16.320.322.500.750;C16.320.400.525.750;C16.320.565.202.715.645;C16.320.565.595.600.645;C17.300.550.575.645;C18.452.648.202.715.645;C18.452.648.595.600.645;C16.320.565.595;C18.452.648.595;F01.829.263.500.490;I01.880.853.150.500.505;M01.781
29210094,"Adult;Colitis, Ulcerative;Colonoscopy;Cytodiagnosis;Drug Monitoring;Humans;Infliximab;Maintenance Chemotherapy;Middle Aged;Recurrence;Retrospective Studies;Wound Healing;Young Adult",M01.060.116;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;E01.370.225.500.384;E05.200.500.384;E05.242.384;E01.370.520.200;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E02.319.509;M01.060.116.630;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G16.762.891;M01.060.116.815
29209658,"Pathology, Surgical",H02.403.650.510
29209600,"Leukemia, Myeloid, Acute;Pediatrics",C04.557.337.539.275;H02.403.670
29209575,Adenoviridae;Electroporation,B04.280.030;E05.200.500.454;E05.242.448;E05.301.500
29209570,Immunotherapy;Neoplasms;Mesothelioma,E02.095.465.425;C04;C04.557.470.035.510;C04.557.470.660.510
29209510,"Extracorporeal Membrane Oxygenation;Oxygen;Hypertension, Pulmonary",E02.880.301;E04.292.451;D01.268.185.550;D01.362.670;C08.381.423
29208433,"Clinical Trials, Phase III as Topic;Decision Making",E05.318.372.250.250.220;N05.715.360.330.250.250.220;N06.850.520.450.250.250.220;F02.463.785.373
29208398,Biomedical Research;Forecasting;Health Planning;Health Priorities;Humans;Medical Oncology;National Cancer Institute (U.S.);Neoplasms;Precision Medicine;United States,H01.770.644.145;I01.320;N03.349;N03.706.615.302;N03.349.330;N05.300.400;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;I01.409.418.750.600.650.496.150;N03.540.052.750.150;N03.540.348.500.500.600.650.496.150;C04;E02.574;H02.403.200.700;Z01.107.567.875
29208005,"Consensus;Critical Illness;Deep Sedation;Delirium;Humans;Intensive Care Units;Length of Stay;Long Term Adverse Effects;Pain Management;Respiration, Artificial;Time Factors;Cognitive Dysfunction;Delirium;Depression;Critical Care;Respiration, Artificial",F01.829.316.068;F02.463.785.373.433;C23.550.291.625;E03.295;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;C23.550.543;E02.745;N04.590.607.500;E02.041.625;E02.365.647.729;E02.880.820;G01.910.857;F03.615.250.700;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;F01.145.126.350;E02.760.190;N02.421.585.190;E02.041.625;E02.365.647.729;E02.880.820
29207624,Apoptosis;Asparaginase;Autophagy;Glioblastoma;Reactive Oxygen Species,G04.146.160;D08.811.277.087.116;G04.146.399;G04.417.350.091;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;D01.339.431;D01.650.775
29206922,Electronic Health Records,E05.318.308.940.968.625.500
29206742,,
29206729,"Adrenergic beta-Agonists;Cardiopulmonary Resuscitation;Child;Cross-Sectional Studies;Epinephrine;Extracorporeal Membrane Oxygenation;Guideline Adherence;Heart Diseases;Hospitals, Pediatric;Humans;Practice Patterns, Physicians';Standard of Care",D27.505.519.625.050.100.200;D27.505.696.577.050.100.200;E02.365.647.110;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;E02.880.301;E04.292.451;N04.761.337;N05.715.360.395;C14.280;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N04.590.374.577;N05.300.625;N04.761.789.900;N05.715.840
29206695,"Anesthesia;Electroencephalography;Endoscopy;Humans;Propofol;Sleep;Sleep Apnea, Obstructive",E03.155;E01.370.376.300;E01.370.405.245;E01.370.388.250;E04.502.250;B01.050.150.900.649.313.988.400.112.400.400;D02.455.426.559.389.657.773;F02.830.855;G11.561.803;C08.618.085.852.850;C10.886.425.800.750.850
29206104,Atlases as Topic;Eukaryotic Cells;Human Body;Humans;International Cooperation;Cell Biology;Computational Biology;Humans;Mice;Systems Biology,L01.178.682.192.836.147;A11.450;I01.076.201.450.560;K01.093.378;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;H01.158.100.433;H01.158.273.160;H01.158.273.180;L01.313.124;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;H01.158.273.180.800
29205631,Placenta;Premature Birth,A16.710;C13.703.420.491.500
29205584,Fetus;Humans;Magnetic Resonance Imaging;Pregnancy;Prenatal Care,A16.378;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786
29205509,alpha-Synuclein;Amyloid;Cerebrospinal Fluid,D12.776.631.860.500;D12.776.637.500;D05.500.049;D12.776.049;A12.207.270.210
29205416,"Antiviral Agents;Carcinoma, Hepatocellular;Cohort Studies;Hepatitis C, Chronic;Humans;Incidence;Interferons;Liver Neoplasms;Middle Aged;Retrospective Studies;Sustained Virologic Response;Time Factors",D27.505.954.122.388;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;C04.588.274.623;C06.301.623;C06.552.697;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800.570;N04.761.559.590.800.665;N05.715.360.575.575.800.665;G01.910.857
29204929,Autism Spectrum Disorder;Diagnosis;Sex Characteristics,F03.625.164.113;E01;G08.686.815
29204812,Beckwith-Wiedemann Syndrome,C16.131.077.133;C16.131.260.080;C16.320.180.080
29204657,"Adult;Aged;Attitude of Health Personnel;Breast Neoplasms;Early Detection of Cancer;Humans;Middle Aged;Morbidity;Physicians;Practice Patterns, Physicians';Social Networking;United States",M01.060.116;M01.060.116.100;F01.100.050;N05.300.100;C04.588.180;C17.800.090.500;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;M01.526.485.810;N02.360.810;N04.590.374.577;N05.300.625;L01.143.910;Z01.107.567.875
29204650,,
29204590,,
29204571,"Sleep Apnea, Obstructive",C08.618.085.852.850;C10.886.425.800.750.850
29204453,Baseball,I03.450.642.845.110
29203948,,
29203833,"Bayes Theorem;Genetic Loci;Genome-Wide Association Study;Humans;Inflammatory Bowel Diseases;Polymorphism, Single Nucleotide",E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;G05.365.795.598
29203011,"Accidents, Traffic;Algorithms;Automobile Driving;Automobiles;Child;Child Behavior;Child Restraint Systems;Craniocerebral Trauma;Databases, Factual;Head;Humans;Posture;Seat Belts",N06.850.135.392;G17.035;L01.224.050;I03.125;J01.937.500.100;M01.060.406;F01.145.179;E07.490.249;E07.700.175;J01.637.708.175;C10.900.300;C26.915.300;L01.313.500.750.300.188.400;L01.470.750.750;A01.456;B01.050.150.900.649.313.988.400.112.400.400;G11.427.695;E07.700.800
29202877,Adenocarcinoma;Adenocarcinoma of Lung;Aged;Contrast Media;Folate Receptor 1;Humans;Intraoperative Period;Lung Neoplasms;Molecular Imaging;Pneumonectomy;Folate Receptor 1;General Surgery,C04.557.470.200.025;C04.557.470.200.025.022;C04.588.894.797.520.055;M01.060.116.100;D27.505.259.500;D27.720.259;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;B01.050.150.900.649.313.988.400.112.400.400;E04.614.374;N02.421.585.753.374;C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.350.557;E05.601.555;E04.620;E04.928.600.600;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;H02.403.810.300
29202483,Drug Therapy;Genetic Therapy;Neurosciences;Therapeutics,E02.319;E02.095.301;E05.393.420.301;H01.158.610;E02
29201002,Hippocampus;Pyramidal Cells;Hippocampus,A08.186.211.180.405;A08.186.211.200.885.287.500.345;A08.675.790;A11.671.790;A08.186.211.180.405;A08.186.211.200.885.287.500.345
29200285,"Amino Acid Sequence;Aminoacyltransferases;Animals;Bacterial Proteins;Catalase;Cell Line;Click Chemistry;Cysteine Endopeptidases;Humans;Intercellular Adhesion Molecule-1;Mice;Mice, Inbred C57BL;Models, Molecular;Platelet Endothelial Cell Adhesion Molecule-1;Single-Chain Antibodies;Tissue Distribution",G02.111.570.060;L01.453.245.667.060;D08.811.913.050.200;B01.050;D12.776.097;D08.811.682.732.332;A11.251.210;E05.197.124;J01.897.836.249.124;D08.811.277.656.262.500;D08.811.277.656.300.200;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550.200.450;D12.776.543.550.200.450;D23.050.301.350.450;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.599.595;D12.776.395.550.200.131;D12.776.543.550.200.131;D23.050.301.264.900.131;D23.050.301.350.131;D23.101.100.900.131;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;G03.787.917;G07.690.725.949
29200205,,
29200158,"Cardiotoxicity;Child, Preschool;Craniospinal Irradiation;Humans;Medulloblastoma;Neoplasm Metastasis;Proton Therapy;Radiation Injuries;Spinal Cord Neoplasms",C23.550.161;C25.100.389;C26.733.266;G01.750.748.500.266;M01.060.406.448;E02.815.230;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;C04.697.650;C23.550.727.650;E02.815.250.500;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;C04.588.614.250.803;C10.228.854.765;C10.551.240.750
29199948,"Action Potentials;Animals;Brain Stem;Electroencephalography;Nerve Net;Rats, Sprague-Dawley;Urinary Bladder;Urination;Barrington's Nucleus;Urinary Bladder;Locus Coeruleus;Urination;Neurosciences;Rats",G04.580.100;G07.265.675.100;G11.561.570.100;B01.050;A08.186.211.132;E01.370.376.300;E01.370.405.245;A08.511;B01.050.150.900.649.313.992.635.505.700.750;A05.810.890;G08.852.880;A08.186.211.132.810.428.600.067;A05.810.890;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;G08.852.880;H01.158.610;B01.050.150.900.649.313.992.635.505.700
29199542,"Adolescent;Analgesics, Opioid;Child;Chronic Pain;Cross-Sectional Studies;Drug Prescriptions;Humans;Musculoskeletal Pain;Pain Management;Pain Measurement;Surveys and Questionnaires;Syndrome;Adolescent;Analgesics, Opioid",M01.060.057;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;M01.060.406;C23.888.592.612.274;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E02.319.307;N02.421.668.778.500;B01.050.150.900.649.313.988.400.112.400.400;C05.651.538;C23.888.592.612.547;F02.830.816.353;G11.561.790.353;E02.745;N04.590.607.500;E01.370.600.550.324;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.550.288.500;M01.060.057;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
29198974,"Adolescent;Adult;Colorado;Contraception;Contraceptive Agents, Female;Cross-Sectional Studies;Humans;Patient Satisfaction;Young Adult;Adolescent;Contraception;Long-Acting Reversible Contraception",M01.060.057;M01.060.116;Z01.107.567.875.760.210;E02.875.194;D27.505.696.875.360.276;D27.505.954.705.360.276;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;M01.060.116.815;M01.060.057;E02.875.194;E02.875.194.589
29198724,"Animals;Bone Morphogenetic Protein 2;Bone and Bones;Child;Child, Preschool;Chromosomes, Human, Pair 20;Cleft Palate;Craniofacial Abnormalities;Developmental Disabilities;Disease Models, Animal;Dwarfism;Haploinsufficiency;Heart;Heart Defects, Congenital;Humans;Infant;Mice;Mice, Knockout;Transforming Growth Factor beta;Bone and Bones;Bone Morphogenetic Proteins;Skeleton",B01.050;D12.644.276.954.200.200;D12.776.467.942.200.200;D23.529.942.200.200;A02.835.232;A10.165.265;M01.060.406;M01.060.406.448;A11.284.187.520.300.460.470;G05.360.162.520.300.460.470;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;C05.660.207;C16.131.621.207;F03.625.421;C22.232;E05.598.500;E05.599.395.080;C05.116.099.343;C16.320.240;C19.297;G05.365.590.029.530.587;G05.380.350.500;A07.541;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775;A02.835.232;A10.165.265;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;A02.835
29197986,"Hypoventilation;Magnetic Resonance Imaging;Obesity;Sleep Apnea, Obstructive",C08.618.846.565;C23.888.852.638;E01.370.350.825.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C08.618.085.852.850;C10.886.425.800.750.850
29197160,Animals;Autophagy;Humans;Neurons;Autophagy;Axonal Transport;Homeostasis;Neurons,B01.050;G04.146.399;G04.417.350.091;B01.050.150.900.649.313.988.400.112.400.400;A08.675;A11.671;G04.146.399;G04.417.350.091;G03.143.355.040;G04.392.040;G11.561.050;G07.410;A08.675;A11.671
29196580,,
29196562,,
29196320,"Animals;Cats;Interneurons;Models, Neurological;Neural Inhibition;Photic Stimulation;Visual Cortex;Visual Cortex",B01.050;B01.050.150.900.649.313.750.377.750.250.125;A08.675.358;A11.671.358;E05.599.395.642;G07.265.755;G11.561.616;E05.723.729;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953
29196138,"Anesthesia, Cardiac Procedures;Heart Failure;Heart Transplantation;Heart-Assist Devices;History, 20th Century;Humans;Time Factors;Treatment Outcome;Echocardiography;Heart Failure;Heart Transplantation;History;Heart Ventricles",E03.155.403;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;E04.050.430;E07.695.300.300;E07.858.082.374.300;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;K01.400;A07.541.560
29195750,Analgesics;Behavioral Medicine;California;Health Care Costs;Health Care Sector;Humans;Opioid-Related Disorders;Patient Protection and Affordable Care Act,D27.505.696.663.850.014;D27.505.954.427.040;F04.096.080;H02.403.090;Z01.107.567.875.580.200;Z01.107.567.875.760.200;N03.219.151.400;N05.300.375;J01.576.489;N03.219.650;B01.050.150.900.649.313.988.400.112.400.400;C25.775.675;F03.900.675;N03.219.521.576.343.918;N03.706.615.806
29195725,"Child Development;Child Welfare;Child, Preschool;Habits;Humans;Parent-Child Relations;Sleep Hygiene;Time Factors;Family;Hygiene;Literacy;Sleep",F01.525.200;G07.345.374.750;I01.880.787.293;M01.060.406.448;F01.145.466;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.290;F01.145.488.725;F02.830.855.734;G01.910.857;F01.829.263;I01.880.853.150;E02.547;N06.850.670;F01.145.209.429;N01.824.196.500;F02.830.855;G11.561.803
29195066,"Animals;CLOCK Proteins;Circadian Clocks;History, 20th Century;History, 21st Century;Humans;Nobel Prize;Physiology",B01.050;D08.811.913.050.134.415.500.049;D12.644.360.138.100;D12.776.260.103.562;D12.776.476.156.200;D12.776.930.125.562;G07.180.562.094.500;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;K01.150.567;H01.158.782
29195017,,
29195016,"Cost Sharing;Medicare;Carcinoma, Renal Cell",N03.219.151.170;N03.219.521.576.090;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
29194751,,
29194281,"Adolescent;Blood Component Transfusion;Child;Child, Preschool;Humans;Infant;Intensive Care Units, Pediatric;Propensity Score;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Retrospective Studies;Risk Factors;Survival Rate",M01.060.057;E02.095.135.140;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
29194219,"Adolescent;Anemia, Sickle Cell;Emergency Service, Hospital;Headache;Hematoma, Epidural, Cranial;Humans;Infarction;Magnetic Resonance Imaging;Skull;Tomography, X-Ray Computed",M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C23.888.592.612.441;C10.228.140.300.535.450.300;C10.900.300.837.300;C14.907.253.573.400.400;C23.550.414.838.349;C23.550.414.913.400;C26.915.300.490.400;B01.050.150.900.649.313.988.400.112.400.400;C23.550.513.355;C23.550.717.489;E01.370.350.825.500;A02.835.232.781;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
29194122,Continuity of Patient Care;Disease Management;HIV Infections;Humans;Medication Adherence;Postpartum Period;United States,E02.760.169;N02.421.585.169;N04.590.233.727.210;N04.590.607;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;G08.686.702;Z01.107.567.875
29194114,,
29194061,Anesthesiology;Data Accuracy;Research,H02.403.066;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;H01.770.644
29193180,Survival Analysis,E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
29192975,"Dermatomyositis;Humans;Interferon-Induced Helicase, IFIH1;Lung Diseases, Interstitial",C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.445.735.720.249.875;C08.381.483
29192315,,
29191751,"Animals;Cysteine;Feeding Behavior;Gene Knockdown Techniques;Ghrelin;Hippocampus;Learning;Olfactory Perception;RNA Interference;RNA, Messenger;Rats, Sprague-Dawley;Receptors, Ghrelin;Social Behavior;Eating;Obesity;Reward;Social Behavior",B01.050;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;F01.145.113.547;F01.145.407;G07.203.650.353;E05.393.335.500;D06.472.699.301;D12.644.548.322;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F02.463.425;F02.784.629.529;F02.463.593.485;G05.308.203.374.790;D13.444.735.544;B01.050.150.900.649.313.992.635.505.700.750;D12.776.543.750.695.322;F01.145.813;G07.203.650.283;G10.261.330;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.463.425.770.836;F01.145.813
29191567,,
29191331,Cardiovascular Diseases;Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Genetic Therapy;Humans;Mutation;Clustered Regularly Interspaced Short Palindromic Repeats;Genetic Therapy;Genetics;Genomics,C14;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E02.095.301;E05.393.420.301;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350
29191242,"Chromosomes, Human, Pair 9;DNA Copy Number Variations;Gene Duplication;Guanine Nucleotide Exchange Factors;Humans;Neurodevelopmental Disorders;Tumor Suppressor Proteins;Meta-Analysis",A11.284.187.520.300.325.345;G05.360.162.520.300.325.345;G05.365.795.297.500;G05.365.590.320;G05.558.320;D12.644.360.325.300;D12.776.476.325.300;B01.050.150.900.649.313.988.400.112.400.400;F03.625;D12.776.624.776;V03.600
29190517,Adolescent;Adolescent Health;Case-Control Studies;Environment;Humans;Residence Characteristics;Risk Factors;Spatial Analysis;Travel;Violence;Adolescent Health;Environmental Exposure;Epidemiologic Methods;Spatial Analysis;Violence,M01.060.057;N01.400.075;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G16.500.275;N06.230;B01.050.150.900.649.313.988.400.112.400.400;N01.224.791;N06.850.505.400.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933;I03.883;I01.198.240.856;I01.880.735.900;N01.400.075;N06.850.460.350;E05.318;N06.850.520;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933;I01.198.240.856;I01.880.735.900
29190340,"Adult;Aged;Biomarkers;Diabetes Mellitus, Type 1;Follow-Up Studies;Glucose;Glycemic Index;Health Knowledge, Attitudes, Practice;Humans;Hypoglycemia;Hypoglycemic Agents;Insulin;Insulin Secretion;Longitudinal Studies;Middle Aged;Monitoring, Physiologic;Prognosis",M01.060.116;M01.060.116.100;D23.101;C18.452.394.750.124;C19.246.267;C20.111.327;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;D09.947.875.359.448;G07.203.650.660.500;J01.576.423.850.730.750.500;N06.850.601.750.500;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.984;D27.505.696.422;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;E01.370.520;E01.789
29190320,Anti-Bacterial Agents,D27.505.954.122.085
29190246,,
29189614,,
29189575,Electronic Health Records,E05.318.308.940.968.625.500
29189506,Centers for Disease Control and Prevention (U.S.);Community-Institutional Relations;Humans;Interinstitutional Relations;Motor Vehicles;New York;North Carolina;Organizational Case Studies;Pennsylvania;Public Health Administration;Safety;Translational Medical Research;United States;Universities;Violence;Wounds and Injuries,I01.409.418.750.600.650.200;N03.540.348.500.500.600.650.225;N04.452.822.210;B01.050.150.900.649.313.988.400.112.400.400;N04.452.822.400;J01.937.500;Z01.107.567.875.075.437;Z01.107.567.875.350.530;Z01.107.567.875.500.530;Z01.107.567.875.075.475;Z01.107.567.875.750.530;N03.349.380.710;N05.715.360.455;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;N04.452.794;N06.850.135.060.075;H01.770.644.145.675;Z01.107.567.875;I02.783.830;J03.832.830;I01.198.240.856;I01.880.735.900;C26
29189474,,
29189267,Calcium;Health Resources;Pilot Projects;Resuscitation,D01.268.552.100;D01.552.539.288;D23.119.100;N03.349.340;N05.300.420;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E02.365.647
29188409,,
29188297,,
29188282,"Adolescent;Antifungal Agents;Arthrodermataceae;Child;Child, Preschool;Foot Dermatoses;Humans;Incidence;Nails;Onychomycosis;Terbinafine;United States;Young Adult",M01.060.057;D27.505.954.122.136;B01.300.107.650.080;M01.060.406;M01.060.406.448;C17.800.321.125;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;A17.600;C01.539.800.200.720.550;C01.703.295.872.458;C17.800.529.550;C17.800.838.208.883.458;D02.455.426.559.847.638.953;D04.615.638.953;Z01.107.567.875;M01.060.116.815
29188225,"Chemistry, Clinical",H01.181.341
29187579,Anti-Bacterial Agents;Child;Clinical Trials as Topic;Humans;Urinary Tract Infections,D27.505.954.122.085;M01.060.406;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;C01.539.895;C12.777.892;C13.351.968.892
29187538,"Animals;Cell Line;Cornea;Cytoplasm;Herpes Simplex;Herpesvirus 1, Human;Lipoylation;Membrane Proteins;Mice;Mice, Inbred C57BL;Mice, Knockout;Microscopy, Electron;Trigeminal Ganglion;Viral Proteins;Virus Latency;Virus Replication;Herpesvirus 1, Human",B01.050;A11.251.210;A09.371.060.217;A11.284.430.214;C02.256.466.382;C02.825.320;C17.800.838.790.320;B04.280.382.100.750.390;G02.111.540;G03.458.875;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E01.370.350.515.402;E05.595.402;A08.340.390.850;A08.800.350.850;A08.800.800.120.760.825;D12.776.964;G06.920.900;G06.920.925;B04.280.382.100.750.390
29187393,,
29187043,Alagille Syndrome;Cholestasis;Jaundice,C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051;C06.130.120.135;C23.550.429.500;C23.888.885.375
29186388,Infant;Walking,M01.060.703;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940
29185443,,
29185077,,
29184810,Endocrine System Diseases;Eye Diseases;Review,C19;C11;V02.600.500;V02.912
29184758,,
29184211,,
29183785,"Animals;Bone Remodeling;Cancellous Bone;Cell Differentiation;GTP-Binding Protein alpha Subunits, Gs;Mice;Osteoclasts;Real-Time Polymerase Chain Reaction;Signal Transduction;Stem Cells;X-Ray Microtomography;Bone Remodeling;Osteoclasts;Cancellous Bone",B01.050;G11.427.213;G16.762.150;A10.165.265.414;G04.152;D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400;B01.050.150.900.649.313.992.635.505.500;A11.329.372.700;A11.627.482.700;E05.393.620.500.706;G02.111.820;G04.835;A11.872;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900;G11.427.213;G16.762.150;A11.329.372.700;A11.627.482.700;A10.165.265.414
29183623,"Cholesterol;Receptors, LDL;Lipoproteins;Triglycerides",D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;D12.776.543.750.710.450;D10.532;D12.776.521;D10.351.801
29183282,"Animals;Cumulative Trauma Disorders;Disease Models, Animal;Fluorescent Antibody Technique;Humans;Muscle Fibers, Skeletal;Myositis;Nerve Fibers;RNA, Messenger;Rabbits;Receptors, Tumor Necrosis Factor, Type I;Receptors, Tumor Necrosis Factor, Type II;Tumor Necrosis Factor-alpha;Up-Regulation;Muscles;Myositis;Tumor Necrosis Factor-alpha;Receptors, Tumor Necrosis Factor, Type I;Receptors, Tumor Necrosis Factor, Type II",B01.050;C26.844.150;C22.232;E05.598.500;E05.599.395.080;E01.370.225.500.607.512.240;E01.370.225.750.551.512.240;E05.200.500.607.512.240;E05.200.750.551.512.240;E05.478.583.375;B01.050.150.900.649.313.988.400.112.400.400;A10.690.552.500.500;A11.620.249;C05.651.594;C10.668.491.562;A08.675.542;A11.671.501;D13.444.735.544;B01.050.150.900.649.313.968.700;D12.776.543.750.690.750;D12.776.543.750.705.852.760.597;D12.776.543.750.705.852.760.798;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;G02.111.905;G05.308.850;G07.690.773.998;A02.633;A10.690;C05.651.594;C10.668.491.562;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;D12.776.543.750.690.750;D12.776.543.750.705.852.760.597;D12.776.543.750.705.852.760.798
29182641,Adult;Ambulatory Care;Anti-HIV Agents;CD4 Lymphocyte Count;HIV Infections;Humans;Public Sector;Rural Population;South Africa;Treatment Adherence and Compliance;Treatment Outcome;Viral Load,M01.060.116;E02.760.106;N02.421.585.106;D27.505.954.122.388.077.088;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;I01.795;N04.452.633.890;N01.600.725;Z01.058.290.175.735;F01.100.150.750;F01.145.488.887;N05.300.150.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.225.875.950;E05.200.875.950;G06.920.850
29181879,"Adolescent;Adult;Child;Child, Preschool;Follow-Up Studies;Hematopoietic Stem Cell Transplantation;Herpesvirus 6, Human;Humans;Infant;Infant, Newborn;Kaplan-Meier Estimate;Logistic Models;Retrospective Studies;Risk Factors;Roseolovirus Infections;Transplantation, Homologous;Viral Load;Viremia;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.095.147.500.500.500;E04.936.225.687.500;B04.280.382.150.750.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C02.256.466.850;E04.936.864;E01.370.225.875.950;E05.200.875.950;G06.920.850;C02.937;C23.550.470.790.500.900;M01.060.116.815
29181795,"Child;Echocardiography, Three-Dimensional;Humans;Mitral Valve;Models, Anatomic;Printing, Three-Dimensional;Retrospective Studies;Simulation Training;Tricuspid Valve;Echocardiography, Three-Dimensional;Printing, Three-Dimensional",M01.060.406;E01.370.350.130.750.230;E01.370.350.400.200;E01.370.350.850.220.230;E01.370.370.380.220.230;B01.050.150.900.649.313.988.400.112.400.400;A07.541.510.507;J01.897.280.500.545.129;L01.178.820.090.545.129;J01.897.564;L01.224.108.150.500;L01.296.110.150.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I02.903.847;A07.541.510.893;E01.370.350.130.750.230;E01.370.350.400.200;E01.370.350.850.220.230;E01.370.370.380.220.230;J01.897.564;L01.224.108.150.500;L01.296.110.150.500
29181601,Enterovirus;Poliomyelitis,B04.820.565.284;C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
29181582,"Administration, Intravesical;Adolescent;Albumins;Child;Child, Preschool;Contrast Media;Fluorocarbons;Humans;Infant;Prospective Studies;Sensitivity and Specificity;Vesico-Ureteral Reflux;Child;Contrast Media;Diagnosis;Vesico-Ureteral Reflux",E02.319.267.120.505;M01.060.057;D12.776.034;M01.060.406;M01.060.406.448;D27.505.259.500;D27.720.259;D02.455.526.510.435;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C12.777.829.920;C13.351.968.829.920;M01.060.406;D27.505.259.500;D27.720.259;E01;C12.777.829.920;C13.351.968.829.920
29181496,"Humans;Practice Guidelines as Topic;Retrospective Studies;Rheumatic Diseases;Rheumatology;Societies, Medical;United States",B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.799;C17.300.775;H02.403.429.730;N03.540.828.589;Z01.107.567.875
29181002,Anesthesia;Cerebrospinal Fluid;Inflammation;Isoflurane;Propofol;General Surgery,E03.155;A12.207.270.210;C23.550.470;D02.355.601.570;D02.455.426.559.389.657.773;H02.403.810.300
29180536,"Animals;CD3 Complex;Cell Line, Tumor;Cell Proliferation;Cytotoxicity, Immunologic;Disease Models, Animal;Encephalitis;Gangliosides;Gene Order;Genetic Vectors;Humans;Immunotherapy, Adoptive;Mice;Neuroblastoma;Receptors, Antigen, T-Cell;Receptors, Chimeric Antigen;Single-Chain Antibodies;T-Lymphocytes;Tumor Necrosis Factor Receptor Superfamily, Member 9;Xenograft Model Antitumor Assays",B01.050;D23.050.301.264.894.095;D23.101.100.894.095;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G12.287;C22.232;E05.598.500;E05.599.395.080;C10.228.140.430;D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475;G05.340;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;B01.050.150.900.649.313.992.635.505.500;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D12.776.543.750.705.816.824;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.543.750.705.852.760.220;E05.337.550.200.900;E05.624.850
29180497,"Acute Coronary Syndrome;Adult;Angina Pectoris;Aspirin;Clinical Decision-Making;Computed Tomography Angiography;Coronary Angiography;Coronary Stenosis;Coronary Vessels;Emergency Service, Hospital;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Middle Aged;Platelet Aggregation Inhibitors;Predictive Value of Tests;Risk Factors;Severity of Illness Index;United States;Emergency Medicine;Primary Prevention",C14.280.647.124;C14.907.585.124;M01.060.116;C14.280.647.187;C14.907.585.187;C23.888.592.612.233.500;D02.455.426.559.389.657.410.595.176;E01.055;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.285;C14.907.585.250.285;A07.015.114.269;A07.015.908.194;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;M01.060.116.630;D27.505.954.502.780;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;Z01.107.567.875;H02.403.250;N02.421.726.758;N06.850.780.680
29180471,"Animals;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p21;Gene Expression Regulation, Neoplastic;Genes, myc;Humans;Lymphoma, B-Cell;Mice, Nude;Ovarian Neoplasms;Prostatic Neoplasms;RNA, Long Noncoding;Xenograft Model Antitumor Assays",B01.050;A11.251.210.190;A11.251.860.180;D12.644.360.225.500;D12.776.157.687.250;D12.776.167.187.500;D12.776.476.225.500;D12.776.624.776.355.500;D12.776.660.720.250;G05.308.370;G05.360.340.024.340.375.500.791.420;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150;B01.050.150.900.649.313.992.635.505.500.550.500;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;D13.444.735.790.375;E05.337.550.200.900;E05.624.850
29180461,Adolescent;Adolescent Behavior;Aggression;Bullying;Crime Victims;Humans;Risk-Taking;Schools;Students;Violence;Weapons,M01.060.057;F01.145.022;F01.145.126.125;F01.145.813.045;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;M01.135;B01.050.150.900.649.313.988.400.112.400.400;F01.145.722;I02.783;J03.832;M01.848;I01.198.240.856;I01.880.735.900;J01.637.870
29180445,"Models, Animal;Gene Targeting;Macrophages;Blood Platelets",E05.598;E05.393.335;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;A11.118.188;A15.145.229.188
29180443,"Models, Animal;Prostaglandin-Endoperoxide Synthases;Macrophages",E05.598;D08.811.600.720;D08.811.682.690.708.715;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
29180430,"Chromosomal Proteins, Non-Histone;Elongin;Protein Binding;RNA Polymerase II;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Stress, Physiological;Transcription Factor TFIIH;Transcription Initiation, Genetic;RNA Polymerase II",D12.776.660.235;D12.776.664.235;D12.776.260.197;D12.776.930.215;G02.111.679;G03.808;D08.811.913.696.445.735.270.762;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;G07.775;D12.776.260.775.875.875;D12.776.930.930.875.875;G02.111.873.625;G05.297.700.625;D08.811.913.696.445.735.270.762
29178982,,
29178641,"Chromosome Deletion;Chromosomes, Human, Pair 22;DiGeorge Syndrome;Health Care Costs;Humans;Models, Theoretical;Health Care Costs;Prenatal Diagnosis",C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;N03.219.151.400;N05.300.375;B01.050.150.900.649.313.988.400.112.400.400;E05.599;N03.219.151.400;N05.300.375;E01.370.378.630
29178601,"Adolescent;Adult;Aged;Aged, 80 and over;Humans;Kidney Transplantation;Liver Transplantation;Medication Adherence;Middle Aged;Pilot Projects;Prospective Studies;Young Adult;Medication Adherence",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;M01.060.116.815;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500
29178462,Dexamethasone;Hyaluronic Acid;Mesenchymal Stem Cells,D04.210.500.745.432.769.344;D04.210.500.908.238;D09.698.373.475;A11.329.830.500;A11.872.590.500
29178194,"Adolescent;Child;Child, Preschool;Ectodermal Dysplasia;Hair;Humans;Infant;Infant, Newborn;Retrospective Studies;Skull;Ectodermal Dysplasia",M01.060.057;M01.060.406;M01.060.406.448;C16.131.077.350;C16.131.831.350;C16.320.850.250;C17.800.804.350;C17.800.827.250;A17.360;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.781;C16.131.077.350;C16.131.831.350;C16.320.850.250;C17.800.804.350;C17.800.827.250
29177461,,
29177190,,
29177121,Bone Morphogenetic Protein Receptors;Myositis Ossificans;Hypoxia,D08.811.913.696.620.682.700.109;D12.776.543.750.750.400.049;C05.651.594.638;C23.888.852.079
29176654,"Animals;Cattle;Cell Movement;Cells, Cultured;Collagenases;Connective Tissue Cells;Extracellular Matrix;Meniscus;Platelet-Derived Growth Factor;Rats;Regeneration;Tissue Engineering;Tissue Scaffolds",B01.050;B01.050.150.900.649.313.500.380.271;G04.198;G07.568.500.180;A11.251;D08.811.277.656.300.480.205;D08.811.277.656.675.374.205;A11.329;A11.284.295.310;A02.165.308.538;A10.165.382.350.163;D12.644.276.910;D12.776.124.625;D12.776.467.910;D23.529.910;B01.050.150.900.649.313.992.635.505.700;G16.762;E05.481.500.311.500;J01.293.069.249.500;E07.206.627;E07.695.825
29176407,,
29176356,Adolescent;Antineoplastic Agents;Child;Clinical Trials as Topic;Drug Development;Genomics;Humans;Medical Oncology;Neoplasms;Pediatrics,M01.060.057;D27.505.954.248;M01.060.406;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E05.290;H01.158.703.007.338;H01.181.466.338;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C04;H02.403.670
29176353,Antibodies;Antineoplastic Agents;Child;Clinical Trials as Topic;Humans;Immunotherapy;Leukemia,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;D27.505.954.248;M01.060.406;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.337
29175973,"Adolescent;Child;Child, Preschool;Clinical Competence;Diagnosis, Differential;Emergency Service, Hospital;Humans;Infant;Lyme Disease;Prospective Studies;Reproducibility of Results;Young Adult",M01.060.057;M01.060.406;M01.060.406.448;I02.399.630.210;N04.761.210;N05.715.175;E01.171;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;M01.060.116.815
29175832,Behavior;Child;Epidemiology,F01.145;M01.060.406;H02.403.720.500
29175625,"Animals;Antibodies, Neutralizing;Antibody Formation;HIV Antibodies;HIV Envelope Protein gp120;HIV Infections;HIV-1;Humans;Immunization, Secondary;Immunoglobulin G;Mice;Mice, Inbred C57BL;Vaccinia virus;HIV;Vaccinia",B01.050;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;G12.070;D12.776.124.486.485.114.254.150.440;D12.776.124.790.651.114.254.150.440;D12.776.377.715.548.114.254.150.440;D12.776.964.775.325.164.249;D12.776.964.775.562.500.500;D12.776.964.970.880.325.164.249;D23.050.327.520.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.485;E05.478.550.550;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B04.280.650.160.650.900;B04.820.650.589.650.350;C02.256.743.929
29175580,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;Lactates;Menthol;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;D02.241.511.459;D02.033.415.510.500.605;D02.455.849.575.750;D10.289.510.500.605;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175579,"Acetals;Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175193,"Animals;Consumer Product Safety;Cyclohexanes;Cyclohexanols;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;Isomerism;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;D02.455.426.392.368.367;D02.033.415.510.500;D02.455.426.392.368.367.318;D10.289.510.500;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.685;G02.607.445;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175192,"Acetates;Animals;Consumer Product Safety;Cyclohexanes;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.241.081.018;D10.251.400.045;B01.050;N06.850.210;D02.455.426.392.368.367;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175191,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Octanols;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D02.033.415.600;D10.289.600;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175189,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Pentanols;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D02.033.415.640;D10.289.640;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175188,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Heptanol;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;D02.033.415.500;D10.289.500;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175186,"Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Hexanols;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;D02.033.415.510;D10.289.510;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29175185,"Acetals;Aldehydes;Animals;Consumer Product Safety;Databases, Chemical;Drug Administration Routes;Endpoint Determination;Humans;No-Observed-Adverse-Effect Level;Perfume;Risk Assessment;Toxicity Tests",D02.355.071;D02.047;B01.050;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;E02.319.267;E05.315;B01.050.150.900.649.313.988.400.112.400.400;E05.940.600;G07.690.936.750;D27.720.269.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.940
29174745,"Cognition;Humans;Incidence;Stroke;Transcatheter Aortic Valve Replacement;American Heart Association;Aorta, Thoracic;Intracranial Embolism;Cognition;Hemorrhage;Heparin;Infarction;Mortality;Stroke;Thrombosis;Transcatheter Aortic Valve Replacement;Ischemic Attack, Transient",F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C10.228.140.300.775;C14.907.253.855;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;N03.540.630.780.110;A07.015.114.056.372;C10.228.140.300.525.400;C14.907.253.566.300;C14.907.355.590.213.300;F02.463.188;C23.550.414;D09.698.373.400;C23.550.513.355;C23.550.717.489;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C10.228.140.300.775;C14.907.253.855;C14.907.355.830;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;C10.228.140.300.150.836;C14.907.253.092.836
29174660,"Anesthesia, Cardiac Procedures;Cardiac Surgical Procedures;Coronary Artery Disease;Heart Valve Diseases;Heart Valve Prosthesis Implantation;Humans;Prosthesis Design;Vascular Surgical Procedures;American Heart Association;Aortic Valve Stenosis;Atrial Fibrillation;Hemorrhage;Cardiopulmonary Bypass;Coronary Artery Bypass;Drug-Eluting Stents;Heart Transplantation;Heart Atria;Mitral Valve Insufficiency;Mortality;Myocardial Infarction;Percutaneous Coronary Intervention;Quality of Life;Seizures;Stroke;Tranexamic Acid;Transcatheter Aortic Valve Replacement",E03.155.403;E04.100.376;E04.928.220;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C14.280.484;E04.100.376.485;E04.650.410;E04.928.220.410;B01.050.150.900.649.313.988.400.112.400.400;E05.320.550;E07.695.680;E04.100.814;N03.540.630.780.110;C14.280.484.150;C14.280.955.249;C14.280.067.198;C23.550.073.198;C23.550.414;E04.292.413;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E07.695.750.500;E04.100.376.475;E04.928.220.390;E04.936.450.475;A07.541.358;C14.280.484.461;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C14.280.647.500;C14.907.585.500;E04.100.814.529.968;E04.502.382.968;I01.800;K01.752.400.750;N06.850.505.400.425.837;C10.597.742;C23.888.592.742;C10.228.140.300.775;C14.907.253.855;D02.241.223.268.860;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
29174378,Child;Europe;Humans;Pediatrics;Radiology;Urologic Diseases;Urology;Nephrology;Pediatrics;Radiology;Reference Standards;Urology,M01.060.406;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;H02.403.740;C12.777;C13.351.968;H02.403.810.860;H02.403.429.580;H02.403.670;H02.403.740;E05.978.808;H02.403.810.860
29174369,,
29174173,Acetyl Coenzyme A;Animals;Cell Nucleus;Chromatin;Cytosol;Humans;Acetyl Coenzyme A;Acetylation;Epigenomics;Metabolism,D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;B01.050;A11.284.430.106;A11.284.430.214.190.875.117;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.284.430.214.200;A11.284.430.429.200;A11.284.835.450.200;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;G02.111.012.052;G02.607.063.052;G03.040.052;H01.158.273.180.350.074;H01.158.273.343.350.042;G03
29173942,Electronic Nicotine Delivery Systems;Electronic Nicotine Delivery Systems,J01.637.767.500;J01.637.767.500
29173314,"Community-Institutional Relations;Cooperative Behavior;Humans;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Interdisciplinary Communication;National Institutes of Health (U.S.);Public Policy;Risk;Science;United States;Universities",N04.452.822.210;F01.145.813.115;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;C16.614.521;F01.829.401.205.249;L01.143.865.500;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;I01.655.500.608;I01.880.604.825.608;N03.623.500.608;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;H01.770;Z01.107.567.875;I02.783.830;J03.832.830
29173312,"Adolescent;Anti-Inflammatory Agents;Child;Child, Preschool;Chronic Disease;Dexamethasone;Drug Administration Schedule;Drug Therapy, Combination;Follow-Up Studies;Humans;Immunologic Factors;Infant;Infusions, Intravenous;Purpura, Thrombocytopenic, Idiopathic;Retrospective Studies;Rituximab;Treatment Outcome;Autoimmune Diseases;Blood Platelets;Thrombocytopenia",M01.060.057;D27.505.954.158;M01.060.406;M01.060.406.448;C23.550.291.500;D04.210.500.745.432.769.344;D04.210.500.908.238;E02.319.283;E02.319.310;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;M01.060.703;E02.319.267.082.500;E02.319.267.510.590;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C20.111;A11.118.188;A15.145.229.188;C15.378.140.855
29173298,"Child, Preschool;Ellis-Van Creveld Syndrome;Follow-Up Studies;Heart Defects, Congenital;Humans;Infant;Infant, Newborn;Postoperative Complications;Respiratory Rate;Retrospective Studies;Thoracotomy;Time Factors;Treatment Outcome;Weight Gain;Ellis-Van Creveld Syndrome",M01.060.406.448;C05.116.099.708.327;C16.131.077.350.398;C16.131.831.350.398;C16.320.850.250.398;C17.800.804.350.398;C17.800.827.250.398;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C23.550.767;E01.370.600.875.875;G09.772.705.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E04.928.760;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.926;G07.345.249.314.120.200.926;C05.116.099.708.327;C16.131.077.350.398;C16.131.831.350.398;C16.320.850.250.398;C17.800.804.350.398;C17.800.827.250.398
29173296,"Adolescent;Body Mass Index;Cardiovascular Diseases;Child;Child, Preschool;Cross-Sectional Studies;Humans;Linear Models;Metabolic Syndrome;Obesity, Abdominal;Pediatric Obesity;Prevalence;Renal Insufficiency, Chronic;Risk Factors;Waist Circumference;Young Adult;Blood Pressure;Dyslipidemias;Metabolic Syndrome;Obesity",M01.060.057;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C14;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;C18.452.394.968.500.570;C18.452.625;C18.654.726.500.697;E01.370.600.115.100.160.120.699.500.249;G07.100.100.160.120.699.500.249;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.600.115.100.160.560;E05.041.124.160.875;G07.100.100.160.560;M01.060.116.815;E01.370.600.875.249;G09.330.380.076;C18.452.584.500;C18.452.394.968.500.570;C18.452.625;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29173067,Dermatology;Telemedicine,H02.403.225;H02.403.840;L01.178.847.652;N04.590.374.800
29172863,,
29172377,Civil Rights;Contracts;Employment;Government Regulation;Humans;Personnel Selection;Privacy;Smokers;Smoking;Social Discrimination;State Government;Tobacco Products;United States;Ethics,I01.880.604.473.352;N03.706.437.352;I01.880.604.583.090;N03.706.535.241;N01.824.245;I01.880.604.394;N03.706.358;B01.050.150.900.649.313.988.400.112.400.400;N04.452.677.500;I01.880.604.473.352.500;N03.706.437.352.500;N03.706.615.862;M01.808;F01.145.805;F01.145.813.629;I01.409.775;N03.540.348.875;J01.637.767.844;Z01.107.567.875;K01.752.566.479;N05.350
29170507,,
29170219,"Host-Pathogen Interactions;Humans;RNA, Long Noncoding;Viruses",G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D13.444.735.790.375;B04
29170192,Cytokines;Humans,D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400
29170109,"Activins;Bone Morphogenetic Protein 4;Bone Morphogenetic Proteins;Cell Differentiation;Cells, Cultured;Gene Expression Regulation;Humans;Myositis Ossificans;Ossification, Heterotopic;Signal Transduction;Smad1 Protein;Smad5 Protein;Smad8 Protein;Ossification, Heterotopic",D06.472.334.500;D06.472.699.009;D12.644.548.009;D12.776.395.022;D12.644.276.954.200.400;D12.776.467.942.200.400;D23.529.942.200.400;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;G04.152;A11.251;G05.308;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;C23.550.751;G02.111.820;G04.835;D12.644.360.024.334.500.100;D12.776.157.057.170.500.100;D12.776.260.713.500.100;D12.776.476.024.428.500.100;D12.776.744.741.500;D12.776.930.806.500.100;D12.644.360.024.334.500.500;D12.776.157.057.170.500.500;D12.776.260.713.500.500;D12.776.476.024.428.500.500;D12.776.744.741.937;D12.776.930.806.500.500;D12.644.360.024.334.500.800;D12.776.157.057.170.500.800;D12.776.260.713.500.800;D12.776.476.024.428.500.800;D12.776.744.741.968;D12.776.930.806.500.800;C23.550.751
29169783,"Education, Medical, Graduate;Humans;Internship and Residency;Personnel Selection;Radiology, Interventional;United States",I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;N04.452.677.500;H02.403.740.675;Z01.107.567.875
29169775,Delusions;Hallucinations;Schizophrenia,F01.145.126.200;C10.597.606.762.300;C23.888.592.604.764.300;F01.700.750.300;F03.700.750
29169519,"Adolescent;Contraception;Contraceptive Agents;Emergency Service, Hospital;Health Services Accessibility;Humans;Text Messaging",M01.060.057;E02.875.194;D27.505.696.875.360;D27.505.954.705.360;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;L01.178.847.698.300.500;L01.559.423.906.377.666
29169474,"Adolescent;Aged;Cardiomyopathy, Dilated;Child;Child, Preschool;Cohort Studies;Follow-Up Studies;Heart Transplantation;Heart Ventricles;Humans;Infant;Middle Aged;Multivariate Analysis;Proportional Hazards Models;Time Factors;Treatment Outcome;Ventricular Remodeling;Cardiomyopathies;Echocardiography;Heart Failure;Pediatrics;Transplantation",M01.060.057;M01.060.116.100;C14.280.195.160;C14.280.238.070;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.100.376.475;E04.928.220.390;E04.936.450.475;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.300.985;G09.330.955.975;C14.280.238;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.280.434;H02.403.670;E04.936
29168904,Apolipoproteins E;Dementia;Hallucinations,D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;C10.228.140.380;F03.615.400;C10.597.606.762.300;C23.888.592.604.764.300;F01.700.750.300
29168899,Parkinson Disease;Dementia,C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.380;F03.615.400
29168144,"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Europe;Genetic Therapy;Granulomatous Disease, Chronic;Hematopoietic Stem Cell Transplantation;Humans;Infant;Middle Aged;Young Adult;Granulomatous Disease, Chronic;Genetic Therapy;Hematopoietic Stem Cell Transplantation;Infection;Inflammation;Therapeutics",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.060.406;M01.060.406.448;Z01.542;E02.095.301;E05.393.420.301;C15.378.553.774.535;C16.320.322.233;C20.673.774.535;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;M01.060.116.815;C15.378.553.774.535;C16.320.322.233;C20.673.774.535;E02.095.301;E05.393.420.301;E02.095.147.500.500.500;E04.936.225.687.500;C01.539;C23.550.470;E02
29167820,,
29167380,"Animals;Cells, Cultured;Disease Models, Animal;Drosophila;Drosophila Proteins;Homozygote;Humans;Mice;Motor Neurons;Muscular Atrophy, Spinal;Mutation, Missense;Nerve Tissue Proteins;Polymerization;RNA-Binding Proteins;Survival of Motor Neuron 1 Protein",B01.050;A11.251;C22.232;E05.598.500;E05.599.395.080;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A08.675.655.500;A11.671.655.500;C10.228.854.468;C10.574.562.500;C10.668.467.500;G05.365.590.650;D12.776.631;G02.750;D12.776.157.725;D12.776.664.962;D12.776.157.725.875.500;D12.776.580.922.500;D12.776.664.962.875.500
29167345,"Animals;Antigens, Viral, Tumor;Carcinoma, Merkel Cell;DNA Replication;Disease Models, Animal;Fibroblasts;Gene Expression;HEK293 Cells;Humans;Merkel cell polyomavirus;Mice;Pan troglodytes;Polyomavirus Infections;Primates;Rabbits;Rats;Skin Neoplasms;Tumor Virus Infections;Virus Replication;Merkel cell polyomavirus",B01.050;D23.050.285.062;D23.050.327.062;C02.256.721.150;C02.928.216;C04.557.465.625.650.240.325;C04.557.470.200.025.370.325;C04.557.580.625.650.240.325;G02.111.225;G05.226;C22.232;E05.598.500;E05.599.395.080;A11.329.228;G05.297;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B04.280.210.700.615.550;B04.613.204.670.615.550;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.988.400.112.400.620;C02.256.721;B01.050.150.900.649.313.988;B01.050.150.900.649.313.968.700;B01.050.150.900.649.313.992.635.505.700;C04.588.805;C17.800.882;C02.928;G06.920.925;B04.280.210.700.615.550;B04.613.204.670.615.550
29165894,Cytodiagnosis;Humans;Salivary Gland Neoplasms;Salivary Glands,E01.370.225.500.384;E05.200.500.384;E05.242.384;B01.050.150.900.649.313.988.400.112.400.400;C04.588.443.591.824;C07.465.530.824;C07.465.815.718;A03.556.500.760;A10.336.779;A14.549.760
29165632,,
29165623,Sleep Initiation and Maintenance Disorders;Menopause,C10.886.425.800.800;F03.870.400.800.800;G08.686.157.500;G08.686.841.249.500
29165616,Blood Culture;Ergonomics;Quality Improvement,E01.370.225.875.185;E05.200.875.185;F02.784.412;J01.293.556;J01.293.754;N04.761.744
29165579,Breast Feeding;Child;Mortality;Pneumonia,F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;M01.060.406;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C08.381.677;C08.730.610
29165423,Amelogenesis;Animals;Cell Culture Techniques;Cell Line;Dental Enamel;Humans;Stem Cells,G07.345.500.325.377.750.190;B01.050;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.251.210;A14.549.167.900.255;B01.050.150.900.649.313.988.400.112.400.400;A11.872
29165242,Actomyosin;Animals;Biological Evolution;Chiroptera;Muscle Contraction;Muscles;Songbirds;Biophysics;Neurosciences,D12.776.210.500.154;B01.050;G05.045;G16.075;B01.050.150.900.649.313.937;G11.427.494;A02.633;A10.690;B01.050.150.900.248.620.750;H01.158.344;H01.671.100;H01.158.610
29165008,"Hematologic Neoplasms;Hodgkin Disease;Humans;Immunotherapy, Adoptive;Leukemia, Myeloid, Acute;Multiple Myeloma;Receptors, Antigen, T-Cell;Receptors, Chimeric Antigen;Recombinant Fusion Proteins;T-Lymphocytes;Hematologic Neoplasms",C04.588.448;C15.378.400;C04.557.386.355;C15.604.515.569.355;C20.683.515.761.355;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.557.337.539.275;C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650;D12.776.543.750.705.816.824;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;D12.776.828.300;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C04.588.448;C15.378.400
29164510,"Adult;Bariatric Surgery;Body Image;Depression;Gonadal Steroid Hormones;Humans;Longitudinal Studies;Marital Status;Middle Aged;Obesity, Morbid;Postoperative Period;Quality of Life;Sexual Behavior;Weight Loss;Bariatric Surgery;Quality of Life;Gonadal Steroid Hormones",M01.060.116;E02.570.500.062;E04.062;F01.752.747.792.110;F02.463.593.112;F01.145.126.350;D06.472.334.851;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F01.829.263.315.500;I01.240.361.500;I01.880.853.150.423.500;N01.224.361.500;N01.824.308.500;M01.060.116.630;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;E04.614.750;N02.421.585.753.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;F01.145.802;C23.888.144.243.963;G07.345.249.314.120.200.963;E02.570.500.062;E04.062;I01.800;K01.752.400.750;N06.850.505.400.425.837;D06.472.334.851
29163977,Qualitative Research;Communication;Patients;Prostatic Neoplasms,H01.770.644.241.850;F01.145.209;L01.143;M01.643;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
29163494,"Receptors, Antigen, T-Cell;Antibodies;Information Dissemination;Immunogenetics;Immunoglobulins",D12.776.543.750.705.816.824;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;L01.143.443;H01.158.273.343.420;D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
29162345,"Adolescent;Child;Child, Preschool;Cohort Studies;Databases, Factual;Hospitalization;Humans;Mental Disorders;Mental Health;Patient Discharge;Patient Transfer;Retrospective Studies;Subacute Care;United States;Young Adult;Depression;Mood Disorders;Psychotic Disorders;Suicidal Ideation",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;F03;F02.418;N01.400.500;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.760.850;N02.421.585.850;Z01.107.567.875;M01.060.116.815;F01.145.126.350;F03.600;F03.700.675;F01.145.126.980.875.149;I01.880.735.856.149
29162334,Immunosuppression;Genotype;Kidney Transplantation;Pharmacogenetics;Pharmacokinetics;Tacrolimus,E02.095.465.425.450;E05.478.610;G05.380;E02.870.500;E04.936.450.485;E04.950.774.400;H01.158.273.343.750;H01.158.703.052;H02.628.479;G03.787;G07.690.725;D02.540.505.810
29161229,"Animals;Benzhydryl Compounds;Dose-Response Relationship, Drug;Endocrine Disruptors;Environmental Pollutants;Epigenesis, Genetic;Insulin;Insulin Secretion;Islets of Langerhans;Maternal Exposure;Mice;Mice, Inbred C57BL;Phenols;Pregnancy;Prenatal Exposure Delayed Effects;Sex Factors",B01.050;D02.455.426.559.389.115;G07.690.773.875;G07.690.936.500;D27.505.696.353;D27.888.141;D27.888.284;G05.308.203;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414;A06.300.414;N06.850.460.350.145;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D02.455.426.559.389.657;G08.686.784.769;C13.703.824.500;N05.715.350.675;N06.850.490.875
29159929,,
29159873,22q11 Deletion Syndrome;DiGeorge Syndrome;DiGeorge Syndrome;DiGeorge Syndrome;Arthritis;Clubfoot;Extremities;Growth;Orthopedics;Scoliosis;Spine;DiGeorge Syndrome,C05.660.207.103;C14.240.400.021;C14.280.400.044;C15.604.451.249;C16.131.077.019;C16.131.240.400.021;C16.131.260.019;C16.131.482.249;C16.131.621.207.103;C16.320.180.019;C19.642.482.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.550.114;C05.330.488.655.063;C05.330.495.681.063;C05.660.585.512.380.813.063;C16.131.621.585.512.500.681.063;A01.378;G07.345.249;H02.403.810.494;C05.116.900.800.875;A02.835.232.834;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
29159786,,
29159707,"Animals;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Disease Models, Animal;Energy Metabolism;Gene Deletion;Genetic Predisposition to Disease;Longevity;Membrane Potential, Mitochondrial;Methylmalonyl-CoA Decarboxylase;Mitochondria;Oxidative Stress;Phenotype;Propionic Acidemia;Mitochondria;Oxidative Phosphorylation;Propionic Acidemia;Propionic Acidemia",B01.050;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;C22.232;E05.598.500;E05.599.395.080;G03.295;G05.365.590.762.320;G05.558.800.320;C23.550.291.687.500;G05.380.355;G07.345.124.519;G07.540;G03.295.770.500;G04.580.550;G07.265.675.550;D08.811.520.224.125.387;A11.284.430.214.190.875.564;A11.284.835.626;G03.673;G07.775.750;G05.695;C16.320.565.100.823;C18.452.648.100.823;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.665.550;G03.295.631;G03.796.550;C16.320.565.100.823;C18.452.648.100.823;C16.320.565.100.823;C18.452.648.100.823
29159215,,
29159140,Longevity,G07.345.124.519;G07.540
29159043,Alzheimer Disease;Brain;Diffusion Tensor Imaging;Down Syndrome;Electroencephalography;Humans;Magnetic Resonance Imaging;Neuroimaging;Positron-Emission Tomography;Biomarkers;Dementia,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D23.101;C10.228.140.380;F03.615.400
29159005,,
29158516,,
29158268,,
29158035,"Cardiopulmonary Resuscitation;Emergency Service, Hospital;Hand;Humans;Infant;Infant, Newborn;Time Factors;Video Recording;Cardiopulmonary Resuscitation",E02.365.647.110;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;A01.378.800.667;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G01.910.857;L01.280.960;E02.365.647.110
29157930,,
29157923,"Abdominal Cavity;Adolescent;Child;Child, Preschool;Cohort Studies;Heart Defects, Congenital;Hospital Mortality;Humans;Infant;Laparoscopy;Length of Stay;Morbidity;Postoperative Complications;Retrospective Studies;Survival Rate;Laparoscopy;Morbidity;Mortality",A01.923.047.025;M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C14.240.400;C14.280.400;C16.131.240.400;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.388.250.520;E04.502.250.520;E02.760.400.480;N02.421.585.400.480;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.370.388.250.520;E04.502.250.520;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
29157731,Adolescent;Child;Creatinine;Cystatin C;Disease Progression;Insulin Resistance,M01.060.057;M01.060.406;D03.383.129.308.207;D12.776.215.300;C23.550.291.656;C18.452.394.968.500;G07.690.773.984.617
29157644,"Adolescent;Humans;Policy Making;Schools;Sleep;Students;Time Factors;Adolescent;Economics, Behavioral;Sleep",M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;N03.706.742;I02.783;J03.832;F02.830.855;G11.561.803;M01.848;G01.910.857;M01.060.057;F04.096.628.286;N03.219.215;F02.830.855;G11.561.803
29157618,Castleman Disease;Humans;Castleman Disease;Pathology,C15.604.515.245;C20.683.515.250;B01.050.150.900.649.313.988.400.112.400.400;C15.604.515.245;C20.683.515.250;H02.403.650
29157581,"Blood Glucose;Child;Diabetes Mellitus, Type 1;Glycated Hemoglobin A;Humans;Hypoglycemia;Parents;Registries;Sleep;Sleep Wake Disorders;Surveys and Questionnaires;Diabetes Mellitus, Type 1",D09.947.875.359.448.500;M01.060.406;C18.452.394.750.124;C19.246.267;C20.111.327;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.984;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;F02.830.855;G11.561.803;C10.886;C23.888.592.796;F03.870;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C18.452.394.750.124;C19.246.267;C20.111.327
29157579,Beds;Global Health;Humans;Infant;Parents;Sleep;Surveys and Questionnaires;Infant,E07.325.220;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F02.830.855;G11.561.803;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.703
29157530,,
29157092,Leukemia;Lymphoma;Multiple Myeloma,C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761;C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650
29156677,,
29156364,"Adult;Bipolar Disorder;Brain;Cerebral Cortex;Cyclothymic Disorder;Depressive Disorder, Major;Frontal Lobe;Gray Matter;Humans;Magnetic Resonance Imaging;Middle Aged;Occipital Lobe;Parietal Lobe;Depression",M01.060.116;F03.084.500;A08.186.211;A08.186.211.200.885.287.500;F03.600.500;F03.600.300.375;A08.186.211.200.885.287.500.270;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;A08.186.211.200.885.287.500.571;A08.186.211.200.885.287.500.670;F01.145.126.350
29156239,"Adult;Alcoholism;Case-Control Studies;Cells, Cultured;Ethanol;Humans;Membrane Potentials;Middle Aged;Neural Stem Cells;Pluripotent Stem Cells;RNA, Messenger;Receptors, GABA-A;Up-Regulation;Electrophysiology;Receptors, GABA;Gene Expression;Induced Pluripotent Stem Cells",M01.060.116;C25.775.100.250;F03.900.100.350;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251;D02.033.375;B01.050.150.900.649.313.988.400.112.400.400;G01.154.535;G04.580;G07.265.675;G11.561.570;M01.060.116.630;A11.872.653;A11.872.700;D13.444.735.544;D12.776.157.530.400.175.562;D12.776.157.530.400.400.100.100;D12.776.543.550.450.175.562;D12.776.543.550.450.500.100.100;D12.776.543.585.400.175.562;D12.776.543.585.400.500.100.100;D12.776.543.750.130.500;D12.776.543.750.720.200.300.300;G02.111.905;G05.308.850;G07.690.773.998;H01.158.344.528;H01.158.782.236;D12.776.543.750.720.200.300;G05.297;A11.872.040.500;A11.872.700.500
29156199,"Aminoglycosides;Antibodies, Monoclonal, Humanized;Cytarabine;Daunorubicin;History, 20th Century;History, 21st Century;Humans;Induction Chemotherapy;Leukemia, Myeloid, Acute;Leukemia, Myeloid, Acute;Cytarabine;Azacitidine;Cladribine;Clofarabine;Cytarabine;Daunorubicin;Etoposide;Idarubicin",D09.408.051;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D03.383.742.680.245.453;D13.570.065.300;D13.570.685.245.453;D02.455.426.559.847.562.050.200;D04.615.562.050.200;D09.408.051.059.200;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;E02.319.499;E02.860.500;C04.557.337.539.275;C04.557.337.539.275;D03.383.742.680.245.453;D13.570.065.300;D13.570.685.245.453;D02.145.150;D03.383.742.680.245.217;D13.570.685.245.217;D13.570.800.286.300;D03.633.100.759.590.138.300.200;D03.633.100.759.590.138.325.075;D13.570.230.229.075;D13.570.583.138.300.200;D13.570.583.138.325.075;D13.570.800.096.300.200;D03.633.100.759.646.138.309;D13.570.065.195;D13.695.667.138.309;D13.695.827.068.309;D03.383.742.680.245.453;D13.570.065.300;D13.570.685.245.453;D02.455.426.559.847.562.050.200;D04.615.562.050.200;D09.408.051.059.200;D02.455.426.559.847.638.960.675.250;D04.615.638.960.675.250;D09.408.348.275;D02.455.426.559.847.562.050.200.300;D04.615.562.050.200.300;D09.408.051.059.200.300
29156186,Counseling;Disease Management;Health Education;Humans;Obesity;Patient Education as Topic;Physician-Patient Relations;Primary Health Care;Referral and Consultation;Weight Loss;Obesity;Primary Health Care;General Surgery;Therapeutics;Weight Reduction Programs,F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;N04.590.607;I02.233.332;N02.421.726.407;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;I02.233.332.500;N02.421.726.407.680;F01.829.401.650.675;N05.300.660.625;N04.590.233.727;N04.452.758.849;C23.888.144.243.963;G07.345.249.314.120.200.963;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;N04.590.233.727;H02.403.810.300;E02;I02.233.332.445.650;N02.421.726.407.579.650
29155357,,
29155184,"Adolescent;Adult;Aged;Aged, 80 and over;Cerebral Cortex;Data Interpretation, Statistical;Datasets as Topic;Humans;Magnetic Resonance Imaging;Middle Aged;Models, Theoretical;Multicenter Studies as Topic;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;A08.186.211.200.885.287.500;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;E05.599;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;M01.060.116.815
29154694,Adolescent;Athletes;Attention;Gait;Humans;Neuropsychological Tests;Post-Concussion Syndrome;Prospective Studies;Task Performance and Analysis;Time Factors,M01.060.057;M01.072;F02.830.104.214;E01.370.600.250;G11.427.410.568.900.750;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;C10.900.300.350.300.500;C26.915.300.450.500.500;C26.974.382.200.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F02.784.412.846;F02.784.692.746;F02.808.600;G01.910.857
29154020,Child Abuse;Systematic Review,I01.198.240.856.350.250;I01.880.735.900.350.250;V03.850
29153930,Anesthetics;Aortic Valve;Aortic Valve Stenosis;Humans;Transcatheter Aortic Valve Replacement;Treatment Outcome,D27.505.696.277.100;D27.505.954.427.210.100;A07.541.510.110;C14.280.484.150;C14.280.955.249;B01.050.150.900.649.313.988.400.112.400.400;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29153862,Animals;Brain;Humans;Neuronal Plasticity;Sleep;Tumor Necrosis Factor-alpha;Autoimmunity;Tumor Necrosis Factor-alpha,B01.050;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;G11.561.638;F02.830.855;G11.561.803;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;G12.450.192;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
29153635,,
29153427,"Extracorporeal Membrane Oxygenation;Hospital Mortality;Humans;Respiratory Distress Syndrome, Adult;Retrospective Studies;Telemedicine;Transportation of Patients;Respiratory Distress Syndrome, Adult;Extracorporeal Membrane Oxygenation;Extracorporeal Membrane Oxygenation",E02.880.301;E04.292.451;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;H02.403.840;L01.178.847.652;N04.590.374.800;E02.365.839;N02.421.297.879;C08.381.840;C08.618.840;E02.880.301;E04.292.451;E02.880.301;E04.292.451
29153328,"Adult;Aged;Aged, 80 and over;Amyotrophic Lateral Sclerosis;Animals;Chromatin Assembly and Disassembly;DNA-Binding Proteins;Disease Models, Animal;Drosophila Proteins;Drosophila melanogaster;Frontotemporal Dementia;HEK293 Cells;Heat-Shock Proteins;Humans;Middle Aged;Drosophila;Amyotrophic Lateral Sclerosis;Chromatin Assembly and Disassembly;Epigenomics;Frontotemporal Dementia;Heat-Shock Proteins",M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;G04.400.095;G05.213.095;G05.308.095;D12.776.260;C22.232;E05.598.500;E05.599.395.080;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;A11.251.210.172.750;A11.436.334;D12.776.580.216;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;B01.050.500.131.617.720.500.500.750.310.250;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;G04.400.095;G05.213.095;G05.308.095;H01.158.273.180.350.074;H01.158.273.343.350.042;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;D12.776.580.216
29153323,"Animals;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Chromosomal Proteins, Non-Histone;Chromosome Segregation;Kinetochores;Microtubules;Spindle Apparatus;Tubulin;Chromosome Segregation;Kinetochores;Microtubules;Mitosis;Tubulin",B01.050;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;D12.776.660.235;D12.776.664.235;G04.144.220.220.625;G05.113.220.625;A11.284.430.106.279.345.190.160.165.500;G05.360.160.165.500;A11.284.430.214.190.750.602;A11.284.430.214.190.750.820;D05.750.078.734.800;D12.776.220.600.800;D12.776.631.920;G04.144.220.220.625;G05.113.220.625;A11.284.430.106.279.345.190.160.165.500;G05.360.160.165.500;A11.284.430.214.190.750.602;G04.144.220.220.781;G05.113.220.781;D05.750.078.734.800;D12.776.220.600.800;D12.776.631.920
29153244,,
29152895,"Child;Cost of Illness;Cross-Sectional Studies;Employment;Family;Health Expenditures;Home Care Services;Humans;Income;Respiration, Artificial;Surveys and Questionnaires;Child;Cost of Illness;Family;Respiration",M01.060.406;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N01.824.245;F01.829.263;I01.880.853.150;N03.219.151.450;N05.300.385;N02.421.143.524;N02.421.539.089;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;E02.041.625;E02.365.647.729;E02.880.820;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.406;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;F01.829.263;I01.880.853.150;G09.772.705
29152323,,
29150972,,
29150892,"Adolescent;Adult;Brain Diseases;Child;Child, Preschool;Chromosome Deletion;Chromosomes, Human, Pair 5;DNA Mutational Analysis;DNA-Binding Proteins;Disease Management;Epilepsy;Facies;Genetic Association Studies;Humans;Infant;Intellectual Disability;Magnetic Resonance Imaging;Phenotype;Syndrome;Transcription Factors;White Matter;Whole Exome Sequencing;Young Adult;Epilepsy;Intellectual Disability",M01.060.057;M01.060.116;C10.228.140;M01.060.406;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.280.290;G05.360.162.520.300.280.290;E05.393.760.700.300;D12.776.260;N04.590.607;C10.228.140.490;C23.550.291.812;E01.370.600.230;E05.393.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;E01.370.350.825.500;G05.695;C23.550.288.500;D12.776.930;A08.186.211.204;A08.186.854.880;E05.393.760.700.825.500;M01.060.116.815;C10.228.140.490;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
29150870,,
29150566,"Animals;CD8-Positive T-Lymphocytes;Cell Differentiation;Cell Proliferation;Cells, Cultured;DNA Methylation;DNA-Binding Proteins;Immunologic Memory;Lymphocyte Activation;Lymphocytic Choriomeningitis;Lymphocytic choriomeningitis virus;Mice;Mice, Inbred C57BL;Mice, Knockout;Proto-Oncogene Proteins;T-Lymphocyte Subsets",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;G04.152;G04.161.750;G07.345.249.410.750;A11.251;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D12.776.260;G12.450.050.500;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;C02.182.550.500;C02.782.082.580;C10.228.228.245.500.500;C10.228.614.400.500;B04.820.057.070.100.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.624.664.700;A11.118.637.555.567.550.500;A11.118.637.555.567.569.500;A15.145.229.637.555.567.550.500;A15.145.229.637.555.567.569.500;A15.382.490.555.567.550.500;A15.382.490.555.567.569.500
29150480,"Aged;Breast Neoplasms;Colorectal Neoplasms;Early Detection of Cancer;Feces;Humans;Incidence;Mammography;Mass Screening;Middle Aged;Models, Statistical;Occult Blood;Papanicolaou Test;Time Factors;Uterine Cervical Neoplasms",M01.060.116.100;C04.588.180;C17.800.090.500;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;A12.459;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E01.370.350.700.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E01.370.225.925;E05.200.925;E01.370.225.500.384.100.422;E01.370.225.998.054.422;E04.074.422;E05.200.500.384.100.422;E05.200.998.054.422;E05.242.384.100.422;G01.910.857;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850
29150036,"Adolescent;Bronchial Diseases;Child;Esophageal Diseases;Heart Defects, Congenital;Humans;Tracheal Diseases;Vascular Ring;Young Adult;Vascular Ring",M01.060.057;C08.127;M01.060.406;C06.405.117;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;C08.907;C14.240.850.992;C14.907.109.239.825;C16.131.240.850.984;M01.060.116.815;C14.240.850.992;C14.907.109.239.825;C16.131.240.850.984
29150032,"Acquired Immunodeficiency Syndrome;Adult;Anti-HIV Agents;Antiretroviral Therapy, Highly Active;Humans;Thoracic Surgical Procedures;Acquired Immunodeficiency Syndrome;HIV;Thoracic Surgery",C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;M01.060.116;D27.505.954.122.388.077.088;E02.319.310.075;B01.050.150.900.649.313.988.400.112.400.400;E04.928;C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;B04.820.650.589.650.350;H02.403.810.803
29150009,,
29149770,"Adolescent;Age Factors;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Mortality;Myopathies, Structural, Congenital;Premature Birth;Respiration, Artificial;Retrospective Studies;Surgical Procedures, Operative;Young Adult;Myopathies, Structural, Congenital;Myopathies, Structural, Congenital;Natural History",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C05.651.575;C10.668.491.550;C13.703.420.491.500;E02.041.625;E02.365.647.729;E02.880.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E04;M01.060.116.815;C05.651.575;C10.668.491.550;C05.651.575;C10.668.491.550;H01.158.273.602;H01.770.552;K01.400.703
29149756,Adult;Antidepressive Agents;Anxiety;Bipolar Disorder;Double-Blind Method;Humans;Lithium Compounds;Recurrence;Treatment Outcome;Venlafaxine Hydrochloride;Anxiety;Lithium;Venlafaxine Hydrochloride,M01.060.116;D27.505.954.427.700.122;F01.470.132;F03.084.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;D01.510;C23.550.291.937;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.033.415.510.500.901;D02.092.471.683.948;D02.455.426.392.368.367.318.750;D10.289.510.500.901;F01.470.132;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;D02.033.415.510.500.901;D02.092.471.683.948;D02.455.426.392.368.367.318.750;D10.289.510.500.901
29148940,Biological Specimen Banks;Biomedical Research;Humans;Informed Consent,N02.278.065;H01.770.644.145;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489
29148858,"Animals;Drug Evaluation, Preclinical;Ebola Vaccines;Ebolavirus;Genetic Vectors;Hemorrhagic Fever, Ebola;Humans;Macaca fascicularis;Vaccines, DNA;Vaccines, Virus-Like Particle;Ebolavirus;Vaccines",B01.050;E05.290.750;E05.337.550;D20.215.894.899.205;B04.820.455.300.200;G05.360.337;C02.782.417.415;C02.782.580.250.400;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.988.400.112.199.120.510.520;D12.776.828.868.910;D20.215.894.865.910;D23.050.865.910;D12.776.828.868.955;D20.215.894.865.955;D23.050.865.955;B04.820.455.300.200;D20.215.894
29148218,Anesthesiology;Humans;Medication Errors;Patient Safety;Pharmaceutical Preparations;Reference Standards;Medication Errors,H02.403.066;B01.050.150.900.649.313.988.400.112.400.400;E02.319.529;N02.421.450.500;N06.850.135.060.075.399;D26;E05.978.808;E02.319.529;N02.421.450.500
29148048,Child;Child Behavior;Child Behavior Disorders;Child Development;Humans;Temperament,M01.060.406;F01.145.179;F03.625.141;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;F01.752.898
29147928,Adenocarcinoma;Aged;Algorithms;Blood Vessels;Endoscopic Mucosal Resection;Esophageal Neoplasms;Esophagectomy;Humans;Lymphatic Metastasis;Lymphatic Vessels;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Neoplasm Staging;Risk Assessment;Risk Factors;Survival Rate;Tumor Burden,C04.557.470.200.025;M01.060.116.100;G17.035;L01.224.050;A07.015;E01.370.372.250.250.250;E01.370.388.250.250.250.230;E04.210.240.250.230;E04.502.250.250.250.230;C04.588.274.476.205;C04.588.443.353;C06.301.371.205;C06.405.117.430;C06.405.249.205;E04.210.346;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;A15.382.520.301;M01.060.116.630;E01.789.612;C04.697.645;C23.550.727.645;E01.789.625;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E05.041.124.892
29147681,Ligaments;Tendons;Tissue Engineering,A02.513;A10.165.669;A02.880;E05.481.500.311.500;J01.293.069.249.500
29146716,,
29146290,Magnetic Resonance Imaging;Naltrexone,E01.370.350.825.500;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550
29145984,"Ambulatory Surgical Procedures;Child;Clinical Protocols;Humans;Orthopedic Procedures;Patient Selection;Ambulatory Surgical Procedures;Ambulatory Surgical Procedures;Anesthesia, Conduction",E04.030;M01.060.406;E02.183;N05.715.360.330.125;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;E05.581.500.653;N04.590.731;E04.030;E04.030;E03.155.086
29145573,,
29145569,Animals;Endocrine Disruptors;Environmental Exposure;Environmental Illness;Global Health;Health Transition;Humans;Immune System;Immune System Diseases;Prevalence,B01.050;D27.505.696.353;D27.888.141;N06.850.460.350;C20.543.312;C21.223;H02.403.371;N01.400.337;I01.240.600.400;N01.224.625.400;N06.850.505.400.700.400;N06.850.650;B01.050.150.900.649.313.988.400.112.400.400;A15.382;C20;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
29144510,"Base Sequence;Chromosome Mapping;Exome;Genome, Human;High-Throughput Nucleotide Sequencing;Humans;Sequence Analysis, DNA;Software;Whole Exome Sequencing;Whole Genome Sequencing;Exome;Genome",G02.111.570.080;G05.360.080;L01.453.245.667.080;E05.393.183;G05.360.340.011;G05.360.340.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E05.393.760.700;L01.224.900;E05.393.760.700.825.500;E05.393.760.700.825;G05.360.340.011;G05.360.340
29144501,"CD4-Positive T-Lymphocytes;Complement Activation;Complement System Proteins;Homeostasis;Humans;Immunity, Innate;Inflammation;Neoplasms",A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;G12.274;D12.776.124.486.274;G07.410;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;C23.550.470;C04
29144493,,
29143887,"Anemia, Aplastic;Bone Marrow Diseases;Bone Marrow Transplantation;Cyclosporine;Hematopoietic Stem Cell Transplantation;Humans;Immunosuppression;Siblings;Tissue Donors;Antilymphocyte Serum;Anemia, Aplastic;Cyclosporine",C15.378.071.085;C15.378.190.196;C15.378.190;E02.095.147.725.040;E04.936.580.040;D04.345.566.235.300;D12.644.641.235.300;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.450;E05.478.610;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;M01.898;A12.207.152.846.500.203;D12.776.124.486.485.114.573.203;D12.776.124.790.651.114.573.203;D12.776.377.715.548.114.573.203;D20.215.401.203;C15.378.071.085;C15.378.190.196;D04.345.566.235.300;D12.644.641.235.300
29143762,"Accidents, Traffic;Adolescent;Adolescent Behavior;Automobile Driving;Executive Function;Humans;Risk Factors;Adolescent;Executive Function",N06.850.135.392;M01.060.057;F01.145.022;I03.125;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.057;F02.463.217
29143534,Bipolar Disorder;Depression;Therapeutics;Treatment Outcome,F03.084.500;F01.145.126.350;E02;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29143331,"Acute Disease;Adolescent;Child;Child Health;Child, Preschool;Electronic Health Records;Emergency Service, Hospital;Humans;Infant;Infant, Newborn;Outcome and Process Assessment (Health Care);Pediatrics;Quality Indicators, Health Care;Quality of Health Care;Reproducibility of Results;Retrospective Studies;Socioeconomic Factors;Wounds and Injuries;Pediatrics;Emergency Service, Hospital",C23.550.291.125;M01.060.057;M01.060.406;N01.400.225;M01.060.406.448;E05.318.308.940.968.625.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N04.761.559;N05.715.360.575;H02.403.670;N04.761.789;N04.761;N05.715;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.880.853.996;N01.824;C26;H02.403.670;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336
29143323,"Centers for Medicare and Medicaid Services (U.S.);Child Health;Emergency Service, Hospital;Health Services Research;Humans;Outcome and Process Assessment (Health Care);Pediatrics;Quality Indicators, Health Care;Quality of Health Care;United States;United States Agency for Healthcare Research and Quality",I01.409.418.750.600.310;N03.540.348.500.500.600.550;N01.400.225;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;N04.761.559;N05.715.360.575;H02.403.670;N04.761.789;N04.761;N05.715;Z01.107.567.875;I01.409.418.750.600.650.592;N03.540.348.500.500.600.650.592
29143319,"Adult;Biomarkers;Biopsy;Castleman Disease;Combined Modality Therapy;Follow-Up Studies;Humans;Kaplan-Meier Estimate;Middle Aged;Phenotype;Positron Emission Tomography Computed Tomography;Radiography, Thoracic;Symptom Assessment;Treatment Outcome;Young Adult;Castleman Disease;Herpesvirus 8, Human;HIV;Positron Emission Tomography Computed Tomography",M01.060.116;D23.101;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;C15.604.515.245;C20.683.515.250;E02.186;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;G05.695;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;E01.370.350.700.730;E01.370.872;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C15.604.515.245;C20.683.515.250;B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330;B04.820.650.589.650.350;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500
29143249,"Antigens, CD19;Cell- and Tissue-Based Therapy;Gene Editing;Graft vs Host Disease;Humans;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;T-Lymphocytes;Transplantation, Homologous",D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;E02.095.147;E05.393.420.270;C20.452;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.705.816.824;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E04.936.864
29143173,,
29143169,Adolescent;Adult;Humans;Medicaid;Mental Disorders;Outpatients;Patient Compliance;Patient Dropouts;Pennsylvania;Poverty;Pregnancy;Pregnancy Complications;Pregnant Women;Psychotherapy;United States,M01.060.057;M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;F03;M01.643.630;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;F01.100.150.750.500.610;F01.145.488.887.500.610;N05.300.150.800.500.610;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;I01.880.735.634;I01.880.853.996.535;N01.824.600;G08.686.784.769;C13.703;M01.975.807;F04.754;Z01.107.567.875
29142983,"Glomerulosclerosis, Focal Segmental;Irbesartan;Nephrotic Syndrome;Proteinuria",C12.777.419.570.363.660;C13.351.968.419.570.363.640;D02.455.426.559.389.185.413;D02.455.426.779.431;D03.383.129.617.351;D04.711.431;C12.777.419.630.643;C13.351.968.419.630.643;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
29142796,Deep Brain Stimulation;Depression;Parkinsonian Disorders;Parkinson Disease,E02.331.300;E04.190;F01.145.126.350;C10.228.140.079.862;C10.228.662.600;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
29142014,"Humans;Models, Cardiovascular;Permeability;Shear Strength;Thromboembolism;Thrombosis;Thromboembolism;Thrombosis",B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.161;G02.723;G01.374.820;C14.907.355.590;C14.907.355.830;C14.907.355.590;C14.907.355.830
29141915,"Adolescent;Anemia;Child;Child, Foster;Child, Preschool;Communicable Diseases;Hemoglobins;Humans;Infant;Lead;Lead Poisoning;Mass Screening;Ohio;Prevalence;Retrospective Studies;Young Adult",M01.060.057;C15.378.071;M01.060.406;M01.107;M01.060.406.448;C01.539.221;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D01.268.556.435;D01.552.544.435;C25.723.522.750;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;Z01.107.567.875.075.512;Z01.107.567.875.350.540;Z01.107.567.875.510.540;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
29141885,Animals;Bacterial Proteins;Crohn Disease;Dysbiosis;Gastrointestinal Microbiome;Humans;Mice;Urease,B01.050;D12.776.097;C06.405.205.731.500;C06.405.469.432.500;C23.550.308;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D08.811.277.087.902
29141802,"Adolescent;Air Pollution;Case-Control Studies;Environmental Exposure;Gene-Environment Interaction;Geography, Medical;Humans;Multiple Sclerosis;Odds Ratio;Referral and Consultation;Regression Analysis;United States;Water Quality",M01.060.057;N06.850.460.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;N06.850.460.350;G05.695.337;H01.277.500.097;H02.403.352;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;N04.452.758.849;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;Z01.107.567.875;N06.850.460.350.080.750;N06.850.460.790.730
29141765,Animals;Chagas Disease;Disease Vectors;Ecology;Humans;Seasons;Southeastern United States;Southwestern United States;Spatial Analysis;Texas;Triatominae;Trypanosoma cruzi,B01.050;C03.752.300.900.200;N06.850.310.350;H01.158.273.248;H01.277.249;B01.050.150.900.649.313.988.400.112.400.400;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525;Z01.107.567.875.750;Z01.107.567.875.760;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933;Z01.107.567.875.760.750;B01.050.500.131.617.412.420.700.850;B01.268.475.868.887.140
29141225,"Animals;Cells, Cultured;Heterografts;Humans;Melanoma;Mice;Xenograft Model Antitumor Assays;Melanoma",B01.050;A11.251;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;E05.337.550.200.900;E05.624.850;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
29141224,"Adult;Aged;Aged, 80 and over;Animals;Cell Line, Tumor;Genome;Heterografts;Humans;MAP Kinase Signaling System;Melanoma;Mice;Middle Aged;Mutation;Oncogenes;Repetitive Sequences, Nucleic Acid;Cell Line;High-Throughput Nucleotide Sequencing;Melanoma",M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050;A11.251.210.190;A11.251.860.180;G05.360.340;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;G02.111.820.560;G03.493.560;G04.835.560;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;M01.060.116.630;G05.365.590;G05.360.340.024.340.375.500;G02.111.570.080.708;G05.360.080.708;A11.251.210;E05.393.760.319;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510
29141082,"Adolescent;Child;Child, Preschool;Cohort Studies;Dermatology;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Observer Variation;Parents;Photography;Prospective Studies;Reproducibility of Results;Skin Diseases;Smartphone;Telemedicine",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;H02.403.225;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E01.370.350.600;E05.712;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C17.800;L01.224.230.260.550.500.500;H02.403.840;L01.178.847.652;N04.590.374.800
29140970,"Canada;Child;Child, Preschool;Critical Illness;Humans;Infant;Intensive Care Units, Pediatric;Intubation, Intratracheal;Japan;Laryngoscopy;Larynx;New Zealand;Propensity Score;Quality Improvement;Registries;Retrospective Studies;Singapore;United States",Z01.107.567.176;M01.060.406;M01.060.406.448;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;Z01.252.474.463;Z01.639.595;E01.370.386.460;E01.370.388.250.525;E04.502.250.525;E04.580.373;A04.329;Z01.639.760.747;Z01.678.100.747;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.252.145.774;Z01.107.567.875
29140968,"Capnography;Carbon Dioxide;Child;Child, Preschool;Cohort Studies;Colorimetry;Emergency Service, Hospital;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Intubation, Intratracheal;Practice Patterns, Physicians';Quality Improvement;Registries;Retrospective Studies",E01.370.386.700.150;D01.200.200;D01.362.150;D01.650.550.200;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.196.922.250;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;N04.590.374.577;N05.300.625;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29140940,"Adolescent;Child;Drug Hypersensitivity;Follow-Up Studies;Gastrointestinal Agents;Humans;Inflammatory Bowel Diseases;Infliximab;Infusions, Intravenous;Prognosis;Remission Induction;United States",M01.060.057;M01.060.406;C20.543.206;C25.100.468;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E02.319.267.082.500;E02.319.267.510.590;E01.789;E02.860;Z01.107.567.875
29140927,"Acute Pain;Adolescent;Aging;Analgesics;Child;Child, Preschool;Clinical Trials as Topic;Humans;Infant",C23.888.592.612.081;M01.060.057;G07.345.124;D27.505.696.663.850.014;D27.505.954.427.040;M01.060.406;M01.060.406.448;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703
29140757,Circulating Tumor DNA;Lymphoma;Metabolism;Mutation;Spliceosomes,D13.444.154.500;D13.444.308.425.500;C04.557.386;C15.604.515.569;C20.683.515.761;G03;G05.365.590;A11.284.430.106.279.345.850
29139030,"Adolescent;Adult;Arthritis, Reactive;Biomarkers;Case-Control Studies;Follow-Up Studies;HLA-B27 Antigen;Humans;Middle Aged;Risk Factors;Symptom Assessment;Young Adult;Biomarkers;Epidemiology;Prognosis;Arthritis, Reactive;Risk Factors;Spondylarthropathies",M01.060.057;M01.060.116;C01.539.100.500;C05.116.900.853.625.800.637;C05.550.114.099.500;C05.550.114.865.800.637;D23.101;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;D12.776.395.550.489.500.270;D12.776.543.550.439.500.270;D23.050.301.500.100.500.270;D23.050.301.500.450.380.270;D23.050.705.552.100.500.270;D23.050.705.552.450.380.270;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.872;M01.060.116.815;D23.101;H02.403.720.500;E01.789;C01.539.100.500;C05.116.900.853.625.800.637;C05.550.114.099.500;C05.550.114.865.800.637;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C05.116.900.853.625.800;C05.550.114.865.800
29138893,Child;Europe;Humans;Pediatrics;Radiology;Terminology as Topic;Urologic Diseases;Urology;Dictionary;Nephrology;Pediatrics;Radiology;Reference Standards;Urology,M01.060.406;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;H02.403.740;L01.559.598.400;C12.777;C13.351.968;H02.403.810.860;V02.310;H02.403.429.580;H02.403.670;H02.403.740;E05.978.808;H02.403.810.860
29138330,,
29138232,"Adolescent;Age Factors;Body Surface Area;Child;Child, Preschool;Continental Population Groups;Databases, Factual;Echocardiography;Ethnic Groups;Healthy Volunteers;Heart;Humans;Nomograms;North America;Predictive Value of Tests;Reproducibility of Results;Retrospective Studies;Sample Size;Sex Factors;Body Surface Area;Echocardiography;Heart;Nomograms;Sample Size",M01.060.057;N05.715.350.075;N06.850.490.250;E01.370.600.115.100.231;E05.041.124.231;G07.100.100.231;M01.060.406;M01.060.406.448;M01.686.508;L01.313.500.750.300.188.400;L01.470.750.750;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;M01.686.754;N01.224.317;M01.774.500;M01.955.236;A07.541;B01.050.150.900.649.313.988.400.112.400.400;E01.789.650;E05.318.740.500.625;E05.599.835.895;G17.582;N05.715.360.750.530.530;N06.850.520.830.500.625;Z01.107.567;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;N05.715.350.675;N06.850.490.875;E01.370.600.115.100.231;E05.041.124.231;G07.100.100.231;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A07.541;E01.789.650;E05.318.740.500.625;E05.599.835.895;G17.582;N05.715.360.750.530.530;N06.850.520.830.500.625;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762
29138070,"Adult;Aged;Aged, 80 and over;Cerebrospinal Fluid;Cervical Vertebrae;Diskectomy;Follow-Up Studies;Humans;Laminectomy;Magnetic Resonance Imaging;Middle Aged;Postoperative Period;Preoperative Period;Retrospective Studies;Spinal Cord Compression;Spinal Fusion;Treatment Outcome;Cerebrospinal Fluid",M01.060.116;M01.060.116.100;M01.060.116.100.080;A12.207.270.210;A02.835.232.834.151;E02.718.444;E04.188.350;E04.555.200;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.718.563;E04.188.400;E04.525.450;E04.555.350;E01.370.350.825.500;M01.060.116.630;E04.614.750;N02.421.585.753.750;E04.614.937;N02.421.585.753.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.854.761;C26.819.678;E04.555.100.700;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A12.207.270.210
29137934,"Disease Progression;Epithelial-Mesenchymal Transition;Esophageal Neoplasms;Esophageal Squamous Cell Carcinoma;Humans;Receptor, Notch1;Receptors, Notch;Signal Transduction;Carcinogenesis;Esophageal Squamous Cell Carcinoma;Pathology, Surgical",C23.550.291.656;G04.356.500;C04.588.274.476.205;C04.588.443.353;C06.301.371.205;C06.405.117.430;C06.405.249.205;C04.557.470.200.400.330;C04.557.470.700.400.565;C04.588.274.476.205.500;C04.588.443.353.500;C06.301.371.205.500;C06.405.117.430.500;C06.405.249.205.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.725.500;D12.776.930.770.500;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;C04.697.098;C23.550.727.098;C04.557.470.200.400.330;C04.557.470.700.400.565;C04.588.274.476.205.500;C04.588.443.353.500;C06.301.371.205.500;C06.405.117.430.500;C06.405.249.205.500;H02.403.650.510
29137933,"Animals;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Cell Differentiation;Host-Pathogen Interactions;Humans;T-Lymphocytes, Helper-Inducer;Virus Diseases",B01.050;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;G04.152;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.567.550.500.400;A11.118.637.555.567.569.200.400;A11.118.637.555.567.569.500.400;A15.145.229.637.555.567.550.500.400;A15.145.229.637.555.567.569.200.400;A15.145.229.637.555.567.569.500.400;A15.382.490.555.567.550.500.400;A15.382.490.555.567.569.200.400;A15.382.490.555.567.569.500.400;C02
29137558,Community Mental Health Services;Referral and Consultation,F04.408.307;N02.421.143.183;N02.421.461.232;N04.452.758.849
29136600,"Adult;Antidepressive Agents;Antimanic Agents;Bipolar Disorder;Depressive Disorder, Major;Double-Blind Method;Humans;Lithium Carbonate;Middle Aged;Quality of Life;Treatment Outcome;Venlafaxine Hydrochloride;Lithium;Quality of Life;Venlafaxine Hydrochloride",M01.060.116;D27.505.954.427.700.122;D27.505.696.277.950.025;D27.505.954.427.210.950.025;D27.505.954.427.700.872.025;F03.084.500;F03.600.300.375;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;D01.045.125.500;D01.200.275.150.550;D01.510.475;M01.060.116.630;I01.800;K01.752.400.750;N06.850.505.400.425.837;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.033.415.510.500.901;D02.092.471.683.948;D02.455.426.392.368.367.318.750;D10.289.510.500.901;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;I01.800;K01.752.400.750;N06.850.505.400.425.837;D02.033.415.510.500.901;D02.092.471.683.948;D02.455.426.392.368.367.318.750;D10.289.510.500.901
29136508,"Animals;Cancer-Associated Fibroblasts;Cell Line, Tumor;Granulocytes;Histone Deacetylase 2;Humans;Imidazoles;Macrophages;Mice, Inbred C57BL;Monocytes;Myeloid-Derived Suppressor Cells;Neoplasms, Experimental;Phenylurea Compounds;Pyridines;Receptor, Macrophage Colony-Stimulating Factor;Receptors, Interleukin-8B;Tumor Burden;Macrophage Colony-Stimulating Factor;Fibroblasts;Granulocytes;Macrophages",B01.050;A11.329.228.105;A11.251.210.190;A11.251.860.180;A11.118.637.415;A11.148.350;A11.627.340;A15.145.229.637.415;A15.378.316.340;A15.382.490.315;D08.811.277.087.520.500.200;D08.811.277.087.520.750.200;D08.811.600.620.200;D08.811.600.795.200;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.308;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A11.627.817;C04.619;E05.598.500.496;D02.455.426.559.389.703;D02.948.681;D03.383.725;D08.811.913.696.620.682.725.400.500;D12.776.543.750.630.492;D12.776.543.750.705.852.150.150;D12.776.543.750.750.400.200.200;D12.776.624.664.700.800;D12.776.543.750.695.160.500.750.750;D12.776.543.750.705.852.125.500.750.750;D12.776.543.750.705.852.420.421.750;E05.041.124.892;D12.644.276.374.410.240.500;D12.776.395.240.500;D12.776.467.374.410.240.500;D23.529.374.410.240.500;A11.329.228;A11.118.637.415;A11.148.350;A11.627.340;A15.145.229.637.415;A15.378.316.340;A15.382.490.315;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
29136445,"Administration, Cutaneous;Adolescent;Adult;Allergens;Arachis;Child;Desensitization, Immunologic;Dose-Response Relationship, Immunologic;Double-Blind Method;Humans;Middle Aged;Peanut Hypersensitivity",E02.319.267.120.060;M01.060.057;M01.060.116;D23.050.063;B01.650.940.800.575.912.250.401.077;M01.060.406;E02.095.465.425.450.310;E05.478.610.310;G12.300;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C20.543.480.370.572.750
29136057,"Ethnic Groups;Health Knowledge, Attitudes, Practice;Humans;Melanoma;Patient Education as Topic;Skin Neoplasms",M01.686.754;N01.224.317;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;I02.233.332.500;N02.421.726.407.680;C04.588.805;C17.800.882
29136037,"Adolescent;Adult;Antibodies, Monoclonal;Antibodies, Neutralizing;Dose-Response Relationship, Drug;Drug Administration Schedule;HIV Antibodies;HIV Infections;HIV-1;Humans;Injections, Intravenous;Injections, Subcutaneous;Middle Aged;Single-Blind Method;Young Adult",M01.060.057;M01.060.116;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;G07.690.773.875;G07.690.936.500;E02.319.283;D12.776.124.486.485.114.254.150.440;D12.776.124.790.651.114.254.150.440;D12.776.377.715.548.114.254.150.440;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.082.750;E02.319.267.530.540;E02.319.267.530.620;M01.060.116.630;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;M01.060.116.815
29135805,"Airway Management;American Heart Association;Child, Preschool;Disease Progression;Heart Arrest;Hospitalization;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Prospective Studies;Registries;Respiratory Insufficiency;Risk Factors;Treatment Failure;United States",E02.041;N03.540.630.780.110;M01.060.406.448;C23.550.291.656;C14.280.383;E02.760.400;N02.421.585.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C08.618.846;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;Z01.107.567.875
29135776,"Algorithms;Colorectal Neoplasms;Electronic Health Records;Humans;Lung Neoplasms;Mutation;Pathology, Molecular;Registries",G17.035;L01.224.050;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;G05.365.590;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
29135770,"Adult;Aged;Algorithms;Breast Neoplasms;Cohort Studies;Electronic Health Records;Humans;Middle Aged;Neoplasm Recurrence, Local;Risk Factors;Sensitivity and Specificity;United States",M01.060.116;M01.060.116.100;G17.035;L01.224.050;C04.588.180;C17.800.090.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.697.655;C23.550.727.655;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;Z01.107.567.875
29134626,,
29134238,"Aortic Valve;Aortic Valve Stenosis;Balloon Valvuloplasty;Cardiac Catheterization;Cohort Studies;Echocardiography;Humans;Infant, Newborn;Postoperative Complications;Retrospective Studies;Treatment Outcome;Aortic Valve Stenosis;Balloon Valvuloplasty;Catheterization;Thrombosis",A07.541.510.110;C14.280.484.150;C14.280.955.249;E02.148.108;E05.157.125;E01.370.370.380.140;E02.148.442;E05.157.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.484.150;C14.280.955.249;E02.148.108;E05.157.125;E02.148;E05.157;C14.907.355.830
29133519,"Cardiovascular Diseases;Cells, Cultured;Gene Expression Regulation;Genome-Wide Association Study;High-Throughput Nucleotide Sequencing;Humans;Macrophage Activation;Macrophages;Metabolic Syndrome;RNA;RNA, Long Noncoding;Reverse Transcriptase Polymerase Chain Reaction;Genomics;Induced Pluripotent Stem Cells;Inflammation;RNA, Long Noncoding;Macrophages",C14;A11.251;G05.308;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G12.287.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;C18.452.394.968.500.570;C18.452.625;D13.444.735;D13.444.735.790.375;E05.393.620.500.725;H01.158.273.180.350;H01.158.273.343.350;A11.872.040.500;A11.872.700.500;C23.550.470;D13.444.735.790.375;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
29133477,"Adolescent;Age Factors;Cardiomyopathy, Dilated;Child;Child, Preschool;Echocardiography;Heart Ventricles;Humans;Infant;Myocardial Contraction;Observer Variation;Ontario;Predictive Value of Tests;Prospective Studies;Reproducibility of Results;Severity of Illness Index;Stroke Volume;United States;Ventricular Function, Left;Young Adult;Cardiomyopathies;Echocardiography;Pediatrics",M01.060.057;N05.715.350.075;N06.850.490.250;C14.280.195.160;C14.280.238.070;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G09.330.580;G11.427.494.570;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;Z01.107.567.176.639;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.370.370.380.150.700;G09.330.380.124.882;Z01.107.567.875;G09.330.955.800;M01.060.116.815;C14.280.238;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;H02.403.670
29133417,"Animals;Biological Therapy;Disease Models, Animal;Gram-Negative Bacteria;Humans;Lipopolysaccharide Receptors;Lipopolysaccharides;Mice;Mice, Inbred C57BL;Mice, Transgenic;Nippostrongylus;Protective Agents;Protein-Serine-Threonine Kinases;Recombinant Proteins;Resistin;STAT3 Transcription Factor;Shock, Septic;Signal Transduction;Toll-Like Receptor 4;Inflammation;Resistin;Sepsis",B01.050;E02.095;C22.232;E05.598.500;E05.599.395.080;B03.440;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550.448.100;D12.776.543.484.500.100;D12.776.543.550.418.100;D12.776.543.750.705.045;D23.050.301.264.900.045;D23.101.100.900.045;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;B01.050.500.500.294.400.968.400.575;D27.505.696.706;D27.720.799;D08.811.913.696.620.682.700;D12.776.828;D06.472.699.042.750;D12.644.276.024.750;D12.644.548.011.750;D12.776.467.024.750;D23.529.024.750;D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;G02.111.820;G04.835;D12.776.543.750.705.910.500.400;C23.550.470;D06.472.699.042.750;D12.644.276.024.750;D12.644.548.011.750;D12.776.467.024.750;D23.529.024.750;C01.539.757;C23.550.470.790.500
29132947,Adolescent;Child;Growth;Malnutrition;Weight Loss,M01.060.057;M01.060.406;G07.345.249;C18.654.521;C23.888.144.243.963;G07.345.249.314.120.200.963
29132857,Anti-Vaccination Movement;Bioethical Issues;Humans;Infant;Refusal to Treat,I03.088;K01.752.566.479.023;N05.350.100;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N04.590.233.727.605;N05.300.100.675
29132161,Efficiency;Health Policy;Health Services Needs and Demand;Health Services Research;Humans;Palliative Care;Patient Selection;Time Factors,F02.784.692.351;N04.452.209;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;N03.349.380.420;N05.300.450;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;E02.760.666;N02.421.585.666;E05.581.500.653;N04.590.731;G01.910.857
29131904,"Appointments and Schedules;Fees, Medical;Health Services Accessibility;Humans;Medicaid;Primary Health Care;United States",N04.452.095;N03.219.300.426;N03.219.442.426;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;N04.590.233.727;Z01.107.567.875
29131700,,
29131142,"Apolipoprotein A-I;Cardiotonic Agents;Computer Simulation;Crystallography, X-Ray;Humans;Lipoproteins, HDL;Models, Molecular;Protein Structure, Secondary",D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;D27.505.954.411.222;D27.720.799.080;L01.224.160;E05.196.309.742.225;B01.050.150.900.649.313.988.400.112.400.400;D10.532.432;D12.776.521.479;E05.599.595;G02.111.570.820.709.600
29131101,"Adolescent;Adult;Brain Neoplasms;Child;Child, Preschool;Follow-Up Studies;Humans;Infant;Oligodendroglioma;Population Surveillance;Prognosis;Retrospective Studies;SEER Program;Survival Rate;Treatment Outcome",M01.060.057;M01.060.116;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.465.625.600.380.590;C04.557.470.670.380.590;C04.557.580.625.600.380.590;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.970.725;N04.452.859.819.725;N05.715.360.300.715.700.725;N06.850.520.308.970.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29130686,Gastric Inhibitory Polypeptide;Glucagon-Like Peptide 1;Protein Stability;Proteolysis;Thioamides,D06.472.317.400;D06.472.699.275;D12.644.400.300;D12.644.548.275;D12.776.631.650.300;D06.472.317.680.500.500;G02.111.700;G02.111.720;G03.812;D02.065.900;D02.886.685
29130632,"Alleles;Child;Child, Preschool;Developmental Disabilities;Facies;Genetic Association Studies;Genotype;Guanine Nucleotide Exchange Factors;Humans;Mutation;Nerve Tissue Proteins;Phenotype;Polymorphism, Single Nucleotide;Sequence Deletion",G05.360.340.024.340.030;M01.060.406;M01.060.406.448;F03.625.421;C23.550.291.812;E01.370.600.230;E05.393.385;G05.380;D12.644.360.325.300;D12.776.476.325.300;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.631;G05.695;G05.365.795.598;G05.365.590.762;G05.558.800
29130604,"Adolescent;Adult;Alleles;Amino Acid Substitution;Child;Child, Preschool;Facies;Genetic Association Studies;Genotype;Humans;Mutation;Pedigree;Phenotype;Transcription Factors;Tumor Suppressor Proteins;Twins, Monozygotic;Young Adult;Cleft Lip;Cleft Palate;Twins, Monozygotic",M01.060.057;M01.060.116;G05.360.340.024.340.030;E05.393.420.601.035;G05.558.109;M01.060.406;M01.060.406.448;C23.550.291.812;E01.370.600.230;E05.393.385;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;E05.393.673;G05.695;D12.776.930;D12.776.624.776;M01.438.873.940;M01.060.116.815;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;M01.438.873.940
29130351,"Anniversaries and Special Events;Dependovirus;Genetic Therapy;Genetic Vectors;Humans;Lentivirus;National Heart, Lung, and Blood Institute (U.S.);Translational Medical Research;United States;Dependovirus;Clinical Trial;Genetic Therapy;Lentivirus",K01.400.095;N04.452.822.070;B04.280.580.650.170;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589;I01.409.418.750.600.650.496.300;N03.540.052.750.300;N03.540.348.500.500.600.650.496.300;H01.770.644.145.675;Z01.107.567.875;B04.280.580.650.170;V03.175.250;E02.095.301;E05.393.420.301;B04.820.650.589
29129389,"Adenocarcinoma, Clear Cell;Brachytherapy;Chemoradiotherapy, Adjuvant;Chemotherapy, Adjuvant;Databases, Factual;Endometrial Neoplasms;Humans;Hysterectomy;Neoplasm Staging;Prevalence;Radiotherapy, Adjuvant;United States;Drug Therapy;Endometrial Neoplasms",C04.557.470.200.025.045;E02.815.150;E02.186.079.500;E02.319.164.500;E02.815.160.500;E02.186.170;E02.319.170;L01.313.500.750.300.188.400;L01.470.750.750;C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200;B01.050.150.900.649.313.988.400.112.400.400;E04.950.300.399;E01.789.625;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E02.186.775;E02.815.600;Z01.107.567.875;E02.319;C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200
29129252,"Adolescent;Aminobutyrates;Angiotensin II Type 1 Receptor Blockers;Angiotensin-Converting Enzyme Inhibitors;Child;Child, Preschool;Dose-Response Relationship, Drug;Drug Therapy, Combination;Enalapril;Follow-Up Studies;Heart Failure;Humans;Infant;Infant, Newborn;Myocardial Ischemia;Prospective Studies;Systole;Tetrazoles;Time Factors;Treatment Outcome;Valsartan;Ventricular Dysfunction, Left;Ventricular Function, Left",M01.060.057;D02.241.081.114.500;D12.125.190;D27.505.519.162.500;D27.505.519.389.745.085;M01.060.406;M01.060.406.448;G07.690.773.875;G07.690.936.500;E02.319.310;D12.644.456.345.360;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C14.280.647;C14.907.585;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G09.330.580.880;G11.427.494.570.880;D03.383.129.617;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D03.383.129.617.850;D12.125.070.950.550;D12.125.142.930.500;C14.280.945.900;G09.330.955.800
29128920,"Anatomic Landmarks;Biopsy, Needle;Bone Diseases;Child;Fluoroscopy;Humans;Image Interpretation, Computer-Assisted;Imaging, Three-Dimensional;Magnetic Resonance Angiography;Prospective Studies;Radiation Dosage;Radiography, Interventional;Tomography, X-Ray Computed;Biopsy;Bone and Bones;Fluoroscopy;Radiology, Interventional;Magnetic Resonance Imaging",A01.111;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;C05.116;M01.060.406;E01.370.350.700.225;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;E01.370.350.400;L01.224.308.410;E01.370.350.825.500.500;E01.370.370.050.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.799.513;G01.750.740;N06.850.810.250;E01.370.350.700.725;E04.502.780;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;A02.835.232;A10.165.265;E01.370.350.700.225;H02.403.740.675;E01.370.350.825.500
29128651,"Body Weight Maintenance;Clinical Competence;Counseling;Cross-Sectional Studies;Curriculum;Education, Medical;Humans;Research Design;Self Efficacy;Education, Medical;Schools, Medical",G07.345.249.314.120.250;I02.399.630.210;N04.761.210;N05.715.175;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;I02.158;I02.358.399;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500;H01.770.644.728;F01.752.747.792.700;I02.358.399;I02.783.495.552;N02.278.020.578
29128615,,
29128612,,
29128581,"Adolescent;Adult;Aged;Aged, 80 and over;Arthroplasty;Cervical Vertebrae;Databases, Factual;Diskectomy;Hospital Costs;Humans;Incidence;Intervertebral Disc Degeneration;Length of Stay;Middle Aged;Patient Acceptance of Health Care;Patient Discharge;Reoperation;Retrospective Studies;Spinal Fusion;United States;Young Adult;Costs and Cost Analysis;Demography;Epidemiology",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;E04.555.110;E04.680.101;A02.835.232.834.151;L01.313.500.750.300.188.400;L01.470.750.750;E02.718.444;E04.188.350;E04.555.200;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C05.116.900.153;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E04.555.100.700;Z01.107.567.875;M01.060.116.815;N03.219.151;I01.240;N01.224;N06.850.505.400;H02.403.720.500
29128433,Decision Making;Family;Hospices,F02.463.785.373;F01.829.263;I01.880.853.150;N02.278.421.556.185;N02.421.143.550
29128372,"Intrauterine Devices, Copper;Retention (Psychology)",E07.190.250.510.520.300;F02.463.425.540.772
29128142,"Adult;Brain Mapping;Cognitive Behavioral Therapy;Depression;Emotions;Gyrus Cinguli;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Memory, Episodic;Mental Recall;Prefrontal Cortex;Treatment Outcome;Young Adult;Cognitive Behavioral Therapy;Depression;Magnetic Resonance Imaging",M01.060.116;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F04.754.137.350;F01.145.126.350;F01.470;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;F02.463.425.540.254;F02.463.425.540.641;A08.186.211.200.885.287.500.270.700;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;F04.754.137.350;F01.145.126.350;E01.370.350.825.500
29128074,Child;Flow Cytometry;Hematologic Neoplasms;Humans;Leukemia;Lymphoma;Leukemia;Lymphoma,M01.060.406;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;C04.588.448;C15.378.400;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761;C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761
29128027,,
29128026,"Hepatopulmonary Syndrome;Humans;Hypertension, Portal;Hypertension, Pulmonary;Liver Transplantation;Lung;Fibrosis;Transplants",C06.552.455;C08.381.385;B01.050.150.900.649.313.988.400.112.400.400;C06.552.494;C08.381.423;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;A04.411;C23.550.355;A01.941
29128023,Humans;Lung;Lung Transplantation;Tissue Donors;Tissue and Organ Procurement;Brain Death;Tissue Donors,B01.050.150.900.649.313.988.400.112.400.400;A04.411;E04.928.600.495;E04.936.450.495;M01.898;N02.421.911;C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;M01.898
29128015,Humans;Lung Transplantation;Primary Graft Dysfunction;Reperfusion Injury;Risk Factors;Acute Lung Injury;Reperfusion Injury;Lung Transplantation;Primary Graft Dysfunction,B01.050.150.900.649.313.988.400.112.400.400;E04.928.600.495;E04.936.450.495;C14.907.725.675;C23.550.767.877.750;C14.907.725;C23.550.767.877;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.381.520.500;C14.907.725;C23.550.767.877;E04.928.600.495;E04.936.450.495;C14.907.725.675;C23.550.767.877.750
29128012,Acute Lung Injury;Hematopoietic Stem Cell Transplantation;Humans;Syndrome;Transplantation Conditioning;Hematopoietic Stem Cell Transplantation,C08.381.520.500;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.288.500;E02.095.465.425.450.800;E05.478.610.800;E02.095.147.500.500.500;E04.936.225.687.500
29128011,"Graft vs Host Disease;Hematologic Neoplasms;Hematopoietic Stem Cell Transplantation;Humans;Transplantation Conditioning;Transplantation, Homologous;Graft vs Host Disease;Hematologic Neoplasms",C20.452;C04.588.448;C15.378.400;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.450.800;E05.478.610.800;E04.936.864;C20.452;C04.588.448;C15.378.400
29128005,"Head;Head and Neck Neoplasms;Humans;Neck;Positron Emission Tomography Computed Tomography;Pets;Positron Emission Tomography Computed Tomography;Carcinoma, Squamous Cell",A01.456;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;A01.598;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;B01.050.050.116.600;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;C04.557.470.200.400;C04.557.470.700.400
29127721,"Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Cohort Studies;Humans;Magnetic Resonance Imaging;Mastectomy, Segmental;Middle Aged;Preoperative Care;Retrospective Studies;Carcinoma, Intraductal, Noninfiltrating;Mastectomy, Segmental;Mastectomy, Segmental",C04.588.180;C17.800.090.500;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E04.466.701;M01.060.116.630;E02.760.795;E04.604.750;N02.421.585.795;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E04.466.701;E04.466.701
29127281,,
29127121,,
29127107,Cancer Vaccines;Heating;Humans;Immunotherapy;Melanins;Neoplasms,D20.215.894.200;N06.230.150.300;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;D12.125.072.050.875.379;D23.767.620;C04
29127053,"Acne Vulgaris;Administration, Oral;Administration, Topical;Anti-Bacterial Agents;Consensus;Dermatologists;Disease Management;Drug Therapy, Combination;Humans;Internationality;Practice Guidelines as Topic;Quality Improvement;Retinoids;Risk Assessment;Severity of Illness Index;Treatment Outcome;Acne Vulgaris;Cicatrix",C17.800.030.150;C17.800.794.111;E02.319.267.100;E02.319.267.120;D27.505.954.122.085;F01.829.316.068;F02.463.785.373.433;M01.526.485.810.215;N02.360.810.215;N04.590.607;E02.319.310;B01.050.150.900.649.313.988.400.112.400.400;I01.615;N04.761.700.350.650;N05.700.350.650;J01.293.754;N04.761.744;D02.455.326.271.665.202.495;D02.455.426.392.368.367.379.249.700;D02.455.849.131.495;D23.767.261.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C17.800.030.150;C17.800.794.111;A10.165.450.300;C23.550.355.274;G16.762.891.249
29126965,Adolescent;Adolescent Development;Adult;Brain;Child;Executive Function;Functional Neuroimaging;Humans;Magnetic Resonance Imaging;Young Adult,M01.060.057;F01.525.049;G07.345.374.500;M01.060.116;A08.186.211;M01.060.406;F02.463.217;E01.370.350.578.875;E01.370.376.537.625;E05.629.875;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.815
29126702,Caregivers;Child;Decision Making;Epilepsy;Humans;Parents;Surveys and Questionnaires;Parents,M01.085;M01.526.485.200;N02.360.200;M01.060.406;F02.463.785.373;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F01.829.263.500.320;I01.880.853.150.500.340;M01.620
29126677,Blood Coagulation Disorders;Blood Coagulation Factors;Humans,C15.378.100;D12.776.124.125;D23.119;B01.050.150.900.649.313.988.400.112.400.400
29126675,"Cerebrovascular Circulation;Oximetry;Oxygen;Spectroscopy, Near-Infrared",G09.330.100.159;E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;D01.268.185.550;D01.362.670;E01.370.350.750;E05.196.867.851
29126497,"Carcinoma, Squamous Cell;Humans;Mouth Neoplasms;Oropharyngeal Neoplasms;Quality of Life;Radiotherapy, Intensity-Modulated;Head and Neck Neoplasms;Oropharyngeal Neoplasms;Radiotherapy",C04.557.470.200.400;C04.557.470.700.400;B01.050.150.900.649.313.988.400.112.400.400;C04.588.443.591;C07.465.530;C04.588.443.665.710.684;C07.550.745.671;C09.647.710.685;C09.775.549.685;I01.800;K01.752.400.750;N06.850.505.400.425.837;E02.815.635.700.700;L01.313.500.750.100.710.600.550.700;C04.588.443;C04.588.443.665.710.684;C07.550.745.671;C09.647.710.685;C09.775.549.685;E02.815
29126495,"Carcinoma, Squamous Cell;Humans;Lymph Node Excision;Lymphatic Metastasis;Margins of Excision;Mouth Neoplasms;Neck Dissection;Neoplasm Staging;Oral Surgical Procedures;Precancerous Conditions;Reconstructive Surgical Procedures;Robotic Surgical Procedures;Glossectomy;Mandibular Osteotomy;Neck Dissection;Mouth Neoplasms",C04.557.470.200.400;C04.557.470.700.400;B01.050.150.900.649.313.988.400.112.400.400;E04.446;C04.697.650.560;C23.550.727.650.560;A10.830;C23.149.625;C04.588.443.591;C07.465.530;E04.446.318;E04.580.411;E01.789.625;E04.545;E06.645;C04.834;E04.680;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;E04.545.380;E06.645.380;E06.645.562.374;E04.446.318;E04.580.411;C04.588.443.591;C07.465.530
29126493,"Diagnostic Imaging;Humans;Lymphatic Metastasis;Mouth Neoplasms;Neoplasm Invasiveness;Neoplasm Metastasis;Neoplasm Staging;Prognosis;Mouth Neoplasms;Positron-Emission Tomography;Carcinoma, Squamous Cell;Neoplasm Staging",E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;C04.588.443.591;C07.465.530;C04.697.645;C23.550.727.645;C04.697.650;C23.550.727.650;E01.789.625;E01.789;C04.588.443.591;C07.465.530;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;C04.557.470.200.400;C04.557.470.700.400;E01.789.625
29126405,"Advisory Committees;Curriculum;Documentation;Education, Medical, Graduate;Educational Measurement;Humans;Internship and Residency;Models, Educational;Pediatrics;Physician Executives;Professional Competence;Records;United States",N03.706.742.500;I02.158;L01.453.245;I02.358.337.350;I02.358.399.350;I02.399;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;E05.599.545;I02.903.302;H02.403.670;M01.526.070.700;M01.526.485.800;N02.360.800;I02.399.630;E05.318.308.940;L01.399.250.900;N04.452.859;N05.715.360.300.715;N06.850.520.308.940;Z01.107.567.875
29126328,Fatigue;Sleep Deprivation,C23.888.369;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
29125828,"Cells, Cultured;Fibroblasts;Friedreich Ataxia;Gene Expression Profiling;Gene Expression Regulation;Gene Ontology;Humans;Protein Biosynthesis;Sequence Analysis, RNA;Fibroblasts;Friedreich Ataxia;Sequence Analysis, RNA",A11.251;A11.329.228;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;E05.393.332;G05.308;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;B01.050.150.900.649.313.988.400.112.400.400;G02.111.660.871;G03.734.871;G05.297.670;E05.393.760.710;A11.329.228;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;E05.393.760.710
29125827,"Animals;Biomarkers;Cerebellum;Disease Models, Animal;Electron Transport;Friedreich Ataxia;Iron-Binding Proteins;Mice, Knockout;Organelle Biogenesis;Protein Subunits;Cerebellum;Friedreich Ataxia;Organelle Biogenesis;Neurodegenerative Diseases",B01.050;D23.101;A08.186.211.132.810.428.200;C22.232;E05.598.500;E05.599.395.080;G02.111.248;G03.295.531.403;G03.493.350;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;D12.776.157.427;D12.776.556.579;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G04.618;G16.645;D12.776.813;A08.186.211.132.810.428.200;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;G04.618;G16.645;C10.574
29125762,"Alkanes;Animals;Cell Line;Dopamine Antagonists;Humans;Ligands;Piperazines;Radioligand Assay;Receptors, Dopamine D3;Spiro Compounds;Structure-Activity Relationship",D02.455.326.146;B01.050;A11.251.210;D27.505.519.625.150.175;D27.505.696.577.150.175;B01.050.150.900.649.313.988.400.112.400.400;D27.720.470.480;D03.383.606;E01.370.225.985;E01.370.374.650;E01.370.384.720;E05.200.985;D12.776.543.750.670.300.400.500.249;D12.776.543.750.695.150.400.500.500;D12.776.543.750.720.330.400.500.249;D02.455.426.779;D04.711;G02.111.830;G07.690.773.997
29125442,Adolescent;Athletic Injuries;Brachial Plexus;Child;Electromyography;Follow-Up Studies;Humans;Magnetic Resonance Imaging;Musculoskeletal Pain;Prospective Studies;Thoracic Outlet Syndrome;Treatment Outcome;Brachial Plexus;Pain;Peripheral Nerves;Thoracic Outlet Syndrome,M01.060.057;C26.115;A08.800.800.720.050;M01.060.406;E01.370.405.255;E01.370.530.255;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C05.651.538;C23.888.592.612.547;F02.830.816.353;G11.561.790.353;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.668.829.550.850;C14.907.863;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A08.800.800.720.050;C23.888.592.612;F02.830.816.444;G11.561.790.444;A08.800.800;C10.668.829.550.850;C14.907.863
29125192,Hodgkin Disease;Survival,C04.557.386.355;C15.604.515.569.355;C20.683.515.761.355;I03.784
29124398,"Aged;Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;Canada;Disease Progression;Glucocorticoids;Health Knowledge, Attitudes, Practice;Humans;Interviews as Topic;Mental Health;Middle Aged;Patient Safety;Patients;Qualitative Research;Quality of Life;Recurrence;Remission Induction;Risk Assessment;Treatment Outcome;United Kingdom;United States;Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;Glucocorticoids;Microscopic Polyangiitis",M01.060.116.100;C14.907.940.897.249;C20.111.193;Z01.107.567.176;C23.550.291.656;D06.472.040.543;D27.505.696.399.472.488;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;F02.418;N01.400.500;M01.060.116.630;N06.850.135.060.075.399;M01.643;H01.770.644.241.850;I01.800;K01.752.400.750;N06.850.505.400.425.837;C23.550.291.937;E02.860;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.542.363;Z01.107.567.875;C14.907.940.897.249;C20.111.193;D06.472.040.543;D27.505.696.399.472.488;C10.228.140.300.275.600;C14.907.253.329.600;C14.907.940.897.249.500;C20.111.193.750
29123652,Sirolimus,D02.540.505.760
29123360,,
29122738,"Acute Disease;Adolescent;Cell Phone;Child;Child, Preschool;Cohort Studies;Fever;Gastroenteritis;Guatemala;Humans;Infant;Infant, Newborn;Mobile Applications;Risk Factors;Rural Population;Sentinel Surveillance;Guatemala;Dengue;Diarrhea;Cell Phone;Norovirus;Sentinel Surveillance",C23.550.291.125;M01.060.057;L01.178.847.698.300;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.888.119.344;C06.405.205;Z01.107.169.454;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;L01.224.900.685;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N01.600.725;E05.318.308.980.438.700.650;E05.318.650;N05.715.360.300.800.438.625.650;N06.850.520.308.980.438.700.650;N06.850.520.699;N06.850.780.675.650;Z01.107.169.454;C02.081.270;C02.782.350.250.214;C02.782.417.214;C23.888.821.214;L01.178.847.698.300;B04.820.095.550;E05.318.308.980.438.700.650;E05.318.650;N05.715.360.300.800.438.625.650;N06.850.520.308.980.438.700.650;N06.850.520.699;N06.850.780.675.650
29122273,,
29121998,"Adult;Aged;Aged, 80 and over;Area Under Curve;Biomarkers;Brain;Case-Control Studies;Cognitive Dysfunction;Cohort Studies;Diagnosis, Differential;Humans;MicroRNAs;Middle Aged;Neurodegenerative Diseases;ROC Curve;Random Allocation;Sex Characteristics;Alzheimer Disease;Amyotrophic Lateral Sclerosis;Frontotemporal Dementia;Parkinson Disease;MicroRNAs",M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;D23.101;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F03.615.250.700;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.171;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;M01.060.116.630;C10.574;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;G08.686.815;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29121770,"Cell Line;Histones;Humans;Mass Spectrometry;Protein Processing, Post-Translational;Reproducibility of Results;Sample Size;Histones;Mass Spectrometry;Protein Processing, Post-Translational",A11.251.210;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
29121188,Adult;Blindness;Exophthalmos;Eye Pain;Granulomatosis with Polyangiitis;Humans;Magnetic Resonance Imaging;Orbital Diseases,M01.060.116;C10.597.751.941.162;C11.966.075;C23.888.592.763.941.162;C11.675.349;C11.300.500;C23.888.307.625;C23.888.592.612.316;C08.381.483.950;C14.907.940.897.249.750;C20.111.193.875;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C11.675
29121125,"Adult;Antilymphocyte Serum;Axilla;Diagnosis, Differential;Erythema;Foot;Groin;Heart Transplantation;Humans;Immunosuppressive Agents;Serum Sickness",M01.060.116;A12.207.152.846.500.203;D12.776.124.486.485.114.573.203;D12.776.124.790.651.114.573.203;D12.776.377.715.548.114.573.203;D20.215.401.203;A01.378.800.090;E01.171;C17.800.229;C23.888.885.328;A01.378.610.250;A01.923.047.365;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;C17.800.174.600.800;C20.543.206.380.800;C20.543.520.770;C25.100.468.380.800
29120638,"Animals;Antineoplastic Agents;Cell Line, Tumor;Crystallography, X-Ray;Drug Discovery;Drug Screening Assays, Antitumor;Enzyme Inhibitors;High-Throughput Screening Assays;Humans;L-Lactate Dehydrogenase;Membranes, Artificial;Mice;Microsomes, Liver;Permeability;Pyrazoles;Rats;Solubility;Structure-Activity Relationship;Thiazoles",B01.050;D27.505.954.248;A11.251.210.190;A11.251.860.180;E05.196.309.742.225;E05.295;H01.158.703.007.675;H01.181.466.675;E01.370.225.500.388;E05.200.500.388;E05.242.417;E05.337.550.200;D27.505.519.389;E05.916.680;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.047.551.400;D08.811.682.047.820.493;D25.479;J01.637.051.479;J01.637.087.500;B01.050.150.900.649.313.992.635.505.500;A11.284.835.540.541;G02.723;D03.383.129.539;B01.050.150.900.649.313.992.635.505.700;G02.805;G02.111.830;G07.690.773.997;D02.886.675;D03.383.129.708
29119134,,
29118214,"Animals;Central Nervous System;Gastrointestinal Tract;Homeostasis;Humans;Immunity, Humoral;Nerve Net;Urination;Pons",B01.050;A08.186;A03.556;G07.410;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.420;A08.511;G08.852.880;A08.186.211.132.810.428.600
29118029,Algorithms;Data Analysis;Data Visualization,G17.035;L01.224.050;H01.548.338;L01.143.288
29117573,"Education, Medical;Research",I02.358.399;H01.770.644
29117357,"Case-Control Studies;Gene Amplification;Gene Expression Regulation, Neoplastic;Gene Frequency;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;N-Myc Proto-Oncogene Protein;Neuroblastoma;Polymorphism, Single Nucleotide",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G05.308.250;G05.365.590.310;G05.558.315;G05.308.370;G05.330;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.365.795.598
29117303,"Chemistry;Dermatology;History, 19th Century;History, 20th Century;Ointment Bases;Petrolatum;Skin Diseases;United States",H01.181;H02.403.225;K01.400.504.937;K01.400.504.968;D26.650.523;D27.720.744.523;D02.455.699;C17.800;Z01.107.567.875
29117090,Cooperative Behavior;Health Occupations;Humans;Internationality;Multicenter Studies as Topic;Pediatrics;Research;Simulation Training,F01.145.813.115;H02;B01.050.150.900.649.313.988.400.112.400.400;I01.615;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;H02.403.670;H01.770.644;I02.903.847
29117060,"Child Development;Cognition;Cohort Studies;Developmental Disabilities;Follow-Up Studies;Humans;Infant;Intensive Care Units, Pediatric;Prospective Studies;United States;Whooping Cough",F01.525.200;G07.345.374.750;F02.463.188;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F03.625.421;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;Z01.107.567.875;C01.252.400.143.740;C01.539.739.969;C08.730.969
29117021,"Behavior, Addictive;Crime;Criminal Law;Humans;Substance-Related Disorders",F01.145.527.100.120;I01.198.240;I01.880.735.191;I01.198.290;I01.880.604.583.100;B01.050.150.900.649.313.988.400.112.400.400;C25.775;F03.900
29116986,"Education, Medical;Faculty, Medical;Humans;Incidence;Internship and Residency;Medical Staff, Hospital;Organizational Culture;Organizational Policy;Sex Offenses;Sexual Harassment;Societies, Medical;Students, Medical;United States;Vulnerable Populations",I02.358.399;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;N04.452.606;I01.655.500.550;I01.880.604.825.550;N03.623.500.550;I01.198.240.748;F01.145.802.950;F01.145.813.606;N03.540.828.589;M01.848.769.602;Z01.107.567.875;M01.965
29116439,"Fibrosis;Humans;Morbidity;Scleroderma, Localized;Scleroderma, Systemic;Mortality;Review;Survival;Scleroderma, Systemic",C23.550.355;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;C17.300.787;C17.800.767;C17.300.799;C17.800.784;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;V02.600.500;V02.912;I03.784;C17.300.799;C17.800.784
29116422,"Animals;Biomarkers, Tumor;Cell Line, Tumor;Cell Movement;Cell Transformation, Neoplastic;Drug Resistance, Neoplasm;Gene Expression Regulation, Neoplastic;Humans;Intercellular Signaling Peptides and Proteins;Neoplasms;Neovascularization, Pathologic;Neovascularization, Physiologic;Progranulins;Neoplasms;Progranulins",B01.050;D23.101.140;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;C04.697.098.500;C23.550.727.098.500;G07.690.773.984.395;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276;D12.776.467;D23.529;C04;C23.550.589.500;G09.330.630;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917;C04;D06.472.699.682;D12.644.276.917;D12.776.467.917;D12.776.811.703;D23.529.917
29115886,"Adolescent;Age Factors;Antineoplastic Agents;Asparaginase;Biomarkers;Child;Child, Preschool;Drug Hypersensitivity;Humans;Incidence;Infusions, Intravenous;Injections, Intramuscular;Leukemia;Polyethylene Glycols;Public Health Surveillance;Severity of Illness Index;Asparaginase;Hypersensitivity",M01.060.057;N05.715.350.075;N06.850.490.250;D27.505.954.248;D08.811.277.087.116;D23.101;M01.060.406;M01.060.406.448;C20.543.206;C25.100.468;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E02.319.267.082.500;E02.319.267.510.590;E02.319.267.530.460;C04.557.337;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;E05.318.308.980.438.700.324;N05.715.360.300.800.438.625.324;N06.850.520.308.980.438.700.324;N06.850.780.675.487;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;D08.811.277.087.116;C20.543
29114921,"Adolescent;Adult;African Americans;European Continental Ancestry Group;Follow-Up Studies;Gray Matter;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Risk Factors;United States;Ventricular Dysfunction, Left;White Matter;Young Adult;Cerebrovascular Disorders",M01.060.057;M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.686.508.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C14.280.945.900;A08.186.211.204;A08.186.854.880;M01.060.116.815;C10.228.140.300;C14.907.253
29114919,"Adult;Antigens, CD34;Blood Component Removal;Case-Control Studies;Cell Count;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Hyperlipidemias;Hyperlipoproteinemia Type II;Lipoproteins;Middle Aged;Stem Cells;Blood Component Removal;Hyperlipoproteinemia Type II",M01.060.116;D23.050.301.264.035.134;D23.101.100.110.134;E02.120;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E01.370.225.500.195;E05.200.500.195;E05.242.195;G04.140;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;C18.452.584.500.500;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;D10.532;D12.776.521;M01.060.116.630;A11.872;E02.120;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481
29114877,Thoracic Surgery;Obesity,H02.403.810.803;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29113960,"Aminolevulinic Acid;Carcinoma in Situ;Head and Neck Neoplasms;Humans;Hypoxia;Lasers, Semiconductor;Neoplasm Recurrence, Local;Neoplasm Staging;Photochemotherapy;Photosensitizing Agents;Precancerous Conditions;Radiation Dosage;Aminolevulinic Acid",D02.241.755.547.276;D12.125.262;C04.557.470.200.240;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;E07.632.490.480;E07.710.520.480;C04.697.655;C23.550.727.655;E01.789.625;E02.186.500;E02.319.685;E02.774.722;D27.505.954.444.600;D27.505.954.600.710;C04.834;E05.799.513;G01.750.740;N06.850.810.250;D02.241.755.547.276;D12.125.262
29113851,"Academic Medical Centers;Adolescent;Adult;Aged;Central Nervous System Neoplasms;Databases, Factual;Glioblastoma;Hospitals;Humans;Middle Aged;Outcome and Process Assessment (Health Care);Young Adult;Morals;Survival",N02.278.020;M01.060.057;M01.060.116;M01.060.116.100;C04.588.614.250;C10.551.240;L01.313.500.750.300.188.400;L01.470.750.750;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.761.559;N05.715.360.575;M01.060.116.815;F01.829.500;K01.752.566;I03.784
29112280,Adolescent;Anorexia Nervosa;Bulimia Nervosa;Cross-Sectional Studies;Exercise Therapy;Humans;Anorexia Nervosa;Bradycardia;Bulimia Nervosa;Exercise;Exercise,M01.060.057;F03.400.125;F03.400.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;B01.050.150.900.649.313.988.400.112.400.400;F03.400.125;C14.280.067.319;C23.550.073.300;F03.400.250;G11.427.410.698.277;I03.350;G11.427.410.698.277;I03.350
29112230,Precursor Cell Lymphoblastic Leukemia-Lymphoma;Quality of Life,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;I01.800;K01.752.400.750;N06.850.505.400.425.837
29112110,,
29112109,,
29112077,Algorithms;Attitude of Health Personnel;Auditory Perception;Clinical Alarms;Critical Illness;Discrimination Learning;Equipment Design;Humans;Intensive Care Units;Mental Fatigue;Music;Sleep Hygiene,G17.035;L01.224.050;F01.100.050;N05.300.100;F02.463.593.071;E07.230.200;C23.550.291.625;F02.463.425.280;E05.320;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;C23.888.369.500;F01.145.126.937;K01.602;F01.145.488.725;F02.830.855.734
29111226,Nutrition Policy;Obesity;Public Policy;Sports,I01.655.500.608.400.650;I01.880.604.825.608.400.650;N03.623.500.608.428.650;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;I01.655.500.608;I01.880.604.825.608;N03.623.500.608;I03.450.642.845
29111122,Echocardiography;Outpatients,E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;M01.643.630
29110982,"Adolescent;Child;Child, Preschool;Emergency Medicine;Emergency Service, Hospital;Humans;Infant;Length of Stay;Pediatrics;Point-of-Care Systems;Soft Tissue Infections;Ultrasonography;Length of Stay;Pediatrics;Soft Tissue Infections",M01.060.057;M01.060.406;M01.060.406.448;H02.403.250;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.760.400.480;N02.421.585.400.480;H02.403.670;N04.452.442.452.680;N04.452.515.360.652;N04.590.874;C01.539.820;E01.370.350.850;E02.760.400.480;N02.421.585.400.480;H02.403.670;C01.539.820
29110873,"Adolescent;Caregivers;Child;Child, Preschool;Chronic Disease;Cross-Sectional Studies;Delayed Diagnosis;Early Diagnosis;Humans;Infant;Musculoskeletal Diseases;Nepal;Patient Acceptance of Health Care;Nepal",M01.060.057;M01.085;M01.526.485.200;N02.360.200;M01.060.406;M01.060.406.448;C23.550.291.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.110;E02.288;E02.760.273;N02.421.585.273;E01.390;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C05;Z01.252.245.674;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;Z01.252.245.674
29110817,,
29110346,"Gene-Environment Interaction;Humans;Meta-Analysis as Topic;Models, Genetic;Polymorphism, Single Nucleotide;Gene-Environment Interaction;Meta-Analysis",G05.695.337;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;E05.599.395.397;G05.365.795.598;G05.695.337;V03.600
29110344,Animals;Brain;Energy Metabolism;Humans;Neurosciences;In Vitro Techniques,B01.050;A08.186.211;G03.295;B01.050.150.900.649.313.988.400.112.400.400;H01.158.610;E05.481
29109276,"Animals;Antibodies, Viral;Antigens, Viral;Chickens;Ferrets;Glycosylation;Hemagglutinin Glycoproteins, Influenza Virus;Humans;Immunogenicity, Vaccine;Influenza A Virus, H3N2 Subtype;Influenza Vaccines;Influenza, Human;Mutation;Neutralization Tests;Ovum;Hemagglutinins;Influenza, Human",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;D23.050.327;B01.050.150.900.248.350.150;B01.050.150.900.248.690.192;B01.050.150.900.649.313.750.250.575.350;G02.111.158.812;G02.607.299;G03.191.812;D12.776.964.970.880.345.500;B01.050.150.900.649.313.988.400.112.400.400;G12.070.500;G12.450.050.370.500;G12.450.050.460;G12.513;B04.820.545.405.400.300;D20.215.894.899.302;C02.782.620.365;C08.730.310;G05.365.590;E01.370.225.812.735.550;E05.200.812.735.550;E05.478.594.760.550;A05.360.490.690;A11.497.497;A16.690;D27.505.696.477.136.377;C02.782.620.365;C08.730.310
29109193,"Clinical Decision-Making;Cost-Benefit Analysis;Diagnostic Techniques, Cardiovascular;Health Care Costs;Heart Diseases;Humans;Practice Guidelines as Topic;Predictive Value of Tests;Preoperative Care;Process Assessment (Health Care);Risk Assessment;Risk Factors;Surgical Procedures, Operative;Treatment Outcome;Value-Based Health Insurance;Perioperative Care;Preoperative Care;Quality of Life",E01.055;N03.219.151.125;E01.370.370;N03.219.151.400;N05.300.375;C14.280;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E02.760.795;E04.604.750;N02.421.585.795;N04.761.559.650;N05.715.360.575.625;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N03.219.521.576.343.972;N04.761.744.750;E02.760.731;E04.604;N02.421.585.722;E02.760.795;E04.604.750;N02.421.585.795;I01.800;K01.752.400.750;N06.850.505.400.425.837
29109116,Mitochondria;Respiration,A11.284.430.214.190.875.564;A11.284.835.626;G09.772.705
29109077,"Adult;Aged;Animals;Antigens, Neoplasm;Biomarkers, Tumor;Breast Neoplasms;Cell Line, Tumor;Cytotoxicity, Immunologic;Disease Models, Animal;Gene Expression;Humans;Immunotherapy;Mice;Middle Aged;Proto-Oncogene Proteins c-met;RNA, Messenger;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;T-Lymphocytes;Treatment Outcome;Xenograft Model Antitumor Assays",M01.060.116;M01.060.116.100;B01.050;D23.050.285;D23.101.140;C04.588.180;C17.800.090.500;A11.251.210.190;A11.251.860.180;G12.287;C22.232;E05.598.500;E05.599.395.080;G05.297;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;B01.050.150.900.649.313.992.635.505.500;M01.060.116.630;D08.811.913.696.620.682.725.400.075;D12.776.543.750.630.186;D12.776.543.750.750.400.100;D12.776.624.664.700.186;D13.444.735.544;D12.776.543.750.705.816.824;D12.776.828.300;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.337.550.200.900;E05.624.850
29108846,Carotid Artery Injuries;Risk Factors,C10.228.140.300.200.345;C10.228.140.300.350.500;C10.900.250.300;C14.907.253.123.345;C14.907.253.535.500;C26.915.200.200;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29108474,"Adenoma;Adolescent;Biomarkers, Tumor;Carcinoma, Papillary;Child;Cross-Sectional Studies;DNA Mutational Analysis;Goiter;Humans;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);Retrospective Studies;Thyroid Gland;Thyroid Neoplasms;Thyroid Nodule;Thyroiditis",C04.557.470.035;M01.060.057;D23.101.140;C04.557.470.200.360;C04.557.470.700.360;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.393.760.700.300;C19.874.283;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D08.811.277.040.330.300.400.500.600;D12.644.360.525.500.600;D12.776.157.325.515.500.600;D12.776.476.525.500.600;D12.776.624.664.700.200;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A06.300.900;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;C19.874.871
29108130,Hypoglycemia;Metformin;Pharmacoepidemiology;Sulfonylurea Compounds,C18.452.394.984;D02.078.370.141.450;H01.158.703.045;H02.403.720.500.650;H02.628.413;D02.886.590.795;D02.948.828
29107738,"Animals;Bone Development;Cell Proliferation;Child;Chondrocytes;Disease Models, Animal;Endopeptidase K;Extracellular Vesicles;Humans;Mesenchymal Stem Cells;Mice, Inbred C57BL;MicroRNAs;Osteogenesis Imperfecta;Ribonucleases;Solubility;Chondrocytes;Extracellular Vesicles;Growth;Mesenchymal Stem Cells;Osteogenesis Imperfecta",B01.050;G07.345.500.325.377.625.050.500;G11.427.578.050.500;G04.161.750;G07.345.249.410.750;M01.060.406;A11.329.171;C22.232;E05.598.500;E05.599.395.080;D08.811.277.656.300.760.247;D08.811.277.656.959.350.247;A11.284.295.588;B01.050.150.900.649.313.988.400.112.400.400;A11.329.830.500;A11.872.590.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;C05.116.099.708.685;C16.320.737;C17.300.200.540;D08.811.277.352.700;G02.805;A11.329.171;A11.284.295.588;G07.345.249;A11.329.830.500;A11.872.590.500;C05.116.099.708.685;C16.320.737;C17.300.200.540
29107597,"Animals;Animals, Genetically Modified;Antigens, Polyomavirus Transforming;Cellular Reprogramming;Chimera;Chromatin;Epigenesis, Genetic;Fibroblasts;Genome;Histone Code;Induced Pluripotent Stem Cells;Mice;Mole Rats;Induced Pluripotent Stem Cells",B01.050;B01.050.050.136;B05.620.136;D12.776.624.664.520.090;D12.776.964.700.090;D23.050.285.062.090;D23.050.327.062.090;G04.152.262;G05.135;B05.200;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.308.203;A11.329.228;G05.360.340;G02.111.570.060.360;G05.360.360;A11.872.040.500;A11.872.700.500;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.600;A11.872.040.500;A11.872.700.500
29107558,"Alternative Splicing;Animals;Cell Differentiation;Cochlea;Hearing Loss;Mice, Knockout;Mutation;RNA-Binding Proteins;Alternative Splicing;Hearing Loss;Stria Vascularis",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;G04.152;A09.246.300.246;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;D12.776.157.725;D12.776.664.962;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;A09.246.300.246.292.876
29107361,"AIDS-Associated Nephropathy;Adult;Aged;Anti-HIV Agents;Coinfection;Databases, Factual;HIV Infections;Hepatitis C;Humans;Middle Aged;Renal Dialysis;Retrospective Studies;Risk Assessment;Risk Factors;Time Factors;Treatment Outcome;United States;Kidney Failure, Chronic;HIV;Renal Dialysis;Transplants",C02.782.815.616.400.050;C02.800.801.400.072;C12.777.419.050;C13.351.968.419.050;C20.673.480.050;M01.060.116;M01.060.116.100;D27.505.954.122.388.077.088;C01.539.218;C02.219;C03.202;L01.313.500.750.300.188.400;L01.470.750.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.870.300;E02.912.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C12.777.419.780.750.500;C13.351.968.419.780.750.500;B04.820.650.589.650.350;E02.870.300;E02.912.800;A01.941
29107342,"Academic Medical Centers;Adrenal Cortex Hormones;Adult;Aged;Anemia;Arthralgia;Colchicine;Dapsone;Filgrastim;Folic Acid Antagonists;Hematologic Agents;Humans;Inflammation;Leukemia, Myeloid, Acute;Leukopenia;Middle Aged;Mutation;Neoplasms;Nuclear Proteins;Potassium Iodide;Retrospective Studies;Sweet Syndrome;Tertiary Care Centers;Thrombocytopenia;Tubulin Modulators;fms-Like Tyrosine Kinase 3;Sweet Syndrome;Sweet Syndrome;Leukemia, Myeloid, Acute;fms-Like Tyrosine Kinase 3;Karyotype;Neutrophils",N02.278.020;D06.472.040;M01.060.116;M01.060.116.100;C15.378.071;C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350;D03.132.225;D02.886.590.263;D12.644.276.374.410.240.350.500;D12.776.395.240.200.500;D12.776.467.374.410.240.350.500;D23.529.374.410.240.350.500;D27.505.519.389.350;D27.505.954.502;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C04.557.337.539.275;C15.378.553.546;M01.060.116.630;G05.365.590;C04;D12.776.660;D01.475.410.700;D01.745.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C17.800.229.800;N02.278.421.830;C15.378.140.855;D27.505.519.593.249.500;D08.811.913.696.620.682.725.400.020;D12.776.543.750.630.020;D12.776.624.664.700.114;C17.800.229.800;C17.800.229.800;C04.557.337.539.275;D08.811.913.696.620.682.725.400.020;D12.776.543.750.630.020;D12.776.624.664.700.114;G05.360.162.679;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
29107020,China;Data Collection;Humans;Inflammatory Bowel Diseases;Patient Care;Quality Improvement;Quality of Health Care,Z01.252.474.164;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;E02.760;N02.421.585;J01.293.754;N04.761.744;N04.761;N05.715
29106667,,
29106589,"Adrenal Cortex Hormones;Child;Child, Preschool;Hematopoietic Stem Cell Transplantation;Hospitalization;Humans;Incidence;Respiratory Therapy;Respiratory Tract Infections;Retrospective Studies;Risk Factors;Time Factors;Treatment Outcome;United States;Virus Diseases",D06.472.040;M01.060.406;M01.060.406.448;E02.095.147.500.500.500;E04.936.225.687.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E02.880;C01.539.739;C08.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C02
29106525,"Animals;Disease Models, Animal;Drosophila;Drosophila Proteins;Drosophila melanogaster;Energy Metabolism;Fragile X Mental Retardation Protein;Fragile X Syndrome;Mitochondria;Signal Transduction",B01.050;C22.232;E05.598.500;E05.599.395.080;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;G03.295;D12.776.157.725.061;D12.776.631.299;D12.776.664.962.124;C10.597.606.360.455.500;C16.131.260.830.300;C16.320.180.830.300;C16.320.322.500.500;C16.320.400.525.500;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.820;G04.835
29106329,North America,Z01.107.567
29105836,"Adolescent;Alopecia Areata;Child;Child, Preschool;Disease Progression;Hair;Humans;Scalp;Severity of Illness Index;Young Adult",M01.060.057;C17.800.329.937.122.147;M01.060.406;M01.060.406.448;C23.550.291.656;A17.360;B01.050.150.900.649.313.988.400.112.400.400;A01.456.810;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815
29105824,"Anti-Bacterial Agents;Baths;Caregivers;Child;Child, Preschool;Drug Resistance, Bacterial;Epidermolysis Bullosa;Humans;Infant;Microbial Sensitivity Tests;New York City;Skin Care;Wound Infection;Epidermolysis Bullosa;Infection;Therapeutics",D27.505.954.122.085;E02.056.110;M01.085;M01.526.485.200;N02.360.200;M01.060.406;M01.060.406.448;G06.099.225;G06.225.347;G07.690.773.984.269.347;C16.131.831.493;C16.320.850.275;C17.800.804.493;C17.800.827.275;C17.800.865.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;Z01.107.567.875.350.530.530;Z01.107.567.875.500.530.530;Z01.433.741;E02.547.800;C01.539.947;C16.131.831.493;C16.320.850.275;C17.800.804.493;C17.800.827.275;C17.800.865.410;C01.539;E02
29105347,"Anti-Inflammatory Agents, Non-Steroidal;Aspirin;Asthma, Aspirin-Induced;Desensitization, Immunologic;Endoscopy;Humans;Paranasal Sinuses;Reoperation;Severity of Illness Index;Sinusitis;Surveys and Questionnaires;Treatment Outcome;Nasal Polyps",D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;D02.455.426.559.389.657.410.595.176;C08.127.108.054;C08.674.095.054;C20.543.206.189;C20.543.480.149;C25.100.468.189;E02.095.465.425.450.310;E05.478.610.310;E01.370.388.250;E04.502.250;B01.050.150.900.649.313.988.400.112.400.400;A04.531.621;E04.690;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C08.460.692.752;C08.730.749;C09.603.692.752;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.460.572;C09.603.557;C23.300.825.557
29105071,"Advisory Committees;Animals;Disease Models, Animal;Epilepsy;Humans;Outcome Assessment (Health Care);Systematic Reviews as Topic;Translational Medical Research;Models, Animal;Meta-Analysis",N03.706.742.500;B01.050;C22.232;E05.598.500;E05.599.395.080;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;L01.178.682.759.575;H01.770.644.145.675;E05.598;V03.600
29105008,"Anxiety Disorders;Child Development;Depression, Postpartum;Fathers;Humans;Infant;Infant, Newborn;Mood Disorders;Mothers;Parent-Child Relations;Postpartum Period;Child Development;Postpartum Period",F03.080;F01.525.200;G07.345.374.750;C13.703.844.253;F03.600.300.350;F01.829.263.500.320.100;I01.880.853.150.500.340.210;M01.620.390;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F03.600;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.829.263.370.290;G08.686.702;F01.525.200;G07.345.374.750;G08.686.702
29104846,DNA;Optical Tweezers,D13.444.308;E05.650
29104161,,
29104114,"Animals;Axons;Cells, Cultured;Diffuse Axonal Injury;Humans;Induced Pluripotent Stem Cells;Rats;Sex Characteristics;Calcium;Microtubules;Sex Characteristics",B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A11.251;C10.228.140.199.388.500;C10.900.300.087.219.500;C26.915.300.200.188.500;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;B01.050.150.900.649.313.992.635.505.700;G08.686.815;D01.268.552.100;D01.552.539.288;D23.119.100;A11.284.430.214.190.750.602;G08.686.815
29103953,"Animals;Apoptosis;Breast;Cell Lineage;Cell Proliferation;Forkhead Box Protein O1;Homeostasis;Mammary Glands, Animal;Mice, Transgenic;Stem Cells;Wnt Signaling Pathway;Wnt Signaling Pathway;Apoptosis",B01.050;G04.146.160;A01.236;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.161.750;G07.345.249.410.750;D12.776.260.950.249.250;D12.776.930.977.249.250;G07.410;A10.336.482;A13.589;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.872;G02.111.820.925;G04.835.925;G02.111.820.925;G04.835.925;G04.146.160
29103795,,
29103089,"Biomarkers;Cholesterol, HDL;Coronary Disease;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Lipid Metabolism;Mendelian Randomization Analysis;Molecular Targeted Therapy;Whole Exome Sequencing;Atherosclerosis;Genomics",D23.101;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;C14.280.647.250;C14.907.585.250;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G03.458;E05.318.416.500;E02.319.574;E05.393.760.700.825.500;C14.907.137.126.307;H01.158.273.180.350;H01.158.273.343.350
29102956,"Adult;Arthritis, Psoriatic;Cohort Studies;Humans;Incidence;Middle Aged;Psoriasis;Risk Factors;Smoking;Survival Analysis;United Kingdom;Epidemiology;Arthritis, Psoriatic;Smoking",M01.060.116;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;C17.800.859.675;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.805;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;Z01.542.363;H02.403.720.500;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;F01.145.805
29102816,"Acute Disease;Adult;Chronic Disease;Educational Status;Humans;Interview, Psychological;Leukocytes;Linear Models;Middle Aged;Polymerase Chain Reaction;Psychiatric Status Rating Scales;Schizophrenia;Severity of Illness Index;Smoking;Telomere;Telomere Shortening;Young Adult;Schizophrenia",C23.550.291.125;M01.060.116;C23.550.291.500;N01.824.196;B01.050.150.900.649.313.988.400.112.400.400;F04.669.599;A11.118.637;A15.145.229.637;A15.382.490;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;M01.060.116.630;E05.393.620.500;F04.711.513.653;F03.700.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F01.145.805;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G02.111.225.940;G04.043.630;G05.226.940;M01.060.116.815;F03.700.750
29102667,,
29102571,Cytochrome P-450 CYP2C19;Clopidogrel;Percutaneous Coronary Intervention;Pharmacogenetics,D08.244.453.491.500.700;D08.811.682.690.708.170.450.500.700;D12.776.422.220.453.491.500.700;D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500;E04.100.814.529.968;E04.502.382.968;H01.158.273.343.750;H01.158.703.052;H02.628.479
29102487,Dermatomyositis;Hand Dermatoses;Humans;Rheumatic Diseases;Classification;Dermatomyositis,C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;C17.800.338;B01.050.150.900.649.313.988.400.112.400.400;C05.799;C17.300.775;L01.100;L01.453.245.275;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185
29102205,Clostridium Infections;Antibiotic Prophylaxis;Thoracic Surgery,C01.252.410.222;E02.319.162.150;E02.319.703.150;H02.403.810.803
29101991,"Diagnostic Imaging;Evidence-Based Medicine;Humans;Hypertension, Renovascular;Societies, Medical;United States;Area Under Curve;Renal Artery Obstruction;Hypertension, Renovascular",E01.370.350;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.331.490;C13.351.968.419.331.490;C14.907.489.631.485;N03.540.828.589;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C12.777.419.775;C13.351.968.419.775;C14.907.137.727;C12.777.419.331.490;C13.351.968.419.331.490;C14.907.489.631.485
29101985,"Breast Neoplasms;Diagnostic Imaging;Evidence-Based Medicine;Humans;Neoadjuvant Therapy;Neoplasm Invasiveness;Societies, Medical;Tumor Burden;United States;Area Under Curve;Breast Neoplasms;Mammography",C04.588.180;C17.800.090.500;E01.370.350;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E02.186.450;C04.697.645;C23.550.727.645;N03.540.828.589;E05.041.124.892;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C04.588.180;C17.800.090.500;E01.370.350.700.500
29101979,"Age Factors;Breast Neoplasms;Diagnostic Imaging;Early Detection of Cancer;Evidence-Based Medicine;Humans;Risk Factors;Societies, Medical;United States;Area Under Curve;Breast Neoplasms;Mammography;Mass Screening",N05.715.350.075;N06.850.490.250;C04.588.180;C17.800.090.500;E01.370.350;E01.390.500;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N03.540.828.589;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C04.588.180;C17.800.090.500;E01.370.350.700.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
29101960,"Accountable Care Organizations;Health Care Costs;Health Expenditures;Humans;Insurance, Health;Quality of Health Care;United States;Accountable Care Organizations;Anesthesia;Delivery of Health Care",N05.300.380.500;N03.219.151.400;N05.300.375;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;N04.761;N05.715;Z01.107.567.875;N05.300.380.500;E03.155;N04.590.374;N05.300
29101959,"Ambulatory Care Facilities;Anesthesia;Child;Humans;Pediatrics;Radiology, Interventional;Sclerotherapy",N02.278.035;E03.155;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;H02.403.740.675;E02.319.805
29101957,"Anesthesia;Colonoscopy;Endoscopy, Gastrointestinal;Humans;Anesthesia;Colonoscopy;Deep Sedation;Conscious Sedation;Propofol",E03.155;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;E01.370.372.250.250;E01.370.388.250.250.250;E04.210.240.250;E04.502.250.250.250;B01.050.150.900.649.313.988.400.112.400.400;E03.155;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;E03.295;E03.250;D02.455.426.559.389.657.773
29101956,"Anesthesia;Endoscopy, Gastrointestinal;Humans",E03.155;E01.370.372.250.250;E01.370.388.250.250.250;E04.210.240.250;E04.502.250.250.250;B01.050.150.900.649.313.988.400.112.400.400
29101954,"Anesthesia;Electrophysiology;Humans;Catheter Ablation;Conscious Sedation;Anesthesia, General",E03.155;H01.158.344.528;H01.158.782.236;B01.050.150.900.649.313.988.400.112.400.400;E02.808.750.500;E04.014.760.500;E03.250;E03.155.197
29101953,Aortic Valve;Cardiac Catheterization;Heart Diseases;Heart Valve Prosthesis;Humans;Transcatheter Aortic Valve Replacement,A07.541.510.110;E01.370.370.380.140;E02.148.442;E05.157.250;C14.280;E07.695.310;B01.050.150.900.649.313.988.400.112.400.400;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
29101225,"Decision Making;Ethics, Medical;Fetus;Humans;Physicians;Practice Patterns, Physicians';Pregnancy;Pregnant Women;Risk Assessment;Surgical Procedures, Operative;Surveys and Questionnaires",F02.463.785.373;K01.752.566.479.171.132.750;N05.350.340.162.500;A16.378;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;N04.590.374.577;N05.300.625;G08.686.784.769;M01.975.807;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E04;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29101212,"Agammaglobulinaemia Tyrosine Kinase;Carrier Proteins;Humans;Inflammasomes;NLR Family, Pyrin Domain-Containing 3 Protein;Pyrin Domain",D08.811.913.696.620.682.725.025;D12.776.157;B01.050.150.900.649.313.988.400.112.400.400;D05.500.224;D12.644.360.539.250;G02.111.570.820.709.275.750.500.395.875
29100873,,
29100517,Aged;Ambulatory Care;Attitude to Health;Boston;Cultural Diversity;Humans;Middle Aged;Mobile Health Units;Patients;Physician-Patient Relations;Preventive Health Services;Qualitative Research;Telemedicine;Qualitative Research,M01.060.116.100;E02.760.106;N02.421.585.106;F01.100.150;N05.300.150;Z01.107.567.875.550.510.210;Z01.433.210;I01.076.201.450.350;I01.880.853.100.450;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N02.278.421.702;N02.421.726.233.628;M01.643;F01.829.401.650.675;N05.300.660.625;N02.421.726;H01.770.644.241.850;H02.403.840;L01.178.847.652;N04.590.374.800;H01.770.644.241.850
29100097,"B-Lymphocytes;Cell Differentiation;Complement System Proteins;DNA Repair;Humans;Immune Tolerance;Immunologic Deficiency Syndromes;Interferons;Lupus Erythematosus, Systemic;Phagocytosis;Phenotype;Signal Transduction",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.152;D12.776.124.486.274;G02.111.222;G05.219;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;C20.673;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;C17.300.480;C20.111.590;G04.417.350;G09.188.665;G12.450.564.809;G12.688;G05.695;G02.111.820;G04.835
29100089,"Animals;Brain;Calcium-Calmodulin-Dependent Protein Kinase Type 2;Cell Line;Exome;Glutamic Acid;HEK293 Cells;Humans;Intellectual Disability;Mice;Mice, Inbred C57BL;Mutation;Neurons;Phosphorylation;Signal Transduction;Intellectual Disability;Neuronal Plasticity",B01.050;A08.186.211;D08.811.913.696.620.682.700.125.200;D12.644.360.100.200;D12.776.476.100.200;A11.251.210;G05.360.340.011;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G05.365.590;A08.675;A11.671;G02.111.665;G02.607.780;G03.796;G02.111.820;G04.835;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G11.561.638
29100078,"Adolescent;Adult;Child;Colon;Colonic Diseases;Colonoscopy;Constriction, Pathologic;Crohn Disease;Dilatation, Pathologic;Humans;Intestinal Obstruction;Magnetic Resonance Imaging;Sensitivity and Specificity;Young Adult",M01.060.057;M01.060.116;M01.060.406;A03.556.124.526.356;A03.556.249.249.356;C06.405.469.158;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C23.300.287;C06.405.205.731.500;C06.405.469.432.500;C23.300.325;B01.050.150.900.649.313.988.400.112.400.400;C06.405.469.531;E01.370.350.825.500;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116.815
29100061,"Animals;Apolipoprotein C-II;Chylomicrons;Gene Expression Regulation;Humans;Hydrolysis;Intestinal Mucosa;Lipolysis;Lipoprotein Lipase;Lipoproteins;Lipoproteins, HDL;Lipoproteins, VLDL;Liver;Macrophages;Mice;Multigene Family;Mutation;Rats;Transcription, Genetic;Triglycerides;Hypertriglyceridemia;Lipoprotein Lipase;Triglycerides",B01.050;D10.532.091.400.750;D12.776.070.400.400.750;D12.776.521.120.400.750;D10.532.183;D12.776.521.242;G05.308;B01.050.150.900.649.313.988.400.112.400.400;G02.380;A03.556.124.369;A10.615.550.444;G02.111.534;G03.458.500;D08.811.277.352.100.430;D10.532;D12.776.521;D10.532.432;D12.776.521.479;D10.532.599;D12.776.521.622;A03.620;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;G05.360.340.024.340.645;G05.365.590;B01.050.150.900.649.313.992.635.505.700;G02.111.873;G05.297.700;D10.351.801;C18.452.584.500.500.851;D08.811.277.352.100.430;D10.351.801
29099947,"Adult;Aged;Aged, 80 and over;Calcium;Chronic Disease;Double-Blind Method;Health Status;Hormone Replacement Therapy;Humans;Hypoparathyroidism;Middle Aged;Parathyroid Hormone;Quality of Life;Recombinant Proteins;Treatment Outcome;Vitamin D",M01.060.116;M01.060.116.100;M01.060.116.100.080;D01.268.552.100;D01.552.539.288;D23.119.100;C23.550.291.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;I01.240.425;N01.224.425;N06.850.505.400.425;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;C19.642.482;M01.060.116.630;D06.472.699.590;D12.644.548.587;I01.800;K01.752.400.750;N06.850.505.400.425.837;D12.776.828;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D04.210.500.812.768
29099651,Metabolism,G03
29099650,Cytokines;Graft vs Host Disease;Rejection (Psychology);Transplantation,D12.644.276.374;D12.776.467.374;D23.529.374;C20.452;F01.145.813.565;E04.936
29099578,Positron-Emission Tomography;Reactive Oxygen Species;Superoxides,E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D01.339.431;D01.650.775;D01.248.497.158.685.750.850;D01.339.431.374.850;D01.650.550.750.800;D02.389.338.732
29099457,,
29099443,"Administration, Inhalation;Adolescent;Bronchodilator Agents;Child;Child, Preschool;Combined Modality Therapy;Humans;Infant;Logistic Models;Nitric Oxide;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Retrospective Studies;Time Factors;Treatment Outcome",E02.319.267.050;M01.060.057;D27.505.696.663.050.110;D27.505.954.796.050.100;M01.060.406;M01.060.406.448;E02.186;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29099410,"Fibrosarcoma;Humans;Infant, Newborn;Infant, Premature;Neonatal Nursing;Soft Tissue Neoplasms",C04.557.450.565.590.350;C04.557.450.795.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;H02.478.676.390.600;H02.478.676.631.600;N02.421.533.460.600;N02.421.533.691.600;C04.588.839
29099288,Epigenomics;Heterochromatin;Lamin Type A;Stem Cells,H01.158.273.180.350.074;H01.158.273.343.350.042;A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;D12.776.660.650.875.500;A11.872
29099240,"Exostoses, Multiple Hereditary;Growth Plate;Heparitin Sulfate;Exostoses, Multiple Hereditary",C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;A02.835.232.251.352;D09.698.373.425;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330
29098740,"Adult;Aged;Aged, 80 and over;Biomarkers;Biopsy;Cytokines;Humans;Inflammation;Middle Aged;Ultrasonic Therapy;Varicose Ulcer;Wound Healing;Wound Infection",M01.060.116;M01.060.116.100;M01.060.116.100.080;D23.101;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;M01.060.116.630;E02.565.280.945;C14.907.927.730;C17.800.893.592.730;G16.762.891;C01.539.947
29098734,Animals;Astrocytes;Humans;Mitochondria;Mitochondrial Dynamics;Astrocytes;Mitochondria,B01.050;A08.637.200;A11.650.200;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;G04.599.750;A08.637.200;A11.650.200;A11.284.430.214.190.875.564;A11.284.835.626
29098494,Critical Care,E02.760.190;N02.421.585.190
29098353,"Adult;Health Knowledge, Attitudes, Practice;Heart Transplantation;Humans;Patient Compliance;Patient Education as Topic;Pilot Projects;Program Evaluation;Prospective Studies;Self Report;Self-Management;Surveys and Questionnaires;Transition to Adult Care;Young Adult;Behavior;Knowledge;Self-Management",M01.060.116;F01.100.150.500;N05.300.150.410;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;I02.233.332.500;N02.421.726.407.680;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.337.820;N04.761.685;N05.715.360.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;N02.421.784.760;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815;F01.145;K01.468;N02.421.784.760
29098350,"Angioplasty;Cardiac Catheterization;Child, Preschool;Echocardiography;Follow-Up Studies;Humans;Infant;Kaplan-Meier Estimate;Postoperative Complications;Pulmonary Artery;Reoperation;Replantation;Retrospective Studies;Risk Factors;Stenosis, Pulmonary Artery;Stents;Treatment Outcome",E02.148.050;E04.100.814.529.124;E04.502.382.124;E05.157.016;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C23.550.767;A07.015.114.715;E04.690;E04.936.494;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907.137.825;E07.695.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29098292,"Health Care Costs;Health Expenditures;Humans;Income;Insurance, Health;United States",N03.219.151.400;N05.300.375;N03.219.151.450;N05.300.385;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;N03.219.521.576.343;Z01.107.567.875
29097692,"Abciximab;Actomyosin;Antibodies, Monoclonal;Biomechanical Phenomena;Blood Platelets;Cell Adhesion;Fibrin;Humans;Image Processing, Computer-Assisted;Immunoglobulin Fab Fragments;Microscopy, Confocal;Microscopy, Fluorescence;Platelet Aggregation Inhibitors;Platelet Glycoprotein GPIIb-IIIa Complex;Pseudopodia;Thrombosis",D12.644.541.500.650.125;D12.776.124.486.485.114.224.060.125;D12.776.124.486.485.680.650.125;D12.776.124.790.651.114.224.060.125;D12.776.124.790.651.680.650.125;D12.776.377.715.548.114.224.200.125;D12.776.377.715.548.680.650.125;D12.776.210.500.154;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;G01.154.090;G01.374.089;A11.118.188;A15.145.229.188;G04.022;D12.776.124.270;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;D12.644.541.500.650;D12.776.124.486.485.680.650;D12.776.124.790.651.680.650;D12.776.377.715.548.680.650;E01.370.350.515.395;E05.595.395;E01.370.350.515.458;E05.595.458;D27.505.954.502.780;D12.776.395.550.625.785;D12.776.543.550.625.785;D12.776.543.750.705.408.460.700;D12.776.543.750.705.675.784;A11.284.180.700;C14.907.355.830
29097680,"Aged;Binding Sites;CCAAT-Enhancer-Binding Protein-beta;CpG Islands;DNA Methylation;Disease Progression;E1A-Associated p300 Protein;Epigenesis, Genetic;Genetic Predisposition to Disease;Genome-Wide Association Study;Glomerular Filtration Rate;Humans;Kidney;Middle Aged;Prospective Studies;Protein Tyrosine Phosphatase, Non-Receptor Type 6;Renal Insufficiency, Chronic;Trans-Activators;Transcription Factors",M01.060.116.100;G02.111.570.120;D12.776.260.108.124.750;D12.776.660.167.750;D12.776.930.127.124.750;G02.111.570.080.380.160;G05.360.080.380.160;G05.360.340.024.159;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C23.550.291.656;D08.811.913.050.134.415.500.575.600;D12.776.930.680.600;G05.308.203;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D08.811.277.352.650.775.300.600;D08.811.277.352.650.775.700.200;D12.644.360.585.600;D12.644.360.800.200;D12.776.476.564.600;D12.776.476.800.200;C12.777.419.780.750;C13.351.968.419.780.750;D12.776.260.755;D12.776.930.900;D12.776.964.925.984;D12.776.930
29097613,"Adolescent;Child;Depressive Disorder, Major;Humans;Learning;Research",M01.060.057;M01.060.406;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;H01.770.644
29097611,"Anti-Bacterial Agents;Cohort Studies;Dose-Response Relationship, Drug;Drug Administration Schedule;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Injections, Intravenous;Inpatients;Patient Readmission;Recurrence;Retrospective Studies;Treatment Outcome;Urinary Tract Infections",D27.505.954.122.085;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G07.690.773.875;G07.690.936.500;E02.319.283;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.319.267.082.750;E02.319.267.530.540;M01.643.470;E02.760.400.620;N02.421.585.400.620;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C01.539.895;C12.777.892;C13.351.968.892
29097498,Animals;Blood Transfusion;Janus Kinase 2;Mice;Protein Kinase Inhibitors;Splenomegaly;beta-Thalassemia,B01.050;E02.095.135;D08.811.913.696.620.682.725.124.200;D12.776.476.393.200;D12.776.624.664.700.117;B01.050.150.900.649.313.992.635.505.500;D27.505.519.389.755;C23.300.775.750;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150
29097381,,
29097363,"Adaptor Proteins, Vesicular Transport;Animals;Atherosclerosis;CRISPR-Cas Systems;Cells, Cultured;Disease Models, Animal;Gene Editing;Gene Expression Regulation;Genetic Predisposition to Disease;Hepatocytes;Heterozygote;Humans;Induced Pluripotent Stem Cells;Mice, Transgenic;Phenotype;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Transcription, Genetic;Animals;Coronary Disease;Gene Expression;Genotype;Liver",D12.776.543.990.150;B01.050;C14.907.137.126.307;G05.308.203.374.394;A11.251;C22.232;E05.598.500;E05.599.395.080;E05.393.420.270;G05.308;C23.550.291.687.500;G05.380.355;A11.436.348;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.695;G05.365.795.598;G05.360.340.024.380.937;G02.111.873;G05.297.700;B01.050;C14.280.647.250;C14.907.585.250;G05.297;G05.380;A03.620
29097342,"Activin Receptors, Type I;Animals;Embryo, Nonmammalian;Humans;Mutation;Myositis Ossificans;RNA, Messenger;Signal Transduction;Myositis Ossificans;Ossification, Heterotopic",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;B01.050;A13.350;A16.331;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C05.651.594.638;D13.444.735.544;G02.111.820;G04.835;C05.651.594.638;C23.550.751
29097292,Adolescent;Adolescent Behavior;Child;Communication;Decision Making;Humans;Mother-Child Relations;Mothers;Pennsylvania;Sexual Abstinence;Sexual Behavior;Sexuality;Communication;Sexual Behavior,M01.060.057;F01.145.022;M01.060.406;F01.145.209;L01.143;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.290.170;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;F01.145.802.900;F01.145.802;F01.145.802.975;G08.686.867;F01.145.209;L01.143;F01.145.802
29097119,,
29097118,,
29097116,,
29096813,,
29096780,Adolescent;Adolescent Development;Adult;Child;Child Development;Executive Function;Humans;Mental Disorders;Philadelphia;Young Adult;Adolescent;Child Development;Executive Function,M01.060.057;F01.525.049;G07.345.374.500;M01.060.116;M01.060.406;F01.525.200;G07.345.374.750;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F03;Z01.107.567.875.500.550.525;Z01.433.820;M01.060.116.815;M01.060.057;F01.525.200;G07.345.374.750;F02.463.217
29096527,"Adaptation, Psychological;Autism Spectrum Disorder;Gender Identity;Sex Characteristics",F01.058;F03.625.164.113;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;G08.686.815
29096027,,
29096010,"Anti-Bacterial Agents;Child;Community-Acquired Infections;Humans;Macrolides;Pneumonia, Bacterial;Treatment Outcome",D27.505.954.122.085;M01.060.406;C01.539.234;B01.050.150.900.649.313.988.400.112.400.400;D02.540.505;D02.540.576.500;D04.345.674.500;C01.252.620;C08.381.677.540;C08.730.610.540;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29095954,Anti-HIV Agents;Antitubercular Agents;HIV Infections;Humans;Pyrazinamide;Tuberculosis,D27.505.954.122.388.077.088;D27.505.954.122.085.255;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;D03.383.679.750;C01.252.410.040.552.846
29095380,,
29095169,,
29094652,"Adolescent;Adult;Cancer Survivors;Child;Health Knowledge, Attitudes, Practice;Humans;Neoplasms;Parents;Surveys and Questionnaires;Survivorship;Young Adult",M01.060.057;M01.060.116;M01.860.350;M01.060.406;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;C04;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F01.058.144.500;M01.060.116.815
29094315,"Administration, Inhalation;Aged;Benzoxazines;Benzyl Alcohols;Bronchodilator Agents;Chlorobenzenes;Cross-Over Studies;Double-Blind Method;Drug Combinations;Forced Expiratory Volume;Humans;Middle Aged;Nebulizers and Vaporizers;Pulmonary Disease, Chronic Obstructive;Quinuclidines;Tiotropium Bromide;Treatment Outcome;Pulmonary Disease, Chronic Obstructive;Tiotropium Bromide",E02.319.267.050;M01.060.116.100;D03.383.533.249;D03.633.100.209;D02.033.160;D02.455.426.559.389.140.200;D27.505.696.663.050.110;D27.505.954.796.050.100;D02.455.426.559.389.261;D02.455.526.439.202;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D26.310;E01.370.386.700.660.230;G09.772.650.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E07.605;C08.381.495.389;D03.605.687;D02.145.074.722.822.887;D03.132.889.601.887;D03.605.084.500.722.822.887;D03.605.869.822.887;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.381.495.389;D02.145.074.722.822.887;D03.132.889.601.887;D03.605.084.500.722.822.887;D03.605.869.822.887
29093133,"Brain;Cell Line, Tumor;Chemokine CXCL12;Monocytes;Receptors, CXCR;Receptors, CXCR4;Signal Transduction;HIV;Chemotaxis",A08.186.211;A11.251.210.190;A11.251.860.180;D12.644.276.374.200.120.600;D12.776.467.374.200.120.600;D23.125.300.120.600;D23.469.200.120.600;D23.529.374.200.120.600;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D12.776.543.750.695.160.500;D12.776.543.750.705.852.125.500;D12.776.543.750.695.160.500.400;D12.776.543.750.705.852.125.500.400;D12.776.543.750.830.700.650;G02.111.820;G04.835;B04.820.650.589.650.350;F01.145.113.780.500;F01.145.875.439.500.500;G04.198.424;G07.568.500.590.500;G11.427.410.568.850.500
29093095,"Adenoviridae;Animals;Antibodies, Neutralizing;Antibodies, Viral;Antibody Specificity;CD4 Lymphocyte Count;Cell Line;Genetic Vectors;Genotype;HIV;Humans;Immunity, Humoral;Immunization;Kaplan-Meier Estimate;Macaca mulatta;Protein Binding;SAIDS Vaccines;Simian Acquired Immunodeficiency Syndrome;Simian Immunodeficiency Virus;T-Lymphocytes;Vaccines, Synthetic;Viral Envelope Proteins;Viral Load;Adenoviridae;Antibodies, Neutralizing;Macaca mulatta",B04.280.030;B01.050;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;G12.100;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;A11.251.210;G05.360.337;G05.380;B04.820.650.589.650.350;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.420;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;B01.050.150.900.649.313.988.400.112.199.120.510.550;G02.111.679;G03.808;D20.215.894.899.790;C02.782.815.616.850;C02.839.850;C22.735.500.850;B04.820.650.589.650.800;B04.820.650.805.700;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.828.868;D20.215.894.865;D23.050.865;D12.776.964.970.880;E01.370.225.875.950;E05.200.875.950;G06.920.850;B04.280.030;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;B01.050.150.900.649.313.988.400.112.199.120.510.550
29093071,,
29093018,Child;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation;Humans;Medical Oncology;Neoplasms,M01.060.406;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C04
29092896,Animals;Biomechanical Phenomena;Biopolymers;Cells;Cytoskeleton;Humans;Intermediate Filaments;Microtubules,B01.050;G01.154.090;G01.374.089;D05.750.078;D25.720.099;J01.637.051.720.099;A11;A11.284.430.214.190.750;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.750.410;A11.284.430.214.190.750.602
29092786,Food Hypersensitivity;Peanut Hypersensitivity,C20.543.480.370;C20.543.480.370.572.750
29091984,Caregivers;Humans;Personal Satisfaction,M01.085;M01.526.485.200;N02.360.200;B01.050.150.900.649.313.988.400.112.400.400;F01.145.677
29091570,"Age of Onset;Disease-Free Survival;Double-Blind Method;Humans;Infant;Injections, Spinal;Motor Skills;Oligonucleotides;Oligonucleotides, Antisense;RNA, Messenger;Respiration, Artificial;Spinal Muscular Atrophies of Childhood;Survival Analysis;Survival of Motor Neuron 2 Protein",N05.715.350.075.100;N06.850.490.250.100;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.319.267.530.580;F02.808.260;D13.695.578.424;D13.150.480;D13.444.600.150.640;D13.695.578.424.480;D27.720.470.530.600.150.640;D13.444.735.544;E02.041.625;E02.365.647.729;E02.880.820;C10.228.854.468.800;C10.574.500.812;C10.574.562.500.750;C10.668.467.500.750;C16.320.400.765;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;D12.776.157.725.875.750;D12.776.580.922.750;D12.776.664.962.875.750
29091492,Adolescent;Adult;Aged;Cell Phone;Disability Evaluation;Humans;Middle Aged;Patient Reported Outcome Measures;Software;Surveys and Questionnaires;Text Messaging;Young Adult;Cell Phone;Text Messaging,M01.060.057;M01.060.116;M01.060.116.100;L01.178.847.698.300;E01.370.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;L01.224.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;L01.178.847.698.300.500;L01.559.423.906.377.666;M01.060.116.815;L01.178.847.698.300;L01.178.847.698.300.500;L01.559.423.906.377.666
29091315,Artifacts;Connectome;Motion,E05.047;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;G01.482
29091079,"Animals;Child;Child, Preschool;Colon;Genes, Modifier;Genetic Association Studies;Genetic Predisposition to Disease;Genome;Genotype;High-Throughput Nucleotide Sequencing;Host-Pathogen Interactions;Humans;Inflammatory Bowel Diseases;Mice;Mice, Inbred C57BL;Mutation, Missense;NADPH Oxidase 1;Polymorphism, Single Nucleotide;Reactive Oxygen Species",B01.050;M01.060.406;M01.060.406.448;A03.556.124.526.356;A03.556.249.249.356;G05.360.340.024.340.370;E05.393.385;C23.550.291.687.500;G05.380.355;G05.360.340;G05.380;E05.393.760.319;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G05.365.590.650;D08.811.682.608.575.750;D12.776.331.894.750;D12.776.543.653.750;G05.365.795.598;D01.339.431;D01.650.775
29090524,Precursor Cell Lymphoblastic Leukemia-Lymphoma;Asparaginase;Hypersensitivity,C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D08.811.277.087.116;C20.543
29090080,"Activities of Daily Living;Adolescent;Adult;Autism Spectrum Disorder;Catechol O-Methyltransferase;Child;Child, Preschool;Chromosome Deletion;Chromosomes, Human, Pair 22;Cohort Studies;Gene Duplication;Humans;Infant;Infant, Newborn;Nuclear Proteins;Oligonucleotide Array Sequence Analysis;Psychometrics;Risk;Social Communication Disorder;Young Adult;DiGeorge Syndrome;Autism Spectrum Disorder;Prosopagnosia;Mass Screening",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.057;M01.060.116;F03.625.164.113;D08.811.913.555.500.250;M01.060.406;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.365.590.320;G05.558.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;D12.776.660;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;F04.711.780;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;F03.625.374.250;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F03.625.164.113;C10.597.606.762.100.650;C23.888.592.604.764.100.650;F01.700.750.100.650;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
29089273,"Adolescent;Child;Colitis, Ulcerative;Colon;Crohn Disease;Diagnosis, Differential;Humans;Ileitis;Ileum;Logistic Models;Multivariate Analysis;ROC Curve;Retrospective Studies;Crohn Disease;Ileitis;Pediatrics;Colitis, Ulcerative",M01.060.057;M01.060.406;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;A03.556.124.526.356;A03.556.249.249.356;C06.405.205.731.500;C06.405.469.432.500;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.462.624;C06.405.469.326.875;C06.405.469.420.520;A03.556.124.684.249;A03.556.249.124;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C06.405.205.731.500;C06.405.469.432.500;C06.405.205.462.624;C06.405.469.326.875;C06.405.469.420.520;H02.403.670;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
29088949,"Brain;Brain Injuries;Cerebrovascular Circulation;Humans;Intracranial Pressure;Monitoring, Physiologic;Multimodal Imaging;Cerebrovascular Circulation;Informatics;Intracranial Pressure;Precision Medicine;Brain Injuries, Traumatic",A08.186.211;C10.228.140.199;C10.900.300.087;C26.915.300.200;G09.330.100.159;B01.050.150.900.649.313.988.400.112.400.400;G11.561.170.505;E01.370.520;E01.370.350.567;G09.330.100.159;L01.313;G11.561.170.505;E02.574;H02.403.200.700;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
29088367,,
29088124,"Cohort Studies;Community-Based Participatory Research;Cross-Sectional Studies;Environmental Monitoring;Gulf of Mexico;Humans;Longitudinal Studies;Louisiana;Mississippi;Petroleum Pollution;Risk Assessment;Self Report;Texas;Water Pollutants, Chemical;Environmental Health;Petroleum Pollution",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;H01.770.644.193;N05.425.104;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N06.850.460.350.080;N06.850.780.375;Z01.756.092.325;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875.750.480;Z01.107.567.875.750.500;N06.850.460.660;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;Z01.107.567.875.760.750;D27.888.284.903.655;H02.229;N06.850.460.660
29087940,"Adult;Color Vision;Humans;Light;Magnetic Resonance Imaging;Middle Aged;Photic Stimulation;Pupil;Retinal Cone Photoreceptor Cells;Retinal Ganglion Cells;Retinal Rod Photoreceptor Cells;Rod Opsins;Visual Cortex;Visual Pathways;Visual Perception;Magnetic Resonance Imaging;Vision, Ocular;Visual Cortex",M01.060.116;F02.830.816.964.124;G11.561.790.964.124;G14.935.124;B01.050.150.900.649.313.988.400.112.400.400;G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578;E01.370.350.825.500;M01.060.116.630;E05.723.729;A09.371.060.450.780;A09.371.894.513.780;A08.675.650.850.625.670.100;A08.675.650.915.937.670.100;A08.800.950.937.670.100;A09.371.729.831.625.670.100;A11.671.650.850.625.670.100;A11.671.650.915.937.670.100;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;A08.675.650.850.625.670.650;A08.675.650.915.937.670.650;A08.800.950.937.670.650;A09.371.729.831.625.670.650;A11.671.650.850.625.670.650;A11.671.650.915.937.670.650;D12.776.306.466.500;D23.767.930.750.500;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.612.220.860;F02.463.593.932;E01.370.350.825.500;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953
29087927,"Adult;Curriculum;Education, Medical, Graduate;Humans;Internship and Residency;Orthopedics;Staff Development;Surveys and Questionnaires;Workforce",M01.060.116;I02.158;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.810.494;I02.574.700;N04.452.677.822;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N04.452.525
29087353,Proteins,D12.776
29086522,Cancer Survivors;Endometrial Neoplasms;Exercise;Humans;Life Style;Middle Aged;Obesity;Quality of Life;Telemedicine;Treatment Outcome;United States;Weight Loss,M01.860.350;C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;H02.403.840;L01.178.847.652;N04.590.374.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C23.888.144.243.963;G07.345.249.314.120.200.963
29086513,"Adiposity;Adult;Aged;Aged, 80 and over;Cardiorespiratory Fitness;Humans;Longitudinal Studies;Middle Aged;Neoplasms;Obesity;Survival Analysis;United States;Veterans;Young Adult",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.060.116;M01.060.116.100;M01.060.116.100.080;G11.427.685.500;I03.450.642.845.054.300;I03.450.642.845.054.800.500;N01.400.150;N01.400.545.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C04;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;Z01.107.567.875;M01.930;M01.060.116.815
29086498,"Aged;Binge-Eating Disorder;Diabetes Mellitus, Type 2;Humans;Middle Aged;Time Factors;Weight Loss",M01.060.116.100;F03.400.188;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G01.910.857;C23.888.144.243.963;G07.345.249.314.120.200.963
29085552,,
29084966,"Animals;Anticoagulants;Blood Platelets;Fibrin;Gene Deletion;Hemostasis;Hyperplasia;Immunity, Mucosal;Inositol 1,4,5-Trisphosphate;Integrases;Lung Neoplasms;Lymphoid Tissue;Melanoma, Experimental;Mice;Mice, Inbred C57BL;Phospholipid Transfer Proteins;Platelet Aggregation;Signal Transduction;Thrombin;Thrombosis",B01.050;D27.505.954.502.119;A11.118.188;A15.145.229.188;D12.776.124.270;G05.365.590.762.320;G05.558.800.320;G09.188.390;C23.550.444;G12.450.573;D02.033.800.519.400.350;D09.853.519.400.350;D09.894.480.350;D08.811.739.500;C04.588.894.797.520;C08.381.540;C08.785.520;A10.549;A15.382.520.604;C04.557.465.625.650.510.525;C04.557.580.625.650.510.525;C04.557.665.510.525;C04.619.600;E05.598.500.496.937;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.157.674;D12.776.543.693;G09.188.370.687;G09.188.390.600.640;G02.111.820;G04.835;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960;C14.907.355.830
29084707,Cohort Studies;Humans;Population Surveillance;Pregnancy;Social Media;Cohort Studies;Data Analysis;Machine Learning;Natural Language Processing;Pregnancy;Social Media;Data Mining,E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;G08.686.784.769;L01.178.751;L01.224.230.110.500.750;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;H01.548.338;G17.035.250.500;L01.224.050.375.530;L01.224.050.375.580;G08.686.784.769;L01.178.751;L01.224.230.110.500.750;L01.313.500.750.280.199;L01.470.625
29084435,"Critical Pathways;Emergency Service, Hospital;Quality Improvement",N04.590.233.624.625;N04.590.275;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;J01.293.754;N04.761.744
29084374,"Biopsy, Fine-Needle;Checklist;Clinical Competence;Computer-Assisted Instruction;Cytodiagnosis;Humans;Internet;Pathology",E01.370.225.500.384.100.119.500;E01.370.225.998.054.119.500;E01.370.388.100.100.500;E04.074.119.500;E04.665.100.500;E05.200.500.384.100.119.500;E05.200.998.054.119.500;E05.242.384.100.119.500;N05.715.360.300.179;I02.399.630.210;N04.761.210;N05.715.175;I02.903.771.500.208;E01.370.225.500.384;E05.200.500.384;E05.242.384;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;H02.403.650
29084368,,
29084309,"Burnout, Professional;Depression;Evidence-Based Medicine;Family Conflict;Humans;Physicians",C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;F01.145.126.350;H02.249.750;H02.403.200.400;F01.829.263.370.054;F01.829.401.142;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810
29084001,"Aorta, Thoracic;Aortic Valve Stenosis;Clinical Decision-Making;Ebstein Anomaly;Fontan Procedure;Heart Defects, Congenital;Heart Septal Defects;Heart Valve Diseases;Heart Ventricles;Humans;Infant;Infant, Newborn;Mitral Valve;Pulmonary Atresia;Ventricular Outflow Obstruction",A07.015.114.056.372;C14.280.484.150;C14.280.955.249;E01.055;C14.240.400.395;C14.280.400.395;C16.131.240.400.395;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;C14.240.400.560;C14.280.400.560;C16.131.240.400.560;C14.280.484;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A07.541.510.507;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;C14.280.955
29083408,"Coronary Artery Disease;Diabetes Mellitus, Type 2;Exome;Genetic Association Studies;Genetic Predisposition to Disease;Genetic Variation;Genotype;Humans;Lipids;Macular Degeneration;Phenotype;Risk Factors",C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C18.452.394.750.149;C19.246.300;G05.360.340.011;E05.393.385;C23.550.291.687.500;G05.380.355;G05.365;G05.380;B01.050.150.900.649.313.988.400.112.400.400;D10;C11.768.585.439;G05.695;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29083227,,
29083092,,
29082553,Paraplegia,C10.597.622.669;C23.888.592.636.637
29081731,Diffusion Tensor Imaging,E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750
29080979,"Common Variable Immunodeficiency;Autoimmunity;Anemia, Hemolytic;Purpura, Thrombocytopenic, Idiopathic;Neutropenia",C20.673.330;G12.450.192;C15.378.071.141;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;C15.378.553.546.184.564
29080905,"Adult;Crack Cocaine;Cross-Sectional Studies;Fetal Blood;Humans;Infant, Newborn;Nerve Tissue Proteins;Postpartum Period;Pregnancy;Crack Cocaine;Infant, Newborn;Oxidative Stress;Pregnancy;Fetal Blood",M01.060.116;D02.145.074.722.388.250;D03.132.889.354.250;D03.605.084.500.722.388.250;D03.605.869.388.250;D26.878.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;A12.207.152.200;A15.145.300;A16.378.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;D12.776.631;G08.686.702;G08.686.784.769;D02.145.074.722.388.250;D03.132.889.354.250;D03.605.084.500.722.388.250;D03.605.869.388.250;D26.878.250;M01.060.703.520;G03.673;G07.775.750;G08.686.784.769;A12.207.152.200;A15.145.300;A16.378.200
29080520,"Anti-Anxiety Agents;Anxiety Disorders;Biomarkers;Chamomile;Follow-Up Studies;Humans;Hydrocortisone;Interview, Psychological;Middle Aged;Photoperiod;Phytotherapy;Plant Extracts;Psychiatric Status Rating Scales;Saliva;Time Factors;Treatment Outcome;Chamomile;Clinical Trial;Hydrocortisone;Psychopharmacology",D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015;F03.080;D23.101;B01.650.940.800.575.912.250.100.195;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;F04.669.599;M01.060.116.630;G01.910.675;E02.190.755;D20.215.784.500;D26.667;F04.711.513.653;A12.200.666;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;B01.650.940.800.575.912.250.100.195;V03.175.250;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;F04.096.712;F04.570.505;H01.158.703.546;H02.628.546
29080380,"Acute Disease;Adolescent;Adult;Age Factors;Allografts;Child;Child, Preschool;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Infant;Infant, Newborn;Malnutrition;Nutrition Assessment;Retrospective Studies;Risk Factors;Sex Factors;Time Factors;Graft vs Host Disease;Malnutrition;Stem Cell Transplantation",C23.550.291.125;M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;A01.941.500;M01.060.406;M01.060.406.448;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C18.654.521;E05.318.308.585;N05.715.360.300.560;N06.850.505.557;N06.850.520.308.585;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;G01.910.857;C20.452;C18.654.521;E02.095.147.500.500;E04.936.225.687
29079959,Informatics;Machine Learning;Natural Language Processing,L01.313;G17.035.250.500;L01.224.050.375.530;L01.224.050.375.580
29079932,"Animals;Energy Metabolism;Enzyme Inhibitors;Glutamate Dehydrogenase;Glutamic Acid;Humans;Metabolic Diseases;Protein Binding;Protein Structure, Secondary;Glutamate Dehydrogenase;Insulin",B01.050;G03.295;D27.505.519.389;D08.811.682.664.500.398;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;B01.050.150.900.649.313.988.400.112.400.400;C18.452;G02.111.679;G03.808;G02.111.570.820.709.600;D08.811.682.664.500.398;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
29079728,"Alcohol Drinking;Alleles;Computational Biology;Databases, Genetic;Diabetes Mellitus, Type 2;Diet;Epistasis, Genetic;Gene Deletion;Gene Dosage;Gene-Environment Interaction;Genome, Human;Genome-Wide Association Study;Genomics;Genotype;Glutamate Decarboxylase;Humans;Models, Genetic;Phenotype;Polymorphism, Single Nucleotide;Programming Languages;Recurrence;Sequence Analysis, DNA;Software;Surveys and Questionnaires",F01.145.317.269;G05.360.340.024.340.030;H01.158.273.180;L01.313.124;L01.313.500.750.300.188.400.325;L01.470.750.750.325;C18.452.394.750.149;C19.246.300;G07.203.650.240;G05.308.207;G05.365.590.762.320;G05.558.800.320;G05.380.350;G05.695.337;G05.360.340.350;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;G05.380;D08.811.520.224.125.250;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;G05.695;G05.365.795.598;L01.224.900.780;C23.550.291.937;E05.393.760.700;L01.224.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29079647,Bone Marrow;Bone Marrow Transplantation;Graft vs Host Disease;Humans,A15.382.216;E02.095.147.725.040;E04.936.580.040;C20.452;B01.050.150.900.649.313.988.400.112.400.400
29079637,Acute Kidney Injury;Creatinine;Leucovorin;Methotrexate,C12.777.419.780.050;C13.351.968.419.780.050;D03.383.129.308.207;D03.633.100.733.631.400.800.350.450;D08.211.840.300.500;D03.633.100.733.631.192.500
29079524,Adolescent;Autistic Disorder;Brain Mapping;Child;Diffusion Tensor Imaging;Humans;Machine Learning;Neural Pathways;White Matter;Autism Spectrum Disorder;Machine Learning,M01.060.057;F03.625.164.113.500;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;M01.060.406;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;A08.612;A08.186.211.204;A08.186.854.880;F03.625.164.113;G17.035.250.500;L01.224.050.375.530
29079372,Blood;Guaiac;Intussusception,A12.207.152;A15.145;D20.215.721.500.490;C06.405.469.531.577
29079325,"Child;Critical Illness;Hospitals, Pediatric;Humans;Magnets",M01.060.406;C23.550.291.625;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;J01.637.507
29079316,"Developmental Disabilities;Follow-Up Studies;Hernias, Diaphragmatic, Congenital;Humans;Infant;Infant, Newborn;Neurodevelopmental Disorders;Neurologic Examination;Retrospective Studies;Risk Factors;Survivors;Hernias, Diaphragmatic, Congenital;Malnutrition",F03.625.421;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F03.625;E01.370.376.550;E01.370.600.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.860;C16.131.433;C23.300.707.500.116;C18.654.521
29079037,"Adolescent;Adult;Aged;Aged, 80 and over;Cross-Sectional Studies;Decision Making;Health Services Accessibility;Humans;Middle Aged;Ovarian Neoplasms;Patient Preference;Travel;Young Adult;Health Policy;Clinical Decision-Making;Ovarian Neoplasms",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F02.463.785.373;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;I03.883;M01.060.116.815;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;E01.055;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705
29078791,Botswana;Clinical Protocols;Developing Countries;Health Resources;Health Services Accessibility;Humans;Interviews as Topic;Qualitative Research;Randomized Controlled Trials as Topic;Research Design;Research Personnel;Research Support as Topic,Z01.058.290.175.230;E02.183;N05.715.360.330.125;I01.615.500.300;N03.349.340;N05.300.420;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;H01.770.644.241.850;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.581.500;H01.770.644.728;M01.526.839;N03.219.483.645
29078378,"Animals;Bone Marrow;Bone Marrow Transplantation;Cyclic AMP Response Element-Binding Protein;Embryonic Development;Gene Expression Regulation, Developmental;Granulocyte Colony-Stimulating Factor;Hematopoiesis;Janus Kinases;Mice;Mice, Knockout;NF-kappa B;STAT3 Transcription Factor;Transcription Factors;Granulocyte Colony-Stimulating Factor",B01.050;A15.382.216;E02.095.147.725.040;E04.936.580.040;D12.776.260.108.184;D12.776.930.127.184;G07.345.500.325.180;G08.686.784.170.104;G05.308.310;D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350;G04.152.825;G09.188.343;D08.811.913.696.620.682.725.124;D12.776.476.393;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300;D12.776.930;D12.644.276.374.410.240.350;D12.776.395.240.200;D12.776.467.374.410.240.350;D23.529.374.410.240.350
29078256,"Adiponectin;Adult;Biomarkers;C-Reactive Protein;Diabetes, Gestational;Follow-Up Studies;Glucose Intolerance;Humans;Pregnancy;Prognosis;Prospective Studies;Adiponectin;Diabetes, Gestational",D06.472.699.042.249;D12.644.276.024.249;D12.644.548.011.249;D12.776.467.024.249;D23.529.024.249;M01.060.116;D23.101;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;C13.703.170;C18.452.394.750.448;C19.246.200;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C18.452.394.952.500;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D06.472.699.042.249;D12.644.276.024.249;D12.644.548.011.249;D12.776.467.024.249;D23.529.024.249;C13.703.170;C18.452.394.750.448;C19.246.200
29078234,,
29077992,"Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Pharmacokinetics",C16;G03.787;G07.690.725
29077633,"Biopsy;Cell Proliferation;Cross-Sectional Studies;Diagnosis, Differential;Humans;Melanocytes;Melanoma;Mohs Surgery;Retrospective Studies;Skin Neoplasms",E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;G04.161.750;G07.345.249.410.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.171;B01.050.150.900.649.313.988.400.112.400.400;A11.409.750;A11.436.613;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;E04.494.575;E04.680.275.580;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.805;C17.800.882
29076949,"Animals;Cell Line, Tumor;GTP Phosphohydrolases;Genotype;Humans;Immunohistochemistry;Melanoma;Membrane Proteins;Mice;Suppression, Genetic",B01.050;A11.251.210.190;A11.251.860.180;D08.811.277.040.330;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D12.776.543;B01.050.150.900.649.313.992.635.505.500;G05.365.590.835;G05.558.835
29076905,"Child, Preschool;Gastrointestinal Hemorrhage;Humans;Incidental Findings;Meckel Diverticulum;Paracentesis;Radionuclide Imaging;Sodium Pertechnetate Tc 99m",M01.060.406.448;C06.405.227;C23.550.414.788;B01.050.150.900.649.313.988.400.112.400.400;E01.410;A03.556.124.684.249.612;A03.556.249.124.612;C01.539.463.199.750.750;C06.198.859;C06.405.205.282.750.750;C16.131.314.556;C23.300.415.750;E01.370.225.998.329;E02.309.805;E02.800.550;E04.237.667;E04.665.600;E05.200.998.329;E01.370.350.710;E01.370.384.730;D01.925.800
29076870,"Cardiac Catheterization;Cardiac Surgical Procedures;Equipment Failure;Heart Septal Defects, Atrial;Humans;Patient Selection;Septal Occluder Device",E01.370.370.380.140;E02.148.442;E05.157.250;E04.100.376;E04.928.220;E05.325;C14.240.400.560.375;C14.280.400.560.375;C16.131.240.400.560.375;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500.653;N04.590.731;E07.695.715
29076829,Asthma;Clinical Trials as Topic;Comparative Effectiveness Research;Decision Support Techniques;Evidence-Based Medicine;Humans;Observer Variation;Reproducibility of Results;Research Design,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;H01.770.644.145.360.500;N05.425.157;E05.245;L01.313.500.750.190;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.581.500;H01.770.644.728
29076559,"Aged;Cognition Disorders;Cohort Studies;Eukaryotic Initiation Factor-3;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Mutation;Myelin Proteins;Neuropsychological Tests;Qa-SNARE Proteins;Supranuclear Palsy, Progressive;tau Proteins;Cognition;Supranuclear Palsy, Progressive",M01.060.116.100;F03.615.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D12.776.835.725.868.437;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;D12.776.543.620;D12.776.631.580;F04.711.513;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690;D12.776.220.600.450.510;D12.776.631.560.510;F02.463.188;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690
29076399,"Biological Psychiatry;Biomarkers;Consensus;Dementia;Humans;Neurodegenerative Diseases;Societies, Medical;Alzheimer Disease;Biomarkers;Cerebrospinal Fluid;Consensus;Dementia",F04.096.544.090;H02.403.690.100;D23.101;F01.829.316.068;F02.463.785.373.433;C10.228.140.380;F03.615.400;B01.050.150.900.649.313.988.400.112.400.400;C10.574;N03.540.828.589;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D23.101;A12.207.270.210;F01.829.316.068;F02.463.785.373.433;C10.228.140.380;F03.615.400
29074554,Retinoblastoma,C04.557.465.625.600.725;C04.557.470.670.725;C04.557.580.625.600.725;C04.588.364.818.760;C11.270.862;C11.319.475.760;C11.768.717.760
29074500,"Antigens, CD19;Cytokines;Endothelial Cells;Fatal Outcome;Humans;Immunotherapy, Adoptive;Interleukin-6;Middle Aged;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell",D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;D12.644.276.374;D12.776.467.374;D23.529.374;A11.436.275;E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;M01.060.116.630;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D12.776.543.750.705.816.824
29074447,,
29074312,Diarrhea;Double-Blind Method;Humans;Malignant Carcinoid Syndrome;Middle Aged;Phenylalanine;Pyrimidines;Treatment Outcome;Diarrhea,C23.888.821.214;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.200.500;C04.557.470.200.025.200.500;C04.557.580.625.650.200.500;M01.060.116.630;D12.125.072.050.685;D12.125.142.666;D03.383.742;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.821.214
29074310,"Animals;Contrast Media;Ear, Inner;Hearing Loss, Sensorineural;Humans;Molecular Imaging;Molecular Imaging",B01.050;D27.505.259.500;D27.720.259;A09.246.300;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.557;E05.601.555;E01.370.350.557;E05.601.555
29074060,"Adolescent;Botswana;Case-Control Studies;Cerebral Palsy;Child;Child, Preschool;HIV Infections;Humans;Incidence;Logistic Models;Odds Ratio;Retrospective Studies;Risk Factors;Africa;HIV;Cerebral Palsy;Risk Factors",M01.060.057;Z01.058.290.175.230;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C10.228.140.140.254;M01.060.406;M01.060.406.448;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.058;B04.820.650.589.650.350;C10.228.140.140.254;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29073952,"Heart Failure;Antiretroviral Therapy, Highly Active;HIV",C14.280.434;E02.319.310.075;B04.820.650.589.650.350
29072892,,
29073311,,
29072717,"Animals;Cells, Cultured;Chromatography, Liquid;Hep G2 Cells;Humans;Isotope Labeling;Liver;Mass Spectrometry;Mice;NAD;NADP;Saccharomyces cerevisiae",B01.050;A11.251;E05.196.181.400;A11.251.860.180.432;A11.436.348.500;B01.050.150.900.649.313.988.400.112.400.400;E05.522;A03.620;E05.196.566;B01.050.150.900.649.313.992.635.505.500;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;D03.633.100.759.646.138.749;D08.211.625;D13.695.667.138.749;D13.695.827.068.749;B01.300.107.795.785.800;B01.300.930.705.655
29072589,"Air Pollutants;Air Pollution;Aptitude Tests;Child;Child, Preschool;Cognition;Cyclohexanones;Environmental Exposure;Humans;Infant;Learning;Linear Models;Longitudinal Studies;Mathematics;Social Environment;Air Pollution;Child Development",D27.888.284.101;N06.850.460.100;F04.711.141;M01.060.406;M01.060.406.448;F02.463.188;D02.455.426.392.368.367.340;D02.522.400;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F02.463.425;F02.784.629.529;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;H01.548;I01.880.853.500;N06.850.460.100;F01.525.200;G07.345.374.750
29071524,Family;Humans;Medical Oncology;Patient Reported Outcome Measures;Patient Satisfaction;Pediatrics;Self Report;Surveys and Questionnaires,F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;H02.403.670;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29071419,Machine Learning,G17.035.250.500;L01.224.050.375.530
29070843,,
29070810,,
29070528,Animals;Editorial Policies;Humans;Immunoassay;Immunotherapy;Periodicals as Topic;Vaccines,B01.050;L01.737.484;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566;E05.601.470;E02.095.465.425;L01.178.682.829.678;D20.215.894
29069605,"Amino Acid Motifs;Ataxia Telangiectasia Mutated Proteins;Chromosomal Instability;Conserved Sequence;DNA Repair;DNA-Binding Proteins;Humans;Lymphocytes;Mutation;Nuclear Proteins;Phosphorylation;Protein Processing, Post-Translational;V(D)J Recombination;Genomic Instability",G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;C23.550.210.110;C23.550.362.180;G05.365.590.175.165;G05.370.180;G02.111.570.580;G02.111.222;G05.219;D12.776.260;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;G05.365.590;D12.776.660;G02.111.665;G02.607.780;G03.796;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;G05.344.900;G05.728.932;C23.550.362;G05.365.590.335;G05.370
29069464,,
29068970,Adult;African Americans;Anthropology;Asian Continental Ancestry Group;Beauty;European Continental Ancestry Group;Face;Facial Recognition;Humans;Individuality;Middle Aged;Personality;Social Perception;Surveys and Questionnaires;Visual Perception,M01.060.116;M01.686.508.100.100;M01.686.754.100;F04.096.879.201;I01.076;M01.686.508.200;F02.463.785.477.304;K01.752.210.304;M01.686.508.400;A01.456.505;F02.463.593.524.500.500;F02.463.593.932.622.500;B01.050.150.900.649.313.988.400.112.400.400;F01.752.488;M01.060.116.630;F01.752;F02.463.593.752;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F02.463.593.932
29068941,"Amputation;Fractures, Open;Humans;Limb Salvage;Retrospective Studies;Tibial Fractures;Treatment Outcome;Vascular System Injuries",E04.555.080;C26.404.311;B01.050.150.900.649.313.988.400.112.400.400;E04.100.814.603;E04.555.400;E04.680.350;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C26.404.875;C26.558.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.907.937;C26.940
29068936,"Child, Preschool;Craniosynostoses;Databases, Factual;Hospitals, High-Volume;Hospitals, Low-Volume;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Length of Stay;Logistic Models;Multivariate Analysis;Odds Ratio;Orthopedic Procedures;Outcome Assessment (Health Care);Postoperative Complications;United States",M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;L01.313.500.750.300.188.400;L01.470.750.750;N02.278.421.414;N02.278.421.434;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E02.718;E04.555;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C23.550.767;Z01.107.567.875
29068935,Adolescent;Adult;Aged;Crowdsourcing;Emotions;Facial Expression;Humans;Middle Aged;Orthognathic Surgical Procedures;Outcome Assessment (Health Care);Personality;Postoperative Period;Preoperative Period;Single-Blind Method;Social Perception;United States;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;L01.399.250.179;F01.470;E01.370.600.225;F01.145.209.530.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.545.562;E04.555.580.289;E06.645.562;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F01.752;E04.614.750;N02.421.585.753.750;E04.614.937;N02.421.585.753.937;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;F02.463.593.752;Z01.107.567.875;M01.060.116.815
29068890,"Imaging, Three-Dimensional;Reconstructive Surgical Procedures;Software;Surgery, Plastic",E01.370.350.400;L01.224.308.410;E04.680;L01.224.900;H02.403.810.788
29068857,Critical Care;Critical Illness;Humans;Intensive Care Units;Personnel Staffing and Scheduling;Retrospective Studies,E02.760.190;N02.421.585.190;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;I03.946.225;N04.452.677.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29068783,"Biomarkers, Tumor;Child;Disease-Free Survival;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Genetic Testing;Humans;Leukemia, Myeloid, Acute;MicroRNAs;RNA, Messenger",D23.101.140;M01.060.406;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.393.332;G05.308.370.500;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D13.444.735.544
29068716,Adolescent;Adult;Focus Groups;HIV Infections;Humans;Infant;Mass Screening;Minority Groups;Postpartum Period;Poverty;Prevalence;Sexual Partners;Spouse Abuse;Substance-Related Disorders;Surveys and Questionnaires,M01.060.057;M01.060.116;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;I01.880.853.300;G08.686.702;I01.880.735.634;I01.880.853.996.535;N01.824.600;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;M01.778;I01.198.240.856.350.750;I01.198.240.856.575.500;I01.880.735.900.350.750;I01.880.735.900.688.500;C25.775;F03.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
29068563,,
29068475,Bone Density;Puberty,G11.427.100;G08.686.760;G08.686.841.374
29067563,"Child;Exercise;Fontan Procedure;Hemodynamics;Humans;Magnetic Resonance Imaging;Models, Cardiovascular;Patient-Specific Modeling;Respiration;Exercise;Respiration",M01.060.406;G11.427.410.698.277;I03.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.599.395.161;E05.599.395.821;L01.224.160.750;G09.772.705;G11.427.410.698.277;I03.350;G09.772.705
29067313,Alzheimer Disease;Clinical Trials as Topic;Comprehension;Consent Forms;Informed Consent;Mental Competency;Third-Party Consent,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;F02.463.188.357;I01.880.604.583.427.134;N03.706.535.489.134;N04.452.859.198;N05.715.360.300.715.245;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;F01.590;F02.410;I01.880.604.583.530;N03.706.535.625;I01.880.604.583.427.635;N03.706.535.489.635
29067271,"Diabetes Mellitus, Type 1;Adolescent",C18.452.394.750.124;C19.246.267;C20.111.327;M01.060.057
29066932,"Efficiency;Anesthesia, General;Anesthesia, Spinal",F02.784.692.351;N04.452.209;E03.155.197;E03.155.086.331
29066740,,
29066375,Choice Behavior;Consumer Behavior;Food Labeling;Food Preferences;Health Behavior;Humans;Intention;Middle Aged;Nutritive Value;Perception;Food Labeling;Obesity,F02.463.785.373.346;F01.145.236;J01.576.423.850.600.400;J01.576.761.400.450;F01.145.407.516;G07.203.650.353.516;F01.145.488;B01.050.150.900.649.313.988.400.112.400.400;F01.658.650;F02.463.306;M01.060.116.630;G07.203.650.660;J01.576.423.850.730.750;N06.850.601.750;F02.463.593;J01.576.423.850.600.400;J01.576.761.400.450;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
29066273,Adult;Aged;Chronic Disease;Dermatomyositis;Disease Progression;Humans;Middle Aged;Retrospective Studies;Severity of Illness Index;Symptom Flare Up;Time Factors;Dermatomyositis,M01.060.116;M01.060.116.100;C23.550.291.500;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C23.550.291.937.500;G01.910.857;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185
29066179,Counseling;Decision Making;Decision Support Techniques;Humans;Neonatology;Pregnancy;Communication;Decision Support Techniques,F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;F02.463.785.373;E05.245;L01.313.500.750.190;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670.400;G08.686.784.769;F01.145.209;L01.143;E05.245;L01.313.500.750.190
29066161,"Adult;Craniospinal Irradiation;Humans;Pregnancy;Pregnancy Trimester, Third;Proton Therapy",M01.060.116;E02.815.230;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;G08.686.707.520;E02.815.250.500
29065656,,
29065200,,
29065123,"Animals;Arginine Vasopressin;Kidney;Mitochondria;Rats;Rats, Long-Evans;Shock, Hemorrhagic",B01.050;D06.472.699.631.692.781.100;D12.644.400.900.100;D12.644.456.925.100;D12.644.548.691.692.781.100;D12.776.631.650.937.100;A05.810.453;A11.284.430.214.190.875.564;A11.284.835.626;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.500;C23.550.414.980;C23.550.835.650
29064869,"Adolescent;Brain Concussion;Child;Child, Preschool;Humans;Post-Concussion Syndrome;Reflex, Vestibulo-Ocular;Retrospective Studies;Vestibular Diseases;Vision Disorders",M01.060.057;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C10.900.300.350.300.500;C26.915.300.450.500.500;C26.974.382.200.500;G11.561.731.795;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C09.218.568.900;C10.597.751.941;C11.966;C23.888.592.763.941
29064744,"Carcinoma, Squamous Cell;Head and Neck Neoplasms;Humans;Oropharyngeal Neoplasms;Radiation Oncology;Squamous Cell Carcinoma of Head and Neck",C04.557.470.200.400;C04.557.470.700.400;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;C04.588.443.665.710.684;C07.550.745.671;C09.647.710.685;C09.775.549.685;H02.403.429.515.500;H02.403.740.650;C04.557.470.200.400.565;C04.588.443.177
29063953,"Adenosine;Adolescent;Child;Child, Preschool;Contrast Media;Exercise Test;Heart Diseases;Humans;Infant;Magnetic Resonance Imaging, Cine;Myocardial Perfusion Imaging;Retrospective Studies;Young Adult",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;M01.060.057;M01.060.406;M01.060.406.448;D27.505.259.500;D27.720.259;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;C14.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500.510;E01.370.350.130.875;E01.370.350.710.600.500;E01.370.370.380.500;E01.370.384.730.354.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
29063713,"Aged;Attention;Cognitive Dysfunction;Disease Progression;Dopamine Plasma Membrane Transport Proteins;Executive Function;Follow-Up Studies;Humans;Language Disorders;Memory Disorders;Memory, Short-Term;Middle Aged;Olfaction Disorders;Parkinson Disease;Prodromal Symptoms;Prognosis;Cognition;Risk Factors",M01.060.116.100;F02.830.104.214;F03.615.250.700;C23.550.291.656;D12.776.157.530.450.625.124;D12.776.157.530.562.374.500.500;D12.776.157.530.937.500;D12.776.543.585.450.625.124;D12.776.543.585.562.374.500.500;D12.776.543.585.937.500;F02.463.217;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.150.500;C23.888.592.604.150.500;C10.597.606.525;C23.888.592.604.529;F01.700.625;F02.463.425.540.407;M01.060.116.630;C10.597.751.600;C23.888.592.763.550;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C23.888.672;E01.599;E01.789;F02.463.188;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29063665,"Adolescent;Analgesia, Epidural;Analgesia, Patient-Controlled;Analgesics, Non-Narcotic;Analgesics, Opioid;Cohort Studies;Funnel Chest;Humans;Length of Stay;Minimally Invasive Surgical Procedures;Pain Management;Pain Measurement;Pain, Postoperative;Retrospective Studies;Thoracic Vertebrae;Treatment Outcome;Acute Pain;Adolescent;Child;Analgesics, Opioid;Quality Improvement",M01.060.057;E03.091.080;E03.091.120;D27.505.696.663.850.014.040;D27.505.954.427.040.100;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C05.116.099.386;C05.660.386;C16.131.621.386;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E04.502;E02.745;N04.590.607.500;E01.370.600.550.324;C23.550.767.700;C23.888.592.612.832;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.592.612.081;M01.060.057;M01.060.406;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;J01.293.754;N04.761.744
29062891,,
29062221,"Calcium Channels, L-Type;DNA Mutational Analysis;Diagnostic Errors;Electroretinography;Exome;Eye Diseases, Hereditary;Genetic Diseases, X-Linked;Genetic Testing;High-Throughput Nucleotide Sequencing;Humans;Infant;Leber Congenital Amaurosis;Myopia;Night Blindness;Nystagmus, Pathologic;Point Mutation;Refractive Errors;Visual Field Tests;Visual Fields",D12.776.157.530.400.150.400;D12.776.543.550.450.150.400;D12.776.543.585.400.150.400;E05.393.760.700.300;E01.354;N02.421.450.280;E01.370.380.225;E01.370.405.270;G05.360.340.011;C11.270;C16.320.290;C16.320.322;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C11.270.516;C11.768.364;C11.744.636;C11.966.671;C10.292.562.675;C11.590.400;G05.365.590.675;C11.744;E01.370.380.850.962;F02.463.593.932.934;G14.950
29061566,"Adult;Aged;Aged, 80 and over;Asymptomatic Diseases;Atrial Fibrillation;Biomarkers;Chi-Square Distribution;Humans;Hypothyroidism;Incidence;Middle Aged;Predictive Value of Tests;Prognosis;Proportional Hazards Models;Risk Assessment;Risk Factors;Thyroid Function Tests;Thyroid Gland;Thyrotropin;Thyroxine;Time Factors;Young Adult;Atrial Fibrillation;Hypothyroidism;Thyrotropin;Thyroxine",M01.060.116;M01.060.116.100;M01.060.116.100.080;C23.550.291.187;C14.280.067.198;C23.550.073.198;D23.101;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;B01.050.150.900.649.313.988.400.112.400.400;C19.874.482;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.374.750;A06.300.900;D06.472.699.631.525.883;D12.644.548.691.525.883;D06.472.931.812;D12.125.072.050.767;G01.910.857;M01.060.116.815;C14.280.067.198;C23.550.073.198;C19.874.482;D06.472.699.631.525.883;D12.644.548.691.525.883;D06.472.931.812;D12.125.072.050.767
29061535,"Aged;CCR5 Receptor Antagonists;Disease-Free Survival;Graft vs Host Disease;Humans;Maraviroc;Middle Aged;Receptors, CCR5;Survival Rate;Maraviroc",M01.060.116.100;D27.505.519.275;D27.505.954.122.388.077.088.104;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C20.452;B01.050.150.900.649.313.988.400.112.400.400;D02.455.426.392.368.367.726;D03.383.129.799.682;M01.060.116.630;D12.776.543.750.695.160.150.500;D12.776.543.750.705.852.125.150.500;D12.776.543.750.830.700.605;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D02.455.426.392.368.367.726;D03.383.129.799.682
29059692,Biomedical Technology;Humans;Office Visits;Physician-Patient Relations;Telemedicine;Tertiary Healthcare,J01.897.115;B01.050.150.900.649.313.988.400.112.400.400;N04.452.758.635;F01.829.401.650.675;N05.300.660.625;H02.403.840;L01.178.847.652;N04.590.374.800;N04.452.758.849.887;N05.300.787
29059597,"Decision Making, Organizational;Ethics Committees, Research;Humans;Research Design",N04.452.190;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500;H01.770.644.728
29059270,,
29059263,"Adolescent;Blood Glucose;Blood Glucose Self-Monitoring;Diabetes Mellitus, Type 1;Glycated Hemoglobin A;Humans;Motivation;Reward;Single-Blind Method;Socioeconomic Factors;Young Adult",M01.060.057;D09.947.875.359.448.500;E01.370.225.124.100.105;E01.370.374.100;E01.370.520.100;E02.900.100;E05.200.124.100.105;C18.452.394.750.124;C19.246.267;C20.111.327;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;F02.463.425.770.836;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;I01.880.853.996;N01.824;M01.060.116.815
29059235,"Child;Cohort Studies;Databases, Factual;Humans;Lymphoma, B-Cell",M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150
29059230,"Amino Acid Substitution;Antigens, Viral;Hemagglutinin Glycoproteins, Influenza Virus;Humans;Influenza A Virus, H3N2 Subtype;Influenza Vaccines;Influenza, Human",E05.393.420.601.035;G05.558.109;D23.050.327;D12.776.964.970.880.345.500;B01.050.150.900.649.313.988.400.112.400.400;B04.820.545.405.400.300;D20.215.894.899.302;C02.782.620.365;C08.730.310
29058739,ADP-Ribosylation;Animals;DNA Damage;Histones;Humans;Nucleosomes;Tandem Mass Spectrometry,G02.111.660.871.790.600.200;G02.111.691.600.200;G03.734.871.790.600.200;G05.308.670.600.200;B01.050;G05.200;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;E05.196.566.880
29058716,"BRCA1 Protein;Breast Neoplasms;European Continental Ancestry Group;Genetic Predisposition to Disease;Genome-Wide Association Study;Heterozygote;Humans;Mutation;Polymorphism, Single Nucleotide;Receptors, Estrogen;Risk Factors",D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;C04.588.180;C17.800.090.500;M01.686.508.400;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G05.365.795.598;D12.776.826.750.350;D12.776.930.778.350;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29058702,"Animals;Cell Polarity;Chemotaxis, Leukocyte;Encephalomyelitis, Autoimmune, Experimental;Inflammation;Intracellular Signaling Peptides and Proteins;Mice;Mice, Inbred C57BL;Mice, Knockout;Phosphatidylinositols;Phosphotransferases (Alcohol Group Acceptor);Signal Transduction;T-Lymphocytes;rac GTP-Binding Proteins",B01.050;G04.250;G04.198.424.233;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;C23.550.470;D12.644.360;D12.776.476;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D10.570.755.375.760.400.942;D08.811.913.696.620;G02.111.820;G04.835;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D08.811.277.040.330.300.400.700.100;D12.644.360.525.700.100;D12.776.157.325.515.700.100;D12.776.476.525.700.100
29058471,"Adult;Aged;Aged, 80 and over;Humans;Marijuana Abuse;Middle Aged;Psychiatric Status Rating Scales;Psychometrics;Reproducibility of Results;Veterans;Young Adult;Medical Marijuana;Veterans",M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050.150.900.649.313.988.400.112.400.400;C25.775.635;F03.900.635;M01.060.116.630;F04.711.513.653;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;M01.930;M01.060.116.815;D26.528;M01.930
29058370,"Adolescent;Adult;Child;Child, Preschool;Disease-Free Survival;Follow-Up Studies;Head and Neck Neoplasms;Humans;Infant;Proton Therapy;Rhabdomyosarcoma;Sarcoma, Ewing;Survival Rate;Proton Therapy;Radiotherapy",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.815.250.500;C04.557.450.590.550.660;C04.557.450.795.550.660;C04.557.450.565.575.650.800;C04.557.450.795.620.800;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E02.815.250.500;E02.815
29057934,"Animals;Cell Line;Dermis;Extracellular Signal-Regulated MAP Kinases;Fibroblasts;Humans;Immediate-Early Proteins;MAP Kinase Signaling System;Mice, Inbred C57BL;Mice, Knockout;Protein Tyrosine Phosphatases;Proto-Oncogene Proteins pp60(c-src);Scleroderma, Systemic;Smad3 Protein;Transforming Growth Factor beta",B01.050;A11.251.210;A17.815.180;D08.811.913.696.620.682.700.567.249;D12.644.360.450.169;D12.776.476.450.169;A11.329.228;B01.050.150.900.649.313.988.400.112.400.400;D12.776.460;D12.776.964.925.968;G02.111.820.560;G03.493.560;G04.835.560;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.277.352.650.775;D08.811.913.696.620.682.725.800.630;D12.776.624.664.700.202;C17.300.799;C17.800.784;D12.644.360.024.334.500.300;D12.776.157.057.170.500.300;D12.776.260.713.500.300;D12.776.476.024.428.500.300;D12.776.744.741.875;D12.776.930.806.500.300;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775
29057385,Neurofeedback;Neuroimaging,E02.190.525.123.500;F02.830.131.500;F04.754.137.301.750;F04.754.308.500.750;E01.370.350.578;E01.370.376.537;E05.629
29057304,Carcinogenesis,C04.697.098;C23.550.727.098
29057240,Lung Neoplasms,C04.588.894.797.520;C08.381.540;C08.785.520
29056552,"Animals;Cell Proliferation;Endocardium;Gene Expression Regulation, Developmental;Heart Valves;Hemodynamics;Kruppel-Like Transcription Factors;Mice, Transgenic;Organogenesis;Signal Transduction;Transcription Factors;Wnt Proteins;Zebrafish;Zebrafish Proteins;Endocardium",B01.050;G04.161.750;G07.345.249.410.750;A07.541.207;G05.308.310;A07.541.510;G09.330.380;D12.776.260.522;D12.776.930.375;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G07.345.500.325.377;G08.686.784.170.450;G02.111.820;G04.835;D12.776.930;D12.776.467.984;D23.529.984;B01.050.150.900.493.200.244.828;D12.776.325.500;A07.541.207
29056344,Adult;Child;Cluster Analysis;DNA Polymerase II;DNA Polymerase III;DNA Replication;Humans;Mutation;Neoplasms;Poly-ADP-Ribose Binding Proteins;DNA Repair;DNA Replication;DNA Mismatch Repair,M01.060.116;M01.060.406;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;D08.811.913.696.445.308.300.230;D08.811.913.696.445.308.300.235;G02.111.225;G05.226;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04;D12.776.157.687;D12.776.660.720;G02.111.222;G05.219;G02.111.225;G05.226;G02.111.222.220;G05.219.220
29056226,"Alleles;Brain;CCCTC-Binding Factor;Cell Line, Tumor;Chromatin;Dementia;Frontotemporal Lobar Degeneration;Gene Expression;Gene Expression Regulation;Genome-Wide Association Study;Genotype;HeLa Cells;Humans;Membrane Proteins;Nerve Tissue Proteins;Neurons;Phenotype;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;Repressor Proteins;Risk;Frontotemporal Dementia;Frontotemporal Lobar Degeneration",G05.360.340.024.340.030;A08.186.211;D12.776.157.687.157;D12.776.260.120;D12.776.660.235.050;D12.776.660.720.157;D12.776.664.235.050;D12.776.930.780.563;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;C10.228.140.380;F03.615.400;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;G05.297;G05.308;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;D12.776.631;A08.675;A11.671;G05.695;G05.365.795.598;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.260.703;D12.776.930.780;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380
29055892,"Adult;Cross-Sectional Studies;Emergency Medical Technicians;Humans;Peer Group;Social Support;Stress, Psychological;Surveys and Questionnaires;Workplace;Allied Health Personnel",M01.060.116;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.526.373.250;M01.526.485.067.150;N02.360.067.150;B01.050.150.900.649.313.988.400.112.400.400;F01.829.316.483;I01.880.853.500.600;F01.145.126.990;F02.830.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N01.824.245.925;N04.452.677.975;M01.526.485.067;N02.360.067
29055613,Health Policy;Public Health;Wounds and Injuries,I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;H02.403.720;N01.400.550;N06.850;C26
29055457,Adult;Aquaporin 4;Autoantibodies;Biomarkers;Disability Evaluation;Disease Progression;Enzyme-Linked Immunosorbent Assay;Follow-Up Studies;Humans;Middle Aged;Neuromyelitis Optica;Retrospective Studies;Neuromyelitis Optica;Neuromyelitis Optica;Recurrence,M01.060.116;D12.776.157.530.400.500.040.468;D12.776.543.550.450.730.040.468;D12.776.543.585.400.730.040.577;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;D23.101;E01.370.400;C23.550.291.656;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;C23.550.291.937
29055420,Hepacivirus;Kidney Transplantation,B04.450.380;B04.820.250.475;E02.870.500;E04.936.450.485;E04.950.774.400
29055142,Bone Transplantation;Cerebrospinal Fluid Leak;Cerebrospinal Fluid Rhinorrhea;Endoscopy;Follow-Up Studies;Humans;Intracranial Hypertension;Middle Aged;Osteogenesis;Retrospective Studies,E02.095.147.725.052;E04.555.130;E04.936.580.052;C10.597.114;C10.900.300.109;C23.888.592.114;C26.915.300.225;C10.597.114.750;C10.900.300.109.750;C23.888.592.114.624;C26.915.300.225.750;E01.370.388.250;E04.502.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.631;M01.060.116.630;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
29055096,"Algorithms;Biomarkers, Tumor;Computer Simulation;Data Collection;Data Interpretation, Statistical;Gene Expression Regulation, Neoplastic;Humans;Likelihood Functions;Meta-Analysis as Topic;Models, Statistical;Multivariate Analysis;N-Myc Proto-Oncogene Protein;Neuroblastoma;Research Design;Sample Size;Statistics as Topic;Stomach Neoplasms",G17.035;L01.224.050;D23.101.140;L01.224.160;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.475;E05.318.740.600.400;E05.599.835.500;N05.715.360.750.530.450;N05.715.360.750.625.450;N06.850.520.830.500.475;N06.850.520.830.600.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E05.581.500;H01.770.644.728;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789
29054878,"Adult;Aged;Animals;Brain;Cells, Cultured;Humans;Mice;Mice, Inbred C57BL;Middle Aged;Neurons;Oligodendroglia;Tauopathies;tau Proteins",M01.060.116;M01.060.116.100;B01.050;A08.186.211;A11.251;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;M01.060.116.630;A08.675;A11.671;A08.637.600;A11.650.600;C10.574.945;D12.776.220.600.450.510;D12.776.631.560.510
29054485,"Adult;Antipsychotic Agents;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Polymorphism, Single Nucleotide;SOXB1 Transcription Factors;Schizophrenia",M01.060.116;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.795.598;D12.776.260.719.100;D12.776.660.235.400.750.100;D12.776.664.235.400.750.100;D12.776.930.823.100;F03.700.750
29054350,"Animals;Biomarkers;Cell Differentiation;Erythrocytes;Erythropoiesis;Hematopoietic Stem Cells;Humans;Iron;Molecular Targeted Therapy;Stress, Physiological;Thalassemia;Erythrocytes;Thalassemia",B01.050;D23.101;G04.152;A11.118.290;A11.443.240;A15.145.229.334;G04.152.825.414;G09.188.343.414;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.412;D01.268.956.287;D01.552.544.412;E02.319.574;G07.775;C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826;A11.118.290;A11.443.240;A15.145.229.334;C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826
29053861,,
29053113,"Anesthesia Department, Hospital;Humans;Medical Records Systems, Computerized;Preoperative Care",N02.278.216.500.968.070;N04.452.442.422.070;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.940.968.625;L01.313.500.750.300.695;N04.452.859.564.650;N05.715.360.300.715.500.530;N06.850.520.308.940.968.625;E02.760.795;E04.604.750;N02.421.585.795
29053005,"Toll-Like Receptor 9;DNA, Mitochondrial",D12.776.260.750;D12.776.543.750.705.910.500.900;D13.444.308.283.225
29052781,"Adolescent;Child;Child, Preschool;Flow Cytometry;Humans;Immunophenotyping;Infant;Lymphocyte Count;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Retrospective Studies;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Child;Flow Cytometry;Induction Chemotherapy",M01.060.057;M01.060.406;M01.060.406.448;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;M01.060.703;E01.370.225.500.195.107.595.500;E01.370.225.625.107.595.500;E05.200.500.195.107.595.500;E05.200.625.107.595.500;E05.242.195.107.595.500;G04.140.107.595.500;G09.188.105.595.500;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;M01.060.406;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;E02.319.499;E02.860.500
29052655,"Adult;Aged;Aged, 80 and over;Cancer Survivors;Cross-Sectional Studies;Health Behavior;Health Status;Humans;Middle Aged;Neoplasms;Neoplasms, Multiple Primary;Quality of Life;Socioeconomic Factors;Stress, Psychological;Surveys and Questionnaires;United States;Health Behavior",M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.860.350;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.488;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04;C04.651;I01.800;K01.752.400.750;N06.850.505.400.425.837;I01.880.853.996;N01.824;F01.145.126.990;F02.830.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;F01.145.488
29052132,"Animals;Chromosome Aberrations;Epstein-Barr Virus Infections;Herpesvirus 4, Human;Humans;Lymphoma, B-Cell;Mice;Transcriptional Activation;Lymphoma, B-Cell;Herpesvirus 4, Human",B01.050;C23.550.210;G05.365.590.175;C02.256.466.313;C02.928.313;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150;B01.050.150.900.649.313.992.635.505.500;G05.308.800;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400
29052131,"Carcinogenesis;Humans;Merkel cell polyomavirus;Neoplasms;Skin Neoplasms;Carcinoma, Merkel Cell;Merkel cell polyomavirus;Carcinogenesis",C04.697.098;C23.550.727.098;B01.050.150.900.649.313.988.400.112.400.400;B04.280.210.700.615.550;B04.613.204.670.615.550;C04;C04.588.805;C17.800.882;C02.256.721.150;C02.928.216;C04.557.465.625.650.240.325;C04.557.470.200.025.370.325;C04.557.580.625.650.240.325;B04.280.210.700.615.550;B04.613.204.670.615.550;C04.697.098;C23.550.727.098
29051494,"Animals;Breast Neoplasms;Cell Line, Tumor;Cell Proliferation;Cell Self Renewal;Down-Regulation;Gene Expression Regulation, Neoplastic;Humans;Mammary Glands, Human;Mice;Mice, Inbred C57BL;Mice, Transgenic;MicroRNAs;NF-kappa B;Neoplastic Stem Cells;Stem Cells;Wnt Proteins;Wnt Signaling Pathway;beta Catenin",B01.050;C04.588.180;C17.800.090.500;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;G02.111.240;G05.308.200;G07.690.773.937;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;A01.236.249;A10.336.532;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;A11.872.650;A11.872;D12.776.467.984;D23.529.984;G02.111.820.925;G04.835.925;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
29051322,,
29051139,"Aorta;Cell Movement;Cell Proliferation;Cells, Cultured;Cluster Analysis;Computational Biology;Coronary Vessels;Data Mining;Extracellular Matrix;Gene Expression Profiling;Gene Expression Regulation;Humans;Hydrogels;Mechanotransduction, Cellular;Muscle, Smooth, Vascular;Myocytes, Smooth Muscle;RNA, Long Noncoding;Transcriptome;Vascular Stiffness;Aorta;Coronary Artery Disease;Extracellular Matrix;RNA, Long Noncoding;Transcriptome;Muscle, Smooth, Vascular;Vascular Stiffness",A07.015.114.056;G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;A11.251;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;H01.158.273.180;L01.313.124;A07.015.114.269;A07.015.908.194;L01.313.500.750.280.199;L01.470.625;A11.284.295.310;E05.393.332;G05.308;B01.050.150.900.649.313.988.400.112.400.400;D20.280.320.375;D26.255.165.320.375;G01.154.090.500;G02.111.820.580;G04.835.580;A02.633.570.491;A07.015.733.500;A10.690.467.491;A11.620.520;D13.444.735.790.375;G02.111.873.750;G05.297.700.750;G05.360.920;G09.330.940;A07.015.114.056;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;A11.284.295.310;D13.444.735.790.375;G02.111.873.750;G05.297.700.750;G05.360.920;A02.633.570.491;A07.015.733.500;A10.690.467.491;G09.330.940
29050718,"Adolescent;Follow-Up Studies;Humans;Imaging, Three-Dimensional;Lumbar Vertebrae;Postoperative Period;Prospective Studies;Radiography;Regression Analysis;Retrospective Studies;Rotation;Scoliosis;Spinal Fusion;Thoracic Vertebrae;Time Factors;Treatment Outcome",M01.060.057;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;A02.835.232.834.519;E04.614.750;N02.421.585.753.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.370.350.700;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.482.703;C05.116.900.800.875;E04.555.100.700;A02.835.232.834.892;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29050695,"Antineoplastic Agents;Clinical Trials as Topic;Dasatinib;Gene Expression Regulation, Leukemic;Hematopoietic Stem Cell Transplantation;Humans;Imatinib Mesylate;Janus Kinases;Molecular Targeted Therapy;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Pyrazoles;STAT Transcription Factors;Signal Transduction;Survival Analysis;Transplantation, Homologous;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Dasatinib;Imatinib Mesylate",D27.505.954.248;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;D02.886.675.184;D03.383.129.708.198;D03.383.742.148;G05.308.370.500;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;D08.811.913.696.620.682.725.124;D12.776.476.393;E02.319.574;A11.284.187.520.300.325.345.500;A11.284.187.520.300.505.515.500;C23.550.210.870.680;G05.360.162.520.300.325.345.700;G05.360.162.520.300.505.515.700;G05.365.590.175.870.680;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D27.505.519.389.755;D03.383.129.539;D12.644.360.024.342;D12.776.157.057.186;D12.776.476.024.430;D12.776.930.840;G02.111.820;G04.835;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E04.936.864;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D02.886.675.184;D03.383.129.708.198;D03.383.742.148;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349
29050506,Health Communication;Implementation Science;Information Dissemination;Persuasive Communication,L01.143.350;N02.208;L01.143.320.400;L01.143.443;L01.143.762
29050392,Animals;Brain Diseases;Epilepsy;Genetic Association Studies;Kv1.2 Potassium Channel;Mutation;Oocytes;Phenotype;Xenopus;Brain Diseases,B01.050;C10.228.140;C10.228.140.490;E05.393.385;D12.776.157.530.400.600.900.500.186;D12.776.543.550.450.750.900.124.342;D12.776.543.550.450.750.900.500.186;D12.776.543.585.400.750.900.624.186;G05.365.590;A05.360.490.690.680;A11.497.497.600;G05.695;B01.050.150.900.090.180.610.500;C10.228.140
29050203,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250;C15.378.190.636.370
29049888,,
29049863,,
29049851,,
29049825,,
29049515,,
29049513,"Conscience;Contraceptive Agents;Health Benefit Plans, Employee;Health Services Accessibility;Humans;Insurance Coverage;Patient Protection and Affordable Care Act;Politics;Religion and Medicine;United States",F01.829.500.359;K01.752.566.359;D27.505.696.875.360;D27.505.954.705.360;N01.824.417.700.325;N03.219.521.576.343.290;N04.452.677.800.325;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343.918;N03.706.615.806;I01.738;K01.844.619;Z01.107.567.875
29049500,"Decision Making;Diagnostic Tests, Routine;Evidence-Based Medicine;Guidelines as Topic;Hospitalization;Humans;Patient Care Team;Unnecessary Procedures",F02.463.785.373;E01.370.395;H02.249.750;H02.403.200.400;N04.761.700.350;N05.700.350;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;N02.421.380.450.500;N05.300.150.395.450.500
29049437,"Adolescent;Adult;Child;Disease Progression;Fluorescein Angiography;Fundus Oculi;Humans;Macular Degeneration;Ophthalmoscopy;Retinal Pigment Epithelium;Retrospective Studies;Tomography, Optical Coherence;Visual Acuity;Young Adult",M01.060.057;M01.060.116;M01.060.406;C23.550.291.656;E01.370.370.050.350;E01.370.380.250;A09.371.729.313;B01.050.150.900.649.313.988.400.112.400.400;C11.768.585.439;E01.370.380.560;A09.371.670.500;A09.371.729.887;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;M01.060.116.815
29049352,"Amniotic Fluid;Animals;Animals, Newborn;Brain;Inflammation;Metabolomics;Mice;Pregnancy;Uterus",A12.098;A16.378.149;B01.050;B01.050.050.282;A08.186.211;C23.550.470;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;B01.050.150.900.649.313.992.635.505.500;G08.686.784.769;A05.360.319.679
29049267,,
29049075,,
29049064,"Breast Feeding;Humans;Milk Banks;Milk, Human",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;B01.050.150.900.649.313.988.400.112.400.400;N02.278.065.600;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500
29048724,DiGeorge Syndrome;Psychiatry;Psychotic Disorders;Schizophrenia,C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F04.096.544;H02.403.690;F03.700.675;F03.700.750
29048590,,
29048421,"Adolescent;Adult;Alleles;Amino Acid Substitution;Child;Child, Preschool;Cohort Studies;Connexins;Deafness;Genetic Testing;Genetic Variation;Genotype;High-Throughput Nucleotide Sequencing;Humans;Infant;Membrane Proteins;Pedigree;Phenotype;Population Surveillance;Saudi Arabia;Young Adult",M01.060.057;M01.060.116;G05.360.340.024.340.030;E05.393.420.601.035;G05.558.109;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D12.776.543.585.250;C09.218.458.341.186;C10.597.751.418.341.186;C23.888.592.763.393.341.186;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;G05.380;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D12.776.543;E05.393.673;G05.695;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;Z01.252.245.500.750;M01.060.116.815
29048414,"Adult;Bronchopulmonary Dysplasia;Child;Counseling;Decision Support Techniques;Health Knowledge, Attitudes, Practice;Humans;Middle Aged;Parents;Patient Education as Topic;Program Development;Qualitative Research",M01.060.116;C08.381.520.750.500;C16.614.521.125;M01.060.406;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;E05.245;L01.313.500.750.190;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I02.233.332.500;N02.421.726.407.680;N04.452.760;H01.770.644.241.850
29046955,"Caregivers;Child;Child, Preschool;Humans;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Sleep Wake Disorders;Precursor Cell Lymphoblastic Leukemia-Lymphoma",M01.085;M01.526.485.200;N02.360.200;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;C10.886;C23.888.592.796;F03.870;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
29046919,"Body Burden;Child, Preschool;Diagnostic Imaging;Film Dosimetry;Humans;Ovary;Phantoms, Imaging;Radiation Dosage;Radiation Protection;Radiography, Abdominal;Gonads;Ovary;Radiography",E05.799.638.231;N06.850.460.200;M01.060.406.448;E01.370.350;E05.799.638.420;N06.850.810.370.310;B01.050.150.900.649.313.988.400.112.400.400;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;E07.671;E05.799.513;G01.750.740;N06.850.810.250;N06.850.810.425;E01.370.350.700.715;A05.360.576;A06.300.312;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;E01.370.350.700
29046453,"Animals;Antiviral Agents;Exoribonucleases;Genome, Viral;Immunity, Innate;Interferon-beta;Mice;Murine hepatitis virus;Mutagenesis;Mutation;RNA, Viral;Viral Nonstructural Proteins;Virus Replication;Exons;Coronavirus;Immunity, Innate;Interferons",B01.050;D27.505.954.122.388;D08.811.277.352.365.300;D08.811.277.352.700.375;G05.360.340.358.840;G12.450.564;D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275;B01.050.150.900.649.313.992.635.505.500;B04.450.580;B04.820.504.540.150.113.875;G05.558;G05.365.590;D13.444.735.828;D12.776.964.900;G06.920.925;G05.360.340.024.340.137.232;B04.820.504.540.150;G12.450.564;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
29046043,Adolescent;Adolescent Health Services;Delivery of Health Care;Health Promotion;Health Services Research;Humans;Self-Management;Transition to Adult Care;Young Adult;Adolescent;Health Behavior,M01.060.057;N02.421.044;N04.590.374;N05.300;I02.233.332.445;N02.421.726.407.579;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;N02.421.784.760;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815;M01.060.057;F01.145.488
29046041,"Adaptation, Psychological;Adolescent;Cancer Survivors;Factor Analysis, Statistical;Humans;Personality Assessment;Psychometrics;Reproducibility of Results;Transition to Adult Care;Young Adult;Adolescent;Neoplasms;Chronic Disease",F01.058;M01.060.057;M01.860.350;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.050.150.900.649.313.988.400.112.400.400;F04.513;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815;M01.060.057;C04;C23.550.291.500
29045844,"Animals;B-Lymphocytes;Biopsy;Cell Differentiation;Cell Line, Tumor;Enhancer Elements, Genetic;Gene Expression Regulation, Neoplastic;Gene Rearrangement;Humans;Lymph Nodes;Lymphoma, B-Cell;Mice;Oncogenes;Proto-Oncogene Proteins c-myc;Receptors, Notch;Signal Transduction;Tumor Microenvironment;Xenograft Model Antitumor Assays;Leukemia, Lymphocytic, Chronic, B-Cell;Lymphoma;Lymphoma, Mantle-Cell",B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;G04.152;A11.251.210.190;A11.251.860.180;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.308.370;G05.344;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150;B01.050.150.900.649.313.992.635.505.500;G05.360.340.024.340.375.500;D12.776.260.103.813;D12.776.624.664.700.189;D12.776.660.765;D12.776.930.125.813;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;G04.366.500;E05.337.550.200.900;E05.624.850;C04.557.337.428.080.125;C15.604.515.560.080.125;C20.683.515.528.080.125;C04.557.386;C15.604.515.569;C20.683.515.761;C04.557.386.480.525;C15.604.515.569.480.525;C20.683.515.761.480.525
29045431,"Animals;HEK293 Cells;Humans;Injections, Intraperitoneal;Mice, Inbred mdx;MicroRNAs;Muscle, Skeletal;Muscular Dystrophy, Duchenne;Oligonucleotides;Protein Binding;Reproducibility of Results;Up-Regulation;Utrophin",B01.050;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.490;B01.050.050.199.520.520.420.500;B01.050.150.900.649.313.992.635.505.500.400.420.500;B01.050.150.900.649.313.992.635.505.500.550.265;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A02.633.567;A10.690.552.500;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;D13.695.578.424;G02.111.679;G03.808;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;G02.111.905;G05.308.850;G07.690.773.998;D12.776.220.987;D12.776.543.985
29045355,Advance Care Planning;Aged;Centers for Medicare and Medicaid Services (U.S.);Chronic Disease;Communication;Costs and Cost Analysis;Electronic Health Records;Hospice Care;Humans;Meaningful Use;Physician-Patient Relations;Prognosis;Retrospective Studies;Risk Assessment;Terminally Ill;United States;Unnecessary Procedures,N04.590.233.624.124;M01.060.116.100;I01.409.418.750.600.310;N03.540.348.500.500.600.550;C23.550.291.500;F01.145.209;L01.143;N03.219.151;E05.318.308.940.968.625.500;E02.760.905.400;N02.421.585.905.400;B01.050.150.900.649.313.988.400.112.400.400;N04.761.744.500;F01.829.401.650.675;N05.300.660.625;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;M01.873;Z01.107.567.875;N02.421.380.450.500;N05.300.150.395.450.500
29045276,,
29045232,Aged;Breast;Breast Neoplasms;Contrast Media;Humans;Magnetic Resonance Imaging;Middle Aged;Molecular Imaging;Neoadjuvant Therapy;Positron Emission Tomography Computed Tomography,M01.060.116.100;A01.236;C04.588.180;C17.800.090.500;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;E01.370.350.557;E05.601.555;E02.186.450;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500
29045162,,
29045080,Adult;Consumer Behavior;Energy Intake;Food Labeling;Humans;Restaurants,M01.060.116;F01.145.236;G07.203.650.240.340;J01.576.423.850.600.400;J01.576.761.400.450;B01.050.150.900.649.313.988.400.112.400.400;J01.576.423.500.700;J03.813
29045018,"Aged;Aged, 80 and over;Combined Modality Therapy;Databases, Factual;Disease-Free Survival;Esthesioneuroblastoma, Olfactory;Humans;Middle Aged;Rare Diseases;Treatment Outcome;United States;Drug Therapy;Esthesioneuroblastoma, Olfactory;Paranasal Sinuses;Radiation;Skull Base",M01.060.116.100;M01.060.116.100.080;E02.186;L01.313.500.750.300.188.400;L01.470.750.750;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.557.465.625.600.590.650.550.150;C04.557.470.670.590.650.550.150;C04.557.580.625.600.590.650.550.150;C10.292.650.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.291.906;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;E02.319;C04.557.465.625.600.590.650.550.150;C04.557.470.670.590.650.550.150;C04.557.580.625.600.590.650.550.150;C10.292.650.200;A04.531.621;G01.750;A01.456.830;A02.835.232.781.750
29044830,"Anesthesia, Inhalation;Anesthesiology;Carbon Dioxide;Humans;Infant;Infant, Newborn;Intubation, Intratracheal;Pulmonary Gas Exchange;Respiration, Artificial;Capnography;Anesthesia, General;Humidifiers;Respiration, Artificial;Respiratory Dead Space",E03.155.197.197;H02.403.066;D01.200.200;D01.362.150;D01.650.550.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.041.500;E02.585.578;E05.497.578;E01.370.386.700.650;G03.143.775.602;G09.772.705.760.602;E02.041.625;E02.365.647.729;E02.880.820;E01.370.386.700.150;E03.155.197;E07.451;J01.494.650;E02.041.625;E02.365.647.729;E02.880.820;G09.772.760
29044765,"Biopsy;Biosynthetic Pathways;Cerebellar Ataxia;DNA Copy Number Variations;Dietary Supplements;Electron Transport;Fibroblasts;Genetic Association Studies;High-Throughput Nucleotide Sequencing;Humans;Leukocytes;Methyltransferases;Mitochondrial Encephalomyopathies;Mitochondrial Proteins;Muscles;Oxygen Consumption;Pedigree;Polymorphism, Single Nucleotide;Siblings;Ubiquinone;Cerebellar Ataxia;Brain Diseases;Precision Medicine",E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;G02.111.098;G03.493.100;C10.228.140.252.190;C10.597.350.090.500;C23.888.592.350.090.200;G05.365.795.297.500;G07.203.300.456;J02.500.456;G02.111.248;G03.295.531.403;G03.493.350;A11.329.228;E05.393.385;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637;A15.145.229.637;A15.382.490;D08.811.913.555.500;C05.651.460.620;C10.228.140.163.540;C10.668.491.500.500;C18.452.132.540;C18.452.660.560.620;D12.776.575;A02.633;A10.690;G03.680;E05.393.673;G05.365.795.598;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;D02.806.250.900;D08.211.935;C10.228.140.252.190;C10.597.350.090.500;C23.888.592.350.090.200;C10.228.140;E02.574;H02.403.200.700
29044710,Mice,B01.050.150.900.649.313.992.635.505.500
29044608,Congenital Hyperinsulinism;Insulin Secretion,C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;G03.442;G07.475
29044551,Binge-Eating Disorder;Cognitive Behavioral Therapy;Metabolic Syndrome,F03.400.188;F04.754.137.350;C18.452.394.968.500.570;C18.452.625
29044470,"Algorithms;Animals;Epistasis, Genetic;Gene Expression Regulation;Genetic Association Studies;Genetic Predisposition to Disease;Genomics;Humans;Machine Learning;Models, Statistical;Disease Susceptibility",G17.035;L01.224.050;B01.050;G05.308.207;G05.308;E05.393.385;C23.550.291.687.500;G05.380.355;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;C23.550.291.687;G07.100.250
29043563,"Mice, Knockout;Mice, Transgenic",B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
29042354,"Blalock-Taussig Procedure;Ductus Arteriosus, Patent;Heart Diseases;Propensity Score;Stents",E04.035.137;E04.100.814.868.374;C14.240.400.340;C14.280.400.340;C16.131.240.400.340;C14.280;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E07.695.750
29040911,"Brain Neoplasms;Glioma;Histological Techniques;Humans;Models, Neurological;Nerve Net;Deep Learning",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;E01.370.225.750;E05.200.750;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.642;A08.511;G17.035.250.500.250;G17.485.500;L01.224.050.375.530.250;L01.224.050.375.605.500
29040797,Adolescent;Adult;Attention Deficit Disorder with Hyperactivity;Child;Comorbidity;DiGeorge Syndrome;Humans;Impulsive Behavior;Psychotic Disorders;Young Adult,M01.060.057;M01.060.116;F03.625.094.150;M01.060.406;N05.715.350.225;N06.850.490.687;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;F01.145.527;F03.700.675;M01.060.116.815
29040592,"Aged;Aged, 80 and over;Biomarkers;Blood Glucose;Cardiovascular Diseases;Cohort Studies;Diabetes Mellitus;Humans;Incidence;Insulin-Like Growth Factor Binding Protein 3;Insulin-Like Growth Factor I;Longitudinal Studies;New England;Prospective Studies;Risk",M01.060.116.100;M01.060.116.100.080;D23.101;D09.947.875.359.448.500;C14;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C18.452.394.750;C19.246;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D12.776.157.420.270;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875.550;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
29040227,,
29040031,"Adolescent;Adult;Aged;Antilymphocyte Serum;Double-Blind Method;Graft vs Host Disease;HLA Antigens;Hematopoietic Stem Cell Transplantation;Humans;Immunosuppressive Agents;Leukemia, Myeloid, Acute;Methotrexate;Middle Aged;Myelodysplastic Syndromes;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prospective Studies;Tacrolimus;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;A12.207.152.846.500.203;D12.776.124.486.485.114.573.203;D12.776.124.790.651.114.573.203;D12.776.377.715.548.114.573.203;D20.215.401.203;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;C20.452;D23.050.301.500.450;D23.050.705.552.450;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;C04.557.337.539.275;D03.633.100.733.631.192.500;M01.060.116.630;C15.378.190.625;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D02.540.505.810;M01.060.116.815
29039684,"Cohort Studies;Continental Population Groups;Heart Defects, Congenital;Humans;Infant;Infant Health;Parent-Child Relations;Parenting;Prospective Studies;Psychometrics;Stress, Psychological;Surveys and Questionnaires;Infant",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.508;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N01.400.388;F01.829.263.370.290;F01.829.263.370.310;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.711.780;F01.145.126.990;F02.830.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.703
29039138,"Animals;GABA Agonists;Humans;Hypnotics and Sedatives;Receptors, GABA",B01.050;D27.505.519.625.240.200;D27.505.696.577.240.200;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.277.350;D27.505.954.427.210.350;D12.776.543.750.720.200.300
29039115,"Gene Editing;Humans;Immunotherapy, Adoptive;Neoplasms;T-Lymphocytes;Immunotherapy;Zinc Finger Nucleases",E05.393.420.270;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02.095.465.425;D08.811.277.352.335.350.925;D08.811.277.352.355.325.850;D12.776.828.300.990
29038110,Atrial Fibrillation;Electrocardiography;Heart Failure;Hospitalization;Torsades de Pointes,C14.280.067.198;C23.550.073.198;E01.370.370.380.240;E01.370.405.240;C14.280.434;E02.760.400;N02.421.585.400;C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700
29038051,"Amyloid beta-Peptides;Animals;Apolipoproteins E;Diet;Disease Models, Animal;Gene Regulatory Networks;Gene-Environment Interaction;Genotype;Immunity, Innate;Mice;Mice, Transgenic;Plaque, Amyloid;Sex Factors;Systems Biology;Alzheimer Disease;Diet;Microglia",D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;B01.050;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;G07.203.650.240;C22.232;E05.598.500;E05.599.395.080;G05.360.080.689.360;G05.695.337;G05.380;G12.450.564;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C23.300.821;N05.715.350.675;N06.850.490.875;H01.158.273.180.800;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G07.203.650.240;A08.637.400;A11.650.400
29037972,"Amygdala;Animals;Corticotropin-Releasing Hormone;Dorsal Raphe Nucleus;Estradiol;Neural Pathways;Neurons;Progesterone;Proto-Oncogene Proteins c-fos;Rats;Receptors, Corticotropin-Releasing Hormone;Sex Characteristics;Anxiety;Connectome;Corticotropin-Releasing Hormone;Estradiol;Progesterone;Sex Characteristics",A08.186.211.180.090;A08.186.211.200.885.287.249.152;B01.050;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;A08.186.211.132.659.413.875.618.249;D04.210.500.365.415.248;D06.472.334.851.437.500;A08.612;A08.675;A11.671;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;D12.776.260.108.765;D12.776.624.664.700.179;D12.776.660.760;D12.776.930.127.765;B01.050.150.900.649.313.992.635.505.700;D12.776.543.750.695.180;D12.776.543.750.720.600.290;D12.776.543.750.750.555.290;D12.776.543.750.750.700.150;G08.686.815;F01.470.132;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;D04.210.500.365.415.248;D06.472.334.851.437.500;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;G08.686.815
29037820,,
29037523,"Antirheumatic Agents;Arthritis, Psoriatic;Humans;Patient Reported Outcome Measures;Quality of Life;Severity of Illness Index;Patient Reported Outcome Measures;Systematic Review;Arthritis, Psoriatic",D27.505.954.329;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;V03.850;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
29037111,Acceleration;Adolescent;Anthropometry;Biomechanical Phenomena;Brain Concussion;Chronic Traumatic Encephalopathy;Electromyography;Head;Humans;Muscle Strength;Neck;Neck Muscles;Rotation;Soccer;Time and Motion Studies;Young Adult;Brain Concussion,G01.482.107;M01.060.057;E01.370.600.024;E05.041;N06.850.505.200.100;G01.154.090;G01.374.089;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;C10.228.140.199.444.500;C10.228.140.199.500.500;C10.574.250;C10.900.300.087.235.500;C10.900.300.087.250.500;C26.915.300.200.194.500;C26.915.300.200.200.500;E01.370.405.255;E01.370.530.255;A01.456;B01.050.150.900.649.313.988.400.112.400.400;E01.370.600.425;G11.427.560;A01.598;A02.633.567.650;G01.482.703;I03.450.642.845.800;F02.784.412.846.707;F02.784.692.746.707;M01.060.116.815;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200
29036922,"Animals;Astrocytes;Cell Line;Gene Expression;Humans;MicroRNAs;Microarray Analysis;Pregnancy;RNA, Messenger;Up-Regulation;Virus Replication;Zika Virus;Zika Virus;Flavivirus;MicroRNAs",B01.050;A08.637.200;A11.650.200;A11.251.210;G05.297;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;E05.588.570;G08.686.784.769;D13.444.735.544;G02.111.905;G05.308.850;G07.690.773.998;G06.920.925;B04.820.250.350.995;B04.820.250.350.995;B04.820.250.350;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
29036412,"Biomarkers, Tumor;Brain Neoplasms;DNA Methylation;Glioblastoma;Humans;Magnetic Resonance Imaging;Prognosis;Promoter Regions, Genetic;Retrospective Studies;Survival Rate;Tumor Burden",D23.101.140;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.789;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E05.041.124.892
29036387,Attention Deficit Disorder with Hyperactivity;Electronic Health Records;Environmental Exposure;Pregnancy;Seasons,F03.625.094.150;E05.318.308.940.968.625.500;N06.850.460.350;G08.686.784.769;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525
29035908,Horner Syndrome;Humans;Myofibroma,C10.177.350;C10.597.690.362.500;C11.710.528.500;C23.888.592.708.362.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.565.540;C17.300.680.540
29035376,"Carcinogenesis;Chromatin;Gene Expression Regulation, Neoplastic;Herpesvirus 4, Human;Humans;Models, Genetic;NM23 Nucleoside Diphosphate Kinases;Neoplasm Metastasis;Neoplasms;Protein Binding",C04.697.098;C23.550.727.098;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.308.370;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;D08.811.913.696.650.550.200;C04.697.650;C23.550.727.650;C04;G02.111.679;G03.808
29035283,"Animals;Cells, Cultured;Fatty Liver;Hepatocytes;Lipogenesis;Liver;Mechanistic Target of Rapamycin Complex 1;Mice, Inbred C57BL;Mice, Transgenic;Phosphatidylcholines;Triglycerides",B01.050;A11.251;C06.552.241;A11.436.348;G02.111.528;G03.458.249;A03.620;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D10.570.755.375.760.400.800;D10.351.801
29034571,"Aged;Asymptomatic Diseases;Bone Density;Fractures, Bone;Humans;Hyperthyroidism;Hypothyroidism;Risk Factors;Bone Density;Hyperthyroidism;Hypothyroidism;Prospective Studies;Thyroid Diseases",M01.060.116.100;C23.550.291.187;G11.427.100;C26.404;B01.050.150.900.649.313.988.400.112.400.400;C19.874.397;C19.874.482;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G11.427.100;C19.874.397;C19.874.482;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C19.874
29034436,"Adult;Antibodies, Viral;Cohort Studies;Humans;Immunologic Factors;JC Virus;Multiple Sclerosis;Natalizumab;Seroconversion;JC Virus;Multiple Sclerosis;Natalizumab",M01.060.116;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;B04.280.210.700.615.400;B04.613.204.670.615.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;G12.800;B04.280.210.700.615.400;B04.613.204.670.615.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813
29034254,Attitude;Neoplasms;Aged;General Surgery,F01.100;C04;M01.060.116.100;H02.403.810.300
29034227,Adolescent;Substance-Related Disorders;Methylphenidate;Psychiatry;Young Adult,M01.060.057;C25.775;F03.900;D02.241.223.601.600;D03.383.621.460;F04.096.544;H02.403.690;M01.060.116.815
29033129,"Animals;Chromatin;Gene Expression Regulation, Developmental;Genome;Histone Deacetylases;Mice;Myocytes, Cardiac;Nuclear Lamina;Stem Cells;Nuclear Lamina",B01.050;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.308.310;G05.360.340;D08.811.277.087.520;B01.050.150.900.649.313.992.635.505.500;A07.541.704.570;A10.690.552.750.570;A11.620.500;A11.284.149.165.630.500;A11.284.430.106.279.345.700.700;A11.284.430.106.279.692.314;A11.284.835.514.700.500;A11.872;A11.284.149.165.630.500;A11.284.430.106.279.345.700.700;A11.284.430.106.279.692.314;A11.284.835.514.700.500
29032125,,
29032124,,
29032123,,
29032122,,
29031786,"Animals;CD8-Positive T-Lymphocytes;Caliciviridae Infections;Cell Differentiation;Cell Line;Cellular Microenvironment;Gastroenteritis;Gene Expression Profiling;Gene Ontology;HEK293 Cells;Host-Pathogen Interactions;Humans;Immunologic Memory;Mice, Inbred C57BL;Norovirus;Oligonucleotide Array Sequence Analysis;Norovirus",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;C02.782.160;G04.152;A11.251.210;G04.366;C06.405.205;E05.393.332;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;A11.251.210.172.750;A11.436.334;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B04.820.095.550;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;B04.820.095.550
29031723,"Acetylcholine;Animals;Casein Kinase II;Cells, Cultured;Cholinergic Agents;Diabetes Mellitus, Type 2;Fatty Acids;Glucose;Humans;Hyperglycemia;Hyperlipidemias;Insulin;Insulin Secretion;Islets of Langerhans;Mice;Receptors, Muscarinic;Signal Transduction;Acetylcholine;Fatty Acids;Insulin Secretion;Islets of Langerhans",D02.092.211.111;B01.050;D08.811.913.696.620.682.700.140.600;D12.776.476.150.600;A11.251;D27.505.519.625.120;D27.505.696.577.120;C18.452.394.750.149;C19.246.300;D10.251;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;C18.452.584.500.500;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414;A06.300.414;B01.050.150.900.649.313.992.635.505.500;D12.776.543.750.695.475;D12.776.543.750.720.360.500;G02.111.820;G04.835;D02.092.211.111;D10.251;G03.442;G07.475;A03.734.414;A06.300.414
29031539,Fetus;Humans;Meningomyelocele;Pregnancy;Prenatal Care;Prenatal Diagnosis;Meningomyelocele;Neural Tube Defects;Prenatal Diagnosis;Spinal Dysraphism,A16.378;B01.050.150.900.649.313.988.400.112.400.400;C10.500.680.610;C16.131.666.680.610;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786;E01.370.378.630;C10.500.680.610;C16.131.666.680.610;C10.500.680;C16.131.666.680;E01.370.378.630;C10.500.680.800;C16.131.666.680.800
29031370,Diagnostic Imaging;Head and Neck Neoplasms;Humans;Lymph Nodes;Lymphatic Metastasis;Neck;Sensitivity and Specificity,E01.370.350;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;C04.697.650.560;C23.550.727.650.560;A01.598;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872
29031368,"Diagnosis, Differential;Diagnostic Imaging;Humans;Lymph Nodes;Lymphadenopathy;Lymphatic Diseases;Lymphatic Metastasis;Neck",E01.171;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;C15.604.338;C15.604;C04.697.650.560;C23.550.727.650.560;A01.598
29031122,"Adult;Humans;Memory, Short-Term;Middle Aged;Motivation;Pleasure;Reward;Schizophrenic Psychology;Self Efficacy;Young Adult;Schizophrenia;Delay Discounting",M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425.540.407;M01.060.116.630;F01.658;F01.752.543.500.750;F01.470.867;F02.830.816.492;F02.463.425.770.836;F04.824;F01.752.747.792.700;M01.060.116.815;F03.700.750;F02.463.785.373.346.700
29030843,"Argonaute Proteins;Base Pairing;Computational Biology;Drosophila Proteins;Gene Expression Profiling;Gene Library;High-Throughput Nucleotide Sequencing;Immunoprecipitation;MicroRNAs;RNA-Binding Proteins;Sequence Analysis, RNA;Software;Gene Silencing;Immunoprecipitation;RNA Processing, Post-Transcriptional;RNA-Binding Proteins;DNA, Complementary",D08.811.277.352.355.350.810.500;D08.811.277.352.700.350.810.500;D12.776.157.725.500.906.500;D12.776.664.962.500.906.500;G02.111.570.820.486.100;G02.111.611.500;G05.360.580.100;H01.158.273.180;L01.313.124;D12.776.093.500.462;E05.393.332;G05.360.325;E05.393.760.319;E05.196.150.639;E05.478.605;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.157.725;D12.776.664.962;E05.393.760.710;L01.224.900;G05.308.203.374;E05.196.150.639;E05.478.605;G02.111.760;G03.839;G05.308.700;D12.776.157.725;D12.776.664.962;D13.444.308.497.220;D13.444.600.223.500;D27.720.470.530.600.223.260
29030576,,
29030452,"Aged;Amyloid beta-Peptides;Apolipoproteins E;Case-Control Studies;Dopamine;Humans;Longitudinal Studies;Middle Aged;Parkinson Disease;Peptide Fragments;Polymorphism, Single Nucleotide;Retrospective Studies;Severity of Illness Index;Time Factors;Tomography, Emission-Computed, Single-Photon;tau Proteins",M01.060.116.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.644.541;G05.365.795.598;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E01.370.350.350.800.800;E01.370.350.600.350.800.800;E01.370.350.710.800.800;E01.370.350.825.800.800;E01.370.384.730.800.800;D12.776.220.600.450.510;D12.776.631.560.510
29030261,,
29030259,,
29030258,,
29030257,,
29030153,"Angiotensin-Converting Enzyme Inhibitors;Heart Failure;Homeostasis;Humans;Hyperkalemia;Hypertension;Hypokalemia;Kidney;Potassium, Dietary;Recommended Dietary Allowances;Renal Elimination;Renal Insufficiency, Chronic;Renin-Angiotensin System;United States;Heart Diseases;Hyperkalemia;Hypokalemia;Potassium;Renal Elimination;Review",D27.505.519.389.745.085;C14.280.434;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C18.452.950.396;C14.907.489;C18.452.950.565;A05.810.453;D01.745.775;G07.203.650.620.500;I01.655.500.608.400.650.500;I01.880.604.825.608.400.650.500;N03.623.500.608.428.650.500;G03.787.410;G07.690.725.609;G08.852.761;C12.777.419.780.750;C13.351.968.419.780.750;G03.820;G09.330.380.813;Z01.107.567.875;C14.280;C18.452.950.396;C18.452.950.565;D01.268.549.550;D01.268.557.575;D01.552.528.652;D01.552.547.650;G03.787.410;G07.690.725.609;G08.852.761;V02.600.500;V02.912
29029928,"Dysplastic Nevus Syndrome;Melanoma;Neoplasm Recurrence, Local;Skin Neoplasms",C04.557.665.560.260;C04.700.305;C16.320.700.305;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.697.655;C23.550.727.655;C04.588.805;C17.800.882
29029909,"Adolescent;Adult;Aged;Aged, 80 and over;Ambulatory Care Facilities;Health Services Accessibility;Humans;Medically Underserved Area;Middle Aged;Retrospective Studies;Skin Diseases;Telemedicine;Triage;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;N02.278.035;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.349.650.340;N05.300.450.520;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C17.800;H02.403.840;L01.178.847.652;N04.590.374.800;N02.421.297.900;M01.060.116.815
29029907,Acne Vulgaris;Adolescent;Adult;Cross-Sectional Studies;Humans;Mental Disorders;Sexual Behavior;United States;Young Adult,C17.800.030.150;C17.800.794.111;M01.060.057;M01.060.116;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;F03;F01.145.802;Z01.107.567.875;M01.060.116.815
29029808,"Angiotensin Receptor Antagonists;Angiotensin-Converting Enzyme Inhibitors;Congresses as Topic;Heart Failure;Homeostasis;Humans;Hyperkalemia;Hypertension;Hypokalemia;Potassium;Potassium, Dietary;Renal Insufficiency, Chronic;Societies, Medical;Potassium;Heart Diseases;Hyperkalemia;Hypokalemia;Renal Elimination;Review",D27.505.519.162;D27.505.519.389.745.085;N03.540.199;C14.280.434;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C18.452.950.396;C14.907.489;C18.452.950.565;D01.268.549.550;D01.268.557.575;D01.552.528.652;D01.552.547.650;D01.745.775;C12.777.419.780.750;C13.351.968.419.780.750;N03.540.828.589;D01.268.549.550;D01.268.557.575;D01.552.528.652;D01.552.547.650;C14.280;C18.452.950.396;C18.452.950.565;G03.787.410;G07.690.725.609;G08.852.761;V02.600.500;V02.912
29029250,Actigraphy;Activities of Daily Living;Adult;Aged;Body Mass Index;Circadian Rhythm;Cross-Sectional Studies;Humans;Independent Living;Middle Aged;Rest;Sleep;Actigraphy;Body Mass Index,E01.370.520.049;E05.003.500;E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116;M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;G07.180.562.190;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;I03.050.500;N01.224.791.550;N06.850.505.400.800.550;M01.060.116.630;I03.450.769.647;F02.830.855;G11.561.803;E01.370.520.049;E05.003.500;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175
29029188,Colombia;Klebsiella pneumoniae,Z01.107.757.284;B03.440.450.425.425.600;B03.660.250.150.400.590
29028998,,
29028952,"Airway Management;Child;Intubation, Intratracheal",E02.041;M01.060.406;E02.041.500;E02.585.578;E05.497.578
29028724,,
29028706,,
29028121,"Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological;Drug Eruptions;Humans;Melanoma;Middle Aged;Programmed Cell Death 1 Receptor;Skin Neoplasms",D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D27.505.954.248.384;C17.800.174.600;C20.543.206.380;C25.100.468.380;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;C04.588.805;C17.800.882
29027741,"Clinical Trials as Topic;Consensus;Hospitals, Pediatric;Humans;Incidence;Predictive Value of Tests;Primary Prevention;Pulmonary Embolism;Research Design;Risk Assessment;Risk Factors;Venous Thromboembolism;Venous Thrombosis",E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;F01.829.316.068;F02.463.785.373.433;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;N02.421.726.758;N06.850.780.680;C08.381.746;C14.907.355.350.700;E05.581.500;H01.770.644.728;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907.355.590.700;C14.907.355.830.925
29027711,Animals;Cattle;Cell Culture Techniques;Mesenchymal Stem Cells;Nanofibers;Phenotype;Plastics;Tissue Scaffolds;Cell Culture Techniques;Biophysics;Mesenchymal Stem Cells,B01.050;B01.050.150.900.649.313.500.380.271;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.329.830.500;A11.872.590.500;J01.637.512.300;G05.695;D05.750.716;D25.720.716;J01.637.051.720.716;E07.206.627;E07.695.825;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;H01.158.344;H01.671.100;A11.329.830.500;A11.872.590.500
29027067,"Ammonia;Biomarkers;Cell Transplantation;Europe;Humans;Hyperammonemia;Infant;Infant, Newborn;Liver;Liver Transplantation;Prospective Studies;Time Factors;Treatment Outcome;Urea;Urea Cycle Disorders, Inborn",D01.362.075;D01.625.050;D23.101;E02.095.147.500;E04.936.225;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;C23.550.421;M01.060.703;M01.060.703.520;A03.620;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.948;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937
29026625,Spirochaetales;Syphilis,B03.851;C01.252.400.840.744;C01.252.810.859;C01.252.847.840.744;C01.539.778.281.859;C12.294.668.281.859;C13.351.500.711.281.859
29026532,,
29026445,Bacteriophages;DNA;Metagenomics;Microbiota;Viruses,B04.123;D13.444.308;H01.158.273.343.350.261;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;B04
29025994,"Africa, Eastern;African Continental Ancestry Group;Animals;Antiporters;DNA-Binding Proteins;Ethnic Groups;Evolution, Molecular;Gene Flow;Genetic Loci;Genome, Human;Genome-Wide Association Study;Humans;Melanins;Melanocytes;Membrane Proteins;Mice;Polymorphism, Single Nucleotide;Radiation Exposure;Skin Pigmentation;Suppression, Genetic;Ultraviolet Rays",Z01.058.290.120;M01.686.508.100;B01.050;D12.776.157.530.450.162;D12.776.543.550.190;D12.776.543.585.450.162;D12.776.260;M01.686.754;N01.224.317;G05.045.250;G16.075.250;G05.330.159;G05.360.340.024.380;G05.360.340.350;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D12.125.072.050.875.379;D23.767.620;A11.409.750;A11.436.613;D12.776.543;B01.050.150.900.649.313.992.635.505.500;G05.365.795.598;G01.750.748;N06.850.460.350.850;E01.370.600.115.450.500;E01.370.600.620.750;G07.100.175.500;G13.750.837;G16.690.890;G05.365.590.835;G05.558.835;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
29025789,"Body Mass Index;Confidence Intervals;Fibroblast Growth Factors;Hypertrophy, Left Ventricular;Logistic Models;Odds Ratio;Prevalence;ErbB Receptors;Renal Insufficiency, Chronic;Adult;Cardiovascular Diseases;Child;Child;Renal Insufficiency, Chronic;Echocardiography;Humans;Hypertrophy, Left Ventricular;Risk Factors",E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;D12.644.276.624;D12.776.467.624;D23.529.624;C14.280.195.400;C23.300.775.250.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;C12.777.419.780.750;C13.351.968.419.780.750;M01.060.116;C14;M01.060.406;M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;C14.280.195.400;C23.300.775.250.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
29025761,"Chromatin;Chromosomes, Human, Pair 5;DiGeorge Syndrome;Genetic Loci;Genome-Wide Association Study;Genotype;High-Throughput Nucleotide Sequencing;Humans;Linkage Disequilibrium;MEF2 Transcription Factors;Oligonucleotide Array Sequence Analysis;Phenotype;Polymorphism, Single Nucleotide;Receptors, G-Protein-Coupled;Sequence Analysis, DNA;Tetralogy of Fallot;DiGeorge Syndrome;Chromosomes;Genotype;Tetralogy of Fallot",A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.284.187.520.300.280.290;G05.360.162.520.300.280.290;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.348.500;D12.776.210.500.570.294;D12.776.260.103.750.294;D12.776.260.400.249.624;D12.776.930.125.750.294;D12.776.930.397.700;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;G05.695;G05.365.795.598;D12.776.543.750.695;E05.393.760.700;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;G05.380;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
29024732,Dermatology;Fellowships and Scholarships;Internship and Residency;Time Factors;United States,H02.403.225;N03.219.483.838.276;I02.358.337.350.500;I02.358.399.350.750;G01.910.857;Z01.107.567.875
29024679,Brain;Connectome;Humans;Neural Pathways;Autistic Disorder;Diffusion Magnetic Resonance Imaging;Schizophrenia,A08.186.211;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;B01.050.150.900.649.313.988.400.112.400.400;A08.612;F03.625.164.113.500;E01.370.350.825.500.150;F03.700.750
29024567,"Animals;Bone and Bones;Disease Models, Animal;Femur;Glycoproteins;Immunohistochemistry;Knee Joint;Mice;Mice, Knockout;Osteoarthritis, Knee;Osteosclerosis;Stress, Mechanical;X-Ray Microtomography",B01.050;A02.835.232;A10.165.265;C22.232;E05.598.500;E05.599.395.080;A02.835.232.043.650.247;D09.400.430;D12.776.395;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;A02.835.583.475;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C05.550.114.606.500;C05.799.613.500;C05.116.099.708.702;G01.374.835;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900
29024363,Military Personnel;Population Health;Sleep Wake Disorders,M01.526.625;N01.400.548;C10.886;C23.888.592.796;F03.870
29024079,"Acne Vulgaris;Administration, Topical;Benzoyl Peroxide;Child;Dermatologic Agents;Humans;Keratolytic Agents;Microbiota;Phylogeny;Pilot Projects;Prospective Studies;Skin;Treatment Outcome;Tretinoin;Propionibacterium;Streptococcus;Acne Vulgaris;Microbiota;Microbiota",C17.800.030.150;C17.800.794.111;E02.319.267.120;D02.241.223.100.133;D02.455.426.559.389.127.133;M01.060.406;D27.505.954.444;B01.050.150.900.649.313.988.400.112.400.400;D27.505.954.444.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G05.697;G16.075.605;L01.100.697;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A17.815;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780;B03.510.024.049.600.600;B03.510.460.400.400.600.600;B03.353.750.737.872;B03.510.400.800.872;B03.510.550.737.872;C17.800.030.150;C17.800.794.111;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
29023970,"Electronic Health Records;Gene Frequency;Genome-Wide Association Study;Genotype;Humans;Models, Genetic;Odds Ratio;Phenotype;Polymorphism, Single Nucleotide",E05.318.308.940.968.625.500;G05.330;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G05.695;G05.365.795.598
29023737,Animals;Homeostasis;Humans;Mitochondria;Oxidative Phosphorylation;Energy Metabolism;Exercise;Oxidative Phosphorylation,B01.050;G07.410;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.665.550;G03.295.631;G03.796.550;G03.295;G11.427.410.698.277;I03.350;G02.111.665.550;G03.295.631;G03.796.550
29023707,Animals;Cell Proliferation;Cell Separation;DNA;False Positive Reactions;Flow Cytometry;Guidelines as Topic;Humans;Immunologic Techniques;Immunophenotyping;Quality Control;RNA;Research Design;Software;T-Lymphocytes,B01.050;G04.161.750;G07.345.249.410.750;E01.370.225.500.363;E05.200.500.363;E05.242.363;D13.444.308;E01.354.506;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;E05.478;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;J01.897.608;D13.444.735;E05.581.500;H01.770.644.728;L01.224.900;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
29023576,"Alkaline Phosphatase;Animals;Blood Chemical Analysis;Body Weight;Calcification, Physiologic;Cells, Cultured;Core Binding Factor Alpha 1 Subunit;Coronary Artery Disease;Coronary Vessels;Cytokines;Diet, Atherogenic;Disease Models, Animal;Echocardiography;Endothelial Cells;Endothelium, Vascular;Enzyme Inhibitors;Humans;Hyperlipoproteinemia Type II;Immunohistochemistry;Mice;Mice, Inbred C57BL;Mice, Transgenic;Myocardium;Placebo Effect;Receptors, LDL;Ventricular Function, Left",D08.811.277.352.650.035;B01.050;E01.370.225.124.100;E05.200.124.100;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;G07.345.155.500;G07.345.500.325.377.625.050.500.175;G11.427.578.050.500.175;A11.251;D12.776.930.155.200.100;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;A07.015.114.269;A07.015.908.194;D12.644.276.374;D12.776.467.374;D23.529.374;G07.203.650.240.242;C22.232;E05.598.500;E05.599.395.080;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A11.436.275;A07.015.700.500;A10.272.491.355;D27.505.519.389;B01.050.150.900.649.313.988.400.112.400.400;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A02.633.580;A07.541.704;A10.690.552.750;N05.715.350.350.625;N06.850.490.734.875;D12.776.543.750.710.450;G09.330.955.800
29023549,"Antibodies, Neutralizing;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;HIV Infections;HIV-1;Humans;Recoverin;Signal Transduction;Virus Replication",D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360.372.500.750;D12.776.157.125.412.500.750;D12.776.306.750;D12.776.476.387.500.750;D12.776.631.645.750;G02.111.820;G04.835;G06.920.925
29023307,"Brain;Child;Child, Preschool;Cohort Studies;Critical Care;Electroencephalography;Heart Arrest;Humans;Infant;Observer Variation;Prospective Studies;Terminology as Topic",A08.186.211;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.760.190;N02.421.585.190;E01.370.376.300;E01.370.405.245;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;L01.559.598.400
29023266,Centromere;Duodenum;Face;Humans;Immunologic Deficiency Syndromes;Infant;Inflammatory Bowel Diseases;Mutation;Repressor Proteins;Whole Exome Sequencing,A11.284.430.106.279.345.190.160.165;G05.360.160.165;A03.556.124.684.124;A03.556.875.249;A01.456.505;B01.050.150.900.649.313.988.400.112.400.400;C20.673;M01.060.703;C06.405.205.731;C06.405.469.432;G05.365.590;D12.776.260.703;D12.776.930.780;E05.393.760.700.825.500
29023244,"Curriculum;Education, Medical, Graduate;Health Equity;Healthcare Disparities;Humans;Quality Improvement",I02.158;I02.358.337.350;I02.358.399.350;N04.590.374.350.500;N05.300.430.383;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;J01.293.754;N04.761.744
29022879,"Anatomy, Regional;Animals;Mice;Nociception;Nociceptors;Receptors, G-Protein-Coupled;Skin;Mice;Neurosciences;Nociceptors",H01.158.100.216;B01.050;B01.050.150.900.649.313.992.635.505.500;F02.463.593.504.500;A08.675.650.915.875;A08.800.950.875;A11.671.650.915.875;D12.776.543.750.695;A17.815;B01.050.150.900.649.313.992.635.505.500;H01.158.610;A08.675.650.915.875;A08.800.950.875;A11.671.650.915.875
29022776,,
29022597,"Alleles;Chromosomes, Human;Disease;Gene Expression Profiling;Gene Expression Regulation;Genetic Variation;Genome, Human;Genotype;Humans;Organ Specificity;Quantitative Trait Loci",G05.360.340.024.340.030;A11.284.187.520.300;G05.360.162.520.300;C23.550.288;E05.393.332;G05.308;G05.365;G05.360.340.350;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G07.650;G05.360.340.024.380.937
29022199,Autism Spectrum Disorder;Epidemiology;Wounds and Injuries;Prevalence,F03.625.164.113;H02.403.720.500;C26;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
29021889,Adolescent;Autism Spectrum Disorder;Child;Communication;Humans;Language;Sensitivity and Specificity;Sex Factors;Social Behavior;Verbal Behavior;Autistic Disorder;Language;Sex Characteristics,M01.060.057;F03.625.164.113;M01.060.406;F01.145.209;L01.143;B01.050.150.900.649.313.988.400.112.400.400;F01.145.209.399;L01.559;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;N05.715.350.675;N06.850.490.875;F01.145.813;F01.145.209.908;F03.625.164.113.500;F01.145.209.399;L01.559;G08.686.815
29021841,"Arrhythmias, Cardiac;Atrial Fibrillation;Atrial Flutter;Catheter Ablation;Stroke",C14.280.067;C23.550.073;C14.280.067.198;C23.550.073.198;C14.280.067.248;C23.550.073.248;E02.808.750.500;E04.014.760.500;C10.228.140.300.775;C14.907.253.855
29021631,,
29021578,,
29021228,"Child, Preschool;Genotype;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Immune Reconstitution;Infant;Infant, Newborn;Infection;Neonatal Screening;Prospective Studies;Risk Factors;Severe Combined Immunodeficiency;Survival Analysis;Tissue Donors",M01.060.406.448;G05.380;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;G12.432;M01.060.703;M01.060.703.520;C01.539;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C16.614.815;C18.452.284.800;C20.673.815;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;M01.898
29020994,"Adolescent;Adult;Aged;Attitude of Health Personnel;Comparative Effectiveness Research;Health Knowledge, Attitudes, Practice;Humans;Informed Consent;Kidney Failure, Chronic;Logistic Models;Middle Aged;Patient Selection;Pragmatic Clinical Trials as Topic;Professional Autonomy;Renal Dialysis;Research Personnel;Research Subjects;Sample Size;Young Adult;Comparative Effectiveness Research;Ethics;Informed Consent;Pragmatic Clinical Trial;Standard of Care",M01.060.057;M01.060.116;M01.060.116.100;F01.100.050;N05.300.100;H01.770.644.145.360.500;N05.425.157;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.581.500.653;N04.590.731;E05.318.372.250.250.365.500.750;N05.715.360.330.250.250.365.500.750;N06.850.520.450.250.250.365.500.750;N04.452.758.752;E02.870.300;E02.912.800;M01.526.839;M01.774;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;M01.060.116.815;H01.770.644.145.360.500;N05.425.157;K01.752.566.479;N05.350;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;V03.175.250.500.500.500;N04.761.789.900;N05.715.840
29020695,,
29020416,,
29020338,HIV;Hepatitis C;Liver Cirrhosis,B04.820.650.589.650.350;C02.440.440;C02.782.350.350;C06.552.380.705.440;C06.552.630
29020232,"Activities of Daily Living;Aged, 80 and over;Aortic Valve Stenosis;Echocardiography;Humans;Hypertension, Pulmonary;Hypertrophy, Left Ventricular;Prognosis;Retrospective Studies;Risk Assessment;Transcatheter Aortic Valve Replacement;Ventricular Dysfunction, Left;Ventricular Dysfunction, Right;Aortic Valve Stenosis;Aortic Valve;Classification;Transcatheter Aortic Valve Replacement;Transcatheter Aortic Valve Replacement",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100.080;C14.280.484.150;C14.280.955.249;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;C14.280.195.400;C23.300.775.250.400;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;C14.280.945.900;C14.280.945.910;C14.280.484.150;C14.280.955.249;A07.541.510.110;L01.100;L01.453.245.275;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
29020184,"Chemical and Drug Induced Liver Injury;HIV Infections;Hepatitis C, Chronic;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Incidence;Middle Aged;Retrospective Studies;Risk Factors;HIV;Hepatitis C;Hydroxymethylglutaryl-CoA Reductase Inhibitors",C06.552.100;C25.100.562;C25.723.260;C02.782.815.616.400;C02.800.801.400;C20.673.480;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;B04.820.650.589.650.350;C02.440.440;C02.782.350.350;C06.552.380.705.440;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
29020116,"Adiponectin;Adolescent;Asian Continental Ancestry Group;Beijing;Biomarkers;Child;Child, Preschool;Confidence Intervals;Humans;Leptin;Metabolic Syndrome;Odds Ratio;Puberty",D06.472.699.042.249;D12.644.276.024.249;D12.644.548.011.249;D12.776.467.024.249;D23.529.024.249;M01.060.057;M01.686.508.200;Z01.252.474.164.225;Z01.433.114;D23.101;M01.060.406;M01.060.406.448;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;C18.452.394.968.500.570;C18.452.625;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G08.686.760;G08.686.841.374
29019815,"Anesthesia, General;Brain;Cerebrovascular Circulation;Humans;Infant;Internationality;Intraoperative Neurophysiological Monitoring;Oximetry;Prospective Studies;Single-Blind Method",E03.155.197;A08.186.211;G09.330.100.159;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I01.615;E01.370.520.510.500;E01.370.520.596.500;E04.510.500;E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850
29019760,Child;Contrast Media;Humans;Lymphatic Diseases;Lymphatic System;Magnetic Resonance Imaging,M01.060.406;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;C15.604;A15.382.520;E01.370.350.825.500
29019752,Child;Contrast Media;Humans;Infant;Ultrasonography;Urination,M01.060.406;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.850;G08.852.880
29019750,"Child;Contrast Media;Diagnosis, Differential;Humans;Liver Diseases;Ultrasonography",M01.060.406;D27.505.259.500;D27.720.259;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C06.552;E01.370.350.850
29019651,"Animals;Biomarkers, Tumor;Cell Line, Tumor;Exosomes;Humans;Machine Learning;Mice;Microfluidic Analytical Techniques;Pancreatic Neoplasms;Proteomics;RNA, Messenger;Exosomes;Machine Learning;Pancreatic Neoplasms",B01.050;D23.101.140;A11.251.210.190;A11.251.860.180;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;B01.050.150.900.649.313.992.635.505.500;E05.588.465;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;D13.444.735.544;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;G17.035.250.500;L01.224.050.375.530;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
29019615,"Adolescent;Cardiac Output, Low;Cardiomyopathies;Child;Child, Preschool;Chronic Disease;Clinical Deterioration;Heart Failure;Heart Ventricles;Hemodynamics;Humans;Infant;Infant, Newborn",M01.060.057;C14.280.148;C23.888.192;C14.280.238;M01.060.406;M01.060.406.448;C23.550.291.500;C23.550.291.656.350;C14.280.434;A07.541.560;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520
29018798,,
29018779,"Gene Regulatory Networks;Obesity;Sequence Analysis, RNA;Medicine, Traditional",G05.360.080.689.360;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.393.760.710;E02.190.488;I01.076.201.450.654
29018178,General Surgery,H02.403.810.300
29018102,Internal Medicine;Nephrologists;Specialty Boards;Nephrology,H02.403.429;M01.526.485.810.628;N02.360.810.628;N03.706.110.120.580;N05.700.200.190.750;H02.403.429.580
29018078,Animals;Genetic Therapy;Half-Life;Hemophilia A;Humans;Treatment Outcome,B01.050;E02.095.301;E05.393.420.301;G01.910.405;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;B01.050.150.900.649.313.988.400.112.400.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
29018035,Coronary Disease,C14.280.647.250;C14.907.585.250
29017958,Delivery of Health Care;Pharmaceutical Preparations;Pharmacy,N04.590.374;N05.300;D26;H02.646
29017081,"Acetamides;Adolescent;Anticonvulsants;Child;Child, Preschool;Cohort Studies;Critical Illness;Electroencephalography;Epilepsy;Humans;Infant;Infant, Newborn;Injections, Intravenous;Lacosamide;Retrospective Studies;Lacosamide;Seizures;Status Epilepticus",D02.065.064;D02.241.081.018.110;M01.060.057;D27.505.954.427.080;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.625;E01.370.376.300;E01.370.405.245;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.319.267.082.750;E02.319.267.530.540;D02.065.064.416;D02.241.081.018.110.432;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D02.065.064.416;D02.241.081.018.110.432;C10.597.742;C23.888.592.742;C10.597.742.785;C23.888.592.742.785
29016845,"Adult;Animals;Brain Neoplasms;Child;Disease Models, Animal;Glioma;Humans;Neoplasm Grading;Pathology, Molecular;Treatment Outcome;Pathology, Molecular",M01.060.116;B01.050;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;C22.232;E05.598.500;E05.599.395.080;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;E01.789.612;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505
29016841,"Atrial Fibrillation;Cardiac Catheterization;Catheter Ablation;Consensus;Cryosurgery;Humans;Risk Factors;Treatment Outcome;Arrhythmias, Cardiac;Atrial Fibrillation;Atrial Flutter;Catheter Ablation;Stroke",C14.280.067.198;C23.550.073.198;E01.370.370.380.140;E02.148.442;E05.157.250;E02.808.750.500;E04.014.760.500;F01.829.316.068;F02.463.785.373.433;E04.014.180;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.067;C23.550.073;C14.280.067.198;C23.550.073.198;C14.280.067.248;C23.550.073.248;E02.808.750.500;E04.014.760.500;C10.228.140.300.775;C14.907.253.855
29016840,"Atrial Fibrillation;Cardiac Catheterization;Catheter Ablation;Consensus;Cryosurgery;Humans;Risk Factors;Treatment Outcome;Arrhythmias, Cardiac;Atrial Fibrillation;Atrial Flutter;Catheter Ablation;Stroke",C14.280.067.198;C23.550.073.198;E01.370.370.380.140;E02.148.442;E05.157.250;E02.808.750.500;E04.014.760.500;F01.829.316.068;F02.463.785.373.433;E04.014.180;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.067;C23.550.073;C14.280.067.198;C23.550.073.198;C14.280.067.248;C23.550.073.248;E02.808.750.500;E04.014.760.500;C10.228.140.300.775;C14.907.253.855
29016658,"Acetylation;Acetyltransferases;Amino Acid Motifs;Binding Sites;Cloning, Molecular;Escherichia coli;Gene Expression;Kinetics;Models, Molecular;Protein Binding;Protein Biosynthesis;Protein Conformation, alpha-Helical;Protein Interaction Domains and Motifs;Protein Processing, Post-Translational;Protein Subunits;Recombinant Proteins;Ribosomes;Schizosaccharomyces;Schizosaccharomyces pombe Proteins;Substrate Specificity",G02.111.012.052;G02.607.063.052;G03.040.052;D08.811.913.050.134;G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;G02.111.570.120;E05.393.220;B03.440.450.425.325.300;B03.660.250.150.180.100;G05.297;G01.374.661;G02.111.490;E05.599.595;G02.111.679;G03.808;G02.111.660.871;G03.734.871;G05.297.670;G02.111.570.820.709.600.020;G02.111.570.820.709.275.750.500;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D12.776.813;D12.776.828;A11.284.430.214.190.875.811;B01.300.107.797;B01.300.930.720;D12.776.354.875;G02.111.835
29016432,,
29016429,"Bone Neoplasms;Child;Exostoses, Multiple Hereditary;Follow-Up Studies;Forecasting;Humans;Magnetic Resonance Imaging;Osteochondroma;Retrospective Studies;Thoracic Vertebrae",C04.588.149;C05.116.231;M01.060.406;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;I01.320;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04.557.450.565.575.610;C05.116.099.708.670;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.834.892
29016426,"Birth Injuries;Brachial Plexus;Brachial Plexus Neuropathies;Cesarean Section;Child;Dystocia;Humans;Incidence;Infant;Infant, Newborn;Logistic Models;Odds Ratio;Pregnancy;Prospective Studies;Risk Factors;United States",C16.614.131;C26.141;A08.800.800.720.050;C10.668.829.100;E04.520.252.500;M01.060.406;C13.703.420.288;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G08.686.784.769;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28993713,Bromthymol Blue;Bromine;Fluorine,D02.455.426.559.389.832.200;D02.455.849.575.875.200;D02.886.590.887.200;D01.268.380.112;D01.268.380.300
28993650,,
28993187,Diabetes Mellitus;Epidemiology;Mass Screening,C18.452.394.750;C19.246;H02.403.720.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
28992828,"African Americans;Child, Preschool;European Continental Ancestry Group;Humans;Sleep Wake Disorders;Socioeconomic Factors;United States;Urban Population;Sleep Initiation and Maintenance Disorders;Sleep Apnea, Obstructive;Continental Population Groups;Sleep",M01.686.508.100.100;M01.686.754.100;M01.060.406.448;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;C10.886;C23.888.592.796;F03.870;I01.880.853.996;N01.824;Z01.107.567.875;N01.600.900;C10.886.425.800.800;F03.870.400.800.800;C08.618.085.852.850;C10.886.425.800.750.850;M01.686.508;F02.830.855;G11.561.803
28992380,Graft Survival,G12.875.545.340
28992328,"Acute Disease;Adolescent;Adult;Anti-Bacterial Agents;Child;Child, Preschool;Drug Resistance, Microbial;Health Knowledge, Attitudes, Practice;Humans;Inappropriate Prescribing;Interviews as Topic;Middle Aged;Parents;Pediatricians;Practice Patterns, Physicians';Respiratory Tract Infections;Risk Assessment;Treatment Failure;Young Adult",C23.550.291.125;M01.060.057;M01.060.116;D27.505.954.122.085;M01.060.406;M01.060.406.448;G06.225;G07.690.773.984.269;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;E02.319.490;N02.421.450.500.249;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;M01.526.485.810.758;N02.360.810.758;N04.590.374.577;N05.300.625;C01.539.739;C08.730;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;M01.060.116.815
28992317,"Adolescent;Empyema, Pleural;Hematopoietic Stem Cell Transplantation;Humans;Immunocompromised Host;Lung Transplantation;Mycoplasma Infections;Mycoplasma hominis;Mycoplasma hominis;Immunocompromised Host",M01.060.057;C01.539.739.484;C01.539.830.305.310;C08.528.240;C08.730.265;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E04.928.600.495;E04.936.450.495;C01.252.400.610.610;B03.440.860.580.553.553.400;B03.440.860.580.553.553.400;G12.470
28992298,"Adolescent;Antifungal Agents;Bone Marrow Diseases;Child;Child, Preschool;Drug Eruptions;Glucocorticoids;Humans;Immunocompromised Host;Incidence;Infant;Infant, Newborn;Opportunistic Infections;Pneumocystis carinii;Pneumonia, Pneumocystis;Retrospective Studies;Trimethoprim, Sulfamethoxazole Drug Combination",M01.060.057;D27.505.954.122.136;C15.378.190;M01.060.406;M01.060.406.448;C17.800.174.600;C20.543.206.380;C25.100.468.380;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;C01.539.597;C02.597;C03.684;B01.300.107.730.650;C01.703.534.700;C01.703.770.700;C08.381.472.700;C08.381.677.675;C08.730.435.700;C08.730.610.675;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D02.065.884.725.867.500;D02.092.146.807.867.500;D02.886.590.700.725.867.500;D03.383.742.906.500;D26.310.875
28992290,"Adolescent;Antifungal Agents;Child;Child, Preschool;Humans;Immunocompromised Host;Immunosuppressive Agents;Incidence;Infant;Invasive Fungal Infections;Organ Transplantation;Pennsylvania;Postoperative Complications;Retrospective Studies;Risk Factors",M01.060.057;D27.505.954.122.136;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;G12.470;D27.505.696.477.656;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;C01.703.492;E04.936.450;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28992265,"Antiviral Agents;Child, Preschool;Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18;Humans;Papillomavirus Infections;Respiratory Tract Infections;Recurrence",D27.505.954.122.388;M01.060.406.448;D20.215.894.899.498.500;B01.050.150.900.649.313.988.400.112.400.400;C02.256.650;C02.928.725;C01.539.739;C08.730;C23.550.291.937
28992185,"Anti-Infective Agents;Benchmarking;Child;Databases, Factual;Drug Prescriptions;Drug Utilization Review;Hospital Charges;Hospital Records;Hospitals, Pediatric;Humans;Medical Records Systems, Computerized;Retrospective Studies;United States",D27.505.954.122;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;E02.319.307;N02.421.668.778.500;N04.452.706.477.400;N04.761.879.300;N05.700.900.300;N03.219.262.300;N03.219.442.613;E05.318.308.940.425;L01.399.250.900.425;N04.452.859.380;N05.715.360.300.715.380;N06.850.520.308.940.425;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.940.968.625;L01.313.500.750.300.695;N04.452.859.564.650;N05.715.360.300.715.500.530;N06.850.520.308.940.968.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28992126,"Anti-Bacterial Agents;Area Under Curve;Bacteremia;Child;Child, Preschool;Humans;Infant;Methicillin-Resistant Staphylococcus aureus;Microbial Sensitivity Tests;Retrospective Studies;Staphylococcal Infections;Vancomycin",D27.505.954.122.085;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.252.410.868;D09.400.420.925;D12.644.233.925
28991947,"Adolescent;Asthma;Child;Child, Preschool;Costs and Cost Analysis;Geography, Medical;Hospital Costs;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Intensive Care Units;Length of Stay;Retrospective Studies;United States",M01.060.057;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;N03.219.151;H01.277.500.097;H02.403.352;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28991918,"Anti-Bacterial Agents;Anti-Infective Agents;Bacteria;Bacterial Infections;Botswana;Child, Preschool;Diarrhea;Humans;Infant;Lactobacillus reuteri;Pilot Projects;Probiotics;Treatment Outcome",D27.505.954.122.085;D27.505.954.122;B03;C01.252;Z01.058.290.175.230;M01.060.406.448;C23.888.821.214;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;B03.353.750.450.475.680;B03.510.460.400.410.475.475.680;B03.510.550.450.475.680;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G07.203.300.456.500;J02.500.456.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28991884,Adolescent;Case Management;Cohort Studies;Continuity of Patient Care;Counseling;HIV Infections;Humans;Patient Compliance;Sexual and Gender Minorities;United States;Young Adult,M01.060.057;N04.590.233.624.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.760.169;N02.421.585.169;N04.590.233.727.210;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;M01.777;Z01.107.567.875;M01.060.116.815
28991832,"Adolescent;Biomarkers;Child;Child, Preschool;Cohort Studies;Diagnosis, Differential;Humans;Infant;Intensive Care Units, Pediatric;Predictive Value of Tests;Prospective Studies;ROC Curve;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Risk Assessment;Sepsis",M01.060.057;D23.101;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.171;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C01.539.757;C23.550.470.790.500
28991375,"Algorithms;Computer Simulation;Data Interpretation, Statistical;Humans;Microbiota;Nasopharynx;Oropharynx;Poisson Distribution;Microbiota",G17.035;L01.224.050;L01.224.160;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;B01.050.150.900.649.313.988.400.112.400.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A04.623.557;A14.724.557;A04.623.603;A14.724.603;E05.318.740.994.750;G17.820.750;N05.715.360.750.750.620;N06.850.520.830.994.750;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
28991257,"Adult;Autistic Disorder;Cardiac Myosins;Case-Control Studies;Child;Exome;Gene Expression;Genetic Predisposition to Disease;Genome-Wide Association Study;Growth Differentiation Factor 1;Heart Defects, Congenital;Heterozygote;High-Throughput Nucleotide Sequencing;Homozygote;Humans;Mutation;Myosin Heavy Chains;Pedigree;Risk;Vascular Endothelial Growth Factor Receptor-3",M01.060.116;F03.625.164.113.500;D05.750.078.730.475.475.124;D08.811.277.040.025.193.750.750.124;D12.776.210.500.600.470.249;D12.776.220.525.475.475.124;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;G05.360.340.011;G05.297;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.644.276.954.300.100;D12.644.276.954.550.100;D12.776.467.942.300.100;D12.776.467.942.550.100;D23.529.942.300.100;D23.529.942.550.100;C14.240.400;C14.280.400;C16.131.240.400;G05.380.383;E05.393.760.319;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D05.750.078.730.475.100;D08.811.277.040.025.193.750.249;D12.776.210.500.600.100;D12.776.220.525.475.100;E05.393.673;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;D08.811.913.696.620.682.725.400.950.300;D12.776.543.750.630.750.300;D12.776.543.750.750.400.910.300
28990967,"Adult;Cardiovascular Nursing;Critical Care;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Mothers;Stress, Psychological;Young Adult",M01.060.116;H02.478.676.112;N02.421.533.099;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.145.126.990;F02.830.900;M01.060.116.815
28990583,,
28990430,"Emergency Service, Hospital",N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336
28990359,"African Americans;Alcoholism;Alleles;European Continental Ancestry Group;Genetic Loci;Genetic Markers;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Polymorphism, Single Nucleotide;Risk-Taking;Sex Factors;Alcoholism;Unsafe Sex",M01.686.508.100.100;M01.686.754.100;C25.775.100.250;F03.900.100.350;G05.360.340.024.340.030;M01.686.508.400;G05.360.340.024.380;D23.101.387;G05.695.450;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;F01.145.722;N05.715.350.675;N06.850.490.875;C25.775.100.250;F03.900.100.350;F01.145.802.987
28989947,Pelvic Neoplasms;Protons;Re-Irradiation;Vaginal Neoplasms,C04.588.699;D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500;E02.815.791;E02.887.500;C04.588.945.418.955;C13.351.500.894.834;C13.351.937.418.937
28989859,Trichotillomania,F03.250.800
28989103,"Adult;Age Factors;Antimalarials;Chloroquine;Cohort Studies;Databases, Factual;Dermatomyositis;Dose-Response Relationship, Drug;Drug Administration Schedule;Drug Eruptions;Follow-Up Studies;Humans;Hydroxychloroquine;Incidence;Lupus Erythematosus, Cutaneous;Middle Aged;Proportional Hazards Models;Retrospective Studies;Risk Assessment;Sex Factors;Treatment Outcome;Chloroquine;Lupus Erythematosus, Cutaneous;Dermatomyositis;Hydroxychloroquine;Quinacrine",M01.060.116;N05.715.350.075;N06.850.490.250;D27.505.954.122.250.100.085;D03.633.100.810.050.180;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;G07.690.773.875;G07.690.936.500;E02.319.283;C17.800.174.600;C20.543.206.380;C25.100.468.380;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.810.050.180.350;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C17.300.475;C17.800.480;M01.060.116.630;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N05.715.350.675;N06.850.490.875;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D03.633.100.810.050.180;C17.300.475;C17.800.480;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;D03.633.100.810.050.180.350;D03.633.300.046.250.760
28988966,"Animals;Antidepressive Agents, Second-Generation;Barrington's Nucleus;Collagen;Corticotropin-Releasing Hormone;Fluoxetine;Mice, Inbred C57BL;Organ Size;Proteome;RNA, Messenger;Random Allocation;Social Behavior;Stress, Psychological;Urinary Bladder;Urination",B01.050;D27.505.954.427.700.122.050;A08.186.211.132.810.428.600.067;D05.750.078.280;D12.776.860.300.250;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;D02.092.831.280;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;D12.776.817;D13.444.735.544;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;F01.145.813;F01.145.126.990;F02.830.900;A05.810.890;G08.852.880
28988415,Ambulatory Care;Humans;Middle Aged;Patient Safety;Quality Improvement;Retrospective Studies;Risk Factors;Thyroidectomy;United States;Ambulatory Surgical Procedures;Postoperative Complications,E02.760.106;N02.421.585.106;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N06.850.135.060.075.399;J01.293.754;N04.761.744;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.270.856;Z01.107.567.875;E04.030;C23.550.767
28988309,"Angiography;Cardiac Catheterization;Child, Preschool;Collateral Circulation;Echocardiography;Embolization, Therapeutic;Fontan Procedure;Heart Ventricles;Hemodynamics;Humans;Hypoplastic Left Heart Syndrome;Infant;Palliative Care;Pulmonary Artery;Hypoplastic Left Heart Syndrome",E01.370.350.700.060;E01.370.370.050;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406.448;G09.330.100.248;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E02.520.360;E02.926.500;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;A07.541.560;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703;E02.760.666;N02.421.585.666;A07.015.114.715;C14.240.400.625;C14.280.400.625;C16.131.240.400.625
28988207,"Absorptiometry, Photon;Adolescent;Adult;Anthropometry;Cross-Sectional Studies;Exercise;Fontan Procedure;Humans;Leg;Muscle, Skeletal;Oxygen Consumption;Prospective Studies;Thinness;Young Adult",E01.370.350.700.024;E05.196.712.224.187;M01.060.057;M01.060.116;E01.370.600.024;E05.041;N06.850.505.200.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G11.427.410.698.277;I03.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.500;A02.633.567;A10.690.552.500;G03.680;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C23.888.144.828;E01.370.600.115.100.160.120.828;G07.100.100.160.120.828;M01.060.116.815
28988167,"Aged;Benzodiazepines;Choice Behavior;Health Promotion;Health Risk Behaviors;Humans;Middle Aged;Motivation;Patient Preference;Patient Selection;Substance-Related Disorders;Economics, Behavioral;Benzodiazepines",M01.060.116.100;D03.633.100.079.080;F02.463.785.373.346;I02.233.332.445;N02.421.726.407.579;F01.145.488.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.658;F01.752.543.500.750;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;E05.581.500.653;N04.590.731;C25.775;F03.900;F04.096.628.286;N03.219.215;D03.633.100.079.080
28988140,,
28988139,,
28988137,"Dermatitis, Phototoxic",C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225
28987648,"Adult;Cognitive Behavioral Therapy;Comprehension;Depression;Depressive Disorder, Major;Fluoxetine;Humans;Middle Aged;Motor Skills;Outpatients;Recurrence;Cognitive Behavioral Therapy;Depression",M01.060.116;F04.754.137.350;F02.463.188.357;F01.145.126.350;F03.600.300.375;D02.092.831.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F02.808.260;M01.643.630;C23.550.291.937;F04.754.137.350;F01.145.126.350
28987478,Hepatopulmonary Syndrome,C06.552.455;C08.381.385
28987397,"Adolescent;Adult;Benchmarking;Cardiac Surgical Procedures;Child;Child, Preschool;Hospital Mortality;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Postoperative Care;Postoperative Complications;Quality Assurance, Health Care;Registries;Respiration, Artificial;Risk Factors;Young Adult",M01.060.057;M01.060.116;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;E04.100.376;E04.928.220;M01.060.406;M01.060.406.448;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E02.760.731.700;E04.604.500;N02.421.585.722.700;C23.550.767;N04.761.700;N05.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E02.041.625;E02.365.647.729;E02.880.820;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28987392,,
28987244,Racism,F01.145.813.550.500;F01.145.813.629.625;F01.829.595.500;I01.880.735.820.500.500
28987191,"Brain;Brain Diseases;Fetal Diseases;Humans;Infant, Newborn;Nervous System Malformations;Pregnancy;Child;Fetus;Infant;Neuropathology",A08.186.211;C10.228.140;C13.703.277;C16.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C10.500;C16.131.666;G08.686.784.769;M01.060.406;A16.378;M01.060.703;H01.158.610.184;H02.403.600.250;H02.403.650.375
28986986,"Myositis Ossificans;Ossification, Heterotopic",C05.651.594.638;C23.550.751
28986842,"Animals;Antibodies, Monoclonal;Disease Models, Animal;Guinea Pigs;Hemorrhagic Fever with Renal Syndrome;Hemorrhagic Fever, Ebola;Mice;Primates;Guinea Pigs;Antibodies, Monoclonal",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.992.550;C02.782.147.420.400;C02.782.417.300;C02.782.417.415;C02.782.580.250.400;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.988;B01.050.150.900.649.313.992.550;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
28986577,"Adaptor Proteins, Signal Transducing;Apoptosis;Cell Line;Cell Survival;Defective Viruses;Gene Knockout Techniques;Genome, Viral;Humans;Paramyxoviridae;Receptors, Tumor Necrosis Factor, Type II;Respiratory Syncytial Virus Infections;Respiratory Syncytial Viruses;Respirovirus Infections;Sendai virus;Signal Transduction;TNF Receptor-Associated Factor 1;Tumor Necrosis Factor-alpha;Virus Replication",D12.644.360.024;D12.776.157.057;D12.776.476.024;G04.146.160;A11.251.210;G04.346;B04.265;E05.393.335.750;G05.360.340.358.840;B01.050.150.900.649.313.988.400.112.400.400;B04.820.455.600;D12.776.543.750.705.852.760.798;C02.782.580.600.550.750;B04.820.455.600.670.600.750;C02.782.580.600.600;B04.820.455.600.650.700.800;G02.111.820;G04.835;D12.644.360.024.500.500;D12.776.157.057.500.500;D12.776.476.024.500.500;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;G06.920.925
28986467,Age Factors;Amyloid beta-Peptides;Biomarkers;Disease Progression;Early Diagnosis;Humans;Longitudinal Studies;Middle Aged;Parkinson Disease;Prevalence;Prospective Studies;Severity of Illness Index;Sex Factors;Biomarkers;Parkinson Disease,N05.715.350.075;N06.850.490.250;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D23.101;C23.550.291.656;E01.390;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N05.715.350.675;N06.850.490.875;D23.101;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28986461,"Alzheimer Disease;Animals;Brain;Disease Models, Animal;Green Fluorescent Proteins;Humans;Injections, Intraventricular;Mice;Mutation;Neurons;Recombinant Proteins;tau Proteins;Alzheimer Disease;Tauopathies",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;B01.050;A08.186.211;C22.232;E05.598.500;E05.599.395.080;D12.776.532.265;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.550;B01.050.150.900.649.313.992.635.505.500;G05.365.590;A08.675;A11.671;D12.776.828;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.574.945
28986451,"False Positive Reactions;Genetic Diseases, Inborn;Humans;Models, Genetic;Observer Variation;Alleles;Confidence Intervals;Genetic Association Studies;Risk;Sample Size;Selection Bias",E01.354.506;C16.320;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;G05.360.340.024.340.030;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;E05.393.385;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;N05.715.350.150.775;N06.850.490.500.500
28986383,"Animals;Cell Line, Tumor;Cell Transformation, Neoplastic;Cells, Cultured;Chelating Agents;Copper;Drug Resistance, Neoplasm;Humans;MAP Kinase Signaling System;Melanoma;Melanoma, Experimental;Mice, Knockout;Mice, Transgenic;Molybdenum;Mutation;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf;Survival Analysis",B01.050;A11.251.210.190;A11.251.860.180;C04.697.098.500;C23.550.727.098.500;A11.251;D27.505.519.914.500;D27.720.832.500;D01.268.556.195;D01.268.956.170;D01.552.544.195;G07.690.773.984.395;B01.050.150.900.649.313.988.400.112.400.400;G02.111.820.560;G03.493.560;G04.835.560;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.557.465.625.650.510.525;C04.557.580.625.650.510.525;C04.557.665.510.525;C04.619.600;E05.598.500.496.937;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D01.268.556.555;D01.268.956.500;D01.552.544.555;G05.365.590;D27.505.519.389.755;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
28986305,Aldehydes;Animals;Caenorhabditis elegans;Flow Cytometry;High-Throughput Screening Assays;Membrane Potentials;Mitochondria;Mitochondrial Membranes;Organometallic Compounds;Staining and Labeling;Flow Cytometry;Mitochondrial Diseases;Mass Screening,D02.047;B01.050;B01.050.500.500.294.400.875.660.250.250;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;E05.916.680;G01.154.535;G04.580;G07.265.675;G11.561.570;A11.284.430.214.190.875.564;A11.284.835.626;A11.284.149.450.349;A11.284.835.514.349;D02.691;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;C18.452.660;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
28986170,,
28986169,,
28986026,Cystic Fibrosis;Humans;Malnutrition;Nutritional Status;Patient Care Management;Cystic Fibrosis;Enteral Nutrition,C06.689.202;C08.381.187;C16.320.190;C16.614.213;B01.050.150.900.649.313.988.400.112.400.400;C18.654.521;G07.203.650.650;N01.224.425.525;N04.590;C06.689.202;C08.381.187;C16.320.190;C16.614.213;E02.421.360;E02.642.500.360
28985863,Adult;Brain Death;Brain Injuries;Humans;Middle Aged;Organ Transplantation;Retrospective Studies;Time Factors;Time Management;Tissue Donors;Tissue and Organ Procurement;Lung Transplantation,M01.060.116;C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;C10.228.140.199;C10.900.300.087;C26.915.300.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.936.450;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;F02.784.412.923;F02.784.692.816;F04.096.628.779.900;N04.452.932;M01.898;N02.421.911;E04.928.600.495;E04.936.450.495
28985737,"Aged;Aged, 80 and over;Cigarette Smoking;Exons;Gene Expression Profiling;Gene Ontology;Humans;Middle Aged;Pulmonary Disease, Chronic Obstructive;RNA, Untranslated;Sequence Analysis, RNA;Cigarette Smoking;Protein Isoforms",M01.060.116.100;M01.060.116.100.080;F01.145.805.375.750;F01.145.958.875.750;G05.360.340.024.340.137.232;E05.393.332;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C08.381.495.389;D13.444.735.790;E05.393.760.710;F01.145.805.375.750;F01.145.958.875.750;D12.776.800
28985580,"Child Behavior;Child, Preschool;Family Characteristics;Habits;Humans;Infant;Infant Behavior;Massage;Mothers;Sleep;Sleep Wake Disorders;Time Factors;Infant;Sleep",F01.145.179;M01.060.406.448;F01.829.263.315;I01.240.361;I01.880.853.150.423;N01.224.361;N01.824.308;N06.850.505.400.400;F01.145.466;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.145.179.500;E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F02.830.855;G11.561.803;C10.886;C23.888.592.796;F03.870;G01.910.857;M01.060.703;F02.830.855;G11.561.803
28985520,,
28985367,"Animals;DNA, Mitochondrial;Evolution, Molecular;Genome;Phylogeny;Sperm Whale;Genome;Sperm Whale",B01.050;D13.444.308.283.225;G05.045.250;G16.075.250;G05.360.340;G05.697;G16.075.605;L01.100.697;B01.050.150.900.649.313.875.865.750;G05.360.340;B01.050.150.900.649.313.875.865.750
28985194,Blood Component Transfusion;Blood Platelets;Cell Culture Techniques;Human Embryonic Stem Cells;Humans;Megakaryocytes,E02.095.135.140;A11.118.188;A15.145.229.188;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.872.700.250.750;B01.050.150.900.649.313.988.400.112.400.400;A11.148.479;A15.378.316.479
28984491,"Antidepressive Agents;Consensus;Depressive Disorder, Major;Drug-Related Side Effects and Adverse Reactions;Humans;Practice Guidelines as Topic;Antidepressive Agents;Depressive Disorder, Major;Drug Therapy",D27.505.954.427.700.122;F01.829.316.068;F02.463.785.373.433;F03.600.300.375;C25.100;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;D27.505.954.427.700.122;F03.600.300.375;E02.319
28984468,Asthma;Bronchoconstriction;Cytokines,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;G09.772.705.700.080;D12.644.276.374;D12.776.467.374;D23.529.374
28983677,"Adolescent;Child;Child, Preschool;Humans;Imaging, Three-Dimensional;Radiation Dosage;Radiation Exposure;Radiation Protection;Radiography, Interventional;Retrospective Studies;Tomography, X-Ray Computed;Child;Radiology, Interventional",M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;E05.799.513;G01.750.740;N06.850.810.250;G01.750.748;N06.850.460.350.850;N06.850.810.425;E01.370.350.700.725;E04.502.780;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;M01.060.406;H02.403.740.675
28982710,"Adult;Anti-Bacterial Agents;Humans;Infant, Extremely Premature;Infant, Newborn;Infant, Premature, Diseases;Registries;Risk Factors;Sepsis;Young Adult",M01.060.116;D27.505.954.122.085;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;M01.060.703.520;C16.614.521;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.757;C23.550.470.790.500;M01.060.116.815
28982690,Cardiovascular Diseases;Genetics;Nitric Oxide;Nitric Oxide Synthase,C14;H01.158.273.343;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D08.811.682.664.500.772
28982668,"Blood Platelets;Cell Line;Gene Expression Regulation, Developmental;Genetic Predisposition to Disease;Hematologic Diseases;Humans;Induced Pluripotent Stem Cells;Megakaryocytes;Phenotype;Platelet Transfusion;Thrombopoiesis;Blood Platelets;Hematopoiesis;Humans;Induced Pluripotent Stem Cells;Megakaryocytes",A11.118.188;A15.145.229.188;A11.251.210;G05.308.310;C23.550.291.687.500;G05.380.355;C15.378;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A11.148.479;A15.378.316.479;G05.695;E02.095.135.140.650;G04.152.825.798;G09.188.343.798;A11.118.188;A15.145.229.188;G04.152.825;G09.188.343;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A11.148.479;A15.378.316.479
28982506,Disease Progression;Family Health;Heart Failure;Humans;Palliative Care;Patient Care Team;Patient Comfort;Quality of Life;Randomized Controlled Trials as Topic;Severity of Illness Index;Heart Failure;Hospices;Palliative Care;Quality of Health Care;Quality of Life,C23.550.291.656;N01.400.300;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E02.760.666;N02.421.585.666;N04.590.715;N02.421.585.683;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C14.280.434;N02.278.421.556.185;N02.421.143.550;E02.760.666;N02.421.585.666;N04.761;N05.715;I01.800;K01.752.400.750;N06.850.505.400.425.837
28982261,Aging;Pragmatic Clinical Trials as Topic,G07.345.124;E05.318.372.250.250.365.500.750;N05.715.360.330.250.250.365.500.750;N06.850.520.450.250.250.365.500.750
28981858,"Animals;Disease Models, Animal;Human Development;Humans;Rodentia;Schizophrenia",B01.050;C22.232;E05.598.500;E05.599.395.080;F01.525;G07.345.374;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992;F03.700.750
28981714,"Alleles;Biological Evolution;Computer Simulation;Evolution, Molecular;Gene Frequency;Genetic Variation;Genetics, Population;Haplotypes;Humans;Polymorphism, Genetic;Selection, Genetic",G05.360.340.024.340.030;G05.045;G16.075;L01.224.160;G05.045.250;G16.075.250;G05.330;G05.365;H01.158.273.343.335;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795;G05.783
28981339,"Animals;Blast Injuries;Brain Injuries, Traumatic;Disease Models, Animal;Forecasting;Humans;Military Personnel;United States;United States Department of Veterans Affairs;United States Department of Veterans Affairs;Models, Theoretical;Brain Injuries, Traumatic",B01.050;C26.120.126;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;C22.232;E05.598.500;E05.599.395.080;I01.320;B01.050.150.900.649.313.988.400.112.400.400;M01.526.625;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;I01.409.418.750.700;N03.540.348.500.500.700;E05.599;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28980714,"Aged;Aniline Compounds;Brain;Brain Mapping;Carbolines;Case-Control Studies;Cognition Disorders;Diagnosis;Humans;Magnetic Resonance Imaging;Middle Aged;Neuropsychological Tests;Parkinson Disease;Positron-Emission Tomography;Severity of Illness Index;Supranuclear Palsy, Progressive;Thiazoles;tau Proteins",M01.060.116.100;D02.092.146;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;D03.383.725.150;D03.633.100.473.155;D03.633.300.154;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F03.615.250;E01;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690;D02.886.675;D03.383.129.708;D12.776.220.600.450.510;D12.776.631.560.510
28980702,"Adolescent;Adult;Aged;Child;Child, Preschool;Electromyography;Epilepsy, Tonic-Clonic;Humans;Middle Aged;Monitoring, Ambulatory;Prospective Studies;Young Adult;Seizures;Seizures",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;M01.060.406.448;E01.370.405.255;E01.370.530.255;C10.228.140.490.375.290;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.520.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;M01.060.116.815;C10.597.742;C23.888.592.742;C10.597.742;C23.888.592.742
28980502,Ophthalmology,H02.403.810.468
28980494,Multiple Sclerosis;Epidemiology;Genetics;Pediatrics,C10.114.375.500;C10.314.350.500;C20.111.258.250.500;H02.403.720.500;H01.158.273.343;H02.403.670
28980269,,
28980061,Child;Safety,M01.060.406;N06.850.135.060.075
28979992,Animals;Biomechanical Phenomena;Bone Density;Bone Remodeling;Cancellous Bone;Finite Element Analysis;Mechanical Phenomena;Rats;Reproduction;Spine,B01.050;G01.154.090;G01.374.089;G11.427.100;G11.427.213;G16.762.150;A10.165.265.414;E05.355;G01.374;B01.050.150.900.649.313.992.635.505.700;G08.686.784;A02.835.232.834
28978797,,
28978515,"Animals;Cobalt;DNA Methylation;Dermatitis;Dietary Supplements;Disease Models, Animal;Fetal Growth Retardation;Folic Acid;Gestational Age;Hypersensitivity;Immunoglobulin E;Mast Cells;Methionine;Ovalbumin;Placenta;Pregnancy;Prenatal Exposure Delayed Effects;Pyroglyphidae;Sheep, Domestic;Skin;Sulfur;Models, Animal;Fetal Development;Folic Acid;Fetal Growth Retardation;Mast Cells",B01.050;D01.268.556.185;D01.268.956.155;D01.552.544.185;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C17.800.174;G07.203.300.456;J02.500.456;C22.232;E05.598.500;E05.599.395.080;C13.703.277.370;C16.300.390;C23.550.393.450;D03.633.100.733.631.400;G07.345.500.325.235.968;G08.686.320;C20.543;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;A11.329.427;A15.382.652;D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;D12.644.861.557;D12.776.034.614;D12.776.256.317.663;D12.776.290.663;D12.776.872.557;A16.710;G08.686.784.769;C13.703.824.500;B01.050.500.131.166.132.419.600;B01.050.150.900.649.313.500.380.791.150;A17.815;D01.268.185.900;E05.598;G07.345.500.325.235;G08.686.784.170.157;D03.633.100.733.631.400;C13.703.277.370;C16.300.390;C23.550.393.450;A11.329.427;A15.382.652
28978489,"Child;Chromatography, High Pressure Liquid;Drug Stability;Humans;Limit of Detection;Linear Models;Midazolam;Reproducibility of Results;Tandem Mass Spectrometry;Midazolam",M01.060.406;E05.196.181.400.300;E05.916.330;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.872.374;N05.715.360.750.725.500;N06.850.520.830.872.500;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;D03.633.100.079.080.575;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.196.566.880;D03.633.100.079.080.575
28977797,"Balloon Occlusion;Fetoscopy;Fetus;Hernias, Diaphragmatic, Congenital;Humans;Magnetic Resonance Imaging;Pregnancy;Trachea;Artifacts;Hernias, Diaphragmatic, Congenital;Magnetic Resonance Imaging",E02.148.106;E02.520.392.500;E02.926.500.074;E05.157.063;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;A16.378;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;G08.686.784.769;A04.889;E05.047;C16.131.433;C23.300.707.500.116;E01.370.350.825.500
28977503,"Acute Disease;Aneurysm, Dissecting;Aorta, Thoracic;Aortic Aneurysm, Thoracic;Blood Vessel Prosthesis Implantation;Echocardiography, Transesophageal;Europe;Follow-Up Studies;Hospital Mortality;Humans;Middle Aged;Ontario;Postoperative Complications;Reoperation;Retrospective Studies;Risk Factors;Time Factors;Treatment Outcome;United States;Aorta, Thoracic;Aneurysm, Dissecting",C23.550.291.125;C14.907.055.050;A07.015.114.056.372;C14.907.055.239.125;C14.907.109.139.125;E04.100.814.868.500;E04.650.200;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;Z01.542;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.176.639;C23.550.767;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;A07.015.114.056.372;C14.907.055.050
28977452,,
28977343,,
28976970,"Animals;Cell Line, Tumor;Cellular Senescence;Chromatin;Cytokines;Cytoplasm;Humans;Immunity, Innate;Inflammation;Liver;Membrane Proteins;Mice;Neoplasms;Nucleotidyltransferases;Oncogene Protein p21(ras);Radiation, Ionizing",B01.050;A11.251.210.190;A11.251.860.180;G04.043;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.644.276.374;D12.776.467.374;D23.529.374;A11.284.430.214;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;C23.550.470;A03.620;D12.776.543;B01.050.150.900.649.313.992.635.505.500;C04;D08.811.913.696.445;D08.811.277.040.330.300.400.500.300;D12.644.360.525.500.300;D12.776.157.325.515.500.300;D12.776.476.525.500.300;D12.776.624.664.520.750.710;D12.776.964.700.750.710;D12.776.964.775.750.710;G01.750.750
28976850,,
28976608,"Adult;Cerebrovascular Circulation;Echocardiography;Fetal Monitoring;Gestational Age;Humans;Hypoplastic Left Heart Syndrome;Infant, Newborn;Middle Cerebral Artery;Mothers;Neurodevelopmental Disorders;Oxygen;Oxygen Inhalation Therapy;Placenta;Pregnancy;Pulsatile Flow;Treatment Outcome;Ultrasonography, Prenatal",M01.060.116;G09.330.100.159;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.378.230;E01.370.520.230;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703.520;A07.015.114.228.550;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F03.625;D01.268.185.550;D01.362.670;E02.880.690;A16.710;G08.686.784.769;G01.482.620;G09.330.380.630.555;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850.865;E01.370.378.630.865
28976571,"Chromatography, Liquid;Drug Stability;Humans;Hydrophobic and Hydrophilic Interactions;Ketamine;Linear Models;Reproducibility of Results;Temperature;Blood;Ketamine;Pharmacokinetics;Plasma",E05.196.181.400;E05.916.330;B01.050.150.900.649.313.988.400.112.400.400;G02.409;D02.455.426.392.368.367.652;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;A12.207.152;A15.145;D02.455.426.392.368.367.652;G03.787;G07.690.725;A12.207.152.693;A12.207.270.695;A15.145.693
28976470,,
28976248,"Biomedical Research;Cardiovascular Diseases;Education, Medical;Evidence-Based Medicine;History, 20th Century;History, 21st Century;Humans;Learning;Mentors;Prognosis;Risk Factors",H01.770.644.145;C14;I02.358.399;H02.249.750;H02.403.200.400;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;M01.395;E01.789;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28975999,Biomarkers;Macrophage Activation Syndrome,D23.101;C20.683.515.800
28975303,Health Services Needs and Demand;Humans;Physicians;United States,N03.349.380.420;N05.300.450;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;Z01.107.567.875
28975195,,
28975127,Central Venous Catheters;Venous Thromboembolism,E07.132.750.500;C14.907.355.590.700
28974650,"Apoptosis;Cell Line, Tumor;Cyclin B1;Drug Resistance, Neoplasm;G2 Phase Cell Cycle Checkpoints;Humans;Indoles;M Phase Cell Cycle Checkpoints;Myeloid Cell Leukemia Sequence 1 Protein;Oncogene Proteins, Fusion;Proto-Oncogene Protein c-fli-1;Proto-Oncogene Proteins c-bcl-2;RNA-Binding Protein EWS;Sarcoma, Ewing;Ubiquitin-Conjugating Enzymes;Vincristine",G04.146.160;A11.251.210.190;A11.251.860.180;D12.644.360.262.120.100;D12.776.167.218.120.100;D12.776.476.262.120.100;G07.690.773.984.395;G04.144.109.500;G04.144.500.340.500;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.473;G04.144.109.750;G04.144.220.220.781.337;G05.113.220.781.338;D12.644.360.075.718.984;D12.776.476.075.718.968;D12.776.624.664.700.169.500;D12.776.602.500.500;D12.776.624.664.500;D12.776.260.665.400;D12.776.624.664.700.175.400;D12.776.930.720.400;D12.644.360.075.718;D12.776.476.075.718;D12.776.624.664.700.169;D12.644.360.650;D12.776.157.142.750;D12.776.157.725.813.750.900;D12.776.476.650;D12.776.624.664.700.913;D12.776.664.962.813.750.900;C04.557.450.565.575.650.800;C04.557.450.795.620.800;D08.811.464.938.500;D03.132.436.681.827.817;D03.633.100.473.402.681.827.817
28974517,American Heart Association;Gene Editing;Genetics;Mosaicism;Mutation,N03.540.630.780.110;E05.393.420.270;H01.158.273.343;G05.365.590.175.595;G05.365.590
28974437,,
28974405,Adolescent;Adult;Humans;Nasal Cavity;Olfaction Disorders;Olfactory Bulb;Olfactory Cortex;Olfactory Pathways;Psychophysics;Psychotic Disorders;Sensory Thresholds;Sex Factors;Young Adult;Nasal Cavity;Smell;Olfactory Bulb;Prefrontal Cortex,M01.060.057;M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;A04.531.449;C10.597.751.600;C23.888.592.763.550;A08.186.211.200.885.388;A08.186.211.200.885.287.500.620;A08.186.211.200.885.287.500.814.695;A08.186.211.200.885.287.750;A08.186.211.180.699;A08.612.220.640;E01.370.685;F04.096.753;F03.700.675;F02.463.593.710;N05.715.350.675;N06.850.490.875;M01.060.116.815;A04.531.449;F02.830.816.643;G11.561.790.643;A08.186.211.200.885.388;A08.186.211.200.885.287.500.270.700
28974385,"A549 Cells;Animals;Antigens, Viral;Antiviral Agents;Cell Survival;Cercopithecus aethiops;Granuloma;Human Umbilical Vein Endothelial Cells;Humans;Immunologic Deficiency Syndromes;Inhibitory Concentration 50;Protein Transport;Rubella;Rubella virus;Skin;Thiazoles;Treatment Outcome;Vero Cells;Virus Replication;Antiviral Agents;Rubella virus",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;B01.050;D23.050.327;D27.505.954.122.388;G04.346;B01.050.150.900.649.313.988.400.112.199.120.126.110;C15.604.515.292;C23.550.382;A11.436.275.682;B01.050.150.900.649.313.988.400.112.400.400;C20.673;E05.940.350;G07.690.936.563;G03.143.700;C02.782.930.700.700;B04.820.850.700.700;A17.815;D02.886.675;D03.383.129.708;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A11.251.210.955;A11.436.955;G06.920.925;D27.505.954.122.388;B04.820.850.700.700
28973891,"Calcium;Cells, Cultured;Complement Activation;Complement C4a;Endothelium, Vascular;Humans;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Receptor, PAR-1;Receptors, G-Protein-Coupled;Receptors, Thrombin;Signal Transduction;Complement System Proteins;Endothelial Cells",D01.268.552.100;D01.552.539.288;D23.119.100;A11.251;G12.274;D12.776.124.486.274.024.260;D12.776.124.486.274.350.250;A07.015.700.500;A10.272.491.355;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.567.249.500;D12.644.360.450.169.500;D12.776.476.450.169.500;D08.811.913.696.620.682.700.567.249.750;D12.644.360.450.169.750;D12.776.476.450.169.750;D12.776.395.550.625.800.790;D12.776.543.550.625.800.790;D12.776.543.750.695.875.500;D12.776.543.750.705.675.892.790;D12.776.543.750.750.850.399;D12.776.543.750.792.500.500;D12.776.543.750.695;D12.776.395.550.625.800;D12.776.543.550.625.800;D12.776.543.750.695.875;D12.776.543.750.705.675.892;D12.776.543.750.750.850;D12.776.543.750.792.500;G02.111.820;G04.835;D12.776.124.486.274;A11.436.275
28973468,"Bacterial Proteins;Codon, Terminator;Escherichia coli;Fluorescence Polarization;Fusidic Acid;Guanosine Triphosphate;Kinetics;Models, Biological;Peptide Elongation Factor G;Prokaryotic Initiation Factor-3;RNA, Bacterial;RNA, Messenger;RNA, Transfer;Ribosome Subunits;Ribosomes;Thiostrepton;Viomycin",D12.776.097;D13.444.735.544.355.250;G05.360.335.355.250;G05.360.340.024.340.137.190.250;B03.440.450.425.325.300;B03.660.250.150.180.100;E05.196.712.516.600.390;D04.210.500.247.222.222.347.389;D04.210.500.247.808.489;D10.570.938.515;D03.633.100.759.646.454.504;D13.695.667.454.504;D13.695.827.426.504;G01.374.661;G02.111.490;E05.599.395;D08.811.277.040.330.300.100.200;D12.776.157.325.150.200;D12.776.835.700.350.200;D12.776.835.725.934.750;D13.444.735.473;D13.444.735.544;D13.444.735.757;A11.284.430.214.190.875.811.870;A11.284.430.214.190.875.811;D04.345.566.825;D12.644.641.825;D04.345.566.875;D12.644.641.875
28973395,"Adolescent;Adult;Atrophy;Basal Ganglia;Brain;Cataract;Cerebellum;Child;Child, Preschool;HeLa Cells;Hereditary Central Nervous System Demyelinating Diseases;Humans;Leukodystrophy, Metachromatic;Magnetic Resonance Imaging;Microtubules;Middle Aged;Mutation;Myelin Sheath;Neurons;Oligodendroglia;Phenotype;Tubulin;Young Adult",M01.060.057;M01.060.116;C23.300.070;A08.186.211.200.885.287.249;A08.186.211;C11.510.245;A08.186.211.132.810.428.200;M01.060.406;M01.060.406.448;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;C10.228.140.163.100.362;C10.228.140.695.625;C10.314.400;C10.574.500.490;C16.320.400.367;C16.320.565.189.362;C18.452.132.100.362;C18.452.648.189.362;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.163.100.362.550;C10.228.140.163.100.435.825.850.500;C10.228.140.695.625.550;C10.314.400.550;C16.320.565.189.362.550;C16.320.565.189.435.825.850.500;C16.320.565.398.641.803.925.500;C16.320.565.595.554.825.850.500;C18.452.132.100.362.550;C18.452.132.100.435.825.850.500;C18.452.584.687.803.925.500;C18.452.648.189.362.550;C18.452.648.189.435.825.850.500;C18.452.648.398.641.803.925.500;C18.452.648.595.554.825.850.500;E01.370.350.825.500;A11.284.430.214.190.750.602;M01.060.116.630;G05.365.590;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;A08.675;A11.671;A08.637.600;A11.650.600;G05.695;D05.750.078.734.800;D12.776.220.600.800;D12.776.631.920;M01.060.116.815
28973367,"Aged;Aged, 80 and over;Aging;Case-Control Studies;Humans;Lens, Crystalline;Lipofuscin;Middle Aged;Optical Imaging;Retina",M01.060.116.100;M01.060.116.100.080;G07.345.124;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;B01.050.150.900.649.313.988.400.112.400.400;A09.371.060.500;D10.460;D23.767.550;M01.060.116.630;E01.370.350.589;E05.642;A09.371.729
28973193,Humans;Insurance;Insurance Carriers;Patient Protection and Affordable Care Act;United States,B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576;N03.219.521.576.160;N03.219.521.576.343.918;N03.706.615.806;Z01.107.567.875
28973128,"Adolescent;Alopecia Areata;Autoimmune Diseases;Child;Child, Preschool;Humans;Incidence;Infant;Mass Screening;Practice Guidelines as Topic;Retrospective Studies;Severity of Illness Index;Thyroid Diseases;Thyroid Function Tests;Young Adult",M01.060.057;C17.800.329.937.122.147;C20.111;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C19.874;E01.370.374.750;M01.060.116.815
28973124,"Acute Kidney Injury;Adolescent;Anti-Bacterial Agents;Child;Child, Preschool;Databases, Factual;Drug Therapy, Combination;Hospital Mortality;Hospitalization;Humans;Length of Stay;Penicillanic Acid;Piperacillin;Piperacillin, Tazobactam Drug Combination;Retrospective Studies;Risk Assessment;United States;Vancomycin",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.057;D27.505.954.122.085;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E02.319.310;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;D02.065.589.099.750.687;D02.886.108.750.687;D03.633.100.300.750.687;D02.065.589.099.750.750.050.650;D02.886.108.750.750.050.650;D03.633.100.300.750.750.050.650;D02.065.589.099.750.687.750.500;D02.065.589.099.750.750.050.650.500;D02.886.108.750.687.750.500;D02.886.108.750.750.050.650.500;D02.886.590.841.500;D03.633.100.300.750.687.750.500;D03.633.100.300.750.750.050.650.500;D26.310.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;Z01.107.567.875;D09.400.420.925;D12.644.233.925
28973115,"Exercise;Family Health;Games, Experimental;Goals;Humans;Middle Aged;Monitoring, Ambulatory;Motivation;Walking",G11.427.410.698.277;I03.350;N01.400.300;E05.385;F01.658.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.520.500;F01.658;F01.752.543.500.750;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940
28972873,Palliative Care;Parenting,E02.760.666;N02.421.585.666;F01.829.263.370.310
28972186,"Amino Acid Sequence;Catalytic Domain;Cell Cycle;Checkpoint Kinase 1;Crystallography, X-Ray;DNA Repair;Enzyme Activation;Humans;Models, Molecular;Protein Conformation;Sequence Alignment;Cell Cycle;Protein Domains;Serine",G02.111.570.060;L01.453.245.667.060;G02.111.570.120.704;G02.111.570.820.709.275.750.188;G04.144;D08.811.913.696.620.682.700.143;E05.196.309.742.225;G02.111.222;G05.219;G02.111.263;G03.328;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595;G02.111.570.820.709;E05.393.751;G04.144;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.125.154.800
28972154,"Actins;Adaptor Proteins, Signal Transducing;Animals;Cell-Derived Microparticles;Cytoskeleton;Humans;Hyperglycemia;Inflammasomes;Interleukin-1beta;Mice, Inbred C57BL;Mice, Knockout;Monocytes;NADPH Oxidases;NLR Family, Pyrin Domain-Containing 3 Protein;Neutrophil Activation;Neutrophils;Nitric Oxide Synthase Type II;Oxidative Stress;Protein Processing, Post-Translational;Protein Stability;RNA Interference;Actins;Inflammasomes;Nitric Oxide",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D12.644.360.024;D12.776.157.057;D12.776.476.024;B01.050;A11.284.295.588.500;A11.284.430.214.190.750;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;D05.500.224;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D08.811.682.608.575;D12.776.331.894;D12.776.543.653;D12.644.360.539.250;G12.604;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;D08.811.682.664.500.772.500;D12.776.157.687.575;D12.776.660.720.575;G03.673;G07.775.750;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;G02.111.700;G05.308.203.374.790;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D05.500.224;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
28972080,"A549 Cells;Cell Line, Tumor;DNA Replication;Dependovirus;Genome, Viral;HeLa Cells;Host-Pathogen Interactions;Humans;Protein Interaction Maps;Proteome;Proteomics;Simplexvirus;Vaccinia virus;Viral Proteins;Virus Diseases;Virus Replication",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;A11.251.210.190;A11.251.860.180;G02.111.225;G05.226;B04.280.580.650.170;G05.360.340.358.840;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G03.493.750;D12.776.817;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;B04.280.382.100.750;B04.280.650.160.650.900;D12.776.964;C02;G06.920.925
28972044,,
28972016,"Animals;Fusion Proteins, bcr-abl;Humans;Philadelphia Chromosome;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Signal Transduction;Translocation, Genetic",B01.050;D08.811.913.696.620.682.725.500.500;D12.776.602.500.500.100;D12.776.624.664.500.100;D12.776.624.664.700.171.500;B01.050.150.900.649.313.988.400.112.400.400;A11.284.187.520.300.325.345.500;A11.284.187.520.300.505.515.500;C23.550.210.870.680;G05.360.162.520.300.325.345.700;G05.360.162.520.300.505.515.700;G05.365.590.175.870.680;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;G02.111.820;G04.835;C23.550.210.870;G05.365.590.175.870;G05.558.860
28971920,"Adolescent;Autism Spectrum Disorder;Child;Child, Preschool;District of Columbia;Health Services Accessibility;Humans;Insurance Coverage;Insurance, Health;Mandatory Programs;Retrospective Studies;United States;Child Health;Insurance;Mental Health",M01.060.057;F03.625.164.113;M01.060.406;M01.060.406.448;Z01.107.567.875.500.210;Z01.433.429;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;I01.880.604.622;N03.706.657;N04.452.521;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;N01.400.225;N03.219.521.576;F02.418;N01.400.500
28971864,"Anti-Bacterial Agents;Carbapenem-Resistant Enterobacteriaceae;Carbapenems;Case-Control Studies;Child;Child, Preschool;Enterobacteriaceae Infections;Hospitals, Pediatric;Humans;Infant;Logistic Models;Respiration, Artificial;Risk Factors;Surgical Procedures, Operative;Tertiary Care Centers;United States;beta-Lactam Resistance;Pediatrics",D27.505.954.122.085;B03.440.450.425.189;B03.660.250.150.097;D02.065.589.099.124;D03.633.100.300.124;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;C01.252.400.310;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E02.041.625;E02.365.647.729;E02.880.820;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04;N02.278.421.830;Z01.107.567.875;G06.099.225.500;G06.225.347.500;G07.690.773.984.269.347.500;H02.403.670
28971270,"Acute Disease;Animals;CD8-Positive T-Lymphocytes;Calcium-Calmodulin-Dependent Protein Kinase Type 4;Cell Line;Chemokines;Chemotaxis, Leukocyte;Cytokines;Disease Models, Animal;Gene Expression Regulation, Enzymologic;Histocompatibility Antigens Class I;Macrophages;Mice, Inbred C57BL;Monocytes;Muscle Development;Muscle, Skeletal;Myoblasts, Skeletal;Myositis;Regeneration;Signal Transduction;Time Factors;Inflammation",C23.550.291.125;B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D08.811.913.696.620.682.700.125.350;D12.644.360.100.350;D12.776.476.100.350;A11.251.210;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;G04.198.424.233;D12.644.276.374;D12.776.467.374;D23.529.374;C22.232;E05.598.500;E05.599.395.080;G05.308.320;D12.776.395.550.489;D12.776.543.550.439;D23.050.301.500.100;D23.050.705.552.100;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;G07.345.500.325.377.625.590;G11.427.578.590;A02.633.567;A10.690.552.500;A11.872.620.500;C05.651.594;C10.668.491.562;G16.762;G02.111.820;G04.835;G01.910.857;C23.550.470
28971234,"Child;Collagen Type XI;Connective Tissue Diseases;Humans;Mutation, Missense;Osteoporotic Fractures;Pedigree;Recurrence;Vitreous Detachment;Zoledronic Acid",M01.060.406;D05.750.078.280.300.500;D12.776.860.300.250.300.500;C17.300;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;C26.404.545;E05.393.673;C23.550.291.937;C11.980;D02.705.429.500.942;D03.383.129.308.990
28971166,"Anemia, Aplastic;Autoimmunity;Myelodysplastic Syndromes",C15.378.071.085;C15.378.190.196;G12.450.192;C15.378.190.625
28971143,,
28971012,"Autism Spectrum Disorder;Child;Epilepsy;Evoked Potentials, Somatosensory;Fingers;Humans;Magnetoencephalography;Physical Stimulation;Somatosensory Cortex;Touch;Touch Perception;Autism Spectrum Disorder;Epilepsy",F03.625.164.113;M01.060.406;C10.228.140.490;G07.265.216.500.400;G11.561.200.500.400;A01.378.800.667.430;B01.050.150.900.649.313.988.400.112.400.400;E01.370.376.500;E01.370.405.440;E05.540.500;E05.723;A08.186.211.200.885.287.500.670.675;A08.186.211.200.885.287.500.814.906;F02.830.816.850;G11.561.790.850;F02.463.593.894;F03.625.164.113;C10.228.140.490
28970962,"Immunoglobulins, Intravenous;Pancytopenia;Prednisone",D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;C15.378.700;D04.210.500.745.432.719.702
28970079,"Aged;Diabetes Mellitus, Type 2;Gene Expression Profiling;Gene Expression Regulation;Gene Regulatory Networks;Glomerular Filtration Rate;Humans;Hypertension;Kidney Tubules;Middle Aged;Oligonucleotide Array Sequence Analysis;Organ Specificity;Regression Analysis;Renal Insufficiency, Chronic;Fibrosis;Gene Expression",M01.060.116.100;C18.452.394.750.149;C19.246.300;E05.393.332;G05.308;G05.360.080.689.360;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;A05.810.453.736.560;M01.060.116.630;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;G07.650;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;C12.777.419.780.750;C13.351.968.419.780.750;C23.550.355;G05.297
28970045,"Adoptive Transfer;Cell Line;Follow-Up Studies;Genetic Therapy;Genetic Vectors;Humans;Lentivirus;T-Lymphocytes;Transduction, Genetic;Virus Replication;Immunotherapy;Lentivirus;Safety",E02.095.465.425.400.330.050;E05.478.550.520.050;A11.251.210;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E05.393.350.800;G05.728.850;G06.920.925;E02.095.465.425;B04.820.650.589;N06.850.135.060.075
28970031,"Education, Medical",I02.358.399
28970024,"Adult;Aged;Computed Tomography Angiography;Decision Support Systems, Clinical;Emergency Service, Hospital;Humans;Middle Aged;Prospective Studies;Pulmonary Embolism;Quality Improvement;Decision Support Systems, Clinical;Pulmonary Embolism",M01.060.116;M01.060.116.100;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;L01.313.500.750.300.190;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C08.381.746;C14.907.355.350.700;J01.293.754;N04.761.744;L01.313.500.750.300.190;C08.381.746;C14.907.355.350.700
28969439,"Cognitive Behavioral Therapy;Depressive Disorder, Major;Humans;Middle Aged;Psychiatric Status Rating Scales;Therapy, Computer-Assisted;Cognitive Behavioral Therapy;Therapy, Computer-Assisted;Psychotherapy",F04.754.137.350;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F04.711.513.653;E02.950;L01.313.500.750.100.710;F04.754.137.350;E02.950;L01.313.500.750.100.710;F04.754
28969374,"Adolescent;Child;Child, Preschool;Consanguinity;DNA Mutational Analysis;Evoked Potentials, Auditory, Brain Stem;Family Health;Genes, Homeobox;Homeodomain Proteins;Humans;Leukoencephalopathies;Magnetic Resonance Imaging;Models, Molecular;Mutation;Neuroimaging;Myelin Sheath",M01.060.057;M01.060.406;M01.060.406.448;G05.090.403.180;G05.180;E05.393.760.700.300;G07.265.216.500.370.300;G11.561.200.500.370.300;N01.400.300;G05.360.340.024.340.230.500;D12.776.260.400;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.695;E01.370.350.825.500;E05.599.595;G05.365.590;E01.370.350.578;E01.370.376.537;E05.629;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553
28969315,"Anesthetics, Inhalation;Animals;Dexmedetomidine;Disease Models, Animal;Dose-Response Relationship, Drug;Drug Interactions;Hypnotics and Sedatives;Neurodegenerative Diseases;Random Allocation;Rats;Rats, Wistar;Sevoflurane;Apoptosis;Brain Injuries;Dexmedetomidine;Inhalation;Neuroprotection;Safety;Sevoflurane",D27.505.696.277.100.035.060;D27.505.954.427.210.100.035.060;B01.050;D03.383.129.308.245;C22.232;E05.598.500;E05.599.395.080;G07.690.773.875;G07.690.936.500;G07.690.773.968;D27.505.696.277.350;D27.505.954.427.210.350;C10.574;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.900;D02.355.601.810;D02.455.526.510.717;G04.146.160;C10.228.140.199;C10.900.300.087;C26.915.300.200;D03.383.129.308.245;G09.772.705.700.390;G11.561.645;N06.850.135.060.075;D02.355.601.810;D02.455.526.510.717
28968636,,
28968169,Age Factors;Biomedical Research;Clinical Trials as Topic;Humans;Medical Oncology;United States,N05.715.350.075;N06.850.490.250;H01.770.644.145;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;Z01.107.567.875
28967884,"Gene Expression Regulation;Genome, Human;Humans;Polyadenylation;Ribonucleoprotein, U1 Small Nuclear;Transcription, Genetic",G05.308;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;G02.111.760.225.710;G03.839.225.710;G05.308.700.225.710;D12.776.157.725.500.875.600;D12.776.157.725.829.313;D12.776.664.962.500.875.600;D12.776.664.962.829.313;G02.111.873;G05.297.700
28967677,"Insurance, Health;Infant Mortality",N03.219.521.576.343;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475
28967624,"Cardiomyopathy, Hypertrophic;Echocardiography, Transesophageal;Genetic Testing;Humans;Perioperative Care;Systole;Ventricular Outflow Obstruction;Cardiomyopathy, Hypertrophic",C14.280.238.100;C14.280.484.150.070.160;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731;E04.604;N02.421.585.722;G09.330.580.880;G11.427.494.570.880;C14.280.955;C14.280.238.100;C14.280.484.150.070.160
28967623,Aortic Valve;Aortic Valve Stenosis;Delirium;Heart Valve Prosthesis;Humans;Postoperative Complications;Transcatheter Aortic Valve Replacement;Treatment Outcome,A07.541.510.110;C14.280.484.150;C14.280.955.249;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;E07.695.310;B01.050.150.900.649.313.988.400.112.400.400;C23.550.767;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28967259,"Adenine;Base Pair Mismatch;Biosensing Techniques;DNA;DNA Damage;DNA Repair;Epigenesis, Genetic;Guanine;Humans;Models, Molecular;Nanopores;Nanotechnology;Neoplasms;Uracil;Nanopores;Neoplasms;Epigenomics",D03.633.100.759.138;G05.365.590.060;E05.601.043;D13.444.308;G05.200;G02.111.222;G05.219;G05.308.203;D03.633.100.759.758.399.454;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595;J01.637.512.650;H01.603;J01.897.520.600;C04;D03.383.742.698.875;J01.637.512.650;C04;H01.158.273.180.350.074;H01.158.273.343.350.042
28966882,Botswana;HIV,Z01.058.290.175.230;B04.820.650.589.650.350
28966657,Genetic Counseling;Genetic Testing,H01.158.273.343.385.500.384;N02.421.308.400;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221
28966563,Menopause;Postpartum Period;Puberty,G08.686.157.500;G08.686.841.249.500;G08.686.702;G08.686.760;G08.686.841.374
28966033,"Adolescent;Brain Stem Neoplasms;Cell Cycle Proteins;Child;Child, Preschool;DNA Topoisomerases, Type I;Exome;F-Box Proteins;F-Box-WD Repeat-Containing Protein 7;Gene Dosage;Glioma;Histones;Humans;Infant;Infant, Newborn;Mutation;Proto-Oncogene Proteins;Repressor Proteins;Ubiquitin-Protein Ligases;Young Adult;Exome;Genome;Glioblastoma;Histones;Methylation",M01.060.057;C04.588.614.250.195.411.100;C10.228.140.211.500.100;C10.551.240.250.400.200;D12.776.167;M01.060.406;M01.060.406.448;D08.811.399.403.483;D12.776.157.687.375;D12.776.660.720.375;G05.360.340.011;D12.776.157.169;D08.811.464.938.750.750.750;D12.776.157.169.750;D12.776.167.242;G05.380.350;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G05.365.590;D12.776.624.664.700;D12.776.260.703;D12.776.930.780;D08.811.464.938.750;M01.060.116.815;G05.360.340.011;G05.360.340;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G02.111.035.538;G02.607.094.538;G03.059.538
28965848,"Chromosome Deletion;Chromosome Inversion;DNA Copy Number Variations;DiGeorge Syndrome;Genetic Predisposition to Disease;Homologous Recombination;Humans;In Situ Hybridization, Fluorescence;Meiosis;Polymorphism, Single Nucleotide;DiGeorge Syndrome;DiGeorge Syndrome;DiGeorge Syndrome;Segmental Duplications, Genomic;Segmental Duplications, Genomic",C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;C23.550.210.190;G05.365.590.175.190;G05.365.590.770.500;G05.558.805.500;G05.365.795.297.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C23.550.291.687.500;G05.380.355;G05.728.615;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;G04.144.220.220.687;G05.113.220.687;G05.365.795.598;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;G02.111.570.080.708.565;G05.360.080.708.565;G02.111.570.080.708.565;G05.360.080.708.565
28965736,Child;Pediatrics;Heart-Assist Devices,M01.060.406;H02.403.670;E04.050.430;E07.695.300.300;E07.858.082.374.300
28965734,"Child;Cryptococcosis;Diagnosis, Differential;Humans;Hyper-IgM Immunodeficiency Syndrome;Scalp Dermatoses;Tinea Capitis;Xanthogranuloma, Juvenile;Cryptococcus neoformans;Xanthogranuloma, Juvenile",M01.060.406;C01.703.248;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C15.378.147.333.249;C16.320.413;C20.673.430.249;C17.800.738;C01.539.800.200.720.730;C01.703.295.872.541;C17.800.738.708;C17.800.838.208.883.558;C15.604.250.410.900;C17.800.973;B01.300.381.258.366;B01.300.930.316.366;C15.604.250.410.900;C17.800.973
28964929,"Animals;Image Processing, Computer-Assisted;Lipids;Magnetic Resonance Imaging;Myelin Sheath;Protons;Sheep;Spinal Cord;Myelin Sheath;White Matter",B01.050;L01.224.308;D10;E01.370.350.825.500;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500;B01.050.150.900.649.313.500.380.791;A08.186.854;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;A08.186.211.204;A08.186.854.880
28964801,Clinical Deterioration;Hospitals;Humans;Public Policy,C23.550.291.656.350;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;I01.655.500.608;I01.880.604.825.608;N03.623.500.608
28964704,,
28964685,Fetal Therapies;Fetoscopy;Fetus;Humans;Pregnancy;Prosthesis Implantation;Endoscopy;Fetus;General Surgery,E02.467;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;A16.378;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;E04.650;E01.370.388.250;E04.502.250;A16.378;H02.403.810.300
28964593,,
28964585,"Adolescent;Adult;Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Child;Child, Preschool;Etoposide;Extremities;Humans;Ifosfamide;Infant;Middle Aged;Neoplasm Recurrence, Local;Pelvic Bones;Retrospective Studies;Sarcoma, Ewing;Treatment Failure",M01.060.057;M01.060.116;E02.183.750.500;E02.319.077.500;E02.319.310.037;C04.588.149;C05.116.231;M01.060.406;M01.060.406.448;D02.455.426.559.847.638.960.675.250;D04.615.638.960.675.250;D09.408.348.275;A01.378;B01.050.150.900.649.313.988.400.112.400.400;D02.455.526.728.650.730.243.250;D02.705.672.500.243.250;D03.383.533.500;M01.060.703;M01.060.116.630;C04.697.655;C23.550.727.655;A02.835.232.043.825;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.450.565.575.650.800;C04.557.450.795.620.800;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
28964310,Child;Congenital Abnormalities;Consensus;Guidelines as Topic;Humans;Larynx;Otolaryngology;Physicians;Surveys and Questionnaires,M01.060.406;C16.131;F01.829.316.068;F02.463.785.373.433;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;A04.329;H02.403.810.526;M01.526.485.810;N02.360.810;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28963916,Adolescent;Adult;Appendicitis;Child;Clinical Competence;Humans;Magnetic Resonance Imaging;Pediatrics;Radiologists;Self Efficacy;Sensitivity and Specificity;Surveys and Questionnaires;Appendicitis;Child,M01.060.057;M01.060.116;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;H02.403.670;M01.526.485.810.877;N02.360.810.877;F01.752.747.792.700;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406
28963393,Humans;Phosphorylation;Prions;RNA-Binding Protein FUS,B01.050.150.900.649.313.988.400.112.400.400;G02.111.665;G02.607.780;G03.796;D12.776.785;D12.776.157.725.813.750.905;D12.776.624.664.700.915;D12.776.664.962.813.750.902
28963080,"Adult;Animals;Biomarkers;Cross-Sectional Studies;Extracellular Matrix Proteins;Humans;Mice;Mice, Transgenic;Myositis Ossificans;Neoplasm Proteins;Ossification, Heterotopic;Osteogenesis;Young Adult;Ossification, Heterotopic",M01.060.116;B01.050;D23.101;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.776.860.300;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C05.651.594.638;D12.776.624;C23.550.751;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;M01.060.116.815;C23.550.751
30675424,"Renal Insufficiency, Chronic",C12.777.419.780.750;C13.351.968.419.780.750
30675421,"Renal Insufficiency, Chronic;Glomerular Filtration Rate;Prevalence;Reference Standards",C12.777.419.780.750;C13.351.968.419.780.750;E01.370.390.400.300;G08.852.357;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.978.808
28962054,Adolescent;Adult;Esthetics;Humans;Middle Aged;Nasal Cartilages;Rhinoplasty;Young Adult,M01.060.057;M01.060.116;F02.463.785.477;K01.752.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;A02.165.407.550;A04.531.413;E02.218.755;E04.580.392.500;E04.680.650;M01.060.116.815
28961293,"Acrylates;Dermatitis, Allergic Contact;Fitness Trackers;Humans;Middle Aged;Patch Tests",D02.241.081.069;C17.800.174.255.100;C17.800.815.255.100;C20.543.418.150;E07.230.300;E07.305.906.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.225.812.871.610;E05.200.812.871.610;E05.478.594.890.610
28961236,"Alternative Splicing;Base Sequence;Cell Line, Tumor;Eukaryotic Initiation Factor-2B;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Genetic Loci;Head and Neck Neoplasms;Humans;Introns;Models, Biological;Nucleotide Motifs;Phosphorylation;Polymerase Chain Reaction;Protein Binding;Protein Biosynthesis;Protein Isoforms;RNA Polymerase II;RNA, Messenger;Regulatory Sequences, Nucleic Acid;Reproducibility of Results;Tumor Hypoxia",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;G02.111.570.080;G05.360.080;L01.453.245.667.080;A11.251.210.190;A11.251.860.180;D12.644.360.325.300.050;D12.776.476.325.300.050;D12.776.835.725.868.374;E05.393.332;G05.308.370;G05.360.340.024.380;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.220.400;G05.360.340.024.340.137.515;E05.599.395;G02.111.570.080.611;G02.111.570.820.486.662;G05.360.080.611;G05.360.580.662;G02.111.665;G02.607.780;G03.796;E05.393.620.500;G02.111.679;G03.808;G02.111.660.871;G03.734.871;G05.297.670;D12.776.800;D08.811.913.696.445.735.270.762;D13.444.735.544;G02.111.570.080.689;G05.360.080.689;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;G03.197.300.500;G04.270.300.500
28960435,Acne Vulgaris;Adolescent;Child;Humans;Pilot Projects;Quality of Life;Severity of Illness Index;Visual Analog Scale;Young Adult;Acne Vulgaris;Quality of Life,C17.800.030.150;C17.800.794.111;M01.060.057;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.370.928;M01.060.116.815;C17.800.030.150;C17.800.794.111;I01.800;K01.752.400.750;N06.850.505.400.425.837
28960434,"Blood Platelet Disorders;Child;Exome;Genetic Predisposition to Disease;Humans;Polymorphism, Single Nucleotide;Sequence Analysis, DNA",C15.378.140;M01.060.406;G05.360.340.011;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;E05.393.760.700
28959498,,
28959368,Microbiota,G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
28959036,,
28958885,"Angiogenesis Inhibitors;Humans;Infant;Infant, Newborn;Laser Therapy;Mass Screening;Retinal Vessels;Retinopathy of Prematurity;Vascular Endothelial Growth Factor A;Vitrectomy",D27.505.696.377.077.099;D27.505.696.377.450.100;D27.505.954.248.025;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.594;E04.014.520;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;A07.015.611;C11.768.836;C16.614.521.731;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;E04.540.960
28958868,,
28958867,,
28958364,"Humans;Magnetic Resonance Imaging;Radiation Dosage;Radiography;Tomography, X-Ray Computed;Ultrasonography;Wounds and Injuries;Ultrasonography",B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.799.513;G01.750.740;N06.850.810.250;E01.370.350.700;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850;C26;E01.370.350.850
28958026,,
28957823,"Animals;Autoimmune Diseases;Biomarkers, Tumor;CARD Signaling Adaptor Proteins;Calcium-Binding Proteins;Humans;Inflammasomes;Inflammation;Interleukin-18;Mutation;Urticaria",B01.050;C20.111;D23.101.140;D12.644.360.024.131;D12.644.360.075.358;D12.776.157.057.006;D12.776.476.024.139;D12.776.476.075.358;D12.776.157.125;B01.050.150.900.649.313.988.400.112.400.400;D05.500.224;C23.550.470;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;G05.365.590;C17.800.862.945;C20.543.480.904
28957732,"Adult;Cues;Feedback, Sensory;Hand;Hand Strength;Humans;Movement;Psychomotor Performance;Size Perception;Young Adult;Body Image;Vision, Ocular",M01.060.116;F02.463.425.234;F04.754.137.301.500;F04.754.308.500.500;F04.754.339;G07.410.732.500;A01.378.800.667;E01.370.600.425.500;G11.427.560.500;B01.050.150.900.649.313.988.400.112.400.400;G07.568;G11.427.410;F02.808;G11.427.700;G11.561.660;F02.463.593.725;F02.463.593.778.794;M01.060.116.815;F01.752.747.792.110;F02.463.593.112;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
28957327,Breast Neoplasms;Genome-Wide Association Study;Humans;Inventions;Research Report,C04.588.180;C17.800.090.500;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;J01.897.400;H01.770.644.864;L01.559.423.906.769
28956515,Acute Disease;Aged;Cerebral Angiography;Comorbidity;Computed Tomography Angiography;Endovascular Procedures;Humans;Operative Time;Punctures;Radial Artery;Retrospective Studies;Thrombosis;Treatment Outcome;Vertebrobasilar Insufficiency;Stroke;Radial Artery,C23.550.291.125;M01.060.116.100;E01.370.350.578.937.180;E01.370.350.700.060.180;E01.370.350.700.560.180;E01.370.370.050.180;E01.370.376.537.750.180;E05.629.937.180;N05.715.350.225;N06.850.490.687;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;E04.614.374.500;N02.421.585.753.374.500;E02.800;E04.665;A07.015.114.740;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.907.355.830;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C10.228.140.300.150.956;C14.907.253.092.956;C10.228.140.300.775;C14.907.253.855;A07.015.114.740
28956293,Clinical Competence;Mental Competency,I02.399.630.210;N04.761.210;N05.715.175;F01.590;F02.410;I01.880.604.583.530;N03.706.535.625
28955654,"Immunotherapy, Adoptive;Antibodies;Lymphoma;Programmed Cell Death 1 Receptor",E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;C04.557.386;C15.604.515.569;C20.683.515.761;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790
28955119,"Radiology, Interventional;Lymphography",H02.403.740.675;E01.370.350.700.475
28954774,"Chronic Disease;Dyspnea;Humans;Pulmonary Disease, Chronic Obstructive",C23.550.291.500;C08.618.326;C23.888.852.371;B01.050.150.900.649.313.988.400.112.400.400;C08.381.495.389
28954429,"Accidents, Traffic;Adult;Aging;Child;Child Restraint Systems;Child, Preschool;Education;Ethnic Groups;Focus Groups;Humans;Parents;Problem Solving;Public Health;Socioeconomic Factors;Telemedicine;Child Restraint Systems;Telemedicine;Stakeholder Participation",N06.850.135.392;M01.060.116;G07.345.124;M01.060.406;E07.490.249;E07.700.175;J01.637.708.175;M01.060.406.448;I02;M01.686.754;N01.224.317;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F02.463.425.725;F02.463.785.810;H02.403.720;N01.400.550;N06.850;I01.880.853.996;N01.824;H02.403.840;L01.178.847.652;N04.590.374.800;E07.490.249;E07.700.175;J01.637.708.175;H02.403.840;L01.178.847.652;N04.590.374.800;I01.738.805;I03.743
28954238,Cellular Reprogramming;Chromatin;Fibroblasts;Humans;Neurons;Chromatin Assembly and Disassembly,G04.152.262;G05.135;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.329.228;B01.050.150.900.649.313.988.400.112.400.400;A08.675;A11.671;G04.400.095;G05.213.095;G05.308.095
28954221,"Animals;Cell Proliferation;Humans;Interleukin-18;Mice;Receptors, Antigen, T-Cell;Interleukin-18;Adoptive Transfer;Neoplasms;Immunotherapy",B01.050;G04.161.750;G07.345.249.410.750;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;B01.050.150.900.649.313.992.635.505.500;D12.776.543.750.705.816.824;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;E02.095.465.425.400.330.050;E05.478.550.520.050;C04;E02.095.465.425
28953887,"Animals;Apoptosis;Cell Line, Tumor;Drug Resistance, Neoplasm;Enzyme Activation;Humans;JNK Mitogen-Activated Protein Kinases;MAP Kinase Signaling System;Melanoma;Mice;Mitogen-Activated Protein Kinase Kinases;Mitogen-Activated Protein Kinases;Mutation;Phosphorylation;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins c-raf;Signal Transduction;TOR Serine-Threonine Kinases;beta Catenin;p21-Activated Kinases",B01.050;G04.146.160;A11.251.210.190;A11.251.860.180;G07.690.773.984.395;G02.111.263;G03.328;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.567.374;D12.644.360.450.340;D12.776.476.450.340;G02.111.820.560;G03.493.560;G04.835.560;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;D08.811.913.696.620.682.700.565;D08.811.913.696.620.682.725.200;D12.644.360.440;D12.776.476.440;D08.811.913.696.620.682.700.567;D12.644.360.450;D12.776.476.450;G05.365.590;G02.111.665;G02.607.780;G03.796;D27.505.519.389.755;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D08.811.913.696.620.682.700.559.842.500;D12.644.360.400.842.500;D12.776.476.400.842.500;D12.776.624.664.700.204.500;G02.111.820;G04.835;D08.811.913.696.620.682.700.931;D12.776.476.925;D12.776.091.249;D12.776.220.145.500;D12.776.930.130;D08.811.913.696.620.682.700.596;D12.644.360.552;D12.776.476.548
28953875,"Acetyl Coenzyme A;Animals;Antineoplastic Agents;Binding, Competitive;Biocatalysis;Catalytic Domain;Cell Line, Tumor;Cell Lineage;Cell Proliferation;Crystallography, X-Ray;Enzyme Inhibitors;Gene Expression Regulation, Neoplastic;Hematologic Neoplasms;Heterocyclic Compounds, 4 or More Rings;Histone Acetyltransferases;Humans;Mice;Mice, SCID;Models, Molecular;Neoplasms;Prostatic Neoplasms, Castration-Resistant;Protein Conformation;Receptors, Androgen;Xenograft Model Antitumor Assays;p300-CBP Transcription Factors",D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;B01.050;D27.505.954.248;E05.196.080;G02.111.084;G02.111.570.120.309;G02.111.086;G02.130.500;G03.105;G02.111.570.120.704;G02.111.570.820.709.275.750.188;A11.251.210.190;A11.251.860.180;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.161.750;G07.345.249.410.750;E05.196.309.742.225;D27.505.519.389;G05.308.370;C04.588.448;C15.378.400;D03.633.400;D08.811.913.050.134.415.500;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.780;E05.599.595;C04;C04.588.945.440.770.500;C12.294.260.750.500;C12.294.565.625.500;C12.758.409.750.500;G02.111.570.820.709;D12.776.826.750.150;E05.337.550.200.900;E05.624.850;D08.811.913.050.134.415.500.575;D12.776.930.680
28953103,,
28952994,"Audiovisual Aids;Communication;Electronic Health Records;Humans;Internship and Residency;Medical Staff, Hospital;Physician Executives",J01.897.280.500;L01.178.820.090;F01.145.209;L01.143;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;M01.526.070.700;M01.526.485.800;N02.360.800
28952989,Clinical Clerkship;Educational Measurement;Knowledge;Motivation;Physical Examination,I02.358.105;I02.399;K01.468;F01.658;F01.752.543.500.750;E01.370.600
28952327,Immunization;Pediatrics;Vaccines,E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;H02.403.670;D20.215.894
28951830,"Animals;Diabetes Mellitus, Type 1;Humans;Insulin;Insulin-Secreting Cells;Islets of Langerhans",B01.050;C18.452.394.750.124;C19.246.267;C20.111.327;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;A03.734.414;A06.300.414
28951441,"Catheter-Related Infections;Catheterization, Central Venous;Central Venous Catheters;Cooperative Behavior;Cross Infection;Guideline Adherence;Humans;Infant, Newborn;Infection Control;Intensive Care Units, Neonatal;Intensive Care, Neonatal;Practice Guidelines as Topic;Program Evaluation;Quality Improvement;Sterilization",C01.539.195;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;E07.132.750.500;F01.145.813.115;C01.539.248;C23.550.291.875.500;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N06.850.780.200.450;N02.278.388.493.390.380;E02.760.190.405;N02.421.585.190.500;N04.761.700.350.650;N05.700.350.650;E05.337.820;N04.761.685;N05.715.360.650;J01.293.754;N04.761.744;N06.850.780.200.450.850
28951327,"Adult;B-Lymphocyte Subsets;Case-Control Studies;Diabetes Mellitus, Type 2;Humans;Immunophenotyping;Phenotype;B-Lymphocytes;Diabetes Mellitus, Type 1",M01.060.116;A11.063.438.450;A11.118.637.555.567.550.450;A11.118.637.555.567.562.200;A15.145.229.637.555.567.550.450;A15.145.229.637.555.567.562.200;A15.382.032.438.450;A15.382.490.555.567.550.300;A15.382.490.555.567.562.450;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;G05.695;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;C18.452.394.750.124;C19.246.267;C20.111.327
28950998,"Child;Child, Preschool;Collagen Type VIII;Developmental Disabilities;Drug Resistant Epilepsy;Encephalocele;Humans;Mutation;Polymicrogyria;Retinal Degeneration;Retinal Detachment;Siblings",M01.060.406;M01.060.406.448;D12.776.860.300.250.400.400;F03.625.421;C10.228.140.490.125;C10.500.680.488;C16.131.666.680.488;C23.300.707.186;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C10.500.507.500.500;C16.131.666.507.500.500;C11.270.612;C11.768.585;C11.768.648;F01.829.263.500.490;I01.880.853.150.500.505;M01.781
28947347,"Adolescent;Case-Control Studies;Child;Crime Victims;Geographic Information Systems;Humans;Philadelphia;Residence Characteristics;Risk Factors;Time Factors;Urban Population;Violence;Wounds, Gunshot",M01.060.057;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.135;L01.313.500.750.300.314;L01.470.750.750.462;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;N01.224.791;N06.850.505.400.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;N01.600.900;I01.198.240.856;I01.880.735.900;C26.986.900
28947307,Biomarkers;Follow-Up Studies;Heart Failure;Heart-Assist Devices;Humans;Middle Aged;Postoperative Period;Prognosis;Retrospective Studies;Serum Albumin;Severity of Illness Index;Survival Rate;United States,D23.101;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280.434;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.614.750;N02.421.585.753.750;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D12.776.034.841;D12.776.124.727;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;Z01.107.567.875
28947294,"Cross-Sectional Studies;Dermatologic Surgical Procedures;Dermatology;Humans;Medicare;Practice Patterns, Physicians';Reconstructive Surgical Procedures;United States",E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E04.680.275;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.590.374.577;N05.300.625;E04.680;Z01.107.567.875
28947287,,
28947283,Confidentiality;Humans;Medical Errors;Mohs Surgery;Photography;Skin Neoplasms;Smartphone;Software,F04.096.544.335.240;I01.880.604.473.650.500;I01.880.604.583.080;N03.706.437.650.124;N03.706.535.230;B01.050.150.900.649.313.988.400.112.400.400;N02.421.450;E04.494.575;E04.680.275.580;E01.370.350.600;E05.712;C04.588.805;C17.800.882;L01.224.230.260.550.500.500;L01.224.900
28947100,Adult;Complementary Therapies;Health Care Surveys;Humans;Larynx;Middle Aged;Occupational Health;Occupations;Patient Acceptance of Health Care;Patient Preference;Voice Disorders;Voice Quality;Voice Training;Complementary Therapies;Dysphonia,M01.060.116;E02.190;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;B01.050.150.900.649.313.988.400.112.400.400;A04.329;M01.060.116.630;N01.400.525;N01.824.547;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;C08.360.940;C09.400.940;C10.597.975;C23.888.592.979;G09.772.925.960;E02.760.169.063.500.727.862;E02.831.727.862;E02.190;C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325
28946028,,
28945692,,
28945526,"Animals;Behavior, Animal;Cell Proliferation;Cell Survival;Conditioning (Psychology);Cosmic Radiation;Dentate Gyrus;Dose-Response Relationship, Radiation;Fear;Memory;Mice;Neurogenesis;Neurons;Silicon;Time Factors;Whole-Body Irradiation",B01.050;F01.145.113;G04.161.750;G07.345.249.410.750;G04.346;F02.463.425.179;G01.060.185;G01.750.750.235;G16.500.200;N06.230.300.100.300;A08.186.211.180.405.200;A08.186.211.200.885.287.500.345.200;E05.799.513.500;G01.750.740.500;G04.712.500;G07.225;G07.738.500;N06.850.810.250.180;F01.470.361;F02.463.425.540;B01.050.150.900.649.313.992.635.505.500;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.675;A11.671;D01.268.513.937;G01.910.857;E02.815.814;E05.980
28945504,"Clinical Trials as Topic;History, 20th Century;History, 21st Century;Humans;Immunotherapy;Neoplasms;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Translational Medical Research;Vaccines, Synthetic",E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04;D12.776.543.750.705.816.824;D12.776.828.300;H01.770.644.145.675;D12.776.828.868;D20.215.894.865;D23.050.865
28945452,,
28944497,"Alleles;Cardiovascular Diseases;Diabetes Mellitus, Type 2;Gene Frequency;Genome-Wide Association Study;Humans;Metabolic Networks and Pathways;Phenotype;Polymorphism, Single Nucleotide;Risk Factors;Diabetes Mellitus, Type 2",G05.360.340.024.340.030;C14;C18.452.394.750.149;C19.246.300;G05.330;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G03.493;G05.695;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C18.452.394.750.149;C19.246.300
28944399,Adult;Behavior;Biomarkers;Humans;Psychomotor Performance;Sleep Deprivation;Sleep Stages;Biomarkers;Individuality;Sleep Deprivation,M01.060.116;F01.145;D23.101;B01.050.150.900.649.313.988.400.112.400.400;F02.808;G11.427.700;G11.561.660;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F02.830.855.796;G11.561.803.754;D23.101;F01.752.488;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
28944318,,
28944280,,
28944163,"Lymphohistiocytosis, Hemophagocytic;Macrophage Activation Syndrome;Precision Medicine",C15.604.250.410.575;C20.683.515.800;E02.574;H02.403.200.700
28943830,Return to Sport,I03.450.642.845.605
28943457,"Humans;Myositis Ossificans;Ossification, Heterotopic;Ossification, Heterotopic",B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;C23.550.751;C23.550.751
28943428,"Animals;Atazanavir Sulfate;Glucose;Glucose Transporter Type 4;Hippocampus;Indinavir;Insulin;Memory, Short-Term;Microinjections;Nelfinavir;Rats;Rats, Sprague-Dawley;Signal Transduction;Spatial Memory;Glucose Transport Proteins, Facilitative;Hippocampus;Insulin;Memory",B01.050;D03.383.725.068;D12.644.456.157;D09.947.875.359.448;D12.776.157.530.500.500.937;D12.776.157.530.937.563.937;D12.776.543.585.500.500.937;D12.776.543.585.937.625.937;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D03.383.725.385;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;F02.463.425.540.407;E02.319.267.530.690;E05.591.570;D03.633.100.531.520;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;G02.111.820;G04.835;F02.463.425.540.886;D12.776.157.530.500.500;D12.776.157.530.937.563;D12.776.543.585.500.500;D12.776.543.585.937.625;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;F02.463.425.540
28943386,,
28942964,"Alleles;Alternative Splicing;Animals;Biological Transport;CRISPR-Cas Systems;Carnitine;Cells, Cultured;Cohort Studies;Gene Expression Regulation;Genome-Wide Association Study;High-Throughput Nucleotide Sequencing;Humans;Liver;Metabolic Diseases;Metabolomics;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Mice, Knockout;Organic Cation Transporter 1;Polymorphism, Single Nucleotide;Tissue Distribution;Allelic Imbalance;Genomics;Metabolomics",G05.360.340.024.340.030;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;G03.143;G05.308.203.374.394;D02.092.877.883.099;A11.251;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.308;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;A03.620;C18.452;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.157.530.450.250.812.500;D12.776.157.530.937.612.500;D12.776.543.585.450.250.812.500;D12.776.543.585.937.701.500;G05.365.795.598;G03.787.917;G07.690.725.949;G05.365.590.029;H01.158.273.180.350;H01.158.273.343.350;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
28942762,"Academies and Institutes;Adult;Humans;Polysomnography;Self Care;Sleep Apnea, Obstructive;United States;Sleep Apnea, Obstructive",N03.540.052;M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;E01.370.520.625;E02.900;I03.050.563;N02.421.784.680;C08.618.085.852.850;C10.886.425.800.750.850;Z01.107.567.875;C08.618.085.852.850;C10.886.425.800.750.850
28942604,,
28942365,"Animals;Gene Expression Regulation;Hair Follicle;Mice;Mice, Transgenic;Models, Animal;Morphogenesis;NF-kappa B;Signal Transduction;Stem Cells",B01.050;G05.308;A10.272.497.500;A17.360.710;A17.815.250.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;E05.598;G07.345.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;G02.111.820;G04.835;A11.872
28941764,"Chronic Kidney Disease-Mineral and Bone Disorder;Humans;Hypercalcemia;Nephrology;Parathyroid Hormone;Renal Insufficiency, Chronic;Calcium;Practice Guideline;Dialysis;Evidence-Based Medicine;Phosphates;Chronic Kidney Disease-Mineral and Bone Disorder",C05.116.198.816.750;C12.777.419.080;C13.351.968.419.795;C18.452.104.816.750;C18.452.174.845.750;C18.654.521.500.133.770.734.750;C19.642.355.480.500;B01.050.150.900.649.313.988.400.112.400.400;C18.452.174.451;C18.452.950.340;H02.403.429.580;D06.472.699.590;D12.644.548.587;C12.777.419.780.750;C13.351.968.419.780.750;D01.268.552.100;D01.552.539.288;D23.119.100;V02.515.500;E05.196.353;G02.186;H02.249.750;H02.403.200.400;D01.029.260.700.675.374;D01.248.497.158.730;D01.695.625.675.650;C05.116.198.816.750;C12.777.419.080;C13.351.968.419.795;C18.452.104.816.750;C18.452.174.845.750;C18.654.521.500.133.770.734.750;C19.642.355.480.500
28941588,"Casein Kinase I;Gene Expression Regulation, Fungal;Mitochondria;Mitochondrial Proteins;Phosphorylation;Protein Processing, Post-Translational;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Sulfurtransferases;Phosphotransferases;Mitochondria;Phosphorylation",D05.500.117.750;D08.811.913.696.620.682.700.140.300;D12.776.476.081.750;D12.776.476.150.299;G05.308.330;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.575;G02.111.665;G02.607.780;G03.796;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;D08.811.913.817.500;D08.811.913.696;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.665;G02.607.780;G03.796
28941543,"Cardiopulmonary Resuscitation;Critical Care;Heart Arrest;Humans;Intensive Care Units, Pediatric;Monitoring, Physiologic;Point-of-Care Systems;Quality of Health Care;Blood Pressure;Carbon Dioxide;Heart Arrest;Critical Care;Survival",E02.365.647.110;E02.760.190;N02.421.585.190;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E01.370.520;N04.452.442.452.680;N04.452.515.360.652;N04.590.874;N04.761;N05.715;E01.370.600.875.249;G09.330.380.076;D01.200.200;D01.362.150;D01.650.550.200;C14.280.383;E02.760.190;N02.421.585.190;I03.784
28941538,Analgesia;Analgesics;Anesthetics;Child;Critical Care;Humans;Hypnotics and Sedatives;Neuromuscular Blockade;Neuromuscular Blocking Agents;Pediatrics;Benzodiazepines;Critical Illness,E03.091;D27.505.696.663.850.014;D27.505.954.427.040;D27.505.696.277.100;D27.505.954.427.210.100;M01.060.406;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.277.350;D27.505.954.427.210.350;E03.706;E05.635;D27.505.696.663.700.710;H02.403.670;D03.633.100.079.080;C23.550.291.625
28941532,Humans;Neurofibromatosis 1;Neuroimaging;Optic Nerve Glioma,B01.050.150.900.649.313.988.400.112.400.400;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;E01.370.350.578;E01.370.376.537;E05.629;C04.557.465.625.600.380.795;C04.557.470.670.380.795;C04.557.580.625.600.380.795;C04.588.614.300.600.600;C04.588.614.596.240.240.500;C10.292.225.800.500;C10.292.700.500.500;C10.551.360.500.500;C10.551.775.250.500.500;C11.640.544.500
28941525,Brain;Child;Disease Management;Humans;Pseudotumor Cerebri,A08.186.211;M01.060.406;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.631.750
28941407,"Aged;Aged, 80 and over;Alleles;Alzheimer Disease;Cognition;Cognitive Dysfunction;Genome-Wide Association Study;Hippocampus;Humans;Middle Aged;Neurogenesis;Organ Size;Receptor, Adenosine A2A;Alzheimer Disease;Memory;Neurogenesis",M01.060.116.100;M01.060.116.100.080;G05.360.340.024.340.030;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F02.463.188;F03.615.250.700;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;D12.776.543.750.695.700.700.200.100;D12.776.543.750.720.700.700.200.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F02.463.425.540;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620
28941293,"Animals;Axon Initial Segment;Axons;Cells, Cultured;Cyclin-Dependent Kinase 5;Cytoskeleton;Dyneins;Microtubule-Associated Proteins;Microtubules;Neurons;Protein Transport;Rats, Sprague-Dawley;Axon Initial Segment;Dyneins",B01.050;A08.675.542.145.250;A11.284.180.075.125;A11.671.137.170;A11.671.501.145.250;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A11.251;D08.811.913.696.620.682.700.646.500.500.500;D12.644.360.250.067.875;D12.776.167.200.067.875;D12.776.476.250.067.875;A11.284.430.214.190.750;D08.811.277.040.013.500.063;D08.811.277.040.025.024.063;D08.811.277.040.025.193.249;D12.776.157.025.750.063;D12.776.220.600.200;D12.776.220.600.450;D12.776.631.560;A11.284.430.214.190.750.602;A08.675;A11.671;G03.143.700;B01.050.150.900.649.313.992.635.505.700.750;A08.675.542.145.250;A11.284.180.075.125;A11.671.137.170;A11.671.501.145.250;D08.811.277.040.013.500.063;D08.811.277.040.025.024.063;D08.811.277.040.025.193.249;D12.776.157.025.750.063;D12.776.220.600.200
28941137,"Adult;Alanine Transaminase;Antiviral Agents;DNA, Viral;Hepatitis B e Antigens;Hepatitis B virus;Hepatitis B, Chronic;Humans;Incidence;Logistic Models;Multivariate Analysis;Pennsylvania;Pregnancy;Pregnancy Complications, Infectious;Retrospective Studies;Hepatitis B virus;Pregnancy",M01.060.116;D08.811.913.477.700.100;D27.505.954.122.388;D13.444.308.568;D23.050.327.495.500.469;B04.280.375.650.425;B04.450.390.650.425;C02.256.430.400.100;C02.440.435.100;C06.552.380.350.100;C06.552.380.705.437.100;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;G08.686.784.769;C01.539.674;C13.703.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;B04.280.375.650.425;B04.450.390.650.425;G08.686.784.769
28940999,"Adolescent;Age Factors;Child;Child, Preschool;Death;Donor Selection;Follow-Up Studies;Graft Survival;Heart Transplantation;Humans;Infant;Infant, Newborn;Kaplan-Meier Estimate;Outcome Assessment (Health Care);Registries;Retrospective Studies;Survival Rate;Tissue Donors",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;C23.550.260;E04.936.537.500;N02.421.911.600;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G12.875.545.340;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;M01.898
28940864,,
28940481,"Administration, Intravaginal;Adult;Birth Weight;Cervical Length Measurement;Cervix Uteri;Fetal Membranes, Premature Rupture;Gestational Age;Humans;Infant, Newborn;Intention to Treat Analysis;Pessaries;Pregnancy;Premature Birth;Progesterone;Progestins;Young Adult;Pessaries;Premature Birth;Randomized Controlled Trial",E02.319.267.120.500;M01.060.116;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;E01.370.350.850.865.249;E01.370.378.630.865.249;A05.360.319.679.256;C13.703.420.339;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;E07.858.499;G08.686.784.769;C13.703.420.491.500;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;D27.505.696.399.472.858;M01.060.116.815;E07.858.499;C13.703.420.491.500;V03.175.250.500.500
28940308,"Adolescent;Adult;Blood Transfusion;Cyclohexanones;Dihydropyridines;Dose-Response Relationship, Drug;Humans;Iron Chelating Agents;Kidney Diseases;Middle Aged;Siderophores;Thiazoles;Young Adult;beta-Thalassemia",M01.060.057;M01.060.116;E02.095.135;D02.455.426.392.368.367.340;D02.522.400;D03.383.725.203;G07.690.773.875;G07.690.936.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.914.500.410;D27.720.832.500.410;C12.777.419;C13.351.968.419;M01.060.116.630;D27.505.519.914.500.410.750;D27.720.832.500.410.750;D02.886.675;D03.383.129.708;M01.060.116.815;C15.378.071.141.150.875.150;C15.378.420.826.150;C16.320.070.875.150;C16.320.365.826.150
28940272,"Child;Diagnosis, Differential;Foot Dermatoses;Humans;Juglans;Nuts;Pigmentation Disorders;Pigments, Biological;Remission, Spontaneous",M01.060.406;E01.171;C17.800.321.125;B01.050.150.900.649.313.988.400.112.400.400;B01.650.940.800.575.912.250.859.750.500.500;A18.024.500.500;G07.203.300.700;J02.500.700;C17.800.621;C23.550.755;D23.767;C23.550.291.656.700;G16.767
28940162,"Central Nervous System Infections;Humans;Immunologic Factors;Immunosuppressive Agents;Multiple Sclerosis;Opportunistic Infections;Fingolimod Hydrochloride;Natalizumab;Leukoencephalopathy, Progressive Multifocal",C01.395;C10.228.228;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;D27.505.696.477.656;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C01.539.597;C02.597;C03.684;D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450
28939992,Cardiopulmonary Resuscitation;Child;Heart Arrest;Humans,E02.365.647.110;M01.060.406;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400
28939732,"Disability Evaluation;Humans;Malingering;Stress Disorders, Post-Traumatic;Veterans",E01.370.400;B01.050.150.900.649.313.988.400.112.400.400;F01.145.126.925;F03.950.750.500;M01.930
28939607,,
28939455,Bone Marrow Transplantation;Cognition;Cognition,E02.095.147.725.040;E04.936.580.040;F02.463.188;F02.463.188
28939374,"Administration, Intravenous;Administration, Oral;Adolescent;Adrenal Cortex Hormones;Anti-Inflammatory Agents, Non-Steroidal;Child;Child, Preschool;Cohort Studies;Colitis, Ulcerative;Humans;Mesalamine;Remission Induction;Treatment Outcome",E02.319.267.082;E02.319.267.100;M01.060.057;D06.472.040;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;B01.050.150.900.649.313.988.400.112.400.400;D02.241.223.100.050.300.500;D02.241.223.100.300.595.100.540;D02.241.511.390.595.100.540;D02.455.426.559.389.127.020.452.750;D02.455.426.559.389.127.281.595.100.540;D02.455.426.559.389.657.410.595.100.540;E02.860;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28939299,,
28939298,,
28939297,,
28939296,,
28939295,,
28939137,"Candidiasis, Chronic Mucocutaneous;Quality of Life",C01.539.800.200.100;C01.703.160.165;C01.703.295.165;C17.800.838.208.165;I01.800;K01.752.400.750;N06.850.505.400.425.837
28938967,"Adolescent;Cardiac Catheterization;Child;Child, Preschool;Echocardiography, Transesophageal;Guideline Adherence;Health Information Systems;Heart Septal Defects, Atrial;Humans;Propensity Score;Retrospective Studies;Septal Occluder Device;Treatment Outcome;United States;United States Food and Drug Administration",M01.060.057;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406;M01.060.406.448;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;N04.761.337;N05.715.360.395;L01.313.500.750.300.361;C14.240.400.560.375;C14.280.400.560.375;C16.131.240.400.560.375;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E07.695.715;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
28938913,"Aged;Antipsychotic Agents;Clozapine;Constipation;Endoscopy, Digestive System;Esophagus;Fatal Outcome;Fecal Impaction;Gastrointestinal Diseases;Gram-Negative Bacterial Infections;Humans;Intestine, Small;Necrosis;Respiratory Aspiration;Respiratory Insufficiency;Schizophrenia;Shock, Septic;Stomach;Vomiting;Clozapine;Quetiapine Fumarate",M01.060.116.100;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;D03.633.300.240.220;C23.888.821.150;E01.370.372.250;E01.370.388.250.250;E04.210.240;E04.502.250.250;A03.556.875.500;E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325;C06.405.469.531.424;C06.405;C01.252.400;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.684;C23.550.717;G04.146.638;C08.618.749;C23.550.773;C08.618.846;F03.700.750;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;A03.556.875.875;C23.888.821.937;D03.633.300.240.220;D02.886.680.702.500.500;D03.633.300.276.500
28938361,"Adolescent;Child;Child, Preschool;Continuous Positive Airway Pressure;Follow-Up Studies;Humans;Nasal Septum;Retrospective Studies;Rhinoplasty;Treatment Outcome",M01.060.057;M01.060.406;M01.060.406.448;E02.041.625.790.259;E02.880.820.790.259;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;A04.531.591;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.218.755;E04.580.392.500;E04.680.650;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28938236,,
28938121,Animals;Endoplasmic Reticulum;Humans;Huntingtin Protein;Huntington Disease;Nerve Tissue Proteins;Nuclear Proteins,B01.050;A11.284.430.214.190.875.248;B01.050.150.900.649.313.988.400.112.400.400;D12.776.441;C10.228.140.079.545;C10.228.140.380.278;C10.228.662.262.249.750;C10.574.500.497;C16.320.400.430;F03.615.250.400;F03.615.400.390;D12.776.631;D12.776.660
28938120,"Humans;Oncogene Proteins, Fusion;Prions;Proto-Oncogene Protein c-fli-1;RNA-Binding Protein EWS;Sarcoma, Ewing;Transcription Factors",B01.050.150.900.649.313.988.400.112.400.400;D12.776.602.500.500;D12.776.624.664.500;D12.776.785;D12.776.260.665.400;D12.776.624.664.700.175.400;D12.776.930.720.400;D12.644.360.650;D12.776.157.142.750;D12.776.157.725.813.750.900;D12.776.476.650;D12.776.624.664.700.913;D12.776.664.962.813.750.900;C04.557.450.565.575.650.800;C04.557.450.795.620.800;D12.776.930
28938095,Chromatin;Humans;Macrophages,A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;B01.050.150.900.649.313.988.400.112.400.400;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
28937912,"Adolescent;Adult;Connecticut;Contraception Behavior;Humans;Postpartum Period;Pregnancy;Pregnant Women;Randomized Controlled Trials as Topic;Substance-Related Disorders;Time Factors;Young Adult;Contraception;Pregnancy, Unplanned",M01.060.057;M01.060.116;Z01.107.567.875.550.200;F01.145.688.500;G08.686.784.891.500;B01.050.150.900.649.313.988.400.112.400.400;G08.686.702;G08.686.784.769;M01.975.807;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C25.775;F03.900;G01.910.857;M01.060.116.815;E02.875.194;G08.686.784.769.570
28937707,Antidepressive Agents;Depression;Humans;Phototherapy;Psychiatric Status Rating Scales;Psychological Techniques;Sleep Deprivation;Transcranial Magnetic Stimulation;Treatment Outcome,D27.505.954.427.700.122;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;E02.774;F04.711.513.653;E05.796;F04.669;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;E02.621.820;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28937441,"Diagnosis, Differential;Granuloma;Humans;Melanoma;Middle Aged;Mohs Surgery;Monitoring, Physiologic;Neoplasm Metastasis;Neoplasm Recurrence, Local;Reoperation;Risk Assessment;Skin Neoplasms",E01.171;C15.604.515.292;C23.550.382;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;E04.494.575;E04.680.275.580;E01.370.520;C04.697.650;C23.550.727.650;C04.697.655;C23.550.727.655;E04.690;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04.588.805;C17.800.882
28936617,Death;Family;Humans;Intensive Care Units;Terminal Care,C23.550.260;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E02.760.905;N02.421.585.905
28936487,Lysosomes;Megakaryocytes;Blood Platelets,A11.284.430.214.190.875.190.550;A11.148.479;A15.378.316.479;A11.118.188;A15.145.229.188
28935694,"Adolescent;Adult;Aged;Antibodies, Monoclonal, Humanized;Bone Marrow Cells;Cell Proliferation;Child;Child, Preschool;Cytokines;Humans;Infant;Kinetics;Leukemia, Lymphocytic, Chronic, B-Cell;Middle Aged;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;Recurrence;Transgenes;Tumor Burden;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;A11.148;A15.378.316;G04.161.750;G07.345.249.410.750;M01.060.406;M01.060.406.448;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G01.374.661;G02.111.490;C04.557.337.428.080.125;C15.604.515.560.080.125;C20.683.515.528.080.125;M01.060.116.630;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.705.816.824;C23.550.291.937;G05.360.340.024.340.825;E05.041.124.892;M01.060.116.815
28935387,"Adolescent;Adolescent Health Services;Bhutan;Health Knowledge, Attitudes, Practice;Health Services Accessibility;Humans;Philadelphia;Qualitative Research;Refugees;Reproductive Health;Sexual Behavior;Adolescent;Family Planning Services;Refugees",M01.060.057;N02.421.044;Z01.252.245.162;F01.100.150.500;N05.300.150.410;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;H01.770.644.241.850;M01.755;N01.400.625;F01.145.802;M01.060.057;N02.421.143.401;N02.421.800.249;M01.755
28935384,Adolescent;Body Mass Index;Gender Identity;Health Status Disparities;Health Surveys;Humans;Longitudinal Studies;Obesity;Risk Factors;Sexual and Gender Minorities;Adolescent;Obesity,M01.060.057;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.777;M01.060.057;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28935134,"Anesthetics;Animals;Humans;Mice;Models, Molecular;Photoaffinity Labels;Propofol;Protein Conformation;Rats;TRPA1 Cation Channel",D27.505.696.277.100;D27.505.954.427.210.100;B01.050;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;E05.599.595;D27.720.470.410.080.600;D02.455.426.559.389.657.773;G02.111.570.820.709;B01.050.150.900.649.313.992.635.505.700;D12.776.157.530.400.901.250;D12.776.543.585.400.901.250
28934762,"Adult;Aged;Body Composition;Cancer Survivors;Colonic Neoplasms;Exercise;Humans;Intra-Abdominal Fat;Middle Aged;Neoplasm Recurrence, Local",M01.060.116;M01.060.116.100;G02.111.130;G03.180;G07.100.049;M01.860.350;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;A10.165.114.830.500.500;M01.060.116.630;C04.697.655;C23.550.727.655
28934596,Methamphetamine,D02.092.471.683.152.619
28934533,"Adult;Aged;Atherosclerosis;Carotid Arteries;Carotid Artery Diseases;Carotid Intima-Media Thickness;Humans;Middle Aged;Obesity;Positive-Pressure Respiration;Risk Factors;Sleep Apnea, Obstructive;Waist Circumference;Atherosclerosis",M01.060.116;M01.060.116.100;C14.907.137.126.307;A07.015.114.186;C10.228.140.300.200;C14.907.253.123;E01.370.350.850.150;E01.370.370.180;G09.330.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02.041.625.790;E02.880.820.790;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.618.085.852.850;C10.886.425.800.750.850;E01.370.600.115.100.160.560;E05.041.124.160.875;G07.100.100.160.560;C14.907.137.126.307
28934364,Animals;Carcinogenesis;DNA Damage;Gene Expression Regulation;Gene Knockout Techniques;HCT116 Cells;Histones;Homeostasis;Humans;Intestinal Mucosa;Intestinal Neoplasms;Intestines;Mice;Regeneration;Stem Cells,B01.050;C04.697.098;C23.550.727.098;G05.200;G05.308;E05.393.335.750;A11.251.210.190.380;A11.251.860.180.380;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G07.410;B01.050.150.900.649.313.988.400.112.400.400;A03.556.124.369;A10.615.550.444;C04.588.274.476.411;C06.301.371.411;C06.405.249.411;C06.405.469.491;A03.556.124;B01.050.150.900.649.313.992.635.505.500;G16.762;A11.872
28934024,Humans;Melanoma;Physical Examination;Skin Neoplasms,B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;E01.370.600;C04.588.805;C17.800.882
28933193,"Education;Subacute Care;Brain Injuries, Traumatic",I02;E02.760.850;N02.421.585.850;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28932688,Congenital Disorders of Glycosylation,C16.320.565.202.125;C18.452.648.202.125
28931652,"Animals;Aorta;Heart Arrest;Hemodynamics;Hemoglobins;Hypoxia;Mitochondria, Heart;Myocardial Ischemia;Myocardium;Myoglobin;Oxidation-Reduction;Oxygen;Rats, Sprague-Dawley;Spectrum Analysis, Raman;Sus scrofa",B01.050;A07.015.114.056;C14.280.383;G09.330.380;D12.776.124.400;D12.776.422.316.762;C23.888.852.079;A11.284.430.214.190.875.564.627.603;A11.284.835.626.627.603;C14.280.647;C14.907.585;A02.633.580;A07.541.704;A10.690.552.750;D12.776.210.500.588;D12.776.422.316.940;G02.700;G03.295.531;D01.268.185.550;D01.362.670;B01.050.150.900.649.313.992.635.505.700.750;E05.196.822.860;E05.196.867.890;B01.050.150.900.649.313.500.880.399
28931594,"Binding Sites;Biological Transport;Cell Adhesion;Cell Membrane;Endosomes;Kinesin;Kinetics;Membrane Lipids;Microtubules;Models, Molecular;Phosphatidylinositol Phosphates;Phosphatidylinositols;Protein Binding;Protein Domains;Protein Transport",G02.111.570.120;G03.143;G04.022;A11.284.149;A11.284.430.214.190.875.190.880.337;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;G01.374.661;G02.111.490;D10.570;A11.284.430.214.190.750.602;E05.599.595;D10.570.755.375.760.400.942.625;D10.570.755.375.760.400.942;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G03.143.700
28931576,Child;Child Health;Child Mortality;Global Health;Humans;International Cooperation,M01.060.406;N01.400.225;E05.318.308.985.550.287;N01.224.935.698.150;N06.850.505.400.975.550.287;N06.850.520.308.985.550.287;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500
28931428,"Alzheimer Disease;Cohort Studies;Forecasting;Health Status Indicators;Humans;Life Expectancy;Life Tables;Mental Status Schedule;Models, Theoretical;Population Surveillance;Predictive Value of Tests;Alzheimer Disease",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;I01.320;E05.318.308.980.438.475;N05.715.360.300.800.438.375;N06.850.520.308.980.438.475;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.450;N01.224.935.464;N06.850.505.400.975.450;N06.850.520.308.985.450;E05.318.308.985.475;E05.318.740.100.500;N01.224.935.530;N06.850.505.400.975.475;N06.850.520.308.985.475;F04.711.513.603.500;F04.711.513.653.574;E05.599;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;C10.228.140.380.100;C10.574.945.249;F03.615.400.100
28931399,"Adult;Child;Child, Preschool;Clinical Competence;Diagnostic Tests, Routine;Fever of Unknown Origin;Humans;Infant;Infant, Newborn;Interviews as Topic;Kenya;Malaria;Primary Health Care;Qualitative Research;Sex Factors;Behavior;Child;Fever;Kenya;Knowledge;Malaria",M01.060.116;M01.060.406;M01.060.406.448;I02.399.630.210;N04.761.210;N05.715.175;E01.370.395;C23.888.119.344.345;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;Z01.058.290.120.400;C03.752.530;N04.590.233.727;H01.770.644.241.850;N05.715.350.675;N06.850.490.875;F01.145;M01.060.406;C23.888.119.344;Z01.058.290.120.400;K01.468;C03.752.530
28931318,Congenital Hypothyroidism,C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281
28930815,"Adolescent;Child;Child, Preschool;Clinical Decision-Making;Clinical Protocols;Decision Support Techniques;Guideline Adherence;Humans;Infant;Infant, Newborn;Practice Guidelines as Topic;Practice Patterns, Physicians';Prospective Studies;Respiration, Artificial;Respiratory Distress Syndrome, Adult;United States",M01.060.057;M01.060.406;M01.060.406.448;E01.055;E02.183;N05.715.360.330.125;E05.245;L01.313.500.750.190;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;Z01.107.567.875
28930765,"Anesthesiology;Critical Care;Education, Medical, Graduate;Formative Feedback;Humans;Internship and Residency;Leadership;Professional Competence;Program Development;Teaching",H02.403.066;E02.760.190;N02.421.585.190;I02.358.337.350;I02.358.399.350;F02.784.629.529.223;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F01.752.609;I02.399.630;N04.452.760;I02.903
28930748,,
28930709,Adolescent;Aggression;Disabled Children;Humans;Intellectual Disability;Morals;Psychomotor Agitation;Psychosurgery,M01.060.057;F01.145.126.125;F01.145.813.045;M01.150.200;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F01.829.500;K01.752.566;C10.597.350.600;C10.597.606.881.700;C23.888.592.350.600;C23.888.592.604.882.700;F01.700.875.700;E04.525.600;F04.570.630
28930659,"Animals;Cell Differentiation;Cell Lineage;Chromatin Assembly and Disassembly;Gene Expression Profiling;Gene Expression Regulation;Genetic Loci;Homeostasis;Immunity, Innate;Inhibitor of Differentiation Protein 2;Killer Cells, Natural;Lymphocyte Subsets;Lymphocytes;Mice;Promoter Regions, Genetic;RNA, Long Noncoding;Regulatory Sequences, Nucleic Acid;STAT5 Transcription Factor;Transcription, Genetic;RNA, Long Noncoding",B01.050;G04.152;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.400.095;G05.213.095;G05.308.095;E05.393.332;G05.308;G05.360.340.024.380;G07.410;G12.450.564;D12.776.930.329.500;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;A11.118.637.555.567.550;A15.145.229.637.555.567.550;A15.382.490.555.567.550;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;B01.050.150.900.649.313.992.635.505.500;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D13.444.735.790.375;G02.111.570.080.689;G05.360.080.689;D12.644.360.024.342.500;D12.776.157.057.186.500;D12.776.476.024.430.500;D12.776.930.840.500;G02.111.873;G05.297.700;D13.444.735.790.375
28929835,"Animals;B-Lymphocytes;CD4-Positive T-Lymphocytes;Diphtheria Toxin;Encephalomyelitis, Autoimmune, Experimental;Interferon-gamma;Interleukin-10;Interleukin-2;Lymph Nodes;Lymphocyte Activation;Macrophages;Mice;Multiple Sclerosis;Recombinant Fusion Proteins;Spinal Cord;Spleen;Tumor Necrosis Factor-alpha;Diphtheria Toxin;Encephalomyelitis, Autoimmune, Experimental;Multiple Sclerosis",B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;D08.811.913.400.725.115.220;D23.946.123.305;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510;D12.644.276.374.465.021;D12.644.276.374.480.372;D12.776.467.374.465.021;D12.776.467.374.480.372;D23.529.374.465.155;D23.529.374.480.372;A10.549.400;A15.382.520.604.412;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.828.300;A08.186.854;A10.549.700;A15.382.520.604.700;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;D08.811.913.400.725.115.220;D23.946.123.305;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
28929296,"Autism Spectrum Disorder;Child;Child Development;Child, Foster;Cohort Studies;Humans;Intellectual Disability;Medicaid;Prevalence;Retrospective Studies;United States;Autistic Disorder;Intellectual Disability;Medicaid",F03.625.164.113;M01.060.406;F01.525.200;G07.345.374.750;M01.107;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;N03.219.521.346.506.564.655;N03.706.615.693;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;F03.625.164.113.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;N03.219.521.346.506.564.655;N03.706.615.693
28928360,"Antibodies, Monoclonal;Antineoplastic Agents;B-Lymphocytes;Cell Survival;Cisplatin;Drug Resistance, Neoplasm;Fibroblast Growth Factor 2;Humans;In Vitro Techniques;Insulin-Like Growth Factor I;Lymphocytes, Tumor-Infiltrating;Melanoma;Paclitaxel;Pilot Projects;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf;Receptor, Fibroblast Growth Factor, Type 3;Skin Neoplasms;Tumor Microenvironment",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D27.505.954.248;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.346;D01.210.375;D01.625.125;D01.710.100;G07.690.773.984.395;D12.644.276.624.120;D12.776.467.624.120;D23.529.624.120;B01.050.150.900.649.313.988.400.112.400.400;E05.481;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D02.455.426.392.368.242.888.777;D02.455.849.291.850.777;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;D27.505.519.389.755;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D08.811.913.696.620.682.725.400.179;D12.776.543.750.630.442;D12.776.543.750.750.400.370.875;D12.776.624.664.700.792;C04.588.805;C17.800.882;G04.366.500
28928113,"Animals;Citric Acid Cycle;Fatty Acids;Glucose;Lactic Acid;Mice;Mice, Inbred C57BL;Myocardium;Pregnancy;Progesterone;Protein-Serine-Threonine Kinases;Pyruvic Acid;Glucose;Heart;Metabolism;Mitochondria;Pregnancy;Progesterone",B01.050;G02.111.165;G03.295.342;G03.493.170;D10.251;D09.947.875.359.448;D02.241.511.459.450;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A02.633.580;A07.541.704;A10.690.552.750;G08.686.784.769;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;D08.811.913.696.620.682.700;D02.241.755.812.800;D09.947.875.359.448;A07.541;G03;A11.284.430.214.190.875.564;A11.284.835.626;G08.686.784.769;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750
28927697,"Acute Disease;Aneurysm, Dissecting;Aorta;Aortic Valve Insufficiency;Echocardiography;Humans;Aortic Valve Insufficiency;Echocardiography, Transesophageal",C23.550.291.125;C14.907.055.050;A07.015.114.056;C14.280.484.095;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;C14.280.484.095;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
28927471,"Adolescent;Alleles;Cardiac Surgical Procedures;Child;Child, Preschool;Echocardiography;Follow-Up Studies;Heart Defects, Congenital;Heart Transplantation;Humans;Infant;Infant, Newborn;Linear Models;Philadelphia;Polymorphism, Single Nucleotide;Vascular Endothelial Growth Factor A;Ventricular Function;Echocardiography;Genes",M01.060.057;G05.360.340.024.340.030;E04.100.376;E04.928.220;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;Z01.107.567.875.500.550.525;Z01.433.820;G05.365.795.598;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;G09.330.955;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;G05.360.340.024.340
28927321,Attention;Craving;Electronic Nicotine Delivery Systems,F02.830.104.214;F01.658.293.195;J01.637.767.500
28927203,"Aspergillosis, Allergic Bronchopulmonary;Blastomycosis;Bone Diseases, Infectious;Candidiasis, Invasive;Child;Coccidioidomycosis;Eye Infections, Fungal;Histoplasmosis;Humans;Immunocompromised Host;Invasive Pulmonary Aspergillosis;Liver Diseases;Lung Diseases, Fungal;Meningoencephalitis;Mucormycosis;Opportunistic Infections;Pneumonia;Pneumonia, Pneumocystis;Sinusitis;Splenic Diseases;Aspergillus;Candida;Blastomycosis;Histoplasmosis;Mucormycosis",C01.703.080.768.500;C08.381.472.850.500;C08.674.060;C08.730.435.090;C20.543.480.680.085;C01.539.800.200.055;C01.703.295.055;C01.703.534.395;C08.381.472.350;C08.730.435.395;C17.800.838.208.055;C01.539.160;C05.116.165;C01.703.160.175;C01.703.492.500;M01.060.406;C01.703.203;C01.539.375.450;C01.703.343;C11.294.450;C01.703.450;B01.050.150.900.649.313.988.400.112.400.400;G12.470;C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750;C06.552;C01.703.534;C08.381.472;C08.730.435;C10.228.140.430.550;C10.228.228.245.550;C10.228.228.570;C10.228.614.500;C01.703.980.600;C01.539.597;C02.597;C03.684;C08.381.677;C08.730.610;C01.703.534.700;C01.703.770.700;C08.381.472.700;C08.381.677.675;C08.730.435.700;C08.730.610.675;C08.460.692.752;C08.730.749;C09.603.692.752;C15.604.744;B01.300.381.081;B01.300.107.795.095;B01.300.381.147;B01.300.930.176;C01.539.800.200.055;C01.703.295.055;C01.703.534.395;C08.381.472.350;C08.730.435.395;C17.800.838.208.055;C01.703.450;C01.703.980.600
28927202,"Antibodies, Fungal;Antigens, Fungal;Aspergillosis;Aspergillus;Biomarkers;Candida;Candidiasis;Child;DNA, Fungal;Humans;Immunoassay;Invasive Fungal Infections;Mannans;Polymerase Chain Reaction;beta-Glucans;Mannans;Polymerase Chain Reaction",D12.776.124.486.485.114.179;D12.776.124.790.651.114.179;D12.776.377.715.548.114.179;D23.050.202;C01.703.080;B01.300.381.081;D23.101;B01.300.107.795.095;B01.300.381.147;B01.300.930.176;C01.703.160;M01.060.406;D13.444.308.300;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566;E05.601.470;C01.703.492;D09.698.550;E05.393.620.500;D09.698.365.089;D09.698.550;E05.393.620.500
28927200,"Aspergillosis;Candidiasis;Child;Critical Illness;Cross Infection;Hematologic Neoplasms;Hematopoietic Stem Cell Transplantation;Hospitalization;Humans;Immunocompromised Host;Immunologic Deficiency Syndromes;Incidence;Intensive Care Units, Neonatal;Intensive Care Units, Pediatric;Invasive Fungal Infections;Opportunistic Infections;Survival Rate;Transplant Recipients;Epidemiology;Candidiasis, Invasive",C01.703.080;C01.703.160;M01.060.406;C23.550.291.625;C01.539.248;C23.550.291.875.500;C04.588.448;C15.378.400;E02.095.147.500.500.500;E04.936.225.687.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;G12.470;C20.673;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;N02.278.388.493.390.380;N02.278.388.493.390;C01.703.492;C01.539.597;C02.597;C03.684;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;M01.925;H02.403.720.500;C01.703.160.175;C01.703.492.500
28927199,Diagnosis;Epidemiology,E01;H02.403.720.500
28926657,Conflict of Interest;Humans;Industry;Pain Management,K01.752.566.479.095;N05.350.225;B01.050.150.900.649.313.988.400.112.400.400;J01.576;E02.745;N04.590.607.500
28926489,"Adolescent;Child;Child, Preschool;Cross-Sectional Studies;Global Health;Hematopoietic Stem Cell Transplantation;Hospital Mortality;Humans;Infant;Infant, Newborn;International Cooperation;Length of Stay;Logistic Models;Prevalence;Prognosis;Prospective Studies;Risk Factors;Sepsis;Severity of Illness Index;Treatment Outcome",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;H02.403.371;N01.400.337;E02.095.147.500.500.500;E04.936.225.687.500;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;I01.615.500;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.757;C23.550.470.790.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28926488,"Adult;Attitude of Health Personnel;Child;Clinical Protocols;Critical Care;Decision Support Systems, Clinical;Humans;Intensive Care Units, Pediatric;Middle Aged;Physicians;Practice Guidelines as Topic;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Surveys and Questionnaires",M01.060.116;F01.100.050;N05.300.100;M01.060.406;E02.183;N05.715.360.330.125;E02.760.190;N02.421.585.190;L01.313.500.750.300.190;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;M01.060.116.630;M01.526.485.810;N02.360.810;N04.761.700.350.650;N05.700.350.650;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28925403,"Animals;Cell Cycle;Cell Line, Tumor;Cell Separation;Flow Cytometry;Humans;Melanocytes;Melanoma;Mice;Neoplasm Invasiveness;Proteomics;Serpin E2;Skin;Skin Neoplasms;Xenograft Model Antitumor Assays",B01.050;G04.144;A11.251.210.190;A11.251.860.180;E01.370.225.500.363;E05.200.500.363;E05.242.363;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;A11.409.750;A11.436.613;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;C04.697.645;C23.550.727.645;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;D12.644.822.468.750;D12.644.861.695.850;D12.776.645.468.750;D12.776.872.695.850;A17.815;C04.588.805;C17.800.882;E05.337.550.200.900;E05.624.850
28924244,"Animals;Antigens;Cell Line, Tumor;Humans;Mice;Mice, Inbred BALB C;Precursor Cell Lymphoblastic Leukemia-Lymphoma",B01.050;D23.050;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600
28924153,"Case-Control Studies;Cell Line, Tumor;Chromosome Deletion;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 11;Genome-Wide Association Study;Humans;Matrix Metalloproteinase 20;Neuroblastoma;Quantitative Trait Loci;Whole Exome Sequencing",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251.210.190;A11.251.860.180;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.235.240;G05.360.162.520.300.235.240;A11.284.187.520.300.325.355;G05.360.162.520.300.325.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.656.300.480.525.700.800;D08.811.277.656.675.374.525.700.800;D12.644.276.848.800;D12.776.467.836.800;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.360.340.024.380.937;E05.393.760.700.825.500
28923757,Clostridium Infections;Fecal Microbiota Transplantation;Microbiota,C01.252.410.222;E02.095.231;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
28923290,Adult;Child;Drug Combinations;Genotype;HIV Infections;Humans;Lopinavir;Middle Aged;Protease Inhibitors;Reproducibility of Results;Ritonavir;Taste;Young Adult;Taste,M01.060.116;M01.060.406;D26.310;G05.380;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;D03.383.742.698.553;M01.060.116.630;D27.505.519.389.745;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;D02.886.675.653;D03.383.129.708.653;F02.830.816.724;G11.561.790.724;M01.060.116.815;F02.830.816.724;G11.561.790.724
28923237,"Animals;B-Lymphocytes;Cell Differentiation;Cytokines;Humans;Models, Immunological;STAT Transcription Factors;Signal Transduction;T-Box Domain Proteins",B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.152;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.500;D12.644.360.024.342;D12.776.157.057.186;D12.776.476.024.430;D12.776.930.840;G02.111.820;G04.835;D12.776.260.725;D12.776.930.850
28922245,"Anatomic Landmarks;Case-Control Studies;Cephalometry;Cranial Sutures;Craniosynostoses;Humans;Infant;Plagiocephaly, Nonsynostotic;Retrospective Studies;Skull Base;Tomography, X-Ray Computed",A01.111;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;A02.835.232.781.200;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C05.660.207.707.624;C16.131.621.207.707.624;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A01.456.830;A02.835.232.781.750;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28922234,"Anesthesia, Cardiac Procedures;Clinical Competence;Consensus;Education, Medical, Graduate;Fellowships and Scholarships;Heart Defects, Congenital;Humans;Societies, Medical",E03.155.403;I02.399.630.210;N04.761.210;N05.715.175;F01.829.316.068;F02.463.785.373.433;I02.358.337.350;I02.358.399.350;N03.219.483.838.276;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;N03.540.828.589
28922233,Craniofacial Abnormalities;Craniosynostoses;Endoscopy;Humans;Infant;Propensity Score;Prospective Studies;Reconstructive Surgical Procedures;Registries;Treatment Outcome,C05.660.207;C16.131.621.207;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E01.370.388.250;E04.502.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E04.680;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28922220,Automobile Driving;Computer Simulation;Humans,I03.125;L01.224.160;B01.050.150.900.649.313.988.400.112.400.400
28922218,"Anesthesia, Dental;Anesthesiology;Humans",E03.155.141;E06.045;H02.403.066;B01.050.150.900.649.313.988.400.112.400.400
28922188,Animals;Glycosylation;Golgi Apparatus;Humans;Lipoproteins;Protein Transport,B01.050;G02.111.158.812;G02.607.299;G03.191.812;A11.284.430.214.190.875.336;B01.050.150.900.649.313.988.400.112.400.400;D10.532;D12.776.521;G03.143.700
28922167,Age Factors;Aged;Apolipoprotein A-I;Cognition Disorders;Cross-Sectional Studies;Enzyme-Linked Immunosorbent Assay;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Longitudinal Studies;Middle Aged;Neuropsychological Tests;Parkinson Disease;Retrospective Studies;Apolipoprotein A-I;Parkinson Disease;Cognition;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Longitudinal Studies;Reactive Oxygen Species,N05.715.350.075;N06.850.490.250;M01.060.116.100;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;F03.615.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F02.463.188;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;D01.339.431;D01.650.775
28921855,"Adolescent;Adult;Blood Platelets;Bone Marrow Diseases;Child;Child, Preschool;Hemorrhage;Humans;Infant;Purpura, Thrombocytopenic, Idiopathic;Retrospective Studies;Hemorrhage;Purpura, Thrombocytopenic, Idiopathic",M01.060.057;M01.060.116;A11.118.188;A15.145.229.188;C15.378.190;M01.060.406;M01.060.406.448;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C23.550.414;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600
28921760,African Americans;Cigarette Smoking;Genome-Wide Association Study,M01.686.508.100.100;M01.686.754.100;F01.145.805.375.750;F01.145.958.875.750;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
28920936,"Animals;Caenorhabditis elegans;Cells, Cultured;Corpus Striatum;Dopamine;Dopaminergic Neurons;Humans;Levodopa;Mice;Mice, Inbred C57BL;Mice, Transgenic;Neurodegenerative Diseases;Substantia Nigra;alpha-Synuclein",B01.050;B01.050.500.500.294.400.875.660.250.250;A11.251;A08.186.211.200.885.287.249.487;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;A08.675.278;A11.671.270;B01.050.150.900.649.313.988.400.112.400.400;D02.092.311.200.480;D02.455.426.559.389.657.166.175.200.480;D12.125.072.050.685.400.500;D12.125.072.050.875.130.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C10.574;A08.186.211.132.659.413.656;D12.776.631.860.500;D12.776.637.500
28920591,"Animals;Central Nervous System Agents;Dose-Response Relationship, Drug;Eating;Exenatide;Glucagon-Like Peptide 1;Glucagon-Like Peptide-1 Receptor;Neural Pathways;Neurons;Peptide Fragments;Peptides;Rats, Sprague-Dawley;Solitary Nucleus;Tegmentum Mesencephali;Venoms",B01.050;D27.505.954.427;G07.690.773.875;G07.690.936.500;G07.203.650.283;G10.261.330;D12.644.187;D20.888.300;D23.946.833.300;D06.472.317.680.500.500;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;A08.612;A08.675;A11.671;D12.644.541;D12.644;B01.050.150.900.649.313.992.635.505.700.750;A08.186.211.132.810.591.500.750;A08.186.211.132.659.413.875;A12.200.935;D20.888;D23.946.833
28920511,Multiple Sclerosis,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
28920007,Macular Degeneration;Geographic Atrophy;Lipofuscin,C11.768.585.439;C11.768.585.439.122;D10.460;D23.767.550
28919048,"Animals;Epigenesis, Genetic;Gene Expression Regulation;Homeostasis;Humans;Immune System;Immunity, Cellular;RNA, Long Noncoding",B01.050;G05.308.203;G05.308;G07.410;B01.050.150.900.649.313.988.400.112.400.400;A15.382;G12.450.050.400;D13.444.735.790.375
28919025,Data Collection;Humans;Internal Medicine;Internship and Residency;Research,E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;H01.770.644
28919002,"ATP Binding Cassette Transporter, Subfamily D, Member 1;Adrenoleukodystrophy;Adult;Age of Onset;Animals;Brain;Coenzyme A Ligases;Demyelinating Diseases;Frontal Lobe;Genetic Association Studies;Humans;Lipids;Magnetic Resonance Imaging;Mutation;Pan troglodytes;Phenotype;Sequence Analysis, DNA",D12.776.157.530.100.209.500;D12.776.395.550.020.419.500;D12.776.543.550.192.419.500;D12.776.543.585.100.209.500;C10.228.140.163.100.084;C10.228.140.163.100.362.250;C10.228.140.695.625.250;C10.314.400.250;C10.597.606.360.455.124;C16.320.322.500.124;C16.320.400.525.124;C16.320.565.189.084;C16.320.565.189.362.250;C16.320.565.663.100;C18.452.132.100.084;C18.452.132.100.362.250;C18.452.648.189.084;C18.452.648.189.362.250;C18.452.648.663.100;C19.053.500.270;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;B01.050;A08.186.211;D08.811.464.267.500;C10.314;A08.186.211.200.885.287.500.270;E05.393.385;B01.050.150.900.649.313.988.400.112.400.400;D10;E01.370.350.825.500;G05.365.590;B01.050.150.900.649.313.988.400.112.400.620;G05.695;E05.393.760.700
28918979,Blood Coagulation Factors;Hemorrhage;Humans;Factor VIIa;Fibrinogen;Hemorrhage,D12.776.124.125;D23.119;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.656.300.760.300;D08.811.277.656.959.350.300;D12.776.124.125.325.300;D23.119.325.300;D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490;C23.550.414
28918945,Arabidopsis Proteins;Chitin Synthase;Cytokinesis;Extracellular Matrix;Microtubule-Associated Proteins;Protein Binding;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Saccharomycetales;Chitin;Cytokinesis,D12.776.765.149;D08.811.913.400.450.460.200;G04.144.220.250;A11.284.295.310;D12.776.220.600.450;D12.776.631.560;G02.111.679;G03.808;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;B01.300.107.795;D05.750.078.139;D09.698.211;G04.144.220.250
28918937,"Animals;Cell Line, Tumor;Enzyme Inhibitors;Glucose;Glyceraldehyde-3-Phosphate Dehydrogenases;Glycolysis;Humans;Machine Learning;Metabolic Flux Analysis;Metabolomics;Mice, Inbred C57BL;Models, Biological;Molecular Targeted Therapy;Neoplasms;Sesquiterpenes;Systems Biology;Metabolic Flux Analysis;Metabolomics;Pharmacogenetics;Precision Medicine;Systems Biology",B01.050;A11.251.210.190;A11.251.860.180;D27.505.519.389;D09.947.875.359.448;D08.811.682.657.163.750;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;E01.370.225.500.810;E05.200.500.810;E05.242.654;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.599.395;E02.319.574;C04;D02.455.849.765;H01.158.273.180.800;E01.370.225.500.810;E05.200.500.810;E05.242.654;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;H01.158.273.343.750;H01.158.703.052;H02.628.479;E02.574;H02.403.200.700;H01.158.273.180.800
28918671,"Expert Testimony;Genetic Therapy;Genotype;Hematopoietic Stem Cell Transplantation;Humans;Infant, Newborn;Neonatal Screening;Severe Combined Immunodeficiency;Transplantation Conditioning;Treatment Outcome;X-Linked Combined Immunodeficiency Diseases;Conditioning (Psychology);Genetic Therapy",I01.880.604.583.232;N03.706.535.253;E02.095.301;E05.393.420.301;G05.380;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;C16.614.815;C18.452.284.800;C20.673.815;E02.095.465.425.450.800;E05.478.610.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C16.320.322.968;C16.614.815.500;C20.673.815.500;F02.463.425.179;E02.095.301;E05.393.420.301
28918484,"Absinthe;Aging;Hordeum;Cannabis;Cinnamomum zeylanicum;Crohn Disease;Herb-Drug Interactions;Aged;Ginger;Herbal;Inflammatory Bowel Diseases;Glycyrrhiza;Cannabis;Mentha piperita;Primula;Dronabinol;Curcuma;Colitis, Ulcerative;Artemisia",G07.203.100.100.100;J02.200.100.100;G07.345.124;B01.650.940.800.575.912.250.822.481;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.595.400.149.500;C06.405.205.731.500;C06.405.469.432.500;G07.690.773.968.755;M01.060.116.100;B01.650.940.800.575.912.250.618.937.900.444;V02.695.500;C06.405.205.731;C06.405.469.432;B01.650.940.800.575.912.250.401.300;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.583.520.483.444;B01.650.940.800.575.912.250.828;D02.455.849.090.810;B01.650.940.800.575.912.250.618.937.900.166;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;B01.650.940.800.575.912.250.100.100
28917994,"Child;Child, Preschool;Dacryocystorhinostomy;Humans;Infant;Intubation;Lacrimal Duct Obstruction;Nasolacrimal Duct;Retrospective Studies;Stents;Treatment Outcome",M01.060.406;M01.060.406.448;E04.540.255;E04.579.255;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.585;E05.497;C11.496.456;A09.371.463.640;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E07.695.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28917560,"Adult;Aged;Aged, 80 and over;Catheter Ablation;Defibrillators, Implantable;Equipment Failure;Extracorporeal Membrane Oxygenation;Heart Failure;Hemodynamics;Humans;Middle Aged;Pennsylvania;Prognosis;Retrospective Studies;Survival Rate;Ventricular Fibrillation;Catheter Ablation;Extracorporeal Membrane Oxygenation;Tachycardia, Ventricular",M01.060.116;M01.060.116.100;M01.060.116.100.080;E02.808.750.500;E04.014.760.500;E07.305.250.159.175;E07.305.250.319.175;E07.695.202.175;E05.325;E02.880.301;E04.292.451;C14.280.434;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C14.280.067.922;C23.550.073.922;E02.808.750.500;E04.014.760.500;E02.880.301;E04.292.451;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
28917461,"Antifungal Agents;Attitude of Health Personnel;Cross-Sectional Studies;Drug Eruptions;Drug Utilization;Humans;Incidence;Practice Patterns, Physicians';Prognosis;Risk Assessment;Skin Neoplasms;Voriconazole",D27.505.954.122.136;F01.100.050;N05.300.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C17.800.174.600;C20.543.206.380;C25.100.468.380;N04.452.706.477;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;N04.590.374.577;N05.300.625;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04.588.805;C17.800.882;D03.383.129.799.950
28917444,Adolescent;Child;Fertility;Fertility Preservation;Humans;Neoplasms;Philadelphia;Referral and Consultation;Reproductive Health;Young Adult;Fertility;Fertility Preservation,M01.060.057;M01.060.406;G08.686.210;E02.875.800.625;E04.936.537.562;E05.820.800.625;B01.050.150.900.649.313.988.400.112.400.400;C04;Z01.107.567.875.500.550.525;Z01.433.820;N04.452.758.849;N01.400.625;M01.060.116.815;G08.686.210;E02.875.800.625;E04.936.537.562;E05.820.800.625
28917343,Adenocarcinoma;Barrett Esophagus;Cryotherapy;Esophageal Neoplasms;Esophagoscopy;Esophagus;Humans;Precancerous Conditions,C04.557.470.200.025;C04.834.154;C06.405.117.102;E02.258;C04.588.274.476.205;C04.588.443.353;C06.301.371.205;C06.405.117.430;C06.405.249.205;E01.370.372.250.250.275;E01.370.388.250.250.250.260;E04.210.240.250.260;E04.502.250.250.250.260;A03.556.875.500;B01.050.150.900.649.313.988.400.112.400.400;C04.834
28916805,"Animals;Gene Expression Regulation;Hepatocyte Nuclear Factor 4;Histone Deacetylases;Homeodomain Proteins;Lipids;Liver;Mice, Knockout;Protein Interaction Mapping;Triglycerides;Tumor Suppressor Proteins",B01.050;G05.308;D12.776.260.262.968;D12.776.660.352.968;D12.776.826.119;D12.776.930.318.968;D08.811.277.087.520;D12.776.260.400;D10;A03.620;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.601.690;D10.351.801;D12.776.624.776
28916722,"Alternative Splicing;Animals;Carbon Isotopes;Cell Line;DNA-Binding Proteins;Embryonic Stem Cells;Gene Knockout Techniques;Glycogen Synthase Kinase 3;Glycogen Synthase Kinase 3 beta;Homeodomain Proteins;Mice;Nitrogen Isotopes;Nuclear Proteins;Peptide Mapping;Phosphorylation;Protein Processing, Post-Translational;Protein Stability;Proteomics;RNA-Binding Proteins;Recombinant Proteins;Serine-Arginine Splicing Factors;Substrate Specificity;Alternative Splicing;Embryonic Stem Cells;Leukemia;Lithium;Spliceosomes",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;D01.268.150.075;D01.496.123;A11.251.210;D12.776.260;A11.872.700.250;E05.393.335.750;D05.500.117.875;D08.811.913.696.620.682.700.429.500;D08.811.913.696.620.682.700.646.625;D12.644.360.300.500;D12.776.476.081.875;D12.776.476.300.500;D05.500.117.875.500;D08.811.913.696.620.682.700.429.500.500;D08.811.913.696.620.682.700.646.625.500;D12.644.360.300.500.500;D12.776.476.081.875.500;D12.776.476.300.500.500;D12.776.260.400;B01.050.150.900.649.313.992.635.505.500;D01.268.604.500;D01.362.625.500;D01.496.586;D12.776.660;E05.196.181.400.454.720;E05.196.401.319.720;E05.196.700;E05.393.760.705.685;G02.111.665;G02.607.780;G03.796;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;G02.111.700;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;D12.776.157.725;D12.776.664.962;D12.776.828;D12.776.157.725.829.500;D12.776.664.962.829.500;G02.111.835;G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;A11.872.700.250;C04.557.337;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;A11.284.430.106.279.345.850
28916711,"Adult;Carrier Proteins;Chromatin;Erythroblasts;Fetus;Gene Expression Regulation, Developmental;Gene Silencing;Humans;Locus Control Region;Nuclear Proteins;Pseudogenes;Regulatory Elements, Transcriptional;Transcriptome;beta-Globins;gamma-Globins;Fetal Hemoglobin",M01.060.116;D12.776.157;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.148.378.590.837.250.200;A11.443.240.497.200;A15.378.316.378.590.837.250.200;A16.378;G05.308.310;G05.308.203.374;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.080.689.450;G05.360.080.689.450;G05.360.340.024.380.249;D12.776.660;G05.360.340.024.340.700;G05.360.340.024.340.137.750;G02.111.873.750;G05.297.700.750;G05.360.920;D12.776.124.400.434.325;D12.776.422.316.762.403.325;D12.776.124.400.434.325.500;D12.776.422.316.762.403.325.500;D12.776.124.400.303;D12.776.422.316.762.320
28916544,"Adult;Aged;Antirheumatic Agents;Arthritis, Rheumatoid;Biological Products;Body Composition;Body Mass Index;Bone Density;Cortical Bone;Humans;Methotrexate;Middle Aged;Muscle Strength;Muscle, Skeletal;Tomography, X-Ray Computed;Body Composition;Muscles;Arthritis, Rheumatoid",M01.060.116;M01.060.116.100;D27.505.954.329;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;D20.215;G02.111.130;G03.180;G07.100.049;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;G11.427.100;A10.165.265.521;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.733.631.192.500;M01.060.116.630;E01.370.600.425;G11.427.560;A02.633.567;A10.690.552.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;G02.111.130;G03.180;G07.100.049;A02.633;A10.690;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199
28916542,,
28916534,"Adolescent;Anticonvulsants;Checklist;Child;Child Behavior Disorders;Child, Preschool;Cross-Over Studies;Double-Blind Method;Electroencephalography;Epilepsy, Absence;Ethosuximide;Follow-Up Studies;Humans;Lamotrigine;Neuropsychological Tests;Outcome Assessment (Health Care);Triazines;Valproic Acid",M01.060.057;D27.505.954.427.080;N05.715.360.300.179;M01.060.406;F03.625.141;M01.060.406.448;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E01.370.376.300;E01.370.405.245;C10.228.140.490.375.260;C10.228.140.490.493.125;D02.478.770.333;D03.383.773.812.852.333;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D03.383.931.480;F04.711.513;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;D03.383.931;D02.241.081.944.509.900;D10.251.400.895.593.900
28916119,"Ammonia;Child, Preschool;Cough;Disease Management;Drug-Related Side Effects and Adverse Reactions;Fever;Glutamine;Glycerol;Humans;Infant;Neutropenia;Phenylbutyrates;Prospective Studies;Retrospective Studies;Urea Cycle Disorders, Inborn;Ammonia;Child;Glutamine;Infant;Urea Cycle Disorders, Inborn",D01.362.075;D01.625.050;M01.060.406.448;C08.618.248;C23.888.852.293;N04.590.607;C25.100;C23.888.119.344;D12.125.068.330;D12.125.095.461;D12.125.154.424;D02.033.800.875.500;D09.853.875.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C15.378.553.546.184.564;D02.241.223.651;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937;D01.362.075;D01.625.050;M01.060.406;D12.125.068.330;D12.125.095.461;D12.125.154.424;M01.060.703;C10.228.140.163.100.937;C16.320.565.100.940;C16.320.565.189.937;C18.452.132.100.937;C18.452.648.100.940;C18.452.648.189.937
28916020,"Child Psychiatry;Delivery of Health Care, Integrated;Humans;Mental Disorders;Mental Health;Pediatrics",F04.096.544.193;H02.403.690.130;N04.590.374.142;N05.300.262;B01.050.150.900.649.313.988.400.112.400.400;F03;F02.418;N01.400.500;H02.403.670
28916010,"Accreditation;Adolescent Psychiatry;Clinical Competence;Delivery of Health Care, Integrated;Humans;Patient Care Team;Pediatrics;Primary Health Care;Psychology, Child;Primary Health Care",N03.706.110.070;N05.700.200.100;F04.096.544.065;H02.403.690.080;I02.399.630.210;N04.761.210;N05.715.175;N04.590.374.142;N05.300.262;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;H02.403.670;N04.590.233.727;F04.096.628.193;N04.590.233.727
28914731,Academic Medical Centers;Adult;Biomedical Research;Faculty;Humans;Middle Aged;Pediatricians;Workload,N02.278.020;M01.060.116;H01.770.644.145;M01.526.702.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;M01.526.485.810.758;N02.360.810.758;I03.946.225.500;N04.452.677.650.500
28914722,"Adolescent;Case-Control Studies;Child;Child, Preschool;Hospitals;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Logistic Models;Odds Ratio;Respiration, Artificial;Retrospective Studies;Risk Factors;United States",M01.060.057;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E02.041.625;E02.365.647.729;E02.880.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28914401,"Arrhythmias, Cardiac;Atrial Fibrillation;Atrial Flutter;Catheter Ablation;Stroke",C14.280.067;C23.550.073;C14.280.067.198;C23.550.073.198;C14.280.067.248;C23.550.073.248;E02.808.750.500;E04.014.760.500;C10.228.140.300.775;C14.907.253.855
28913726,"Animals;Antibodies, Viral;Humans;Immunologic Factors;Immunosuppressive Agents;JC Virus;Leukoencephalopathy, Progressive Multifocal;Multiple Sclerosis;Natalizumab;JC Virus;Multiple Sclerosis;Natalizumab;Leukoencephalopathy, Progressive Multifocal;Virus Diseases",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;D27.505.696.477.656;B04.280.210.700.615.400;B04.613.204.670.615.400;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;B04.280.210.700.615.400;B04.613.204.670.615.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450;C02
28912419,"Algorithms;Cell Line, Tumor;Chromatin;Gene Expression;Genome;Humans;Models, Genetic;Mutation;Neoplasms",G17.035;L01.224.050;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.297;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.397;G05.365.590;C04
28912187,Age of Onset;Cardiac Imaging Techniques;Cardiomyopathies;Genetic Markers;Genetic Predisposition to Disease;Humans;Incidence;Molecular Diagnostic Techniques;Mutation;Myocardium;Phenotype;Prognosis;Risk Factors;Ventricular Function;Epidemiology;Genetics;Pediatrics,N05.715.350.075.100;N06.850.490.250.100;E01.370.350.130;C14.280.238;D23.101.387;G05.695.450;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E01.370.225.880;E05.200.880;E05.393.520;G05.365.590;A02.633.580;A07.541.704;A10.690.552.750;G05.695;E01.789;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G09.330.955;H02.403.720.500;H01.158.273.343;H02.403.670
28912132,"Cell Line, Tumor;Fluorescein-5-isothiocyanate;Humans;In Situ Hybridization, Fluorescence;Interphase;Mitosis;RNA, Messenger;Reverse Transcriptase Polymerase Chain Reaction;Staining and Labeling;Transcription, Genetic;Transcriptional Activation;Uridine Triphosphate",A11.251.210.190;A11.251.860.180;D02.455.426.779.347.400;D02.500.375.250;D02.886.250.250;D03.633.300.953.275.400;D04.711.347.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;G04.144.500;G04.144.220.220.781;G05.113.220.781;D13.444.735.544;E05.393.620.500.725;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670;G02.111.873;G05.297.700;G05.308.800;D03.383.742.686.850.950;D13.695.740.850.950;D13.695.827.919.950
28911726,"Antineoplastic Combined Chemotherapy Protocols;Chemotherapy, Adjuvant;Disease Progression;Humans;Iodine Radioisotopes;Neoplasm Metastasis;Protein Kinase Inhibitors;Thyroid Neoplasms;Treatment Failure;Thyroid Neoplasms",E02.183.750.500;E02.319.077.500;E02.319.310.037;E02.186.170;E02.319.170;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;D01.268.380.400.500.496;D01.496.448.496;D01.496.749.474;C04.697.650;C23.550.727.650;D27.505.519.389.755;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
28911167,"Animals;Body Weight;DNA Methylation;Diet, High-Fat;Gene Expression Regulation;Liver;Maternal Nutritional Physiological Phenomena;Metabolic Syndrome;Mice;Pregnancy;Prenatal Exposure Delayed Effects;Sex Characteristics",B01.050;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G07.203.650.240.267;G05.308;A03.620;G07.203.650.566;C18.452.394.968.500.570;C18.452.625;B01.050.150.900.649.313.992.635.505.500;G08.686.784.769;C13.703.824.500;G08.686.815
28911123,"Benchmarking;Chemistry Techniques, Synthetic;DNA;Deoxyribonuclease I;Escherichia coli Proteins;Genes, Synthetic;High-Throughput Nucleotide Sequencing;MutS DNA Mismatch-Binding Protein;Oligodeoxyribonucleotides",N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;E05.197;J01.897.836.249;D13.444.308;D08.811.277.352.335.350.250;D12.776.097.275;G05.360.340.024.340.465;E05.393.760.319;D08.811.074.844.500;D08.811.277.040.025.292.500;D12.776.097.537;D12.776.260.556.500;D13.695.578.424.450
28910521,"Cannula;Carbon Dioxide;Continuous Positive Airway Pressure;Humans;Infant, Premature;Nose",E07.132.125;D01.200.200;D01.362.150;D01.650.550.200;E02.041.625.790.259;E02.880.820.790.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520;A01.456.505.733;A04.531;A09.531
28910455,"Administration, Topical;Aged;Algorithms;Cohort Studies;Coloring Agents;Conjunctiva;Diagnostic Techniques, Ophthalmological;Dry Eye Syndromes;Humans;Image Processing, Computer-Assisted;Lissamine Green Dyes;Middle Aged;Observer Variation;Photography;Reproducibility of Results;Staining and Labeling",E02.319.267.120;M01.060.116.100;G17.035;L01.224.050;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D27.720.233;A09.371.060.200;A09.371.337.168;E01.370.380;C11.496.260;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;D02.092.877.475;D02.675.276.475;D02.886.645.600.080.050.550;M01.060.116.630;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.350.600;E05.712;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670
28906025,Aged;Dopamine Plasma Membrane Transport Proteins;Humans;Middle Aged;Olfaction Disorders;Parkinson Disease;Risk;Vitamin D;Vitamin D Deficiency;Parkinson Disease;Cognition;Cohort Studies;Vitamin D,M01.060.116.100;D12.776.157.530.450.625.124;D12.776.157.530.562.374.500.500;D12.776.157.530.937.500;D12.776.543.585.450.625.124;D12.776.543.585.562.374.500.500;D12.776.543.585.937.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.597.751.600;C23.888.592.763.550;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;D04.210.500.812.768;C18.654.521.500.133.770;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F02.463.188;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D04.210.500.812.768
28905721,"Animals;Blood Cell Count;Blood Glucose;Diabetes Mellitus, Type 2;Glycated Hemoglobin A;Macaca fascicularis;Monitoring, Physiologic;Point-of-Care Systems",B01.050;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;D09.947.875.359.448.500;C18.452.394.750.149;C19.246.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.199.120.510.520;E01.370.520;N04.452.442.452.680;N04.452.515.360.652;N04.590.874
28905717,"Anesthetics, Local;Animals;Bupivacaine;Buprenorphine;Delayed-Action Preparations;Dose-Response Relationship, Drug;Liposomes;Pain, Postoperative;Postoperative Period;Random Allocation;Rats",D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;B01.050;D02.065.199.239;D02.092.146.113.239;D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;D26.255.210;E02.319.300.253;G07.690.773.875;G07.690.936.500;D25.479.517;D26.255.260.517;J01.637.051.479.517;J01.637.087.500.517;C23.550.767.700;C23.888.592.612.832;E04.614.750;N02.421.585.753.750;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;B01.050.150.900.649.313.992.635.505.700
28905310,,
28905259,"Abortion, Induced;Anxiety;Depression;Humans;Mental Health;Pregnancy;Pregnancy, Unplanned;Pregnancy, Unwanted;Anxiety;Depression;Depression, Postpartum;Substance-Related Disorders",E04.520.050;F01.470.132;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;F02.418;N01.400.500;G08.686.784.769;G08.686.784.769.570;G08.686.784.769.580;F01.470.132;F01.145.126.350;C13.703.844.253;F03.600.300.350;C25.775;F03.900
28904984,,
28904950,"Adult;Aged;Brain Mapping;Cerebrovascular Circulation;Gyrus Cinguli;Humans;Magnetic Resonance Imaging;Middle Aged;Spin Labels;Urinary Bladder, Overactive;Urinary Incontinence, Urge",M01.060.116;M01.060.116.100;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;G09.330.100.159;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;D02.389.678;C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780;C12.777.934.852.500;C13.351.968.934.814.750;C23.888.942.343.800.750
28904633,,
28904632,Breech Presentation,C13.703.420.183;G08.686.520.150;G08.686.784.769.326.520.150
28903521,"Administration, Oral;Anti-Bacterial Agents;Child;Hospitalization;Humans;Infusions, Parenteral;Lyme Disease;Lyme Neuroborreliosis;Lyme Disease;Central Venous Catheters",E02.319.267.100;D27.505.954.122.085;M01.060.406;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.510;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;C01.252.200.450;C01.252.400.155.569.600;C01.252.400.825.480.700;C01.252.847.193.569.600;C10.228.228.180.437;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;E07.132.750.500
28903365,Apoptosis;Ischemia,G04.146.160;C23.550.513
28903167,,
28903144,"History, 19th Century;History, 20th Century;Humans;Quackery;Radiation Injuries;Radiotherapy;Radium;Skin Diseases",K01.400.504.937;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;I01.880.735.728;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;E02.815;D01.268.271.770;D01.268.552.775;D01.268.556.775;D01.496.749.305.770;D01.552.539.745;D01.552.544.775;C17.800
28903040,"Animals;Apoptosis;CD8-Positive T-Lymphocytes;Cell Differentiation;Immunity;Immunologic Memory;Mice, Inbred C57BL;Mice, Knockout;MicroRNAs;Proto-Oncogene Proteins c-myb;Virus Diseases",B01.050;G04.146.160;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;G04.152;G12.450;G12.450.050.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.260.675;D12.776.624.664.700.188;D12.776.930.725;C02
28902792,"Acinar Cells;Animals;Cells, Cultured;Flow Cytometry;Gene Expression;Humans;Metaplasia;Mice;Pancreas, Exocrine;Pancreatic Ducts;Paracrine Communication;Reverse Transcriptase Polymerase Chain Reaction;Tissue Culture Techniques;Transforming Growth Factor beta",A11.031;B01.050;A11.251;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G05.297;B01.050.150.900.649.313.988.400.112.400.400;C23.550.589;B01.050.150.900.649.313.992.635.505.500;A03.734.540;A10.336.645;A03.734.667;G04.085.600;E05.393.620.500.725;E05.481.500.617;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775
28902673,Anesthesia;Disease Susceptibility;Humans;Malignant Hyperthermia,E03.155;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505.700;C23.550.767.600
28902671,Free Tissue Flaps;Humans;Microsurgery;Surgical Flaps;Telemedicine,A10.850.710.500;E07.862.710.500;B01.050.150.900.649.313.988.400.112.400.400;E04.494;E05.591.580;A10.850.710;E07.862.710;H02.403.840;L01.178.847.652;N04.590.374.800
28902574,Child;Emigration and Immigration;Health Policy;Humans;Mental Health;Undocumented Immigrants;United States,M01.060.406;I01.240.600.525.500;N01.224.625.525.500;N06.850.505.400.700.525.500;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;F02.418;N01.400.500;M01.189.500;Z01.107.567.875
28902564,,
28902459,"Adolescent;Adult;Aged;Aged, 80 and over;Case-Control Studies;Exome;Family;Genetic Markers;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Mental Status and Dementia Tests;Middle Aged;Neurocognitive Disorders;Polymorphism, Single Nucleotide;Risk Factors;Schizophrenia;Young Adult;Schizophrenia;Neuronal Plasticity",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G05.360.340.011;F01.829.263;I01.880.853.150;D23.101.387;G05.695.450;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.603;M01.060.116.630;F03.615;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F03.700.750;M01.060.116.815;F03.700.750;G11.561.638
28902088,,
28901790,"Animals;Antigens, CD19;Antigens, Neoplasm;Clinical Trials as Topic;Combined Modality Therapy;Cytotoxicity, Immunologic;Drug Evaluation, Preclinical;Hematologic Neoplasms;Hematopoiesis;Humans;Immunity, Cellular;Immunotherapy, Adoptive;Interleukin-3 Receptor alpha Subunit;Neoplastic Stem Cells;Receptors, Antigen, T-Cell;Receptors, Chimeric Antigen;T-Lymphocytes;Treatment Outcome;Genetic Therapy",B01.050;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;D23.050.285;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E02.186;G12.287;E05.290.750;E05.337.550;C04.588.448;C15.378.400;G04.152.825;G09.188.343;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.776.543.750.705.852.420.340.500;A11.872.650;D12.776.543.750.705.816.824;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02.095.301;E05.393.420.301
28901637,"Adolescent;Adult;Biopsy;Bone Marrow;Child;Child, Preschool;Humans;Infant;Neoplasm Staging;Neoplasms;Positron-Emission Tomography;Retrospective Studies;Tomography, X-Ray Computed;Pets",M01.060.057;M01.060.116;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;A15.382.216;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.789.625;C04;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;B01.050.050.116.600
28900261,,
28900170,,
28899105,Bacteria;Fungi;HIV Infections;Humans;Microbial Interactions;Microbiota;Symbiosis;HIV;Inflammation,B03;B01.300;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;G06.550;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G06.550.800;G16.840;B04.820.650.589.650.350;C23.550.470
28898695,"Animals;Antibodies, Neoplasm;Cell Death;Cell Line, Tumor;Cell Membrane;Cell Proliferation;Child;Gene Expression Regulation, Neoplastic;Genome, Human;Glypicans;Humans;Immunotherapy;Mice, Inbred NOD;Mice, SCID;Molecular Targeted Therapy;N-Myc Proto-Oncogene Protein;Neuroblastoma;Oncogene Proteins;RNA, Messenger;Risk Factors;Glypicans;Immunotherapy;Medulloblastoma;Neuroblastoma",B01.050;D12.776.124.486.485.114.240;D12.776.124.790.651.114.240;D12.776.377.715.548.114.240;G04.146;A11.251.210.190;A11.251.860.180;A11.284.149;G04.161.750;G07.345.249.410.750;M01.060.406;G05.308.370;G05.360.340.350;D12.776.395.550.448.500;D12.776.395.650.350.249;D12.776.543.484.500.550;D12.776.543.550.418.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.150.900.649.313.992.635.505.500.550.780;E02.319.574;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D12.776.624.664;D13.444.735.544;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.395.550.448.500;D12.776.395.650.350.249;D12.776.543.484.500.550;D12.776.543.550.418.500;E02.095.465.425;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
28898227,,
28895958,,
28895953,,
28895472,"Aldo-Keto Reductase Family 1 Member C3;Animals;Antineoplastic Agents;Breast Neoplasms;Drug Design;Enzyme Inhibitors;Humans;Leukemia, Myeloid, Acute;Patents as Topic;Prostatic Neoplasms, Castration-Resistant;Leukemia, Myeloid, Acute;Aldo-Keto Reductases;Receptors, Androgen;Estrenes;Indomethacin;Prostatic Neoplasms",D08.811.682.047.150.700.156.875;D08.811.682.047.436.375.140;D08.811.682.047.820.284.937;D08.811.682.047.820.375.500;B01.050;D27.505.954.248;C04.588.180;C17.800.090.500;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;D27.505.519.389;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;I01.880.604.583.458.650;N03.706.535.518.650;C04.588.945.440.770.500;C12.294.260.750.500;C12.294.565.625.500;C12.758.409.750.500;C04.557.337.539.275;D08.811.682.047.150.700.156;D08.811.682.047.820.284;D12.776.826.750.150;D04.210.500.365.415;D03.633.100.473.420;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28895072,"Adaptive Immunity;Animals;Caspase 1;Caspases;Central Nervous System;Coronavirus Infections;Gene Expression Regulation;Immunity, Innate;Inflammasomes;Interferon-gamma;Interleukin-1;Interleukin-18;Liver;Mice;Mice, Inbred C57BL;Mice, Knockout;Murine hepatitis virus;Receptors, Antigen, T-Cell, alpha-beta;Signal Transduction;Survival Analysis;T-Lymphocytes;Viral Load;Virus Replication;Interleukin-1;Interleukin-18;Inflammasomes;Murine hepatitis virus",G12.450.050;B01.050;D08.811.277.656.262.500.126.550.100;D08.811.277.656.300.200.126.550.100;D12.644.360.075.405.550.100;D12.776.476.075.405.550.100;D08.811.277.656.262.500.126;D08.811.277.656.300.200.126;D12.644.360.075.405;D12.776.476.075.405;A08.186;C02.782.600.550.200;G05.308;G12.450.564;D05.500.224;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;A03.620;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B04.450.580;B04.820.504.540.150.113.875;D12.776.543.750.705.816.824.825;G02.111.820;G04.835;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.370.225.875.950;E05.200.875.950;G06.920.850;G06.920.925;D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;D05.500.224;B04.450.580;B04.820.504.540.150.113.875
28894889,"Albumins;Catheters;Contrast Media;Equipment Design;Fluorocarbons;Humans;Image Enhancement;Injections;Microbubbles;Needles;Phantoms, Imaging;Ultrasonography;Child;In Vitro Techniques",D12.776.034;E07.132;D27.505.259.500;D27.720.259;E05.320;D02.455.526.510.435;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.600.350;L01.224.308.380;E02.319.267.530;E07.553;E07.612;E07.671;E01.370.350.850;M01.060.406;E05.481
28894301,,
28893946,"Animals;Cell Adhesion;Cell Movement;Chemotactic Factors;Gene Expression Regulation, Developmental;Humans;Islets of Langerhans;Ligands;Mice;Mice, Knockout;Morphogenesis;Mutation;Neurons;Neuropilin-2;Pancreas;Semaphorin-3A;Signal Transduction;Humans;Mice;Semaphorin-3A",B01.050;G04.022;G04.198;G07.568.500.180;D23.125;G05.308.310;B01.050.150.900.649.313.988.400.112.400.400;A03.734.414;A06.300.414;D27.720.470.480;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G07.345.500;G05.365.590;A08.675;A11.671;D12.776.543.750.590.750;A03.734;D12.644.276.923.374;D12.776.467.923.374;D23.529.923.374;G02.111.820;G04.835;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.644.276.923.374;D12.776.467.923.374;D23.529.923.374
28893936,Ataxia Telangiectasia Mutated Proteins;Carcinogenesis;DNA Damage;DNA Repair;DNA Tumor Viruses;DNA-Activated Protein Kinase;Humans;Protein Kinases;Signal Transduction;Viral Proteins,D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;C04.697.098;C23.550.727.098;G05.200;G02.111.222;G05.219;B04.280.210;B04.613.204;D08.811.913.696.620.682.700.250;D12.776.157.687.438;D12.776.660.720.438;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682;G02.111.820;G04.835;D12.776.964
28893774,"Antifungal Agents;Biological Availability;Candida;Candidiasis;Clinical Trials as Topic;Drug Administration Schedule;Fluconazole;Humans;Infant;Infant, Newborn;Infant, Premature;Models, Statistical;Predictive Value of Tests;Fluconazole;Infant;Pediatrics;Pharmacokinetics",D27.505.954.122.136;G03.787.151;G07.690.725.129;B01.300.107.795.095;B01.300.381.147;B01.300.930.176;C01.703.160;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E02.319.283;D03.383.129.799.450;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;D03.383.129.799.450;M01.060.703;H02.403.670;G03.787;G07.690.725
28893514,Nurse Practitioners;Physician Assistants;Primary Health Care,M01.526.485.650.640;N02.360.650.640;M01.526.485.067.740;N02.360.067.740;N04.590.233.727
28893446,Antimicrobial Stewardship;Art;Child;Humans;Inappropriate Prescribing;Information Dissemination;Interinstitutional Relations;Internet;Medication Therapy Management;Pennsylvania;Child,N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;K01.093;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.319.490;N02.421.450.500.249;L01.143.443;N04.452.822.400;L01.224.230.110.500;N02.421.668.438;N03.219.521.576.343.575.500.500;N03.219.521.576.343.840.938.500;N04.590.661;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;M01.060.406
28893277,"AIDS Vaccines;Animals;Genetic Vectors;Guinea Pigs;HIV Antibodies;HIV Envelope Protein gp120;HIV-1;Humans;Immunity, Humoral;Macaca;Mice;Vesicular stomatitis Indiana virus;Gene Products, env;HIV",D20.215.894.899.050;B01.050;G05.360.337;B01.050.150.900.649.313.992.550;D12.776.124.486.485.114.254.150.440;D12.776.124.790.651.114.254.150.440;D12.776.377.715.548.114.254.150.440;D12.776.964.775.325.164.249;D12.776.964.775.562.500.500;D12.776.964.970.880.325.164.249;D23.050.327.520.350;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.420;B01.050.150.900.649.313.988.400.112.199.120.510;B01.050.150.900.649.313.992.635.505.500;B04.820.455.750.900.900;D12.776.775.320;D12.776.964.775.325;D12.776.964.970.880.325;B04.820.650.589.650.350
28893019,,
28892343,,
28892334,,
28892533,"Acute Chest Syndrome;Adolescent;Anemia, Sickle Cell;Anti-Bacterial Agents;Child;Child, Preschool;Databases, Factual;Guideline Adherence;Humans;Infant;Infant, Newborn;Patient Readmission;Practice Guidelines as Topic;Practice Patterns, Physicians';Retrospective Studies;United States;Young Adult",C08.381.074;C08.618.009;C15.378.071.141.150.150.219;C15.378.420.155.219;C16.320.070.150.219;C16.320.365.155.219;M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.122.085;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.760.400.620;N02.421.585.400.620;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;M01.060.116.815
28891816,A549 Cells;Animals;Cell Proliferation;Humans;MCF-7 Cells;Mice;Microtubule-Associated Proteins;Mitochondria;NIH 3T3 Cells;Neoplasm Metastasis;Neoplasm Proteins;Neoplasms;Nerve Tissue Proteins;Vesicular Transport Proteins,A11.251.210.190.080;A11.251.860.180.080;A11.436.054;B01.050;G04.161.750;G07.345.249.410.750;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.630;B01.050.150.900.649.313.992.635.505.500;D12.776.220.600.450;D12.776.631.560;A11.284.430.214.190.875.564;A11.284.835.626;A11.251.210.100.550;A11.329.228.100.550;C04.697.650;C23.550.727.650;D12.776.624;C04;D12.776.631;D12.776.543.990
28891741,"CREB-Binding Protein;Chromatin;Enhancer Elements, Genetic;Epigenesis, Genetic;Gene Expression Regulation;Genetic Loci;Humans;Protein Interaction Domains and Motifs;RNA, Untranslated;Transcription, Genetic;RNA, Untranslated",D08.811.913.050.134.415.500.575.249;D12.776.930.680.300;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.308.203;G05.308;G05.360.340.024.380;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.820.709.275.750.500;D13.444.735.790;G02.111.873;G05.297.700;D13.444.735.790
28891730,"Computer Simulation;Data Interpretation, Statistical;Disease Management;Eye Diseases;Humans;Models, Statistical;Sample Size",L01.224.160;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;N04.590.607;C11;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762
28891717,"Adolescent;Adult;Anti-HIV Agents;Antiretroviral Therapy, Highly Active;Cohort Studies;HIV Infections;Humans;Incidence;Proportional Hazards Models;Retrospective Studies;Treatment Outcome;Viral Load;Young Adult;Viral Load",M01.060.057;M01.060.116;D27.505.954.122.388.077.088;E02.319.310.075;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.225.875.950;E05.200.875.950;G06.920.850;M01.060.116.815;E01.370.225.875.950;E05.200.875.950;G06.920.850
28890798,Global Health;Inventions;Sports Medicine,H02.403.371;N01.400.337;J01.897.400;H02.403.830
28890163,"Age Factors;Animals;Disease Susceptibility;Flow Cytometry;Humans;In Situ Hybridization, Fluorescence;Mice;Molecular Imaging;Muscle Fibers, Skeletal;Muscle, Skeletal;Muscular Dystrophy, Duchenne;Phenotype;Reproducibility of Results;Single-Cell Analysis;Stem Cells;Telomere;Telomere Homeostasis;Telomere Shortening;Muscular Dystrophy, Duchenne;Flow Cytometry;Telomere",N05.715.350.075;N06.850.490.250;B01.050;C23.550.291.687;G07.100.250;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;B01.050.150.900.649.313.992.635.505.500;E01.370.350.557;E05.601.555;A10.690.552.500.500;A11.620.249;A02.633.567;A10.690.552.500;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;G05.695;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.242.900;A11.872;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G04.144.220.625;G04.161.750.500.500;G05.113.610;G07.345.249.410.750.500.750;G02.111.225.940;G04.043.630;G05.226.940;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;A11.284.430.106.279.345.190.160.845;G05.360.160.845
28890145,"Anemia, Sickle Cell;Antisickling Agents;Biomarkers;Erythrocyte Indices;Fetal Hemoglobin;Hemoglobin, Sickle;Humans;Hypoxia;Oximetry;Oxygen",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.502.135;D23.101;E01.370.225.625.230;E05.200.625.230;G09.188.260;D12.776.124.400.303;D12.776.422.316.762.320;D12.776.124.400.463.588;D12.776.422.316.762.426.588;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;D01.268.185.550;D01.362.670
28890115,,
28889833,"Acute Kidney Injury;Humans;Hypoplastic Left Heart Syndrome;Infant, Newborn;Length of Stay;Norwood Procedures;Odds Ratio;Palliative Care;Postoperative Complications;Retrospective Studies;Risk Factors;United States;Acute Kidney Injury;Hypoplastic Left Heart Syndrome",C12.777.419.780.050;C13.351.968.419.780.050;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E04.100.376.724;E04.928.220.560;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E02.760.666;N02.421.585.666;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C12.777.419.780.050;C13.351.968.419.780.050;C14.240.400.625;C14.280.400.625;C16.131.240.400.625
28889104,"Animals;Drosophila Proteins;Drosophila melanogaster;Machine Learning;Memory;Models, Genetic;Mushroom Bodies;Social Behavior;Transcription Factors;Drosophila melanogaster;Behavior;Memory, Long-Term",B01.050;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;G17.035.250.500;L01.224.050.375.530;F02.463.425.540;E05.599.395.397;A13.641;F01.145.813;D12.776.930;B01.050.500.131.617.720.500.500.750.310.250.500;F01.145;F02.463.425.540.305
28888770,"Adult;Algorithms;Brain;Cerebrovascular Circulation;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Middle Aged;Reference Values;Reproducibility of Results;Rest;Spin Labels;Cerebrovascular Circulation;Magnetic Resonance Imaging",M01.060.116;G17.035;L01.224.050;A08.186.211;G09.330.100.159;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;M01.060.116.630;E05.978.810;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;I03.450.769.647;D02.389.678;G09.330.100.159;E01.370.350.825.500
28888574,"Academic Medical Centers;Adrenal Cortex Hormones;Adult;Cohort Studies;De Quervain Disease;Disability Evaluation;Follow-Up Studies;Humans;Injections, Intralesional;Logistic Models;Middle Aged;Multivariate Analysis;Orthopedic Procedures;Patient Selection;Retrospective Studies;Severity of Illness Index;Tendinopathy;Treatment Outcome;Risk Factors;Tendinopathy;Tendinopathy;Therapeutics",N02.278.020;D06.472.040;M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C05.651.869.816.200;E01.370.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.430;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.718;E04.555;E05.581.500.653;N04.590.731;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C05.651.869;C26.874.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C05.651.869;C26.874.800;C05.651.869;C26.874.800;E02
28888260,Bronchiectasis;Humans,C08.127.384;B01.050.150.900.649.313.988.400.112.400.400
28888256,Anaphylaxis,C20.543.480.099
28887905,"Anniversaries and Special Events;History, 19th Century;History, 20th Century;History, 21st Century;Humans;Parkinson Disease;Parkinson Disease",K01.400.095;N04.452.822.070;K01.400.504.937;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28887756,Antineoplastic Combined Chemotherapy Protocols;Antineoplastic Protocols;Brain Neoplasms;Child;Humans;Medical Oncology;Needs Assessment;Observer Variation;Psychometrics;Reproducibility of Results;Brain Neoplasms,E02.183.750.500;E02.319.077.500;E02.319.310.037;E02.183.750;E02.319.077;N05.715.360.330.125.500;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;I02.594;N03.349.380.565;N05.300.537;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C04.588.614.250.195;C10.228.140.211;C10.551.240.250
28887373,"Adult;Aged;Atrophy;Cross-Sectional Studies;DNA-Binding Proteins;Disease Progression;Frontotemporal Dementia;Frontotemporal Lobar Degeneration;Humans;Mental Status Schedule;Middle Aged;ROC Curve;Retina;Retrospective Studies;Tomography, Optical Coherence;Visual Pathways",M01.060.116;M01.060.116.100;C23.300.070;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.776.260;C23.550.291.656;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.603.500;F04.711.513.653.574;M01.060.116.630;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;A09.371.729;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;A08.612.220.860
28887091,,
28886383,"Animals;Homeostasis;Lung;Mesoderm;Mice;Organoids;Pulmonary Alveoli;Receptors, G-Protein-Coupled;Sequence Analysis, RNA;Single-Cell Analysis;Transcription, Genetic;Lung",B01.050;G07.410;A04.411;A16.504.660;B01.050.150.900.649.313.992.635.505.500;A10.802;A04.411.715;D12.776.543.750.695;E05.393.760.710;E05.242.900;G02.111.873;G05.297.700;A04.411
28886382,Algorithms;Animals;Epithelial Cells;Fibrosis;Gene Expression Profiling;Lung;Lung Injury;Mesoderm;Mice;Organoids;Paracrine Communication;Regeneration;Signal Transduction;Single-Cell Analysis;Stem Cells;Lung;Mesoderm;Organoids;Regeneration,G17.035;L01.224.050;B01.050;A11.436;C23.550.355;E05.393.332;A04.411;C08.381.520;C26.891.554;A16.504.660;B01.050.150.900.649.313.992.635.505.500;A10.802;G04.085.600;G16.762;G02.111.820;G04.835;E05.242.900;A11.872;A04.411;A16.504.660;A10.802;G16.762
28886366,"Adult;Cell Lineage;Cells, Cultured;Cellular Reprogramming;Chromatin;Chromatin Assembly and Disassembly;DNA Methylation;Electrophysiological Phenomena;Epigenesis, Genetic;Fibroblasts;Gene Expression Profiling;Heterochromatin;Humans;MicroRNAs;Motor Neurons;Neurogenesis;Neurons;Spinal Cord;Time Factors;Transcription, Genetic;Transcriptional Activation;DNA Methylation;Chromatin Assembly and Disassembly;Epigenomics;MicroRNAs;Motor Neurons;Neurogenesis",M01.060.116;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.251;G04.152.262;G05.135;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G07.265;G05.308.203;A11.329.228;E05.393.332;A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A08.675.655.500;A11.671.655.500;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.675;A11.671;A08.186.854;G01.910.857;G02.111.873;G05.297.700;G05.308.800;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G04.400.095;G05.213.095;G05.308.095;H01.158.273.180.350.074;H01.158.273.343.350.042;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A08.675.655.500;A11.671.655.500;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620
28885950,"Child Abuse;Child, Preschool;Continental Population Groups;Educational Status;Family Characteristics;Humans;Infant;Mental Disorders;Military Personnel;Proportional Hazards Models;Risk Factors;Sex Factors;Stress, Psychological;United States",I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406.448;M01.686.508;N01.824.196;F01.829.263.315;I01.240.361;I01.880.853.150.423;N01.224.361;N01.824.308;N06.850.505.400.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F03;M01.526.625;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;F01.145.126.990;F02.830.900;Z01.107.567.875
28885700,"Adolescent;Antibodies, Monoclonal;Antineoplastic Combined Chemotherapy Protocols;Cause of Death;Child;Child, Preschool;Clinical Trials, Phase I as Topic;Clinical Trials, Phase II as Topic;Combined Modality Therapy;Disease Progression;Disease-Free Survival;Follow-Up Studies;Humans;Infant;Medical Oncology;Neoplasm Recurrence, Local;Neuroblastoma;Response Evaluation Criteria in Solid Tumors;Risk Assessment;Treatment Outcome;United States",M01.060.057;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;E02.183.750.500;E02.319.077.500;E02.319.310.037;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;M01.060.406;M01.060.406.448;E05.318.372.250.250.200;N05.715.360.330.250.250.200;N06.850.520.450.250.250.200;E05.318.372.250.250.210;N05.715.360.330.250.250.210;N06.850.520.450.250.250.210;E02.186;C23.550.291.656;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H02.403.429.515;C04.697.655;C23.550.727.655;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E01.789.800.379;N04.761.559.590.800.569;N05.715.360.575.575.800.569;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
28885696,"Academic Medical Centers;Adult;Aftercare;Age Factors;Aged;Aged, 80 and over;Cancer Survivors;Humans;Melanoma;Middle Aged;Oncologists;Patient Care Planning;Physicians, Primary Care;Skin Neoplasms;Supervised Machine Learning;Survivorship;United States;Machine Learning;Melanoma;Skin Neoplasms;Survivorship",N02.278.020;M01.060.116;E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;M01.860.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;M01.526.485.810.699;N02.360.810.699;N04.590.233.624;M01.526.485.810.800;N02.360.810.795;C04.588.805;C17.800.882;G17.035.250.500.500;L01.224.050.375.530.500;F01.058.144.500;Z01.107.567.875;G17.035.250.500;L01.224.050.375.530;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.588.805;C17.800.882;F01.058.144.500
28885498,"Adult;Amyloidosis;Graft Survival;Humans;Kidney Failure, Chronic;Kidney Transplantation;Middle Aged;Propensity Score;Retrospective Studies;Transplantation, Homologous",M01.060.116;C18.452.845.500;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E04.936.864
28885438,Case-Control Studies;Cephalometry;Craniosynostoses;Humans;Skull Base,E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;A01.456.830;A02.835.232.781.750
28885425,"Adolescent;Adolescent Health Services;Anesthetics, Local;Humans;Injections;Intrauterine Devices, Medicated;Lidocaine;Pain Measurement;Pelvic Pain;Philadelphia;Single-Blind Method;Treatment Outcome;Young Adult",M01.060.057;N02.421.044;D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530;E07.190.250.510.520;D02.065.199.092.500;D02.092.146.113.092.500;E01.370.600.550.324;C23.888.592.612.944;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28884915,"Antibodies, Monoclonal;Antineoplastic Combined Chemotherapy Protocols;Basiliximab;Child, Preschool;Herpes Simplex;Humans;Immunosuppressive Agents;Pityriasis Lichenoides;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Recombinant Fusion Proteins;Skin;Stem Cell Transplantation",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;E02.183.750.500;E02.319.077.500;E02.319.310.037;D12.776.124.486.485.114.224.060.344;D12.776.124.790.651.114.224.060.407;D12.776.377.715.548.114.224.200.407;M01.060.406.448;C02.256.466.382;C02.825.320;C17.800.838.790.320;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;C17.800.859.475.650;C17.800.859.575.650;C17.800.859.600.650;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;D12.776.828.300;A17.815;E02.095.147.500.500;E04.936.225.687
28884881,Adolescent;Bone Density;Obesity,M01.060.057;G11.427.100;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28884254,"Adult;Age of Onset;Aged;Anti-Inflammatory Agents;Colectomy;Colitis, Ulcerative;Humans;Immunosuppressive Agents;Medical Records;Middle Aged;Retrospective Studies;Steroids;Time Factors;Treatment Outcome;United States;United States Department of Veterans Affairs;Colectomy;Immunologic Factors;Colitis, Ulcerative",M01.060.116;N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100;D27.505.954.158;E04.210.219;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D04.210.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;E04.210.219;D27.505.696.477;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28884176,"Fibrin;Fibrinogen;Humans;Microscopy, Atomic Force;Microscopy, Confocal;Microscopy, Electron, Scanning;Nephelometry and Turbidimetry;Protein Conformation;Thrombin;Thrombosis",D12.776.124.270;D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.666.400;E05.595.666.400;E01.370.350.515.395;E05.595.395;E01.370.350.515.402.541;E05.595.402.541;E05.196.712.650;G02.111.570.820.709;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960;C14.907.355.830
28883987,"Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28882870,"ATP Binding Cassette Transporter 1;Apolipoprotein A-I;Apolipoprotein B-100;CRISPR-Cas Systems;Cell Differentiation;Chemokine CCL5;Cholesterol Esters;Gene Editing;Gene Expression Regulation, Enzymologic;Gene Knockdown Techniques;Genotype;HEK293 Cells;Hep G2 Cells;Humans;Hydrolysis;Induced Pluripotent Stem Cells;Interleukin-1beta;Interleukin-6;Lipoproteins, LDL;Lysosomes;Macrophages;Phenotype;Proteolysis;Sterol Esterase;Time Factors;Transfection;Cholesterol;Genetics;Macrophages;Stem Cells",D12.776.157.530.100.050.500;D12.776.395.550.020.381.500;D12.776.543.550.192.381.500;D12.776.543.585.100.190.500;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;D10.532.091.300.249;D12.776.070.400.300.249;D12.776.521.120.300.249;G05.308.203.374.394;G04.152;D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250;D04.210.500.247.222.284.200;D04.210.500.247.808.197.200;D10.570.938.208.250;E05.393.420.270;G05.308.320;E05.393.335.500;G05.380;A11.251.210.172.750;A11.436.334;A11.251.860.180.432;A11.436.348.500;B01.050.150.900.649.313.988.400.112.400.400;G02.380;A11.872.040.500;A11.872.700.500;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;D10.532.515;D12.776.521.550;A11.284.430.214.190.875.190.550;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;G05.695;G02.111.720;G03.812;D08.811.277.352.100.700;G01.910.857;E05.393.350.810;G05.728.860;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;H01.158.273.343;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;A11.872
28882819,"Age Factors;Cardiomyopathies;Case-Control Studies;DNA Damage;Heart Failure;Humans;In Situ Hybridization, Fluorescence;Myocytes, Cardiac;Sex Factors;Single-Cell Analysis;Stroke Volume;Telomere;Telomere Shortening;Ventricular Function, Left;Ventricular Remodeling;Myocytes, Cardiac;Cardiomyopathies",N05.715.350.075;N06.850.490.250;C14.280.238;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G05.200;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;A07.541.704.570;A10.690.552.750.570;A11.620.500;N05.715.350.675;N06.850.490.875;E05.242.900;E01.370.370.380.150.700;G09.330.380.124.882;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G02.111.225.940;G04.043.630;G05.226.940;G09.330.955.800;C23.300.985;G09.330.955.975;A07.541.704.570;A10.690.552.750.570;A11.620.500;C14.280.238
28882727,"Anti-Bacterial Agents;Costs and Cost Analysis;Drug Therapy;Glycopeptides;Humans;Lipoglycopeptides;Network Meta-Analysis;Skin Diseases, Bacterial;Soft Tissue Infections;Teicoplanin;Costs and Cost Analysis;Meta-Analysis;Systematic Review",D27.505.954.122.085;N03.219.151;E02.319;D09.400.420;D12.644.233;B01.050.150.900.649.313.988.400.112.400.400;D09.400.420.405;D12.644.233.352;D12.644.365.625;E05.318.370.500.500;E05.581.500.501.500;N05.715.360.325.515.500;N06.850.520.445.500.500;C01.252.825;C01.539.800.720;C17.800.838.765;C01.539.820;D09.400.420.405.500;D12.644.233.352.500;N03.219.151;V03.600;V03.850
28882377,"Adult;African Americans;Body Burden;Depression;Firearms;Foreign Bodies;Humans;Lead;Prospective Studies;Radiography;Stress Disorders, Post-Traumatic;Surveys and Questionnaires;Trauma Centers;United States;Violence;Wounds, Gunshot;Young Adult;Depression;Gun Violence;Stress Disorders, Post-Traumatic",M01.060.116;M01.686.508.100.100;M01.686.754.100;E05.799.638.231;N06.850.460.200;F01.145.126.350;J01.637.870.350;C26.392;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.435;D01.552.544.435;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.370.350.700;F03.950.750.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;Z01.107.567.875;I01.198.240.856;I01.880.735.900;C26.986.900;M01.060.116.815;F01.145.126.350;I01.198.240.856.519;I01.880.735.900.632;F03.950.750.500
28882308,"Alzheimer Disease;Animals;Brain;Cells, Cultured;Disease Models, Animal;Humans;Mice;Mice, Inbred C57BL;Neurons;Tauopathies;tau Proteins;Alzheimer Disease;Mice, Transgenic",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;B01.050;A08.186.211;A11.251;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A08.675;A11.671;C10.574.945;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
28882284,Adolescent;Adult;Boston;Cardiac Catheterization;Child;Feasibility Studies;Heart Valve Prosthesis;Heart Valve Prosthesis Implantation;Humans;Ohio;Ontario;Postoperative Complications;Prospective Studies;Prosthesis Design;Pulmonary Valve;Pulmonary Valve Insufficiency;Recovery of Function;Severity of Illness Index;Time Factors;Treatment Outcome;Young Adult;Tetralogy of Fallot,M01.060.057;M01.060.116;Z01.107.567.875.550.510.210;Z01.433.210;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;E07.695.310;E04.100.376.485;E04.650.410;E04.928.220.410;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.075.512;Z01.107.567.875.350.540;Z01.107.567.875.510.540;Z01.107.567.176.639;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.320.550;E07.695.680;A07.541.510.738;C14.280.484.660;G16.757;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
28882238,"Cardiovascular Diseases;Diagnostic Imaging;Humans;Immunity, Innate;Inflammation;Risk Factors;Vasculitis;T-Lymphocytes;Monocytes;Neutrophils",C14;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;C23.550.470;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907.940;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
28882000,"Alternative Splicing;Animals;Bayes Theorem;Brain;Exons;Genomics;Mice;Models, Genetic;Muscle, Skeletal;Myocardium;Neural Networks (Computer);Sequence Analysis, RNA;Software;Transcriptome",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;A08.186.211;G05.360.340.024.340.137.232;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.992.635.505.500;E05.599.395.397;A02.633.567;A10.690.552.500;A02.633.580;A07.541.704;A10.690.552.750;G17.485;L01.224.050.375.605;E05.393.760.710;L01.224.900;G02.111.873.750;G05.297.700.750;G05.360.920
28881294,Adolescent;Adult;Affect;Antidepressive Agents;Antipsychotic Agents;Bipolar Disorder;Choice Behavior;Humans;Irritable Mood;Lithium Compounds;Middle Aged;Psychotic Disorders;Quetiapine Fumarate;Sleep Wake Disorders;Treatment Outcome,M01.060.057;M01.060.116;F01.470.047;D27.505.954.427.700.122;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;F03.084.500;F02.463.785.373.346;B01.050.150.900.649.313.988.400.112.400.400;F01.470.047.110;D01.510;M01.060.116.630;F03.700.675;D02.886.680.702.500.500;D03.633.300.276.500;C10.886;C23.888.592.796;F03.870;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28880978,"Adolescent;Antibodies, Viral;Child;Child, Preschool;Eye Infections, Viral;Humans;Infant;Photoreceptor Cells, Vertebrate;Pregnancy;Pregnancy Complications, Infectious;Retinal Degeneration;Retinal Ganglion Cells;Retrospective Studies;Tomography, Optical Coherence;Visual Acuity;Vitamin B 12 Deficiency;Zika Virus;Zika Virus Infection",M01.060.057;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;M01.060.406;M01.060.406.448;C02.325;C11.294.800;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A08.675.650.850.625.670;A08.675.650.915.937.670;A08.800.950.937.670;A09.371.729.831.625.670;A11.671.650.850.625.670;A11.671.650.915.937.670;G08.686.784.769;C01.539.674;C13.703.700;C11.270.612;C11.768.585;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;C18.654.521.500.133.699.923;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
28880939,"ADP-Ribosylation Factors;Animals;Humans;Kidney;Membrane Proteins;Mice;Mice, Inbred C57BL;Mice, Knockout;Nephritis;Podocytes;Receptors, IgG;Signal Transduction",D08.811.277.040.330.300.400.100;D12.644.360.525.100;D12.776.157.325.515.100;D12.776.476.525.100;B01.050;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C12.777.419.570;C13.351.968.419.570;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720;D12.776.543.750.705.871.300;G02.111.820;G04.835
28880481,"Animals;Biomarkers;Biomedical Research;Cell Lineage;Diabetes Mellitus, Type 1;Diabetes Mellitus, Type 2;Gene Expression Profiling;Gene Expression Regulation;Humans;Insulin;Insulin Secretion;Insulin-Secreting Cells;Single-Cell Analysis;Species Specificity;Transcriptome",B01.050;D23.101;H01.770.644.145;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;C18.452.394.750.124;C19.246.267;C20.111.327;C18.452.394.750.149;C19.246.300;E05.393.332;G05.308;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;E05.242.900;G16.824;G02.111.873.750;G05.297.700.750;G05.360.920
28880260,"Cardiotonic Agents;Critical Illness;Double-Blind Method;Early Termination of Clinical Trials;Heart Defects, Congenital;Heart Failure;Humans;Hydrocortisone;Infant, Newborn;Infant, Premature;Informed Consent;Neurodevelopmental Disorders;Patient Selection",D27.505.954.411.222;D27.720.799.080;C23.550.291.625;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.581.500.400;N04.761.559.590.800.379;N05.715.360.575.575.800.379;C14.240.400;C14.280.400;C16.131.240.400;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;M01.060.703.520;M01.060.703.520.520;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;F03.625;E05.581.500.653;N04.590.731
28880258,Confidence Intervals;Humans;Logistic Models;Meta-Analysis as Topic;Neonatology;Outcome Assessment (Health Care);Randomized Controlled Trials as Topic;Review Literature as Topic;Uncertainty,E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;H02.403.670.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;L01.178.682.759;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900
28879858,"Animals;Bacterial Infections;Bacterial Proteins;CRISPR-Associated Protein 9;CRISPR-Cas Systems;Clustered Regularly Interspaced Short Palindromic Repeats;DNA End-Joining Repair;Endonucleases;Gene Editing;Genetic Engineering;Genome;Humans;Industrial Microbiology;Mycoses;RNA, Guide;Recombinational DNA Repair;Virus Diseases",B01.050;C01.252;D12.776.097;D08.811.277.352.355.325.150;D12.776.097.219;D12.776.212.500;G05.308.203.374.394;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G02.111.222.200;G05.219.200;D08.811.277.352.355;E05.393.420.270;E05.393.420;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.540.460;J01.897.120.460;C01.703;D13.444.735.790.552.625;G02.111.222.700;G05.219.700;G05.728.615.612;C02
28879490,"Autistic Disorder;Child;Child, Preschool;Cognition;Developmental Disabilities;Humans;Language Development;Motor Skills;Phenotype;Autistic Disorder;Autism Spectrum Disorder;Phenotype",F03.625.164.113.500;M01.060.406;M01.060.406.448;F02.463.188;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;F01.525.200.310;F02.808.260;G05.695;F03.625.164.113.500;F03.625.164.113;G05.695
28879195,Biotin;Hair;Nails;Vitamins,D03.383.129.308.080;D08.211.096;A17.360;A17.600;D27.505.696.377.683.500.600;G07.203.300.681.500.600;J02.500.681.500.600
28879186,Alopecia Areata;Bullying;Quality of Life,C17.800.329.937.122.147;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;I01.800;K01.752.400.750;N06.850.505.400.425.837
28878934,"Diabetes Mellitus, Type 2",C18.452.394.750.149;C19.246.300
28877748,"Adult;Aged;Blood Gas Analysis;Double-Blind Method;Humans;Intensive Care Units;Middle Aged;North America;Peptidyl-Dipeptidase A;Pilot Projects;Placebos;Respiratory Distress Syndrome, Adult;Acute Lung Injury;Adult;Humans;Interleukin-6;Renin-Angiotensin System",M01.060.116;M01.060.116.100;E01.370.225.124.100.100;E01.370.386.700.100;E05.200.124.100.100;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;M01.060.116.630;Z01.107.567;D08.811.277.656.350.350.687;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;D26.660;E02.785;C08.381.840;C08.618.840;C08.381.520.500;M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;G03.820;G09.330.380.813
28877549,"Antiviral Agents;Biomedical Research;DNA, Viral;Drug Discovery;Hepatitis B virus;Hepatitis B, Chronic;Humans",D27.505.954.122.388;H01.770.644.145;D13.444.308.568;E05.295;H01.158.703.007.675;H01.181.466.675;B04.280.375.650.425;B04.450.390.650.425;C02.256.430.400.100;C02.440.435.100;C06.552.380.350.100;C06.552.380.705.437.100;B01.050.150.900.649.313.988.400.112.400.400
28877192,"Adult;Demography;Exercise;Humans;Middle Aged;Models, Theoretical;Sleep;Time Factors",M01.060.116;I01.240;N01.224;N06.850.505.400;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.599;F02.830.855;G11.561.803;G01.910.857
28877030,"Administration, Intranasal;Animals;Disease Models, Animal;Dose-Response Relationship, Drug;Fibrosis;Lung;Mice;Oxidative Stress;Peptides;Radiation Pneumonitis",E02.319.267.120.655.500;B01.050;C22.232;E05.598.500;E05.599.395.080;G07.690.773.875;G07.690.936.500;C23.550.355;A04.411;B01.050.150.900.649.313.992.635.505.500;G03.673;G07.775.750;D12.644;C08.381.483.675;C08.381.520.734;C26.733.762;G01.750.748.500.762
28875481,Aged;Brain Ischemia;Cohort Studies;Humans;Middle Aged;Platelet Aggregation Inhibitors;Predictive Value of Tests;Proteinuria;Recurrence;Stroke;Proteinuria;Stroke,M01.060.116.100;C10.228.140.300.150;C14.907.253.092;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D27.505.954.502.780;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;C12.777.934.734;C13.351.968.934.734;C23.888.942.750;C23.550.291.937;C10.228.140.300.775;C14.907.253.855;C12.777.934.734;C13.351.968.934.734;C23.888.942.750;C10.228.140.300.775;C14.907.253.855
28875459,"Adrenal Cortex Hormones;Adult;Aged;Aged, 80 and over;Androstadienes;Bronchodilator Agents;Budesonide;Double-Blind Method;Formoterol Fumarate;Humans;Middle Aged;Nebulizers and Vaporizers;Pulmonary Disease, Chronic Obstructive;United Kingdom;Budesonide;Costs and Cost Analysis",D06.472.040;M01.060.116;M01.060.116.100;M01.060.116.100.080;D04.210.500.054.079.129;D27.505.696.663.050.110;D27.505.954.796.050.100;D04.210.500.745.745.654.105;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D02.033.100.291.425;D02.092.063.291.425;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E07.605;C08.381.495.389;Z01.542.363;D04.210.500.745.745.654.105;N03.219.151
28875364,Acute Coronary Syndrome;Age Factors;Chest Pain;Computed Tomography Angiography;Coronary Angiography;Health Care Costs;Hospitalization;Humans;Middle Aged;Sex Factors;Coronary Stenosis;Costs and Cost Analysis,C14.280.647.124;C14.907.585.124;N05.715.350.075;N06.850.490.250;C23.888.592.612.233;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;N03.219.151.400;N05.300.375;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N05.715.350.675;N06.850.490.875;C14.280.647.250.285;C14.907.585.250.285;N03.219.151
28874804,,
28874408,"A549 Cells;Adhesins, Bacterial;Bacterial Adhesion;Bacterial Proteins;Cell Line, Tumor;Epithelial Cells;Host-Pathogen Interactions;Humans;Kingella kingae;Microscopy, Electron, Transmission;Kingella kingae;Bacterial Capsules",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;D12.776.097.120.050;D12.776.543.100.050;D23.050.161.050;G06.099.050;D12.776.097;A11.251.210.190;A11.251.860.180;A11.436;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;B03.440.400.425.550.400.375;B03.660.075.525.410.410;E01.370.350.515.402.580;E05.595.402.580;B03.440.400.425.550.400.375;B03.660.075.525.410.410;A20.186
28874404,,
28874278,"Adolescent;Aging;Child;Child, Preschool;Finite Element Analysis;Humans;Infant;Models, Biological;Thoracic Vertebrae;Growth;Spine",M01.060.057;G07.345.124;M01.060.406;M01.060.406.448;E05.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.599.395;A02.835.232.834.892;G07.345.249;A02.835.232.834
28874212,"Adolescent;Bacteremia;Catheter-Related Infections;Catheterization, Central Venous;Child;Child, Preschool;Cross Infection;Enterobacter cloacae;Equipment Contamination;Escherichia coli;Hospitals, Pediatric;Humans;Infection Control;Klebsiella Infections;Klebsiella pneumoniae;Leukemia;Philadelphia;Retrospective Studies;Streptococcal Infections;Streptococcus mitis",M01.060.057;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;C01.539.195;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;M01.060.406;M01.060.406.448;C01.539.248;C23.550.291.875.500;B03.440.450.425.275.200;B03.660.250.150.170.100;N06.850.540;B03.440.450.425.325.300;B03.660.250.150.180.100;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N06.850.780.200.450;C01.252.400.310.503;B03.440.450.425.425.600;B03.660.250.150.400.590;C04.557.337;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.252.410.890;B03.353.750.737.872.875.500;B03.510.400.800.872.875.500;B03.510.550.737.872.875.500
28874075,,
28873254,Uranium,D01.268.271.100.950;D01.268.556.900;D01.496.749.305.100.950;D01.552.020.940;D01.552.544.900
28873191,Risk Assessment;Testosterone,E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D04.210.500.054.079.429.824;D06.472.334.851.968.984
28873121,Adolescent;Child;Critical Illness;Cultural Characteristics;Culturally Competent Care;Humans;Middle East;Pediatrics;Professional-Family Relations;Truth Disclosure;United States,M01.060.057;M01.060.406;C23.550.291.625;I01.076.201.450.324;I01.880.853.100.329;N04.590.374.052;N05.300.206;B01.050.150.900.649.313.988.400.112.400.400;Z01.252.245.500;H02.403.670;F01.829.401.550;F01.829.401.046.800;I01.880.604.583.080.134.800;Z01.107.567.875
28873106,Acne Vulgaris;Adolescent;Adult;Chemexfoliation;Facial Dermatoses;Humans;Keratolytic Agents;Phototherapy;Prospective Studies;Quality of Life;Salicylic Acid;Severity of Illness Index;Single-Blind Method;Surveys and Questionnaires;Treatment Outcome;Young Adult,C17.800.030.150;C17.800.794.111;M01.060.057;M01.060.116;E02.218.170;E04.680.275.200;C17.800.271;B01.050.150.900.649.313.988.400.112.400.400;D27.505.954.444.400;E02.774;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;D02.241.223.100.300.595.608;D02.241.511.390.595.608;D02.455.426.559.389.127.281.595.608;D02.455.426.559.389.657.410.595.608;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28873067,"Adolescent;Adult;Anticonvulsants;Chorioamnionitis;Humans;Magnesium Sulfate;Pregnancy;Pregnancy, Twin;Retrospective Studies;Young Adult;Chorioamnionitis;Magnesium Sulfate;Twins",M01.060.057;M01.060.116;D27.505.954.427.080;C13.703.277.030;C13.703.420.339.260;C13.703.590.268;C16.300.030;B01.050.150.900.649.313.988.400.112.400.400;D01.524.550;D01.875.800.800.850.500;G08.686.784.769;G08.686.710.253;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;C13.703.277.030;C13.703.420.339.260;C13.703.590.268;C16.300.030;D01.524.550;D01.875.800.800.850.500;M01.438.873
28872902,"Adolescent;Child;Child, Preschool;Cognition Disorders;Humans;Infant;Multiple Sclerosis;Neuropsychological Tests",M01.060.057;M01.060.406;M01.060.406.448;F03.615.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;F04.711.513
28872634,"Brain Neoplasms;DNA, Neoplasm;Glioma;Humans;Image Interpretation, Computer-Assisted;Magnetic Resonance Imaging;Multimodal Imaging",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;D13.444.308.425;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;E01.370.350.825.500;E01.370.350.567
28872566,"Adolescent;Brain Concussion;Child;Disease Management;Ear;Emergency Service, Hospital;Humans;Incidence;Mental Status and Dementia Tests;Mood Disorders;Neuroimaging;Rest",M01.060.057;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;N04.590.607;A01.456.313;A09.246;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;F04.711.513.603;F03.600;E01.370.350.578;E01.370.376.537;E05.629;I03.450.769.647
28872531,"Child;Databases, Factual;Fracture Fixation, Internal;Humans;Humeral Fractures;Patient Selection;Peripheral Nerve Injuries;Prevalence;Retrospective Studies;Trauma Centers;Ulnar Nerve",M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;E04.555.300.300;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;E05.581.500.653;N04.590.731;C10.668.829.712;C10.900.575;C26.915.650;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;A08.800.800.720.050.850
28872353,Primary Graft Dysfunction,C14.907.725.675;C23.550.767.877.750
28872278,,
28872046,"Acute Disease;Adolescent;African Americans;Anti-Bacterial Agents;Child, Preschool;Drug Utilization;Emergency Service, Hospital;European Continental Ancestry Group;Healthcare Disparities;Hispanic Americans;Humans;Inappropriate Prescribing;Infant;Infant, Newborn;Logistic Models;Practice Patterns, Physicians';Registries;Respiratory Tract Infections;Retrospective Studies;United States;Virus Diseases",C23.550.291.125;M01.060.057;M01.686.508.100.100;M01.686.754.100;D27.505.954.122.085;M01.060.406.448;N04.452.706.477;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;M01.686.508.400;N04.590.374.380;N05.300.493;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;E02.319.490;N02.421.450.500.249;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N04.590.374.577;N05.300.625;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C01.539.739;C08.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C02
28872032,Brain Mapping;Electroencephalography;Humans;Artifacts,E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;E05.047
28871606,"Adolescent;Child;Cystic Fibrosis;Follow-Up Studies;Graft Rejection;Graft Survival;Humans;Longitudinal Studies;Lung Diseases, Fungal;Lung Transplantation;Postoperative Complications;Prognosis;Prospective Studies;Risk Factors;Lung Transplantation;Pediatrics;Lung Diseases, Fungal",M01.060.057;M01.060.406;C06.689.202;C08.381.187;C16.320.190;C16.614.213;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G12.875.545.328;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C01.703.534;C08.381.472;C08.730.435;E04.928.600.495;E04.936.450.495;C23.550.767;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.928.600.495;E04.936.450.495;H02.403.670;C01.703.534;C08.381.472;C08.730.435
28870971,"Adult;Aged;Cholesterol, HDL;Genetic Variation;Genotype;High-Throughput Nucleotide Sequencing;Humans;Middle Aged;Multifactorial Inheritance;Dyslipidemias;Genetics;Genomics",M01.060.116;M01.060.116.100;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;G05.365;G05.380;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.420.590;C18.452.584.500;H01.158.273.343;H01.158.273.180.350;H01.158.273.343.350
28870169,Adult;Colorado;Counseling;Exercise;Exercise Therapy;Guideline Adherence;Humans;Logistic Models;North Carolina;Obesity;Oklahoma;Patient Compliance;Pregnancy;Pregnancy Complications;Pregnancy Trimesters;Prenatal Care;Risk Assessment;Surveys and Questionnaires;Thinness;Weight Gain;Young Adult;Exercise;Pregnancy;Prenatal Care,M01.060.116;Z01.107.567.875.760.210;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;G11.427.410.698.277;I03.350;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;Z01.107.567.875.075.475;Z01.107.567.875.750.530;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;Z01.107.567.875.510.550;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;G08.686.784.769;C13.703;G08.686.707;E02.760.786;N02.421.143.620.704;N02.421.585.786;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.888.144.828;E01.370.600.115.100.160.120.828;G07.100.100.160.120.828;C23.888.144.243.926;G07.345.249.314.120.200.926;M01.060.116.815;G11.427.410.698.277;I03.350;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786
28869486,"Adolescent;Antioxidants;Child;Humans;Muscular Dystrophy, Duchenne;Respiration;Ubiquinone;Vital Capacity;Muscular Dystrophy, Duchenne;Vital Capacity;Respiration",M01.060.057;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;G09.772.705;D02.806.250.900;D08.211.935;E01.370.386.700.485.750.900;G09.772.850.970;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.386.700.485.750.900;G09.772.850.970;G09.772.705
28868660,,
28868584,"Ambulatory Care Facilities;Efficiency, Organizational;Emergency Service, Hospital;Humans;Medical Overuse",N02.278.035;N04.452.209.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;N02.421.380.450;N05.300.150.395.450
28867556,"Animals;Antigens, Neoplasm;Cancer Vaccines;Humans;Immunogenicity, Vaccine;Immunotherapy;Neoplasms",B01.050;D23.050.285;D20.215.894.200;B01.050.150.900.649.313.988.400.112.400.400;G12.070.500;G12.450.050.370.500;G12.450.050.460;G12.513;E02.095.465.425;C04
28867356,Arylsulfotransferase;DNA Copy Number Variations;Estrogens;Estrone;Genotype;Humans;Hypersensitivity;Estrogens;Metabolism,D08.811.913.817.400.300;G05.365.795.297.500;D27.505.696.399.472.277;D04.210.500.365.415.414;D04.210.500.578.502.497;D06.472.040.502.497;D06.472.334.851.437.996;G05.380;B01.050.150.900.649.313.988.400.112.400.400;C20.543;D27.505.696.399.472.277;G03
28867147,"Animals;Animals, Genetically Modified;Carcinogenesis;Cell Line, Tumor;Cell Movement;DNA-Binding Proteins;Extracellular Matrix;Gene Expression Regulation, Neoplastic;Humans;Hyperplasia;LIM Domain Proteins;Models, Biological;N-Myc Proto-Oncogene Protein;Neoplasm Invasiveness;Neoplasm Metastasis;Neuroblastoma;Signal Transduction;Transcription Factors;Transgenes;Zebrafish;Neoplasm Metastasis;Neuroblastoma;Carcinogenesis",B01.050;B01.050.050.136;B05.620.136;C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;D12.776.260;A11.284.295.310;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;C23.550.444;D12.776.512;E05.599.395;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.697.645;C23.550.727.645;C04.697.650;C23.550.727.650;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G02.111.820;G04.835;D12.776.930;G05.360.340.024.340.825;B01.050.150.900.493.200.244.828;C04.697.650;C23.550.727.650;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C04.697.098;C23.550.727.098
28867130,"Angiogenesis Inhibitors;Bevacizumab;Dose-Response Relationship, Drug;Fluorescein Angiography;Follow-Up Studies;Fundus Oculi;Humans;Infant;Infant, Newborn;Intravitreal Injections;Laser Coagulation;Retina;Retinopathy of Prematurity;Retrospective Studies;Time Factors;Treatment Outcome;Vascular Endothelial Growth Factor A",D27.505.696.377.077.099;D27.505.696.377.450.100;D27.505.954.248.025;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;G07.690.773.875;G07.690.936.500;E01.370.370.050.350;E01.370.380.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A09.371.729.313;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.319.267.530.475.500;E02.520.745.410;E02.594.530;E04.014.520.530;E04.350.750.410;E04.540.630.410;A09.371.729;C11.768.836;C16.614.521.731;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200
28867065,"Aortic Coarctation;Cross-Sectional Studies;Eye Abnormalities;Humans;Infant, Newborn;Neurocutaneous Syndromes;Placenta Previa;Pre-Eclampsia;Pregnancy;Prenatal Care;Registries;Risk Factors;United States;Hemangioma",C14.240.400.090;C14.280.400.090;C16.131.240.400.090;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C11.250;C16.131.384;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C10.562;C16.131.077.350.712;C16.131.831.350.712;C16.320.850.250.712;C17.800.804.350.712;C17.800.827.250.712;C13.703.420.714;C13.703.590.734;C13.703.395.249;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C04.557.645.375
28866611,Chromatin,A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180
28866451,Cystic Fibrosis;Women's Health,C06.689.202;C08.381.187;C16.320.190;C16.614.213;N01.400.900
28866367,"Adolescent;Adult;Aged;Child;Child, Preschool;Disease Progression;Humans;Infant;Middle Aged;Myositis Ossificans;Ossification, Heterotopic;Registries;Young Adult;Myositis Ossificans;Ossification, Heterotopic;Natural History;Registries",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;M01.060.406.448;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;C05.651.594.638;C23.550.751;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;M01.060.116.815;C05.651.594.638;C23.550.751;H01.158.273.602;H01.770.552;K01.400.703;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28866073,"Adult;Aged;Brain Neoplasms;Carcinoma, Non-Small-Cell Lung;Databases, Factual;Humans;Lung Neoplasms;Middle Aged;Radiosurgery;United States;Brain;Lung Neoplasms;Neoplasm Metastasis;Radiosurgery",M01.060.116;M01.060.116.100;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;E02.815.530;E04.525.800.650;E05.873.500;Z01.107.567.875;A08.186.211;C04.588.894.797.520;C08.381.540;C08.785.520;C04.697.650;C23.550.727.650;E02.815.530;E04.525.800.650;E05.873.500
28865972,"Adult;Aged;Humans;Immunoglobulin Light-chain Amyloidosis;Kidney Failure, Chronic;Kidney Transplantation;Melphalan;Middle Aged;Renal Dialysis;Stem Cell Transplantation;Treatment Outcome;Immunoglobulin Light-chain Amyloidosis;Kidney Failure, Chronic;Melphalan;Renal Insufficiency",M01.060.116;M01.060.116.100;B01.050.150.900.649.313.988.400.112.400.400;C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.500;E04.936.450.485;E04.950.774.400;D02.455.526.728.650.594;D12.125.072.050.685.500;M01.060.116.630;E02.870.300;E02.912.800;E02.095.147.500.500;E04.936.225.687;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565;C12.777.419.780.750.500;C13.351.968.419.780.750.500;D02.455.526.728.650.594;D12.125.072.050.685.500;C12.777.419.780;C13.351.968.419.780
28865779,"Acute Disease;Aortic Diseases;Global Health;Humans;Morbidity;Seasons;Syndrome;Aortic Diseases;Aneurysm, Dissecting",C23.550.291.125;C14.907.109;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;G01.910.645.661;G16.500.275.071.590;N06.230.300.100.250.525;C23.550.288.500;C14.907.109;C14.907.055.050
28865719,"Adaptation, Psychological;Adult;Aged;Emergency Service, Hospital;Factor Analysis, Statistical;Hospitalization;Humans;Middle Aged;Psychometrics;Reproducibility of Results;Risk Factors;Suicidal Ideation;Suicide;Young Adult",F01.058;M01.060.116;M01.060.116.100;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.980.875;I01.880.735.856;M01.060.116.815
28865661,"Bullying;Child;Child Welfare;Child of Impaired Parents;Domestic Violence;Exposure to Violence;Health Policy;Humans;Income;Life Change Events;Mental Disorders;Parental Death;Prejudice;Psychological Trauma;Reproducibility of Results;Residence Characteristics;Risk Assessment;Socioeconomic Factors;Stress, Psychological;Substance-Related Disorders;Adverse Childhood Experiences;Child Health",F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;M01.060.406;I01.880.787.293;M01.106;I01.198.240.856.350;I01.880.735.900.350;I01.880.735.900.869;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;F01.829.458.410;F03;C23.550.260.730;I01.880.735.607;F01.145.813.550;F01.829.595;F03.950.750.375;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;N01.224.791;N06.850.505.400.800;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;I01.880.853.996;N01.824;F01.145.126.990;F02.830.900;C25.775;F03.900;I01.198.240.856.175;I01.880.735.035;I01.880.735.900.175;I01.880.853.050;N01.400.225
28865645,"Advisory Committees;Child;Cooperative Behavior;Humans;Life Change Events;Organizational Case Studies;Philadelphia;Research;Residence Characteristics;Resilience, Psychological;Stress, Psychological",N03.706.742.500;M01.060.406;F01.145.813.115;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;N03.349.380.710;N05.715.360.455;Z01.107.567.875.500.550.525;Z01.433.820;H01.770.644;N01.224.791;N06.850.505.400.800;F02.940;F01.145.126.990;F02.830.900
28865345,Anisotropy;Case-Control Studies;DiGeorge Syndrome;Diffusion Tensor Imaging;Gyrus Cinguli;Humans;White Matter;Young Adult;DiGeorge Syndrome;Diffusion Tensor Imaging;Psychotic Disorders,G01.590.040;G02.050;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;B01.050.150.900.649.313.988.400.112.400.400;A08.186.211.204;A08.186.854.880;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;F03.700.675
28865296,"Animals;Cell Hypoxia;Cell Membrane;Cells, Cultured;Endothelial Cells;Hydrogen Peroxide;Lipid Peroxidation;Lung;Mice;Mice, Inbred C57BL;Mice, Knockout;Microvessels;Peroxiredoxin VI;Recombinant Proteins;Endothelial Cells;Hyperoxia;Lipid Peroxidation",B01.050;G03.197.300;G04.270.300;A11.284.149;A11.251;A11.436.275;D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253;G02.111.515;G03.295.531.587;A04.411;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A07.015.461;D08.811.277.352.100.680.750.937.300.500;D08.811.277.352.100.680.750.937.625.624;D08.811.641.773;D08.811.682.732.850.500;D12.776.828;A11.436.275;C23.888.852.567;G02.111.515;G03.295.531.587
28864845,"Adolescent;Adverse Childhood Experiences;Autistic Disorder;Child;Child Health;Child, Preschool;Cross-Sectional Studies;Delayed Diagnosis;Humans;Surveys and Questionnaires;Treatment Outcome;Adverse Childhood Experiences;Autism Spectrum Disorder;Diagnosis",M01.060.057;I01.198.240.856.175;I01.880.735.035;I01.880.735.900.175;I01.880.853.050;F03.625.164.113.500;M01.060.406;N01.400.225;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.110;E02.288;E02.760.273;N02.421.585.273;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;I01.198.240.856.175;I01.880.735.035;I01.880.735.900.175;I01.880.853.050;F03.625.164.113;E01
28864822,"Acetylation;Amino Acid Motifs;Animals;Epigenesis, Genetic;Erythropoietin;Gene Expression Regulation;Hepcidins;Histone Deacetylases;Histones;Humans;Iron;Mice, Inbred C57BL;Promoter Regions, Genetic",G02.111.012.052;G02.607.063.052;G03.040.052;G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;B01.050;G05.308.203;D12.644.276.374.410.240.150;D12.776.395.240.150;D12.776.467.374.410.240.150;D23.529.374.410.240.150;G05.308;D12.776.494.249;D12.776.543.695.054.425;D08.811.277.087.520;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.412;D01.268.956.287;D01.552.544.412;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680
28864676,"Aged;Aged, 80 and over;Case-Control Studies;Humans;Medicare;Olfaction Disorders;Parkinson Disease;Predictive Value of Tests;ROC Curve;Retrospective Studies;Sleep Wake Disorders;United States",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C10.597.751.600;C23.888.592.763.550;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.886;C23.888.592.796;F03.870;Z01.107.567.875
28864443,"Aged;Aged, 80 and over;Anesthesia, General;Aortic Valve Stenosis;Comparative Effectiveness Research;Conscious Sedation;Hospital Mortality;Humans;Intention to Treat Analysis;Length of Stay;Patient Discharge;Practice Patterns, Physicians';Registries;Risk Assessment;Risk Factors;Time Factors;Transcatheter Aortic Valve Replacement;Treatment Outcome;United States;Anesthesia;Transcatheter Aortic Valve Replacement",M01.060.116.100;M01.060.116.100.080;E03.155.197;C14.280.484.150;C14.280.955.249;H01.770.644.145.360.500;N05.425.157;E03.250;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;E02.760.400.480;N02.421.585.400.480;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;N04.590.374.577;N05.300.625;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;E03.155;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
28864296,,
28864127,,
28863857,Adrenal Insufficiency;Adult;Child;Demyelinating Diseases;Gallbladder;Genetic Predisposition to Disease;Hereditary Central Nervous System Demyelinating Diseases;Humans;Leukoencephalopathies;Lysosomal Storage Diseases;Quality of Life;Consensus;Therapeutics,C19.053.500;M01.060.116;M01.060.406;C10.314;A03.159.439;C23.550.291.687.500;G05.380.355;C10.228.140.163.100.362;C10.228.140.695.625;C10.314.400;C10.574.500.490;C16.320.400.367;C16.320.565.189.362;C18.452.132.100.362;C18.452.648.189.362;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.695;C16.320.565.595;C18.452.648.595;I01.800;K01.752.400.750;N06.850.505.400.425.837;F01.829.316.068;F02.463.785.373.433;E02
28863437,Animals;Catecholamines;Disease Progression;Fenfluramine;Heart Valve Diseases;Humans;Neurotransmitter Agents;Serotonin;Heart Valve Diseases;Neurotransmitter Agents;Serotonin,B01.050;D02.092.311;D02.455.426.559.389.657.166.175;C23.550.291.656;D02.092.471.683.467;C14.280.484;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.625;D27.505.696.577;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650;C14.280.484;D27.505.519.625;D27.505.696.577;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650
28863353,"Activities of Daily Living;Aged;Aged, 80 and over;Disabled Persons;Hospitalization;Humans;Long-Term Care;Medicare;Mortality;Nursing Homes;Prospective Studies;Skilled Nursing Facilities;Surveys and Questionnaires;United States;Medicare",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;M01.060.116.100.080;M01.150;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.476;N02.421.585.476;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;N02.278.825.610;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N02.278.825.610.770;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696
28863267,Adult;Body Mass Index;Breast Feeding;Cohort Studies;Florida;Humans;Lactation;Lactation Disorders;Obesity;Prospective Studies;Self Report;Time Factors;Weight Gain;Breast Feeding;Lactation,M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;Z01.107.567.875.750.350;B01.050.150.900.649.313.988.400.112.400.400;G08.686.523;G08.686.702.500;C13.703.844.506;C17.800.090.937;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;G01.910.857;C23.888.144.243.926;G07.345.249.314.120.200.926;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;G08.686.523;G08.686.702.500
28863095,,
28863091,,
28863076,"Adolescent;Age of Onset;Biopsy;Canada;Child;Child, Preschool;Colitis, Ulcerative;Colon;Colonoscopy;Eosinophilia;Humans;Predictive Value of Tests;Prospective Studies;Rectum;Severity of Illness Index;United States",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;Z01.107.567.176;M01.060.406;M01.060.406.448;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;A03.556.124.526.356;A03.556.249.249.356;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C15.378.553.231;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A03.556.124.526.767;A03.556.249.249.767;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;Z01.107.567.875
28863006,"ADAM Proteins;Animals;Chemokine CXCL1;Disease Models, Animal;Intervertebral Disc Degeneration;Mice;Mice, Inbred C57BL;RNA, Messenger",D08.811.277.656.675.374.102;D09.400.430.500;D12.776.395.033;B01.050;D12.644.276.374.200.120.050;D12.776.467.374.200.120.050;D12.776.624.664.700.049;D23.125.300.120.050;D23.469.200.120.050;D23.529.374.200.120.050;C22.232;E05.598.500;E05.599.395.080;C05.116.900.153;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D13.444.735.544
28862971,Affect;Aged;Benzaldehydes;Chi-Square Distribution;Chronic Disease;Coronary Disease;Exercise;Health Status;Heart Failure;Humans;Kaplan-Meier Estimate;Middle Aged;Multivariate Analysis;Myocardial Infarction;Odds Ratio;Oximes;Patient Reported Outcome Measures;Phospholipase A2 Inhibitors;Proportional Hazards Models;Randomized Controlled Trials as Topic;Self Report;Stroke;Time Factors;Treatment Outcome;Coronary Artery Disease,F01.470.047;M01.060.116.100;D02.047.222;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;C23.550.291.500;C14.280.647.250;C14.907.585.250;G11.427.410.698.277;I03.350;I01.240.425;N01.224.425;N06.850.505.400.425;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;C14.280.647.500;C14.907.585.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;D02.092.570.665;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;D27.505.519.389.737;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;C10.228.140.300.775;C14.907.253.855;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
28862644,Adoptive Transfer;Immunotherapy;Mesothelioma,E02.095.465.425.400.330.050;E05.478.550.520.050;E02.095.465.425;C04.557.470.035.510;C04.557.470.660.510
28862076,Circadian Clocks;Circadian Rhythm;Gastrointestinal Microbiome;Humans;Circadian Rhythm;Gastrointestinal Microbiome;Metabolome,G07.180.562.094.500;G07.180.562.190;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;G07.180.562.190;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G03.500
28861551,HIV;Adolescent;Mental Health;Transgender Persons,B04.820.650.589.650.350;M01.060.057;F02.418;N01.400.500;M01.777.500
28860605,,
28860221,"Adolescent;Adult;Biological Transport;Biomarkers;Cholesterol, HDL;Coronary Disease;Humans;Middle Aged;Risk Factors;Triglycerides;Young Adult;Genetics;Lipoprotein(a);Phospholipids;Triglycerides;Ultracentrifugation",M01.060.057;M01.060.116;G03.143;D23.101;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;C14.280.647.250;C14.907.585.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D10.351.801;M01.060.116.815;H01.158.273.343;D10.532.350;D12.776.521.400;D10.570.755;D10.351.801;E05.181.724;E05.196.941
28860204,"Dendritic Cells;Granulocyte-Macrophage Colony-Stimulating Factor;Humans;Immunoglobulin A;Nasal Mucosa;Toll-Like Receptor 5;Granulocyte-Macrophage Colony-Stimulating Factor;Immunity, Mucosal;Nasal Mucosa",A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.026;D12.776.124.790.651.114.619.026;D12.776.377.715.548.114.619.026;A04.531.520;A04.760.600;A10.615.550.760.600;D12.776.543.750.705.910.500.500;D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375;G12.450.573;A04.531.520;A04.760.600;A10.615.550.760.600
28860152,"3T3 Cells;Animals;Apoptosis;Bone Remodeling;Bortezomib;Cell Line;Cell Survival;DNA Repair;Humans;Mice;Mice, Inbred C57BL;Mice, Transgenic;Osteoblasts;Osteoporosis;Proteasome Inhibitors;Radiation Injuries;Radiation-Protective Agents;X-Ray Microtomography;DNA Repair;Apoptosis;Bone and Bones;Osteoblasts",A11.251.210.100;A11.329.228.100;B01.050;G04.146.160;G11.427.213;G16.762.150;D01.029.260.110.500;D01.132.285.500;D02.203.200.500;D03.383.679.450;A11.251.210;G04.346;G02.111.222;G05.219;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.329.629;C05.116.198.579;C18.452.104.579;D27.505.519.389.745.705;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;D27.505.696.706.776;D27.720.799.763;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900;G02.111.222;G05.219;G04.146.160;A02.835.232;A10.165.265;A11.329.629
28860024,"Centralized Hospital Services;Delivery, Obstetric;Gestational Age;Health Policy;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Outcome Assessment (Health Care);Parental Leave;Perinatal Care;Population Health;Pregnancy;Premature Birth;Public Health;Parental Leave;Infant, Newborn",N02.278.216.500.750;N04.452.442.110;E04.520.252;G07.345.500.325.235.968;G08.686.320;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;N01.824.417.700.162.500;N04.452.677.800.162.500;E02.760.703;N02.421.088.120.180;N02.421.143.620.550;N02.421.585.703;N01.400.548;G08.686.784.769;C13.703.420.491.500;H02.403.720;N01.400.550;N06.850;N01.824.417.700.162.500;N04.452.677.800.162.500;M01.060.703.520
28860023,African Continental Ancestry Group;Health Services Research;Humans;Maternal Mortality;Pregnancy;Pregnancy Outcome;Risk Factors;United States,M01.686.508.100;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.550.500;N01.224.935.698.653;N06.850.505.400.975.550.500;N06.850.520.308.985.550.500;G08.686.784.769;E01.789.700;G08.686.784.769.496;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28859944,Adult;Age Factors;Aged;Antihypertensive Agents;Australia;Blood Pressure Determination;Catheter Ablation;Drug Resistance;Europe;Humans;Hypertension;Internationality;Middle Aged;Patient Safety;Prognosis;Reference Values;Risk Assessment;Severity of Illness Index;Sex Factors;Single-Blind Method;Sympathectomy;Treatment Outcome;United States,M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;D27.505.954.411.162;Z01.639.100;Z01.678.100.373;E01.370.370.140;E01.370.600.100;E02.808.750.500;E04.014.760.500;G07.690.773.984;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;I01.615;M01.060.116.630;N06.850.135.060.075.399;E01.789;E05.978.810;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N05.715.350.675;N06.850.490.875;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;E04.525.210.105.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
28859887,,
28859081,Africa;Coinfection;HIV Infections;Humans;Neurosyphilis,Z01.058;C01.539.218;C02.219;C03.202;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;C01.252.200.750;C01.252.400.840.744.456;C01.252.847.840.744.456;C10.228.228.180.600
28858903,,
28858774,"Accidents, Traffic;Adolescent;Adult;Age Factors;Automobile Driving;Humans;Licensure;Longitudinal Studies;New Jersey;Young Adult;Jurisprudence",N06.850.135.392;M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;I03.125;B01.050.150.900.649.313.988.400.112.400.400;N03.706.110.510;N05.700.200.450;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875.500.525;M01.060.116.815;I01.880.604.583;N03.706.535
28858508,"Anemia, Sickle Cell;Antisickling Agents;Chemistry, Pharmaceutical;Crystallization;Crystallography, X-Ray;Drug Design;Erythrocytes;Esters;Ethers;Furaldehyde;Healthy Volunteers;Hemoglobin, Sickle;Humans;Models, Molecular;Oxygen;Protein Binding;Structure-Activity Relationship;Time Factors;Treatment Outcome;Furaldehyde;Hemoglobins;Polymerization;Anemia, Sickle Cell",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;D27.505.954.502.135;H01.158.703.007;H01.181.466;E05.196.300;G02.171;E05.196.309.742.225;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;A11.118.290;A11.443.240;A15.145.229.334;D02.241.400;D02.355;D02.047.466;D03.383.312.355;M01.774.500;M01.955.236;D12.776.124.400.463.588;D12.776.422.316.762.426.588;B01.050.150.900.649.313.988.400.112.400.400;E05.599.595;D01.268.185.550;D01.362.670;G02.111.679;G03.808;G02.111.830;G07.690.773.997;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.047.466;D03.383.312.355;D12.776.124.400;D12.776.422.316.762;G02.750;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
28858394,"Adult;Aged;Aged, 80 and over;Cognition;Humans;Intensive Care Units;Middle Aged;Modafinil;Retrospective Studies;Wakefulness-Promoting Agents;Glasgow Coma Scale;Cognition;Intensive Care Units;Modafinil;Analgesics, Opioid;Hypnotics and Sedatives",M01.060.116;M01.060.116.100;M01.060.116.100.080;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;M01.060.116.630;D02.455.426.559.389.115.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.954.427.220.612;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;F02.463.188;N02.278.388.493;D02.455.426.559.389.115.550;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;D27.505.696.277.350;D27.505.954.427.210.350
28858287,"Animals;CD8-Positive T-Lymphocytes;Genetic Vectors;Mice;Retroviridae;Transduction, Genetic",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;G05.360.337;B01.050.150.900.649.313.992.635.505.500;B04.613.807;B04.820.650;E05.393.350.800;G05.728.850
28858191,,
28858071,Adult;Aged;Biomarkers;C-Reactive Protein;Cohort Studies;Diet;Endoscopy;Feces;Humans;Inflammatory Bowel Diseases;Leukocyte L1 Antigen Complex;Middle Aged;Severity of Illness Index;Young Adult,M01.060.116;M01.060.116.100;D23.101;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G07.203.650.240;E01.370.388.250;E04.502.250;A12.459;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.776.157.125.750.500;D12.776.631.655.500;D23.050.301.562;M01.060.116.630;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815
28858068,Academic Medical Centers;Adult;Electronic Health Records;Humans;Inflammatory Bowel Diseases;Logistic Models;Middle Aged;Multivariate Analysis;Patient Readmission;Pennsylvania;Prognosis;Retrospective Studies;Risk Factors;Time Factors;Young Adult,N02.278.020;M01.060.116;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.760.400.620;N02.421.585.400.620;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.060.116.815
28857627,"Sleep Apnea, Central;Cognitive Behavioral Therapy;Sleep Initiation and Maintenance Disorders;Sleep Apnea, Obstructive",C08.618.085.852.800;C10.886.425.800.750.800;F04.754.137.350;C10.886.425.800.800;F03.870.400.800.800;C08.618.085.852.850;C10.886.425.800.750.850
28857623,Asthma;Bronchopulmonary Dysplasia,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C08.381.520.750.500;C16.614.521.125
28857309,"Adult;Aged;Aged, 80 and over;Case-Control Studies;Citalopram;Drug Approval;Drug Labeling;Drug Prescriptions;General Practitioners;Humans;Interrupted Time Series Analysis;Middle Aged;Pharmacovigilance;Phosphodiesterase 5 Inhibitors;Practice Patterns, Physicians';United Kingdom;United States;Young Adult;Drug Labeling;Interrupted Time Series Analysis;Pharmacoepidemiology;Practice Patterns, Physicians'",M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D02.092.831.170;D02.626.320;D03.633.100.127.187;E05.290.250;E05.337.300;I01.880.604.605.250.250;E05.916.310;J01.576.655.750.321.400;J01.576.761.300.400;E02.319.307;N02.421.668.778.500;M01.526.485.810.485;N02.360.810.485;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.931;N05.715.360.330.500.912;N06.850.520.450.500.912;M01.060.116.630;E05.337.800.600;N06.850.505.636;D27.505.519.389.735.500;N04.590.374.577;N05.300.625;Z01.542.363;Z01.107.567.875;M01.060.116.815;E05.916.310;J01.576.655.750.321.400;J01.576.761.300.400;E05.318.372.500.931;N05.715.360.330.500.912;N06.850.520.450.500.912;H01.158.703.045;H02.403.720.500.650;H02.628.413;N04.590.374.577;N05.300.625
28857146,Leukoencephalopathies,C10.228.140.695
28856921,Humans;Inflammation;Lung Neoplasms;Mesothelioma;Neoadjuvant Therapy;Inflammation;General Surgery,B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.470.035.510;C04.557.470.660.510;E02.186.450;C23.550.470;H02.403.810.300
28856605,"Adult;Aged;Aged, 80 and over;Hernia, Ventral;Humans;Interviews as Topic;Middle Aged;Patient Care Team;Patient Reported Outcome Measures;Patient Satisfaction;Qualitative Research;Reproducibility of Results",M01.060.116;M01.060.116.100;M01.060.116.100.080;C23.300.707.374.937;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;N04.590.715;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;H01.770.644.241.850;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
28856480,"Autistic Disorder;Child;Child, Preschool;Humans;Infant;Parents;Sensitivity and Specificity;Socioeconomic Factors;Surveys and Questionnaires;Autistic Disorder;Demography",F03.625.164.113.500;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;I01.880.853.996;N01.824;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F03.625.164.113.500;I01.240;N01.224;N06.850.505.400
28856395,"Adolescent;Cardiac Surgical Procedures;Child;Cross-Sectional Studies;Exercise Test;Health Status;Heart;Humans;Magnetic Resonance Imaging, Cine;Oxygen Consumption;Propensity Score;Pulmonary Valve Insufficiency;Pulmonary Valve Stenosis;Quality of Life;Self Report;Surveys and Questionnaires;Tetralogy of Fallot;Ventricular Function, Right;Health Status;Pulmonary Valve Stenosis;Quality of Life;Tetralogy of Fallot",M01.060.057;E04.100.376;E04.928.220;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;I01.240.425;N01.224.425;N06.850.505.400.425;A07.541;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.510;G03.680;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;C14.280.484.660;C14.280.484.716;C14.280.955.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;G09.330.955.900;I01.240.425;N01.224.425;N06.850.505.400.425;C14.280.484.716;C14.280.955.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
28856392,"Animals;Antibodies;B7-1 Antigen;CTLA-4 Antigen;Humans;Interleukin-2 Receptor alpha Subunit;Lymphocytes, Tumor-Infiltrating;Mice;Pancreatic Neoplasms;Signal Transduction;T-Lymphocytes, Regulatory;Immunotherapy;Pancreatic Neoplasms",B01.050;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;D12.776.467.150.100;D12.776.543.095.100;D23.050.301.285.100;D23.529.168.100;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.852.420.320.500;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;B01.050.150.900.649.313.992.635.505.500;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;G02.111.820;G04.835;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;E02.095.465.425;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
28856043,,
28855741,"Animals;Biological Transport;Cytoskeleton;Humans;Models, Neurological;Molecular Motor Proteins;Neurons",B01.050;G03.143;A11.284.430.214.190.750;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.642;D05.500.500;D08.811.277.040.025.193;A08.675;A11.671
28855730,"Adipose Tissue, Brown;Fatty Acids;Humans;NFI Transcription Factors;Obesity",A10.165.114.322;D10.251;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.605;D12.776.930.612;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28855262,"Animals;Callithrix;DNA Transposable Elements;Evolution, Molecular;Gene Expression Regulation;Humans;Regulatory Elements, Transcriptional;Species Specificity",B01.050;B01.050.150.900.649.313.988.400.600.150.150.114;D13.444.308.520;G02.111.570.080.708.330.200;G05.360.080.708.330.200;G05.360.340.024.425.200;G05.045.250;G16.075.250;G05.308;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.340.137.750;G16.824
28855250,"Animals;CCCTC-Binding Factor;Cell Nucleus;Chromosomes, Human;Enhancer Elements, Genetic;Gene Deletion;Gene Expression Regulation, Neoplastic;Genetic Predisposition to Disease;Genome, Human;Humans;Mutation;Neoplasms;Nucleic Acid Conformation;Phenotype;Promoter Regions, Genetic;Protein Binding;Zinc Fingers",B01.050;D12.776.157.687.157;D12.776.260.120;D12.776.660.235.050;D12.776.660.720.157;D12.776.664.235.050;D12.776.930.780.563;A11.284.430.106;A11.284.430.214.190.875.117;A11.284.187.520.300;G05.360.162.520.300;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.365.590.762.320;G05.558.800.320;G05.308.370;C23.550.291.687.500;G05.380.355;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04;G02.111.570.820.486;G05.360.580;G05.695;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;G02.111.570.820.709.275.500.985
28854814,"Animals;Cells, Cultured;Genetic Therapy;Genetic Vectors;HEK293 Cells;Humans;Lentivirus;Macrophages;Mice;Peptide Elongation Factor 1;Promoter Regions, Genetic;Pulmonary Alveolar Proteinosis;Receptors, Granulocyte-Macrophage Colony-Stimulating Factor;Transduction, Genetic;Lentivirus;Macrophages",B01.050;A11.251;E02.095.301;E05.393.420.301;G05.360.337;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;D08.811.277.040.330.300.100.101;D12.776.157.325.150.101;D12.776.835.700.350.101;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;C08.381.719;D12.776.543.750.705.852.150.310;D12.776.543.750.750.400.200.420;E05.393.350.800;G05.728.850;B04.820.650.589;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
28854576,Genetic Predisposition to Disease;Genetic Therapy;Genome-Wide Association Study;Humans;Macular Degeneration;Precision Medicine;Risk Factors,C23.550.291.687.500;G05.380.355;E02.095.301;E05.393.420.301;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C11.768.585.439;E02.574;H02.403.200.700;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28854314,,
28853623,"Aged;Cohort Studies;Databases, Factual;Humans;Length of Stay;Logistic Models;Middle Aged;Multivariate Analysis;Odds Ratio;Operative Time;Patient Readmission;Postoperative Complications;Prospective Studies;Prostatectomy;Prostatic Neoplasms;Quality Improvement;Risk Assessment;Robotic Surgical Procedures;United States;Prostatectomy;Risk Factors;Robotics",M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E04.614.374.500;N02.421.585.753.374.500;E02.760.400.620;N02.421.585.400.620;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E04.950.774.860.625;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;J01.293.754;N04.761.744;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;Z01.107.567.875;E04.950.774.860.625;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H01.671.293.643;J01.897.104.834;L01.224.050.375.630
28852967,Minimally Invasive Surgical Procedures;Neoadjuvant Therapy;Pancreatic Neoplasms,E04.502;E02.186.450;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421
28852935,"Adult;Aged;Brain Neoplasms;Carcinogenesis;Cell Culture Techniques;Cell Line, Tumor;Cell Proliferation;Gene Expression Regulation, Neoplastic;Gene Knockdown Techniques;Glioma;Humans;Neoplastic Stem Cells;Protein Tyrosine Phosphatase, Non-Receptor Type 11;SOXB1 Transcription Factors;Tissue Scaffolds;Glioma;Stem Cells",M01.060.116;M01.060.116.100;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.697.098;C23.550.727.098;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G05.308.370;E05.393.335.500;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;A11.872.650;D08.811.277.352.650.775.300.800;D08.811.277.352.650.775.700.800;D12.644.360.585.800;D12.776.476.564.800;D12.776.476.800.800;D12.776.260.719.100;D12.776.660.235.400.750.100;D12.776.664.235.400.750.100;D12.776.930.823.100;E07.206.627;E07.695.825;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;A11.872
28852836,"Adult;Aged;Aged, 80 and over;Flail Chest;Fracture Fixation;Humans;Middle Aged;Practice Patterns, Physicians';Rib Fractures;Societies, Medical;Surveys and Questionnaires;Thoracic Injuries;Thoracic Wall;Rib Fractures;Surveys and Questionnaires",M01.060.116;M01.060.116.100;M01.060.116.100.080;C26.891.315;E04.555.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.590.374.577;N05.300.625;C26.404.593;C26.891.733;N03.540.828.589;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C26.891;A01.923.761.850;C26.404.593;C26.891.733;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28852817,"Cardiac Surgical Procedures;Child;Child, Preschool;Health Care Costs;Heart Defects, Congenital;Heart Failure;Hospitalization;Humans;Infant;Infant, Newborn;Medicaid;Prevalence;Retrospective Studies;Risk Factors;South Carolina;United States;Heart Failure;Risk Factors",E04.100.376;E04.928.220;M01.060.406;M01.060.406.448;N03.219.151.400;N05.300.375;C14.240.400;C14.280.400;C16.131.240.400;C14.280.434;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N03.219.521.346.506.564.655;N03.706.615.693;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875.075.662;Z01.107.567.875.750.700;Z01.107.567.875;C14.280.434;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28852767,"Anal Canal;Child;Child, Preschool;Cloaca;Diagnostic Imaging;Humans;Infant;Infant, Newborn;Ovary;Pediatrics;Rectum;Terminology as Topic;Torsion Abnormality;Urogenital System;Urology;Anorectal Malformations;Child;Cloaca;Consensus;Fluoroscopy;Magnetic Resonance Imaging;Terminology",A03.556.124.526.070;A03.556.249.249.070;M01.060.406;M01.060.406.448;A13.223;A16.178;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;H02.403.670;A03.556.124.526.767;A03.556.249.249.767;L01.559.598.400;C23.300.970;A05;H02.403.810.860;C06.198.025;C16.131.314.047;M01.060.406;A13.223;A16.178;F01.829.316.068;F02.463.785.373.433;E01.370.350.700.225;E01.370.350.825.500;V02.938
28852496,Tissue Donors;Hepatitis C;Kidney Transplantation,M01.898;C02.440.440;C02.782.350.350;C06.552.380.705.440;E02.870.500;E04.936.450.485;E04.950.774.400
28851989,,
28851719,"Adolescent;Adult;Cardiac Catheterization;Child;Child, Preschool;Disease-Free Survival;Fontan Procedure;Hospitals, Pediatric;Humans;Hypoplastic Left Heart Syndrome;Infant;Kaplan-Meier Estimate;Palliative Care;Philadelphia;Postoperative Complications;Proportional Hazards Models;Reoperation;Retrospective Studies;Risk Factors;Survivors;Time Factors;Treatment Outcome;Young Adult;Fontan Procedure;Catheterization;Cyanosis;Hypoplastic Left Heart Syndrome;Mortality;Tricuspid Atresia",M01.060.057;M01.060.116;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406;M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E02.760.666;N02.421.585.666;Z01.107.567.875.500.550.525;Z01.433.820;C23.550.767;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.860;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;E02.148;E05.157;C23.888.248;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C14.240.400.920;C14.280.400.920;C14.280.484.845;C16.131.240.400.920
28851718,"Adolescent;Adult;Bioprosthesis;Blood Vessel Prosthesis;Blood Vessel Prosthesis Implantation;Cardiac Catheterization;Child;Feasibility Studies;Heart Valve Prosthesis;Heart Valve Prosthesis Implantation;Heart Ventricles;Humans;Middle Aged;Postoperative Complications;Prosthesis Design;Pulmonary Valve;Pulmonary Valve Insufficiency;Recovery of Function;Retrospective Studies;Risk Factors;Time Factors;Transposition of Great Vessels;Treatment Outcome;United States;Ventricular Function, Left;Ventricular Function, Right;Young Adult;Catheterization;Pulmonary Valve;Pulmonary Valve Insufficiency;Transposition of Great Vessels",M01.060.057;M01.060.116;E07.695.100;E07.695.110;E04.100.814.868.500;E04.650.200;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;E07.695.310;E04.100.376.485;E04.650.410;E04.928.220.410;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.767;E05.320.550;E07.695.680;A07.541.510.738;C14.280.484.660;G16.757;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;C14.240.400.915;C14.280.400.915;C16.131.240.400.915;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;G09.330.955.800;G09.330.955.900;M01.060.116.815;E02.148;E05.157;A07.541.510.738;C14.280.484.660;C14.240.400.915;C14.280.400.915;C16.131.240.400.915
28851610,,
28851608,,
28851607,,
28851540,"Animals;Aprepitant;Cromolyn Sodium;Disease Models, Animal;Mast Cells;Mice;Morpholines;Myositis Ossificans;Ossification, Heterotopic;Cromolyn Sodium;Ossification, Heterotopic;Mast Cells",B01.050;D03.383.533.640.125;D03.383.663.283.266.300;D03.633.100.150.266.300;C22.232;E05.598.500;E05.599.395.080;A11.329.427;A15.382.652;B01.050.150.900.649.313.992.635.505.500;D03.383.533.640;C05.651.594.638;C23.550.751;D03.383.663.283.266.300;D03.633.100.150.266.300;C23.550.751;A11.329.427;A15.382.652
28851265,Adult;Cost-Benefit Analysis;Fever;Humans;Orthopedic Procedures;Postoperative Period;Orthopedics,M01.060.116;N03.219.151.125;C23.888.119.344;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;E04.614.750;N02.421.585.753.750;H02.403.810.494
20301440,,
28849992,Epidemiology;Ethnic Groups;Continental Population Groups,H02.403.720.500;M01.686.754;N01.224.317;M01.686.508
28848242,Antineoplastic Agents;Apoptosis;Humans;Myeloid Cell Leukemia Sequence 1 Protein;Ovarian Neoplasms;Phosphatidylinositol 3-Kinases;Systems Biology;TOR Serine-Threonine Kinases;X-Linked Inhibitor of Apoptosis Protein,D27.505.954.248;G04.146.160;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360.075.718.984;D12.776.476.075.718.968;D12.776.624.664.700.169.500;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D08.811.913.696.620.500;H01.158.273.180.800;D08.811.913.696.620.682.700.931;D12.776.476.925;D08.811.464.938.750.210.750;D12.644.360.075.437.750;D12.776.476.075.437.750
28847986,Health Equity;Health Services Accessibility;Humans;Quality of Health Care,N04.590.374.350.500;N05.300.430.383;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N04.761;N05.715
28847332,"Abnormalities, Multiple;Cardiac Catheterization;Cardiac Surgical Procedures;Child;Computed Tomography Angiography;Humans;Pulmonary Artery;Pulmonary Veins;Scimitar Syndrome",C16.131.077;E01.370.370.380.140;E02.148.442;E05.157.250;E04.100.376;E04.928.220;M01.060.406;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;B01.050.150.900.649.313.988.400.112.400.400;A07.015.114.715;A07.015.908.713;C08.381.844;C08.695.815;C14.240.850.968;C14.907.780;C16.131.240.850.937;C16.131.740.815
28846772,"Aged;Animals;Blood-Retinal Barrier;Blotting, Western;Capillary Permeability;Cation Transport Proteins;Disease Models, Animal;Ependymoglial Cells;Ferritins;Humans;Immunohistochemistry;Iron;Mass Spectrometry;Mice;Mice, Inbred C57BL;Mice, Inbred CBA;Mice, Transgenic;Middle Aged;RNA, Messenger;Real-Time Polymerase Chain Reaction;Receptors, Transferrin;Retina;Retinal Telangiectasis",M01.060.116.100;B01.050;A07.040;A09.371.729.055;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;G03.143.330;G09.330.165;D12.776.157.530.450.250;D12.776.543.585.450.250;C22.232;E05.598.500;E05.599.395.080;A08.637.300;A11.650.300;D12.776.157.427.249;D12.776.556.579.249;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;D01.268.556.412;D01.268.956.287;D01.552.544.412;E05.196.566;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.199.520.520.440;B01.050.150.900.649.313.992.635.505.500.400.440;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;M01.060.116.630;D13.444.735.544;E05.393.620.500.706;D12.776.157.905.500;D12.776.543.750.800;A09.371.729;C11.768.748;C14.907.823.502
28846763,"Adolescent;Brain Injuries, Traumatic;Child;Child, Preschool;Databases, Factual;Hospital Mortality;Humans;Infant;Intracranial Pressure;Length of Stay;Monitoring, Physiologic;Patient Discharge;Propensity Score;Survival Rate;United States",M01.060.057;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G11.561.170.505;E02.760.400.480;N02.421.585.400.480;E01.370.520;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;Z01.107.567.875
28846687,Animals;Cell Self Renewal;Hepatocyte Nuclear Factor 1-alpha;Lymphoid Enhancer-Binding Factor 1;Mice;Palate;Taste Buds;Taste Perception;Tongue;Wnt Signaling Pathway;Wnt3 Protein;beta Catenin,B01.050;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;D12.776.260.262.500.500;D12.776.260.400.218.500;D12.776.660.352.500.500;D12.776.930.318.500.500;D12.776.260.730.500;D12.776.660.235.400.800.500;D12.776.664.235.400.800.500;D12.776.930.875.500;B01.050.150.900.649.313.992.635.505.500;A14.521.658;A14.549.617;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779;F02.463.593.817;A03.556.500.885;A14.549.885;G02.111.820.925;G04.835.925;D12.776.467.984.300;D23.529.984.300;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
28846646,"Adiposity;Adolescent;Adolescent Development;Adolescent Nutritional Physiological Phenomena;Age Factors;Body Mass Index;Child;Cohort Studies;Feeding and Eating Disorders;Follow-Up Studies;Health Knowledge, Attitudes, Practice;Healthy Diet;Humans;National Institutes of Health (U.S.);Overweight;Patient Education as Topic;Pediatric Obesity;Psychotherapy, Group;Risk;United States;Weight Gain;Adiposity;Adolescent;Obesity;Continental Population Groups",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.060.057;F01.525.049;G07.345.374.500;G07.203.650.220.060;N05.715.350.075;N06.850.490.250;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F03.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;F01.100.150.500;N05.300.150.410;F01.829.458.205.500;G07.203.650.240.629;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;I02.233.332.500;N02.421.726.407.680;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;F04.754.864.581;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;Z01.107.567.875;C23.888.144.243.926;G07.345.249.314.120.200.926;E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.060.057;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;M01.686.508
28846519,"Beneficence;Child;Delivery of Health Care;Empathy;Humans;Patient-Centered Care;Pediatrics;Principle-Based Ethics;Social Justice;Stress Disorders, Post-Traumatic",K01.752.566.479.830.500;N05.350.958.500;M01.060.406;N04.590.374;N05.300;F01.752.355;F01.752.543.500.500;B01.050.150.900.649.313.988.400.112.400.400;N04.590.233.727.407;H02.403.670;K01.752.566.479.830;N05.350.958;I01.880.604.473.700;K01.752.566.479.830.750;N03.706.437.700;N05.350.958.750;F03.950.750.500
28846439,Metagenomics;Microbiota;Sarcoidosis,H01.158.273.343.350.261;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C15.604.515.827
28846092,"Crystallography, X-Ray;Models, Molecular;Mutant Proteins;Protein Conformation;Shaker Superfamily of Potassium Channels",E05.196.309.742.225;E05.599.595;D12.776.602;G02.111.570.820.709;D12.776.157.530.400.600.900.500;D12.776.543.550.450.750.900.500;D12.776.543.585.400.750.900.624
28845882,"Aged;Alanine Transaminase;Antiviral Agents;Cohort Studies;Hepatitis B;Hepatitis B Antibodies;Hepatitis B virus;Hepatitis C;Hepatitis C, Chronic;Humans;Liver;Middle Aged;Telbivudine;Tenofovir;United States;Veterans;Virus Activation;Hepatitis B;Hepatitis C;Humans;Veterans",M01.060.116.100;D08.811.913.477.700.100;D27.505.954.122.388;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.256.430.400;C02.440.435;C06.552.380.705.437;D12.776.124.486.485.114.254.450.504;D12.776.124.790.651.114.254.450.504;D12.776.377.715.548.114.254.450.504;B04.280.375.650.425;B04.450.390.650.425;C02.440.440;C02.782.350.350;C06.552.380.705.440;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;A03.620;M01.060.116.630;D03.383.742.680.705.888;D13.570.230.855.888;D13.570.685.705.888;D02.705.429.906;D03.633.100.759.138.881;Z01.107.567.875;M01.930;G06.920.925.940;C02.256.430.400;C02.440.435;C06.552.380.705.437;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;M01.930
28845594,Glioma;Magnetic Resonance Imaging,C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;E01.370.350.825.500
28845517,"Animals;Antioxidants;Disease Models, Animal;Humans;Oxidative Stress;Resuscitation;Resveratrol;Shock, Hemorrhagic;Stilbenes;Sirtuin 1;Shock, Hemorrhagic;Inflammation;Mitochondria;Resveratrol",B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;G03.673;G07.775.750;E02.365.647;D02.455.426.559.389.150.700.375;D02.455.426.559.389.657.715.500;D03.633.100.150.266.450.260.777.500;C23.550.414.980;C23.550.835.650;D02.455.426.559.389.150.700;D08.811.277.087.520.200.650.100;D12.776.476.900.100;C23.550.414.980;C23.550.835.650;C23.550.470;A11.284.430.214.190.875.564;A11.284.835.626;D02.455.426.559.389.150.700.375;D02.455.426.559.389.657.715.500;D03.633.100.150.266.450.260.777.500
28845483,"Blood Coagulation;Factor V;Models, Molecular",G09.188.390.150;D12.776.124.125.300;D23.119.300;E05.599.595
28845440,Chromatin;Micrococcal Nuclease;Viruses,A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D08.811.277.352.335.350.500;D08.811.277.352.355.325.500;D08.811.277.352.355.350.500;D08.811.277.352.700.350.500;B04
28844905,"Actins;Aminoacyltransferases;Animals;Arginine;Brain;Cell Movement;Growth Cones;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;Microtubule-Associated Proteins;Models, Biological;Neurites;Neuronal Outgrowth;Neuropeptides;Protein Biosynthesis;RNA, Messenger",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D08.811.913.050.200;B01.050;D12.125.068.050;D12.125.095.104;D12.125.142.087;A08.186.211;G04.198;G07.568.500.180;A11.284.180.075.249;A11.284.180.225.340;A11.284.180.610.345;A11.671.137.340;A11.671.240.340;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D12.776.220.600.450;D12.776.631.560;E05.599.395;A08.675.256.500;A08.675.542.145.500;A11.284.180.610;A11.671.501.145.500;A11.671.543;G04.152.912.750;G07.345.500.325.377.687.750;G08.686.784.170.450.500.750;G11.561.620.750;D12.644.400;D12.776.631.650;G02.111.660.871;G03.734.871;G05.297.670;D13.444.735.544
28844837,"Alprostadil;Animals;Cell Line, Tumor;Cell Self Renewal;Drug Synergism;Hematopoietic Stem Cells;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Mice;Misoprostol;Neoplastic Stem Cells;Proto-Oncogene Proteins c-fos;Receptors, Prostaglandin E, EP4 Subtype;Transcription Factor AP-1;Transcription, Genetic;Xenograft Model Antitumor Assays;beta Catenin;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Misoprostol;Alprostadil;Heterografts",D10.251.355.255.550.250.100;D10.251.355.325.050;D23.469.050.175.725.250.100;B01.050;A11.251.210.190;A11.251.860.180;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;G07.690.773.968.477;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;C04.557.337.539.250;C15.378.190.636.370;B01.050.150.900.649.313.992.635.505.500;D10.251.355.255.550.775.450.500;D23.469.050.175.725.775.450.500;D23.469.700.660.500;A11.872.650;D12.776.260.108.765;D12.776.624.664.700.179;D12.776.660.760;D12.776.930.127.765;D12.776.543.750.695.200.700.600.400;D12.776.260.108.875;D12.776.930.127.875;G02.111.873;G05.297.700;E05.337.550.200.900;E05.624.850;D12.776.091.249;D12.776.220.145.500;D12.776.930.130;C04.557.337.539.250;C15.378.190.636.370;D10.251.355.255.550.775.450.500;D23.469.050.175.725.775.450.500;D23.469.700.660.500;D10.251.355.255.550.250.100;D10.251.355.325.050;D23.469.050.175.725.250.100;A01.941.875
28844826,"Accidental Falls;Accidents, Traffic;Adolescent;Adult;Case-Control Studies;Homicide;Humans;Maternal Mortality;Middle Aged;Pennsylvania;Pregnancy;Pregnancy Complications;Regression Analysis;Risk;Violence;Wounds and Injuries;Young Adult;Burns;Critical Care;Ethnic Groups;Homicide;Intubation;Maternal Mortality;Pregnancy;Suicide;Wounds and Injuries;Violence",N06.850.135.122;N06.850.135.392;M01.060.057;M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;I01.198.240.470;I01.880.735.344;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.550.500;N01.224.935.698.653;N06.850.505.400.975.550.500;N06.850.520.308.985.550.500;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;G08.686.784.769;C13.703;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;I01.198.240.856;I01.880.735.900;C26;M01.060.116.815;C26.200;E02.760.190;N02.421.585.190;M01.686.754;N01.224.317;I01.198.240.470;I01.880.735.344;E02.585;E05.497;E05.318.308.985.550.500;N01.224.935.698.653;N06.850.505.400.975.550.500;N06.850.520.308.985.550.500;G08.686.784.769;F01.145.126.980.875;I01.880.735.856;C26;I01.198.240.856;I01.880.735.900
28844789,"Acoustic Stimulation;Animals;Auditory Perception;Autism Spectrum Disorder;Baclofen;Cadherins;Chromatography, High Pressure Liquid;Electrocorticography;Electrodes, Implanted;Evoked Potentials;GABA-B Receptor Agonists;Gamma Rhythm;Glutamine;Mice, Transgenic;Sex Characteristics;Theta Rhythm;gamma-Aminobutyric Acid;Baclofen;Electrophysiology;gamma-Aminobutyric Acid",E02.037;E02.190.888.030;E05.723.136;B01.050;F02.463.593.071;F03.625.164.113;D02.241.081.114.500.350.100;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;E05.196.181.400.300;E01.370.376.300.294;E01.370.405.245.431;E07.305.250.319;E07.695.202;G07.265.216.500;G11.561.200.500;D27.505.519.625.240.200.750;D27.505.696.577.240.200.750;E01.370.376.300.150.906;E01.370.405.245.287.906;G07.265.087.906;G11.561.127.906;D12.125.068.330;D12.125.095.461;D12.125.154.424;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G08.686.815;E01.370.376.300.150.937;E01.370.405.245.287.937;G07.265.087.937;G11.561.127.937;D02.241.081.114.500.350;D12.125.190.350;D02.241.081.114.500.350.100;H01.158.344.528;H01.158.782.236;D02.241.081.114.500.350;D12.125.190.350
28844699,Aging;Animals;Circadian Clocks;Humans;Microbiota;Suprachiasmatic Nucleus;Aging;Circadian Clocks;Metabolism;Microbiota,G07.345.124;B01.050;G07.180.562.094.500;B01.050.150.900.649.313.988.400.112.400.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A08.186.211.180.497.342.625;A08.186.211.200.317.357.342.625;G07.345.124;G07.180.562.094.500;G03;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
28844586,Acute Kidney Injury;Adult;Area Under Curve;Biomarkers;Cohort Studies;Creatinine;Cross-Sectional Studies;Fatty Acid-Binding Proteins;Hepatitis A Virus Cellular Receptor 1;Humans;Interleukin-18;Kidney Transplantation;Kidney Tubules;Lipocalin-2;Middle Aged;Prospective Studies;ROC Curve;Severity of Illness Index;Tissue Donors;Interleukin-18,C12.777.419.780.050;C13.351.968.419.780.050;M01.060.116;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;D23.101;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D03.383.129.308.207;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.776.157.170;D12.776.395.550.469;D12.776.543.550.435;D12.776.543.750.830.187;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518;E02.870.500;E04.936.450.485;E04.950.774.400;A05.810.453.736.560;D12.776.124.050.475;D12.776.157.469.325;D12.776.624.664.700.123;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.898;D12.644.276.374.465.518;D12.776.467.374.465.518;D23.529.374.465.518
28844499,"Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Cancer Vaccines;Dacarbazine;Disease-Free Survival;Dose-Response Relationship, Drug;Double-Blind Method;Drug Administration Schedule;ErbB Receptors;Follow-Up Studies;Gene Expression Regulation, Neoplastic;Glioblastoma;Humans;Internationality;Kaplan-Meier Estimate;Middle Aged;Patient Selection;Proportional Hazards Models;Survival Analysis;Temozolomide;Time Factors;Treatment Outcome;Vaccines, Subunit;Young Adult",M01.060.116;M01.060.116.100;E02.183.750.500;E02.319.077.500;E02.319.310.037;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;D20.215.894.200;D02.925.200;D03.383.129.308.240;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.283;D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G05.308.370;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;I01.615;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.581.500.653;N04.590.731;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;D02.925.200.500;D03.383.129.308.240.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D20.215.894.860;M01.060.116.815
28844280,"Aged, 80 and over;Amyloidosis;Bradycardia;Dizziness;Dyspnea;Echocardiography;Edema;Electrocardiography;Heart Diseases;Heart Failure, Diastolic;Humans;Renal Insufficiency, Chronic",M01.060.116.100.080;C18.452.845.500;C14.280.067.319;C23.550.073.300;C23.888.592.763.237;C08.618.326;C23.888.852.371;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C23.888.277;E01.370.370.380.240;E01.370.405.240;C14.280;C14.280.434.611;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750;C13.351.968.419.780.750
28844152,Autism Spectrum Disorder;Executive Function,F03.625.164.113;F02.463.217
28844086,"Aged;Aged, 80 and over;Caregivers;Colorectal Neoplasms;Humans;Middle Aged;Ostomy;Qualitative Research;Quality of Life;Surveys and Questionnaires;Survivors;Colorectal Neoplasms;Ostomy",M01.060.116.100;M01.060.116.100.080;M01.085;M01.526.485.200;N02.360.200;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E04.579;H01.770.644.241.850;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.860;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E04.579
28843460,"Cohort Studies;Emergency Service, Hospital;Humans;Hypoglycemia;Hypoglycemic Agents;Infant;Infant, Newborn;Medical Errors;Patient Simulation;Pediatrics;Prospective Studies;Seizures;Surveys and Questionnaires;Glucose;Pediatrics",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.984;D27.505.696.422;M01.060.703;M01.060.703.520;N02.421.450;I02.903.847.500;H02.403.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.597.742;C23.888.592.742;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;D09.947.875.359.448;H02.403.670
28843418,"Catheter Ablation;Electrocardiography;Heart Conduction System;Humans;Italy;Middle Aged;Recurrence;Survival Rate;Tachycardia, Ventricular;Treatment Outcome;United States;Catheter Ablation;Tachycardia, Ventricular",E02.808.750.500;E04.014.760.500;E01.370.370.380.240;E01.370.405.240;A07.541.409;B01.050.150.900.649.313.988.400.112.400.400;Z01.542.489;M01.060.116.630;C23.550.291.937;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;E02.808.750.500;E04.014.760.500;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
28843074,"Adolescent;Adult;Afghan Campaign 2001-;Anxiety;Combat Disorders;Humans;Military Personnel;Psychological Trauma;Sleep Initiation and Maintenance Disorders;Social Perception;Social Support;Stress Disorders, Post-Traumatic;United States;Young Adult;Stress Disorders, Post-Traumatic;Psychometrics;Social Support",M01.060.057;M01.060.116;I01.880.735.950.250.094;K01.400.504.984.124;F01.470.132;F03.950.750.249;B01.050.150.900.649.313.988.400.112.400.400;M01.526.625;F03.950.750.375;C10.886.425.800.800;F03.870.400.800.800;F02.463.593.752;I01.880.853.500.600;F03.950.750.500;Z01.107.567.875;M01.060.116.815;F03.950.750.500;F04.711.780;I01.880.853.500.600
28842840,,
28842795,"Apoptosis Inducing Factor;Genes, X-Linked;Genetic Predisposition to Disease;Humans;Intellectual Disability;Mutation;Myelin Sheath;Osteochondrodysplasias;Pedigree;Phenotype;Sequence Analysis, DNA;Myelin Sheath",D08.811.682.608.047;D12.644.360.075.311;D12.776.157.687.063;D12.776.331.161;D12.776.476.075.311;D12.776.660.720.063;G05.360.340.024.340.500;G05.420.457;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553;C05.116.099.708;C16.320.728;E05.393.673;G05.695;E05.393.760.700;A08.637.600.500;A08.637.800.500;A08.675.542.512.560;A08.800.800.690.500;A10.755.503;A11.284.149.165.600;A11.650.600.500;A11.650.800.500;A11.671.501.512.560;A11.671.514.553
28842498,Animals;Basic Helix-Loop-Helix Transcription Factors;Humans;Neoplasm Proteins;Neoplasms;Oxygen;Neoplasms;Glucose;Glutamine;Hypoxia;Lipid Metabolism;Metabolism,B01.050;D12.776.260.103;D12.776.930.125;B01.050.150.900.649.313.988.400.112.400.400;D12.776.624;C04;D01.268.185.550;D01.362.670;C04;D09.947.875.359.448;D12.125.068.330;D12.125.095.461;D12.125.154.424;C23.888.852.079;G03.458;G03
28842435,"Animals;Coculture Techniques;Collagen Type I;Collagen Type III;Diabetes Mellitus, Experimental;Extracellular Matrix Proteins;Fibroblasts;Gene Expression Regulation;Matrix Metalloproteinase 9;Mesenchymal Stem Cell Transplantation;Mesenchymal Stem Cells;Mice, Transgenic;MicroRNAs;Proteolysis;Wound Healing;Extracellular Matrix;Mesenchymal Stem Cells;Proteolysis;Wound Healing",B01.050;E05.481.500.374;D05.750.078.280.300.100;D12.776.860.300.250.300.100;D05.750.078.280.300.300;D12.776.860.300.250.300.300;C18.452.394.750.074;C19.246.240;E05.598.500.374;D12.776.860.300;A11.329.228;G05.308;D08.811.277.656.300.480.205.360;D08.811.277.656.300.480.252.445;D08.811.277.656.300.480.525.700.350;D08.811.277.656.675.374.205.360;D08.811.277.656.675.374.252.445;D08.811.277.656.675.374.525.700.350;D12.644.276.848.350;D12.776.467.836.350;E02.095.147.500.500.625;E04.936.225.687.625;A11.329.830.500;A11.872.590.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;G02.111.720;G03.812;G16.762.891;A11.284.295.310;A11.329.830.500;A11.872.590.500;G02.111.720;G03.812;G16.762.891
28842329,"Aged;Analgesics, Opioid;Combined Modality Therapy;Dermatologic Agents;Double-Blind Method;Humans;Lower Extremity;Middle Aged;Prognosis;Risk Assessment;Time Factors;Varicose Ulcer;Wound Closure Techniques;Wound Healing",M01.060.116.100;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;E02.186;D27.505.954.444;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610;M01.060.116.630;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;G01.910.857;C14.907.927.730;C17.800.893.592.730;E04.987;G16.762.891
28841802,Brain Neoplasms;Diffusion Magnetic Resonance Imaging;Diffusion Tensor Imaging;Glioblastoma;Humans;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Prognosis;Sensitivity and Specificity;Glioblastoma;Diffusion;Perfusion;Radiation Oncology;Spectrum Analysis,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E01.370.350.825.500.150;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.196.867.519;E01.789;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;G01.202;G02.196;E05.680;H02.403.429.515.500;H02.403.740.650;E05.196.867
28841651,"Animals;Autism Spectrum Disorder;Behavior, Animal;Cell Adhesion Molecules, Neuronal;Disease Models, Animal;Genetic Predisposition to Disease;Humans;Mice;Mice, Transgenic;Mutation, Missense;Neurons;Pedigree;Proteolysis;Social Behavior;Spine;Synapses",B01.050;F03.625.164.113;F01.145.113;D12.776.395.550.200.250;D12.776.543.550.200.250;D23.050.301.350.250;C22.232;E05.598.500;E05.599.395.080;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.365.590.650;A08.675;A11.671;E05.393.673;G02.111.720;G03.812;F01.145.813;A02.835.232.834;A08.850;A11.284.149.165.420.780
28841453,"Adolescent;Argon;Argon Plasma Coagulation;Diverticulum;Embolism, Air;Humans;Kidney Calices;Kidney Diseases;Laparoscopy;Ligation;Patient Positioning;Postoperative Complications;Solubility;Ventricular Outflow Obstruction",M01.060.057;D01.268.613.050;D01.362.641.113;E02.154.402.054;E02.520.089;E04.014.170.402.054;E04.350.500;C01.539.463.199.750;C06.405.205.282.750;C23.300.415;C14.907.355.350.254;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453.537.503;C12.777.419;C13.351.968.419;E01.370.388.250.520;E04.502.250.520;E04.426;E02.760.670;N02.421.585.700;C23.550.767;G02.805;C14.280.955
28841438,"Animals;Brain;Humans;Mammals;Models, Neurological;Sleep",B01.050;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649;E05.599.395.642;F02.830.855;G11.561.803
28840491,,
28840373,"Child;Child, Preschool;Cross-Sectional Studies;Ethiopia;Humans;Infant;Intussusception;Prospective Studies;Treatment Outcome;Ultrasonography, Interventional;Intestinal Obstruction;Intussusception;General Surgery",M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;Z01.058.290.120.310;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C06.405.469.531.577;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850.855;E04.502.890;C06.405.469.531;C06.405.469.531.577;H02.403.810.300
28840306,Child;Fused Kidney;Humans;Kidney Function Tests;Magnetic Resonance Imaging;Child;Kidney;Magnetic Resonance Imaging;Urinary Tract,M01.060.406;C12.706.445;C13.351.875.420;C16.131.939.445;B01.050.150.900.649.313.988.400.112.400.400;E01.370.390.400;E01.370.350.825.500;M01.060.406;A05.810.453;E01.370.350.825.500;A05.810
28840247,,
28840157,Mental Health;Prefrontal Cortex,F02.418;N01.400.500;A08.186.211.200.885.287.500.270.700
28838920,"Animals;Arteries;Atherosclerosis;CRISPR-Associated Proteins;CRISPR-Cas Systems;Clustered Regularly Interspaced Short Palindromic Repeats;Dyslipidemias;Gene Editing;Gene Expression Regulation;Genetic Therapy;Humans;Lipid Metabolism;Lipids;Plaque, Atherosclerotic;Animals;Atherosclerosis;Gene Editing;Lipids;Mice",B01.050;A07.015.114;C14.907.137.126.307;D12.776.212;G05.308.203.374.394;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C18.452.584.500;E05.393.420.270;G05.308;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;G03.458;D10;C23.300.823;B01.050;C14.907.137.126.307;E05.393.420.270;D10;B01.050.150.900.649.313.992.635.505.500
28838005,,
28837717,"Advance Directives;Bioethical Issues;Commitment of Mentally Ill;Hospitals, Psychiatric;Humans;Mental Competency;Mental Disorders;Semantics;Terminology as Topic",I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050;K01.752.566.479.023;N05.350.100;F04.096.544.335.200;N03.706.535.351.200;N02.278.421.556.508;B01.050.150.900.649.313.988.400.112.400.400;F01.590;F02.410;I01.880.604.583.530;N03.706.535.625;F03;L01.559.598.745;L01.559.598.400
28837220,,
28837055,"Humans;Molecular Imaging;Monitoring, Intraoperative;Neoplasms;Surgical Oncology;Surgical Procedures, Operative",B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.557;E05.601.555;E01.370.520.510;E04.510;C04;H02.403.429.515.750;H02.403.810.796;E04
28836107,"Anesthesia, General;Carbon Dioxide;Child;Humans;Intubation, Intratracheal;Laryngeal Masks;Monitoring, Physiologic;Neural Networks (Computer);Respiration;Algorithms;Laryngeal Masks;Neural Networks (Computer)",E03.155.197;D01.200.200;D01.362.150;D01.650.550.200;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E02.041.500;E02.585.578;E05.497.578;E02.041.500.475;E02.585.578.475;E05.497.578.475;E07.700.500.450;J01.637.708.560.782.450;E01.370.520;G17.485;L01.224.050.375.605;G09.772.705;G17.035;L01.224.050;E02.041.500.475;E02.585.578.475;E05.497.578.475;E07.700.500.450;J01.637.708.560.782.450;G17.485;L01.224.050.375.605
28835803,Prostaglandin-Endoperoxide Synthases;Lipoxygenase,D08.811.600.720;D08.811.682.690.708.715;D08.811.682.690.416.583.625;D12.776.556.579.374.568.750
28835476,"Clinical Laboratory Techniques;Diagnostic Tests, Routine;Humans;Practice Guidelines as Topic;Societies;Blood Culture",E01.370.225;E05.200;E01.370.395;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;N03.540.828;E01.370.225.875.185;E05.200.875.185
28835397,"Aged;Aged, 80 and over;Geography, Medical;Humans;Logistic Models;Medicare;Parkinson Disease;Physical Therapy Modalities;United States",M01.060.116.100;M01.060.116.100.080;H01.277.500.097;H02.403.352;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E02.779;E02.831.535;Z01.107.567.875
28835385,"Aminopyridines;Animals;Apoptosis;Cell Line, Tumor;Cell Proliferation;Combined Modality Therapy;Endothelial Cells;Humans;Imidazoles;Mice;Morpholines;Myeloid Cell Leukemia Sequence 1 Protein;Neoplasm Recurrence, Local;Neoplasms;Neovascularization, Pathologic;Oxidative Stress;Phosphatidylinositol 3-Kinases;Photochemotherapy;Porphyrins;Protein Kinase Inhibitors;Quinolines;Signal Transduction;Thiazoles;Verteporfin;Xenograft Model Antitumor Assays",D02.092.080;D03.383.725.050;B01.050;G04.146.160;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;E02.186;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.308;B01.050.150.900.649.313.992.635.505.500;D03.383.533.640;D12.644.360.075.718.984;D12.776.476.075.718.968;D12.776.624.664.700.169.500;C04.697.655;C23.550.727.655;C04;C23.550.589.500;G03.673;G07.775.750;D08.811.913.696.620.500;E02.186.500;E02.319.685;E02.774.722;D03.383.129.578.840.500;D03.633.400.909.500;D04.345.783.500;D23.767.727;D27.505.519.389.755;D03.633.100.810;G02.111.820;G04.835;D02.886.675;D03.383.129.708;D03.383.129.578.840.500.940;D03.633.400.909.500.940;D04.345.783.500.940;E05.337.550.200.900;E05.624.850
28835382,"Adolescent;Anti-Bacterial Agents;Bacteremia;Bacteria;Blood Culture;Child;Child, Preschool;Community-Acquired Infections;Cross-Sectional Studies;Hospitalization;Humans;Infant;Microbial Sensitivity Tests;Penicillins;Pneumonia, Bacterial;Retrospective Studies",M01.060.057;D27.505.954.122.085;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;B03;E01.370.225.875.185;E05.200.875.185;M01.060.406;M01.060.406.448;C01.539.234;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;D02.065.589.099.750;D02.886.108.750;D03.633.100.300.750;C01.252.620;C08.381.677.540;C08.730.610.540;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28834725,"Actins;Amino Acid Sequence;Animals;Crystallography, X-Ray;Humans;Microfilament Proteins;Models, Molecular;Muscle Proteins;Protein Binding;Protein Conformation, alpha-Helical;Protein Domains;Protein Multimerization",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;G02.111.570.060;L01.453.245.667.060;B01.050;E05.196.309.742.225;B01.050.150.900.649.313.988.400.112.400.400;D05.750.078.730;D12.776.220.525;E05.599.595;D12.776.210.500;G02.111.679;G03.808;G02.111.570.820.709.600.020;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.694
28834442,"Cartilage, Articular;Humans;Knee Injuries;Magnetic Resonance Imaging;Cartilage",A02.165.407.150;A02.835.583.192;B01.050.150.900.649.313.988.400.112.400.400;C26.558.554;E01.370.350.825.500;A02.165;A10.165.382
28834048,"Adolescent;Anaphylaxis;Child;Child, Preschool;Drug Contamination;Humans;Infant;Mass Spectrometry;Neoplasms;Risk Factors;Vincristine;Hypersensitivity;Anaphylaxis;Mass Spectrometry;Vincristine",M01.060.057;C20.543.480.099;M01.060.406;M01.060.406.448;N06.850.360;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.196.566;C04;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D03.132.436.681.827.817;D03.633.100.473.402.681.827.817;C20.543;C20.543.480.099;E05.196.566;D03.132.436.681.827.817;D03.633.100.473.402.681.827.817
28832883,"Autism Spectrum Disorder;DNA, Mitochondrial;Genetic Predisposition to Disease;Genome-Wide Association Study;Haplotypes;Humans;Polymorphism, Single Nucleotide",F03.625.164.113;D13.444.308.283.225;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598
28832874,"Clinical Competence;Dermatology;Humans;Internship and Residency;Licensure, Medical;United States",I02.399.630.210;N04.761.210;N05.715.175;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;N03.706.110.510.410;N05.700.200.450.500;Z01.107.567.875
28832561,"Animals;Carotid Arteries;Cell Line;Coronary Restenosis;Dependovirus;Drug Delivery Systems;Drug-Eluting Stents;Gene Transfer Techniques;Genetic Therapy;Genetic Vectors;HEK293 Cells;Humans;Nitric Oxide Synthase Type II;Rats;Rats, Sprague-Dawley;Stents",B01.050;A07.015.114.186;A11.251.210;C14.280.647.250.285.200;C14.907.585.250.285.200;B04.280.580.650.170;E02.319.300;E07.695.750.500;E05.393.350;E02.095.301;E05.393.420.301;G05.360.337;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.664.500.772.500;D12.776.157.687.575;D12.776.660.720.575;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E07.695.750
28832468,Carbon Dioxide;Fetoscopy;Humans;Insufflation;Neural Tube Defects;Pregnancy,D01.200.200;D01.362.150;D01.650.550.200;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;B01.050.150.900.649.313.988.400.112.400.400;E01.370.450;E02.583;C10.500.680;C16.131.666.680;G08.686.784.769
28831981,,
28831680,"Cognitive Dysfunction;Diagnosis, Differential;Humans;Olfaction Disorders;Parkinson Disease;Prognosis;Smell;Parkinsonian Disorders;Parkinson Disease;Pathology",F03.615.250.700;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C10.597.751.600;C23.888.592.763.550;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E01.789;F02.830.816.643;G11.561.790.643;C10.228.140.079.862;C10.228.662.600;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;H02.403.650
28831617,"Adult;Botswana;HIV Infections;HIV Seroprevalence;Hospitalization;Hospitals, Psychiatric;Humans;Inpatients;Mental Disorders;Mental Health;Middle Aged;Prevalence;Referral and Consultation;Retrospective Studies;Seroepidemiologic Studies;Sex Distribution;Gender Identity;HIV;Mental Health;Psychiatry",M01.060.116;Z01.058.290.175.230;C02.782.815.616.400;C02.800.801.400;C20.673.480;E05.318.372.500.950.375;N05.715.360.330.500.950.375;N06.850.520.450.500.950.375;E02.760.400;N02.421.585.400;N02.278.421.556.508;B01.050.150.900.649.313.988.400.112.400.400;M01.643.470;F03;F02.418;N01.400.500;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.372.500.950;N05.715.360.330.500.950;N06.850.520.450.500.950;I01.240.800;N01.224.803;N06.850.505.400.850;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;B04.820.650.589.650.350;F02.418;N01.400.500;F04.096.544;H02.403.690
28831413,Bacteremia,C01.252.100;C01.539.757.100;C23.550.470.790.500.100
28831235,Heart Murmurs,C23.888.447
28831036,"Adult;Aged;BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;DNA Methylation;Germ-Line Mutation;Humans;Kaplan-Meier Estimate;Loss of Heterozygosity;Middle Aged;Outcome Assessment (Health Care);Ovarian Neoplasms;Promoter Regions, Genetic;Proportional Hazards Models",M01.060.116;M01.060.116.100;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;D12.776.313.249;D12.776.624.776.101;D12.776.660.105;C04.588.180;C17.800.090.500;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;G05.365.590.029.530;M01.060.116.630;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725
28831005,"Alleles;Animals;Anti-Bacterial Agents;Autoimmunity;Diabetes Mellitus, Type 1;Gastrointestinal Microbiome;Histocompatibility Antigens Class II;Humans;Infant, Newborn;Islets of Langerhans;Maternal-Fetal Exchange;Mice;Mice, Inbred NOD;Mice, Transgenic;Pregnancy;Mice, Inbred NOD;Autoimmune Diseases;Microbiota;Diabetes Mellitus, Type 1",G05.360.340.024.340.030;B01.050;D27.505.954.122.085;G12.450.192;C18.452.394.750.124;C19.246.267;C20.111.327;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;A03.734.414;A06.300.414;G08.686.784.769.455;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G08.686.784.769;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;C20.111;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C18.452.394.750.124;C19.246.267;C20.111.327
28830827,"Cyclin-Dependent Kinase Inhibitor p18;DNA Mutational Analysis;Family Health;Genotype;Germ-Line Mutation;Humans;Melanoma;Nevus;Nevus, Pigmented;Odds Ratio;Phenotype;Registries;Skin Neoplasms",D12.644.360.225.300;D12.776.167.187.300;D12.776.476.225.300;D12.776.624.776.355.300;E05.393.760.700.300;N01.400.300;G05.380;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.557.665.560;C04.557.665.560.615;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G05.695;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C04.588.805;C17.800.882
28830742,"Acyclovir;Adolescent;Adult;Antipsychotic Agents;Antiviral Agents;Cognition Disorders;Emotions;Follow-Up Studies;Herpes Simplex;Humans;Middle Aged;Neuropsychological Tests;Randomized Controlled Trials as Topic;Severity of Illness Index;Valacyclovir;Valine;Young Adult;Cognition;Emotions;Herpesvirus 1, Human;Memory;Schizophrenia;Valacyclovir",D03.633.100.759.758.399.454.250;M01.060.057;M01.060.116;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;D27.505.954.122.388;F03.615.250;F01.470;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C02.256.466.382;C02.825.320;C17.800.838.790.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F04.711.513;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;D03.633.100.759.758.399.454.250.650;D12.125.070.950;D12.125.142.930;M01.060.116.815;F02.463.188;F01.470;B04.280.382.100.750.390;F02.463.425.540;F03.700.750;D03.633.100.759.758.399.454.250.650
28830669,"Adult;Age Factors;Arterial Pressure;Blood Pressure Determination;Carotid Arteries;Cross-Over Studies;Diet, Sodium-Restricted;Femoral Artery;Humans;Hypertension;Incidence;Middle Aged;Pulse Wave Analysis;Sodium, Dietary;Vascular Stiffness;Young Adult;Diet",M01.060.116;N05.715.350.075;N06.850.490.250;G09.330.380.076.347;E01.370.370.140;E01.370.600.100;A07.015.114.186;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E02.642.249.290;G07.203.650.240.290;A07.015.114.351;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E01.370.370.680;D01.857.875;G09.330.940;M01.060.116.815;G07.203.650.240
28830662,Access to Information;Decision Making;Diagnostic Imaging;Humans;Patient Participation;Physician-Patient Relations;Truth Disclosure,I01.880.604.473.352.500.030;L01.143.024;L01.737.030;F02.463.785.373;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;F01.829.401.650.675;N05.300.660.625;F01.829.401.046.800;I01.880.604.583.080.134.800
28830504,Aged;Alcoholism;Hospitalization;Humans;Middle Aged;Opioid-Related Disorders;Substance-Related Disorders;United States;Substance-Related Disorders,M01.060.116.100;C25.775.100.250;F03.900.100.350;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C25.775.675;F03.900.675;C25.775;F03.900;Z01.107.567.875;C25.775;F03.900
28829877,"Adult;Aged;Antiviral Agents;Critical Illness;Cytomegalovirus;Cytomegalovirus Infections;Double-Blind Method;Follow-Up Studies;Ganciclovir;Humans;Intention to Treat Analysis;Interleukin-6;Length of Stay;Middle Aged;Respiration, Artificial;Respiratory Insufficiency;Sepsis;Treatment Outcome;Valganciclovir;Virus Activation;Wounds and Injuries",M01.060.116;M01.060.116.100;D27.505.954.122.388;C23.550.291.625;B04.280.382.150.150;C02.256.466.245;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;D03.633.100.759.758.399.454.250.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;E02.041.625;E02.365.647.729;E02.880.820;C08.618.846;C01.539.757;C23.550.470.790.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D03.633.100.759.758.399.454.250.300.500;G06.920.925.940;C26
28829438,Adult;B-Lymphocytes;Cell Lineage;Clone Cells;Humans;Middle Aged;Organ Specificity;Young Adult,M01.060.116;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.251.353;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G07.650;M01.060.116.815
28829332,"Biomedical Research;Humans;Information Storage and Retrieval;Literature Based Discovery;Problem-Based Learning;Publications;Publishing;Students, Medical;Writing",H01.770.644.145;B01.050.150.900.649.313.988.400.112.400.400;L01.313.500.750.280;L01.470;L01.178.682.099.325.750;F02.463.425.720;I02.158.660;I02.903.565;L01.178.682;L01.737;M01.848.769.602;L01.559.423.906
28828924,Brain Death;Health Surveys;Humans;Intensive Care Units;Neurologic Examination;Neurology;Pediatrics;United States;Brain Death,C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E01.370.376.550;E01.370.600.550;H02.403.600;H02.403.670;Z01.107.567.875;C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159
28828641,"Dreams;Humans;Sleep Wake Disorders;Stress Disorders, Post-Traumatic;Sleep Initiation and Maintenance Disorders;Dreams;Stress Disorders, Post-Traumatic;Sleep Wake Disorders;Wounds and Injuries",F02.463.188.634.309;F02.830.855.268;B01.050.150.900.649.313.988.400.112.400.400;C10.886;C23.888.592.796;F03.870;F03.950.750.500;C10.886.425.800.800;F03.870.400.800.800;F02.463.188.634.309;F02.830.855.268;F03.950.750.500;C10.886;C23.888.592.796;F03.870;C26
28828568,"Adolescent;Child;Child, Preschool;Humans;Parents;Personal Satisfaction;Proxy;Psychometrics;Quality of Life;Reproducibility of Results;Surveys and Questionnaires;Child",M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.145.677;M01.380.600;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.406
28828481,Follow-Up Studies;Humans;Melanoma;Middle Aged;Neoplasm Metastasis;Prognosis;Proportional Hazards Models;Retrospective Studies;Risk Assessment;Risk Factors;Time Factors;Uveal Neoplasms,E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;C04.697.650;C23.550.727.650;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;C04.588.364.978;C11.319.494;C11.941.855
28828242,"Genome-Wide Association Study;Meta-Analysis;Methylation;Diabetes Mellitus, Type 2",E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;V03.600;G02.111.035.538;G02.607.094.538;G03.059.538;C18.452.394.750.149;C19.246.300
28827758,Animals;Cardiac Catheterization;Coronary Artery Disease;Histocytochemistry;Humans;Optical Imaging;Swine;Ultrasonography,B01.050;E01.370.370.380.140;E02.148.442;E05.157.250;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E01.370.225.500.607;E01.370.225.750.551;E05.200.500.607;E05.200.750.551;H01.158.100.656.234;H01.158.201.344;H01.181.122.573;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.589;E05.642;B01.050.150.900.649.313.500.880;E01.370.350.850
28827695,,
28827501,"Aged;Aged, 80 and over;Bone Screws;Cohort Studies;Confidence Intervals;Equipment Design;Fracture Fixation, Intramedullary;Fracture Healing;Hip Fractures;Humans;Internal Fixators;Middle Aged;Postoperative Complications;Range of Motion, Articular;Recovery of Function;Retrospective Studies;Risk Assessment;Statistics, Nonparametric;Trauma Centers;Treatment Outcome;United States",M01.060.116.100;M01.060.116.100.080;E07.695.370.437;E07.858.442.660.460.437;E07.858.690.725.460.437;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;E05.320;E04.555.300.300.300;G16.762.891.500;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;E07.695.370;E07.858.442.660.460;E07.858.690.725.460;M01.060.116.630;C23.550.767;E01.370.600.700;G11.427.760;G16.757;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
28827399,"Breast Neoplasms;Cell Line, Tumor;Cell Movement;Humans;Lung Neoplasms;Melanoma;Membrane Glycoproteins;Prognosis;Breast Neoplasms;Melanoma;Proteomics",C04.588.180;C17.800.090.500;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D12.776.395.550;D12.776.543.550;E01.789;C04.588.180;C17.800.090.500;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
28827079,"Anemia, Sickle Cell;Animals;Blood Grouping and Crossmatching;Blood Transfusion;DNA;Genomics;Genotype;Genotyping Techniques;Humans;Oligonucleotide Array Sequence Analysis;Polymorphism, Single Nucleotide;Rh-Hr Blood-Group System;Treatment Outcome;Anemia, Sickle Cell",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;B01.050;E01.370.225.625.120;E01.370.225.812.385.120;E05.200.625.120;E05.200.812.385.120;E05.478.594.385.120;E02.095.135;D13.444.308;H01.158.273.180.350;H01.158.273.343.350;G05.380;E05.393.442;B01.050.150.900.649.313.988.400.112.400.400;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;G05.365.795.598;D23.050.301.290.775;D23.050.705.230.775;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
28827013,"Adult;Aged;Aged, 80 and over;Angiography;Angioplasty;Arteriovenous Shunt, Surgical;Catheterization, Central Venous;Contrast Media;Graft Occlusion, Vascular;Humans;Middle Aged;Recurrence;Renal Dialysis;Retrospective Studies;Risk Factors",M01.060.116;M01.060.116.100;M01.060.116.100.080;E01.370.350.700.060;E01.370.370.050;E02.148.050;E04.100.814.529.124;E04.502.382.124;E05.157.016;E04.035.087;E04.100.814.868.249;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;D27.505.259.500;D27.720.259;C23.550.767.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.291.937;E02.870.300;E02.912.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28827012,"Adult;Anatomy;Curriculum;Education, Medical, Undergraduate;Educational Measurement;Humans;Radiology, Interventional;Surveys and Questionnaires",M01.060.116;H01.158.100;I02.158;I02.358.399.450;I02.399;B01.050.150.900.649.313.988.400.112.400.400;H02.403.740.675;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28826991,"Adult;Cardiac Surgical Procedures;Child;Heart Defects, Congenital;Humans;Morbidity;Parents;Philadelphia;Surveys and Questionnaires;Survival Rate",M01.060.116;E04.100.376;E04.928.220;M01.060.406;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
28826946,"Adolescent;Adult;Autism Spectrum Disorder;Child;Cohort Studies;Diffusion Tensor Imaging;Humans;Image Processing, Computer-Assisted;Multicenter Studies as Topic;White Matter;Young Adult;Diffusion",M01.060.057;M01.060.116;F03.625.164.113;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;A08.186.211.204;A08.186.854.880;M01.060.116.815;G01.202;G02.196
28826887,,
28826872,"Aged;Aged, 80 and over;Aggression;Alzheimer Disease;Apathy;Dementia;Depression;Humans;Middle Aged;Psychomotor Agitation;Psychotic Disorders",M01.060.116.100;M01.060.116.100.080;F01.145.126.125;F01.145.813.045;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F01.470.137;C10.228.140.380;F03.615.400;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.597.350.600;C10.597.606.881.700;C23.888.592.350.600;C23.888.592.604.882.700;F01.700.875.700;F03.700.675
28826846,American Heart Association;Cardiology;Disease Management;Humans;Lower Extremity;Perioperative Care;Peripheral Arterial Disease;Practice Guidelines as Topic;United States;Atherosclerosis;Intermittent Claudication;Peripheral Arterial Disease,N03.540.630.780.110;H02.403.429.163;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610;E02.760.731;E04.604;N02.421.585.722;C14.907.137.126.307.500;C14.907.617.671;N04.761.700.350.650;N05.700.350.650;Z01.107.567.875;C14.907.137.126.307;C14.907.137.126.669;C23.888.531;C14.907.137.126.307.500;C14.907.617.671
28826842,"Animals;Chondrogenesis;Humans;Myositis Ossificans;Ossification, Heterotopic;Osteogenesis;Retinoids;Signal Transduction;Myositis Ossificans;Exostoses, Multiple Hereditary;Ossification, Heterotopic;Exostoses, Multiple Hereditary",B01.050;G07.345.500.325.377.625.180;G11.427.578.180;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;C23.550.751;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;D02.455.326.271.665.202.495;D02.455.426.392.368.367.379.249.700;D02.455.849.131.495;D23.767.261.700;G02.111.820;G04.835;C05.651.594.638;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;C23.550.751;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330
28826684,Anticoagulants;Extracorporeal Membrane Oxygenation;Heart Failure;Humans;Intraoperative Complications;Nervous System Diseases;Respiratory Insufficiency,D27.505.954.502.119;E02.880.301;E04.292.451;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505;C10;C08.618.846
28826666,"Adult;Aged;Cholesterol Ester Transfer Proteins;Coronary Artery Disease;Humans;Lipid Metabolism, Inborn Errors;Lipoproteins, HDL;Middle Aged;Phosphatidylcholines;Coronary Artery Disease;Phospholipids",M01.060.116;M01.060.116.100;D09.400.430.750;D12.776.124.197;D12.776.157.165;D12.776.395.199;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;B01.050.150.900.649.313.988.400.112.400.400;C16.320.565.398;C18.452.584.562;C18.452.648.398;D10.532.432;D12.776.521.479;M01.060.116.630;D10.570.755.375.760.400.800;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;D10.570.755
28826208,Bacterial Proteins;DNA Damage;Escherichia coli;Gene Regulatory Networks;Rec A Recombinases;SOS Response (Genetics);Serine Endopeptidases;DNA Repair;Mutagenesis,D12.776.097;G05.200;B03.440.450.425.325.300;B03.660.250.150.180.100;G05.360.080.689.360;D08.811.739.650;D08.811.913.696.445.692;G02.111.222.830;G05.219.830;D08.811.277.656.300.760;D08.811.277.656.959.350;G02.111.222;G05.219;G05.558
28825717,"Aged;Animals;Antibodies, Monoclonal;Apolipoprotein C-III;Apolipoproteins B;Cholesterol, HDL;Chromatography, Liquid;Computer Simulation;Coronary Disease;Cross-Sectional Studies;Humans;Immunoblotting;Lipid Metabolism;Lipoproteins;Lipoproteins, VLDL;Mass Spectrometry;Mice;Mice, Knockout;Mice, Transgenic;Middle Aged;Mutation, Missense;Protective Factors;Tandem Mass Spectrometry;Triglycerides",M01.060.116.100;B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D10.532.091.400.875;D12.776.070.400.400.875;D12.776.521.120.400.875;D10.532.091.300;D12.776.070.400.300;D12.776.521.120.300;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;E05.196.181.400;L01.224.160;C14.280.647.250;C14.907.585.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566.320;E05.601.470.320;G03.458;D10.532;D12.776.521;D10.532.599;D12.776.521.622;E05.196.566;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;M01.060.116.630;G05.365.590.650;E05.318.740.600.800.582;N05.715.350.200.675;N05.715.360.750.625.700.570;N06.850.490.625.625;N06.850.520.830.600.800.582;E05.196.566.880;D10.351.801
28825123,"Adolescent;Adult;Cerebellar Neoplasms;Chemoradiotherapy;Child;Child, Preschool;Craniotomy;Humans;Medulloblastoma;T-Lymphocytes, Regulatory;Young Adult;Immunotherapy;Medulloblastoma;Infratentorial Neoplasms;T-Lymphocytes, Regulatory",M01.060.057;M01.060.116;C04.588.614.250.195.411.211;C10.228.140.211.500.200;C10.228.140.252.200;C10.551.240.250.400.300;E02.186.079;E02.319.164;E02.815.160;M01.060.406;M01.060.406.448;E04.525.190;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;M01.060.116.815;E02.095.465.425;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;C04.588.614.250.195.411;C10.228.140.211.500;C10.551.240.250.400;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
28825050,"Amygdala;Hippocampus;Stress Disorders, Post-Traumatic;Veterans",A08.186.211.180.090;A08.186.211.200.885.287.249.152;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F03.950.750.500;M01.930
28824164,"1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine;Animals;Blood Glucose;Cell Differentiation;Cell Line;Gene Expression Profiling;Humans;Induced Pluripotent Stem Cells;Insulin;Insulin Secretion;Insulin-Secreting Cells;Mice, SCID;Pluripotent Stem Cells;Stem Cell Transplantation;Transplantation, Heterologous;rho-Associated Kinases",D02.886.590.700.545;D03.383.606.527;D03.633.100.531.400;B01.050;D09.947.875.359.448.500;G04.152;A11.251.210;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;B01.050.150.900.649.313.992.635.505.500.550.780;A11.872.700;E02.095.147.500.500;E04.936.225.687;E04.936.764;D08.811.913.696.620.682.700.814;D12.644.360.590;D12.776.476.595
28823848,"Antidepressive Agents;Brain Mapping;Cerebrovascular Circulation;Cross-Sectional Studies;Depressive Disorder, Major;Follow-Up Studies;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Middle Aged;Motor Cortex;Movement Disorders;Treatment Outcome;Cerebrovascular Circulation;Depressive Disorder, Major;Motor Cortex",D27.505.954.427.700.122;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;G09.330.100.159;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F03.600.300.375;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;M01.060.116.630;A08.186.211.200.885.287.500.270.548;A08.186.211.200.885.287.500.814.624;C10.228.662;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.100.159;F03.600.300.375;A08.186.211.200.885.287.500.270.548;A08.186.211.200.885.287.500.814.624
28823757,Dalteparin;Enoxaparin;Wounds and Injuries,D09.698.373.400.300.150;D09.698.373.400.300.200;C26
28823630,,
28823485,"Adult;Cardiac Catheterization;Clinical Studies as Topic;Echocardiography;Feasibility Studies;Follow-Up Studies;Heart Valve Prosthesis Implantation;Heart Ventricles;Humans;Magnetic Resonance Imaging, Cine;Patient Selection;Prospective Studies;Pulmonary Valve;Pulmonary Valve Insufficiency;Time Factors;Treatment Outcome",M01.060.116;E01.370.370.380.140;E02.148.442;E05.157.250;E05.318.372.250;N05.715.360.330.250;N06.850.520.450.250;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.100.376.485;E04.650.410;E04.928.220.410;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.510;E05.581.500.653;N04.590.731;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A07.541.510.738;C14.280.484.660;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28823051,"Adolescent;Adult;Cartilage Diseases;Cartilage, Articular;Child;Child, Preschool;Humans;Magnetic Resonance Imaging;Retrospective Studies;Shoulder Joint;Shoulder",M01.060.057;M01.060.116;C05.182;C17.300.182;A02.165.407.150;A02.835.583.192;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.583.748;A01.378.800.750
28822792,"Activin Receptors, Type I;Adult;Humans;Magnetic Resonance Imaging;Myositis Ossificans;Ossification, Heterotopic;Radiography;Tomography, X-Ray Computed;Bone Morphogenetic Proteins;Ossification, Heterotopic;Magnetic Resonance Imaging",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C05.651.594.638;C23.550.751;E01.370.350.700;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;C23.550.751;E01.370.350.825.500
28822791,"Acute Disease;Adolescent;Adult;Child;Child, Preschool;Humans;Middle Aged;Myositis Ossificans;Pain;Pelvic Bones;Young Adult;Ossification, Heterotopic",C23.550.291.125;M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C05.651.594.638;C23.888.592.612;F02.830.816.444;G11.561.790.444;A02.835.232.043.825;M01.060.116.815;C23.550.751
28822538,"Aged;Arteriovenous Shunt, Surgical;Cell Movement;Cell Proliferation;Down-Regulation;Humans;Kidney Failure, Chronic;Middle Aged;Muscle, Smooth, Vascular;NADPH Oxidases;Nitric Oxide;Renal Dialysis;Sarcoplasmic Reticulum Calcium-Transporting ATPases",M01.060.116.100;E04.035.087;E04.100.814.868.249;G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;G02.111.240;G05.308.200;G07.690.773.937;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;M01.060.116.630;A02.633.570.491;A07.015.733.500;A10.690.467.491;D08.811.682.608.575;D12.776.331.894;D12.776.543.653;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E02.870.300;E02.912.800;D08.811.277.040.025.314.250.500;D12.776.157.530.450.250.500.500;D12.776.157.530.813.250.500;D12.776.543.585.450.250.500.500;D12.776.543.585.813.250.500
28822502,"Attitude of Health Personnel;Humans;Motivation;Physician Incentive Plans;Physicians;Reimbursement, Incentive;Risk Management;Value-Based Health Insurance",F01.100.050;N05.300.100;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;N04.452.677.740;M01.526.485.810;N02.360.810;N03.219.521.710.305.380;N03.219.463.800;N04.452.871;N03.219.521.576.343.972;N04.761.744.750
28822501,"Attitude of Health Personnel;Hospitals, Religious;Humans;Motivation;Physicians;Prospective Payment System;Protestantism;Social Theory;Texas",F01.100.050;N05.300.100;N02.278.421.481.600;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;M01.526.485.810;N02.360.810;N03.219.521.710.305.200;K01.844.188.644;F02.970;Z01.107.567.875.760.750
28821404,,
28821330,"Adolescent;Child, Preschool;Heart Defects, Congenital;Heart Diseases;Heart Valves;Heart-Assist Devices;Humans;Prosthesis Implantation;Retrospective Studies",M01.060.057;M01.060.406.448;C14.240.400;C14.280.400;C16.131.240.400;C14.280;A07.541.510;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;E04.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28821329,"Animals;Disease Models, Animal;Fetal Heart;Myocardial Infarction;Myocardium;Myocytes, Cardiac;Neovascularization, Physiologic;Sheep;Stem Cell Transplantation;X-Ray Microtomography",B01.050;C22.232;E05.598.500;E05.599.395.080;A07.541.278;A16.378.303;C14.280.647.500;C14.907.585.500;A02.633.580;A07.541.704;A10.690.552.750;A07.541.704.570;A10.690.552.750.570;A11.620.500;G09.330.630;B01.050.150.900.649.313.500.380.791;E02.095.147.500.500;E04.936.225.687;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900
28821206,,
28820965,"Aequorin;Animals;Calcium;Calcium Channel Blockers;Calcium Channels;Dose-Response Relationship, Drug;Drug Discovery;Energy Metabolism;HEK293 Cells;HeLa Cells;High-Throughput Screening Assays;Humans;Kinetics;Lactic Acid;Mannitol;Membrane Potentials;Mice, Transgenic;Mitochondria;Mitoxantrone;Models, Molecular;Molecular Structure;Saccharomyces cerevisiae;Structure-Activity Relationship;Sucrose;Xenopus laevis;Energy Metabolism;Calcium;Calcium Signaling;Drug Discovery;Drug Evaluation, Preclinical;Mitochondria",D12.776.532.020;B01.050;D01.268.552.100;D01.552.539.288;D23.119.100;D27.505.519.562.249;D27.505.696.260.500;D27.505.954.411.192;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;G07.690.773.875;G07.690.936.500;E05.295;H01.158.703.007.675;H01.181.466.675;G03.295;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;E05.916.680;B01.050.150.900.649.313.988.400.112.400.400;G01.374.661;G02.111.490;D02.241.511.459.450;D02.033.800.609;D09.853.609;G01.154.535;G04.580;G07.265.675;G11.561.570;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.284.430.214.190.875.564;A11.284.835.626;D02.455.426.559.847.117.159.500;D02.806.100.500;D04.615.117.159.500;E05.599.595;G02.111.570;G02.466;B01.300.107.795.785.800;B01.300.930.705.655;G02.111.830;G07.690.773.997;D09.698.629.305.770;D09.947.750.770;B01.050.150.900.090.180.610.500.562;G03.295;D01.268.552.100;D01.552.539.288;D23.119.100;G02.111.820.800.100;G03.143.500.100;G04.835.800.100;E05.295;H01.158.703.007.675;H01.181.466.675;E05.290.750;E05.337.550;A11.284.430.214.190.875.564;A11.284.835.626
28820433,Antiviral Agents;Humans;Papillomaviridae;Papillomavirus Infections;Papillomavirus Vaccines;Uterine Cervical Neoplasms;Therapeutics;Vaccines,D27.505.954.122.388;B01.050.150.900.649.313.988.400.112.400.400;B04.280.210.655;B04.613.204.655;C02.256.650;C02.928.725;D20.215.894.899.498;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;E02;D20.215.894
28820328,Apoptosis;Cell Cycle;Inflammation;Neurons,G04.146.160;G04.144;C23.550.470;A08.675;A11.671
28819907,"Body Image;Genital Neoplasms, Female;Humans;Obesity;Overweight;Polycystic Ovary Syndrome;Postpartum Period;Pregnancy;Reproductive Health;Women's Health;Body Image;Postpartum Period;Pregnancy",F01.752.747.792.110;F02.463.593.112;C04.588.945.418;C13.351.937.418;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;G08.686.702;G08.686.784.769;N01.400.625;N01.400.900;F01.752.747.792.110;F02.463.593.112;G08.686.702;G08.686.784.769
28819634,Uterine Cervical Neoplasms,C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850
28819196,"Animal Structures;Animals;Animals, Genetically Modified;Ants;Cues;Drosophila melanogaster;Hydrocarbons;Insect Proteins;Insecta;Pheromones;Phylogeny;Receptors, Odorant;Social Behavior",A13;B01.050;B01.050.050.136;B05.620.136;B01.050.500.131.617.720.500.500.875.205;F02.463.425.234;B01.050.500.131.617.720.500.500.750.310.250.500;D02.455;D12.776.093.500;B01.050.500.131.617;D23.641;G05.697;G16.075.605;L01.100.697;D12.776.543.750.695.600;F01.145.813
28819166,,
28819062,Autoantibodies;Axons;Cell Adhesion Molecules;Contactin 1;Humans;Peripheral Nerves;Polyneuropathies;Ranvier's Nodes,D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;D12.776.395.550.200;D12.776.543.550.200;D23.050.301.350;D12.776.395.550.200.250.325.100;D12.776.395.550.448.250.100;D12.776.543.484.500.250.100;D12.776.543.550.200.250.325.100;D12.776.543.550.418.250.100;D23.050.301.350.250.325.100;B01.050.150.900.649.313.988.400.112.400.400;A08.800.800;C10.668.829.800;A08.637.800.500.700;A08.675.542.512.560.700;A08.800.800.690.500.700;A10.755.503.700;A11.284.149.165.760;A11.650.800.500.700;A11.671.501.512.560.700;A11.671.514.553.640
28818993,"Certification;Education, Medical;History, 20th Century;History, 21st Century;Humans;Nuclear Medicine",N03.706.110.120;N05.700.200.190;I02.358.399;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;H02.403.740.500
28818846,"Blood Pressure;Cohort Studies;Confounding Factors (Epidemiology);Glomerular Filtration Rate;Humans;Kidney Failure, Chronic;Proportional Hazards Models;Regression Analysis;Systole;Time Factors;Cohort Studies;Renal Insufficiency;Probability;Proportional Hazards Models;Renal Insufficiency;Blood Pressure;Renal Insufficiency, Chronic;Survival Analysis",E01.370.600.875.249;G09.330.380.076;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.240;N06.850.490.718;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.750;N05.715.360.750.695;N06.850.520.830.750;G09.330.580.880;G11.427.494.570.880;G01.910.857;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C12.777.419.780;C13.351.968.419.780;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C12.777.419.780;C13.351.968.419.780;E01.370.600.875.249;G09.330.380.076;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
28818837,"Adaptation, Psychological;Child;Child, Hospitalized;Child, Preschool;Hospitalization;Hospitals, Pediatric;Humans;Parents;Psychosocial Support Systems;Stress, Psychological",F01.058;M01.060.406;M01.643.259;M01.060.406.448;E02.760.400;N02.421.585.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I01.880.853.500.600.500;F01.145.126.990;F02.830.900
28818439,"Adolescent;Age of Onset;Asthma;Child;Child, Preschool;Cohort Studies;Dermatitis, Atopic;Humans;Incidence;Infant;Prevalence;Registries;Rhinitis, Allergic, Seasonal;Risk Factors;Rhinitis, Allergic;Asthma;Dermatitis, Atopic;Eczema;Epidemiology;Rhinitis, Allergic, Seasonal",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C08.460.799.315.750;C08.674.453.750;C09.603.799.315.750;C20.543.480.680.443.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C17.800.174.620;C17.800.815.620;H02.403.720.500;C08.460.799.315.750;C08.674.453.750;C09.603.799.315.750;C20.543.480.680.443.750
28818389,"Adolescent;Adult;Child;Child, Preschool;Cohort Studies;Humans;Infant;Middle Aged;Muscle, Skeletal;Mutation;Myopathies, Structural, Congenital;Phenotype;Ryanodine Receptor Calcium Release Channel;Myopathies, Structural, Congenital;Ryanodine Receptor Calcium Release Channel",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;A02.633.567;A10.690.552.500;G05.365.590;C05.651.575;C10.668.491.550;G05.695;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800;C05.651.575;C10.668.491.550;D12.776.157.530.400.150.800;D12.776.210.500.800;D12.776.543.550.450.150.800;D12.776.543.585.400.150.800
28817743,"Codes of Ethics;Ethics, Medical;Europe;Germany;History, 20th Century;Human Experimentation;Humans;Informed Consent;United States",K01.752.566.479.068;K01.752.566.479.171.066;N04.761.700.350.324;N05.350.213;N05.350.340.080;N05.700.350.324;K01.752.566.479.171.132.750;N05.350.340.162.500;Z01.542;Z01.542.315;K01.400.504.968;E05.445;H01.770.644.145.365;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;Z01.107.567.875
28817394,"Adult;Aged;Consumer Behavior;Education, Continuing;Health Personnel;Humans;Middle Aged;Primary Health Care;Qualitative Research;Surveys and Questionnaires;United States;United States Department of Veterans Affairs;Women's Health Services;Workforce",M01.060.116;M01.060.116.100;F01.145.236;I02.358.212;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.590.233.727;H01.770.644.241.850;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;N02.421.920;N04.452.525
28817376,Costs and Cost Analysis;Hospices,N03.219.151;N02.278.421.556.185;N02.421.143.550
28817301,"Attitude to Health;Cholesterol, LDL;Humans;Hypercholesterolemia;Hypolipidemic Agents;Interviews as Topic;Middle Aged;Motivation;Physician-Patient Relations;Reimbursement, Incentive;Risk Reduction Behavior",F01.100.150;N05.300.150;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;B01.050.150.900.649.313.988.400.112.400.400;C18.452.584.500.500.396;D27.505.519.186.071;D27.505.954.557.500;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;F01.658;F01.752.543.500.750;F01.829.401.650.675;N05.300.660.625;N03.219.521.710.305.380;F01.145.699
28817123,"Carbocyanines;Humans;In Situ Hybridization, Fluorescence;Myocardium;Peptide Nucleic Acids;Telomere",D02.455.326.397.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;A02.633.580;A07.541.704;A10.690.552.750;D13.695.578.424.550;A11.284.430.106.279.345.190.160.845;G05.360.160.845
28816917,"Adolescent;Autism Spectrum Disorder;Child;Child, Preschool;Humans;Medicaid;Pediatricians;Practice Patterns, Physicians';Psychotropic Drugs;Retrospective Studies;United States",M01.060.057;F03.625.164.113;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;M01.526.485.810.758;N02.360.810.758;N04.590.374.577;N05.300.625;D27.505.954.427.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28816912,"Adult;Attention Deficit Disorder with Hyperactivity;Child;Child, Preschool;Education, Distance;Humans;Outcome and Process Assessment (Health Care);Pediatric Nurse Practitioners;Pediatricians;Primary Health Care;Psychiatric Status Rating Scales;Quality Improvement",M01.060.116;F03.625.094.150;M01.060.406;M01.060.406.448;I02.195;B01.050.150.900.649.313.988.400.112.400.400;N04.761.559;N05.715.360.575;M01.526.485.650.640.500;N02.360.650.640.500;M01.526.485.810.758;N02.360.810.758;N04.590.233.727;F04.711.513.653;J01.293.754;N04.761.744
28816720,"Adult;African Americans;Educational Status;European Continental Ancestry Group;HIV Infections;Health Status Disparities;Healthcare Disparities;Hispanic Americans;Humans;Philadelphia;Population Surveillance;Prevalence;Prisoners;Risk-Taking;Sexual Behavior;Socioeconomic Factors;Substance Abuse, Intravenous",M01.060.116;M01.686.508.100.100;M01.686.754.100;N01.824.196;M01.686.508.400;C02.782.815.616.400;C02.800.801.400;C20.673.480;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;N04.590.374.380;N05.300.493;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;M01.729;F01.145.722;F01.145.802;I01.880.853.996;N01.824;C25.775.793;F03.900.793
28816098,Perfusion,E05.680
28815994,"Humans;Machine Learning;Quality Assurance, Health Care;Radiometry;Radiotherapy Dosage;Radiotherapy, Intensity-Modulated;Machine Learning;Radiotherapy",B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;N04.761.700;N05.700;E05.799;E02.815.639;E02.815.635.700.700;L01.313.500.750.100.710.600.550.700;G17.035.250.500;L01.224.050.375.530;E02.815
28815879,Adult;Brain Mapping;Calibration;Cerebrovascular Circulation;Cohort Studies;Diffusion Tensor Imaging;Gray Matter;Humans;Magnetic Resonance Imaging;Middle Aged;Multiple Sclerosis;Oxygen;Severity of Illness Index;Visual Cortex;White Matter;Diffusion Tensor Imaging;Multiple Sclerosis;White Matter,M01.060.116;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E05.978.155;G09.330.100.159;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D01.268.185.550;D01.362.670;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.186.211.204;A08.186.854.880;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A08.186.211.204;A08.186.854.880
28815617,"Aged;Carcinoma, Squamous Cell;Continental Population Groups;Databases, Factual;Health Status Disparities;Humans;Income;Insurance, Health;Medicaid;Medicare;Middle Aged;Multivariate Analysis;Paranasal Sinus Neoplasms;Patient Readmission;Proportional Hazards Models;Treatment Outcome;United States;Continental Population Groups;Carcinoma, Squamous Cell",M01.060.116.100;C04.557.470.200.400;C04.557.470.700.400;M01.686.508;L01.313.500.750.300.188.400;L01.470.750.750;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;N03.219.521.576.343;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;C04.588.443.665.650.693;C08.460.669.693;C08.460.692.503;C08.785.600.693;C09.603.669.693;C09.603.692.503;C09.647.685.693;E02.760.400.620;N02.421.585.400.620;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.686.508;C04.557.470.200.400;C04.557.470.700.400
28815573,"Adenoma;Colonoscopy;Colorectal Neoplasms;Early Detection of Cancer;Feces;Humans;Mass Screening;Models, Statistical;Colorectal Neoplasms",C04.557.470.035;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;A12.459;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
28815363,"Adolescent;Child;Child, Preschool;Electronic Health Records;Humans;Natural Language Processing;Prospective Studies;Radiology;Sensitivity and Specificity;Ultrasonography;Venous Thromboembolism;Venous Thrombosis;Epidemiology;Natural Language Processing;Pediatrics;Quality Improvement;Venous Thromboembolism;Venous Thrombosis",M01.060.057;M01.060.406;M01.060.406.448;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.050.375.580;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H02.403.740;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.850;C14.907.355.590.700;C14.907.355.830.925;H02.403.720.500;L01.224.050.375.580;H02.403.670;J01.293.754;N04.761.744;C14.907.355.590.700;C14.907.355.830.925
28815346,"Adenocarcinoma;Antineoplastic Agents, Immunological;Humans;Middle Aged;Ovarian Neoplasms;Paraneoplastic Syndromes, Ocular;Retinal Diseases;Rituximab;Steroids;Treatment Outcome;Paraneoplastic Syndromes, Ocular;Paraneoplastic Syndromes, Ocular;Rituximab",C04.557.470.200.025;D27.505.954.248.384;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;C04.588.364.738;C04.730.900;C11.319.466;C11.768;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785;D04.210.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.588.364.738;C04.730.900;C11.319.466;C04.588.364.738;C04.730.900;C11.319.466;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
28814882,"Carcinoma, Hepatocellular;Ethiodized Oil",C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;D10.627.700.550.300;D20.215.784.750.550.300
28814673,Allergy and Immunology,H02.403.044
28814634,"Action Potentials;Animals;Brachyura;Central Pattern Generators;Electric Stimulation;Feedback, Sensory;Ganglia, Invertebrate;Mastication;Microelectrodes;Movement;Neural Pathways;Neurons;Periodicity;Proprioception;Sensory Gating;Tissue Culture Techniques;Central Pattern Generators",G04.580.100;G07.265.675.100;G11.561.570.100;B01.050;B01.050.500.131.365.190.110;A08.511.500;E05.723.402;F04.754.137.301.500;F04.754.308.500.500;F04.754.339;G07.410.732.500;A08.340.352;A13.408;G07.203.650.283.500;G10.261.330.500;E07.305.250.500;G07.568;G11.427.410;A08.612;A08.675;A11.671;G01.910.645;G07.180.562;F02.830.816.541;G11.561.790.541;G11.561.794;E05.481.500.617;A08.511.500
28813652,"Chromatin;Glucocorticoids;NF-kappa B;Protein Binding;Receptors, Glucocorticoid;Transcriptional Activation",A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D06.472.040.543;D27.505.696.399.472.488;D12.776.260.600;D12.776.660.600;D12.776.930.600;G02.111.679;G03.808;D12.776.826.750.430;G05.308.800
28813324,,
28812047,,
28811730,Prostatic Neoplasms;Continental Population Groups;Social Class;Therapeutics,C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;M01.686.508;I01.880.853.996.755;N01.824.782;E02
28811679,"Animals;Benzhydryl Compounds;Cell Differentiation;Cells, Cultured;Dendritic Cells;Estrogens;Flow Cytometry;Interleukin-12;Lipopolysaccharides;Mice;Mice, Inbred C57BL;Oligodeoxyribonucleotides;Phenols;Selective Estrogen Receptor Modulators;Toll-Like Receptor 4;Toll-Like Receptors;Tumor Necrosis Factor-alpha",B01.050;D02.455.426.559.389.115;G04.152;A11.251;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;D27.505.696.399.472.277;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;D12.644.276.374.465.512;D12.776.467.374.465.512;D23.529.374.465.512;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D13.695.578.424.450;D02.455.426.559.389.657;D06.347.360.827;D27.505.696.399.450.360.827;D12.776.543.750.705.910.500.400;D12.776.543.750.705.910.500;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
28811185,"Adult;Aged;Breast Neoplasms;Carcinoma, Ductal, Breast;Clinical Decision-Making;Humans;Mastectomy, Segmental;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Patient Selection;Prophylactic Mastectomy;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;SEER Program;Young Adult;Database;Hormones;General Surgery",M01.060.116;M01.060.116.100;C04.588.180;C17.800.090.500;C04.557.470.200.025.232.500;C04.557.470.615.132.500;C04.588.180.390;C17.800.090.500.390;E01.055;B01.050.150.900.649.313.988.400.112.400.400;E04.466.701;M01.060.116.630;C04.697.655;C23.550.727.655;E01.789.625;E05.581.500.653;N04.590.731;E04.466.911;E04.625.500;D08.811.913.696.620.682.725.400.009.400;D12.776.543.750.630.009.400;D12.776.543.750.750.400.074.400;D12.776.624.664.700.642;D23.050.301.500.600.700;D23.050.705.552.600.550;D23.101.140.642;D12.776.826.750.350;D12.776.930.778.350;D12.776.826.750.765;E05.318.308.970.725;N04.452.859.819.725;N05.715.360.300.715.700.725;N06.850.520.308.970.725;M01.060.116.815;V02.300;D06.472;D27.505.696.399.472;H02.403.810.300
28811175,,
28811121,"Adolescent;Adult;Age Factors;Cross-Sectional Studies;Domestic Violence;Emergency Service, Hospital;Humans;Perinatal Care;Pregnancy;Pregnancy Complications;Retrospective Studies;Risk Factors;Smoking;Substance-Related Disorders;Young Adult",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;I01.198.240.856.350;I01.880.735.900.350;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E02.760.703;N02.421.088.120.180;N02.421.143.620.550;N02.421.585.703;G08.686.784.769;C13.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.805;C25.775;F03.900;M01.060.116.815
28809853,"Amygdala;Down-Regulation;Gene Expression Profiling;Humans;Schizophrenia;Sequence Analysis, RNA;Transcriptome;Up-Regulation",A08.186.211.180.090;A08.186.211.200.885.287.249.152;G02.111.240;G05.308.200;G07.690.773.937;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;F03.700.750;E05.393.760.710;G02.111.873.750;G05.297.700.750;G05.360.920;G02.111.905;G05.308.850;G07.690.773.998
28808141,"Animals;Arthritis;Autoantibodies;Bradykinin;Cytokines;Factor XII;Humans;Interleukin-1beta;Interleukin-6;Mice;Mice, Knockout;Monocytes;Plasma Kallikrein;Polymerase Chain Reaction;Arthritis;Antigen-Antibody Complex;Kallikrein-Kinin System;Monocytes",B01.050;C05.550.114;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;D12.644.276.812.169;D12.644.400.090;D12.644.456.193;D12.776.467.812.169;D12.776.631.650.090;D23.469.050.375.110;D23.529.812.169;D12.644.276.374;D12.776.467.374;D23.529.374;D12.776.124.125.450;D23.119.450;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D08.811.277.656.300.760.442.700;D08.811.277.656.959.350.442.700;E05.393.620.500;C05.550.114;D12.776.124.486.485.114.257;D12.776.124.790.651.114.257;D12.776.377.715.548.114.257;D23.050.101;G02.111.635.500.500;G03.493.485;G03.615.500.500;G07.410.810.500.500;G09.330.380.690;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
28807941,Animals;Humans;Neoplasms;Signal Transduction;rho GTP-Binding Proteins,B01.050;B01.050.150.900.649.313.988.400.112.400.400;C04;G02.111.820;G04.835;D08.811.277.040.330.300.400.700;D12.644.360.525.700;D12.776.157.325.515.700;D12.776.476.525.700
28807867,"Alternative Splicing;Child;Codon, Nonsense;Facies;Frameshift Mutation;Humans;Hyperventilation;Intellectual Disability;Loss of Function Mutation;Middle Aged;Phenotype;Protein Domains;Transcription Factor 4",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;M01.060.406;D13.444.735.544.355.250.235;G05.360.335.355.250.235;G05.365.590.195;C23.550.291.812;E01.370.600.230;G05.365.590.265;B01.050.150.900.649.313.988.400.112.400.400;C08.618.501;C23.888.852.591;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590.538;M01.060.116.630;G05.695;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.260.108.092.937;D12.776.930.125.500.937
28807699,"Child;Communication;Comprehension;Critical Care;Education, Medical, Continuing;Family;Humans;Interviews as Topic;Neoplasms;Oncologists;Palliative Care;Patient Care Team;Pediatrics;Professional-Family Relations;Qualitative Research;Communication Barriers;Patient Care Planning",M01.060.406;F01.145.209;L01.143;F02.463.188.357;E02.760.190;N02.421.585.190;I02.358.212.350;I02.358.399.250;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;C04;M01.526.485.810.699;N02.360.810.699;E02.760.666;N02.421.585.666;N04.590.715;H02.403.670;F01.829.401.550;H01.770.644.241.850;L01.143.230;N04.590.233.624
28807611,"Anticonvulsants;Child, Preschool;Drug Therapy, Combination;Epilepsy;Humans;Infant;Retrospective Studies;Treatment Outcome;Anticonvulsants;Epilepsy;Seizures;Seizures;Levetiracetam;Oxcarbazepine;Phenobarbital",D27.505.954.427.080;M01.060.406.448;E02.319.310;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D27.505.954.427.080;C10.228.140.490;C10.597.742;C23.888.592.742;C10.597.742;C23.888.592.742;D02.065.064.432;D02.241.081.018.110.463;D03.383.773.812.362;D03.633.300.240.127.500;D03.383.742.698.253.650
28807468,"African Americans;Aged;Anticoagulants;Arthroplasty, Replacement, Hip;Body Mass Index;Comorbidity;Humans;Middle Aged;Multivariate Analysis;Odds Ratio;Pulmonary Embolism;Quality Improvement;Reoperation;Retrospective Studies;Risk Factors;Venous Thromboembolism;Venous Thrombosis;Venous Thrombosis;Pulmonary Embolism",M01.686.508.100.100;M01.686.754.100;M01.060.116.100;D27.505.954.502.119;E04.555.110.110.110;E04.650.110.110;E04.680.101.110.110;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;C08.381.746;C14.907.355.350.700;J01.293.754;N04.761.744;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907.355.590.700;C14.907.355.830.925;C14.907.355.830.925;C08.381.746;C14.907.355.350.700
28807423,"Adaptation, Psychological;Adult;Critical Care;Focus Groups;Heart Defects, Congenital;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Mindfulness;Mother-Child Relations;Mothers;Qualitative Research;Stress, Psychological;Mindfulness",F01.058;M01.060.116;E02.760.190;N02.421.585.190;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;F02.463.551;F04.754.137.350.500;F01.829.263.370.290.170;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;H01.770.644.241.850;F01.145.126.990;F02.830.900;F02.463.551;F04.754.137.350.500
28806897,"Animals;Central Nervous System Diseases;Dependovirus;Dogs;Gene Transfer Techniques;Genetic Therapy;Genetic Vectors;Haplorhini;Head-Down Tilt;Infusions, Intraventricular;Injections, Spinal;Models, Animal;Spinal Puncture;Central Nervous System;Genetic Therapy;Mucopolysaccharidoses",B01.050;C10.228;B04.280.580.650.170;B01.050.150.900.649.313.750.250.216.200;E05.393.350;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400;G11.427.695.300;E02.319.267.510.692;E02.319.267.530.580;E05.598;E01.370.225.998.054.790;E01.370.376.700;E02.800.779;E04.074.790;E04.665.700;E05.200.998.054.790;A08.186;E02.095.301;E05.393.420.301;C16.320.565.202.715;C16.320.565.595.600;C17.300.550.575;C18.452.648.202.715;C18.452.648.595.600
28806574,"Adolescent;Bone Neoplasms;Bone and Bones;Child;Diffusion Magnetic Resonance Imaging;Humans;Osteosarcoma;Sarcoma, Ewing;Treatment Outcome;Tumor Burden;Sarcoma, Ewing;Magnetic Resonance Imaging;Osteosarcoma",M01.060.057;C04.588.149;C05.116.231;A02.835.232;A10.165.265;M01.060.406;E01.370.350.825.500.150;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.565.575.650;C04.557.450.795.620;C04.557.450.565.575.650.800;C04.557.450.795.620.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.041.124.892;C04.557.450.565.575.650.800;C04.557.450.795.620.800;E01.370.350.825.500;C04.557.450.565.575.650;C04.557.450.795.620
28806457,"Adolescent;Adult;Brain;Child;Child, Preschool;Electroencephalography;Genome-Wide Association Study;Genotype;Humans;Magnetic Resonance Imaging;Mutation, Missense;Neurodevelopmental Disorders;Phenotype;Shab Potassium Channels;Young Adult",M01.060.057;M01.060.116;A08.186.211;M01.060.406;M01.060.406.448;E01.370.376.300;E01.370.405.245;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;G05.365.590.650;F03.625;G05.695;D12.776.157.530.400.600.900.124.500;D12.776.157.530.400.600.900.500.249;D12.776.543.550.450.750.900.124.500;D12.776.543.550.450.750.900.500.249;D12.776.543.585.400.750.900.124.500;D12.776.543.585.400.750.900.624.249;M01.060.116.815
28806448,Computers;Humans;Neonatal Sepsis;Sepsis,L01.224.230.260;B01.050.150.900.649.313.988.400.112.400.400;C01.539.757.580;C16.614.627;C23.550.470.790.500.470;C01.539.757;C23.550.470.790.500
28806393,"Adolescent;Animals;Cell Line, Tumor;Child;Child, Preschool;Dimerization;Glioma;Humans;Mice;NIH 3T3 Cells;Neoplasm Grading;Oncogene Fusion;Proto-Oncogene Proteins c-raf;Signal Transduction;Transfection",M01.060.057;B01.050;A11.251.210.190;A11.251.860.180;M01.060.406;M01.060.406.448;G02.206;G03.230;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.251.210.100.550;A11.329.228.100.550;E01.789.612;G05.728.385.500;D08.811.913.696.620.682.700.559.842.500;D12.644.360.400.842.500;D12.776.476.400.842.500;D12.776.624.664.700.204.500;G02.111.820;G04.835;E05.393.350.810;G05.728.860
28806370,Behavioral Risk Factor Surveillance System;Gender Identity;Humans;Sexual Behavior;Sexual and Gender Minorities;Surveys and Questionnaires;United States;United States Department of Veterans Affairs;Veterans;Veterans Health,E05.318.308.980.438.149;N05.715.360.300.800.438.149;N06.850.520.308.980.438.149;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;B01.050.150.900.649.313.988.400.112.400.400;F01.145.802;M01.777;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;M01.930;N01.400.850
28806367,Delphi Technique;Humans;Interviews as Topic;Minority Groups;Patient Participation;Patient-Centered Care;Primary Health Care;Staff Development;Surveys and Questionnaires;United States;United States Department of Veterans Affairs,L01.906.197;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;I01.880.853.300;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;N04.590.233.727.407;N04.590.233.727;I02.574.700;N04.452.677.822;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700
28806366,African Americans;Antihypertensive Agents;Behavior Therapy;Blood Pressure;Disease Management;Humans;Hypertension;Narration;Patient Education as Topic;Veterans,M01.686.508.100.100;M01.686.754.100;D27.505.954.411.162;F04.754.137;E01.370.600.875.249;G09.330.380.076;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.308.502;F01.145.209.459;L01.399.250.660;N05.715.360.300.480;N06.850.520.308.502;I02.233.332.500;N02.421.726.407.680;M01.930
28806346,Child;Combined Modality Therapy;Humans;Magnetic Resonance Imaging;Neurofibromatosis 1;Optic Nerve Glioma;Optic Nerve Neoplasms;Visual Acuity,M01.060.406;E02.186;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;C04.557.465.625.600.380.795;C04.557.470.670.380.795;C04.557.580.625.600.380.795;C04.588.614.300.600.600;C04.588.614.596.240.240.500;C10.292.225.800.500;C10.292.700.500.500;C10.551.360.500.500;C10.551.775.250.500.500;C11.640.544.500;C04.588.614.300.600;C04.588.614.596.240.240;C10.292.225.800;C10.292.700.500;C10.551.360.500;C10.551.775.250.500;C11.640.544;E01.370.380.850.950;F02.463.593.932.901;G14.940
28806345,"Child;Diagnostic Imaging;Humans;Magnetic Resonance Imaging;Optic Disk;Optic Neuritis;Tomography, Optical Coherence;Visual Acuity",M01.060.406;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A08.800.800.120.680.660;A09.371.729.690;C10.292.700.550;C11.640.576;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940
28806343,"Child;Disease Management;Eye Diseases;Humans;Neurology;Ophthalmology;Periodicals as Topic;Societies, Medical",M01.060.406;N04.590.607;C11;B01.050.150.900.649.313.988.400.112.400.400;H02.403.600;H02.403.810.468;L01.178.682.829.678;N03.540.828.589
28806253,3-Iodobenzylguanidine;Adult;Cysts;Ganglioneuroblastoma;Humans;Kidney Neoplasms,D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;M01.060.116;C04.182;C23.300.306;C04.557.465.625.600.590.650.550.300;C04.557.470.670.590.650.550.300;C04.557.580.625.600.590.650.550.300;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473
28805309,"Aged;Aged, 80 and over;Cohort Studies;Herpes Zoster;Herpes Zoster Vaccine;Humans;Inflammatory Bowel Diseases;Middle Aged;Retrospective Studies;Risk;Tumor Necrosis Factor-alpha;Vaccination",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.256.466.930.750;D20.215.894.899.290.130.400;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
28805300,Kidney Transplantation;Pediatrics;Risk Assessment,E02.870.500;E04.936.450.485;E04.950.774.400;H02.403.670;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
28804712,Adolescent;Adult;Brain-Computer Interfaces;Humans;Motor Activity;Robotics;Visual Perception,M01.060.057;M01.060.116;E07.305.076;B01.050.150.900.649.313.988.400.112.400.400;F01.145.632;G11.427.410.698;H01.671.293.643;J01.897.104.834;L01.224.050.375.630;F02.463.593.932
28803700,"Androgen Antagonists;Antineoplastic Agents, Hormonal;Depression;Depressive Disorder;Humans;Prostatic Neoplasms;Risk Factors;Behavioral Symptoms;Depression;Prostatic Neoplasms",D06.347.065;D27.505.696.399.450.065;D27.505.954.248.169;F01.145.126.350;F03.600.300;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126;F01.145.126.350;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28803489,"Humans;Lymphoma, T-Cell, Cutaneous;Skin Neoplasms",B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480.750.800;C15.604.515.569.480.750.800;C20.683.515.761.480.750.800;C04.588.805;C17.800.882
28802938,"Disruptive, Impulse Control, and Conduct Disorders;Humans;Parkinson Disease;Dopamine Agonists;Parkinson Disease;Gambling",F03.250;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D27.505.519.625.150.151;D27.505.696.577.150.151;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F01.145.722.408;F03.250.400
28802694,"Air Pollution;Environmental Pollution;Idiopathic Pulmonary Fibrosis;Lung Diseases, Interstitial;Pulmonary Fibrosis",N06.850.460.100;N06.850.460;C08.381.483.487.500;C08.381.765.500;C08.381.483;C08.381.765
28802530,,
28802510,"Adolescent;Adult;Aged;Aorta, Thoracic;Aortic Aneurysm, Thoracic;Aortic Valve;Child;Child, Preschool;Echocardiography;Follow-Up Studies;Heart Valve Diseases;Hemodynamics;Humans;Infant;Middle Aged;Prevalence;Registries;Retrospective Studies;Risk Factors;Sex Factors;United States;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;A07.015.114.056.372;C14.907.055.239.125;C14.907.109.139.125;A07.541.510.110;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280.484;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;Z01.107.567.875;M01.060.116.815
28802498,"Carcinoma, Squamous Cell;Diagnosis, Differential;Humans;Risk Factors;Skin Neoplasms;Sunlight;Keratosis, Actinic;Keratoacanthoma;Carcinoma, Squamous Cell",C04.557.470.200.400;C04.557.470.700.400;E01.171;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C04.588.805;C17.800.882;G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525;C04.834.450;C17.800.428.570;C17.800.417;C04.557.470.200.400;C04.557.470.700.400
28802335,"Cesarean Section;Cross Infection;Delivery, Obstetric;Humans;Infant, Newborn;Infant, Very Low Birth Weight;Neonatal Sepsis;Outcome Assessment (Health Care);Perinatology;Pregnancy;Prenatal Care;Quality Improvement;Quality of Health Care;Retinopathy of Prematurity;Cesarean Section;Mortality;Perinatal Care",E04.520.252.500;C01.539.248;C23.550.291.875.500;E04.520.252;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.460.600;C01.539.757.580;C16.614.627;C23.550.470.790.500.470;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;H02.403.670.500;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786;J01.293.754;N04.761.744;N04.761;N05.715;C11.768.836;C16.614.521.731;E04.520.252.500;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E02.760.703;N02.421.088.120.180;N02.421.143.620.550;N02.421.585.703
28802044,"Animals;Ants;Behavior, Animal;Gene Expression Regulation, Developmental;Insect Proteins;Neuropeptides;Social Behavior;Ants;Brain;Epigenomics;Neuropeptides;Social Behavior;Transcriptome;Vitellogenins",B01.050;B01.050.500.131.617.720.500.500.875.205;F01.145.113;G05.308.310;D12.776.093.500;D12.644.400;D12.776.631.650;F01.145.813;B01.050.500.131.617.720.500.500.875.205;A08.186.211;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.644.400;D12.776.631.650;F01.145.813;G02.111.873.750;G05.297.700.750;G05.360.920;D12.776.093.500.925;D12.776.290.812.500;D12.776.744.925
28801082,"Academic Medical Centers;Adult;Clinical Competence;Computer Simulation;Curriculum;Education, Medical, Graduate;Electronic Health Records;General Surgery;Hospitals, University;Humans;Perioperative Care;Prospective Studies;Quality Improvement;Statistics, Nonparametric;Task Performance and Analysis;Videotape Recording;Electronic Health Records;Instructional Films and Videos;Internship and Residency;Mobile Applications",N02.278.020;M01.060.116;I02.399.630.210;N04.761.210;N05.715.175;L01.224.160;I02.158;I02.358.337.350;I02.358.399.350;E05.318.308.940.968.625.500;H02.403.810.300;N02.278.020.300.310;N02.278.421.639.725;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731;E04.604;N02.421.585.722;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;J01.293.754;N04.761.744;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;F02.784.412.846;F02.784.692.746;F02.808.600;J01.897.280.500.846.734;J01.897.280.500.898.840;L01.178.590.875.840;L01.178.820.090.846.734;L01.178.820.090.898.840;L01.280.940.840;L01.280.960.880;E05.318.308.940.968.625.500;V01.255.500.500;V02.575;I02.358.337.350.500;I02.358.399.350.750;L01.224.900.685
28800990,"Anesthesiologists;Humans;Intubation, Intratracheal;Respiration, Artificial",M01.526.485.140.040;M01.526.485.810.040;N02.360.140.040;N02.360.810.040;B01.050.150.900.649.313.988.400.112.400.400;E02.041.500;E02.585.578;E05.497.578;E02.041.625;E02.365.647.729;E02.880.820
30270895,Monte Carlo Method;Dogs;Geographic Information Systems;Rabies;Spatial Analysis,E05.318.740.525;L01.906.394.422;N05.715.360.750.540;N06.850.520.830.525;B01.050.150.900.649.313.750.250.216.200;L01.313.500.750.300.314;L01.470.750.750.462;C02.782.580.830.750;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933
28800496,Adolescent;Alcohol Abstinence;Alcoholism;Goals;Harm Reduction;Humans;Surveys and Questionnaires;Treatment Outcome;Underage Drinking;Adolescent;Alcoholism;Treatment Outcome,M01.060.057;F01.145.317.134;C25.775.100.250;F03.900.100.350;F01.658.500;F01.145.477;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;F01.145.022.750;F01.145.317.269.875;I01.880.735.878;M01.060.057;C25.775.100.250;F03.900.100.350;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28799483,Confidentiality;Humans;Morals;Precision Medicine;Schizophrenia;Ethics;Genomics;Mental Health;Precision Medicine;Psychiatry;Schizophrenia,F04.096.544.335.240;I01.880.604.473.650.500;I01.880.604.583.080;N03.706.437.650.124;N03.706.535.230;B01.050.150.900.649.313.988.400.112.400.400;F01.829.500;K01.752.566;E02.574;H02.403.200.700;F03.700.750;K01.752.566.479;N05.350;H01.158.273.180.350;H01.158.273.343.350;F02.418;N01.400.500;E02.574;H02.403.200.700;F04.096.544;H02.403.690;F03.700.750
28798906,Cerebrovascular Disorders;Stroke;Thrombosis,C10.228.140.300;C14.907.253;C10.228.140.300.775;C14.907.253.855;C14.907.355.830
28798345,"Animals;Biomarkers;Cell Line;Disease Models, Animal;Enzyme Activation;Gene Expression;Humans;Intracellular Space;Mice;Mice, Knockout;Mice, Transgenic;Models, Biological;Mutation;Nedd4 Ubiquitin Protein Ligases;Polycystic Kidney, Autosomal Recessive;Protein Transport;Rats;Receptors, Cell Surface;Signal Transduction;rho GTP-Binding Proteins",B01.050;D23.101;A11.251.210;C22.232;E05.598.500;E05.599.395.080;G02.111.263;G03.328;G05.297;B01.050.150.900.649.313.988.400.112.400.400;A10.082.750;A11.284.430;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;E05.599.395;G05.365.590;D05.500.199.500;D08.811.464.938.750.257;D12.776.543.990.493.500;C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;G03.143.700;B01.050.150.900.649.313.992.635.505.700;D12.776.543.750;G02.111.820;G04.835;D08.811.277.040.330.300.400.700;D12.644.360.525.700;D12.776.157.325.515.700;D12.776.476.525.700
28797735,Epidemiology;Food Hypersensitivity;Incidence;Milk Hypersensitivity;Prevalence,H02.403.720.500;C20.543.480.370;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C20.543.480.370.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
28797390,,
28797240,"Algorithms;Gene Expression Profiling;High-Throughput Nucleotide Sequencing;Sequence Analysis, RNA",G17.035;L01.224.050;E05.393.332;E05.393.760.319;E05.393.760.710
28797023,"Adolescent;Adult;Anti-HIV Agents;CD4 Lymphocyte Count;Continuity of Patient Care;Databases, Factual;Guidelines as Topic;HIV Infections;Health Services Accessibility;Humans;Insurance Claim Review;Insurance, Health;Medicaid;Middle Aged;Primary Health Care;United States;Viral Load;Young Adult",M01.060.057;M01.060.116;D27.505.954.122.388.077.088;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;E02.760.169;N02.421.585.169;N04.590.233.727.210;L01.313.500.750.300.188.400;L01.470.750.750;N04.761.700.350;N05.700.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.215;N03.219.521.576.343;N03.219.521.346.506.564.655;N03.706.615.693;M01.060.116.630;N04.590.233.727;Z01.107.567.875;E01.370.225.875.950;E05.200.875.950;G06.920.850;M01.060.116.815
28796856,"Acute Disease;Birth Weight;Gestational Age;Humans;Image Processing, Computer-Assisted;Infant;Infant, Newborn;Infant, Premature;Infant, Very Low Birth Weight;Ophthalmoscopy;Retinopathy of Prematurity;Risk Factors;Telemedicine",C23.550.291.125;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.703;M01.060.703.520;M01.060.703.520.520;M01.060.703.520.460.600;E01.370.380.560;C11.768.836;C16.614.521.731;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H02.403.840;L01.178.847.652;N04.590.374.800
28796432,"Adolescent;Adult;Cerebral Cortex;Humans;Magnetic Resonance Imaging;Multiple Sclerosis, Relapsing-Remitting;Pilot Projects;Time Factors;Young Adult",M01.060.057;M01.060.116;A08.186.211.200.885.287.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G01.910.857;M01.060.116.815
28796392,"Adolescent;Charcot-Marie-Tooth Disease;Child;Child, Preschool;Disease Progression;Humans;Longitudinal Studies;Mutation;Myelin Proteins;Young Adult",M01.060.057;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;M01.060.406;M01.060.406.448;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;G05.365.590;D12.776.543.620;D12.776.631.580;M01.060.116.815
28795976,Biomedical Research;Career Choice;Humans;Physicians;Research Personnel,H01.770.644.145;F02.463.785.373.346.400;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;M01.526.839
28795973,"Academic Medical Centers;Academies and Institutes;Burnout, Professional;Clinical Competence;Faculty, Medical;Humans;Leadership;Staff Development;Vocational Guidance",N02.278.020;N03.540.052;C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;I02.399.630.210;N04.761.210;N05.715.175;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;F01.752.609;I02.574.700;N04.452.677.822;F02.784.629.937;F02.784.692.887
28795523,African Americans;Anesthesia;Appendectomy;Child;Cohort Studies;Continental Population Groups;European Continental Ancestry Group;Humans;Intraoperative Care;Philadelphia;Preoperative Care;Retrospective Studies;Anesthesia and Analgesia;Child Health;Delivery of Health Care;Minority Health;Pediatrics;Race Relations,M01.686.508.100.100;M01.686.754.100;E03.155;E04.210.078;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.508;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.400;E04.604.249;N02.421.585.722.400;Z01.107.567.875.500.550.525;Z01.433.820;E02.760.795;E04.604.750;N02.421.585.795;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E03;N01.400.225;N04.590.374;N05.300;N01.400.512;H02.403.670;I01.880.735.820.500
28795517,"Adaptation, Physiological;Cardiovascular Physiological Phenomena;Fontan Procedure;Heart Defects, Congenital;Humans;Pulmonary Circulation",G07.025;G16.012.500;G09.330;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;G09.330.100.770;G09.772.593
28795506,"Administration, Oral;Adult;Aged;Apolipoprotein A-I;Dose-Response Relationship, Drug;Humans;Inflammation;Lipoproteins, HDL;Middle Aged;Risk Factors;Time Factors",E02.319.267.100;M01.060.116;M01.060.116.100;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;G07.690.773.875;G07.690.936.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D10.532.432;D12.776.521.479;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857
28795424,"Adolescent;Adult;Bronchopulmonary Sequestration;Diagnosis, Differential;Humans;Lung;Middle Aged;Pregnancy;Ultrasonography, Prenatal;Young Adult;Bronchopulmonary Sequestration;Prenatal Diagnosis",M01.060.057;M01.060.116;C08.695.214;C16.131.740.214;E01.171;B01.050.150.900.649.313.988.400.112.400.400;A04.411;M01.060.116.630;G08.686.784.769;E01.370.350.850.865;E01.370.378.630.865;M01.060.116.815;C08.695.214;C16.131.740.214;E01.370.378.630
28795150,,
28794231,,
28794130,Intellectual Disability;Retinitis Pigmentosa,C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C11.270.684;C11.768.585.658.500;C16.320.290.684
28794075,Botulinum Toxins;Graves Disease;Hyaluronic Acid;Exophthalmos;Triamcinolone,D08.811.277.656.300.480.153;D08.811.277.656.675.374.153;D12.776.097.156;D23.946.123.179;C11.675.349.500;C19.874.283.605;C19.874.397.370;C20.111.555;D09.698.373.475;C11.675.349;D04.210.500.745.432.915;D04.210.500.908.891
28794020,,
28793971,Biomarkers;Humans;Parkinson Disease;Pharmacogenetics;Precision Medicine;Parkinson Disease;Pharmacogenetics;Precision Medicine,D23.101;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;H01.158.273.343.750;H01.158.703.052;H02.628.479;E02.574;H02.403.200.700;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;H01.158.273.343.750;H01.158.703.052;H02.628.479;E02.574;H02.403.200.700
28792001,"Acid Phosphatase;Bone Density;Cell Line;GTPase-Activating Proteins;Genetic Loci;Genome-Wide Association Study;Humans;Regulatory Sequences, Nucleic Acid",D08.811.277.352.650.025;G11.427.100;A11.251.210;D12.644.360.325.150;D12.776.476.325.150;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.080.689;G05.360.080.689
28791722,"Blood Pressure;Causality;Cohort Studies;Computer Simulation;Confounding Factors (Epidemiology);Disease Progression;Glomerular Filtration Rate;Humans;Markov Chains;Models, Statistical;Probability;Renal Insufficiency, Chronic;Risk Factors",E01.370.600.875.249;G09.330.380.076;N05.715.350.200;N06.850.490.625;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.224.160;N05.715.350.240;N06.850.490.718;C23.550.291.656;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.500;E05.318.740.996.500;G17.830.500;N05.715.360.750.625.500;N05.715.360.750.770.500;N06.850.520.830.600.500;N06.850.520.830.996.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28791703,"Affect;Animals;Anxiety;Behavior, Addictive;Humans;Interpeduncular Nucleus;Nicotinic Agonists;Substance Withdrawal Syndrome;Epithalamus;Interpeduncular Nucleus;Affect",F01.470.047;B01.050;F01.470.132;F01.145.527.100.120;B01.050.150.900.649.313.988.400.112.400.400;A08.186.211.132.659.413.875.618.436;D27.505.519.625.120.140.700;D27.505.696.577.120.140.700;C25.775.835;F03.900.825;A08.186.211.180.200;A08.186.211.200.317.200;A08.186.211.132.659.413.875.618.436;F01.470.047
28791511,"Animals;Centromere;Centromere Protein A;Chromatin Assembly and Disassembly;Epigenesis, Genetic;Germ Cells;Humans;Inheritance Patterns;Centromere;Wills",B01.050;A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;G04.400.095;G05.213.095;G05.308.095;G05.308.203;A05.360.490;A11.497;B01.050.150.900.649.313.988.400.112.400.400;G05.420;A11.284.430.106.279.345.190.160.165;G05.360.160.165;I01.880.604.583.927
28791427,Cerebral Ventricles;Humans;Hydrocephalus;Pregnancy;Prenatal Care,A08.186.211.140;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;G08.686.784.769;E02.760.786;N02.421.143.620.704;N02.421.585.786
28790973,Opiate Alkaloids,D03.132.577
28790140,Communication;Decision Making;Humans;Infant;Internship and Residency;Parental Consent;Pediatrics;Physician's Role;Professional-Family Relations;Respiratory Tract Infections,F01.145.209;L01.143;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I02.358.337.350.500;I02.358.399.350.750;I01.880.604.583.427.635.500;N03.706.535.489.635.500;H02.403.670;F01.829.316.616.625.600;F01.829.401.550;C01.539.739;C08.730
28789775,"Adult;Aged;Aged, 80 and over;Cardiorespiratory Fitness;Ethnic Groups;Exercise Test;Humans;Incidence;Middle Aged;Neoplasms;Physical Fitness;Predictive Value of Tests;Prospective Studies;United States;Veterans;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;G11.427.685.500;I03.450.642.845.054.300;I03.450.642.845.054.800.500;N01.400.150;N01.400.545.500;M01.686.754;N01.224.317;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;C04;G11.427.685;I03.450.642.845.054.800;N01.400.545;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;Z01.107.567.875;M01.930;M01.060.116.815
28787647,"Humans;Models, Theoretical;Monte Carlo Method;Neuroimaging;Spectrophotometry, Infrared",B01.050.150.900.649.313.988.400.112.400.400;E05.599;E05.318.740.525;L01.906.394.422;N05.715.360.750.540;N06.850.520.830.525;E01.370.350.578;E01.370.376.537;E05.629;E05.196.712.726.676;E05.196.867.826.676
28787505,"Acute Kidney Injury;Aged;Aortic Valve;Aortic Valve Stenosis;Arrhythmias, Cardiac;Brain Infarction;Delirium;Embolic Protection Devices;Heart Valve Prosthesis;Heart Valve Prosthesis Implantation;Humans;Incidence;Postoperative Complications;Risk Factors;Treatment Outcome",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.116.100;A07.541.510.110;C14.280.484.150;C14.280.955.249;C14.280.067;C23.550.073;C10.228.140.300.150.477;C10.228.140.300.775.200;C14.907.253.092.477;C14.907.253.855.200;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;E07.695.207;E07.695.310;E04.100.376.485;E04.650.410;E04.928.220.410;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C23.550.767;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28787311,Adult;Follow-Up Studies;Humans;Kidney Transplantation;Living Donors;Middle Aged;Phenotype,M01.060.116;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;M01.898.656;M01.060.116.630;G05.695
28787227,,
28786872,"Aged;Attitude of Health Personnel;Attitude to Health;Exercise;Focus Groups;Humans;Pain;Qualitative Research;Urinary Incontinence, Urge",M01.060.116.100;F01.100.050;N05.300.100;F01.100.150;N05.300.150;G11.427.410.698.277;I03.350;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;B01.050.150.900.649.313.988.400.112.400.400;C23.888.592.612;F02.830.816.444;G11.561.790.444;H01.770.644.241.850;C12.777.934.852.500;C13.351.968.934.814.750;C23.888.942.343.800.750
28786752,"Adolescent;Adult;Autistic Disorder;Brain;Child;Child, Preschool;Chromosome Deletion;Chromosome Disorders;Chromosomes, Human, Pair 16;Cluster Analysis;Cross-Sectional Studies;DNA Copy Number Variations;Gene Deletion;Gene Duplication;Humans;Infant;Intellectual Disability;Magnetic Resonance Imaging;Middle Aged;Young Adult",M01.060.057;M01.060.116;F03.625.164.113.500;A08.186.211;M01.060.406;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;C16.131.260;C16.320.180;A11.284.187.520.300.415.420;G05.360.162.520.300.415.420;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G05.365.795.297.500;G05.365.590.762.320;G05.558.800.320;G05.365.590.320;G05.558.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;E01.370.350.825.500;M01.060.116.630;M01.060.116.815
28786560,Child;Cystic Fibrosis;Humans;Lung Transplantation;Terminal Care;Lung Transplantation,M01.060.406;C06.689.202;C08.381.187;C16.320.190;C16.614.213;B01.050.150.900.649.313.988.400.112.400.400;E04.928.600.495;E04.936.450.495;E02.760.905;N02.421.585.905;E04.928.600.495;E04.936.450.495
28786432,"Child;Child, Preschool;Clinical Alarms;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Monitoring, Physiologic;Reaction Time",M01.060.406;M01.060.406.448;E07.230.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E01.370.520;E05.796.817;F02.830.650;F04.669.817;G11.561.677
28786427,Adult;Aftercare;Aged;Appointments and Schedules;Cohort Studies;Follow-Up Studies;Hospitalization;Humans;Medicine;Middle Aged;Patient Discharge;Primary Health Care;Risk Factors,M01.060.116;E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;M01.060.116.100;N04.452.095;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;H02.403;M01.060.116.630;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;N04.590.233.727;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28786078,"African Continental Ancestry Group;Aged;Aged, 80 and over;Asian Americans;Atherosclerosis;Atrial Fibrillation;Ethnic Groups;European Continental Ancestry Group;Follow-Up Studies;Gonadal Steroid Hormones;Humans;Middle Aged;Prevalence;Risk Assessment;Sex Characteristics;Socioeconomic Factors;Testosterone;United States;Atrial Fibrillation;Epidemiology;Risk;Gonadal Steroid Hormones",M01.686.508.100;M01.060.116.100;M01.060.116.100.080;M01.686.508.200.100;M01.686.754.225;C14.907.137.126.307;C14.280.067.198;C23.550.073.198;M01.686.754;N01.224.317;M01.686.508.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;D06.472.334.851;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;G08.686.815;I01.880.853.996;N01.824;D04.210.500.054.079.429.824;D06.472.334.851.968.984;Z01.107.567.875;C14.280.067.198;C23.550.073.198;H02.403.720.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;D06.472.334.851
28786026,"Animals;Humans;Immunologic Deficiency Syndromes;Infection;Travel;Global Warming;Immunoglobulins, Intravenous;Phenotype",B01.050;B01.050.150.900.649.313.988.400.112.400.400;C20.673;C01.539;I03.883;G16.500.175.374.500;D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632;G05.695
28785981,,
28785782,"Humans;Shaken Baby Syndrome;Social Work;Sweden;Technology Assessment, Biomedical",B01.050.150.900.649.313.988.400.112.400.400;C10.900.300.087.850;C26.915.300.200.825;I01.880.792;N02.421.849;Z01.542.816.500;N03.880;N05.715.360.825
28785599,,
28785562,"Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28785301,,
28785035,"Fibrinolysin;Fibrinolysis;Humans;Kinetics;Models, Theoretical;Tissue Plasminogen Activator",D08.811.277.656.300.760.330;D08.811.277.656.959.350.330;G09.188.390.150.390;B01.050.150.900.649.313.988.400.112.400.400;G01.374.661;G02.111.490;E05.599;D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
28784785,"Age Factors;Animals;Animals, Newborn;Behavior, Animal;Bonding, Human-Pet;Choice Behavior;Cognition;Dogs;Humans;Maternal Behavior;Temperament;Visually Impaired Persons;Cognition;Temperament",N05.715.350.075;N06.850.490.250;B01.050;B01.050.050.282;F01.145.113;F02.739.794.624.120;F02.463.785.373.346;F02.463.188;B01.050.150.900.649.313.750.250.216.200;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.215;F01.752.898;M01.150.850;F02.463.188;F01.752.898
28784703,Acute Disease;Humans;Infant;Otitis Media,C23.550.291.125;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C09.218.705.663
28784655,"Adult;Aged;Brachial Artery;Cardiovascular Diseases;Chi-Square Distribution;Cross-Sectional Studies;Endothelium, Vascular;Humans;Kidney;Linear Models;Logistic Models;Middle Aged;Multivariate Analysis;Nitroglycerin;Odds Ratio;Regional Blood Flow;Renal Insufficiency, Chronic;Risk Factors;Severity of Illness Index;Vasodilation;Vasodilator Agents;Accidental Falls;Brachial Artery;Cohort Studies;Dilatation;Endothelium, Vascular;Humans;Nitroglycerin;Renal Insufficiency, Chronic;Arteries;Cardiovascular Diseases;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Coronary Artery Disease;Kidney Failure, Chronic;Endothelium;Hypertension;Nitric Oxide;Risk Factors;Vascular Diseases",M01.060.116;M01.060.116.100;A07.015.114.139;C14;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;A07.015.700.500;A10.272.491.355;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;D02.640.636;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G09.330.100.780;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G09.330.380.928;D27.505.954.411.918;N06.850.135.122;A07.015.114.139;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.284;A07.015.700.500;A10.272.491.355;B01.050.150.900.649.313.988.400.112.400.400;D02.640.636;C12.777.419.780.750;C13.351.968.419.780.750;A07.015.114;C14;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C12.777.419.780.750.500;C13.351.968.419.780.750.500;A10.272.491;C14.907.489;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907
28784256,"Crowding;Early Intervention (Education);Emergency Service, Hospital;Hospital Mortality;Humans;Sepsis",F01.145.875.281;N02.421.143.130.320;N02.421.726.320;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;C01.539.757;C23.550.470.790.500
28783722,"Adoptive Transfer;Animals;Antigen Presentation;Apelin;Apelin Receptors;CRISPR-Cas Systems;Cell Line, Tumor;Genes, Essential;Genome;Histocompatibility Antigens Class I;Humans;Immunotherapy;Interferon-gamma;Janus Kinase 1;Knowledge Bases;Melanoma;Mice;Mutation;Neoplasms;Reproducibility of Results;T-Lymphocytes, Cytotoxic",E02.095.465.425.400.330.050;E05.478.550.520.050;B01.050;G12.119;G12.450.050.400.070;D12.644.276.150;D23.529.134;D12.776.543.750.695.006;G05.308.203.374.394;A11.251.210.190;A11.251.860.180;G05.360.340.024.340.270;G05.360.340;D12.776.395.550.489;D12.776.543.550.439;D23.050.301.500.100;D23.050.705.552.100;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D08.811.913.696.620.682.725.124.100;D12.776.476.393.100;L01.224.050.375.480;L01.313.500.750.300.550;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;G05.365.590;C04;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
28783126,HEK293 Cells;Heterogeneous-Nuclear Ribonucleoprotein K;Humans;Marine Biology;Neuroprotective Agents;Protein Binding;RNA-Binding Proteins;Tyrosine,A11.251.210.172.750;A11.436.334;D12.776.157.725.813.750.500;D12.776.260.268;D12.776.664.962.813.750.500;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.248.750.500;H01.277.249.750.500;H01.277.750.500;D27.505.696.706.548;D27.505.954.427.575;G02.111.679;G03.808;D12.776.157.725;D12.776.664.962;D12.125.072.050.875
28783105,"Cell Nucleus;Cells, Cultured;Fibroblasts;Gene Expression Regulation;Herpesvirus 1, Human;Host-Pathogen Interactions;Humans;Immediate-Early Proteins;MicroRNAs;Nerve Tissue Proteins;Neurons;Protein Binding;Proteolysis;RNA-Binding Proteins;Ubiquitin-Protein Ligases;Virus Replication;Zinc Finger E-box-Binding Homeobox 1;Ubiquitin-Protein Ligases;Herpesvirus 1, Human;Simplexvirus;MicroRNAs",A11.284.430.106;A11.284.430.214.190.875.117;A11.251;A11.329.228;G05.308;B04.280.382.100.750.390;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D12.776.460;D12.776.964.925.968;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;D12.776.631;A08.675;A11.671;G02.111.679;G03.808;G02.111.720;G03.812;D12.776.157.725;D12.776.664.962;D08.811.464.938.750;G06.920.925;D12.776.260.400.906;D12.776.260.703.800;D12.776.930.780.945;D08.811.464.938.750;B04.280.382.100.750.390;B04.280.382.100.750;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
28782226,"Adult;Attitude of Health Personnel;Australia;Child;Clinical Competence;Emergency Service, Hospital;Humans;Middle Aged;New Zealand;Surveys and Questionnaires;Wounds and Injuries;Child;Emergency Service, Hospital;Mental Health;Stress Disorders, Post-Traumatic",M01.060.116;F01.100.050;N05.300.100;Z01.639.100;Z01.678.100.373;M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.639.760.747;Z01.678.100.747;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C26;M01.060.406;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;F02.418;N01.400.500;F03.950.750.500
28781219,"Art;Clinical Competence;Education, Medical;Educational Measurement;Eye Diseases;Humans;Observation;Ophthalmology;Philadelphia;Schools, Medical;Single-Blind Method;Students, Medical",K01.093;I02.399.630.210;N04.761.210;N05.715.175;I02.358.399;I02.399;C11;B01.050.150.900.649.313.988.400.112.400.400;E05.581.249;H02.403.810.468;Z01.107.567.875.500.550.525;Z01.433.820;I02.783.495.552;N02.278.020.578;E05.318.370.850;N05.715.360.325.730;N06.850.520.445.850;M01.848.769.602
28780023,"Activin Receptors, Type I;Brain Stem Neoplasms;Glioma;Humans;Mutation;Myositis Ossificans;Rare Diseases;Myositis Ossificans",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;C04.588.614.250.195.411.100;C10.228.140.211.500.100;C10.551.240.250.400.200;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C05.651.594.638;C23.550.291.906;C05.651.594.638
28779862,Humans;Kidney Diseases;Nervous System Diseases,B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C10
28779374,"DNA Methylation;Epigenesis, Genetic;Epstein-Barr Virus Infections;Genome, Viral;Herpesvirus 4, Human;Humans;Stomach Neoplasms;DNA Methylation;Herpesvirus 4, Human",G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G05.308.203;C02.256.466.313;C02.928.313;G05.360.340.358.840;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400
28779307,"ADAM10 Protein;Adrenergic Neurons;Amyloid Precursor Protein Secretases;Amyloid beta-Peptides;Amyloid beta-Protein Precursor;Animals;Aspartic Acid Endopeptidases;Benzylamines;Cerebral Cortex;Dopamine beta-Hydroxylase;Locus Coeruleus;Mice, Knockout;Microscopy, Electron;Neural Pathways;Neurotransmitter Uptake Inhibitors;Norepinephrine;Peptide Fragments;Rats;Rats, Sprague-Dawley;Subcellular Fractions;Tyrosine 3-Monooxygenase;Receptors, Adrenergic;Amyloid;Norepinephrine",D08.811.277.656.675.374.102.250;D09.400.430.500.250;D12.776.395.033.250;A08.675.100;A11.671.050;D08.811.277.656.300.032;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D12.776.049.407.249;D12.776.543.039;D12.776.645.468.500;D12.776.811.050;B01.050;D08.811.277.656.074.500;D08.811.277.656.300.048;D02.092.200;D02.455.426.559.389.140.210;A08.186.211.200.885.287.500;D08.811.682.690.708.292;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E01.370.350.515.402;E05.595.402;A08.612;D27.505.519.562.437;D27.505.519.625.600;D27.505.696.577.600;D02.033.100.291.502;D02.092.063.480;D02.092.211.215.746;D02.092.311.830;D02.455.426.559.389.657.166.175.830;D12.644.541;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;A11.284.835;D08.811.682.690.708.923;D12.776.556.579.374.925;D12.776.543.750.670.300.300;D12.776.543.750.695.150.300;D12.776.543.750.720.330.300;D05.500.049;D12.776.049;D02.033.100.291.502;D02.092.063.480;D02.092.211.215.746;D02.092.311.830;D02.455.426.559.389.657.166.175.830
28779205,"Dilatation;Dilatation, Pathologic;Humans;Urinary Tract",E05.284;C23.300.325;B01.050.150.900.649.313.988.400.112.400.400;A05.810
28779200,"Consensus;Dilatation, Pathologic;Humans;Infant, Newborn;Pregnancy;Terminology as Topic;Ultrasonography;Ultrasonography, Prenatal;Urinary Tract;Urologic Diseases;Urinary Bladder;Child;Hydronephrosis;Kidney;Ureter;Urinary Tract",F01.829.316.068;F02.463.785.373.433;C23.300.325;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;G08.686.784.769;L01.559.598.400;E01.370.350.850;E01.370.350.850.865;E01.370.378.630.865;A05.810;C12.777;C13.351.968;A05.810.890;M01.060.406;C12.777.419.307;C13.351.968.419.307;A05.810.453;A05.810.776;A05.810
28779198,"Abdominal Pain;Appendicitis;Appendix;Child;Child, Preschool;Diagnosis, Differential;Humans;Infant;Infant, Newborn;Ultrasonography;Appendicitis;Appendix;Child",C23.888.592.612.054;C23.888.821.030;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;A03.556.124.526.209.290;A03.556.249.249.209.290;M01.060.406;M01.060.406.448;E01.171;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.350.850;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;A03.556.124.526.209.290;A03.556.249.249.209.290;M01.060.406
28779194,"Biliary Tract;Biliary Tract Diseases;Child;Child, Preschool;Genetic Predisposition to Disease;Humans;Infant;Infant, Newborn;Liver;Liver Diseases;Pancreas;Pancreatic Diseases;Spleen;Splenic Diseases;Ultrasonography;Liver;Pancreas;Pediatrics;Spleen",A03.159;C06.130;M01.060.406;M01.060.406.448;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A03.620;C06.552;A03.734;C06.689;A10.549.700;A15.382.520.604.700;C15.604.744;E01.370.350.850;A03.620;A03.734;H02.403.670;A10.549.700;A15.382.520.604.700
28779191,"Child;Child, Preschool;Humans;Infant;Infant, Newborn;Inflammatory Bowel Diseases;Intestinal Diseases;Ultrasonography;Abdomen;Child;Inflammatory Bowel Diseases;Pain",M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C06.405.205.731;C06.405.469.432;C06.405.469;E01.370.350.850;A01.923.047;M01.060.406;C06.405.205.731;C06.405.469.432;C23.888.592.612;F02.830.816.444;G11.561.790.444
28779190,"Abdominal Pain;Adolescent;Child;Genital Diseases, Female;Humans;Pelvic Pain;Pelvis;Pregnancy;Pregnancy Complications;Ultrasonography;Adolescent;Child;Ovary;Pelvis;Uterus",C23.888.592.612.054;C23.888.821.030;M01.060.057;M01.060.406;C13.351.500;B01.050.150.900.649.313.988.400.112.400.400;C23.888.592.612.944;A01.923.600;G08.686.784.769;C13.703;E01.370.350.850;M01.060.057;M01.060.406;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;A01.923.600;A05.360.319.679
28779188,"Adolescent;Arthritis, Juvenile;Child;Child, Preschool;Humans;Infant;Synovial Membrane;Synovitis;Ultrasonography;Child;Arthritis, Juvenile;Synovitis",M01.060.057;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A02.835.583.443.800;C05.550.870;E01.370.350.850;M01.060.406;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;C05.550.870
28778925,"A549 Cells;AMP-Activated Protein Kinases;Adenosine Triphosphate;Amino Acid Substitution;Apoptosis;Autophagy;Carcinoma;Carrier Proteins;Cell Line, Tumor;Dimerization;Energy Metabolism;Humans;Isoenzymes;Lung Neoplasms;Membrane Proteins;Mitochondrial Dynamics;Mutation;Neoplasm Proteins;Organelle Biogenesis;Protein Transport;Pyruvate Kinase;RNA Interference;Recombinant Fusion Proteins;Thyroid Hormones;Energy Metabolism;Mitochondria",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;D08.811.913.696.620.682.700.085;D12.644.360.062;D12.776.476.062;D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;E05.393.420.601.035;G05.558.109;G04.146.160;G04.146.399;G04.417.350.091;C04.557.470.200;D12.776.157;A11.251.210.190;A11.251.860.180;G02.206;G03.230;G03.295;B01.050.150.900.649.313.988.400.112.400.400;D08.811.348;D12.776.800.300;C04.588.894.797.520;C08.381.540;C08.785.520;D12.776.543;G04.599.750;G05.365.590;D12.776.624;G04.618;G16.645;G03.143.700;D08.811.913.696.620.695;G05.308.203.374.790;D12.776.828.300;D06.472.931;G03.295;A11.284.430.214.190.875.564;A11.284.835.626
28778907,,
28778278,Embryo Transfer;Fertilization in Vitro;Freezing,E02.875.800.500;E05.820.800.500;E02.875.800.750;E05.820.800.750;G01.645.500;G01.906.595.272.437;G02.734.466
28778228,Circadian Clocks;Circadian Rhythm;Genetic Markers;Genome-Wide Association Study;Humans;Sleep;Individuality;Sleep;Sleepiness,G07.180.562.094.500;G07.180.562.190;D23.101.387;G05.695.450;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;F02.830.855;G11.561.803;F01.752.488;F02.830.855;G11.561.803;C23.888.900
28777995,Adolescent;Adolescent Development;Brain;Humans;Risk-Taking;Dopamine,M01.060.057;F01.525.049;G07.345.374.500;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;F01.145.722;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342
28777931,"Adolescent;Base Sequence;Child;Child, Preschool;DNA, Mitochondrial;Exome;Humans;Infant;Leigh Disease;Mitochondria;Mitochondrial Diseases;Mitochondrial Proteins;Oxidative Phosphorylation;Proteomics;RNA Splicing;Ribosomal Proteins;Ribosome Subunits, Small, Eukaryotic;Sequence Analysis, DNA;Leigh Disease;Mitochondrial Diseases;Mitochondrial Ribosomes;Electron Transport",M01.060.057;G02.111.570.080;G05.360.080;L01.453.245.667.080;M01.060.406;M01.060.406.448;D13.444.308.283.225;G05.360.340.011;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.228.140.163.100.412;C16.320.565.189.412;C16.320.565.202.810.444;C18.452.132.100.412;C18.452.648.189.412;C18.452.648.202.810.444;C18.452.660.520;A11.284.430.214.190.875.564;A11.284.835.626;C18.452.660;D12.776.575;G02.111.665.550;G03.295.631;G03.796.550;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.760.700;G03.839.700;G05.308.700.700;D12.776.835;A11.284.430.214.190.875.811.870.750.750;E05.393.760.700;C10.228.140.163.100.412;C16.320.565.189.412;C16.320.565.202.810.444;C18.452.132.100.412;C18.452.648.189.412;C18.452.648.202.810.444;C18.452.660.520;C18.452.660;A11.284.430.214.190.875.564.755;A11.284.430.214.190.875.811.370;G02.111.248;G03.295.531.403;G03.493.350
28777929,"Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Genome, Human;Humans;Social Change;Clustered Regularly Interspaced Short Palindromic Repeats;Ethics;Eugenics;Gene Editing;Genetic Therapy;Gene Editing;Genome, Human",G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;I01.076.201.450.776;I01.880.853.400;N01.824.737;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;K01.752.566.479;N05.350;K01.400.307;E05.393.420.270;E02.095.301;E05.393.420.301;E05.393.420.270;G05.360.340.350
28777481,"Adult;Glycosylation;Homozygote;Humans;Infant, Newborn;Mutation, Missense;Nucleotide Transport Proteins;Osteochondrodysplasias;Prognosis",M01.060.116;G02.111.158.812;G02.607.299;G03.191.812;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;G05.365.590.650;D12.776.157.530.625.875;D12.776.543.585.625.875;C05.116.099.708;C16.320.728;E01.789
28777456,"Education, Graduate;Health Services Research;Professional Competence;Stakeholder Participation",I02.358.337;H01.770.644.145.360;N03.349.380;N05.425;I02.399.630;I01.738.805;I03.743
28777421,"Adult;Aged;Ambulatory Care;Attitude of Health Personnel;Catheterization, Peripheral;Equipment Design;Humans;Middle Aged;Patient Satisfaction;Prospective Studies;Radiography, Interventional;Time Factors;Vascular Access Devices",M01.060.116;M01.060.116.100;E02.760.106;N02.421.585.106;F01.100.050;N05.300.100;E02.148.224;E04.100.814.529.937;E04.502.382.937;E05.157.375;E05.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.370.350.700.725;E04.502.780;G01.910.857;E07.132.750
28777196,"Aged;Aged, 80 and over;Comorbidity;Hospital Mortality;Humans;Logistic Models;Medicare;Models, Statistical;Organ Dysfunction Scores;Retrospective Studies;Risk Adjustment;United States",M01.060.116.100;M01.060.116.100.080;N05.715.350.225;N06.850.490.687;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.308.980.438.475.456.500.625;N05.715.360.300.800.438.375.364.500.625;N06.850.520.308.980.438.475.364.500.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N04.452.871.715.800;N04.761.789.800;N05.715.360.750.625.700.690.800;Z01.107.567.875
28777140,"Animals;Carcinoma;Carcinoma, Papillary;Diagnosis, Differential;Humans;Neoplasm Invasiveness;Thyroid Cancer, Papillary;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",B01.050;C04.557.470.200;C04.557.470.200.360;C04.557.470.700.360;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C04.697.645;C23.550.727.645;C04.557.470.200.025.085.612;C04.588.322.894.400;C04.588.443.915.400;C19.344.894.400;C19.874.788.400;A06.300.900;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;E04.270.856
28776406,,
28775763,Anti-Infective Agents;Antimicrobial Stewardship;Cross-Sectional Studies;Global Health;Humans;Intraabdominal Infections;Postoperative Complications;Surveys and Questionnaires;Anti-Bacterial Agents;Antimicrobial Stewardship;Infection;General Surgery,D27.505.954.122;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;C01.539.463;C23.550.767;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;D27.505.954.122.085;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;C01.539;H02.403.810.300
28775051,"Estrogens;Familial Primary Pulmonary Hypertension;Humans;Hypertension, Pulmonary",D27.505.696.399.472.277;C08.381.423.300;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423
28774749,Cystic Fibrosis;Women's Health,C06.689.202;C08.381.187;C16.320.190;C16.614.213;N01.400.900
28772296,Humans;Intracranial Hypertension;Intracranial Pressure;Ultrasonography,B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.631;G11.561.170.505;E01.370.350.850
28772292,Endoscopy;Mouth;Robotic Surgical Procedures,E01.370.388.250;E04.502.250;A01.456.505.631;A03.556.500;A14.549;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500
28771805,"Child;Child, Preschool;Diagnosis, Differential;Humans;Inflammatory Bowel Diseases;Skin;Skin Diseases, Vascular;Vasculitis",M01.060.406;M01.060.406.448;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;A17.815;C17.800.862;C14.907.940
28771710,"Animals;Astrocytes;Brain;Coculture Techniques;Endothelial Cells;Excitatory Amino Acid Transporter 2;Glutamic Acid;Mice;Neurons;Rats, Sprague-Dawley;Receptors, Notch;Signal Transduction;Astrocytes;Blood-Brain Barrier;Endothelial Cells",B01.050;A08.637.200;A11.650.200;A08.186.211;E05.481.500.374;A11.436.275;D12.776.157.530.200.249.500.500.750;D12.776.157.530.450.625.147.750;D12.776.157.530.562.374.781.750;D12.776.157.530.937.250.500.750;D12.776.543.585.200.249.500.500.750;D12.776.543.585.450.625.147.750;D12.776.543.585.562.374.781.750;D12.776.543.585.937.250.500.750;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;B01.050.150.900.649.313.992.635.505.500;A08.675;A11.671;B01.050.150.900.649.313.992.635.505.700.750;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;A08.637.200;A11.650.200;A07.035;A08.186.211.035;A11.436.275
28771485,Access to Information;Botswana;Communication;Dominican Republic;Greece;Humans;Patient Acceptance of Health Care;Vaccination;Vaccines,I01.880.604.473.352.500.030;L01.143.024;L01.737.030;Z01.058.290.175.230;F01.145.209;L01.143;Z01.107.084.900.300;Z01.639.880.300;Z01.542.383;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;D20.215.894
28771246,"Canada;Cyclohexanones;Diet Therapy;Disease Management;Genetic Counseling;Genotype;Humans;Infant, Newborn;Liver Transplantation;Medication Adherence;Neonatal Screening;Nitrobenzoates;Phenotype;Pregnancy;Pregnancy Complications;Tyrosinemias;United States",Z01.107.567.176;D02.455.426.392.368.367.340;D02.522.400;E02.642.249;N04.590.607;H01.158.273.343.385.500.384;N02.421.308.400;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;D02.241.223.100.600;D02.455.426.559.389.127.650;G05.695;G08.686.784.769;C13.703;C10.228.140.163.100.875;C16.320.565.100.880;C16.320.565.189.875;C18.452.132.100.875;C18.452.648.100.880;C18.452.648.189.875;Z01.107.567.875
28771093,"Administration, Oral;Affect;Analysis of Variance;Dronabinol;Hallucinogens;Humans;Placebo Effect;Surveys and Questionnaires;Time Factors;Young Adult;Cannabis;Cannabis",E02.319.267.100;F01.470.047;E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;D02.455.849.090.810;D27.505.696.388;D27.505.954.427.700.372;B01.050.150.900.649.313.988.400.112.400.400;N05.715.350.350.625;N06.850.490.734.875;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;G01.910.857;M01.060.116.815;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.859.937.055.500
28770550,Heme Oxygenase-1;Humans;Inflammatory Bowel Diseases;Interleukin-10;STAT3 Transcription Factor,D08.811.682.690.708.410.500;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510;D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
28770313,Humans;Hyperparathyroidism;Middle Aged;Parathyroid Glands;Parathyroid Hormone;Recurrence;Reoperation;Retrospective Studies;Hyperparathyroidism,B01.050.150.900.649.313.988.400.112.400.400;C19.642.355;M01.060.116.630;A06.300.560;D06.472.699.590;D12.644.548.587;C23.550.291.937;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C19.642.355
28770306,"Echocardiography, Doppler;Fetus;Gestational Age;Heart Defects, Congenital;Heart Ventricles;Humans;Infant, Newborn;Pulmonary Atresia;Pulmonary Valve Stenosis;Ultrasonography, Prenatal;Ventricular Septum",E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;A16.378;G07.345.500.325.235.968;G08.686.320;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;C14.280.484.716;C14.280.955.750;E01.370.350.850.865;E01.370.378.630.865;A07.541.459.750
28770039,Adolescent;Autism Spectrum Disorder;Brain;Child;Connectome;Humans;Rest;Attention;Autism Spectrum Disorder;Child,M01.060.057;F03.625.164.113;A08.186.211;M01.060.406;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;B01.050.150.900.649.313.988.400.112.400.400;I03.450.769.647;F02.830.104.214;F03.625.164.113;M01.060.406
28770004,Molecular Epidemiology;Genetics;Lipids,E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;H01.158.273.343;D10
28768847,"Adolescent;Adult;Aged;Aged, 80 and over;Amino Acid Sequence;Charcot-Marie-Tooth Disease;Child;Connexins;Cross-Sectional Studies;Family;Genetic Association Studies;Genotyping Techniques;Humans;Middle Aged;Mutation;Neural Conduction;Phenotype;Sex Characteristics;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;G02.111.570.060;L01.453.245.667.060;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;M01.060.406;D12.776.543.585.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.829.263;I01.880.853.150;E05.393.385;E05.393.442;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;G07.265.753;G11.561.601;G05.695;G08.686.815;M01.060.116.815
28768282,Adolescent;Body Composition;Body Mass Index;Child;Cholesterol;Cross-Sectional Studies;Humans;Lipoproteins;Nutrition Surveys;Retrospective Studies;Turner Syndrome;Child;Cholesterol;Lipids;Turner Syndrome;Young Adult,M01.060.057;G02.111.130;G03.180;G07.100.049;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;D10.532;D12.776.521;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;M01.060.406;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;D10;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;M01.060.116.815
28768252,Amniotic Fluid;Gestational Age;Glial Fibrillary Acidic Protein;Humans;Meningomyelocele;Neural Tube Defects;Pregnancy;Registries;Retrospective Studies;Amniotic Fluid;Biomarkers;Glial Fibrillary Acidic Protein;Meningomyelocele;Spinal Dysraphism,A12.098;A16.378.149;G07.345.500.325.235.968;G08.686.320;D05.750.078.593.400;D12.776.220.475.400;B01.050.150.900.649.313.988.400.112.400.400;C10.500.680.610;C16.131.666.680.610;C10.500.680;C16.131.666.680;G08.686.784.769;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A12.098;A16.378.149;D23.101;D05.750.078.593.400;D12.776.220.475.400;C10.500.680.610;C16.131.666.680.610;C10.500.680.800;C16.131.666.680.800
28767621,Adult;Biomarkers;Cross-Sectional Studies;Humans;Intervertebral Disc Degeneration;Low Back Pain;Lumbar Vertebrae;Lumbosacral Region;Magnetic Resonance Imaging;Middle Aged;Phenotype,M01.060.116;D23.101;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;C05.116.900.153;C23.888.592.612.107.400;A02.835.232.834.519;A01.923.176.519;E01.370.350.825.500;M01.060.116.630;G05.695
28766913,"Adult;Breast Feeding;Connecticut;Feasibility Studies;Focus Groups;Food Assistance;Humans;Patient Acceptance of Health Care;Patient Education as Topic;Patient Satisfaction;Peer Influence;Pilot Projects;Postpartum Period;Pregnancy;Pregnancy Trimester, Second;Pregnancy Trimester, Third;Social Support;Telemedicine;Text Messaging;Workforce;Young Adult;Breast Feeding;Infant",M01.060.116;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;Z01.107.567.875.550.200;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;I01.880.787.839.500;N03.219.521.346.506.281;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;I02.233.332.500;N02.421.726.407.680;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;F01.829.316.483.750;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G08.686.702;G08.686.784.769;G08.686.707.490;G08.686.707.520;I01.880.853.500.600;H02.403.840;L01.178.847.652;N04.590.374.800;L01.178.847.698.300.500;L01.559.423.906.377.666;N04.452.525;M01.060.116.815;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;M01.060.703
28766759,"Adult;Complement System Proteins;Cytotoxicity Tests, Immunologic;Flow Cytometry;Follow-Up Studies;Graft Rejection;Graft Survival;Heart Transplantation;Histocompatibility Testing;Humans;Middle Aged;Prognosis;Retrospective Studies;Risk Factors;Heart Transplantation;Immunologic Techniques;Outcome Assessment (Health Care)",M01.060.116;D12.776.124.486.274;E01.370.225.812.160;E05.200.812.160;E05.478.594.160;E05.940.245;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G12.875.545.328;G12.875.545.340;E04.100.376.475;E04.928.220.390;E04.936.450.475;E01.370.225.812.385;E05.200.812.385;E05.478.594.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04.100.376.475;E04.928.220.390;E04.936.450.475;E05.478;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575
28766241,"Acquired Immunodeficiency Syndrome;Adolescent;Adult;African Americans;Aged;Cross-Sectional Studies;HIV Infections;Health Status Disparities;Homosexuality, Male;Humans;Middle Aged;Poverty;Residence Characteristics;Risk-Taking;Sex Work;Sexual Behavior;Socioeconomic Factors;Substance-Related Disorders;United States;Young Adult;HIV;Residence Characteristics",C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;M01.060.057;M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C02.782.815.616.400;C02.800.801.400;C20.673.480;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;F01.145.802.975.500.600;G08.686.867.500.600;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;I01.880.735.634;I01.880.853.996.535;N01.824.600;N01.224.791;N06.850.505.400.800;F01.145.722;F01.145.802.790;I01.880.735.679;F01.145.802;I01.880.853.996;N01.824;C25.775;F03.900;Z01.107.567.875;M01.060.116.815;B04.820.650.589.650.350;N01.224.791;N06.850.505.400.800
28766212,"Biomarkers, Tumor;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Intraductal, Noninfiltrating;Follow-Up Studies;Humans;Middle Aged;Neoplasm Invasiveness;Prognosis;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Risk Factors;Survival Rate",D23.101.140;C04.588.180;C17.800.090.500;C04.557.470.200.025.232.500;C04.557.470.615.132.500;C04.588.180.390;C17.800.090.500.390;C04.557.470.200.025.275;C04.557.470.200.240.187.250;C04.557.470.615.275;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04.697.645;C23.550.727.645;E01.789;D08.811.913.696.620.682.725.400.009.400;D12.776.543.750.630.009.400;D12.776.543.750.750.400.074.400;D12.776.624.664.700.642;D23.050.301.500.600.700;D23.050.705.552.600.550;D23.101.140.642;D12.776.826.750.350;D12.776.930.778.350;D12.776.826.750.765;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
28765526,Cadherins;Cone-Rod Dystrophies;Genetic Association Studies;High-Throughput Nucleotide Sequencing;Humans;Mutation;Nerve Tissue Proteins;Retinitis Pigmentosa,D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;C11.270.152;C11.768.585.658.250;C16.320.290.152;E05.393.385;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.631;C11.270.684;C11.768.585.658.500;C16.320.290.684
28765381,"Adolescent;Child;Child, Preschool;Emergency Service, Hospital;Humans;Infant;Longitudinal Studies;Medicaid;Multiple Chronic Conditions;Retrospective Studies;United States",M01.060.057;M01.060.406;M01.060.406.448;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;N03.219.521.346.506.564.655;N03.706.615.693;C23.550.291.500.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28765325,"Adult;Aged;BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;Cell-Free Nucleic Acids;Drug Resistance, Neoplasm;Germ-Line Mutation;Humans;Middle Aged;Mutation;Ovarian Neoplasms;Platinum;Poly(ADP-ribose) Polymerase Inhibitors",M01.060.116;M01.060.116.100;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;D12.776.313.249;D12.776.624.776.101;D12.776.660.105;C04.588.180;C17.800.090.500;D13.444.154;G07.690.773.984.395;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D01.268.556.690;D01.268.956.734;D01.552.544.690;D27.505.519.389.739;D27.505.954.248.692
28765161,"Animals;Cellular Reprogramming;Epigenesis, Genetic;Humans;Neoplasms;Regeneration;Stem Cells;Teratocarcinoma;Tumor Suppressor Protein p53;Epigenomics;Stem Cells",B01.050;G04.152.262;G05.135;G05.308.203;B01.050.150.900.649.313.988.400.112.400.400;C04;G16.762;A11.872;C04.557.465.900;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.872
28764860,"CRISPR-Cas Systems;Genome, Human;Humans",G05.308.203.374.394;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400
28763791,,
28762038,"Cell- and Tissue-Based Therapy;Genetic Therapy;Humans;Immunotherapy, Adoptive;Leukemia, B-Cell;Lymphoma;T-Lymphocytes;Transfection;Genetic Therapy;Immunotherapy;Lymphoma",E02.095.147;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.557.337.428.080;C15.604.515.560.080;C20.683.515.528.080;C04.557.386;C15.604.515.569;C20.683.515.761;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E05.393.350.810;G05.728.860;E02.095.301;E05.393.420.301;E02.095.465.425;C04.557.386;C15.604.515.569;C20.683.515.761
28761081,"Adolescent;Adult;Aged;Child;Cohort Studies;Cooperative Behavior;DNA Copy Number Variations;Data Mining;DiGeorge Syndrome;Genetic Predisposition to Disease;Genome;Humans;Middle Aged;Models, Genetic;Models, Neurological;Phenotype;Schizophrenia;Scholarly Communication;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.813.115;G05.365.795.297.500;L01.313.500.750.280.199;L01.470.625;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C23.550.291.687.500;G05.380.355;G05.360.340;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.599.395.397;E05.599.395.642;G05.695;F03.700.750;L01.143.865;L01.143.910.500;M01.060.116.815
28760895,"Anti-Bacterial Agents;Bacteremia;Genome, Bacterial;Humans;Latin America;Methicillin-Resistant Staphylococcus aureus;Microbial Sensitivity Tests;Molecular Epidemiology;Multilocus Sequence Typing;Prospective Studies;Staphylococcal Infections;Latin America;Staphylococcus aureus;Bacteremia",D27.505.954.122.085;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;G05.360.340.358.207;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.424;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;E01.370.225.875.150.125.457.500;E05.200.875.150.125.457.500;E05.393.542.500;E05.393.760.700.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C01.252.410.868;Z01.107.424;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;C01.252.100;C01.539.757.100;C23.550.470.790.500.100
28760854,"Adenocarcinoma;Animals;Cdh1 Proteins;Humans;Liver Neoplasms;Lung Neoplasms;Lymphatic Metastasis;Mice;Mice, Inbred C57BL;Mice, Knockout;Proto-Oncogene Proteins p21(ras);Stomach Neoplasms;Survival Rate;Tumor Suppressor Protein p53",C04.557.470.200.025;B01.050;D08.811.464.938.750.092.999;D12.776.167.024.999;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;C04.588.894.797.520;C08.381.540;C08.785.520;C04.697.650.560;C23.550.727.650.560;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.277.040.330.300.400.500.600;D12.644.360.525.500.600;D12.776.157.325.515.500.600;D12.776.476.525.500.600;D12.776.624.664.700.200;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845
28760719,"Aged;Aged, 80 and over;Atherosclerosis;Chicago;Cross-Sectional Studies;Environmental Exposure;Environmental Pollutants;Humans;Middle Aged;Minnesota;North Carolina;Particle Size;Particulate Matter;Risk Factors;Ventricular Dysfunction, Right",M01.060.116.100;M01.060.116.100.080;C14.907.137.126.307;Z01.107.567.875.350.350.200;Z01.107.567.875.510.350.200;Z01.433.305;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N06.850.460.350;D27.888.284;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.350.510;Z01.107.567.875.510.510;Z01.107.567.875.075.475;Z01.107.567.875.750.530;G02.712;D20.633;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.945.910
28760470,Adult;Cohort Studies;Device Removal;Follow-Up Studies;Heart Failure;Heart-Assist Devices;Hospital Mortality;Humans;Kaplan-Meier Estimate;Middle Aged;Operative Time;Prosthesis Design;Prosthesis Failure;Quality Improvement;Reoperation;Retrospective Studies;Risk Assessment;Sternotomy;Survival Rate;Thoracic Wall;Treatment Outcome,M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.199;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280.434;E04.050.430;E07.695.300.300;E07.858.082.374.300;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E04.614.374.500;N02.421.585.753.374.500;E05.320.550;E07.695.680;C23.550.767.865;E05.325.771;J01.293.754;N04.761.744;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E04.928.710;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;A01.923.761.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28760206,"Death, Sudden, Cardiac;Health Resources;Humans;Incidence;Population Surveillance;Qualitative Research;United States;Young Adult",C14.280.383.220;C23.550.260.322.250;N03.349.340;N05.300.420;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;H01.770.644.241.850;Z01.107.567.875;M01.060.116.815
28759889,"Animals;CTLA-4 Antigen;Cell Cycle Checkpoints;Cell Line, Tumor;DNA Breaks, Double-Stranded;DNA Damage;Disease Models, Animal;Humans;Inflammation;Interferons;Melanoma, Experimental;Membrane Proteins;Mice;Mice, Inbred C57BL;Micronuclei, Chromosome-Defective;Mitosis;Nucleotidyltransferases;Receptors, Pattern Recognition;Signal Transduction",B01.050;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;G04.144.109;A11.251.210.190;A11.251.860.180;G05.200.210.220;G05.200;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;C04.557.465.625.650.510.525;C04.557.580.625.650.510.525;C04.557.665.510.525;C04.619.600;E05.598.500.496.937;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.284.430.106.570;A11.284.430.214.190.875.117.570;C23.550.210.570;G05.365.590.175.570;G04.144.220.220.781;G05.113.220.781;D08.811.913.696.445;D12.776.543.750.705.910;G02.111.820;G04.835
28759667,"Adolescent;Child;Child, Preschool;Cohort Studies;Epilepsy;Follow-Up Studies;Genetic Predisposition to Disease;Genetic Testing;Humans;Infant;Prospective Studies;United States",M01.060.057;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C10.228.140.490;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;Z01.107.567.875
28759651,"Adolescent;Adult;Cohort Studies;HIV Infections;HIV-1;High-Throughput Nucleotide Sequencing;Humans;Immune Evasion;Middle Aged;T-Lymphocytes, Cytotoxic;Young Adult",M01.060.057;M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G06.462.400;G12.413;G16.527.200.700;M01.060.116.630;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200;M01.060.116.815
28759490,,
28759413,"Bacterial Infections;Cross-Sectional Studies;Fever;Humans;Infant;Infant, Newborn;Prospective Studies;Risk Assessment;Severity of Illness Index",C01.252;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.888.119.344;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28758365,"Adolescent;Anaphylaxis;Anemia, Iron-Deficiency;Child;Child, Preschool;Humans;Infant;Inpatients;Iron-Dextran Complex;Molecular Weight;Parenteral Nutrition;Pediatrics;Young Adult;Anaphylaxis;Iron;Parenteral Nutrition;Safety",M01.060.057;C20.543.480.099;C15.378.071.196.300;C18.452.565.100;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.643.470;D02.691.550.100.500;D09.698.365.272.400;G02.494;E02.421.505;E02.642.500.505;H02.403.670;M01.060.116.815;C20.543.480.099;D01.268.556.412;D01.268.956.287;D01.552.544.412;E02.421.505;E02.642.500.505;N06.850.135.060.075
28757884,Neoplasms;Genomics;Precision Medicine,C04;H01.158.273.180.350;H01.158.273.343.350;E02.574;H02.403.200.700
28757316,"Adenocarcinoma;Aged;Barrett Esophagus;Biopsy;Diagnosis, Computer-Assisted;Endoscopy, Gastrointestinal;Esophageal Neoplasms;Humans;Middle Aged;Neural Networks (Computer);Prospective Studies;Watchful Waiting",C04.557.470.200.025;M01.060.116.100;C04.834.154;C06.405.117.102;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E01.158;L01.313.500.750.100.158;E01.370.372.250.250;E01.370.388.250.250.250;E04.210.240.250;E04.502.250.250.250;C04.588.274.476.205;C04.588.443.353;C06.301.371.205;C06.405.117.430;C06.405.249.205;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G17.485;L01.224.050.375.605;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N04.761.559.590.900
28757308,"Appointments and Schedules;Humans;Insurance, Health;Internet;Medicaid;Medicare;Patient Acceptance of Health Care;Patient Protection and Affordable Care Act;Primary Health Care;United States;Insurance, Health;Primary Health Care",N04.452.095;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;L01.224.230.110.500;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;N03.219.521.576.343.918;N03.706.615.806;N04.590.233.727;Z01.107.567.875;N03.219.521.576.343;N04.590.233.727
28757265,"Adult;Age Factors;Allergens;Biopsy;Child;Cytokines;Ehlers-Danlos Syndrome;Eosinophilic Esophagitis;Eosinophils;Epigenesis, Genetic;Esophageal Stenosis;Esophagus;Fibrosis;Food Hypersensitivity;Gastroesophageal Reflux;Gastrointestinal Microbiome;Genetic Predisposition to Disease;Glucocorticoids;Humans;Loeys-Dietz Syndrome;Mast Cells;Prevalence;Proton Pump Inhibitors;Sex Factors;Transcriptome;Hypersensitivity;Desmosomes;Genetics;Inflammation",M01.060.116;N05.715.350.075;N06.850.490.250;D23.050.063;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;D12.644.276.374;D12.776.467.374;D23.529.374;C14.907.454.240;C15.378.463.515.240;C16.131.831.428;C16.320.850.260;C17.300.200.310;C17.800.804.428;C17.800.827.260;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;G05.308.203;C06.405.117.544;A03.556.875.500;C23.550.355;C20.543.480.370;C06.405.117.119.500.484;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;C23.550.291.687.500;G05.380.355;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C05.660.207.532;C14.907.055.050.362;C14.907.055.239.587;C14.907.109.139.587;C16.131.077.537;C16.320.510;A11.329.427;A15.382.652;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;D27.505.519.389.848;N05.715.350.675;N06.850.490.875;G02.111.873.750;G05.297.700.750;G05.360.920;C20.543;A11.284.149.165.420.297;H01.158.273.343;C23.550.470
28757204,"Cholestanetriol 26-Monooxygenase;Cytochrome P450 Family 2;Gene Frequency;Genetic Predisposition to Disease;Genome, Human;Genome-Wide Association Study;Humans;Multiple Sclerosis;Polymorphism, Single Nucleotide;Risk Factors;Vitamin D;Vitamin D Deficiency;Multiple Sclerosis;Vitamin D",D08.244.453.499.750;D08.244.453.915.149;D08.811.682.690.708.170.493.750;D08.811.682.690.708.170.915.150;D12.776.422.220.453.499.750;D12.776.422.220.453.915.150;D08.244.453.491;D08.811.682.690.708.170.450;D12.776.422.220.453.491;G05.330;C23.550.291.687.500;G05.380.355;G05.360.340.350;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D04.210.500.812.768;C18.654.521.500.133.770;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D04.210.500.812.768
28757096,"Alzheimer Disease;Animals;Ecotoxicology;Energy Metabolism;Environmental Exposure;Environmental Pollutants;Humans;Mitochondria;Mitochondrial Diseases;Oxidative Stress;Parkinson Disease, Secondary;Risk Assessment;Neurodegenerative Diseases;Oxidative Phosphorylation",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;B01.050;H01.158.273.248.500;H01.158.891.211;H01.277.249.500;H02.884.211;G03.295;N06.850.460.350;D27.888.284;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;C18.452.660;G03.673;G07.775.750;C10.228.140.079.862.800;C10.228.662.600.700;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C10.574;G02.111.665.550;G03.295.631;G03.796.550
28757070,Adolescent;Adult;Attention;Brain;Brain Mapping;Dopamine Plasma Membrane Transport Proteins;Genetic Markers;Genotype;Health Promotion;Humans;Individuality;Magnetic Resonance Imaging;Middle Aged;Smoking;Smoking Cessation;Video Recording;Young Adult;Genetics;Health Communication;Smoking;Magnetic Resonance Imaging,M01.060.057;M01.060.116;F02.830.104.214;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;D12.776.157.530.450.625.124;D12.776.157.530.562.374.500.500;D12.776.157.530.937.500;D12.776.543.585.450.625.124;D12.776.543.585.562.374.500.500;D12.776.543.585.937.500;D23.101.387;G05.695.450;G05.380;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;F01.752.488;E01.370.350.825.500;M01.060.116.630;F01.145.805;F01.145.488.732;L01.280.960;M01.060.116.815;H01.158.273.343;L01.143.350;N02.208;F01.145.805;E01.370.350.825.500
28756949,"Animals;Cell Line;Centromere;Centromere Protein A;Meiosis;Mice;Microsatellite Repeats;Centromere;Chromosomes;Epigenomics;Histones;Meiosis;Nucleosomes;Oocytes;DNA, Satellite",B01.050;A11.251.210;A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500;A11.284.430.106.279.345.190.160.165;G05.360.160.165;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G04.144.220.220.687;G05.113.220.687;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;A05.360.490.690.680;A11.497.497.600;D13.444.308.480;G02.111.570.080.708.800.150;G05.360.080.708.800.150;G05.360.340.024.220.150;G05.360.340.024.850.150
28756567,Accidental Falls;Adolescent;Athletic Injuries;Growth Plate;Humans;Magnetic Resonance Imaging;Retrospective Studies;Salter-Harris Fractures;Shoulder Joint;Pediatrics;Shoulder,N06.850.135.122;M01.060.057;C26.115;A02.835.232.251.352;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.550.518.336.875;C26.289.336.875;C26.404.026.500;A02.835.583.748;H02.403.670;A01.378.800.750
28756411,"Case-Control Studies;Chromosome Deletion;Cohort Studies;DNA Copy Number Variations;Epilepsies, Partial;Epilepsy, Generalized;Epilepsy, Rolandic;Gene Expression;Genetic Association Studies;Humans;Epilepsy",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.365.795.297.500;C10.228.140.490.360;C10.228.140.490.375;C10.228.140.490.360.280;C10.228.140.490.493.250;G05.297;E05.393.385;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.490
28755550,"Brain;Brain Mapping;Cognition Disorders;Cross-Over Studies;Double-Blind Method;Executive Function;Humans;Life Change Events;Magnetic Resonance Imaging;Menopause;Middle Aged;Nerve Net;Placebo Effect;Serotonin;Tryptophan;Adverse Childhood Experiences;Menopause;Memory, Short-Term",A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F03.615.250;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;E01.370.350.825.500;G08.686.157.500;G08.686.841.249.500;M01.060.116.630;A08.511;N05.715.350.350.625;N06.850.490.734.875;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650;D12.125.072.050.850;D12.125.142.875;I01.198.240.856.175;I01.880.735.035;I01.880.735.900.175;I01.880.853.050;G08.686.157.500;G08.686.841.249.500;F02.463.425.540.407
28755516,"Adaptor Proteins, Signal Transducing;Diabetic Foot;Genetic Variation;Humans;Longitudinal Studies;Middle Aged;Stem Cells;Wound Healing",D12.644.360.024;D12.776.157.057;D12.776.476.024;C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250;G05.365;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;A11.872;G16.762.891
28755207,"Dreams;Stress Disorders, Post-Traumatic;Prazosin;Sex Offenses;Wounds and Injuries",F02.463.188.634.309;F02.830.855.268;F03.950.750.500;D03.633.100.786.750;I01.198.240.748;C26
28755158,"Animals;Aorta;Cattle;Cell- and Tissue-Based Therapy;Cells, Cultured;Coculture Techniques;Endothelial Cells;Magnetite Nanoparticles;Myocytes, Smooth Muscle;Nitric Oxide;Nitric Oxide Synthase;Oleic Acid;Rats;Zinc;Endothelial Cells;Nitric Oxide;Myocytes, Smooth Muscle",B01.050;A07.015.114.056;B01.050.150.900.649.313.500.380.271;E02.095.147;A11.251;E05.481.500.374;A11.436.275;D01.490.100.375.500;D01.490.200.350.500;D01.578.285.500;J01.637.507.500;J01.637.512.600.500.287;A11.620.520;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D08.811.682.664.500.772;D10.251.355.325.600.525;B01.050.150.900.649.313.992.635.505.700;D01.268.556.940;D01.268.956.906;D01.552.544.940;A11.436.275;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;A11.620.520
28755066,"Adolescent;Adult;Age of Onset;Aged;Aged, 80 and over;Arthritis;Autoimmunity;Bronchitis;Cell Transformation, Neoplastic;Child;Child, Preschool;Common Variable Immunodeficiency;Databases, Factual;Depression;Developmental Disabilities;Failure to Thrive;Humans;Longitudinal Studies;Middle Aged;Otitis Media;Phenotype;Retrospective Studies;United States;Young Adult;Common Variable Immunodeficiency;Autoimmunity;Fatigue;Infection;Inflammation",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100;M01.060.116.100.080;C05.550.114;G12.450.192;C08.127.446;C08.381.495.146;C08.730.099;C04.697.098.500;C23.550.727.098.500;M01.060.406;M01.060.406.448;C20.673.330;L01.313.500.750.300.188.400;L01.470.750.750;F01.145.126.350;F03.625.421;C23.888.338;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C09.218.705.663;G05.695;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;M01.060.116.815;C20.673.330;G12.450.192;C23.888.369;C01.539;C23.550.470
28755025,"Humans;Immunologic Deficiency Syndromes;Inflammatory Bowel Diseases;Colitis, Ulcerative",B01.050.150.900.649.313.988.400.112.400.400;C20.673;C06.405.205.731;C06.405.469.432;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28754659,"Animals;Ataxia Telangiectasia Mutated Proteins;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Loss of Function Mutation;Movement;Neurons;Sleep;Stress, Physiological;Tumor Suppressor Protein p53;Ultraviolet Rays;Behavior;Sleep;Ultraviolet Rays",B01.050;D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;G05.365.590.538;G07.568;G11.427.410;A08.675;A11.671;F02.830.855;G11.561.803;G07.775;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600;F01.145;F02.830.855;G11.561.803;G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
28754001,"Models, Animal;Genetics, Behavioral;Machine Learning",E05.598;F04.096.276;H01.158.273.343.290;G17.035.250.500;L01.224.050.375.530
28753733,Drug Interactions;Drug Prescriptions;Humans;Publications;Translational Medical Research,G07.690.773.968;E02.319.307;N02.421.668.778.500;B01.050.150.900.649.313.988.400.112.400.400;L01.178.682;H01.770.644.145.675
28753039,"Aged;Aged, 80 and over;Air Pollutants, Occupational;Cohort Studies;Ethnic Groups;Humans;Logistic Models;Lung Diseases, Interstitial;Middle Aged;Occupational Diseases;Occupational Exposure;Pulmonary Disease, Chronic Obstructive;Risk Factors;United States;Epidemiology;Lung Diseases, Interstitial;Occupational Exposure",M01.060.116.100;M01.060.116.100.080;D27.888.284.101.268;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.754;N01.224.317;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C08.381.483;M01.060.116.630;C24;N06.850.460.350.600;C08.381.495.389;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;H02.403.720.500;C08.381.483;N06.850.460.350.600
28753038,Adult;Cross-Sectional Studies;Health Services Research;Humans;Internal Medicine;Internship and Residency;Middle Aged;Quality of Health Care;Surveys and Questionnaires;United States;Delivery of Health Care;Health Care Costs;Internship and Residency,M01.060.116;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;M01.060.116.630;N04.761;N05.715;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;N04.590.374;N05.300;N03.219.151.400;N05.300.375;I02.358.337.350.500;I02.358.399.350.750
28752837,"Australia;Canada;Follow-Up Studies;Gestational Age;Humans;Incidence;Infant, Newborn;Infant, Premature;New Zealand;Ophthalmoscopy;Oxygen;Oxygen Consumption;Oxygen Inhalation Therapy;Prospective Studies;Reproducibility of Results;Retinopathy of Prematurity;United Kingdom;United States",Z01.639.100;Z01.678.100.373;Z01.107.567.176;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703.520;M01.060.703.520.520;Z01.639.760.747;Z01.678.100.747;E01.370.380.560;D01.268.185.550;D01.362.670;G03.680;E02.880.690;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C11.768.836;C16.614.521.731;Z01.542.363;Z01.107.567.875
28752206,"Adolescent;Bone Neoplasms;Child;Child, Preschool;Humans;Orthopedic Procedures;Pelvis;Postoperative Complications;Retrospective Studies;Sarcoma;Survival Rate;Treatment Outcome;Hemipelvectomy",M01.060.057;C04.588.149;C05.116.231;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;A01.923.600;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.450.795;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E04.555.080.380
28751666,"Adenosine Triphosphate;Air;Animals;Calcium Channels;Cilia;Connexins;Epithelial Cells;Mice, Inbred C57BL;Mice, Knockout;Nerve Tissue Proteins;Nose",D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;G16.500.275.063.150;N06.230.300.100.150;B01.050;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;A11.284.180.165;D12.776.543.585.250;A11.436;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.631;A01.456.505.733;A04.531;A09.531
28751576,Biomarkers;Cohort Studies;Disease Progression;Humans;Renal Insufficiency;Kidney;Risk Factors,D23.101;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780;C13.351.968.419.780;A05.810.453;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28751571,"Animals;Base Composition;Biomarkers;CRISPR-Cas Systems;Cell Line, Tumor;Cholesterol;Codon, Nonsense;Down-Regulation;Gene Editing;Gene Expression Regulation, Enzymologic;Genetic Therapy;Genotype;HEK293 Cells;Humans;Induced Pluripotent Stem Cells;Liver;Mice, Inbred C57BL;Phenotype;Proprotein Convertase 9;Time Factors;Transfection;Genetic Therapy;Molecular Biology;Nucleotides",B01.050;G02.111.080;D23.101;G05.308.203.374.394;A11.251.210.190;A11.251.860.180;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;D13.444.735.544.355.250.235;G05.360.335.355.250.235;G05.365.590.195;G02.111.240;G05.308.200;G07.690.773.937;E05.393.420.270;G05.308.320;E02.095.301;E05.393.420.301;G05.380;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A03.620;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G05.695;D08.811.277.656.300.760.718;D08.811.277.656.837.688;D08.811.277.656.959.350.718;G01.910.857;E05.393.350.810;G05.728.860;E02.095.301;E05.393.420.301;H01.158.201.636;H01.158.273.343.595;H01.181.122.650;D09.408.620;D13.695
28751525,"Animals;Fibrosis;Humans;Kidney;Mice;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;Receptor, Notch1;Receptors, Notch;Transcription Factors;Mitochondria",B01.050;C23.550.355;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;B01.050.150.900.649.313.992.635.505.500;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650;D12.776.543.750.725.500;D12.776.930.770.500;D12.776.543.750.725;D12.776.930.770;D12.776.930;A11.284.430.214.190.875.564;A11.284.835.626
28751444,"Adolescent;Age Factors;Antineoplastic Agents, Immunological;Central Nervous System Neoplasms;Child;Child, Preschool;Humans;Magnetic Resonance Imaging;Neoplasms;Recombinant Fusion Proteins;Recurrence;Retreatment;Treatment Outcome;Young Adult",M01.060.057;N05.715.350.075;N06.850.490.250;D27.505.954.248.384;C04.588.614.250;C10.551.240;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04;D12.776.828.300;C23.550.291.937;E02.887;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28751258,"Animals;Humans;Neurodegenerative Diseases;Protein Aggregation, Pathological;Protein Conformation;alpha-Synuclein;Multiple System Atrophy;Parkinson Disease;Protein Aggregates",B01.050;B01.050.150.900.649.313.988.400.112.400.400;C10.574;C23.550.770;G02.111.675;G02.111.570.820.709;D12.776.631.860.500;D12.776.637.500;C10.177.575.550;C10.228.140.079.612;C10.228.662.550;C10.574.625;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D05.875
28751125,Adolescent;Caregivers;Child;Cross-Sectional Studies;Down Syndrome;Humans;Psychometrics;Quality of Life;Surveys and Questionnaires;Young Adult;Down Syndrome;Obesity;Quality of Life;Adolescent,M01.060.057;M01.085;M01.526.485.200;N02.360.200;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260;B01.050.150.900.649.313.988.400.112.400.400;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;M01.060.057
28750948,"Animals;Caenorhabditis elegans;Cell Respiration;Cells, Cultured;Child, Preschool;Congenital Disorders of Glycosylation;Electron Transport;Fibroblasts;Gene Knockout Techniques;Genetic Complementation Test;Humans;Membrane Potential, Mitochondrial;Mice, Knockout;Mitochondria;Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase;Fibroblasts;Glycosylation;Mitochondria;Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase",B01.050;B01.050.500.500.294.400.875.660.250.250;G03.197;G04.270;A11.251;M01.060.406.448;C16.320.565.202.125;C18.452.648.202.125;G02.111.248;G03.295.531.403;G03.493.350;A11.329.228;E05.393.335.750;E05.393.281.526;B01.050.150.900.649.313.988.400.112.400.400;G03.295.770.500;G04.580.550;G07.265.675.550;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.284.430.214.190.875.564;A11.284.835.626;D08.811.277.087.725;A11.329.228;G02.111.158.812;G02.607.299;G03.191.812;A11.284.430.214.190.875.564;A11.284.835.626;D08.811.277.087.725
28750581,"Adult;Autism Spectrum Disorder;Autistic Disorder;Chromosome Deletion;Chromosome Disorders;Chromosomes, Human, Pair 16;DNA Copy Number Variations;DiGeorge Syndrome;Humans;Intellectual Disability;Middle Aged;Schizophrenia;22q11 Deletion Syndrome;DiGeorge Syndrome;Psychotic Disorders;Schizophrenia;DiGeorge Syndrome",M01.060.116;F03.625.164.113;F03.625.164.113.500;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;C16.131.260;C16.320.180;A11.284.187.520.300.415.420;G05.360.162.520.300.415.420;G05.365.795.297.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;M01.060.116.630;F03.700.750;C05.660.207.103;C14.240.400.021;C14.280.400.044;C15.604.451.249;C16.131.077.019;C16.131.240.400.021;C16.131.260.019;C16.131.482.249;C16.131.621.207.103;C16.320.180.019;C19.642.482.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F03.700.675;F03.700.750;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
28749477,"Alleles;Cadherins;Chromosome Mapping;DNA Copy Number Variations;Databases, Genetic;Eye Proteins;Genetic Predisposition to Disease;Genome, Human;Genome-Wide Association Study;Genomics;Humans;Open Reading Frames;RNA, Untranslated;Regulatory Sequences, Nucleic Acid;Retinal Diseases;Sequence Analysis, DNA;Sequence Deletion",G05.360.340.024.340.030;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;E05.393.183;G05.365.795.297.500;L01.313.500.750.300.188.400.325;L01.470.750.750.325;D12.776.306;C23.550.291.687.500;G05.380.355;G05.360.340.350;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;G05.360.335.760.640;G05.360.340.024.340.137.650;D13.444.735.790;G02.111.570.080.689;G05.360.080.689;C11.768;E05.393.760.700;G05.365.590.762;G05.558.800
28749475,Disease Management;Humans;Mitochondrial Diseases;Standard of Care,N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C18.452.660;N04.761.789.900;N05.715.840
28749311,Adult;Aged;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Fingolimod Hydrochloride;Follow-Up Studies;Humans;Immunosuppressive Agents;Lymphocyte Count;Lymphopenia;Middle Aged;Multiple Sclerosis;Multiple Sclerosis;T-Lymphocytes;Fingolimod Hydrochloride;Lymphopenia,M01.060.116;M01.060.116.100;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;E01.370.225.500.195.107.595.500;E01.370.225.625.107.595.500;E05.200.500.195.107.595.500;E05.200.625.107.595.500;E05.242.195.107.595.500;G04.140.107.595.500;G09.188.105.595.500;C15.378.553.546.605;C20.673.627;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;C15.378.553.546.605;C20.673.627
28748812,Early Detection of Cancer;Humans;Lung Neoplasms;Mass Screening,E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
28748630,"Antibodies, Monoclonal;Child;Child, Preschool;Humans;Magnetic Resonance Imaging;Myelitis, Transverse;Neuroblastoma;Neuroblastoma;Myelitis, Transverse",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04.588.614.550.550;C04.730.856.543;C10.114.375.600;C10.228.228.618.250;C10.228.854.525.553;C10.314.350.600;C10.574.781.625;C20.111.258.250.550;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C04.588.614.550.550;C04.730.856.543;C10.114.375.600;C10.228.228.618.250;C10.228.854.525.553;C10.314.350.600;C10.574.781.625;C20.111.258.250.550
28748621,"Adolescent;Allografts;Bone Marrow Transplantation;Calcineurin Inhibitors;Child;Child, Preschool;Graft vs Host Disease;Histocompatibility Testing;Humans;Infant;Methotrexate;Neoplasms;Retrospective Studies;Siblings;Tissue Donors;Graft vs Host Disease;Tacrolimus",M01.060.057;A01.941.500;E02.095.147.725.040;E04.936.580.040;D27.505.519.389.174;M01.060.406;M01.060.406.448;C20.452;E01.370.225.812.385;E05.200.812.385;E05.478.594.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D03.633.100.733.631.192.500;C04;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;M01.898;C20.452;D02.540.505.810
28748602,"Adolescent;Antineoplastic Combined Chemotherapy Protocols;Camptothecin;Child;Child, Preschool;Dacarbazine;Disease-Free Survival;Follow-Up Studies;Humans;Irinotecan;Neoplasm Recurrence, Local;Rhabdomyoma;Survival Rate;Temozolomide;Vinculin;Drug Therapy;Irinotecan;Recurrence;Rhabdomyosarcoma;Temozolomide",M01.060.057;E02.183.750.500;E02.319.077.500;E02.319.310.037;D03.132.151;M01.060.406;M01.060.406.448;D02.925.200;D03.383.129.308.240;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;D03.132.151.425;C04.697.655;C23.550.727.655;C04.557.450.590.540.700;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D02.925.200.500;D03.383.129.308.240.500;D12.776.220.990;E02.319;D03.132.151.425;C23.550.291.937;C04.557.450.590.550.660;C04.557.450.795.550.660;D02.925.200.500;D03.383.129.308.240.500
28748451,Animals;Citric Acid Cycle;Humans;Molecular Targeted Therapy;Neoplasms;Oncogenes;Tumor Suppressor Proteins;Glycolysis,B01.050;G02.111.165;G03.295.342;G03.493.170;B01.050.150.900.649.313.988.400.112.400.400;E02.319.574;C04;G05.360.340.024.340.375.500;D12.776.624.776;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360
28748224,Neonatal Screening,E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580
28748042,"Models, Animal;Complement System Proteins;Periodontitis",E05.598;D12.776.124.486.274;C07.465.714.533
28747451,,
28747429,"Animals;Circadian Clocks;Feeding Behavior;Gene Expression Regulation;Gene Knockout Techniques;Lipid Metabolism;Lipogenesis;Liver;Membrane Proteins;Mice;Mice, Inbred C57BL;Nuclear Receptor Subfamily 1, Group F, Member 1;Nuclear Receptor Subfamily 1, Group F, Member 3;Sterol Regulatory Element Binding Protein 2;Transcriptional Activation;Liver;Metabolism",B01.050;G07.180.562.094.500;F01.145.113.547;F01.145.407;G07.203.650.353;G05.308;E05.393.335.750;G03.458;G02.111.528;G03.458.249;A03.620;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.260.643.100;D12.776.476.156.437;D12.776.826.209.100;D12.776.260.643.182;D12.776.826.209.182;D12.776.260.103.500.750.750;D12.776.260.108.092.750.750;D12.776.930.125.500.750.750;D12.776.930.127.092.750.750;G05.308.800;A03.620;G03
28747279,"Adult;Aged;Aged, 80 and over;Disease Progression;Hand;Humans;Middle Aged;Movement;Parkinson Disease;Physical Examination;Psychomotor Performance;Severity of Illness Index;Parkinson Disease",M01.060.116;M01.060.116.100;M01.060.116.100.080;C23.550.291.656;A01.378.800.667;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G07.568;G11.427.410;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E01.370.600;F02.808;G11.427.700;G11.561.660;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28747100,Bevacizumab;Drug Carriers;Microspheres;Polymers;Polyvinyl Alcohol;Microspheres,D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;D26.255.260;E02.319.300.380;E07.565;D05.750;D25.720;J01.637.051.720;D02.033.750;D02.455.326.271.884.533.532;D05.750.716.721.616;D25.720.716.721.616;J01.637.051.720.716.721.616;E07.565
28746152,"Adenocarcinoma;Adult;Aged;Contrast Media;Fluorodeoxyglucose F18;Humans;Intraoperative Care;Lung Neoplasms;Middle Aged;Molecular Imaging;Pilot Projects;Pneumonectomy;Positron-Emission Tomography;Preoperative Care;Radiopharmaceuticals;Sensitivity and Specificity;Solitary Pulmonary Nodule;Spectroscopy, Near-Infrared",C04.557.470.200.025;M01.060.116;M01.060.116.100;D27.505.259.500;D27.720.259;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.400;E04.604.249;N02.421.585.722.400;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;E01.370.350.557;E05.601.555;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E04.620;E04.928.600.600;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E02.760.795;E04.604.750;N02.421.585.795;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C08.381.884;E01.370.350.750;E05.196.867.851
28746082,"Child, Preschool;Coronary Aneurysm;Extracorporeal Membrane Oxygenation;Heart Arrest;Heart Failure;Heart Transplantation;Heart-Assist Devices;Humans;Mucocutaneous Lymph Node Syndrome;Myocardial Infarction;Retrospective Studies;Treatment Outcome",M01.060.406.448;C14.280.647.250.250;C14.907.055.395;C14.907.585.250.250;E02.880.301;E04.292.451;C14.280.383;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;C14.907.940.560;C15.604.560;C17.800.862.560;C14.280.647.500;C14.907.585.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28746071,"Aged;Delivery of Health Care;Humans;Models, Educational;Patient Care Team;Problem-Based Learning;Pulmonary Disease, Chronic Obstructive",M01.060.116.100;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;E05.599.545;I02.903.302;N04.590.715;F02.463.425.720;I02.158.660;I02.903.565;C08.381.495.389
28744889,"Adolescent;Adult;Botswana;Caregivers;Cerebral Palsy;Child;Child, Preschool;Consumer Health Information;Cost of Illness;Disabled Children;Folklore;Health Knowledge, Attitudes, Practice;Health Services Accessibility;Humans;Interviews as Topic;Prognosis;Qualitative Research;Social Stigma;Young Adult;Africa;Cerebral Palsy;Qualitative Research",M01.060.057;M01.060.116;Z01.058.290.175.230;M01.085;M01.526.485.200;N02.360.200;C10.228.140.140.254;M01.060.406;M01.060.406.448;I02.233.332.186;N02.421.726.407.229;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;M01.150.200;I01.076.201.450.515;F01.100.150.500;N05.300.150.410;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;E01.789;H01.770.644.241.850;F01.145.813.840;M01.060.116.815;Z01.058;C10.228.140.140.254;H01.770.644.241.850
28743984,Animals;Dysbiosis;Gastrointestinal Microbiome;Humans;Inflammatory Bowel Diseases,B01.050;C23.550.308;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432
28743860,"Body Weight;Bone Density;Carrier Proteins;Child;Gene Expression;Genetic Pleiotropy;Genome-Wide Association Study;Humans;Meta-Analysis as Topic;Multivariate Analysis;Musculoskeletal Development;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Sterol Regulatory Element Binding Protein 1",C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;G11.427.100;D12.776.157;M01.060.406;G05.297;G05.420.556;G05.695.550;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;G07.345.500.325.377.625;G11.427.578;G05.365.795.598;G05.360.340.024.380.937;D12.776.260.103.500.750.500;D12.776.260.108.092.750.500;D12.776.930.125.500.750.500;D12.776.930.127.092.750.500
28743525,,
28743524,,
28743523,,
28743522,,
28743480,"Child;Emergencies;Emergency Service, Hospital;Health Care Surveys;Healthcare Disparities;Humans;Insurance Coverage;Insurance, Health;Medically Uninsured;Patient Transfer;Referral and Consultation;Retrospective Studies;United States;Emergency Medicine;Insurance;Pediatrics",M01.060.406;C23.550.291.781;N06.230.100.083;N06.850.376;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;M01.385;E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;H02.403.250;N03.219.521.576;H02.403.670
28743203,"Norwood Procedures;Aorta, Thoracic;Infant, Newborn",E04.100.376.724;E04.928.220.560;A07.015.114.056.372;M01.060.703.520
28742964,"Fibrinogen;Humans;Hydrodynamics;Models, Molecular;Pliability;Protein Conformation;Solutions",D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490;B01.050.150.900.649.313.988.400.112.400.400;G01.342;E05.599.595;G01.374.705;G02.111.570.820.709;D26.776
28742772,"Adverse Drug Reaction Reporting Systems;Anesthesia;Databases, Factual;Humans;Medication Errors;Pediatrics;Quality Improvement;Research Report;Wakefulness",E05.337.800.120;N02.421.668.320.120;E03.155;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;E02.319.529;N02.421.450.500;H02.403.670;J01.293.754;N04.761.744;H01.770.644.864;L01.559.423.906.769;F02.830.104.821;G11.561.035.738
28742549,Aged;Cohort Studies;Gastrointestinal Diseases;Hospital Mortality;Humans;Michigan;Middle Aged;Patient Readmission;Recurrence;Retrospective Studies;Sepsis;Urinary Tract Infections,M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C06.405;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.350.500;Z01.107.567.875.510.500;M01.060.116.630;E02.760.400.620;N02.421.585.400.620;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.539.757;C23.550.470.790.500;C01.539.895;C12.777.892;C13.351.968.892
28742080,22q11 Deletion Syndrome;Adolescent;Adult;Child;Humans;Longitudinal Studies;Prospective Studies;Psychiatric Status Rating Scales;Psychotic Disorders;Risk Factors;Young Adult,C05.660.207.103;C14.240.400.021;C14.280.400.044;C15.604.451.249;C16.131.077.019;C16.131.240.400.021;C16.131.260.019;C16.131.482.249;C16.131.621.207.103;C16.320.180.019;C19.642.482.500;M01.060.057;M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.711.513.653;F03.700.675;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28741812,Absenteeism;Activities of Daily Living;Adult;Aged;Binge-Eating Disorder;Case-Control Studies;Community Participation;Cross-Sectional Studies;Efficiency;Health Surveys;Humans;Middle Aged;Presenteeism;United States,F02.784.692.107;E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116;M01.060.116.100;F03.400.188;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;N02.421.143.212;N03.540.245.360;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F02.784.692.351;N04.452.209;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F02.784.692.586;F04.096.628.779.450;Z01.107.567.875
28741043,Adult;Aged;Brain Neoplasms;Breast Neoplasms;Humans;Indocyanine Green;Infrared Rays;Middle Aged;Optical Imaging;Photography;Brain Neoplasms;Fluorescence,M01.060.116;M01.060.116.100;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.588.180;C17.800.090.500;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.473.400;G01.358.500.505.650.552;G01.590.540.552;G01.750.250.650.552;G01.750.770.578.552;G16.500.275.063.725.525.400;G16.500.750.775.525.400;N06.230.300.100.725.525.400;M01.060.116.630;E01.370.350.589;E05.642;E01.370.350.600;E05.712;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;G01.358.500.505.650.665.500;G01.590.540.665.500
28740904,,
28740787,,
28739594,"Animals;Bone Marrow;Bone Marrow Cells;Cell Survival;Cellular Microenvironment;Humans;Mice;Models, Biological;Plasma Cells;Signal Transduction",B01.050;A15.382.216;A11.148;A15.378.316;G04.346;G04.366;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;E05.599.395;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;G02.111.820;G04.835
28739540,"Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Cancer Survivors;Cost-Benefit Analysis;Diet, Reducing;Exercise;Humans;Life Style;Lymphedema;Middle Aged;Neoplasm Recurrence, Local;Obesity;Quality of Life;Research Design;Resistance Training;Weight Reduction Programs;Biomarkers;Breast Neoplasms;Lymphedema;Recurrence",M01.060.116;M01.060.116.100;M01.060.116.100.080;D23.101.140;C04.588.180;C17.800.090.500;M01.860.350;N03.219.151.125;E02.642.249.285;G07.203.650.240.285;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;C15.604.496;M01.060.116.630;C04.697.655;C23.550.727.655;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.581.500;H01.770.644.728;E02.760.169.063.500.387.875;E02.779.483.875;E02.831.535.483.875;G11.427.410.698.277.311.750;I03.350.311.750;I02.233.332.445.650;N02.421.726.407.579.650;D23.101;C04.588.180;C17.800.090.500;C15.604.496;C23.550.291.937
28739391,"Blood Culture;Crowding;Emergency Service, Hospital",E01.370.225.875.185;E05.200.875.185;F01.145.875.281;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336
28739201,"Autoimmune Diseases of the Nervous System;Child, Preschool;Chromatography, High Pressure Liquid;Chromatography, Liquid;Dried Blood Spot Testing;Exodeoxyribonucleases;Humans;Infant;Infant, Newborn;Inflammation;Interferons;Lysophosphatidylcholines;Mutation;Neonatal Screening;Nervous System Malformations;Phosphoproteins;Retrospective Studies;Sensitivity and Specificity;Tandem Mass Spectrometry;Transcriptome",C10.114;C20.111.258;M01.060.406.448;E05.196.181.400.300;E05.196.181.400;E01.370.225.124.100.232;E05.200.124.100.232;D08.811.277.352.335.375;D08.811.277.352.365.290;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C23.550.470;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;D10.570.755.375.760.550.550;G05.365.590;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;C10.500;C16.131.666;D12.776.744;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.196.566.880;G02.111.873.750;G05.297.700.750;G05.360.920
28739145,,
28739077,"Animals;Antibodies, Viral;B-Lymphocyte Subsets;B-Lymphocytes;HIV Infections;Hepatitis C;Humans;Immunoglobulin G;Models, Immunological;T-Box Domain Proteins;B-Lymphocytes;HIV",B01.050;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;A11.063.438.450;A11.118.637.555.567.550.450;A11.118.637.555.567.562.200;A15.145.229.637.555.567.550.450;A15.145.229.637.555.567.562.200;A15.382.032.438.450;A15.382.490.555.567.550.300;A15.382.490.555.567.562.450;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;C02.782.815.616.400;C02.800.801.400;C20.673.480;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;E05.599.395.500;D12.776.260.725;D12.776.930.850;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;B04.820.650.589.650.350
28738749,"Adolescent;Age of Onset;Central Nervous System;Child;Clinical Trials as Topic;Cognitive Dysfunction;Demyelinating Diseases;Humans;Multiple Sclerosis, Relapsing-Remitting;Psychosocial Support Systems;Risk;Multiple Sclerosis;Demyelinating Diseases",M01.060.057;N05.715.350.075.100;N06.850.490.250.100;A08.186;M01.060.406;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;F03.615.250.700;C10.314;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;I01.880.853.500.600.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C10.314
28738683,"Analgesics, Opioid;Drug Overdose;Humans;Prescription Drug Monitoring Programs;State Government;United States",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;C25.775.383;E02.319.306.500.500;B01.050.150.900.649.313.988.400.112.400.400;E05.337.800.800;N02.421.668.320.600;I01.409.775;N03.540.348.875;Z01.107.567.875
28738447,"Aged;Aged, 80 and over;Anesthesia, General;Anesthesia, Local;Aortic Valve;Aortic Valve Stenosis;Humans;Length of Stay;Operative Time;Postoperative Complications;Risk Factors;Severity of Illness Index;Time Factors;Transcatheter Aortic Valve Replacement;Treatment Outcome;Anesthesia, General;Anesthesia, Local;Meta-Analysis;Transcatheter Aortic Valve Replacement",M01.060.116.100;M01.060.116.100.080;E03.155.197;E03.155.086.231;A07.541.510.110;C14.280.484.150;C14.280.955.249;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E04.614.374.500;N02.421.585.753.374.500;C23.550.767;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E03.155.197;E03.155.086.231;V03.600;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
28738127,"Age of Onset;Aged;Aged, 80 and over;Alzheimer Disease;Biological Transport;Caribbean Region;Carrier Proteins;Case-Control Studies;European Continental Ancestry Group;Exome;Guanine Nucleotide Exchange Factors;Hispanic Americans;Humans;Intracellular Signaling Peptides and Proteins;Middle Aged;Risk Factors;Vacuolar Proton-Translocating ATPases",N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G03.143;Z01.107.084;D12.776.157;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.686.508.400;G05.360.340.011;D12.644.360.325.300;D12.776.476.325.300;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360;D12.776.476;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D08.811.277.040.025.325.875;D08.811.913.696.650.150.500.875;D12.776.157.530.450.250.875.500.875;D12.776.543.585.450.250.875.500.875
28738086,"Cell Proliferation;Epstein-Barr Virus Infections;Epstein-Barr Virus Nuclear Antigens;Gene Expression Regulation;Herpesvirus 4, Human;Host-Pathogen Interactions;Humans;Interferon Regulatory Factors;Promoter Regions, Genetic;Protein Binding;Proteolysis;Proto-Oncogene Proteins c-bcl-6",G04.161.750;G07.345.249.410.750;C02.256.466.313;C02.928.313;D23.050.290.249;D23.050.327.300;G05.308;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360.024.302;D12.776.157.057.050;D12.776.260.504;D12.776.476.024.385;D12.776.930.332;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;G02.111.720;G03.812;D12.776.260.660;D12.776.624.664.700.170;D12.776.930.715
28738063,"Auditory Perception;Autism Spectrum Disorder;Brain;Child;Child, Preschool;Electroencephalography;Evoked Potentials;Evoked Potentials, Auditory;Humans;Phonetics;Speech;Speech Perception",F02.463.593.071;F03.625.164.113;A08.186.211;M01.060.406;M01.060.406.448;E01.370.376.300;E01.370.405.245;G07.265.216.500;G11.561.200.500;G07.265.216.500.370;G11.561.200.500.370;B01.050.150.900.649.313.988.400.112.400.400;L01.559.598.518;F01.145.209.908.677;G11.561.812;L01.559.423.676;F02.463.593.071.875
28737594,"Acute Kidney Injury;Adolescent;Child;Child, Preschool;Heart Arrest;Humans;Infant;Infant, Newborn;Prevalence;Retrospective Studies;Risk Factors;Severity of Illness Index",C12.777.419.780.050;C13.351.968.419.780.050;M01.060.057;M01.060.406;M01.060.406.448;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28737530,,
28736929,Medicare;Chronic Disease,N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C23.550.291.500
28736513,Cotinine;Epidemiology;Smoking;Tobacco,D03.383.773.812.180;H02.403.720.500;F01.145.805;B01.650.940.800.575.912.250.908.500.900
28736432,,
28736245,"Activin Receptors, Type I;Adolescent;Bone Morphogenetic Proteins;Child;Child, Preschool;Humans;Imatinib Mesylate;Mutation;Myositis Ossificans;Ossification, Heterotopic;Proto-Oncogene Proteins c-kit;Receptor, Platelet-Derived Growth Factor alpha;Ossification, Heterotopic;Imatinib Mesylate;Receptor, Platelet-Derived Growth Factor alpha",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;M01.060.057;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;G05.365.590;C05.651.594.638;C23.550.751;D08.811.913.696.620.682.725.400.050;D12.776.543.750.630.124;D12.776.543.750.705.852.150.100;D12.776.543.750.750.400.200.170;D12.776.624.664.700.183;D08.811.913.696.620.682.725.400.900.500;D12.776.543.750.630.625.300;D12.776.543.750.750.400.630.300;C23.550.751;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;D08.811.913.696.620.682.725.400.900.500;D12.776.543.750.630.625.300;D12.776.543.750.750.400.630.300
28736199,"Adolescent;Aging;Child;Child, Preschool;Dermatitis, Atopic;Hepatitis B;Hepatitis B Antibodies;Hepatitis B Surface Antigens;Hepatitis B Vaccines;Humans;Immunogenicity, Vaccine;Psoriasis;Scleroderma, Localized;Vaccination;Dermatitis, Atopic;Hepatitis B Vaccines;Scleroderma, Localized;Psoriasis",M01.060.057;G07.345.124;M01.060.406;M01.060.406.448;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C02.256.430.400;C02.440.435;C06.552.380.705.437;D12.776.124.486.485.114.254.450.504;D12.776.124.790.651.114.254.450.504;D12.776.377.715.548.114.254.450.504;D23.050.327.495.500.475;D20.215.894.899.955.400;B01.050.150.900.649.313.988.400.112.400.400;G12.070.500;G12.450.050.370.500;G12.450.050.460;G12.513;C17.800.859.675;C17.300.787;C17.800.767;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D20.215.894.899.955.400;C17.300.787;C17.800.767;C17.800.859.675
28735803,"Aged;Arthroplasty, Replacement, Hip;Arthroplasty, Replacement, Knee;Blood Transfusion;Erythrocyte Transfusion;Hemoglobins;Hip Fractures;Humans;Length of Stay;Middle Aged;Orthopedic Procedures;Orthopedics;Quality Control;Randomized Controlled Trials as Topic;Infection;Arthroplasty, Replacement, Knee;Systematic Review",M01.060.116.100;E04.555.110.110.110;E04.650.110.110;E04.680.101.110.110;E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;E02.095.135;E02.095.135.140.275;D12.776.124.400;D12.776.422.316.762;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;E02.718;E04.555;H02.403.810.494;J01.897.608;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C01.539;E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;V03.850
28735706,"Adult;Amniotic Fluid;Case-Control Studies;Down-Regulation;Fetal Therapies;Folate Receptor 1;GAP-43 Protein;GTPase-Activating Proteins;Gene Expression Profiling;Gestational Age;Humans;Inositol 1,4,5-Trisphosphate Receptors;LIM Domain Proteins;Membrane Proteins;Meningomyelocele;Microarray Analysis;Nerve Tissue Proteins;Pregnancy;Pregnancy Trimester, Second;Transcription Factor HES-1;Up-Regulation;Wnt-5a Protein;Wnt1 Protein;Zinc Finger E-box-Binding Homeobox 1;Zinc Finger Protein Gli3;rab GTP-Binding Proteins;Cell-Free Nucleic Acids;Fetus;Genes;Meningomyelocele",M01.060.116;A12.098;A16.378.149;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G02.111.240;G05.308.200;G07.690.773.937;E02.467;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;D12.776.395.550.400;D12.776.543.550.400;D12.776.631.400;D12.644.360.325.150;D12.776.476.325.150;E05.393.332;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530.400.150.760;D12.776.543.550.450.150.760;D12.776.543.585.400.150.760;D12.776.826.179;D12.776.512;D12.776.543;C10.500.680.610;C16.131.666.680.610;E05.588.570;D12.776.631;G08.686.784.769;G08.686.707.490;D12.776.260.103.844;D12.776.930.125.844;G02.111.905;G05.308.850;G07.690.773.998;D12.776.467.984.050;D12.776.624.664.700.962;D23.529.984.050;D12.776.467.984.100;D12.776.624.664.700.967;D23.529.984.100;D12.776.260.400.906;D12.776.260.703.800;D12.776.930.780.945;D12.776.260.522.875;D12.776.260.703.900;D12.776.930.375.875;D12.776.930.780.972;D08.811.277.040.330.300.400.400;D12.644.360.525.400;D12.776.157.325.515.400;D12.776.476.525.400;D13.444.154;A16.378;G05.360.340.024.340;C10.500.680.610;C16.131.666.680.610
28735484,"DNA Methylation;DNA, Neoplasm;Humans;Leukemia, Myeloid, Acute;Microspheres;Polymerase Chain Reaction;Prognosis;Leukemia, Myeloid, Acute;Methylation",G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D13.444.308.425;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;E07.565;E05.393.620.500;E01.789;C04.557.337.539.275;G02.111.035.538;G02.607.094.538;G03.059.538
28735478,"Humans;Immunophenotyping;Leukemia, Myeloid, Acute;Staining and Labeling;Leukemia, Myeloid, Acute;Bone Marrow",B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;C04.557.337.539.275;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670;C04.557.337.539.275;A15.382.216
28734830,"Appointments and Schedules;Choice Behavior;Colonoscopy;Colorectal Neoplasms;Early Detection of Cancer;Economics, Behavioral;Electronic Mail;Financing, Personal;Humans;Middle Aged;Motivation;Patient Acceptance of Health Care;Predictive Value of Tests;Prospective Studies;Economics, Behavioral",N04.452.095;F02.463.785.373.346;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;F04.096.628.286;N03.219.215;L01.178.847.249;L01.559.423.906.377.333;N03.219.559;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.658;F01.752.543.500.750;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.096.628.286;N03.219.215
28734657,Adolescent;Child;Cross-Sectional Studies;DiGeorge Syndrome;Exercise;Exercise Test;Health Status;Humans;Quality of Life;Surveys and Questionnaires;Tetralogy of Fallot;Health Status,M01.060.057;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;G11.427.410.698.277;I03.350;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;I01.240.425;N01.224.425;N06.850.505.400.425
28734655,"Adolescent;Child;Child, Preschool;Cognition;Cohort Studies;Cross-Sectional Studies;Glomerular Filtration Rate;Glucocorticoids;Humans;Lupus Nephritis;Prednisone;Propensity Score;Quality of Life;Renal Insufficiency, Chronic;Quality of Life;Adolescent;Renal Insufficiency, Chronic;Glomerulonephritis",M01.060.057;M01.060.406;M01.060.406.448;F02.463.188;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.390.400.300;G08.852.357;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.570.363.680;C13.351.968.419.570.363.680;C17.300.480.680;C20.111.590.560;D04.210.500.745.432.719.702;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;C12.777.419.780.750;C13.351.968.419.780.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;M01.060.057;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.570.363;C13.351.968.419.570.363
28734628,"Receptors, Adrenergic;Genetics;Hypoplastic Left Heart Syndrome",D12.776.543.750.670.300.300;D12.776.543.750.695.150.300;D12.776.543.750.720.330.300;H01.158.273.343;C14.240.400.625;C14.280.400.625;C16.131.240.400.625
28734384,,
28734046,"Clinical Competence;Geriatrics;Health Knowledge, Attitudes, Practice;Humans;Independent Living;Internal Medicine;Internship and Residency;Physicians;Problem-Based Learning;Residence Characteristics;Education;Internal Medicine",I02.399.630.210;N04.761.210;N05.715.175;H02.403.355;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;I03.050.500;N01.224.791.550;N06.850.505.400.800.550;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.810;N02.360.810;F02.463.425.720;I02.158.660;I02.903.565;N01.224.791;N06.850.505.400.800;I02;H02.403.429
28733953,"Bone Density;Fractures, Bone;Humans;Risk Factors",G11.427.100;C26.404;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28733933,"Child;Child, Preschool;Disease-Free Survival;Ependymoma;Humans;Infant;Infratentorial Neoplasms;Jumonji Domain-Containing Histone Demethylases;Prognosis;Registries;Survival Rate;Epigenomics",M01.060.406;M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.557.465.625.600.380.290;C04.557.470.670.380.290;C04.557.580.625.600.380.290;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.588.614.250.195.411;C10.228.140.211.500;C10.551.240.250.400;D08.811.682.662.582.475.500;D08.811.682.690.416.388;E01.789;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;H01.158.273.180.350.074;H01.158.273.343.350.042
28733799,"Adult;Caregivers;Child, Preschool;Depression;Education, Nonprofessional;Feasibility Studies;Humans;Infant;Parenting;Primary Health Care;Social Support;Socioeconomic Factors;Stress, Psychological;Depression;Parenting",M01.060.116;M01.085;M01.526.485.200;N02.360.200;M01.060.406.448;F01.145.126.350;I02.233;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.370.310;N04.590.233.727;I01.880.853.500.600;I01.880.853.996;N01.824;F01.145.126.990;F02.830.900;F01.145.126.350;F01.829.263.370.310
28733343,"Brain;Electroencephalography;Epilepsy;Hospitals, Pediatric;Humans;Infant, Newborn;KCNQ2 Potassium Channel;KCNQ3 Potassium Channel;Prospective Studies;Registries;Seizures;Tertiary Care Centers;United States",A08.186.211;E01.370.376.300;E01.370.405.245;C10.228.140.490;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;D12.776.157.530.400.600.900.124.249.750;D12.776.543.550.450.750.900.124.249.750;D12.776.543.585.400.750.900.124.249.750;D12.776.157.530.400.600.900.124.249.875;D12.776.543.550.450.750.900.124.249.875;D12.776.543.585.400.750.900.124.249.875;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C10.597.742;C23.888.592.742;N02.278.421.830;Z01.107.567.875
28733303,"Administration, Oral;Adolescent;Adult;Arthritis, Rheumatoid;Asthma;Child;Child, Preschool;Chronic Disease;Dose-Response Relationship, Drug;Glucocorticoids;Humans;Inflammation;Inflammatory Bowel Diseases;Lupus Erythematosus, Systemic;Middle Aged;Osteonecrosis;Proportional Hazards Models;Psoriasis;Retrospective Studies;Young Adult;Gastroenterology;Glucocorticoids;Rheumatology",E02.319.267.100;M01.060.057;M01.060.116;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;C23.550.291.500;G07.690.773.875;G07.690.936.500;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C06.405.205.731;C06.405.469.432;C17.300.480;C20.111.590;M01.060.116.630;C05.116.852;C23.550.717.732;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C17.800.859.675;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;H02.403.429.405;D06.472.040.543;D27.505.696.399.472.488;H02.403.429.730
28733232,,
28733195,Breast Neoplasms;Gene Expression Profiling;High-Throughput Nucleotide Sequencing;Humans;Metabolomics;Proteomics;Signal Transduction,C04.588.180;C17.800.090.500;E05.393.332;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.820;G04.835
28733119,Artificial Intelligence;Computational Biology;Humans;Medicine,G17.035.250;L01.224.050.375;H01.158.273.180;L01.313.124;B01.050.150.900.649.313.988.400.112.400.400;H02.403
28732780,,
28732770,Zebrafish,B01.050.150.900.493.200.244.828
28732721,Alleles;Feasibility Studies;Gene Library;Genotype;Genotyping Techniques;HLA Antigens;Health Information Interoperability;High-Throughput Nucleotide Sequencing;Histocompatibility Testing;Humans;Polymerase Chain Reaction;Reproducibility of Results;Sensitivity and Specificity;Software,G05.360.340.024.340.030;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;G05.360.325;G05.380;E05.393.442;D23.050.301.500.450;D23.050.705.552.450;L01.313.500.750.280.555;L01.470.813;E05.393.760.319;E01.370.225.812.385;E05.200.812.385;E05.478.594.385;B01.050.150.900.649.313.988.400.112.400.400;E05.393.620.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;L01.224.900
28732496,"Adolescent;Adult;African Continental Ancestry Group;Circumcision, Male;Cross-Sectional Studies;HIV Infections;Health Knowledge, Attitudes, Practice;Humans;Logistic Models;Mass Screening;Perception;Risk Factors;Safe Sex;Sexual Behavior;Sexual Partners;Sexually Transmitted Diseases;South Africa;Young Adult;South Africa;Women",M01.060.057;M01.060.116;M01.686.508.100;E02.218.085.170;E04.085.170;E04.950.774.860.226;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C02.782.815.616.400;C02.800.801.400;C20.673.480;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F02.463.593;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.802.845;F01.145.802;M01.778;C01.539.778;C02.800;C12.294.668;C13.351.500.711;Z01.058.290.175.735;M01.060.116.815;Z01.058.290.175.735;M01.975
28731848,"Adolescent;Age Factors;Child;Child, Preschool;Dermatology;Health Services Accessibility;Humans;Infant;Mobile Applications;Patient Satisfaction;Prospective Studies;Socioeconomic Factors;Telemedicine;User-Computer Interface;Waiting Lists;Young Adult;Dermatology;Pediatrics;Telemedicine;Telemedicine",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;H02.403.225;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;L01.224.900.685;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.880.853.996;N01.824;H02.403.840;L01.178.847.652;N04.590.374.800;L01.224.900.910;N04.452.095.738;M01.060.116.815;H02.403.225;H02.403.670;H02.403.840;L01.178.847.652;N04.590.374.800;H02.403.840;L01.178.847.652;N04.590.374.800
28731566,"Animals;Cell Line, Tumor;Drosophila;Drosophila Proteins;Humans;Kinesin;Molecular Dynamics Simulation;Motion;Protein Domains;Kinesin",B01.050;A11.251.210.190;A11.251.860.180;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;E05.599.595.500;G02.111.570.895;L01.224.160.500;G01.482;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450
28730721,"Arteriovenous Malformations;Capillaries;Child;Humans;Mutation, Missense;Port-Wine Stain;Receptor, EphB4;p120 GTPase Activating Protein",C14.240.850.750;C14.907.150;C16.131.240.850.750;A07.015.461.165;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;C16.131.831.675;C17.800.804.675;D08.811.913.696.620.682.725.400.850.750;D12.776.543.750.630.500.781;D12.644.360.325.150.500.500;D12.776.476.325.150.500.500
28730184,,
28730158,Guatemala;Norovirus;Prevalence,Z01.107.169.454;B04.820.095.550;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
28729679,,
28729433,Blood Coagulation;Factor VIII;Factor VIIIa;Factor VIIa;Factor Xa;Humans;Thrombin;Thromboplastin,G09.188.390.150;D12.776.124.125.350;D23.119.350;D12.776.124.125.350.300;D23.119.350.300;D08.811.277.656.300.760.300;D08.811.277.656.959.350.300;D12.776.124.125.325.300;D23.119.325.300;D08.811.277.656.300.760.315;D08.811.277.656.959.350.315;D12.776.124.125.400.315;D23.119.400.315;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960;D12.776.124.125.900;D23.119.965
28729432,"Actins;Animals;Bone Marrow;Cell Differentiation;Cell Nucleus;Cell Nucleus Shape;Cell Polarity;Erythroblasts;Fetus;Gene Knockdown Techniques;Lamins;Liver;Mice, Inbred C57BL;Nonmuscle Myosin Type IIB;Protein Isoforms;Tropomodulin",D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;B01.050;A15.382.216;G04.152;A11.284.430.106;A11.284.430.214.190.875.117;G04.655.270;G04.250;A11.148.378.590.837.250.200;A11.443.240.497.200;A15.378.316.378.590.837.250.200;A16.378;E05.393.335.500;D12.776.660.650.875;A03.620;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D05.750.078.730.475.475.500;D08.811.277.040.025.193.750.750.500;D12.776.210.500.600.470.500;D12.776.220.525.475.475.500;D12.776.800;D05.750.078.730.032.750;D12.776.210.500.847;D12.776.220.525.032.750
28729240,,
28729032,"Animals;Cilia;Disease Models, Animal;Epitopes;Exons;Fluorescent Antibody Technique;Gene Knock-In Techniques;Hemagglutinin Glycoproteins, Influenza Virus;Humans;Kidney;Mice;Mice, Inbred C57BL;Mice, Transgenic;Mutation;Nuclear Localization Signals;Peptide Fragments;Phenotype;Polycystic Kidney, Autosomal Recessive;Protein Domains;Receptors, Cell Surface;TRPP Cation Channels;Polycystic Kidney, Autosomal Recessive",B01.050;A11.284.180.165;C22.232;E05.598.500;E05.599.395.080;D23.050.550;G05.360.340.024.340.137.232;E01.370.225.500.607.512.240;E01.370.225.750.551.512.240;E05.200.500.607.512.240;E05.200.750.551.512.240;E05.478.583.375;E05.393.335.249;D12.776.964.970.880.345.500;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G05.365.590;D12.644.770.610;G02.111.570.060.670.610;D12.644.541;G05.695;C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.543.750;D12.776.157.530.400.150.900;D12.776.157.530.400.901.777;D12.776.543.585.400.150.900;D12.776.543.585.400.901.777;C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510
28729009,"Adult;Aged;Delphi Technique;Education, Medical, Graduate;Hospice Care;Humans;Middle Aged;Palliative Care;Palliative Medicine;Surveys and Questionnaires;United States;Young Adult;Fellowships and Scholarships;Education, Medical, Graduate;Hospices;Palliative Care",M01.060.116;M01.060.116.100;L01.906.197;I02.358.337.350;I02.358.399.350;E02.760.905.400;N02.421.585.905.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.760.666;N02.421.585.666;H02.403.645;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;M01.060.116.815;N03.219.483.838.276;I02.358.337.350;I02.358.399.350;N02.278.421.556.185;N02.421.143.550;E02.760.666;N02.421.585.666
28728956,"Adolescent;Child;Codon, Nonsense;Double-Blind Method;Dystrophin;Global Health;Humans;Muscular Dystrophy, Duchenne;Oxadiazoles;Treatment Outcome;Walking",M01.060.057;M01.060.406;D13.444.735.544.355.250.235;G05.360.335.355.250.235;G05.365.590.195;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D12.776.210.500.250;D12.776.220.250;D12.776.543.250;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;D03.383.129.462.580;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940
28728784,Equipment Design;Mitral Valve;Sutures,E05.320;A07.541.510.507;E07.858.690.820
28728782,,
28728626,,
28728423,Antimicrobial Stewardship;Primary Health Care,N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;N04.590.233.727
28728040,Adult;Affect;Craving;Humans;Logistic Models;Medication Adherence;Middle Aged;Nicotine;Nicotinic Agonists;Randomized Controlled Trials as Topic;Saliva;Self Report;Smoking Cessation;Substance Withdrawal Syndrome;Tobacco Use Disorder;Varenicline;Tobacco Use Disorder;Smoking Cessation;Varenicline,M01.060.116;F01.470.047;F01.658.293.195;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;D03.132.760.570;D03.383.725.518;D27.505.519.625.120.140.700;D27.505.696.577.120.140.700;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;A12.200.666;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;F01.145.488.732;C25.775.835;F03.900.825;C25.775.912;F03.900.912;D03.633.100.079.900;D03.633.100.857.942;C25.775.912;F03.900.912;F01.145.488.732;D03.633.100.079.900;D03.633.100.857.942
28727983,,
28727950,"Adolescent;Adult;Aged;Bisexuality;Cross-Sectional Studies;Health Behavior;Health Status;Healthy People Programs;Homosexuality, Female;Homosexuality, Male;Humans;Middle Aged;Sexual and Gender Minorities;Socioeconomic Factors;Young Adult;Demography;Epidemiology;Sexual and Gender Minorities",M01.060.057;M01.060.116;M01.060.116.100;F01.145.802.975.200;G08.686.867.200;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.488;I01.240.425;N01.224.425;N06.850.505.400.425;I02.233.332.445.300;N02.421.726.407.579.300;F01.145.802.975.500.400;G08.686.867.500.400;F01.145.802.975.500.600;G08.686.867.500.600;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;M01.777;I01.880.853.996;N01.824;M01.060.116.815;I01.240;N01.224;N06.850.505.400;H02.403.720.500;M01.777
28727948,Adolescent;Adult;Anxiety Disorders;Cross-Sectional Studies;Depression;Feasibility Studies;Humans;Mental Health Services;Middle Aged;Pilot Projects;Prevalence;Psychiatric Status Rating Scales;Surveys and Questionnaires;United States;Women's Health;Anxiety;Depression;Mass Screening;Women,M01.060.057;M01.060.116;F03.080;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.126.350;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;F04.408;N02.421.461;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;F04.711.513.653;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;N01.400.900;F01.470.132;F01.145.126.350;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.975
28727288,"Child;Humans;Leukemia, Myeloid, Acute;Critical Care;Mortality;Outcome Assessment (Health Care);Continental Population Groups",M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;E02.760.190;N02.421.585.190;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;M01.686.508
28727185,Automation;Principal Component Analysis,J01.897.104;E05.318.740.562
28727136,"Adult;African Americans;Aged;Aged, 80 and over;Cohort Studies;Continental Population Groups;European Continental Ancestry Group;Health Services Accessibility;Healthcare Disparities;Humans;Middle Aged;Philadelphia;Prostatic Neoplasms;Registries;United States;Prostatic Neoplasms",M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.508;M01.686.508.400;N04.590.374.350;N05.300.430;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.500.550.525;Z01.433.820;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;Z01.107.567.875;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28726280,"Alleles;Child;Computer Simulation;DNA Mutational Analysis;Genetic Predisposition to Disease;Genetic Variation;Genome-Wide Association Study;Humans;Likelihood Functions;Linkage Disequilibrium;Models, Genetic;Nuclear Family;Pedigree;Research Design;Haplotypes",G05.360.340.024.340.030;M01.060.406;L01.224.160;E05.393.760.700.300;C23.550.291.687.500;G05.380.355;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.475;E05.318.740.600.400;E05.599.835.500;N05.715.360.750.530.450;N05.715.360.750.625.450;N06.850.520.830.500.475;N06.850.520.830.600.400;G05.348.500;E05.599.395.397;F01.829.263.500;I01.880.853.150.500;E05.393.673;E05.581.500;H01.770.644.728;G05.380.360
28725878,"Brain Neoplasms;Glioma;Models, Statistical",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500
28725630,Neoplasms;Chemoprevention;Curcumin;Curcuma,C04;E02.319.162;D02.455.326.146.485.222.222;D02.455.426.559.389.657.166.200;D02.455.426.559.694.222;B01.650.940.800.575.912.250.618.937.900.166
28724797,Metabolism;Nephrology,G03;H02.403.429.580
28724774,"Adult;Aged;Arteriovenous Shunt, Surgical;Humans;Kidney Failure, Chronic;Middle Aged;Neointima;Renal Dialysis;Vascular Calcification;Veins;Arteriovenous Fistula;Pathology",M01.060.116;M01.060.116.100;E04.035.087;E04.100.814.868.249;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;M01.060.116.630;C23.550.722;E02.870.300;E02.912.800;C18.452.174.130.780;A07.015.908;C14.240.850.750.147;C14.240.850.984.750;C14.907.150.125;C14.907.933.555;C16.131.240.850.750.125;C23.300.575.950.250;H02.403.650
28724582,"Adolescent;Anticonvulsants;Child;Child, Preschool;Double-Blind Method;Electroencephalography;Epilepsy, Absence;Eye Movements;Follow-Up Studies;Humans;Outcome Assessment (Health Care);Seizures",M01.060.057;D27.505.954.427.080;M01.060.406;M01.060.406.448;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E01.370.376.300;E01.370.405.245;C10.228.140.490.375.260;C10.228.140.490.493.125;G11.427.410.140;G14.350;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C10.597.742;C23.888.592.742
28724573,"Aged;Brain Neoplasms;Cell- and Tissue-Based Therapy;ErbB Receptors;Glioblastoma;Humans;Immunohistochemistry;Immunotherapy, Adoptive;Middle Aged;Neoplasm Recurrence, Local;Receptors, Antigen, T-Cell",M01.060.116.100;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E02.095.147;D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;M01.060.116.630;C04.697.655;C23.550.727.655;D12.776.543.750.705.816.824
28724340,Friedreich Ataxia;Humans;Friedreich Ataxia;Deferiprone;Genetic Therapy;Methylprednisolone;Thiamine,C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.252.700.150;C10.228.854.787.200;C10.574.500.825.200;C16.320.400.780.200;C18.452.660.300;D03.383.725.791.298;E02.095.301;E05.393.420.301;D04.210.500.745.432.769.795.539;D02.886.675.900;D03.383.129.708.900;D03.383.742.795
28723883,,
28723878,Adolescent;Bone Screws;Humans;Neurosurgical Procedures;Physician's Role;Recovery of Function;Retrospective Studies;Scoliosis;Spinal Fusion;Spine;Thoracic Vertebrae;Treatment Outcome;Young Adult,M01.060.057;E07.695.370.437;E07.858.442.660.460.437;E07.858.690.725.460.437;B01.050.150.900.649.313.988.400.112.400.400;E04.525;F01.829.316.616.625.600;G16.757;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.116.900.800.875;E04.555.100.700;A02.835.232.834;A02.835.232.834.892;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28723589,"Asphyxia;Bedding and Linens;Beds;Consumer Product Safety;Humans;Infant;Infant Equipment;Infant, Newborn;Prone Position;Sleep;Sudden Infant Death;United States;Infant Mortality;Asphyxia",C23.550.260.095;C26.103;E07.325.137;J01.494.221;E07.325.220;N06.850.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E07.490;M01.060.703.520;G11.427.695.525;F02.830.855;G11.561.803;C23.550.260.322.625;C23.550.260.657.500;Z01.107.567.875;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;C23.550.260.095;C26.103
28723334,"Angiopoietin-like Proteins;Angiopoietins;Antibodies, Monoclonal;Cholesterol, LDL;Genotype;Humans;Hyperlipoproteinemia Type II;Receptors, LDL",D12.644.276.100.050;D12.776.467.100.050;D23.529.100.050;D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;D12.776.543.750.710.450
28722580,Acute Disease;Adolescent;Caliciviridae Infections;Child;Gastroenteritis;Guatemala;Humans;Norovirus;Population Surveillance,C23.550.291.125;M01.060.057;C02.782.160;M01.060.406;C06.405.205;Z01.107.169.454;B01.050.150.900.649.313.988.400.112.400.400;B04.820.095.550;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675
28722244,"Chemical and Drug Induced Liver Injury, Chronic;Coinfection;HIV Infections;Hepatitis C, Chronic;Humans;Incidence;Liver;Liver Cirrhosis;Liver Failure;Middle Aged;Mitochondria;Proportional Hazards Models;Retrospective Studies;Reverse Transcriptase Inhibitors;HIV;Chemical and Drug Induced Liver Injury;Hepatitis C;Pharmacoepidemiology",C06.552.100.200;C25.100.562.200;C25.723.260.200;C01.539.218;C02.219;C03.202;C02.782.815.616.400;C02.800.801.400;C20.673.480;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;A03.620;C06.552.630;C06.552.308.500;M01.060.116.630;A11.284.430.214.190.875.564;A11.284.835.626;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.519.389.675.850;D27.505.954.122.388.077.750;B04.820.650.589.650.350;C06.552.100;C25.100.562;C25.723.260;C02.440.440;C02.782.350.350;C06.552.380.705.440;H01.158.703.045;H02.403.720.500.650;H02.628.413
28721859,"Arthritis, Juvenile;Case-Control Studies;Child;Child, Preschool;Hepatitis A;Hepatitis A Antibodies;Hepatitis A Vaccines;Humans;Immunogenicity, Vaccine;Immunoglobulin G;Immunosuppressive Agents;Methotrexate;Vaccines, Inactivated",C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;C02.440.420;C02.782.687.359.500;C06.552.380.705.422;D12.776.124.486.485.114.254.450.251;D12.776.124.790.651.114.254.450.251;D12.776.377.715.548.114.254.450.251;D20.215.894.899.955.395;B01.050.150.900.649.313.988.400.112.400.400;G12.070.500;G12.450.050.370.500;G12.450.050.460;G12.513;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;D27.505.696.477.656;D03.633.100.733.631.192.500;D20.215.894.830
28720664,"Animals;Axonal Transport;Axons;Brain-Derived Neurotrophic Factor;Cells, Cultured;Cytoplasmic Dyneins;Cytoskeleton;Dendrites;Endosomes;Hippocampus;Kinesin;Microtubules;Myosins;Neurons;Protein Transport;Rats;Receptor, trkB;Signal Transduction",B01.050;G03.143.355.040;G04.392.040;G11.561.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;A11.251;D08.811.277.040.025.193.249.750;A11.284.430.214.190.750;A08.675.256;A11.284.180.225;A11.671.240;A11.284.430.214.190.875.190.880.337;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;A11.284.430.214.190.750.602;D05.750.078.730.475;D08.811.277.040.025.193.750;D12.776.210.500.600;D12.776.220.525.475;A08.675;A11.671;G03.143.700;B01.050.150.900.649.313.992.635.505.700;D08.811.913.696.620.682.725.400.700;D12.776.543.750.630.498;D12.776.543.750.750.400.550.600;G02.111.820;G04.835
28720658,"Adenosine;Aged;Aortic Diseases;Aspirin;Atherosclerosis;Carotid Stenosis;Humans;Intracranial Embolism;Ischemic Attack, Transient;Middle Aged;Mortality;Myocardial Infarction;Platelet Aggregation Inhibitors;Recurrence;Stroke;Ticagrelor;Treatment Outcome;Aspirin;Embolism;Stroke;Ischemic Attack, Transient",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;M01.060.116.100;C14.907.109;D02.455.426.559.389.657.410.595.176;C14.907.137.126.307;C10.228.140.300.200.360;C14.907.137.230;C14.907.253.123.360;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.525.400;C14.907.253.566.300;C14.907.355.590.213.300;C10.228.140.300.150.836;C14.907.253.092.836;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C14.280.647.500;C14.907.585.500;D27.505.954.502.780;C23.550.291.937;C10.228.140.300.775;C14.907.253.855;D03.633.100.759.590.138.806;D13.570.583.138.806;D13.570.800.096.815;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.455.426.559.389.657.410.595.176;C14.907.355.350;C10.228.140.300.775;C14.907.253.855;C10.228.140.300.150.836;C14.907.253.092.836
28719991,"Adolescent;Adult;Arthralgia;Child;Child, Preschool;Fractures, Bone;Ganglion Cysts;Humans;Infant;Magnetic Resonance Imaging;Retrospective Studies;Scaphoid Bone;Wrist Joint;Young Adult;Diagnosis;Pain;Wrist",M01.060.057;M01.060.116;C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350;M01.060.406;M01.060.406.448;C26.404;C04.182.347;C17.300.550.274;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.087.319.150.750;A02.835.583.405.930;M01.060.116.815;E01;C23.888.592.612;F02.830.816.444;G11.561.790.444;A01.378.800.667.715
28719854,"Adult;Aged;Aged, 80 and over;Alzheimer Disease;Brain;Executive Function;Healthy Aging;Humans;Magnetic Resonance Imaging;Memory;Nerve Net;White Matter;Young Adult;Aging",M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;F02.463.217;F01.829.458.205.250;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F02.463.425.540;A08.511;A08.186.211.204;A08.186.854.880;M01.060.116.815;G07.345.124
28719755,"Adult;Body Mass Index;Humans;Hypertension, Pulmonary;Linear Models;Logistic Models;Lung;Lung Transplantation;Middle Aged;Obesity;Primary Graft Dysfunction;Prognosis;Retrospective Studies;Risk Factors;Time Factors;Tissue Donors;United States;Young Adult;Lung Transplantation;Primary Graft Dysfunction;Hypertension, Pulmonary",M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;A04.411;E04.928.600.495;E04.936.450.495;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C14.907.725.675;C23.550.767.877.750;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.898;Z01.107.567.875;M01.060.116.815;E04.928.600.495;E04.936.450.495;C14.907.725.675;C23.550.767.877.750;C08.381.423
28719605,"Animals;HEK293 Cells;Humans;Mice;Neurons;Pain;Phosphorylation;Rats;Receptor, EphB2;Receptors, N-Methyl-D-Aspartate;Sequence Analysis, Protein;Spinal Cord;Tyrosine",B01.050;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A08.675;A11.671;C23.888.592.612;F02.830.816.444;G11.561.790.444;G02.111.665;G02.607.780;G03.796;B01.050.150.900.649.313.992.635.505.700;D08.811.913.696.620.682.725.400.850.650;D12.776.543.750.630.500.500;D12.776.157.530.400.400.500.500;D12.776.543.550.450.500.200.500;D12.776.543.585.400.500.200.500;D12.776.543.750.720.200.450.400.500;E05.393.760.705;A08.186.854;D12.125.072.050.875
28719391,Child;Hand Transplantation;Humans;Immunosuppression;Quality of Life,M01.060.406;E04.936.450.825.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.450;E05.478.610;I01.800;K01.752.400.750;N06.850.505.400.425.837
28718522,,
28718445,"Animals;Disease Models, Animal;Humans;Mice;Neoplasms;Neutrophil Infiltration;Neutrophils;Tumor Microenvironment",B01.050;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;C04;G12.632;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;G04.366.500
28718170,"Attitude of Health Personnel;Burnout, Professional;Delivery of Health Care;Emotions;Health Knowledge, Attitudes, Practice;Humans;Medical Missions;Orthopedic Surgeons;Resilience, Psychological;Volunteers",F01.100.050;N05.300.100;C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;N04.590.374;N05.300;F01.470;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500.750;M01.526.485.810.910.875;N02.360.810.910.875;F02.940;M01.955
28718031,"Age of Onset;Child;Humans;Infant, Newborn;Inflammatory Bowel Diseases;Intestinal Diseases;Child;Inflammatory Bowel Diseases",N05.715.350.075.100;N06.850.490.250.100;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C06.405.205.731;C06.405.469.432;C06.405.469;M01.060.406;C06.405.205.731;C06.405.469.432
28716862,"Adult;Cell Proliferation;Child, Preschool;Clinical Trials as Topic;Clone Cells;Cytokines;Genetic Therapy;Humans;Lymphocyte Subsets;T-Lymphocytes;Vaccination;Wiskott-Aldrich Syndrome",M01.060.116;G04.161.750;G07.345.249.410.750;M01.060.406.448;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;A11.251.353;D12.644.276.374;D12.776.467.374;D23.529.374;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.567.550;A15.145.229.637.555.567.550;A15.382.490.555.567.550;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;C15.378.100.100.970;C15.378.463.960;C15.378.553.546.605.900;C16.320.099.970;C16.320.322.937;C20.673.627.900
28716856,"Heart Failure;Hospitalization;Humans;Models, Statistical;Poisson Distribution;Proportional Hazards Models;Recurrence;Renal Insufficiency, Chronic;Risk Factors;Cohort Studies;Humans;Renal Insufficiency;Survival Analysis;Renal Insufficiency, Chronic;Heart Failure;Hospitalization;Risk Factors",C14.280.434;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.740.994.750;G17.820.750;N05.715.360.750.750.620;N06.850.520.830.994.750;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C23.550.291.937;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780;C13.351.968.419.780;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;C12.777.419.780.750;C13.351.968.419.780.750;C14.280.434;E02.760.400;N02.421.585.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28716803,"Adolescent;Hospitals, Pediatric;Humans;Length of Stay;Massachusetts;Mental Disorders;Mental Health Services;Patient Admission;Retrospective Studies",M01.060.057;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;Z01.107.567.875.550.510;F03;F04.408;N02.421.461;E02.760.400.600;N02.421.585.400.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28716717,Adult;Brain;Datasets as Topic;Humans;Magnetic Resonance Spectroscopy;Young Adult;gamma-Aminobutyric Acid;gamma-Aminobutyric Acid,M01.060.116;A08.186.211;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;B01.050.150.900.649.313.988.400.112.400.400;E05.196.867.519;M01.060.116.815;D02.241.081.114.500.350;D12.125.190.350;D02.241.081.114.500.350;D12.125.190.350
28716337,"Bronchoscopy;Clinical Competence;Education, Medical;Humans;Imaging, Three-Dimensional;Middle Ear Ventilation;Otolaryngology;Simulation Training;User-Computer Interface;Virtual Reality;Education, Medical;Otolaryngology;Virtual Reality",E01.370.386.105;E01.370.388.250.100;E04.502.250.100;E04.928.600.080;I02.399.630.210;N04.761.210;N05.715.175;I02.358.399;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;E04.579.592;E04.580.450.472;H02.403.810.526;I02.903.847;L01.224.900.910;L01.224.160.875;L01.296.555;I02.358.399;H02.403.810.526;L01.224.160.875;L01.296.555
28716309,"Adult;Arginine Vasopressin;Biomarkers;Blood Component Transfusion;Enzyme-Linked Immunosorbent Assay;Glycopeptides;Humans;Immunoassay;Injury Severity Score;Predictive Value of Tests;Prospective Studies;Resuscitation;Shock, Hemorrhagic;Wounds and Injuries;Shock, Hemorrhagic;Wounds and Injuries;Vasopressins",M01.060.116;D06.472.699.631.692.781.100;D12.644.400.900.100;D12.644.456.925.100;D12.644.548.691.692.781.100;D12.776.631.650.937.100;D23.101;E02.095.135.140;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;D09.400.420;D12.644.233;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566;E05.601.470;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.365.647;C23.550.414.980;C23.550.835.650;C26;C23.550.414.980;C23.550.835.650;C26;D06.472.699.631.692.781;D12.644.400.900;D12.644.456.925;D12.644.548.691.692.781;D12.776.631.650.937
28716170,"Bacillus cereus;Bodily Secretions;Cells, Cultured;Chronic Disease;Cilia;Gram-Positive Bacterial Infections;Humans;Immunity, Innate;Mucociliary Clearance;Nasal Mucosa;Nitric Oxide;Phospholipase C beta;Receptors, G-Protein-Coupled;Rhinitis;Signal Transduction;Sinusitis;TRPM Cation Channels;Taste",B03.300.390.400.158.218.252;B03.353.500.100.218.252;B03.510.100.100.218.252;B03.510.415.400.158.218.252;B03.510.460.410.158.218.252;A12.200;A11.251;C23.550.291.500;A11.284.180.165;C01.252.410;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;E01.370.386.520;G09.772.555;A04.531.520;A04.760.600;A10.615.550.760.600;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;D08.811.277.352.640.700.700.562.500;D12.644.360.571.500;D12.776.476.556.500;D12.776.543.750.695;C08.460.799;C08.730.674;C09.603.799;G02.111.820;G04.835;C08.460.692.752;C08.730.749;C09.603.692.752;D12.776.157.530.400.901.555;D12.776.543.585.400.901.555;F02.830.816.724;G11.561.790.724
28715837,Domestic Violence;Humans;Mother-Child Relations;Philadelphia;Physicians,I01.198.240.856.350;I01.880.735.900.350;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.290.170;Z01.107.567.875.500.550.525;Z01.433.820;M01.526.485.810;N02.360.810
28715553,"Birth Weight;Cohort Studies;Ethnic Groups;Gestational Age;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Infant, Premature;Logistic Models;Philadelphia;Retinopathy of Prematurity;Retrospective Studies;Risk Factors;Sensitivity and Specificity;Weight Gain",C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.754;N01.224.317;G07.345.500.325.235.968;G08.686.320;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;Z01.107.567.875.500.550.525;Z01.433.820;C11.768.836;C16.614.521.731;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C23.888.144.243.926;G07.345.249.314.120.200.926
28715528,"Bone Diseases, Metabolic;Eyelid Diseases;Humans;Infant;Ophthalmologic Surgical Procedures;Ossification, Heterotopic;Skin Diseases, Genetic;Suture Techniques",C05.116.198;C18.452.104;C11.338;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E04.540;C23.550.751;C16.320.850;C17.800.827;E04.987.775
28715505,"Animals;Cecum;Dendritic Cells;Disease Models, Animal;Ligation;Mice;Monocytes;Punctures;Sepsis;Survival Analysis;Time Factors",B01.050;A03.556.124.526.209;A03.556.249.249.209;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;C22.232;E05.598.500;E05.599.395.080;E04.426;B01.050.150.900.649.313.992.635.505.500;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;E02.800;E04.665;C01.539.757;C23.550.470.790.500;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G01.910.857
28715374,"Animals;Hypoglossal Nerve;Models, Animal;Rats;Tongue",B01.050;A08.800.800.120.330;E05.598;B01.050.150.900.649.313.992.635.505.700;A03.556.500.885;A14.549.885
28715357,"Analgesia, Epidural;Analgesia, Patient-Controlled;Analgesics, Opioid;Humans;Pain;Pain Management;Pain, Postoperative",E03.091.080;E03.091.120;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;B01.050.150.900.649.313.988.400.112.400.400;C23.888.592.612;F02.830.816.444;G11.561.790.444;E02.745;N04.590.607.500;C23.550.767.700;C23.888.592.612.832
28715278,"Breast Neoplasms;Cohort Studies;Diagnosis, Differential;Early Detection of Cancer;Humans;Mammography;Middle Aged;Neoplasm Grading;Radiographic Image Enhancement;Reproducibility of Results;Sensitivity and Specificity;Tomography, Spiral Computed;United States",C04.588.180;C17.800.090.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.171;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.500;M01.060.116.630;E01.789.612;E01.370.350.600.350.700;E01.370.350.700.700;L01.224.308.380.600;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.350.810.800;E01.370.350.600.350.700.810.800;E01.370.350.700.700.810.800;E01.370.350.700.810.810.800;E01.370.350.825.810.810.800;Z01.107.567.875
28715257,"Adolescent;Calculi;Child;Child, Preschool;Humans;Odds Ratio;Retrospective Studies;Testicular Diseases;Testicular Neoplasms;Ultrasonography",M01.060.057;C23.300.175;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C12.294.829;C19.391.829;C04.588.322.762;C04.588.945.440.915;C12.294.260.937;C12.758.409.937;C19.344.762;C19.391.829.782;E01.370.350.850
28714976,"Adaptor Proteins, Signal Transducing;Alzheimer Disease;Amino Acid Sequence;Case-Control Studies;Exome;Gene Expression Profiling;Gene Frequency;Genetic Predisposition to Disease;Genotype;Humans;Immunity, Innate;Linkage Disequilibrium;Membrane Glycoproteins;Microglia;Odds Ratio;Phospholipase C gamma;Polymorphism, Single Nucleotide;Protein Interaction Maps;Receptors, Immunologic;Sequence Homology, Amino Acid",D12.644.360.024;D12.776.157.057;D12.776.476.024;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G02.111.570.060;L01.453.245.667.060;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G05.360.340.011;E05.393.332;G05.330;C23.550.291.687.500;G05.380.355;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;G05.348.500;D12.776.395.550;D12.776.543.550;A08.637.400;A11.650.400;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;D08.811.277.352.640.700.700.562.750;D12.644.360.571.750;D12.776.476.556.750;G05.365.795.598;G03.493.750;D12.776.543.750.705;G02.111.810.200;G05.810.200
28714851,"Animals;Arteries;Embryo, Mammalian;Endothelial Cells;Endothelium, Vascular;Gene Deletion;Genotype;Mesoderm;Mice;Neural Crest;Receptor, Platelet-Derived Growth Factor alpha;Endothelium;Neural Crest;Receptor, Platelet-Derived Growth Factor alpha",B01.050;A07.015.114;A16.254;A11.436.275;A07.015.700.500;A10.272.491.355;G05.365.590.762.320;G05.558.800.320;G05.380;A16.504.660;B01.050.150.900.649.313.992.635.505.500;A16.627;D08.811.913.696.620.682.725.400.900.500;D12.776.543.750.630.625.300;D12.776.543.750.750.400.630.300;A10.272.491;A16.627;D08.811.913.696.620.682.725.400.900.500;D12.776.543.750.630.625.300;D12.776.543.750.750.400.630.300
28714229,Blood Transfusion;Cardiac Surgical Procedures;Clinical Protocols;Comorbidity;Coronary Artery Bypass;Hospital Mortality;Humans;Postoperative Care,E02.095.135;E04.100.376;E04.928.220;E02.183;N05.715.360.330.125;N05.715.350.225;N06.850.490.687;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.700;E04.604.500;N02.421.585.722.700
28714222,"Humans;Immunization Schedule;Immunocompromised Host;Insurance, Health;Kidney Transplantation;Practice Guidelines as Topic;Societies, Medical;Transplant Recipients;United States;Vaccination;Vaccines",B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.470;E05.478.550.545;G12.470;N03.219.521.576.343;E02.870.500;E04.936.450.485;E04.950.774.400;N04.761.700.350.650;N05.700.350.650;N03.540.828.589;M01.925;Z01.107.567.875;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;D20.215.894
28713870,,
28713673,Mesothelioma;Surgical Oncology,C04.557.470.035.510;C04.557.470.660.510;H02.403.429.515.750;H02.403.810.796
28713160,"Animals;Cell-Derived Microparticles;Diabetic Retinopathy;Endothelial Cells;Endothelium, Vascular;Humans;Inflammation;Metalloendopeptidases;MicroRNAs;Microvessels;Neovascularization, Pathologic;Stem Cells",B01.050;A11.284.295.588.500;C11.768.257;C14.907.320.382;C19.246.099.500.382;A11.436.275;A07.015.700.500;A10.272.491.355;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D08.811.277.656.300.480;D08.811.277.656.675.374;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A07.015.461;C23.550.589.500;A11.872
28712537,Adolescent;Genetic Therapy;Genetic Vectors;Humans;Mutation;Retinal Dystrophies;Treatment Outcome;United States;cis-trans-Isomerases,M01.060.057;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C11.768.585.658;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;D08.811.399.325
28711813,"Brain;Conditioning (Psychology);Consensus;Craving;Cues;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Sex Characteristics;Smoking;Tobacco Smoking;Tobacco Use Disorder;Nicotine;Tobacco Use Disorder;Sex Characteristics;Magnetic Resonance Imaging",A08.186.211;F02.463.425.179;F01.829.316.068;F02.463.785.373.433;F01.658.293.195;F02.463.425.234;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;G08.686.815;F01.145.805;F01.145.805.375;F01.145.958.875;C25.775.912;F03.900.912;D03.132.760.570;D03.383.725.518;C25.775.912;F03.900.912;G08.686.815;E01.370.350.825.500
28711726,Myelodysplastic Syndromes,C15.378.190.625
28711294,Adult;Aged;Central Nervous System Neoplasms;Hemangiopericytoma;Humans;Middle Aged;Postoperative Complications;Radiosurgery;Survival Analysis;Hemangiopericytoma;Radiation;Radiosurgery;General Surgery;Survival,M01.060.116;M01.060.116.100;C04.588.614.250;C10.551.240;C04.557.645.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.767;E02.815.530;E04.525.800.650;E05.873.500;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;C04.557.645.380;G01.750;E02.815.530;E04.525.800.650;E05.873.500;H02.403.810.300;I03.784
28711192,"Adult;Aged;Aged, 80 and over;Anxiety;Cognition Disorders;Cohort Studies;Humans;Middle Aged;Neuropsychological Tests;Parkinson Disease;Predictive Value of Tests;Psychiatric Status Rating Scales;Time Factors;Anxiety;Neuropsychiatry;Parkinson Disease;Risk Factors",M01.060.116;M01.060.116.100;M01.060.116.100.080;F01.470.132;F03.615.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;F04.711.513.653;G01.910.857;F01.470.132;F04.096.544.504;H02.403.690.754;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28711176,"Abatacept;Adalimumab;Adolescent;Antibodies, Monoclonal, Humanized;Arthritis, Juvenile;Biological Factors;Child;Etanercept;Humans;Prognosis;Rheumatic Diseases;Risk Assessment;Rituximab;Severity of Illness Index;Treatment Outcome;United States;United States Food and Drug Administration",D12.776.124.790.651.114.580.225;D12.776.377.715.548.114.580.225;D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;M01.060.057;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;D23;M01.060.406;D12.644.541.500.697.624;D12.776.124.486.485.538.500.624;D12.776.124.486.485.680.697.624;D12.776.124.790.651.538.500.624;D12.776.124.790.651.680.660.624;D12.776.377.715.548.538.500.624;D12.776.377.715.548.680.660.624;D12.776.543.750.705.852.760.232;B01.050.150.900.649.313.988.400.112.400.400;E01.789;C05.799;C17.300.775;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
28711093,"Dermatology;Health Care Costs;Humans;Medicaid;Medicare;Practice Patterns, Physicians';Rural Population;Skin Diseases;United States;Workforce",H02.403.225;N03.219.151.400;N05.300.375;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.590.374.577;N05.300.625;N01.600.725;C17.800;Z01.107.567.875;N04.452.525
28711090,"Academic Medical Centers;Administration, Oral;Adult;Aged;Antimalarials;Databases, Factual;Dermatomyositis;Dose-Response Relationship, Drug;Drug Administration Schedule;Humans;Lupus Erythematosus, Cutaneous;Middle Aged;Quinacrine;Retrospective Studies;Severity of Illness Index",N02.278.020;E02.319.267.100;M01.060.116;M01.060.116.100;D27.505.954.122.250.100.085;L01.313.500.750.300.188.400;L01.470.750.750;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;G07.690.773.875;G07.690.936.500;E02.319.283;B01.050.150.900.649.313.988.400.112.400.400;C17.300.475;C17.800.480;M01.060.116.630;D03.633.300.046.250.760;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28711085,"Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;Cross-Sectional Studies;Foot;Genitalia;Guideline Adherence;Hand;Head and Neck Neoplasms;Humans;Leg;Margins of Excision;Melanoma;Middle Aged;Neoplasm, Residual;Practice Guidelines as Topic;Retrospective Studies;Risk Factors;Skin Neoplasms;Young Adult;Counseling",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;A01.378.610.250;A05.360;N04.761.337;N05.715.360.395;A01.378.800.667;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.500;A10.830;C23.149.625;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;C04.697.700;C23.550.727.700;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C04.588.805;C17.800.882;M01.060.116.815;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363
28710775,"Animals;Anti-Inflammatory Agents, Non-Steroidal;Cardiovascular Diseases;Cyclooxygenase Inhibitors;Gastrointestinal Diseases;Humans;Inflammation;Pain",B01.050;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;C14;D27.505.519.389.310;D27.505.696.663.850.014.040.500.500;D27.505.954.158.030.500;D27.505.954.329.030.500;C06.405;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C23.888.592.612;F02.830.816.444;G11.561.790.444
28710739,Rehabilitation;Return to Sport,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784;I03.450.642.845.605
28710091,"Adult;Aged;Arteriovenous Shunt, Surgical;Constriction, Pathologic;Humans;Hyperplasia;Middle Aged;Peripheral Vascular Diseases;Postoperative Complications;Prospective Studies;Regional Blood Flow;Renal Dialysis;Tunica Intima;Ultrasonography",M01.060.116;M01.060.116.100;E04.035.087;E04.100.814.868.249;C23.300.287;B01.050.150.900.649.313.988.400.112.400.400;C23.550.444;M01.060.116.630;C14.907.617;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G09.330.100.780;E02.870.300;E02.912.800;A07.015.700;E01.370.350.850
28710076,Environmental Exposure;Humans;Microbiota;Occupational Exposure;Risk Assessment,N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;N06.850.460.350.600;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
28709967,"Air Pollution;Animals;Asthma;Biomarkers;Climate;Comorbidity;Humans;Lung;Patient Outcome Assessment;Precision Medicine;Risk Factors;Virus Diseases;Air Pollution;Desensitization, Immunologic;Hypersensitivity;Asthma;Biomarkers;Pulmonary Disease, Chronic Obstructive;Climate;Eosinophils;Genetics;Medication Adherence;Microbiota;Pregnancy;Respiratory Syncytial Viruses;Rhinovirus;Tiotropium Bromide",N06.850.460.100;B01.050;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;D23.101;G16.500.275.071;N06.230.300.100.250;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;A04.411;N04.761.559.590.399;N05.715.360.575.575.399;E02.574;H02.403.200.700;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C02;N06.850.460.100;E02.095.465.425.450.310;E05.478.610.310;C20.543;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;D23.101;C08.381.495.389;G16.500.275.071;N06.230.300.100.250;A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251;H01.158.273.343;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G08.686.784.769;B04.820.455.600.670.600.750;B04.820.565.775;D02.145.074.722.822.887;D03.132.889.601.887;D03.605.084.500.722.822.887;D03.605.869.822.887
28709161,"Adolescent;Anti-HIV Agents;Caregivers;Child;Cohort Studies;Executive Function;HIV Infections;Humans;Infectious Disease Transmission, Vertical;Medication Adherence",M01.060.057;D27.505.954.122.388.077.088;M01.085;M01.526.485.200;N02.360.200;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F02.463.217;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;N06.850.310.425;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500
28709002,"Breast Neoplasms;DEAD Box Protein 58;Exosomes;Humans;Interferon Regulatory Factors;MCF-7 Cells;Neoplasm Metastasis;RNA Polymerase III;RNA, Untranslated;Receptors, Pattern Recognition;Signal Recognition Particle;Stromal Cells;Tumor Microenvironment;Virus Diseases;RNA-Binding Proteins;Breast Neoplasms;Exosomes;Fibroblasts;Receptors, Pattern Recognition;Radiotherapy;Tumor Microenvironment",C04.588.180;C17.800.090.500;D08.811.913.696.445.735.720.249.750;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360.024.302;D12.776.157.057.050;D12.776.260.504;D12.776.476.024.385;D12.776.930.332;A11.251.210.190.630;C04.697.650;C23.550.727.650;D08.811.913.696.445.735.270.775;D13.444.735.790;D12.776.543.750.705.910;D12.776.157.725.500.750.800;D12.776.664.962.500.750.800;A11.329.830;G04.366.500;C02;D12.776.157.725;D12.776.664.962;C04.588.180;C17.800.090.500;A11.284.295.588.750;A11.284.430.214.190.875.190.880.495;A11.329.228;D12.776.543.750.705.910;E02.815;G04.366.500
28708801,"Arthritis, Infectious;Disease Management;Disease Susceptibility;Humans;Osteomyelitis",C01.539.100;C05.550.114.099;N04.590.607;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;C01.539.160.495;C05.116.165.495
28708309,"Age Factors;Animals;Bony Callus;Cell Proliferation;Fracture Healing;Inflammation;Mice;Mice, Inbred C57BL;Principal Component Analysis;Signal Transduction;Bone Regeneration",N05.715.350.075;N06.850.490.250;B01.050;A10.165.265.200;G04.161.750;G07.345.249.410.750;G16.762.891.500;C23.550.470;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.318.740.562;G02.111.820;G04.835;G11.427.213.140;G16.762.150.150
28708124,Electronic Nicotine Delivery Systems;Harm Reduction;Interviews as Topic;Product Labeling;Electronic Nicotine Delivery Systems;Health Communication,J01.637.767.500;F01.145.477;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;J01.576.761.700;J01.637.767.500;L01.143.350;N02.208
28707678,,
28707510,Adolescent;Adult;Aged;Connective Tissue Diseases;Fingers;Humans;Ischemia;Middle Aged;Retrospective Studies;Sympathectomy;Treatment Outcome;Young Adult;Sympathectomy,M01.060.057;M01.060.116;M01.060.116.100;C17.300;A01.378.800.667.430;B01.050.150.900.649.313.988.400.112.400.400;C23.550.513;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E04.525.210.105.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;E04.525.210.105.800
28707191,"Bacterial Proteins;Bacterial Toxins;Biopsy;Child;Clostridium difficile;Colitis;Colonoscopy;Diarrhea;Enterocolitis, Pseudomembranous;Enterotoxins;Feces;Humans;Sensitivity and Specificity;Child;Clostridium difficile;Colitis;Colonoscopy;Enterocolitis, Pseudomembranous",D12.776.097;D23.946.123;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;C06.405.205.265;C06.405.469.158.188;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C23.888.821.214;C01.252.410.222.310;C06.405.205.596.800;C06.405.469.363.800;D23.946.330;A12.459;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.406;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;C06.405.205.265;C06.405.469.158.188;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C01.252.410.222.310;C06.405.205.596.800;C06.405.469.363.800
28706564,"Animals;Ascorbic Acid;Cell Line;Embryonic Stem Cells;Histones;Jumonji Domain-Containing Histone Demethylases;Methylation;Mice;Protein Processing, Post-Translational;Vitamins;Embryonic Stem Cells;Epigenomics;Ascorbic Acid",B01.050;D02.241.081.844.107;D02.241.511.902.107;D09.811.100;A11.251.210;A11.872.700.250;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D08.811.682.662.582.475.500;D08.811.682.690.416.388;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.150.900.649.313.992.635.505.500;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D27.505.696.377.683.500.600;G07.203.300.681.500.600;J02.500.681.500.600;A11.872.700.250;H01.158.273.180.350.074;H01.158.273.343.350.042;D02.241.081.844.107;D02.241.511.902.107;D09.811.100
28706462,,
28705860,"Antigens, CD19;Antigens, Neoplasm;Apoptosis;B-Lymphocytes;Child, Preschool;Cytokines;Eyelids;Humans;Immunotherapy, Adoptive;Leukemic Infiltration;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Recombinant Fusion Proteins;T-Lymphocytes",D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;D23.050.285;G04.146.160;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;M01.060.406.448;D12.644.276.374;D12.776.467.374;D23.529.374;A01.456.505.420.504;A09.371.337;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.697.645.500;C23.550.727.645.500;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D12.776.828.300;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28705557,"Adult;Aged;Aged, 80 and over;Contrast Media;Humans;Image Enhancement;Liver;Liver Neoplasms;Middle Aged;Ultrasonography;Young Adult;Automation;Contrast Media;Liver Neoplasms",M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.259.500;D27.720.259;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.600.350;L01.224.308.380;A03.620;C04.588.274.623;C06.301.623;C06.552.697;M01.060.116.630;E01.370.350.850;M01.060.116.815;J01.897.104;D27.505.259.500;D27.720.259;C04.588.274.623;C06.301.623;C06.552.697
28705022,Vilazodone Hydrochloride;Child;Poisoning,D03.383.606.980;D03.633.100.127.818;D03.633.100.473.957;M01.060.406;C25.723
28704921,"Ciliopathies;Tomography, Optical Coherence",C16.131.077.245;C16.320.184;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500
28704847,,
28704648,"Alveolar Bone Loss;Animals;Bacteria;Bone Resorption;Colony Count, Microbial;DNA, Bacterial;Diabetes Mellitus, Experimental;Genes, Bacterial;Inflammation;Interleukin-17;Interleukin-6;Mice;Mice, Inbred C57BL;Microbiota;Mouth;Neutrophil Infiltration;Osteoclasts;Periodontitis;RANK Ligand;RNA, Ribosomal, 16S;Sequence Analysis;Tooth Loss;Virulence;Interleukin-17;Dysbiosis;Microbiota;Osteoclasts;Periodontitis",C05.116.264.150;C07.465.714.354.500;B01.050;B03;C05.116.264;G11.427.213.150;E01.370.225.875.220;E05.200.875.220;D13.444.308.212;C18.452.394.750.074;C19.246.240;E05.598.500.374;G05.360.340.024.340.364.249;G05.360.340.358.024.249;G05.360.340.358.207.249;C23.550.470;D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A01.456.505.631;A03.556.500;A14.549;G12.632;A11.329.372.700;A11.627.482.700;C07.465.714.533;D12.644.276.374.750.562;D12.776.467.374.750.562;D23.529.374.750.562;D13.444.735.686.670;E05.393.760;C07.465.714.804;C07.793.870;G06.930;D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517;C23.550.308;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A11.329.372.700;A11.627.482.700;C07.465.714.533
28704250,Adult;Blood Substitutes;Calcium;Health Resources;Hospital Mortality;Humans;Hypercalcemia;Hypocalcemia;Middle Aged;Mortality;Pilot Projects;Resuscitation;Wounds and Injuries;Young Adult,M01.060.116;D27.505.954.502.140;J01.637.087.249;D01.268.552.100;D01.552.539.288;D23.119.100;N03.349.340;N05.300.420;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;C18.452.174.451;C18.452.950.340;C18.452.174.509;C18.452.950.509;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E02.365.647;C26;M01.060.116.815
28704225,,
28703949,,
28703948,"Humans;Insurance Coverage;Insurance, Health;Patient Protection and Affordable Care Act;United States;Young Adult",B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;N03.219.521.576.343.918;N03.706.615.806;Z01.107.567.875;M01.060.116.815
28702543,"Amino Acid Sequence;Antimicrobial Cationic Peptides;Hydrophobic and Hydrophilic Interactions;Lipid Bilayers;Molecular Dynamics Simulation;Peptides;Phosphatidylcholines;Phosphatidylethanolamines;Phosphatidylglycerols;Phosphatidylserines;Protein Structure, Secondary",G02.111.570.060;L01.453.245.667.060;D12.644.050;D12.776.543.695.054;G02.409;D10.570.510;J01.637.087.500.510;E05.599.595.500;G02.111.570.895;L01.224.160.500;D12.644;D10.570.755.375.760.400.800;D10.570.755.375.760.400.840;D10.570.755.375.760.400.885;D10.570.755.375.760.400.971;G02.111.570.820.709.600
28702330,"Adiposity;Animals;Exenatide;Glucagon-Like Peptide-1 Receptor;Hypothalamus;Incretins;Mice;Mice, Inbred C57BL;Neurons;Orexins;Peptides;Venoms;Adipose Tissue, Beige;Incretins;Metabolism;Obesity",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;B01.050;D12.644.187;D20.888.300;D23.946.833.300;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;A08.186.211.180.497;A08.186.211.200.317.357;D27.505.696.399.472.580;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A08.675;A11.671;D12.644.400.360;D12.776.631.650.363;D12.644;A12.200.935;D20.888;D23.946.833;A10.165.114.161;D27.505.696.399.472.580;G03;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28701496,"Animals;Brain Concussion;Diagnosis, Differential;Humans",B01.050;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;E01.171;B01.050.150.900.649.313.988.400.112.400.400
28701476,"Adenocarcinoma;Aged;Biomarkers, Tumor;CA-19-9 Antigen;Carcinoma, Pancreatic Ductal;Case-Control Studies;Demography;Early Detection of Cancer;Humans;Middle Aged;Reproducibility of Results;Thrombospondins",C04.557.470.200.025;M01.060.116.100;D23.101.140;D23.050.285.050.119;D23.050.301.290.544.119;D23.050.550.325.119;D23.050.705.230.544.119;D23.101.140.075.119;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;I01.240;N01.224;N06.850.505.400;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;D12.776.395.550.895;D12.776.543.550.895
28700992,"Amniotic Fluid;Humans;Infant, Newborn;North America;Pregnancy;Registries;Retrospective Studies;Ultrasonography, Prenatal;Urethral Obstruction;Fetal Therapies;Oligohydramnios",A12.098;A16.378.149;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;Z01.107.567;G08.686.784.769;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.850.865;E01.370.378.630.865;C12.777.767.700;C13.351.968.767.700;E02.467;C13.703.560
28700940,"ADP-Ribosylation Factors;Adenylyl Cyclases;Alleles;Animals;Antigens, Neoplasm;Cilia;Fibroblasts;Hedgehog Proteins;Homozygote;Humans;Mice;Mice, Knockout;Mutation;Neoplasm Proteins;Receptors, G-Protein-Coupled;Smoothened Receptor;Ciliopathies;Organoids;Retinal Degeneration",D08.811.277.040.330.300.400.100;D12.644.360.525.100;D12.776.157.325.515.100;D12.776.476.525.100;D08.811.520.650.200;D12.644.360.050;D12.776.476.050;G05.360.340.024.340.030;B01.050;D23.050.285;A11.284.180.165;A11.329.228;D12.644.276.671;D12.776.467.671;D23.529.671;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;D12.776.624;D12.776.543.750.695;D12.776.543.750.695.017.500;D12.776.543.750.850.500.500;C16.131.077.245;C16.320.184;A10.802;C11.270.612;C11.768.585
28700795,"Dermatology;History, 19th Century;History, 20th Century;Humans;Skin Diseases;Textbooks as Topic;United Kingdom",H02.403.225;K01.400.504.937;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;C17.800;L01.178.682.192.900;L01.178.820.900;Z01.542.363
28700415,"Age of Onset;Child, Preschool;Genetic Markers;Genetic Predisposition to Disease;Genetic Testing;Genetic Variation;Humans;Inflammatory Bowel Diseases;Phenotype;Severity of Illness Index;Whole Exome Sequencing",N05.715.350.075.100;N06.850.490.250.100;M01.060.406.448;D23.101.387;G05.695.450;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;G05.695;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.393.760.700.825.500
28700413,Adult;Anticoagulants;Follow-Up Studies;Humans;Incidence;Injury Severity Score;Intraoperative Period;Postoperative Period;Retrospective Studies;Risk Assessment;Risk Factors;United States;Vascular Surgical Procedures;Vascular System Injuries;Venous Thromboembolism;Young Adult,M01.060.116;D27.505.954.502.119;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E04.614.374;N02.421.585.753.374;E04.614.750;N02.421.585.753.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;E04.100.814;C14.907.937;C26.940;C14.907.355.590.700;M01.060.116.815
28699832,Adolescent;Central Nervous System;Central Nervous System Stimulants;Cognition;Humans;Neuropsychological Tests;Nootropic Agents;Placebo Effect;Students;Surveys and Questionnaires;Task Performance and Analysis;Young Adult,M01.060.057;A08.186;D27.505.696.282;D27.505.954.427.220;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;D27.505.954.427.637;N05.715.350.350.625;N06.850.490.734.875;M01.848;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F02.784.412.846;F02.784.692.746;F02.808.600;M01.060.116.815
28699543,"Adverse Drug Reaction Reporting Systems;Data Mining;Humans;Patient Safety;Signal Detection, Psychological;Vaccines",E05.337.800.120;N02.421.668.320.120;L01.313.500.750.280.199;L01.470.625;B01.050.150.900.649.313.988.400.112.400.400;N06.850.135.060.075.399;E01.370.685.814;E05.796.908;F02.463.593.257.800;F02.463.593.710.725;F04.096.753.814;F04.669.908;D20.215.894
28698942,"Consensus;Europe;Humans;Magnetic Resonance Imaging;Penis;Scrotum;Societies, Medical;Urology;Evidence-Based Medicine;Scrotum;Testis",F01.829.316.068;F02.463.785.373.433;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A05.360.444.492;A05.360.444.661;N03.540.828.589;H02.403.810.860;H02.249.750;H02.403.200.400;A05.360.444.661;A05.360.444.849;A05.360.576.782;A06.300.312.782
28698313,"HIV Infections;HIV-1;Humans;Inhibitor of Apoptosis Proteins;Interleukins;Lipopolysaccharides;MAP Kinase Signaling System;Macrophages;Phosphatidylinositol 3-Kinases;Protein Tyrosine Phosphatase, Non-Receptor Type 6;TNF Receptor-Associated Factor 6;p38 Mitogen-Activated Protein Kinases;tat Gene Products, Human Immunodeficiency Virus;HIV Infections",C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;D08.811.464.938.750.210;D12.644.360.075.437;D12.776.476.075.437;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;G02.111.820.560;G03.493.560;G04.835.560;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;D08.811.913.696.620.500;D08.811.277.352.650.775.300.600;D08.811.277.352.650.775.700.200;D12.644.360.585.600;D12.644.360.800.200;D12.776.476.564.600;D12.776.476.800.200;D12.644.360.024.500.968;D12.776.157.057.500.968;D12.776.476.024.500.968;D08.811.913.696.620.682.700.567.843;D12.644.360.450.835;D12.776.476.450.835;D12.776.260.755.199.500;D12.776.930.900.199.500;D12.776.964.775.562.773;D12.776.964.925.984.400.500;C02.782.815.616.400;C02.800.801.400;C20.673.480
28697782,"Biomedical Research;Career Choice;Education, Graduate;Education, Medical, Graduate;Humans;Physicians;Research Personnel;Specialization;Training Support",H01.770.644.145;F02.463.785.373.346.400;I02.358.337;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;M01.526.839;H02.811;N03.219.483.838
28697740,Algorithms;Genomics;Humans;Principal Component Analysis;Principal Component Analysis,G17.035;L01.224.050;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.562;E05.318.740.562
28697537,"Adolescent;Adult;Child;Child, Preschool;Humans;Prospective Studies;Reproducibility of Results;Retinal Dystrophies;Task Performance and Analysis;Vision Tests;Visual Acuity;Visual Fields;Visually Impaired Persons;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C11.768.585.658;F02.784.412.846;F02.784.692.746;F02.808.600;E01.370.380.850;E01.370.380.850.950;F02.463.593.932.901;G14.940;F02.463.593.932.934;G14.950;M01.150.850;M01.060.116.815
28697361,,
28696504,"Child, Preschool;Disease-Free Survival;Ganglioneuroma;Gene Amplification;Gene Dosage;Humans;Infant;Linear Models;N-Myc Proto-Oncogene Protein;Neoplasm Staging;Neuroblastoma;Proportional Hazards Models;Retrospective Studies;Neuroblastoma;Ploidies;Prognosis",M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.557.465.625.600.355;C04.557.470.670.355;C04.557.580.625.600.355;G05.308.250;G05.365.590.310;G05.558.315;G05.380.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;E01.789.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.700;E01.789
28696298,"Animals;Ants;Behavior, Animal;Insect Proteins;Pheromones;Receptors, Odorant;Social Behavior;Transcriptome;Ants;Receptors, Odorant",B01.050;B01.050.500.131.617.720.500.500.875.205;F01.145.113;D12.776.093.500;D23.641;D12.776.543.750.695.600;F01.145.813;G02.111.873.750;G05.297.700.750;G05.360.920;B01.050.500.131.617.720.500.500.875.205;D12.776.543.750.695.600
28695822,"Animals;Behavior, Animal;Brain;Developmental Disabilities;Disease Models, Animal;Gene Expression Regulation;Growth Hormone-Releasing Hormone;Haploinsufficiency;Heterozygote;Insulin-Like Growth Factor I;Mental Disorders;Mice;Protein-Serine-Threonine Kinases;Transcription Factors;Autism Spectrum Disorder;Endocrinology;Humans;Medicine;Mice;Neurodevelopmental Disorders;Neurosciences",B01.050;F01.145.113;A08.186.211;F03.625.421;C22.232;E05.598.500;E05.599.395.080;G05.308;D06.472.699.327.740.860;D12.644.400.400.740.860;D12.644.548.365.740.860;D12.776.631.650.405.740.860;G05.365.590.029.530.587;G05.380.350.500;G05.380.383;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;F03;B01.050.150.900.649.313.992.635.505.500;D08.811.913.696.620.682.700;D12.776.930;F03.625.164.113;H01.158.782.323;H02.403.429.323;B01.050.150.900.649.313.988.400.112.400.400;H02.403;B01.050.150.900.649.313.992.635.505.500;F03.625;H01.158.610
28695672,"Affective Symptoms;Autism Spectrum Disorder;Child, Preschool;Developmental Disabilities;Humans;Parents;Autistic Disorder;Mental Health",F01.145.126.100;F03.625.164.113;M01.060.406.448;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F03.625.164.113.500;F02.418;N01.400.500
28695349,"Animals;Cognition;Dogs;Factor Analysis, Statistical;Principal Component Analysis;Problem Solving;Temperament;Behavior;Cognition;Problem Solving;Temperament",B01.050;F02.463.188;B01.050.150.900.649.313.750.250.216.200;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;E05.318.740.562;F02.463.425.725;F02.463.785.810;F01.752.898;F01.145;F02.463.188;F02.463.425.725;F02.463.785.810;F01.752.898
28694390,Amides;Animals;Antiviral Agents;Cercopithecus aethiops;Drug Synergism;Humans;Inhibitory Concentration 50;Microbial Sensitivity Tests;Pyrazines;Ribavirin;Spatio-Temporal Analysis;Vero Cells;Zika Virus;Zika Virus Infection,D02.065;B01.050;D27.505.954.122.388;B01.050.150.900.649.313.988.400.112.199.120.126.110;G07.690.773.968.477;B01.050.150.900.649.313.988.400.112.400.400;E05.940.350;G07.690.936.563;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;D03.383.679;D13.570.800.790;E05.318.740.933.500;N05.715.360.750.746.500;N06.850.520.830.933.500;A11.251.210.955;A11.436.955;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
28694237,"Blood Coagulation;Blood Platelets;Elasticity;Erythrocytes;Humans;Models, Biological;Platelet-Rich Plasma;Phase Transition;Erythrocytes",G09.188.390.150;A11.118.188;A15.145.229.188;G01.374.590;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;A12.207.152.693.600;A12.207.270.695.600;A15.145.693.600;G01.645;G02.734;A11.118.290;A11.443.240;A15.145.229.334
28694063,"Adult;Behavior, Addictive;Crowdsourcing;Data Collection;Drug Labeling;Humans;Internet;Prevalence;Public Health;Smoking;Surveys and Questionnaires;Tobacco Use;Crowdsourcing;Young Adult",M01.060.116;F01.145.527.100.120;L01.399.250.179;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;E05.916.310;J01.576.655.750.321.400;J01.576.761.300.400;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;H02.403.720;N01.400.550;N06.850;F01.145.805;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F01.145.958;L01.399.250.179;M01.060.116.815
28693852,Delivery of Health Care;Humans;Otolaryngology;Patient Care Team;Simulation Training;Otolaryngology;Safety,N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;H02.403.810.526;N04.590.715;I02.903.847;H02.403.810.526;N06.850.135.060.075
28692593,"Adult;Aged;Carcinoma, Squamous Cell;Databases, Factual;Ear Neoplasms;Ear, Middle;Humans;Kaplan-Meier Estimate;Keratins;Middle Aged;Multivariate Analysis;Prognosis;Proportional Hazards Models;Radiotherapy;Radiotherapy, Adjuvant;Retrospective Studies;United States",M01.060.116;M01.060.116.100;C04.557.470.200.400;C04.557.470.700.400;L01.313.500.750.300.188.400;L01.470.750.750;C04.588.443.665.312;C09.218.334;C09.647.312;A09.246.397;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;D05.750.078.593.450;D12.776.220.475.450;D12.776.860.607;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E02.815;E02.186.775;E02.815.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28692578,"Adult;African Americans;Child Development;Humans;Infant;Intelligence;Mothers;Residence Characteristics;Social Environment;Socioeconomic Factors;Stress, Psychological;Vulnerable Populations",M01.060.116;M01.686.508.100.100;M01.686.754.100;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.752.543;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;N01.224.791;N06.850.505.400.800;I01.880.853.500;I01.880.853.996;N01.824;F01.145.126.990;F02.830.900;M01.965
28692575,"Blood Coagulation;Clinical Trials, Phase I as Topic;Enzyme Precursors;Factor Va;Factor Xa;Hemorrhage;Hemostatic Techniques;Humans",G09.188.390.150;E05.318.372.250.250.200;N05.715.360.330.250.250.200;N06.850.520.450.250.250.200;D08.622;D12.776.124.125.300.300;D23.119.300.300;D08.811.277.656.300.760.315;D08.811.277.656.959.350.315;D12.776.124.125.400.315;D23.119.400.315;C23.550.414;E02.520;B01.050.150.900.649.313.988.400.112.400.400
28692529,"Adult;Aged;Anti-HIV Agents;Benzoxazines;Botswana;Cytochrome P-450 CYP2B6;Drug-Related Side Effects and Adverse Reactions;Genotype;Genotyping Techniques;HIV Infections;Humans;Middle Aged;Prospective Studies;RNA, Viral;Surveys and Questionnaires;Survival Analysis;Treatment Outcome;Viral Load;Young Adult",M01.060.116;M01.060.116.100;D27.505.954.122.388.077.088;D03.383.533.249;D03.633.100.209;Z01.058.290.175.230;D08.244.453.005.575;D08.244.453.491.344;D08.811.682.690.708.170.010.575;D08.811.682.690.708.170.450.344;D12.776.422.220.453.010.575;D12.776.422.220.453.491.344;C25.100;G05.380;E05.393.442;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D13.444.735.828;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.225.875.950;E05.200.875.950;G06.920.850;M01.060.116.815
28692128,Adult;Aged;Carpal Tunnel Syndrome;Charcot-Marie-Tooth Disease;Humans;Median Nerve;Middle Aged;Pain Measurement;Retrospective Studies;Severity of Illness Index;Charcot-Marie-Tooth Disease;Carpal Tunnel Syndrome,M01.060.116;M01.060.116.100;C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;B01.050.150.900.649.313.988.400.112.400.400;A08.800.800.720.050.500;M01.060.116.630;E01.370.600.550.324;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.500.300.200;C10.574.500.495.200;C10.668.829.800.300.200;C16.131.666.300.200;C16.320.400.375.200;C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206
28691958,"Adolescent;Child;Child Nutritional Physiological Phenomena;Child, Preschool;Critical Care;Critical Illness;Humans;Infant;Intensive Care Units, Pediatric;Malnutrition;Nutritional Requirements;Nutritional Status;Nutritional Support",M01.060.057;M01.060.406;G07.203.650.220;M01.060.406.448;E02.760.190;N02.421.585.190;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;C18.654.521;G07.203.650.620;G07.203.650.650;N01.224.425.525;E02.642.500
28691569,Arnold-Chiari Malformation;Case-Control Studies;Cervical Vertebrae;Child;Edema;Encephalocele;Humans;Magnetic Resonance Imaging;Spinal Canal;Spinal Cord;Syringomyelia;Spine,C10.500.680.291;C16.131.666.680.291;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A02.835.232.834.151;M01.060.406;C23.888.277;C10.500.680.488;C16.131.666.680.488;C23.300.707.186;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A02.835.232.834.803;A08.186.854;C10.228.854.833;A02.835.232.834
28691223,Arachis;Humans;Immune Tolerance;Immunoglobulin E;Peanut Hypersensitivity;Skin Tests,B01.650.940.800.575.912.250.401.077;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;C20.543.480.370.572.750;E01.370.225.812.871;E05.200.812.871;E05.478.594.890
28690502,Eye Movements,G11.427.410.140;G14.350
28689737,Actomyosin;Animals;Body Patterning;Drosophila Proteins;Drosophila melanogaster;Extremities;rho-Associated Kinases,D12.776.210.500.154;B01.050;G07.345.500.100;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;A01.378;D08.811.913.696.620.682.700.814;D12.644.360.590;D12.776.476.595
28689661,"A549 Cells;ATP Citrate (pro-S)-Lyase;Acetyl Coenzyme A;Acetylation;Animals;BRCA1 Protein;Cell Nucleus;DNA Breaks, Double-Stranded;G2 Phase Cell Cycle Checkpoints;Genomic Instability;Glucose;HCT116 Cells;HeLa Cells;Histones;Humans;Melanoma, Experimental;Mice, Inbred C57BL;Phosphorylation;Poly(ADP-ribose) Polymerase Inhibitors;Protein Binding;Protein Processing, Post-Translational;RNA Interference;Recombinational DNA Repair;S Phase Cell Cycle Checkpoints;Serine;Time Factors;Transfection;Tumor Suppressor p53-Binding Protein 1;DNA Damage;DNA Repair;Acetyl Coenzyme A;Homologous Recombination;Metabolism",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;D08.811.913.050.331;D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;G02.111.012.052;G02.607.063.052;G03.040.052;B01.050;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;A11.284.430.106;A11.284.430.214.190.875.117;G05.200.210.220;G04.144.109.500;G04.144.500.340.500;C23.550.362;G05.365.590.335;G05.370;D09.947.875.359.448;A11.251.210.190.380;A11.251.860.180.380;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510.525;C04.557.580.625.650.510.525;C04.557.665.510.525;C04.619.600;E05.598.500.496.937;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.111.665;G02.607.780;G03.796;D27.505.519.389.739;D27.505.954.248.692;G02.111.679;G03.808;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;G05.308.203.374.790;G02.111.222.700;G05.219.700;G05.728.615.612;G04.144.109.875;G04.144.500.800.500;D12.125.154.800;G01.910.857;E05.393.350.810;G05.728.860;D12.776.260.805;D12.776.660.235.850;D12.776.664.235.950;G05.200;G02.111.222;G05.219;D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;G05.728.615;G03
30800803,"Burnout, Psychological;Leadership;Medical Errors;Burnout, Professional;Resilience, Psychological",F01.145.126.990.367;F02.830.900.333;F01.752.609;N02.421.450;C24.580.500;F01.145.126.990.367.500;F02.830.900.333.500;F02.940
28689329,Adolescent;Amygdala;Anxiety Disorders;Autism Spectrum Disorder;Child;Humans;Magnetic Resonance Imaging;Organ Size;Amygdala;Anxiety Disorders;Comorbidity,M01.060.057;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F03.080;F03.625.164.113;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F03.080;N05.715.350.225;N06.850.490.687
28689249,"Adolescent;Brain Neoplasms;Cancer Survivors;Caregivers;Child;Executive Function;Focus Groups;Humans;Middle Aged;Models, Psychological;Psychometrics;Social Adjustment;Social Environment;Social Skills;Social Skills",M01.060.057;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.860.350;M01.085;M01.526.485.200;N02.360.200;M01.060.406;F02.463.217;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.599.695;F04.711.780;F01.145.813.621;I01.880.853.500;F01.145.813.828;F01.829.401.737;F01.145.813.828;F01.829.401.737
28689248,Adolescent;Body Composition;Body Mass Index;Body Weight Maintenance;Health Behavior;Humans;Longitudinal Studies;Overweight;Time Factors;Weight Gain;Young Adult,M01.060.057;G02.111.130;G03.180;G07.100.049;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;G07.345.249.314.120.250;F01.145.488;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;G01.910.857;C23.888.144.243.926;G07.345.249.314.120.200.926;M01.060.116.815
28689245,"Adolescent;Carcinoma, Medullary;Child;Humans;Kidney Neoplasms;Lymphatic Metastasis;Neoplasm Staging;Retrospective Studies;Young Adult;Child;Carcinoma, Medullary",M01.060.057;C04.557.465.625.650.240.315;C04.557.470.200.025.370.315;C04.557.470.615.315;C04.557.580.625.650.240.315;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C04.697.650.560;C23.550.727.650.560;E01.789.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;M01.060.406;C04.557.465.625.650.240.315;C04.557.470.200.025.370.315;C04.557.470.615.315;C04.557.580.625.650.240.315
28688892,"5'-Nucleotidase;Animals;Diphosphates;GPI-Linked Proteins;Humans;Ossification, Heterotopic;RANK Ligand;Vascular Calcification;alpha-2-HS-Glycoprotein;Ossification, Heterotopic;Review;Vascular Calcification",D08.811.277.352.650.600.600;B01.050;D01.029.260.700.675.374.775.150;D01.248.497.158.730.650.200;D01.695.625.675.650.775.150;D12.776.395.550.448;D12.776.543.484.500;D12.776.543.550.418;B01.050.150.900.649.313.988.400.112.400.400;C23.550.751;D12.644.276.374.750.562;D12.776.467.374.750.562;D23.529.374.750.562;C18.452.174.130.780;D12.776.124.790.106.304.500;D12.776.157.125.283.500;D12.776.215.625.500;D12.776.377.715.085.304.500;D12.776.395.086;C23.550.751;V02.600.500;V02.912;C18.452.174.130.780
28688538,"Animals;Cartilage, Articular;Fibrillar Collagens;Mandibular Condyle;Mice, Inbred C57BL;Microscopy, Atomic Force;Osteoarthritis;Temporomandibular Joint;Fibrocartilage;Temporomandibular Joint",B01.050;A02.165.407.150;A02.835.583.192;D05.750.078.280.300;D12.776.860.300.250.300;A02.835.232.781.324.502.632.600;A14.521.632.600;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E01.370.350.515.666.400;E05.595.666.400;C05.550.114.606;C05.799.613;A02.835.583.861;A14.907;A02.165.308;A10.165.382.350;A02.835.583.861;A14.907
28688263,"Adolescent;Adult;Aged;Anisotropy;Attention;Case-Control Studies;Depressive Disorder, Major;Diffusion Tensor Imaging;Executive Function;Gyrus Cinguli;Humans;Middle Aged;White Matter;Young Adult;Diffusion Tensor Imaging;Depressive Disorder, Major",M01.060.057;M01.060.116;M01.060.116.100;G01.590.040;G02.050;F02.830.104.214;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F03.600.300.375;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;F02.463.217;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;A08.186.211.204;A08.186.854.880;M01.060.116.815;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;F03.600.300.375
28687708,"Arteriovenous Malformations;Capillaries;Databases, Genetic;Genome-Wide Association Study;Germ-Line Mutation;Humans;MAP Kinase Signaling System;Pedigree;Port-Wine Stain;Receptor, EphB4;p120 GTPase Activating Protein;Arteriovenous Fistula;Arteriovenous Malformations;Capillaries;Genetics;Vascular Diseases",C14.240.850.750;C14.907.150;C16.131.240.850.750;A07.015.461.165;L01.313.500.750.300.188.400.325;L01.470.750.750.325;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;G02.111.820.560;G03.493.560;G04.835.560;E05.393.673;C16.131.831.675;C17.800.804.675;D08.811.913.696.620.682.725.400.850.750;D12.776.543.750.630.500.781;D12.644.360.325.150.500.500;D12.776.476.325.150.500.500;C14.240.850.750.147;C14.240.850.984.750;C14.907.150.125;C14.907.933.555;C16.131.240.850.750.125;C23.300.575.950.250;C14.240.850.750;C14.907.150;C16.131.240.850.750;A07.015.461.165;H01.158.273.343;C14.907
28687270,,
28686870,"Animals;Antigens, Differentiation;Enteroendocrine Cells;Gene Expression Regulation;Intestinal Mucosa;Jejunum;Mice;Mice, Transgenic;Stem Cells",B01.050;D23.050.301.264;D23.101.100;A06.390;A11.382.625;A11.436.294;G05.308;A03.556.124.369;A10.615.550.444;A03.556.124.684.500;A03.556.249.750;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.872
28686853,"Amino Acid Sequence;Base Sequence;Child, Preschool;Chromosome Deletion;Facies;Gait;Growth and Development;Haploinsufficiency;Humans;Intellectual Disability;Mutation;Proteins;RNA Stability;Seizures;Syndrome;Intellectual Disability;Seizures",G02.111.570.060;L01.453.245.667.060;G02.111.570.080;G05.360.080;L01.453.245.667.080;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;C23.550.291.812;E01.370.600.230;E01.370.600.250;G11.427.410.568.900.750;G07.345;G05.365.590.029.530.587;G05.380.350.500;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590;D12.776;G02.111.780;C10.597.742;C23.888.592.742;C23.550.288.500;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C10.597.742;C23.888.592.742
28686844,"Child;Child Nutrition Disorders;Critical Care;Critical Illness;Dietary Proteins;Enteral Nutrition;Humans;Intensive Care Units, Pediatric;Length of Stay;Nutrition Assessment;Nutritional Requirements;Nutritional Status;Parenteral Nutrition;Randomized Controlled Trials as Topic;Societies, Medical;Adolescent;Algorithms;Child;Critical Illness;Enteral Nutrition;Calorimetry, Indirect;Infant;Intensive Care Units;Malnutrition;Obesity;Parenteral Nutrition",M01.060.406;C18.654.180;E02.760.190;N02.421.585.190;C23.550.291.625;D12.776.256;G07.203.300.428;J02.500.428;E02.421.360;E02.642.500.360;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E02.760.400.480;N02.421.585.400.480;E05.318.308.585;N05.715.360.300.560;N06.850.505.557;N06.850.520.308.585;G07.203.650.620;G07.203.650.650;N01.224.425.525;E02.421.505;E02.642.500.505;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;N03.540.828.589;M01.060.057;G17.035;L01.224.050;M01.060.406;C23.550.291.625;E02.421.360;E02.642.500.360;E05.196.131.655;M01.060.703;N02.278.388.493;C18.654.521;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02.421.505;E02.642.500.505
28686821,,
28686080,"African Americans;Anticoagulants;Cytochrome P-450 CYP2C9;Cytochrome P450 Family 4;European Continental Ancestry Group;Exome;Genome-Wide Association Study;Humans;Linkage Disequilibrium;Pharmacogenomic Variants;Polymorphism, Single Nucleotide;Vitamin K Epoxide Reductases;Warfarin;Cytochrome P-450 CYP2C9;Genome-Wide Association Study;Warfarin",M01.686.508.100.100;M01.686.754.100;D27.505.954.502.119;D08.244.453.491.500.500;D08.811.682.690.708.170.450.500.500;D12.776.422.220.453.491.500.500;D08.244.453.870;D08.811.682.690.708.170.496;D12.776.422.220.453.870;M01.686.508.400;G05.360.340.011;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.348.500;G05.365.795.446;G05.365.795.598;D08.811.682.690.708.961;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914;D08.244.453.491.500.500;D08.811.682.690.708.170.450.500.500;D12.776.422.220.453.491.500.500;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
28685988,Child;Fasting;Humans;Preoperative Care,M01.060.406;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.795;E04.604.750;N02.421.585.795
28685970,"Adolescent;Animals;Biomarkers;Cattle;Child;Cytokines;Desensitization, Immunologic;Humans;Immunization;Immunoglobulin E;Immunophenotyping;Milk;Milk Hypersensitivity;Natural Killer T-Cells;Skin Tests;T-Lymphocyte Subsets;Food Hypersensitivity;Natural Killer T-Cells",M01.060.057;B01.050;D23.101;B01.050.150.900.649.313.500.380.271;M01.060.406;D12.644.276.374;D12.776.467.374;D23.529.374;E02.095.465.425.450.310;E05.478.610.310;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525;C20.543.480.370.500;A11.118.637.555.567.569.290;A15.145.229.637.555.567.569.360;A15.382.490.555.567.569.470;E01.370.225.812.871;E05.200.812.871;E05.478.594.890;A11.118.637.555.567.550.500;A11.118.637.555.567.569.500;A15.145.229.637.555.567.550.500;A15.145.229.637.555.567.569.500;A15.382.490.555.567.550.500;A15.382.490.555.567.569.500;C20.543.480.370;A11.118.637.555.567.569.290;A15.145.229.637.555.567.569.360;A15.382.490.555.567.569.470
28685427,"Aging;Animals;Flavoproteins;Mice;Mice, Inbred C57BL;Mice, Transgenic;Mitochondria;Muscles;NAD;Optical Imaging;Oxidation-Reduction;Flavin-Adenine Dinucleotide;Mitochondria;Muscles;NAD",G07.345.124;B01.050;D12.776.331;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.284.430.214.190.875.564;A11.284.835.626;A02.633;A10.690;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694;E01.370.350.589;E05.642;G02.700;G03.295.531;D03.633.100.733.315.650.249;D03.633.100.759.646.138.506;D03.633.300.507.650.249;D08.211.474.650.249;D13.695.667.138.506;D13.695.827.068.506;D23.767.405.650.249;A11.284.430.214.190.875.564;A11.284.835.626;A02.633;A10.690;D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694
28684617,Embryonic Stem Cells,A11.872.700.250
28684559,"Advisory Committees;Arthritis, Psoriatic;Axis, Cervical Vertebra;Consensus;Decision Making;Humans;Severity of Illness Index;Spondylitis, Ankylosing;Spondylitis, Ankylosing;Outcome Assessment (Health Care);Arthritis, Psoriatic;Therapeutics",N03.706.742.500;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;A02.835.232.834.151.383;F01.829.316.068;F02.463.785.373.433;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850;C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;E02
28684244,,
28684174,"Brain;Child, Preschool;Connectome;Humans;Infant;Infant, Newborn;Neural Pathways;Connectome",A08.186.211;M01.060.406.448;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A08.612;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500
28684102,"Adaptation, Psychological;Aged;Alzheimer Disease;Caregivers;Cross-Sectional Studies;Depression;Humans;Prevalence;Quality of Life;Sleep Wake Disorders;Dementia;Depression;Quality of Life",F01.058;M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;M01.085;M01.526.485.200;N02.360.200;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;C10.886;C23.888.592.796;F03.870;C10.228.140.380;F03.615.400;F01.145.126.350;I01.800;K01.752.400.750;N06.850.505.400.425.837
28683962,"Adult;Antibiotics, Antineoplastic;Antineoplastic Agents;Arginine;Biomarkers, Tumor;Breast Neoplasms;Cardiomyopathies;Doxorubicin;Follow-Up Studies;Humans;Middle Aged;Nitric Oxide;Oxidative Stress;Prospective Studies;Time Factors;Trastuzumab;Cardiotoxicity;Doxorubicin;Nitrosative Stress;Trastuzumab",M01.060.116;D27.505.954.248.106;D27.505.954.248;D12.125.068.050;D12.125.095.104;D12.125.142.087;D23.101.140;C04.588.180;C17.800.090.500;C14.280.238;D02.455.426.559.847.562.050.200.175;D04.615.562.050.200.175;D09.408.051.059.200.175;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;G03.673;G07.775.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G01.910.857;D12.776.124.486.485.114.224.060.875;D12.776.124.790.651.114.224.060.875;D12.776.377.715.548.114.224.200.875;C23.550.161;C25.100.389;C26.733.266;G01.750.748.500.266;D02.455.426.559.847.562.050.200.175;D04.615.562.050.200.175;D09.408.051.059.200.175;G03.673.345;G07.775.750.500;D12.776.124.486.485.114.224.060.875;D12.776.124.790.651.114.224.060.875;D12.776.377.715.548.114.224.200.875
28683815,"Chromatography, High Pressure Liquid;HeLa Cells;Histone Code;Histones;Humans;Mass Spectrometry;Proteomics;Epigenomics;Histones;Mass Spectrometry;Methylation;Protein Processing, Post-Translational",E05.196.181.400.300;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;G02.111.570.060.360;G05.360.360;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;H01.158.273.180.350.074;H01.158.273.343.350.042;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G02.111.035.538;G02.607.094.538;G03.059.538;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
28682945,Critical Care;Critical Illness;Humans;Inflammation;Intensive Care Units;Malnutrition;Risk Factors,E02.760.190;N02.421.585.190;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;N02.278.388.493;C18.654.521;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28682835,"Clinical Alarms;Critical Illness;Decision Support Systems, Clinical;Drug Hypersensitivity;Drug Interactions;Humans;Intensive Care Units;Mental Fatigue;Practice Guidelines as Topic",E07.230.200;C23.550.291.625;L01.313.500.750.300.190;C20.543.206;C25.100.468;G07.690.773.968;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;C23.888.369.500;F01.145.126.937;N04.761.700.350.650;N05.700.350.650
28682812,,
28682528,Humans;Mental Disorders;Nervous System Diseases;S-Adenosylmethionine,B01.050.150.900.649.313.988.400.112.400.400;F03;C10;D02.886.030.676.180;D03.633.100.759.590.138.264;D12.125.166.676.180;D13.570.583.138.264;D13.570.800.096.264
28682339,,
28682326,,
28682306,"Amino Acid Sequence;Cell Cycle Proteins;Chromosomal Proteins, Non-Histone;Gene Silencing;Heterochromatin;Histones;Hydroxamic Acids;Methylation;Methyltransferases;Mutation;RNA Interference;Repressor Proteins;Schizosaccharomyces;Schizosaccharomyces pombe Proteins;Transcription, Genetic",G02.111.570.060;L01.453.245.667.060;D12.776.167;D12.776.660.235;D12.776.664.235;G05.308.203.374;A11.284.430.106.279.345.190.160.180.383;D12.776.664.224.466;G05.360.160.180.383;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D02.092.570.394;D02.241.511.372;G02.111.035.538;G02.607.094.538;G03.059.538;D08.811.913.555.500;G05.365.590;G05.308.203.374.790;D12.776.260.703;D12.776.930.780;B01.300.107.797;B01.300.930.720;D12.776.354.875;G02.111.873;G05.297.700
28681533,Communicable Diseases,C01.539.221
28680578,Mitochondria,A11.284.430.214.190.875.564;A11.284.835.626
28679811,Advance Directives;Decision Making;Humans;Surveys and Questionnaires;Terminal Care;United States;Advance Care Planning;Advance Directives;Living Wills,I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E02.760.905;N02.421.585.905;Z01.107.567.875;N04.590.233.624.124;I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050;I01.880.604.583.020.500;I01.880.604.583.927.500;N03.706.535.020.500;N04.590.233.624.124.050.500
28679751,"Animals;Antiviral Agents;Autoimmunity;Cytosol;DNA;DNA-Binding Proteins;Exodeoxyribonucleases;HEK293 Cells;Humans;Immunity, Innate;Interferon Type I;Interferon-beta;Macrophages;Mice;Mice, Inbred C57BL;Mice, Knockout;NIH 3T3 Cells;Pathogen-Associated Molecular Pattern Molecules;Phosphoproteins;Retroelements;Tumor Suppressor Proteins;Endogenous Retroviruses;Retroelements",B01.050;D27.505.954.122.388;G12.450.192;A11.284.430.214.200;A11.284.430.429.200;A11.284.835.450.200;D13.444.308;D12.776.260;D08.811.277.352.335.375;D08.811.277.352.365.290;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890;D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.251.210.100.550;A11.329.228.100.550;D23.585;D12.776.744;D13.444.308.760;G02.111.570.080.708.330.800;G05.360.080.708.330.800;G05.360.340.024.425.800;D12.776.624.776;B04.613.807.250;B04.820.650.250;G02.111.570.080.708.330.800.175;G05.360.080.708.330.800.175;G05.360.340.024.425.800.175;D13.444.308.760;G02.111.570.080.708.330.800;G05.360.080.708.330.800;G05.360.340.024.425.800
28679675,"Age Distribution;Aged;Body Mass Index;Colorectal Neoplasms;Diet, Mediterranean;Humans;Longitudinal Studies;Middle Aged;Obesity;Overweight;Proportional Hazards Models;Prospective Studies;Risk Factors;Sex Distribution;United States;Body Mass Index;Colorectal Neoplasms;Diet;Food",I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E02.642.249.270;G07.203.650.240.270;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;I01.240.800;N01.224.803;N06.850.505.400.850;Z01.107.567.875;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;G07.203.650.240;G07.203.300;J02.500
28679090,Delivery of Health Care;Humans;Refusal to Treat,N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;N04.590.233.727.605;N05.300.100.675
28678581,"Animals;Biomarkers;Bone Marrow Cells;Cell Differentiation;Cell Line;Cell Self Renewal;Gene Expression Regulation;Hematopoiesis;Hematopoietic Stem Cells;Immunophenotyping;Mice;Mice, Knockout;Receptor, Interferon alpha-beta;eIF-2 Kinase;Casein Kinase I;Interferons",B01.050;D23.101;A11.148;A15.378.316;G04.152;A11.251.210;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;G05.308;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.543.750.705.852.400.500;D08.811.913.696.620.682.700.300;D12.644.360.275;D12.776.476.275;D05.500.117.750;D08.811.913.696.620.682.700.140.300;D12.776.476.081.750;D12.776.476.150.299;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
28677912,"Adolescent;Aged;Child, Preschool;Cornea;Corneal Diseases;DNA;DNA Mutational Analysis;Eye Abnormalities;Humans;Mutation, Missense;Pedigree;Proteoglycans;Siblings;Tomography, Optical Coherence;Turkey;Young Adult;Phenotype",M01.060.057;M01.060.116.100;M01.060.406.448;A09.371.060.217;C11.204;D13.444.308;E05.393.760.700.300;C11.250;C16.131.384;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;E05.393.673;D09.698.735;D12.776.395.650;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;Z01.252.245.500.850;M01.060.116.815;G05.695
28677077,Aged;Cancer Survivors;Exercise;Humans;Quality of Life;Rectal Neoplasms;Quality of Life;Exercise;Rectal Neoplasms;Survivorship,M01.060.116.100;M01.860.350;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;I01.800;K01.752.400.750;N06.850.505.400.425.837;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;G11.427.410.698.277;I03.350;C04.588.274.476.411.307.790;C06.301.371.411.307.790;C06.405.249.411.307.790;C06.405.469.491.307.790;C06.405.469.860.180.500;F01.058.144.500
28676426,Humans;Minimal Clinically Important Difference;Patient-Centered Care;Quality of Life;Quality of Life;Minimal Clinically Important Difference;Prostatic Neoplasms,B01.050.150.900.649.313.988.400.112.400.400;N04.761.559.590.399.750;N05.715.360.575.575.399.750;N04.590.233.727.407;I01.800;K01.752.400.750;N06.850.505.400.425.837;I01.800;K01.752.400.750;N06.850.505.400.425.837;N04.761.559.590.399.750;N05.715.360.575.575.399.750;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28676187,Anesthesia;Anesthesiologists;Anesthetics;Aortic Valve Stenosis;Humans;Physician's Role;Transcatheter Aortic Valve Replacement;Conscious Sedation;Transcatheter Aortic Valve Replacement,E03.155;M01.526.485.140.040;M01.526.485.810.040;N02.360.140.040;N02.360.810.040;D27.505.696.277.100;D27.505.954.427.210.100;C14.280.484.150;C14.280.955.249;B01.050.150.900.649.313.988.400.112.400.400;F01.829.316.616.625.600;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E03.250;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
28674986,"Brain Diseases;Carrier Proteins;Channelopathies;Electroencephalography;Epilepsies, Myoclonic;Epilepsy;Genotype;Group VI Phospholipases A2;High-Throughput Nucleotide Sequencing;Humans;Interneurons;Ion Channels;Neuroaxonal Dystrophies;Neurodegenerative Diseases;Pantothenate Kinase-Associated Neurodegeneration;Phenotype;Phosphotransferases (Alcohol Group Acceptor);Sequence Analysis, DNA;Synaptic Transmission;Whole Exome Sequencing;Brain Diseases;Epilepsy;Whole Exome Sequencing",C10.228.140;D12.776.157;C23.550.177;E01.370.376.300;E01.370.405.245;C10.228.140.490.375.130;C10.228.140.490.493.063;C10.228.140.490;G05.380;D08.811.277.352.100.680.750.937.300.249;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;A08.675.358;A11.671.358;D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400;C10.228.140.744;C10.574;C10.228.140.079.800;C10.228.140.744.320;C10.228.662.575;C10.574.500.700;C16.320.400.650;G05.695;D08.811.913.696.620;E05.393.760.700;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830;E05.393.760.700.825.500;C10.228.140;C10.228.140.490;E05.393.760.700.825.500
28674531,Enterovirus;Morbidity;Norovirus;Viruses,B04.820.565.284;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;B04.820.095.550;B04
28674172,"Animals;Glutamates;Hippocampus;Memory;Memory Disorders;Mice;Mice, Inbred C57BL;Mice, Knockout;Nerve Net;Neurons;Protein-Serine-Threonine Kinases",B01.050;D12.125.067.625;D12.125.119.409;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F02.463.425.540;C10.597.606.525;C23.888.592.604.529;F01.700.625;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A08.511;A08.675;A11.671;D08.811.913.696.620.682.700
28674121,Adenoma;Adolescent;Child;Fibroma;Genetic Predisposition to Disease;Germ-Line Mutation;Humans;Hyperparathyroidism;Jaw Neoplasms;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type 2b;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Risk Factors;Tumor Suppressor Proteins,C04.557.470.035;M01.060.057;M01.060.406;C04.557.450.565.590.340;C23.550.291.687.500;G05.380.355;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;C19.642.355;C04.588.149.721.450;C05.116.231.754.450;C05.500.499;C07.320.515;C04.588.322.400;C04.651.600;C04.700.630;C16.320.700.630;C19.344.400;C04.588.322.400.510;C04.651.600.510;C04.700.630.510;C16.320.700.630.510;C19.344.400.510;D12.776.624.664.700;D08.811.913.696.620.682.725.400.087;D12.776.395.550.200.188.500;D12.776.543.131.500;D12.776.543.750.630.217;D12.776.624.664.700.194;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.624.776
28674120,Early Detection of Cancer;Europe;Genetic Predisposition to Disease;Hepatoblastoma;Humans;Infant;Medical Oncology;Risk Factors;United States;Wilms Tumor,E01.390.500;Z01.542;C23.550.291.687.500;G05.380.355;C04.557.435.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H02.403.429.515;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;C04.557.435.595;C04.588.945.947.535.585;C04.700.900;C12.758.820.750.585;C12.777.419.473.585;C13.351.937.820.535.585;C13.351.968.419.473.585;C16.320.700.900
28674118,Anaplastic Lymphoma Kinase;Genetic Predisposition to Disease;Homeodomain Proteins;Humans;Neuroblastoma;Neuroimaging;Pinealoma;Receptor Protein-Tyrosine Kinases;Retinoblastoma;Retinoblastoma Binding Proteins;Transcription Factors;Ubiquitin-Protein Ligases,D08.811.913.696.620.682.725.400.002;D12.776.543.750.630.002;C23.550.291.687.500;G05.380.355;D12.776.260.400;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E01.370.350.578;E01.370.376.537;E05.629;C04.557.465.625.600.657;C04.557.470.670.657;C04.557.580.625.600.657;C04.588.614.250.195.766;C10.228.140.211.788;C10.551.240.250.625;D08.811.913.696.620.682.725.400;D12.776.543.750.630;C04.557.465.625.600.725;C04.557.470.670.725;C04.557.580.625.600.725;C04.588.364.818.760;C11.270.862;C11.319.475.760;C11.768.717.760;D12.644.360.024.328;D12.776.157.057.158;D12.776.476.024.420;D12.776.660.769;D12.776.930;D08.811.464.938.750
28674117,Child;Counselors;Genetic Counseling;Genetic Predisposition to Disease;Genetic Testing;Humans;Medical Oncology;Neoplasms;Pediatrics;Risk Assessment,M01.060.406;M01.526.225;H01.158.273.343.385.500.384;N02.421.308.400;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C04;H02.403.670;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
28674037,"Aged;Blood Pressure Determination;Cohort Studies;Humans;Hypertension;Kidney Failure, Chronic;Middle Aged;Myocardial Infarction;Prognosis;Proportional Hazards Models;Prospective Studies;Renal Dialysis;Risk Assessment;Risk Factors;Stroke;United States;Blood Pressure;Dialysis;Heart Failure;Renal Dialysis;Stroke",M01.060.116.100;E01.370.370.140;E01.370.600.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;C12.777.419.780.750.500;C13.351.968.419.780.750.500;M01.060.116.630;C14.280.647.500;C14.907.585.500;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.870.300;E02.912.800;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.228.140.300.775;C14.907.253.855;Z01.107.567.875;E01.370.600.875.249;G09.330.380.076;E05.196.353;G02.186;C14.280.434;E02.870.300;E02.912.800;C10.228.140.300.775;C14.907.253.855
28674028,"Aminoglycosides;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Clinical Trials, Phase III as Topic;Follow-Up Studies;Hepatic Veno-Occlusive Disease;Humans;Infant;Kaplan-Meier Estimate;Multicenter Studies as Topic;Pilot Projects;Proportional Hazards Models;Randomized Controlled Trials as Topic;Remission Induction;Treatment Outcome",D09.408.051;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D27.505.954.248.384;E02.183.750.500;E02.319.077.500;E02.319.310.037;E05.318.372.250.250.220;N05.715.360.330.250.250.220;N06.850.520.450.250.250.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C06.552.360;C14.907.460;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E02.860;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28672325,Aged;Apolipoprotein E4;Case-Control Studies;Cognition Disorders;Cohort Studies;Depression;Exercise;Football;Humans;Mental Health;Middle Aged;Neuropsychological Tests;Psychiatric Status Rating Scales;Schools,M01.060.116.100;D10.532.091.500.750;D12.776.070.400.500.750;D12.776.521.120.500.750;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F03.615.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.126.350;G11.427.410.698.277;I03.350;I03.450.642.845.300;B01.050.150.900.649.313.988.400.112.400.400;F02.418;N01.400.500;M01.060.116.630;F04.711.513;F04.711.513.653;I02.783;J03.832
28672318,"Bayes Theorem;Humans;Hypothermia, Induced;Hypoxia-Ischemia, Brain;Infant;Infant, Newborn;Neurodevelopmental Disorders;Time Factors;Treatment Failure",E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703;M01.060.703.520;F03.625;G01.910.857;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
28672287,"Absorptiometry, Photon;Adolescent;Body Composition;Bone Density;Child;Child Development;Humans;Longitudinal Studies;United States;Young Adult",E01.370.350.700.024;E05.196.712.224.187;M01.060.057;G02.111.130;G03.180;G07.100.049;G11.427.100;M01.060.406;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875;M01.060.116.815
28671878,,
28671857,"Adrenal Cortex Hormones;Adult Survivors of Child Adverse Events;Age Factors;Antineoplastic Combined Chemotherapy Protocols;Asparaginase;Child;Cognition;Dexamethasone;Humans;Insurance, Health;Intelligence;Leucovorin;Medicaid;Memory, Short-Term;Methotrexate;Polyethylene Glycols;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Prednisone;Reaction Time;United States",D06.472.040;M01.860.300;N05.715.350.075;N06.850.490.250;E02.183.750.500;E02.319.077.500;E02.319.310.037;D08.811.277.087.116;M01.060.406;F02.463.188;D04.210.500.745.432.769.344;D04.210.500.908.238;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;F01.752.543;D03.633.100.733.631.400.800.350.450;D08.211.840.300.500;N03.219.521.346.506.564.655;N03.706.615.693;F02.463.425.540.407;D03.633.100.733.631.192.500;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D04.210.500.745.432.719.702;E05.796.817;F02.830.650;F04.669.817;G11.561.677;Z01.107.567.875
28671729,"Urinary Bladder, Overactive;Urinary Incontinence;Urinary Tract;Urination;Women, Working",C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780;C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800;A05.810;G08.852.880;M01.975.825
28671688,"Adolescent;Adult;Cell Lineage;Child;Child, Preschool;Cohort Studies;Epigenesis, Genetic;Gene Expression Regulation, Neoplastic;Gene Rearrangement;Genomics;Humans;Middle Aged;Mutation;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptor, Notch1;Signal Transduction;Young Adult",M01.060.057;M01.060.116;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.308.203;G05.308.370;G05.344;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.725.500;D12.776.930.770.500;G02.111.820;G04.835;M01.060.116.815
28671302,Animals;Antioxidants;Neuralgia;Pain Threshold;Polymers;Porosity;Radiculopathy;Rats;Superoxide Dismutase;Antioxidants;Neuralgia;Superoxide Dismutase,B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;C10.668.829.600;C23.888.592.612.664;F02.463.593.710.560;F02.830.816.444.700;G11.561.790.444.700;D05.750;D25.720;J01.637.051.720;G01.374.710;C10.668.829.820;B01.050.150.900.649.313.992.635.505.700;D08.811.682.881;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;C10.668.829.600;C23.888.592.612.664;D08.811.682.881
28671140,"Consensus;Health Status;Humans;Outcome Assessment (Health Care);Parkinson Disease;Societies, Medical;Treatment Outcome;Activities of Daily Living;Aged;Delivery of Health Care;Delivery of Health Care;Disability Evaluation;Disease Progression;Efficiency;Delivery of Health Care;Health Surveys;Health Surveys;Humans;International Cooperation;Middle Aged;Outcome Assessment (Health Care);Outcome and Process Assessment (Health Care);Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinsonian Disorders;Psychometrics;Quality of Health Care;Quality of Life",F01.829.316.068;F02.463.785.373.433;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;N03.540.828.589;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;N04.590.374;N05.300;N04.590.374;N05.300;E01.370.400;C23.550.291.656;F02.784.692.351;N04.452.209;N04.590.374;N05.300;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;M01.060.116.630;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;N04.761.559;N05.715.360.575;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862;C10.228.662.600;F04.711.780;N04.761;N05.715;I01.800;K01.752.400.750;N06.850.505.400.425.837
28670871,"Attitude of Health Personnel;Brazil;Canada;Child;Graft Rejection;Health Care Surveys;Healthcare Disparities;Heart Transplantation;Hospitals, Pediatric;Humans;Immunosuppressive Agents;Perioperative Care;Practice Patterns, Physicians';United Kingdom;United States;Heart Transplantation;Immunosuppression",F01.100.050;N05.300.100;Z01.107.757.176;Z01.107.567.176;M01.060.406;G12.875.545.328;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;N04.590.374.380;N05.300.493;E04.100.376.475;E04.928.220.390;E04.936.450.475;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;E02.760.731;E04.604;N02.421.585.722;N04.590.374.577;N05.300.625;Z01.542.363;Z01.107.567.875;E04.100.376.475;E04.928.220.390;E04.936.450.475;E02.095.465.425.450;E05.478.610
28670576,Cytokines;Meningitis;Metabolomics;Neonatology;Proteomics,D12.644.276.374;D12.776.467.374;D23.529.374;C10.228.614;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;H02.403.670.400;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
28669757,"Animals;Animals, Genetically Modified;Circadian Clocks;Drosophila Proteins;Drosophila melanogaster;Locomotion;Neuropeptides;Receptors, Cell Surface;Drosophila;Behavior;Circadian Rhythm;Locomotion",B01.050;B01.050.050.136;B05.620.136;G07.180.562.094.500;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;G07.568.500;G11.427.410.568;D12.644.400;D12.776.631.650;D12.776.543.750;B01.050.500.131.617.720.500.500.750.310.250;F01.145;G07.180.562.190;G07.568.500;G11.427.410.568
28669672,"Animals;Disease Models, Animal;Dysbiosis;Humans;Hypersensitivity;Inflammation;Leishmania braziliensis;Leishmania major;Leishmaniasis, Cutaneous;Mice;Mice, Inbred C57BL;Microbiota;Skin;Staphylococcus;Streptococcus;Dysbiosis;Leishmania;Microbiota;Skin",B01.050;C22.232;E05.598.500;E05.599.395.080;C23.550.308;B01.050.150.900.649.313.988.400.112.400.400;C20.543;C23.550.470;B01.268.475.868.488.080;B01.268.475.868.488.405;C03.752.300.500.400;C03.858.560.400;C17.800.838.775.560.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A17.815;B03.300.390.400.800.750;B03.353.500.750.750;B03.510.100.750.750;B03.510.400.790.750;B03.353.750.737.872;B03.510.400.800.872;B03.510.550.737.872;C23.550.308;B01.268.475.868.488;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A17.815
28669606,Biomarkers;Life Style;Exercise;Survivorship,D23.101;F01.829.458;G11.427.410.698.277;I03.350;F01.058.144.500
28669553,"Antidotes;Consensus;Emergency Medical Services;Guidelines as Topic;Hospitals;Humans;Pharmacy Service, Hospital;Poisoning;Surveys and Questionnaires",D27.505.696.706.037;D27.720.799.037;F01.829.316.068;F02.463.785.373.433;N02.421.297;N04.761.700.350;N05.700.350;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;N02.278.216.500.968.603;N02.421.668.556;N04.452.442.422.603;C25.723;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28669544,"Amyloid;Amyotrophic Lateral Sclerosis;Animals;Brain;Cognition;DNA-Binding Proteins;Mice, Transgenic;Microglia;Synapses;Alzheimer Disease;Amyloid;Amyotrophic Lateral Sclerosis;Frontotemporal Lobar Degeneration;Microglia;Phagocytosis;Neuronal Plasticity",D05.500.049;D12.776.049;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;A08.186.211;F02.463.188;D12.776.260;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A08.637.400;A11.650.400;A08.850;A11.284.149.165.420.780;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;A08.637.400;A11.650.400;G04.417.350;G09.188.665;G12.450.564.809;G12.688;G11.561.638
28669500,"Adult;Aged;Cohort Studies;Emergency Medical Services;Extracorporeal Membrane Oxygenation;Hospitalization;Humans;Middle Aged;Outcome Assessment (Health Care);Patient Care Team;Program Development;Program Evaluation;Respiratory Distress Syndrome, Adult;Retrospective Studies;Risk Assessment;Survival Rate;Tertiary Care Centers;Time Factors",M01.060.116;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N02.421.297;E02.880.301;E04.292.451;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;N04.590.715;N04.452.760;E05.337.820;N04.761.685;N05.715.360.650;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;N02.278.421.830;G01.910.857
28669420,"Humans;Radius;Upper Extremity Deformities, Congenital",B01.050.150.900.649.313.988.400.112.400.400;A02.835.232.087.090.700;C05.660.585.988;C16.131.621.585.988
28669032,"Humans;Immunosenescence;Immunotherapy;Multiple Sclerosis;Immune System;Immunosenescence;Multiple Sclerosis;Leukoencephalopathy, Progressive Multifocal",B01.050.150.900.649.313.988.400.112.400.400;G07.345.124.390;G12.460.500;E02.095.465.425;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A15.382;G07.345.124.390;G12.460.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450
28668829,"Animals;Cell Line, Tumor;Cell Proliferation;Dacarbazine;Drug Synergism;Heterografts;Humans;Indazoles;Melanoma;Mice;Mice, Nude;Temozolomide;Transplantation, Heterologous;Melanoma;Temozolomide",B01.050;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;D02.925.200;D03.383.129.308.240;G07.690.773.968.477;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;D03.383.129.539.487;D03.633.100.449;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.500;D02.925.200.500;D03.383.129.308.240.500;E04.936.764;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D02.925.200.500;D03.383.129.308.240.500
28668420,"Adult;Aged;Contrast Media;Cross-Sectional Studies;Glioma;Humans;Magnetic Resonance Imaging;Middle Aged;Neovascularization, Pathologic;Prognosis;Retrospective Studies;Supratentorial Neoplasms;Thromboplastin;Glioma;Magnetic Resonance Imaging;Thromboplastin",M01.060.116;M01.060.116.100;D27.505.259.500;D27.720.259;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;C23.550.589.500;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.614.250.195.885;C10.228.140.211.885;C10.551.240.250.700;D12.776.124.125.900;D23.119.965;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;E01.370.350.825.500;D12.776.124.125.900;D23.119.965
30603509,,
28667701,"Alleles;Brain Neoplasms;Case-Control Studies;Cell Line, Tumor;Cyclin-Dependent Kinase Inhibitor p27;Gene Expression Regulation, Neoplastic;Gene Frequency;Genetic Predisposition to Disease;Genome-Wide Association Study;HEK293 Cells;Humans;Neuroblastoma;Plasmids;Polymorphism, Single Nucleotide;Promoter Regions, Genetic;Risk;Neuroblastoma",G05.360.340.024.340.030;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251.210.190;A11.251.860.180;D12.644.360.225.600;D12.776.167.187.600;D12.776.476.225.600;D12.776.624.776.355.600;G05.308.370;G05.330;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.360.600;G05.365.795.598;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
28667458,"Adolescent;Biological Variation, Population;Biomarkers;Bone and Bones;Calcium;Child;Child, Preschool;Clinical Decision-Making;Fibroblast Growth Factors;Humans;Kidney Failure, Chronic;Longitudinal Studies;Minerals;Parathyroid Hormone;Phosphates;Prospective Studies;Renal Dialysis;Vitamin D;Kidney Failure, Chronic;Renal Dialysis;Bone Diseases, Metabolic;Parathyroid Hormone;Pediatrics",M01.060.057;G16.117;D23.101;A02.835.232;A10.165.265;D01.268.552.100;D01.552.539.288;D23.119.100;M01.060.406;M01.060.406.448;E01.055;D12.644.276.624;D12.776.467.624;D23.529.624;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;D01.578;D06.472.699.590;D12.644.548.587;D01.029.260.700.675.374;D01.248.497.158.730;D01.695.625.675.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.870.300;E02.912.800;D04.210.500.812.768;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.300;E02.912.800;C05.116.198;C18.452.104;D06.472.699.590;D12.644.548.587;H02.403.670
28666932,"Acute Disease;Adult;Aneurysm, Dissecting;Aortic Aneurysm, Thoracic;Cesarean Section;Humans;Infant, Extremely Premature;Pregnancy;Pregnancy Complications, Cardiovascular;Ultrasonography, Prenatal;Marfan Syndrome;Cardiopulmonary Bypass;Circulatory Arrest, Deep Hypothermia Induced;Fetus;Infant;Magnetic Resonance Imaging;Mothers;Placenta;Pregnancy;Echocardiography, Transesophageal;Echocardiography",C23.550.291.125;M01.060.116;C14.907.055.050;C14.907.055.239.125;C14.907.109.139.125;E04.520.252.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;G08.686.784.769;C13.703.634;C14.583;E01.370.350.850.865;E01.370.378.630.865;C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;E04.292.413;E04.100.376.374.500;E04.928.220.360.500;A16.378;M01.060.703;E01.370.350.825.500;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;A16.710;G08.686.784.769;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
28666788,"Computer Simulation;Humans;Imaging, Three-Dimensional;Photogrammetry",L01.224.160;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;E01.370.350.600.630
28665899,"Enteral Nutrition;Gastric Outlet Obstruction;Gastrostomy;Humans;Infant;Intubation, Gastrointestinal;Ultrasonography",E02.421.360;E02.642.500.360;C06.405.748.340;E04.210.496;E04.579.408;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.585.412;E05.497.412;E01.370.350.850
28664850,"Biomarkers;Gene Expression Profiling;Humans;Metabolomics;Microbiota;Precision Medicine;Proteomics;Research Design;Respiratory Distress Syndrome, Adult;Risk Factors",D23.101;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;E02.574;H02.403.200.700;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;E05.581.500;H01.770.644.728;C08.381.840;C08.618.840;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28664624,"Adolescent;Adolescent Behavior;Body Mass Index;Child;Child Behavior;Cohort Studies;Diabetes Mellitus, Type 2;Glycated Hemoglobin A;Healthy Lifestyle;Humans;Hyperglycemia;Hypoglycemia;Intention to Treat Analysis;Patient Compliance;Patient Dropouts;Pediatric Obesity;Self-Management;United States;Weight Loss;Weight Reduction Programs;Pediatric Obesity;Diabetes Mellitus, Type 2",M01.060.057;F01.145.022;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;F01.145.179;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C18.452.394.750.149;C19.246.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;F01.829.458.205;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;C18.452.394.984;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;F01.100.150.750.500.610;F01.145.488.887.500.610;N05.300.150.800.500.610;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;N02.421.784.760;Z01.107.567.875;C23.888.144.243.963;G07.345.249.314.120.200.963;I02.233.332.445.650;N02.421.726.407.579.650;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;C18.452.394.750.149;C19.246.300
28664361,Clinical Coding;Economics,N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;I01.261;N03.219
28663228,"Abiraterone Acetate;Adrenal Glands;Androgens;Antineoplastic Agents, Hormonal;Glucuronides;Humans;Leuprolide;Neoadjuvant Therapy;Prednisone;Prostatic Neoplasms;Sulfates;Testis;Testosterone;Testosterone Congeners;Abiraterone Acetate",D04.210.500.054.079.065;A06.300.071;D27.505.696.399.472.161;D27.505.954.248.169;D02.241.081.844.915.162.500;D02.241.152.811.162.750;D02.241.511.902.915.162.750;D09.811.922.162.750;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.327.740.320.400;D12.644.400.400.740.320.400;D12.644.456.460.480;D12.644.548.365.740.320.400;D12.776.631.650.405.740.320.400;E02.186.450;D04.210.500.745.432.719.702;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;D01.248.497.158.845;D01.875.800.800.850;A05.360.444.849;A05.360.576.782;A06.300.312.782;D04.210.500.054.079.429.824;D06.472.334.851.968.984;D06.472.334.851.968;D04.210.500.054.079.065
28663124,"Acetamides;Adult;Age Factors;Anti-Anxiety Agents;Depressive Disorder, Major;Dose-Response Relationship, Drug;Double-Blind Method;Drug Substitution;Follow-Up Studies;Humans;Middle Aged;Piperazines;Psychiatric Status Rating Scales;Sulfides;Time Factors;Vortioxetine;Comparative Effectiveness Research;Drug Substitution;Drug-Related Side Effects and Adverse Reactions;Depressive Disorder, Major;Vortioxetine",D02.065.064;D02.241.081.018.110;M01.060.116;N05.715.350.075;N06.850.490.250;D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015;F03.600.300.375;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.307.312;N02.421.668.778.500.312;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D03.383.606;F04.711.513.653;D01.248.497.158.874;D01.875.350.850;D02.886.520;G01.910.857;D03.383.606.990;H01.770.644.145.360.500;N05.425.157;E02.319.307.312;N02.421.668.778.500.312;C25.100;F03.600.300.375;D03.383.606.990
28663064,,
28662712,"Chromosome Deletion;Chromosomes, Human, Pair 11;DNA Methylation;Gene Regulatory Networks;Haploinsufficiency;Humans;Neuroblastoma;Neoplasms;Neoplasm Metastasis;Neuroblastoma;Review",C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.325.355;G05.360.162.520.300.325.355;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G05.360.080.689.360;G05.365.590.029.530.587;G05.380.350.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C04;C04.697.650;C23.550.727.650;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;V02.600.500;V02.912
28662545,"Adult;Arachidonic Acid;Blood Platelet Disorders;Blood Platelets;Case-Control Studies;Child, Preschool;Core Binding Factor Alpha 2 Subunit;Haploinsufficiency;Humans;Hydrolases;Mutation;Phospholipids;Platelet Count;Secretory Vesicles;Serotonin;Thromboxanes;Blood Platelets",M01.060.116;D10.251.355.255.100.100;D10.251.355.310.166.100;C15.378.140;A11.118.188;A15.145.229.188;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406.448;D12.776.930.155.200.200;G05.365.590.029.530.587;G05.380.350.500;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277;G05.365.590;D10.570.755;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;A11.284.430.214.190.875.190.880.810;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650;D10.251.355.255.100.825;D10.251.355.310.166.971;A11.118.188;A15.145.229.188
28662028,"Antifungal Agents;Biomedical Research;Global Health;Humans;Meningitis, Cryptococcal;Neglected Diseases;Tropical Medicine",D27.505.954.122.136;H01.770.644.145;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;C23.550.291.890;H02.403.879
28661969,"Aged;Cardiac Surgical Procedures;Hospital Mortality;Humans;Intensive Care Units;Internship and Residency;Length of Stay;Logistic Models;Medical Staff, Hospital;Middle Aged;Nursing Staff, Hospital;Patient Care Team;Pennsylvania;Personnel Staffing and Scheduling;Quality of Health Care;Retrospective Studies",M01.060.116.100;E04.100.376;E04.928.220;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;I02.358.337.350.500;I02.358.399.350.750;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;M01.060.116.630;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;N04.590.715;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;I03.946.225;N04.452.677.650;N04.761;N05.715;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28661930,"Adolescent;Blepharoptosis;Child;Child, Preschool;Humans;Infant;Oculomotor Muscles;Postoperative Complications;Reoperation;Retrospective Studies;Strabismus",M01.060.057;C11.338.204;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A02.633.567.700;C23.550.767;E04.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.292.562.887;C11.590.810
28660717,Adolescent;Adult;Anorexia Nervosa;Humans;Proportional Hazards Models;Retrospective Studies;Risk Assessment;Urolithiasis;Young Adult;Anorexia Nervosa;Feeding and Eating Disorders;Kidney Calculi;Nephrolithiasis;Urolithiasis,M01.060.057;M01.060.116;F03.400.125;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C12.777.967;C13.351.968.967;M01.060.116.815;F03.400.125;F03.400;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C12.777.967;C13.351.968.967
28660712,Animals;Biocompatible Materials;Bone Development;Bone Regeneration;Cellular Microenvironment;Developmental Biology;Humans;Interdisciplinary Communication;Tissue Engineering;Biocompatible Materials;Bone and Bones;Cartilage,B01.050;D25.130;D27.720.102.130;J01.637.051.130;G07.345.500.325.377.625.050.500;G11.427.578.050.500;G11.427.213.140;G16.762.150.150;G04.366;H01.158.273.200;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;E05.481.500.311.500;J01.293.069.249.500;D25.130;D27.720.102.130;J01.637.051.130;A02.835.232;A10.165.265;A02.165;A10.165.382
28660677,"Administration, Topical;Adrenergic beta-Antagonists;Hemangioma;Humans;Pharmaceutical Solutions;Skin Neoplasms;Timolol",E02.319.267.120;D27.505.519.625.050.200.200;D27.505.696.577.050.200.200;C04.557.645.375;B01.050.150.900.649.313.988.400.112.400.400;D26.776.708;D27.505.954.578;D27.720.752;C04.588.805;C17.800.882;D02.033.100.624.915;D02.033.755.624.915;D02.092.063.624.915;D02.886.675.867.768;D03.383.129.708.867.768;D03.383.533.640.775
28660430,Analysis of Variance;Bariatric Surgery;Body Mass Index;Breast Density;Breast Neoplasms;Humans;Mammography;Public Health Surveillance;Risk Assessment;Weight Loss;Bariatric Surgery;Breast Density;Gastric Bypass;Mammography,E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;E02.570.500.062;E04.062;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E01.370.600.115.275;G07.100.138;C04.588.180;C17.800.090.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.500;E05.318.308.980.438.700.324;N05.715.360.300.800.438.625.324;N06.850.520.308.980.438.700.324;N06.850.780.675.487;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C23.888.144.243.963;G07.345.249.314.120.200.963;E02.570.500.062;E04.062;E01.370.600.115.275;G07.100.138;E02.570.500.062.249;E04.035.398.385;E04.062.249;E04.210.457.430;E01.370.350.700.500
28660405,"Alagille Syndrome;Biopsy;Child, Preschool;Combined Modality Therapy;Diagnosis, Differential;Granuloma;Humans;Humeral Fractures;Magnetic Resonance Imaging;Osteomyelitis;Xanthomatosis;Alagille Syndrome",C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406.448;E02.186;E01.171;C15.604.515.292;C23.550.382;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;E01.370.350.825.500;C01.539.160.495;C05.116.165.495;C18.452.584.750;C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051
28660274,"Adult;Animals;Blindness;Humans;Leber Congenital Amaurosis;Middle Aged;Photoreceptor Cells, Vertebrate;Reflex, Pupillary;Retinal Ganglion Cells;Rod Opsins;Young Adult",M01.060.116;B01.050;C10.597.751.941.162;C11.966.075;C23.888.592.763.941.162;B01.050.150.900.649.313.988.400.112.400.400;C11.270.516;C11.768.364;M01.060.116.630;A08.675.650.850.625.670;A08.675.650.915.937.670;A08.800.950.937.670;A09.371.729.831.625.670;A11.671.650.850.625.670;A11.671.650.915.937.670;E01.370.376.550.650.690;E01.370.600.550.650.690;G11.561.731.705;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;D12.776.306.466.500;D23.767.930.750.500;M01.060.116.815
28659916,"Killer Cells, Natural",A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537
28659753,Alzheimer Disease,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
28659379,Carbon Isotopes;Cell Movement;Cell Proliferation;Culture Media;Endothelial Cells;Gene Deletion;Glutaminase;Glutamine;Human Umbilical Vein Endothelial Cells;Humans;Isotope Labeling;Endothelium;Glutamine,D01.268.150.075;D01.496.123;G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;D27.720.470.305;E07.206;A11.436.275;G05.365.590.762.320;G05.558.800.320;D08.811.277.087.483;D12.125.068.330;D12.125.095.461;D12.125.154.424;A11.436.275.682;B01.050.150.900.649.313.988.400.112.400.400;E05.522;A10.272.491;D12.125.068.330;D12.125.095.461;D12.125.154.424
28659278,"Adult;Biopsy;Clinical Competence;Diagnosis, Differential;Diagnostic Errors;Humans;Melanoma;Middle Aged;Nevus, Pigmented;Observer Variation;Pathology, Clinical;Reproducibility of Results;Skin Neoplasms;United States",M01.060.116;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;I02.399.630.210;N04.761.210;N05.715.175;E01.171;E01.354;N02.421.450.280;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;C04.557.665.560.615;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;H02.403.650.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C04.588.805;C17.800.882;Z01.107.567.875
28658533,"Adult;Aged;Coronary Artery Disease;Databases, Factual;Follow-Up Studies;Humans;Logistic Models;Lung Diseases;Lung Transplantation;Middle Aged;Myocardial Revascularization;Perioperative Care;Prevalence;Survival Analysis;Treatment Outcome;Coronary Artery Disease;Lung Transplantation",M01.060.116;M01.060.116.100;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C08.381;E04.928.600.495;E04.936.450.495;M01.060.116.630;E04.100.376.719;E04.928.220.520;E02.760.731;E04.604;N02.421.585.722;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E04.928.600.495;E04.936.450.495
28658462,Cicatrix;Dermatologic Agents;Dermatologic Surgical Procedures;Humans;Isotretinoin;Skin;Time Factors;Wound Healing,A10.165.450.300;C23.550.355.274;G16.762.891.249;D27.505.954.444;E04.680.275;B01.050.150.900.649.313.988.400.112.400.400;D02.455.326.271.665.202.495.325;D02.455.426.392.368.367.379.249.700.325;D02.455.849.131.495.325;D23.767.261.700.325;A17.815;G01.910.857;G16.762.891
28658197,"Adolescent;Adrenal Insufficiency;Anti-Inflammatory Agents;Biomarkers;Catecholamines;Child;Child, Preschool;Critical Illness;Drug Therapy, Combination;Humans;Hydrocortisone;Infant;Retrospective Studies;Severity of Illness Index;Shock, Septic;Treatment Outcome;Vasoconstrictor Agents",M01.060.057;C19.053.500;D27.505.954.158;D23.101;D02.092.311;D02.455.426.559.389.657.166.175;M01.060.406;M01.060.406.448;C23.550.291.625;E02.319.310;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;M01.060.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D27.505.954.411.793
28658184,"Academic Medical Centers;Body Weight;Child;Gastrointestinal Diseases;Guideline Adherence;Hospitals, Pediatric;Humans;Inpatients;Quality Improvement",N02.278.020;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;M01.060.406;C06.405;N04.761.337;N05.715.360.395;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.643.470;J01.293.754;N04.761.744
28657951,"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Firearms;Humans;Infant;Infant, Newborn;Middle Aged;United States;Violence;Wounds, Gunshot;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.060.406;M01.060.406.448;J01.637.870.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.116.630;Z01.107.567.875;I01.198.240.856;I01.880.735.900;C26.986.900;M01.060.116.815
28657692,"Adolescent;Aged, 80 and over;Angiogenesis Inhibitors;Bevacizumab;Child;Disease Progression;Humans;Lung;Middle Aged;Papillomavirus Infections;Radiography;Respiratory Tract Infections;Surveys and Questionnaires;Treatment Outcome;United States;Young Adult;Bevacizumab;Bevacizumab",M01.060.057;M01.060.116.100.080;D27.505.696.377.077.099;D27.505.696.377.450.100;D27.505.954.248.025;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;M01.060.406;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;A04.411;M01.060.116.630;C02.256.650;C02.928.725;E01.370.350.700;C01.539.739;C08.730;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.060.116.815;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438
28656539,Adult;Cryopreservation;Fertility Preservation;Humans;Oocyte Retrieval;Oocytes;Ovulation Induction;Young Adult;Fertility Preservation,M01.060.116;E01.370.225.500.620.760.160;E01.370.225.750.600.760.160;E02.792.156;E05.200.500.620.760.160;E05.200.750.600.760.160;E05.760.156;E02.875.800.625;E04.936.537.562;E05.820.800.625;B01.050.150.900.649.313.988.400.112.400.400;E02.875.800.976;E04.936.537.625;E05.820.800.976;A05.360.490.690.680;A11.497.497.600;E02.875.800.984;E05.820.800.984;M01.060.116.815;E02.875.800.625;E04.936.537.562;E05.820.800.625
28656386,"Anti-Bacterial Agents;Bacteremia;Bacterial Typing Techniques;Blood Culture;Gram-Negative Bacteria;Gram-Negative Bacterial Infections;Gram-Positive Bacteria;Gram-Positive Bacterial Infections;Humans;Microbial Sensitivity Tests;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",D27.505.954.122.085;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;E01.370.225.875.150.125;E05.200.875.150.125;E01.370.225.875.185;E05.200.875.185;B03.440;C01.252.400;B03.510;C01.252.410;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;E05.196.566.755
28655926,"Alzheimer Disease;Amyloid beta-Peptides;Animals;Apoptosis;Brain;Cell Differentiation;Cognition;Computational Biology;Diet, High-Fat;Disease Models, Animal;Gene Expression Profiling;Lipid Metabolism;Maze Learning;Metabolome;Mice;Mice, Transgenic;Mitochondria;Neurons;Phenotype;Plaque, Amyloid;Protein Aggregation, Pathological;Transcriptome",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;B01.050;G04.146.160;A08.186.211;G04.152;F02.463.188;H01.158.273.180;L01.313.124;G07.203.650.240.267;C22.232;E05.598.500;E05.599.395.080;E05.393.332;G03.458;F02.463.425.874.500;G03.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A11.284.430.214.190.875.564;A11.284.835.626;A08.675;A11.671;G05.695;C23.300.821;C23.550.770;G02.111.675;G02.111.873.750;G05.297.700.750;G05.360.920
28655787,"Adult;Apoptosis;Ataxia Telangiectasia Mutated Proteins;Cell Cycle Checkpoints;Checkpoint Kinase 1;Child;Cytidine Deaminase;DNA Replication;Drug Resistance, Neoplasm;Humans;Leukemia, Myeloid, Acute;Phosphorylation;Protein Kinase Inhibitors;Proteins;Signal Transduction;Tumor Cells, Cultured",M01.060.116;G04.146.160;D08.811.913.696.620.682.700.097;D12.776.157.687.125;D12.776.660.720.125;G04.144.109;D08.811.913.696.620.682.700.143;M01.060.406;D08.811.277.151.486.250;G02.111.225;G05.226;G07.690.773.984.395;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;G02.111.665;G02.607.780;G03.796;D27.505.519.389.755;D12.776;G02.111.820;G04.835;A11.251.860
28655753,"Adenosine Triphosphate;Animals;Glucose;Humans;Insulin;Insulin Secretion;Insulin-Secreting Cells;Models, Biological;Oxidative Phosphorylation;Thermodynamics;Glucokinase;Oxidative Phosphorylation;Pancreas",D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;B01.050;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;E05.599.395;G02.111.665.550;G03.295.631;G03.796.550;G01.906;D08.811.913.696.620.250;G02.111.665.550;G03.295.631;G03.796.550;A03.734
28655733,"Aged;Aged, 80 and over;Aortic Valve Stenosis;Chi-Square Distribution;Coronary Artery Disease;Coronary Stenosis;Humans;Middle Aged;Odds Ratio;Patient Selection;Percutaneous Coronary Intervention;Postoperative Complications;Risk Assessment;Risk Factors;Severity of Illness Index;Time Factors;Transcatheter Aortic Valve Replacement;Treatment Outcome;Coronary Artery Disease;Percutaneous Coronary Intervention;Transcatheter Aortic Valve Replacement",M01.060.116.100;M01.060.116.100.080;C14.280.484.150;C14.280.955.249;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C14.280.647.250.285;C14.907.585.250.285;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.581.500.653;N04.590.731;E04.100.814.529.968;E04.502.382.968;C23.550.767;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E04.100.814.529.968;E04.502.382.968;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
28655663,"Electrodes;Energy Metabolism;HeLa Cells;Humans;Membrane Potential, Mitochondrial;Microfluidics;Mitochondria;Nanotechnology;Nanotubes;Energy Metabolism;Nanotubes, Carbon;Mitochondria",E07.305.250;G03.295;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;G03.295.770.500;G04.580.550;G07.265.675.550;E05.830.666;H01.671.808.500;J01.897.520.500.500;A11.284.430.214.190.875.564;A11.284.835.626;H01.603;J01.897.520.600;J01.637.512.850;G03.295;D01.268.150.250.500;J01.637.512.850.500;A11.284.430.214.190.875.564;A11.284.835.626
28655623,Drowning;Humans;Laryngismus;Pulmonary Edema;Terminology as Topic,C23.550.260.393;C26.304;N06.850.135.696;B01.050.150.900.649.313.988.400.112.400.400;C08.360.895.500;C08.618.980.500;C09.400.895.500;C08.381.742;L01.559.598.400
28655174,"Calcitriol;Combined Modality Therapy;Consensus;Evidence-Based Medicine;Hematopoietic Stem Cell Transplantation;Humans;Incidence;Osteopetrosis;Practice Guidelines as Topic;Prognosis;Tomography, X-Ray Computed;Treatment Outcome",D04.210.500.247.222.159.478.387.300;D04.210.500.247.808.146.478.387.300;D04.210.500.812.768.196.478.387.300;D10.570.938.146.478.387.300;E02.186;F01.829.316.068;F02.463.785.373.433;H02.249.750;H02.403.200.400;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C05.116.099.708.702.678;N04.761.700.350.650;N05.700.350.650;E01.789;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28654952,"Fibrinolytic Agents;Humans;Platelet Aggregation Inhibitors;Risk Assessment;Thrombocythemia, Essential;Thrombosis",D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;B01.050.150.900.649.313.988.400.112.400.400;D27.505.954.502.780;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C15.378.100.832;C15.378.140.860.800;C15.378.190.636.860.800;C15.378.463.825;C14.907.355.830
28654618,"Child, Preschool;Craniosynostoses;Evidence-Based Medicine;Humans;Preoperative Care;Reconstructive Surgical Procedures",M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.795;E04.604.750;N02.421.585.795;E04.680
28654610,"Child;Child, Preschool;Craniosynostoses;Humans;Infant;Orthopedic Procedures;Reconstructive Surgical Procedures;Syndrome",M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.718;E04.555;E04.680;C23.550.288.500
28654550,"Adult;Attitude of Health Personnel;Checklist;Child;Critical Care;Focus Groups;Follow-Up Studies;Humans;Intensive Care Units, Pediatric;Interviews as Topic;Intubation, Intratracheal;Middle Aged;Patient Care Bundles;Patient Safety;Prospective Studies;Qualitative Research;Quality Improvement;Registries",M01.060.116;F01.100.050;N05.300.100;N05.715.360.300.179;M01.060.406;E02.760.190;N02.421.585.190;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;E02.041.500;E02.585.578;E05.497.578;M01.060.116.630;E02.765;N06.850.135.060.075.399;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H01.770.644.241.850;J01.293.754;N04.761.744;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28654520,"Health Promotion;Humans;Schools, Medical;Student Health Services;United States",I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;I02.783.495.552;N02.278.020.578;N02.421.897;Z01.107.567.875
28654450,Breast Feeding;Decision Making;Goals;Humans;Mothers,F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;F02.463.785.373;F01.658.500;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630
28654432,,
28654161,"Animals;Antigens, Ly;Bone Marrow Cells;Flow Cytometry;Immunophenotyping;Leukocyte Common Antigens;Membrane Proteins;Mice;Peyer's Patches;Plasma Cells;Positive Regulatory Domain I-Binding Factor 1;Spleen;Syndecan-1;Transcription Factors;B-Lymphocytes;Flow Cytometry;Plasma Cells",B01.050;D23.050.301.264.920;D23.101.100.920;A11.148;A15.378.316;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;D08.811.277.352.650.775.400.100.500;D12.644.360.587.100.500;D12.776.476.592.100.500;D12.776.543.733.937.500;D12.776.543;B01.050.150.900.649.313.992.635.505.500;A10.549.600;A15.382.520.604.600;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;D08.811.913.555.500.800.700;D12.776.260.703.650;D12.776.930.780.904;A10.549.700;A15.382.520.604.700;D12.776.395.550.847.100;D12.776.395.650.350.500.100;D12.776.543.550.847.100;D12.776.930;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725
28654094,"Adaptation, Psychological;Animals;Encephalitis;Hippocampus;Inflammation Mediators;MicroRNAs;Neurons;Rats, Long-Evans;Rats, Sprague-Dawley;Resilience, Psychological;Social Behavior;Stress, Psychological;Vascular Remodeling",F01.058;B01.050;C10.228.140.430;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D23.469;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A08.675;A11.671;B01.050.150.900.649.313.992.635.505.700.500;B01.050.150.900.649.313.992.635.505.700.750;F02.940;F01.145.813;F01.145.126.990;F02.830.900;C23.300.977;C23.550.918;G09.330.930
28653662,"Animals;Antineoplastic Agents;Autophagy;Breast Neoplasms;Cell Cycle;Cell Line, Tumor;Cellular Senescence;Cyclin E;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Cytoplasm;Drug Synergism;Humans;Mice;Mice, Nude;Piperazines;Protein Kinase Inhibitors;Pyridines;Retinoblastoma Protein",B01.050;D27.505.954.248;G04.146.399;G04.417.350.091;C04.588.180;C17.800.090.500;G04.144;A11.251.210.190;A11.251.860.180;G04.043;D12.644.360.262.180;D12.776.167.218.180;D12.776.476.262.180;D08.811.913.696.620.682.700.646.500.875;D12.644.360.250.451;D12.776.167.200.451;D12.776.476.250.451;D08.811.913.696.620.682.700.646.500.937;D12.644.360.250.515;D12.776.167.200.515;D12.776.476.250.515;A11.284.430.214;G07.690.773.968.477;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.500;D03.383.606;D27.505.519.389.755;D03.383.725;D12.776.260.704;D12.776.624.776.745;D12.776.660.807;D12.776.744.770
28653617,"Animals;Antineoplastic Agents;Cell Line, Tumor;Chromatin;Disease Models, Animal;Heterocyclic Compounds, 4 or More Rings;Heterografts;Humans;Leukemia, Biphenotypic, Acute;Mice;Nerve Tissue Proteins;Protein Binding;Receptors, Cell Surface;Treatment Outcome;Humans;Leukemia;Mice",B01.050;D27.505.954.248;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;C22.232;E05.598.500;E05.599.395.080;D03.633.400;A01.941.875;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.100;C15.604.515.560.100;C20.683.515.528.100;B01.050.150.900.649.313.992.635.505.500;D12.776.631;G02.111.679;G03.808;D12.776.543.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337;B01.050.150.900.649.313.992.635.505.500
28653465,"Aorta, Thoracic;Child;Coronary Vessel Anomalies;Coronary Vessels;Death, Sudden, Cardiac;Diagnostic Imaging;Exercise Test;Global Health;Humans;Incidence;Survival Rate;Pediatrics;Death, Sudden",A07.015.114.056.372;M01.060.406;C14.240.400.210;C14.280.400.210;C16.131.240.400.210;A07.015.114.269;A07.015.908.194;C14.280.383.220;C23.550.260.322.250;E01.370.350;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;H02.403.670;C23.550.260.322
28653463,"Blood Flow Velocity;Blood Pressure;Cardiopulmonary Bypass;Cerebrovascular Circulation;Homeostasis;Humans;Hypothermia, Induced;Infant, Newborn;Monitoring, Intraoperative;Retrospective Studies;Texas;Infant, Newborn;General Surgery",E01.370.370.130;G09.330.380.630.080;E01.370.600.875.249;G09.330.380.076;E04.292.413;G09.330.100.159;G07.410;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;M01.060.703.520;E01.370.520.510;E04.510;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875.760.750;M01.060.703.520;H02.403.810.300
28653249,,
28653125,Animals;Child;Eosinophilic Esophagitis;Humans;Food Hypersensitivity,B01.050;M01.060.406;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;B01.050.150.900.649.313.988.400.112.400.400;C20.543.480.370
28652469,"Adolescent;Adult;Ambulatory Care;Blood Pressure;Blood Pressure Determination;Child;Glomerular Filtration Rate;Humans;Hypertension;Hypertension, Malignant;Middle Aged;Nephrotic Syndrome;Observer Variation;Outcome and Process Assessment (Health Care);Prognosis;Proportional Hazards Models;Risk Factors;United States;Adult;Blood Pressure;Hypertension;Nephrotic Syndrome;Prevalence",M01.060.057;M01.060.116;E02.760.106;N02.421.585.106;E01.370.600.875.249;G09.330.380.076;E01.370.370.140;E01.370.600.100;M01.060.406;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;C14.907.489.330;M01.060.116.630;C12.777.419.630.643;C13.351.968.419.630.643;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;N04.761.559;N05.715.360.575;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;M01.060.116;E01.370.600.875.249;G09.330.380.076;C14.907.489;C12.777.419.630.643;C13.351.968.419.630.643;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
28652154,"Dermatitis, Atopic;gamma-Aminobutyric Acid;Substance P",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D02.241.081.114.500.350;D12.125.190.350;D12.644.276.812.900.866;D12.644.400.800.750;D12.644.456.800.866;D12.776.467.812.900.866;D12.776.631.650.800.750;D23.469.050.375.850.890;D23.529.812.900.866
28652048,"Absorptiometry, Photon;Adult;Aged;Bone Density;Cancellous Bone;Chronic Kidney Disease-Mineral and Bone Disorder;Cortical Bone;Cross-Sectional Studies;Double-Blind Method;Fibula;Humans;Kidney Failure, Chronic;Magnetic Resonance Imaging;Middle Aged;Muscle, Skeletal;Parathyroid Hormone;Patient Compliance;Pilot Projects;Renal Dialysis;Spine;Tibia;Tomography, X-Ray Computed;Vibration;Young Adult;Bone and Bones;Muscles",E01.370.350.700.024;E05.196.712.224.187;M01.060.116;M01.060.116.100;G11.427.100;A10.165.265.414;C05.116.198.816.750;C12.777.419.080;C13.351.968.419.795;C18.452.104.816.750;C18.452.174.845.750;C18.654.521.500.133.770.734.750;C19.642.355.480.500;A10.165.265.521;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;A02.835.232.043.650.321;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E01.370.350.825.500;M01.060.116.630;A02.633.567;A10.690.552.500;D06.472.699.590;D12.644.548.587;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E02.870.300;E02.912.800;A02.835.232.834;A02.835.232.043.650.883;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;G01.374.930;M01.060.116.815;A02.835.232;A10.165.265;A02.633;A10.690
28651925,Accountable Care Organizations;Health Care Costs;Humans;Medicare;Primary Health Care;Small Business;United States;Value-Based Health Insurance,N05.300.380.500;N03.219.151.400;N05.300.375;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.590.233.727;J01.219.921;Z01.107.567.875;N03.219.521.576.343.972;N04.761.744.750
28651917,Cardiopulmonary Resuscitation;Heart Arrest;Humans;Sepsis,E02.365.647.110;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;C01.539.757;C23.550.470.790.500
28651847,"Animals;Anti-Inflammatory Agents, Non-Steroidal;Cardiovascular System;Humans;Meta-Analysis as Topic;Randomized Controlled Trials as Topic",B01.050;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;A07;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500
28651040,,
28650886,Fluorodeoxyglucose F18;Humans;Infant;Magnetic Resonance Imaging;Positron Emission Tomography Computed Tomography;Rhabdoid Tumor;Skull Neoplasms;Sphenoid Bone,D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;C04.557.435.710;C04.588.149.721;C05.116.231.754;A02.835.232.781.802
28650674,Actigraphy;Adolescent;Adult;Aged;Child;Circadian Rhythm;Demography;Humans;Middle Aged;Motor Activity;Rest;Sleep;Young Adult;Actigraphy;Demography;Epidemiology,E01.370.520.049;E05.003.500;M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;G07.180.562.190;I01.240;N01.224;N06.850.505.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.145.632;G11.427.410.698;I03.450.769.647;F02.830.855;G11.561.803;M01.060.116.815;E01.370.520.049;E05.003.500;I01.240;N01.224;N06.850.505.400;H02.403.720.500
28650582,"Animals;Body Composition;CX3C Chemokine Receptor 1;Diet, High-Fat;Glucose Intolerance;Inflammation;Insulin;Insulin Resistance;Insulin Secretion;Macrophages;Mice;Mice, Inbred C57BL;Mice, Knockout;Obesity;Receptors, CCR2;Weight Gain",B01.050;G02.111.130;G03.180;G07.100.049;D12.776.543.750.695.160.500.150;D12.776.543.750.705.852.125.500.150;D12.776.543.750.830.700.315;G07.203.650.240.267;C18.452.394.952.500;C23.550.470;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;C18.452.394.968.500;G07.690.773.984.617;G03.442;G07.475;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D12.776.543.750.695.160.150.200;D12.776.543.750.705.852.125.150.200;C23.888.144.243.926;G07.345.249.314.120.200.926
28650415,"Child;Child, Preschool;Equipment Design;Fiber Optic Technology;Humans;Infant;Intubation, Intratracheal;Laryngoscopes;Laryngoscopy;Registries;Videotape Recording",M01.060.406;M01.060.406.448;E05.320;H01.671.617.249;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.041.500;E02.585.578;E05.497.578;E07.230.220.525;E07.858.240.525;E01.370.386.460;E01.370.388.250.525;E04.502.250.525;E04.580.373;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;J01.897.280.500.846.734;J01.897.280.500.898.840;L01.178.590.875.840;L01.178.820.090.846.734;L01.178.820.090.898.840;L01.280.940.840;L01.280.960.880
28650215,"Administration, Ophthalmic;Animals;Antibodies, Monoclonal, Humanized;Conjunctiva;Cytokines;Dogs;Eye Proteins;Gene Expression;Ophthalmic Solutions;Pilot Projects;RNA, Messenger;Tears;Dogs;Ophthalmic Solutions;Interleukin-6",E02.319.267.120.805;B01.050;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;A09.371.060.200;A09.371.337.168;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.750.250.216.200;D12.776.306;G05.297;D26.776.708.645;D27.505.954.578.645;D27.720.752.608;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;D13.444.735.544;A12.200.882;B01.050.150.900.649.313.750.250.216.200;D26.776.708.645;D27.505.954.578.645;D27.720.752.608;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
28650199,"Adolescent;Child;Humans;Psychological Tests;Psychology;Stress Disorders, Post-Traumatic;Stress, Psychological;Wounds and Injuries",M01.060.057;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;F04.711;F04.096.628;F03.950.750.500;F01.145.126.990;F02.830.900;C26
28649883,"Animals;Chromatin;Histone Code;Humans;Protein Processing, Post-Translational;Proteomics;Chromatin;Histones;Mass Spectrometry;Protein Processing, Post-Translational;Proteomics",B01.050;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G02.111.570.060.360;G05.360.360;B01.050.150.900.649.313.988.400.112.400.400;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;E05.196.566;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
28649662,,
28649645,,
28649593,Metabolic Syndrome;Microbiota,C18.452.394.968.500.570;C18.452.625;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
28649449,Education,I02
28649447,,
28649317,"Animals;Biomedical Research;Ethics Committees, Research;Humans;National Institutes of Health (U.S.);Research Design;Sex Characteristics;Sex Factors;United States;Ethics;Gender Identity;Informed Consent;Ethics Committees, Research;Research;Sex",B01.050;H01.770.644.145;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;E05.581.500;H01.770.644.728;G08.686.815;N05.715.350.675;N06.850.490.875;Z01.107.567.875;K01.752.566.479;N05.350;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;K01.752.566.479.147.750;N04.452.758.788.300.750;N05.350.268.750;N05.700.685.300.750;H01.770.644;G08.686.810
28648487,"Gene Expression Regulation, Neoplastic;Genetic Variation;Humans;Immunotherapy, Adoptive;Neoplasms;Receptors, Antigen;T-Lymphocytes",G05.308.370;G05.365;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04;D12.776.543.750.705.816;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28648301,"African Americans;Aged;Albuminuria;Brain;Cardiovascular Diseases;Cholesterol, LDL;Cognition;Cognitive Dysfunction;Creatinine;Cross-Sectional Studies;Diabetes Mellitus, Type 2;Glomerular Filtration Rate;Glycated Hemoglobin A;Gray Matter;Humans;Hypertension;Linear Models;Magnetic Resonance Imaging;Middle Aged;Multivariate Analysis;Neuropsychological Tests;Organ Size;Renal Insufficiency, Chronic;Smoking;United States;White Matter;Albuminuria;Brain",M01.686.508.100.100;M01.686.754.100;M01.060.116.100;C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;A08.186.211;C14;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;F02.463.188;F03.615.250.700;D03.383.129.308.207;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C18.452.394.750.149;C19.246.300;E01.370.390.400.300;G08.852.357;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E01.370.350.825.500;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;F04.711.513;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;C12.777.419.780.750;C13.351.968.419.780.750;F01.145.805;Z01.107.567.875;A08.186.211.204;A08.186.854.880;C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;A08.186.211
28647952,Advanced Practice Nursing;Body Height;Child;Continental Population Groups;Dwarfism;Growth Disorders;Health Status Disparities;Humans;Nurse's Role;Prejudice;Sex Factors;Child,H02.478.676.074;E01.370.600.115.100.160.100;E05.041.124.160.500;G07.100.100.160.100;G07.345.249.314.100;M01.060.406;M01.686.508;C05.116.099.343;C16.320.240;C19.297;C23.550.393;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;B01.050.150.900.649.313.988.400.112.400.400;F01.829.316.616.625.450;N05.300.100.337;F01.145.813.550;F01.829.595;N05.715.350.675;N06.850.490.875;M01.060.406
28647950,"Adolescent;Age Factors;Child;Child, Preschool;Diagnostic Techniques, Endocrine;Growth Charts;Humans;Infant;Infant, Newborn;Parturition;Pregnancy;Prenatal Diagnosis;Sexual Maturation;Turner Syndrome;Estrogens;Growth Hormone;Primary Ovarian Insufficiency;Puberty;Turner Syndrome",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;E01.370.374;E05.978.808.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G08.686.784.769.490;G08.686.784.769;E01.370.378.630;G07.345.750.750;G08.686.841.750;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750;D27.505.696.399.472.277;D06.472.699.631.525.425;D12.644.548.691.525.425;C13.351.500.056.630.750;C19.391.630.750;G08.686.760;G08.686.841.374;C12.706.316.309.872;C12.706.316.795.750;C13.351.875.253.309.872;C13.351.875.253.795.750;C14.240.400.980;C14.280.400.980;C16.131.240.400.970;C16.131.260.830.835.750;C16.131.939.316.309.872;C16.131.939.316.795.750;C16.320.180.830.835.750;C19.391.119.309.872;C19.391.119.795.750
28647947,"Adolescent;Blood Glucose;Blood Glucose Self-Monitoring;Child;Child, Preschool;Diabetes Mellitus, Type 1;Humans;Insulin Infusion Systems;Practice Patterns, Physicians';Quality of Life;Risk Assessment;Adolescent;Child;Pediatrics;Technology",M01.060.057;D09.947.875.359.448.500;E01.370.225.124.100.105;E01.370.374.100;E01.370.520.100;E02.900.100;E05.200.124.100.105;M01.060.406;M01.060.406.448;C18.452.394.750.124;C19.246.267;C20.111.327;B01.050.150.900.649.313.988.400.112.400.400;E02.319.300.508;E07.505.508;E07.858.082.505.508;N04.590.374.577;N05.300.625;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;M01.060.057;M01.060.406;H02.403.670;J01.897
28647944,"Caregivers;Child, Preschool;Choice Behavior;Diabetes Mellitus, Type 1;Humans;Infant;Infant, Newborn;Insulin Infusion Systems;Parents;Parenting",M01.085;M01.526.485.200;N02.360.200;M01.060.406.448;F02.463.785.373.346;C18.452.394.750.124;C19.246.267;C20.111.327;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.319.300.508;E07.505.508;E07.858.082.505.508;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.829.263.370.310
28647722,"Adolescent;Child;Child, Preschool;Evidence-Based Practice;Firearms;Government Programs;Health Promotion;Humans;National Institute of Mental Health (U.S.);Needs Assessment;Primary Health Care;Research Design;Safety;Suicide;Surveys and Questionnaires;United States;Wounds, Gunshot;Adolescent;Firearms;Suicide",M01.060.057;M01.060.406;M01.060.406.448;H02.249;J01.637.870.350;I01.451;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496.460;N03.540.052.750.460;N03.540.348.500.500.600.650.496.460;I02.594;N03.349.380.565;N05.300.537;N04.590.233.727;E05.581.500;H01.770.644.728;N06.850.135.060.075;F01.145.126.980.875;I01.880.735.856;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;C26.986.900;M01.060.057;J01.637.870.350;F01.145.126.980.875;I01.880.735.856
28647386,Internship and Residency;Physicians;Radiography;Radiology;Teaching,I02.358.337.350.500;I02.358.399.350.750;M01.526.485.810;N02.360.810;E01.370.350.700;H02.403.740;I02.903
28647272,"Decision Making;Humans;Infant;Infant Mortality;Infant, Newborn;Infant, Premature;Life Support Care;Morbidity;Outcome Assessment (Health Care);Registries;Retrospective Studies;Survival Rate;Withholding Treatment;Ethics;Infant, Newborn;Palliative Care;Prognosis",F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;M01.060.703.520.520;E02.760.440;N02.421.585.440;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E02.760.952;N02.421.585.952;K01.752.566.479;N05.350;M01.060.703.520;E02.760.666;N02.421.585.666;E01.789
28645441,"Bronchopulmonary Dysplasia;Child, Preschool;Combined Modality Therapy;Disease Management;Disease Progression;Humans;Hypertension, Pulmonary;Infant;Infant, Newborn;Infant, Very Low Birth Weight;Practice Guidelines as Topic;Prognosis;Risk Assessment;Severity of Illness Index;Survival Rate;Bronchopulmonary Dysplasia;Cardiac Catheterization;Echocardiography;Hypertension, Pulmonary",C08.381.520.750.500;C16.614.521.125;M01.060.406.448;E02.186;N04.590.607;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;M01.060.703;M01.060.703.520;M01.060.703.520.460.600;N04.761.700.350.650;N05.700.350.650;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;C08.381.520.750.500;C16.614.521.125;E01.370.370.380.140;E02.148.442;E05.157.250;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C08.381.423
28645129,Hemostasis;Humans;Outcome Assessment (Health Care);Prognosis;Severity of Illness Index;Thrombosis,G09.188.390;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E01.789;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C14.907.355.830
28644897,"15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid;Animals;Cells, Cultured;Coronary Vessels;Endothelial Cells;Large-Conductance Calcium-Activated Potassium Channel alpha Subunits;Mice, Inbred C57BL;Mice, Knockout;Microvessels;Nitric Oxide Synthase Type III;Propofol;TRPA1 Cation Channel;TRPV Cation Channels;Transient Receptor Potential Channels;Vasoconstrictor Agents;Vasodilation;Vasodilator Agents",D01.248.497.158.685.750.744.650.500.500;D01.339.431.374.744.650.500.500;D01.650.550.750.700.650.500.500;D02.389.338.638.650.500.500;D10.251.355.255.550.025.650.500.500;D23.469.050.175.725.025.650.500.500;D23.469.700.630.500;B01.050;A11.251;A07.015.114.269;A07.015.908.194;A11.436.275;D12.776.157.530.400.600.150.500.500;D12.776.543.550.450.750.150.500.500;D12.776.543.585.400.750.150.500.249;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A07.015.461;D08.811.682.664.500.772.750;D02.455.426.559.389.657.773;D12.776.157.530.400.901.250;D12.776.543.585.400.901.250;D12.776.157.530.400.901.888;D12.776.157.530.400.901;D12.776.543.585.400.901;D27.505.954.411.793;G09.330.380.928;D27.505.954.411.918
28644774,"Adolescent;Adult;Alleles;Aminoglycosides;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Child;Child, Preschool;Disease-Free Survival;Heterozygote;Homozygote;Humans;Infant;Infant, Newborn;Leukemia, Myeloid, Acute;Polymorphism, Single Nucleotide;RNA, Messenger;Sialic Acid Binding Ig-like Lectin 3;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;G05.360.340.024.340.030;D09.408.051;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;E02.183.750.500;E02.319.077.500;E02.319.310.037;M01.060.406;M01.060.406.448;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;G05.380.383;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04.557.337.539.275;G05.365.795.598;D13.444.735.544;D12.776.503.921.400;D23.050.301.264.900.565;D23.101.100.900.565;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28644188,"Arthroplasty, Replacement, Knee;Biomechanical Phenomena;Humans;Osteoarthritis, Knee;Range of Motion, Articular;Rotation",E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;G01.154.090;G01.374.089;B01.050.150.900.649.313.988.400.112.400.400;C05.550.114.606.500;C05.799.613.500;E01.370.600.700;G11.427.760;G01.482.703
28643572,"Adolescent;Antiretroviral Therapy, Highly Active;Botswana;Caregivers;Discrimination (Psychology);Focus Groups;HIV Infections;Humans;Interviews as Topic;Longitudinal Studies;Medication Adherence;Pain Management;Poverty;Social Stigma;Social Support;Time Factors;Young Adult;Social Support;Organization and Administration",M01.060.057;E02.319.310.075;Z01.058.290.175.230;M01.085;M01.526.485.200;N02.360.200;F02.463.593.257;E05.318.308.112;N05.715.360.300.269;N06.850.520.308.112;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E02.745;N04.590.607.500;I01.880.735.634;I01.880.853.996.535;N01.824.600;F01.145.813.840;I01.880.853.500.600;G01.910.857;M01.060.116.815;I01.880.853.500.600;N04.452
28643402,"Angiography;Echocardiography;Heart Ventricles;Humans;Hypoplastic Left Heart Syndrome;Infant, Newborn;Norwood Procedures;Retrospective Studies;Ventricular Dysfunction, Right;Ventricular Function, Right;Hypoplastic Left Heart Syndrome",E01.370.350.700.060;E01.370.370.050;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703.520;E04.100.376.724;E04.928.220.560;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.280.945.910;G09.330.955.900;C14.240.400.625;C14.280.400.625;C16.131.240.400.625
28643117,Adolescent;Child;Family Relations;Humans;Psychometrics;Quality of Life;Reproducibility of Results;Child;Family Relations,M01.060.057;M01.060.406;F01.829.263.370;I01.880.853.150.439;B01.050.150.900.649.313.988.400.112.400.400;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;M01.060.406;F01.829.263.370;I01.880.853.150.439
28642300,"Adolescent;Adverse Drug Reaction Reporting Systems;Child;Child, Preschool;Electronic Health Records;Humans;Leukemia, Myeloid, Acute;Observer Variation;Reproducibility of Results",M01.060.057;E05.337.800.120;N02.421.668.320.120;M01.060.406;M01.060.406.448;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
28642263,"Adult;Brain;Humans;Magnetic Resonance Imaging;Middle Aged;Multiple Sclerosis, Relapsing-Remitting;Neuroimaging;Reproducibility of Results",M01.060.116;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;E01.370.350.578;E01.370.376.537;E05.629;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725
28640504,Cardiovascular Diseases;Liver Transplantation,C14;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
28639489,"Decision Support Systems, Clinical;Electronic Health Records;Health Personnel;Pharmacogenetics;Precision Medicine;United States;Decision Support Systems, Clinical;Education;Pharmacogenetics;Pharmacogenetics",L01.313.500.750.300.190;E05.318.308.940.968.625.500;M01.526.485;N02.360;H01.158.273.343.750;H01.158.703.052;H02.628.479;E02.574;H02.403.200.700;Z01.107.567.875;L01.313.500.750.300.190;I02;H01.158.273.343.750;H01.158.703.052;H02.628.479;H01.158.273.343.750;H01.158.703.052;H02.628.479
28639398,"Adolescent;Bronchoalveolar Lavage Fluid;Child;Child, Preschool;DNA, Viral;Herpesvirus 4, Human;Humans;Infant;Kaplan-Meier Estimate;Lung Transplantation;Lymphoproliferative Disorders;Polymerase Chain Reaction;Postoperative Complications;Prospective Studies;Risk Factors;Viral Load;Young Adult;Herpesvirus 4, Human;Bronchoalveolar Lavage;Lung Transplantation;Pediatrics",M01.060.057;E05.927.100.500;M01.060.406;M01.060.406.448;D13.444.308.568;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E04.928.600.495;E04.936.450.495;C15.604.515;C20.683.515;E05.393.620.500;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.225.875.950;E05.200.875.950;G06.920.850;M01.060.116.815;B04.280.210.400.500.450;B04.280.382.400.500.400;B04.613.204.500.500.400;E05.927.100;E04.928.600.495;E04.936.450.495;H02.403.670
28639106,Adult;Humans;Logistic Models;Motivation;Reward;Smoking;Smoking Cessation;Smoking Prevention;Social Support;Time Factors;Smoking Cessation;Tobacco Use Disorder,M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;F01.658;F01.752.543.500.750;F02.463.425.770.836;F01.145.805;F01.145.488.732;I02.233.332.812;N02.421.726.407.840;I01.880.853.500.600;G01.910.857;F01.145.488.732;C25.775.912;F03.900.912
28638599,"Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28638534,,
28638328,Cognition;Consciousness;Sleep,F02.463.188;F02.463.188.409;F02.830.233;F02.830.855;G11.561.803
28637667,"Humans;Platelet Count;Pregnancy;Pregnancy Complications, Hematologic;Thrombocytopenia",B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;G08.686.784.769;C13.703.667;C15.378.785;C15.378.140.855
28637664,Alleles;Base Sequence;Blood Platelets;Guanine Nucleotide Exchange Factors;Hemorrhage;Humans;Mutation;Pedigree,G05.360.340.024.340.030;G02.111.570.080;G05.360.080;L01.453.245.667.080;A11.118.188;A15.145.229.188;D12.644.360.325.300;D12.776.476.325.300;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;E05.393.673
28637521,Achievement;Adult;Affect;Cognitive Behavioral Therapy;Cognitive Dysfunction;Executive Function;Humans;Middle Aged;Outcome Assessment (Health Care);Schizophrenia;Self Concept;Cognitive Behavioral Therapy;Schizophrenia,F01.658.059;F02.784.629.054;M01.060.116;F01.470.047;F04.754.137.350;F03.615.250.700;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F03.700.750;F01.752.747.792;F04.754.137.350;F03.700.750
28636716,,
28636407,"Humans;Lung;Muscular Dystrophy, Duchenne;Respiratory Muscles;Muscular Dystrophy, Duchenne;Respiratory Insufficiency",B01.050.150.900.649.313.988.400.112.400.400;A04.411;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;A02.633.567.900;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;C08.618.846
28636076,Comorbidity;Exercise;Guidelines as Topic;Hemophilia A;Humans;Obesity;Overweight;Prevalence;United States;Weight Loss;Hemophilia A;Obesity;Overweight;Weight Loss,N05.715.350.225;N06.850.490.687;G11.427.410.698.277;I03.350;N04.761.700.350;N05.700.350;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;Z01.107.567.875;C23.888.144.243.963;G07.345.249.314.120.200.963;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;C23.888.144.243.963;G07.345.249.314.120.200.963
28635055,"Adult;Humans;Immunologic Factors;Melanoma;Multiple Sclerosis;Natalizumab;Neoplasms, Second Primary;Melanoma;Multiple Sclerosis;Natalizumab",M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;C04.692;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813
28635008,"Adult;Cohort Studies;Congenital Abnormalities;Fertility;Humans;Infant, Low Birth Weight;Infant, Newborn;Infant, Premature;Infertility;Live Birth;Massachusetts;Multiple Birth Offspring;Parturition;Pregnancy;Pregnancy Outcome;Pregnancy, Multiple;Premature Birth;Reproductive Techniques, Assisted;Retrospective Studies;Single Embryo Transfer;Reproductive Techniques, Assisted;Congenital Abnormalities;Infertility;Negotiating;Multiple Birth Offspring;Infertility",M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C16.131;G08.686.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.460;M01.060.703.520;M01.060.703.520.520;C12.294.365;C13.351.500.365;G08.686.784.769.496.249;Z01.107.567.875.550.510;M01.438;G08.686.784.769.490;G08.686.784.769;E01.789.700;G08.686.784.769.496;G08.686.710;G08.686.784.769.525;C13.703.420.491.500;E02.875.800;E05.820.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.875.800.500.500;E05.820.800.500.500;E02.875.800;E05.820.800;C16.131;C12.294.365;C13.351.500.365;F01.145.209.520;F01.829.401.520;F02.463.785.373.520;L01.143.620;N04.452.677.430;M01.438;C12.294.365;C13.351.500.365
28634624,"Animals;Anisotropy;Autopsy;Brain;Brain Mapping;Diffusion Tensor Imaging;Image Processing, Computer-Assisted;Macaca mulatta;Magnetic Resonance Imaging;White Matter;Atlas",B01.050;G01.590.040;G02.050;E01.370.060;E05.070;I01.198.780.937.120;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;L01.224.308;B01.050.150.900.649.313.988.400.112.199.120.510.550;E01.370.350.825.500;A08.186.211.204;A08.186.854.880;V02.150
28634384,Alternative Splicing;Amino Acid Motifs;Amino Acid Sequence;Animals;Cell Nucleus;Exons;HeLa Cells;Humans;Intracellular Space;Mice;Protein Sorting Signals;RNA Isoforms;RNA Splice Sites;RNA Transport;RNA-Binding Proteins,G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;G02.111.570.060;L01.453.245.667.060;B01.050;A11.284.430.106;A11.284.430.214.190.875.117;G05.360.340.024.340.137.232;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;A10.082.750;A11.284.430;B01.050.150.900.649.313.992.635.505.500;D12.644.770;G02.111.570.060.670;D13.444.735.064;D13.444.735.544.550;G02.111.570.080.689.687.490;G05.360.080.689.687.490;G05.360.340.024.340.137.800;G03.143.850;D12.776.157.725;D12.776.664.962
28634248,"Adult;Child, Preschool;Family;Food Supply;Humans;Infant;Middle Aged;Philadelphia;Primary Health Care;Prospective Studies;Suburban Population;United States;Young Adult",M01.060.116;M01.060.406.448;F01.829.263;I01.880.853.150;J01.576.423.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;Z01.107.567.875.500.550.525;Z01.433.820;N04.590.233.727;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N01.600.775;Z01.107.567.875;M01.060.116.815
28634247,"Attitude of Health Personnel;Child, Preschool;Feasibility Studies;Food Supply;Humans;Infant;Pediatrics;Practice Patterns, Physicians';Prospective Studies;Suburban Health Services;United States",F01.100.050;N05.300.100;M01.060.406.448;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;J01.576.423.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H02.403.670;N04.590.374.577;N05.300.625;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N02.421.908;Z01.107.567.875
28634168,"Adolescent;Child, Preschool;Health Care Rationing;Health Status Disparities;Hospital Costs;Hospitalization;Hospitals, Pediatric;Humans;Mental Disorders;Multiple Chronic Conditions;Retrospective Studies;United States",M01.060.057;M01.060.406.448;I01.261.750.500;N03.349.270;N05.300.430.375;I01.240.425.675;N01.224.425.437;N06.850.505.400.425.675;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;E02.760.400;N02.421.585.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;F03;C23.550.291.500.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875
28634024,,
28633680,"Bacteremia;Bacteria;Catheter-Related Infections;Catheterization, Central Venous;Cross Infection;Humans;Philadelphia;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization",C01.252.100;C01.539.757.100;C23.550.470.790.500.100;B03;C01.539.195;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;C01.539.248;C23.550.291.875.500;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;E05.196.566.755
28633483,"Computer Security;Continuity of Patient Care;Decision Support Systems, Clinical;Family;Hospitalization;Humans;Informatics;Patient Participation;Patient Portals;Patient Participation;Patient Portals;Quality of Health Care",L01.224.134;N04.452.910.200;E02.760.169;N02.421.585.169;N04.590.233.727.210;L01.313.500.750.300.190;F01.829.263;I01.880.853.150;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;L01.313;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;E05.318.308.940.968.249.750;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;E05.318.308.940.968.249.750;N04.761;N05.715
28633356,Accidents;Alcohol Drinking;Motor Vehicles;Transportation,N06.850.135;F01.145.317.269;J01.937.500;J01.937
28633289,,
28632699,3-Iodobenzylguanidine;Adrenal Gland Neoplasms;Arteries;Child;Forearm;Humans;Injections,D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;C04.588.322.078;C19.053.347;C19.344.078;A07.015.114;M01.060.406;A01.378.800.585;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530
28632697,"Adolescent;Esophagus;Gastric Emptying;Hernia, Hiatal;Humans;Image Interpretation, Computer-Assisted;Lung;Radionuclide Imaging;Stomach",M01.060.057;A03.556.875.500;G10.261.360.400;C23.300.707.500.467;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;A04.411;E01.370.350.710;E01.370.384.730;A03.556.875.875
28632583,"Animals;Aorta, Thoracic;Balloon Occlusion;Disease Models, Animal;Endovascular Procedures;Reperfusion;Resuscitation;Shock, Hemorrhagic;Swine",B01.050;A07.015.114.056.372;E02.148.106;E02.520.392.500;E02.926.500.074;E05.157.063;C22.232;E05.598.500;E05.599.395.080;E04.100.814.529;E04.502.382;E04.100.700;E05.680.730;E02.365.647;C23.550.414.980;C23.550.835.650;B01.050.150.900.649.313.500.880
28631208,"Anastomosis, Surgical;Blalock-Taussig Procedure;Cardiovascular Surgical Procedures;Echocardiography, Doppler;Heart Defects, Congenital;Heart Ventricles;Humans;Infant;Norwood Procedures;Palliative Care;Pulmonary Artery;Pulmonary Veins;Regional Blood Flow;Retrospective Studies;Echocardiography",E04.035;E04.035.137;E04.100.814.868.374;E04.100;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E04.100.376.724;E04.928.220.560;E02.760.666;N02.421.585.666;A07.015.114.715;A07.015.908.713;G09.330.100.780;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220
28630914,"Arrhythmias, Cardiac;Heart Diseases",C14.280.067;C23.550.073;C14.280
28630913,Symbiosis;Bioengineering;Coronary Artery Disease;Cyanobacteria;Myocardial Ischemia;Myocardial Infarction;Photosynthesis,G06.550.800;G16.840;J01.293.069;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;B03.280;B03.440.475.100;C14.280.647;C14.907.585;C14.280.647.500;C14.907.585.500;G02.111.158.937;G02.111.669.700;G02.740.921;G03.191.937;G03.493.700;G03.800.700;G15.568
28630651,Anti-HIV Agents;Delivery of Health Care;Forecasting;HIV Infections;Humans;Patient Compliance;Text Messaging;World Health Organization;HIV,D27.505.954.122.388.077.088;N04.590.374;N05.300;I01.320;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;L01.178.847.698.300.500;L01.559.423.906.377.666;N03.540.514.718.800;B04.820.650.589.650.350
28630485,"Animals;Blood-Brain Barrier;Brain Injuries, Traumatic;Catalase;Endothelial Cells;Hydrogen Peroxide;Intercellular Adhesion Molecule-1;Mice;Microglia;Neuroglia;Oxidative Stress;Protective Agents;Reactive Oxygen Species;Tyrosine",B01.050;A07.035;A08.186.211.035;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;D08.811.682.732.332;A11.436.275;D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253;D12.776.395.550.200.450;D12.776.543.550.200.450;D23.050.301.350.450;B01.050.150.900.649.313.992.635.505.500;A08.637.400;A11.650.400;A08.637;A11.650;G03.673;G07.775.750;D27.505.696.706;D27.720.799;D01.339.431;D01.650.775;D12.125.072.050.875
28630421,,
28630329,"Cytochromes c;Kinetics;Models, Molecular;Nuclear Magnetic Resonance, Biomolecular;Protein Folding;Proteins;Ribonuclease H;Protein Folding",D08.244.286.100;D12.776.422.220.286.100;G01.374.661;G02.111.490;E05.599.595;E05.196.867.519.550;G01.154.651;G02.111.688;D12.776;D08.811.277.352.355.350.700;D08.811.277.352.700.350.700;G01.154.651;G02.111.688
28630312,"A549 Cells;Carcinogenesis;Carcinoma;Cell Transformation, Neoplastic;Cyclin-Dependent Kinase 9;Drug Screening Assays, Antitumor;Epigenesis, Genetic;Gene Expression Regulation, Neoplastic;HEK293 Cells;HeLa Cells;Humans;Nuclear Proteins;Oncogene Proteins;Oncogene Proteins, Fusion;Oncogenes;Phosphorylation;Signal Transduction;Transcription Factors;Neoplasms",A11.251.210.190.080;A11.251.860.180.080;A11.436.054;C04.697.098;C23.550.727.098;C04.557.470.200;C04.697.098.500;C23.550.727.098.500;D08.811.641.752;D08.811.913.696.620.682.700.646.500.500.750;D12.644.360.250.067.900;D12.776.167.200.067.900;D12.776.476.250.067.900;D12.776.930.955.500.500;E01.370.225.500.388;E05.200.500.388;E05.242.417;E05.337.550.200;G05.308.203;G05.308.370;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;D12.776.660;D12.776.624.664;D12.776.602.500.500;D12.776.624.664.500;G05.360.340.024.340.375.500;G02.111.665;G02.607.780;G03.796;G02.111.820;G04.835;D12.776.930;C04
28630195,"Administration, Cutaneous;Animals;Anti-Bacterial Agents;Anti-Infective Agents, Local;Mice;Microbiota;Skin;Staphylococcal Skin Infections;Staphylococcus aureus;Staphylococcus aureus;Anti-Infective Agents;Microbiota;Skin",E02.319.267.120.060;B01.050;D27.505.954.122.085;D27.505.954.122.187;B01.050.150.900.649.313.992.635.505.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A17.815;C01.252.410.868.820;C01.252.825.770;C01.539.800.720.770;C17.800.838.765.770;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;D27.505.954.122;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A17.815
28629897,"Animals;Diabetes Complications;Diabetes Mellitus, Type 2;Humans;Metabolic Networks and Pathways;Models, Biological;Oxidative Stress;Diabetes Mellitus, Type 2",B01.050;C19.246.099;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;G03.493;E05.599.395;G03.673;G07.775.750;C18.452.394.750.149;C19.246.300
28629894,"Animals;Biological Transport, Active;Cartilage;Cattle;Chondrocytes;Coculture Techniques;Extracellular Matrix;Mesenchymal Stem Cells;Porosity;Tissue Engineering;Tissue Scaffolds;Coculture Techniques;Hyaluronic Acid;Mesenchymal Stem Cells",B01.050;G03.143.310;A02.165;A10.165.382;B01.050.150.900.649.313.500.380.271;A11.329.171;E05.481.500.374;A11.284.295.310;A11.329.830.500;A11.872.590.500;G01.374.710;E05.481.500.311.500;J01.293.069.249.500;E07.206.627;E07.695.825;E05.481.500.374;D09.698.373.475;A11.329.830.500;A11.872.590.500
28629687,"Adolescent;Anti-Bacterial Agents;Cross-Sectional Studies;Emergency Service, Hospital;Hospitals, Pediatric;Humans;Retrospective Studies;Sensitivity and Specificity;Sexually Transmitted Diseases;Young Adult;Chlamydia trachomatis;Neisseria gonorrhoeae;Adolescent;Emergency Service, Hospital;Sexually Transmitted Diseases",M01.060.057;D27.505.954.122.085;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C01.539.778;C02.800;C12.294.668;C13.351.500.711;M01.060.116.815;B03.440.190.190.190.750;B03.440.400.425.550.550.474;B03.660.075.525.520.400;M01.060.057;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C01.539.778;C02.800;C12.294.668;C13.351.500.711
28629457,Biomarkers;Cell- and Tissue-Based Therapy;Humans;Immunotherapy;Metabolome;Molecular Imaging;Neoplasms;T-Lymphocytes,D23.101;E02.095.147;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;G03.500;E01.370.350.557;E05.601.555;C04;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28628764,"Adult;Anxiety Disorders;Cognition Disorders;Comorbidity;Cross-Sectional Studies;Depressive Disorder, Major;Humans;Mental Disorders;Middle Aged;Military Personnel;Prevalence;Sleep Initiation and Maintenance Disorders;Stress Disorders, Post-Traumatic;Surveys and Questionnaires;United States;Young Adult;Cognition;Sleep Initiation and Maintenance Disorders",M01.060.116;F03.080;F03.615.250;N05.715.350.225;N06.850.490.687;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;F03;M01.060.116.630;M01.526.625;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C10.886.425.800.800;F03.870.400.800.800;F03.950.750.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875;M01.060.116.815;F02.463.188;C10.886.425.800.800;F03.870.400.800.800
28628665,"Adult;Chromosomes, Human, Pair 5;Endemic Diseases;Genome-Wide Association Study;HIV;HIV Infections;Haplotypes;Humans;Mycobacterium tuberculosis;Skin Tests;Tanzania;Tuberculin Test;Tuberculosis;Uganda",M01.060.116;A11.284.187.520.300.280.290;G05.360.162.520.300.280.290;N06.850.392;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B04.820.650.589.650.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702;E01.370.225.812.871;E05.200.812.871;E05.478.594.890;Z01.058.290.120.840;E01.370.225.812.871.800;E05.200.812.871.800;E05.478.594.890.800;C01.252.410.040.552.846;Z01.058.290.120.880
28628560,"Adult;Aged;Cardiovascular Diseases;Case-Control Studies;Cholesterol, HDL;Cholesterol, LDL;Delayed-Action Preparations;Genotyping Techniques;Humans;Hypolipidemic Agents;Lipoprotein(a);Middle Aged;Niacin;Polymorphism, Single Nucleotide;Receptors, G-Protein-Coupled;Receptors, Nicotinic;Sequence Analysis, DNA;Treatment Outcome;Triglycerides;Young Adult",M01.060.116;M01.060.116.100;C14;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;D26.255.210;E02.319.300.253;E05.393.442;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071;D27.505.954.557.500;D10.532.350;D12.776.521.400;M01.060.116.630;D03.066.515.475;D03.383.725.547.475;G05.365.795.598;D12.776.543.750.695;D12.776.157.530.400.400.100.500;D12.776.543.550.450.500.100.500;D12.776.543.585.400.500.100.500;D12.776.543.750.130.687;D12.776.543.750.720.360.550;E05.393.760.700;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D10.351.801;M01.060.116.815
28628533,"Activities of Daily Living;Aged;Aged, 80 and over;Disabled Persons;Hospitalization;Humans;Long-Term Care;Medicare;Proportional Hazards Models;Risk Factors;United States",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;M01.060.116.100.080;M01.150;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.760.476;N02.421.585.476;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28628351,Adolescent;Adult;Cancer Survivors;Child;Humans;Neoplasms;Quality of Life;Sleep;Young Adult;Cancer Survivors;Sleep Initiation and Maintenance Disorders;Quality of Life;Sleep,M01.060.057;M01.060.116;M01.860.350;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04;I01.800;K01.752.400.750;N06.850.505.400.425.837;F02.830.855;G11.561.803;M01.060.116.815;M01.860.350;C10.886.425.800.800;F03.870.400.800.800;I01.800;K01.752.400.750;N06.850.505.400.425.837;F02.830.855;G11.561.803
28628244,"Adult;Aged;Aged, 80 and over;Amyotrophic Lateral Sclerosis;Biomarkers;C9orf72 Protein;Case-Control Studies;Disease Progression;Humans;Middle Aged;Neurofilament Proteins;Phosphorylation;Proteins;Survival Analysis;Young Adult",M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;D23.101;D12.776.141;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D05.750.078.593.630;D12.776.220.475.630;D12.776.631.630;G02.111.665;G02.607.780;G03.796;D12.776;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;M01.060.116.815
28628108,"Amino Acid Transport System ASC;CARD Signaling Adaptor Proteins;Cohort Studies;DNA Mutational Analysis;Dermatitis, Atopic;Genes, Dominant;Germ-Line Mutation;Glutamine;Guanylate Cyclase;Humans;Jurkat Cells;Lymphocyte Activation;Mechanistic Target of Rapamycin Complex 1;Minor Histocompatibility Antigens;Multiprotein Complexes;NF-kappa B;Pedigree;T-Lymphocytes;TOR Serine-Threonine Kinases",D12.776.157.530.200.500.200;D12.776.543.585.200.500.200;D12.644.360.024.131;D12.644.360.075.358;D12.776.157.057.006;D12.776.476.024.139;D12.776.476.075.358;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.393.760.700.300;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;G05.360.340.024.340.240;G05.420.320;G05.365.590.350;D12.125.068.330;D12.125.095.461;D12.125.154.424;D08.811.520.650.600;D12.644.360.350;D12.776.476.350;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.495;A11.251.860.180.495;A15.382.490.555.567.569.440;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;D23.050.301.500.600;D23.050.705.552.600;D05.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;E05.393.673;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D08.811.913.696.620.682.700.931;D12.776.476.925
28628100,"Amino Acid Sequence;Autistic Disorder;Exome;Genetic Predisposition to Disease;Humans;Mutation, Missense;Receptors, AMPA;Receptors, Glutamate",G02.111.570.060;L01.453.245.667.060;F03.625.164.113.500;G05.360.340.011;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;D12.776.157.530.400.400.500.100;D12.776.543.550.450.500.200.100;D12.776.543.585.400.500.200.100;D12.776.543.750.720.200.450.400.100;D12.776.543.750.720.200.450
28627729,"Chromosome Deletion;Chromosomes, Human, Pair 22;DiGeorge Syndrome;Humans;Immunologic Deficiency Syndromes;T-Lymphocytes;Immunoglobulin G;T-Lymphocytes;Hypersensitivity;Neoplasms",C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;C20.673;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C20.543;C04
28627475,"Adolescent;Adult;Bone Morphogenetic Proteins;Child;Child, Preschool;Cross-Sectional Studies;Humans;Infant;Infant, Newborn;Joints;Middle Aged;Myositis Ossificans;Ossification, Heterotopic;Young Adult;Myositis Ossificans;Ossification, Heterotopic;Risk",M01.060.057;M01.060.116;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A02.835.583;M01.060.116.630;C05.651.594.638;C23.550.751;M01.060.116.815;C05.651.594.638;C23.550.751;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
28627413,Cell Culture Techniques;Cell Line;Esophagitis;Esophagus;Humans;Inflammation;Oxidative Stress,E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;A11.251.210;C06.405.117.620;C06.405.205.663;A03.556.875.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;G03.673;G07.775.750
28626932,X-Rays;Hippocampus;Neurogenesis;Opiate Alkaloids,G01.358.500.505.970;G01.750.250.970;G01.750.750.918;A08.186.211.180.405;A08.186.211.200.885.287.500.345;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;D03.132.577
28626779,,
28625976,"Apoptosis;Benzothiazoles;Cell Line, Tumor;Cell Proliferation;Child;Clustered Regularly Interspaced Short Palindromic Repeats;Drug Resistance, Neoplasm;Humans;Leukemia, Myeloid, Acute;Mutation;Phenylurea Compounds;Protein Kinase Inhibitors;Signal Transduction;Transfection;fms-Like Tyrosine Kinase 3",G04.146.160;D03.383.129.708.089;D03.633.100.185;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;M01.060.406;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G07.690.773.984.395;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;G05.365.590;D02.455.426.559.389.703;D02.948.681;D27.505.519.389.755;G02.111.820;G04.835;E05.393.350.810;G05.728.860;D08.811.913.696.620.682.725.400.020;D12.776.543.750.630.020;D12.776.624.664.700.114
28625879,,
28625878,,
28625877,,
28625551,"Animals;Base Sequence;DEAD Box Protein 58;Encephalitis Virus, Venezuelan Equine;Encephalomyelitis, Venezuelan Equine;HEK293 Cells;HeLa Cells;Host-Pathogen Interactions;Humans;Immune Tolerance;Immunity, Innate;Introns;Mice;Nucleic Acid Conformation;Protein Binding;RAW 264.7 Cells;RNA;RNA Processing, Post-Transcriptional;RNA, Messenger;RNA-Binding Proteins;Spliceosomes;Transfection;Immunity, Innate;Introns",B01.050;G02.111.570.080;G05.360.080;L01.453.245.667.080;D08.811.913.696.445.735.720.249.750;B04.820.230.369;B04.820.850.054.340;C02.081.355.355;C02.182.525.450.250;C02.290.450.225;C02.782.930.100.370.325;C10.228.140.430.520.750.450.600;C10.228.228.245.340.450.600;C10.228.228.291.323.325;C10.228.228.399.750.450.600;C10.228.440.406.225;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;G12.450.564;G05.360.340.024.220.400;G05.360.340.024.340.137.515;B01.050.150.900.649.313.992.635.505.500;G02.111.570.820.486;G05.360.580;G02.111.679;G03.808;A11.251.210.172.875;A11.733.397.815;D13.444.735;G02.111.760;G03.839;G05.308.700;D13.444.735.544;D12.776.157.725;D12.776.664.962;A11.284.430.106.279.345.850;E05.393.350.810;G05.728.860;G12.450.564;G05.360.340.024.220.400;G05.360.340.024.340.137.515
28625466,"Adolescent;Antibodies, Monoclonal, Humanized;Humans;Immunologic Factors;Longitudinal Studies;Neuromyelitis Optica;Sjogren's Syndrome",M01.060.057;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774
28625002,"Adolescent;Bariatric Surgery;Eating;Feeding Behavior;Feeding and Eating Disorders;Follow-Up Studies;Humans;Life Style;Longitudinal Studies;Obesity, Morbid;Pediatric Obesity;Postoperative Period;Weight Loss;Adolescent;Bariatric Surgery;Energy Intake",M01.060.057;E02.570.500.062;E04.062;G07.203.650.283;G10.261.330;F01.145.113.547;F01.145.407;G07.203.650.353;F03.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;E04.614.750;N02.421.585.753.750;C23.888.144.243.963;G07.345.249.314.120.200.963;M01.060.057;E02.570.500.062;E04.062;G07.203.650.240.340
28624980,"Kidney Failure, Chronic;Pediatrics",C12.777.419.780.750.500;C13.351.968.419.780.750.500;H02.403.670
28623880,Adolescent;Adolescent Behavior;Anhedonia;Cohort Studies;Humans;Longitudinal Studies;Los Angeles;Marijuana Use;Self Report;Adolescent;Anhedonia;Marijuana Use;Policy,M01.060.057;F01.145.022;C10.597.606.057;C23.888.592.604.039;F01.700.039;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875.580.200.450;Z01.107.567.875.760.200.450;Z01.433.565;F01.145.610;F03.900.643;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;M01.060.057;C10.597.606.057;C23.888.592.604.039;F01.700.039;F01.145.610;F03.900.643;I01.655;N03.623
28623346,,
28623100,,
28622089,"Animals;Menisci, Tibial;Outcome Assessment (Health Care);Regeneration;Species Specificity;Wound Healing;Meniscus;Systematic Review",B01.050;A02.165.308.538.500;A02.835.583.475.590;A10.165.382.350.163.500;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;G16.762;G16.824;G16.762.891;A02.165.308.538;A10.165.382.350.163;V03.850
28622079,"Adult;Aged;Analgesics, Opioid;Automation;Cell Phone;Humans;Middle Aged;Pain;Patient Satisfaction;Postoperative Period;Prospective Studies;Reminder Systems;Socioeconomic Factors;Text Messaging;Telemedicine;Telemedicine",M01.060.116;M01.060.116.100;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;J01.897.104;L01.178.847.698.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.888.592.612;F02.830.816.444;G11.561.790.444;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E04.614.750;N02.421.585.753.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;L01.143.820;L01.313.500.750.300.790;I01.880.853.996;N01.824;L01.178.847.698.300.500;L01.559.423.906.377.666;H02.403.840;L01.178.847.652;N04.590.374.800;H02.403.840;L01.178.847.652;N04.590.374.800
28622012,,
28621875,Editorial;Liver Diseases;Liver Transplantation,V01.250;V02.335;C06.552;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
28621297,,
28620718,"Adolescent;Adult;Epilepsies, Partial;Family;Humans;Intellectual Disability;Phenotype;Rho Guanine Nucleotide Exchange Factors;Seizures, Febrile;Young Adult;Seizures, Febrile;Epilepsies, Partial;Intellectual Disability",M01.060.057;M01.060.116;C10.228.140.490.360;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.695;D12.644.360.325.300.099;D12.776.476.325.300.099;C10.597.742.571;C23.888.592.742.571;M01.060.116.815;C10.597.742.571;C23.888.592.742.571;C10.228.140.490.360;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
28620653,,
28620347,Developmental Biology;Locus Coeruleus;Sleep Deprivation,H01.158.273.200;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
28620009,"Abnormalities, Multiple;Brain Neoplasms;Colorectal Neoplasms;Congenital Hypothyroidism;Costello Syndrome;Craniofacial Abnormalities;Hand Deformities, Congenital;Humans;Intellectual Disability;Mutation;Nails, Malformed;Neoplastic Syndromes, Hereditary;Noonan Syndrome;Protein Tyrosine Phosphatase, Non-Receptor Type 11;Risk Factors;Rubinstein-Taybi Syndrome;Sotos Syndrome;Thyroid Nuclear Factor 1",C16.131.077;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;C05.116.099.343.347;C05.116.132.256;C16.320.240.625;C19.297.155;C19.874.482.281;C05.660.207.219;C16.131.077.256;C16.320.185;C05.660.207;C16.131.621.207;C05.390.408;C05.660.585.988.425;C16.131.621.585.988.500;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590;C23.300.820;C04.700;C16.320.700;C05.660.207.690;C14.240.400.787;C14.280.400.787;C16.131.240.400.784;C16.131.621.207.690;C17.300.690;D08.811.277.352.650.775.300.800;D08.811.277.352.650.775.700.800;D12.644.360.585.800;D12.776.476.564.800;D12.776.476.800.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C05.116.099.370.797;C05.660.207.850;C10.597.606.360.700;C16.131.077.804;C16.131.260.790;C16.131.621.207.850;C16.320.180.790;C16.131.077.889;C16.131.260.905;C16.320.180.905;D12.776.260.400.871;D12.776.660.823;D12.776.930.888
28620007,Adrenal Gland Neoplasms;Early Detection of Cancer;Humans;Mutation;Neoplasm Proteins;Paraganglioma;Pheochromocytoma;Risk Factors;von Hippel-Lindau Disease,C04.588.322.078;C19.053.347;C19.344.078;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.624;C04.557.465.625.650.700;C04.557.580.625.650.700;C04.557.465.625.650.700.725;C04.557.580.625.650.700.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.562.925;C14.907.077.925;C16.131.077.245.750;C16.320.184.750
28620006,"Basal Cell Nevus Syndrome;Brain Neoplasms;Child, Preschool;Chromatin Assembly and Disassembly;DNA Helicases;Germ-Line Mutation;Humans;Infant;Kidney Neoplasms;Nuclear Proteins;Patched-1 Receptor;Repressor Proteins;Rhabdoid Tumor;SMARCB1 Protein;Transcription Factors",C04.182.089.530.690.150;C04.557.470.200.165.150;C04.557.470.565.165.150;C04.700.175;C05.116.099.105;C05.500.470.690.150;C07.320.450.670.130;C16.131.077.130;C16.320.700.175;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406.448;G04.400.095;G05.213.095;G05.308.095;D08.811.277.040.025.159;D08.811.399.340;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;D12.776.660;D12.776.543.750.058.500;D12.776.624.776.633.500;D12.776.260.703;D12.776.930.780;C04.557.435.710;D12.776.260.716;D12.776.660.235.650;D12.776.664.235.900;D12.776.930.809;D12.776.930
28619862,"Animals;Decision Making;Elephants;History, 16th Century;History, 17th Century;India;Jurisprudence",B01.050;F02.463.785.373;B01.050.150.900.649.833.249;K01.400.475.750;K01.400.504.750;Z01.252.245.393;I01.880.604.583;N03.706.535
28619756,"Actinium;Alpha Particles;Animals;Biological Transport;Blood-Brain Barrier;Capillary Permeability;Cell Line, Tumor;DNA Damage;Drug Delivery Systems;Glioblastoma;Humans;Integrin alphaVbeta3;Liposomes;Mice;Neovascularization, Pathologic",D01.268.271.100.033;D01.268.556.025;D01.496.749.305.100.033;D01.552.020.042;D01.552.544.025;G01.750.750.055;B01.050;G03.143;A07.035;A08.186.211.035;G03.143.330;G09.330.165;A11.251.210.190;A11.251.860.180;G05.200;E02.319.300;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550.625.439;D12.776.543.550.625.439;D12.776.543.750.705.408.460.870.500;D12.776.543.750.705.675.541;D25.479.517;D26.255.260.517;J01.637.051.479.517;J01.637.087.500.517;B01.050.150.900.649.313.992.635.505.500;C23.550.589.500
28619716,"Caseins;Cryoelectron Microscopy;Heat-Shock Proteins;Hydrolysis;Nucleotides;Peptides;Promoter Regions, Genetic;Protein Domains;Protein Transport;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins;Substrate Specificity;Tyrosine",D12.776.256.626.207;D12.776.744.150;E01.370.350.515.402.150;E05.595.402.150;D12.776.580.216;G02.380;D09.408.620;D13.695;D12.644;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G03.143.700;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750;G02.111.835;D12.125.072.050.875
28619624,Animals;Fetal Diseases;Fetal Therapies;Genetic Therapy;Hematopoietic Stem Cell Transplantation;Humans;Pregnancy;Hematopoietic Stem Cells;Stem Cell Niche,B01.050;C13.703.277;C16.300;E02.467;E02.095.301;E05.393.420.301;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;A11.148.378;A11.872.378;A15.378.316.378;G04.366.249
28619571,"Adhesives;Anesthesia, Local;Anesthetics, Local;Dermatologic Surgical Procedures;Humans;Intraoperative Complications;Occlusive Dressings;Time Factors;Anesthesia;Cysts;Safety",D27.720.013;J01.637.016;E03.155.086.231;D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;E04.680.275;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505;E07.101.650;G01.910.857;E03.155;C04.182;C23.300.306;N06.850.135.060.075
28619476,"Adult;Antidepressive Agents;Depression, Postpartum;Double-Blind Method;Drug Combinations;Humans;Infusions, Intravenous;Pregnanolone;Psychiatric Status Rating Scales;Treatment Outcome;Young Adult;beta-Cyclodextrins",M01.060.116;D27.505.954.427.700.122;C13.703.844.253;F03.600.300.350;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D26.310;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.082.500;E02.319.267.510.590;D04.210.500.745.640;F04.711.513.653;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;D04.345.103.333;D09.301.915.400.375.333;D09.698.365.855.400.375.333
28619260,"Adult;Decision Making;Humans;Motion Perception;Parietal Lobe;Rotation;Spectroscopy, Near-Infrared;Decision Making;Neuroimaging;Psychophysics",M01.060.116;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;F02.463.593.932.567;A08.186.211.200.885.287.500.670;G01.482.703;E01.370.350.750;E05.196.867.851;F02.463.785.373;E01.370.350.578;E01.370.376.537;E05.629;E01.370.685;F04.096.753
28619193,"Adolescent;Adult;Child;Child, Preschool;Embolization, Therapeutic;Follow-Up Studies;Heart Defects, Congenital;Humans;Lymphography;Middle Aged;Protein-Losing Enteropathies;Retrospective Studies;Treatment Outcome;Young Adult;Central Venous Pressure",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E02.520.360;E02.926.500;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.475;M01.060.116.630;C06.405.469.818;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;G09.330.380.076.732.336
28619123,"Antiviral Agents;Child, Preschool;Consensus;DNA, Viral;Dose-Response Relationship, Drug;Heart Defects, Congenital;Humans;Immunization;Infant;Palivizumab;Respiratory Syncytial Virus Infections;Respiratory Syncytial Viruses;Palivizumab;Respiratory Syncytial Viruses",D27.505.954.122.388;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;D13.444.308.568;G07.690.773.875;G07.690.936.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;M01.060.703;D12.776.124.486.485.114.224.060.860;D12.776.124.790.651.114.224.060.860;D12.776.377.715.548.114.224.200.860;C02.782.580.600.550.750;B04.820.455.600.670.600.750;D12.776.124.486.485.114.224.060.860;D12.776.124.790.651.114.224.060.860;D12.776.377.715.548.114.224.200.860;B04.820.455.600.670.600.750
28618202,"Adolescent;Anaerobic Threshold;Child;Cross-Sectional Studies;Exercise Test;Exercise Tolerance;Fontan Procedure;Heart Defects, Congenital;Humans;Oxygen Consumption;Prognosis",M01.060.057;G03.680.110;G11.427.680.134;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;G11.427.680.270;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;G03.680;E01.789
28617996,,
28617934,Acylation;Anaerobiosis;Animals;Clostridium beijerinckii;Dihydroxyacetone Phosphate;Plasmalogens;Bacteria,G02.111.012;G02.607.063;G03.040;G02.111.062;G03.078;B01.050;B03.300.390.400.200.100;B03.353.625.375.500.100;B03.510.415.400.200.100;D09.894.150;D10.570.755.375.760.400.985.820;B03
28617738,"Adolescent;Child;Child, Preschool;Craniosynostoses;Humans;Infant;Observer Variation;Outcome Assessment (Health Care);Reconstructive Surgical Procedures;Reproducibility of Results;Retrospective Studies;Young Adult",M01.060.057;M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E04.680;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
28617430,Attitude of Health Personnel;Counseling;Fetal Diseases;Fetoscopy;Gestational Age;Humans;Maternal Death;Meningomyelocele;Neonatologists;Obstetrics;Pediatricians;Pregnancy;Risk;Surveys and Questionnaires,F01.100.050;N05.300.100;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;C13.703.277;C16.300;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;C13.703.401;C23.550.260.730.500;I01.880.735.607.500;C10.500.680.610;C16.131.666.680.610;M01.526.485.810.758.500;N02.360.810.758.500;H02.403.810.450;M01.526.485.810.758;N02.360.810.758;G08.686.784.769;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28617415,"Administration, Oral;Adolescent;Blood Coagulation;Blood Glucose;Child;Child, Preschool;Creatine Kinase;Dose-Response Relationship, Drug;Galactose;Glycogen Storage Disease;Glycoproteins;Humans;Infant;Phosphoglucomutase;Pilot Projects;Prospective Studies;Skin;Transferrin;Young Adult",E02.319.267.100;M01.060.057;G09.188.390.150;D09.947.875.359.448.500;M01.060.406;M01.060.406.448;D08.811.913.696.640.150;G07.690.773.875;G07.690.936.500;D09.947.875.359.377;C16.320.565.202.449;C18.452.648.202.449;D09.400.430;D12.776.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D08.811.399.520.750.625;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A17.815;D12.776.124.050.800;D12.776.124.790.223.839;D12.776.157.427.750.500;D12.776.377.715.182.839;D12.776.556.579.750.500;M01.060.116.815
28617244,"Child Health Services;Child, Preschool;Chronic Disease;Continuity of Patient Care;Humans;Infant;Outcome Assessment (Health Care);Quality Improvement",N02.421.143.130;M01.060.406.448;C23.550.291.500;E02.760.169;N02.421.585.169;N04.590.233.727.210;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;J01.293.754;N04.761.744
28616025,,
28615313,"Aging;Animals;Diabetes Mellitus;Endothelium, Vascular;Energy Metabolism;Humans;Neovascularization, Pathologic;Signal Transduction",G07.345.124;B01.050;C18.452.394.750;C19.246;A07.015.700.500;A10.272.491.355;G03.295;B01.050.150.900.649.313.988.400.112.400.400;C23.550.589.500;G02.111.820;G04.835
28614578,,
28614576,,
28614566,"Dermatology;Gonorrhea;History, 19th Century;History, 20th Century;Humans;Leprosy;Nobel Prize;Prussia;Syphilis",H02.403.225;C01.252.400.625.391;C01.252.810.401;C01.539.778.281.401;C12.294.668.281.401;C13.351.500.711.281.401;K01.400.504.937;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;C01.252.410.040.552.386;K01.150.567;Z01.586.772;C01.252.400.840.744;C01.252.810.859;C01.252.847.840.744;C01.539.778.281.859;C12.294.668.281.859;C13.351.500.711.281.859
28614546,"Animals;Brain Diseases;DNA Mutational Analysis;DNA, Mitochondrial;Depressive Disorder;Energy Metabolism;Gene Expression;Humans;Hyperkinesis;Mental Disorders;Mice;Mitochondrial Diseases;Oxidative Phosphorylation;Reference Values",B01.050;C10.228.140;E05.393.760.700.300;D13.444.308.283.225;F03.600.300;G03.295;G05.297;B01.050.150.900.649.313.988.400.112.400.400;C10.597.350.350;C23.888.592.350.350;F03;B01.050.150.900.649.313.992.635.505.500;C18.452.660;G02.111.665.550;G03.295.631;G03.796.550;E05.978.810
28614293,"Adipose Tissue, Brown;Animals;Cell Respiration;Cold Temperature;Enhancer Elements, Genetic;Gene Expression Regulation;Histone Deacetylases;Hot Temperature;Humans;Mice;Mitochondria;Oxidative Phosphorylation;Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha;Receptors, Estrogen;Thermogenesis;Uncoupling Protein 1",A10.165.114.322;B01.050;G03.197;G04.270;G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.308;D08.811.277.087.520;G01.906.595.543;G16.500.275.063.725.710.380;G16.500.750.775.710.380;N06.230.300.100.725.232;N06.230.300.100.725.710.380;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.284.430.214.190.875.564;A11.284.835.626;G02.111.665.550;G03.295.631;G03.796.550;D12.644.360.024.314.650;D12.776.157.057.080.650;D12.776.157.725.813.875;D12.776.476.024.394.650;D12.776.660.675.650;D12.776.664.962.813.875;D12.776.930.617.650;D12.776.826.750.350;D12.776.930.778.350;G07.110.232.778;G07.410.421.778;G16.012.500.535.778;D12.776.157.530.937.598.500;D12.776.543.585.475.688.500;D12.776.543.585.937.696.500;D12.776.575.750.688.500
28614223,"Adolescent;Adult;Aged;Aged, 80 and over;Child;Child, Preschool;Follow-Up Studies;Glaucoma;Humans;Infant;Infant, Newborn;Intraocular Pressure;Microsurgery;Middle Aged;Multivariate Analysis;Ophthalmologic Surgical Procedures;Proportional Hazards Models;Prospective Studies;Risk Factors;Survival Analysis;Treatment Failure;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C11.525.381;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G14.440;E04.494;E05.591.580;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E04.540;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;M01.060.116.815
28614192,Antibiotic Prophylaxis;Humans;Kidney Transplantation;Liver Transplantation;Organ Transplantation;Pancreas Transplantation;Surgical Wound Infection;Tissue Donors,E02.319.162.150;E02.319.703.150;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E04.936.450;E04.210.725;E04.936.450.650;C01.539.947.692;C23.550.767.925;M01.898
28614084,"Autophagy;Blotting, Western;Calcium;Cell Culture Techniques;Cell Differentiation;Cell Proliferation;Cell Survival;Dose-Response Relationship, Drug;Homeostasis;Humans;Hypnotics and Sedatives;Neurogenesis;Neurons;Propofol",G04.146.399;G04.417.350.091;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;D01.268.552.100;D01.552.539.288;D23.119.100;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;G04.152;G04.161.750;G07.345.249.410.750;G04.346;G07.690.773.875;G07.690.936.500;G07.410;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.277.350;D27.505.954.427.210.350;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;A08.675;A11.671;D02.455.426.559.389.657.773
28613935,"Aged;Biomarkers;Body Mass Index;Cross-Sectional Studies;Humans;Linear Models;Lung Diseases, Interstitial;Matrix Metalloproteinase 7;Middle Aged;Polysomnography;Prospective Studies;Pulmonary Surfactant-Associated Protein A;Severity of Illness Index;Sleep Apnea, Obstructive;Tomography, X-Ray Computed;United States;Biomarkers;Epidemiologic Studies;Lung Diseases, Interstitial;Lung Injury;Sleep Apnea Syndromes",M01.060.116.100;D23.101;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;C08.381.483;D08.811.277.656.300.480.525.700.250;D08.811.277.656.675.374.525.700.250;D12.644.276.848.250;D12.776.467.836.250;M01.060.116.630;E01.370.520.625;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.503.280.249.600;D12.776.823.100;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C08.618.085.852.850;C10.886.425.800.750.850;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875;D23.101;E05.318.372.500;N05.715.360.330.500;N06.850.520.450.500;C08.381.483;C08.381.520;C26.891.554;C08.618.085.852;C10.886.425.800.750
28613923,"Antibodies, Monoclonal;Antineoplastic Agents;B7-H1 Antigen;Biomarkers, Tumor;CTLA-4 Antigen;Carcinoma, Non-Small-Cell Lung;Humans;Immunotherapy;Lung Neoplasms;Programmed Cell Death 1 Receptor;Randomized Controlled Trials as Topic;T-Lymphocytes;Tomography, X-Ray Computed;Tumor Microenvironment;Immunotherapy;Lung Neoplasms;Lymphocytes;Tumor Microenvironment",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D27.505.954.248;D12.776.467.150.300;D12.776.543.095.300;D23.050.301.285.400;D23.529.168.300;D23.101.140;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.588.894.797.520;C08.381.540;C08.785.520;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;G04.366.500;E02.095.465.425;C04.588.894.797.520;C08.381.540;C08.785.520;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;G04.366.500
28613921,"Aged;Aged, 80 and over;Cohort Studies;Humans;Lung;Lung Diseases, Interstitial;Middle Aged;Tomography, X-Ray Computed;Epidemiology;Hospitalization;Mortality;Pulmonary Fibrosis",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.381.483;M01.060.116.630;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;H02.403.720.500;E02.760.400;N02.421.585.400;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C08.381.765
28612973,Brain Neoplasms;Caregivers;Child;Humans;Survivors,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.085;M01.526.485.200;N02.360.200;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;M01.860
28612004,"Aneurysm;Polycystic Kidney, Autosomal Recessive;Hypertension, Portal",C14.907.055;C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;C06.552.494
28611971,"Polycystic Kidney, Autosomal Recessive;Cholangitis;Esophageal and Gastric Varices;Hypertension, Portal",C12.777.419.403.875.510;C13.351.968.419.403.875.510;C16.131.077.717.510;C16.320.184.625.510;C06.130.120.200;C06.405.117.240;C06.552.494.414;C06.552.494
28611894,"Authorship;Education, Medical;Emergency Medicine;Faculty, Medical;Humans;Peer Review;Publishing;Staff Development",L01.559.423.906.215;I02.358.399;H02.403.250;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;F01.829.316.549;I01.880.604.640;N03.706.700;L01.737;I02.574.700;N04.452.677.822
28611428,"Adaptation, Biological;Animals;Cells, Cultured;Genome, Viral;High-Throughput Nucleotide Sequencing;Marburg Virus Disease;Marburgvirus;Mice;RNA, Viral;Serial Passage;Viral Load;Viral Proteins",G16.012;B01.050;A11.251;G05.360.340.358.840;E05.393.760.319;C02.782.417.560;C02.782.580.250.500;C22.735.500.500;B04.820.455.300.650;B01.050.150.900.649.313.992.635.505.500;D13.444.735.828;E01.370.225.875.837;E05.200.875.837;E01.370.225.875.950;E05.200.875.950;G06.920.850;D12.776.964
28611413,"Cells, Cultured;Endothelium, Vascular;Erythrocyte Transfusion;Hemodynamics;Humans;Lung Injury;Microfluidics;Pulmonary Circulation;Stress, Mechanical",A11.251;A07.015.700.500;A10.272.491.355;E02.095.135.140.275;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;C08.381.520;C26.891.554;E05.830.666;H01.671.808.500;J01.897.520.500.500;G09.330.100.770;G09.772.593;G01.374.835
28611197,"Animals;Antineoplastic Agents;Autophagy;Biomarkers, Tumor;Cell Line, Tumor;Chloroquine;DNA Copy Number Variations;Disease Models, Animal;Energy Metabolism;Genetic Variation;Glutamine;Humans;Hypoglycemic Agents;Metabolic Networks and Pathways;Metabolomics;Metformin;Mice;Mutation;Pancreatic Neoplasms;Phenformin;Xenograft Model Antitumor Assays",B01.050;D27.505.954.248;G04.146.399;G04.417.350.091;D23.101.140;A11.251.210.190;A11.251.860.180;D03.633.100.810.050.180;G05.365.795.297.500;C22.232;E05.598.500;E05.599.395.080;G03.295;G05.365;D12.125.068.330;D12.125.095.461;D12.125.154.424;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;G03.493;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;D02.078.370.141.450;B01.050.150.900.649.313.992.635.505.500;G05.365.590;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;D02.078.370.141.700;E05.337.550.200.900;E05.624.850
28611190,"Animals;Cell Line, Tumor;Cell Proliferation;Cytokines;Enzyme Stability;Hematopoietic Stem Cells;Humans;Intracellular Signaling Peptides and Proteins;Janus Kinase 2;Leukemia, Myeloid, Acute;Mice;Mutation;Proteolysis;Proto-Oncogene Proteins c-cbl;Signal Transduction;Ubiquitination;Ubiquitin",B01.050;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;D12.644.276.374;D12.776.467.374;D23.529.374;E05.916.360;G02.111.700.500;A11.148.378;A11.872.378;A15.378.316.378;B01.050.150.900.649.313.988.400.112.400.400;D12.644.360;D12.776.476;D08.811.913.696.620.682.725.124.200;D12.776.476.393.200;D12.776.624.664.700.117;C04.557.337.539.275;B01.050.150.900.649.313.992.635.505.500;G05.365.590;G02.111.720;G03.812;D08.811.464.938.750.374;D12.776.624.664.700.172;G02.111.820;G04.835;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831;D12.776.947.500
28611159,"Africa South of the Sahara;Cryptococcosis;Cryptococcus neoformans;Evolution, Molecular;Fungal Proteins;Genetics, Population;Genome-Wide Association Study;Humans;Transcription Factors;Virulence Factors",Z01.058.290;C01.703.248;B01.300.381.258.366;B01.300.930.316.366;G05.045.250;G16.075.250;D12.776.354;H01.158.273.343.335;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.930;D23.946.896
28611146,"Child;Health Care Surveys;Hospitals, Pediatric;Humans;Needs Assessment;Nursing Staff, Hospital;Patient Care Management;Personnel Management;Quality Improvement;Quality of Health Care;United States",M01.060.406;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;I02.594;N03.349.380.565;N05.300.537;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;N04.590;N04.452.677;J01.293.754;N04.761.744;N04.761;N05.715;Z01.107.567.875
28611118,,
28611107,"Animals;Antineoplastic Agents;Carcinoma, Pancreatic Ductal;Cell Death;Cell Line, Tumor;Cell Proliferation;Disease Models, Animal;Humans;Mice;Mice, Transgenic;Models, Biological;Monocytes;Pancreatic Neoplasms;Phosphorylation;Receptors, Interleukin-6;STAT Transcription Factors;Signal Transduction;Tumor Microenvironment",B01.050;D27.505.954.248;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;G04.146;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;E05.599.395;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;G02.111.665;G02.607.780;G03.796;D12.776.543.750.705.852.420.400;D12.644.360.024.342;D12.776.157.057.186;D12.776.476.024.430;D12.776.930.840;G02.111.820;G04.835;G04.366.500
28611062,"Amino Acid Substitution;Animals;Cells, Cultured;Coloring Agents;Embryo, Mammalian;Endocytosis;Endosomes;Fluorescent Dyes;Green Fluorescent Proteins;Hippocampus;Humans;Hydrogen-Ion Concentration;Lysosomes;Mice;Microscopy, Electron, Transmission;Mutation;Neurons;Porphobilinogen;Protein Aggregation, Pathological;Recombinant Fusion Proteins;Rhodamines;Trypan Blue;alpha-Synuclein;alpha-Synuclein;Amyloid;Microscopy, Confocal;Lysosomes;Neurodegenerative Diseases",E05.393.420.601.035;G05.558.109;B01.050;A11.251;D27.720.233;A16.254;G04.417;A11.284.430.214.190.875.190.880.337;D27.720.233.348;D27.720.470.410.505.500;D12.776.532.265;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;G02.300;A11.284.430.214.190.875.190.550;B01.050.150.900.649.313.992.635.505.500;E01.370.350.515.402.580;E05.595.402.580;G05.365.590;A08.675;A11.671;D03.383.129.578.617;C23.550.770;G02.111.675;D12.776.828.300;D03.633.300.953.600;D02.172.975;D02.455.426.559.847.638.555.875;D02.886.645.600.080.050.650.875;D04.615.638.555.875;D12.776.631.860.500;D12.776.637.500;D12.776.631.860.500;D12.776.637.500;D05.500.049;D12.776.049;E01.370.350.515.395;E05.595.395;A11.284.430.214.190.875.190.550;C10.574
28610964,Body Weight;Humans,C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;B01.050.150.900.649.313.988.400.112.400.400
28610741,,
28609519,Certification;Clinical Competence;Humans;Physicians;Specialty Boards;United States,N03.706.110.120;N05.700.200.190;I02.399.630.210;N04.761.210;N05.715.175;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;N03.706.110.120.580;N05.700.200.190.750;Z01.107.567.875
28609483,"Animals;Brain;Cocaine-Related Disorders;Computer Simulation;Exons;Histones;Mice;Models, Genetic;Nerve Tissue Proteins;Protein Processing, Post-Translational;RNA Splice Sites",B01.050;A08.186.211;C25.775.300;F03.900.300;L01.224.160;G05.360.340.024.340.137.232;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.992.635.505.500;E05.599.395.397;D12.776.631;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;D13.444.735.544.550;G02.111.570.080.689.687.490;G05.360.080.689.687.490;G05.360.340.024.340.137.800
28609357,"Consensus;Digestive System Surgical Procedures;Evidence-Based Medicine;Humans;Intestinal Neoplasms;Intestine, Small;Medical Oncology;Neuroendocrine Tumors;Predictive Value of Tests;Risk Factors;Societies, Medical;Treatment Outcome",F01.829.316.068;F02.463.785.373.433;E04.210;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.476.411;C06.301.371.411;C06.405.249.411;C06.405.469.491;A03.556.124.684;H02.403.429.515;C04.557.465.625.650;C04.557.580.625.650;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N03.540.828.589;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28609217,Islam;Islam;Breast Feeding,K01.844.275;K01.844.275;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199
28609176,"Adult;Breast Feeding;Breast Milk Expression;Hernias, Diaphragmatic, Congenital;Humans;Infant;Infant, Newborn;Intensive Care Units, Neonatal;Longitudinal Studies;Milk, Human;Mothers;Prospective Studies;Qualitative Research;Breast Feeding;Hernias, Diaphragmatic, Congenital;Milk, Human;Lactation",M01.060.116;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;F01.145.407.199.500;G07.203.650.220.500.500.500;G07.203.650.353.199.500;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390.380;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H01.770.644.241.850;F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;C16.131.433;C23.300.707.500.116;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;G08.686.523;G08.686.702.500
28608950,"B7-H1 Antigen;Bone Neoplasms;Burkitt Lymphoma;Child;Glioblastoma;Humans;Immunohistochemistry;Lymphocytes, Tumor-Infiltrating;Macrophages;Neoplasm Proteins;Neoplasms;Neuroblastoma;Osteosarcoma;Rhabdomyosarcoma;Sarcoma, Ewing;Tissue Array Analysis;Immunotherapy;Neuroblastoma;Lymphocytes, Tumor-Infiltrating",D12.776.467.150.300;D12.776.543.095.300;D23.050.301.285.400;D23.529.168.300;C04.588.149;C05.116.231;C02.256.466.313.165;C02.928.313.165;C04.557.386.480.150.165;C15.604.515.569.480.150.165;C20.683.515.761.480.150.165;M01.060.406;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;D12.776.624;C04;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C04.557.450.565.575.650;C04.557.450.795.620;C04.557.450.590.550.660;C04.557.450.795.550.660;C04.557.450.565.575.650.800;C04.557.450.795.620.800;E05.588.570.850;E02.095.465.425;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650
28608728,Case-Control Studies;Multiple Sclerosis;Neurology,E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;H02.403.600
28607920,,
28607905,Peru;Telemedicine;Global Health;Qualitative Research,Z01.107.757.702;H02.403.840;L01.178.847.652;N04.590.374.800;H02.403.371;N01.400.337;H01.770.644.241.850
28607872,,
28607484,"Animals;Cell Line, Tumor;Cellular Reprogramming;DNA-Binding Proteins;Drug Resistance, Neoplasm;Epigenesis, Genetic;ErbB Receptors;Gene Expression Regulation, Neoplastic;Genetic Markers;Humans;In Situ Hybridization, Fluorescence;Indoles;Melanoma;Nuclear Proteins;Oncogene Protein p65(gag-jun);SOXE Transcription Factors;Signal Transduction;Single-Cell Analysis;Sulfonamides;Transcription Factor AP-1;Transcription Factors;Transcription, Genetic;Vemurafenib;Xenograft Model Antitumor Assays",B01.050;A11.251.210.190;A11.251.860.180;G04.152.262;G05.135;D12.776.260;G07.690.773.984.395;G05.308.203;D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;G05.308.370;D23.101.387;G05.695.450;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;D03.633.100.473;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;D12.776.660;D12.776.602.500.500.320.700;D12.776.624.664.500.320.700;D12.776.624.664.520.750.320.700;D12.776.964.700.750.320.700;D12.776.964.775.350.320.700;D12.776.964.775.750.320.700;D12.776.260.719.500;D12.776.660.235.400.750.500;D12.776.664.235.400.750.500;D12.776.930.823.500;G02.111.820;G04.835;E05.242.900;D02.065.884;D02.886.590.700;D12.776.260.108.875;D12.776.930.127.875;D12.776.930;G02.111.873;G05.297.700;D02.065.884.919;D02.886.590.700.919;D03.633.100.473.936;E05.337.550.200.900;E05.624.850
28606988,"Antiviral Agents;Base Sequence;Cells, Cultured;Child, Preschool;DNA Mutational Analysis;Fibroblasts;Gene Expression;Genes, Recessive;Heterozygote;Homozygote;Host-Pathogen Interactions;Humans;Interferon-Induced Helicase, IFIH1;Interferons;Mutation;Pedigree;Picornaviridae Infections;Rhinovirus",D27.505.954.122.388;G02.111.570.080;G05.360.080;L01.453.245.667.080;A11.251;M01.060.406.448;E05.393.760.700.300;A11.329.228;G05.297;G05.360.340.024.340.415;G05.420.325;G05.380.383;G05.380.554;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.445.735.720.249.875;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;G05.365.590;E05.393.673;C02.782.687;B04.820.565.775
28606585,Neoplasms;Common Variable Immunodeficiency;Leukemia;Lymphoma,C04;C20.673.330;C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761
28606101,"Activin Receptors, Type I;Data Collection;Delphi Technique;Global Health;Humans;Myositis Ossificans;Physicians;Myositis Ossificans",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;L01.906.197;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;C05.651.594.638;M01.526.485.810;N02.360.810;C05.651.594.638
28606098,"Adolescent;Anemia, Sickle Cell;Child;Child, Preschool;Health Status;Humans;Outcome Assessment (Health Care);Pain;Prospective Studies;Quality of Life;Young Adult;Quality of Life;Anemia, Sickle Cell",M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;M01.060.406;M01.060.406.448;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C23.888.592.612;F02.830.816.444;G11.561.790.444;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;M01.060.116.815;I01.800;K01.752.400.750;N06.850.505.400.425.837;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
28605823,,
28605777,"Adolescent;Adult;African Continental Ancestry Group;Blood Glucose;Blood Glucose Self-Monitoring;Child;Diabetes Mellitus, Type 1;European Continental Ancestry Group;Fructosamine;Glycated Hemoglobin A;Humans;Middle Aged;Prospective Studies;Serum Albumin;United States;Young Adult",M01.060.057;M01.060.116;M01.686.508.100;D09.947.875.359.448.500;E01.370.225.124.100.105;E01.370.374.100;E01.370.520.100;E02.900.100;E05.200.124.100.105;M01.060.406;C18.452.394.750.124;C19.246.267;C20.111.327;M01.686.508.400;D09.067.342.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.034.841;D12.776.124.727;Z01.107.567.875;M01.060.116.815
28605399,Computer Simulation;Data Accuracy;Epidemiologic Methods;Hospital Mortality;Humans;Intensive Care Units;Length of Stay;Outcome and Process Assessment (Health Care);Time Factors;Bias;Epidemiology;Length of Stay,L01.224.160;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;E05.318;N06.850.520;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;N04.761.559;N05.715.360.575;G01.910.857;N05.715.350.150;N06.850.490.500;H02.403.720.500;E02.760.400.480;N02.421.585.400.480
28605376,"Animals;Axons;Brain;Cell Aggregation;Hydrogel, Polyethylene Glycol Dimethacrylate;Nerve Net;Nerve Regeneration;Rats;Tissue Engineering",B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.186.211;G04.198.251;D02.033.455.250.700.485;D05.750.741.485;D25.720.741.485;D26.255.165.320.375.375;J01.637.051.720.741.485;A08.511;G11.561.585;G16.762.611;B01.050.150.900.649.313.992.635.505.700;E05.481.500.311.500;J01.293.069.249.500
28604931,"Accidents, Traffic;Adolescent;Age Factors;Attention Deficit Disorder with Hyperactivity;Automobile Driving;Cohort Studies;Comorbidity;Humans;Retrospective Studies;Risk Factors;Safety;Substance-Related Disorders;United States;Young Adult",N06.850.135.392;M01.060.057;N05.715.350.075;N06.850.490.250;F03.625.094.150;I03.125;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N06.850.135.060.075;C25.775;F03.900;Z01.107.567.875;M01.060.116.815
28604732,"Adult;Chromosome Mapping;Chromosomes, Human, X;Computational Biology;Computer Simulation;Family Health;Genetic Markers;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Haplotypes;Humans;Neoplasms, Germ Cell and Embryonal;Polymorphism, Single Nucleotide;Risk;Testicular Neoplasms;Young Adult",M01.060.116;E05.393.183;A11.284.187.520.300.325.680;A11.284.187.865.982.500;G05.360.162.520.300.325.680;G05.360.162.865.982.500;H01.158.273.180;L01.313.124;L01.224.160;N01.400.300;D23.101.387;G05.695.450;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;G05.380.360;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465;G05.365.795.598;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C04.588.322.762;C04.588.945.440.915;C12.294.260.937;C12.758.409.937;C19.344.762;C19.391.829.782;M01.060.116.815
28604724,"Adenosine;Cell Line;Humans;In Situ Hybridization, Fluorescence;Inosine;Molecular Imaging;Neurons;Optical Imaging;RNA Editing",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;A11.251.210;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;D03.633.100.759.590.616;D13.570.583.616;D13.570.800.573;E01.370.350.557;E05.601.555;A08.675;A11.671;E01.370.350.589;E05.642;G02.111.760.250;G03.839.250;G05.308.700.250
28604606,Diagnosis;Metabolism;Multiple Sclerosis,E01;G03;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
28604512,,
28603714,Rare Diseases,C23.550.291.906
28603310,Bangladesh;Bolivia;Ethiopia;General Surgery;Guatemala;Health Care Surveys;Health Resources;Health Services Accessibility;Humans;Laos;Liberia;Rwanda;Time Factors,Z01.252.245.131;Z01.107.757.136;Z01.058.290.120.310;H02.403.810.300;Z01.107.169.454;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;N03.349.340;N05.300.420;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;Z01.252.145.435;Z01.058.290.190.425;Z01.058.290.120.680;G01.910.857
28603067,Biopsy;Fontan Procedure;Humans;Liver Cirrhosis,E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;B01.050.150.900.649.313.988.400.112.400.400;C06.552.630
28603051,,
28602725,"Animals;Calcification, Physiologic;Gene Expression Regulation;Interleukin-15 Receptor alpha Subunit;Mice;Mice, Knockout;Osteoblasts;Osteogenesis;Calcification, Physiologic;Cortical Bone;Interleukin-15;Interleukin-15 Receptor alpha Subunit;Osteoblasts;Osteoblasts",B01.050;G07.345.155.500;G07.345.500.325.377.625.050.500.175;G11.427.578.050.500.175;G05.308;D12.776.543.750.705.852.420.800.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.329.629;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;G07.345.155.500;G07.345.500.325.377.625.050.500.175;G11.427.578.050.500.175;A10.165.265.521;D12.644.276.374.465.515;D12.776.467.374.465.515;D23.529.374.465.515;D12.776.543.750.705.852.420.800.550;A11.329.629;A11.329.629
28601685,"Hematopoietic Stem Cell Transplantation;Candidiasis, Chronic Mucocutaneous;Graft Rejection;Graft vs Host Disease;Lymphohistiocytosis, Hemophagocytic",E02.095.147.500.500.500;E04.936.225.687.500;C01.539.800.200.100;C01.703.160.165;C01.703.295.165;C17.800.838.208.165;G12.875.545.328;C20.452;C15.604.250.410.575
28601390,"Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;Biopsy;Cross-Sectional Studies;Foot;Genitalia;Hand;Head and Neck Neoplasms;Humans;Leg;Margins of Excision;Melanoma;Middle Aged;Neoplasm Staging;Neoplasm, Residual;Retrospective Studies;Risk Factors;Skin;Skin Neoplasms;Young Adult;Mohs Surgery;Melanoma;Prognosis;Sentinel Lymph Node Biopsy",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;A01.378.610.250;A05.360;A01.378.800.667;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.500;A10.830;C23.149.625;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;E01.789.625;C04.697.700;C23.550.727.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A17.815;C04.588.805;C17.800.882;M01.060.116.815;E04.494.575;E04.680.275.580;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;E01.789;E01.370.225.500.384.100.580;E01.370.225.998.054.580;E01.370.388.100.580;E04.074.580;E04.446.819;E05.200.500.384.100.580;E05.200.998.054.580;E05.242.384.100.580
28601295,"Adult;Animals;Animals, Newborn;Apoptosis;B-Lymphocytes;Cell Death;Cells, Cultured;Coculture Techniques;Humans;Middle Aged;Multiple Sclerosis;Neuroglia;Neurons;Oligodendroglia;Rats;Young Adult;B-Lymphocytes;Cell Death;Cytokines;Multiple Sclerosis;Neurons;Oligodendroglia",M01.060.116;B01.050;B01.050.050.282;G04.146.160;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.146;A11.251;E05.481.500.374;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A08.637;A11.650;A08.675;A11.671;A08.637.600;A11.650.600;B01.050.150.900.649.313.992.635.505.700;M01.060.116.815;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.146;D12.644.276.374;D12.776.467.374;D23.529.374;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;A08.675;A11.671;A08.637.600;A11.650.600
28601288,"Adult;Aged;Autoantibodies;Biomarkers;Humans;Middle Aged;Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis, Relapsing-Remitting;Random Allocation;Autoantibodies;Biomarkers;Multiple Sclerosis",M01.060.116;M01.060.116.100;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;D23.101;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.114.375.500.200;C10.314.350.500.200;C20.111.258.250.500.200;C10.114.375.500.600;C10.314.350.500.600;C20.111.258.250.500.600;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;D23.101;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
28601270,"Acute Pain;Adult;Analgesics;Analgesics, Opioid;Emergency Service, Hospital;Humans;Pain Management;Pain Measurement;Self Administration",C23.888.592.612.081;M01.060.116;D27.505.696.663.850.014;D27.505.954.427.040;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E02.745;N04.590.607.500;E01.370.600.550.324;E02.319.890;E02.900.890
28601180,"Child;Child, Preschool;Diagnosis, Differential;Diagnostic Imaging;Humans;Infant;Infant, Newborn;Musculoskeletal System",M01.060.406;M01.060.406.448;E01.171;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A02
28601174,"Child;Diagnosis, Differential;Diagnostic Imaging;Humans;Thoracic Neoplasms;Mediastinal Neoplasms",M01.060.406;E01.171;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894;C04.588.894.479;C08.846.187.580
28600386,"Adolescent;Adult;Age Factors;Aged;Aged, 80 and over;Aortic Aneurysm;Aortic Diseases;Aortic Valve;Cardiovascular Diseases;Child;Child, Preschool;Cohort Studies;Heart Defects, Congenital;Heart Valve Diseases;Humans;Infant;Marfan Syndrome;Middle Aged;National Heart, Lung, and Blood Institute (U.S.);Phenotype;Registries;Sex Factors;United States;Young Adult;Marfan Syndrome;Adult;Aneurysm;Dilatation;Prevalence",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;C14.907.055.239;C14.907.109.139;C14.907.109;A07.541.510.110;C14;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C14.240.400;C14.280.400;C16.131.240.400;C14.280.484;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;M01.060.116.630;I01.409.418.750.600.650.496.300;N03.540.052.750.300;N03.540.348.500.500.600.650.496.300;G05.695;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;N05.715.350.675;N06.850.490.875;Z01.107.567.875;M01.060.116.815;C05.116.099.674;C14.240.400.725;C14.280.400.725;C16.131.077.550;C16.131.240.400.720;C16.320.540;C17.300.500;M01.060.116;C14.907.055;E05.284;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750
28600340,Bioethics;Ethics;Genetic Testing;Hematologic Neoplasms;Humans,K01.752.566.479.045;N05.350.200;K01.752.566.479;N05.350;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;C04.588.448;C15.378.400;B01.050.150.900.649.313.988.400.112.400.400
28600158,Adult;Benzazepines;Body Mass Index;Caloric Restriction;Combined Modality Therapy;Diet Therapy;Healthy Lifestyle;Humans;Middle Aged;Obesity;Outcome Assessment (Health Care);Research Design;Weight Loss;Research Design,M01.060.116;D03.633.100.079;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E02.642.249.200;G07.203.650.240.340.150;E02.186;E02.642.249;F01.829.458.205;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.581.500;H01.770.644.728;C23.888.144.243.963;G07.345.249.314.120.200.963;E05.581.500;H01.770.644.728
28600150,"Activin Receptors, Type I;Adolescent;Adult;Child;Child, Preschool;Disease Progression;Humans;Infant;Longitudinal Studies;Middle Aged;Myositis Ossificans;Ossification, Heterotopic;Young Adult;Myositis Ossificans;Ossification, Heterotopic",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C05.651.594.638;C23.550.751;M01.060.116.815;C05.651.594.638;C23.550.751
28599896,"Actigraphy;Adult;Body Mass Index;Cohort Studies;Continental Population Groups;Diabetes, Gestational;Humans;Hypertension, Pregnancy-Induced;Personnel Staffing and Scheduling;Pregnancy;Sleep Initiation and Maintenance Disorders;United States;Young Adult;Actigraphy;Diabetes, Gestational;Hypertension;Pregnancy Outcome",E01.370.520.049;E05.003.500;M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.508;C13.703.170;C18.452.394.750.448;C19.246.200;B01.050.150.900.649.313.988.400.112.400.400;C13.703.395;C14.907.489.480;I03.946.225;N04.452.677.650;G08.686.784.769;C10.886.425.800.800;F03.870.400.800.800;Z01.107.567.875;M01.060.116.815;E01.370.520.049;E05.003.500;C13.703.170;C18.452.394.750.448;C19.246.200;C14.907.489;E01.789.700;G08.686.784.769.496
28599881,,
28599880,,
28599544,,
28599389,"Administration, Intranasal;Administration, Oral;Antidiuretic Agents;Deamino Arginine Vasopressin;Diabetes Insipidus;Humans;Infant;Infant, Newborn;Retrospective Studies;Treatment Outcome;Infant, Newborn",E02.319.267.120.655.500;E02.319.267.100;D27.505.696.560.249;D06.472.699.631.692.781.100.250;D12.644.400.900.100.250;D12.644.456.925.100.250;D12.644.548.691.692.781.100.250;D12.776.631.650.937.100.250;C12.777.419.135;C13.351.968.419.135;C19.700.159;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.703.520
28598945,"Adolescent;Child;Child, Preschool;Extracorporeal Membrane Oxygenation;Follow-Up Studies;Health Status Indicators;Heart Diseases;Humans;Infant;Infant, Newborn;Patient Reported Outcome Measures;Quality of Life;Retrospective Studies;Treatment Outcome",M01.060.057;M01.060.406;M01.060.406.448;E02.880.301;E04.292.451;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E05.318.308.980.438.475;N05.715.360.300.800.438.375;N06.850.520.308.980.438.475;C14.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28598878,Cardiopulmonary Resuscitation;Extracorporeal Membrane Oxygenation;Heart Arrest;Humans;Incidence;Logistic Models;Patient Selection;Tissue and Organ Procurement,E02.365.647.110;E02.880.301;E04.292.451;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.581.500.653;N04.590.731;N02.421.911
28598437,"Animals;Arginine;Centromere;Centromere Protein A;Chromosomal Proteins, Non-Histone;DNA;Humans;Mice;Nucleosomes;Protein Binding;Protein Domains",B01.050;D12.125.068.050;D12.125.095.104;D12.125.142.087;A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;D12.776.660.235;D12.776.664.235;D13.444.308;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500
28597942,"Brain Neoplasms;Child;DNA Copy Number Variations;Glioma;Humans;Leukemia, Lymphoid;Oncogene Fusion;Polymorphism, Single Nucleotide",C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;G05.365.795.297.500;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428;C15.604.515.560;C20.683.515.528;G05.728.385.500;G05.365.795.598
28597462,"Anticoagulants;Cardiac Surgical Procedures;Cardiopulmonary Bypass;Fibrinolytic Agents;Heparin;Heparin, Low-Molecular-Weight;Humans;Platelet Count;Thrombocytopenia",D27.505.954.502.119;E04.100.376;E04.928.220;E04.292.413;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;D09.698.373.400;D09.698.373.400.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;C15.378.140.855
28596604,Apoptosis;Cell Adhesion;Cell Cycle;Cell Line;Cell Membrane Permeability;Cervix Uteri;Epithelial Cells;Humans;MicroRNAs;Mucous Membrane;RNA Interference,G04.146.160;G04.022;G04.144;A11.251.210;G03.143.335;G04.175;A05.360.319.679.256;A11.436;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A10.615.550;G05.308.203.374.790
28596426,Asia;Australia;Bronchiectasis;Clinical Trials as Topic;Consensus;Cough;Delphi Technique;Disease Progression;Dyspnea;Europe;Humans;Lung;North America;Pulmonary Medicine;South Africa;Sputum,Z01.252;Z01.639.100;Z01.678.100.373;C08.127.384;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;F01.829.316.068;F02.463.785.373.433;C08.618.248;C23.888.852.293;L01.906.197;C23.550.291.656;C08.618.326;C23.888.852.371;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;A04.411;Z01.107.567;H02.403.429.675;Z01.058.290.175.735;A12.200.808
28595960,,
28595957,,
28595955,,
28595763,"Checklist;Child;Education, Medical;Educational Measurement;Humans",N05.715.360.300.179;M01.060.406;I02.358.399;I02.399;B01.050.150.900.649.313.988.400.112.400.400
28595647,"Body Mass Index;Breast Neoplasms;Canada;Child;Child, Preschool;Cohort Studies;Humans;Incidence;Kaplan-Meier Estimate;Menarche;Odds Ratio;Population Surveillance;Puberty;Risk;United States;Breast Neoplasms;Menarche",E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C04.588.180;C17.800.090.500;Z01.107.567.176;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;G08.686.760.410;G08.686.841.374.410;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;G08.686.760;G08.686.841.374;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;Z01.107.567.875;C04.588.180;C17.800.090.500;G08.686.760.410;G08.686.841.374.410
28595292,"Abruptio Placentae;Adult;Apnea;Asphyxia Neonatorum;Comorbidity;Health Behavior;Humans;Infant;Infant Mortality;Infant, Newborn;Infant, Newborn, Diseases;Intensive Care Units, Neonatal;Length of Stay;Pregnancy;Pregnancy Outcome;Resuscitation;Retrospective Studies;Socioeconomic Factors;United States;Apnea;Perinatal Mortality",C13.703.420.078;C13.703.590.132;M01.060.116;C08.618.085;C23.888.852.130;C16.614.092;N05.715.350.225;N06.850.490.687;F01.145.488;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;C16.614;N02.278.388.493.390.380;E02.760.400.480;N02.421.585.400.480;G08.686.784.769;E01.789.700;G08.686.784.769.496;E02.365.647;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.880.853.996;N01.824;Z01.107.567.875;C08.618.085;C23.888.852.130;E05.318.308.985.550.475.500;N01.224.935.698.489.500;N06.850.505.400.975.550.475.500;N06.850.520.308.985.550.475.500
28594681,"Benzodiazepines;Child, Preschool;Critical Illness;Delirium;Humans;Infant;Intensive Care Units, Pediatric;Length of Stay;Prospective Studies;Risk Factors;Severity of Illness Index;Time Factors",D03.633.100.079.080;M01.060.406.448;C23.550.291.625;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E02.760.400.480;N02.421.585.400.480;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857
28594529,,
28594525,,
28594152,"Humans;Information Dissemination;Models, Theoretical",B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;E05.599
28593682,Checklist;Child;Critical Care;Developing Countries;Emergency Medical Services;Humans;Medical Informatics;Mobile Applications;Pediatrics;Resuscitation;Smartphone;Anesthesia;Checklist;Critical Care;Education;Medical Informatics;Pediatrics;Quality Improvement;Resuscitation;Safety;Smartphone;Software,N05.715.360.300.179;M01.060.406;E02.760.190;N02.421.585.190;I01.615.500.300;N02.421.297;B01.050.150.900.649.313.988.400.112.400.400;L01.313.500;L01.224.900.685;H02.403.670;E02.365.647;L01.224.230.260.550.500.500;E03.155;N05.715.360.300.179;E02.760.190;N02.421.585.190;I02;L01.313.500;H02.403.670;J01.293.754;N04.761.744;E02.365.647;N06.850.135.060.075;L01.224.230.260.550.500.500;L01.224.900
28592905,"Animals;Humans;Models, Neurological;Neurons;Neuropeptides;Neurotransmitter Agents;Synaptic Transmission",B01.050;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.642;A08.675;A11.671;D12.644.400;D12.776.631.650;D27.505.519.625;D27.505.696.577;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830
28592796,"Animals;Antibodies, Monoclonal;Apolipoprotein A-I;Humans;Lipoproteins, HDL;Mice, Inbred BALB C;Protein Binding;Protein Conformation",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;B01.050.150.900.649.313.988.400.112.400.400;D10.532.432;D12.776.521.479;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;G02.111.679;G03.808;G02.111.570.820.709
28592659,"Actinin;Actins;Biomechanical Phenomena;Cytoskeletal Proteins;DNA, Mitochondrial;Gene Expression Regulation;Humans;Point Mutation;Actins;Microscopy, Atomic Force;Cytoskeleton;Mitochondria",D05.750.078.730.248;D12.776.210.500.095;D12.776.220.525.250;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;G01.154.090;G01.374.089;D12.776.220;D13.444.308.283.225;G05.308;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.675;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;E01.370.350.515.666.400;E05.595.666.400;A11.284.430.214.190.750;A11.284.430.214.190.875.564;A11.284.835.626
28592562,"Autistic Disorder;Behavior;Child, Preschool;Functional Neuroimaging;Humans;Infant;Magnetic Resonance Imaging;Nerve Net;Risk Factors",F03.625.164.113.500;F01.145;M01.060.406.448;E01.370.350.578.875;E01.370.376.537.625;E05.629.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;A08.511;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28591479,"Child;Child, Preschool;Comorbidity;Drug Resistant Epilepsy;Endocrine System Diseases;Epilepsies, Partial;Gonadotropin-Releasing Hormone;Hamartoma;Hormones, Ectopic;Humans;Hypothalamic Diseases;Hypothalamus;Infant;Nerve Net;Puberty, Precocious;Transforming Growth Factor alpha;gamma-Aminobutyric Acid;Gonadotropin-Releasing Hormone;Hypothalamus;Puberty, Precocious",M01.060.406;M01.060.406.448;N05.715.350.225;N06.850.490.687;C10.228.140.490.125;C19;C10.228.140.490.360;D06.472.699.327.740.320;D12.644.400.400.740.320;D12.644.456.460;D12.644.548.365.740.320;D12.776.631.650.405.740.320;C04.445;D06.472.397;D23.101.140.375;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.617;A08.186.211.180.497;A08.186.211.200.317.357;M01.060.703;A08.511;C19.391.693;D12.644.276.382.750;D12.644.276.963.360;D12.776.467.382.750;D12.776.467.960.360;D23.529.382.750;D23.529.960.360;D02.241.081.114.500.350;D12.125.190.350;D06.472.699.327.740.320;D12.644.400.400.740.320;D12.644.456.460;D12.644.548.365.740.320;D12.776.631.650.405.740.320;A08.186.211.180.497;A08.186.211.200.317.357;C19.391.693
28590263,Adult;Aged;Follow-Up Studies;Humans;Middle Aged;Physicians;Professional-Family Relations;Psychiatry;Suicide;Surveys and Questionnaires,M01.060.116;M01.060.116.100;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;M01.526.485.810;N02.360.810;F01.829.401.550;F04.096.544;H02.403.690;F01.145.126.980.875;I01.880.735.856;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28589954,"Amino Acid Sequence;Animals;Animals, Newborn;Axin Protein;Base Sequence;Cell Differentiation;Cell Lineage;Cell Proliferation;Cell Self Renewal;Ectodermal Dysplasia;Embryonic Development;Epidermis;Epithelium;Hair Follicle;Humans;Kruppel-Like Transcription Factors;Loss of Function Mutation;Mice;Molar;Mutation;Nerve Tissue Proteins;Organ Specificity;Pedigree;Protein Binding;Stem Cells;Wnt Proteins;Wnt Signaling Pathway;beta Catenin",G02.111.570.060;L01.453.245.667.060;B01.050;B01.050.050.282;D05.500.117.500;D12.776.476.081.500;G02.111.570.080;G05.360.080;L01.453.245.667.080;G04.152;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.161.750;G07.345.249.410.750;G04.144.220.235;G04.161.750.500.375;G05.113.415;G07.345.249.410.750.500.625;C16.131.077.350;C16.131.831.350;C16.320.850.250;C17.800.804.350;C17.800.827.250;G07.345.500.325.180;G08.686.784.170.104;A10.272.497;A17.815.250;A10.272;A10.272.497.500;A17.360.710;A17.815.250.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.522;D12.776.930.375;G05.365.590.538;B01.050.150.900.649.313.992.635.505.500;A14.549.167.860.525;G05.365.590;D12.776.631;G07.650;E05.393.673;G02.111.679;G03.808;A11.872;D12.776.467.984;D23.529.984;G02.111.820.925;G04.835.925;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
28589934,"Animals;Mice, Knockout;Receptor, Interferon alpha-beta;Spermatozoa;Testis;Vaccines, DNA;Viral Envelope Proteins;Viral Vaccines;Zika Virus;Zika Virus Infection",B01.050;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.543.750.705.852.400.500;A05.360.490.890;A11.497.760;A05.360.444.849;A05.360.576.782;A06.300.312.782;D12.776.828.868.910;D20.215.894.865.910;D23.050.865.910;D12.776.964.970.880;D20.215.894.899;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
28589856,"Alzheimer Disease;Amyloid beta-Peptides;Apolipoproteins E;Chromosomes, Human, Pair 19;Humans;Neuroimaging;Peptide Fragments;Polymorphism, Single Nucleotide;Whole Genome Sequencing;Neuroimaging;Whole Genome Sequencing",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;A11.284.187.520.300.460.465;G05.360.162.520.300.460.465;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;D12.644.541;G05.365.795.598;E05.393.760.700.825;E01.370.350.578;E01.370.376.537;E05.629;E05.393.760.700.825
28589494,Adult;Autistic Disorder;Child;Communication;Community Mental Health Centers;Humans;Neuropsychological Tests;Sensitivity and Specificity;Adult;Autism Spectrum Disorder;Psychotic Disorders,M01.060.116;F03.625.164.113.500;M01.060.406;F01.145.209;L01.143;N02.278.035.158;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116;F03.625.164.113;F03.700.675
28588803,"Anemia;Indians, North American;Thrombocytopenia",C15.378.071;M01.686.508.150.600;C15.378.140.855
28588409,Alzheimer Disease;Neurons;tau Proteins,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.675;A11.671;D12.776.220.600.450.510;D12.776.631.560.510
28588118,"Airway Resistance;Continuous Positive Airway Pressure;Humans;Practice Patterns, Physicians';Respiratory Mechanics;Surveys and Questionnaires",E01.370.386.700.050;G09.772.060;E02.041.625.790.259;E02.880.820.790.259;B01.050.150.900.649.313.988.400.112.400.400;N04.590.374.577;N05.300.625;G09.772.705.700;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28588017,"Animals;Antigens, Differentiation;Antigens, Ly;Arteries;Cell Lineage;Embryonic Stem Cells;Endothelial Cells;Gene Expression Regulation, Developmental;Hematopoiesis;Hematopoietic Stem Cells;Leukocyte Common Antigens;Membrane Proteins;Mice;Multigene Family;Tumor Necrosis Factor Receptor Superfamily, Member 7;Up-Regulation",B01.050;D23.050.301.264;D23.101.100;D23.050.301.264.920;D23.101.100.920;A07.015.114;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.872.700.250;A11.436.275;G05.308.310;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;D08.811.277.352.650.775.400.100.500;D12.644.360.587.100.500;D12.776.476.592.100.500;D12.776.543.733.937.500;D12.776.543;B01.050.150.900.649.313.992.635.505.500;G05.360.340.024.340.645;D12.776.543.750.705.852.760.048;D23.050.301.264.894.127;D23.101.100.894.127;G02.111.905;G05.308.850;G07.690.773.998
28587872,"Adolescent;Anisotropy;Automation;Case-Control Studies;Child;Diffusion Tensor Imaging;Geniculate Bodies;Humans;Image Processing, Computer-Assisted;Medical Illustration;Neurofibromatosis 1;Occipital Lobe;Optic Nerve Glioma;Thalamus;Visual Acuity;Visual Cortex;Visual Pathways;White Matter;Diffusion Tensor Imaging;Neurofibromatosis 1;Visual Acuity",M01.060.057;G01.590.040;G02.050;J01.897.104;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A08.186.211.200.317.826.701.444;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;H02.385;J01.897.280.500.480;K01.093.410;L01.178.820.090.480;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;A08.186.211.200.885.287.500.571;C04.557.465.625.600.380.795;C04.557.470.670.380.795;C04.557.580.625.600.380.795;C04.588.614.300.600.600;C04.588.614.596.240.240.500;C10.292.225.800.500;C10.292.700.500.500;C10.551.360.500.500;C10.551.775.250.500.500;C11.640.544.500;A08.186.211.200.317.826;E01.370.380.850.950;F02.463.593.932.901;G14.940;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.612.220.860;A08.186.211.204;A08.186.854.880;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;E01.370.380.850.950;F02.463.593.932.901;G14.940
28586963,,
28586407,"Bayes Theorem;Diagnostic Tests, Routine;Humans;Models, Statistical;Network Meta-Analysis;Venous Thrombosis;Diagnostic Tests, Routine;Network Meta-Analysis",E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;E01.370.395;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.370.500.500;E05.581.500.501.500;N05.715.360.325.515.500;N06.850.520.445.500.500;C14.907.355.830.925;E01.370.395;E05.318.370.500.500;E05.581.500.501.500;N05.715.360.325.515.500;N06.850.520.445.500.500
28585710,"Abortifacient Agents, Nonsteroidal;Abortion, Induced;Adult;California;Cohort Studies;Dilatation and Curettage;Humans;Misoprostol;Postoperative Complications;Pregnancy;Pregnancy Trimester, Second;Retrospective Studies;Misoprostol;Pregnancy Trimester, Second",D27.505.696.875.131.100;D27.505.954.705.131.100;E04.520.050;M01.060.116;Z01.107.567.875.580.200;Z01.107.567.875.760.200;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.157.310;E04.950.300.299;B01.050.150.900.649.313.988.400.112.400.400;D10.251.355.255.550.775.450.500;D23.469.050.175.725.775.450.500;D23.469.700.660.500;C23.550.767;G08.686.784.769;G08.686.707.490;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D10.251.355.255.550.775.450.500;D23.469.050.175.725.775.450.500;D23.469.700.660.500;G08.686.707.490
28585438,"Animals;Cytokines;Gene Expression Regulation;Influenza A Virus, H1N1 Subtype;Lung;Mice;Mice, Inbred C57BL;Mice, Knockout;Orthomyxoviridae Infections;Receptors, Interleukin-1 Type I;Influenza, Human;Pneumonia;Neutrophils",B01.050;D12.644.276.374;D12.776.467.374;D23.529.374;G05.308;B04.820.545.405.400.214;A04.411;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C02.782.620;D12.776.543.750.705.852.420.300.500;C02.782.620.365;C08.730.310;C08.381.677;C08.730.610;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
28585383,"Adult;Cell Transformation, Neoplastic;Headache;Humans;Magnetic Resonance Imaging;Meningeal Neoplasms;Oligodendroglioma;Seizures;Young Adult",M01.060.116;C04.697.098.500;C23.550.727.098.500;C23.888.592.612.441;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04.588.614.250.580;C10.551.240.500;C04.557.465.625.600.380.590;C04.557.470.670.380.590;C04.557.580.625.600.380.590;C10.597.742;C23.888.592.742;M01.060.116.815
28585191,Acne Vulgaris;Adapalene;Tretinoin,C17.800.030.150;C17.800.794.111;D02.455.426.559.847.638.090;D04.615.638.090;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780
28584625,"Nephrosis, Lipoid;Nephrotic Syndrome;Proteinuria",C12.777.419.630.477;C13.351.968.419.630.477;C12.777.419.630.643;C13.351.968.419.630.643;C12.777.934.734;C13.351.968.934.734;C23.888.942.750
28583403,"Adolescent;Child;Child, Preschool;Clinical Alarms;Clinical Protocols;Cohort Studies;Emergency Service, Hospital;Humans;Infant;Quality Improvement;Sensitivity and Specificity;Sepsis;Vital Signs",M01.060.057;M01.060.406;M01.060.406.448;E07.230.200;E02.183;N05.715.360.330.125;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;J01.293.754;N04.761.744;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C01.539.757;C23.550.470.790.500;E01.370.600.875
28582295,"Adolescent;Cephalometry;Child;Child, Preschool;Humans;Micrognathism;Open Bite;Osteogenesis, Distraction;Postoperative Complications;Prospective Studies;Retrognathia",M01.060.057;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C05.500.460.457;C05.660.207.540.460.457;C07.320.440.457;C07.650.500.460.457;C16.131.621.207.540.460.457;C16.131.850.500.460.457;C07.793.494.825;E04.555.120.690;C23.550.767;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C05.500.460.827;C05.660.207.540.460.827;C07.320.440.827;C07.320.610.827;C07.650.500.460.827;C16.131.621.207.540.460.827;C16.131.850.500.460.827
28581814,"Adolescent;Adult;Algorithms;Anemia, Sickle Cell;Chronic Pain;Humans;Models, Biological;Models, Statistical;Pilot Projects;Telemedicine;Young Adult;Pain;Anemia, Sickle Cell;Models, Statistical",M01.060.057;M01.060.116;G17.035;L01.224.050;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;C23.888.592.612.274;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;H02.403.840;L01.178.847.652;N04.590.374.800;M01.060.116.815;C23.888.592.612;F02.830.816.444;G11.561.790.444;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500
28580955,"Animals;Antigen Presentation;Carrier Proteins;Cell Membrane;Cell Proliferation;Forkhead Transcription Factors;Glycolysis;Hyaluronan Receptors;Inflammation;Interleukin-4;Mechanistic Target of Rapamycin Complex 1;Membrane Proteins;Mice;Mice, Knockout;Mice, Transgenic;Proteomics;Signal Transduction;T-Lymphocytes, Regulatory;Th2 Cells;Ubiquitination",B01.050;G12.119;G12.450.050.400.070;D12.776.157;A11.284.149;G04.161.750;G07.345.249.410.750;D12.776.260.950.249;D12.776.930.977.249;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;D09.698.735.200.625;D12.776.395.550.200.625.144;D12.776.395.650.750.281;D12.776.543.550.200.625.144;D12.776.543.750.705.877.144;D23.050.301.350.625.144;C23.550.470;D12.644.276.374.465.186;D12.776.467.374.465.178;D23.529.374.465.186;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.820;G04.835;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;A11.118.637.555.567.550.500.400.905;A11.118.637.555.567.569.200.400.905;A11.118.637.555.567.569.500.400.905;A15.145.229.637.555.567.550.500.400.750;A15.145.229.637.555.567.569.200.400.750;A15.145.229.637.555.567.569.500.400.750;A15.382.490.555.567.550.500.400.905;A15.382.490.555.567.569.200.400.905;A15.382.490.555.567.569.500.400.905;G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
28579988,HLA-B Antigens,D12.776.395.550.489.500;D12.776.543.550.439.500;D23.050.301.500.100.500;D23.050.301.500.450.380;D23.050.705.552.100.500;D23.050.705.552.450.380
28579421,"Accreditation;Ambulatory Care;Clinical Competence;Curriculum;Humans;Internal Medicine;Internship and Residency;Nephrology;Program Evaluation;Surveys and Questionnaires;Teaching;Education, Medical",N03.706.110.070;N05.700.200.100;E02.760.106;N02.421.585.106;I02.399.630.210;N04.761.210;N05.715.175;I02.158;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;H02.403.429.580;E05.337.820;N04.761.685;N05.715.360.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.903;I02.358.399
28579396,"Animals;Apoptosis;Cell Differentiation;Cell Line;Cell Proliferation;Cell Survival;DNA-Binding Proteins;Dystonia;Gene Expression Regulation, Developmental;Mice;Mouse Embryonic Stem Cells;Mutation;Apoptosis;Dystonia;Embryonic Stem Cells;Survival",B01.050;G04.146.160;G04.152;A11.251.210;G04.161.750;G07.345.249.410.750;G04.346;D12.776.260;C10.597.350.300;C23.888.592.350.300;G05.308.310;B01.050.150.900.649.313.992.635.505.500;A11.872.700.250.875;G05.365.590;G04.146.160;C10.597.350.300;C23.888.592.350.300;A11.872.700.250;I03.784
28579093,"Adult;Firearms;History, 20th Century;Housing;Humans;Philadelphia;Racism;Social Segregation;Spatial Analysis;Urban Population;Violence;Wounds, Gunshot;Discrimination (Psychology);Philadelphia;Spatial Analysis;United States;Violence",M01.060.116;J01.637.870.350;K01.400.504.968;J03.340;N01.224.791.400;N06.230.150.360;N06.850.505.400.800.400;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;F01.145.813.550.500;F01.145.813.629.625;F01.829.595.500;I01.880.735.820.500.500;I01.880.735.820;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933;N01.600.900;I01.198.240.856;I01.880.735.900;C26.986.900;F02.463.593.257;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.740.933;N05.715.360.750.746;N06.850.520.830.933;Z01.107.567.875;I01.198.240.856;I01.880.735.900
28578475,Air;Contrast Media;Enema;Fluoroscopy;Humans;Insufflation;Intussusception;Radiation Dosage;Retrospective Studies;Treatment Outcome;Child;Enema;Fluoroscopy;Intussusception,G16.500.275.063.150;N06.230.300.100.150;D27.505.259.500;D27.720.259;E02.319.347;E01.370.350.700.225;B01.050.150.900.649.313.988.400.112.400.400;E01.370.450;E02.583;C06.405.469.531.577;E05.799.513;G01.750.740;N06.850.810.250;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.406;E02.319.347;E01.370.350.700.225;C06.405.469.531.577
28578223,"Antigens, Neoplasm;Cell Line;Chromatin;Cyclin-Dependent Kinase 9;HEK293 Cells;Histone Code;Humans;Inflammation;JNK Mitogen-Activated Protein Kinases;Lipopolysaccharides;Positive Transcriptional Elongation Factor B;Promoter Regions, Genetic;Protein Binding;RNA Polymerase II;RNA, Messenger;Regulatory Sequences, Nucleic Acid;Serpins;Transcription Factors;Histone Code;Positive Transcriptional Elongation Factor B;Plasminogen Activator Inhibitor 2",D23.050.285;A11.251.210;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D08.811.641.752;D08.811.913.696.620.682.700.646.500.500.750;D12.644.360.250.067.900;D12.776.167.200.067.900;D12.776.476.250.067.900;D12.776.930.955.500.500;A11.251.210.172.750;A11.436.334;G02.111.570.060.360;G05.360.360;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D08.811.913.696.620.682.700.567.374;D12.644.360.450.340;D12.776.476.450.340;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;D08.811.913.696.620.682.700.626;D12.776.930.955.500;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;D08.811.913.696.445.735.270.762;D13.444.735.544;G02.111.570.080.689;G05.360.080.689;D12.644.861;D12.776.872;D27.505.519.389.745.800.675;D12.776.930;G02.111.570.060.360;G05.360.360;D08.811.913.696.620.682.700.626;D12.776.930.955.500;D12.644.861.695.520;D12.776.124.125.645;D12.776.872.695.520;D23.119.832.750
28578103,,
28578102,,
28577836,Combined Modality Therapy;Humans;Immunotherapy;Neoplasm Metastasis;Neoplasms;Tumor Escape,E02.186;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.697.650;C23.550.727.650;C04;G12.900
28577680,"Adolescent;Cardiac Output;Dose-Response Relationship, Drug;Drug Administration Schedule;Echocardiography;Follow-Up Studies;Fontan Procedure;Heart Defects, Congenital;Heart Ventricles;Humans;Phosphodiesterase 5 Inhibitors;Postoperative Care;Pulmonary Circulation;Pyrimidines;Sulfonamides;Time Factors;Treatment Outcome;Vascular Resistance",M01.060.057;E01.370.370.380.150;G09.330.380.124;G07.690.773.875;G07.690.936.500;E02.319.283;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.389.735.500;E02.760.731.700;E04.604.500;N02.421.585.722.700;G09.330.100.770;G09.772.593;D03.383.742;D02.065.884;D02.886.590.700;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.380.921
28577078,"Adult;Aged;Breast Neoplasms;Chemotherapy, Adjuvant;Disease Progression;Disease-Free Survival;Humans;Kaplan-Meier Estimate;Mastectomy;Middle Aged;Neoadjuvant Therapy;Neoplasm Staging;Neoplasm, Residual;Predictive Value of Tests;Proportional Hazards Models;Risk Factors;Time Factors;Treatment Outcome;Breast Neoplasms;Neoplasm Staging;Disease-Free Survival;Neoplasm Recurrence, Local;Lymph Nodes;Neoadjuvant Therapy;Neoplasm, Residual",M01.060.116;M01.060.116.100;C04.588.180;C17.800.090.500;E02.186.170;E02.319.170;C23.550.291.656;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E04.466;M01.060.116.630;E02.186.450;E01.789.625;C04.697.700;C23.550.727.700;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.588.180;C17.800.090.500;E01.789.625;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.697.655;C23.550.727.655;A10.549.400;A15.382.520.604.412;E02.186.450;C04.697.700;C23.550.727.700
28576927,"Animals;Cell Differentiation;Cell Line, Tumor;Gene Expression Profiling;Hodgkin Disease;Humans;Interleukin-3 Receptor alpha Subunit;K562 Cells;Macrophages;Mice;Recombinant Fusion Proteins;T-Lymphocytes;Tumor Microenvironment",B01.050;G04.152;A11.251.210.190;A11.251.860.180;E05.393.332;C04.557.386.355;C15.604.515.569.355;C20.683.515.761.355;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.852.420.340.500;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;D12.776.828.300;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;G04.366.500
28576878,"Animals;Blood Platelets;Humans;Membrane Glycoproteins;Mice;Mice, Knockout;Platelet Activation;Platelet Glycoprotein GPIIb-IIIa Complex;Thrombosis",B01.050;A11.118.188;A15.145.229.188;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550;D12.776.543.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G09.188.390.600;D12.776.395.550.625.785;D12.776.543.550.625.785;D12.776.543.750.705.408.460.700;D12.776.543.750.705.675.784;C14.907.355.830
28576853,"Animals;Apoptosis;Catecholamines;Cell Proliferation;Cells, Cultured;Chemotaxis;Mesenchymal Stem Cells;Mice;Mice, Inbred C57BL;Myocytes, Cardiac;Physical Conditioning, Animal;Rats;Stress, Physiological;Exercise;Apoptosis;Heart;Mesenchymal Stem Cells",B01.050;G04.146.160;D02.092.311;D02.455.426.559.389.657.166.175;G04.161.750;G07.345.249.410.750;A11.251;F01.145.113.780.500;F01.145.875.439.500.500;G04.198.424;G07.568.500.590.500;G11.427.410.568.850.500;A11.329.830.500;A11.872.590.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A07.541.704.570;A10.690.552.750.570;A11.620.500;G11.427.410.698.277.280;B01.050.150.900.649.313.992.635.505.700;G07.775;G11.427.410.698.277;I03.350;G04.146.160;A07.541;A11.329.830.500;A11.872.590.500
28576468,,
28576467,"Acetic Acid;Animals;Chemistry;Consumer Product Safety;Databases, Chemical;Esters;Humans;Perfume;Registries;Dermatitis, Phototoxic",D02.241.081.018.165;D10.251.400.045.500;B01.050;H01.181;N06.850.210;L01.313.500.750.300.188.400.300;L01.470.750.750.300;D02.241.400;B01.050.150.900.649.313.988.400.112.400.400;D27.720.269.700;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C17.800.174.255.400.225;C17.800.600.335;C17.800.815.255.400.225
28576126,"Animals;Anti-Retroviral Agents;Antiretroviral Therapy, Highly Active;Ape Diseases;CD4 Lymphocyte Count;Drug Resistance, Viral;Mutation;Pan troglodytes;RNA, Viral;Simian Acquired Immunodeficiency Syndrome;Simian Immunodeficiency Virus;Viral Load;Acquired Immunodeficiency Syndrome;Pan troglodytes;Drug Resistance",B01.050;D27.505.954.122.388.077;E02.319.310.075;C22.735.050;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;G06.225.420;G06.920.225;G07.690.773.984.269.420;G05.365.590;B01.050.150.900.649.313.988.400.112.400.620;D13.444.735.828;C02.782.815.616.850;C02.839.850;C22.735.500.850;B04.820.650.589.650.800;B04.820.650.805.700;E01.370.225.875.950;E05.200.875.950;G06.920.850;C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;B01.050.150.900.649.313.988.400.112.400.620;G07.690.773.984
28575649,"Animals;Base Sequence;Gene Expression Regulation;Gene Knockdown Techniques;Gene Regulatory Networks;Genetic Variation;Genome-Wide Association Study;Humans;Kidney;Kidney Diseases;Linkage Disequilibrium;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Quantitative Trait, Heritable;Reproducibility of Results;Zebrafish;beta-Mannosidase;Gene Regulatory Networks;Kidney",B01.050;G02.111.570.080;G05.360.080;L01.453.245.667.080;G05.308;E05.393.335.500;G05.360.080.689.360;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C12.777.419;C13.351.968.419;G05.348.500;G05.365.795.598;G05.360.340.024.380.937;G05.420.720;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;B01.050.150.900.493.200.244.828;D08.811.277.450.625.750;G05.360.080.689.360;A05.810.453
28575231,Activities of Daily Living;Aged;Awareness;HIV Infections;Humans;Middle Aged;Neurocognitive Disorders;Neuropsychological Tests;Online Systems;Statistics as Topic;Aging;Executive Function;HIV,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;F02.463.188.150;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F03.615;F04.711.513;L01.313.500.750.300.742;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;G07.345.124;F02.463.217;B04.820.650.589.650.350
28575174,"Animals;Appetite Regulation;Diet, High-Fat;Eating;Energy Metabolism;Rats;Rats, Sprague-Dawley;Rats, Transgenic;Receptors, Oxytocin;Satiation;Signal Transduction;Solitary Nucleus;Thermogenesis",B01.050;G07.203.650.170;G07.203.650.390.070.290;G10.261.390.070.290;G07.203.650.240.267;G07.203.650.283;G10.261.330;G03.295;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;B01.050.050.136.700;B01.050.150.900.649.313.992.635.505.700.825;D12.776.543.750.695.630;D12.776.543.750.720.600.630;D12.776.543.750.750.555.630;D12.776.543.750.750.660.600;F02.830.749;G02.111.820;G04.835;A08.186.211.132.810.591.500.750;G07.110.232.778;G07.410.421.778;G16.012.500.535.778
28575147,"Aged;Aged, 80 and over;Alzheimer Disease;Amygdala;Computational Biology;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Machine Learning;Middle Aged;Phenotype;Polymorphism, Genetic;Positron Emission Tomography Computed Tomography;Software",M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211.180.090;A08.186.211.200.885.287.249.152;H01.158.273.180;L01.313.124;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;M01.060.116.630;G05.695;G05.365.795;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;L01.224.900
28575069,Amputation;Animals;Nerve Regeneration;Peripheral Nerves;Small Molecule Libraries;Topoisomerase I Inhibitors;Zebrafish,E04.555.080;B01.050;G11.561.585;G16.762.611;A08.800.800;D27.720.470.765;D27.505.519.389.892.500;D27.505.954.248.794.500;B01.050.150.900.493.200.244.828
28574542,Aged;Geriatric Assessment;Hospitals;Humans;Mobility Limitation;Prognosis,M01.060.116.100;E05.318.308.225;I01.240.425.350;N01.224.425.350;N05.715.360.300.360;N06.850.505.400.425.350;N06.850.520.308.225;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;C23.888.550;E01.789
28574509,"Animals;Blotting, Western;Cell Line;Elongation Factor 2 Kinase;Flow Cytometry;HEK293 Cells;Humans;Immunohistochemistry;Mice;Mice, SCID;N-Myc Proto-Oncogene Protein;Neuroblastoma;RNA, Messenger;Tissue Array Analysis",B01.050;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;A11.251.210;D08.811.913.696.620.682.700.125.425;D12.644.360.100.425;D12.776.476.100.425;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.780;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D13.444.735.544;E05.588.570.850
28573161,,
28572842,Computational Biology;Genome-Wide Association Study;Machine Learning,H01.158.273.180;L01.313.124;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G17.035.250.500;L01.224.050.375.530
28572479,Autoantibodies;Child;Humans;Neuromyelitis Optica;Sjogren's Syndrome,D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.600.500;C10.114.375.800;C10.292.700.550.500;C10.314.350.600.500;C10.314.350.800;C11.640.576.695;C20.111.258.250.550.500;C20.111.258.250.775;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774
28572262,Adolescent;Early Detection of Cancer;Gadolinium;Genetic Predisposition to Disease;Humans;Magnetic Resonance Imaging;Neoplasms;Whole Body Imaging,M01.060.057;E01.390.500;D01.268.558.362.484;D01.552.550.399.484;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04;E01.370.350.925;E05.979
28572261,Child;Early Detection of Cancer;Genetic Predisposition to Disease;Genetic Testing;Genotype;Germ-Line Mutation;Humans;Medical Oncology;Neoplasms,M01.060.406;E01.390.500;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.380;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C04
28572258,"B7-H1 Antigen;Breast Neoplasms;Epitopes, T-Lymphocyte;Humans;Immunotherapy;Lymphocytes, Tumor-Infiltrating;Programmed Cell Death 1 Receptor;Tumor Microenvironment",D12.776.467.150.300;D12.776.543.095.300;D23.050.301.285.400;D23.529.168.300;C04.588.180;C17.800.090.500;D23.050.550.402;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;G04.366.500
28572090,"Animals;Child Development;Child, Preschool;Growth Differentiation Factor 15;Growth Hormone;Humans;Mice, Inbred C57BL;Mice, Knockout;Models, Animal;Myocytes, Cardiac;Signal Transduction;Failure to Thrive;Heart Diseases",B01.050;F01.525.200;G07.345.374.750;M01.060.406.448;D12.644.276.374.305;D12.644.276.954.300.915;D12.776.467.374.305;D12.776.467.942.300.915;D23.529.374.305;D23.529.942.300.915;D06.472.699.631.525.425;D12.644.548.691.525.425;B01.050.150.900.649.313.988.400.112.400.400;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.598;A07.541.704.570;A10.690.552.750.570;A11.620.500;G02.111.820;G04.835;C23.888.338;C14.280
28571906,"Aged;Aged, 80 and over;Biopsy;Humans;Lung Neoplasms;Middle Aged;Patient Selection;Predictive Value of Tests;Risk Assessment;Risk Factors;Solitary Pulmonary Nodule;Tomography, X-Ray Computed;Tumor Burden",M01.060.116.100;M01.060.116.100.080;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;M01.060.116.630;E05.581.500.653;N04.590.731;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.381.884;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E05.041.124.892
28571639,"Adolescent;Child;Cross-Sectional Studies;Echocardiography;Follow-Up Studies;Fontan Procedure;Forecasting;Health Status;Heart Defects, Congenital;Heart Ventricles;Humans;Ontario;Quality of Life;Retrospective Studies;Risk Factors;Survival Rate;Treatment Outcome;United States;Young Adult;Fontan Procedure;Exercise",M01.060.057;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;I01.320;I01.240.425;N01.224.425;N06.850.505.400.425;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.176.639;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.060.116.815;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;G11.427.410.698.277;I03.350
28570405,"Adult;Bone Transplantation;Cephalometry;Child;Child, Preschool;Craniosynostoses;Follow-Up Studies;Humans;Infant;Nose;Postoperative Complications;Retrospective Studies;Tomography, X-Ray Computed;Young Adult",M01.060.116;E02.095.147.725.052;E04.555.130;E04.936.580.052;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A01.456.505.733;A04.531;A09.531;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;M01.060.116.815
28570361,"Adolescent;Anti-Arrhythmia Agents;Arrhythmias, Cardiac;Death, Sudden, Cardiac;Defibrillators, Implantable;Diagnosis, Differential;Electrocardiography;Emergency Service, Hospital;Exercise;Genetic Testing;Humans;Syncope;Tachycardia, Ventricular",M01.060.057;D27.505.954.411.097;C14.280.067;C23.550.073;C14.280.383.220;C23.550.260.322.250;E07.305.250.159.175;E07.305.250.319.175;E07.695.202.175;E01.171;E01.370.370.380.240;E01.370.405.240;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;G11.427.410.698.277;I03.350;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.358.800.600;C23.888.592.604.359.800.600;C14.280.067.845.940;C14.280.123.875.940;C23.550.073.845.940
28570349,,
28570150,,
28569744,"Acute Lung Injury;Adult;Bronchopulmonary Dysplasia;Continuous Positive Airway Pressure;Delivery Rooms;Gestational Age;Humans;Infant, Extremely Premature;Infant, Newborn;Intubation, Intratracheal;Oxygen Inhalation Therapy;Pregnancy;Pulmonary Surfactants;Randomized Controlled Trials as Topic;Resuscitation;Risk Factors;Young Adult",C08.381.520.500;M01.060.116;C08.381.520.750.500;C16.614.521.125;E02.041.625.790.259;E02.880.820.790.259;N02.278.388.150;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;M01.060.703.520;E02.041.500;E02.585.578;E05.497.578;E02.880.690;G08.686.784.769;D27.505.954.796.600;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E02.365.647;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28569047,Adolescent;Adult;Enzyme Replacement Therapy;Follow-Up Studies;Gaucher Disease;Glucosylceramidase;Humans;Middle Aged;Prevalence;Registries;Splenectomy,M01.060.057;M01.060.116;E02.319.353.500;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C10.228.140.163.100.435.825.400;C16.320.565.189.435.825.400;C16.320.565.398.641.803.441;C16.320.565.595.554.825.400;C18.452.132.100.435.825.400;C18.452.584.687.803.441;C18.452.648.189.435.825.400;C18.452.648.398.641.803.441;C18.452.648.595.554.825.400;D08.811.277.450.420.412;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E04.726
28567500,Chronobiology Disorders;Parkinson Disease;REM Sleep Behavior Disorder;Sleep,C10.281;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.886.659.633.700;F03.870.664.633.700;F02.830.855;G11.561.803
28566553,"Calcineurin;Calcium;Cluster Analysis;Cytoplasm;Genes, Fungal;Homeostasis;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins",D08.811.277.352.650.625.150;D12.644.360.087;D12.776.476.087;D01.268.552.100;D01.552.539.288;D23.119.100;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;A11.284.430.214;G05.360.340.024.340.364.500;G05.360.340.358.024.500;G05.360.340.358.365.500;G07.410;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750
28566552,"Epilepsy;Genome, Human;Humans;Mutation;NAV1.1 Voltage-Gated Sodium Channel;Phenotype;Sequence Analysis, DNA",C10.228.140.490;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D12.776.157.530.400.875.750.100;D12.776.543.550.450.875.750.100;D12.776.543.585.400.875.750.100;D12.776.631.960.100;G05.695;E05.393.760.700
28566273,"Diabetes Mellitus, Type 2;European Continental Ancestry Group;Gene Expression Regulation;Genetic Variation;Genome-Wide Association Study;Humans",C18.452.394.750.149;C19.246.300;M01.686.508.400;G05.308;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400
28566226,"Animals;Carrier Proteins;Dependovirus;Disease Models, Animal;Dogs;Eye Proteins;G-Protein-Coupled Receptor Kinase 1;Gene Expression;Gene Order;Genes, Reporter;Genes, X-Linked;Genetic Therapy;Genetic Vectors;Humans;Mutation;Phenotype;Photoreceptor Cells, Vertebrate;Primates;Promoter Regions, Genetic;Retina;Retinitis Pigmentosa;Transduction, Genetic;Transgenes;Vision Tests;Genetic Therapy",B01.050;D12.776.157;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.750.250.216.200;D12.776.306;D08.811.913.696.620.682.700.364.100;D12.644.360.293.500;D12.776.306.399;D12.776.476.293.500;G05.297;G05.340;G05.360.340.024.340.435;G05.360.340.024.340.500;G05.420.457;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G05.695;A08.675.650.850.625.670;A08.675.650.915.937.670;A08.800.950.937.670;A09.371.729.831.625.670;A11.671.650.850.625.670;A11.671.650.915.937.670;B01.050.150.900.649.313.988;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;A09.371.729;C11.270.684;C11.768.585.658.500;C16.320.290.684;E05.393.350.800;G05.728.850;G05.360.340.024.340.825;E01.370.380.850;E02.095.301;E05.393.420.301
28566217,"Animals;Cholecystectomy, Laparoscopic;Clinical Competence;Curriculum;Education, Medical, Graduate;Educational Measurement;Hospitals, University;Humans;Internship and Residency;Motor Skills;Philadelphia;Simulation Training;Suture Techniques;Swine;Task Performance and Analysis;Cholecystectomy;Laparoscopy",B01.050;E04.210.120.172.140;E04.502.250.520.160;I02.399.630.210;N04.761.210;N05.715.175;I02.158;I02.358.337.350;I02.358.399.350;I02.399;N02.278.020.300.310;N02.278.421.639.725;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F02.808.260;Z01.107.567.875.500.550.525;Z01.433.820;I02.903.847;E04.987.775;B01.050.150.900.649.313.500.880;F02.784.412.846;F02.784.692.746;F02.808.600;E04.210.120.172;E01.370.388.250.520;E04.502.250.520
28566046,"Airway Management;Clinical Competence;Endoscopy;Equipment Design;Humans;Intubation, Intratracheal;Manikins;Otolaryngology;Education;Manikins",E02.041;I02.399.630.210;N04.761.210;N05.715.175;E01.370.388.250;E04.502.250;E05.320;B01.050.150.900.649.313.988.400.112.400.400;E02.041.500;E02.585.578;E05.497.578;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;H02.403.810.526;I02;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400
28564706,Adult;Clinical Competence;Communication;Humans;Interviews as Topic;Middle Aged;Patient Satisfaction;Professional-Patient Relations;Qualitative Research;Quality Improvement;Resuscitation;Trauma Centers;Video Recording,M01.060.116;I02.399.630.210;N04.761.210;N05.715.175;F01.145.209;L01.143;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;F01.829.401.650;N05.300.660;H01.770.644.241.850;J01.293.754;N04.761.744;E02.365.647;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;L01.280.960
28564696,,
28562462,,
28562450,"Education, Medical, Graduate;Education, Medical, Undergraduate;Emigration and Immigration;Employment;Hospitals, Veterans;Humans;Internship and Residency;Licensure;School Admission Criteria;Schools, Medical;Undocumented Immigrants;United States",I02.358.337.350;I02.358.399.350;I02.358.399.450;I01.240.600.525.500;N01.224.625.525.500;N06.850.505.400.700.525.500;N01.824.245;N02.278.421.510.180.400;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;N03.706.110.510;N05.700.200.450;I02.399.750;I02.783.495.552;N02.278.020.578;M01.189.500;Z01.107.567.875
28562288,Aggression;Bullying;Humans;Students,F01.145.126.125;F01.145.813.045;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;B01.050.150.900.649.313.988.400.112.400.400;M01.848
28562285,"Adolescent;Child;Consensus;Decision Making;Dissent and Disputes;Humans;Mental Competency;Models, Psychological;Parent-Child Relations;Parental Consent;Pediatricians;Physician's Role",M01.060.057;M01.060.406;F01.829.316.068;F02.463.785.373.433;F02.463.785.373;F01.829.401.094;F02.463.785.373.476;B01.050.150.900.649.313.988.400.112.400.400;F01.590;F02.410;I01.880.604.583.530;N03.706.535.625;E05.599.695;F01.829.263.370.290;I01.880.604.583.427.635.500;N03.706.535.489.635.500;M01.526.485.810.758;N02.360.810.758;F01.829.316.616.625.600
28562284,Anti-Bacterial Agents;Bacteremia;Catheter-Related Infections;Child;Community-Acquired Infections;Hospitalization;Humans;Logistic Models;Methicillin-Resistant Staphylococcus aureus;Musculoskeletal Diseases;Recurrence;Retrospective Studies;Risk Factors;Staphylococcal Infections;Treatment Failure;Vancomycin;Vascular Diseases,D27.505.954.122.085;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;C01.539.195;M01.060.406;C01.539.234;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;C05;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.252.410.868;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;D09.400.420.925;D12.644.233.925;C14.907
28562270,"Catheterization, Peripheral;Clinical Competence;Ethics, Medical;Fellowships and Scholarships;Humans;Infant;Internship and Residency;Interprofessional Relations;Patient Safety;Pediatrics;Quality Improvement;Radial Artery;United States",E02.148.224;E04.100.814.529.937;E04.502.382.937;E05.157.375;I02.399.630.210;N04.761.210;N05.715.175;K01.752.566.479.171.132.750;N05.350.340.162.500;N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I02.358.337.350.500;I02.358.399.350.750;F01.829.401.205;N06.850.135.060.075.399;H02.403.670;J01.293.754;N04.761.744;A07.015.114.740;Z01.107.567.875
28562260,Adolescent;Adolescent Behavior;Attitude;Bullying;Child;Humans;Maryland;Prevalence;Students;Surveys and Questionnaires,M01.060.057;F01.145.022;F01.100;F01.145.126.125.550;F01.145.813.213.500;I01.880.735.070;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.075.418;Z01.107.567.875.500.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;M01.848;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28562252,"Adolescent;Appendectomy;Appendicitis;Child;Child, Preschool;Cross-Sectional Studies;Emergency Service, Hospital;Humans;Intestinal Perforation;Prospective Studies;Time Factors",M01.060.057;E04.210.078;C01.539.463.099;C06.405.205.099;C06.405.469.110.207;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;C06.405.469.557;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G01.910.857
28561710,Breast Neoplasms;Genomics;Humans;Neoplasm Metastasis;Neoplasm Staging;Precision Medicine;Prognosis,C04.588.180;C17.800.090.500;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650;C23.550.727.650;E01.789.625;E02.574;H02.403.200.700;E01.789
28561678,"Adenocarcinoma;Carcinoma, Pancreatic Ductal;Humans;Immunity, Cellular;Immunotherapy;Myeloid Cells;T-Lymphocytes",C04.557.470.200.025;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;E02.095.465.425;A11.627;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28561664,"Biomedical Research;Child;Databases, Factual;Humans;Medical Oncology;Neuroblastoma",H01.770.644.145;M01.060.406;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429.515;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
28561434,"Adenosine Diphosphate;Arachidonic Acid;Blood Platelets;Calcimycin;Calcium Ionophores;Cell-Derived Microparticles;Collagen;Flow Cytometry;Humans;Microscopy, Electron, Scanning;Microscopy, Electron, Transmission;Platelet Activation;Thrombin;Microscopy, Electron;Platelet Activation;Blood Platelets",D03.633.100.759.646.138.124;D13.695.667.138.124;D13.695.827.068.124;D10.251.355.255.100.100;D10.251.355.310.166.100;A11.118.188;A15.145.229.188;D03.633.100.221.173;D27.505.519.562.374.100;D27.720.395.100;A11.284.295.588.500;D05.750.078.280;D12.776.860.300.250;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.402.541;E05.595.402.541;E01.370.350.515.402.580;E05.595.402.580;G09.188.390.600;D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960;E01.370.350.515.402;E05.595.402;G09.188.390.600;A11.118.188;A15.145.229.188
28561207,"Adenosine Deaminase;Adolescent;Adult;Autoimmune Diseases of the Nervous System;Biomarkers;Child;Child, Preschool;Humans;Infant;Interferon Type I;Mutation;Nervous System Malformations;Phenotype;RNA-Binding Proteins;Young Adult",D08.811.277.151.486.075;M01.060.057;M01.060.116;C10.114;C20.111.258;D23.101;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890;G05.365.590;C10.500;C16.131.666;G05.695;D12.776.157.725;D12.776.664.962;M01.060.116.815
28560946,"Anti-Bacterial Agents;Antimicrobial Stewardship;Benchmarking;Community-Acquired Infections;Drug Resistance, Bacterial;Hospitals;Humans;Pneumonia, Bacterial",D27.505.954.122.085;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;C01.539.234;G06.099.225;G06.225.347;G07.690.773.984.269.347;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;C01.252.620;C08.381.677.540;C08.730.610.540
28560706,"Blood Flow Velocity;Blood Vessel Prosthesis;Child, Preschool;Exercise Tolerance;Fontan Procedure;Humans;Pulmonary Artery;Exercise Tolerance;Hemodynamics",E01.370.370.130;G09.330.380.630.080;E07.695.110;M01.060.406.448;G11.427.680.270;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;B01.050.150.900.649.313.988.400.112.400.400;A07.015.114.715;G11.427.680.270;G09.330.380
28560670,"Biomarkers, Tumor;Flow Cytometry;Humans;Neoplasms;Neoplastic Cells, Circulating;Neoplastic Cells, Circulating;Flow Cytometry",D23.101.140;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;C04;A11.642;C04.697.650.900;C23.550.727.650.900;A11.642;C04.697.650.900;C23.550.727.650.900;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350
28560267,,
28560097,Computational Biology;Single-Cell Analysis,H01.158.273.180;L01.313.124;E05.242.900
28559929,Coronary Artery Disease;Heart Failure,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C14.280.434
28559805,"Aphasia, Primary Progressive",C10.228.140.380.132;C10.597.606.150.500.800.100.155;C23.888.592.604.150.500.800.100.155;F03.615.400.125
28558955,"Anticonvulsants;Brain;Electroencephalography;Gestational Age;Humans;Hypoxia-Ischemia, Brain;Infant, Newborn;Infant, Premature;Intracranial Hemorrhages;Phenobarbital;Seizures;Electroencephalography;Hypoxia-Ischemia, Brain",D27.505.954.427.080;A08.186.211;E01.370.376.300;E01.370.405.245;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703.520;M01.060.703.520.520;C10.228.140.300.535;C14.907.253.573;C23.550.414.913;D03.383.742.698.253.650;C10.597.742;C23.888.592.742;E01.370.376.300;E01.370.405.245;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716
28558795,"Animals;Blood-Brain Barrier;Brain Neoplasms;Cell Line, Tumor;Contrast Media;Gadolinium DTPA;Glioma;Humans;Hydrogen-Ion Concentration;Magnetic Resonance Imaging;Molecular Imaging;Neoplasms;Non-Nutritive Sweeteners;Phantoms, Imaging;Rats;Rats, Inbred F344;Neoplasms;Gadolinium;Glioma",B01.050;A07.035;A08.186.211.035;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;A11.251.210.190;A11.251.860.180;D27.505.259.500;D27.720.259;D02.092.782.590.401;D02.241.081.018.639.400;D02.691.400;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;G02.300;E01.370.350.825.500;E01.370.350.557;E05.601.555;C04;D27.720.372.300.353.609.500;G07.203.300.514.500.400.700.500;J02.500.514.500.400.700.500;E07.671;B01.050.150.900.649.313.992.635.505.700;B01.050.050.199.520.760.200;B01.050.150.900.649.313.992.635.505.700.400.200;C04;D01.268.558.362.484;D01.552.550.399.484;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380
30107024,,
28558090,Humans;Malignant Hyperthermia;Neuroleptic Malignant Syndrome;Parkinson Disease,B01.050.150.900.649.313.988.400.112.400.400;C23.550.505.700;C23.550.767.600;C10.228.140.079.737;C10.720.737;C25.723.705.600;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28557947,"Adult;Clinical Competence;Education, Medical, Graduate;Educational Measurement;Humans;Internship and Residency;Pediatrics;Program Evaluation;Reproducibility of Results;Students, Medical;United States;Young Adult",M01.060.116;I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;I02.399;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.670;E05.337.820;N04.761.685;N05.715.360.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;M01.848.769.602;Z01.107.567.875;M01.060.116.815
28557744,"Biomedical Research;Child;Health Policy;Humans;Off-Label Use;Pediatrics;Practice Patterns, Physicians';Risk Assessment;United States;United States Food and Drug Administration",H01.770.644.145;M01.060.406;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;E02.319.307.500;H02.403.670;N04.590.374.577;N05.300.625;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;Z01.107.567.875;I01.409.418.750.600.650.760;N03.540.348.500.500.600.650.760
28557725,"Cerebrospinal Fluid Shunts;Child;Critical Pathways;Emergency Service, Hospital;Humans;Radiation Dosage;Radiation Exposure;Tomography, X-Ray Computed",E04.035.188;E04.525.170;M01.060.406;N04.590.233.624.625;N04.590.275;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.799.513;G01.750.740;N06.850.810.250;G01.750.748;N06.850.460.350.850;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28557719,"Cause of Death;Child Abuse;Child, Preschool;Cross-Sectional Studies;Humans;Infant;Poverty;Residence Characteristics;Retrospective Studies;Risk Factors;United States",E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I01.880.735.634;I01.880.853.996.535;N01.824.600;N01.224.791;N06.850.505.400.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28557558,"Adolescent;Adult;Ethnic Groups;Feasibility Studies;Feeding Behavior;Health Knowledge, Attitudes, Practice;Humans;Infant;Infant, Newborn;Maternal Health;Medicaid;Mothers;Parenting;Pediatric Obesity;Peer Group;Poverty;Pregnancy;Risk Factors;Social Media;United States;Internet;Infant;Telemedicine;Social Media",M01.060.057;M01.060.116;M01.686.754;N01.224.317;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;F01.145.113.547;F01.145.407;G07.203.650.353;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N01.400.900.500;N03.219.521.346.506.564.655;N03.706.615.693;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.829.263.370.310;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;F01.829.316.483;I01.880.735.634;I01.880.853.996.535;N01.824.600;G08.686.784.769;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;L01.178.751;L01.224.230.110.500.750;Z01.107.567.875;L01.224.230.110.500;M01.060.703;H02.403.840;L01.178.847.652;N04.590.374.800;L01.178.751;L01.224.230.110.500.750
28557000,"Animals;Data Accuracy;Data Interpretation, Statistical;Endpoint Determination;Randomized Controlled Trials as Topic;Risk Assessment;Treatment Outcome;Veterinary Medicine;Epidemiology",B01.050;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;E05.315;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;H02.956;H02.403.720.500
28555648,Cost-Benefit Analysis;Costs and Cost Analysis;Humans;Public Health,N03.219.151.125;N03.219.151;B01.050.150.900.649.313.988.400.112.400.400;H02.403.720;N01.400.550;N06.850
28555406,"Adolescent;Adult;Child;Child, Preschool;Family Health;Genome-Wide Association Study;Genotype;Humans;Linkage Disequilibrium;Microtubule-Associated Proteins;Middle Aged;Polymorphism, Single Nucleotide;Severity of Illness Index;Tic Disorders;Tryptophan Hydroxylase;Young Adult;Obsessive-Compulsive Disorder;Tourette Syndrome",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;N01.400.300;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G05.348.500;D12.776.220.600.450;D12.776.631.560;M01.060.116.630;G05.365.795.598;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.228.662.825;F03.625.992;D08.811.682.690.708.870;M01.060.116.815;F03.080.600;C10.228.140.079.898;C10.228.662.825.800;C10.574.500.850;C16.320.400.820;F03.625.992.850
28554803,"Animals;Epigenesis, Genetic;Genomics;Histone Deacetylases;Kinetics;Lipid Metabolism;Metabolic Flux Analysis;Metabolomics;Mice, Knockout;Muscle, Skeletal;Nuclear Receptor Co-Repressor 1;Proteomics;Transcriptome",B01.050;G05.308.203;H01.158.273.180.350;H01.158.273.343.350;D08.811.277.087.520;G01.374.661;G02.111.490;G03.458;E01.370.225.500.810;E05.200.500.810;E05.242.654;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A02.633.567;A10.690.552.500;D12.776.930.780.625.374;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.873.750;G05.297.700.750;G05.360.920
28554747,"Adenocarcinoma;Biopsy;Case-Control Studies;Cell Proliferation;Diagnosis, Differential;Humans;Neoplasm Invasiveness;Observer Variation;Predictive Value of Tests;Reproducibility of Results;Uterine Cervical Neoplasms",C04.557.470.200.025;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G04.161.750;G07.345.249.410.750;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C04.697.645;C23.550.727.645;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850
28554680,,
28553750,"Accidents, Traffic;Adolescent;Adolescent Behavior;Automobile Driving;Behavior, Addictive;Cell Phone;Dangerous Behavior;Humans;Risk Reduction Behavior;Text Messaging;Therapy, Computer-Assisted;Adolescent;Distracted Driving;School Nursing",N06.850.135.392;M01.060.057;F01.145.022;I03.125;F01.145.527.100.120;L01.178.847.698.300;F01.145.263;I01.880.735.223;B01.050.150.900.649.313.988.400.112.400.400;F01.145.699;L01.178.847.698.300.500;L01.559.423.906.377.666;E02.950;L01.313.500.750.100.710;M01.060.057;I03.125.474;H02.478.676.824;N02.421.726.809.742
28553273,Candida albicans;Immune Evasion,B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326;G06.462.400;G12.413;G16.527.200.700
28552704,"Amylin Receptor Agonists;Angiotensin II;Animals;Anxiety;Calcitonin;Choice Behavior;Dietary Carbohydrates;Dietary Fats;Dietary Sucrose;Drinking Water;Feeding Behavior;Rats, Sprague-Dawley;Receptors, Islet Amyloid Polypeptide;Saccharin;Salmon;Ventral Tegmental Area;Diet;Nutrients;Obesity;Reward",D27.505.519.143;D27.505.696.422.374;D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;B01.050;F01.470.132;D06.472.699.150;D06.472.931.052;D12.644.400.095;D12.644.548.150;D12.776.631.650.095;F02.463.785.373.346;D09.301;G07.203.300.362;J02.500.362;D10.212.302;G07.203.300.375;J02.500.375;D09.301.831.250;D09.698.629.305.770.200;D09.947.500.250;D09.947.750.770.200;D27.720.372.300.353.609.750.250;G07.203.300.362.831.250;G07.203.300.514.500.400.700.750.250;J02.500.362.831.250;J02.500.514.500.400.700.750.250;D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418;F01.145.113.547;F01.145.407;G07.203.650.353;B01.050.150.900.649.313.992.635.505.700.750;D12.776.543.750.695.360;D02.886.675.687;D03.383.129.708.089.708;D03.633.100.185.708;B01.050.150.900.493.817.750.705;A08.186.211.132.659.413.875.820;G07.203.650.240;D27.505.696.377.683;G07.203.300.681;J02.500.681;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.463.425.770.836
28552658,"Cardiopulmonary Resuscitation;Child;Child, Preschool;Drug Administration Schedule;Epinephrine;Heart Arrest;Humans;Infant;Infant, Newborn;Logistic Models;Odds Ratio;Registries;Retrospective Studies;Vasoconstrictor Agents;American Heart Association;Cardiopulmonary Resuscitation;Child;Epinephrine;Humans;Registries;Retrospective Studies;Vasoconstrictor Agents",E02.365.647.110;M01.060.406;M01.060.406.448;E02.319.283;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.954.411.793;N03.540.630.780.110;E02.365.647.110;M01.060.406;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.954.411.793
28552437,"Mexico;Mexico;Arthritis, Rheumatoid;Safety",Z01.107.567.589;Z01.107.567.589;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;N06.850.135.060.075
28552407,"Animals;CD11b Antigen;Disease Models, Animal;Endothelial Cells;Factor VIII;Gene Expression;Genes, Reporter;Genetic Vectors;Hemophilia A;Immune Tolerance;Immunization;Immunosuppression;Isoantibodies;Lentivirus;Mice;Mice, 129 Strain;Mice, Inbred BALB C;Mice, Inbred C57BL;Organ Specificity;Promoter Regions, Genetic;T-Lymphocytes, Regulatory;Transduction, Genetic;Transgenes;Whole Blood Coagulation Time;Genetic Therapy;Hemophilia A",B01.050;D12.776.395.550.200.074.750;D12.776.543.550.200.093.750;D12.776.543.750.705.408.100.150;D12.776.543.750.705.833.062;D23.050.301.350.074.049;C22.232;E05.598.500;E05.599.395.080;A11.436.275;D12.776.124.125.350;D23.119.350;G05.297;G05.360.340.024.340.435;G05.360.337;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500;G12.535.425;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;E02.095.465.425.450;E05.478.610;D12.776.124.486.485.114.664;D12.776.124.790.651.114.664;D12.776.377.715.548.114.664;B04.820.650.589;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.400.025;B01.050.150.900.649.313.992.635.505.500.550.025;B01.050.150.900.649.313.992.635.505.500.800.500.025;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G07.650;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;E05.393.350.800;G05.728.850;G05.360.340.024.340.825;E01.370.225.625.115.950;E05.200.625.115.950;G09.188.960;E02.095.301;E05.393.420.301;C15.378.100.100.500;C15.378.100.141.500;C15.378.463.500;C16.320.099.500
28552347,"Animals;Epithelial Cells;Hair Follicle;Humans;Inflammation;Jagged-1 Protein;Mice;Stem Cells;T-Lymphocytes, Regulatory;Jagged-1 Protein;Alopecia Areata;Hair;Skin",B01.050;A11.436;A10.272.497.500;A17.360.710;A17.815.250.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.644.276.930.500;D12.776.157.125.797.500;D12.776.543.800.500;D23.529.930.500;B01.050.150.900.649.313.992.635.505.500;A11.872;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;D12.644.276.930.500;D12.776.157.125.797.500;D12.776.543.800.500;D23.529.930.500;C17.800.329.937.122.147;A17.360;A17.815
28552198,Genetic Association Studies;Genetic Predisposition to Disease;Genomics;Humans;Reproducibility of Results;Genetic Testing,E05.393.385;C23.550.291.687.500;G05.380.355;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221
28551734,Adrenal Cortex Hormones;Alopecia Areata;Child;Drug Administration Routes;Humans;Off-Label Use,D06.472.040;C17.800.329.937.122.147;M01.060.406;E02.319.267;B01.050.150.900.649.313.988.400.112.400.400;E02.319.307.500
28551277,"Artificial Organs;Child Development;Humans;Infant, Newborn;Infant, Premature;Placenta;Pregnancy;Extracorporeal Membrane Oxygenation;Premature Birth",E07.858.082;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;A16.710;G08.686.784.769;E02.880.301;E04.292.451;C13.703.420.491.500
28551276,"Biomedical Research;Ethics, Medical;Fetal Therapies;Humans;Fetal Therapies;Ethics, Medical",H01.770.644.145;K01.752.566.479.171.132.750;N05.350.340.162.500;E02.467;B01.050.150.900.649.313.988.400.112.400.400;E02.467;K01.752.566.479.171.132.750;N05.350.340.162.500
28550993,"Cardiovascular Diseases;Cholesterol, LDL;Drug Prescriptions;Health Personnel;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Proprotein Convertase 9;Protease Inhibitors;Societies, Medical;Surveys and Questionnaires;Dyslipidemias;Hyperlipoproteinemia Type II;Hydroxymethylglutaryl-CoA Reductase Inhibitors",C14;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;E02.319.307;N02.421.668.778.500;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;D08.811.277.656.300.760.718;D08.811.277.656.837.688;D08.811.277.656.959.350.718;D27.505.519.389.745;N03.540.828.589;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C18.452.584.500;C16.320.565.398.481;C18.452.584.500.500.644.475;C18.452.648.398.481;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
28550986,Adult;Atypical Bacterial Forms;Bacterial Infections;Debridement;Humans;Middle Aged;Retrospective Studies;Risk Factors;Soft Tissue Infections;Upper Extremity;Culture;Debridement;Infection,M01.060.116;B03.110;B05.110;C01.252;E04.176;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.820;A01.378.800;I01.076.201.450;I01.880.853.100;E04.176;C01.539
28550381,"Animals;CRISPR-Cas Systems;Cholesterol;Dyslipidemias;Gene Editing;Humans;Mice;Mutagenesis, Site-Directed;Proprotein Convertase 9;Clustered Regularly Interspaced Short Palindromic Repeats;Cardiovascular Diseases;Dyslipidemias;Gene Editing",B01.050;G05.308.203.374.394;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;C18.452.584.500;E05.393.420.270;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;E05.393.420.601.575;D08.811.277.656.300.760.718;D08.811.277.656.837.688;D08.811.277.656.959.350.718;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C14;C18.452.584.500;E05.393.420.270
28550246,"Aged;Aged, 80 and over;Alzheimer Disease;Apolipoproteins E;Atrophy;Brain;Cognitive Dysfunction;Cross-Sectional Studies;Humans;Magnetic Resonance Imaging;Neuropsychological Tests;Psychiatric Status Rating Scales;tau Proteins;Alzheimer Disease;Magnetic Resonance Imaging;Cognitive Dysfunction;Plasma;tau Proteins",M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;C23.300.070;A08.186.211;F03.615.250.700;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F04.711.513;F04.711.513.653;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;E01.370.350.825.500;F03.615.250.700;A12.207.152.693;A12.207.270.695;A15.145.693;D12.776.220.600.450.510;D12.776.631.560.510
28550188,"Anemia, Hemolytic, Congenital;Guidelines as Topic;Humans;Splenectomy;Thrombosis",C15.378.071.141.150;C16.320.070;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;E04.726;C14.907.355.830
28550162,"Animals;Cell Cycle;Cell Division;Cell Proliferation;E2F Transcription Factors;Gene Expression Profiling;Hematopoietic Stem Cells;Homeostasis;Immunoblotting;Janus Kinase 2;Mice, Knockout;Mice, Transgenic;Phosphorylation;RNA Interference;Retinoblastoma Protein;Retinoblastoma-Like Protein p107;Retinoblastoma-Like Protein p130;Reverse Transcriptase Polymerase Chain Reaction;Suppressor of Cytokine Signaling 3 Protein;Thrombopoietin;Transcriptional Activation",B01.050;G04.144;G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500;G04.161.750;G07.345.249.410.750;D12.776.930.211;E05.393.332;A11.148.378;A11.872.378;A15.378.316.378;G07.410;E05.478.566.320;E05.601.470.320;D08.811.913.696.620.682.725.124.200;D12.776.476.393.200;D12.776.624.664.700.117;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G02.111.665;G02.607.780;G03.796;G05.308.203.374.790;D12.776.260.704;D12.776.624.776.745;D12.776.660.807;D12.776.744.770;D12.776.624.776.717;D12.776.660.770;D12.776.744.747;D12.776.624.776.735;D12.776.660.794;D12.776.744.755;E05.393.620.500.725;D12.644.360.024.374.750;D12.776.157.057.249.750;D12.776.476.024.437.750;D12.644.276.374.410.240.750;D12.776.395.240.750;D12.776.467.374.410.240.750;D23.529.374.410.240.750;G05.308.800
28549796,Adolescent;Adult;Cerebral Cortex;Child;Electroencephalography;Evoked Potentials;Human Development;Humans;Magnetic Resonance Imaging;Psychomotor Performance;Young Adult;Adolescent;Gyrus Cinguli,M01.060.057;M01.060.116;A08.186.211.200.885.287.500;M01.060.406;E01.370.376.300;E01.370.405.245;G07.265.216.500;G11.561.200.500;F01.525;G07.345.374;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;F02.808;G11.427.700;G11.561.660;M01.060.116.815;M01.060.057;A08.186.211.180.590.500;A08.186.211.200.885.287.500.382.500
28549783,"Adolescent;Alanine Transaminase;Anemia;Antibodies, Monoclonal;Antineoplastic Combined Chemotherapy Protocols;Camptothecin;Child;Child, Preschool;Dacarbazine;Disease-Free Survival;Fever;Ganglioneuroblastoma;Gene Amplification;Granulocyte-Macrophage Colony-Stimulating Factor;Humans;Hypokalemia;Hypoxia;Infant;Infection;Irinotecan;N-Myc Proto-Oncogene Protein;Neoplasm Recurrence, Local;Neuroblastoma;Neutropenia;Pain;Response Evaluation Criteria in Solid Tumors;Retreatment;Sirolimus;Survival Rate;Temozolomide;Thrombocytopenia",M01.060.057;D08.811.913.477.700.100;C15.378.071;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;E02.183.750.500;E02.319.077.500;E02.319.310.037;D03.132.151;M01.060.406;M01.060.406.448;D02.925.200;D03.383.129.308.240;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C23.888.119.344;C04.557.465.625.600.590.650.550.300;C04.557.470.670.590.650.550.300;C04.557.580.625.600.590.650.550.300;G05.308.250;G05.365.590.310;G05.558.315;D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375;B01.050.150.900.649.313.988.400.112.400.400;C18.452.950.565;C23.888.852.079;M01.060.703;C01.539;D03.132.151.425;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;C04.697.655;C23.550.727.655;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;C15.378.553.546.184.564;C23.888.592.612;F02.830.816.444;G11.561.790.444;E01.789.800.379;N04.761.559.590.800.569;N05.715.360.575.575.800.569;E02.887;D02.540.505.760;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D02.925.200.500;D03.383.129.308.240.500;C15.378.140.855
28549535,"Adolescent;Biomarkers;Blood Urea Nitrogen;Body Height;Child;Cohort Studies;Contrast Media;Creatinine;Cystatin C;Disease Progression;Glomerular Filtration Rate;Humans;Iohexol;Kidney Function Tests;Prognosis;Prospective Studies;Renal Insufficiency, Chronic;Severity of Illness Index;United States;Adolescent;Child;Iohexol",M01.060.057;D23.101;E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115;E01.370.600.115.100.160.100;E05.041.124.160.500;G07.100.100.160.100;G07.345.249.314.100;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D27.505.259.500;D27.720.259;D03.383.129.308.207;D12.776.215.300;C23.550.291.656;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;D02.241.223.100.400.880.400;D02.455.426.559.389.127.375.880.400;E01.370.390.400;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;Z01.107.567.875;M01.060.057;M01.060.406;D02.241.223.100.400.880.400;D02.455.426.559.389.127.375.880.400
28549516,Adolescent;Adult;Aged;Atrophy;Child;Cohort Studies;Cross-Sectional Studies;Disease Progression;Follow-Up Studies;Humans;Macular Degeneration;Middle Aged;Prospective Studies;Retina;Risk Factors;Vision Disorders;Visual Acuity;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;C23.300.070;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C11.768.585.439;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A09.371.729;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.597.751.941;C11.966;C23.888.592.763.941;E01.370.380.850.950;F02.463.593.932.901;G14.940;M01.060.116.815
28549184,"Amino Acid Sequence;Attachment Sites, Microbiological;Bacteriophages;Binding Sites;Cloning, Molecular;Crystallography, X-Ray;DNA, Bacterial;Escherichia coli;Gene Expression;Integrases;Kinetics;Listeria;Models, Molecular;Mutagenesis, Insertional;Protein Binding;Protein Conformation, alpha-Helical;Protein Interaction Domains and Motifs;Protein Multimerization;Recombinant Proteins;Recombination, Genetic;Sequence Alignment;Sequence Homology, Amino Acid;Serine;Substrate Specificity;Thermodynamics;Viral Proteins",G02.111.570.060;L01.453.245.667.060;G05.360.340.024.079;B04.123;G02.111.570.120;E05.393.220;E05.196.309.742.225;D13.444.308.212;B03.440.450.425.325.300;B03.660.250.150.180.100;G05.297;D08.811.739.500;G01.374.661;G02.111.490;B03.353.500.500;B03.510.100.500;B03.510.460.400.410.485;E05.599.595;E05.393.420.601.550;G05.365.590.575;G05.558.550;G02.111.679;G03.808;G02.111.570.820.709.600.020;G02.111.570.820.709.275.750.500;G02.111.694;D12.776.828;G05.728;E05.393.751;G02.111.810.200;G05.810.200;D12.125.154.800;G02.111.835;G01.906;D12.776.964
28549148,"Adolescent;Adrenal Cortex Hormones;Age Factors;Antineoplastic Agents;Child;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Immunosuppressive Agents;Invasive Fungal Infections;Leukemia, Myeloid, Acute;Neoplasms;Neutropenia;Risk Factors",M01.060.057;D06.472.040;N05.715.350.075;N06.850.490.250;D27.505.954.248;M01.060.406;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;C01.703.492;C04.557.337.539.275;C04;C15.378.553.546.184.564;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28549143,"Animals;Benzhydryl Compounds;Bile Acids and Salts;Dose-Response Relationship, Drug;Estrogens, Non-Steroidal;Liver;Mice;Phenols;Pregnancy;Prenatal Exposure Delayed Effects;Tryptophan",B01.050;D02.455.426.559.389.115;D04.210.500.105;G07.690.773.875;G07.690.936.500;D27.505.696.399.472.277.540;A03.620;B01.050.150.900.649.313.992.635.505.500;D02.455.426.559.389.657;G08.686.784.769;C13.703.824.500;D12.125.072.050.850;D12.125.142.875
28549024,"Academic Medical Centers;Adolescent;Child;Child, Preschool;Critical Illness;Hospital Mortality;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Ohio;Philadelphia;Prognosis;Retrospective Studies;Sepsis;Severity of Illness Index",N02.278.020;M01.060.057;M01.060.406;M01.060.406.448;C23.550.291.625;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;Z01.107.567.875.075.512;Z01.107.567.875.350.540;Z01.107.567.875.510.540;Z01.107.567.875.500.550.525;Z01.433.820;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.539.757;C23.550.470.790.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28548707,"Adolescent;Adult;Cell Cycle Proteins;Child;Child, Preschool;Chromosomal Proteins, Non-Histone;De Lange Syndrome;Exome;Humans;Infant;Infant, Newborn;Middle Aged;Netherlands;Proteins;Rett Syndrome;Spasms, Infantile;Young Adult;De Lange Syndrome;De Lange Syndrome;Rett Syndrome;Behavior;Self-Injurious Behavior",M01.060.057;M01.060.116;D12.776.167;M01.060.406;M01.060.406.448;D12.776.660.235;D12.776.664.235;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;G05.360.340.011;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.116.630;Z01.542.651;D12.776;C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937;C10.228.140.490.375.760;C10.228.140.490.493.875;M01.060.116.815;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937;F01.145;F01.145.126.980
28548586,"Allografts;Ankle Joint;Fractures, Stress;Humans;Pain Measurement;Prospective Studies;Talus;Transplantation, Homologous;Treatment Outcome;Visual Analog Scale;Allografts;Arthroscopy",A01.941.500;A02.835.583.378.062;C26.404.437;B01.050.150.900.649.313.988.400.112.400.400;E01.370.600.550.324;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A02.835.232.043.300.710.780;E04.936.864;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.928;A01.941.500;E01.370.388.250.070;E04.502.250.070;E04.555.113
28548184,"Adult;Body Mass Index;Child;Epidemics;Humans;Kidney Neoplasms;Nephrolithiasis;Obesity;Renal Insufficiency, Chronic;Risk Factors;Weight Gain",M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;N06.850.290.200;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C23.888.144.243.926;G07.345.249.314.120.200.926
28547317,"Acute Disease;Adolescent;Child;Diagnosis, Differential;Emergency Service, Hospital;Humans;Magnetic Resonance Imaging;Pelvic Pain;Adolescent;Child;Emergencies;Magnetic Resonance Imaging;Pelvis",C23.550.291.125;M01.060.057;M01.060.406;E01.171;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C23.888.592.612.944;M01.060.057;M01.060.406;C23.550.291.781;N06.230.100.083;N06.850.376;E01.370.350.825.500;A01.923.600
28546809,"Adolescent;Adult;Brain;Brain-Computer Interfaces;Hand;Humans;Imagination;Movement;Psychomotor Performance;Spectroscopy, Near-Infrared;Young Adult",M01.060.057;M01.060.116;A08.186.211;E07.305.076;A01.378.800.667;B01.050.150.900.649.313.988.400.112.400.400;F02.463.188.634;G07.568;G11.427.410;F02.808;G11.427.700;G11.561.660;E01.370.350.750;E05.196.867.851;M01.060.116.815
28546511,"Animals;Epithelial Cells;Gene Expression Regulation, Developmental;Homeostasis;Humans;Immunity, Cellular;Lung;Mice;Nuclear Proteins;RNA, Long Noncoding;Thyroid Nuclear Factor 1;Transcription Factors;Lung;Transcription Factors",B01.050;A11.436;G05.308.310;G07.410;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;A04.411;B01.050.150.900.649.313.992.635.505.500;D12.776.660;D13.444.735.790.375;D12.776.260.400.871;D12.776.660.823;D12.776.930.888;D12.776.930;A04.411;D12.776.930
28546439,"Adult;Databases, Factual;Diabetes Mellitus;Donor Selection;Humans;Kaplan-Meier Estimate;Kidney Transplantation;Middle Aged;Multivariate Analysis;Proportional Hazards Models;Risk Assessment;Risk Factors;Time Factors;Tissue Donors;Treatment Outcome;Waiting Lists;Confidence Intervals;Death;Follow-Up Studies;Humans;Tissue Donors;Tissue and Organ Procurement;Transplant Recipients;Waiting Lists;Diabetes Mellitus;Kidney Transplantation;Mortality;Tissue Donors;Transplant Recipients",M01.060.116;L01.313.500.750.300.188.400;L01.470.750.750;C18.452.394.750;C19.246;E04.936.537.500;N02.421.911.600;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.898;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N04.452.095.738;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;C23.550.260;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.898;N02.421.911;M01.925;N04.452.095.738;C18.452.394.750;C19.246;E02.870.500;E04.936.450.485;E04.950.774.400;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;M01.898;M01.925
28546380,"Airway Management;Child;Drainage, Postural;Humans;Neuromuscular Diseases;Respiration, Artificial;Respiratory Insufficiency;Noninvasive Ventilation;Sleep Apnea Syndromes",E02.041;M01.060.406;E02.309.221;E02.779.358;E02.831.535.358;E02.880.150;B01.050.150.900.649.313.988.400.112.400.400;C10.668;E02.041.625;E02.365.647.729;E02.880.820;C08.618.846;E02.041.625.591;E02.880.820.657;C08.618.085.852;C10.886.425.800.750
28546269,"Congresses as Topic;Consensus;Delphi Technique;Dyspnea;Europe;Evidence-Based Medicine;Health Policy;Hospitals;Humans;International Cooperation;Models, Theoretical;Pulmonary Medicine;Surveys and Questionnaires;Syndrome;United States",N03.540.199;F01.829.316.068;F02.463.785.373.433;L01.906.197;C08.618.326;C23.888.852.371;Z01.542;H02.249.750;H02.403.200.400;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;E05.599;H02.403.429.675;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.550.288.500;Z01.107.567.875
28546090,Adult;Aged;Antiviral Agents;Double-Blind Method;HIV Infections;HIV-1;Humans;Injections;Middle Aged;Pre-Exposure Prophylaxis;Pyridones;Young Adult,M01.060.116;M01.060.116.100;D27.505.954.122.388;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530;M01.060.116.630;N02.421.726.758.655;N06.850.780.680.655;D03.383.725.791;M01.060.116.815
28545784,"Animals;Arrhythmias, Cardiac;Death, Sudden, Cardiac;Diabetes Mellitus, Type 2;Heart Rate;Humans;Hypoglycemic Agents;Incidence;Ischemic Preconditioning, Myocardial;Sulfonylurea Compounds;KATP Channels;Arrhythmias, Cardiac;Epidemiology;Death, Sudden, Cardiac;Sulfonylurea Compounds",B01.050;C14.280.067;C23.550.073;C14.280.383.220;C23.550.260.322.250;C18.452.394.750.149;C19.246.300;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E02.592.325;E05.516.325;D02.886.590.795;D02.948.828;D12.776.157.530.400.600.450.550;D12.776.543.550.450.750.450.550;D12.776.543.585.400.750.450.550;C14.280.067;C23.550.073;H02.403.720.500;C14.280.383.220;C23.550.260.322.250;D02.886.590.795;D02.948.828
28545128,"Carboxypeptidases;Case-Control Studies;Cell Line, Tumor;Cell Proliferation;Chromosomes, Human, Pair 3;Chromosomes, Human, Pair 4;Gene Silencing;Homozygote;Humans;Neuroblastoma;Nuclear Proteins;Polymorphism, Single Nucleotide;Proteins",D08.811.277.656.350.245;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;A11.284.187.520.300.235.250;G05.360.162.520.300.235.250;A11.284.187.520.300.280.285;G05.360.162.520.300.280.285;G05.308.203.374;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D12.776.660;G05.365.795.598;D12.776
28544946,"Aged;Aged, 80 and over;Cohort Studies;Health Services Accessibility;Humans;Logistic Models;Medicare;Patient Acceptance of Health Care;Perception;United States;Aged;Medicare",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;F02.463.593;Z01.107.567.875;M01.060.116.100;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696
28544766,"Biomedical Research;Cooperative Behavior;Curriculum;Education, Medical, Graduate;Humans;Interinstitutional Relations;Mentors;Needs Assessment;Program Development;Qualitative Research;Research Personnel;Rheumatologists;Rheumatology",H01.770.644.145;F01.145.813.115;I02.158;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;N04.452.822.400;M01.395;I02.594;N03.349.380.565;N05.300.537;N04.452.760;H01.770.644.241.850;M01.526.839;M01.526.485.810.888;N02.360.810.888;H02.403.429.730
28544585,Cilia;Humans;Nasal Mucosa;Off-Label Use;Ophthalmic Solutions;Paranasal Sinuses;Anti-Bacterial Agents;Cilia;Ophthalmic Solutions;Sinusitis;Steroids;Therapeutics,A11.284.180.165;B01.050.150.900.649.313.988.400.112.400.400;A04.531.520;A04.760.600;A10.615.550.760.600;E02.319.307.500;D26.776.708.645;D27.505.954.578.645;D27.720.752.608;A04.531.621;D27.505.954.122.085;A11.284.180.165;D26.776.708.645;D27.505.954.578.645;D27.720.752.608;C08.460.692.752;C08.730.749;C09.603.692.752;D04.210.500;E02
28544570,Bacteria;Candida albicans;Microbial Sensitivity Tests;Nitric Oxide;Respiratory System;Microbiota;Nitric Oxide,B03;B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;A04;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
28544568,"Adolescent;Adult;Age of Onset;Depressive Disorder, Major;Educational Status;Follow-Up Studies;Health Status;Humans;Longitudinal Studies;Lupus Erythematosus, Systemic;Mental Health;Middle Aged;Prevalence;Prospective Studies;Risk Assessment;Risk Factors;Time Factors;Young Adult",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;F03.600.300.375;N01.824.196;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C17.300.480;C20.111.590;F02.418;N01.400.500;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.060.116.815
28544530,"Antimicrobial Cationic Peptides;Bacteriolysis;Calcium Signaling;Cell Growth Processes;Cells, Cultured;Chronic Disease;Cilia;Disease Progression;Endoscopy;Humans;Immunity, Innate;Nasal Polyps;Pseudomonas Infections;Pseudomonas aeruginosa;Quaternary Ammonium Compounds;Rhinitis;Sinusitis;Treatment Outcome;Sinusitis",D12.644.050;D12.776.543.695.054;G06.099.115;G02.111.820.800.100;G03.143.500.100;G04.835.800.100;G04.161;G07.345.249.410;A11.251;C23.550.291.500;A11.284.180.165;C23.550.291.656;E01.370.388.250;E04.502.250;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;C08.460.572;C09.603.557;C23.300.825.557;C01.252.400.739;B03.440.400.425.625.625.100;B03.660.250.580.590.050;D01.625.062.500;D02.092.877;D02.675.276;C08.460.799;C08.730.674;C09.603.799;C08.460.692.752;C08.730.749;C09.603.692.752;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.460.692.752;C08.730.749;C09.603.692.752
28544518,Class I Phosphatidylinositol 3-Kinases;Humans;Kidney Neoplasms;Mutation;Wilms Tumor,D08.811.913.696.620.500.100.100;D08.811.913.696.620.500.200.100;D12.776.476.162;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;G05.365.590;C04.557.435.595;C04.588.945.947.535.585;C04.700.900;C12.758.820.750.585;C12.777.419.473.585;C13.351.937.820.535.585;C13.351.968.419.473.585;C16.320.700.900
28544305,"Disease Susceptibility;Disorders of Sex Development;Gonads;Humans;Neoplasms, Germ Cell and Embryonal;Risk Factors;Sexual Development;Neoplasms, Germ Cell and Embryonal;Gonadoblastoma",C23.550.291.687;G07.100.250;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119;A05.360.576;A06.300.312;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G07.345.750;G08.686.841;C04.557.465;C04.557.465.420;C04.557.475.395;C12.706.316.096.687.500;C12.706.316.309.388.500;C13.351.875.253.096.687.500;C13.351.875.253.309.388.500;C16.131.939.316.096.687.500;C16.131.939.316.309.388.500;C19.391.119.096.687.500;C19.391.119.309.388.500
28544027,"Arthrogryposis;Cholestasis;Fatal Outcome;Humans;Infant, Newborn;Mutation;Renal Insufficiency;Vesicular Transport Proteins",C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;C06.130.120.135;E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;G05.365.590;C12.777.419.780;C13.351.968.419.780;D12.776.543.990
28543773,"Antiviral Agents;Astrocytes;Cells, Cultured;Cohort Studies;Cysteine Proteinase Inhibitors;Fetus;HIV Infections;Heme Oxygenase-1;Humans;Interferon-gamma;Leupeptins;Lipopolysaccharides;NAD(P)H Dehydrogenase (Quinone);Prefrontal Cortex;Proteasome Endopeptidase Complex;RNA;Time Factors;Hand",D27.505.954.122.388;A08.637.200;A11.650.200;A11.251;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D27.505.519.389.745.325;A16.378;C02.782.815.616.400;C02.800.801.400;C20.673.480;D08.811.682.690.708.410.500;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.456.580;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;D08.811.682.608.800.500;A08.186.211.200.885.287.500.270.700;D05.500.562.500;D08.811.277.656.918;D08.811.600.730;D13.444.735;G01.910.857;A01.378.800.667
28543215,Adult;Case-Control Studies;Cohort Studies;HIV Infections;Heart Failure;Humans;Liver Cirrhosis;Middle Aged;Severity of Illness Index,M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;C06.552.630;M01.060.116.630;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28542918,"Bacteremia;Child;Child, Preschool;Datasets as Topic;Febrile Neutropenia;Gram-Negative Bacterial Infections;Humans;Immunocompromised Host;Models, Statistical;Neoplasms;Predictive Value of Tests;Retrospective Studies;Risk;Staphylococcal Infections;Staphylococcus aureus;Uncertainty;Febrile Neutropenia;Health Services Research",C01.252.100;C01.539.757.100;C23.550.470.790.500.100;M01.060.406;M01.060.406.448;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;C15.378.553.546.184.564.750;C01.252.400;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;C04;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C01.252.410.868;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;E05.318.740.600.900;F02.463.785.373.820;G17.680.875;N05.715.360.750.625.850;N06.850.520.830.600.900;C15.378.553.546.184.564.750;H01.770.644.145.360;N03.349.380;N05.425
28542697,"Disease Progression;Electroretinography;Europe;Fluorescein Angiography;Follow-Up Studies;Forecasting;Fundus Oculi;Humans;Incidence;Macular Degeneration;Ophthalmoscopy;Retinal Pigment Epithelium;Retrospective Studies;Tomography, Optical Coherence;United States;Visual Acuity;Young Adult",C23.550.291.656;E01.370.380.225;E01.370.405.270;Z01.542;E01.370.370.050.350;E01.370.380.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;I01.320;A09.371.729.313;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C11.768.585.439;E01.370.380.560;A09.371.670.500;A09.371.729.887;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;Z01.107.567.875;E01.370.380.850.950;F02.463.593.932.901;G14.940;M01.060.116.815
28542628,"Cryoelectron Microscopy;Escherichia coli;Peptide Chain Termination, Translational;Peptide Elongation Factor G;Peptide Termination Factors;Prokaryotic Initiation Factor-3;RNA, Messenger;RNA, Transfer;Ribosomal Proteins;Ribosomes",E01.370.350.515.402.150;E05.595.402.150;B03.440.450.425.325.300;B03.660.250.150.180.100;G02.111.660.871.720;G03.734.871.720;D08.811.277.040.330.300.100.200;D12.776.157.325.150.200;D12.776.835.700.350.200;D12.776.835.862;D12.776.835.725.934.750;D13.444.735.544;D13.444.735.757;D12.776.835;A11.284.430.214.190.875.811
28542444,"Aged;Alzheimer Disease;Amyloid;Amyloid beta-Peptides;Aniline Compounds;Brain;Cognition;Cognition Disorders;Dementia;Ethylene Glycols;Humans;Middle Aged;Parkinson Disease;Plaque, Amyloid;Positron-Emission Tomography",M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D02.092.146;A08.186.211;F02.463.188;F03.615.250;C10.228.140.380;F03.615.400;D02.033.455.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C23.300.821;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399
28541969,Adolescent;Autism Spectrum Disorder;Humans;Sex Education;Sex Offenses;Sexual Behavior;Social Behavior,M01.060.057;F03.625.164.113;B01.050.150.900.649.313.988.400.112.400.400;F04.096.837.500;I02.233.332.749;I01.198.240.748;F01.145.802;F01.145.813
28541807,Anemia;Antibiotic Prophylaxis;Biomedical Research;Clinical Trials as Topic;Glycated Hemoglobin A;Humans;Obesity;Surgical Wound Infection;Anemia;Antibiotic Prophylaxis;Guideline;Surgical Wound Infection,C15.378.071;E02.319.162.150;E02.319.703.150;H01.770.644.145;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C01.539.947.692;C23.550.767.925;C15.378.071;E02.319.162.150;E02.319.703.150;V02.515;C01.539.947.692;C23.550.767.925
28541519,"Animals;DNA-Binding Proteins;Drosophila Proteins;Drosophila melanogaster;Eukaryotic Initiation Factor-2;Heat-Shock Proteins;Phosphorylation;RNA Splicing;Signal Transduction;Sleep;Social Isolation;Stress, Physiological;Unfolded Protein Response;Up-Regulation;Drosophila;Sleep;Social Isolation",B01.050;D12.776.260;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;D12.776.835.725.868.249;D12.776.580.216;G02.111.665;G02.607.780;G03.796;G02.111.760.700;G03.839.700;G05.308.700.700;G02.111.820;G04.835;F02.830.855;G11.561.803;F01.145.813.781;I01.880.853.748;G07.775;G02.111.660.871.790.600.962;G02.111.691.600.850;G03.734.871.790.600.850;G05.308.670.600.850;G02.111.905;G05.308.850;G07.690.773.998;B01.050.500.131.617.720.500.500.750.310.250;F02.830.855;G11.561.803;F01.145.813.781;I01.880.853.748
28541508,"Adolescent;Caregivers;Child;Continuous Positive Airway Pressure;Humans;Patient Compliance;Self Efficacy;Self Report;Sleep Apnea, Obstructive;Surveys and Questionnaires;Child",M01.060.057;M01.085;M01.526.485.200;N02.360.200;M01.060.406;E02.041.625.790.259;E02.880.820.790.259;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;F01.752.747.792.700;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;C08.618.085.852.850;C10.886.425.800.750.850;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.406
28541463,,
28541158,"Adult;Blood Flow Velocity;Blood Pressure;Cerebrovascular Circulation;Craniocerebral Trauma;Healthy Volunteers;Humans;Intracranial Pressure;Microvessels;Models, Biological;Monitoring, Physiologic;Optical Imaging;Sensitivity and Specificity;Spectrum Analysis;Ultrasonography, Doppler, Transcranial;Arterioles",M01.060.116;E01.370.370.130;G09.330.380.630.080;E01.370.600.875.249;G09.330.380.076;G09.330.100.159;C10.900.300;C26.915.300;M01.774.500;M01.955.236;B01.050.150.900.649.313.988.400.112.400.400;G11.561.170.505;A07.015.461;E05.599.395;E01.370.520;E01.370.350.589;E05.642;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.196.867;E01.370.350.578.937.260.850;E01.370.350.700.560.260.850;E01.370.350.850.260.850;E01.370.350.850.850.870;E01.370.376.537.750.260.850;E05.629.937.260.850;A07.015.114.060;A07.015.461.080
28540671,"Biomarkers, Tumor;Combined Modality Therapy;Disease Management;Genomics;Humans;Mycosis Fungoides;Prognosis;Sezary Syndrome;Skin Neoplasms;Treatment Outcome",D23.101.140;E02.186;N04.590.607;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480.750.800.550;C15.604.515.569.480.750.800.550;C20.683.515.761.480.750.800.550;E01.789;C04.557.386.480.750.800.775;C15.604.515.569.480.750.800.775;C15.604.515.841;C20.683.515.761.480.750.800.775;C20.683.515.920;C04.588.805;C17.800.882;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28540525,"Chromosomes, Human, Pair 22;DiGeorge Syndrome;Humans;Immunophenotyping;In Situ Hybridization, Fluorescence;Infant, Newborn;Lymphocyte Count;Neonatal Screening;Retrospective Studies;Segmental Duplications, Genomic;Severe Combined Immunodeficiency;DiGeorge Syndrome;Neonatal Screening",A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;M01.060.703.520;E01.370.225.500.195.107.595.500;E01.370.225.625.107.595.500;E05.200.500.195.107.595.500;E05.200.625.107.595.500;E05.242.195.107.595.500;G04.140.107.595.500;G09.188.105.595.500;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G02.111.570.080.708.565;G05.360.080.708.565;C16.614.815;C18.452.284.800;C20.673.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580
28540343,Mental Health;Social Networking,F02.418;N01.400.500;L01.143.910
28540218,,
28540195,Child;Critical Care;Methadone,M01.060.406;E02.760.190;N02.421.585.190;D02.522.675
28540059,"Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28539799,Blindness,C10.597.751.941.162;C11.966.075;C23.888.592.763.941.162
28539185,Agammaglobulinemia;Bronchiectasis;Humans;Immunoglobulins,C15.378.147.142;C15.604.515.032;C20.673.088;C08.127.384;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
28538746,Hidradenitis Suppurativa;Humans;Drug Therapy;Hidradenitis Suppurativa,C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320;B01.050.150.900.649.313.988.400.112.400.400;E02.319;C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320
28538625,Adult;Aged;Hospital Mortality;Humans;Middle Aged;Pennsylvania;Registries;Retrospective Studies;Trauma Centers;Trauma Severity Indices;Treatment Failure;Wounds and Injuries,M01.060.116;M01.060.116.100;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;E05.318.308.940.968.875;E05.944;N04.452.859.564.800;N05.715.360.300.715.500.800;N06.850.520.308.940.968.875;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;C26
28538588,Child;Cleft Lip;Cleft Palate;Humans,M01.060.406;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;B01.050.150.900.649.313.988.400.112.400.400
28538184,"Aminopyridines;Animals;Antineoplastic Agents;Benzazepines;Bridged-Ring Compounds;Carboplatin;Carcinoma, Non-Small-Cell Lung;Cell Line, Tumor;Disease-Free Survival;Drug Resistance, Neoplasm;Enzyme Inhibitors;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Histones;Humans;Hydrazones;Jumonji Domain-Containing Histone Demethylases;Lung Neoplasms;Methylation;Mice;Neoadjuvant Therapy;Pyrimidines;Taxoids;Transcription, Genetic;Drug Resistance;Histone Demethylases;Lung Neoplasms",D02.092.080;D03.383.725.050;B01.050;D27.505.954.248;D03.633.100.079;D02.455.426.100;D04.075;D02.691.800.338;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;A11.251.210.190;A11.251.860.180;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;G07.690.773.984.395;D27.505.519.389;E05.393.332;G05.308.370;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;D02.442.288;D08.811.682.662.582.475.500;D08.811.682.690.416.388;C04.588.894.797.520;C08.381.540;C08.785.520;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.150.900.649.313.992.635.505.500;E02.186.450;D03.383.742;D02.455.426.392.368.242.888;D02.455.849.291.850;G02.111.873;G05.297.700;G07.690.773.984;D08.811.682.662.582.475;C04.588.894.797.520;C08.381.540;C08.785.520
28538136,"Aged;Angiopoietin-like Proteins;Angiopoietins;Animals;Antibodies, Monoclonal;Atherosclerosis;Cardiovascular Diseases;Coronary Artery Disease;Disease Models, Animal;Dose-Response Relationship, Drug;Double-Blind Method;Dyslipidemias;Humans;Lipid Metabolism;Lipids;Mice;Mice, Inbred Strains;Middle Aged;Mutation",M01.060.116.100;D12.644.276.100.050;D12.776.467.100.050;D23.529.100.050;D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100;B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;C14.907.137.126.307;C14;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C22.232;E05.598.500;E05.599.395.080;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;C18.452.584.500;B01.050.150.900.649.313.988.400.112.400.400;G03.458;D10;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520;B01.050.150.900.649.313.992.635.505.500.400;M01.060.116.630;G05.365.590
28538134,"Adolescent;Anticonvulsants;Cannabidiol;Child;Child, Preschool;Double-Blind Method;Epilepsies, Myoclonic;Fatigue;Humans;Liver;Liver Function Tests;Seizures",M01.060.057;D27.505.954.427.080;D02.455.849.090.100;M01.060.406;M01.060.406.448;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;C10.228.140.490.375.130;C10.228.140.490.493.063;C23.888.369;B01.050.150.900.649.313.988.400.112.400.400;A03.620;E01.370.372.460;C10.597.742;C23.888.592.742
28538042,"Cross-Over Studies;Developmental Disabilities;Humans;Infant;Infant, Premature;Neuropsychological Tests;Severity of Illness Index",E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520.520;F04.711.513;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28538024,"Adult;Anxiety Disorders;Depressive Disorder, Major;Double-Blind Method;Humans;Randomized Controlled Trials as Topic;Serotonin Uptake Inhibitors;Suicidal Ideation;Suicide, Attempted;Vilazodone Hydrochloride;Young Adult",M01.060.116;F03.080;F03.600.300.375;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.980.875.600;I01.880.735.856.600;D03.383.606.980;D03.633.100.127.818;D03.633.100.473.957;M01.060.116.815
28537979,"Anesthesia, Dental;Anesthesiology;Computer Systems;Humans",E03.155.141;E06.045;H02.403.066;L01.224.230;B01.050.150.900.649.313.988.400.112.400.400
28537553,"Aging;Animals;Behavior, Animal;Caenorhabditis elegans;Longitudinal Studies;Optical Imaging;Parasitology;Phenotype;Aging;Behavior;Chromosomes;Genes;Longevity;Neurosciences",G07.345.124;B01.050;F01.145.113;B01.050.500.500.294.400.875.660.250.250;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.589;E05.642;H01.158.273.688;G05.695;G07.345.124;F01.145;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;G05.360.340.024.340;G07.345.124.519;G07.540;H01.158.610
28537500,Disasters;Humans;Nuclear Power Plants;Potassium Iodide;Radioactive Hazard Release;Thyroid Gland;United States;Nuclear Power Plants;Potassium Iodide,N06.230.100;B01.050.150.900.649.313.988.400.112.400.400;E07.710.600.500;J01.780.600;J03.540.680.600;D01.475.410.700;D01.745.680;N06.850.135.848;A06.300.900;Z01.107.567.875;E07.710.600.500;J01.780.600;J03.540.680.600;D01.475.410.700;D01.745.680
28536854,"Data Mining;Databases, Factual;Health Services Research;Humans;Orthopedic Procedures;Orthopedics",L01.313.500.750.280.199;L01.470.625;L01.313.500.750.300.188.400;L01.470.750.750;H01.770.644.145.360;N03.349.380;N05.425;B01.050.150.900.649.313.988.400.112.400.400;E02.718;E04.555;H02.403.810.494
28536810,"Adolescent;Analgesics, Non-Narcotic;Analgesics, Opioid;Anti-Inflammatory Agents;Anticonvulsants;Antidepressive Agents;Cognitive Behavioral Therapy;Exercise Therapy;Fibromyalgia;Humans;Neuromuscular Agents;Pain;Pain Management;Syndrome",M01.060.057;D27.505.696.663.850.014.040;D27.505.954.427.040.100;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;D27.505.954.158;D27.505.954.427.080;D27.505.954.427.700.122;F04.754.137.350;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;C05.651.324;C05.799.321;C10.668.491.425;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.663.700;C23.888.592.612;F02.830.816.444;G11.561.790.444;E02.745;N04.590.607.500;C23.550.288.500
28536741,HIV;Mental Disorders;Root Cause Analysis;Treatment Adherence and Compliance,B04.820.650.589.650.350;F03;N05.715.360.700;F01.100.150.750;F01.145.488.887;N05.300.150.800
28536513,gamma-Aminobutyric Acid;Parkinson Disease;Dopamine;Humans;Neurons;Substantia Nigra,D02.241.081.114.500.350;D12.125.190.350;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;B01.050.150.900.649.313.988.400.112.400.400;A08.675;A11.671;A08.186.211.132.659.413.656
28536180,"CCCTC-Binding Factor;Cell Differentiation;Cell Line;Chromatin;Chromatin Assembly and Disassembly;Enhancer Elements, Genetic;Genome-Wide Association Study;Human Embryonic Stem Cells;Humans;Neural Stem Cells;YY1 Transcription Factor",D12.776.157.687.157;D12.776.260.120;D12.776.660.235.050;D12.776.660.720.157;D12.776.664.235.050;D12.776.930.780.563;G04.152;A11.251.210;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;A11.872.700.250.750;B01.050.150.900.649.313.988.400.112.400.400;A11.872.653;D12.776.260.235.875;D12.776.930.216.875
28535802,"Adult;Aged;Aged, 80 and over;Animals;Cadherins;Cell Movement;Cell Proliferation;Cohort Studies;Colorectal Neoplasms;Epithelial-Mesenchymal Transition;Gene Expression Regulation, Neoplastic;Genetic Loci;HCT116 Cells;Humans;Leukemia, Lymphocytic, Chronic, B-Cell;MicroRNAs;Middle Aged;Neoplasm Invasiveness;Neoplasm Staging;Nucleotide Motifs;RNA, Long Noncoding;RNA, Messenger;Survival Analysis;Transcription, Genetic;Zinc Finger E-box-Binding Homeobox 1;RNA, Untranslated;RNA, Long Noncoding",M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;G04.356.500;G05.308.370;G05.360.340.024.380;A11.251.210.190.380;A11.251.860.180.380;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.080.125;C15.604.515.560.080.125;C20.683.515.528.080.125;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;M01.060.116.630;C04.697.645;C23.550.727.645;E01.789.625;G02.111.570.080.611;G02.111.570.820.486.662;G05.360.080.611;G05.360.580.662;D13.444.735.790.375;D13.444.735.544;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G02.111.873;G05.297.700;D12.776.260.400.906;D12.776.260.703.800;D12.776.930.780.945;D13.444.735.790;D13.444.735.790.375
28535084,Antineoplastic Combined Chemotherapy Protocols;Asparaginase;Central Nervous System Neoplasms;Cerebrospinal Fluid;Child;Clinical Trials as Topic;Cranial Irradiation;Dexamethasone;Disease-Free Survival;Erythrocyte Count;Humans;Leucovorin;Leukocyte Count;Methotrexate;Polyethylene Glycols;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Prednisone;Risk Factors;Survival Rate,E02.183.750.500;E02.319.077.500;E02.319.310.037;D08.811.277.087.116;C04.588.614.250;C10.551.240;A12.207.270.210;M01.060.406;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;E02.815.190;D04.210.500.745.432.769.344;D04.210.500.908.238;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E01.370.225.500.195.107.330;E01.370.225.625.107.330;E05.200.500.195.107.330;E05.200.625.107.330;E05.242.195.107.330;G04.140.107.330;G09.188.105.330;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.733.631.400.800.350.450;D08.211.840.300.500;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;D03.633.100.733.631.192.500;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D04.210.500.745.432.719.702;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
28534416,"Asbestos;Biomarkers, Tumor;Blood Chemical Analysis;Case-Control Studies;Environmental Exposure;Humans;Lipids;Mesothelioma;Statistics as Topic;Passive Cutaneous Anaphylaxis;Mesothelioma",D01.578.725.050;D01.837.725.700.760.070;D23.101.140;E01.370.225.124.100;E05.200.124.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;D10;C04.557.470.035.510;C04.557.470.660.510;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;E01.370.225.812.871.600;E05.200.812.871.600;E05.478.594.890.600;G12.122.754;C04.557.470.035.510;C04.557.470.660.510
28534237,Autism Spectrum Disorder;Child;Cognitive Behavioral Therapy;Feeding and Eating Disorders;Humans;Program Development;Autism Spectrum Disorder;Cognitive Behavioral Therapy,F03.625.164.113;M01.060.406;F04.754.137.350;F03.400;B01.050.150.900.649.313.988.400.112.400.400;N04.452.760;F03.625.164.113;F04.754.137.350
28534048,CADASIL;Peru;South America;Smell;Stroke,C10.228.140.300.275.249;C10.228.140.300.400.203;C10.228.140.300.510.200.175;C10.228.140.380.230.124;C14.907.253.329.249;C14.907.253.560.200.175;C16.320.129;Z01.107.757.702;Z01.107.757;F02.830.816.643;G11.561.790.643;C10.228.140.300.775;C14.907.253.855
28533393,"Adenosine Triphosphate;Avidin;Biophysical Phenomena;Biotin;Cytoplasmic Dyneins;Humans;Microscopy, Fluorescence;Microtubules;Molecular Dynamics Simulation;Molecular Motor Proteins;Nanotubes;Protein Structure, Quaternary;Recombinant Proteins;Rotation;Dyneins;Molecular Dynamics Simulation",D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;D12.776.034.614.300;D12.776.256.317.663.300;D12.776.290.663.100;D12.776.395.175;G01.154;D03.383.129.308.080;D08.211.096;D08.811.277.040.025.193.249.750;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.458;E05.595.458;A11.284.430.214.190.750.602;E05.599.595.500;G02.111.570.895;L01.224.160.500;D05.500.500;D08.811.277.040.025.193;J01.637.512.850;G02.111.570.820.709.550;D12.776.828;G01.482.703;D08.811.277.040.013.500.063;D08.811.277.040.025.024.063;D08.811.277.040.025.193.249;D12.776.157.025.750.063;D12.776.220.600.200;E05.599.595.500;G02.111.570.895;L01.224.160.500
28533135,"Amino Acid Substitution;Child;Cysteine;Deamino Arginine Vasopressin;Disulfides;Humans;Mass Spectrometry;Mutant Proteins;Mutation, Missense;Platelet Aggregation;Platelet Glycoprotein GPIb-IX Complex;Plethysmography, Impedance;Surface Plasmon Resonance;Thrombocytopenia;von Willebrand Factor;von Willebrand Diseases;von Willebrand Factor",E05.393.420.601.035;G05.558.109;M01.060.406;D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230;D06.472.699.631.692.781.100.250;D12.644.400.900.100.250;D12.644.456.925.100.250;D12.644.548.691.692.781.100.250;D12.776.631.650.937.100.250;D01.248.497.158.874.390;D01.875.350.850.150;D02.886.520.150;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;D12.776.602;G05.365.590.650;G09.188.370.687;G09.188.390.600.640;D12.776.395.550.625.460;D12.776.543.550.625.460;D12.776.543.750.705.675.568;E01.370.370.610.610;E01.370.405.610;E05.196.890;E05.601.043.700;C15.378.140.855;D12.776.124.125.920;D23.119.985;C15.378.100.100.900;C15.378.100.141.900;C15.378.140.900;C15.378.463.920;C16.320.099.920;D12.776.124.125.920;D23.119.985
28533129,,
28532983,"Biomedical Research;Congresses as Topic;Fontan Procedure;Goals;Heart Defects, Congenital;Humans;Internationality;Intersectoral Collaboration;Quality of Life;Treatment Outcome",H01.770.644.145;N03.540.199;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;F01.658.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;I01.615;N04.226;I01.800;K01.752.400.750;N06.850.505.400.425.837;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28532892,Association;Attitude of Health Personnel;Health Personnel;Health Services Research;Healthcare Disparities;Humans;Physician-Patient Relations;Psychological Tests;Racism;Health Personnel,F02.463.425.069;F04.754.720.346;F01.100.050;N05.300.100;M01.526.485;N02.360;H01.770.644.145.360;N03.349.380;N05.425;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.650.675;N05.300.660.625;F04.711;F01.145.813.550.500;F01.145.813.629.625;F01.829.595.500;I01.880.735.820.500.500;M01.526.485;N02.360
28532637,"Acidosis;Aged;Biomarkers;Canagliflozin;Diabetes Mellitus, Type 2;Humans;Hypoglycemic Agents;Kidney Tubules, Proximal;Sodium-Glucose Transporter 2",C18.452.076.176;M01.060.116.100;D23.101;D02.886.778.075;D03.383.903.075;D09.408.348.113;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;A05.810.453.736.560.570;D12.776.157.530.450.625.437.750;D12.776.157.530.500.750.750;D12.776.157.530.937.700;D12.776.543.585.450.625.562.750;D12.776.543.585.500.750.750;D12.776.543.585.937.825
28532625,Animals;DNA Damage;Humans;Immunity;V(D)J Recombination;V(D)J Recombination,B01.050;G05.200;B01.050.150.900.649.313.988.400.112.400.400;G12.450;G05.344.900;G05.728.932;G05.344.900;G05.728.932
28532207,"Biomedical Research;Biostatistics;Data Interpretation, Statistical;Disease Management;Eye Diseases;Humans",H01.770.644.145;E05.318.740.237;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;N04.590.607;C11;B01.050.150.900.649.313.988.400.112.400.400
28531909,African Americans;Aged;Colonic Polyps;Colonoscopy;Colorectal Neoplasms;Early Detection of Cancer;European Continental Ancestry Group;Follow-Up Studies;Healthcare Disparities;Humans;Incidence;Medicare;Risk Factors;United States,M01.686.508.100.100;M01.686.754.100;M01.060.116.100;C23.300.825.411.235;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E01.390.500;M01.686.508.400;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875
28531242,Accountable Care Organizations;Ambulatory Care;Coronary Artery Bypass;Episode of Care;Fee-for-Service Plans;Hospital Costs;Humans;Medicare;Myocardial Infarction;Patient Discharge;Reimbursement Mechanisms;Surgicenters;Time Factors;United States,N05.300.380.500;E02.760.106;N02.421.585.106;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E02.760.300;N02.421.585.300;N03.219.442.195;N03.219.521.710.305.090;N04.452.758.745.225;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;C14.280.647.500;C14.907.585.500;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;N03.219.521.710.305;N02.278.035.652;N02.278.421.556.868;G01.910.857;Z01.107.567.875
28530674,"Arteries;Atherosclerosis;Cell Adhesion;Chemotaxis, Leukocyte;Coronary Artery Disease;Energy Metabolism;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Histone Code;Humans;Muscle, Smooth, Vascular;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Risk Factors",A07.015.114;C14.907.137.126.307;G04.022;G04.198.424.233;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;G03.295;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;G02.111.570.060.360;G05.360.360;B01.050.150.900.649.313.988.400.112.400.400;A02.633.570.491;A07.015.733.500;A10.690.467.491;G05.365.795.598;G05.360.340.024.380.937;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28530141,"Child;Chronic Disease;Clinical Decision-Making;Home Care Services;Humans;Physicians;Respiration, Artificial;Respiratory Insufficiency;Ventilators, Mechanical;Child;Respiration",M01.060.406;C23.550.291.500;E01.055;N02.421.143.524;N02.421.539.089;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;E02.041.625;E02.365.647.729;E02.880.820;C08.618.846;E07.950;M01.060.406;G09.772.705
28529898,Immunotherapy;Radiotherapy,E02.095.465.425;E02.815
28529897,Immunotherapy;Radiotherapy,E02.095.465.425;E02.815
28529894,Immunotherapy,E02.095.465.425
28528705,Causality;Community-Acquired Infections;Confounding Factors (Epidemiology);Hip Fractures;Humans;Observational Studies as Topic;Pneumonia;Proton Pump Inhibitors;Research Design;Gastroesophageal Reflux,N05.715.350.200;N06.850.490.625;C01.539.234;N05.715.350.240;N06.850.490.718;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.500;N05.715.360.330.250.500;N06.850.520.450.250.500;C08.381.677;C08.730.610;D27.505.519.389.848;E05.581.500;H01.770.644.728;C06.405.117.119.500.484
28527315,Age of Onset;Aged;Brain Mapping;Dementia;Gray Matter;Humans;Language Disorders;Linguistics;Longitudinal Studies;Magnetic Resonance Imaging;Middle Aged;Motor Cortex;Narration;Neuropsychological Tests;Parkinson Disease;Speech;Language;Longitudinal Studies;Parkinson Disease;Speech,N05.715.350.075.100;N06.850.490.250.100;M01.060.116.100;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;C10.228.140.380;F03.615.400;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.150.500;C23.888.592.604.150.500;L01.559.598;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;M01.060.116.630;A08.186.211.200.885.287.500.270.548;A08.186.211.200.885.287.500.814.624;E05.318.308.502;F01.145.209.459;L01.399.250.660;N05.715.360.300.480;N06.850.520.308.502;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F01.145.209.908.677;G11.561.812;L01.559.423.676;F01.145.209.399;L01.559;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F01.145.209.908.677;G11.561.812;L01.559.423.676
28527097,Adolescent;Autism Spectrum Disorder;Case-Control Studies;Child;Cognition;Executive Function;Humans;Psychological Tests;Social Behavior;Autism Spectrum Disorder;Child;Executive Function;Pliability,M01.060.057;F03.625.164.113;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;F02.463.188;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F04.711;F01.145.813;F03.625.164.113;M01.060.406;F02.463.217;G01.374.705
28526800,"Aged;Antacids;Gastroesophageal Reflux;Histamine H2 Antagonists;Humans;Linear Models;Lung Diseases, Interstitial;Middle Aged;Multivariate Analysis;Proton Pump Inhibitors;Risk Factors",M01.060.116.100;D27.505.519.170;D27.505.954.483.080;C06.405.117.119.500.484;D27.505.519.625.375.425.425;D27.505.696.577.375.425.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;C08.381.483;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;D27.505.519.389.848;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28526779,"Atypical Hemolytic Uremic Syndrome;Child, Preschool;DNA Mutational Analysis;Diacylglycerol Kinase;Glomerulonephritis, Membranoproliferative;Humans;Incidence;Infant;Lithuania;Phenotype;Atypical Hemolytic Uremic Syndrome;Glomerulonephritis, Membranoproliferative;Thrombotic Microangiopathies",C12.777.419.936.463.500;C13.351.968.419.936.463.500;C15.378.071.141.610.500;C15.378.140.855.925.500.500;M01.060.406.448;E05.393.760.700.300;D08.811.913.696.620.200;C12.777.419.570.363.615;C13.351.968.419.570.363.615;C20.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;Z01.542.248.136.580;G05.695;C12.777.419.936.463.500;C13.351.968.419.936.463.500;C15.378.071.141.610.500;C15.378.140.855.925.500.500;C12.777.419.570.363.615;C13.351.968.419.570.363.615;C20.425;C15.378.140.855.925
28526371,"Adolescent;Crime Victims;Emergency Service, Hospital;Hospitals, Urban;Humans;Retrospective Studies;Risk Factors;Stress, Psychological;Violence;Wounds and Injuries;Adolescent;Crime Victims;Mental Health;Violence",M01.060.057;M01.135;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;N02.278.421.660;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.990;F02.830.900;I01.198.240.856;I01.880.735.900;C26;M01.060.057;M01.135;F02.418;N01.400.500;I01.198.240.856;I01.880.735.900
28526330,"AIDS Vaccines;Adolescent;Adult;Clinical Trials, Phase II as Topic;Disease Transmission, Infectious;HIV Infections;Homosexuality, Male;Humans;Middle Aged;Patient Selection;Philadelphia;Retrospective Studies;Social Media;Young Adult;Social Media",D20.215.894.899.050;M01.060.057;M01.060.116;E05.318.372.250.250.210;N05.715.360.330.250.250.210;N06.850.520.450.250.250.210;N06.850.310;C02.782.815.616.400;C02.800.801.400;C20.673.480;F01.145.802.975.500.600;G08.686.867.500.600;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.581.500.653;N04.590.731;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;L01.178.751;L01.224.230.110.500.750;M01.060.116.815;L01.178.751;L01.224.230.110.500.750
28526327,,
28526220,"Cohort Studies;Emergency Service, Hospital;Fever;Humans;Incidence;Infant;Meningitis, Bacterial;Registries;Retrospective Studies;Spinal Puncture;Spinal Puncture;Quality of Health Care",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;C23.888.119.344;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;C01.252.200.500;C10.228.228.180.500;C10.228.614.280;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.225.998.054.790;E01.370.376.700;E02.800.779;E04.074.790;E04.665.700;E05.200.998.054.790;E01.370.225.998.054.790;E01.370.376.700;E02.800.779;E04.074.790;E04.665.700;E05.200.998.054.790;N04.761;N05.715
28525723,"Adult;Age Factors;Aged;Chest Pain;Choice Behavior;Continental Population Groups;Decision Making;Decision Support Techniques;Health Knowledge, Attitudes, Practice;Health Literacy;Humans;Middle Aged;Patient Acceptance of Health Care;Patient Participation;Sex Factors;Socioeconomic Factors;Trust;Acute Coronary Syndrome;Decision Making;Healthcare Disparities",M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;C23.888.592.612.233;F02.463.785.373.346;M01.686.508;F02.463.785.373;E05.245;L01.313.500.750.190;F01.100.150.500;N05.300.150.410;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;N05.715.350.675;N06.850.490.875;I01.880.853.996;N01.824;F01.829.401.825;C14.280.647.124;C14.907.585.124;F02.463.785.373;N04.590.374.380;N05.300.493
28525450,"3-Iodobenzylguanidine;Child, Preschool;Fluorodeoxyglucose F18;Humans;Neuroblastoma;Positron Emission Tomography Computed Tomography;Soft Tissue Neoplasms",D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;M01.060.406.448;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;C04.588.839
28525404,"Adolescent;Child;Dwarfism, Pituitary;Growth Disorders;Hearing Loss, Sensorineural;Human Growth Hormone;Humans;Insulin-Like Growth Factor I;Practice Guidelines as Topic;United States",M01.060.057;M01.060.406;C05.116.099.343.445;C05.116.132.358;C10.228.140.617.738.300.300;C19.297.312;C19.700.482.311;C23.550.393;C09.218.458.341.887;C10.597.751.418.341.887;C23.888.592.763.393.341.887;D06.472.699.631.525.425.875;D12.644.548.691.525.425.875;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400;N04.761.700.350.650;N05.700.350.650;Z01.107.567.875
28525369,Humans;Hypertension;Middle Aged;Resistin;Risk Factors;Hypertension;Meta-Analysis;Resistin,B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;M01.060.116.630;D06.472.699.042.750;D12.644.276.024.750;D12.644.548.011.750;D12.776.467.024.750;D23.529.024.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.907.489;V03.600;D06.472.699.042.750;D12.644.276.024.750;D12.644.548.011.750;D12.776.467.024.750;D23.529.024.750
28525294,Adult;Communication;Curriculum;Delivery of Health Care;Humans;Leadership;Middle Aged;Palliative Care;Program Development;Program Evaluation;Staff Development;United States;Interview;Leadership;Palliative Care,M01.060.116;F01.145.209;L01.143;I02.158;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;F01.752.609;M01.060.116.630;E02.760.666;N02.421.585.666;N04.452.760;E05.337.820;N04.761.685;N05.715.360.650;I02.574.700;N04.452.677.822;Z01.107.567.875;V01.175.250;V02.170.500;V02.530.150.500;F01.752.609;E02.760.666;N02.421.585.666
28523862,"Adolescent;Adult;Cardiology;Child;Child, Preschool;Czech Republic;Diagnosis, Computer-Assisted;Heart Defects, Congenital;Humans;Infant;Infant, Newborn;Remote Consultation;Retrospective Studies;United States;Videoconferencing;Young Adult;Telemedicine;Videoconferencing",M01.060.057;M01.060.116;H02.403.429.163;M01.060.406;M01.060.406.448;Z01.542.248.395;E01.158;L01.313.500.750.100.158;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;L01.178.847.652.550;N04.452.758.849.550;N04.590.374.800.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;L01.178.847.900;M01.060.116.815;H02.403.840;L01.178.847.652;N04.590.374.800;L01.178.847.900
28523743,"Curriculum;Disclosure;Humans;Medical Errors;Physician-Patient Relations;Psychology, Social;Truth Disclosure",I02.158;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;B01.050.150.900.649.313.988.400.112.400.400;N02.421.450;F01.829.401.650.675;N05.300.660.625;F01.829;F04.096.628.829;F01.829.401.046.800;I01.880.604.583.080.134.800
28523569,Adult;Age Distribution;Age Factors;Aged;Breast Neoplasms;Early Detection of Cancer;Humans;Mammography;Mass Screening;Middle Aged;Multimodal Imaging;Radiographic Image Enhancement;Sensitivity and Specificity;Biopsy;Breast Neoplasms;Mammography;Mass Screening,M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;N05.715.350.075;N06.850.490.250;M01.060.116.100;C04.588.180;C17.800.090.500;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;E01.370.350.567;E01.370.350.600.350.700;E01.370.350.700.700;L01.224.308.380.600;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;C04.588.180;C17.800.090.500;E01.370.350.700.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500
28523432,"Animals;CD28 Antigens;Electroporation;Humans;Immunity, Cellular;Interleukin-2;K562 Cells;Mice;Muromonab-CD3;Neoplasms, Experimental;RNA, Messenger;T-Lymphocytes;Tumor Necrosis Factor Receptor Superfamily, Member 9;T-Lymphocytes",B01.050;D12.776.543.750.705.222.500;D23.050.301.264.894.128;D23.101.100.894.128;E05.200.500.454;E05.242.448;E05.301.500;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;D12.644.276.374.465.021;D12.644.276.374.480.372;D12.776.467.374.465.021;D12.776.467.374.480.372;D23.529.374.465.155;D23.529.374.480.372;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;B01.050.150.900.649.313.992.635.505.500;D12.776.124.486.485.114.224.075.570;D12.776.124.486.485.114.619.393.570;D12.776.124.790.651.114.224.075.570;D12.776.124.790.651.114.619.393.570;D12.776.377.715.548.114.224.284.570;D12.776.377.715.548.114.619.393.570;C04.619;E05.598.500.496;D13.444.735.544;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.543.750.705.852.760.220;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28522732,"Animals;Lewy Bodies;Mice;Mice, Inbred C57BL;Mice, Transgenic;Nerve Tissue Proteins;Parkinson Disease;Protein-Serine-Threonine Kinases;Proteome;alpha-Synuclein;Parkinson Disease;alpha-Synuclein",B01.050;A08.675.460;A11.284.420.460;A11.671.460;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D12.776.631;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D08.811.913.696.620.682.700;D12.776.817;D12.776.631.860.500;D12.776.637.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.776.631.860.500;D12.776.637.500
28522658,"Adolescent;Anaerobic Threshold;Exercise;Exercise Test;Exercise Tolerance;Fontan Procedure;Heart Defects, Congenital;Hemodynamics;Humans;Magnetic Resonance Imaging;Models, Cardiovascular;Oxygen Consumption;Patient-Specific Modeling;Quality of Life;Retrospective Studies;Time Factors;Treatment Outcome;Young Adult;Hydrodynamics",M01.060.057;G03.680.110;G11.427.680.134;G11.427.410.698.277;I03.350;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;G11.427.680.270;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E05.599.395.161;G03.680;E05.599.395.821;L01.224.160.750;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;G01.342
28522462,"Blast Crisis;Humans;Imatinib Mesylate;Leukemia, Myelogenous, Chronic, BCR-ABL Positive",C04.557.337.539.250.100;C04.697.098.500.110;C15.378.190.636.370.100;C23.550.727.098.500.110;B01.050.150.900.649.313.988.400.112.400.400;D02.065.277.456;D02.241.223.100.100.435;D02.455.426.559.389.127.085.465;D03.383.606.405;D03.383.742.349;C04.557.337.539.250;C15.378.190.636.370
28522067,"Emergency Service, Hospital;Humans;Physical Examination;Sex Offenses",N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E01.370.600;I01.198.240.748
28522064,"Botulinum Toxins, Type A;Deoxycholic Acid;Drug Synergism;Drug Therapy, Combination;Esthetics;Follow-Up Studies;Humans;Injections, Subcutaneous;Middle Aged;Neck;Patient Satisfaction;Skin Aging;Subcutaneous Fat;Treatment Outcome;Botulinum Toxins;Deoxycholic Acid",D08.811.277.656.300.480.153.100;D08.811.277.656.675.374.153.100;D12.776.097.156.100;D23.946.123.179.050;D04.210.500.105.225.272;D04.210.500.221.430.342;G07.690.773.968.477;E02.319.310;F02.463.785.477;K01.752.210;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.620;M01.060.116.630;A01.598;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;G13.750.804;A10.165.114.830.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D08.811.277.656.300.480.153;D08.811.277.656.675.374.153;D12.776.097.156;D23.946.123.179;D04.210.500.105.225.272;D04.210.500.221.430.342
28521775,"Adult;African Americans;Aged;Aged, 80 and over;Asian Continental Ancestry Group;European Continental Ancestry Group;Genome-Wide Association Study;Hispanic Americans;Humans;Longitudinal Studies;Lung Diseases, Interstitial;Middle Aged;Polymorphism, Single Nucleotide;Population Surveillance;Epidemiology;Genetics;Genome-Wide Association Study;Lung Diseases, Interstitial",M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;M01.060.116.100.080;M01.686.508.200;M01.686.508.400;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C08.381.483;M01.060.116.630;G05.365.795.598;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;H02.403.720.500;H01.158.273.343;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;C08.381.483
28521519,"Adolescent;Adult;Brain Concussion;Child;Child, Preschool;Decision Support Systems, Clinical;Electronic Health Records;Humans;Infant;Practice Guidelines as Topic;Practice Patterns, Physicians';Primary Health Care;Young Adult;Decision Support Systems, Clinical;Electronic Health Records;Primary Health Care;Brain Injuries, Traumatic",M01.060.057;M01.060.116;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;M01.060.406.448;L01.313.500.750.300.190;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;N04.590.233.727;M01.060.116.815;L01.313.500.750.300.190;E05.318.308.940.968.625.500;N04.590.233.727;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28520820,"Aged;Early Detection of Cancer;Health Knowledge, Attitudes, Practice;Humans;Middle Aged;Physician-Patient Relations;Prostate-Specific Antigen;Prostatic Neoplasms",M01.060.116.100;E01.390.500;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.829.401.650.675;N05.300.660.625;D08.811.277.656.300.760.442.750;D08.811.277.656.959.350.442.750;D12.776.866.249.500;D23.050.285.625;D23.101.140.625;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28520803,"Adult;Aged;Aged, 80 and over;Amyloid beta-Peptides;Biomarkers;Brain-Derived Neurotrophic Factor;Catechol O-Methyltransferase;Cognitive Dysfunction;Diffusion Tensor Imaging;Dopamine Plasma Membrane Transport Proteins;Humans;Magnetic Resonance Imaging;Middle Aged;Parkinson Disease;Polymorphism, Single Nucleotide;Tomography, Emission-Computed, Single-Photon;tau Proteins",M01.060.116;M01.060.116.100;M01.060.116.100.080;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D23.101;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;D08.811.913.555.500.250;F03.615.250.700;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;D12.776.157.530.450.625.124;D12.776.157.530.562.374.500.500;D12.776.157.530.937.500;D12.776.543.585.450.625.124;D12.776.543.585.562.374.500.500;D12.776.543.585.937.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;G05.365.795.598;E01.370.350.350.800.800;E01.370.350.600.350.800.800;E01.370.350.710.800.800;E01.370.350.825.800.800;E01.370.384.730.800.800;D12.776.220.600.450.510;D12.776.631.560.510
28516217,Fetal Diseases;Humans;Hydrocephalus;Meningomyelocele;Neurosurgical Procedures;Prenatal Diagnosis;Rhombencephalon;Meningomyelocele;Spinal Dysraphism,C13.703.277;C16.300;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;C10.500.680.610;C16.131.666.680.610;E04.525;E01.370.378.630;A08.186.211.132.810;C10.500.680.610;C16.131.666.680.610;C10.500.680.800;C16.131.666.680.800
28516161,,
28515265,"Aged;Alzheimer Disease;Aphasia, Primary Progressive;Brain;Cost of Illness;Follow-Up Studies;Frontotemporal Lobar Degeneration;Humans;Language Tests;Longitudinal Studies;Magnetic Resonance Imaging;Neuropsychological Tests;Phonetics;Retrospective Studies",M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.380.132;C10.597.606.150.500.800.100.155;C23.888.592.604.150.500.800.100.155;F03.615.400.125;A08.186.211;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C10.228.140.380.266;C10.574.950.300;C18.452.845.800.300;F03.615.400.380;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.240;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;F04.711.513;L01.559.598.518;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28515118,"Adult;Aged;Albuminuria;Anemia;Biomarkers;Comorbidity;Creatinine;Cystatin C;Diabetes Mellitus;Glomerular Filtration Rate;Heart Failure;Humans;Incidence;Inflammation;Insulin Resistance;Kidney;Middle Aged;Prognosis;Renal Insufficiency, Chronic;Risk Assessment;Risk Factors;Time Factors;United States;Young Adult;Albuminuria;Renal Insufficiency, Chronic;Glomerular Filtration Rate;Heart Failure;Risk Factors",M01.060.116;M01.060.116.100;C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;C15.378.071;D23.101;N05.715.350.225;N06.850.490.687;D03.383.129.308.207;D12.776.215.300;C18.452.394.750;C19.246;E01.370.390.400.300;G08.852.357;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C23.550.470;C18.452.394.968.500;G07.690.773.984.617;A05.810.453;M01.060.116.630;E01.789;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;Z01.107.567.875;M01.060.116.815;C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;C12.777.419.780.750;C13.351.968.419.780.750;E01.370.390.400.300;G08.852.357;C14.280.434;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28515089,Amino Acids;Animals;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Calcium;Calcium Channels;Electrophysiology;Humans;Membrane Glycoproteins;Membrane Potentials;Mutant Proteins;Patch-Clamp Techniques;Point Mutation;Sequence Deletion,D12.125;B01.050;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;D01.268.552.100;D01.552.539.288;D23.119.100;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;H01.158.344.528;H01.158.782.236;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550;D12.776.543.550;G01.154.535;G04.580;G07.265.675;G11.561.570;D12.776.602;E05.200.500.905;E05.242.800;G05.365.590.675;G05.365.590.762;G05.558.800
28514670,"Adolescent;Age Factors;Child;Child, Preschool;Consensus;Fluoroscopy;Heart Defects, Congenital;Humans;Infant;Infant, Newborn;Multimodal Imaging;Patient Safety;Predictive Value of Tests;Radiation Dosage;Radiation Exposure;Radiation Injuries;Radiography, Interventional;Radionuclide Imaging;Risk Assessment;Risk Factors;Tomography, X-Ray Computed;Child;Radiation, Ionizing",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;E01.370.350.700.225;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.350.567;N06.850.135.060.075.399;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.799.513;G01.750.740;N06.850.810.250;G01.750.748;N06.850.460.350.850;C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360;E01.370.350.700.725;E04.502.780;E01.370.350.710;E01.370.384.730;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;M01.060.406;G01.750.750
28514664,"Abetalipoproteinemia;Apolipoproteins B;Carrier Proteins;Gene Editing;Hepatocytes;Humans;Induced Pluripotent Stem Cells;Myocytes, Cardiac;Phenotype;Stress, Physiological;Apolipoproteins B;Induced Pluripotent Stem Cells",C16.320.565.398.500.440.500;C18.452.584.500.875.440.500;C18.452.648.398.500.440.500;D10.532.091.300;D12.776.070.400.300;D12.776.521.120.300;D12.776.157;E05.393.420.270;A11.436.348;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A07.541.704.570;A10.690.552.750.570;A11.620.500;G05.695;G07.775;D10.532.091.300;D12.776.070.400.300;D12.776.521.120.300;A11.872.040.500;A11.872.700.500
28514463,Adult;Age Factors;Child;Comorbidity;Humans;Mass Screening;Practice Guidelines as Topic;Psoriasis;Risk Factors,M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.406;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;N04.761.700.350.650;N05.700.350.650;C17.800.859.675;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28514318,"Adolescent;Brain;Brain Injuries;Calibration;Cardiac Catheterization;Cerebrovascular Circulation;Child;Child, Preschool;Heart Defects, Congenital;Hemoglobins;Humans;Hypoxia;Infant;Linear Models;Monitoring, Physiologic;Oximetry;Oxygen;Prospective Studies;Spectroscopy, Near-Infrared",M01.060.057;A08.186.211;C10.228.140.199;C10.900.300.087;C26.915.300.200;E05.978.155;E01.370.370.380.140;E02.148.442;E05.157.250;G09.330.100.159;M01.060.406;M01.060.406.448;C14.240.400;C14.280.400;C16.131.240.400;D12.776.124.400;D12.776.422.316.762;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;M01.060.703;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E01.370.520;E01.370.225.124.100.100.600;E01.370.370.380.600;E01.370.386.700.100.600;E05.200.124.100.100.600;D01.268.185.550;D01.362.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E01.370.350.750;E05.196.867.851
28514262,,
28514223,Bacterial Infections;Bone and Bones;Child;Humans;Infant;Magnetic Resonance Imaging;Osteomyelitis,C01.252;A02.835.232;A10.165.265;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;C01.539.160.495;C05.116.165.495
28512742,"Animals;Cell Differentiation;Cell Lineage;Cells, Cultured;Demyelinating Diseases;Gene Expression Regulation;Neurons;Oligodendroglia;Prosencephalon;Rats;Stem Cells;Genes, Homeobox",B01.050;G04.152;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.251;C10.314;G05.308;A08.675;A11.671;A08.637.600;A11.650.600;A08.186.211.200;B01.050.150.900.649.313.992.635.505.700;A11.872;G05.360.340.024.340.230.500
28512194,"Alternative Splicing;Animals;CELF Proteins;Cells, Cultured;Diabetes Mellitus, Type 1;Heart;Humans;Jurkat Cells;Mice;Muscles;Myotonic Dystrophy;RNA Splicing Factors",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;D12.776.157.725.813.250;D12.776.664.962.813.250;A11.251;C18.452.394.750.124;C19.246.267;C20.111.327;A07.541;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.495;A11.251.860.180.495;A15.382.490.555.567.569.440;B01.050.150.900.649.313.992.635.505.500;A02.633;A10.690;C05.651.534.500.500;C05.651.662.750;C10.574.500.547;C10.668.491.175.500.500;C10.668.491.606.750;C16.320.400.542;C16.320.577.500;D12.776.157.725.829;D12.776.664.962.829
28512171,Attention,F02.830.104.214
28512138,"Adaptation, Psychological;Adult;Anxiety;Child, Hospitalized;Child, Preschool;Craniofacial Abnormalities;Elective Surgical Procedures;Humans;Infant;Pain, Postoperative;Parent-Child Relations;Parents;Perioperative Period;Psychological Techniques;Self Efficacy",F01.058;M01.060.116;F01.470.132;M01.643.259;M01.060.406.448;C05.660.207;C16.131.621.207;E04.249;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C23.550.767.700;C23.888.592.612.832;F01.829.263.370.290;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E04.614;N02.421.585.753;E05.796;F04.669;F01.752.747.792.700
28511259,"Disruptive, Impulse Control, and Conduct Disorders;Dopamine;Dopamine Agonists;Humans;Impulsive Behavior;Parkinson Disease",F03.250;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;D27.505.519.625.150.151;D27.505.696.577.150.151;B01.050.150.900.649.313.988.400.112.400.400;F01.145.527;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28510626,"Adolescent;Adult;Antigens, Neoplasm;Child;Child, Preschool;Clinical Trials as Topic;DNA;DNA Mutational Analysis;Electroretinography;Humans;Leber Congenital Amaurosis;Middle Aged;Mutation;Neoplasm Proteins;Outcome Assessment (Health Care);Retinal Cone Photoreceptor Cells;Retrospective Studies;Tomography, Optical Coherence;Young Adult",M01.060.057;M01.060.116;D23.050.285;M01.060.406;M01.060.406.448;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;D13.444.308;E05.393.760.700.300;E01.370.380.225;E01.370.405.270;B01.050.150.900.649.313.988.400.112.400.400;C11.270.516;C11.768.364;M01.060.116.630;G05.365.590;D12.776.624;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;A08.675.650.850.625.670.100;A08.675.650.915.937.670.100;A08.800.950.937.670.100;A09.371.729.831.625.670.100;A11.671.650.850.625.670.100;A11.671.650.915.937.670.100;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;M01.060.116.815
28510528,"Animals;Diptera;Neurons;Octopamine;Sexual Behavior, Animal;Sleep;Drosophila melanogaster;Courtship;Motivation;Neurosciences;Octopamine;Sex;Sleep",B01.050;B01.050.500.131.617.720.500.500.750;A08.675;A11.671;D02.033.100.291.525;D02.092.063.291.525;D02.092.211.215.811.651;D02.092.471.683.725;F01.145.113.252.748;F02.830.855;G11.561.803;B01.050.500.131.617.720.500.500.750.310.250.500;F01.145.802.279;F01.658;F01.752.543.500.750;H01.158.610;D02.033.100.291.525;D02.092.063.291.525;D02.092.211.215.811.651;D02.092.471.683.725;G08.686.810;F02.830.855;G11.561.803
28510503,"Caregivers;Depression;Emotions;Humans;Students, Medical;Workload",M01.085;M01.526.485.200;N02.360.200;F01.145.126.350;F01.470;B01.050.150.900.649.313.988.400.112.400.400;M01.848.769.602;I03.946.225.500;N04.452.677.650.500
28510072,"Cerebral Ventricles;Fetus;Humans;Hydrocephalus;Magnetic Resonance Imaging;Pregnancy;Prenatal Diagnosis;Ultrasonography, Prenatal;Fetus;Hydrocephalus",A08.186.211.140;A16.378;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;E01.370.350.825.500;G08.686.784.769;E01.370.378.630;E01.370.350.850.865;E01.370.378.630.865;A16.378;C10.228.140.602
28509814,Adult;Hot Flashes;Humans;Menopause;Middle Aged;Psychometrics;Quality of Life;Reproducibility of Results;Surveys and Questionnaires,M01.060.116;C23.888.475;B01.050.150.900.649.313.988.400.112.400.400;G08.686.157.500;G08.686.841.249.500;M01.060.116.630;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28509749,,
28509730,"Anesthesia;Biomarkers;Cardiovascular Agents;Child;Critical Care;Extracorporeal Membrane Oxygenation;Fluid Therapy;Hemodynamics;Hospital Mortality;Humans;Infant, Newborn;Monitoring, Physiologic;Patient Care Bundles;Practice Guidelines as Topic;Resuscitation;Shock, Septic;Time Factors;United States",E03.155;D23.101;D27.505.954.411;M01.060.406;E02.760.190;N02.421.585.190;E02.880.301;E04.292.451;E02.319.360;G09.330.380;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.370.520;E02.765;N04.761.700.350.650;N05.700.350.650;E02.365.647;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;G01.910.857;Z01.107.567.875
28509433,"Antineoplastic Agents;Child, Preschool;Dose-Response Relationship, Drug;Humans;Infant;Infant, Newborn;Neoplasms;Practice Guidelines as Topic;Prognosis;Body Surface Area;Infant",D27.505.954.248;M01.060.406.448;G07.690.773.875;G07.690.936.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04;N04.761.700.350.650;N05.700.350.650;E01.789;E01.370.600.115.100.231;E05.041.124.231;G07.100.100.231;M01.060.703
28509428,,
28508897,"Animal Communication;Animals;Biomphalaria;DNA Transposable Elements;Evolution, Molecular;Fresh Water;Gene Expression Regulation;Genome;Host-Parasite Interactions;Pheromones;Proteome;Schistosoma mansoni;Schistosomiasis mansoni;Sequence Analysis, DNA;Stress, Physiological",F01.145.113.055;B01.050;B01.050.500.644.400.750.185;D13.444.308.520;G02.111.570.080.708.330.200;G05.360.080.708.330.200;G05.360.340.024.425.200;G05.045.250;G16.075.250;G16.500.275.280;N06.230.232;G05.308;G05.360.340;G16.527.200.400;D23.641;D12.776.817;B01.050.500.500.736.715.770.680.700;C03.335.865.859.576;E05.393.760.700;G07.775
28508868,"Adolescent;Age Factors;Child;Child Health Services;Child, Preschool;Cohort Studies;Colorado;Eosinophilic Esophagitis;Esophageal Stenosis;Esophagoscopy;Humans;Pennsylvania;Prospective Studies",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;N02.421.143.130;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;Z01.107.567.875.760.210;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C06.405.117.544;E01.370.372.250.250.275;E01.370.388.250.250.250.260;E04.210.240.250.260;E04.502.250.250.250.260;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650
28508569,"Humans;Immune Tolerance;Immunosuppression;Immunosuppressive Agents;Liver Transplantation;T-Lymphocytes, Regulatory",B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;E02.095.465.425.450;E05.478.610;D27.505.696.477.656;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
28508310,Animals;Calcium;Calcium Signaling;Humans;Protein Transport;TRPC Cation Channels,B01.050;D01.268.552.100;D01.552.539.288;D23.119.100;G02.111.820.800.100;G03.143.500.100;G04.835.800.100;B01.050.150.900.649.313.988.400.112.400.400;G03.143.700;D12.776.157.530.400.901.500;D12.776.543.585.400.901.500
28507737,,
28507543,Dendritic Cells;Immunosuppression;Monocytes;Sepsis;Stem Cells,A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;E02.095.465.425.450;E05.478.610;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;C01.539.757;C23.550.470.790.500;A11.872
28507210,"Blood Glucose;Carcinoma, Pancreatic Ductal;Causality;Diabetes Mellitus;Diabetes Mellitus, Type 2;Genetic Predisposition to Disease;Humans;Hypoglycemic Agents;Inflammation;Obesity;Pancreatic Neoplasms;Pancreatitis, Chronic;Risk Factors",D09.947.875.359.448.500;C04.557.470.200.025.232.750;C04.557.470.615.132.750;C04.588.274.761.750;C04.588.322.475.750;C06.301.761.750;C06.689.667.625;C19.344.421.750;N05.715.350.200;N06.850.490.625;C18.452.394.750;C19.246;C18.452.394.750.149;C19.246.300;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;C23.550.470;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;C06.689.750.830;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28506957,Adult;Computers;Health Planning;Humans;Suicide;Telemedicine;Computers;Health Planning;Safety;Suicide;Technology;Telemedicine,M01.060.116;L01.224.230.260;N03.349;N03.706.615.302;B01.050.150.900.649.313.988.400.112.400.400;F01.145.126.980.875;I01.880.735.856;H02.403.840;L01.178.847.652;N04.590.374.800;L01.224.230.260;N03.349;N03.706.615.302;N06.850.135.060.075;F01.145.126.980.875;I01.880.735.856;J01.897;H02.403.840;L01.178.847.652;N04.590.374.800
28506916,"Ablation Techniques;Atrial Fibrillation;Cardiology;Catheter Ablation;Consensus Development Conferences as Topic;Heart Conduction System;Humans;Societies, Medical;Arrhythmias, Cardiac;Atrial Fibrillation;Atrial Flutter;Catheter Ablation;Stroke",E04.014;C14.280.067.198;C23.550.073.198;H02.403.429.163;E02.808.750.500;E04.014.760.500;L01.178.682.759.150;N03.540.199.205;A07.541.409;B01.050.150.900.649.313.988.400.112.400.400;N03.540.828.589;C14.280.067;C23.550.073;C14.280.067.198;C23.550.073.198;C14.280.067.248;C23.550.073.248;E02.808.750.500;E04.014.760.500;C10.228.140.300.775;C14.907.253.855
28506826,"Animals;Body Temperature;Electron Transport Complex I;Exhalation;Genes, X-Linked;Genetic Predisposition to Disease;Membrane Proteins;Mice;Mice, 129 Strain;Mice, Transgenic;Neurodegenerative Diseases;Pregnancy;Mitochondrial Diseases;Electron Transport Complex I",B01.050;E01.370.600.875.374;G07.110;D05.500.562.249;D08.811.600.250.500.500;D08.811.682.608.504;D12.776.157.427.374.375.863;D12.776.157.530.450.250.875.300;D12.776.331.199.500;D12.776.543.277.500.500;D12.776.543.585.450.250.875.437;D12.776.556.579.374.375.140;G09.772.705.700.275;G05.360.340.024.340.500;G05.420.457;C23.550.291.687.500;G05.380.355;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.400.025;B01.050.150.900.649.313.992.635.505.500.550.025;B01.050.150.900.649.313.992.635.505.500.800.500.025;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C10.574;G08.686.784.769;C18.452.660;D05.500.562.249;D08.811.600.250.500.500;D08.811.682.608.504;D12.776.157.427.374.375.863;D12.776.157.530.450.250.875.300;D12.776.331.199.500;D12.776.543.277.500.500;D12.776.543.585.450.250.875.437;D12.776.556.579.374.375.140
28506544,"Child, Preschool;Cohort Studies;Critical Care;Critical Illness;Delirium;Humans;Infant;Pediatrics;Prospective Studies;Psychiatry;Reproducibility of Results;Surveys and Questionnaires;Delirium;Education;Psychiatry;Teaching",M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.760.190;N02.421.585.190;C23.550.291.625;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H02.403.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.096.544;H02.403.690;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;I02;F04.096.544;H02.403.690;I02.903
28506444,"Animals;Antigen-Presenting Cells;Antigens, CD19;Cell Lineage;Coculture Techniques;Cytokines;Humans;Interleukin-6;Lymphocyte Activation;Mice, Inbred NOD;Monocytes;Receptors, Antigen, T-Cell;Recombinant Proteins;T-Lymphocytes;Xenograft Model Antitumor Assays;Interleukin-6",B01.050;A11.066;A15.382.066;D23.050.301.264.035.119;D23.050.301.264.051.119;D23.050.301.500.600.200;D23.050.705.552.600.200;D23.101.100.110.119;D23.101.100.150.119;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;E05.481.500.374;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D12.776.543.750.705.816.824;D12.776.828;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E05.337.550.200.900;E05.624.850;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
28505328,"AIDS-Related Opportunistic Infections;Adolescent;Adult;Aged;Aged, 80 and over;Anti-Retroviral Agents;Botswana;Child;Child, Preschool;HIV Infections;Humans;Incidence;Infant;Infant, Newborn;Meningitis, Cryptococcal;Middle Aged;Retrospective Studies;Young Adult;Botswana;HIV;Meningitis, Cryptococcal;Incidence;Africa South of the Sahara",C01.539.597.050;C02.597.050;C02.782.815.616.400.100;C03.684.050;C20.673.480.100;M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.388.077;Z01.058.290.175.230;M01.060.406;M01.060.406.448;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;Z01.058.290.175.230;B04.820.650.589.650.350;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;Z01.058.290
28505093,DNA Methylation;Neuronal Plasticity,G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;G11.561.638
28504904,"Genetic Predisposition to Disease;Genetic Testing;High-Throughput Nucleotide Sequencing;Humans;Mutation;Neoplasms;Colorectal Neoplasms, Hereditary Nonpolyposis;Breast Neoplasms",C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04;C04.588.274.476.411.307.190;C04.700.250;C06.301.371.411.307.190;C06.405.249.411.307.190;C06.405.469.158.356.190;C06.405.469.491.307.190;C16.320.700.250;C18.452.284.255;C04.588.180;C17.800.090.500
28504353,"Adaptor Proteins, Signal Transducing;Adolescent;Autism Spectrum Disorder;Developmental Disabilities;Exons;Gastrointestinal Diseases;Haploinsufficiency;Humans;In Situ Hybridization, Fluorescence;Phenotype;Sequence Deletion;Autistic Disorder",D12.644.360.024;D12.776.157.057;D12.776.476.024;M01.060.057;F03.625.164.113;F03.625.421;G05.360.340.024.340.137.232;C06.405;G05.365.590.029.530.587;G05.380.350.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;G05.695;G05.365.590.762;G05.558.800;F03.625.164.113.500
28504212,Adjustment Disorders;Disorders of Sex Development;Gender Identity;Genitalia;Parents,F03.950.500;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;A05.360;F01.829.263.500.320;I01.880.853.150.500.340;M01.620
28504111,Humans;Neurodegenerative Diseases;Olfactory Perception;Perceptual Disorders,B01.050.150.900.649.313.988.400.112.400.400;C10.574;F02.463.593.485;C10.597.606.762;C23.888.592.604.764;F01.700.750
28503412,,
28503404,Glycogen Synthase Kinase 3;Colorectal Neoplasms;Hematopoietic Stem Cells,D05.500.117.875;D08.811.913.696.620.682.700.429.500;D08.811.913.696.620.682.700.646.625;D12.644.360.300.500;D12.776.476.081.875;D12.776.476.300.500;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;A11.148.378;A11.872.378;A15.378.316.378
28502730,"Animals;Clinical Trials as Topic;Fingers;Genetic Testing;Genetic Variation;High-Throughput Nucleotide Sequencing;Humans;Hydrocephalus;Hypoglycemia;Limb Deformities, Congenital;Lipoma;Malformations of Cortical Development;Mosaicism;Musculoskeletal Abnormalities;Nevus;Phosphatidylinositol 3-Kinase;Polydactyly;Proto-Oncogene Proteins c-akt;Signal Transduction;TOR Serine-Threonine Kinases;Vascular Malformations",B01.050;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;A01.378.800.667.430;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;C18.452.394.984;C05.660.585;C16.131.621.585;C04.557.450.550.400;C10.500.507;C16.131.666.507;G05.365.590.175.595;C05.660;C16.131.621;C04.557.665.560;D08.811.913.696.620.500.100;C05.660.585.600;C16.131.621.585.600;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168;G02.111.820;G04.835;D08.811.913.696.620.682.700.931;D12.776.476.925;C14.240.850;C16.131.240.850
28502727,"Alleles;Genotype;Genotyping Techniques;High-Throughput Nucleotide Sequencing;Humans;Pharmacogenetics;Pharmacogenomic Testing;Polymorphism, Genetic;Sequence Analysis, DNA",G05.360.340.024.340.030;G05.380;E05.393.442;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.343.750;H01.158.703.052;H02.628.479;E01.370.225.562.500;E05.200.562.500;E05.393.435.500;N02.421.308.430.500;N02.421.726.233.221.500;G05.365.795;E05.393.760.700
28502725,"Adolescent;Adult;Child;Child, Preschool;Genetic Testing;Genetic Variation;High-Throughput Nucleotide Sequencing;Humans;Hydrocephalus;Infant;Infant, Newborn;Lipoma;Malformations of Cortical Development;Mosaicism;Musculoskeletal Abnormalities;Nevus;Phosphatidylinositol 3-Kinase;Polydactyly;Pregnancy;Prenatal Diagnosis;Proteus Syndrome;Proto-Oncogene Proteins c-akt;TOR Serine-Threonine Kinases;Vascular Malformations;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;M01.060.703;M01.060.703.520;C04.557.450.550.400;C10.500.507;C16.131.666.507;G05.365.590.175.595;C05.660;C16.131.621;C04.557.665.560;D08.811.913.696.620.500.100;C05.660.585.600;C16.131.621.585.600;G08.686.784.769;E01.370.378.630;C04.445.435.500;C04.651.435.500;C05.116.099.750;C05.660.585.620;C16.131.077.740;C16.131.621.585.620;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168;D08.811.913.696.620.682.700.931;D12.776.476.925;C14.240.850;C16.131.240.850;M01.060.116.815
28502456,"Carcinoma, Renal Cell;Diaphragm;Disease Management;Humans;Kidney Neoplasms;Middle Aged;Neoplastic Cells, Circulating;Patient Care Team;Hemorrhage;Cardiopulmonary Bypass;Circulatory Arrest, Deep Hypothermia Induced;Vena Cava, Inferior;Intensive Care Units;Magnetic Resonance Imaging;Positron-Emission Tomography;Pulmonary Embolism;Carcinoma, Renal Cell;Heart Atria;Echocardiography, Transesophageal",C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160;A02.633.567.900.300;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;M01.060.116.630;A11.642;C04.697.650.900;C23.550.727.650.900;N04.590.715;C23.550.414;E04.292.413;E04.100.376.374.500;E04.928.220.360.500;A07.015.908.949.648;N02.278.388.493;E01.370.350.825.500;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;C08.381.746;C14.907.355.350.700;C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160;A07.541.358;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
28502439,"Adolescent;Child;Diagnosis, Differential;Disease Management;Glucocorticoids;Humans;Immunologic Factors;Inflammatory Bowel Diseases;Adolescent;Inflammatory Bowel Diseases;Pediatrics;Colitis, Ulcerative",M01.060.057;M01.060.406;E01.171;N04.590.607;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;C06.405.205.731;C06.405.469.432;M01.060.057;C06.405.205.731;C06.405.469.432;H02.403.670;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28502433,"Allergens;Diagnosis, Differential;Enteritis;Eosinophilia;Eosinophilic Esophagitis;Gastritis;Glucocorticoids;Humans;Proton Pump Inhibitors;Eosinophilic Esophagitis",D23.050.063;E01.171;C06.405.205.462;C06.405.469.326;C15.378.553.231;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C06.405.205.697;C06.405.748.398;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.389.848;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356
28501374,"Echocardiography, Doppler;Heart Bypass, Right;Heart Defects, Congenital;Heart Ventricles;Humans;Infant;North America;Ventricular Remodeling;Ventricular Remodeling",E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;E04.035.410;E04.100.376.410;E04.100.814.868.875;E04.928.220.370;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;Z01.107.567;C23.300.985;G09.330.955.975;C23.300.985;G09.330.955.975
28500417,"Animals;Brain Injuries, Traumatic;Cognition Disorders;Disease Models, Animal;Humans;Memory;Memory Disorders;Treatment Outcome;Hippocampus;Memory;Prefrontal Cortex;Brain Injuries, Traumatic",B01.050;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;F03.615.250;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425.540;C10.597.606.525;C23.888.592.604.529;F01.700.625;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A08.186.211.180.405;A08.186.211.200.885.287.500.345;F02.463.425.540;A08.186.211.200.885.287.500.270.700;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28500398,"Adult;Aged;Breast Neoplasms;DNA, Neoplasm;Disease Progression;Genomics;High-Throughput Nucleotide Sequencing;Humans;Middle Aged;Mutation;Neoplasm Metastasis;Prognosis;Cell-Free Nucleic Acids;Liquid Biopsy;High-Throughput Nucleotide Sequencing",M01.060.116;M01.060.116.100;C04.588.180;C17.800.090.500;D13.444.308.425;C23.550.291.656;H01.158.273.180.350;H01.158.273.343.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;C04.697.650;C23.550.727.650;E01.789;D13.444.154;E01.370.225.500.384.100.396;E01.370.225.998.054.396;E05.200.500.384.100.396;E05.200.998.054.396;E05.242.384.100.396;E05.393.760.319
28500137,"Cardiac Catheterization;Chi-Square Distribution;Coronary Circulation;Disease-Free Survival;Heart Defects, Congenital;Hemodynamics;Humans;Infant, Newborn;Multivariate Analysis;Odds Ratio;Pulmonary Atresia;Recovery of Function;Retreatment;Retrospective Studies;Risk Factors;Severity of Illness Index;Time Factors;Treatment Outcome;Tricuspid Valve Insufficiency;United States;Ventricular Function, Right;Decompression;Pulmonary Atresia;Pulmonary Valve",E01.370.370.380.140;E02.148.442;E05.157.250;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;G09.330.100.324;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C14.240.400;C14.280.400;C16.131.240.400;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;G16.757;E02.887;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.484.856;Z01.107.567.875;G09.330.955.900;E02.278;G01.374.715.250;C14.240.850.937;C14.280.484.640;C16.131.240.850.906;A07.541.510.738
28500077,"Animals;Antigen Presentation;CD8-Positive T-Lymphocytes;Codon, Nonsense;Codon, Terminator;Epitopes, T-Lymphocyte;Humans;Immune Tolerance;Mice;Mice, Inbred C57BL;Ornithine Carbamoyltransferase;Peptides;T-Lymphocytes, Cytotoxic",B01.050;G12.119;G12.450.050.400.070;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D13.444.735.544.355.250.235;G05.360.335.355.250.235;G05.365.590.195;D13.444.735.544.355.250;G05.360.335.355.250;G05.360.340.024.340.137.190.250;D23.050.550.402;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D08.811.913.555.275.600;D12.644;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
28499826,,
28499772,Adult;Asthma;Follow-Up Studies;Health Services Accessibility;Humans;Patient Advocacy;Patient Education as Topic;Patient Participation;Patient-Centered Care;Physician-Patient Relations;Poverty;Surveys and Questionnaires;Urban Population;Health Services Accessibility;Asthma;Patient Participation,M01.060.116;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.631;N03.706.678;I02.233.332.500;N02.421.726.407.680;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;N04.590.233.727.407;F01.829.401.650.675;N05.300.660.625;I01.880.735.634;I01.880.853.996.535;N01.824.600;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N01.600.900;N04.590.374.350;N05.300.430;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620
28499652,"Acute Kidney Injury;Area Under Curve;Cardiac Surgical Procedures;Cardiopulmonary Bypass;Creatinine;Diuretics;Furosemide;Heart Defects, Congenital;Humans;Infant;Postoperative Complications;ROC Curve;Retrospective Studies;Urine;Urodynamics",C12.777.419.780.050;C13.351.968.419.780.050;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E04.100.376;E04.928.220;E04.292.413;D03.383.129.308.207;D27.505.696.560.500;D02.065.884.725.300;D02.092.146.807.300;D02.886.590.700.725.300;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C23.550.767;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A12.207.927;G08.852.898
28499401,"Attitude of Health Personnel;Cross-Sectional Studies;Evidence-Based Practice;Health Knowledge, Attitudes, Practice;Health Personnel;Humans;Leadership;Organizational Culture;Philadelphia",F01.100.050;N05.300.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;H02.249;F01.100.150.500;N05.300.150.410;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;F01.752.609;N04.452.606;Z01.107.567.875.500.550.525;Z01.433.820
28499079,Acne Vulgaris;Adult;Algorithms;Cicatrix;Evidence-Based Medicine;Humans;Risk Assessment;Severity of Illness Index;Young Adult,C17.800.030.150;C17.800.794.111;M01.060.116;G17.035;L01.224.050;A10.165.450.300;C23.550.355.274;G16.762.891.249;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815
28498854,"African Americans;Animals;Basic Helix-Loop-Helix Transcription Factors;Blood Pressure;Cadherins;Case-Control Studies;Genetic Loci;Genome-Wide Association Study;Humans;Hypertension;Membrane Proteins;Mice;Multifactorial Inheritance;Polymorphism, Single Nucleotide",M01.686.508.100.100;M01.686.754.100;B01.050;D12.776.260.103;D12.776.930.125;E01.370.600.875.249;G09.330.380.076;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G05.360.340.024.380;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;D12.776.543;B01.050.150.900.649.313.992.635.505.500;G05.420.590;G05.365.795.598
28497802,"Adult;Anxiety Disorders;Brain;Brain Mapping;Comorbidity;Depressive Disorder, Major;Humans;Magnetic Resonance Imaging;Neural Pathways;Psychiatric Status Rating Scales;Recurrence;Rest;Severity of Illness Index",M01.060.116;F03.080;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;N05.715.350.225;N06.850.490.687;F03.600.300.375;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A08.612;F04.711.513.653;C23.550.291.937;I03.450.769.647;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28497787,"Acetylation;Animals;CRISPR-Cas Systems;Cell Line, Tumor;Chromatin;Epigenomics;Gene Expression Profiling;Gene Expression Regulation;Genetic Loci;HEK293 Cells;Histone Deacetylases;Histones;Humans;Mice;Promoter Regions, Genetic",G02.111.012.052;G02.607.063.052;G03.040.052;B01.050;G05.308.203.374.394;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180.350.074;H01.158.273.343.350.042;E05.393.332;G05.308;G05.360.340.024.380;A11.251.210.172.750;A11.436.334;D08.811.277.087.520;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680
28497511,"Attitude of Health Personnel;Health Knowledge, Attitudes, Practice;Humans;Internal Medicine;Obesity;Perception;Physician-Patient Relations;Physicians;Students, Medical;Surveys and Questionnaires;Weight Loss;Young Adult",F01.100.050;N05.300.100;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.463.593;F01.829.401.650.675;N05.300.660.625;M01.526.485.810;N02.360.810;M01.848.769.602;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.888.144.243.963;G07.345.249.314.120.200.963;M01.060.116.815
28497233,Adenocarcinoma of Lung;Fluorescence;Folate Receptor 1;Humans;Intraoperative Care;Lung;Molecular Imaging;Reference Standards;Thorax;Time Factors,C04.557.470.200.025.022;C04.588.894.797.520.055;G01.358.500.505.650.665.500;G01.590.540.665.500;D12.776.157.530.450.074.500.299.500.500;D12.776.395.550.448.370.500;D12.776.543.484.500.370.500;D12.776.543.550.418.370.500;D12.776.543.585.450.074.500.224.500.500;D12.776.543.750.301.500;D23.050.285.384;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.400;E04.604.249;N02.421.585.722.400;A04.411;E01.370.350.557;E05.601.555;E05.978.808;A01.923.761;G01.910.857
28496398,"Infant, Premature;Thalamus",M01.060.703.520.520;A08.186.211.200.317.826
28495824,,
28495654,Atrial Fibrillation;Catheter Ablation;Humans;Minimally Invasive Surgical Procedures,C14.280.067.198;C23.550.073.198;E02.808.750.500;E04.014.760.500;B01.050.150.900.649.313.988.400.112.400.400;E04.502
28495588,,
28495453,"Animals;Body Weight;Carcinoma, Hepatocellular;Diethylnitrosamine;Disease Models, Animal;Embolization, Therapeutic;Fibrosis;Fluoroscopy;Liver Neoplasms;Magnetic Resonance Imaging;Rats;Rats, Wistar;Retrospective Studies;Survival Rate",B01.050;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;D02.654.442.200;C22.232;E05.598.500;E05.599.395.080;E02.520.360;E02.926.500;C23.550.355;E01.370.350.700.225;C04.588.274.623;C06.301.623;C06.552.697;E01.370.350.825.500;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.900;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
28495406,"Animals;Gene Expression Regulation;Genomics;Humans;Receptors, Cytoplasmic and Nuclear;Receptors, Glucocorticoid;Transcription Factors;Transcriptional Activation;Receptors, Glucocorticoid",B01.050;G05.308;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;D12.776.826;D12.776.826.750.430;D12.776.930;G05.308.800;D12.776.826.750.430
28495230,"Diagnosis, Differential;Echocardiography;Electrocardiography;Electrodes;Heart Diseases;Humans;Middle Aged;Radiography, Thoracic;Retrospective Studies;Risk Factors;Electrocardiography",E01.171;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.370.380.240;E01.370.405.240;E07.305.250;C14.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.350.700.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.370.380.240;E01.370.405.240
28495211,"Adult;Aged;Aged, 80 and over;Aortic Valve;Computed Tomography Angiography;Heart Valve Prosthesis;Humans;Middle Aged;Observer Variation;Organ Size;Retrospective Studies;Systole;Transcatheter Aortic Valve Replacement",M01.060.116;M01.060.116.100;M01.060.116.100.080;A07.541.510.110;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E07.695.310;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G09.330.580.880;G11.427.494.570.880;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500
28495150,"Adolescent;Adult;Aged;Aged, 80 and over;Biopsy, Fine-Needle;Child;Chromosome Aberrations;Chromosomes, Human, Pair 3;Chromosomes, Human, Pair 6;Chromosomes, Human, Pair 8;Cytogenetic Analysis;DNA, Neoplasm;Genome-Wide Association Study;Humans;Kaplan-Meier Estimate;Melanoma;Middle Aged;Neoplasm Metastasis;Nucleic Acid Amplification Techniques;Prognosis;Retrospective Studies;Uveal Neoplasms",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;E01.370.225.500.384.100.119.500;E01.370.225.998.054.119.500;E01.370.388.100.100.500;E04.074.119.500;E04.665.100.500;E05.200.500.384.100.119.500;E05.200.998.054.119.500;E05.242.384.100.119.500;M01.060.406;C23.550.210;G05.365.590.175;A11.284.187.520.300.235.250;G05.360.162.520.300.235.250;A11.284.187.520.300.325.330;G05.360.162.520.300.325.330;A11.284.187.520.300.325.340;G05.360.162.520.300.325.340;E01.370.225.500.385;E05.200.500.385;E05.242.385;E05.393.285;D13.444.308.425;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;C04.697.650;C23.550.727.650;E05.393.620;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.364.978;C11.319.494;C11.941.855
28494978,"Adolescent;Child;Child, Preschool;Chylothorax;Heart Defects, Congenital;Humans;Infant;Magnetic Resonance Imaging;Postoperative Complications;Retrospective Studies;Thoracic Surgery;Lymphatic System;Magnetic Resonance Imaging;Thoracic Duct",M01.060.057;M01.060.406;M01.060.406.448;C08.528.142;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;H02.403.810.803;A15.382.520;E01.370.350.825.500;A15.382.520.301.750
28494946,Animals;Humans;Muscle Proteins;Muscles;Tropomodulin,B01.050;B01.050.150.900.649.313.988.400.112.400.400;D12.776.210.500;A02.633;A10.690;D05.750.078.730.032.750;D12.776.210.500.847;D12.776.220.525.032.750
28494916,"Anesthesia;Humans;Magnetic Resonance Imaging;Anesthesia;Infant, Newborn",E03.155;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E03.155;M01.060.703.520
28493866,"Biliary Atresia;Bilirubin;Biopsy;Cholestasis;Diagnosis, Differential;Follow-Up Studies;Gallbladder;Humans;Infant;Infant, Newborn;Prospective Studies",C06.130.120.123;C06.198.125;C16.131.314.125;D03.383.129.578.840.249.184;D03.633.400.909.249.184;D04.345.783.249.184;D23.767.193.184;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;C06.130.120.135;E01.171;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A03.159.439;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650
28493806,"Bone Neoplasms;Diagnosis, Differential;Diagnostic Imaging;Humans;Pediatrics",C04.588.149;C05.116.231;E01.171;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670
28493596,,
28492938,"Breast Feeding;Feces;Gastrointestinal Microbiome;Humans;Infant;Infant, Newborn;Longitudinal Studies;Milk, Human;Mothers;Nipples;Phylogeny;Prospective Studies;Sequence Analysis, RNA",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;A12.459;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;A01.236.500;G05.697;G16.075.605;L01.100.697;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.393.760.710
28492886,Humans;Thyroid Neoplasms,B01.050.150.900.649.313.988.400.112.400.400;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
28492825,Dermatologists;Medicare;Mohs Surgery;United States,M01.526.485.810.215;N02.360.810.215;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E04.494.575;E04.680.275.580;Z01.107.567.875
28492817,Cardiopulmonary Resuscitation;Child;Heart Arrest;Humans,E02.365.647.110;M01.060.406;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400
28492595,Dermatology;Health Services Accessibility;Humans;Physician's Role;Physician-Patient Relations;Sexual and Gender Minorities;United States,H02.403.225;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;F01.829.316.616.625.600;F01.829.401.650.675;N05.300.660.625;M01.777;Z01.107.567.875
28492404,"Adolescent;Canada;Child;Child, Preschool;Databases, Factual;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Intubation, Intratracheal;Japan;Laryngoscopes;Laryngoscopy;Logistic Models;New Zealand;Practice Patterns, Physicians';Retrospective Studies;Singapore;United States;Video Recording",M01.060.057;Z01.107.567.176;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;Z01.252.474.463;Z01.639.595;E07.230.220.525;E07.858.240.525;E01.370.386.460;E01.370.388.250.525;E04.502.250.525;E04.580.373;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;Z01.639.760.747;Z01.678.100.747;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.252.145.774;Z01.107.567.875;L01.280.960
28492403,"Acute Disease;Adolescent;American Heart Association;Child;Child, Preschool;Heart Arrest;Hospital Mortality;Hospitalization;Humans;Infant;Infant, Newborn;Logistic Models;Registries;Respiration, Artificial;Respiratory Insufficiency;Treatment Outcome;United States",C23.550.291.125;M01.060.057;N03.540.630.780.110;M01.060.406;M01.060.406.448;C14.280.383;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E02.041.625;E02.365.647.729;E02.880.820;C08.618.846;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
28492399,"Acute Kidney Injury;Biomarkers;Blood Glucose;Cardiac Surgical Procedures;Child, Preschool;Critical Care;Heart Defects, Congenital;Humans;Hyperglycemia;Hypoglycemia;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Monitoring, Physiologic;Postoperative Complications;Retrospective Studies;Risk Factors;Treatment Outcome",C12.777.419.780.050;C13.351.968.419.780.050;D23.101;D09.947.875.359.448.500;E04.100.376;E04.928.220;M01.060.406.448;E02.760.190;N02.421.585.190;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;C18.452.394.984;M01.060.703;M01.060.703.520;N02.278.388.493.390;E01.370.520;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28492044,,
28492020,,
28490576,"Animals;Antacids;Calcium;Calmodulin;Complement Activation;Complement C5a;Glucose;Humans;Hydrogen-Ion Concentration;Lactates;Lactoferrin;Mice;Neutrophil Activation;Neutrophils;Peroxidase;Protein Kinase C;Receptor, Anaphylatoxin C5a;Sepsis;Signal Transduction",B01.050;D27.505.519.170;D27.505.954.483.080;D01.268.552.100;D01.552.539.288;D23.119.100;D12.644.360.372.249;D12.776.157.125.412.249;D12.776.476.387.249;G12.274;D12.776.124.486.274.024.270;D12.776.124.486.274.450.250;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;G02.300;D02.241.511.459;D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249;B01.050.150.900.649.313.992.635.505.500;G12.604;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;D08.811.682.732.700;D08.811.913.696.620.682.700.725;D12.776.543.750.695.024;D12.776.543.750.705.833.550;C01.539.757;C23.550.470.790.500;G02.111.820;G04.835
28490482,"Adaptor Proteins, Signal Transducing;Animals;Infertility, Male;Mechanistic Target of Rapamycin Complex 1;Meiosis;Mice;Mice, Knockout;Multiprotein Complexes;Regulatory-Associated Protein of mTOR;Sex Chromosomes;Spermatogenesis;TOR Serine-Threonine Kinases;Germ Cells;Meiosis",D12.644.360.024;D12.776.157.057;D12.776.476.024;B01.050;C12.294.365.700;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D05.500;D05.500.337.500;D08.811.913.696.620.682.700.931.500.500;D12.644.360.024.324;D12.776.157.057.157;D12.776.476.024.419;D12.776.476.925.500.500;A11.284.187.865;G05.360.162.865;G04.152.650.624;G08.686.784.310.760;D08.811.913.696.620.682.700.931;D12.776.476.925;A05.360.490;A11.497;G04.144.220.220.687;G05.113.220.687
28490230,"Adult;Anemia, Sickle Cell;Fetal Diseases;Hematopoietic Stem Cell Transplantation;Humans;Middle Aged;Patient Acceptance of Health Care;Pregnancy;Surveys and Questionnaires;Treatment Outcome;Young Adult;Decision Making;Fetal Therapies;Hematopoietic Stem Cell Transplantation;Risk;Anemia, Sickle Cell",M01.060.116;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;C13.703.277;C16.300;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;G08.686.784.769;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;F02.463.785.373;E02.467;E02.095.147.500.500.500;E04.936.225.687.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
28490202,"Animals;Antibodies, Monoclonal;Antirheumatic Agents;Arthritis, Psoriatic;Biosimilar Pharmaceuticals;Disease Progression;Humans;Treatment Outcome;Tumor Necrosis Factor-alpha;Adalimumab;Etanercept;Infliximab;Methotrexate;Antibodies, Monoclonal;Arthritis, Psoriatic",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D27.505.954.329;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;D20.215.261;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;D12.644.541.500.697.624;D12.776.124.486.485.538.500.624;D12.776.124.486.485.680.697.624;D12.776.124.790.651.538.500.624;D12.776.124.790.651.680.660.624;D12.776.377.715.548.538.500.624;D12.776.377.715.548.680.660.624;D12.776.543.750.705.852.760.232;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;D03.633.100.733.631.192.500;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
28489816,"Animals;Anti-Bacterial Agents;Disease Susceptibility;Endothelial Cells;Gastrointestinal Microbiome;Germ-Free Life;Gram-Negative Bacteria;Hemangioma, Cavernous, Central Nervous System;Humans;Immunity, Innate;Injections, Intravenous;Lipopolysaccharide Receptors;Lipopolysaccharides;Mice;Signal Transduction;Toll-Like Receptor 4",B01.050;D27.505.954.122.085;C23.550.291.687;G07.100.250;A11.436.275;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G06.320;B03.440;C04.557.645.375.385.500;C10.500.190.200;C14.240.850.875.249;C14.907.454.385.500;C15.378.463.515.385.500;C16.131.666.190.200;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;E02.319.267.082.750;E02.319.267.530.540;D12.776.395.550.448.100;D12.776.543.484.500.100;D12.776.543.550.418.100;D12.776.543.750.705.045;D23.050.301.264.900.045;D23.101.100.900.045;D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500;B01.050.150.900.649.313.992.635.505.500;G02.111.820;G04.835;D12.776.543.750.705.910.500.400
28489744,"Central Nervous System Neoplasms;HIV Infections;Humans;Lymphoma;Magnetic Resonance Spectroscopy;Positron-Emission Tomography;Tomography, Emission-Computed, Single-Photon",C04.588.614.250;C10.551.240;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386;C15.604.515.569;C20.683.515.761;E05.196.867.519;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E01.370.350.350.800.800;E01.370.350.600.350.800.800;E01.370.350.710.800.800;E01.370.350.825.800.800;E01.370.384.730.800.800
28489460,"Adult;Aged;Biomarkers;Blood Platelets;Carbon Monoxide;Carbon Monoxide Poisoning;Carboxyhemoglobin;Electron Transport Complex IV;Humans;Lactates;Leukocytes, Mononuclear;Middle Aged;Mitochondria;Pilot Projects;Prospective Studies;Biomarkers;Carbon Monoxide;Poisoning",M01.060.116;M01.060.116.100;D23.101;A11.118.188;A15.145.229.188;D01.200.250;D01.362.200;D01.650.550.250;C25.723.455.245;D12.776.124.400.141;D12.776.422.316.762.149;D05.500.562.374;D08.811.600.250.687;D08.811.682.285;D12.776.157.530.450.250.875.304;D12.776.543.277.687;D12.776.543.585.450.250.875.484;B01.050.150.900.649.313.988.400.112.400.400;D02.241.511.459;A11.118.637.555;A15.145.229.637.555;A15.382.490.555;M01.060.116.630;A11.284.430.214.190.875.564;A11.284.835.626;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D23.101;D01.200.250;D01.362.200;D01.650.550.250;C25.723
28489457,"Anesthetics, Local;Antidotes;Child;Drug Overdose;Fat Emulsions, Intravenous;Humans;Mepivacaine;Nerve Block;Seizures;Anesthetics;Antidotes;Hypertriglyceridemia",D27.505.696.277.100.200;D27.505.696.663.850.025;D27.505.954.427.210.100.200;D27.505.696.706.037;D27.720.799.037;M01.060.406;C25.775.383;E02.319.306.500.500;D26.255.165.260.270;D26.776.708.733.500;D27.505.954.578.733.500;D27.720.752.733.500;B01.050.150.900.649.313.988.400.112.400.400;D03.383.621.450;E03.155.086.711;E04.525.210.550;C10.597.742;C23.888.592.742;D27.505.696.277.100;D27.505.954.427.210.100;D27.505.696.706.037;D27.720.799.037;C18.452.584.500.500.851
28489323,Adult;Binge-Eating Disorder;Cross-Sectional Studies;Diagnostic and Statistical Manual of Mental Disorders;Humans;Young Adult;Anorexia Nervosa;Binge-Eating Disorder;Bulimia Nervosa;Diagnosis,M01.060.116;F03.400.188;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.815;F03.400.125;F03.400.188;F03.400.250;E01
28488939,Adult;African Americans;Aged;Biological Specimen Banks;Circadian Rhythm;Cohort Studies;European Continental Ancestry Group;Humans;Middle Aged;Sleep;Wakefulness;Ethnic Groups;Continental Population Groups,M01.060.116;M01.686.508.100.100;M01.686.754.100;M01.060.116.100;N02.278.065;G07.180.562.190;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F02.830.855;G11.561.803;F02.830.104.821;G11.561.035.738;M01.686.754;N01.224.317;M01.686.508
28488348,"Aged;Atherosclerosis;Cohort Studies;Cross-Sectional Studies;Emphysema;Ethnic Groups;Gases;Heart;Humans;Lung;Middle Aged;Observer Variation;Plethysmography;Pulmonary Artery;Pulmonary Disease, Chronic Obstructive;Pulmonary Emphysema;Risk Factors;Sensitivity and Specificity;Spirometry;Tomography, X-Ray Computed;Vascular Stiffness;Pulmonary Artery;Sprains and Strains",M01.060.116.100;C14.907.137.126.307;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.325;M01.686.754;N01.224.317;D01.362;A07.541;B01.050.150.900.649.313.988.400.112.400.400;A04.411;M01.060.116.630;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.370.610;A07.015.114.715;C08.381.495.389;C08.381.495.389.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.386.700.750;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;G09.330.940;A07.015.114.715;C26.844
28488296,Adrenergic beta-Antagonists;Glucocorticoids;Hemangioma;Hemorrhage;Humans;Infant;Prednisolone;Propranolol;Scalp;Skin Neoplasms,D27.505.519.625.050.200.200;D27.505.696.577.050.200.200;D06.472.040.543;D27.505.696.399.472.488;C04.557.645.375;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D04.210.500.745.432.769.795;D02.033.100.624.698.711;D02.033.755.624.698.711;D02.092.063.624.698.711;D02.455.426.559.847.638.945;D04.615.638.945;A01.456.810;C04.588.805;C17.800.882
28488230,,
28488156,,
28487886,"Genetic Testing;Genomics;Humans;Infant, Newborn;Mass Screening;Metabolomics;Neonatal Screening;Parents",E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;F01.829.263.500.320;I01.880.853.150.500.340;M01.620
28487348,,
28487137,"Acute Coronary Syndrome;Adult;Area Under Curve;Computed Tomography Angiography;Coronary Angiography;Coronary Artery Disease;Humans;Middle Aged;Predictive Value of Tests;Prognosis;ROC Curve;Randomized Controlled Trials as Topic;Reproducibility of Results;Risk Assessment;Risk Factors;Severity of Illness Index;Coronary Artery Disease;Emergency Service, Hospital",C14.280.647.124;C14.907.585.124;M01.060.116;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336
22855961,,
20301538,,
28486708,Adult;Delay Discounting;Humans;Motivation;Smoking;Smoking Cessation;Substance Withdrawal Syndrome;Tobacco Use Disorder,M01.060.116;F02.463.785.373.346.700;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;F01.145.805;F01.145.488.732;C25.775.835;F03.900.825;C25.775.912;F03.900.912
28486706,Adolescent;Adolescent Behavior;Adult;Anhedonia;California;Cross-Sectional Studies;Depression;Humans;Smoking,M01.060.057;F01.145.022;M01.060.116;C10.597.606.057;C23.888.592.604.039;F01.700.039;Z01.107.567.875.580.200;Z01.107.567.875.760.200;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;F01.145.805
28485718,"Animals;Disease Models, Animal;Epilepsy;Hippocampus;Rats;Species Specificity;Status Epilepticus;Transcriptome",B01.050;C22.232;E05.598.500;E05.599.395.080;C10.228.140.490;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.992.635.505.700;G16.824;C10.597.742.785;C23.888.592.742.785;G02.111.873.750;G05.297.700.750;G05.360.920
28485368,,
28484993,"Accidental Falls;Aged;Aged, 80 and over;Hip Fractures;Hospitalization;Hospitals;Humans;Middle Aged;Osteoporotic Fractures;Referral and Consultation;Retrospective Studies;Sex Distribution;Tanzania;Africa, Eastern",N06.850.135.122;M01.060.116.100;M01.060.116.100.080;C26.404.061.425;C26.531.750;C26.558.276.425;E02.760.400;N02.421.585.400;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C26.404.545;N04.452.758.849;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.240.800;N01.224.803;N06.850.505.400.850;Z01.058.290.120.840;Z01.058.290.120
28484878,"Adolescent;Atherosclerosis;Child;Creatinine;Cross-Sectional Studies;Cystatin C;Glomerular Filtration Rate;Humans;Kidney Function Tests;Prevalence;Renal Insufficiency, Chronic;Risk Factors;Cardiovascular Diseases;Renal Insufficiency, Chronic",M01.060.057;C14.907.137.126.307;M01.060.406;D03.383.129.308.207;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.776.215.300;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;E01.370.390.400;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14;C12.777.419.780.750;C13.351.968.419.780.750
28484868,"Adolescent;Bone Neoplasms;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Spinal Cord Neoplasms;Spine;Treatment Outcome;Child;Health Care Costs;Radiation;Spinal Cord Neoplasms;Survival",M01.060.057;C04.588.149;C05.116.231;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04.588.614.250.803;C10.228.854.765;C10.551.240.750;A02.835.232.834;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.406;N03.219.151.400;N05.300.375;G01.750;C04.588.614.250.803;C10.228.854.765;C10.551.240.750;I03.784
28483798,Adult;Humans;Immunization;Kidney Transplantation;Living Donors;Middle Aged;Pregnancy;Transplantation Immunology;Kidney Transplantation;Pregnancy,M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;E02.870.500;E04.936.450.485;E04.950.774.400;M01.898.656;M01.060.116.630;G08.686.784.769;G12.875;E02.870.500;E04.936.450.485;E04.950.774.400;G08.686.784.769
28483776,"Adult;Aged;Aged, 80 and over;Aortic Valve;Aortic Valve Insufficiency;Aortic Valve Stenosis;Bioprosthesis;Calcinosis;Calcium;Comorbidity;Depsipeptides;Device Removal;Disease Progression;Heart Valve Prosthesis;Heart Valve Prosthesis Implantation;Heart Valves;Humans;Mass Spectrometry;Middle Aged;Oxidative Stress;Prosthesis Design;Prosthesis Failure;Registries;Risk Factors;Spectrophotometry, Atomic;Time Factors;Treatment Outcome;Tyrosine;Young Adult;Bioprosthesis;Oxidative Stress",M01.060.116;M01.060.116.100;M01.060.116.100.080;A07.541.510.110;C14.280.484.095;C14.280.484.150;C14.280.955.249;E07.695.100;C18.452.174.130;D01.268.552.100;D01.552.539.288;D23.119.100;N05.715.350.225;N06.850.490.687;D04.345.566.297;D12.644.641.297;E04.199;C23.550.291.656;E07.695.310;E04.100.376.485;E04.650.410;E04.928.220.410;A07.541.510;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;M01.060.116.630;G03.673;G07.775.750;E05.320.550;E07.695.680;C23.550.767.865;E05.325.771;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.196.712.726.551;E05.196.867.826.551;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.125.072.050.875;M01.060.116.815;E07.695.100;G03.673;G07.775.750
28483721,"Algorithms;Brain;Brain Mapping;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Models, Neurological;Neural Pathways",G17.035;L01.224.050;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;E05.599.395.642;A08.612
28483418,"Animals;CRISPR-Cas Systems;Cell Line;Embryonic Stem Cells;Enhancer Elements, Genetic;Gene Editing;Gene Expression Regulation, Developmental;Histone-Lysine N-Methyltransferase;Histones;Methylation;Mice;Mutation;Promoter Regions, Genetic;RNA;Time Factors;Transcription, Genetic;Transcriptional Activation;Transfection",B01.050;G05.308.203.374.394;A11.251.210;A11.872.700.250;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;E05.393.420.270;G05.308.310;D08.811.913.555.500.800.200.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.150.900.649.313.992.635.505.500;G05.365.590;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D13.444.735;G01.910.857;G02.111.873;G05.297.700;G05.308.800;E05.393.350.810;G05.728.860
28483415,"Adolescent;Adult;Aged;Aged, 80 and over;Anti-Retroviral Agents;Antigens, Fungal;CD4 Lymphocyte Count;Global Burden of Disease;Global Health;HIV Infections;Humans;Incidence;Lost to Follow-Up;Meningitis, Cryptococcal;Middle Aged;Prevalence;Survival Analysis;Treatment Failure;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.388.077;D23.050.202;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;N05.425.184;N06.850.520.308.980.438.475.091;H02.403.371;N01.400.337;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.370.438;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;M01.060.116.815
28483324,"Adolescent;Antibodies, Fungal;Aspergillosis, Allergic Bronchopulmonary;Aspergillus fumigatus;Asthma;Cystic Fibrosis;Humans;Immunoglobulin E;Itraconazole;Prednisone;Skin Tests;Aspergillosis, Allergic Bronchopulmonary;Cystic Fibrosis",M01.060.057;D12.776.124.486.485.114.179;D12.776.124.790.651.114.179;D12.776.377.715.548.114.179;C01.703.080.768.500;C08.381.472.850.500;C08.674.060;C08.730.435.090;C20.543.480.680.085;B01.300.381.081.295;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C06.689.202;C08.381.187;C16.320.190;C16.614.213;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;D03.383.129.799.550;D03.383.606.530;D04.210.500.745.432.719.702;E01.370.225.812.871;E05.200.812.871;E05.478.594.890;C01.703.080.768.500;C08.381.472.850.500;C08.674.060;C08.730.435.090;C20.543.480.680.085;C06.689.202;C08.381.187;C16.320.190;C16.614.213
28482002,"Adolescent;Adult;Aged;Aged, 80 and over;Cohort Studies;Fractures, Bone;Hip Fractures;Humans;Middle Aged;Proportional Hazards Models;Prospective Studies;Risk Factors;Spinal Fractures;Thyrotropin;Thyroxine;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C26.404;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26.117.500.500;C26.404.812;D06.472.699.631.525.883;D12.644.548.691.525.883;D06.472.931.812;D12.125.072.050.767;M01.060.116.815
28481839,"Afghan Campaign 2001-;Cause of Death;Child;Child, Preschool;Emergency Medical Services;Erythrocyte Transfusion;Hemorrhage;Hospital Mortality;Hospitals, Military;Humans;Iraq War, 2003-2011;Plasma;Platelet Transfusion;Proportional Hazards Models;Registries;Resuscitation;Wounds and Injuries",I01.880.735.950.250.094;K01.400.504.984.124;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;M01.060.406;M01.060.406.448;N02.421.297;E02.095.135.140.275;C23.550.414;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;N02.278.421.510.180.250;B01.050.150.900.649.313.988.400.112.400.400;I01.880.735.950.250.782;K01.400.504.984.249;A12.207.152.693;A12.207.270.695;A15.145.693;E02.095.135.140.650;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E02.365.647;C26
28481829,"Adolescent;Anti-Bacterial Agents;Body Temperature;Body Weight;Child;Child, Preschool;Combined Modality Therapy;Critical Care;Heart Arrest;Humans;Hypothermia, Induced;Infant;Kidney;Metabolic Clearance Rate;Models, Biological;Resuscitation;Retrospective Studies;Vancomycin",M01.060.057;D27.505.954.122.085;E01.370.600.875.374;G07.110;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;M01.060.406;M01.060.406.448;E02.186;E02.760.190;N02.421.585.190;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;M01.060.703;A05.810.453;E01.370.225.843;E05.200.843;G03.490;G07.690.595;G07.690.725.513;E05.599.395;E02.365.647;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D09.400.420.925;D12.644.233.925
28481785,"Adult;African Continental Ancestry Group;Alleles;Anti-HIV Agents;Benzoxazines;Botswana;CD4 Lymphocyte Count;Case-Control Studies;Cytochrome P-450 CYP2B6;Cytochrome P-450 CYP2B6 Inducers;Genotype;HIV Infections;HIV-1;Humans;Polymorphism, Single Nucleotide;Treatment Failure",M01.060.116;M01.686.508.100;G05.360.340.024.340.030;D27.505.954.122.388.077.088;D03.383.533.249;D03.633.100.209;Z01.058.290.175.230;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D08.244.453.005.575;D08.244.453.491.344;D08.811.682.690.708.170.010.575;D08.811.682.690.708.170.450.344;D12.776.422.220.453.010.575;D12.776.422.220.453.491.344;D27.505.389.249.260;D27.505.519.349.260;G05.380;C02.782.815.616.400;C02.800.801.400;C20.673.480;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760
28481769,Adult;Biomarkers;Case-Control Studies;Cyclooxygenase 1;Eyelid Diseases;Humans;Immunohistochemistry;Inflammation Mediators;Middle Aged;Nitric Oxide Synthase Type II;Retrospective Studies;T-Lymphocytes;Xanthomatosis,M01.060.116;D23.101;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D08.811.600.720.500;C11.338;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;D23.469;M01.060.116.630;D08.811.682.664.500.772.500;D12.776.157.687.575;D12.776.660.720.575;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C18.452.584.750
28481687,"Adjuvants, Immunologic;Alum Compounds;Animals;Antibodies, Neutralizing;Antibodies, Viral;Antigens, Viral;Disease Models, Animal;Glycoproteins;Guinea Pigs;Herpes Genitalis;Herpesvirus Vaccines;Immunotherapy;Oligodeoxyribonucleotides;Secondary Prevention;Treatment Outcome;Vaccines, Subunit;Herpes Genitalis;Herpesvirus 2, Human;Complement System Proteins;Guinea Pigs;Immune Evasion",D27.505.696.477.067;D01.056.025;D01.875.800.800.850.025;B01.050;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;D23.050.327;C22.232;E05.598.500;E05.599.395.080;D09.400.430;D12.776.395;B01.050.150.900.649.313.992.550;C02.256.466.382.290;C02.800.801.350;C12.294.329;C13.351.500.342;D20.215.894.899.290;E02.095.465.425;D13.695.578.424.450;E02.897;N02.421.726.825;N06.850.780.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D20.215.894.860;C02.256.466.382.290;C02.800.801.350;C12.294.329;C13.351.500.342;B04.280.382.100.750.440;D12.776.124.486.274;B01.050.150.900.649.313.992.550;G06.462.400;G12.413;G16.527.200.700
28481653,"Humans;Kartagener Syndrome;Microscopy, Electron;Nitric Oxide;Sensitivity and Specificity;Kartagener Syndrome;Nitric Oxide;Ciliary Motility Disorders",B01.050.150.900.649.313.988.400.112.400.400;C08.127.384.500;C08.200.531;C08.695.501;C09.150.531;C14.240.400.280.500;C14.280.400.280.500;C16.131.077.245.500.531;C16.131.240.400.280.500;C16.131.740.501;C16.131.810.250.500;C16.320.184.500.531;C16.320.480;E01.370.350.515.402;E05.595.402;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C08.127.384.500;C08.200.531;C08.695.501;C09.150.531;C14.240.400.280.500;C14.280.400.280.500;C16.131.077.245.500.531;C16.131.240.400.280.500;C16.131.740.501;C16.131.810.250.500;C16.320.184.500.531;C16.320.480;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;C08.200;C09.150;C16.131.077.245.500;C16.320.184.500
28481222,"Animals;Arginase;Bile;Cation Transport Proteins;Glycosylation;HEK293 Cells;Homeostasis;Humans;Liver;Manganese;Mice, Inbred C57BL;Mice, Knockout;N-Acetyllactosamine Synthase;Protein Processing, Post-Translational",B01.050;D08.811.277.913.292;A12.200.087;D12.776.157.530.450.250;D12.776.543.585.450.250;G02.111.158.812;G02.607.299;G03.191.812;A11.251.210.172.750;A11.436.334;G07.410;B01.050.150.900.649.313.988.400.112.400.400;A03.620;D01.268.556.484;D01.268.956.374;D01.552.544.484;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.641.260;D08.811.913.400.450.400.500.100;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
28480256,"Algeria;Brucella melitensis;Africa, Northern",Z01.058.266.104;B03.440.400.425.215.500.500;B03.660.050.070.100.500;Z01.058.266
28479194,"Age of Onset;Child;Child, Preschool;Cohort Studies;Cross-Sectional Studies;Cytokines;Dermatitis, Atopic;Genotype;Humans;Infant;Intermediate Filament Proteins;Mutation;Polymorphism, Single Nucleotide",N05.715.350.075.100;N06.850.490.250.100;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.644.276.374;D12.776.467.374;D23.529.374;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D05.750.078.593;D12.776.220.475;G05.365.590;G05.365.795.598
28479164,"Adolescent;Adult;Allografts;Child;Child, Preschool;Consensus;Hematopoietic Stem Cell Transplantation;Humans;Infant;Infant, Newborn;Practice Guidelines as Topic;Severe Combined Immunodeficiency;Bone Marrow Transplantation;Severe Combined Immunodeficiency",M01.060.057;M01.060.116;A01.941.500;M01.060.406;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N04.761.700.350.650;N05.700.350.650;C16.614.815;C18.452.284.800;C20.673.815;E02.095.147.725.040;E04.936.580.040;C16.614.815;C18.452.284.800;C20.673.815
28479127,"Bacteremia;Bacterial Proteins;Enterococcus faecium;Genome, Bacterial;Humans;Polymorphism, Single Nucleotide;Protein Kinases;Transcription Factors;Vancomycin;Whole Genome Sequencing",C01.252.100;C01.539.757.100;C23.550.470.790.500.100;D12.776.097;B03.353.750.250.250.300;B03.510.550.250.250.300;G05.360.340.358.207;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;D08.811.913.696.620.682;D12.776.930;D09.400.420.925;D12.644.233.925;E05.393.760.700.825
28478943,"Animals;Atrial Natriuretic Factor;Diuretics;Dog Diseases;Dogs;Dose-Response Relationship, Drug;Heart Failure;Heart Valve Diseases;Mitral Valve;Natriuretic Peptide, Brain;Heart Failure",B01.050;D06.472.699.584.500;D12.644.548.585.500;D27.505.696.560.500;C22.268;B01.050.150.900.649.313.750.250.216.200;G07.690.773.875;G07.690.936.500;C14.280.434;C14.280.484;A07.541.510.507;D06.472.699.584.625;D12.644.548.585.625;D12.776.631.590;C14.280.434
28478502,Alagille Syndrome;Humans;Liver Neoplasms;Serrate-Jagged Proteins,C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;D12.644.276.930;D12.776.157.125.797;D12.776.543.800;D23.529.930
28477452,,
28476491,Centers for Disease Control and Prevention (U.S.);Fellowships and Scholarships;Guideline Adherence;Health Personnel;Humans;Infection Control;Patient Safety;Quality Improvement;United States;Mentors;Quality Improvement,I01.409.418.750.600.650.200;N03.540.348.500.500.600.650.225;N03.219.483.838.276;N04.761.337;N05.715.360.395;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;N06.850.780.200.450;N06.850.135.060.075.399;J01.293.754;N04.761.744;Z01.107.567.875;M01.395;J01.293.754;N04.761.744
28476461,"Adolescent;Child;Child, Preschool;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Patient Discharge;Patient Readmission;Reimbursement, Incentive;Retrospective Studies;Risk Adjustment;Socioeconomic Factors;United States;Reimbursement, Incentive;Risk Adjustment",M01.060.057;M01.060.406;M01.060.406.448;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E02.760.400.620;N02.421.585.400.620;N03.219.521.710.305.380;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N04.452.871.715.800;N04.761.789.800;N05.715.360.750.625.700.690.800;I01.880.853.996;N01.824;Z01.107.567.875;N03.219.521.710.305.380;N04.452.871.715.800;N04.761.789.800;N05.715.360.750.625.700.690.800
28476446,"Academic Medical Centers;Anesthesia;Anesthetics;Europe;Expert Testimony;Hospitals, High-Volume;Humans;Operating Rooms;Transcatheter Aortic Valve Replacement;United States;World Health Organization;Vascular Access Devices;Cardiologists;Cardiopulmonary Bypass;Checklist;Anesthesia, General;Neuroprotection;Remifentanil;Transcatheter Aortic Valve Replacement;Echocardiography, Transesophageal",N02.278.020;E03.155;D27.505.696.277.100;D27.505.954.427.210.100;Z01.542;I01.880.604.583.232;N03.706.535.253;N02.278.421.414;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.700;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;Z01.107.567.875;N03.540.514.718.800;E07.132.750;M01.526.485.810.128;N02.360.810.128;E04.292.413;N05.715.360.300.179;E03.155.197;G11.561.645;D02.241.081.751.756;D03.383.621.828;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;E01.370.350.130.750.235;E01.370.350.850.220.235;E01.370.370.380.220.235
28476273,Adult;Alcohol Drinking;Alcoholism;Ambulatory Care;Cell Phone;Follow-Up Studies;Humans;Interviews as Topic;Middle Aged;Mobile Applications;Patient Acceptance of Health Care;Residential Treatment;Self-Help Groups;Telemedicine;Time Factors;Aftercare;Negotiating;Telemedicine;Randomized Controlled Trial;Smartphone,M01.060.116;F01.145.317.269;C25.775.100.250;F03.900.100.350;E02.760.106;N02.421.585.106;L01.178.847.698.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;L01.224.900.685;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;F04.754.864.696;N03.540.782;H02.403.840;L01.178.847.652;N04.590.374.800;G01.910.857;E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;F01.145.209.520;F01.829.401.520;F02.463.785.373.520;L01.143.620;N04.452.677.430;H02.403.840;L01.178.847.652;N04.590.374.800;V03.175.250.500.500;L01.224.230.260.550.500.500
28476228,Adolescent;Child;Humans;Thyroid Neoplasms;Thyroid Nodule;Gene Fusion;Mutation;Oncogenes;Thyroid Neoplasms,M01.060.057;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;G05.728.385;G05.365.590;G05.360.340.024.340.375.500;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788
28476139,Animals;Humans;Metagenomics;Microbiological Techniques;Microbiota;Reproducibility of Results;Research Design;Practice Guidelines as Topic;Metagenomics;Methods,B01.050;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.343.350.261;E01.370.225.875;E05.200.875;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.581.500;H01.770.644.728;N04.761.700.350.650;N05.700.350.650;H01.158.273.343.350.261;E05.581
30229160,,
28475924,"Animals;Antibodies, Monoclonal;Antibodies, Viral;Cross Reactions;Flavivirus;Flavivirus Infections;Humans;Mice;Viral Envelope Proteins;Zika Virus;Zika Virus Infection;Flavivirus;Zika Virus",B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;G12.122.281;B04.820.250.350;C02.782.350.250;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.964.970.880;B04.820.250.350.995;C02.081.990;C02.782.350.250.990;B04.820.250.350;B04.820.250.350.995
28475866,"DNA;Genome;Genome, Human;Humans;Nucleic Acid Amplification Techniques;Polymerase Chain Reaction;Polymorphism, Single Nucleotide;Single-Cell Analysis",D13.444.308;G05.360.340;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;E05.393.620;E05.393.620.500;G05.365.795.598;E05.242.900
28475689,Aged;Asian Continental Ancestry Group;Circadian Rhythm;Cognition;Humans;Longitudinal Studies;Middle Aged;Retrospective Studies;Sleep;Time Factors,M01.060.116.100;M01.686.508.200;G07.180.562.190;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;F02.830.855;G11.561.803;G01.910.857
28475543,Child;Humans;Morbidity;Multiple Organ Failure;Phenotype;Sepsis,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;C23.550.835.525;G05.695;C01.539.757;C23.550.470.790.500
28475532,Goals;Resuscitation,F01.658.500;E02.365.647
28475507,,
28475229,Beckwith-Wiedemann Syndrome,C16.131.077.133;C16.131.260.080;C16.320.180.080
28474973,"Portoenterostomy, Hepatic",E04.035.775;E04.210.120.775
28474810,Child;Cost of Illness;Elective Surgical Procedures;Humans;Otologic Surgical Procedures;Parents;Travel,M01.060.406;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;E04.249;B01.050.150.900.649.313.988.400.112.400.400;E04.580.450;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;I03.883
28474255,"Biopsy, Needle;Bone Diseases;Child;Fluoroscopy;Humans;Image-Guided Biopsy;Prospective Studies;Radiation Dosage;Radiographic Image Interpretation, Computer-Assisted;Radiology, Interventional;Retrospective Studies;Software;Tomography, X-Ray Computed;Child;Radiology, Interventional",E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;C05.116;M01.060.406;E01.370.350.700.225;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.384.100.370;E01.370.225.998.054.370;E01.370.388.100.370;E04.074.370;E05.200.500.384.100.370;E05.200.998.054.370;E05.242.384.100.370;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.799.513;G01.750.740;N06.850.810.250;E01.158.600.680;E01.370.350.350.700;E01.370.350.700.705;L01.313.500.750.100.158.600.680;H02.403.740.675;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;L01.224.900;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;M01.060.406;H02.403.740.675
28473531,"Animals;Cell Line, Tumor;Cell Proliferation;Genes, ras;Heterografts;High-Throughput Nucleotide Sequencing;Humans;Mice;Mice, Nude;Neoplasms;RNA, Long Noncoding;Signal Transduction",B01.050;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G05.360.340.024.340.375.500.791.550;A01.941.875;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.500;C04;D13.444.735.790.375;G02.111.820;G04.835
28473467,"Animals;Blood Glucose;Energy Metabolism;Fasting;Gene Expression Regulation, Enzymologic;Gluconeogenesis;Glucose-6-Phosphatase;Glycogen;Liver;Mice;Mice, Knockout;Organ Specificity;Phosphoenolpyruvate Carboxykinase (ATP);Protein Phosphatase 1;Gluconeogenesis;Glycogen;Glycogen Storage Disease;Glycogen Synthase;Glycolysis;Liver",B01.050;D09.947.875.359.448.500;G03.295;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;G05.308.320;G02.111.158.500;G03.191.500;D08.811.277.352.650.225;D05.750.078.562.388;D09.698.365.388;A03.620;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G07.650;D08.811.520.224.125.500;D08.811.277.352.650.625.687;G02.111.158.500;G03.191.500;D05.750.078.562.388;D09.698.365.388;C16.320.565.202.449;C18.452.648.202.449;D08.811.913.400.450.460.375;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;A03.620
28473337,"Amylases;Biomarkers;Blood Glucose;Clinical Trials as Topic;Diabetes Mellitus, Type 2;Humans;Hypoglycemic Agents;Lipase;Liraglutide;Middle Aged;Obesity;Overweight;Pancreatitis, Acute Necrotizing;Prediabetic State;Treatment Outcome",D08.811.277.450.066;D23.101;D09.947.875.359.448.500;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;D08.811.277.352.100.400;D06.472.317.680.500.500.500;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;C06.689.750.650;C18.452.394.750.774;C19.246.774;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28473318,Career Choice;Nephrology,F02.463.785.373.346.400;H02.403.429.580
28473268,"Activin Receptors, Type I;Humans;Infant;Mutation;Myositis Ossificans;Polymorphism, Single Nucleotide;Toes;Brachydactyly;Myositis Ossificans;Ossification, Heterotopic",D08.811.913.696.620.682.700.062.500;D12.776.543.750.750.400.820.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.365.590;C05.651.594.638;G05.365.795.598;A01.378.610.250.300.792;C05.660.585.262;C16.131.621.585.262;C05.651.594.638;C23.550.751
28473128,"Aged;Aged, 80 and over;Aortic Valve;Bioprosthesis;Follow-Up Studies;Heart Valve Prosthesis;Humans;Prospective Studies;Prosthesis Failure;Quality of Life;Registries;Reoperation;Transcatheter Aortic Valve Replacement;Aortic Valve Stenosis;Mortality;Registries",M01.060.116.100;M01.060.116.100.080;A07.541.510.110;E07.695.100;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E07.695.310;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C23.550.767.865;E05.325.771;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E04.690;E04.100.376.485.500;E04.650.410.500;E04.928.220.410.500;C14.280.484.150;C14.280.955.249;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28473093,"Child;Child, Preschool;Glomerulonephritis;Humans;Infant;Infant, Newborn;Kidney;Radiology;Radionuclide Imaging;Recurrence;Sex Factors;Societies, Medical;Ultrasonography;United States;Urinary Tract Infections;Vesico-Ureteral Reflux;Area Under Curve;Child;Pyelonephritis;Urinary Tract Infections;Vesico-Ureteral Reflux",M01.060.406;M01.060.406.448;C12.777.419.570.363;C13.351.968.419.570.363;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A05.810.453;H02.403.740;E01.370.350.710;E01.370.384.730;C23.550.291.937;N05.715.350.675;N06.850.490.875;N03.540.828.589;E01.370.350.850;Z01.107.567.875;C01.539.895;C12.777.892;C13.351.968.892;C12.777.829.920;C13.351.968.829.920;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;M01.060.406;C12.777.419.570.643.790;C12.777.419.570.821.717;C13.351.968.419.570.643.790;C13.351.968.419.570.821.717;C01.539.895;C12.777.892;C13.351.968.892;C12.777.829.920;C13.351.968.829.920
28473090,"Child Abuse;Contrast Media;Craniocerebral Trauma;Fractures, Bone;Humans;Infant;Infant, Newborn;Radiology;Rib Fractures;Societies, Medical;Tomography, X-Ray Computed;United States;Area Under Curve;Child Abuse",I01.198.240.856.350.250;I01.880.735.900.350.250;D27.505.259.500;D27.720.259;C10.900.300;C26.915.300;C26.404;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;H02.403.740;C26.404.593;C26.891.733;N03.540.828.589;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;I01.198.240.856.350.250;I01.880.735.900.350.250
28473084,"Diagnostic Imaging;Evidence-Based Medicine;Graft Survival;Humans;Kidney Transplantation;Magnetic Resonance Imaging;Postoperative Complications;Primary Graft Dysfunction;Radiology;Societies, Medical;Time Factors;United States;Area Under Curve;Rejection (Psychology);Kidney Transplantation",E01.370.350;H02.249.750;H02.403.200.400;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;E01.370.350.825.500;C23.550.767;C14.907.725.675;C23.550.767.877.750;H02.403.740;N03.540.828.589;G01.910.857;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;F01.145.813.565;E02.870.500;E04.936.450.485;E04.950.774.400
28473070,"Adult;Age Factors;Diagnostic Imaging;Humans;Mammography;Middle Aged;Nipple Discharge;Radiology;Societies, Medical;United States;Area Under Curve;Mammography;Mammography;Nipple Discharge",M01.060.116;N05.715.350.075;N06.850.490.250;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700.500;M01.060.116.630;A12.207.824;H02.403.740;N03.540.828.589;Z01.107.567.875;E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;E01.370.350.700.500;E01.370.350.700.500;A12.207.824
28472923,"Adult;Age Factors;Alcoholism;Humans;Logistic Models;Middle Aged;Risk Factors;Spain;Suicidal Ideation;Suicide;Suicide, Attempted;Survival Analysis;Young Adult;Alcoholism;Personality Disorders",M01.060.116;N05.715.350.075;N06.850.490.250;C25.775.100.250;F03.900.100.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.542.846;F01.145.126.980.875.149;I01.880.735.856.149;F01.145.126.980.875;I01.880.735.856;F01.145.126.980.875.600;I01.880.735.856.600;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;M01.060.116.815;C25.775.100.250;F03.900.100.350;F03.675
28472448,"Adult;Anti-HIV Agents;Antitubercular Agents;Bacterial Translocation;Biological Availability;Biomarkers;Cohort Studies;Gastrointestinal Tract;HIV Infections;Humans;Middle Aged;Prospective Studies;Rifampin;Tuberculosis, Pulmonary",M01.060.116;D27.505.954.122.388.077.088;D27.505.954.122.085.255;G06.099.114;G03.787.151;G07.690.725.129;D23.101;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;A03.556;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D03.633.400.811.700;D04.345.295.750.700;C01.252.410.040.552.846.899;C08.381.922;C08.730.939
28472417,"Adolescent;Adolescent Development;Child;Child Development;Cognition;Cognitive Dysfunction;Evidence-Based Medicine;Fertilization in Vitro;Humans;Risk;Sperm Injections, Intracytoplasmic;Cryopreservation;Epidemiology;Infertility;Ovulation Induction;Psychology",M01.060.057;F01.525.049;G07.345.374.500;M01.060.406;F01.525.200;G07.345.374.750;F02.463.188;F03.615.250.700;H02.249.750;H02.403.200.400;E02.875.800.750;E05.820.800.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E02.875.800.750.700;E05.820.800.750.700;E01.370.225.500.620.760.160;E01.370.225.750.600.760.160;E02.792.156;E05.200.500.620.760.160;E05.200.750.600.760.160;E05.760.156;H02.403.720.500;C12.294.365;C13.351.500.365;E02.875.800.984;E05.820.800.984;F04.096.628
28472239,"Anti-Inflammatory Agents, Non-Steroidal;Blood Transfusion;Child;Child, Preschool;Humans;Ibuprofen;Pain, Postoperative;Postoperative Hemorrhage;Retrospective Studies;Risk Factors;Severity of Illness Index;Tonsillectomy",D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;E02.095.135;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;D02.241.223.701.430;C23.550.767.700;C23.888.592.612.832;C23.550.414.941;C23.550.767.850;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E04.580.848
28471976,Comparative Effectiveness Research;Humans;Patient Outcome Assessment;Prostatic Neoplasms,H01.770.644.145.360.500;N05.425.157;B01.050.150.900.649.313.988.400.112.400.400;N04.761.559.590.399;N05.715.360.575.575.399;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750
28471908,"Adolescent;Humans;Low Back Pain;Lumbar Vertebrae;Magnetic Resonance Imaging;Spondylolysis;Tomography, X-Ray Computed",M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;C23.888.592.612.107.400;A02.835.232.834.519;E01.370.350.825.500;C05.116.900.938.500;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28471816,"Adult;Attitude of Health Personnel;Brain Death;Critical Illness;Decision Making;Family;Health Education;Humans;Intensive Care Units, Pediatric;Life Support Care;Middle Aged;United States",M01.060.116;F01.100.050;N05.300.100;C10.228.140.151;C10.597.606.358.800.200.100;C23.550.260.159;C23.550.291.625;F02.463.785.373;F01.829.263;I01.880.853.150;I02.233.332;N02.421.726.407;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;E02.760.440;N02.421.585.440;M01.060.116.630;Z01.107.567.875
28471719,3-Iodobenzylguanidine;Bone Marrow Neoplasms;Bone Neoplasms;Consensus;Fluorodeoxyglucose F18;Humans;Immunohistochemistry;Neuroblastoma;Positron-Emission Tomography;Radiopharmaceuticals;Response Evaluation Criteria in Solid Tumors;Soft Tissue Neoplasms,D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;C04.588.448.200;C15.378.190.250;C15.378.400.200;C04.588.149;C05.116.231;F01.829.316.068;F02.463.785.373.433;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;E01.789.800.379;N04.761.559.590.800.569;N05.715.360.575.575.800.569;C04.588.839
28471517,"Animals;Antigens, Dermatophagoides;Asthma;Chemokines;Disease Models, Animal;Disease Susceptibility;Duffy Blood-Group System;Gene Expression;Genetic Loci;Humans;Leukocytes;Mice;Mice, Knockout;Neutrophils;Patient Acceptance of Health Care;Patient Outcome Assessment;Phenotype;Polymorphism, Single Nucleotide;Prognosis;Receptors, Cell Surface;Respiratory Hypersensitivity;Respiratory Mucosa;Severity of Illness Index;Asthma",B01.050;D23.050.181;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;C22.232;E05.598.500;E05.599.395.080;C23.550.291.687;G07.100.250;D23.050.301.290.301;D23.050.705.230.301;G05.297;G05.360.340.024.380;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637;A15.145.229.637;A15.382.490;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;N04.761.559.590.399;N05.715.360.575.575.399;G05.695;G05.365.795.598;E01.789;D12.776.543.750;C08.674;C20.543.480.680;A04.760;A10.615.550.760;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
28471021,"Cell Degranulation;Cell Line;Cytoplasmic Granules;Cytotoxicity, Immunologic;Endosomes;Exocytosis;Gene Knockdown Techniques;Humans;Lysosomal-Associated Membrane Protein 1;Protein Transport;Qa-SNARE Proteins;T-Lymphocytes, Cytotoxic;Qa-SNARE Proteins",G04.468.160;A11.251.210;A11.284.430.214.190.500;A11.284.430.214.190.875.190.190;G12.287;A11.284.430.214.190.875.190.880.337;G04.468;E05.393.335.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.395.550.550.500;D12.776.395.550.625.449;D12.776.543.550.527.500;D12.776.543.550.625.449;D12.776.543.750.705.675.554;G03.143.700;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500
28470889,"Animals;Bone Marrow Transplantation;Cells, Cultured;Graft vs Host Disease;Humans;Immune Tolerance;In Vitro Techniques;Kynurenine;Mice;Survival Rate;T-Lymphocytes, Regulatory;Tryptophan;Bone Marrow;Immunosuppression;Translational Medical Research;Transplantation, Heterologous",B01.050;E02.095.147.725.040;E04.936.580.040;A11.251;C20.452;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;E05.481;D12.125.608;B01.050.150.900.649.313.992.635.505.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;D12.125.072.050.850;D12.125.142.875;A15.382.216;E02.095.465.425.450;E05.478.610;H01.770.644.145.675;E04.936.764
28470018,Antimicrobial Stewardship;Colistin,N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;D04.345.566.780.110;D10.477.750.110;D12.644.050.600.110;D12.644.641.780.110;D12.776.543.695.054.600.110
28470014,Chemical and Drug Induced Liver Injury,C06.552.100;C25.100.562;C25.723.260
28469969,Oligodendroglioma;Vascular Endothelial Growth Factor A,C04.557.465.625.600.380.590;C04.557.470.670.380.590;C04.557.580.625.600.380.590;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200
28469964,Signal Transduction;Neurofibromatosis 1,G02.111.820;G04.835;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650
28469457,Ambulatory Surgical Procedures;Quality of Health Care,E04.030;N04.761;N05.715
28468935,"Animals;Disease Models, Animal;Humans;Neurodegenerative Diseases",B01.050;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.988.400.112.400.400;C10.574
28468798,"Animals;CD8-Positive T-Lymphocytes;Capsid Proteins;Dendritic Cells;Dependovirus;Genetic Therapy;Lymphocyte Activation;Mice;Mice, Knockout;Myeloid Differentiation Factor 88;Plasma Cells;Toll-Like Receptor 9",B01.050;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;D12.776.964.970.600.550;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;B04.280.580.650.170;E02.095.301;E05.393.420.301;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.644.360.024.311;D12.776.157.057.074;D12.776.476.024.390;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;D12.776.260.750;D12.776.543.750.705.910.500.900
28468790,"Cohort Studies;Databases, Factual;Gene Frequency;Genome-Wide Association Study;Genotype;Heart Defects, Congenital;Humans;Introns;Membrane Proteins;Polymorphism, Single Nucleotide;Epidemiology;Genome-Wide Association Study;Heart Defects, Congenital;Polymorphism, Single Nucleotide",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;G05.330;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.220.400;G05.360.340.024.340.137.515;D12.776.543;G05.365.795.598;H02.403.720.500;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;C14.240.400;C14.280.400;C16.131.240.400;G05.365.795.598
28468148,"Adolescent;Cephalometry;Child;Child, Preschool;Humans;Imaging, Three-Dimensional;Infant;Malocclusion;Mandible;Mandibulofacial Dysostosis;Retrognathia;Retrospective Studies;Tomography, X-Ray Computed;Tooth Abnormalities;Young Adult",M01.060.057;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;M01.060.703;C07.793.494;A02.835.232.781.324.502.632;A14.521.632;C05.116.099.370.231.576;C05.660.207.231.576;C11.270.147.750;C16.131.621.207.231.576;C05.500.460.827;C05.660.207.540.460.827;C07.320.440.827;C07.320.610.827;C07.650.500.460.827;C16.131.621.207.540.460.827;C16.131.850.500.460.827;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C07.650.800;C07.793.700;C16.131.850.800;M01.060.116.815
28467646,"Alendronate;Animals;Humans;Osteogenesis;Osteoporosis, Postmenopausal;Ovariectomy;Parathyroid Hormone;Rats;Rats, Sprague-Dawley;X-Ray Microtomography;Diphosphonates;Osteogenesis;Parathyroid Hormone",D02.705.429.500.100;B01.050;B01.050.150.900.649.313.988.400.112.400.400;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;C05.116.198.579.610;C18.452.104.579.610;E04.270.282.685;E04.950.165.685;E04.950.300.680;D06.472.699.590;D12.644.548.587;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E01.370.350.700.810.810.900;E01.370.350.825.810.810.900;D02.705.429.500;G07.345.500.325.377.625.050.500.729;G11.427.578.050.500.729;D06.472.699.590;D12.644.548.587
28467614,"Adult;Bariatric Surgery;Body Contouring;Body Mass Index;Databases, Factual;Epigastric Arteries;Esthetics;Humans;Mammaplasty;Middle Aged;Obesity, Morbid;Retrospective Studies;Risk Assessment;Statistics, Nonparametric;Surgical Flaps;Transplantation, Autologous;Treatment Outcome;Weight Loss",M01.060.116;E02.570.500.062;E04.062;E02.218.064;E04.680.127;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;L01.313.500.750.300.188.400;L01.470.750.750;A07.015.114.330;F02.463.785.477;K01.752.210;B01.050.150.900.649.313.988.400.112.400.400;E02.218.565;E04.680.500;M01.060.116.630;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;A10.850.710;E07.862.710;E04.936.664;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C23.888.144.243.963;G07.345.249.314.120.200.963
28467028,"Humans;Practice Guidelines as Topic;Societies, Medical;Supranuclear Palsy, Progressive;Supranuclear Palsy, Progressive",B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;N03.540.828.589;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690;C10.228.140.079.882;C10.228.662.700;C10.292.562.750.500;C10.574.945.500;C10.597.622.447.690;C11.590.472.500;C23.888.592.636.447.690
28466667,"Administration, Oral;Adolescent;Animals;Child;Child, Preschool;Desensitization, Immunologic;Humans;Immunoglobulin E;Milk;Milk Hypersensitivity;Treatment Outcome;Asthma;Child;Eosinophilic Esophagitis;Milk Hypersensitivity",E02.319.267.100;M01.060.057;B01.050;M01.060.406;M01.060.406.448;E02.095.465.425.450.310;E05.478.610.310;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525;C20.543.480.370.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;C20.543.480.370.500
28466453,"Chronic Pain;Exostoses, Multiple Hereditary;Humans;Mutation;N-Acetylglucosaminyltransferases;Nerve Compression Syndromes;Genetic Association Studies;Heparitin Sulfate;Exostoses, Multiple Hereditary;Exostoses, Multiple Hereditary",C23.888.592.612.274;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;D08.811.913.400.100.250;C10.668.829.550;E05.393.385;D09.698.373.425;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330
28465412,"Animals;Enhancer Elements, Genetic;Gene Expression Profiling;Gene Expression Regulation, Leukemic;Genome, Human;Humans;Mice;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Promoter Regions, Genetic;Protein Binding;Receptors, Notch;Signal Transduction;Transcription Factors;Tumor Cells, Cultured",B01.050;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;E05.393.332;G05.308.370.500;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;D12.776.930;A11.251.860
28465250,"Activities of Daily Living;Adolescent;Adult;Age Factors;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Middle Aged;Myositis Ossificans;Ossification, Heterotopic;Young Adult;Activities of Daily Living;Walking;Myositis Ossificans;Ossification, Heterotopic",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.116.630;C05.651.594.638;C23.550.751;M01.060.116.815;E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940;C05.651.594.638;C23.550.751
28465187,,
28465174,"Awards and Prizes;Biomedical Research;Digestive System Diseases;Gastroenterology;History, 20th Century;History, 21st Century;Humans",K01.150;H01.770.644.145;C06;H02.403.429.405;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400
28465118,Heart Failure;Heart Transplantation;Pediatrics,C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;H02.403.670
28464909,"Adolescent;Anti-Inflammatory Agents, Non-Steroidal;Antirheumatic Agents;Arthritis, Juvenile;Child;Cohort Studies;Cross-Sectional Studies;HLA-B27 Antigen;Humans;Internationality;Retrospective Studies;Treatment Outcome;HLA-B27 Antigen;Arthritis, Juvenile",M01.060.057;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;D27.505.954.329;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;D12.776.395.550.489.500.270;D12.776.543.550.439.500.270;D23.050.301.500.100.500.270;D23.050.301.500.450.380.270;D23.050.705.552.100.500.270;D23.050.705.552.450.380.270;B01.050.150.900.649.313.988.400.112.400.400;I01.615;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.776.395.550.489.500.270;D12.776.543.550.439.500.270;D23.050.301.500.100.500.270;D23.050.301.500.450.380.270;D23.050.705.552.100.500.270;D23.050.705.552.450.380.270;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198
28464426,Urinary Incontinence,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
28464154,Bioethical Issues;Conflict of Interest;Decision Making;Judgment;Malpractice;Perception;Physicians;Prejudice;Research Personnel,K01.752.566.479.023;N05.350.100;K01.752.566.479.095;N05.350.225;F02.463.785.373;F02.463.785.626;I01.880.604.583.524;N03.706.535.606;F02.463.593;M01.526.485.810;N02.360.810;F01.145.813.550;F01.829.595;M01.526.839
28463971,"Aged;Cohort Studies;Cross-Sectional Studies;Forced Expiratory Volume;Heart;Humans;Hypertension, Pulmonary;Lung;Magnetic Resonance Imaging;Middle Aged;Organ Size;Plethysmography, Whole Body;Pulmonary Artery;Pulmonary Disease, Chronic Obstructive;Pulmonary Emphysema;Residual Volume;Tomography, X-Ray Computed",M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.386.700.660.230;G09.772.650.430;A07.541;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;A04.411;E01.370.350.825.500;M01.060.116.630;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E01.370.370.610.805;E01.370.386.700.615;A07.015.114.715;C08.381.495.389;C08.381.495.389.750;E01.370.386.700.485.750.275.650;G09.772.850.390.820;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28463563,"Diagnosis, Differential;Diagnostic Imaging;Humans;Infant, Newborn;Soft Tissue Neoplasms",E01.171;E01.370.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C04.588.839
28462942,"Animals;Behavior, Animal;Depression;Disease Models, Animal;Disease Susceptibility;Dominance-Subordination;Epigenesis, Genetic;Mice;Mice, Transgenic;Nucleus Accumbens;Phenotype;Proto-Oncogene Proteins c-fos;Receptors, Dopamine D1;Receptors, Dopamine D2;Stress, Psychological",B01.050;F01.145.113;F01.145.126.350;C22.232;E05.598.500;E05.599.395.080;C23.550.291.687;G07.100.250;F01.145.813.650.400;G05.308.203;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A08.186.211.200.885.287.249.487.775.500;G05.695;D12.776.260.108.765;D12.776.624.664.700.179;D12.776.660.760;D12.776.930.127.765;D12.776.543.750.670.300.400.400;D12.776.543.750.695.150.400.400;D12.776.543.750.720.330.400.400;D12.776.543.750.670.300.400.500;D12.776.543.750.695.150.400.500;D12.776.543.750.720.330.400.500;F01.145.126.990;F02.830.900
28462858,"Combined Modality Therapy;Humans;Hypercapnia;Infant, Newborn;Neuromuscular Diseases;Respiration;Ventilators, Mechanical;Hypercapnia;Respiration, Artificial;Neuromuscular Diseases;Noninvasive Ventilation",E02.186;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.544;M01.060.703.520;C10.668;G09.772.705;E07.950;C23.888.852.544;E02.041.625;E02.365.647.729;E02.880.820;C10.668;E02.041.625.591;E02.880.820.657
28462369,,
28461695,,
28461624,"ADAMTS7 Protein;Adult;Aged;Aged, 80 and over;Cells, Cultured;Coronary Disease;Coronary Vessels;Gene-Environment Interaction;Genetic Loci;Genetic Predisposition to Disease;Humans;Middle Aged;Polymorphism, Single Nucleotide;Smoking;ADAMTS7 Protein;Coronary Artery Disease;Gene-Environment Interaction;Genome-Wide Association Study;Smoking",D08.811.277.656.675.374.102.500.937;D09.400.430.500.500.937;D12.776.395.033.500.937;D12.776.860.300.085.937;M01.060.116;M01.060.116.100;M01.060.116.100.080;A11.251;C14.280.647.250;C14.907.585.250;A07.015.114.269;A07.015.908.194;G05.695.337;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.795.598;F01.145.805;D08.811.277.656.675.374.102.500.937;D09.400.430.500.500.937;D12.776.395.033.500.937;D12.776.860.300.085.937;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;G05.695.337;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;F01.145.805
28461542,"Adult;Attitude of Health Personnel;Communication;Critical Care;Humans;Intensive Care Units;Interviews as Topic;Middle Aged;Nursing Staff, Hospital;Pennsylvania;Personnel Staffing and Scheduling;Telephone",M01.060.116;F01.100.050;N05.300.100;F01.145.209;L01.143;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;I03.946.225;N04.452.677.650;L01.178.847.698
28461533,"Arthritis, Psoriatic;Dermatology;Humans;Patient Participation;Psoriasis;Rheumatology;Psoriasis;Arthritis, Psoriatic",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;C17.800.859.675;H02.403.429.730;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
28461531,"Antirheumatic Agents;Arthritis, Psoriatic;Humans;Outcome Assessment (Health Care);Rheumatology;Treatment Outcome;Outcome Assessment (Health Care);Psoriasis;Arthritis, Psoriatic",D27.505.954.329;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;H02.403.429.730;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
28461529,"Ambulatory Care Facilities;Arthritis, Psoriatic;Dermatology;Humans;Psoriasis;Rheumatology;Severity of Illness Index;Psoriasis;Arthritis, Psoriatic",N02.278.035;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;C17.800.859.675;H02.403.429.730;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
28461525,"Arthritis, Psoriatic;Dermatology;Humans;Practice Guidelines as Topic;Psoriasis;Research;Rheumatology;Nail Diseases;Psoriasis;Arthritis, Psoriatic",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;C17.800.859.675;H01.770.644;H02.403.429.730;C17.800.529;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175
28461522,"Arthritis, Psoriatic;Biomedical Research;Dermatology;Humans;Psoriasis;Rheumatology;Education;Psoriasis;Arthritis, Psoriatic;Research",C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H01.770.644.145;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;C17.800.859.675;H02.403.429.730;I02;C17.800.859.675;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;H01.770.644
28461325,"Adenocarcinoma;Animals;Cell Line, Tumor;Cell Movement;Cell Proliferation;Cisplatin;Drug Resistance, Neoplasm;Epithelial-Mesenchymal Transition;Fluorouracil;Humans;Mice;Neoplastic Stem Cells;Signal Transduction;Spheroids, Cellular;Stomach Neoplasms;Xenograft Model Antitumor Assays;rac1 GTP-Binding Protein",C04.557.470.200.025;B01.050;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;D01.210.375;D01.625.125;D01.710.100;G07.690.773.984.395;G04.356.500;D03.383.742.698.875.404;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;A11.872.650;G02.111.820;G04.835;A11.251.800;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;E05.337.550.200.900;E05.624.850;D08.811.277.040.330.300.400.700.100.500;D12.644.360.525.700.100.100;D12.776.157.325.515.700.100.100;D12.776.476.525.700.100.100
28460789,Carrier Proteins;Intercellular Signaling Peptides and Proteins;Mutation,D12.776.157;D12.644.276;D12.776.467;D23.529;G05.365.590
28460700,Equipment and Supplies;Humans;Iatrogenic Disease;Noninvasive Ventilation;Respiratory Insufficiency;Tracheostomy,E07;B01.050.150.900.649.313.988.400.112.400.400;C23.550.291.875;E02.041.625.591;E02.880.820.657;C08.618.846;E02.041.750;E04.579.935;E04.580.900;E04.928.780
28460658,"Adolescent;Adult;Aorta, Thoracic;Body Mass Index;Child;Coronary Vessel Anomalies;Exercise Therapy;Exercise Tolerance;Follow-Up Studies;Humans;Retrospective Studies;Time Factors;Young Adult;Body Mass Index",M01.060.057;M01.060.116;A07.015.114.056.372;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;C14.240.400.210;C14.280.400.210;C16.131.240.400.210;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;G11.427.680.270;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;M01.060.116.815;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175
28460589,"Abnormalities, Multiple;Adolescent;Child;Epilepsy;Humans;Infant;Intellectual Disability;Motor Disorders;Movement Disorders;Muscle Hypotonia;Mutation, Missense;Pedigree;Phenotype;Receptors, GABA-A;Severity of Illness Index;Speech Disorders;Epilepsy;Genetics;Phenotype;Seizures",C16.131.077;M01.060.057;M01.060.406;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F03.608;C10.228.662;C10.597.613.575;C23.888.592.608.575;G05.365.590.650;E05.393.673;G05.695;D12.776.157.530.400.175.562;D12.776.157.530.400.400.100.100;D12.776.543.550.450.175.562;D12.776.543.550.450.500.100.100;D12.776.543.585.400.175.562;D12.776.543.585.400.500.100.100;D12.776.543.750.130.500;D12.776.543.750.720.200.300.300;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.597.606.150.500.800;C23.888.592.604.150.500.800;C10.228.140.490;H01.158.273.343;G05.695;C10.597.742;C23.888.592.742
28460401,,
28460398,,
28460104,Chronic Disease;Humans;Lyme Disease;Post-Lyme Disease Syndrome,C23.550.291.500;B01.050.150.900.649.313.988.400.112.400.400;C01.252.400.155.569;C01.252.400.825.480;C01.252.847.193.569;C01.252.400.155.569.800;C01.252.400.825.480.850;C01.252.847.193.569.800
28460029,"Age Factors;Aged;Aged, 80 and over;Atrial Fibrillation;Calcinosis;Cardiomyopathies;Cohort Studies;Disease Progression;Electrocardiography;Ethnic Groups;Humans;Kaplan-Meier Estimate;Middle Aged;Mitral Valve;Multivariate Analysis;Prognosis;Proportional Hazards Models;Prospective Studies;Risk Assessment;Sex Factors;Tomography, X-Ray Computed;United States",N05.715.350.075;N06.850.490.250;M01.060.116.100;M01.060.116.100.080;C14.280.067.198;C23.550.073.198;C18.452.174.130;C14.280.238;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.656;E01.370.370.380.240;E01.370.405.240;M01.686.754;N01.224.317;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;A07.541.510.507;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N05.715.350.675;N06.850.490.875;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875
28459614,Anti-Bacterial Agents;Antifungal Agents;Child;Febrile Neutropenia;Hematopoietic Stem Cell Transplantation;Humans;Invasive Fungal Infections;Neoplasms;Practice Guidelines as Topic,D27.505.954.122.085;D27.505.954.122.136;M01.060.406;C15.378.553.546.184.564.750;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;C01.703.492;C04;N04.761.700.350.650;N05.700.350.650
28459453,"Alternative Splicing;Animals;Evolution, Molecular;Exocrine Glands;Fibroins;Gene Expression;Genome;Phylogeny;Polymorphism, Genetic;Repetitive Sequences, Nucleic Acid;Silk;Spiders",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;B01.050;G05.045.250;G16.075.250;A10.336;D05.750.078.875.500;D12.776.093.750.500;G05.297;G05.360.340;G05.697;G16.075.605;L01.100.697;G05.365.795;G02.111.570.080.708;G05.360.080.708;D05.750.078.875;D12.776.093.750;B01.050.500.131.166.803
28459327,"Forecasting;History, 20th Century;History, 21st Century;Humans;Lung Neoplasms",I01.320;K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520
28458925,"Aged;Aged, 80 and over;Alzheimer Disease;Amyloid beta-Peptides;Animals;Brain;Cells, Cultured;Dendritic Spines;Disks Large Homolog 4 Protein;Humans;Mice, Inbred C57BL;Mice, Knockout;Mice, Transgenic;NIMA-Interacting Peptidylprolyl Isomerase;Nerve Tissue Proteins;Neuronal Plasticity;Phosphorylation;Post-Synaptic Density;Receptors, N-Methyl-D-Aspartate;Ubiquitin;tau Proteins",M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;B01.050;A08.186.211;A11.251;A08.675.256.200;A11.284.180.225.169;A11.671.240.169;D08.811.913.696.650.450.750;D12.644.360.265;D12.776.476.265;D12.776.543.219;D12.776.631.224;B01.050.150.900.649.313.988.400.112.400.400;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D08.811.399.325.500.700;D12.776.631;G11.561.638;G02.111.665;G02.607.780;G03.796;A08.850.800.500;A11.284.149.165.420.780.800.500;D12.776.157.530.400.400.500.500;D12.776.543.550.450.500.200.500;D12.776.543.585.400.500.200.500;D12.776.543.750.720.200.450.400.500;D12.776.947.500;D12.776.220.600.450.510;D12.776.631.560.510
28458792,Glomus Tumor;General Surgery;Trachea,C04.557.645.350;H02.403.810.300;A04.889
28458126,"Alleles;Anaplastic Lymphoma Kinase;Genetic Predisposition to Disease;Genome-Wide Association Study;Homeodomain Proteins;Humans;Mutation;Neuroblastoma;Polymorphism, Single Nucleotide;Receptor Protein-Tyrosine Kinases;Transcription Factors",G05.360.340.024.340.030;D08.811.913.696.620.682.725.400.002;D12.776.543.750.630.002;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.776.260.400;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;G05.365.795.598;D08.811.913.696.620.682.725.400;D12.776.543.750.630;D12.776.930
28458017,Adolescent;Adult;Automobile Driving;Cell Phone;Distracted Driving;Humans;Parent-Child Relations;Parents;Peer Group;Risk-Taking;Surveys and Questionnaires;Distracted Driving;Cell Phone,M01.060.057;M01.060.116;I03.125;L01.178.847.698.300;I03.125.474;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.370.290;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.829.316.483;F01.145.722;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I03.125.474;L01.178.847.698.300
28457697,"Adult;Aged;Allografts;Analysis of Variance;Cohort Studies;Databases, Factual;Graft Survival;Heart Transplantation;Humans;Kaplan-Meier Estimate;Middle Aged;Retrospective Studies;Survival Analysis;Time Factors;Time-to-Treatment;Tissue Donors;Tissue and Organ Harvesting;Tissue and Organ Procurement;Transplant Recipients;United States;Allografts;Tissue Donors;Patient Selection",M01.060.116;M01.060.116.100;A01.941.500;E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;G12.875.545.340;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G01.910.857;E02.760.928;N02.421.585.928;M01.898;E04.936.537;N02.421.911;M01.925;Z01.107.567.875;A01.941.500;M01.898;E05.581.500.653;N04.590.731
28457475,,
28457235,"Ablation Techniques;Adult;Atrial Fibrillation;Electrocardiography;Heart Defects, Congenital;Humans;Tachycardia, Supraventricular;Atrial Fibrillation",E04.014;M01.060.116;C14.280.067.198;C23.550.073.198;E01.370.370.380.240;E01.370.405.240;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;C14.280.067.845.880;C14.280.123.875.880;C23.550.073.845.880;C14.280.067.198;C23.550.073.198
28457152,Buprenorphine;Humans;Naltrexone;Narcotic Antagonists;Opioid-Related Disorders;Substance Withdrawal Syndrome;Buprenorphine;Naltrexone;Opioid-Related Disorders;Outpatients,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;B01.050.150.900.649.313.988.400.112.400.400;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;D27.505.696.543;D27.505.696.663.850.512;D27.505.954.427.550;C25.775.675;F03.900.675;C25.775.835;F03.900.825;D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;C25.775.675;F03.900.675;M01.643.630
28456991,Animals;Autophagy;Endocytosis;Humans;Lysosomes;Neoplasms;Phagocytosis;Autophagy;Neoplasms;Drug Therapy;Lysosomes,B01.050;G04.146.399;G04.417.350.091;G04.417;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.190.550;C04;G04.417.350;G09.188.665;G12.450.564.809;G12.688;G04.146.399;G04.417.350.091;C04;E02.319;A11.284.430.214.190.875.190.550
28456694,"Activities of Daily Living;Aged;Aged, 80 and over;Chronic Disease;Cohort Studies;Health Status;Humans;Institutionalization;Insurance Benefits;Medicare;Outcome Assessment (Health Care);Predictive Value of Tests;Recovery of Function;Surveys and Questionnaires;United States",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116.100;M01.060.116.100.080;C23.550.291.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;E02.760.415;N02.421.585.415;N03.219.521.576.130;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;G16.757;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875
28456065,Adolescent;Adult;Anti-HIV Agents;Child;HIV Infections;Humans;Outcome Assessment (Health Care);Philadelphia;Post-Exposure Prophylaxis;Retrospective Studies;Sex Offenses,M01.060.057;M01.060.116;D27.505.954.122.388.077.088;M01.060.406;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;Z01.107.567.875.500.550.525;Z01.433.820;N02.421.726.755;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.198.240.748
28455909,"Adolescent;Child;Child, Preschool;Databases, Factual;Emergency Service, Hospital;Heart Transplantation;Hospital Charges;Humans;Infant;Infant, Newborn;Length of Stay;Logistic Models;Patient Admission;Postoperative Complications;Retrospective Studies;United States;Emergency Service, Hospital;Heart Transplantation",M01.060.057;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E04.100.376.475;E04.928.220.390;E04.936.450.475;N03.219.262.300;N03.219.442.613;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E02.760.400.600;N02.421.585.400.600;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E04.100.376.475;E04.928.220.390;E04.936.450.475
28455385,"Administration, Intravenous;Brain Ischemia;Endovascular Procedures;Humans;Multicenter Studies as Topic;Randomized Controlled Trials as Topic;Stroke;Thrombectomy;Time Factors;Tissue Plasminogen Activator;Treatment Outcome",E02.319.267.082;C10.228.140.300.150;C14.907.253.092;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C10.228.140.300.775;C14.907.253.855;E04.100.814.842;G01.910.857;D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28455282,"Animals;Apoptosis;Arterioles;Biomarkers;Blood Platelets;Bone Marrow Cells;Cell Differentiation;Cell Lineage;Endocytosis;Factor V;Flow Cytometry;Gene Expression;Humans;Immunophenotyping;Lasers;Megakaryocyte Progenitor Cells;Megakaryocytes;Mice;Mice, SCID;Platelet Glycoprotein GPIb-IX Complex",B01.050;G04.146.160;A07.015.114.060;A07.015.461.080;D23.101;A11.118.188;A15.145.229.188;A11.148;A15.378.316;G04.152;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.417;D12.776.124.125.300;D23.119.300;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G05.297;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;E07.632.490;E07.710.520;A11.148.378.590.837.625;A11.872.378.590.817.625;A15.378.316.378.590.837.625;A11.148.479;A15.378.316.479;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.780;D12.776.395.550.625.460;D12.776.543.550.625.460;D12.776.543.750.705.675.568
28455078,"Adult;Androgens;Cross-Sectional Studies;Humans;Infertility, Female;Polycystic Ovary Syndrome;Sexual Dysfunction, Physiological;Infertility;Polycystic Ovary Syndrome",M01.060.116;D27.505.696.399.472.161;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;C13.351.500.365.700;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;C12.294.644;C13.351.500.665;C12.294.365;C13.351.500.365;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765
28454986,"Child;Debridement;Follow-Up Studies;Humans;Penis;Radiography;Reconstructive Surgical Procedures;Urethra;Urologic Surgical Procedures, Male;Wounds, Gunshot",M01.060.406;E04.176;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;A05.360.444.492;E01.370.350.700;E04.680;A05.360.444.492.726;A05.810.876;E04.950.774.860;C26.986.900
28454906,Ambulatory Care Facilities;Anticoagulants;Blood Coagulation;Drug Monitoring;Humans;International Normalized Ratio;Medication Adherence;Middle Aged;Multicenter Studies as Topic;Prospective Studies;Self Report;Thromboembolism;Urban Health Services;Visual Analog Scale;Warfarin;Medication Adherence;Warfarin,N02.278.035;D27.505.954.502.119;G09.188.390.150;E01.370.520.200;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.625.115.320;E05.200.625.115.320;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;C14.907.355.590;N02.421.914;E01.370.928;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
28454787,,
28454786,,
28454785,,
28454291,Apoptosis;Cell Cycle Checkpoints;Thioridazine,G04.146.160;G04.144.109;D02.886.369.843;D03.633.300.783.843
28454238,"Receptors, Dopamine;Stomach Neoplasms;Thioridazine",D12.776.543.750.670.300.400;D12.776.543.750.695.150.400;D12.776.543.750.720.330.400;C04.588.274.476.767;C06.301.371.767;C06.405.249.767;C06.405.748.789;D02.886.369.843;D03.633.300.783.843
28453910,"Central Nervous System Diseases;Humans;Infant;Leukemia, Myeloid, Acute;Prognosis;Treatment Outcome;Therapeutics",C10.228;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.337.539.275;E01.789;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02
28453858,"Exome;Genetic Predisposition to Disease;Genotype;Heterozygote;Humans;Hypopituitarism;Infant, Newborn;Membrane Proteins;Mutation;Pedigree;Pituitary Gland;Proto-Oncogene Proteins;Receptors, G-Protein-Coupled;Receptors, Peptide;Syndrome",G05.360.340.011;C23.550.291.687.500;G05.380.355;G05.380;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.617.738.300;C19.700.482;M01.060.703.520;D12.776.543;G05.365.590;E05.393.673;A06.300.747;A06.688.357.750;A08.186.211.180.497.352.435.500;A08.186.211.200.317.357.352.435.500;A08.713.357.750;D12.776.624.664.700;D12.776.543.750.695;D12.776.543.750.750;C23.550.288.500
28453665,,
28453637,"Adolescent;Algorithms;Body Height;Body Weight;Child;Child, Preschool;Datasets as Topic;Electronic Health Records;Growth;Growth Charts;Humans;Infant;Primary Health Care;Young Adult;Data Accuracy;Growth;Research Design",M01.060.057;G17.035;L01.224.050;E01.370.600.115.100.160.100;E05.041.124.160.500;G07.100.100.160.100;G07.345.249.314.100;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;M01.060.406;M01.060.406.448;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;E05.318.308.940.968.625.500;G07.345.249;E05.978.808.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N04.590.233.727;M01.060.116.815;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;G07.345.249;E05.581.500;H01.770.644.728
28453612,"Animals;Aspartic Acid;Cell Cycle Proteins;Cells, Cultured;DNA Breaks, Double-Stranded;DNA Breaks, Single-Stranded;DNA, Single-Stranded;DNA-Binding Proteins;Immunoprecipitation;Meiosis;Mice;Models, Molecular;Replication Protein A;Meiosis",B01.050;D12.125.067.500;D12.125.119.170;D12.125.427.040;D12.776.167;A11.251;G05.200.210.220;G05.200.210.230;D13.444.308.497;G02.111.570.820.486.437;G05.360.580.437;D12.776.260;E05.196.150.639;E05.478.605;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;E05.599.595;D12.776.260.700;G04.144.220.220.687;G05.113.220.687
28453469,"Aged;Aged, 80 and over;Analgesics, Opioid;Anti-Inflammatory Agents, Non-Steroidal;Autopsy;Brain;Cohort Studies;Dementia;Humans;Residence Characteristics;Alzheimer Disease;Plaque, Amyloid;Neurofibrillary Tangles;Neuropathology;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Opioid",M01.060.116.100;M01.060.116.100.080;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;E01.370.060;E05.070;I01.198.780.937.120;A08.186.211;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C10.228.140.380;F03.615.400;B01.050.150.900.649.313.988.400.112.400.400;N01.224.791;N06.850.505.400.800;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C23.300.821;A08.675.609.520;A11.284.430.214.190.750.640.520;A11.671.573.520;H01.158.610.184;H02.403.600.250;H02.403.650.375;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
28453189,"Adolescent;Child;Child, Preschool;Humans;Infant;Isoquinolines;Nausea;Neoplasms;Palonosetron;Practice Guidelines as Topic;Quinuclidines;Serotonin Antagonists;Vomiting;Drug Therapy;Guideline;Nausea;Pediatrics;Vomiting",M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D03.633.100.531;C23.888.821.712;C04;D03.605.687.319;D03.633.100.531.629;N04.761.700.350.650;N05.700.350.650;D03.605.687;D27.505.519.625.850.850;D27.505.696.577.850.850;C23.888.821.937;E02.319;V02.515;C23.888.821.712;H02.403.670;C23.888.821.937
28452704,"Bacterial Infections;Bacteriolysis;Cells, Cultured;Chronic Disease;Humans;Immunity, Innate;Mucociliary Clearance;Nasal Mucosa;Nitric Oxide;Paranasal Sinuses;Primary Cell Culture;Receptors, G-Protein-Coupled;Rhinitis;Sinusitis;Taste",C01.252;G06.099.115;A11.251;C23.550.291.500;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;E01.370.386.520;G09.772.555;A04.531.520;A04.760.600;A10.615.550.760.600;D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600;A04.531.621;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;D12.776.543.750.695;C08.460.799;C08.730.674;C09.603.799;C08.460.692.752;C08.730.749;C09.603.692.752;F02.830.816.724;G11.561.790.724
28452409,"Adult;Anesthetics, Dissociative;Biomarkers;Bipolar Disorder;Brain-Derived Neurotrophic Factor;Dose-Response Relationship, Drug;Double-Blind Method;Drug Monitoring;GABA Modulators;Humans;Ketamine;Memory;Midazolam;Middle Aged;Suicidal Ideation;Treatment Outcome;Bipolar Disorder;Depression;Ketamine;Midazolam;Suicidal Ideation",M01.060.116;D27.505.696.277.100.035.075.035;D27.505.954.427.210.100.035.075.035;D23.101;F03.084.500;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E01.370.520.200;D27.505.519.625.240.500;D27.505.696.577.240.500;B01.050.150.900.649.313.988.400.112.400.400;D02.455.426.392.368.367.652;F02.463.425.540;D03.633.100.079.080.575;M01.060.116.630;F01.145.126.980.875.149;I01.880.735.856.149;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;F03.084.500;F01.145.126.350;D02.455.426.392.368.367.652;D03.633.100.079.080.575;F01.145.126.980.875.149;I01.880.735.856.149
28451963,,
28451918,"Adolescent;Adult;Aged;Bone Density;Bone Diseases;Bone and Bones;Child;Child, Preschool;Cross-Sectional Studies;Humans;Infant;Infant, Newborn;Middle Aged;Mitochondrial Diseases;Retrospective Studies;Risk Assessment;Risk Factors;Young Adult;Bone Density;Mitochondrial Diseases;Bone Diseases, Metabolic;Osteoporosis",M01.060.057;M01.060.116;M01.060.116.100;G11.427.100;C05.116;A02.835.232;A10.165.265;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.116.630;C18.452.660;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815;G11.427.100;C18.452.660;C05.116.198;C18.452.104;C05.116.198.579;C18.452.104.579
28451895,"Humans;Hypernatremia;Kidney Failure, Chronic;Sodium Chloride;Sodium Chloride, Dietary;Sweat;Bethanechol;Kidney Failure, Chronic;Hypernatremia",B01.050.150.900.649.313.988.400.112.400.400;C18.452.950.452;C12.777.419.780.750.500;C13.351.968.419.780.750.500;D01.210.450.150.875;D01.857.650;D01.857.650.705;D01.857.875.705;A12.200.849;D02.092.877.883.088.100;D02.241.081.251.133.100;D02.675.276.148.100;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C18.452.950.452
28451894,"Bethanechol;Child, Preschool;Humans;Hypernatremia;Infant;Kidney Failure, Chronic;Muscarinic Agonists;Renal Dialysis;Sweating;Kidney Failure, Chronic;Hypernatremia",D02.092.877.883.088.100;D02.241.081.251.133.100;D02.675.276.148.100;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C18.452.950.452;M01.060.703;C12.777.419.780.750.500;C13.351.968.419.780.750.500;D27.505.519.625.120.140.500;D27.505.696.577.120.140.500;E02.870.300;E02.912.800;G07.110.232.693;G07.410.421.693;G13.750.860;G16.012.500.535.693;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C18.452.950.452
28450890,Artificial Intelligence;Classification;Data Mining;Machine Learning,G17.035.250;L01.224.050.375;L01.100;L01.453.245.275;L01.313.500.750.280.199;L01.470.625;G17.035.250.500;L01.224.050.375.530
28450349,"Animals;Atherosclerosis;Capillary Permeability;Endothelial Cells;Humans;Mice;Mice, Inbred C57BL;Mice, Knockout;Receptors, CXCR4;Wnt Signaling Pathway;Atherosclerosis;Cadherins;Endothelial Cells;Permeability;Receptors, CXCR4",B01.050;C14.907.137.126.307;G03.143.330;G09.330.165;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.543.750.695.160.500.400;D12.776.543.750.705.852.125.500.400;D12.776.543.750.830.700.650;G02.111.820.925;G04.835.925;C14.907.137.126.307;D12.776.395.550.200.200;D12.776.543.550.200.200;D23.050.301.350.200;A11.436.275;G02.723;D12.776.543.750.695.160.500.400;D12.776.543.750.705.852.125.500.400;D12.776.543.750.830.700.650
28450230,"Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Brain Neoplasms;Humans;Immunohistochemistry;Laminectomy;Lung Neoplasms;Magnetic Resonance Imaging;Metastasectomy;Sarcoma, Alveolar Soft Part;Spinal Cord Neoplasms;Thoracic Vertebrae;Young Adult;Sarcoma, Alveolar Soft Part;Laminectomy;Spinal Cord",D12.776.260.103.500;D12.776.260.108.092;D12.776.930.125.500;D12.776.930.127.092;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E02.718.563;E04.188.400;E04.525.450;E04.555.350;C04.588.894.797.520;C08.381.540;C08.785.520;E01.370.350.825.500;E04.480;C04.557.450.590.775;C04.557.450.795.775;C04.588.614.250.803;C10.228.854.765;C10.551.240.750;A02.835.232.834.892;M01.060.116.815;C04.557.450.590.775;C04.557.450.795.775;E02.718.563;E04.188.400;E04.525.450;E04.555.350;A08.186.854
28450221,"Adiposity;Adult;Birth Weight;Forecasting;Gestational Age;Humans;Infant;Infant, Newborn;Inflammation;Life Style;Mothers;Obesity;Pregnancy;Pregnancy Complications;Pregnancy Outcome;Prospective Studies;Psychology;Socioeconomic Factors;United States;Inflammation;Pregnancy;Social Class",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.060.116;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;I01.320;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C23.550.470;F01.829.458;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G08.686.784.769;C13.703;E01.789.700;G08.686.784.769.496;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.096.628;I01.880.853.996;N01.824;Z01.107.567.875;C23.550.470;G08.686.784.769;I01.880.853.996.755;N01.824.782
28449959,"Adolescent;Costs and Cost Analysis;Databases, Factual;Health Resources;Humans;Length of Stay;Operative Time;Orthopedic Surgeons;Pedicle Screws;Procedures and Techniques Utilization;Prospective Studies;Scoliosis;Spinal Fusion;Treatment Outcome;Costs and Cost Analysis;Operative Time;Scoliosis",M01.060.057;N03.219.151;L01.313.500.750.300.188.400;L01.470.750.750;N03.349.340;N05.300.420;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;E04.614.374.500;N02.421.585.753.374.500;M01.526.485.810.910.875;N02.360.810.910.875;E07.695.370.437.500;E07.858.442.660.460.437.500;E07.858.690.725.460.437.500;E05.318.740.675;H01.548.832.750;N05.715.360.750.660;N06.850.520.830.675;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C05.116.900.800.875;E04.555.100.700;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N03.219.151;E04.614.374.500;N02.421.585.753.374.500;C05.116.900.800.875
28449820,"Adolescent;Age Factors;Blood Pressure;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Kidney Function Tests;Outcome Assessment (Health Care);Quality of Life;Randomized Controlled Trials as Topic;Recurrence;Renal Insufficiency, Chronic;Young Adult;Child;Renal Insufficiency, Chronic;Systematic Review",M01.060.057;N05.715.350.075;N06.850.490.250;E01.370.600.875.249;G09.330.380.076;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.390.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C23.550.291.937;C12.777.419.780.750;C13.351.968.419.780.750;M01.060.116.815;M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;V03.850
28449393,"Adolescent;Adult;Child;Child, Preschool;Drug Resistance, Neoplasm;Humans;Infant;Maximum Tolerated Dose;Neoplasm Recurrence, Local;Neoplasm Staging;Neoplasms;Pilot Projects;Prognosis;Proto-Oncogene Proteins c-met;Pyrrolidinones;Quinolines;Salvage Therapy;Tissue Distribution;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;G07.690.773.984.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.940.481;G07.690.936.625;C04.697.655;C23.550.727.655;E01.789.625;C04;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E01.789;D08.811.913.696.620.682.725.400.075;D12.776.543.750.630.186;D12.776.543.750.750.400.100;D12.776.624.664.700.186;D03.383.773.812;D03.633.100.810;E02.895;G03.787.917;G07.690.725.949;M01.060.116.815
28449033,Brain;Brain Neoplasms;Child;Humans;Medulloblastoma;Meningeal Neoplasms;Neoplasm Seeding;Neuroimaging;Brain;Medulloblastoma;Neoplasms,A08.186.211;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;C04.588.614.250.580;C10.551.240.500;C04.697.650.830;C23.550.727.650.830;E01.370.350.578;E01.370.376.537;E05.629;A08.186.211;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;C04
28448387,"Arthroplasty, Replacement;Decision Making;Humans;Patient Participation;Practice Patterns, Physicians'",E04.555.110.110;E04.650.110;E04.680.101.110;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;N04.590.374.577;N05.300.625
28448199,Deferiprone;Erythrocyte Transfusion;Humans;Iron;Iron Overload;Myocardium;Neutropenia;Pyridones;Thalassemia;Thalassemia;Deferiprone;Iron Overload;Magnetic Resonance Imaging,D03.383.725.791.298;E02.095.135.140.275;B01.050.150.900.649.313.988.400.112.400.400;D01.268.556.412;D01.268.956.287;D01.552.544.412;C18.452.565.500;A02.633.580;A07.541.704;A10.690.552.750;C15.378.553.546.184.564;D03.383.725.791;C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826;C15.378.071.141.150.875;C15.378.420.826;C16.320.070.875;C16.320.365.826;D03.383.725.791.298;C18.452.565.500;E01.370.350.825.500
28447668,"Alleles;Cell Line, Tumor;Chromosome Mapping;Chromosomes, Human, Pair 5;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Genetic Loci;Genetic Predisposition to Disease;Genome-Wide Association Study;Histones;Humans;Lung Neoplasms;Melanoma;Pancreatic Neoplasms;Polymorphism, Single Nucleotide;RNA, Small Interfering;Signal Transduction;Skin Neoplasms;Telomerase;Telomere Homeostasis;Testicular Neoplasms;Transcription Factors",G05.360.340.024.340.030;A11.251.210.190;A11.251.860.180;E05.393.183;A11.284.187.520.300.280.290;G05.360.162.520.300.280.290;D12.776.260;G05.308.370;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;G05.365.795.598;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;G02.111.820;G04.835;C04.588.805;C17.800.882;D08.811.913.696.445.308.300.750.750;D12.776.157.687.613;D12.776.157.725.500.921;D12.776.660.720.613;D12.776.664.962.500.921;G04.144.220.625;G04.161.750.500.500;G05.113.610;G07.345.249.410.750.500.750;C04.588.322.762;C04.588.945.440.915;C12.294.260.937;C12.758.409.937;C19.344.762;C19.391.829.782;D12.776.930
28447413,"Administration, Oral;Adult;Aged;Aged, 80 and over;Animals;Anticoagulants;Drug Monitoring;Electronic Health Records;Humans;Middle Aged;Pyrazoles;Pyridones;Retrospective Studies;Rivaroxaban;Laboratories",E02.319.267.100;M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050;D27.505.954.502.119;E01.370.520.200;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D03.383.129.539;D03.383.725.791;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D02.886.778.727;D03.383.533.640.713;D03.383.903.727;J03.520;N02.278.487
28447379,,
28446663,Adult;Age Factors;Aged;Biomarkers;California;Cohort Studies;Graft Rejection;Graft Survival;Humans;Living Donors;Lung Transplantation;Middle Aged;Risk Assessment;Risk Factors;Telomere;Telomere Shortening;Transplant Recipients;Treatment Outcome;Lung Transplantation,M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;D23.101;Z01.107.567.875.580.200;Z01.107.567.875.760.200;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G12.875.545.328;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;M01.898.656;E04.928.600.495;E04.936.450.495;M01.060.116.630;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G02.111.225.940;G04.043.630;G05.226.940;M01.925;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E04.928.600.495;E04.936.450.495
28446492,"Adolescent;Biopsy;Cardiac Catheterization;Collagen;Cross-Sectional Studies;Echocardiography;Fontan Procedure;Heart Defects, Congenital;Hemodynamics;Humans;Liver;Liver Cirrhosis;Retrospective Studies;Risk Factors;Time Factors;Treatment Outcome;Young Adult;Fontan Procedure;Fibrosis",M01.060.057;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;E01.370.370.380.140;E02.148.442;E05.157.250;D05.750.078.280;D12.776.860.300.250;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;A03.620;C06.552.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C23.550.355
28446380,"Adult;Continuous Positive Airway Pressure;Humans;Intellectual Disability;Sleep Apnea, Obstructive",M01.060.116;E02.041.625.790.259;E02.880.820.790.259;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C08.618.085.852.850;C10.886.425.800.750.850
28446220,"Algorithms;Alleles;Animals;Blastocyst;Cells, Cultured;Diploidy;Fibroblasts;Gene Expression Profiling;Humans;Mice;Models, Genetic;Sequence Analysis, RNA;Single-Cell Analysis",G17.035;L01.224.050;G05.360.340.024.340.030;B01.050;A16.254.500;A11.251;G05.700.264;A11.329.228;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;E05.599.395.397;E05.393.760.710;E05.242.900
28446159,Aged;Centers for Medicare and Medicaid Services (U.S.);Hospitalization;Humans;Insurance Claim Reporting;Medicaid;Medicare;Middle Aged;Pharmacoepidemiology;United States;Centers for Medicare and Medicaid Services (U.S.);Data Accuracy;International Classification of Diseases;Medicaid;Medicare;Pharmacoepidemiology,M01.060.116.100;I01.409.418.750.600.310;N03.540.348.500.500.600.550;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.210;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.630;H01.158.703.045;H02.403.720.500.650;H02.628.413;Z01.107.567.875;I01.409.418.750.600.310;N03.540.348.500.500.600.550;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;L01.453.245.945.400;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;H01.158.703.045;H02.403.720.500.650;H02.628.413
28445797,"Cohort Studies;Colectomy;Delivery of Health Care;Health Care Costs;Humans;Incidence;Incisional Hernia;Middle Aged;Models, Statistical;Postoperative Complications;Retrospective Studies;Risk Assessment;Risk Factors",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E04.210.219;N04.590.374;N05.300;N03.219.151.400;N05.300.375;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C23.300.707.945;C23.550.767.500;M01.060.116.630;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28445472,"Animals;Bone Morphogenetic Proteins;Cervical Cord;Chondrogenesis;Disease Models, Animal;Embryonic Development;Exostoses, Multiple Hereditary;Growth Plate;Heparitin Sulfate;Humans;Magnetic Resonance Imaging;Mice;Mice, Knockout;Mutation;N-Acetylglucosaminyltransferases;Osteochondroma;Pyrazoles;Pyrimidines;Smad1 Protein;Tomography, Emission-Computed",B01.050;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;A08.186.854.126;G07.345.500.325.377.625.180;G11.427.578.180;C22.232;E05.598.500;E05.599.395.080;G07.345.500.325.180;G08.686.784.170.104;C04.557.450.565.575.610.615.325;C04.700.330;C05.116.099.708.670.615.325;C05.116.540.310.500;C16.320.700.330;A02.835.232.251.352;D09.698.373.425;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;D08.811.913.400.100.250;C04.557.450.565.575.610;C05.116.099.708.670;D03.383.129.539;D03.383.742;D12.644.360.024.334.500.100;D12.776.157.057.170.500.100;D12.776.260.713.500.100;D12.776.476.024.428.500.100;D12.776.744.741.500;D12.776.930.806.500.100;E01.370.350.350.800;E01.370.350.600.350.800;E01.370.350.710.800;E01.370.350.825.800;E01.370.384.730.800
28444867,"Adult;Antiviral Agents;Chromatography, Liquid;Drug Administration Schedule;Emtricitabine;HIV Infections;Humans;Medication Adherence;Middle Aged;Pilot Projects;Pre-Exposure Prophylaxis;Tandem Mass Spectrometry;Tenofovir;Young Adult;Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination;Pre-Exposure Prophylaxis",M01.060.116;D27.505.954.122.388;E05.196.181.400;E02.319.283;D03.383.742.680.245.500.600;D13.570.230.329.525;D13.570.685.245.500.600;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;N02.421.726.758.655;N06.850.780.680.655;E05.196.566.880;D02.705.429.906;D03.633.100.759.138.881;M01.060.116.815;D02.705.429.906.750;D03.383.742.680.245.500.600.750;D03.633.100.759.138.881.750;D13.570.230.329.525.500;D13.570.685.245.500.600.500;D26.310.423;N02.421.726.758.655;N06.850.780.680.655
28444784,"Adolescent;Adult;Aged;Child;Child, Preschool;Drug Administration Schedule;Hematopoietic Stem Cell Transplantation;Hepatic Veno-Occlusive Disease;Humans;Infant;Middle Aged;Platelet Aggregation Inhibitors;Polydeoxyribonucleotides;Prospective Studies;Survival Analysis;Transplantation Conditioning;Treatment Outcome;Young Adult;Hepatic Veno-Occlusive Disease;Survival",M01.060.057;M01.060.116;M01.060.116.100;M01.060.406;M01.060.406.448;E02.319.283;E02.095.147.500.500.500;E04.936.225.687.500;C06.552.360;C14.907.460;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;D27.505.954.502.780;D13.695.578.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;E02.095.465.425.450.800;E05.478.610.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C06.552.360;C14.907.460;I03.784
28444518,Parenting,F01.829.263.370.310
28444278,Aged;Cohort Studies;Colonoscopy;Colorectal Neoplasms;Disease Progression;Early Detection of Cancer;Humans;Middle Aged;Neoplasm Staging;Occult Blood;Odds Ratio;Retrospective Studies;Risk Factors;Time Factors,M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;C23.550.291.656;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.789.625;E01.370.225.925;E05.200.925;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857
28444172,,
28443274,Guatemala;Capacity Building;Global Health,Z01.107.169.454;N02.138;N04.452.105;H02.403.371;N01.400.337
28442885,"Animals;Calcium-Binding Proteins;Cell Movement;Gene Knockout Techniques;Light;Macrophages;Mice;Mice, Inbred BALB C;Mice, Knockout;Microfilament Proteins;Microglia;RNA, Messenger;Radiation Injuries, Experimental;Real-Time Polymerase Chain Reaction;Receptor, Anaphylatoxin C5a;Receptors, G-Protein-Coupled;Retina;Retinal Degeneration",B01.050;D12.776.157.125;G04.198;G07.568.500.180;E05.393.335.750;G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D05.750.078.730;D12.776.220.525;A08.637.400;A11.650.400;D13.444.735.544;C26.733.720;E05.598.500.750;G01.750.748.500.720;N06.850.460.350.850.500.285;N06.850.810.300.360.285;E05.393.620.500.706;D12.776.543.750.695.024;D12.776.543.750.705.833.550;D12.776.543.750.695;A09.371.729;C11.270.612;C11.768.585
28442472,"Alanine;Calcium;Carbon Isotopes;Case-Control Studies;Congenital Hyperinsulinism;Flow Cytometry;Gene Expression;Glucose;Glutamine;Glycine;Glycolysis;Humans;Immunohistochemistry;Infant;Infant, Newborn;Insulin;Insulin Secretion;Insulin-Secreting Cells;Islets of Langerhans;KATP Channels;Metabolomics;Microscopy, Electron, Transmission;Mutation;Oxygen Consumption;Pancreatectomy;Potassium Channels, Inwardly Rectifying;RNA, Messenger;Sequence Analysis, RNA;Serine;Sulfonylurea Receptors;gamma-Aminobutyric Acid",D12.125.042;D01.268.552.100;D01.552.539.288;D23.119.100;D01.268.150.075;D01.496.123;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G05.297;D09.947.875.359.448;D12.125.068.330;D12.125.095.461;D12.125.154.424;D12.125.481;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.703;M01.060.703.520;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;G03.442;G07.475;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;A03.734.414;A06.300.414;D12.776.157.530.400.600.450.550;D12.776.543.550.450.750.450.550;D12.776.543.585.400.750.450.550;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;E01.370.350.515.402.580;E05.595.402.580;G05.365.590;G03.680;E04.210.752;D12.776.157.530.400.600.450;D12.776.543.550.450.750.450;D12.776.543.585.400.750.450;D13.444.735.544;E05.393.760.710;D12.125.154.800;D12.776.157.530.400.600.450.550.500;D12.776.543.550.450.750.450.550.500;D12.776.543.585.100.805;D12.776.543.585.400.750.450.550.500;D12.776.827.775;D02.241.081.114.500.350;D12.125.190.350
28442194,Child;Child Abuse;Humans;International Cooperation;Interprofessional Relations;Multicenter Studies as Topic;Physical Abuse;Research;Surveys and Questionnaires;Physical Abuse,M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;F01.829.401.205;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;I01.198.240.856.688;I01.880.735.900.744;H01.770.644;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I01.198.240.856.688;I01.880.735.900.744
28442181,"Adolescent;Adult;Child;Child, Preschool;Cost of Illness;Cross-Sectional Studies;Databases, Factual;Health Services Research;Hospital Mortality;Hospitalization;Humans;Infant;Longitudinal Studies;Middle Aged;Mitochondrial Diseases;United States;Young Adult;Health Services Research;Hospitalization;Mitochondrial Diseases",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;L01.313.500.750.300.188.400;L01.470.750.750;H01.770.644.145.360;N03.349.380;N05.425;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;C18.452.660;Z01.107.567.875;M01.060.116.815;H01.770.644.145.360;N03.349.380;N05.425;E02.760.400;N02.421.585.400;C18.452.660
28441626,"Adenosine;Adipocytes;Aminoisobutyric Acids;Animals;Cardiomegaly;Cyclic AMP;Fatty Acids;Fibrosis;Humans;Liver;Muscle, Skeletal;Myocardium;Vasodilation",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;A11.329.114;D02.241.081.114.968.249;D12.125.070.075;D12.125.190.055;B01.050;C14.280.195;C23.300.775.250;D03.633.100.759.646.138.395;D13.695.462.200;D13.695.667.138.395;D13.695.827.068.395;D10.251;C23.550.355;B01.050.150.900.649.313.988.400.112.400.400;A03.620;A02.633.567;A10.690.552.500;A02.633.580;A07.541.704;A10.690.552.750;G09.330.380.928
28441569,Animals;Autophagy;Cytoskeleton;Humans;Phagosomes;Protein Transport,B01.050;G04.146.399;G04.417.350.091;A11.284.430.214.190.750;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.190.700;G03.143.700
28441533,"Arabidopsis;Arabidopsis Proteins;Cell Nucleus;Gene Expression Regulation, Plant;Plant Roots;Plants, Genetically Modified;RNA;Transcription Factors;RNA-Binding Proteins;Plant Development",B01.650.940.800.575.912.250.157.100;D12.776.765.149;A11.284.430.106;A11.284.430.214.190.875.117;G05.308.375;A18.400;B01.650.520;B05.620.600;D13.444.735;D12.776.930;D12.776.157.725;D12.776.664.962;G07.345.625;G15.589
28441280,,
28441241,,
28441234,Adult;Aged;Algorithms;Clinical Coding;Hospital Administration;Hospital Charges;Hospital Departments;Humans;Intensive Care Units;Middle Aged;Patient Admission;Radio Frequency Identification Device;Retrospective Studies;Sensitivity and Specificity;Socioeconomic Factors;United States,M01.060.116;M01.060.116.100;G17.035;L01.224.050;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;H02.309;N02.278.216.500;N02.278.354;N04.452.442;N03.219.262.300;N03.219.442.613;N02.278.216.500.968;N04.452.442.422;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;M01.060.116.630;E02.760.400.600;N02.421.585.400.600;E07.715;N04.452.653.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;I01.880.853.996;N01.824;Z01.107.567.875
28440921,Child;Humans;Lung Diseases;Neuromuscular Diseases;Pulmonary Medicine;Rare Diseases;Sleep;Bronchoscopy,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C08.381;C10.668;H02.403.429.675;C23.550.291.906;F02.830.855;G11.561.803;E01.370.386.105;E01.370.388.250.100;E04.502.250.100;E04.928.600.080
28440792,"Animals;Animals, Newborn;Extracorporeal Membrane Oxygenation;Fetal Monitoring;Fetus;Hemodynamics;Humans;Infant, Extremely Premature;Lung;Models, Animal;Oxygenators, Membrane;Pilot Projects;Pregnancy;Premature Birth;Sheep, Domestic;Treatment Outcome",B01.050;B01.050.050.282;E02.880.301;E04.292.451;E01.370.378.230;E01.370.520.230;A16.378;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;A04.411;E05.598;E07.652.582;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G08.686.784.769;C13.703.420.491.500;B01.050.150.900.649.313.500.380.791.150;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28440017,Adolescent;Adult;Aged;Ankle Brachial Index;Blood Pressure;Blood Pressure Determination;Head-Down Tilt;Hemodynamics;Humans;Middle Aged;Supine Position;United States;Vascular Stiffness;Young Adult;Vascular Stiffness,M01.060.057;M01.060.116;M01.060.116.100;E01.370.370.140.049;E01.370.600.875.249;G09.330.380.076;E01.370.370.140;E01.370.600.100;G11.427.695.300;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G11.427.695.625;Z01.107.567.875;G09.330.940;M01.060.116.815;G09.330.940
28439762,"Comorbidity;Humans;Mental Disorders;Obesity;Risk Factors;Sex Factors;Anxiety;Depression;Feeding and Eating Disorders;Obesity;Stress Disorders, Post-Traumatic;Substance-Related Disorders",N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;F03;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;F01.470.132;F01.145.126.350;F03.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F03.950.750.500;C25.775;F03.900
28438969,"Animals;Cats;Evoked Potentials, Visual;Excitatory Postsynaptic Potentials;Synapses;Thalamus;Visual Cortex;Visual Fields;Excitatory Postsynaptic Potentials",B01.050;B01.050.150.900.649.313.750.377.750.250.125;G07.265.216.500.425;G11.561.200.500.425;G14.330;G04.580.887.249;G07.265.675.887.249;G07.265.880.750.199;G11.561.570.918.249;G11.561.830.750.199;A08.850;A11.284.149.165.420.780;A08.186.211.200.317.826;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;F02.463.593.932.934;G14.950;G04.580.887.249;G07.265.675.887.249;G07.265.880.750.199;G11.561.570.918.249;G11.561.830.750.199
28438606,"Animals;Cartilage, Articular;Cell Differentiation;Cell Lineage;Cell Proliferation;Cell Size;Chondrocytes;Chondrogenesis;Collagen;Growth Differentiation Factor 5;Knee Injuries;Knee Joint;Mesenchymal Stem Cells;Mice;Mice, Transgenic;Synovial Membrane;Mice",B01.050;A02.165.407.150;A02.835.583.192;G04.152;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;G04.161.750;G07.345.249.410.750;G04.325;A11.329.171;G07.345.500.325.377.625.180;G11.427.578.180;D05.750.078.280;D12.776.860.300.250;D12.644.276.954.300.500;D12.776.467.942.300.500;D23.529.942.300.500;C26.558.554;A02.835.583.475;A11.329.830.500;A11.872.590.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;A02.835.583.443.800;B01.050.150.900.649.313.992.635.505.500
28438461,"Adult;Anti-Bacterial Agents;Bacteremia;Bone Marrow Transplantation;Humans;Leukemia, Myeloid, Acute;Rhodopseudomonas;Leukemia, Myeloid, Acute;Bacteremia;Rhodopseudomonas",M01.060.116;D27.505.954.122.085;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;E02.095.147.725.040;E04.936.580.040;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;B03.440.400.425.200.700;B03.660.050.035.700;C04.557.337.539.275;C01.252.100;C01.539.757.100;C23.550.470.790.500.100;B03.440.400.425.200.700;B03.660.050.035.700
28438431,"Aged;Glottis;Humans;Laryngeal Neoplasms;Middle Aged;Neoplasm Staging;Organ Sparing Treatments;Phantoms, Imaging;Radiation Dose Hypofractionation;Radiosurgery;Radiotherapy Dosage;Radiotherapy Planning, Computer-Assisted;Radiotherapy, Image-Guided;Reproducibility of Results;Sensitivity and Specificity;Treatment Outcome;Laryngeal Neoplasms",M01.060.116.100;A04.329.364;B01.050.150.900.649.313.988.400.112.400.400;C04.588.443.665.481;C08.360.369;C08.785.481;C09.400.369;C09.647.481;M01.060.116.630;E01.789.625;E02.674;E07.671;E02.815.639.200.500;E02.815.530;E04.525.800.650;E05.873.500;E02.815.639;E02.950.825;L01.313.500.750.100.710.600.608;E02.815.768;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.588.443.665.481;C08.360.369;C08.785.481;C09.400.369;C09.647.481
28438156,"Adult;Aged;Alleles;Diabetes Mellitus, Type 1;Diabetes Mellitus, Type 2;Humans;Middle Aged;Protein Tyrosine Phosphatase, Non-Receptor Type 22;Latent Autoimmune Diabetes in Adults",M01.060.116;M01.060.116.100;G05.360.340.024.340.030;C18.452.394.750.124;C19.246.267;C20.111.327;C18.452.394.750.149;C19.246.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D08.811.277.352.650.775.300.930;D12.644.360.585.930;D12.776.476.564.930;C18.452.394.750.714;C19.246.656;C20.111.576
28437520,"Apnea;Birth Weight;Caffeine;Central Nervous System Stimulants;Child Behavior Disorders;Child Development;Citrates;Developmental Disabilities;Double-Blind Method;Educational Status;Follow-Up Studies;Humans;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Infant, Very Low Birth Weight;Motor Disorders",C08.618.085;C23.888.852.130;C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;D03.132.960.175;D03.633.100.759.758.824.175;D27.505.696.282;D27.505.954.427.220;F03.625.141;F01.525.200;G07.345.374.750;D02.241.081.901.434;F03.625.421;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;N01.824.196;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;C16.614.521;M01.060.703.520.460.600;F03.608
28437291,"Behcet Syndrome;Child;Diagnosis, Differential;Humans;Rheumatic Diseases;Venous Thrombosis",C07.465.075;C11.941.879.780.880.200;C14.907.940.100;C16.320.382.250;C17.800.827.368.250;C17.800.862.150;M01.060.406;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C05.799;C17.300.775;C14.907.355.830.925
28437266,"Child, Preschool;Cleft Palate;Gelatin Sponge, Absorbable;Hemostatics;Humans;Infant;Nose Diseases;Oral Fistula;Postoperative Hemorrhage;Reconstructive Surgical Procedures;Retrospective Studies",M01.060.406.448;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;E07.858.740.300;D27.505.954.502.270.463;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C08.460;C09.603;C07.465.614;C23.300.575.500;C23.550.414.941;C23.550.767.850;E04.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28437216,"Adult;Cigarette Smoking;Depression;Humans;Perinatal Care;Pregnancy;Pregnancy Complications;Psychiatric Status Rating Scales;Smoking;Stress Disorders, Post-Traumatic;Stress, Psychological;Surveys and Questionnaires;Urban Population;Young Adult;Stress Disorders, Post-Traumatic;Obstetrics;Pregnancy;Smoking",M01.060.116;F01.145.805.375.750;F01.145.958.875.750;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;E02.760.703;N02.421.088.120.180;N02.421.143.620.550;N02.421.585.703;G08.686.784.769;C13.703;F04.711.513.653;F01.145.805;F03.950.750.500;F01.145.126.990;F02.830.900;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N01.600.900;M01.060.116.815;F03.950.750.500;H02.403.810.450;G08.686.784.769;F01.145.805
28437090,"Antineoplastic Agents;Cell Line, Tumor;Cell Survival;Drug Carriers;Drug Compounding;Drug Liberation;Epithelial Cells;Erlotinib Hydrochloride;Humans;Kinetics;Light;Micelles;Photochemotherapy;Photosensitizing Agents;Polyesters;Polyethylene Glycols;Protoporphyrins",D27.505.954.248;A11.251.210.190;A11.251.860.180;G04.346;D26.255.260;E02.319.300.380;E05.916.270;G02.211;G03.787.321;G07.690.725.321;A11.436;D03.633.100.786.375;B01.050.150.900.649.313.988.400.112.400.400;G01.374.661;G02.111.490;G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578;D05.374;D26.255.560;E02.186.500;E02.319.685;E02.774.722;D27.505.954.444.600;D27.505.954.600.710;D05.750.728;D25.720.728;J01.637.051.720.728;D02.033.455.250.700;D05.750.741;D25.720.741;J01.637.051.720.741;D03.383.129.578.840.500.725;D03.633.400.909.500.725;D04.345.783.500.725;D23.767.727.725
28436984,"Adolescent;Age Factors;Body Mass Index;Databases, Genetic;Genetic Predisposition to Disease;Genome-Wide Association Study;Genomic Imprinting;Humans;Intercellular Signaling Peptides and Proteins;Membrane Proteins;Menarche;Neoplasms;Polymorphism, Single Nucleotide;Puberty;Quantitative Trait Loci;Ribonucleoproteins;Risk Factors",M01.060.057;N05.715.350.075;N06.850.490.250;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;L01.313.500.750.300.188.400.325;L01.470.750.750.325;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.308.203.500;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276;D12.776.467;D23.529;D12.776.543;G08.686.760.410;G08.686.841.374.410;C04;G05.365.795.598;G08.686.760;G08.686.841.374;G05.360.340.024.380.937;D12.776.157.725.500;D12.776.664.962.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28436935,"Animals;Caspase 1;Caspases;Cell Line;Chemical and Drug Induced Liver Injury;Enzyme Activation;Mice, Inbred C57BL;Mice, Knockout;Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein;Natural Killer T-Cells;Neoplasm Proteins;Protein Transport;Pyroptosis;Receptors, OX40",B01.050;D08.811.277.656.262.500.126.550.100;D08.811.277.656.300.200.126.550.100;D12.644.360.075.405.550.100;D12.776.476.075.405.550.100;D08.811.277.656.262.500.126;D08.811.277.656.300.200.126;D12.644.360.075.405;D12.776.476.075.405;A11.251.210;C06.552.100;C25.100.562;C25.723.260;G02.111.263;G03.328;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.277.656.262.500.126.775;D08.811.277.656.300.200.126.775;D08.811.464.938.750.233;A11.118.637.555.567.569.290;A15.145.229.637.555.567.569.360;A15.382.490.555.567.569.470;D12.776.624;G03.143.700;G04.146.160.530;D12.776.543.750.705.852.760.350
28436618,"Adolescent;Adult;Age of Onset;Aorta;Child;Child, Preschool;Cohort Studies;Dilatation, Pathologic;Echocardiography;Ehlers-Danlos Syndrome;Humans;Joint Instability;Young Adult;Ehlers-Danlos Syndrome;Aorta;Echocardiography;Genetics",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;A07.015.114.056;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.300.325;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;C14.907.454.240;C15.378.463.515.240;C16.131.831.428;C16.320.850.260;C17.300.200.310;C17.800.804.428;C17.800.827.260;B01.050.150.900.649.313.988.400.112.400.400;C05.550.521;M01.060.116.815;C14.907.454.240;C15.378.463.515.240;C16.131.831.428;C16.320.850.260;C17.300.200.310;C17.800.804.428;C17.800.827.260;A07.015.114.056;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;H01.158.273.343
28436445,Adolescent;Anxiety Disorders;Child;Gray Matter;Hippocampus;Humans;Magnetic Resonance Imaging;Prefrontal Cortex,M01.060.057;F03.080;M01.060.406;A08.186.211.168;A08.186.854.348;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A08.186.211.200.885.287.500.270.700
28436162,Child;Humans;Neurilemmoma;Neurofibromatoses;Neurofibromatosis 1;Neurofibromatosis 2;Pediatrics;Skin Neoplasms;Neurofibromatosis 1;Neurofibromatosis 2;Rare Diseases,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.595;C04.557.580.600.610.595;C04.557.580.625.650.595;C04.557.580.600.580.590;C04.700.631;C10.562.600;C10.574.500.549;C16.320.400.560;C16.320.700.633;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;C04.557.465.625.650.595.610.500;C04.557.580.600.580.590.655;C04.557.580.600.610.595.610.500;C04.700.631.655;C09.218.807.800.675.500;C09.647.675.500;C10.292.225.750.500;C10.292.910.600.500;C10.562.600.750;C10.574.500.549.700;C16.320.400.560.700;C16.320.700.633.655;H02.403.670;C04.588.805;C17.800.882;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;C04.557.465.625.650.595.610.500;C04.557.580.600.580.590.655;C04.557.580.600.610.595.610.500;C04.700.631.655;C09.218.807.800.675.500;C09.647.675.500;C10.292.225.750.500;C10.292.910.600.500;C10.562.600.750;C10.574.500.549.700;C16.320.400.560.700;C16.320.700.633.655;C23.550.291.906
28436160,Ehlers-Danlos Syndrome;Collagen;Osteogenesis Imperfecta,C14.907.454.240;C15.378.463.515.240;C16.131.831.428;C16.320.850.260;C17.300.200.310;C17.800.804.428;C17.800.827.260;D05.750.078.280;D12.776.860.300.250;C05.116.099.708.685;C16.320.737;C17.300.200.540
28435883,"Animals;Astrocytes;Biological Clocks;Brain;Drosophila melanogaster;Fatty Acid-Binding Protein 7;Humans;Mice;Mice, Knockout;Mutation, Missense;Signal Transduction;Sleep;Tumor Suppressor Proteins;Astrocytes;Genes;Neuroglia;Sleep;Sleep Deprivation",B01.050;A08.637.200;A11.650.200;G07.180.562.094;A08.186.211;B01.050.500.131.617.720.500.500.750.310.250.500;D12.776.157.170.250;D12.776.631.274;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590.650;G02.111.820;G04.835;F02.830.855;G11.561.803;D12.776.624.776;A08.637.200;A11.650.200;G05.360.340.024.340;A08.637;A11.650;F02.830.855;G11.561.803;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
28435847,,
28434525,"Biopsy;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Kidney;Myelodysplastic Syndromes;Nephrotic Syndrome;Renal Insufficiency, Chronic;Young Adult",E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;C20.452;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C15.378.190.625;C12.777.419.630.643;C13.351.968.419.630.643;C12.777.419.780.750;C13.351.968.419.780.750;M01.060.116.815
28434148,"Animals;Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Humans;Immunotherapy;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Clustered Regularly Interspaced Short Palindromic Repeats;T-Lymphocytes;Immunotherapy, Adoptive;Genetic Therapy",B01.050;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;D12.776.543.750.705.816.824;D12.776.828.300;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;E02.095.301;E05.393.420.301
28434147,"Cell Movement;Cell Proliferation;Gene Expression;Genetic Vectors;Humans;Immunotherapy, Adoptive;Lymphocyte Activation;Lymphocytes, Tumor-Infiltrating;Neoplasms;Patient Safety;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Signal Transduction;Single-Chain Antibodies;T-Lymphocytes;Treatment Outcome;T-Lymphocytes;Receptors, Chimeric Antigen;Gene Editing;Genetic Therapy",G04.198;G07.568.500.180;G04.161.750;G07.345.249.410.750;G05.297;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;A11.118.637.555.567.650;A15.145.229.637.555.567.650;A15.382.490.555.567.650;C04;N06.850.135.060.075.399;D12.776.543.750.705.816.824;D12.776.828.300;G02.111.820;G04.835;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500;E05.393.420.270;E02.095.301;E05.393.420.301
28433949,"Adolescent;Adult;Bayes Theorem;Child;DiGeorge Syndrome;Factor Analysis, Statistical;Humans;Mental Disorders;Middle Aged;Psychiatric Status Rating Scales;Psychopathology;Young Adult;DiGeorge Syndrome;Psychopathology;Schizophrenia",M01.060.057;M01.060.116;E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;M01.060.406;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.050.150.900.649.313.988.400.112.400.400;F03;M01.060.116.630;F04.711.513.653;F04.096.670;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F04.096.670;F03.700.750
28433895,"Adult;Behavior Therapy;Follow-Up Studies;HIV Infections;Humans;Interpersonal Relations;Peer Group;Philadelphia;Risk-Taking;Social Support;Substance Abuse, Intravenous;Treatment Outcome;HIV;Social Networking",M01.060.116;F04.754.137;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401;F01.829.316.483;Z01.107.567.875.500.550.525;Z01.433.820;F01.145.722;I01.880.853.500.600;C25.775.793;F03.900.793;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;B04.820.650.589.650.350;L01.143.910
28433741,"Animals;Corpus Striatum;DNA-Binding Proteins;Hyperkinesis;Locomotion;Mice;Mice, 129 Strain;Mice, Inbred C57BL;Mice, Knockout;Neurodevelopmental Disorders;Schizophrenia",B01.050;A08.186.211.200.885.287.249.487;D12.776.260;C10.597.350.350;C23.888.592.350.350;G07.568.500;G11.427.410.568;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.400.025;B01.050.150.900.649.313.992.635.505.500.550.025;B01.050.150.900.649.313.992.635.505.500.800.500.025;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;F03.625;F03.700.750
28433550,"Aftercare;Aged;Aged, 80 and over;Caregivers;Community Health Services;Cost of Illness;Dementia;Disease Management;Humans;Middle Aged;Program Evaluation;Spouses;Telephone;Dementia;Caregivers;Disease Management;Patient-Centered Care;Psychosocial Support Systems",E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;M01.060.116.100;M01.060.116.100.080;M01.085;M01.526.485.200;N02.360.200;N02.421.143;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;C10.228.140.380;F03.615.400;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.337.820;N04.761.685;N05.715.360.650;F01.829.263.500.660;I01.880.853.150.500.670;M01.816;L01.178.847.698;C10.228.140.380;F03.615.400;M01.085;M01.526.485.200;N02.360.200;N04.590.607;N04.590.233.727.407;I01.880.853.500.600.500
28433519,Comprehension;Consumer Health Informatics;Humans;Internet;Knee;Language;Magnetic Resonance Imaging;Medical Illustration;Patient Satisfaction;Radiology;Radiology Information Systems;Surveys and Questionnaires;Terminology as Topic,F02.463.188.357;L01.313.187;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;A01.378.610.450;F01.145.209.399;L01.559;E01.370.350.825.500;H02.385;J01.897.280.500.480;K01.093.410;L01.178.820.090.480;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;H02.403.740;N04.452.515.825;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;L01.559.598.400
28433470,"Animal Feed;Animals;Anti-Obesity Agents;Diet, High-Fat;Dietary Proteins;Dietary Supplements;Dipeptidyl-Peptidase IV Inhibitors;Disease Models, Animal;Energy Intake;Glucagon-Like Peptide 1;Glucose Tolerance Test;Obesity;Rats, Sprague-Dawley;Sitagliptin Phosphate",G07.203.300.300.100;J02.500.300.100;B01.050;D27.505.954.203;G07.203.650.240.267;D12.776.256;G07.203.300.428;J02.500.428;G07.203.300.456;J02.500.456;D27.505.519.389.745.335;D27.505.696.422.500;C22.232;E05.598.500;E05.599.395.080;G07.203.650.240.340;D06.472.317.680.500.500;E01.370.225.124.100.355;E01.370.374.355;E05.200.124.100.355;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;B01.050.150.900.649.313.992.635.505.700.750;D03.383.129.799.725;D03.383.679.875
28433444,Adolescent;Adult;Aged;Cohort Studies;Glucocorticoids;Humans;Incidence;Intraocular Pressure;Middle Aged;Ocular Hypertension;Prevalence;Retrospective Studies;Risk Assessment;Risk Factors;Uveitis;Visual Acuity;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;G14.440;M01.060.116.630;C11.525;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C11.941.879;E01.370.380.850.950;F02.463.593.932.901;G14.940;M01.060.116.815
28433088,Adolescent;Age Factors;Child;Cohort Studies;Comorbidity;Humans;Logistic Models;Maternal Age;Neurodevelopmental Disorders;Parents;Psychiatric Status Rating Scales;Schizophrenia;Social Environment;Young Adult;Epidemiology;Maternal Age;Parents;Paternal Age;Psychopathology,M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;G08.686.560;N05.715.350.075.550;N06.850.490.250.550;F03.625;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F04.711.513.653;F03.700.750;I01.880.853.500;M01.060.116.815;H02.403.720.500;G08.686.560;N05.715.350.075.550;N06.850.490.250.550;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;G08.686.700;F04.096.670
28432632,"Fluorescence;Glucokinase;Humans;Mutation;Protein Conformation;Spectrometry, Fluorescence;Substrate Specificity;Tryptophan;Glucokinase;Glucose;Glycerol",G01.358.500.505.650.665.500;G01.590.540.665.500;D08.811.913.696.620.250;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G02.111.570.820.709;E05.196.712.516.600.676;E05.196.867.726;G02.111.835;D12.125.072.050.850;D12.125.142.875;D08.811.913.696.620.250;D09.947.875.359.448;D02.033.800.875.500;D09.853.875.500
28432223,"Animals;Blood Platelets;Cell Differentiation;Cell Line;Humans;Induced Pluripotent Stem Cells;Jacobsen Distal 11q Deletion Syndrome;Megakaryocytes;Mice;Mice, SCID;Proto-Oncogene Protein c-fli-1;Thrombopoiesis",B01.050;A11.118.188;A15.145.229.188;G04.152;A11.251.210;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;C15.378.140.855.440;C16.131.260.440;C16.320.180.440;A11.148.479;A15.378.316.479;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.780;D12.776.260.665.400;D12.776.624.664.700.175.400;D12.776.930.720.400;G04.152.825.798;G09.188.343.798
28432144,Adolescent;Aging;Brain;Child;Connectome;Gray Matter;Humans;Magnetic Resonance Imaging;Organ Size;Reproducibility of Results;Sensitivity and Specificity;Sex Characteristics;Young Adult,M01.060.057;G07.345.124;A08.186.211;M01.060.406;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;G08.686.815;M01.060.116.815
28432135,Animals;Drosophila;Homeostasis;Humans;Mammals;Neuronal Plasticity;Sleep,B01.050;B01.050.500.131.617.720.500.500.750.310.250;G07.410;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649;G11.561.638;F02.830.855;G11.561.803
28432132,,
28432026,"Heart Arrest;Humans;Hypothermia, Induced;Survivors",C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;M01.860
28431737,,
28431438,,
28431109,Aged;Arthritis;Crystallization;Decision Support Techniques;Gout;Humans;Middle Aged;Netherlands;Predictive Value of Tests;Primary Health Care;Prospective Studies;ROC Curve;Retrospective Studies;Sensitivity and Specificity;Uric Acid;Gout;Primary Health Care,M01.060.116.100;C05.550.114;E05.196.300;G02.171;E05.245;L01.313.500.750.190;C05.550.114.423;C05.550.354.500;C05.799.414;C16.320.565.798.368;C18.452.648.798.368;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.542.651;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;N04.590.233.727;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;D03.132.960.877;D03.633.100.759.758.824.877;C05.550.114.423;C05.550.354.500;C05.799.414;C16.320.565.798.368;C18.452.648.798.368;N04.590.233.727
28431089,"Analgesics, Opioid;Humans;Practice Guidelines as Topic;Practice Patterns, Physicians';Prescription Drug Monitoring Programs",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;E05.337.800.800;N02.421.668.320.600
28430829,"Access to Information;Adult;Aged;Attitude of Health Personnel;Clinical Decision-Making;Clinical Laboratory Techniques;Cost-Benefit Analysis;Electronic Health Records;Humans;Inpatients;Laboratories, Hospital;Medicare;Middle Aged;Practice Patterns, Physicians';United States",I01.880.604.473.352.500.030;L01.143.024;L01.737.030;M01.060.116;M01.060.116.100;F01.100.050;N05.300.100;E01.055;E01.370.225;E05.200;N03.219.151.125;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;M01.643.470;N02.278.216.500.968.420;N02.278.487.410;N04.452.442.422.420;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.630;N04.590.374.577;N05.300.625;Z01.107.567.875
28430825,"Adiposity;African Continental Ancestry Group;Anthropometry;Body Mass Index;Chromosome Mapping;European Continental Ancestry Group;Gene Frequency;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Linkage Disequilibrium;Obesity;Polymorphism, Single Nucleotide;Serine Endopeptidases;Transcription Factor 7-Like 2 Protein;Waist-Hip Ratio",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;M01.686.508.100;E01.370.600.024;E05.041;N06.850.505.200.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.393.183;M01.686.508.400;G05.330;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.348.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G05.365.795.598;D08.811.277.656.300.760;D08.811.277.656.959.350;D12.776.260.730.875;D12.776.660.235.400.800.875;D12.776.664.235.400.800.875;D12.776.930.875.875;E01.370.600.115.100.960;E05.041.124.946;G07.100.100.960
28430547,"Education;Humans;Hypertension, Pulmonary;National Heart, Lung, and Blood Institute (U.S.);Precision Medicine;United States;Precision Medicine;Hypertension, Pulmonary",I02;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;I01.409.418.750.600.650.496.300;N03.540.052.750.300;N03.540.348.500.500.600.650.496.300;E02.574;H02.403.200.700;Z01.107.567.875;E02.574;H02.403.200.700;C08.381.423
28429849,,
28429464,"Aged;Alopecia;Antigens, CD;CD4-CD8 Ratio;CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Hair Follicle;Humans;Inflammation;Middle Aged",M01.060.116.100;C17.800.329.937.122;C23.300.035;D23.050.301.264.035;D23.101.100.110;E01.370.225.500.195.107.595.500.150.160;E01.370.225.625.107.595.500.150.160;E05.200.500.195.107.595.500.150.160;E05.200.625.107.595.500.150.160;E05.242.195.107.595.500.150.160;G04.140.107.595.500.150.160;G09.188.105.595.500.150.160;G12.248;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;A10.272.497.500;A17.360.710;A17.815.250.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;M01.060.116.630
28428443,"ATP Binding Cassette Transporter, Subfamily B;Benzimidazoles;Biomarkers, Tumor;Cell Line, Tumor;Drug Resistance, Neoplasm;Gene Expression Regulation, Leukemic;Gene Rearrangement;Histone-Lysine N-Methyltransferase;Histones;Humans;Leukemia;Lysine;Methylation;Models, Biological;Myeloid-Lymphoid Leukemia Protein;RNA, Messenger",D12.776.157.530.100.075;D12.776.157.530.450.074.500.500.250;D12.776.395.550.020.400;D12.776.543.550.192.400;D12.776.543.585.100.200;D12.776.543.585.450.074.500.500.250;D03.633.100.103;D23.101.140;A11.251.210.190;A11.251.860.180;G07.690.773.984.395;G05.308.370.500;G05.344;D08.811.913.555.500.800.200.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337;D12.125.068.555;D12.125.095.647;D12.125.142.497;G02.111.035.538;G02.607.094.538;G03.059.538;E05.599.395;D12.776.260.560;D12.776.624.664.700.148;D12.776.930.483;D13.444.735.544
28428261,"Adipogenesis;Adipose Tissue, Brown;Animals;Basic Helix-Loop-Helix Transcription Factors;Cell Lineage;Cells, Cultured;Chromatin;Chromatin Assembly and Disassembly;Chromosomal Proteins, Non-Histone;DNA-Binding Proteins;Gene Expression Regulation;Histones;Mice;Mice, Inbred C57BL;Mice, Knockout;Transcription Factors;Transcription, Genetic",G04.152.149;A10.165.114.322;B01.050;D12.776.260.103;D12.776.930.125;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.251;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;D12.776.660.235;D12.776.664.235;D12.776.260;G05.308;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D12.776.930;G02.111.873;G05.297.700
28428190,"Adolescent;Adult;Aged;Aged, 80 and over;Brain Neoplasms;Cohort Studies;ErbB Receptors;Glioblastoma;Humans;Magnetic Resonance Angiography;Middle Aged;Mutation;Reproducibility of Results;Sensitivity and Specificity;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.913.696.620.682.725.400.009;D12.776.543.750.630.009;D12.776.543.750.750.400.074;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500.500;E01.370.370.050.500;M01.060.116.630;G05.365.590;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116.815
28428095,"Anemia;Arthritis;Cost of Illness;Cranial Nerve Diseases;Cystitis, Interstitial;Fatigue;Gastrointestinal Diseases;Humans;Leukopenia;Lung Diseases;Lymphoma, B-Cell;Nephritis, Interstitial;Otorhinolaryngologic Diseases;Peripheral Nervous System Diseases;Practice Guidelines as Topic;Sjogren's Syndrome",C15.378.071;C05.550.114;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;C10.292;C12.777.829.495.500;C13.351.968.829.495.500;C23.888.369;C06.405;B01.050.150.900.649.313.988.400.112.400.400;C15.378.553.546;C08.381;C04.557.386.480.150;C15.604.515.569.480.150;C20.683.515.761.480.150;C12.777.419.570.643;C13.351.968.419.570.643;C09;C10.668.829;N04.761.700.350.650;N05.700.350.650;C05.550.114.154.774;C05.799.114.774;C07.465.815.929.669;C11.496.260.719;C17.300.775.099.774;C20.111.199.774
28428018,"Adolescent;Airway Management;Child;Child, Preschool;Computer Graphics;Data Interpretation, Statistical;Humans;Infant;Infant, Newborn;Neoplasms;Radiotherapy",M01.060.057;E02.041;M01.060.406;M01.060.406.448;L01.224.108;L01.296.110;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C04;E02.815
28427986,"Adolescent;Adult;Aged;Brain Neoplasms;Databases, Factual;Glioblastoma;Humans;Kaplan-Meier Estimate;Middle Aged;Prognosis;Prospective Studies;Sex Distribution;Treatment Outcome;United States;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;L01.313.500.750.300.188.400;L01.470.750.750;C04.557.465.625.600.380.080.335;C04.557.470.670.380.080.335;C04.557.580.625.600.380.080.335;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.240.800;N01.224.803;N06.850.505.400.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.060.116.815
28427954,California;Colorectal Neoplasms;Continental Population Groups;Early Detection of Cancer;Ethnic Groups;Healthcare Disparities;Humans;Mass Screening;Middle Aged;Occult Blood;Retrospective Studies,Z01.107.567.875.580.200;Z01.107.567.875.760.200;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;M01.686.508;E01.390.500;M01.686.754;N01.224.317;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;E01.370.225.925;E05.200.925;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28426847,"Adult;Chin;Cryosurgery;Follow-Up Studies;Humans;Imaging, Three-Dimensional;Lipectomy;Middle Aged;Neck;Outcome Assessment (Health Care);Patient Satisfaction;Prospective Studies;Subcutaneous Fat",M01.060.116;A01.456.505.259;A02.835.232.781.324.502.632.130;A14.521.632.300;E04.014.180;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.400;L01.224.308.410;E02.218.530;E02.570.500.062.937;E04.062.937;E04.680.450;M01.060.116.630;A01.598;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A10.165.114.830.750
28426728,"Aged;Aged, 80 and over;Dyspnea;Heart Ventricles;Humans;Lung;Magnetic Resonance Imaging;Middle Aged",M01.060.116.100;M01.060.116.100.080;C08.618.326;C23.888.852.371;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E01.370.350.825.500;M01.060.116.630
28426489,"Back;Biopsy, Needle;Child;Delayed Diagnosis;Humans;Hyperpigmentation;Immunohistochemistry;Magnetic Resonance Imaging;Nevus, Blue;Prognosis;Risk Assessment;Skin Neoplasms;Treatment Outcome",A01.923.176;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;M01.060.406;E01.110;E02.288;E02.760.273;N02.421.585.273;B01.050.150.900.649.313.988.400.112.400.400;C17.800.621.430;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E01.370.350.825.500;C04.557.665.560.615.550;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04.588.805;C17.800.882;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28426313,"Antiviral Agents;Drug Costs;Eligibility Determination;Health Services Accessibility;Hepatitis C, Chronic;Humans;Insurance Coverage;Insurance, Health, Reimbursement;Medicaid;Sofosbuvir;Substance-Related Disorders;United States",D27.505.954.122.388;N03.219.151.400.350;N05.300.375.300;N04.452.264;N04.590.374.350;N05.300.430;C02.440.440.120;C02.782.350.350.120;C06.552.380.350.120;C06.552.380.705.440.120;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343.480;N03.219.521.710;N03.219.521.346.506.564.655;N03.706.615.693;D03.383.742.686.850.877.500;D13.695.740.850.877.500;D13.695.827.919.877.500;C25.775;F03.900;Z01.107.567.875
28425419,"ATP Binding Cassette Transporter, Subfamily B, Member 11;ATP-Binding Cassette Transporters;Biopsy, Large-Core Needle;Child;Child, Preschool;Cholestasis, Intrahepatic;DNA Mutational Analysis;Genetic Predisposition to Disease;Heredity;Heterozygote;Humans;Immunohistochemistry;Microscopy, Electron, Transmission;Mutation, Missense;Pedigree;Phenotype;Severity of Illness Index",D12.776.157.530.100.075.125;D12.776.157.530.450.074.500.500.250.438;D12.776.395.550.020.400.534;D12.776.543.550.192.400.534;D12.776.543.585.100.200.438;D12.776.543.585.450.074.500.500.250.438;D12.776.157.530.100;D12.776.395.550.020;D12.776.543.550.192;D12.776.543.585.100;E01.370.225.500.384.100.119.750;E01.370.225.998.054.119.750;E01.370.388.100.100.750;E04.074.119.750;E04.665.100.750;E05.200.500.384.100.119.750;E05.200.998.054.119.750;E05.242.384.100.119.750;M01.060.406;M01.060.406.448;C06.130.120.135.250;C06.552.150;E05.393.760.700.300;C23.550.291.687.500;G05.380.355;G05.390;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E01.370.350.515.402.580;E05.595.402.580;G05.365.590.650;E05.393.673;G05.695;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28424583,Electromyography;Facial Nerve;Paralysis;Rodentia,E01.370.405.255;E01.370.530.255;A08.800.050.050.275;A08.800.050.600.149;A08.800.800.060.275;A08.800.800.120.250;C10.597.622;C23.888.592.636;B01.050.150.900.649.313.992
28424165,"Cell Death;Cell Line, Tumor;Class I Phosphatidylinositol 3-Kinases;Dexamethasone;Drug Resistance, Neoplasm;Gene Expression Regulation;Glucocorticoids;Humans;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cells, B-Lymphoid;Proto-Oncogene Proteins c-bcr;RNA, Small Interfering;Receptors, Glucocorticoid;Signal Transduction",G04.146;A11.251.210.190;A11.251.860.180;D08.811.913.696.620.500.100.100;D08.811.913.696.620.500.200.100;D12.776.476.162;D04.210.500.745.432.769.344;D04.210.500.908.238;G07.690.773.984.395;G05.308;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;A11.118.637.555.567.562.800;A11.148.378.294.374;A11.872.378.294.500;D08.811.913.696.620.682.700.759;D12.644.360.325.300.099.500;D12.776.476.325.300.099.500;D12.776.624.664.700.171;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D12.776.826.750.430;G02.111.820;G04.835
28423460,"Adolescent;African Americans;Child;Cross-Sectional Studies;Emergency Service, Hospital;Emergency Treatment;Firearms;Humans;Residence Characteristics;Retrospective Studies;Risk Factors;Wounds, Gunshot",M01.060.057;M01.686.508.100.100;M01.686.754.100;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.365;J01.637.870.350;B01.050.150.900.649.313.988.400.112.400.400;N01.224.791;N06.850.505.400.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26.986.900
28423118,"Adult;Body Mass Index;Child;Disease Progression;Humans;Obesity;Renal Insufficiency, Chronic;Risk Assessment;Risk Factors",M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28422816,"Career Choice;Clinical Clerkship;Clinical Competence;Curriculum;Education, Medical, Undergraduate;Educational Measurement;Humans;Licensure, Medical;Schools, Medical;Time Factors;United States",F02.463.785.373.346.400;I02.358.105;I02.399.630.210;N04.761.210;N05.715.175;I02.158;I02.358.399.450;I02.399;B01.050.150.900.649.313.988.400.112.400.400;N03.706.110.510.410;N05.700.200.450.500;I02.783.495.552;N02.278.020.578;G01.910.857;Z01.107.567.875
28422752,Acquired Immunodeficiency Syndrome;Allergy and Immunology,C02.782.815.616.400.040;C02.800.801.400.040;C02.839.040;C20.673.480.040;H02.403.044
28422352,Adolescent;Adult;Age Factors;Alcohol Drinking;Humans;Marijuana Smoking;Social Environment;Tobacco Smoking;Young Adult;Cannabis;Tobacco;Young Adult,M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;F01.145.317.269;B01.050.150.900.649.313.988.400.112.400.400;F01.145.610.875;F01.145.805.250.500;I01.880.853.500;F01.145.805.375;F01.145.958.875;M01.060.116.815;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.908.500.900;M01.060.116.815
28421970,Adolescent;Adult;Aged;Device Removal;Endovascular Procedures;Humans;Middle Aged;Postoperative Complications;Prosthesis Failure;Retrospective Studies;Risk;Vena Cava Filters;Young Adult,M01.060.057;M01.060.116;M01.060.116.100;E04.199;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.550.767;C23.550.767.865;E05.325.771;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E07.695.207.500;M01.060.116.815
28421884,Adolescent;Attitude;Biomedical Research;Child;Communication;Decision Making;Humans;Informed Consent By Minors;Patient Participation;Perception;Personal Autonomy;Professional-Patient Relations;Research Personnel;Self Efficacy;Social Justice;Surveys and Questionnaires;Decision Making;Ethics;Informed Consent,M01.060.057;F01.100;H01.770.644.145;M01.060.406;F01.145.209;L01.143;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718.500;I01.880.604.583.427.384;N03.706.437.650.312.500;N03.706.535.489.384;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;F02.463.593;F02.600;I01.880.604.473.380.500;K01.752.566.479.830.650;N03.706.437.380.500;N05.350.958.650;F01.829.401.650;N05.300.660;M01.526.839;F01.752.747.792.700;I01.880.604.473.700;K01.752.566.479.830.750;N03.706.437.700;N05.350.958.750;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F02.463.785.373;K01.752.566.479;N05.350;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489
28421620,"Acoustic Stimulation;Adult;Auditory Cortex;Electroencephalography;Evoked Potentials, Auditory;Functional Laterality;Humans;Magnetoencephalography;Middle Aged;Electroencephalography;Magnetoencephalography;Temporal Lobe",E02.037;E02.190.888.030;E05.723.136;M01.060.116;A08.186.211.200.885.287.500.814.249;A08.186.211.200.885.287.500.863.297;E01.370.376.300;E01.370.405.245;G07.265.216.500.370;G11.561.200.500.370;F02.830.297.425;G11.561.225.425;B01.050.150.900.649.313.988.400.112.400.400;E01.370.376.500;E01.370.405.440;E05.540.500;M01.060.116.630;E01.370.376.300;E01.370.405.245;E01.370.376.500;E01.370.405.440;E05.540.500;A08.186.211.200.885.287.500.863
28421601,Child;Dermatologists;Dermatomyositis;Humans;Neurologists;Observer Variation;Physical Examination;Rheumatologists;Sensitivity and Specificity;Severity of Illness Index,M01.060.406;M01.526.485.810.215;N02.360.810.215;C05.651.594.819.500;C10.668.491.562.575.500;C17.300.250;C17.800.185;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810.652;N02.360.810.652;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E01.370.600;M01.526.485.810.888;N02.360.810.888;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28421516,"Arthroplasty, Replacement, Knee;Humans;Knee;Knee Joint;Surveys and Questionnaires",E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.450;A02.835.583.475;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28421515,Bayes Theorem;Humans;Osteosarcoma;Sarcoma,E05.318.740.600.200;N05.715.360.750.625.150;N06.850.520.830.600.200;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.565.575.650;C04.557.450.795.620;C04.557.450.795
28420729,"Amino Acid Substitution;Anticoagulants;Blood Coagulation;Factor V;Factor Xa;Humans;Lipoproteins;Mutation, Missense;Protein Domains;Protein S;Prothrombin;Anticoagulants;Blood Coagulation Factors;Protein S",E05.393.420.601.035;G05.558.109;D27.505.954.502.119;G09.188.390.150;D12.776.124.125.300;D23.119.300;D08.811.277.656.300.760.315;D08.811.277.656.959.350.315;D12.776.124.125.400.315;D23.119.400.315;B01.050.150.900.649.313.988.400.112.400.400;D10.532;D12.776.521;G05.365.590.650;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;D12.776.124.670;D12.776.395.642;D23.113.725;D08.622.709;D12.776.124.125.800;D23.119.945;D27.505.954.502.119;D12.776.124.125;D23.119;D12.776.124.670;D12.776.395.642;D23.113.725
28420318,Neuroblastoma;Proteomics,C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
28420261,"Child Development;Child, Preschool;Developmental Disabilities;Humans;Literacy;Mass Screening;Psychometrics;Surveys and Questionnaires;Child, Preschool",F01.525.200;G07.345.374.750;M01.060.406.448;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;F01.145.209.429;N01.824.196.500;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F04.711.780;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.406.448
28420131,"Aged;Employment;Factor Analysis, Statistical;Health Status;Health Surveys;Humans;Middle Aged;Occupational Health;Social Environment;Women's Health;Social Environment;Women's Health;Workplace",M01.060.116.100;N01.824.245;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;I01.240.425;N01.224.425;N06.850.505.400.425;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N01.400.525;I01.880.853.500;N01.400.900;I01.880.853.500;N01.400.900;N01.824.245.925;N04.452.677.975
28419849,,
28419773,"Canada;Congresses as Topic;Humans;Pathology, Clinical;Practice Guidelines as Topic;Societies, Medical;Thyroid Nodule;United States",Z01.107.567.176;N03.540.199;B01.050.150.900.649.313.988.400.112.400.400;H02.403.650.500;N04.761.700.350.650;N05.700.350.650;N03.540.828.589;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;Z01.107.567.875
28419486,"Adolescent;Antineoplastic Agents;Body Surface Area;Bortezomib;Child;Child, Preschool;Humans;Leukemia, Myeloid, Acute;Models, Biological;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Bortezomib;Leukemia;Multiple Myeloma;Proteasome Inhibitors",M01.060.057;D27.505.954.248;E01.370.600.115.100.231;E05.041.124.231;G07.100.100.231;D01.029.260.110.500;D01.132.285.500;D02.203.200.500;D03.383.679.450;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;E05.599.395;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D01.029.260.110.500;D01.132.285.500;D02.203.200.500;D03.383.679.450;C04.557.337;C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650;D27.505.519.389.745.705
28419360,"Animals;Basement Membrane;Bone and Bones;Child;Collagen Type IV;Connective Tissue;Humans;Mice;Mice, Knockout;Muscles;Mutation;Osteochondrodysplasias;Procollagen-Proline Dioxygenase;Prolyl Hydroxylases;Tendons",B01.050;A10.272.220;A10.615.179;A02.835.232;A10.165.265;M01.060.406;D12.776.860.300.250.400.100;A10.165;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A02.633;A10.690;G05.365.590;C05.116.099.708;C16.320.728;D08.811.682.690.416.617.750;D08.811.682.690.708.694.750;D08.811.682.690.416.617;D08.811.682.690.708.694;A02.880
28419085,"Adult;Humans;Infant;Infant Mortality;Infant, Newborn;Infant, Premature;Pregnancy;Prospective Studies;Registries;Treatment Outcome;United States;Young Adult",M01.060.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;M01.060.703.520.520;G08.686.784.769;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.060.116.815
28419061,"Adolescent;Child;Child, Preschool;Extracorporeal Membrane Oxygenation;Health Status;Health Status Indicators;Hospital Mortality;Humans;Infant;Infant, Newborn;Intensive Care Units;Linear Models;Multivariate Analysis;Patient Discharge;Recovery of Function;Risk Factors",M01.060.057;M01.060.406;M01.060.406.448;E02.880.301;E04.292.451;I01.240.425;N01.224.425;N06.850.505.400.425;E05.318.308.980.438.475;N05.715.360.300.800.438.375;N06.850.520.308.980.438.475;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;G16.757;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28419036,"Adolescent;Bone Nails;Casts, Surgical;Child;Child, Preschool;Databases, Factual;Fracture Fixation;Humans;Humeral Fractures;Infant;Infant, Newborn;Open Fracture Reduction;Standard of Care;United States",M01.060.057;E07.695.370.249;E07.858.442.660.460.249;E07.858.690.725.460.249;E07.858.442.660.430.500;E07.858.690.725.430.500;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E04.555.300;B01.050.150.900.649.313.988.400.112.400.400;C26.088.390;C26.404.500;M01.060.703;M01.060.703.520;E04.555.300.690;N04.761.789.900;N05.715.840;Z01.107.567.875
28418952,Bone Diseases;Chronic Disease;Fluorodeoxyglucose F18;Hodgkin Disease;Humans;Lymph Nodes;Mediastinum;Positron Emission Tomography Computed Tomography;Recurrence;Sclerosis;Young Adult,C05.116;C23.550.291.500;D09.254.229.500;C04.557.386.355;C15.604.515.569.355;C20.683.515.761.355;B01.050.150.900.649.313.988.400.112.400.400;A10.549.400;A15.382.520.604.412;A01.923.761.800.500;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;C23.550.291.937;C23.550.823;M01.060.116.815
28418563,"Animals;Biomechanical Phenomena;Cervix Uteri;Collagen;Materials Testing;Mice;Pregnancy;Stress, Mechanical;Tensile Strength",B01.050;G01.154.090;G01.374.089;A05.360.319.679.256;D05.750.078.280;D12.776.860.300.250;E05.570;B01.050.150.900.649.313.992.635.505.500;G08.686.784.769;G01.374.835;G01.374.850
28418321,"Adult;African Americans;Annexin A2;Calcium;European Continental Ancestry Group;Gene-Environment Interaction;Genome-Wide Association Study;Globus Pallidus;Homeostasis;Humans;Magnetic Resonance Imaging;Marijuana Abuse;Parietal Lobe;Polymorphism, Single Nucleotide;S100 Proteins;Unsafe Sex;Young Adult",M01.060.116;M01.686.508.100.100;M01.686.754.100;D12.776.157.125.050.060;D01.268.552.100;D01.552.539.288;D23.119.100;M01.686.508.400;G05.695.337;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;A08.186.211.200.885.287.249.487.397;G07.410;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C25.775.635;F03.900.635;A08.186.211.200.885.287.500.670;G05.365.795.598;D12.776.157.125.750;D12.776.631.655;F01.145.802.987;M01.060.116.815
28418145,"Dermatitis, Atopic;Erythema;Humans;Outcome Assessment (Health Care);Pigmentation;Skin",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C17.800.229;C23.888.885.328;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E01.370.600.620;G16.690;A17.815
28417671,"Adolescent;Adrenalectomy;Child;Child, Preschool;Humans;Infant;Noninvasive Ventilation;Positive-Pressure Respiration;Postoperative Complications;Postoperative Hemorrhage;Tonsillectomy;Hemorrhage;Positive-Pressure Respiration;Tonsillectomy",M01.060.057;E04.270.115;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E02.041.625.591;E02.880.820.657;E02.041.625.790;E02.880.820.790;C23.550.767;C23.550.414.941;C23.550.767.850;E04.580.848;C23.550.414;E02.041.625.790;E02.880.820.790;E04.580.848
28417430,"Adolescent;Adult;Bone Density;Child;Child, Preschool;Coronary Disease;Fractures, Bone;Humans;Hypertension;Incidence;Kidney Calculi;Renal Insufficiency, Chronic;Secondary Prevention;Young Adult;Child;Nephrolithiasis;Patient Transfer",M01.060.057;M01.060.116;G11.427.100;M01.060.406;M01.060.406.448;C14.280.647.250;C14.907.585.250;C26.404;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;C12.777.419.780.750;C13.351.968.419.780.750;E02.897;N02.421.726.825;N06.850.780.750;M01.060.116.815;M01.060.406;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624
28417277,"Aged, 80 and over;Cosmetic Techniques;Foreign Bodies;Humans;Incidental Findings;Needles;Republic of Korea;Tomography, X-Ray Computed;Radiography",M01.060.116.100.080;E02.218;C26.392;B01.050.150.900.649.313.988.400.112.400.400;E01.410;E07.612;Z01.252.474.557.750;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.700
28417112,,
28416818,African Americans;Atrial Fibrillation;European Continental Ancestry Group;Genetic Loci;Genetic Predisposition to Disease;Genome-Wide Association Study;Humans;Quantitative Trait Loci,M01.686.508.100.100;M01.686.754.100;C14.280.067.198;C23.550.073.198;M01.686.508.400;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.380.937
28416581,"Adipogenesis;Adipose Tissue, Brown;Adipose Tissue, White;Adult;Anti-Bacterial Agents;Calcium Channels;Cell Differentiation;Gene Expression Regulation;Humans;Membrane Proteins;Mesenchymal Stem Cells;Protein Isoforms;Receptors, Cell Surface;Streptomycin;Transient Receptor Potential Channels;Young Adult;Adipogenesis",G04.152.149;A10.165.114.322;A10.165.114.830;M01.060.116;D27.505.954.122.085;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;G04.152;G05.308;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;A11.329.830.500;A11.872.590.500;D12.776.800;D12.776.543.750;D09.408.051.885;D12.776.157.530.400.901;D12.776.543.585.400.901;M01.060.116.815;G04.152.149
28416525,Atrial Fibrillation;Heart Failure;Humans;Stroke Volume;Anti-Arrhythmia Agents;Atrial Fibrillation;Catheter Ablation;Heart Failure,C14.280.067.198;C23.550.073.198;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E01.370.370.380.150.700;G09.330.380.124.882;D27.505.954.411.097;C14.280.067.198;C23.550.073.198;E02.808.750.500;E04.014.760.500;C14.280.434
28416506,"Adult;Hemorrhage;Humans;Platelet Count;Practice Guidelines as Topic;Purpura, Thrombocytopenic, Idiopathic;Receptors, Thrombopoietin;Splenectomy",M01.060.116;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;N04.761.700.350.650;N05.700.350.650;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;D12.776.543.750.705.852.610;E04.726
28416449,"Animals;Antibodies, Blocking;Clinical Trials as Topic;Complement Activation;Complement C3;Evidence-Based Medicine;Glomerulonephritis, Membranous;Humans;Immune Complex Diseases;Inflammation;Models, Immunological;Molecular Targeted Therapy;Treatment Outcome",B01.050;D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;G12.274;D12.776.124.050.140;D12.776.124.486.274.250;H02.249.750;H02.403.200.400;C12.777.419.570.363.625;C13.351.968.419.570.363.625;C20.111.535;B01.050.150.900.649.313.988.400.112.400.400;C20.543.520;C23.550.470;E05.599.395.500;E02.319.574;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28416361,Animals;Carbohydrate Metabolism;Glucose;Humans;Insulin;Insulin Resistance;Lipid Metabolism;Lipogenesis;Liver;Metabolic Networks and Pathways,B01.050;G02.111.158;G03.191;D09.947.875.359.448;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;C18.452.394.968.500;G07.690.773.984.617;G03.458;G02.111.528;G03.458.249;A03.620;G03.493
28416285,"Animals;Cell Line;Cell Lineage;Cells, Cultured;Cerebral Cortex;Embryonic Stem Cells;Interneurons;Mice;Neural Stem Cells;Neurogenesis;Parvalbumins;Protein Kinase C;Receptors, Notch;Signal Transduction;Somatostatin;Cyclin D2;Embryonic Stem Cells;Mice;Somatostatin",B01.050;A11.251.210;G04.172;G07.345.500.325.180.500;G08.686.155;G08.686.784.170.104.249;A11.251;A08.186.211.200.885.287.500;A11.872.700.250;A08.675.358;A11.671.358;B01.050.150.900.649.313.992.635.505.500;A11.872.653;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;D12.776.034.700;D12.776.210.500.750;D08.811.913.696.620.682.700.725;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835;D06.472.699.327.700.875;D06.472.699.587.780;D12.644.400.400.700.875;D12.644.548.365.700.875;D12.644.548.586.780;D12.776.631.650.405.700.875;D12.644.360.262.150.200;D12.776.167.218.150.200;D12.776.476.262.150.200;A11.872.700.250;B01.050.150.900.649.313.992.635.505.500;D06.472.699.327.700.875;D06.472.699.587.780;D12.644.400.400.700.875;D12.644.548.365.700.875;D12.644.548.586.780;D12.776.631.650.405.700.875
28416194,"Animals;Cell Line;Cellular Microenvironment;Cellular Reprogramming;Forkhead Transcription Factors;Glucose;Glycolysis;Humans;Lactic Acid;Mice;Mice, Inbred BALB C;Mice, Knockout;Oxidative Phosphorylation;Proto-Oncogene Proteins c-myc;T-Lymphocytes, Regulatory",B01.050;A11.251.210;G04.366;G04.152.262;G05.135;D12.776.260.950.249;D12.776.930.977.249;D09.947.875.359.448;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;B01.050.150.900.649.313.988.400.112.400.400;D02.241.511.459.450;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G02.111.665.550;G03.295.631;G03.796.550;D12.776.260.103.813;D12.776.624.664.700.189;D12.776.660.765;D12.776.930.125.813;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
28416043,"Achievement;Adolescent;Circadian Rhythm;Health Promotion;Humans;Learning;Public Policy;Schools;Sleep Deprivation;Societies, Medical;Students;Time;United States;Health;Students",F01.658.059;F02.784.629.054;M01.060.057;G07.180.562.190;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;F02.463.425;F02.784.629.529;I01.655.500.608;I01.880.604.825.608;N03.623.500.608;I02.783;J03.832;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;N03.540.828.589;M01.848;G01.910;Z01.107.567.875;N01.400;M01.848
30675530,Outpatients;Risk Factors,M01.643.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28414616,Animals;Cartilage;Cattle;Finite Element Analysis;Tissue Engineering;Mesenchymal Stem Cells,B01.050;A02.165;A10.165.382;B01.050.150.900.649.313.500.380.271;E05.355;E05.481.500.311.500;J01.293.069.249.500;A11.329.830.500;A11.872.590.500
28414475,Adolescent;Cannabis;Cognition;Executive Function;Humans;Marijuana Smoking;Memory;Neuropsychological Tests;Philadelphia;Prospective Studies;Social Perception;Young Adult,M01.060.057;B01.650.940.800.575.912.250.859.937.055.500;F02.463.188;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F01.145.610.875;F01.145.805.250.500;F02.463.425.540;F04.711.513;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F02.463.593.752;M01.060.116.815
28414186,Alzheimer Disease;Cognitive Dysfunction;Humans;Machine Learning;Neuroimaging;Prodromal Symptoms;Alzheimer Disease;Classification;Machine Learning;Cognitive Dysfunction;Neuroimaging,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;F03.615.250.700;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;E01.370.350.578;E01.370.376.537;E05.629;C23.888.672;E01.599;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;L01.100;L01.453.245.275;G17.035.250.500;L01.224.050.375.530;F03.615.250.700;E01.370.350.578;E01.370.376.537;E05.629
28414122,,
28412602,"Adolescent;Child;Cognitive Behavioral Therapy;Dose-Response Relationship, Drug;Humans;Obsessive-Compulsive Disorder;Parents;Psychiatric Status Rating Scales;Retrospective Studies;Serotonin Uptake Inhibitors;Treatment Outcome;Obsessive-Compulsive Disorder;Therapeutics",M01.060.057;M01.060.406;F04.754.137.350;G07.690.773.875;G07.690.936.500;B01.050.150.900.649.313.988.400.112.400.400;F03.080.600;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F04.711.513.653;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;F03.080.600;E02
28412334,Adolescent;Humans;Ovotesticular Disorders of Sex Development,M01.060.057;B01.050.150.900.649.313.988.400.112.400.400;C12.706.316.343;C13.351.875.253.343;C16.131.939.316.343;C19.391.119.343
28411914,"Ablation Techniques;Humans;Kidney Neoplasms;Nephrectomy;Postoperative Complications;Treatment Outcome;Tumor Burden;Ablation Techniques;Cryosurgery;Radiofrequency Ablation;Carcinoma, Renal Cell",E04.014;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;E04.950.774.435;C23.550.767;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.041.124.892;E04.014;E04.014.180;E02.808.750;E04.014.760;C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
28411795,"Dermatitis, Atopic;Eczema;Humans",C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;C17.800.174.620;C17.800.815.620;B01.050.150.900.649.313.988.400.112.400.400
28411773,Humans;Melanoma;Risk;Skin Neoplasms,B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;C04.588.805;C17.800.882
28411753,,
28411507,Adult;Affect;Bipolar Disorder;Depressive Disorder;Diagnostic and Statistical Manual of Mental Disorders;Humans;Middle Aged;Severity of Illness Index;Young Adult;Bipolar Disorder;Diagnostic and Statistical Manual of Mental Disorders,M01.060.116;F01.470.047;F03.084.500;F03.600.300;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;M01.060.116.815;F03.084.500;L01.453.245.945.200
28411282,"Child;Child, Preschool;Cohort Studies;DNA Copy Number Variations;DNA, Neoplasm;Disease-Free Survival;Genetic Markers;Genotype;Humans;Infant;Kaplan-Meier Estimate;Leukemia, Myeloid, Acute;Prognosis;Proportional Hazards Models;Risk Factors;Treatment Outcome",M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.365.795.297.500;D13.444.308.425;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;D23.101.387;G05.695.450;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C04.557.337.539.275;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28411062,"Humans;Infant, Newborn;Infant, Premature;Intubation, Intratracheal;Positive-Pressure Respiration;Practice Guidelines as Topic;Prospective Studies;Quality Improvement;Resuscitation;Statistics, Nonparametric;Time Factors;Delivery Rooms;Epidemiology;Infant, Newborn;Positive-Pressure Respiration;Quality Improvement",B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;E02.041.500;E02.585.578;E05.497.578;E02.041.625.790;E02.880.820.790;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;J01.293.754;N04.761.744;E02.365.647;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;G01.910.857;N02.278.388.150;H02.403.720.500;M01.060.703.520;E02.041.625.790;E02.880.820.790;J01.293.754;N04.761.744
28410919,"Aged;Aged, 80 and over;Comorbidity;Databases, Factual;Emergency Service, Hospital;Florida;Humans;Incidence;Income;Logistic Models;Multivariate Analysis;Patient Admission;Patient Discharge;Retrospective Studies;Risk Factors;Wounds and Injuries",M01.060.116.100;M01.060.116.100.080;N05.715.350.225;N06.850.490.687;L01.313.500.750.300.188.400;L01.470.750.750;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;Z01.107.567.875.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;N01.824.417;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.760.400.600;N02.421.585.400.600;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C26
28410602,"Animals;Congenital Hyperinsulinism;Humans;Hyperinsulinism;Hypoglycemia;Infant, Newborn;Sirolimus;TOR Serine-Threonine Kinases;Sirolimus",B01.050;C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968;C18.452.394.984;M01.060.703.520;D02.540.505.760;D08.811.913.696.620.682.700.931;D12.776.476.925;D02.540.505.760
28410089,"Adolescent;Case-Control Studies;Child;Child, Preschool;Cohort Studies;Databases, Factual;Heart Defects, Congenital;Humans;Infant;Infant, Newborn;Intubation;Laparoscopy;Patient Readmission;Propensity Score;Severity of Illness Index;United States;Laparoscopy;Minimally Invasive Surgical Procedures",M01.060.057;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E02.585;E05.497;E01.370.388.250.520;E04.502.250.520;E02.760.400.620;N02.421.585.400.620;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;Z01.107.567.875;E01.370.388.250.520;E04.502.250.520;E04.502
28410087,"African Americans;Child;Child, Preschool;Critical Care;European Continental Ancestry Group;Hispanic Americans;Humans;Infant;Parents;Refusal to Participate",M01.686.508.100.100;M01.686.754.100;M01.060.406;M01.060.406.448;E02.760.190;N02.421.585.190;M01.686.508.400;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F02.463.785.373.476.850
28409758,"Clinical Competence;Critical Illness;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Intubation, Intratracheal;Neonatology;Patient Safety;Quality Assurance, Health Care;Quality Improvement;Intubation, Intratracheal;Patient Safety;Quality Improvement",I02.399.630.210;N04.761.210;N05.715.175;C23.550.291.625;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;E02.041.500;E02.585.578;E05.497.578;H02.403.670.400;N06.850.135.060.075.399;N04.761.700;N05.700;J01.293.754;N04.761.744;E02.041.500;E02.585.578;E05.497.578;N06.850.135.060.075.399;J01.293.754;N04.761.744
28409479,,
28409251,Abdomen;Child;Humans;Magnetic Resonance Imaging;Pelvis;Abdomen;Child;Magnetic Resonance Imaging,A01.923.047;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A01.923.600;A01.923.047;M01.060.406;E01.370.350.825.500
28408562,Biomedical Technology;Cell Transplantation;Humans;Self Concept;Tissue Engineering,J01.897.115;E02.095.147.500;E04.936.225;B01.050.150.900.649.313.988.400.112.400.400;F01.752.747.792;E05.481.500.311.500;J01.293.069.249.500
28408464,"Child;Fusion Proteins, bcr-abl;Gene Expression Regulation, Leukemic;Gene Fusion;Humans;Interleukin-7 Receptor alpha Subunit;Janus Kinase 2;Mutation;Philadelphia Chromosome;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinases;Receptors, Cytokine;Retrospective Studies;Transcriptome",M01.060.406;D08.811.913.696.620.682.725.500.500;D12.776.602.500.500.100;D12.776.624.664.500.100;D12.776.624.664.700.171.500;G05.308.370.500;G05.728.385;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.852.420.420.450;D08.811.913.696.620.682.725.124.200;D12.776.476.393.200;D12.776.624.664.700.117;G05.365.590;A11.284.187.520.300.325.345.500;A11.284.187.520.300.505.515.500;C23.550.210.870.680;G05.360.162.520.300.325.345.700;G05.360.162.520.300.505.515.700;G05.365.590.175.870.680;C04.557.337.428.600.600;C15.604.515.560.600.600;C20.683.515.528.600.600;D08.811.913.696.620.682;D12.776.543.750.705.852;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G02.111.873.750;G05.297.700.750;G05.360.920
28408444,Endothelium;Fatty Acids;Lipid Droplets;Muscles,A10.272.491;D10.251;A11.284.430.214.190.875.393;A02.633;A10.690
28408438,Adipocytes;Animals;DNA-Binding Proteins;Gene Expression Regulation;Interferon Regulatory Factor-1;Interferon Type I;Mice;Mitochondria;STAT1 Transcription Factor;Thermogenesis;Transcription Factors;Uncoupling Protein 1;Mitochondria,A11.329.114;B01.050;D12.776.260;G05.308;D12.644.360.024.302.124;D12.776.157.057.050.124;D12.776.260.108.374;D12.776.260.504.124;D12.776.476.024.385.124;D12.776.930.127.374;D12.776.930.332.124;D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890;B01.050.150.900.649.313.992.635.505.500;A11.284.430.214.190.875.564;A11.284.835.626;D12.644.360.024.303.500.500;D12.644.360.024.342.100;D12.776.157.057.061.500.500;D12.776.157.057.186.100;D12.776.260.513.249.500;D12.776.476.024.386.500.500;D12.776.476.024.430.100;D12.776.930.354.249.500;D12.776.930.840.100;G07.110.232.778;G07.410.421.778;G16.012.500.535.778;D12.776.930;D12.776.157.530.937.598.500;D12.776.543.585.475.688.500;D12.776.543.585.937.696.500;D12.776.575.750.688.500;A11.284.430.214.190.875.564;A11.284.835.626
28408422,Factor IX;Hemophilia B;Hemorrhage;Humans,D08.622.355;D12.776.124.125.375;D23.119.375;C15.378.100.100.510;C15.378.100.141.510;C15.378.463.510;C16.320.099.510;C16.320.322.235;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400
28408323,"Apoprotein(a);Biomarkers;Case-Control Studies;Coronary Disease;Genetic Predisposition to Disease;Genotype;Humans;Incidence;Lipoprotein(a);Mendelian Randomization Analysis;Middle Aged;Myocardial Infarction;Pakistan;Phenotype;Polymorphism, Single Nucleotide;Protein Isoforms;Risk Factors",D10.532.350.500;D12.776.521.400.500;D23.101;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C14.280.647.250;C14.907.585.250;C23.550.291.687.500;G05.380.355;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D10.532.350;D12.776.521.400;E05.318.416.500;M01.060.116.630;C14.280.647.500;C14.907.585.500;Z01.252.245.723;G05.695;G05.365.795.598;D12.776.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28408189,"Cardiovascular Diseases;DNA;Exome;Genotype;Ghana;Humans;Morbidity;Plasminogen Activator Inhibitor 1;Polymorphism, Single Nucleotide;Risk Assessment;Risk Factors",C14;D13.444.308;G05.360.340.011;G05.380;Z01.058.290.190.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;D12.644.861.695.500;D12.776.124.125.640;D12.776.872.695.500;D23.119.832.500;G05.365.795.598;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28407726,Adolescent;Amygdala;Anxiety Disorders;Arousal;Attentional Bias;Behavior Therapy;Cerebral Cortex;Child;Cognitive Behavioral Therapy;Combined Modality Therapy;Humans;Magnetic Resonance Imaging;Nerve Net;Prognosis;Reference Values;Adolescent;Anxiety Disorders;Child Psychiatry;Cognitive Neuroscience,M01.060.057;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F03.080;F02.830.104;G11.561.035;F02.830.104.214.500;F04.754.137;A08.186.211.200.885.287.500;M01.060.406;F04.754.137.350;E02.186;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;A08.511;E01.789;E05.978.810;M01.060.057;F03.080;F04.096.544.193;H02.403.690.130;F04.096.628.255.500;H01.158.610.030
28407503,"Accidental Falls;Aged;Aged, 80 and over;Cognition;Dementia;Executive Function;Follow-Up Studies;Gait;Humans;Incidence;Middle Aged;Neurologic Examination;Parkinsonian Disorders;Pennsylvania;Retrospective Studies;Risk Assessment;Risk Factors;Survival Rate;Time Factors;Cohort Studies;Parkinsonian Disorders",N06.850.135.122;M01.060.116.100;M01.060.116.100.080;F02.463.188;C10.228.140.380;F03.615.400;F02.463.217;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E01.370.600.250;G11.427.410.568.900.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;E01.370.376.550;E01.370.600.550;C10.228.140.079.862;C10.228.662.600;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;G01.910.857;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C10.228.140.079.862;C10.228.662.600
28407441,"Adolescent;Adult;Algorithms;Data Interpretation, Statistical;Geography;Health Policy;Health Services Accessibility;Hepatitis C;Humans;Liver;Liver Cirrhosis, Alcoholic;Liver Failure;Liver Transplantation;Middle Aged;Outcome Assessment (Health Care);Severity of Illness Index;Time Factors;Tissue Donors;Tissue and Organ Procurement;Treatment Outcome;United States;Waiting Lists;Young Adult",M01.060.057;M01.060.116;G17.035;L01.224.050;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;H01.277.500;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;N04.590.374.350;N05.300.430;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;A03.620;C06.552.630.380;C06.552.645.590;C25.775.100.087.645.550;C06.552.308.500;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;M01.898;N02.421.911;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;N04.452.095.738;M01.060.116.815
28406878,"Arthroplasty, Replacement, Knee;Bone Cements;Bone Resorption;Femur;Humans;Knee Prosthesis;Postoperative Complications;Reoperation;Tibia",E04.555.110.110.115;E04.650.110.115;E04.680.101.110.115;D05.750.716.822.300;D25.720.716.822.300;D27.720.102.158;J01.637.051.720.716.822.300;C05.116.264;G11.427.213.150;A02.835.232.043.650.247;B01.050.150.900.649.313.988.400.112.400.400;E07.695.400.410;C23.550.767;E04.690;A02.835.232.043.650.883
28406212,1-Alkyl-2-acetylglycerophosphocholine Esterase;Apolipoprotein C-III;Cohort Studies;Consanguinity;Coronary Disease;Cytochrome P450 Family 2;DNA Mutational Analysis;Dietary Fats;Exome;Fasting;Gene Deletion;Gene Frequency;Genes;Genetic Association Studies;Homozygote;Humans;Interleukin-8;Middle Aged;Myocardial Infarction;Neuregulins;Pakistan;Pedigree;Phenotype;Phosphoproteins;Postprandial Period;RNA Splice Sites;Reverse Genetics;Sodium-Hydrogen Exchangers;Triglycerides,D08.811.277.352.100.680.750.937.249;D10.532.091.400.875;D12.776.070.400.400.875;D12.776.521.120.400.875;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.090.403.180;G05.180;C14.280.647.250;C14.907.585.250;D08.244.453.491;D08.811.682.690.708.170.450;D12.776.422.220.453.491;E05.393.760.700.300;D10.212.302;G07.203.300.375;J02.500.375;G05.360.340.011;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;G05.365.590.762.320;G05.558.800.320;G05.330;G05.360.340.024.340;E05.393.385;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312;M01.060.116.630;C14.280.647.500;C14.907.585.500;D12.644.276.860.550;D12.776.467.860.550;D12.776.631.600.550;D23.529.850.550;Z01.252.245.723;E05.393.673;G05.695;D12.776.744;G10.261.700;D13.444.735.544.550;G02.111.570.080.689.687.490;G05.360.080.689.687.490;G05.360.340.024.340.137.800;E05.393.731;D12.776.157.530.450.162.775;D12.776.157.530.937.703;D12.776.543.550.190.775;D12.776.543.585.450.162.775;D12.776.543.585.937.828;D10.351.801
28404661,Animals;Caenorhabditis elegans;Fats;Larva;Lipid Droplets;Lipid Metabolism;Microscopy;Mutation;Staining and Labeling,B01.050;B01.050.500.500.294.400.875.660.250.250;D10.212;B05.500.500;G07.345.500.550.500.500;A11.284.430.214.190.875.393;G03.458;E01.370.350.515;E05.595;H01.671.617.562;G05.365.590;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670
28404638,"Animals;Fasting;Fatty Acids, Nonesterified;Kidney;Mice;Mice, Inbred C57BL;Oxidation-Reduction;Triglycerides;Lipoprotein Lipase",B01.050;F01.145.407.400;G07.203.650.240.587;G07.203.650.353.400;D10.251.310;A05.810.453;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.700;G03.295.531;D10.351.801;D08.811.277.352.100.430
28404578,"Calcium;Calcium, Dietary;Child;Dietary Fats;Energy Intake;Humans",D01.268.552.100;D01.552.539.288;D23.119.100;D01.146.395;M01.060.406;D10.212.302;G07.203.300.375;J02.500.375;G07.203.650.240.340;B01.050.150.900.649.313.988.400.112.400.400
28403437,"Adult;Brain;Diffusion Tensor Imaging;Guanylate Cyclase;Humans;Leber Congenital Amaurosis;Magnetic Resonance Imaging;Middle Aged;Mutation;Nerve Fibers;Optic Chiasm;Photic Stimulation;Photoreceptor Cells, Vertebrate;Receptors, Cell Surface;Retinal Ganglion Cells;Tomography, Optical Coherence;Visual Acuity;Visual Pathways;Young Adult",M01.060.116;A08.186.211;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;D08.811.520.650.600;D12.644.360.350;D12.776.476.350;B01.050.150.900.649.313.988.400.112.400.400;C11.270.516;C11.768.364;E01.370.350.825.500;M01.060.116.630;G05.365.590;A08.675.542;A11.671.501;A08.186.211.200.317.578;A08.800.800.120.680.600;E05.723.729;A08.675.650.850.625.670;A08.675.650.915.937.670;A08.800.950.937.670;A09.371.729.831.625.670;A11.671.650.850.625.670;A11.671.650.915.937.670;D12.776.543.750;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;A08.612.220.860;M01.060.116.815
28403134,"Adolescent;Child;Cleft Lip;Cleft Palate;Computer-Aided Design;Humans;Osteogenesis, Distraction;Osteotomy, Le Fort;Recurrence;Retrognathia;Retrospective Studies;Young Adult",M01.060.057;M01.060.406;C07.465.409.225;C07.465.525.164;C07.650.525.164;C16.131.850.525.164;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;L01.224.108.150;L01.296.110.150;B01.050.150.900.649.313.988.400.112.400.400;E04.555.120.690;E04.545.575;E04.555.580.580;E06.645.575;C23.550.291.937;C05.500.460.827;C05.660.207.540.460.827;C07.320.440.827;C07.320.610.827;C07.650.500.460.827;C16.131.621.207.540.460.827;C16.131.850.500.460.827;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
28403049,"Age of Onset;Anti-Bacterial Agents;Blood Culture;Cesarean Section;Chorioamnionitis;Disease Management;Early Diagnosis;Fetal Membranes, Premature Rupture;Gram-Negative Bacteria;Gram-Negative Bacterial Infections;Gram-Positive Bacteria;Gram-Positive Bacterial Infections;Humans;Infant, Newborn;Infant, Very Low Birth Weight;Intensive Care Units, Neonatal;Obstetric Labor, Premature;Pre-Eclampsia;Pregnancy;Retrospective Studies;Sepsis",N05.715.350.075.100;N06.850.490.250.100;D27.505.954.122.085;E01.370.225.875.185;E05.200.875.185;E04.520.252.500;C13.703.277.030;C13.703.420.339.260;C13.703.590.268;C16.300.030;N04.590.607;E01.390;C13.703.420.339;B03.440;C01.252.400;B03.510;C01.252.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.460.600;N02.278.388.493.390.380;C13.703.420.491;C13.703.395.249;G08.686.784.769;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.539.757;C23.550.470.790.500
28402859,"Animals;Carcinogenesis;Cell Line, Tumor;Cell Movement;Chemokine CXCL13;Gene Expression Regulation, Neoplastic;Humans;Mice;NF-kappa B;Neoplasm Metastasis;PTEN Phosphohydrolase;Prostatic Neoplasms;Protein Kinase C-epsilon;Receptors, CXCR5;Signal Transduction;NF-kappa B;Prostatic Neoplasms;Mice, Transgenic",B01.050;C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;G04.198;G07.568.500.180;D12.644.276.374.200.120.650;D12.776.467.374.200.120.650;D23.125.300.120.650;D23.469.200.120.650;D23.529.374.200.120.650;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;D12.776.260.600;D12.776.660.600;D12.776.930.600;C04.697.650;C23.550.727.650;D08.811.277.352.650.850;D12.776.476.590;D12.776.624.776.695;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;D08.811.913.696.620.682.700.725.750;D12.776.543.750.695.160.500.500;D12.776.543.750.705.852.125.500.500;G02.111.820;G04.835;D12.776.260.600;D12.776.660.600;D12.776.930.600;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
28402780,Disease Management;Humans;Obesity,N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28402697,"Adult;Affect;Anxiety Disorders;Depression;Factor Analysis, Statistical;Humans;Mass Screening;Mood Disorders;Pregnancy;Pregnant Women;Prenatal Diagnosis;Psychiatric Status Rating Scales;Reproducibility of Results;Surveys and Questionnaires;Pregnancy",M01.060.116;F01.470.047;F03.080;F01.145.126.350;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;F03.600;G08.686.784.769;M01.975.807;E01.370.378.630;F04.711.513.653;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;G08.686.784.769
28402167,"Adolescent;Adult;Aged;Aged, 80 and over;Humans;Middle Aged;Practice Guidelines as Topic;Radiology;Reproducibility of Results;Risk Assessment;Sensitivity and Specificity;Societies, Medical;Thyroid Nodule;Ultrasonography;United States;Young Adult;Thyroid Neoplasms;Thyroid Nodule",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.761.700.350.650;N05.700.350.650;H02.403.740;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;N03.540.828.589;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800;E01.370.350.850;Z01.107.567.875;M01.060.116.815;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;C04.588.322.894.800;C04.588.443.915.800;C19.344.894.800;C19.874.788.800
28401998,"Anticonvulsants;Child, Preschool;Cohort Studies;Electroencephalography;Epilepsies, Partial;Follow-Up Studies;Humans;Hypothermia, Induced;Hypoxia-Ischemia, Brain;Infant;Infant, Newborn;Intensive Care Units, Neonatal;Likelihood Functions;Magnetic Resonance Imaging;Monitoring, Physiologic;Patient Discharge;Recurrence;Retrospective Studies;Hypoxia-Ischemia, Brain;Hypothermia, Induced",D27.505.954.427.080;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.376.300;E01.370.405.245;C10.228.140.490.360;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703;M01.060.703.520;N02.278.388.493.390.380;E05.318.740.500.475;E05.318.740.600.400;E05.599.835.500;N05.715.360.750.530.450;N05.715.360.750.625.450;N06.850.520.830.500.475;N06.850.520.830.600.400;E01.370.350.825.500;E01.370.520;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;C23.550.291.937;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;E02.258.750
28401680,"Animals;Biomarkers;Combined Modality Therapy;DNA Methylation;Diabetes Complications;Diabetes Mellitus, Type 1;Diabetes Mellitus, Type 2;Epigenesis, Genetic;Gene Expression Regulation, Developmental;Health Transition;Humans;Insulin Resistance;Risk Factors;DNA Methylation;Epigenomics;Insulin Secretion;Insulin Resistance;Diabetes Mellitus, Type 2",B01.050;D23.101;E02.186;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;C19.246.099;C18.452.394.750.124;C19.246.267;C20.111.327;C18.452.394.750.149;C19.246.300;G05.308.203;G05.308.310;I01.240.600.400;N01.224.625.400;N06.850.505.400.700.400;N06.850.650;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500;G07.690.773.984.617;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;H01.158.273.180.350.074;H01.158.273.343.350.042;G03.442;G07.475;C18.452.394.968.500;G07.690.773.984.617;C18.452.394.750.149;C19.246.300
28400166,"Acetanilides;Adrenergic beta-3 Receptor Agonists;Thiazoles;Urinary Bladder, Overactive",D02.065.199.092;D02.092.146.113.092;D27.505.519.625.050.100.200.300;D27.505.696.577.050.100.200.300;D02.886.675;D03.383.129.708;C12.777.829.866;C13.351.968.829.813;C23.888.942.343.780
28399975,"Antitubercular Agents;Botswana;Child;Contact Tracing;Cross-Sectional Studies;Health Knowledge, Attitudes, Practice;Health Personnel;Humans;Interviews as Topic;Isoniazid;Mass Screening;Pilot Projects;Rural Health Services;Surveys and Questionnaires;Tuberculosis;Urban Health Services",D27.505.954.122.085.255;Z01.058.290.175.230;M01.060.406;E05.318.270;N06.850.520.270;N06.850.780.200.225;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.100.150.500;N05.300.150.410;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;D02.442.436;D03.066.349.410;D03.383.725.394.582;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;N02.421.816;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C01.252.410.040.552.846;N02.421.914
28399931,"Adolescent;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antirheumatic Agents;Arthritis, Juvenile;Child;Child, Preschool;Consensus;Drug Therapy, Combination;Feasibility Studies;Glucocorticoids;Humans;Interleukin 1 Receptor Antagonist Protein;Methotrexate;Pilot Projects;Practice Guidelines as Topic;Prospective Studies;Registries;Rheumatology;Treatment Outcome;Registries",M01.060.057;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D27.505.954.329;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;M01.060.406.448;F01.829.316.068;F02.463.785.373.433;E02.319.310;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.460;D12.776.467.374.460;D23.529.374.460;D03.633.100.733.631.192.500;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;H02.403.429.730;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28399056,Bacteria;Botswana;Humans;Infant;Microbiota;Nasopharynx;Prospective Studies;Respiratory Tract Infections,B03;Z01.058.290.175.230;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;A04.623.557;A14.724.557;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C01.539.739;C08.730
28399050,"Child;Child, Preschool;Follow-Up Studies;Humans;Lung;Prostheses and Implants;Respiration, Artificial;Ribs;Scoliosis;Spinal Muscular Atrophies of Childhood;Syndrome;Thoracic Wall;Titanium;Treatment Outcome",M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;A04.411;E07.695;E02.041.625;E02.365.647.729;E02.880.820;A02.835.232.570.500;C05.116.900.800.875;C10.228.854.468.800;C10.574.500.812;C10.574.562.500.750;C10.668.467.500.750;C16.320.400.765;C23.550.288.500;A01.923.761.850;D01.268.557.800;D01.268.956.878;D01.552.547.800;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28398701,Cervical Length Measurement;Cervix Uteri;Humans;Pessaries;Pregnancy;Premature Birth;Cervix Uteri;Meta-Analysis;Obstetrics;Premature Birth;Review,E01.370.350.850.865.249;E01.370.378.630.865.249;A05.360.319.679.256;B01.050.150.900.649.313.988.400.112.400.400;E07.858.499;G08.686.784.769;C13.703.420.491.500;A05.360.319.679.256;V03.600;H02.403.810.450;C13.703.420.491.500;V02.600.500;V02.912
28398664,"Adolescent;Adult;Case-Control Studies;Child;Child, Preschool;Cohort Studies;DNA Copy Number Variations;Gene Expression Profiling;Gene Ontology;Gene Regulatory Networks;Genetic Heterogeneity;Genetic Predisposition to Disease;Genotype;Heart Defects, Congenital;Humans;Molecular Sequence Annotation;Phenotype;Polymorphism, Single Nucleotide;Heart Defects, Congenital",M01.060.057;M01.060.116;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G05.365.795.297.500;E05.393.332;H01.158.273.343.249.099;H01.770.644.145.350.124;L01.224.050.375.480.500.500;L01.313.500.750.300.550.500.500;L01.453.245.945.079.500;G05.360.080.689.360;G05.365.331;C23.550.291.687.500;G05.380.355;G05.380;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E05.393.760.479;L01.453.245.667.580;G05.695;G05.365.795.598;C14.240.400;C14.280.400;C16.131.240.400
28398525,"Biomedical Research;Data Accuracy;Datasets as Topic;Electronic Health Records;Hospitals, Pediatric;Longitudinal Studies;Data Accuracy;Electronic Health Records",H01.770.644.145;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;E05.318.308.056;L01.313.500.750.300.188.400.500;L01.399.250.224;L01.470.750.750.431;N05.715.360.300.224;N06.850.520.308.056;E05.318.308.940.968.625.500;N02.278.421.556.437;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E05.318.308.028;E05.318.370.725.250;L01.399.250.202;N05.715.360.300.202;N05.715.360.325.685.250;E05.318.308.940.968.625.500
28397821,"Antibodies, Monoclonal, Humanized;CD8-Positive T-Lymphocytes;Humans;Ki-67 Antigen;Melanoma;Neoplasm Staging;Phenotype;Programmed Cell Death 1 Receptor;Treatment Outcome;Tumor Burden",D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;B01.050.150.900.649.313.988.400.112.400.400;D12.776.660.625.500;D23.050.290.500;D23.101.140.400;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;E01.789.625;G05.695;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.041.124.892
28396020,Brain;Brain Neoplasms;Child;Humans;Infratentorial Neoplasms;Perfusion;Survivors;Brain Neoplasms,A08.186.211;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C04.588.614.250.195.411;C10.228.140.211.500;C10.551.240.250.400;E05.680;M01.860;C04.588.614.250.195;C10.228.140.211;C10.551.240.250
28395554,Animals;Humans;Mass Spectrometry;Peptide Hydrolases;Proteolysis;Proteomics;Substrate Specificity;Proteolysis;Isotope Labeling;Mass Spectrometry;Proteomics,B01.050;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;D08.811.277.656;G02.111.720;G03.812;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.835;G02.111.720;G03.812;E05.522;E05.196.566;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
28395338,"Animals;Embryo Implantation;Endometrium;Epithelium;Hydrogen-Ion Concentration;Macrolides;Mice, Inbred C57BL;Pregnancy;Vacuolar Proton-Translocating ATPases;Embryo Implantation",B01.050;G08.686.784.170.104.500;A05.360.319.679.490;A10.272;G02.300;D02.540.505;D02.540.576.500;D04.345.674.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G08.686.784.769;D08.811.277.040.025.325.875;D08.811.913.696.650.150.500.875;D12.776.157.530.450.250.875.500.875;D12.776.543.585.450.250.875.500.875;G08.686.784.170.104.500
28394995,"Child;Child, Preschool;Clinical Alarms;Clinical Competence;Clinical Nursing Research;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Monitoring, Physiologic;Nursing Staff, Hospital;Pediatric Nursing;Philadelphia;Prospective Studies;Reaction Time;Video Recording",M01.060.406;M01.060.406.448;E07.230.200;I02.399.630.210;N04.761.210;N05.715.175;H01.770.644.145.390.234;H02.478.395.234;N04.590.233.508.613.234;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E01.370.520;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;H02.478.676.631;N02.421.533.691;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.796.817;F02.830.650;F04.669.817;G11.561.677;L01.280.960
28394851,"Adolescent;Anemia, Sickle Cell;Arthritis, Juvenile;Child;Chronic Pain;Diagnostic Self Evaluation;Fibromyalgia;Humans;Pain Measurement;Psychometrics;Reproducibility of Results;Self Report;Severity of Illness Index",M01.060.057;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198;M01.060.406;C23.888.592.612.274;E01.370.360;F01.752.747.792.220;C05.651.324;C05.799.321;C10.668.491.425;B01.050.150.900.649.313.988.400.112.400.400;E01.370.600.550.324;F04.711.780;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28394779,"Clinical Competence;Ergonomics;Hospitals, Pediatric;Humans",I02.399.630.210;N04.761.210;N05.715.175;F02.784.412;J01.293.556;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400
28394581,"Antimetabolites, Antineoplastic;Cytarabine;DNA Modification Methylases;Epigenesis, Genetic;Humans;Leukemia, Myeloid, Acute",D27.505.519.186.144;D27.505.954.248.144;D27.888.569.042.030;D03.383.742.680.245.453;D13.570.065.300;D13.570.685.245.453;D08.811.150.240;D08.811.913.555.500.350;G05.308.203;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275
28394509,"Adolescent;Adult;Child;Child Abuse;Child Abuse, Sexual;Child of Impaired Parents;Child, Preschool;Cohort Studies;Cross-Sectional Studies;Depressive Disorder, Major;Domestic Violence;Family Conflict;Humans;Life Change Events;Menopause;Middle Aged;Risk Factors;Surveys and Questionnaires",M01.060.057;M01.060.116;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;I01.198.240.748.300;I01.198.240.856.350.250.255;I01.880.735.900.350.250.255;M01.106;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F03.600.300.375;I01.198.240.856.350;I01.880.735.900.350;F01.829.263.370.054;F01.829.401.142;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;G08.686.157.500;G08.686.841.249.500;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28394443,"Adolescent;Adult;Atrial Flutter;Child;Electrocardiography, Ambulatory;Electrophysiologic Techniques, Cardiac;Exercise Test;Heart Valve Prosthesis Implantation;Humans;Logistic Models;Multivariate Analysis;Odds Ratio;Perioperative Period;Pulmonary Valve;Retrospective Studies;Risk Factors;Tachycardia, Reciprocating;Tetralogy of Fallot;Time Factors;Treatment Outcome;Young Adult;Atrial Flutter;Tetralogy of Fallot;Vectorcardiography",M01.060.057;M01.060.116;C14.280.067.248;C23.550.073.248;M01.060.406;E01.370.370.380.240.230;E01.370.405.240.230;E01.370.520.500.230;E01.370.370.380.245;E01.370.405.267;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;E04.100.376.485;E04.650.410;E04.928.220.410;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E04.614;N02.421.585.753;A07.541.510.738;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.067.845.787;C14.280.123.875.787;C23.550.073.845.787;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C14.280.067.248;C23.550.073.248;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;E01.370.370.380.240.850;E01.370.405.240.850
28393830,"Calorimetry;Crystallography, X-Ray;DNA;HEK293 Cells;Humans;Mutant Proteins;Mutation;Protein Binding;Structure-Activity Relationship;Telomerase;Telomere;Telomere-Binding Proteins",E05.196.131;E05.196.309.742.225;D13.444.308;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D12.776.602;G05.365.590;G02.111.679;G03.808;G02.111.830;G07.690.773.997;D08.811.913.696.445.308.300.750.750;D12.776.157.687.613;D12.776.157.725.500.921;D12.776.660.720.613;D12.776.664.962.500.921;A11.284.430.106.279.345.190.160.845;G05.360.160.845;D12.776.260.735;D12.776.660.235.700
28393437,"Aged;Aged, 80 and over;Esophageal Diseases;Esophagogastric Junction;Humans;Middle Aged;Tertiary Care Centers;Treatment Outcome;Deglutition Disorders",M01.060.116.100;M01.060.116.100.080;C06.405.117;A03.556.875.500.414;A03.556.875.875.330;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N02.278.421.830;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C06.405.117.119;C09.775.174
28393317,Adolescent;Health Behavior;Humans;Medication Adherence;Multiple Sclerosis;Quality of Life;Multiple Sclerosis;Quality of Life,M01.060.057;F01.145.488;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;I01.800;K01.752.400.750;N06.850.505.400.425.837
28392081,"Autism Spectrum Disorder;Axis, Cervical Vertebra;Cerebral Ventricles;Cerebrospinal Fluid;Child, Preschool;Genetic Predisposition to Disease;Humans;Image Processing, Computer-Assisted;Infant;Longitudinal Studies;Magnetic Resonance Imaging;Motor Skills;Organ Size;Pattern Recognition, Automated;Prodromal Symptoms;Prognosis;Sensitivity and Specificity;Severity of Illness Index;Siblings;Subarachnoid Space;Autistic Disorder",F03.625.164.113;A02.835.232.834.151.383;A08.186.211.140;A12.207.270.210;M01.060.406.448;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;F02.808.260;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;L01.399.750;C23.888.672;E01.599;E01.789;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;A08.186.566.166.686;F03.625.164.113.500
28391397,"Absorptiometry, Photon;Adult;Aged;Arm;Body Composition;Bone Density;Breast Neoplasms;Exercise;Humans;Life Style;Lymphedema;Weight Lifting;Lymphedema;Exercise;Survivorship",E01.370.350.700.024;E05.196.712.224.187;M01.060.116;M01.060.116.100;A01.378.800.075;G02.111.130;G03.180;G07.100.049;G11.427.100;C04.588.180;C17.800.090.500;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458;C15.604.496;I03.450.642.845.950;C15.604.496;G11.427.410.698.277;I03.350;F01.058.144.500
28391349,"Adult;Aged;Blood Pressure;C-Reactive Protein;Cohort Studies;Enzyme-Linked Immunosorbent Assay;Fibrinogen;Follow-Up Studies;Humans;Inflammation;Interleukin 1 Receptor Antagonist Protein;Interleukin-1beta;Interleukin-6;Linear Models;Middle Aged;Proteinuria;Pulse Wave Analysis;Renal Insufficiency, Chronic;Transforming Growth Factor beta;Tumor Necrosis Factor-alpha;Vascular Stiffness;Vascular Stiffness;Blood Pressure;Renal Insufficiency, Chronic;Hypertension;Inflammation",M01.060.116;M01.060.116.100;E01.370.600.875.249;G09.330.380.076;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;D12.776.124.050.250;D12.776.124.125.500;D12.776.811.300;D23.119.490;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.644.276.374.460;D12.776.467.374.460;D23.529.374.460;D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;M01.060.116.630;C12.777.934.734;C13.351.968.934.734;C23.888.942.750;E01.370.370.680;C12.777.419.780.750;C13.351.968.419.780.750;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;G09.330.940;G09.330.940;E01.370.600.875.249;G09.330.380.076;C12.777.419.780.750;C13.351.968.419.780.750;C14.907.489;C23.550.470
28391347,"Apolipoprotein L1;Apolipoproteins;Glomerulosclerosis, Focal Segmental;Humans;Hypertension, Renal;Lipoproteins, HDL;Nephritis;Renal Insufficiency, Chronic;Glomerulosclerosis, Focal Segmental;Inflammation;Podocytes",D10.532.091.750.500;D12.776.070.400.750.500;D12.776.521.120.750.500;D10.532.091;D12.776.070.400;D12.776.521.120;C12.777.419.570.363.660;C13.351.968.419.570.363.640;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.331;C13.351.968.419.331;C14.907.489.631;D10.532.432;D12.776.521.479;C12.777.419.570;C13.351.968.419.570;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.570.363.660;C13.351.968.419.570.363.640;C23.550.470;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720
28391012,"Age Factors;Animals;Animals, Newborn;Brain;Brain Mapping;Chlorides;Disease Models, Animal;Formaldehyde;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Manganese Compounds;Pain;Pain Measurement;Rats;Time Factors;Brain;Nociception",N05.715.350.075;N06.850.490.250;B01.050;B01.050.050.282;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;D01.210.450.150;D01.248.497.158.215;C22.232;E05.598.500;E05.599.395.080;D02.047.407;L01.224.308;E01.370.350.825.500;D01.530;C23.888.592.612;F02.830.816.444;G11.561.790.444;E01.370.600.550.324;B01.050.150.900.649.313.992.635.505.700;G01.910.857;A08.186.211;F02.463.593.504.500
28391001,"Adolescent;Age Distribution;Aging;Child;Child, Preschool;Echocardiography;Humans;Image Interpretation, Computer-Assisted;Imaging, Three-Dimensional;Infant;Infant, Newborn;Mitral Valve;Observer Variation;Reproducibility of Results;Sensitivity and Specificity;Young Adult;Mitral Valve;Echocardiography, Three-Dimensional",M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;G07.345.124;M01.060.406;M01.060.406.448;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;E01.370.350.400;L01.224.308.410;M01.060.703;M01.060.703.520;A07.541.510.507;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.116.815;A07.541.510.507;E01.370.350.130.750.230;E01.370.350.400.200;E01.370.350.850.220.230;E01.370.370.380.220.230
28390860,"Interleukin-4;Immunoglobulin E;Dermatitis, Atopic;Basophils;Mast Cells",D12.644.276.374.465.186;D12.776.467.374.465.178;D23.529.374.465.186;D12.776.124.486.485.114.619.312;D12.776.124.790.651.114.619.312;D12.776.377.715.548.114.619.312;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;A11.118.637.415.120;A11.627.340.120;A15.145.229.637.415.120;A15.382.490.315.120;A11.329.427;A15.382.652
28390597,"Adolescent;Adult;Child;Child, Preschool;Chromosome Deletion;Chromosomes, Human, Pair 22;Comorbidity;DiGeorge Syndrome;Hospitals, Pediatric;Humans;Infant;Philadelphia;Pregnancy;Prevalence;Respiratory Tract Diseases;Retrospective Studies;Young Adult;DiGeorge Syndrome;Larynx;Polyhydramnios;Trachea",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;N05.715.350.225;N06.850.490.687;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;Z01.107.567.875.500.550.525;Z01.433.820;G08.686.784.769;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C08;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;A04.329;C13.703.610;A04.889
28390438,"Academic Medical Centers;Adolescent;Adult;Aged;Aged, 80 and over;Anti-Bacterial Agents;Cohort Studies;Escherichia coli;Escherichia coli Infections;Fluoroquinolones;Humans;Microbial Sensitivity Tests;Middle Aged;Outpatients;Philadelphia;Retrospective Studies;Treatment Failure;Urinary Tract Infections;Young Adult;Escherichia coli;Urinary Tract Infections",N02.278.020;M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;D27.505.954.122.085;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B03.440.450.425.325.300;B03.660.250.150.180.100;C01.252.400.310.330;D03.633.100.810.835.322;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;M01.060.116.630;M01.643.630;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800.760;N04.761.559.590.800.760;N05.715.360.575.575.800.760;C01.539.895;C12.777.892;C13.351.968.892;M01.060.116.815;B03.440.450.425.325.300;B03.660.250.150.180.100;C01.539.895;C12.777.892;C13.351.968.892
28389863,"Attitude of Health Personnel;Books;Emotions;Goals;Health Knowledge, Attitudes, Practice;Humans;Interpersonal Relations;Orthopedic Surgeons;Resilience, Psychological",F01.100.050;N05.300.100;L01.178.682.192;F01.470;F01.658.500;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401;M01.526.485.810.910.875;N02.360.810.910.875;F02.940
28389745,"Adolescent;Antihypertensive Agents;Blood Pressure Determination;Cross-Over Studies;Feasibility Studies;Humans;Hypertension;Insurance, Health, Reimbursement;Kidney Failure, Chronic;Midwestern United States;Nephrology;Pilot Projects;Renal Dialysis;Time Factors;Treatment Outcome;Child;Kidney Failure, Chronic;Hypertension",M01.060.057;D27.505.954.411.162;E01.370.370.140;E01.370.600.100;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;N03.219.521.576.343.480;N03.219.521.710;C12.777.419.780.750.500;C13.351.968.419.780.750.500;Z01.107.567.875.510;H02.403.429.580;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E02.870.300;E02.912.800;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.406;C12.777.419.780.750.500;C13.351.968.419.780.750.500;C14.907.489
28389532,Amyotrophic Lateral Sclerosis;Calmodulin-Binding Proteins;Cytoplasmic Granules;DNA-Binding Proteins;Frontotemporal Dementia;Heterogeneous Nuclear Ribonucleoprotein A1;Heterogeneous-Nuclear Ribonucleoprotein Group A-B;Humans;Mutation;Neurodegenerative Diseases;Prion Proteins;Protein Domains;Proteostasis Deficiencies;RNA-Binding Protein EWS;RNA-Binding Protein FUS;RNA-Binding Proteins;TATA-Binding Protein Associated Factors;TDP-43 Proteinopathies;RNA-Binding Proteins,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;D12.776.157.142;A11.284.430.214.190.500;A11.284.430.214.190.875.190.190;D12.776.260;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;D12.776.157.687.462;D12.776.157.725.813.750.100.500;D12.776.260.735.500.500;D12.776.660.235.700.500.500;D12.776.664.962.813.750.100.500;D12.776.157.725.813.750.100;D12.776.260.735.500;D12.776.660.235.700.500;D12.776.664.962.813.750.100;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C10.574;D12.776.395.550.448.600;D12.776.543.484.500.625;D12.776.543.550.418.600;D12.776.785.340;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;C18.452.845;D12.644.360.650;D12.776.157.142.750;D12.776.157.725.813.750.900;D12.776.476.650;D12.776.624.664.700.913;D12.776.664.962.813.750.900;D12.776.157.725.813.750.905;D12.776.624.664.700.915;D12.776.664.962.813.750.902;D12.776.157.725;D12.776.664.962;D12.776.260.775.186;D12.776.930.930.186;C10.574.950;C18.452.845.800;D12.776.157.725;D12.776.664.962
28389524,"Adipose Tissue;Adolescent;Adult;DNA Transposable Elements;Endotoxemia;Gene Expression Profiling;Genome-Wide Association Study;Humans;Inflammation;Lipopolysaccharide Receptors;Middle Aged;Monocytes;Polymorphism, Single Nucleotide;RNA, Long Noncoding;Young Adult;Humans;Inflammation",A10.165.114;M01.060.057;M01.060.116;D13.444.308.520;G02.111.570.080.708.330.200;G05.360.080.708.330.200;G05.360.340.024.425.200;C01.539.757.100.275;C01.539.861.375;C23.550.470.790.500.100.275;E05.393.332;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;D12.776.395.550.448.100;D12.776.543.484.500.100;D12.776.543.550.418.100;D12.776.543.750.705.045;D23.050.301.264.900.045;D23.101.100.900.045;M01.060.116.630;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;G05.365.795.598;D13.444.735.790.375;M01.060.116.815;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470
28389510,"Abiraterone Acetate;Antineoplastic Combined Chemotherapy Protocols;Genotype;Germ-Line Mutation;Gonadotropin-Releasing Hormone;Humans;Organic Anion Transporters;Polymorphism, Single Nucleotide;Prednisone;Prostate;Prostate-Specific Antigen;Prostatic Neoplasms, Castration-Resistant;Testosterone;Treatment Outcome",D04.210.500.054.079.065;E02.183.750.500;E02.319.077.500;E02.319.310.037;G05.380;G05.365.590.350;D06.472.699.327.740.320;D12.644.400.400.740.320;D12.644.456.460;D12.644.548.365.740.320;D12.776.631.650.405.740.320;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530.450.074.500;D12.776.543.585.450.074.500;G05.365.795.598;D04.210.500.745.432.719.702;A05.360.444.575;A10.336.707;D08.811.277.656.300.760.442.750;D08.811.277.656.959.350.442.750;D12.776.866.249.500;D23.050.285.625;D23.101.140.625;C04.588.945.440.770.500;C12.294.260.750.500;C12.294.565.625.500;C12.758.409.750.500;D04.210.500.054.079.429.824;D06.472.334.851.968.984;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28389234,Audiology;Crowdsourcing;Data Curation;Electronic Health Records;Humans;Radiology;Crowdsourcing;Logistic Models,H02.010.150;L01.399.250.179;L01.313.500.875.500;L01.453.245.332;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;H02.403.740;L01.399.250.179;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450
28388693,Animals;Bunyaviridae Infections;China;Fever;Glycolipids;Humans;Japan;Orthobunyavirus;Phlebovirus;Republic of Korea;Thrombocytopenia;Virus Internalization,B01.050;C02.782.147;Z01.252.474.164;C23.888.119.344;D09.400.410;D10.390;B01.050.150.900.649.313.988.400.112.400.400;Z01.252.474.463;Z01.639.595;B04.820.087.640;B04.820.087.710;Z01.252.474.557.750;C15.378.140.855;G06.920.881
28388526,"Acidosis;Adult;Cardiomyopathies;Cardiopulmonary Resuscitation;Child;Heart Arrest;Hospitalization;Humans;Hypoxia;Incidence;Risk Factors;Sepsis;Shock, Septic;United States;Heart Arrest;Cardiopulmonary Resuscitation;Sepsis;Shock, Septic",C18.452.076.176;M01.060.116;C14.280.238;E02.365.647.110;M01.060.406;C14.280.383;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;C23.888.852.079;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.539.757;C23.550.470.790.500;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;Z01.107.567.875;C14.280.383;E02.365.647.110;C01.539.757;C23.550.470.790.500;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712
28388454,"Adult;Antidepressive Agents, Second-Generation;Cognitive Behavioral Therapy;Depressive Disorder, Major;Fluoxetine;Humans;Middle Aged;Patient Selection;Recurrence;Risk Factors;Cognitive Behavioral Therapy;Fluoxetine;Depressive Disorder, Major;Precision Medicine;Recurrence;Recurrence",M01.060.116;D27.505.954.427.700.122.050;F04.754.137.350;F03.600.300.375;D02.092.831.280;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.581.500.653;N04.590.731;C23.550.291.937;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F04.754.137.350;D02.092.831.280;F03.600.300.375;E02.574;H02.403.200.700;C23.550.291.937;C23.550.291.937
28388437,"Animals;Binding Sites;CCCTC-Binding Factor;CRISPR-Cas Systems;Cell Line;Chromatin;Chromatin Assembly and Disassembly;Chromosomal Proteins, Non-Histone;Embryonic Stem Cells;Enhancer Elements, Genetic;GATA1 Transcription Factor;Gene Editing;In Situ Hybridization, Fluorescence;Membrane Transport Proteins;Mice;Nuclear Proteins;Protein Binding;RNA, Messenger;Receptors, Estrogen;Recombinant Fusion Proteins;Repressor Proteins;Single Molecule Imaging;Transcription Factors;Transcription, Genetic;Transfection",B01.050;G02.111.570.120;D12.776.157.687.157;D12.776.260.120;D12.776.660.235.050;D12.776.660.720.157;D12.776.664.235.050;D12.776.930.780.563;G05.308.203.374.394;A11.251.210;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;D12.776.660.235;D12.776.664.235;A11.872.700.250;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;D12.776.260.235.500;D12.776.260.257.100;D12.776.930.216.500;D12.776.930.314.100;E05.393.420.270;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;D12.776.157.530;D12.776.543.585;B01.050.150.900.649.313.992.635.505.500;D12.776.660;G02.111.679;G03.808;D13.444.735.544;D12.776.826.750.350;D12.776.930.778.350;D12.776.828.300;D12.776.260.703;D12.776.930.780;E01.370.350.515.899;E01.370.350.557.750;E05.595.899;E05.601.555.500;D12.776.930;G02.111.873;G05.297.700;E05.393.350.810;G05.728.860
28388432,"Animals;Base Sequence;Cohort Studies;Gene Expression Profiling;Genetic Loci;Genetic Predisposition to Disease;Genetic Variation;Genome-Wide Association Study;Hepatocytes;Humans;Induced Pluripotent Stem Cells;Lipid Metabolism;Lipids;Liver;Mice;Organ Specificity;Polymorphism, Single Nucleotide;Quantitative Trait Loci;Clustered Regularly Interspaced Short Palindromic Repeats;Genetics;Genome-Wide Association Study;Genomics;Induced Pluripotent Stem Cells",B01.050;G02.111.570.080;G05.360.080;L01.453.245.667.080;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.393.332;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;G05.365;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;A11.436.348;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;G03.458;D10;A03.620;B01.050.150.900.649.313.992.635.505.500;G07.650;G05.365.795.598;G05.360.340.024.380.937;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;H01.158.273.343;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;H01.158.273.180.350;H01.158.273.343.350;A11.872.040.500;A11.872.700.500
28388428,"Animals;Apolipoproteins B;Cardiac Glycosides;Cholesterol, LDL;Drug Evaluation, Preclinical;Hep G2 Cells;Hepatocytes;Homozygote;Humans;Hypercholesterolemia;Hypolipidemic Agents;Induced Pluripotent Stem Cells;Mice;Mice, Inbred NOD;Proteolysis;Small Molecule Libraries;Hepatocytes;Hypercholesterolemia;Induced Pluripotent Stem Cells",B01.050;D10.532.091.300;D12.776.070.400.300;D12.776.521.120.300;D04.210.500.155.580;D09.408.180;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;E05.290.750;E05.337.550;A11.251.860.180.432;A11.436.348.500;A11.436.348;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;C18.452.584.500.500.396;D27.505.519.186.071;D27.505.954.557.500;A11.872.040.500;A11.872.700.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;G02.111.720;G03.812;D27.720.470.765;A11.436.348;C18.452.584.500.500.396;A11.872.040.500;A11.872.700.500
28387684,Aged;Amnesia;Cognition;Cognitive Dysfunction;Executive Function;Humans;Neuropsychological Tests;Parkinson Disease;Parkinson Disease;Cognition;Latent Class Analysis;Neuropsychology,M01.060.116.100;C10.597.606.525.100;C23.888.592.604.529.100;F01.700.625.100;F03.615.200;F02.463.188;F03.615.250.700;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F02.463.188;E05.318.740.250.338;G17.035.625;L01.224.050.687;N05.715.360.750.200.375;N06.850.520.830.250.338;F04.096.795.600;H01.158.782.795.110
28387639,"Administration, Intravenous;Contrast Media;Creatinine;Gadolinium DTPA;Glomerular Filtration Rate;Humans;Infant, Newborn;Iohexol;Kidney Diseases;Magnetic Resonance Imaging;Retrospective Studies;Risk Factors;Tomography, X-Ray Computed;Triiodobenzoic Acids",E02.319.267.082;D27.505.259.500;D27.720.259;D03.383.129.308.207;D02.092.782.590.401;D02.241.081.018.639.400;D02.691.400;E01.370.390.400.300;G08.852.357;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;D02.241.223.100.400.880.400;D02.455.426.559.389.127.375.880.400;C12.777.419;C13.351.968.419;E01.370.350.825.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;D02.241.223.100.400.880;D02.455.426.559.389.127.375.880
28387632,Brain Neoplasms;Fluorescence;Indocyanine Green;Meningioma,C04.588.614.250.195;C10.228.140.211;C10.551.240.250;G01.358.500.505.650.665.500;G01.590.540.665.500;D03.633.100.473.400;C04.557.580.520;C04.557.645.520;C04.588.614.250.580.500;C10.551.240.500.500
28387431,"Adult;Animals;Computed Tomography Angiography;Coronary Angiography;Defibrillators;Defibrillators, Implantable;Electric Countershock;Electrocardiography;Energy Drinks;Humans;Magnetic Resonance Imaging;Out-of-Hospital Cardiac Arrest;Pregnancy;Risk Assessment;Risk Factors;Treatment Outcome;Ventricular Fibrillation;Young Adult;Caffeine;Energy Drinks;Death, Sudden, Cardiac",M01.060.116;B01.050;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;E07.305.250.159;E07.305.250.159.175;E07.305.250.319.175;E07.695.202.175;E02.331.350;E01.370.370.380.240;E01.370.405.240;G07.203.100.512;J02.200.512;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C14.280.383.610;G08.686.784.769;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.067.922;C23.550.073.922;M01.060.116.815;D03.132.960.175;D03.633.100.759.758.824.175;G07.203.100.512;J02.200.512;C14.280.383.220;C23.550.260.322.250
28387420,Confounding Factors (Epidemiology);Family;Humans;Placenta Diseases;Pregnancy;Risk,N05.715.350.240;N06.850.490.718;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;C13.703.590;G08.686.784.769;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
28386933,"Aged;Aged, 80 and over;Antibodies, Monoclonal;Brain;Humans;Lewy Bodies;Neurites;Parkinson Disease;Primary Cell Culture;Protein Conformation;alpha-Synuclein;Parkinson Disease;Amyloid",M01.060.116.100;M01.060.116.100.080;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;A08.675.460;A11.284.420.460;A11.671.460;A08.675.256.500;A08.675.542.145.500;A11.284.180.610;A11.671.501.145.500;A11.671.543;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;G02.111.570.820.709;D12.776.631.860.500;D12.776.637.500;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D05.500.049;D12.776.049
28386912,"Adult;Aged;Anti-Obesity Agents;Brain;Clinical Trials, Phase II as Topic;Clinical Trials, Phase III as Topic;Diabetes Mellitus, Type 2;Dose-Response Relationship, Drug;Double-Blind Method;Humans;Liraglutide;Mental Disorders;Mental Health;Middle Aged;Neuropsychological Tests;Neurotoxicity Syndromes;Obesity;Randomized Controlled Trials as Topic;Surveys and Questionnaires;Weight Loss;Liraglutide",M01.060.116;M01.060.116.100;D27.505.954.203;A08.186.211;E05.318.372.250.250.210;N05.715.360.330.250.250.210;N06.850.520.450.250.250.210;E05.318.372.250.250.220;N05.715.360.330.250.250.220;N06.850.520.450.250.250.220;C18.452.394.750.149;C19.246.300;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;D06.472.317.680.500.500.500;F03;F02.418;N01.400.500;M01.060.116.630;F04.711.513;C10.720;C25.723.705;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C23.888.144.243.963;G07.345.249.314.120.200.963;D06.472.317.680.500.500.500
28386063,"Alleles;Biomarkers, Tumor;Breast Neoplasms;Case-Control Studies;Cell Cycle Proteins;DNA Damage;DNA Mutational Analysis;Fanconi Anemia Complementation Group D2 Protein;Gene Frequency;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Germ-Line Mutation;Humans;Meta-Analysis as Topic;Mutation;Neoplastic Syndromes, Hereditary;RNA Stability;RNA, Messenger;Workflow",G05.360.340.024.340.030;D23.101.140;C04.588.180;C17.800.090.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;D12.776.167;G05.200;E05.393.760.700.300;D12.776.313.812;D12.776.660.285;D12.776.744.484;G05.330;E05.393.385;C23.550.291.687.500;G05.380.355;G05.380;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;G05.365.590;C04.700;C16.320.700;G02.111.780;D13.444.735.544;L01.906.893
28385835,,
28385783,"Adolescent;Adult;Aged;Aged, 80 and over;Blood Platelet Disorders;Child;Child, Preschool;Hemorrhage;Humans;Incidence;Middle Aged;Patient Outcome Assessment;Postoperative Complications;Premedication;Risk Assessment;Risk Factors;Surgical Procedures, Operative;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;C15.378.140;M01.060.406;M01.060.406.448;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;N04.761.559.590.399;N05.715.360.575.575.399;C23.550.767;E02.319.703;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E04;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28385713,"DNA Damage;DNA Topoisomerases, Type II;Genetic Loci;Humans;K562 Cells;Leukemia;Neoplasm Proteins;Poly-ADP-Ribose Binding Proteins;RNA, Long Noncoding;Transcription Elongation, Genetic",G05.200;D08.811.399.403.741;G05.360.340.024.380;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;C04.557.337;D12.776.624;D12.776.157.687;D12.776.660.720;D13.444.735.790.375;G02.111.873.562;G05.297.700.562
28385639,Adult;Age Factors;Cardiopulmonary Resuscitation;Drowning;Humans;Odds Ratio;Out-of-Hospital Cardiac Arrest;Registries;Retrospective Studies;Risk Factors;Young Adult;Heart Arrest;Drowning;Mortality,M01.060.116;N05.715.350.075;N06.850.490.250;E02.365.647.110;C23.550.260.393;C26.304;N06.850.135.696;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;C14.280.383.610;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815;C14.280.383;C23.550.260.393;C26.304;N06.850.135.696;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
28385496,"Adult;Angiopoietin-like Proteins;Angiopoietins;Animals;Atherosclerosis;Case-Control Studies;Coronary Artery Disease;Humans;Lipids;Mice, Inbred C57BL;Mice, Knockout;Middle Aged;Mutation, Missense;Myocardial Infarction;Risk Factors;Human Genetics;Myocardial Infarction",M01.060.116;D12.644.276.100.050;D12.776.467.100.050;D23.529.100.050;D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100;B01.050;C14.907.137.126.307;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;B01.050.150.900.649.313.988.400.112.400.400;D10;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;M01.060.116.630;G05.365.590.650;C14.280.647.500;C14.907.585.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;H01.158.273.343.385;C14.280.647.500;C14.907.585.500
28385410,Aged;Amputation;Ankle Brachial Index;Combined Modality Therapy;Endovascular Procedures;Evidence-Based Medicine;Exercise Test;Exercise Therapy;Exercise Tolerance;Humans;Intermittent Claudication;Limb Salvage;Middle Aged;Odds Ratio;Peripheral Arterial Disease;Randomized Controlled Trials as Topic;Recovery of Function;Risk Factors;Time Factors;Treatment Outcome;Walking;Intermittent Claudication;Peripheral Arterial Disease,M01.060.116.100;E04.555.080;E01.370.370.140.049;E02.186;E04.100.814.529;E04.502.382;H02.249.750;H02.403.200.400;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;G11.427.680.270;B01.050.150.900.649.313.988.400.112.400.400;C14.907.137.126.669;C23.888.531;E04.100.814.603;E04.555.400;E04.680.350;M01.060.116.630;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;C14.907.137.126.307.500;C14.907.617.671;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;G16.757;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G11.427.410.568.900;G11.427.410.698.277.937;I03.350.937;I03.450.642.845.940;C14.907.137.126.669;C23.888.531;C14.907.137.126.307.500;C14.907.617.671
28385177,"Adolescent;Adult;Child;Child, Preschool;Follow-Up Studies;Fontan Procedure;Forecasting;Heart Defects, Congenital;Humans;Infant;Morbidity;Pennsylvania;Postoperative Complications;Retrospective Studies;Risk Assessment;Risk Factors;Treatment Outcome;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;I01.320;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28385043,Activities of Daily Living;Adult;Athletic Injuries;Exercise;Exercise Therapy;Humans;Musculoskeletal System;Premenopause;Risk Factors;Joints;Exercise,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;M01.060.116;C26.115;G11.427.410.698.277;I03.350;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;B01.050.150.900.649.313.988.400.112.400.400;A02;G08.686.157.500.812;G08.686.841.249.500.812;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A02.835.583;G11.427.410.698.277;I03.350
28384795,Adolescent;Adolescent Health;Age Factors;Cause of Death;Child;Child Health;Child Mortality;Disabled Children;Global Burden of Disease;Global Health;Humans;Pregnancy;Pregnancy Complications;Risk Factors;Sex Factors;Wounds and Injuries,M01.060.057;N01.400.075;N05.715.350.075;N06.850.490.250;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;M01.060.406;N01.400.225;E05.318.308.985.550.287;N01.224.935.698.150;N06.850.505.400.975.550.287;N06.850.520.308.985.550.287;M01.150.200;N05.425.184;N06.850.520.308.980.438.475.091;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;C13.703;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N05.715.350.675;N06.850.490.875;C26
28384677,,
28384671,"Adolescent;Color Vision;Electroretinography;Fluorescein Angiography;Fundus Oculi;Humans;Retinal Cone Photoreceptor Cells;Scotoma;Tomography, Optical Coherence;Visual Acuity;Visual Fields",M01.060.057;F02.830.816.964.124;G11.561.790.964.124;G14.935.124;E01.370.380.225;E01.370.405.270;E01.370.370.050.350;E01.370.380.250;A09.371.729.313;B01.050.150.900.649.313.988.400.112.400.400;A08.675.650.850.625.670.100;A08.675.650.915.937.670.100;A08.800.950.937.670.100;A09.371.729.831.625.670.100;A11.671.650.850.625.670.100;A11.671.650.915.937.670.100;C10.597.751.941.811;C11.966.811;C23.888.592.763.941.811;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;F02.463.593.932.934;G14.950
28384349,"Animals;Antigens, Ly;Cytokines;Humans;Legionella pneumophila;Legionnaires' Disease;Lung;Mice;Mice, Inbred C57BL;Monocytes;Neutrophils",B01.050;D23.050.301.264.920;D23.101.100.920;D12.644.276.374;D12.776.467.374;D23.529.374;B01.050.150.900.649.313.988.400.112.400.400;B03.440.400.425.450.450.500;B03.660.250.460.460.580;C01.252.400.500.501;C08.730.382.380;A04.411;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
28384053,"Animals;Caprolactam;Cartilage;Cattle;Chondrocytes;Hydrogels;Polymers;Rats;Rats, Nude;Tissue Engineering;Cartilage;Hydrogels;Injections",B01.050;D02.065.589.200;D03.383.066.150;D03.383.411.200;A02.165;A10.165.382;B01.050.150.900.649.313.500.380.271;A11.329.171;D20.280.320.375;D26.255.165.320.375;D05.750;D25.720;J01.637.051.720;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.550.508;E05.481.500.311.500;J01.293.069.249.500;A02.165;A10.165.382;D20.280.320.375;D26.255.165.320.375;E02.319.267.530
28383813,"3-Iodobenzylguanidine;Biomarkers, Tumor;Cohort Studies;Gene Expression Profiling;Gene Expression Regulation, Neoplastic;Humans;Infant;Neoplasm Staging;Neuroblastoma;Prognosis;Radionuclide Imaging;Radiopharmaceuticals;Survival Rate;3-Iodobenzylguanidine;Neuroblastoma;Norepinephrine Plasma Membrane Transport Proteins",D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;D23.101.140;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.393.332;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.789.625;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E01.789;E01.370.350.710;E01.370.384.730;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D12.776.157.530.450.625.186;D12.776.157.530.562.374.500.750;D12.776.157.530.937.600;D12.776.543.585.450.625.186;D12.776.543.585.562.374.500.750;D12.776.543.585.937.700
28382543,"Animals;Antiparkinson Agents;Antipsychotic Agents;Apomorphine;Corpus Striatum;Dopamine Agonists;Magnetic Resonance Imaging;Mice;Mice, Knockout;Neostriatum;Receptors, Dopamine D2;Signal Transduction;beta-Arrestin 2;Dopamine;Dopamine Agents;Receptors, Dopamine",B01.050;D27.505.954.427.090.050;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;D03.132.098.038.290;D03.633.100.531.085.030.290;D03.633.400.095.290;A08.186.211.200.885.287.249.487;D27.505.519.625.150.151;D27.505.696.577.150.151;E01.370.350.825.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A08.186.211.200.885.287.249.487.550;D12.776.543.750.670.300.400.500;D12.776.543.750.695.150.400.500;D12.776.543.750.720.330.400.500;G02.111.820;G04.835;D12.644.360.024.098.525.750;D12.776.157.057.005.525.750;D12.776.476.024.104.525.750;D12.776.543.090.525.750;D02.092.211.215.406;D02.092.311.342;D02.455.426.559.389.657.166.175.342;D27.505.519.625.150;D27.505.696.577.150;D12.776.543.750.670.300.400;D12.776.543.750.695.150.400;D12.776.543.750.720.330.400
28382374,Adolescent;Ankle Injuries;Football;Humans;Magnetic Resonance Imaging;Tendon Injuries;Adolescent;Compartment Syndromes,M01.060.057;C26.558.100;I03.450.642.845.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C26.874;M01.060.057;C05.651.180;C14.907.303
28381515,"Adolescent;Brain;Child;Child, Preschool;Demyelinating Autoimmune Diseases, CNS;Follow-Up Studies;Gray Matter;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Organ Size;Prospective Studies;Young Adult",M01.060.057;A08.186.211;M01.060.406;M01.060.406.448;C10.114.375;C10.228.140.695.562;C10.314.350;C20.111.258.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;A08.186.211.168;A08.186.854.348;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;M01.060.116.815
28381270,"Aged, 80 and over;Endoscopy;Hernia, Diaphragmatic;Humans;Tomography, X-Ray Computed;Ureter;Ureteral Diseases;Ureteral Obstruction;Ureter",M01.060.116.100.080;E01.370.388.250;E04.502.250;C23.300.707.500;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;A05.810.776;C12.777.725;C13.351.968.725;C12.777.725.776;C13.351.968.725.776;A05.810.776
28380384,"Animals;Cell Line, Tumor;Cells, Cultured;Circadian Clocks;Circadian Rhythm;Creatine;Cryptochromes;Gene Regulatory Networks;Hepatocytes;Humans;Liver;Metabolome;Mice;Nitrogen;Time Factors;Transcription, Genetic;Circadian Clocks;Mass Spectrometry;Metabolomics",B01.050;A11.251.210.190;A11.251.860.180;A11.251;G07.180.562.094.500;G07.180.562.190;D02.078.370.280;D12.125.373;D12.644.360.138.150;D12.776.331.180;D12.776.476.156.250;D12.776.765.593.500;G05.360.080.689.360;A11.436.348;B01.050.150.900.649.313.988.400.112.400.400;A03.620;G03.500;B01.050.150.900.649.313.992.635.505.500;D01.268.604;D01.362.625;G01.910.857;G02.111.873;G05.297.700;G07.180.562.094.500;E05.196.566;H01.158.201.586;H01.158.273.180.599;H01.181.122.638
28380380,"Adult;Aging;Cell Differentiation;Cell Transdifferentiation;Cellular Microenvironment;Diabetes Mellitus, Type 1;Gene Expression Profiling;Glucagon;Glucagon-Secreting Cells;Humans;Insulin;Insulin-Secreting Cells;Tissue Donors;Transcription, Genetic;Urocortins;Insulin;Stem Cells",M01.060.116;G07.345.124;G04.152;G04.356;G04.366;C18.452.394.750.124;C19.246.267;C20.111.327;E05.393.332;D06.472.699.587.730.500;D12.644.548.586.730.500;A03.734.414.065;A06.300.414.043;A06.390.087;A11.382.625.064;A11.436.294.064;B01.050.150.900.649.313.988.400.112.400.400;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;M01.898;G02.111.873;G05.297.700;D06.472.699.857;D12.644.400.837;D12.644.548.887;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A11.872
28379861,"Adult;Ambulatory Care;Amphetamine-Related Disorders;Combined Modality Therapy;Delayed-Action Preparations;Drug Administration Schedule;Follow-Up Studies;Hospitalization;Humans;Injections, Intramuscular;Models, Statistical;Naltrexone;Narcotic Antagonists;Psychotherapy;Recurrence;Secondary Prevention;Substance Abuse Treatment Centers;Treatment Outcome",M01.060.116;E02.760.106;N02.421.585.106;C25.775.225;F03.900.225;E02.186;D26.255.210;E02.319.300.253;E02.319.283;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.460;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;D27.505.696.543;D27.505.696.663.850.512;D27.505.954.427.550;F04.754;C23.550.291.937;E02.897;N02.421.726.825;N06.850.780.750;N02.278.035.128.800;N02.278.808.930;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28379829,"Adenocarcinoma;Aged;Aged, 80 and over;Choice Behavior;Counseling;Decision Making;Humans;Middle Aged;Physician-Patient Relations;Physicians, Primary Care;Primary Health Care;Prostatic Neoplasms;Qualitative Research;Referral and Consultation;Urologists;Adenocarcinoma;Choice Behavior;Counseling;Physicians, Primary Care;Prostatic Neoplasms;Referral and Consultation;Research;Specialization;Telephone",C04.557.470.200.025;M01.060.116.100;M01.060.116.100.080;F02.463.785.373.346;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F01.829.401.650.675;N05.300.660.625;M01.526.485.810.800;N02.360.810.795;N04.590.233.727;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;H01.770.644.241.850;N04.452.758.849;M01.526.485.810.955;N02.360.810.955;C04.557.470.200.025;F02.463.785.373.346;F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;M01.526.485.810.800;N02.360.810.795;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;N04.452.758.849;H01.770.644;H02.811;L01.178.847.698
28379789,"Codes of Ethics;Conscience;Delivery of Health Care;Ethics, Medical;History, 20th Century;Humans;Military Personnel;Organizational Policy;Physicians;Refusal to Treat;Societies;United States",K01.752.566.479.068;K01.752.566.479.171.066;N04.761.700.350.324;N05.350.213;N05.350.340.080;N05.700.350.324;F01.829.500.359;K01.752.566.359;N04.590.374;N05.300;K01.752.566.479.171.132.750;N05.350.340.162.500;K01.400.504.968;B01.050.150.900.649.313.988.400.112.400.400;M01.526.625;I01.655.500.550;I01.880.604.825.550;N03.623.500.550;M01.526.485.810;N02.360.810;N04.590.233.727.605;N05.300.100.675;N03.540.828;Z01.107.567.875
28379504,,
28379408,"Anti-Bacterial Agents;Antimicrobial Stewardship;Benchmarking;Hospitals, Pediatric;Humans;Information Dissemination;Interinstitutional Relations;Prescription Drug Overuse;Quality Improvement;United States",D27.505.954.122.085;N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;N04.452.822.400;E02.319.306.500.750;J01.293.754;N04.761.744;Z01.107.567.875
28379373,"Adolescent;Adult;Age of Onset;Child;Child, Preschool;Denmark;Epilepsy;Humans;Infant;Mutation;NAV1.2 Voltage-Gated Sodium Channel;Neurodevelopmental Disorders;Phenotype;Sodium Channel Blockers;Young Adult;Epilepsy;Sodium Channel Blockers",M01.060.057;M01.060.116;N05.715.350.075.100;N06.850.490.250.100;M01.060.406;M01.060.406.448;Z01.542.816.124;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G05.365.590;D12.776.157.530.400.875.750.200;D12.776.543.550.450.875.750.200;D12.776.543.585.400.875.750.200;D12.776.631.960.200;F03.625;G05.695;D27.505.519.562.750;D27.505.954.411.720;M01.060.116.815;C10.228.140.490;D27.505.519.562.750;D27.505.954.411.720
28379322,"Antineoplastic Agents;Consensus;Contrast Media;Disease Progression;Disease-Free Survival;Endpoint Determination;Fluorodeoxyglucose F18;Humans;Lymphoma, Non-Hodgkin;Neoplasm Staging;Positron-Emission Tomography;Predictive Value of Tests;Response Evaluation Criteria in Solid Tumors;Time Factors;Tomography, X-Ray Computed;Treatment Outcome;Tumor Burden;Immunotherapy;Lymphoma",D27.505.954.248;F01.829.316.068;F02.463.785.373.433;D27.505.259.500;D27.720.259;C23.550.291.656;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;E05.315;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386.480;C15.604.515.569.480;C20.683.515.761.480;E01.789.625;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789.800.379;N04.761.559.590.800.569;N05.715.360.575.575.800.569;G01.910.857;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.041.124.892;E02.095.465.425;C04.557.386;C15.604.515.569;C20.683.515.761
28379007,Adenosine Triphosphate;Heat-Shock Proteins;Peptides;Protein Binding;Saccharomyces cerevisiae Proteins,D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;D12.776.580.216;D12.644;G02.111.679;G03.808;D12.776.354.750
28378429,"Adolescent;Child;Cohort Studies;Diabetes Mellitus, Type 2;Diet;Glycated Hemoglobin A;Humans;Physical Fitness;Risk Reduction Behavior;Adolescent;Diet",M01.060.057;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C18.452.394.750.149;C19.246.300;G07.203.650.240;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;G11.427.685;I03.450.642.845.054.800;N01.400.545;F01.145.699;M01.060.057;G07.203.650.240
28378301,"Delivery of Health Care, Integrated;Depression;Humans;Hypertension;Middle Aged;Pilot Projects;Social Determinants of Health;Surveys and Questionnaires;Depression;Hypertension;Primary Health Care",N04.590.374.142;N05.300.262;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;M01.060.116.630;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;N01.224.425.762;N01.400.675;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F01.145.126.350;C14.907.489;N04.590.233.727
28378157,"Adolescent;Adult;Aged;Antidepressive Agents;Depressive Disorder, Major;Follow-Up Studies;Humans;Insurance, Health;Kaplan-Meier Estimate;Logistic Models;Medication Adherence;Middle Aged;Multivariate Analysis;Odds Ratio;Retrospective Studies;Time Factors;United States;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;D27.505.954.427.700.122;F03.600.300.375;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;Z01.107.567.875;M01.060.116.815
28378050,Adrenal Glands;Aged;Aldosterone;Antihypertensive Agents;Humans;Hyperaldosteronism;Middle Aged;Renin;Veins;Adrenal Glands,A06.300.071;M01.060.116.100;D04.210.500.745.745.654.062;D06.472.040.585.353.118;D27.505.954.411.162;B01.050.150.900.649.313.988.400.112.400.400;C19.053.800.604;M01.060.116.630;D08.811.277.656.074.500.780;D08.811.277.656.300.048.780;D08.811.277.656.837.750;A07.015.908;A06.300.071
28377940,,
28377601,"Amino Acid Sequence;Chromatin;Computational Biology;DNA-Binding Proteins;Gene Expression Profiling;Histones;Life Cycle Stages;Plasmodium falciparum;Protein Processing, Post-Translational;Proteomics;Transcriptome",G02.111.570.060;L01.453.245.667.060;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;H01.158.273.180;L01.313.124;D12.776.260;E05.393.332;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B05.500;G07.345.500.550.500;B01.043.075.380.611.561;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;G02.111.873.750;G05.297.700.750;G05.360.920
28377535,"Brain Diseases;Heterozygote;Humans;Magnetic Resonance Imaging;Memantine;Molecular Targeted Therapy;Mutation;Neuroimaging;Phenotype;Receptors, N-Methyl-D-Aspartate;Channelopathies;Precision Medicine",C10.228.140;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;D02.455.426.100.050.035.500;E02.319.574;G05.365.590;E01.370.350.578;E01.370.376.537;E05.629;G05.695;D12.776.157.530.400.400.500.500;D12.776.543.550.450.500.200.500;D12.776.543.585.400.500.200.500;D12.776.543.750.720.200.450.400.500;C23.550.177;E02.574;H02.403.200.700
28377249,"Aneurysm, Ruptured;Craniotomy;Databases, Factual;Education, Medical, Graduate;Endovascular Procedures;Humans;Internship and Residency;Intracranial Aneurysm;Neurosurgery;Neurosurgical Procedures;Rupture, Spontaneous;Surgical Instruments;Intracranial Aneurysm",C14.907.055.185;E04.525.190;L01.313.500.750.300.188.400;L01.470.750.750;I02.358.337.350;I02.358.399.350;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;C10.228.140.300.510.600;C14.907.055.635;C14.907.253.560.300;H02.403.810.425;E04.525;C23.300.909;E07.858.700;C10.228.140.300.510.600;C14.907.055.635;C14.907.253.560.300
28377094,"Animals;Antigens, Neoplasm;Cancer Vaccines;Genital Neoplasms, Female;Humans;Immunotherapy;Immunotherapy, Adoptive;Molecular Targeted Therapy;T-Lymphocytes;Uterine Cervical Neoplasms;Endometrial Neoplasms;Immunotherapy;Ovarian Neoplasms;Receptors, Antigen, T-Cell",B01.050;D23.050.285;D20.215.894.200;C04.588.945.418;C13.351.937.418;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;E02.319.574;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;C04.588.945.418.948.585;C13.351.500.852.762.200;C13.351.937.418.875.200;E02.095.465.425;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D12.776.543.750.705.816.824
28376847,"Animals;Biomarkers;Computer Simulation;Humans;Least-Squares Analysis;Metabolomics;Models, Theoretical;Multivariate Analysis;ROC Curve;Reproducibility of Results;Statistics as Topic",B01.050;D23.101;L01.224.160;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.750.400;N05.715.360.750.695.440;N06.850.520.830.750.400;H01.158.201.586;H01.158.273.180.599;H01.181.122.638;E05.599;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830
28376415,"Anti-Bacterial Agents;Aortic Valve;Ceftriaxone;Corynebacterium;Corynebacterium Infections;Endocarditis, Bacterial;Humans;Middle Aged;Predictive Value of Tests;Ribotyping;Treatment Outcome;Endocarditis",D27.505.954.122.085;A07.541.510.110;D02.065.589.099.249.190.190.155;D02.886.665.074.190.190.155;D03.633.100.300.249.190.190.155;B03.510.024.049.180;B03.510.460.400.400.200;C01.252.410.040.246;C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.370.225.875.150.125.765;E05.200.875.150.125.765;E05.393.290.765;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.282
28376230,"Anaplastic Lymphoma Kinase;Antineoplastic Agents;Child;Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Humans;MAP Kinase Kinase Kinases;Molecular Targeted Therapy;Neoplasms;Oncogene Proteins;Phosphatidylinositol 3-Kinase;Protein Kinase Inhibitors;Receptor Protein-Tyrosine Kinases;Receptors, Fibroblast Growth Factor;Receptors, Platelet-Derived Growth Factor;Research Design;TOR Serine-Threonine Kinases",D08.811.913.696.620.682.725.400.002;D12.776.543.750.630.002;D27.505.954.248;M01.060.406;D08.811.913.696.620.682.700.646.500.875;D12.644.360.250.451;D12.776.167.200.451;D12.776.476.250.451;D08.811.913.696.620.682.700.646.500.937;D12.644.360.250.515;D12.776.167.200.515;D12.776.476.250.515;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.559;D12.644.360.400;D12.776.476.400;E02.319.574;C04;D12.776.624.664;D08.811.913.696.620.500.100;D27.505.519.389.755;D08.811.913.696.620.682.725.400;D12.776.543.750.630;D12.776.543.750.750.400.370;D08.811.913.696.620.682.725.400.900;D12.776.543.750.630.625;D12.776.543.750.750.400.630;E05.581.500;H01.770.644.728;D08.811.913.696.620.682.700.931;D12.776.476.925
28376175,"Adolescent;Adult;Breast Neoplasms;Genes, BRCA1;Genes, BRCA2;Genetic Predisposition to Disease;Heterozygote;Humans;Middle Aged;Multifactorial Inheritance;Mutation;Ovarian Neoplasms;Polymorphism, Single Nucleotide;Prognosis;Proportional Hazards Models;Receptors, Estrogen;Risk Assessment;Risk Factors;Young Adult",M01.060.057;M01.060.116;C04.588.180;C17.800.090.500;G05.360.340.024.340.375.249.100;G05.360.340.024.340.415.400.100;G05.360.340.024.340.375.249.105;G05.360.340.024.340.415.400.105;C23.550.291.687.500;G05.380.355;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.420.590;G05.365.590;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G05.365.795.598;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;D12.776.826.750.350;D12.776.930.778.350;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28376048,,
28375580,"Acute Disease;Allergens;Biomarkers;C-Reactive Protein;Child, Preschool;Dietary Proteins;Enterocolitis;Follow-Up Studies;Food Hypersensitivity;Humans;Infant;Neutrophils;Syndrome;T-Lymphocytes;C-Reactive Protein",C23.550.291.125;D23.050.063;D23.101;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;M01.060.406.448;D12.776.256;G07.203.300.428;J02.500.428;C06.405.205.596;C06.405.469.363;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C20.543.480.370;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;C23.550.288.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
28375517,Anti-Bacterial Agents;Community-Acquired Infections;Humans;Methicillin-Resistant Staphylococcus aureus;Soft Tissue Infections;Staphylococcal Infections;United States;Methicillin-Resistant Staphylococcus aureus;Staphylococcus aureus;Epidemics;Phylogeny,D27.505.954.122.085;C01.539.234;B01.050.150.900.649.313.988.400.112.400.400;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;C01.539.820;C01.252.410.868;Z01.107.567.875;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;N06.850.290.200;G05.697;G16.075.605;L01.100.697
28375448,Adult;Alginates;Antacids;Gastroesophageal Reflux;Glucuronic Acid;Hexuronic Acids;Histamine H2 Antagonists;Humans;Proton Pump Inhibitors;Randomized Controlled Trials as Topic;Treatment Outcome;Alginates;Gastroesophageal Reflux;Meta-Analysis,M01.060.116;D09.698.068;D27.505.519.170;D27.505.954.483.080;C06.405.117.119.500.484;D02.241.081.844.915.162.249;D02.241.152.811.162.500;D02.241.511.902.915.162.500;D09.811.922.162.500;D02.241.081.844.915.400;D02.241.152.811.400;D02.241.511.902.915.400;D09.811.922.400;D27.505.519.625.375.425.425;D27.505.696.577.375.425.425;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.389.848;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D09.698.068;C06.405.117.119.500.484;V03.600
28374939,Aged;Algorithms;Enzyme-Linked Immunosorbent Assay;Heparin;Humans;Immunoglobulin G;Likelihood Functions;Middle Aged;Platelet Factor 4;Predictive Value of Tests;Reproducibility of Results;Serotonin;Thrombocytopenia;Diagnosis;Enzyme-Linked Immunosorbent Assay;Heparin;Thrombocytopenia;Thrombosis,M01.060.116.100;G17.035;L01.224.050;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;D09.698.373.400;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;E05.318.740.500.475;E05.318.740.600.400;E05.599.835.500;N05.715.360.750.530.450;N05.715.360.750.625.450;N06.850.520.830.500.475;N06.850.520.830.600.400;M01.060.116.630;D12.644.276.374.200.120.900;D12.776.124.125.720;D12.776.467.374.200.120.900;D23.119.940;D23.125.300.120.900;D23.469.200.120.900;D23.529.374.200.120.900;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;D02.092.211.215.801.852;D03.633.100.473.914.814;D23.469.050.650;C15.378.140.855;E01;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;D09.698.373.400;C15.378.140.855;C14.907.355.830
28374818,"Abdominal Pain;Adolescent;Autoimmune Diseases;Child;Child, Preschool;Diagnosis, Differential;Disease Management;Glucocorticoids;Humans;Immunoglobulin G;International Cooperation;Jaundice, Obstructive;Pancreas;Pancreatic Function Tests;Pancreatitis, Chronic;Registries",C23.888.592.612.054;C23.888.821.030;M01.060.057;C20.111;M01.060.406;M01.060.406.448;E01.171;N04.590.607;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393;I01.615.500;C23.550.429.500.755;C23.888.885.375.500;A03.734;E01.370.372.600;C06.689.750.830;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28374599,Transportation,J01.937
28374553,Aminoacyltransferases;Bacterial Proteins;Cysteine Endopeptidases;Peptides;Time Factors;Protein Engineering,D08.811.913.050.200;D12.776.097;D08.811.277.656.262.500;D08.811.277.656.300.200;D12.644;G01.910.857;E05.393.420.601
28374350,"Casts, Surgical;Clinical Competence;Education, Medical, Graduate;Fracture Fixation;Humans;Internship and Residency;Medical Staff, Hospital;Models, Anatomic;Observer Variation;Operative Time;Orthopedic Surgeons;Orthopedics;Prospective Studies;Radius Fractures;Reproducibility of Results;Simulation Training",E07.858.442.660.430.500;E07.858.690.725.430.500;I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;E04.555.300;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.630.490;M01.526.485.740.422;N02.360.630.490;N02.360.740.422;J01.897.280.500.545.129;L01.178.820.090.545.129;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E04.614.374.500;N02.421.585.753.374.500;M01.526.485.810.910.875;N02.360.810.910.875;H02.403.810.494;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C26.088.268.556;C26.404.562;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;I02.903.847
28373689,"Cooperative Behavior;Depression;Gene-Environment Interaction;Genetic Predisposition to Disease;Genotype;Humans;Life Change Events;Serotonin Plasma Membrane Transport Proteins;Stress, Psychological",F01.145.813.115;F01.145.126.350;G05.695.337;C23.550.291.687.500;G05.380.355;G05.380;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;D12.776.157.530.450.625.311;D12.776.157.530.562.374.875;D12.776.157.530.937.624;D12.776.543.585.450.625.374;D12.776.543.585.562.374.875;D12.776.543.585.937.747;F01.145.126.990;F02.830.900
28373588,"Adolescent;Antihypertensive Agents;Blood Pressure;Carotid Arteries;Child;Child, Preschool;Cohort Studies;Creatinine;Heart Rate;Humans;Infant;Manometry;Pulse Wave Analysis;Renal Insufficiency, Chronic;Vascular Stiffness;Arteriosclerosis;Renal Insufficiency, Chronic;Pediatrics;Pulse Wave Analysis;Vascular Stiffness",M01.060.057;D27.505.954.411.162;E01.370.600.875.249;G09.330.380.076;A07.015.114.186;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D03.383.129.308.207;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.559;E01.370.370.680;C12.777.419.780.750;C13.351.968.419.780.750;G09.330.940;C14.907.137.126;C12.777.419.780.750;C13.351.968.419.780.750;H02.403.670;E01.370.370.680;G09.330.940
28373404,"Animals;Cancer Vaccines;Cellular Microenvironment;DNA, Mitochondrial;Epigenesis, Genetic;Genetic Predisposition to Disease;Genome-Wide Association Study;Germ-Line Mutation;High-Throughput Nucleotide Sequencing;Humans;Mitochondria;Neoplasms;Precancerous Conditions;Precision Medicine;Single-Cell Analysis",B01.050;D20.215.894.200;G04.366;D13.444.308.283.225;G05.308.203;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.365.590.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.214.190.875.564;A11.284.835.626;C04;C04.834;E02.574;H02.403.200.700;E05.242.900
28373169,Adult;Biomarkers;Cross-Sectional Studies;Humans;Linear Models;Middle Aged;Residence Characteristics;Social Class;Surveys and Questionnaires;Telomere;Telomere Shortening;United States;Urban Population,M01.060.116;D23.101;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;M01.060.116.630;N01.224.791;N06.850.505.400.800;I01.880.853.996.755;N01.824.782;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G02.111.225.940;G04.043.630;G05.226.940;Z01.107.567.875;N01.600.900
28371850,Cardiovascular Diseases;Circadian Rhythm;Cohort Studies;Comorbidity;Cross-Sectional Studies;Diet;Exercise;Health Risk Behaviors;Health Surveys;Humans;Middle Aged;Overweight;Prospective Studies;Risk Factors;Sedentary Behavior;Sleep;Time Factors;Tobacco Use;United Kingdom,C14;G07.180.562.190;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G07.203.650.240;G11.427.410.698.277;I03.350;F01.145.488.250;E05.318.308.980.438;N05.715.360.300.800.438;N06.850.520.308.980.438;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.749;F01.829.458.705;F02.830.855;G11.561.803;G01.910.857;F01.145.958;Z01.542.363
28371507,"Biopsy, Fine-Needle;Humans;Medical Records;Salivary Gland Neoplasms;Review;Salivary Glands",E01.370.225.500.384.100.119.500;E01.370.225.998.054.119.500;E01.370.388.100.100.500;E04.074.119.500;E04.665.100.500;E05.200.500.384.100.119.500;E05.200.998.054.119.500;E05.242.384.100.119.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;C04.588.443.591.824;C07.465.530.824;C07.465.815.718;V02.600.500;V02.912;A03.556.500.760;A10.336.779;A14.549.760
28370517,"Adolescent;Adult;Aged;Aged, 80 and over;Brain;Case-Control Studies;Cognition;Depression;Dopamine Plasma Membrane Transport Proteins;Humans;Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;Middle Aged;Mutation;Parkinson Disease;Primary Dysautonomias;Prodromal Symptoms;REM Sleep Behavior Disorder;Surveys and Questionnaires;Tomography, Emission-Computed, Single-Photon;Young Adult;Parkinson Disease",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F02.463.188;F01.145.126.350;D12.776.157.530.450.625.124;D12.776.157.530.562.374.500.500;D12.776.157.530.937.500;D12.776.543.585.450.625.124;D12.776.543.585.562.374.500.500;D12.776.543.585.937.500;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.534;D12.776.637.750;M01.060.116.630;G05.365.590;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.177.575;C23.888.672;E01.599;C10.886.659.633.700;F03.870.664.633.700;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.350.350.800.800;E01.370.350.600.350.800.800;E01.370.350.710.800.800;E01.370.350.825.800.800;E01.370.384.730.800.800;M01.060.116.815;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28370197,Nocturia,C23.888.942.343.550
28369934,"Anemia, Hemolytic, Autoimmune;Child, Preschool;Erythrocyte Transfusion;Hemoglobinuria, Paroxysmal;Hemolysis;Humans;Immunoglobulins;Methylprednisolone",C15.378.071.141.125;C20.111.175;M01.060.406.448;E02.095.135.140.275;C15.378.071.141.560;C15.378.190.625.460;C23.550.403;G12.122.545;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548;D04.210.500.745.432.769.795.539
28369923,"Blood Transfusion;Erythrocytes;Humans;National Heart, Lung, and Blood Institute (U.S.);Plasma Exchange;Platelet Transfusion;Transfusion Medicine;United States",E02.095.135;A11.118.290;A11.443.240;A15.145.229.334;B01.050.150.900.649.313.988.400.112.400.400;I01.409.418.750.600.650.496.300;N03.540.052.750.300;N03.540.348.500.500.600.650.496.300;E02.095.135.750;E02.095.135.140.650;H02.403.429.445.500;Z01.107.567.875
28369616,"Adenosine Triphosphate;Chromatin;Chromatin Assembly and Disassembly;DNA Helicases;DNA Repair;DNA Repair Enzymes;Histone Chaperones;Humans;Nucleosome Assembly Protein 1;Nucleosomes;Poly-ADP-Ribose Binding Proteins;Transcription, Genetic",D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G04.400.095;G05.213.095;G05.308.095;D08.811.277.040.025.159;D08.811.399.340;G02.111.222;G05.219;D08.811.074;D12.776.580.219;B01.050.150.900.649.313.988.400.112.400.400;D12.776.580.219.550;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625;D12.776.157.687;D12.776.660.720;G02.111.873;G05.297.700
28369543,"Actigraphy;Adult;Age Factors;Body Mass Index;Continental Population Groups;Ethnic Groups;Humans;Insurance Coverage;Insurance, Health;Pregnancy;Prospective Studies;Sleep;Smoking;Time Factors;Wakefulness;Young Adult;Pregnancy",E01.370.520.049;E05.003.500;M01.060.116;N05.715.350.075;N06.850.490.250;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.686.508;M01.686.754;N01.224.317;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.265;N03.219.521.576.343;G08.686.784.769;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F02.830.855;G11.561.803;F01.145.805;G01.910.857;F02.830.104.821;G11.561.035.738;M01.060.116.815;G08.686.784.769
28369513,"Aneuploidy;Animals;Aurora Kinase B;Aurora Kinase C;Chromosome Segregation;Chromosomes, Human, Pair 17;Chromosomes, Human, Pair 19;Embryo, Mammalian;Gene Expression;High-Throughput Nucleotide Sequencing;Humans;Meiosis;Mice;Oocytes;Polymorphism, Single Nucleotide;Pregnancy;Aneuploidy;Infertility;Meiosis;Oocytes",C23.550.210.050;G05.365.590.175.050;G05.700.131;B01.050;D08.811.913.696.620.682.700.103.750;D12.776.167.049.750;D08.811.913.696.620.682.700.103.875;D12.776.167.049.875;G04.144.220.220.625;G05.113.220.625;A11.284.187.520.300.415.425;G05.360.162.520.300.415.425;A11.284.187.520.300.460.465;G05.360.162.520.300.460.465;A16.254;G05.297;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;G04.144.220.220.687;G05.113.220.687;B01.050.150.900.649.313.992.635.505.500;A05.360.490.690.680;A11.497.497.600;G05.365.795.598;G08.686.784.769;C23.550.210.050;G05.365.590.175.050;G05.700.131;C12.294.365;C13.351.500.365;G04.144.220.220.687;G05.113.220.687;A05.360.490.690.680;A11.497.497.600
28369466,"Animals;Clathrin-Coated Vesicles;Eye Proteins;Light Signal Transduction;Membrane Transport Proteins;Mice;Mice, Knockout;Mutation;Photoreceptor Cells, Vertebrate;Protein Isoforms;Protein Transport;Qa-SNARE Proteins;Retinal Degeneration;Retinal Rod Photoreceptor Cells;Retinitis Pigmentosa;SNARE Proteins",B01.050;A11.284.430.214.190.875.190.880.180.170;D12.776.306;G02.111.820.480;G04.835.480;D12.776.157.530;D12.776.543.585;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;G05.365.590;A08.675.650.850.625.670;A08.675.650.915.937.670;A08.800.950.937.670;A09.371.729.831.625.670;A11.671.650.850.625.670;A11.671.650.915.937.670;D12.776.800;G03.143.700;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500;C11.270.612;C11.768.585;A08.675.650.850.625.670.650;A08.675.650.915.937.670.650;A08.800.950.937.670.650;A09.371.729.831.625.670.650;A11.671.650.850.625.670.650;A11.671.650.915.937.670.650;C11.270.684;C11.768.585.658.500;C16.320.290.684;D12.776.543.512.249;D12.776.543.990.775
28369305,Cohort Studies;Hepatitis C;Humans;Kaplan-Meier Estimate;Middle Aged;ROC Curve;Severity of Illness Index;Treatment Outcome;Mortality;Therapeutics,E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E02
28369050,"Adaptor Proteins, Signal Transducing;Agammaglobulinaemia Tyrosine Kinase;Animals;B-Lymphocytes;Chromatin Immunoprecipitation;Flow Cytometry;Gene Expression Regulation, Neoplastic;Humans;Ikaros Transcription Factor;Interferon Regulatory Factors;Mice;Multiplex Polymerase Chain Reaction;NF-kappa B p50 Subunit;PAX5 Transcription Factor;Pre-B Cell Receptors;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Prognosis;Protein Kinase C beta;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Real-Time Polymerase Chain Reaction;STAT5 Transcription Factor;Signal Transduction;Survival Rate;Trans-Activators",D12.644.360.024;D12.776.157.057;D12.776.476.024;D08.811.913.696.620.682.725.025;B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;E05.393.170;E05.478.605.160;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.522.500;D12.776.930.375.500;D12.644.360.024.302;D12.776.157.057.050;D12.776.260.504;D12.776.476.024.385;D12.776.930.332;B01.050.150.900.649.313.992.635.505.500;E05.393.620.500.487;D12.776.260.600.124;D12.776.660.600.124;D12.776.930.600.124;D12.776.260.645.500;D12.776.930.700.500;D12.776.124.790.651.950.750;D12.776.377.715.548.950.750;D12.776.543.750.705.816.821.750;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E01.789;D08.811.913.696.620.682.700.725.049;D08.811.913.696.620.682.725;D12.776.624.664.700;E05.393.620.500.706;D12.644.360.024.342.500;D12.776.157.057.186.500;D12.776.476.024.430.500;D12.776.930.840.500;G02.111.820;G04.835;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D12.776.260.755;D12.776.930.900;D12.776.964.925.984
28368977,Adult;Autografts;Bacterial Infections;Burns;Gastrointestinal Microbiome;Graft Survival;Humans;Middle Aged;Sepsis;Skin Transplantation;Wound Infection,M01.060.116;A01.941.750;C01.252;C26.200;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C01.539.757;C23.550.470.790.500;E02.095.147.725.700;E04.680.275.850;E04.936.580.700;C01.539.947
28368963,Cardiopulmonary Resuscitation;Chest Wall Oscillation;Humans;Manikins;Middle Aged;Nursing Staff;Prospective Studies;Psychomotor Performance;Retention (Psychology);Simulation Training,E02.365.647.110;E02.880.130;B01.050.150.900.649.313.988.400.112.400.400;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;M01.060.116.630;M01.526.485.680;N02.360.680;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F02.808;G11.427.700;G11.561.660;F02.463.425.540.772;I02.903.847
28368873,"Back;Biopsy, Needle;Child;Follow-Up Studies;Humans;Hyperpigmentation;Immunohistochemistry;Magnetic Resonance Imaging;Nevus, Blue;Risk Assessment;Skin Neoplasms;Treatment Outcome",A01.923.176;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C17.800.621.430;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E01.370.350.825.500;C04.557.665.560.615.550;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04.588.805;C17.800.882;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28368384,"Animals;Avoidance Learning;Exenatide;Gene Knockdown Techniques;Glucagon-Like Peptide 1;Glucagon-Like Peptide-1 Receptor;Habenula;Interpeduncular Nucleus;Mice;Mice, Knockout;Neural Pathways;Nicotine;Peptides;Rats;Reward;Self Stimulation;Sitagliptin Phosphate;Solitary Nucleus;Venoms",B01.050;F02.463.425.097;F02.463.785.373.173;D12.644.187;D20.888.300;D23.946.833.300;E05.393.335.500;D06.472.317.680.500.500;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;A08.186.211.180.200.360;A08.186.211.200.317.200.360;A08.186.211.132.659.413.875.618.436;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A08.612;D03.132.760.570;D03.383.725.518;D12.644;B01.050.150.900.649.313.992.635.505.700;F02.463.425.770.836;F01.145.775;F02.830.784;D03.383.129.799.725;D03.383.679.875;A08.186.211.132.810.591.500.750;A12.200.935;D20.888;D23.946.833
28366881,"Adult;Blood-Brain Barrier;Brain;Cell Movement;Chemokine CCL2;Chemokines;Culture Media, Conditioned;Endothelial Cells;Humans;Macrophages;Microvessels;Monocytes;Substance P;Up-Regulation;HIV;Receptors, Neurokinin-1",M01.060.116;A07.035;A08.186.211.035;A08.186.211;G04.198;G07.568.500.180;D12.644.276.374.200.110.990.600;D12.776.467.374.200.110.990.600;D23.125.300.110.990.600;D23.469.200.110.990.600;D23.529.374.200.110.990.500;D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200;D27.720.470.305.250;E07.206.250;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;A07.015.461;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;D12.644.276.812.900.866;D12.644.400.800.750;D12.644.456.800.866;D12.776.467.812.900.866;D12.776.631.650.800.750;D23.469.050.375.850.890;D23.529.812.900.866;G02.111.905;G05.308.850;G07.690.773.998;B04.820.650.589.650.350;D12.776.543.750.695.862.500;D12.776.543.750.720.600.830.500;D12.776.543.750.750.555.830.500
28366681,"Beckwith-Wiedemann Syndrome;Child;Disease Management;Glossectomy;Humans;Macroglossia;Risk Assessment;Risk Factors;Sleep Apnea, Obstructive;Sleep Apnea Syndromes;Child;Infant;Macroglossia;Syndrome",C16.131.077.133;C16.131.260.080;C16.320.180.080;M01.060.406;N04.590.607;E04.545.380;E06.645.380;B01.050.150.900.649.313.988.400.112.400.400;C07.465.910.460;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.618.085.852.850;C10.886.425.800.750.850;C08.618.085.852;C10.886.425.800.750;M01.060.406;M01.060.703;C07.465.910.460;C23.550.288.500
28366641,"Animals;Animals, Genetically Modified;Binding Sites;Cell Line;Chromatin;Drosophila Proteins;Drosophila melanogaster;Ecdysone;Enhancer Elements, Genetic;Genotype;Insulator Elements;Mutation;Nuclear Pore Complex Proteins;Phenotype;Promoter Regions, Genetic;Protein Binding;RNA Interference;Transcription, Genetic;Transcriptional Activation;Transfection;Nuclear Pore;Nuclear Pore Complex Proteins",B01.050;B01.050.050.136;B05.620.136;G02.111.570.120;A11.251.210;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;D04.210.500.247.222.265.165.500;D06.472.445.573.271.500;G02.111.570.080.689.330;G05.360.080.689.330;G05.360.340.024.340.137.750.249;G05.380;G02.111.570.080.689.390;G05.360.080.689.390;G05.360.340.024.420;G05.365.590;D12.776.157.530.750.625;D12.776.543.585.750.625;G05.695;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;G02.111.679;G03.808;G05.308.203.374.790;G02.111.873;G05.297.700;G05.308.800;E05.393.350.810;G05.728.860;A11.284.430.106.279.692.630;D12.776.157.530.750.625;D12.776.543.585.750.625
28366345,"Asian Continental Ancestry Group;Child, Preschool;Cross-Cultural Comparison;European Continental Ancestry Group;Humans;Infant;Infant, Newborn;Middle East;Mothers;Prevalence;Sleep;Sleep Wake Disorders;Child;Sleep",M01.686.508.200;M01.060.406.448;I01.076.201.450.281;I01.880.853.100.257;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;Z01.252.245.500;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;F02.830.855;G11.561.803;C10.886;C23.888.592.796;F03.870;M01.060.406;F02.830.855;G11.561.803
28365920,"Antirheumatic Agents;Arthritis, Psoriatic;Humans;Precision Medicine;Randomized Controlled Trials as Topic;Research Design;Severity of Illness Index;Treatment Outcome;Arthritis, Psoriatic;Therapeutics",D27.505.954.329;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;B01.050.150.900.649.313.988.400.112.400.400;E02.574;H02.403.200.700;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E05.581.500;H01.770.644.728;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;E02
28365486,"Adolescent;Adult;Drug Monitoring;Gastrointestinal Agents;Humans;Inflammatory Bowel Diseases;Infliximab;Retrospective Studies;Serum;Treatment Outcome;Young Adult;Colitis, Ulcerative",M01.060.057;M01.060.116;E01.370.520.200;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A12.207.152.846;A15.145.846;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28365478,Adult;Bipolar Disorder;Case-Control Studies;Diagnostic and Statistical Manual of Mental Disorders;Humans;Psychotic Disorders;Young Adult;Bipolar Disorder;Bipolar Disorder;Psychotic Disorders,M01.060.116;F03.084.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;F03.700.675;M01.060.116.815;F03.084.500;F03.084.500;F03.700.675
28365203,"Adult;Aged;Aged, 80 and over;Anxiety;Cohort Studies;Depression;Geriatric Assessment;Humans;Middle Aged;Parkinson Disease;Psychiatric Status Rating Scales;Severity of Illness Index;Sleep Initiation and Maintenance Disorders;Anxiety;Depression;Sleep Initiation and Maintenance Disorders;Parkinson Disease;Risk Factors",M01.060.116;M01.060.116.100;M01.060.116.100.080;F01.470.132;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.126.350;E05.318.308.225;I01.240.425.350;N01.224.425.350;N05.715.360.300.360;N06.850.505.400.425.350;N06.850.520.308.225;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;F04.711.513.653;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.886.425.800.800;F03.870.400.800.800;F01.470.132;F01.145.126.350;C10.886.425.800.800;F03.870.400.800.800;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28364549,"Adaptor Proteins, Vesicular Transport;Brain Diseases;Cells, Cultured;Child, Preschool;Consanguinity;Family Health;Fibroblasts;Genetic Association Studies;Green Fluorescent Proteins;Humans;Infant;Magnetic Resonance Imaging;Mitochondria;Mitochondrial Dynamics;Oxygen Consumption;Protein Transport;Transfection;Rare Diseases",D12.776.543.990.150;C10.228.140;A11.251;M01.060.406.448;G05.090.403.180;G05.180;N01.400.300;A11.329.228;E05.393.385;D12.776.532.265;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.825.500;A11.284.430.214.190.875.564;A11.284.835.626;G04.599.750;G03.680;G03.143.700;E05.393.350.810;G05.728.860;C23.550.291.906
28364516,"Accidents, Traffic;Adolescent;Adult;Aged;Automobile Driving;Automobiles;Fatigue;Health Education;Health Promotion;Humans;Motivation;Public Health;Risk Factors;Safety;Sleep Deprivation;Sleep Stages;United States;Young Adult;Public Health",N06.850.135.392;M01.060.057;M01.060.116;M01.060.116.100;I03.125;J01.937.500.100;C23.888.369;I02.233.332;N02.421.726.407;I02.233.332.445;N02.421.726.407.579;B01.050.150.900.649.313.988.400.112.400.400;F01.658;F01.752.543.500.750;H02.403.720;N01.400.550;N06.850;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N06.850.135.060.075;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F02.830.855.796;G11.561.803.754;Z01.107.567.875;M01.060.116.815;H02.403.720;N01.400.550;N06.850
28364508,"Adolescent;Child;Child, Preschool;Continuous Positive Airway Pressure;Cost-Benefit Analysis;Follow-Up Studies;Humans;Patient Compliance;Pediatrics;Polysomnography;Sleep Apnea, Obstructive;Treatment Outcome;Continuous Positive Airway Pressure;Sleep Apnea, Obstructive;Organizational Innovation;Pediatrics",M01.060.057;M01.060.406;M01.060.406.448;E02.041.625.790.259;E02.880.820.790.259;N03.219.151.125;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;H02.403.670;E01.370.520.625;C08.618.085.852.850;C10.886.425.800.750.850;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02.041.625.790.259;E02.880.820.790.259;C08.618.085.852.850;C10.886.425.800.750.850;N04.452.610;H02.403.670
28364486,Animals;Circadian Rhythm;European Continental Ancestry Group;Genome-Wide Association Study;Humans;Phenotype;Sleep;Circadian Rhythm;Genetics;Genome-Wide Association Study;Sleep,B01.050;G07.180.562.190;M01.686.508.400;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;G05.695;F02.830.855;G11.561.803;G07.180.562.190;H01.158.273.343;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;F02.830.855;G11.561.803
28364472,"Actigraphy;Adult;Environment;Gene Expression Profiling;Humans;Immunity;Leukocytes;Oxidative Phosphorylation;Phenotype;Sleep;Time Factors;Transcriptome;Twins, Monozygotic;Up-Regulation;Gene Expression;Twins",E01.370.520.049;E05.003.500;M01.060.116;G16.500.275;N06.230;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;G12.450;A11.118.637;A15.145.229.637;A15.382.490;G02.111.665.550;G03.295.631;G03.796.550;G05.695;F02.830.855;G11.561.803;G01.910.857;G02.111.873.750;G05.297.700.750;G05.360.920;M01.438.873.940;G02.111.905;G05.308.850;G07.690.773.998;G05.297;M01.438.873
28364451,"Adult;Body Composition;Diet;Energy Intake;Energy Metabolism;Feeding Behavior;Healthy Volunteers;Humans;Middle Aged;Polysomnography;Sleep;Sleep, REM;Young Adult;Energy Intake;Polysomnography",M01.060.116;G02.111.130;G03.180;G07.100.049;G07.203.650.240;G07.203.650.240.340;G03.295;F01.145.113.547;F01.145.407;G07.203.650.353;M01.774.500;M01.955.236;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.520.625;F02.830.855;G11.561.803;F02.830.855.796.671;G11.561.803.754.671;M01.060.116.815;G07.203.650.240.340;E01.370.520.625
28364424,"Adult;Bariatric Surgery;Elective Surgical Procedures;Humans;Hypertension;Intensive Care Units;Length of Stay;Middle Aged;Obesity, Morbid;Odds Ratio;Postoperative Complications;Preoperative Care;Risk Factors;Sleep Apnea Syndromes;Sleep Apnea, Obstructive;Sleep Apnea, Obstructive;Postoperative Complications",M01.060.116;E02.570.500.062;E04.062;E04.249;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;N02.278.388.493;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;C23.550.767;E02.760.795;E04.604.750;N02.421.585.795;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C08.618.085.852;C10.886.425.800.750;C08.618.085.852.850;C10.886.425.800.750.850;C08.618.085.852.850;C10.886.425.800.750.850;C23.550.767
28364354,Biomarkers;Diabetic Nephropathies;Humans;Precision Medicine;Prognosis;Diabetic Nephropathies;Epigenomics;Genomics;Precision Medicine,D23.101;C12.777.419.192;C13.351.968.419.192;C19.246.099.875;B01.050.150.900.649.313.988.400.112.400.400;E02.574;H02.403.200.700;E01.789;C12.777.419.192;C13.351.968.419.192;C19.246.099.875;H01.158.273.180.350.074;H01.158.273.343.350.042;H01.158.273.180.350;H01.158.273.343.350;E02.574;H02.403.200.700
28363971,Actins;Bacterial Proteins;Polymerization;Vibrio;Virulence Factors,D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;D12.776.097;G02.750;B03.440.450.900.859;B03.660.250.830.830;D23.946.896
28363676,"Clinical Competence;Education, Medical, Graduate;Hand;Humans;Internship and Residency;Surgery, Plastic;United States;Patient Care;Hand;Surgery, Plastic",I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;A01.378.800.667;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.810.788;Z01.107.567.875;E02.760;N02.421.585;A01.378.800.667;H02.403.810.788
28363511,"Adolescent;Age Distribution;Botswana;Case-Control Studies;Cerebral Palsy;Child;Child, Preschool;Humans;Malnutrition;Odds Ratio;ROC Curve;Retrospective Studies;Sensitivity and Specificity;Socioeconomic Factors;Africa;Cerebral Palsy;Malnutrition;Nervous System Diseases",M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;Z01.058.290.175.230;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C10.228.140.140.254;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C18.654.521;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;I01.880.853.996;N01.824;Z01.058;C10.228.140.140.254;C18.654.521;C10
28363400,,
28363364,"Certification;Clinical Competence;Education, Medical, Continuing;Hospitals;Humans;Pediatrics;Quality Improvement;Self-Assessment;United States;Quality Improvement",N03.706.110.120;N05.700.200.190;I02.399.630.210;N04.761.210;N05.715.175;I02.358.212.350;I02.358.399.250;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;J01.293.754;N04.761.744;F01.752.747.792.537;Z01.107.567.875;J01.293.754;N04.761.744
28363199,"Adolescent;Cardiac Surgical Procedures;Cohort Studies;Electrocardiography;Exercise Test;Exercise Tolerance;Follow-Up Studies;Heart Function Tests;Humans;Longitudinal Studies;Magnetic Resonance Imaging, Cine;Monitoring, Physiologic;Predictive Value of Tests;Retrospective Studies;Stroke Volume;Tetralogy of Fallot;Time Factors;Ventricular Dysfunction, Right;Heart Ventricles;Tetralogy of Fallot",M01.060.057;E04.100.376;E04.928.220;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E01.370.370.380.240;E01.370.405.240;E01.370.370.380.250;E01.370.386.700.250;E05.333.250;G11.427.680.270;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E01.370.370.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500.510;E01.370.520;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.370.380.150.700;G09.330.380.124.882;C14.240.400.849;C14.280.400.849;C16.131.240.400.849;G01.910.857;C14.280.945.910;A07.541.560;C14.240.400.849;C14.280.400.849;C16.131.240.400.849
28362690,"Adolescent;Anal Canal;Child;Child, Preschool;Crohn Disease;Cross-Sectional Studies;Databases, Factual;Humans;Logistic Models;Longitudinal Studies;Phenotype;Prognosis;Rectal Fistula;Severity of Illness Index",M01.060.057;A03.556.124.526.070;A03.556.249.249.070;M01.060.406;M01.060.406.448;C06.405.205.731.500;C06.405.469.432.500;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;G05.695;E01.789;C06.267.550.600;C06.405.469.471.600;C06.405.469.860.752;C23.300.575.185.550.600;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28362567,Adolescent;Adult;Beverages;Carbohydrates;Dietary Sucrose;Economics;Health Education;Humans;Middle Aged;New York City;Nutrition Policy;Young Adult;Economics;Health,M01.060.057;M01.060.116;G07.203.100;J02.200;D09;D09.301.831.250;D09.698.629.305.770.200;D09.947.500.250;D09.947.750.770.200;D27.720.372.300.353.609.750.250;G07.203.300.362.831.250;G07.203.300.514.500.400.700.750.250;J02.500.362.831.250;J02.500.514.500.400.700.750.250;I01.261;N03.219;I02.233.332;N02.421.726.407;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.107.567.875.350.530.530;Z01.107.567.875.500.530.530;Z01.433.741;I01.655.500.608.400.650;I01.880.604.825.608.400.650;N03.623.500.608.428.650;M01.060.116.815;I01.261;N03.219;N01.400
28362528,,
28362255,"Adaptor Proteins, Signal Transducing;Adenosine Deaminase;Cell Death;Cell Line, Tumor;Endoribonucleases;Epithelial Cells;Humans;Interferon-Induced Helicase, IFIH1;RNA-Binding Proteins;Adenosine Deaminase;Cell Death;Humans;Allergy and Immunology;Communicable Diseases;Microbiology",D12.644.360.024;D12.776.157.057;D12.776.476.024;D08.811.277.151.486.075;G04.146;A11.251.210.190;A11.251.860.180;D08.811.277.352.355.350;D08.811.277.352.700.350;A11.436;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.445.735.720.249.875;D12.776.157.725;D12.776.664.962;D08.811.277.151.486.075;G04.146;B01.050.150.900.649.313.988.400.112.400.400;H02.403.044;C01.539.221;H01.158.273.540
28362156,"Clinical Laboratory Services;Exome;Genetic Diseases, Inborn;Genetic Testing;Genome, Human;Genomics;Germ-Line Mutation;High-Throughput Nucleotide Sequencing;Humans;Incidental Findings;Sequence Analysis, DNA",N02.421.726.233.110;G05.360.340.011;C16.320;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.360.340.350;H01.158.273.180.350;H01.158.273.343.350;G05.365.590.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E01.410;E05.393.760.700
28361895,,
28361575,"Adolescent;Adult;Age Distribution;Child;Child, Preschool;Epidemics;Humans;Incidence;Kidney Diseases;Obesity;Pediatric Obesity;Prevalence;Prognosis;Protective Factors;Risk Assessment;Risk Factors;Time Factors;Young Adult;Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",M01.060.057;M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.406;M01.060.406.448;N06.850.290.200;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;E05.318.740.600.800.582;N05.715.350.200.675;N05.715.360.750.625.700.570;N06.850.490.625.625;N06.850.520.830.600.800.582;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G01.910.857;M01.060.116.815;C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28360970,,
28360128,Animals;Circadian Rhythm;Circadian Rhythm Signaling Peptides and Proteins;Drosophila Proteins;Drosophila melanogaster;Sleep;Circadian Rhythm;Neurosciences;Sleep,B01.050;G07.180.562.190;D12.644.360.138;D12.776.476.156;D12.776.093.500.462;B01.050.500.131.617.720.500.500.750.310.250.500;F02.830.855;G11.561.803;G07.180.562.190;H01.158.610;F02.830.855;G11.561.803
28359192,"Attitude to Health;Biomedical Research;Brain Injuries, Traumatic;Clinical Trials, Phase III as Topic;Emergencies;Glasgow Coma Scale;Glasgow Outcome Scale;Humans;Informed Consent;Injury Severity Score;Multicenter Studies as Topic;Progesterone;Progestins;Proxy;Randomized Controlled Trials as Topic;Treatment Outcome;Ethics, Research;Bioethics;Informed Consent;Brain Injuries, Traumatic",F01.100.150;N05.300.150;H01.770.644.145;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;E05.318.372.250.250.220;N05.715.360.330.250.250.220;N06.850.520.450.250.250.220;C23.550.291.781;N06.230.100.083;N06.850.376;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;E05.318.308.940.968.875.260;E05.944.510;N04.452.859.564.800.260;N05.715.360.300.715.500.800.335;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;E05.318.308.940.968.875.500;E05.944.600;N04.452.859.564.800.500;N05.715.360.300.715.500.800.400;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750;D27.505.696.399.472.858;M01.380.600;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;K01.752.566.479.173;N05.350.670;K01.752.566.479.045;N05.350.200;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28358981,"Humans;Obsessive-Compulsive Disorder;Postpartum Period;Pregnancy;Pregnancy Complications;Recurrence;Remission, Spontaneous;Young Adult",B01.050.150.900.649.313.988.400.112.400.400;F03.080.600;G08.686.702;G08.686.784.769;C13.703;C23.550.291.937;C23.550.291.656.700;G16.767;M01.060.116.815
28358763,"Blood Coagulation Disorders;Blood Coagulation Tests;Blood Loss, Surgical;Blood Transfusion;Child, Preschool;Cohort Studies;Craniosynostoses;Craniotomy;Humans;Infant;Postoperative Complications;Reconstructive Surgical Procedures;Registries",C15.378.100;E01.370.225.625.115;E05.200.625.115;C23.550.414.300;C23.550.505.300;E02.095.135;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E04.525.190;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C23.550.767;E04.680;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970
28358134,,
28357917,"Africa, Western;Animals;Antibodies, Monoclonal;Antibodies, Viral;Clinical Trials as Topic;Ebolavirus;Hemorrhagic Fever, Ebola;Humans;Immunotherapy;Treatment Outcome;Ebolavirus;Antibodies, Monoclonal;Therapeutics",Z01.058.290.190;B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B04.820.455.300.200;C02.782.417.415;C02.782.580.250.400;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;B04.820.455.300.200;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;E02
28356657,,
28356537,"Animal Structures;Animals;Disease Models, Animal;Epithelial Cells;Feces;Leukocytes;Macaca;Nasopharynx;Poliomyelitis;Poliovirus;Virus Shedding;Models, Animal;Macaca;Poliomyelitis",A13;B01.050;C22.232;E05.598.500;E05.599.395.080;A11.436;A12.459;A11.118.637;A15.145.229.637;A15.382.490;B01.050.150.900.649.313.988.400.112.199.120.510;A04.623.557;A14.724.557;C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864;B04.820.565.284.689;G07.925;E05.598;B01.050.150.900.649.313.988.400.112.199.120.510;C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
28356511,"Adult;Aged;Amyotrophic Lateral Sclerosis;Animals;Biomarkers;Brain;C9orf72 Protein;Cell Line;Dinucleotide Repeats;Humans;Induced Pluripotent Stem Cells;Leukocytes, Mononuclear;Longitudinal Studies;Mice;Middle Aged;Neurons;Oligonucleotides, Antisense;Prognosis;RNA",M01.060.116;M01.060.116.100;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;D23.101;A08.186.211;D12.776.141;A11.251.210;G02.111.570.080.708.800.500.150;G05.360.080.708.800.500.150;G05.360.340.024.850.500.150;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A11.118.637.555;A15.145.229.637.555;A15.382.490.555;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;B01.050.150.900.649.313.992.635.505.500;M01.060.116.630;A08.675;A11.671;D13.150.480;D13.444.600.150.640;D13.695.578.424.480;D27.720.470.530.600.150.640;E01.789;D13.444.735
28356466,Adolescent;Age of Onset;Biomarkers;Body Mass Index;European Continental Ancestry Group;Genetic Predisposition to Disease;HLA-DRB1 Chains;Humans;Mendelian Randomization Analysis;Multiple Sclerosis;Risk;Sweden;United States;Vitamin D,M01.060.057;N05.715.350.075.100;N06.850.490.250.100;D23.101;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.686.508.400;C23.550.291.687.500;G05.380.355;D12.776.395.550.509.400.440.200.010;D12.776.543.550.440.400.440.200.010;D23.050.301.500.400.400.440.200.010;D23.050.301.500.450.400.440.333.500;D23.050.705.552.410.400.440.200.010;D23.050.705.552.450.400.440.333.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.416.500;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;Z01.542.816.500;Z01.107.567.875;D04.210.500.812.768
28356414,"Adolescent;Bacteriological Techniques;Child;Child, Preschool;Humans;Prospective Studies;Sensitivity and Specificity;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Urinary Tract Infections;Mass Spectrometry;Urinary Tract Infections",M01.060.057;E01.370.225.875.150;E05.200.875.150;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.196.566.755;C01.539.895;C12.777.892;C13.351.968.892;E05.196.566;C01.539.895;C12.777.892;C13.351.968.892
28356173,"Accidents, Traffic;Advisory Committees;Automobile Driving;Awareness;Humans;Risk Factors;Safety;Sleep Apnea, Obstructive;Sleep Medicine Specialty;Societies, Medical;United States;Sleep Apnea, Obstructive",N06.850.135.392;N03.706.742.500;I03.125;F02.463.188.150;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N06.850.135.060.075;C08.618.085.852.850;C10.886.425.800.750.850;H02.403.429.865;N03.540.828.589;Z01.107.567.875;C08.618.085.852.850;C10.886.425.800.750.850
28356149,Age Factors;Aged;Cohort Studies;Humans;Medicare;Middle Aged;Odds Ratio;Patient Acceptance of Health Care;Quality of Health Care;Risk Factors;United States;Medicare;Quality of Health Care,N05.715.350.075;N06.850.490.250;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.630;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;N04.761;N05.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;N04.761;N05.715
28355566,"Animals;Antioxidants;Autophagy;Carcinogenesis;Cell Line, Tumor;Cell Transformation, Neoplastic;Mice, Inbred BALB C;Mice, Nude;NF-E2-Related Factor 2;Nuclear Respiratory Factor 1;Oncogenes;Oxidative Stress;Phenotype;Proteasome Endopeptidase Complex;Protein Folding;Proteolysis;Tripartite Motif Proteins;Ubiquitin-Protein Ligases;Up-Regulation;Tripartite Motif Proteins;Breast Neoplasms;Proteasome Endopeptidase Complex",B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;G04.146.399;G04.417.350.091;C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;C04.697.098.500;C23.550.727.098.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.150.900.649.313.992.635.505.500.550.500;D12.776.260.108.737;D12.776.930.127.737;D12.776.260.615.500;D12.776.930.618.500;G05.360.340.024.340.375.500;G03.673;G07.775.750;G05.695;D05.500.562.500;D08.811.277.656.918;D08.811.600.730;G01.154.651;G02.111.688;G02.111.720;G03.812;D12.776.934;D08.811.464.938.750;G02.111.905;G05.308.850;G07.690.773.998;D12.776.934;C04.588.180;C17.800.090.500;D05.500.562.500;D08.811.277.656.918;D08.811.600.730
28355548,"Fluorescence Resonance Energy Transfer;Kinetics;Macromolecular Substances;Models, Theoretical;Probability",E05.196.712.516.600.676.500;G01.154.240.280;G02.111.255.280;G01.374.661;G02.111.490;D05;E05.599;E05.318.740.600;G17.680;N05.715.360.750.625;N06.850.520.830.600
28355410,"Adult;Child;Humans;Obesity;Renal Insufficiency, Chronic",M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C12.777.419.780.750;C13.351.968.419.780.750
28353166,"B-Lymphocytes;Humans;Immunologic Deficiency Syndromes;Infant, Newborn;Lymphopenia;Neonatal Screening;Severe Combined Immunodeficiency;T-Lymphocytes;Allergy and Immunology",A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;B01.050.150.900.649.313.988.400.112.400.400;C20.673;M01.060.703.520;C15.378.553.546.605;C20.673.627;E01.370.225.910;E01.370.500.580;E05.200.910;E05.318.308.980.438.580.580;N02.421.726.233.443.816;N05.715.360.300.800.438.500.575;N06.850.520.308.980.438.580.580;N06.850.780.500.580;C16.614.815;C18.452.284.800;C20.673.815;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;H02.403.044
28352619,Neoplasm Grading;Middle Aged;Testosterone,E01.789.612;M01.060.116.630;D04.210.500.054.079.429.824;D06.472.334.851.968.984
28352003,,
28351890,"Animals;Antineoplastic Agents, Immunological;Autophagy;CD47 Antigen;Carcinoma, Non-Small-Cell Lung;Cell Line;Cell Line, Tumor;Cell Survival;Chloroquine;Drug Therapy, Combination;Humans;Lung Neoplasms;Mice;Mice, Inbred BALB C;Mice, Nude;Phagocytosis;Proto-Oncogene Proteins c-akt;Reactive Oxygen Species;Recombinant Fusion Proteins;TOR Serine-Threonine Kinases",B01.050;D27.505.954.248.384;G04.146.399;G04.417.350.091;D12.776.395.550.014;D12.776.543.550.147;C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500;A11.251.210;A11.251.210.190;A11.251.860.180;G04.346;D03.633.100.810.050.180;E02.319.310;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.150.900.649.313.992.635.505.500.550.500;G04.417.350;G09.188.665;G12.450.564.809;G12.688;D08.811.913.696.620.682.700.755;D12.776.476.565;D12.776.624.664.700.168;D01.339.431;D01.650.775;D12.776.828.300;D08.811.913.696.620.682.700.931;D12.776.476.925
28351774,,
28351771,,
28351066,"Attitude of Health Personnel;Education, Medical, Graduate;Humans;Internal Medicine;Internship and Residency;Models, Educational;Patient-Centered Care;Qualitative Research;Surveys and Questionnaires;Teaching Rounds",F01.100.050;N05.300.100;I02.358.337.350;I02.358.399.350;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;E05.599.545;I02.903.302;N04.590.233.727.407;H01.770.644.241.850;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.358.399.822
28350923,"Financing, Government;Health Expenditures;Health Priorities;Humans;Public Health",N03.219.521.346;N03.219.151.450;N05.300.385;N03.349.330;N05.300.400;B01.050.150.900.649.313.988.400.112.400.400;H02.403.720;N01.400.550;N06.850
28350903,"Anti-Bacterial Agents;Bacterial Infections;Biological Specimen Banks;Clinical Studies as Topic;Drug Resistance, Bacterial;Host-Pathogen Interactions;Humans;Laboratories;Leadership;Molecular Diagnostic Techniques;Professional Staff Committees;Research Design;Sepsis",D27.505.954.122.085;C01.252;N02.278.065;E05.318.372.250;N05.715.360.330.250;N06.850.520.450.250;G06.099.225;G06.225.347;G07.690.773.984.269.347;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;J03.520;N02.278.487;F01.752.609;E01.370.225.880;E05.200.880;E05.393.520;N04.452.758.788;N05.700.685;E05.581.500;H01.770.644.728;C01.539.757;C23.550.470.790.500
28350902,"Anti-Bacterial Agents;Bacterial Infections;Bacteriological Techniques;Clinical Studies as Topic;Community-Acquired Infections;Drug Resistance, Bacterial;Humans;Infection Control;Leadership;Pneumonia, Bacterial;Research Personnel",D27.505.954.122.085;C01.252;E01.370.225.875.150;E05.200.875.150;E05.318.372.250;N05.715.360.330.250;N06.850.520.450.250;C01.539.234;G06.099.225;G06.225.347;G07.690.773.984.269.347;B01.050.150.900.649.313.988.400.112.400.400;N06.850.780.200.450;F01.752.609;C01.252.620;C08.381.677.540;C08.730.610.540;M01.526.839
28350767,Autonomic Nervous System;Cerebral Palsy;Child;Heart Rate;Humans,A08.800.050;C10.228.140.140.254;M01.060.406;E01.370.600.875.500;G09.330.380.500;B01.050.150.900.649.313.988.400.112.400.400
28350723,,
28350679,"Adolescent;Child;Child, Preschool;Craniosynostoses;Frontal Bone;Frontal Sinus;Humans;Organ Size;Retrospective Studies;Tomography, X-Ray Computed",M01.060.057;M01.060.406;M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;A02.835.232.781.375;A04.531.621.387;B01.050.150.900.649.313.988.400.112.400.400;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28350644,"Adolescent;Blood Gas Analysis;Child;Child, Preschool;Humans;Infant;Intensive Care Units, Pediatric;Lung;Oxygen;Prospective Studies;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Respiratory Mechanics",M01.060.057;E01.370.225.124.100.100;E01.370.386.700.100;E05.200.124.100.100;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;A04.411;D01.268.185.550;D01.362.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;G09.772.705.700
28350380,"Cell Line, Tumor;Gene Expression Profiling;Humans;Mutation;Neuroblastoma",A11.251.210.190;A11.251.860.180;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
28348269,"Animals;Biological Evolution;Gene Frequency;Genotype;Gorilla gorilla;HLA-B Antigens;Histocompatibility Antigens Class I;Humans;Immune System;Immunodominant Epitopes;Killer Cells, Natural;Pan paniscus;Pan troglodytes;Phylogeny;Polymorphism, Genetic",B01.050;G05.045;G16.075;G05.330;G05.380;B01.050.150.900.649.313.988.400.112.400.375;D12.776.395.550.489.500;D12.776.543.550.439.500;D23.050.301.500.100.500;D23.050.301.500.450.380;D23.050.705.552.100.500;D23.050.705.552.450.380;D12.776.395.550.489;D12.776.543.550.439;D23.050.301.500.100;D23.050.705.552.100;B01.050.150.900.649.313.988.400.112.400.400;A15.382;D23.050.550.500;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;B01.050.150.900.649.313.988.400.112.400.600;B01.050.150.900.649.313.988.400.112.400.620;G05.697;G16.075.605;L01.100.697;G05.365.795
28348065,"Child;Cognitive Dysfunction;Genetic Diseases, Inborn;Genomics;Humans;Nervous System Diseases;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Human Genetics",M01.060.406;F03.615.250.700;C16.320;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;C10;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;H01.158.273.343.385
28347975,"Adolescent;Asthma;Child;Child, Preschool;Clinical Protocols;Medication Adherence;Metered Dose Inhalers;Pediatrics;Pilot Projects;Randomized Controlled Trial;Text Messaging",M01.060.057;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;E02.183;N05.715.360.330.125;F01.100.150.750.500.600.500;F01.145.488.887.500.600.500;N05.300.150.800.500.600.500;E07.605.750;H02.403.670;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;V03.175.250.500.500;L01.178.847.698.300.500;L01.559.423.906.377.666
28347435,,
28347308,,
28346928,"Animals;Bacteria;Choline;Diet;Dietary Carbohydrates;Dysbiosis;Fecal Microbiota Transplantation;Gastrointestinal Microbiome;Health Status;Humans;Inflammatory Bowel Diseases;Methylamines;Renal Insufficiency, Chronic",B01.050;B03;D02.033.100.291.211;D02.092.063.291.211;D02.092.877.883.333;D02.675.276.232;G07.203.650.240;D09.301;G07.203.300.362;J02.500.362;C23.550.308;E02.095.231;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;I01.240.425;N01.224.425;N06.850.505.400.425;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;D02.092.668;C12.777.419.780.750;C13.351.968.419.780.750
28346484,Aged;Health Services Accessibility;Humans;Income;Middle Aged;Neoplasm Grading;Neoplasm Invasiveness;Poverty;Prostatic Neoplasms;Residence Characteristics;Risk Factors;Severity of Illness Index;Social Support,M01.060.116.100;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N01.824.417;M01.060.116.630;E01.789.612;C04.697.645;C23.550.727.645;I01.880.735.634;I01.880.853.996.535;N01.824.600;C04.588.945.440.770;C12.294.260.750;C12.294.565.625;C12.758.409.750;N01.224.791;N06.850.505.400.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;I01.880.853.500.600
28346442,"Alleles;BRCA1 Protein;BRCA2 Protein;Carcinoma, Ovarian Epithelial;Genetic Loci;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Meta-Analysis as Topic;Mutation;Neoplasms, Glandular and Epithelial;Ovarian Neoplasms;Polymorphism, Single Nucleotide;Risk Factors;Telomere-Binding Proteins",G05.360.340.024.340.030;D12.776.313.125;D12.776.624.776.100;D12.776.660.100;D12.776.744.100;D12.776.930.137;D12.776.313.249;D12.776.624.776.101;D12.776.660.105;C04.557.470.200.295;C04.588.322.455.199;C13.351.500.056.630.705.350;C13.351.937.418.685.350;C19.344.410.199;C19.391.630.705.350;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;G05.365.590;C04.557.470;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G05.365.795.598;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.260.735;D12.776.660.235.700
28346324,"Child, Preschool;Electrocardiography;Humans;Long QT Syndrome",M01.060.406.448;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;C14.280.067.565;C14.280.123.625;C16.131.240.400.715;C23.550.073.547
28346032,"Aged;Aged, 80 and over;Follow-Up Studies;Hospitalization;Humans;Medicare;Prevalence;Retrospective Studies;Risk Factors;Self Report;United States;Vision Disorders;Medicare;Aged;Hospitalization;Vision Disorders",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;Z01.107.567.875;C10.597.751.941;C11.966;C23.888.592.763.941;N03.219.521.346.506.564.663;N03.219.521.576.343.840;N03.706.615.696;M01.060.116.100;E02.760.400;N02.421.585.400;C10.597.751.941;C11.966;C23.888.592.763.941
28345608,"Adult;Alcoholism;Alleles;Case-Control Studies;Cognition;Gene Frequency;Gray Matter;Heroin Dependence;Humans;Monoamine Oxidase;Polymorphism, Genetic;Temporal Lobe;White Matter",M01.060.116;C25.775.100.250;F03.900.100.350;G05.360.340.024.340.030;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;F02.463.188;G05.330;A08.186.211.168;A08.186.854.348;C25.775.675.400;F03.900.675.300;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.664.750;G05.365.795;A08.186.211.200.885.287.500.863;A08.186.211.204;A08.186.854.880
28345240,Clinical Laboratory Techniques;Genetic Counseling;Humans;Pregnancy;Prenatal Diagnosis;Whole Genome Sequencing,E01.370.225;E05.200;H01.158.273.343.385.500.384;N02.421.308.400;B01.050.150.900.649.313.988.400.112.400.400;G08.686.784.769;E01.370.378.630;E05.393.760.700.825
28345115,Counseling;Cross-Sectional Studies;Echocardiography;Health Care Surveys;Humans;Hypoplastic Left Heart Syndrome;Internet;Prenatal Care;Professional Practice;Fontan Procedure;Hypoplastic Left Heart Syndrome;Norwood Procedures;Protein-Losing Enteropathies,F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.308.980.344;N03.349.380.210;N05.425.210;N05.715.360.300.800.344;N06.850.520.308.980.344;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;L01.224.230.110.500;E02.760.786;N02.421.143.620.704;N02.421.585.786;N04.452.758;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E04.100.376.724;E04.928.220.560;C06.405.469.818
28344992,"Muscular Dystrophy, Duchenne;Pseudogenes",C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;G05.360.340.024.340.700
28344780,Cytidine Monophosphate N-Acetylneuraminic Acid;Ciliopathies;Glycosylation,D02.241.081.844.562.668.250;D02.241.511.902.562.668.250;D03.383.742.686.246.370.250;D09.067.687.668.250;D09.811.589.668.250;D13.695.740.246.370.250;D13.695.827.232.370.250;C16.131.077.245;C16.320.184;G02.111.158.812;G02.607.299;G03.191.812
28344086,,
28343820,"Animals;Chemokine CCL20;Hair Follicle;Immune Tolerance;Mice;Microbiota;Morphogenesis;Receptors, CCR6;Skin;Symbiosis;T-Lymphocytes, Regulatory;Hair Follicle;T-Lymphocytes, Regulatory",B01.050;D12.644.276.374.200.110.880;D12.644.276.374.200.600.880;D12.776.467.374.200.110.880;D12.776.467.374.200.600.880;D23.125.300.110.880;D23.125.300.600.880;D23.469.200.110.880;D23.469.200.600.880;D23.529.374.200.110.880;D23.529.374.200.600.880;A10.272.497.500;A17.360.710;A17.815.250.500;G12.535.425;B01.050.150.900.649.313.992.635.505.500;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;G07.345.500;D12.776.543.750.695.160.150.600;D12.776.543.750.705.852.125.150.600;A17.815;G06.550.800;G16.840;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;A10.272.497.500;A17.360.710;A17.815.250.500;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700
28342697,Alzheimer Disease;Brain;Clinical Trials as Topic;Disease Progression;Humans;Neuroimaging;Alzheimer Disease;Amyloid;Disease Progression;Cognitive Dysfunction,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;A08.186.211;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D05.500.049;D12.776.049;C23.550.291.656;F03.615.250.700
28342621,"Humans;Models, Organizational;Patient-Centered Care;Practice Patterns, Nurses';Quality of Health Care;United States;Delivery of Health Care;Organization and Administration;Primary Care Nursing;Primary Health Care",B01.050.150.900.649.313.988.400.112.400.400;E05.599.670;N04.452.534;N04.590.233.727.407;N04.590.374.553;N05.300.581;N04.761;N05.715;Z01.107.567.875;N04.590.374;N05.300;N04.452;E02.760.611.735;N04.590.233.727
28341799,"Adolescent;Brain Injuries, Traumatic;Child;Decision Support Systems, Clinical;Decision Support Techniques;Emergency Service, Hospital;Emergency Treatment;Humans;Retrospective Studies;Tomography, X-Ray Computed",M01.060.057;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;L01.313.500.750.300.190;E05.245;L01.313.500.750.190;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.365;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28341625,Adult;Aged;Elective Surgical Procedures;Heart Failure;Heart-Assist Devices;Hemostasis;Hospitalization;Humans;Middle Aged;Patient Admission;Postoperative Complications;Retrospective Studies;Survival Rate;Treatment Outcome;Abdomen;Cardiovascular Diseases,M01.060.116;M01.060.116.100;E04.249;C14.280.434;E04.050.430;E07.695.300.300;E07.858.082.374.300;G09.188.390;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.760.400.600;N02.421.585.400.600;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A01.923.047;C14
28341535,"Biomechanical Phenomena;Cell Nucleus;Chromatin;DNA Breaks, Double-Stranded;Genomic Instability;Mechanical Phenomena;Porosity",G01.154.090;G01.374.089;A11.284.430.106;A11.284.430.214.190.875.117;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G05.200.210.220;C23.550.362;G05.365.590.335;G05.370;G01.374;G01.374.710
28341469,Mortality;Transplantation,E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;E04.936
28341068,"Adolescent;Age Factors;Child;Child, Preschool;Drug Resistance, Microbial;Fingers;Humans;Infant;Retrospective Studies;Tenosynovitis;Young Adult;Infection",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;G06.225;G07.690.773.984.269;A01.378.800.667.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.651.869.870;M01.060.116.815;C01.539
28341027,Blood Pressure;Humans;Hypertension;Pressure,E01.370.600.875.249;G09.330.380.076;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;G01.374.715
28340885,"Allografts;Forecasting;Graft Rejection;Graft Survival;Humans;Immunosuppression;Immunosuppressive Agents;Kidney Failure, Chronic;Kidney Transplantation;Prognosis;Risk Assessment;Transplantation Immunology;Transplantation, Homologous",A01.941.500;I01.320;G12.875.545.328;G12.875.545.340;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.450;E05.478.610;D27.505.696.477.656;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.500;E04.936.450.485;E04.950.774.400;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;G12.875;E04.936.864
28340442,Adolescent;Adult;Aged;Bipolar Disorder;Case-Control Studies;Child;Cognition;Cross-Sectional Studies;Emotions;Endophenotypes;Executive Function;Family;Humans;Middle Aged;Mood Disorders;Neuropsychological Tests;Young Adult;Bipolar Disorder;Endophenotypes;Mood Disorders,M01.060.057;M01.060.116;M01.060.116.100;F03.084.500;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;F02.463.188;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F01.470;G05.695.224;F02.463.217;F01.829.263;I01.880.853.150;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F03.600;F04.711.513;M01.060.116.815;F03.084.500;G05.695.224;F03.600
28340012,"Activities of Daily Living;Adipose Tissue;Aged;Arthritis, Rheumatoid;Body Mass Index;Cross-Sectional Studies;Disabled Persons;Humans;Middle Aged;Muscle Strength;Muscle, Skeletal;Obesity;Physical Fitness;Retrospective Studies;Arthritis, Rheumatoid",E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110;A10.165.114;M01.060.116.100;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.150;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.600.425;G11.427.560;A02.633.567;A10.690.552.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G11.427.685;I03.450.642.845.054.800;N01.400.545;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199
28339914,"Anti-Bacterial Agents;Enterococcus;Hospitalization;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Methicillin-Resistant Staphylococcus aureus;Microbial Sensitivity Tests;Prospective Studies;Risk Factors;Staphylococcal Infections;Staphylococcus aureus;United States;Vancomycin Resistance;Vancomycin-Resistant Enterococci;Methicillin-Resistant Staphylococcus aureus;Risk Factors",D27.505.954.122.085;B03.353.750.250.250;B03.510.550.250.250;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.252.410.868;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100;Z01.107.567.875;G06.099.225.984;G06.225.347.984;G07.690.773.984.269.347.984;B03.353.750.250.250.650;B03.510.550.250.250.650;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28339890,"Analgesics, Opioid;Clinical Competence;Curriculum;Education, Medical, Undergraduate;Humans;Opioid-Related Disorders;Pennsylvania;Clinical Competence;Curriculum;Pain Management",D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500;I02.399.630.210;N04.761.210;N05.715.175;I02.158;I02.358.399.450;B01.050.150.900.649.313.988.400.112.400.400;C25.775.675;F03.900.675;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;I02.399.630.210;N04.761.210;N05.715.175;I02.158;E02.745;N04.590.607.500
28339881,Animals;Birds;Encephalitozoon;Enterocytozoon;Gastrointestinal Diseases;Gastrointestinal Tract;Genotype;HIV Infections;Humans;Mammals;Microsporidia;Microsporidiosis;Prevalence;Water Microbiology;Encephalitozoon;Enterocytozoon;Microsporidia;Microsporidiosis,B01.050;B01.050.150.900.248;B01.300.360.500.500.100.175;B01.300.360.500.500.100.200;C06.405;A03.556;G05.380;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649;B01.300.360;C01.703.617;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;H01.158.273.540.274.777;N06.850.425.450;B01.300.360.500.500.100.175;B01.300.360.500.500.100.200;B01.300.360;C01.703.617
28339747,Drug-Related Side Effects and Adverse Reactions;Humans;Machine Learning;Natural Language Processing;Neural Networks (Computer);Pharmacovigilance;Social Media;Social Media;Drug-Related Side Effects and Adverse Reactions;Natural Language Processing;Neural Networks (Computer);Social Media,C25.100;B01.050.150.900.649.313.988.400.112.400.400;G17.035.250.500;L01.224.050.375.530;L01.224.050.375.580;G17.485;L01.224.050.375.605;E05.337.800.600;N06.850.505.636;L01.178.751;L01.224.230.110.500.750;L01.178.751;L01.224.230.110.500.750;C25.100;L01.224.050.375.580;G17.485;L01.224.050.375.605;L01.178.751;L01.224.230.110.500.750
28339689,"Adult;Attitude of Health Personnel;Attitude to Computers;Child;Decision Support Systems, Clinical;Electronic Health Records;Genetic Testing;Genomics;Humans;Interviews as Topic;Middle Aged;Pediatric Nurse Practitioners;Pediatricians;Pediatrics;Primary Health Care;User-Computer Interface;Electronic Health Records",M01.060.116;F01.100.050;N05.300.100;F01.100.100;M01.060.406;L01.313.500.750.300.190;E05.318.308.940.968.625.500;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;M01.060.116.630;M01.526.485.650.640.500;N02.360.650.640.500;M01.526.485.810.758;N02.360.810.758;H02.403.670;N04.590.233.727;L01.224.900.910;E05.318.308.940.968.625.500
28339686,Adult;Affect;Cohort Studies;Depression;Depressive Disorder;Exercise;Humans;Mobile Applications;Pregnancy;Self Report;Smartphone;Surveys and Questionnaires;Mobile Applications,M01.060.116;F01.470.047;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.126.350;F03.600.300;G11.427.410.698.277;I03.350;B01.050.150.900.649.313.988.400.112.400.400;L01.224.900.685;G08.686.784.769;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;L01.224.230.260.550.500.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;L01.224.900.685
28339637,Attitude of Health Personnel;Child;Delivery of Health Care;Humans;Interdisciplinary Communication;Interviews as Topic;Neoplasms;Pediatrics;Psychiatric Status Rating Scales;Psycho-Oncology;Qualitative Research;Risk Assessment;Neoplasms,F01.100.050;N05.300.100;M01.060.406;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;C04;H02.403.670;F04.711.513.653;F04.096.628.808.500;H02.403.429.515.250;H02.720.500;H01.770.644.241.850;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C04
28339623,"Adolescent;Carbapenem-Resistant Enterobacteriaceae;Cephalosporin Resistance;Child;Child, Preschool;Cross Infection;Enterobacteriaceae Infections;Escherichia coli Infections;Hospitals, Pediatric;Humans;Infant;Infant, Newborn;Klebsiella Infections;Molecular Epidemiology;United States;Young Adult;Enterobacteriaceae;Pediatrics",M01.060.057;B03.440.450.425.189;B03.660.250.150.097;G06.099.225.500.175;G06.225.347.500.175;G07.690.773.984.269.347.500.175;M01.060.406;M01.060.406.448;C01.539.248;C23.550.291.875.500;C01.252.400.310;C01.252.400.310.330;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C01.252.400.310.503;E05.318.416;E05.393.522;H01.158.201.636.475.500;H01.158.273.343.595.475.500;H01.181.122.650.475.550;H02.403.720.500.300;N06.850.520.470;Z01.107.567.875;M01.060.116.815;B03.440.450.425;B03.660.250.150;H02.403.670
28339588,"Biomarkers, Tumor;Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 19;Combined Modality Therapy;Disease Progression;Follow-Up Studies;Glioma;Humans;Isocitrate Dehydrogenase;Magnetic Resonance Imaging;Mutation;Neoplasm Grading;Survival Rate",D23.101.140;C04.588.614.250.195;C10.228.140.211;C10.551.240.250;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.235.240;G05.360.162.520.300.235.240;A11.284.187.520.300.460.465;G05.360.162.520.300.460.465;E02.186;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;D08.811.682.047.820.475;E01.370.350.825.500;G05.365.590;E01.789.612;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900
28339136,"Adrenal Cortex Hormones;Adult;Animals;Asthma;Child;Deglutition Disorders;Diagnosis, Differential;Diet Therapy;Eosinophilic Esophagitis;Esophagus;Feeding and Eating Disorders;Humans;Inflammatory Bowel Diseases;Phenotype;Prevalence;Eosinophilic Esophagitis;Phenotype;Therapeutics",D06.472.040;M01.060.116;B01.050;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;C06.405.117.119;C09.775.174;E01.171;E02.642.249;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;A03.556.875.500;F03.400;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;G05.695;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C06.405.117.620.209;C06.405.205.663.209;C15.378.553.231.341;C20.543.480.356;G05.695;E02
28338946,"Bias;Body Mass Index;Computer Simulation;Confounding Factors (Epidemiology);Data Interpretation, Statistical;Glycated Hemoglobin A;Humans;Hypoglycemic Agents;Least-Squares Analysis;Metformin;Outcome Assessment (Health Care);Research Design;Sulfonylurea Compounds;Weight Gain",N05.715.350.150;N06.850.490.500;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;L01.224.160;N05.715.350.240;N06.850.490.718;E05.245.380;E05.318.740.300;L01.313.500.750.190.380;N05.715.360.750.300;N06.850.520.830.300;D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;E05.318.740.750.400;N05.715.360.750.695.440;N06.850.520.830.750.400;D02.078.370.141.450;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.581.500;H01.770.644.728;D02.886.590.795;D02.948.828;C23.888.144.243.926;G07.345.249.314.120.200.926
28338485,"Breast Feeding;Congresses as Topic;Evidence-Based Practice;Health Policy;Hospitals;Humans;Infant, Newborn;Intensive Care Units, Neonatal;Lactation;Milk, Human;Nurses, Neonatal;Nursing Staff, Hospital;Practice Guidelines as Topic;Prospective Studies;Surveys and Questionnaires",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;N03.540.199;H02.249;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390.380;G08.686.523;G08.686.702.500;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500;M01.526.485.650.648.940.500;N02.360.650.648.940.500;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;N04.761.700.350.650;N05.700.350.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28338087,"Animals;Cell Differentiation;Cells, Cultured;Chromogranins;Cortical Bone;Cyclic AMP;Cyclic AMP Response Element-Binding Protein;Cyclic AMP-Dependent Protein Kinases;Cyclin D1;GTP-Binding Protein alpha Subunits, Gs;Mice;Mice, Inbred C57BL;NFATC Transcription Factors;Osteoclasts;Signal Transduction;Wnt Proteins;beta Catenin",B01.050;G04.152;A11.251;D12.776.631.199;D12.776.811.185;A10.165.265.521;D03.633.100.759.646.138.395;D13.695.462.200;D13.695.667.138.395;D13.695.827.068.395;D12.776.260.108.184;D12.776.930.127.184;D08.811.913.696.620.682.700.150.125;D12.644.360.200.125;D12.776.476.200.125;D12.644.360.262.150.100;D12.776.167.218.150.100;D12.776.476.262.150.100;D12.776.624.664.700.100;D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.930.608;A11.329.372.700;A11.627.482.700;G02.111.820;G04.835;D12.776.467.984;D23.529.984;D12.776.091.249;D12.776.220.145.500;D12.776.930.130
28337690,"Adult;Aged;Choice Behavior;Electronic Health Records;Humans;Influenza Vaccines;Influenza, Human;Middle Aged;Patient Participation;Random Allocation;Vaccination;Economics, Behavioral;Electronic Health Records",M01.060.116;M01.060.116.100;F02.463.785.373.346;E05.318.308.940.968.625.500;B01.050.150.900.649.313.988.400.112.400.400;D20.215.894.899.302;C02.782.620.365;C08.730.310;M01.060.116.630;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890;F04.096.628.286;N03.219.215;E05.318.308.940.968.625.500
28336680,"Child;Emergency Service, Hospital;Humans;Stroke;Delayed Diagnosis;Diagnosis;Neuroimaging;Stroke",M01.060.406;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.775;C14.907.253.855;E01.110;E02.288;E02.760.273;N02.421.585.273;E01;E01.370.350.578;E01.370.376.537;E05.629;C10.228.140.300.775;C14.907.253.855
28336485,"Counseling;Decision Making;Early Detection of Cancer;Humans;Lung Neoplasms;Quality Assurance, Health Care;Radiation Dosage;Tomography, X-Ray Computed",F02.784.176;F04.408.413;N02.421.143.303;N02.421.461.363;F02.463.785.373;E01.390.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;N04.761.700;N05.700;E05.799.513;G01.750.740;N06.850.810.250;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28336472,"Birth Weight;Guidelines as Topic;Humans;Image Processing, Computer-Assisted;Infant;Infant, Newborn;Infant, Premature;Ophthalmoscopy;Referral and Consultation;Reproducibility of Results;Retina;Retinopathy of Prematurity;Severity of Illness Index",C23.888.144.186;E01.370.600.115.100.160.120.186;E05.041.124.160.750.149;G07.100.100.160.120.186;G07.345.249.314.120.186;N04.761.700.350;N05.700.350;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;M01.060.703;M01.060.703.520;M01.060.703.520.520;E01.370.380.560;N04.452.758.849;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;A09.371.729;C11.768.836;C16.614.521.731;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28336252,"Academic Medical Centers;Adult;Aged;Aged, 80 and over;Brachytherapy;Cancer Care Facilities;Cohort Studies;Databases, Factual;Humans;Internship and Residency;Middle Aged;Radiation Oncology;United States;Uterine Cervical Neoplasms;Brachytherapy;Uterine Cervical Neoplasms",N02.278.020;M01.060.116;M01.060.116.100;M01.060.116.100.080;E02.815.150;N02.278.421.556.070;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.060.116.630;H02.403.429.515.500;H02.403.740.650;Z01.107.567.875;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850;E02.815.150;C04.588.945.418.948.850;C13.351.500.852.593.131;C13.351.500.852.762.850;C13.351.937.418.875.850
28334875,"Adolescent;Anisotropy;Brain;Case-Control Studies;Child;Child, Preschool;Demyelinating Diseases;Diffusion Tensor Imaging;Disease Progression;Humans;Multiple Sclerosis;Neuroimaging;Sex Characteristics;White Matter;Encephalomyelitis, Acute Disseminated;Demyelinating Diseases",M01.060.057;G01.590.040;G02.050;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;C10.314;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E01.370.350.578;E01.370.376.537;E05.629;G08.686.815;A08.186.211.204;A08.186.854.880;C10.114.375.225;C10.228.140.695.562.225;C10.314.350.225;C20.111.258.250.350;C10.314
28334856,"Adolescent;Adult;Child;Education, Continuing;Education, Distance;Formative Feedback;Guideline Adherence;Health Personnel;Humans;Kenya;Longitudinal Studies;Primary Health Care;Quality of Health Care",M01.060.057;M01.060.116;M01.060.406;I02.358.212;I02.195;F02.784.629.529.223;N04.761.337;N05.715.360.395;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;Z01.058.290.120.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;N04.590.233.727;N04.761;N05.715
28334020,"AIDS-Related Opportunistic Infections;HIV Infections;Humans;Immunocompromised Host;Meningitis, Cryptococcal",C01.539.597.050;C02.597.050;C02.782.815.616.400.100;C03.684.050;C20.673.480.100;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;G12.470;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500
28333849,"Adolescent;Adult;Autism Spectrum Disorder;Child;Child, Preschool;Comorbidity;Humans;Klinefelter Syndrome;Severity of Illness Index;XYY Karyotype;Young Adult",M01.060.057;M01.060.116;F03.625.164.113;M01.060.406;M01.060.406.448;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;C12.706.316.795.500;C13.351.875.253.795.500;C16.131.260.830.835.500;C16.131.939.316.795.500;C16.320.180.830.835.500;C19.391.119.795.500;C19.391.482.629;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C23.550.210.024.500;C23.550.210.815.970;G05.360.162.679.500.500;G05.365.590.175.024.500;G05.365.590.175.815.970;M01.060.116.815
28333597,Consensus;Enteral Nutrition;Gastrointestinal Diseases;Humans;Malnutrition;Meta-Analysis as Topic;Observational Studies as Topic;Parenteral Nutrition;Practice Guidelines as Topic;Randomized Controlled Trials as Topic;Time Factors,F01.829.316.068;F02.463.785.373.433;E02.421.360;E02.642.500.360;C06.405;B01.050.150.900.649.313.988.400.112.400.400;C18.654.521;E05.318.370.500;E05.581.500.501;N05.715.360.325.515;N06.850.520.445.500;E05.318.372.250.500;N05.715.360.330.250.500;N06.850.520.450.250.500;E02.421.505;E02.642.500.505;N04.761.700.350.650;N05.700.350.650;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;G01.910.857
28333442,"Anesthetics, Inhalation;Animals;Binding Sites;Humans;Ion Channel Gating;Kv1.2 Potassium Channel;Ligands;Methyl Ethers;Mutagenesis, Site-Directed;Oocytes;Photoaffinity Labels;Sevoflurane;Shaker Superfamily of Potassium Channels;Xenopus laevis",D27.505.696.277.100.035.060;D27.505.954.427.210.100.035.060;B01.050;G02.111.570.120;B01.050.150.900.649.313.988.400.112.400.400;G02.111.820.400;G04.835.400;G07.265.625;D12.776.157.530.400.600.900.500.186;D12.776.543.550.450.750.900.124.342;D12.776.543.550.450.750.900.500.186;D12.776.543.585.400.750.900.624.186;D27.720.470.480;D02.355.601;E05.393.420.601.575;A05.360.490.690.680;A11.497.497.600;D27.720.470.410.080.600;D02.355.601.810;D02.455.526.510.717;D12.776.157.530.400.600.900.500;D12.776.543.550.450.750.900.500;D12.776.543.585.400.750.900.624;B01.050.150.900.090.180.610.500.562
28333362,"Adult;Anti-Inflammatory Agents;Anti-Inflammatory Agents, Non-Steroidal;Budesonide;Colitis, Ulcerative;Colonoscopy;Delayed-Action Preparations;Double-Blind Method;Humans;Hydrocortisone;Intention to Treat Analysis;Mesalamine;Middle Aged;Remission Induction;Retreatment;Severity of Illness Index;Colitis, Ulcerative;Inflammation;Inflammatory Bowel Diseases",M01.060.116;D27.505.954.158;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;D04.210.500.745.745.654.105;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;D26.255.210;E02.319.300.253;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;D02.241.223.100.050.300.500;D02.241.223.100.300.595.100.540;D02.241.511.390.595.100.540;D02.455.426.559.389.127.020.452.750;D02.455.426.559.389.127.281.595.100.540;D02.455.426.559.389.657.410.595.100.540;M01.060.116.630;E02.860;E02.887;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;C23.550.470;C06.405.205.731;C06.405.469.432
28333286,Anxiety;Comorbidity;Depression;Humans;Polycystic Ovary Syndrome;Prevalence;Severity of Illness Index;Anxiety;Depression;Meta-Analysis;Polycystic Ovary Syndrome,F01.470.132;N05.715.350.225;N06.850.490.687;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F01.470.132;F01.145.126.350;V03.600;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765
28333160,"Anemia;Anti-Bacterial Agents;Enterocolitis, Necrotizing;Erythrocyte Transfusion;Georgia;Gestational Age;Hemoglobin A;Humans;Infant;Infant, Low Birth Weight;Infant, Newborn;Infant, Newborn, Diseases;Infant, Premature;Intensive Care Units, Neonatal;Multivariate Analysis;Proportional Hazards Models;Prospective Studies;Risk Factors;Severity of Illness Index",C15.378.071;D27.505.954.122.085;C06.405.205.596.700;C06.405.469.363.700;E02.095.135.140.275;Z01.107.567.875.075.250;Z01.107.567.875.750.370;G07.345.500.325.235.968;G08.686.320;D12.776.124.400.405;D12.776.422.316.762.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520.460;M01.060.703.520;C16.614;M01.060.703.520.520;N02.278.388.493.390.380;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500
28333002,Fellowships and Scholarships;Humans;Internship and Residency;Radiation Oncologists;Radiation Oncology;United States;Workforce,N03.219.483.838.276;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.810.699.500;M01.526.485.810.877.500;N02.360.810.699.500;N02.360.810.877.500;H02.403.429.515.500;H02.403.740.650;Z01.107.567.875;N04.452.525
28332939,"Adolescent;African Americans;Age Distribution;Anti-Asthmatic Agents;Asthma;Body Mass Index;Child;Child, Preschool;Continuity of Patient Care;Electronic Health Records;Health Services Accessibility;Hospitalization;Humans;Influenza Vaccines;Minority Groups;Patient Care Planning;Primary Health Care;Quality of Health Care;Reimbursement, Incentive;Retrospective Studies;Severity of Illness Index;Sex Distribution;Spirometry;Urban Population;Pediatrics",M01.060.057;M01.686.508.100.100;M01.686.754.100;I01.240.050;N01.224.033;N06.850.505.400.050;D27.505.954.796.050;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;M01.060.406.448;E02.760.169;N02.421.585.169;N04.590.233.727.210;E05.318.308.940.968.625.500;N04.590.374.350;N05.300.430;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;D20.215.894.899.302;I01.880.853.300;N04.590.233.624;N04.590.233.727;N04.761;N05.715;N03.219.521.710.305.380;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;I01.240.800;N01.224.803;N06.850.505.400.850;E01.370.386.700.750;N01.600.900;H02.403.670
28332504,"Animals;Cell Line, Tumor;Circadian Clocks;Gene Expression Regulation, Neoplastic;Humans;Liver Neoplasms;Mice;Nuclear Receptor Subfamily 1, Group D, Member 1;Proto-Oncogene Proteins c-myc;Time Factors",B01.050;A11.251.210.190;A11.251.860.180;G07.180.562.094.500;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;B01.050.150.900.649.313.992.635.505.500;D12.776.260.643.080;D12.776.476.156.300;D12.776.826.209.080;D12.776.260.103.813;D12.776.624.664.700.189;D12.776.660.765;D12.776.930.125.813;G01.910.857
28332103,"Behavior;Child, Preschool;Hong Kong;Humans;Infant;Infant, Newborn;Parents;Self Report;Sleep;Infant;Sleep;Sleep",F01.145;M01.060.406.448;Z01.252.474.164.450;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;F02.830.855;G11.561.803;M01.060.703;F02.830.855;G11.561.803;F02.830.855;G11.561.803
28331088,"Antibody-Dependent Cell Cytotoxicity;Antigens, CD;CD4 Antigens;Epitopes;GPI-Linked Proteins;HIV-1;Human Immunodeficiency Virus Proteins;Humans;Immune Evasion;Interferon-beta;Interleukins;Jurkat Cells;Molecular Mimicry;Up-Regulation;Viral Regulatory and Accessory Proteins;env Gene Products, Human Immunodeficiency Virus;Antibody-Dependent Cell Cytotoxicity;HIV-1;Interleukin-27;Interferons",G12.287.070;D23.050.301.264.035;D23.101.100.110;D12.776.543.750.705.852.420.810.500;D12.776.543.750.830.700.025;D23.050.301.264.894.100;D23.101.100.894.100;D23.050.550;D12.776.395.550.448;D12.776.543.484.500;D12.776.543.550.418;B04.820.650.589.650.350.400;D12.776.964.775.562;B01.050.150.900.649.313.988.400.112.400.400;G06.462.400;G12.413;G16.527.200.700;D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;A11.251.210.190.495;A11.251.860.180.495;A15.382.490.555.567.569.440;G02.111.560;G05.545;G16.012.750.500;G02.111.905;G05.308.850;G07.690.773.998;D12.776.964.925;D12.776.964.775.325.164;D12.776.964.775.562.500;D12.776.964.970.880.325.164;G12.287.070;B04.820.650.589.650.350.400;D12.644.276.374.465.800;D12.776.467.374.465.800;D23.529.374.465.600;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
28330960,"Adolescent;Age Factors;Brain Stem;Brain Stem Neoplasms;Child;Child, Preschool;Cross-Sectional Studies;Disease Progression;Disease-Free Survival;Glioma;Humans;Infant;Neurofibromatosis 1;Retrospective Studies;Young Adult",M01.060.057;N05.715.350.075;N06.850.490.250;A08.186.211.132;C04.588.614.250.195.411.100;C10.228.140.211.500.100;C10.551.240.250.400.200;M01.060.406;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;C23.550.291.656;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.580.600.580.590.650;C04.700.631.650;C10.562.600.500;C10.574.500.549.400;C10.668.829.675;C16.320.400.560.400;C16.320.700.633.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.060.116.815
28330813,"ATP Binding Cassette Transporter 1;Angiopoietin-like Proteins;Apolipoprotein A-I;Cell Differentiation;Cells, Cultured;Cholesterol;Hepatocytes;Humans;Induced Pluripotent Stem Cells;Lipoproteins, HDL;Tangier Disease;Transcriptome;Triglycerides;Induced Pluripotent Stem Cells;Tangier Disease",D12.776.157.530.100.050.500;D12.776.395.550.020.381.500;D12.776.543.550.192.381.500;D12.776.543.585.100.190.500;D12.644.276.100.050;D12.776.467.100.050;D23.529.100.050;D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100;G04.152;A11.251;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;A11.436.348;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;D10.532.432;D12.776.521.479;C10.668.829.800.875;C16.320.565.398.500.330.750;C18.452.584.500.875.330.750;C18.452.648.398.500.330.750;G02.111.873.750;G05.297.700.750;G05.360.920;D10.351.801;A11.872.040.500;A11.872.700.500;C10.668.829.800.875;C16.320.565.398.500.330.750;C18.452.584.500.875.330.750;C18.452.648.398.500.330.750
28330522,"Anthropometry;Child Development;Feasibility Studies;Heart Defects, Congenital;Humans;Infant, Newborn;Length of Stay;Logistic Models;Motion Therapy, Continuous Passive;Norwood Procedures;Pilot Projects;Time Factors;Treatment Outcome;United States;Hypoplastic Left Heart Syndrome;Exercise Therapy;Growth;Range of Motion, Articular",E01.370.600.024;E05.041;N06.850.505.200.100;F01.525.200;G07.345.374.750;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E02.760.169.063.500.387.500;E02.779.483.500;E02.779.867.761;E02.831.535.483.500;E02.831.535.867.761;E04.100.376.724;E04.928.220.560;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;G07.345.249;E01.370.600.700;G11.427.760
28330499,"Biopsy;Esophagus;Fibrosis;Gene Regulatory Networks;Humans;Leukocytes, Mononuclear;Lung;Organ Specificity;Scleroderma, Systemic;Skin;Transcriptome;Lung Diseases;Macrophages;Scleroderma, Systemic",E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;A03.556.875.500;C23.550.355;G05.360.080.689.360;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555;A15.145.229.637.555;A15.382.490.555;A04.411;G07.650;C17.300.799;C17.800.784;A17.815;G02.111.873.750;G05.297.700.750;G05.360.920;C08.381;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;C17.300.799;C17.800.784
30051026,,
28329460,"Adolescent;Computer Simulation;Fontan Procedure;Heart Defects, Congenital;Heart Ventricles;Hemodynamics;Humans;Models, Cardiovascular;Pulmonary Artery;Exercise;Respiration",M01.060.057;L01.224.160;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;A07.541.560;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395.161;A07.015.114.715;G11.427.410.698.277;I03.350;G09.772.705
28329355,,
28329124,"Actigraphy;Adult;Attention;Fatigue;Humans;Internal Medicine;Internship and Residency;Shift Work Schedule;Sleep;Sleep Deprivation;Wakefulness;Work Schedule Tolerance;Actigraphy;Fatigue;Education, Medical;Sleep Deprivation",E01.370.520.049;E05.003.500;M01.060.116;F02.830.104.214;C23.888.369;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;I03.946.225.250;N04.452.677.650.250;F02.830.855;G11.561.803;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F02.830.104.821;G11.561.035.738;I03.946.225.375;N04.452.677.650.375;E01.370.520.049;E05.003.500;C23.888.369;I02.358.399;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
28329079,"Adipokines;Adiponectin;Adolescent;Asian Continental Ancestry Group;Blood Glucose;Body Mass Index;Cardiovascular Diseases;Child;China;Cholesterol, HDL;Fibroblast Growth Factors;Humans;Hyperglycemia;Insulin;Insulin Resistance;Leptin;Metabolic Syndrome;Obesity;Resistin;Retinol-Binding Proteins, Plasma;Risk Factors;Sleep;Time Factors;Triglycerides;Waist Circumference;Adipokines",D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024;D06.472.699.042.249;D12.644.276.024.249;D12.644.548.011.249;D12.776.467.024.249;D23.529.024.249;M01.060.057;M01.686.508.200;D09.947.875.359.448.500;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C14;M01.060.406;Z01.252.474.164;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;D12.644.276.624;D12.776.467.624;D23.529.624;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.952;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;C18.452.394.968.500;G07.690.773.984.617;D06.472.699.042.500;D12.644.276.024.500;D12.644.548.011.500;D12.776.467.024.500;D23.529.024.500;C18.452.394.968.500.570;C18.452.625;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;D06.472.699.042.750;D12.644.276.024.750;D12.644.548.011.750;D12.776.467.024.750;D23.529.024.750;D12.776.124.698;D12.776.124.790.106.745;D12.776.157.469.550;D12.776.157.700.500;D12.776.377.715.085.745;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F02.830.855;G11.561.803;G01.910.857;D10.351.801;E01.370.600.115.100.160.560;E05.041.124.160.875;G07.100.100.160.560;D06.472.699.042;D12.644.276.024;D12.644.548.011;D12.776.467.024;D23.529.024
28328639,"Adolescent;Age Factors;Child;Child, Preschool;Cleft Palate;Follow-Up Studies;Humans;Palate, Soft;Reconstructive Surgical Procedures;Retrospective Studies;Speech Disorders;Time Factors;Treatment Outcome;Velopharyngeal Insufficiency",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;M01.060.406.448;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;A14.549.617.780;E04.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C10.597.606.150.500.800;C23.888.592.604.150.500.800;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C07.465.525.955;C07.550.966;C07.650.525.955;C09.775.955;C16.131.850.525.955
28328623,"Adrenal Cortex Hormones;Adult;Aged;Anemia, Iron-Deficiency;Cohort Studies;Colitis, Ulcerative;Colonoscopy;Databases, Factual;Humans;Hypoalbuminemia;Logistic Models;Middle Aged;Models, Theoretical;Multivariate Analysis;Prognosis;ROC Curve;Severity of Illness Index;Time Factors;United States",D06.472.040;M01.060.116;M01.060.116.100;C15.378.071.196.300;C18.452.565.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C15.378.147.607.500;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.599;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E01.789;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;Z01.107.567.875
28328585,"Adult;Catheter Ablation;Electrophysiologic Techniques, Cardiac;Heart-Assist Devices;Humans;Prosthesis Design;Tachycardia, Supraventricular;Transposition of Great Vessels;Treatment Outcome",M01.060.116;E02.808.750.500;E04.014.760.500;E01.370.370.380.245;E01.370.405.267;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;E05.320.550;E07.695.680;C14.280.067.845.880;C14.280.123.875.880;C23.550.073.845.880;C14.240.400.915;C14.280.400.915;C16.131.240.400.915;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28328579,Adult;Brain;Chronic Pain;Connectome;Disease Progression;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Nerve Net;Pelvic Pain;Postal Service;Reproducibility of Results;Rest;Sensitivity and Specificity;Syndrome;Urologic Diseases,M01.060.116;A08.186.211;C23.888.592.612.274;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;A08.511;C23.888.592.612.944;I01.451.617;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;I03.450.769.647;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C23.550.288.500;C12.777;C13.351.968
28328563,"Child;Child, Preschool;Humans;Intraoperative Neurophysiological Monitoring;Orthotic Devices;Prostheses and Implants;Retrospective Studies;Ribs;Scoliosis;Spinal Cord Injuries;Spine;Titanium",M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;E01.370.520.510.500;E01.370.520.596.500;E04.510.500;E07.858.442.743;E07.695;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A02.835.232.570.500;C05.116.900.800.875;C10.228.854.763;C10.900.850;C26.819;A02.835.232.834;D01.268.557.800;D01.268.956.878;D01.552.547.800
28328243,"Adolescent;Child;Child, Preschool;Extracorporeal Membrane Oxygenation;Heart Failure;Hemolysis;Hemorrhage;Humans;Incidence;Infant;Prospective Studies;Respiratory Insufficiency;Retrospective Studies;Thrombosis;Extracorporeal Membrane Oxygenation;Hemolysis",M01.060.057;M01.060.406;M01.060.406.448;E02.880.301;E04.292.451;C14.280.434;C23.550.403;G12.122.545;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C08.618.846;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.907.355.830;E02.880.301;E04.292.451;C23.550.403;G12.122.545
28328131,"Arthrogryposis;Bone and Bones;Child;Electroencephalography;Gene Expression;Glycosylation;Heterozygote;Humans;Intellectual Disability;Microcephaly;Mutation;Nucleotide Transport Proteins;Quadriplegia;Siblings;Spasms, Infantile;Genetics;Spasms, Infantile",C05.550.150;C05.651.102;C05.660.077;C16.131.621.077;A02.835.232;A10.165.265;M01.060.406;E01.370.376.300;E01.370.405.245;G05.297;G02.111.158.812;G02.607.299;G03.191.812;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;C05.660.207.620;C10.500.507.400.500;C16.131.621.207.620;C16.131.666.507.400.500;G05.365.590;D12.776.157.530.625.875;D12.776.543.585.625.875;C10.597.622.760;C23.888.592.636.786;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;C10.228.140.490.375.760;C10.228.140.490.493.875;H01.158.273.343;C10.228.140.490.375.760;C10.228.140.490.493.875
28328118,"Adolescent;Adult;African Continental Ancestry Group;Asian Continental Ancestry Group;Biometric Identification;Child;Child, Preschool;Chromosomes, Human, Pair 22;DiGeorge Syndrome;European Continental Ancestry Group;Facies;Heart Defects, Congenital;Hispanic Americans;Humans;Image Interpretation, Computer-Assisted;In Situ Hybridization, Fluorescence;Infant;Infant, Newborn;Learning Disorders;Phenotype;DiGeorge Syndrome;DiGeorge Syndrome;DiGeorge Syndrome",M01.060.057;M01.060.116;M01.686.508.100;M01.686.508.200;E05.318.740.225.500;N04.452.910.099;M01.060.406;M01.060.406.448;A11.284.187.520.300.505.515;G05.360.162.520.300.505.515;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;M01.686.508.400;C23.550.291.812;E01.370.600.230;C14.240.400;C14.280.400;C16.131.240.400;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;M01.060.703;M01.060.703.520;C10.597.606.150.550;C23.888.592.604.150.550;F03.625.562;G05.695;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
28327899,Adult;Deep Brain Stimulation;Humans;Patient Readmission;Pennsylvania;Postoperative Complications;Retrospective Studies;Deep Brain Stimulation;Movement Disorders;Parkinson Disease,M01.060.116;E02.331.300;E04.190;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.620;N02.421.585.400.620;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C23.550.767;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E02.331.300;E04.190;C10.228.662;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28327332,Cognitive Dysfunction;Dementia;Humans;Neuropsychological Tests;Parkinson Disease,F03.615.250.700;C10.228.140.380;F03.615.400;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28326803,Alveolar Epithelial Cells;Animals;Humans;Lung;Lung Diseases;Regenerative Medicine;Stem Cells;Embryonic Stem Cells,A04.411.715.100;A11.436.081;B01.050;B01.050.150.900.649.313.988.400.112.400.400;A04.411;C08.381;H02.403.750;A11.872;A11.872.700.250
28326214,,
28326162,"Stress Disorders, Post-Traumatic;Emergency Medical Services;Allied Health Personnel",F03.950.750.500;N02.421.297;M01.526.485.067;N02.360.067
28325811,"Humans;Infant, Newborn;Infant, Premature;Models, Theoretical;Oxygen;Oxygen Consumption",B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;E05.599;D01.268.185.550;D01.362.670;G03.680
28325654,"Cardiovascular Diseases;Cardiovascular Surgical Procedures;Critical Care;Humans;Thoracic Surgical Procedures;Acute Kidney Injury;Respiratory Distress Syndrome, Adult;Atrial Fibrillation;Electric Countershock;Critical Care;Database;Delirium;Dexmedetomidine;Antithrombins;Extracorporeal Membrane Oxygenation;Extracorporeal Membrane Oxygenation;Critical Care;Respiration, Artificial;Postoperative Hemorrhage;Quality Improvement;Renal Insufficiency;Renal Replacement Therapy",C14;E04.100;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;E04.928;C12.777.419.780.050;C13.351.968.419.780.050;C08.381.840;C08.618.840;C14.280.067.198;C23.550.073.198;E02.331.350;E02.760.190;N02.421.585.190;V02.300;C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350;D03.383.129.308.245;D27.505.519.389.745.800.449;D27.505.954.502.119.500;E02.880.301;E04.292.451;E02.880.301;E04.292.451;E02.760.190;N02.421.585.190;E02.041.625;E02.365.647.729;E02.880.820;C23.550.414.941;C23.550.767.850;J01.293.754;N04.761.744;C12.777.419.780;C13.351.968.419.780;E02.870
28325630,"Adult;Aged;Aged, 80 and over;Attitude of Health Personnel;Evidence-Based Practice;Health Knowledge, Attitudes, Practice;Humans;Middle Aged;Panic Disorder;Truth Disclosure;Attitude;Evidence-Based Practice;Implosive Therapy",M01.060.116;M01.060.116.100;M01.060.116.100.080;F01.100.050;N05.300.100;H02.249;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F03.080.700;F01.829.401.046.800;I01.880.604.583.080.134.800;F01.100;H02.249;F04.754.137.506.325
28325488,"Abdominal Neoplasms;Adrenal Gland Neoplasms;Algorithms;Data Mining;Humans;Kidney Neoplasms;Liver Neoplasms;Magnetic Resonance Imaging;Pancreatic Neoplasms;Radiology Information Systems;Software;Tomography, X-Ray Computed",C04.588.033;C04.588.322.078;C19.053.347;C19.344.078;G17.035;L01.224.050;L01.313.500.750.280.199;L01.470.625;B01.050.150.900.649.313.988.400.112.400.400;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C04.588.274.623;C06.301.623;C06.552.697;E01.370.350.825.500;C04.588.274.761;C04.588.322.475;C06.301.761;C06.689.667;C19.344.421;N04.452.515.825;L01.224.900;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28325398,Adult;Aged;Antimalarials;Dermatologic Agents;Diabetes Complications;Dyslipidemias;Glucose Intolerance;Granuloma Annulare;Humans;Hydroxychloroquine;Middle Aged;Retrospective Studies;Thyroid Diseases,M01.060.116;M01.060.116.100;D27.505.954.122.250.100.085;D27.505.954.444;C19.246.099;C18.452.584.500;C18.452.394.952.500;C17.300.200.495.380;C17.800.550.380;C23.550.382.375;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.810.050.180.350;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C19.874
28325392,"Administration, Oral;Adolescent;Alopecia;Child;Dermatologic Agents;Humans;Janus Kinase 1;Piperidines;Pyrimidines;Pyrroles;Treatment Outcome;Young Adult",E02.319.267.100;M01.060.057;C17.800.329.937.122;C23.300.035;M01.060.406;D27.505.954.444;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.725.124.100;D12.776.476.393.100;D03.383.621;D03.383.742;D03.383.129.578;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28325246,Africa;Health Services Accessibility;Health Services Needs and Demand;Humans;Neoplasms;Quality of Health Care;Radiation Oncology,Z01.058;N04.590.374.350;N05.300.430;N03.349.380.420;N05.300.450;B01.050.150.900.649.313.988.400.112.400.400;C04;N04.761;N05.715;H02.403.429.515.500;H02.403.740.650
28325118,Asthma;Cognitive Dysfunction;Humans;Asthma;Brain;Meta-Analysis;Neuropsychology,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;F03.615.250.700;B01.050.150.900.649.313.988.400.112.400.400;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;A08.186.211;V03.600;F04.096.795.600;H01.158.782.795.110
28324682,"Down-Regulation;Epilepsy, Absence;Gene Expression;Gene Expression Profiling;Genome-Wide Association Study;Humans;Epilepsy, Absence;Gene Expression",G02.111.240;G05.308.200;G07.690.773.937;C10.228.140.490.375.260;C10.228.140.490.493.125;G05.297;E05.393.332;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.490.375.260;C10.228.140.490.493.125;G05.297
28324661,"Biomarkers;Chemokine CCL3;Child;Child, Preschool;Cohort Studies;Granzymes;HSP70 Heat-Shock Proteins;Humans;Infant;Interleukin-8;Matrix Metalloproteinase 8;RNA, Messenger;ROC Curve;Reproducibility of Results;Risk Assessment;Shock, Septic;Biomarkers;Mortality;Sepsis",D23.101;D12.644.276.374.200.110.150;D12.644.276.374.200.600.150;D12.776.467.374.200.110.150;D12.776.467.374.200.600.150;D23.125.300.110.150;D23.125.300.600.500;D23.469.200.110.150;D23.469.200.600.150;D23.529.374.200.110.150;D23.529.374.200.600.150;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.277.656.300.760.397;D08.811.277.656.959.350.397;D12.776.580.216.375;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312;D08.811.277.656.300.480.205.358;D08.811.277.656.300.480.525.700.300;D08.811.277.656.675.374.205.358;D08.811.277.656.675.374.525.700.300;D12.644.276.848.300;D12.776.467.836.300;D13.444.735.544;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;D23.101;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C01.539.757;C23.550.470.790.500
28324030,"Adult;Chromatography, Liquid;Cryptorchidism;Disorders of Sex Development;Estradiol;Estrone;Humans;Hypospadias;Infant, Newborn;Linear Models;Phthalic Acids;Pregnancy;Pregnancy Trimester, First;Prenatal Exposure Delayed Effects;Tandem Mass Spectrometry;Testicular Hydrocele;Testosterone;United States;Urogenital Abnormalities;Young Adult",M01.060.116;E05.196.181.400;C12.294.829.258;C12.706.258;C16.131.939.258;C19.391.829.258;C12.706.316;C13.351.875.253;C16.131.939.316;C19.391.119;D04.210.500.365.415.248;D06.472.334.851.437.500;D04.210.500.365.415.414;D04.210.500.578.502.497;D06.472.040.502.497;D06.472.334.851.437.996;B01.050.150.900.649.313.988.400.112.400.400;C12.294.494.400;C12.706.516;C13.351.875.466;C16.131.939.516;M01.060.703.520;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;D02.241.223.805;G08.686.784.769;G08.686.707.408;C13.703.824.500;E05.196.566.880;C12.294.882;D04.210.500.054.079.429.824;D06.472.334.851.968.984;Z01.107.567.875;C12.706;C13.351.875;C16.131.939;M01.060.116.815
28324029,"Biomedical Research;Community Participation;Delivery of Health Care;Evidence-Based Medicine;Health Care Costs;Health Facilities;Health Personnel;Health Priorities;Healthcare Disparities;Humans;National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division;Power (Psychology);Reimbursement, Incentive;United States",H01.770.644.145;N02.421.143.212;N03.540.245.360;N04.590.374;N05.300;H02.249.750;H02.403.200.400;N03.219.151.400;N05.300.375;N02.278;M01.526.485;N02.360;N03.349.330;N05.300.400;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;N03.540.052.500.500;F01.658.780;N03.219.521.710.305.380;Z01.107.567.875
28324001,"Adolescent;Calcitriol;Calcium;Child;Cytochrome P-450 CYP3A Inducers;Humans;Hypercalcemia;Hypercalciuria;Infant, Newborn, Diseases;Metabolism, Inborn Errors;Mutation;Nephrocalcinosis;Parathyroid Hormone;Phosphorus;Rifampin;Treatment Outcome;Vitamin D;Vitamin D3 24-Hydroxylase",M01.060.057;D04.210.500.247.222.159.478.387.300;D04.210.500.247.808.146.478.387.300;D04.210.500.812.768.196.478.387.300;D10.570.938.146.478.387.300;D01.268.552.100;D01.552.539.288;D23.119.100;M01.060.406;D27.505.389.249.700;D27.505.519.349.700;B01.050.150.900.649.313.988.400.112.400.400;C18.452.174.451;C18.452.950.340;C23.888.942.337;C16.614;C16.320.565;C18.452.648;G05.365.590;C12.777.419.590;C13.351.968.419.590;C18.452.174.130.560;D06.472.699.590;D12.644.548.587;D01.268.666;D03.633.400.811.700;D04.345.295.750.700;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D04.210.500.812.768;D08.244.453.496.500;D08.811.682.690.708.170.469.500;D12.776.422.220.453.496.500
28323992,"Adenocarcinoma, Follicular;Adolescent;Adult;Carcinoma;Carcinoma, Papillary;Case-Control Studies;Cohort Studies;DEAD-box RNA Helicases;Family;Germ-Line Mutation;Goiter, Nodular;Humans;Incidence;Neoplastic Syndromes, Hereditary;Prevalence;Ribonuclease III;Risk;Sequence Analysis, DNA;Thyroid Cancer, Papillary;Thyroid Neoplasms;Thyroidectomy;Ultrasonography;Young Adult",C04.557.470.200.025.060;M01.060.057;M01.060.116;C04.557.470.200;C04.557.470.200.360;C04.557.470.700.360;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.913.696.445.735.720.249;F01.829.263;I01.880.853.150;G05.365.590.350;C19.874.283.501;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C04.700;C16.320.700;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;D08.811.277.352.700.350.707;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.393.760.700;C04.557.470.200.025.085.612;C04.588.322.894.400;C04.588.443.915.400;C19.344.894.400;C19.874.788.400;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;E04.270.856;E01.370.350.850;M01.060.116.815
28323942,"Animals;Cell Count;Cell Proliferation;Diabetes Mellitus, Type 2;Diet, Fat-Restricted;Diet, High-Fat;Exenatide;Hypoglycemic Agents;Incretins;Insulin-Secreting Cells;Mice;Mice, Inbred C57BL;Pancreas;Peptides;Sitagliptin Phosphate;Venoms",B01.050;E01.370.225.500.195;E05.200.500.195;E05.242.195;G04.140;G04.161.750;G07.345.249.410.750;C18.452.394.750.149;C19.246.300;E02.642.249.260;G07.203.650.240.260;G07.203.650.240.267;D12.644.187;D20.888.300;D23.946.833.300;D27.505.696.422;D27.505.696.399.472.580;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A03.734;D12.644;D03.383.129.799.725;D03.383.679.875;A12.200.935;D20.888;D23.946.833
28323930,"Adolescent;Adult;Aged;Case-Control Studies;Cell Transdifferentiation;Child;Child, Preschool;Diabetes Mellitus, Type 1;Glucagon;Glucagon-Secreting Cells;Humans;In Situ Nick-End Labeling;Infant;Infant, Newborn;Insulin;Insulin-Secreting Cells;Islets of Langerhans;Ki-67 Antigen;Middle Aged;Pancreas;Regeneration;Time Factors;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;G04.356;M01.060.406;M01.060.406.448;C18.452.394.750.124;C19.246.267;C20.111.327;D06.472.699.587.730.500;D12.644.548.586.730.500;A03.734.414.065;A06.300.414.043;A06.390.087;A11.382.625.064;A11.436.294.064;B01.050.150.900.649.313.988.400.112.400.400;E05.393.475;M01.060.703;M01.060.703.520;D06.472.699.587.200.500.625;D12.644.548.586.200.500.625;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;A03.734.414;A06.300.414;D12.776.660.625.500;D23.050.290.500;D23.101.140.400;M01.060.116.630;A03.734;G16.762;G01.910.857;M01.060.116.815
28323927,"Heterozygote;Humans;Hypoparathyroidism;Middle Aged;Mutation;Pedigree;Polyendocrinopathies, Autoimmune;Primary Ovarian Insufficiency;Sequence Analysis, DNA;Siblings;Transcription Factors",G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;C19.642.482;M01.060.116.630;G05.365.590;E05.393.673;C19.787;C20.111.750;C13.351.500.056.630.750;C19.391.630.750;E05.393.760.700;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;D12.776.930
28323645,"Adolescent;Child;Diagnosis, Differential;Humans;Multiple Sclerosis;Prognosis;Risk Factors",M01.060.057;M01.060.406;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E01.789;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28322851,"Complement C3 Nephritic Factor;Glomerulonephritis, Membranoproliferative",D12.776.124.486.274.920.287;D12.776.124.486.485.114.323.300;D12.776.124.790.651.114.323.300;D12.776.377.715.548.114.323.300;C12.777.419.570.363.615;C13.351.968.419.570.363.615;C20.425
28322587,"Clinical Laboratory Services;Genetic Diseases, Inborn;Genetic Testing;Germ-Line Mutation;High-Throughput Nucleotide Sequencing;Humans;Sequence Analysis, DNA",N02.421.726.233.110;C16.320;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590.350;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E05.393.760.700
28322235,Brain;Child;Child Abuse;Cross-Over Studies;Double-Blind Method;Executive Function;Humans;Magnetic Resonance Imaging;Menopause;Middle Aged;Neuropsychological Tests;Tryptophan,A08.186.211;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;G08.686.157.500;G08.686.841.249.500;M01.060.116.630;F04.711.513;D12.125.072.050.850;D12.125.142.875
28321971,"Blood Transfusion;Humans;Infant;Infant, Newborn;Infant, Premature;Intraoperative Period;Perioperative Period;Postoperative Period;Retrospective Studies;Risk Factors;Sacrococcygeal Region;Spinal Neoplasms;Survival Analysis;Teratoma;Hydrops Fetalis",E02.095.135;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;E04.614.374;N02.421.585.753.374;E04.614;N02.421.585.753;E04.614.750;N02.421.585.753.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;A01.923.176.780;C04.588.149.828;C05.116.231.828;C05.116.900.801;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;C04.557.465.910;C13.703.277.060.480;C15.378.295.480;C15.378.420.826.100.350;C16.300.060.480;C16.320.365.826.100.350;C20.306.480;C23.888.277.395
28321543,"Adult;Aged;Aged, 80 and over;Drainage;Humans;Lung Abscess;Microbiota;Middle Aged;Pneumothorax;Retrospective Studies;Treatment Outcome;Young Adult;Drainage;Microbiology;Lung Abscess",M01.060.116;M01.060.116.100;M01.060.116.100.080;E02.309;E04.237;B01.050.150.900.649.313.988.400.112.400.400;C01.539.830.025.490;C08.381.450;C08.730.407;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;M01.060.116.630;C08.528.778;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;E02.309;E04.237;H01.158.273.540;C01.539.830.025.490;C08.381.450;C08.730.407
28320767,"Aged;Aged, 80 and over;Alemtuzumab;Animals;Antibodies;Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Antilymphocyte Serum;Basiliximab;Cohort Studies;Humans;Immunosuppressive Agents;Kidney Transplantation;Middle Aged;Rabbits;Recombinant Fusion Proteins;Retrospective Studies;Treatment Outcome;Neoplasms;Immunosuppression;Survival",M01.060.116.100;M01.060.116.100.080;D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375;B01.050;D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;A12.207.152.846.500.203;D12.776.124.486.485.114.573.203;D12.776.124.790.651.114.573.203;D12.776.377.715.548.114.573.203;D20.215.401.203;D12.776.124.486.485.114.224.060.344;D12.776.124.790.651.114.224.060.407;D12.776.377.715.548.114.224.200.407;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;B01.050.150.900.649.313.968.700;D12.776.828.300;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04;E02.095.465.425.450;E05.478.610;I03.784
28320631,Adolescent;Adult;Survival;Transplantation,M01.060.057;M01.060.116;I03.784;E04.936
28320512,Thoracic Surgery;Neurodevelopmental Disorders;Triplets;Twins,H02.403.810.803;F03.625;M01.438.768;M01.438.873
28320241,Adult;Attitude to Health;Cervical Length Measurement;Cervix Uteri;Cohort Studies;Ethnic Groups;Gestational Age;Humans;Mass Screening;Parity;Pregnancy;Premature Birth;Prospective Studies,M01.060.116;F01.100.150;N05.300.150;E01.370.350.850.865.249;E01.370.378.630.865.249;A05.360.319.679.256;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.754;N01.224.317;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;G08.686.677;G08.686.784.769.472;N06.850.490.812.600;G08.686.784.769;C13.703.420.491.500;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650
28320170,Adolescent;Asthma;Case-Control Studies;Cohort Studies;Disease Susceptibility;Humans;Hypersensitivity;Multiple Sclerosis;Risk Factors;Hypersensitivity;Multiple Sclerosis,M01.060.057;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;C20.543;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C20.543;C10.114.375.500;C10.314.350.500;C20.111.258.250.500
29766086,Wounds and Injuries,C26
28319942,"Adult;Cephalometry;Extracorporeal Membrane Oxygenation;Gestational Age;Hernias, Diaphragmatic, Congenital;Humans;Infant, Newborn;Liver;Lung;Lung Volume Measurements;Magnetic Resonance Imaging;Middle Aged;Philadelphia;Predictive Value of Tests;Retrospective Studies;Risk Factors;Treatment Outcome;Ultrasonography, Prenatal;Young Adult;Hernias, Diaphragmatic, Congenital",M01.060.116;E01.370.600.024.250;E05.041.250;N06.850.505.200.100.300;E02.880.301;E04.292.451;G07.345.500.325.235.968;G08.686.320;C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;A03.620;A04.411;E01.370.386.700.485;E01.370.350.825.500;M01.060.116.630;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.350.850.865;E01.370.378.630.865;M01.060.116.815;C16.131.433;C23.300.707.500.116
28319805,"Adult;Aged;Cross-Sectional Studies;Depressive Disorder, Major;Diabetes Mellitus;Humans;Middle Aged;Nutrition Surveys;United States;Young Adult;Adult;Nutrition Surveys",M01.060.116;M01.060.116.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F03.600.300.375;C18.452.394.750;C19.246;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469;Z01.107.567.875;M01.060.116.815;M01.060.116;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469
28319426,"Adult;Age Factors;Arthroplasty, Replacement, Shoulder;Humans;Middle Aged;Osteoarthritis;Patient Satisfaction;Retrospective Studies;Return to Sport;Shoulder Joint;Surveys and Questionnaires;Treatment Outcome;Young Adult;Sports",M01.060.116;N05.715.350.075;N06.850.490.250;E04.555.110.110.299;E04.650.110.299;E04.680.101.110.299;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C05.550.114.606;C05.799.613;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I03.450.642.845.605;A02.835.583.748;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;I03.450.642.845
28319245,"Adult;Age Factors;Appointments and Schedules;Health Transition;Humans;Medicaid;Medicine;Middle Aged;Office Visits;Patient Protection and Affordable Care Act;Physicians;Physicians, Primary Care;Retirement;Schools, Medical;Time Factors;United States;Waiting Lists",M01.060.116;N05.715.350.075;N06.850.490.250;N04.452.095;I01.240.600.400;N01.224.625.400;N06.850.505.400.700.400;N06.850.650;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.346.506.564.655;N03.706.615.693;H02.403;M01.060.116.630;N04.452.758.635;N03.219.521.576.343.918;N03.706.615.806;M01.526.485.810;N02.360.810;M01.526.485.810.800;N02.360.810.795;I03.702;I02.783.495.552;N02.278.020.578;G01.910.857;Z01.107.567.875;N04.452.095.738
28319025,"Child, Preschool;Cohort Studies;Follow-Up Studies;Humans;Laparoscopy;Length of Stay;Morbidity;Operative Time;Postoperative Complications;Recovery of Function;Registries;Replantation;Retrospective Studies;Risk Assessment;Robotic Surgical Procedures;Treatment Outcome;Ureter;Vesico-Ureteral Reflux;Vesico-Ureteral Reflux",M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;E02.760.400.480;N02.421.585.400.480;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;E04.614.374.500;N02.421.585.753.374.500;C23.550.767;G16.757;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E04.936.494;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;A05.810.776;C12.777.829.920;C13.351.968.829.920;C12.777.829.920;C13.351.968.829.920
28318992,Certification;Computer-Assisted Instruction;Feedback;Humans;Internship and Residency;Radiology;United States,N03.706.110.120;N05.700.200.190;I02.903.771.500.208;L01.906.394.211;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.740;Z01.107.567.875
28318911,Adolescent;Cannabis;Comorbidity;Humans;Marijuana Smoking;Philadelphia;Prospective Studies;Psychotic Disorders;Cannabis;Cannabis;Psychotic Disorders;Schizophrenia,M01.060.057;B01.650.940.800.575.912.250.859.937.055.500;N05.715.350.225;N06.850.490.687;B01.050.150.900.649.313.988.400.112.400.400;F01.145.610.875;F01.145.805.250.500;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F03.700.675;B01.650.940.800.575.912.250.859.937.055.500;B01.650.940.800.575.912.250.859.937.055.500;F03.700.675;F03.700.750
28318799,"Alternative Splicing;Biomarkers;Cells, Cultured;Cluster Analysis;Gene Expression Profiling;Gene Expression Regulation;High-Throughput Nucleotide Sequencing;Humans;Immunophenotyping;Interleukin-10;Macrophage Activation;Macrophages;Phenotype;Transcriptome;Wound Healing;Gene Expression;Interleukin-10;Macrophages;Phenotype;Wound Healing",G02.111.760.700.100;G03.839.700.100;G05.308.700.700.100;D23.101;A11.251;E05.318.740.250;N05.715.360.750.200;N06.850.520.830.250;E05.393.332;G05.308;E05.393.760.319;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510;G12.287.500;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;G05.695;G02.111.873.750;G05.297.700.750;G05.360.920;G16.762.891;G05.297;D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;G05.695;G16.762.891
28318530,"Gestational Age;Humans;Infant;Infant, Extremely Premature;Infant, Newborn;Oxygen;Pulmonary Surfactants;Surface-Active Agents;Mortality",G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520.520.500;M01.060.703.520;D01.268.185.550;D01.362.670;D27.505.954.796.600;D27.720.877;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
28318341,,
28318322,"Aged;Arrhythmias, Cardiac;Cardiac Pacing, Artificial;Cardiomyopathy, Dilated;Electrocardiography;Heart Conduction System;Heart Transplantation;Humans;Pacemaker, Artificial",M01.060.116.100;C14.280.067;C23.550.073;E02.331.200;C14.280.195.160;C14.280.238.070;E01.370.370.380.240;E01.370.405.240;A07.541.409;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;E07.305.250.750
28317027,Kingella kingae;Polymerase Chain Reaction,B03.440.400.425.550.400.375;B03.660.075.525.410.410;E05.393.620.500
28316772,"Autism Spectrum Disorder;Brain;Brain Mapping;Child, Preschool;Diffusion Tensor Imaging;Humans;Infant;Longitudinal Studies;Stereotyped Behavior;Autistic Disorder;Diffusion Tensor Imaging;Infant;White Matter",F03.625.164.113;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;M01.060.406.448;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F01.145.896;F03.625.164.113.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;M01.060.703;A08.186.211.204;A08.186.854.880
28316277,Anticoagulants;Humans;Morpholines;Rivaroxaban;Thiophenes;Veins;Venous Thromboembolism,D27.505.954.502.119;B01.050.150.900.649.313.988.400.112.400.400;D03.383.533.640;D02.886.778.727;D03.383.533.640.713;D03.383.903.727;D02.886.778;D03.383.903;A07.015.908;C14.907.355.590.700
28316126,"Adult;Aged;Follow-Up Studies;Humans;Kidney Failure, Chronic;Kidney Transplantation;Middle Aged;Prognosis;Prospective Studies;Renal Dialysis;Sex Factors;Social Networking;Social Support;Surveys and Questionnaires;Young Adult;Dialysis;Gender Identity;Kidney Transplantation;Models, Theoretical;Social Sciences;Surveys and Questionnaires",M01.060.116;M01.060.116.100;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E02.870.300;E02.912.800;N05.715.350.675;N06.850.490.875;L01.143.910;I01.880.853.500.600;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.116.815;E05.196.353;G02.186;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;E02.870.500;E04.936.450.485;E04.950.774.400;E05.599;F04.096.879;I01;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28315846,Adult;Aged;Amyloid beta-Peptides;Cohort Studies;Delusions;Dementia;Disease Progression;Follow-Up Studies;Hallucinations;Humans;Middle Aged;Parkinson Disease;Peptide Fragments;Psychotic Disorders;Risk Factors,M01.060.116;M01.060.116.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.126.200;C10.228.140.380;F03.615.400;C23.550.291.656;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C10.597.606.762.300;C23.888.592.604.764.300;F01.700.750.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D12.644.541;F03.700.675;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28315780,"Adult;Consumer Behavior;Dietary Sugars;Food Labeling;Health Knowledge, Attitudes, Practice;Humans;Intention;Internet;Nutrition Policy;United States;Obesity",M01.060.116;F01.145.236;D09.301.831;D09.947.500;G07.203.300.362.831;J02.500.362.831;J01.576.423.850.600.400;J01.576.761.400.450;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;F01.658.650;F02.463.306;L01.224.230.110.500;I01.655.500.608.400.650;I01.880.604.825.608.400.650;N03.623.500.608.428.650;Z01.107.567.875;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28315560,"Adult;Cell- and Tissue-Based Therapy;Chimera;Drug-Related Side Effects and Adverse Reactions;Education, Nursing, Continuing;Humans;Immunotherapy;Inpatients;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;T-Lymphocytes;Treatment Outcome;Young Adult;Immunotherapy, Adoptive;Immunotherapy",M01.060.116;E02.095.147;B05.200;C25.100;I02.358.212.450;I02.358.462.399;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;M01.643.470;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.705.816.824;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;E02.095.465.425
28315554,"Adult;Aged;Aged, 80 and over;Biomedical Research;Curriculum;Education, Nursing;Education, Nursing, Continuing;Humans;Immunotherapy;Middle Aged;Neoplasms;Immunotherapy;Nursing Research;Precision Medicine",M01.060.116;M01.060.116.100;M01.060.116.100.080;H01.770.644.145;I02.158;I02.358.462;I02.358.212.450;I02.358.462.399;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;M01.060.116.630;C04;E02.095.465.425;H01.770.644.145.390;H02.478.395;N04.590.233.508.613;E02.574;H02.403.200.700
28315553,"Adolescent;Cell- and Tissue-Based Therapy;Child;Chimera;Education, Nursing, Continuing;Humans;Immunotherapy;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Receptors, Antigen, T-Cell;Recurrence;T-Lymphocytes;Immunotherapy, Adoptive;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Immunotherapy",M01.060.057;E02.095.147;M01.060.406;B05.200;I02.358.212.450;I02.358.462.399;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D12.776.543.750.705.816.824;C23.550.291.937;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;E02.095.465.425
28315552,"Adult;Aged;Aged, 80 and over;Antibodies, Monoclonal;Education, Nursing, Continuing;Evidence-Based Nursing;Humans;Immunotherapy;Melanoma;Middle Aged;Patient-Centered Care;Practice Guidelines as Topic;Immunotherapy;Antibodies, Monoclonal",M01.060.116;M01.060.116.100;M01.060.116.100.080;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;I02.358.212.450;I02.358.462.399;H02.249.875;H02.478.197;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;N04.590.233.727.407;N04.761.700.350.650;N05.700.350.650;E02.095.465.425;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
28315551,"Antineoplastic Agents;Clinical Competence;Education, Nursing, Continuing;Humans;Immunotherapy;Neoplasms;Nursing Staff, Hospital;Oncology Nursing;Practice Guidelines as Topic;Safety Management;Societies, Nursing;Drug Therapy",D27.505.954.248;I02.399.630.210;N04.761.210;N05.715.175;I02.358.212.450;I02.358.462.399;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425;C04;M01.526.485.680.490;M01.526.485.740.523;N02.360.680.490;N02.360.740.523;H02.478.676.605;N02.421.533.600;N04.761.700.350.650;N05.700.350.650;N04.452.871.900;N06.850.135.060.075.800;N03.540.828.672;E02.319
28315481,"Adult;Aged;Asthma;Chronic Disease;Communication;Comorbidity;Continuity of Patient Care;Emergency Service, Hospital;Forced Expiratory Volume;Humans;Middle Aged;Patient Navigation;Poverty;Quality of Life;Research Design;Self Care;Severity of Illness Index;Urban Population;Asthma;Health Literacy",M01.060.116;M01.060.116.100;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;C23.550.291.500;F01.145.209;L01.143;N05.715.350.225;N06.850.490.687;E02.760.169;N02.421.585.169;N04.590.233.727.210;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E01.370.386.700.660.230;G09.772.650.430;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.590.233.727.407.500;I01.880.735.634;I01.880.853.996.535;N01.824.600;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.581.500;H01.770.644.728;E02.900;I03.050.563;N02.421.784.680;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N01.600.900;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500
28315415,"Child;Clinical Competence;Communication;Education, Medical, Continuing;Humans;Life Change Events;Pediatrics;Physician-Patient Relations;Practice Guidelines as Topic;Resilience, Psychological;Practice Guidelines as Topic;Communication;Education;Patients",M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;F01.145.209;L01.143;I02.358.212.350;I02.358.399.250;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;H02.403.670;F01.829.401.650.675;N05.300.660.625;N04.761.700.350.650;N05.700.350.650;F02.940;N04.761.700.350.650;N05.700.350.650;F01.145.209;L01.143;I02;M01.643
28315025,"Age Factors;Canada;Disclosure;Education, Medical, Graduate;Emergency Medicine;Emergency Service, Hospital;Humans;Internship and Residency;Leadership;Physician-Patient Relations;Radiation Exposure;Risk Assessment;Surveys and Questionnaires;Tomography, X-Ray Computed;United States;Disclosure;Emergency Service, Hospital",N05.715.350.075;N06.850.490.250;Z01.107.567.176;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;I02.358.337.350;I02.358.399.350;H02.403.250;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;F01.752.609;F01.829.401.650.675;N05.300.660.625;G01.750.748;N06.850.460.350.850;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;Z01.107.567.875;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336
28314702,"Bladder Exstrophy;Child, Preschool;Humans;Infant;Infant, Newborn;Postoperative Complications;Reconstructive Surgical Procedures;Sex Factors;Time Factors;Treatment Outcome;Urologic Surgical Procedures;Bladder Exstrophy;Pediatrics;Reconstructive Surgical Procedures",C12.706.132;C12.777.829.132;C13.351.875.132;C13.351.968.829.132;C16.131.939.132;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C23.550.767;E04.680;N05.715.350.675;N06.850.490.875;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E04.950.774;C12.706.132;C12.777.829.132;C13.351.875.132;C13.351.968.829.132;C16.131.939.132;H02.403.670;E04.680
28314701,"Adolescent;Age Factors;Child;Cohort Studies;Comorbidity;Disease Management;Female Urogenital Diseases;Follow-Up Studies;Humans;Incidence;Male Urogenital Diseases;Petrolatum;Retrospective Studies;Risk Assessment;Severity of Illness Index;Sex Factors;Statistics, Nonparametric;Stevens-Johnson Syndrome;Tertiary Care Centers;Treatment Outcome;Pediatrics;Stevens-Johnson Syndrome;Stevens-Johnson Syndrome;Urinary Catheters",M01.060.057;N05.715.350.075;N06.850.490.250;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;N04.590.607;C13.351;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C12;D02.455.699;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;N05.715.350.675;N06.850.490.875;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;C07.465.864.500;C17.800.174.600.900;C17.800.229.400.683;C17.800.865.475.683;C20.543.206.380.900;C25.100.468.380.900;N02.278.421.830;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;H02.403.670;C07.465.864.500;C17.800.174.600.900;C17.800.229.400.683;C17.800.865.475.683;C20.543.206.380.900;C25.100.468.380.900;C07.465.864.500;C17.800.174.600.900;C17.800.229.400.683;C17.800.865.475.683;C20.543.206.380.900;C25.100.468.380.900;E07.132.625
28314504,Adult;Cause of Death;Follow-Up Studies;Graft Survival;Heart Failure;Heart Transplantation;Humans;Retrospective Studies;Stroke Volume;Survival Rate;Time Factors;Tissue Donors;Tissue and Organ Procurement;United States;Ventricular Function;Young Adult;Heart Transplantation;Tissue and Organ Procurement,M01.060.116;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;G12.875.545.340;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.370.380.150.700;G09.330.380.124.882;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;G01.910.857;M01.898;N02.421.911;Z01.107.567.875;G09.330.955;M01.060.116.815;E04.100.376.475;E04.928.220.390;E04.936.450.475;N02.421.911
28314489,"Cooperative Behavior;Education, Medical, Graduate;Global Health;Humans;International Cooperation;International Educational Exchange;Internship and Residency",F01.145.813.115;I02.358.337.350;I02.358.399.350;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;I01.615.500.650;I02.581;I02.358.337.350.500;I02.358.399.350.750
28314451,Adolescent;Adult;Family;Human Development;Humans;Mental Disorders;Young Adult;Family Therapy;Mental Health;Young Adult,M01.060.057;M01.060.116;F01.829.263;I01.880.853.150;F01.525;G07.345.374;B01.050.150.900.649.313.988.400.112.400.400;F03;M01.060.116.815;F04.754.864.581.273;F02.418;N01.400.500;M01.060.116.815
28306647,,
28306396,"Bioethical Issues;Databases, Genetic;Genetic Privacy;Genetic Testing;Humans;Ethics",K01.752.566.479.023;N05.350.100;L01.313.500.750.300.188.400.325;L01.470.750.750.325;I01.880.604.473.352.500.320;I01.880.604.473.650.500.320;I01.880.604.583.080.320;N03.706.437.352.500.320;N03.706.437.650.124.320;N03.706.535.230.320;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;B01.050.150.900.649.313.988.400.112.400.400;K01.752.566.479;N05.350
28304294,"Aged;Aged, 80 and over;Analysis of Variance;Cognition Disorders;Cohort Studies;Humans;International Cooperation;Lewy Body Disease;Mental Status Schedule;Middle Aged;Multicenter Study",M01.060.116.100;M01.060.116.100.080;E05.318.740.150;N05.715.360.750.125;N06.850.520.830.150;F03.615.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;C10.228.140.079.862.400;C10.228.140.380.422;C10.228.662.600.200;C10.574.531;F03.615.400.512;F04.711.513.603.500;F04.711.513.653.574;M01.060.116.630;V03.650
28303901,"Animals;Apoptosis;Down-Regulation;Dyskeratosis Congenita;Feedback, Physiological;Gene Expression;Intestinal Mucosa;Mice;Mice, Knockout;Paneth Cells;RNA;Stem Cell Niche;Stem Cells;Telomerase;Telomere;Telomere Shortening;Wnt Signaling Pathway",B01.050;G04.146.160;G02.111.240;G05.308.200;G07.690.773.937;C16.131.831.150;C16.320.322.108;C16.320.850.235;C17.800.804.150;C17.800.827.235;G07.410.732;G05.297;A03.556.124.369;A10.615.550.444;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A03.556.124.369.700;A10.615.550.444.700;A11.436.700;D13.444.735;G04.366.249;A11.872;D08.811.913.696.445.308.300.750.750;D12.776.157.687.613;D12.776.157.725.500.921;D12.776.660.720.613;D12.776.664.962.500.921;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G02.111.225.940;G04.043.630;G05.226.940;G02.111.820.925;G04.835.925
28303452,"Adolescent;Adult;Child;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation;Humans;Li-Fraumeni Syndrome;Parent-Child Relations;Young Adult;Child;Genetic Testing;Li-Fraumeni Syndrome;Genes, p53",M01.060.057;M01.060.116;M01.060.406;C23.550.291.687.500;G05.380.355;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;C04.700.600;C16.320.700.600;C18.452.284.520;F01.829.263.370.290;M01.060.116.815;M01.060.406;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;C04.700.600;C16.320.700.600;C18.452.284.520;G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385
28303425,Biomedical Research;Common Data Elements;Data Collection;Humans;Mitochondrial Diseases;National Institute of Neurological Disorders and Stroke (U.S.);Nervous System Diseases;Research Design;Stroke;United States,H01.770.644.145;L01.399.250.090;E05.318.308;L01.399.250;N05.715.360.300;N06.850.520.308;B01.050.150.900.649.313.988.400.112.400.400;C18.452.660;I01.409.418.750.600.650.496.461;N03.540.052.750.461;N03.540.348.500.500.600.650.496.461;C10;E05.581.500;H01.770.644.728;C10.228.140.300.775;C14.907.253.855;Z01.107.567.875
28302591,"Adolescent;Adult;Benchmarking;Child;Connectome;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Young Adult;Artifacts;Motion;Noise;Magnetic Resonance Imaging",M01.060.057;M01.060.116;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;M01.060.406;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;M01.060.116.815;E05.047;G01.482;G01.750.770.776.567;G16.500.275.600;N06.230.400;N06.850.460.610;E01.370.350.825.500
28301843,Attitude of Health Personnel;Cross-Sectional Studies;Fetoscopy;Humans;Meningomyelocele;Physicians;Pregnancy;Treatment Outcome;Meningomyelocele;Prenatal Diagnosis;Spinal Dysraphism,F01.100.050;N05.300.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.378.630.300;E01.370.388.250.280;E02.467.750;E04.502.250.280;E04.520.280;B01.050.150.900.649.313.988.400.112.400.400;C10.500.680.610;C16.131.666.680.610;M01.526.485.810;N02.360.810;G08.686.784.769;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C10.500.680.610;C16.131.666.680.610;E01.370.378.630;C10.500.680.800;C16.131.666.680.800
28301428,Adalimumab;Adolescent;Biomarkers;Body Size;Child;Child Development;Crohn Disease;Double-Blind Method;Humans;Linear Models;Logistic Models;Remission Induction;Severity of Illness Index;Time Factors;Treatment Outcome;Tumor Necrosis Factor-alpha;United States,D12.776.124.486.485.114.224.060.250;D12.776.124.790.651.114.224.060.250;D12.776.377.715.548.114.224.200.250;M01.060.057;D23.101;E01.370.600.115.100.160;E05.041.124.160;G07.100.100.160;G07.345.249.314;M01.060.406;F01.525.200;G07.345.374.750;C06.405.205.731.500;C06.405.469.432.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E02.860;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626;Z01.107.567.875
28300632,,
28300631,,
28299880,"Autism Spectrum Disorder;Child;Child, Preschool;Follow-Up Studies;Heart Defects, Congenital;Humans;Incidence;Infant;Infant, Newborn;Prospective Studies;Risk Assessment;Risk Factors;Surveys and Questionnaires;Time Factors;United States;Autistic Disorder",F03.625.164.113;M01.060.406;M01.060.406.448;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.703;M01.060.703.520;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;G01.910.857;Z01.107.567.875;F03.625.164.113.500
28299650,"Animals;Blood Cells;Cell Transdifferentiation;Core Binding Factor Alpha 2 Subunit;Embryonic Development;Embryonic Stem Cells;Endothelium, Vascular;Hemangioblasts;Hematopoiesis;Hematopoietic Stem Cells;Stem Cells;Hematopoiesis;Hematopoietic Stem Cells;Hemangioblasts",B01.050;A11.118;A15.145.229;G04.356;D12.776.930.155.200.200;G07.345.500.325.180;G08.686.784.170.104;A11.872.700.250;A07.015.700.500;A10.272.491.355;A11.436.275.365;A11.872.378.270;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;A11.872;G04.152.825;G09.188.343;A11.148.378;A11.872.378;A15.378.316.378;A11.436.275.365;A11.872.378.270
28299542,Health Education;Survivorship,I02.233.332;N02.421.726.407;F01.058.144.500
28298468,"Animals;Attention;Competitive Behavior;Feathers;Galliformes;Mating Preference, Animal;Sexual Behavior, Animal;Wings, Animal;Attention;Communication;Vision, Ocular",B01.050;F02.830.104.214;F01.145.813.105;A13.370;B01.050.150.900.248.350;F01.145.113.252.748.300;F01.145.113.252.748;A13.395.823;F02.830.104.214;F01.145.209;L01.143;F02.830.816.964;G02.111.820.480.900;G04.835.480.900;G11.561.790.964;G14.935
28298420,"Antibodies, Neutralizing;Crystallography, X-Ray;HIV-1;Humans;Mutation;Neutralization Tests;Phylogeny;Polysaccharides;Protein Binding;env Gene Products, Human Immunodeficiency Virus",D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;E05.196.309.742.225;B04.820.650.589.650.350.400;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;E01.370.225.812.735.550;E05.200.812.735.550;E05.478.594.760.550;G05.697;G16.075.605;L01.100.697;D09.698;G02.111.679;G03.808;D12.776.964.775.325.164;D12.776.964.775.562.500;D12.776.964.970.880.325.164
28298410,"Amyotrophic Lateral Sclerosis;Animals;Cell Line;Cytoplasm;Glutamic Acid;Inclusion Bodies;Kinesin;Mice;Microtubules;Mutation;NIH 3T3 Cells;Protein Transport;RNA;RNA, Messenger;RNA-Binding Protein FUS;RNA-Binding Proteins;Sarcoma;Tubulin;Tubulin Modulators;Tyrosine",C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;A11.251.210;A11.284.430.214;D12.125.067.625.349;D12.125.119.409.349;D12.125.427.300;A11.284.420;D08.811.277.040.025.193.500;D12.776.220.600.450.450;D12.776.631.560.450;B01.050.150.900.649.313.992.635.505.500;A11.284.430.214.190.750.602;G05.365.590;A11.251.210.100.550;A11.329.228.100.550;G03.143.700;D13.444.735;D13.444.735.544;D12.776.157.725.813.750.905;D12.776.624.664.700.915;D12.776.664.962.813.750.902;D12.776.157.725;D12.776.664.962;C04.557.450.795;D05.750.078.734.800;D12.776.220.600.800;D12.776.631.920;D27.505.519.593.249.500;D12.125.072.050.875
28298170,"Animals;Brain Concussion;Disease Models, Animal;Hippocampus;Swine;Hippocampus;Brain Injuries, Traumatic",B01.050;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;C22.232;E05.598.500;E05.599.395.080;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.500.880;A08.186.211.180.405;A08.186.211.200.885.287.500.345;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194
28298142,"Ankle Injuries;Ankle Joint;Bone Screws;Humans;Ligaments, Articular;Tibia;Ankle Injuries",C26.558.100;A02.835.583.378.062;E07.695.370.437;E07.858.442.660.460.437;E07.858.690.725.460.437;B01.050.150.900.649.313.988.400.112.400.400;A02.513.514;A02.835.583.512;A10.165.669.514;A02.835.232.043.650.883;C26.558.100
28297155,"Botswana;Dermatology;Humans;Infant;International Cooperation;Nevus, Pigmented;Skin Neoplasms;Telemedicine;United States",Z01.058.290.175.230;H02.403.225;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;I01.615.500;C04.557.665.560.615;C04.588.805;C17.800.882;H02.403.840;L01.178.847.652;N04.590.374.800;Z01.107.567.875
28296979,Bone Density;Bone and Bones;Feasibility Studies;Humans;Magnetic Resonance Imaging,G11.427.100;A02.835.232;A10.165.265;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500
28296976,"Cardiomyopathy, Dilated;Exome;Genetic Predisposition to Disease;Humans;Mutation, Missense;Polymorphism, Single Nucleotide",C14.280.195.160;C14.280.238.070;G05.360.340.011;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.650;G05.365.795.598
28296808,Cysts;Decision Making;End Stage Liver Disease;Follow-Up Studies;Humans;Liver Diseases;Liver Transplantation;Middle Aged;Odds Ratio;Patient Selection;Retrospective Studies;Time Factors;Tissue and Organ Procurement;Waiting Lists,C04.182;C23.300.306;F02.463.785.373;C06.552.308.500.177;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C06.552;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E05.581.500.653;N04.590.731;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G01.910.857;N02.421.911;N04.452.095.738
28296752,African Americans;Age Factors;Body Mass Index;Comorbidity;Continental Population Groups;Cross-Sectional Studies;Ethnic Groups;European Continental Ancestry Group;Health Services Accessibility;Healthcare Disparities;Hispanic Americans;Humans;Logistic Models;Middle Aged;Obesity;Residence Characteristics;Risk Factors;Safety-net Providers;Sex Factors;Socioeconomic Factors;United States,M01.686.508.100.100;M01.686.754.100;N05.715.350.075;N06.850.490.250;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;N05.715.350.225;N06.850.490.687;M01.686.508;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.686.754;N01.224.317;M01.686.508.400;N04.590.374.350;N05.300.430;N04.590.374.380;N05.300.493;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;N01.224.791;N06.850.505.400.800;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;N04.590.374.700;N05.715.350.675;N06.850.490.875;I01.880.853.996;N01.824;Z01.107.567.875
28296563,Healthcare Disparities;Humans;Organizational Innovation;Sexual and Gender Minorities;Health Promotion;Organizational Innovation,N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;N04.452.610;M01.777;I02.233.332.445;N02.421.726.407.579;N04.452.610
28296242,"Adiposity;Body Mass Index;Body Weight;Child;Child Behavior;Child, Preschool;Feeding Behavior;Humans;Mothers;Obesity;Overweight;Parent-Child Relations;Parenting;Pediatric Obesity;Surveys and Questionnaires;Observation;Parent-Child Relations;Parenting",E01.370.600.115.100.062.500;G02.111.130.134.500;G03.180.134.500;G07.100.049.134.500;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;M01.060.406;F01.145.179;M01.060.406.448;F01.145.113.547;F01.145.407;G07.203.650.353;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;F01.829.263.370.290;F01.829.263.370.310;C18.654.726.500.720;C23.888.144.699.500.750;E01.370.600.115.100.160.120.699.500.750;G07.100.100.160.120.699.500.750;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.581.249;F01.829.263.370.290;F01.829.263.370.310
28295923,"Adult;Aged;Antiviral Agents;Drug Therapy, Combination;Genotype;Hepacivirus;Hepatic Veins;Hepatitis C;Humans;Hypertension, Portal;Liver Cirrhosis;Middle Aged;Portal Pressure;RNA, Viral;Sustained Virologic Response;Time Factors;Viral Load;Fibrosis;Hypertension, Portal",M01.060.116;M01.060.116.100;D27.505.954.122.388;E02.319.310;G05.380;B04.450.380;B04.820.250.475;A07.015.908.380;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400;C06.552.494;C06.552.630;M01.060.116.630;G09.330.380.076.732.650;D13.444.735.828;E01.789.800.570;N04.761.559.590.800.665;N05.715.360.575.575.800.665;G01.910.857;E01.370.225.875.950;E05.200.875.950;G06.920.850;C23.550.355;C06.552.494
28295300,"Animals;B-Lymphocytes;Cell Proliferation;Interferon-gamma;Lymphocyte Activation;Mice;Mice, Knockout;Mice, Transgenic;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Precursor Cells, B-Lymphoid;Signal Transduction;Suppressor of Cytokine Signaling 1 Protein;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Preleukemia",B01.050;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;G04.161.750;G07.345.249.410.750;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;A11.118.637.555.567.562.800;A11.148.378.294.374;A11.872.378.294.500;G02.111.820;G04.835;D12.644.360.024.374.500;D12.776.157.057.249.500;D12.776.476.024.437.500;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;C04.834.770;C15.378.800
28295208,"Autism Spectrum Disorder;Child Development;Humans;Infant;Infant Behavior;Risk;Siblings;Signal Processing, Computer-Assisted;Social Behavior;Verbal Behavior",F03.625.164.113;F01.525.200;G07.345.374.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;F01.145.179.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;F01.829.263.500.490;I01.880.853.150.500.505;M01.781;L01.224.800;F01.145.813;F01.145.209.908
28295182,"Adolescent;Antineoplastic Combined Chemotherapy Protocols;Child;Child, Preschool;Dose-Response Relationship, Drug;Drug Administration Schedule;Humans;Induction Chemotherapy;Infant;Phosphatidylinositol 3-Kinase;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Protein Kinase Inhibitors;Recurrence;Sirolimus;Treatment Outcome;Young Adult;Recurrence",M01.060.057;E02.183.750.500;E02.319.077.500;E02.319.310.037;M01.060.406;M01.060.406.448;G07.690.773.875;G07.690.936.500;E02.319.283;B01.050.150.900.649.313.988.400.112.400.400;E02.319.499;E02.860.500;M01.060.703;D08.811.913.696.620.500.100;C04.557.337.428.600;C15.604.515.560.600;C20.683.515.528.600;D27.505.519.389.755;C23.550.291.937;D02.540.505.760;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;C23.550.291.937
28294551,Animals;Biomedical Research;Consensus;Cooperative Behavior;Drug-Related Side Effects and Adverse Reactions;Evidence-Based Medicine;Genotype;Humans;Interdisciplinary Communication;National Institutes of Health (U.S.);Pharmacogenetics;Pharmacogenomic Variants;Phenotype;Practice Guidelines as Topic;Risk Assessment;United States,B01.050;H01.770.644.145;F01.829.316.068;F02.463.785.373.433;F01.145.813.115;C25.100;H02.249.750;H02.403.200.400;G05.380;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;I01.409.418.750.600.650.496;N03.540.052.750;N03.540.348.500.500.600.650.496;H01.158.273.343.750;H01.158.703.052;H02.628.479;G05.365.795.446;G05.695;N04.761.700.350.650;N05.700.350.650;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;Z01.107.567.875
28294464,"Brain Injuries, Traumatic;Connectome;Diffusion Tensor Imaging;Executive Function;Factor Analysis, Statistical;Glasgow Coma Scale;Humans;Longitudinal Studies;Magnetic Resonance Imaging;Neural Pathways;Neuropsychological Tests;Statistics as Topic;Verbal Learning;Behavior;Cognition;Diffuse Axonal Injury;Diffusion",C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;E01.370.350.578.875.500.249;E01.370.376.537.625.500.249;E05.629.875.500.500;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;F02.463.217;E05.318.740.400;N05.715.360.750.350;N06.850.520.830.400;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.825.500;A08.612;F04.711.513;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;F02.463.425.952;F01.145;F02.463.188;C10.228.140.199.388.500;C10.900.300.087.219.500;C26.915.300.200.188.500;G01.202;G02.196
28294077,"Adolescent;Antifungal Agents;Antiviral Agents;Bone Marrow Transplantation;Child;Child, Preschool;Drug Prescriptions;Hospitals, Pediatric;Humans;Neoplasms;Organ Transplantation;Retrospective Studies;Risk Factors",M01.060.057;D27.505.954.122.136;D27.505.954.122.388;E02.095.147.725.040;E04.936.580.040;M01.060.406;M01.060.406.448;E02.319.307;N02.421.668.778.500;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;C04;E04.936.450;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28293912,"Aged;Body Mass Index;Disease-Free Survival;Humans;Lymphatic Metastasis;Middle Aged;Obesity;Proportional Hazards Models;Receptor, ErbB-2;Retrospective Studies;Treatment Outcome;Triple Negative Breast Neoplasms;Breast Neoplasms;Obesity;Overweight",M01.060.116.100;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;C04.697.650.560;C23.550.727.650.560;M01.060.116.630;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;D08.811.913.696.620.682.725.400.009.400;D12.776.543.750.630.009.400;D12.776.543.750.750.400.074.400;D12.776.624.664.700.642;D23.050.301.500.600.700;D23.050.705.552.600.550;D23.101.140.642;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.588.180.788;C17.800.090.500.788;C04.588.180;C17.800.090.500;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699
28293166,,
28292874,Child;Child Abuse;Humans;Mandatory Reporting;Physician's Role;United States,M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.583.080.134.300;I01.880.604.583.527;I01.880.604.622.249;N03.706.535.615;N03.706.657.249;F01.829.316.616.625.600;Z01.107.567.875
28292736,"Aggrecans;Animals;Extracellular Matrix;Hippocampus;Interneurons;Metalloproteases;Neuronal Plasticity;Parvalbumins;Rats, Sprague-Dawley;Seizures;Status Epilepticus;Epilepsy;Status Epilepticus",D09.698.735.200.500;D12.776.395.650.750.687.100;D12.776.503.280.437.100;D12.776.860.300.140;B01.050;A11.284.295.310;A08.186.211.180.405;A08.186.211.200.885.287.500.345;A08.675.358;A11.671.358;D08.811.277.656.675;G11.561.638;D12.776.034.700;D12.776.210.500.750;B01.050.150.900.649.313.992.635.505.700.750;C10.597.742;C23.888.592.742;C10.597.742.785;C23.888.592.742.785;C10.228.140.490;C10.597.742.785;C23.888.592.742.785
28291826,"Aged;Emphysema;Endothelial Progenitor Cells;Flow Cytometry;Humans;Immunophenotyping;Magnetic Resonance Imaging;Middle Aged;Plethysmography;Pulmonary Disease, Chronic Obstructive",M01.060.116.100;C23.550.325;A11.148.174;A11.436.275.182;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;E01.370.350.825.500;M01.060.116.630;E01.370.370.610;C08.381.495.389
28291725,Clinical Competence;General Surgery;Humans;Operating Rooms;Simulation Training;Patient Care;Professionalism;Operating Rooms;Systematic Review,I02.399.630.210;N04.761.210;N05.715.175;H02.403.810.300;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.700;I02.903.847;E02.760;N02.421.585;K01.752.566.479.171.566;N05.350.340.581;N02.278.388.700;V03.850
28291658,"Adolescent;Child;Child, Preschool;Emergency Service, Hospital;Humans;Retrospective Studies;Spermatic Cord Torsion;Time Factors;Transportation of Patients;Treatment Outcome;Spermatic Cord Torsion",M01.060.057;M01.060.406;M01.060.406.448;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C12.294.693;G01.910.857;E02.365.839;N02.421.297.879;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C12.294.693
28290990,,
28290425,,
28289224,Adolescent;Brain;Cerebral Cortex;Child;Humans;Magnetic Resonance Imaging;Neuroimaging;Young Adult,M01.060.057;A08.186.211;A08.186.211.200.885.287.500;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;M01.060.116.815
28289137,"Child, Preschool;Emergency Service, Hospital;Humans;Infant;Infant Equipment;Nurseries, Hospital;Retrospective Studies;United States;Wounds and Injuries",M01.060.406.448;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E07.490;N02.278.388.540;N02.278.617.473;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;C26
28289108,"Appointments and Schedules;Health Services Accessibility;Humans;Insurance, Health;Medicaid;Patient Protection and Affordable Care Act;Primary Health Care;Random Allocation;United States;Health Care Reform;Waiting Lists",N04.452.095;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343;N03.219.521.346.506.564.655;N03.706.615.693;N03.219.521.576.343.918;N03.706.615.806;N04.590.233.727;E05.318.370.700;E05.581.500.805;N05.715.360.325.675;N06.850.520.445.700;Z01.107.567.875;I01.655.500.608.400.285;I01.880.604.825.608.400.285;N03.349.285;N03.623.500.608.428.285;N04.590.374.285;N05.300.380;N04.452.095.738
28289084,"Amino Acid Motifs;Bacteriophages;Gene Expression Regulation, Viral;Integrases;Listeria;Protein Domains;Recombination, Genetic;Serine;Viral Proteins;Virus Integration;Listeria monocytogenes",G02.111.570.820.709.275.500;G02.111.570.820.709.600.500;B04.123;G05.308.385;D08.811.739.500;B03.353.500.500;B03.510.100.500;B03.510.460.400.410.485;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G05.728;D12.125.154.800;D12.776.964;G05.935;G06.920.877;B03.353.500.500.500;B03.510.100.500.500;B03.510.460.400.410.485.500
28289030,"Adhesins, Escherichia coli;Anti-Bacterial Agents;Antibiotic Prophylaxis;Bacterial Outer Membrane Proteins;Bacterial Proteins;Cephalosporin Resistance;Cephalosporins;Child;Child, Preschool;Escherichia coli;Escherichia coli Infections;Fimbriae Proteins;Humans;Infant;Klebsiella Infections;Klebsiella pneumoniae;Microbial Sensitivity Tests;beta-Lactam Resistance;beta-Lactamases;Drug Resistance, Microbial",D12.776.097.120.050.040;D12.776.097.275.500;D12.776.543.100.050.040;D23.050.161.050.040;D27.505.954.122.085;E02.319.162.150;E02.319.703.150;D12.776.097.120;D12.776.543.100;D12.776.097;G06.099.225.500.175;G06.225.347.500.175;G07.690.773.984.269.347.500.175;D02.065.589.099.249;D02.886.665.074;D03.633.100.300.249;M01.060.406;M01.060.406.448;B03.440.450.425.325.300;B03.660.250.150.180.100;C01.252.400.310.330;D12.776.097.120.425;D12.776.543.100.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C01.252.400.310.503;B03.440.450.425.425.600;B03.660.250.150.400.590;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;G06.099.225.500;G06.225.347.500;G07.690.773.984.269.347.500;D08.811.277.087.180;G06.225;G07.690.773.984.269
28288929,,
28288834,Body Size;Gender Identity;Healthcare Disparities;Human Body;Humans;Liver Transplantation;Retrospective Studies;Sex Distribution;Organ Size,E01.370.600.115.100.160;E05.041.124.160;G07.100.100.160;G07.345.249.314;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;N04.590.374.380;N05.300.493;I01.076.201.450.560;K01.093.378;B01.050.150.900.649.313.988.400.112.400.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.240.800;N01.224.803;N06.850.505.400.850;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690
28288244,Brain Concussion;Humans;Post-Concussion Syndrome,C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;B01.050.150.900.649.313.988.400.112.400.400;C10.900.300.350.300.500;C26.915.300.450.500.500;C26.974.382.200.500
28288241,Acute Kidney Injury;Child;Diabetic Ketoacidosis;Fluid Therapy;Hospitalization;Humans;Kidney Function Tests,C12.777.419.780.050;C13.351.968.419.780.050;M01.060.406;C18.452.076.176.652.500;C18.452.394.750.535;C19.246.099.812;E02.319.360;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.390.400
28288189,"Antibodies, Monoclonal;Antibodies, Neutralizing;Antibodies, Viral;Antigens, Viral;Genetic Variation;Hemagglutinin Glycoproteins, Influenza Virus;High-Throughput Nucleotide Sequencing;Immune Evasion;Mutation;Neutralization Tests;Orthomyxoviridae",D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;D23.050.327;G05.365;D12.776.964.970.880.345.500;E05.393.760.319;G06.462.400;G12.413;G16.527.200.700;G05.365.590;E01.370.225.812.735.550;E05.200.812.735.550;E05.478.594.760.550;B04.820.545
28288103,Computational Biology;Gene Expression Profiling;Machine Learning;Reproducibility of Results;Sensitivity and Specificity;Software;User-Computer Interface;Workflow,H01.158.273.180;L01.313.124;E05.393.332;G17.035.250.500;L01.224.050.375.530;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;L01.224.900;L01.224.900.910;L01.906.893
28287536,"Animals;Carrier Proteins;Cell Differentiation;Cells, Cultured;Mice;Models, Animal;Osteoclasts;Receptors, Notch;Signal Transduction",B01.050;D12.776.157;G04.152;A11.251;B01.050.150.900.649.313.992.635.505.500;E05.598;A11.329.372.700;A11.627.482.700;D12.776.543.750.725;D12.776.930.770;G02.111.820;G04.835
28287055,"Atrial Septum;Autopsy;Cardiac Surgical Procedures;Databases, Factual;Humans;Hypoplastic Left Heart Syndrome;Infant, Newborn;Lung;Lung Diseases;Lymphangiectasis;Pennsylvania;Retrospective Studies;Hypoplastic Left Heart Syndrome;Mortality",A07.541.459.249;E01.370.060;E05.070;I01.198.780.937.120;E04.100.376;E04.928.220;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;M01.060.703.520;A04.411;C08.381;C15.604.360;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.240.400.625;C14.280.400.625;C16.131.240.400.625;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550
28286723,"Crohn Disease;Inflammatory Bowel Diseases;Peroxidase;Colitis, Ulcerative",C06.405.205.731.500;C06.405.469.432.500;C06.405.205.731;C06.405.469.432;D08.811.682.732.700;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28286158,"Adolescent;Adult;B-Lymphocytes;Child;Child, Preschool;Cohort Studies;DEAD Box Protein 58;Humans;Immunoglobulin Class Switching;Immunologic Deficiency Syndromes;Immunologic Memory;Infant;Intellectual Disability;Mutation;Otitis;Pneumonia;Prevalence;Sinusitis;Smith-Magenis Syndrome;Young Adult;Smith-Magenis Syndrome",M01.060.057;M01.060.116;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.913.696.445.735.720.249.750;B01.050.150.900.649.313.988.400.112.400.400;G05.344.401.501.450;G12.500.274.501.450;C20.673;G12.450.050.500;M01.060.703;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;G05.365.590;C09.218.705;C08.381.677;C08.730.610;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C08.460.692.752;C08.730.749;C09.603.692.752;C10.281.900;C16.131.077.879;C16.131.260.887;C16.320.180.887;M01.060.116.815;C10.281.900;C16.131.077.879;C16.131.260.887;C16.320.180.887
28286057,"Adolescent;Arizona;Child;Child Health Services;Child, Preschool;Cross-Sectional Studies;Disabled Children;Humans;Indiana;Infant;Kansas;Kentucky;Medicaid;Missouri;New Jersey;New Mexico;Pediatrics;Primary Health Care;Quality Assurance, Health Care;Quality of Health Care;United States;Virginia;Wisconsin;Medicaid;Child;Pediatrics;Quality of Health Care",M01.060.057;Z01.107.567.875.760.100;M01.060.406;N02.421.143.130;M01.060.406.448;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.150.200;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.350.360;Z01.107.567.875.510.360;M01.060.703;Z01.107.567.875.510.390;Z01.107.567.875.075.400;Z01.107.567.875.510.400;N03.219.521.346.506.564.655;N03.706.615.693;Z01.107.567.875.510.515;Z01.107.567.875.500.525;Z01.107.567.875.760.560;H02.403.670;N04.590.233.727;N04.761.700;N05.700;N04.761;N05.715;Z01.107.567.875;Z01.107.567.875.075.837;Z01.107.567.875.750.870;Z01.107.567.875.350.900;Z01.107.567.875.510.900;N03.219.521.346.506.564.655;N03.706.615.693;M01.060.406;H02.403.670;N04.761;N05.715
28286003,"Acetylation;Binding Sites;Crystallography, X-Ray;HeLa Cells;Histone Acetyltransferases;Histones;Humans;Lysine;Mass Spectrometry;Protein Binding;Protein Domains;Protein Processing, Post-Translational;Epigenomics",G02.111.012.052;G02.607.063.052;G03.040.052;G02.111.570.120;E05.196.309.742.225;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;D08.811.913.050.134.415.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;D12.125.068.555;D12.125.095.647;D12.125.142.497;E05.196.566;G02.111.679;G03.808;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.273.180.350.074;H01.158.273.343.350.042
28285832,"Accident Prevention;Accidental Falls;Child;Child, Preschool;Hospitals, Pediatric;Humans;Incidence;Inpatients;Patient Safety;Philadelphia;Risk Assessment",N06.850.135.060;N06.850.135.122;M01.060.406;M01.060.406.448;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.643.470;N06.850.135.060.075.399;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
28285767,"African Continental Ancestry Group;Algorithms;Cell Line;Gene Expression Profiling;Gene Expression Regulation;HapMap Project;Humans;Polymorphism, Single Nucleotide;Protein Interaction Maps;Quantitative Trait Loci;Transcription, Genetic",M01.686.508.100;G17.035;L01.224.050;A11.251.210;E05.393.332;G05.308;H01.158.273.180.350.162;H01.158.273.343.249.199;H01.158.273.343.350.130;H01.158.273.343.385.750;H01.770.644.145.350.249;B01.050.150.900.649.313.988.400.112.400.400;G05.365.795.598;G03.493.750;G05.360.340.024.380.937;G02.111.873;G05.297.700
28285706,"Adolescent;Barium Sulfate;Child;Child, Preschool;Clinical Competence;Contrast Media;Enema;Hirschsprung Disease;Humans;Infant;Radiography, Abdominal;Radiology;Retrospective Studies",M01.060.057;D01.103.075;D01.875.800.800.850.075;M01.060.406;M01.060.406.448;I02.399.630.210;N04.761.210;N05.715.175;D27.505.259.500;D27.720.259;E02.319.347;C06.198.439;C06.405.469.158.701.439;C16.131.314.439;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E01.370.350.700.715;H02.403.740;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28285667,"Cardiac Surgical Procedures;Cardiology;Diffusion of Innovation;Education, Medical, Graduate;Heart Defects, Congenital;History, 19th Century;History, 20th Century;History, 21st Century;Hospitals, Pediatric;Humans;Philadelphia;Thoracic Surgery;Translational Medical Research;Thoracic Surgery;Cardiopulmonary Bypass;Heart Defects, Congenital;History",E04.100.376;E04.928.220;H02.403.429.163;L01.143.320;I02.358.337.350;I02.358.399.350;C14.240.400;C14.280.400;C16.131.240.400;K01.400.504.937;K01.400.504.968;K01.400.504.984;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.875.500.550.525;Z01.433.820;H02.403.810.803;H01.770.644.145.675;H02.403.810.803;E04.292.413;C14.240.400;C14.280.400;C16.131.240.400;K01.400
28285428,"Adult;Aged;Anemia, Iron-Deficiency;Colitis, Ulcerative;Humans;Middle Aged;Models, Biological;Predictive Value of Tests;Anemia;Colitis, Ulcerative",M01.060.116;M01.060.116.100;C15.378.071.196.300;C18.452.565.100;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.599.395;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;C15.378.071;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28285322,"Biomedical Research;Cardiopulmonary Resuscitation;Coma;Coronary Angiography;Critical Care;Humans;Hypothermia, Induced;Neuroprotective Agents;Out-of-Hospital Cardiac Arrest;Outcome Assessment (Health Care);Percutaneous Coronary Intervention;Randomized Controlled Trials as Topic;Respiration, Artificial;Time-to-Treatment;Heart Arrest;Cardiopulmonary Resuscitation",H01.770.644.145;E02.365.647.110;C10.597.606.358.800.200;C23.888.592.604.359.800.200;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;D27.505.696.706.548;D27.505.954.427.575;C14.280.383.610;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E04.100.814.529.968;E04.502.382.968;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;E02.041.625;E02.365.647.729;E02.880.820;E02.760.928;N02.421.585.928;C14.280.383;E02.365.647.110
28285079,Adolescent;Adult;Fibrinolytic Agents;Hematopoietic Stem Cell Transplantation;Hepatic Veno-Occlusive Disease;Humans;Hypotension;Multiple Organ Failure;Polydeoxyribonucleotides;Survival Rate;Transplantation Conditioning;Young Adult;Hematopoietic Stem Cell Transplantation;Hepatic Veno-Occlusive Disease,M01.060.057;M01.060.116;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;E02.095.147.500.500.500;E04.936.225.687.500;C06.552.360;C14.907.460;B01.050.150.900.649.313.988.400.112.400.400;C14.907.514;C23.550.835.525;D13.695.578.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E02.095.465.425.450.800;E05.478.610.800;M01.060.116.815;E02.095.147.500.500.500;E04.936.225.687.500;C06.552.360;C14.907.460
28284829,"Acute Disease;Adult;Antibody-Dependent Cell Cytotoxicity;Autoantibodies;Glomerulonephritis;Graft Rejection;Humans;Incidence;Isoantibodies;Kidney;Kidney Transplantation;Middle Aged;Receptor, Angiotensin, Type 1;Retrospective Studies;Vasculitis;Rejection (Psychology)",C23.550.291.125;M01.060.116;G12.287.070;D12.776.124.486.485.114.323;D12.776.124.790.651.114.323;D12.776.377.715.548.114.323;C12.777.419.570.363;C13.351.968.419.570.363;G12.875.545.328;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D12.776.124.486.485.114.664;D12.776.124.790.651.114.664;D12.776.377.715.548.114.664;A05.810.453;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;D12.776.543.750.695.047.625;D12.776.543.750.750.130.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.907.940;F01.145.813.565
28284476,"After-Hours Care;California;Humans;Infant, Newborn;Infant, Premature;Infant, Premature, Diseases;Infant, Very Low Birth Weight;Neurocognitive Disorders;Pennsylvania;Retrospective Studies;Bronchopulmonary Dysplasia;Retinopathy of Prematurity",N04.590.374.034;N05.300.049;Z01.107.567.875.580.200;Z01.107.567.875.760.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;C16.614.521;M01.060.703.520.460.600;F03.615;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C08.381.520.750.500;C16.614.521.125;C11.768.836;C16.614.521.731
28284296,"Critical Care;Humans;Inventions;Oxygen Inhalation Therapy;Respiration, Artificial;Intensive Care Units;Oxygen;Therapeutics;Ventilation",E02.760.190;N02.421.585.190;B01.050.150.900.649.313.988.400.112.400.400;J01.897.400;E02.880.690;E02.041.625;E02.365.647.729;E02.880.820;N02.278.388.493;D01.268.185.550;D01.362.670;E02;N06.230.150.520
28284294,"Critical Care;Extracorporeal Membrane Oxygenation;Humans;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Respiratory Distress Syndrome, Adult;Extracorporeal Membrane Oxygenation;Neuromuscular Blockade",E02.760.190;N02.421.585.190;E02.880.301;E04.292.451;B01.050.150.900.649.313.988.400.112.400.400;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;C08.381.840;C08.618.840;E02.880.301;E04.292.451;E03.706;E05.635
28283697,"Animals;Carcinogenesis;Cell Communication;Cell Differentiation;Humans;Immunity, Cellular;Lung Neoplasms;Mice;Neutrophils;Phenotype;Tumor Escape;Tumor Microenvironment",B01.050;C04.697.098;C23.550.727.098;G04.085;G04.152;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689;G05.695;G12.900;G04.366.500
28283656,Biomarkers;Brain;Depression;Humans;Parkinson Disease,D23.101;A08.186.211;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812
28283553,"ATP-Binding Cassette Transporters;Adaptor Proteins, Signal Transducing;Cohort Studies;Endopeptidases;Forkhead Transcription Factors;GTPase-Activating Proteins;Genome-Wide Association Study;Genotype;Humans;Infant, Extremely Premature;Infant, Newborn;Ion Channels;Microfilament Proteins;Polymorphism, Single Nucleotide;Sepsis;Genetics;Infection",D12.776.157.530.100;D12.776.395.550.020;D12.776.543.550.192;D12.776.543.585.100;D12.644.360.024;D12.776.157.057;D12.776.476.024;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.277.656.300;D12.776.260.950.249;D12.776.930.977.249;D12.644.360.325.150;D12.776.476.325.150;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520.520.500;M01.060.703.520;D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400;D05.750.078.730;D12.776.220.525;G05.365.795.598;C01.539.757;C23.550.470.790.500;H01.158.273.343;C01.539
28283409,"Advance Care Planning;Advance Directives;Anxiety;Clinical Coding;Decision Making;Delivery of Health Care;Humans;Patient Preference;Proxy;Pulmonary Medicine;Reimbursement Mechanisms;Respiratory Tract Diseases;Stress, Psychological;Terminal Care;Advance Care Planning;Clinical Coding",N04.590.233.624.124;I01.880.604.583.020;N03.706.535.020;N04.590.233.624.124.050;F01.470.132;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249;F02.463.785.373;N04.590.374;N05.300;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.625.500;F01.145.488.887.625.500;N04.452.822.700.500;N05.300.150.800.625.500;M01.380.600;H02.403.429.675;N03.219.521.710.305;C08;F01.145.126.990;F02.830.900;E02.760.905;N02.421.585.905;N04.590.233.624.124;N04.452.758.708.200.400.500;N04.452.859.564.274;N05.715.360.300.715.500.249;N06.850.520.308.940.968.249
28283349,"Aging;Animals;Dependovirus;Disease Models, Animal;Genetic Therapy;Genetic Vectors;Humans;Liver Cirrhosis;Mice;Mice, Knockout;Ornithine Carbamoyltransferase;Ornithine Carbamoyltransferase Deficiency Disease;Treatment Outcome;Genetic Therapy;Liver Cirrhosis;Ornithine Carbamoyltransferase Deficiency Disease",G07.345.124;B01.050;B04.280.580.650.170;C22.232;E05.598.500;E05.599.395.080;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;C06.552.630;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D08.811.913.555.275.600;C10.228.140.163.100.937.750;C16.320.322.828;C16.320.565.100.940.750;C16.320.565.189.937.750;C18.452.132.100.937.500;C18.452.648.100.940.500;C18.452.648.189.937.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E02.095.301;E05.393.420.301;C06.552.630;C10.228.140.163.100.937.750;C16.320.322.828;C16.320.565.100.940.750;C16.320.565.189.937.750;C18.452.132.100.937.500;C18.452.648.100.940.500;C18.452.648.189.937.500
28283109,"Humans;Immunologic Factors;Leukoencephalopathy, Progressive Multifocal;Multiple Sclerosis;Risk;Dimethyl Fumarate;Fingolimod Hydrochloride;Multiple Sclerosis;Natalizumab;Leukoencephalopathy, Progressive Multifocal;Rituximab",B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;D02.241.081.337.302.500;D02.033.100.700.350;D02.033.455.706.431;D02.092.063.700.350;C10.114.375.500;C10.314.350.500;C20.111.258.250.500;D12.776.124.486.485.114.224.060.813;D12.776.124.790.651.114.224.060.813;D12.776.377.715.548.114.224.200.813;C02.182.525.500;C02.256.721.500;C02.290.575;C02.839.550;C10.228.140.430.520.750.500;C10.228.140.695.750;C10.228.228.245.340.500;C10.228.228.399.750.500;C10.314.450;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
28282303,"African Americans;Continental Population Groups;Critical Care;Cross-Sectional Studies;Cultural Diversity;Hispanic Americans;Humans;Indians, North American;Internship and Residency;Physicians, Women;Retrospective Studies;Sex Distribution;Socioeconomic Factors",M01.686.508.100.100;M01.686.754.100;M01.686.508;E02.760.190;N02.421.585.190;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;I01.076.201.450.350;I01.880.853.100.450;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;M01.686.508.150.600;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.810.820;M01.975.790;N02.360.810.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.240.800;N01.224.803;N06.850.505.400.850;I01.880.853.996;N01.824
28282246,"Adult;African Continental Ancestry Group;Anti-HIV Agents;Antiretroviral Therapy, Highly Active;CD4 Lymphocyte Count;Canada;Cohort Studies;HIV Infections;Healthcare Disparities;Humans;Incidence;Middle Aged;Patient Acceptance of Health Care;Proportional Hazards Models;Risk;Sex Factors;Substance Abuse, Intravenous;United States;Retention (Psychology);Sex",M01.060.116;M01.686.508.100;D27.505.954.122.388.077.088;E02.319.310.075;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;Z01.107.567.176;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C02.782.815.616.400;C02.800.801.400;C20.673.480;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;F01.100.150.750.500;F01.145.488.887.500;N05.300.150.800.500;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;N05.715.350.675;N06.850.490.875;C25.775.793;F03.900.793;Z01.107.567.875;F02.463.425.540.772;G08.686.810
28281865,"Achievement;Career Mobility;Efficiency;Faculty, Medical;Humans;Leadership;Minority Groups;Pennsylvania;Physicians, Women;Schools, Medical;Self Efficacy;United States;Work-Life Balance",F01.658.059;F02.784.629.054;N01.824.245.175;N01.824.547.330;F02.784.692.351;N04.452.209;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;F01.752.609;I01.880.853.300;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;M01.526.485.810.820;M01.975.790;N02.360.810.820;I02.783.495.552;N02.278.020.578;F01.752.747.792.700;Z01.107.567.875;I01.940;I03.946.225.438;N04.452.677.650.438
28281411,"Adolescent;Adult;Biomarkers;Cardiac Output;Child;Follow-Up Studies;Fontan Procedure;Heart Defects, Congenital;Humans;Monitoring, Physiologic;Prognosis;Prospective Studies;ROC Curve;Young Adult;Biomarkers",M01.060.057;M01.060.116;D23.101;E01.370.370.380.150;G09.330.380.124;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E04.035.410.295;E04.100.376.410.295;E04.100.376.724.500;E04.100.814.868.875.295;E04.928.220.370.295;E04.928.220.560.500;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.520;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;M01.060.116.815;D23.101
28280653,Decision Support Techniques;Microvascular Decompression Surgery;Radiosurgery;Trigeminal Neuralgia,E05.245;L01.313.500.750.190;E04.188.600;E04.525.500;E02.815.530;E04.525.800.650;E05.873.500;C07.465.299.625.500.700;C10.292.319.625.700.700
28280546,,
28280170,"Anti-Inflammatory Agents, Non-Steroidal;Chronic Pain;Drug Design;Drug Evaluation, Preclinical;Humans;Induced Pluripotent Stem Cells;Neurons;Randomized Controlled Trials as Topic;Substance-Related Disorders",D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;C23.888.592.612.274;E05.290.500;H01.158.703.007.338.500;H01.181.466.338.500;E05.290.750;E05.337.550;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A08.675;A11.671;E05.318.372.250.250.365.500;N05.715.360.330.250.250.365.500;N06.850.520.450.250.250.365.500;C25.775;F03.900
28280140,Allografts;DNA;Graft Rejection;Humans;Kidney Transplantation;Middle Aged;Postoperative Complications;Cell-Free Nucleic Acids;Kidney;Rejection (Psychology);Transplants,A01.941.500;D13.444.308;G12.875.545.328;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;C23.550.767;D13.444.154;A05.810.453;F01.145.813.565;A01.941
28280123,"Animals;Anti-Inflammatory Agents;Disease Models, Animal;Drug Monitoring;Fibroblasts;Glycosides;Idiopathic Pulmonary Fibrosis;Mice;Mice, Inbred C57BL;Signal Transduction;Tissue Inhibitor of Metalloproteinase-1;Toll-Like Receptor 4",B01.050;D27.505.954.158;C22.232;E05.598.500;E05.599.395.080;E01.370.520.200;A11.329.228;D09.408;C08.381.483.487.500;C08.381.765.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G02.111.820;G04.835;D12.776.645.875.450;D12.776.543.750.705.910.500.400
28279885,"Anemia, Sickle Cell;Brain;Case-Control Studies;Child;Follow-Up Studies;Humans;Image Processing, Computer-Assisted;Intelligence;Magnetic Resonance Imaging;Pilot Projects;Prognosis;Prospective Studies;Socioeconomic Factors;Cognitive Dysfunction;Magnetic Resonance Spectroscopy;Anemia, Sickle Cell",C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155;A08.186.211;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;F01.752.543;E01.370.350.825.500;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E01.789;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.880.853.996;N01.824;F03.615.250.700;E05.196.867.519;C15.378.071.141.150.150;C15.378.420.155;C16.320.070.150;C16.320.365.155
28279623,"Adult;Cerebral Cortex;Cohort Studies;Humans;Image Processing, Computer-Assisted;Magnetic Resonance Imaging;Middle Aged;Psychiatric Status Rating Scales;Stress Disorders, Post-Traumatic;United States;Veterans;Young Adult;Neuroimaging;Stress Disorders, Post-Traumatic;Veterans",M01.060.116;A08.186.211.200.885.287.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;L01.224.308;E01.370.350.825.500;M01.060.116.630;F04.711.513.653;F03.950.750.500;Z01.107.567.875;M01.930;M01.060.116.815;E01.370.350.578;E01.370.376.537;E05.629;F03.950.750.500;M01.930
28278582,Animals;Antioxidants;Blood Substitutes;Drug Stability;Drug Storage;Heme;Hemoglobins;Oligochaeta;Oxidation-Reduction;Oxygen;Temperature;Time Factors;Blood Substitutes;Hemoglobins,B01.050;D27.505.519.217;D27.505.696.706.125;D27.720.799.047;D27.505.954.502.140;J01.637.087.249;E05.916.330;E05.916.350;D03.383.129.578.840.500.640.587;D03.633.400.909.500.640.587;D04.345.783.500.640.587;D23.767.727.640.587;D12.776.124.400;D12.776.422.316.762;B01.050.500.091.657;G02.700;G03.295.531;D01.268.185.550;D01.362.670;G01.906.595;G16.500.275.063.725.710;G16.500.750.775.710;N06.230.150.450;N06.230.300.100.725.710;G01.910.857;D27.505.954.502.140;J01.637.087.249;D12.776.124.400;D12.776.422.316.762
28277088,"African Americans;Child, Preschool;Cohort Studies;Demography;Family Characteristics;Health Literacy;Humans;Immunization;Immunization Programs;Infant;Longitudinal Studies;Maternal Health;Medicaid;Mothers;Poverty;Prospective Studies;Socioeconomic Factors;United States;Urban Population;Cohort Studies;Immunization;Vaccination",M01.686.508.100.100;M01.686.754.100;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;I01.240;N01.224;N06.850.505.400;F01.829.263.315;I01.240.361;I01.880.853.150.423;N01.224.361;N01.824.308;N06.850.505.400.400;I02.233.332.186.500;L01.143.450.500;N02.421.726.407.229.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;N02.421.726.608;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;N01.400.900.500;N03.219.521.346.506.564.655;N03.706.615.693;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;I01.880.735.634;I01.880.853.996.535;N01.824.600;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.880.853.996;N01.824;Z01.107.567.875;N01.600.900;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.095.465.425.400;E05.478.550;N02.421.726.758.310;N06.850.780.200.425;N06.850.780.680.310;E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
28275588,"Renal Insufficiency, Chronic;Pulse Wave Analysis",C12.777.419.780.750;C13.351.968.419.780.750;E01.370.370.680
28275204,"Adolescent;Anti-Bacterial Agents;Child;Child, Preschool;Databases, Factual;Guideline Adherence;Hospitals, Pediatric;Humans;Infant;Inpatients;Pneumonia",M01.060.057;D27.505.954.122.085;M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;N04.761.337;N05.715.360.395;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.643.470;C08.381.677;C08.730.610
28275140,B-Lymphocytes;CD4-Positive T-Lymphocytes;Candida albicans;Coculture Techniques;Cytokines;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;Humans;Lymphocyte Activation;Mycoses,A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200;B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326;E05.481.500.374;D12.644.276.374;D12.776.467.374;D23.529.374;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;C01.703
28275135,"Adoptive Transfer;Animals;Cell Separation;Disease Models, Animal;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;Immunity, Innate;Killer Cells, Natural;Lymphocyte Activation;Lymphocyte Subsets;Mice;Mice, Inbred C57BL;Mice, Knockout;Pneumonia",E02.095.465.425.400.330.050;E05.478.550.520.050;B01.050;E01.370.225.500.363;E05.200.500.363;E05.242.363;C22.232;E05.598.500;E05.599.395.080;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G12.450.564;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;E01.370.225.812.482;E05.200.812.482;E05.478.594.530;G12.450.050.400.545;G12.565;A11.118.637.555.567.550;A15.145.229.637.555.567.550;A15.382.490.555.567.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;C08.381.677;C08.730.610
28274812,"Cardiopulmonary Resuscitation;Case-Control Studies;Child;Child, Preschool;Cognitive Dysfunction;Coma;Drowning;Follow-Up Studies;Humans;Infant;Intensive Care Units, Pediatric;Neuropsychological Tests;Out-of-Hospital Cardiac Arrest;Prospective Studies;Recovery of Function;Respiration, Artificial;Risk Factors;Heart Arrest;Cognition;Drowning;Pediatrics;Hypothermia, Induced",E02.365.647.110;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;F03.615.250.700;C10.597.606.358.800.200;C23.888.592.604.359.800.200;C23.550.260.393;C26.304;N06.850.135.696;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;F04.711.513;C14.280.383.610;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G16.757;E02.041.625;E02.365.647.729;E02.880.820;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C14.280.383;F02.463.188;C23.550.260.393;C26.304;N06.850.135.696;H02.403.670;E02.258.750
28274641,Brain;Child;Humans;Neuroimaging;Pediatrics;Stroke;Magnetic Resonance Imaging,A08.186.211;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.578;E01.370.376.537;E05.629;H02.403.670;C10.228.140.300.775;C14.907.253.855;E01.370.350.825.500
28274640,"Adolescent;Attention;Brain Ischemia;Child;Child, Preschool;Comorbidity;Cross-Sectional Studies;Executive Function;Humans;Neuropsychological Tests;Prognosis;Registries;Stroke;Cognition",M01.060.057;F02.830.104.214;C10.228.140.300.150;C14.907.253.092;M01.060.406;M01.060.406.448;N05.715.350.225;N06.850.490.687;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513;E01.789;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;C10.228.140.300.775;C14.907.253.855;F02.463.188
28274558,Critical Care;Critical Care;Morbidity;Pediatrics,E02.760.190;N02.421.585.190;E02.760.190;N02.421.585.190;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;H02.403.670
28274557,,
28273780,Parents;Protective Factors;Quality of Life,F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.740.600.800.582;N05.715.350.200.675;N05.715.360.750.625.700.570;N06.850.490.625.625;N06.850.520.830.600.800.582;I01.800;K01.752.400.750;N06.850.505.400.425.837
28273451,"Biomarkers, Tumor;Cell Line, Tumor;Cell Membrane;Cell Survival;Cystadenocarcinoma, Serous;Epithelial Cells;Gene Regulatory Networks;Humans;Neoplasm Grading;Ovarian Neoplasms;Phenotype;Prognosis;Tetraspanin 24;Xenograft Model Antitumor Assays;Zinc Finger E-box Binding Homeobox 2;Zinc Finger E-box-Binding Homeobox 1",D23.101.140;A11.251.210.190;A11.251.860.180;A11.284.149;G04.346;C04.557.470.200.025.480.240;C04.557.470.590.480.240;A11.436;G05.360.080.689.360;B01.050.150.900.649.313.988.400.112.400.400;E01.789.612;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;G05.695;E01.789;D12.776.543.900.028;E05.337.550.200.900;E05.624.850;D12.776.260.400.883;D12.776.260.703.700;D12.776.930.780.918;D12.776.260.400.906;D12.776.260.703.800;D12.776.930.780.945
28273297,"Firearms;Humans;Incidence;Philadelphia;Surgeons;Urban Population;Violence;Wounds, Gunshot",J01.637.870.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;Z01.107.567.875.500.550.525;Z01.433.820;M01.526.485.810.910;N02.360.810.910;N01.600.900;I01.198.240.856;I01.880.735.900;C26.986.900
28273196,,
28271612,"Aged;Choroid;Clinical Trials as Topic;Disease Management;Fluorescein Angiography;Fundus Oculi;Humans;Middle Aged;Ophthalmoscopy;Regional Blood Flow;Retinal Drusen;Retinal Vessels;Risk Factors;Tomography, Optical Coherence;Wet Macular Degeneration",M01.060.116.100;A09.371.894.223;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;N04.590.607;E01.370.370.050.350;E01.370.380.250;A09.371.729.313;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E01.370.380.560;G09.330.100.780;C11.768.585.585;A07.015.611;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;C11.768.585.439.622
28271432,Anti-Obesity Agents;Congresses as Topic;Drug Utilization;Humans;Obesity;Obesity Management;United States;United States Department of Veterans Affairs;Veterans Health;Obesity;Pharmaceutical Services;Veterans,D27.505.954.203;N03.540.199;N04.452.706.477;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E02.570;N02.421.726.407.579.650.500;N04.590.607.250;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;N01.400.850;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;N02.421.668;M01.930
28271316,"Adolescent;Brain Injuries, Traumatic;Child;Humans;Neurology;Patient Reported Outcome Measures;Proxy;Psychometrics;Quality of Life;Surveys and Questionnaires;Adolescent;Brain Injuries;Child;Outcome Assessment (Health Care);Patient Outcome Assessment",M01.060.057;C10.228.140.199.444;C10.900.300.087.235;C26.915.300.200.194;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;H02.403.600;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;M01.380.600;F04.711.780;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.060.057;C10.228.140.199;C10.900.300.087;C26.915.300.200;M01.060.406;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;N04.761.559.590.399;N05.715.360.575.575.399
28271030,"3' Untranslated Regions;Animals;CRISPR-Cas Systems;Diabetes Mellitus, Type 2;Gene Knock-In Techniques;Gene Targeting;Genetic Engineering;Genetic Techniques;Glucagon;Glucagon-Secreting Cells;Islets of Langerhans;Mice;Mice, Transgenic;Tamoxifen;Transgenes;Clustered Regularly Interspaced Short Palindromic Repeats;Glucagon",D13.444.735.544.875.880;D13.444.735.790.878.880;G05.360.340.024.220.880.880;G05.360.340.024.340.137.910.880;B01.050;G05.308.203.374.394;C18.452.394.750.149;C19.246.300;E05.393.335.249;E05.393.335;E05.393.420;E05.393;D06.472.699.587.730.500;D12.644.548.586.730.500;A03.734.414.065;A06.300.414.043;A06.390.087;A11.382.625.064;A11.436.294.064;A03.734.414;A06.300.414;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D02.455.426.559.389.150.700.900;G05.360.340.024.340.825;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D06.472.699.587.730.500;D12.644.548.586.730.500
28270991,,
28270546,"Adolescent;Ambulatory Care;Anti-Bacterial Agents;Child;Child, Preschool;Cohort Studies;Community-Acquired Infections;Humans;Infant;Pneumonia;Practice Patterns, Physicians';Retrospective Studies",M01.060.057;E02.760.106;N02.421.585.106;D27.505.954.122.085;M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C01.539.234;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C08.381.677;C08.730.610;N04.590.374.577;N05.300.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28270455,Humans;Legislation as Topic;Psychological Trauma,B01.050.150.900.649.313.988.400.112.400.400;N03.706.615;F03.950.750.375
28270438,"Animals;Cells, Cultured;Cyclic AMP Response Element-Binding Protein;Cyclic AMP-Dependent Protein Kinases;Down-Regulation;Forkhead Box Protein O1;Glucagon-Like Peptide-1 Receptor;Humans;Mice;Mice, Inbred C57BL;Mice, Transgenic;Phosphorylation;Protein-Arginine N-Methyltransferases;Proto-Oncogene Proteins;Signal Transduction",B01.050;A11.251;D12.776.260.108.184;D12.776.930.127.184;D08.811.913.696.620.682.700.150.125;D12.644.360.200.125;D12.776.476.200.125;G02.111.240;G05.308.200;G07.690.773.937;D12.776.260.950.249.250;D12.776.930.977.249.250;D12.776.543.750.695.021.500;D12.776.543.750.750.360.100.500;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;G02.111.665;G02.607.780;G03.796;D08.811.913.555.500.800.750;D12.776.624.664.700;G02.111.820;G04.835
28270337,"Adult;Aftercare;Age Factors;Child;Chronic Disease;Health Knowledge, Attitudes, Practice;Humans;Neoplasms;Parents;Surveys and Questionnaires;Survivors;Transition to Adult Care;Young Adult;Transition to Adult Care;Young Adult",M01.060.116;E02.760.169.063;N02.421.585.169.063;N04.590.233.727.210.063;N05.715.350.075;N06.850.490.250;M01.060.406;C23.550.291.500;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;C04;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;M01.860;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815;E02.760.169.718;N02.421.585.169.718;N04.590.233.727.210.718;M01.060.116.815
28270327,"Adult;Cognition;Humans;Implosive Therapy;Severity of Illness Index;Stress Disorders, Post-Traumatic;Survivors;Treatment Outcome;Young Adult;Cognition;Implosive Therapy;Stress Disorders, Post-Traumatic;Wounds and Injuries;Therapeutics",M01.060.116;F02.463.188;B01.050.150.900.649.313.988.400.112.400.400;F04.754.137.506.325;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;F03.950.750.500;M01.860;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;F02.463.188;F04.754.137.506.325;F03.950.750.500;C26;E02
28270264,"Bacterial Proteins;DNA Transposable Elements;Depsipeptides;Electrophoretic Mobility Shift Assay;Escherichia coli;Flagella;Gene Expression Regulation, Bacterial;Genes, Regulator;Mass Spectrometry;Metalloendopeptidases;Prodigiosin;Secondary Metabolism;Serratia marcescens;Transcription Factors",D12.776.097;D13.444.308.520;G02.111.570.080.708.330.200;G05.360.080.708.330.200;G05.360.340.024.425.200;D04.345.566.297;D12.644.641.297;E05.196.401.500;B03.440.450.425.325.300;B03.660.250.150.180.100;A11.284.180.290;G05.308.300;G05.360.340.024.340.425;E05.196.566;D08.811.277.656.300.480;D08.811.277.656.675.374;D03.383.129.578.748;D23.767.778;G03.493.875;B03.440.450.425.814.664;B03.660.250.150.720.500;D12.776.930
28270213,Animals;Anopheles;Biodiversity;Botswana;Entomology;Mosquito Vectors;Anopheles;Botswana;Malaria;Plasmodium falciparum,B01.050;B01.050.500.131.617.720.500.500.750.712.500.875.120;G16.500.275.157.049;N06.230.124.049;Z01.058.290.175.230;H01.158.273.943.409;N06.850.310.350.100.500.500;B01.050.500.131.617.720.500.500.750.712.500.875.120;Z01.058.290.175.230;C03.752.530;B01.043.075.380.611.561
28270105,Cognitive Behavioral Therapy;Cost-Benefit Analysis;Health Care Costs;Humans;Motivational Interviewing;Pregnancy;Pregnancy Complications;Quality of Life;Substance-Related Disorders;Treatment Outcome;Costs and Cost Analysis;Cost-Benefit Analysis;Pregnancy;Randomized Controlled Trial,F04.754.137.350;N03.219.151.125;N03.219.151.400;N05.300.375;B01.050.150.900.649.313.988.400.112.400.400;F02.784.176.279.500;F04.408.413.349.500;N02.421.461.363.349.500;G08.686.784.769;C13.703;I01.800;K01.752.400.750;N06.850.505.400.425.837;C25.775;F03.900;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;N03.219.151;N03.219.151.125;G08.686.784.769;V03.175.250.500.500
28269950,"Adolescent;Child;Child, Preschool;Data Mining;Decision Trees;Electronic Health Records;Hospitalization;Humans;Infant;Machine Learning;Models, Theoretical;ROC Curve;Respiratory Tract Infections;Retrospective Studies;Sensitivity and Specificity;Virus Diseases;Viruses",M01.060.057;M01.060.406;M01.060.406.448;L01.313.500.750.280.199;L01.470.625;G17.162.500;E05.318.308.940.968.625.500;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;G17.035.250.500;L01.224.050.375.530;E05.599;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;C01.539.739;C08.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;C02;B04
28269935,Computer Simulation;Disease;Electronic Health Records;Genome-Wide Association Study;Genotype;Hospital Administration;Humans;Logistic Models;Medical Errors,L01.224.160;C23.550.288;E05.318.308.940.968.625.500;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;H02.309;N02.278.216.500;N02.278.354;N04.452.442;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;N02.421.450
28268011,"Printing, Three-Dimensional",J01.897.564;L01.224.108.150.500;L01.296.110.150.500
28267856,Adult;Age of Onset;Case-Control Studies;Coronary Artery Disease;Cross-Sectional Studies;Genotype;Heterozygote;Humans;Lipoprotein Lipase;Lipoproteins;Middle Aged;Mutation;Odds Ratio;Triglycerides,M01.060.116;N05.715.350.075.100;N06.850.490.250.100;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;G05.380;G05.380.383;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.352.100.430;D10.532;D12.776.521;M01.060.116.630;G05.365.590;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;D10.351.801
28267851,"Cardiopulmonary Resuscitation;Child;Heart Arrest;Hospitals, Pediatric;Humans;Resuscitation",E02.365.647.110;M01.060.406;C14.280.383;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;E02.365.647
28267048,"Age of Onset;Humans;Inflammatory Bowel Diseases;Mutation;Phenotype;Receptors, Interleukin-10;Surveys and Questionnaires",N05.715.350.075.100;N06.850.490.250.100;B01.050.150.900.649.313.988.400.112.400.400;C06.405.205.731;C06.405.469.432;G05.365.590;G05.695;D12.776.543.750.705.852.420.550;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28266961,"Adult;Aged;Aneurysm;Computed Tomography Angiography;Humans;Hypertension, Pulmonary;Hypertrophy, Right Ventricular;Klippel-Trenaunay-Weber Syndrome;Middle Aged;Pulmonary Embolism;Radiography, Thoracic;Retrospective Studies;Tomography, X-Ray Computed",M01.060.116;M01.060.116.100;C14.907.055;E01.370.350.350.810.335;E01.370.350.567.250;E01.370.350.600.350.700.810.335;E01.370.350.700.700.810.335;E01.370.350.700.810.810.568;E01.370.350.825.810.810.499;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;C14.280.195.410;C23.300.775.250.401;C14.907.077.410;M01.060.116.630;C08.381.746;C14.907.355.350.700;E01.370.350.700.730;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28266594,"Action Potentials;Computer Simulation;Models, Neurological;Neurons;Synaptic Transmission",G04.580.100;G07.265.675.100;G11.561.570.100;L01.224.160;E05.599.395.642;A08.675;A11.671;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830
28266033,Adnexa Uteri;Adnexal Diseases;Humans;Magnetic Resonance Imaging;Ultrasonography,A05.360.319.114;C13.351.500.056;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.850
28265826,"Adult;Aged;Cohort Studies;Humans;Inflammation;Inflammatory Bowel Diseases;Metabolic Syndrome;Middle Aged;Non-alcoholic Fatty Liver Disease;Obesity;Retrospective Studies;Crohn Disease;Inflammatory Bowel Diseases;Non-alcoholic Fatty Liver Disease;Colitis, Ulcerative",M01.060.116;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;C23.550.470;C06.405.205.731;C06.405.469.432;C18.452.394.968.500.570;C18.452.625;M01.060.116.630;C06.552.241.519;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C06.405.205.731.500;C06.405.469.432.500;C06.405.205.731;C06.405.469.432;C06.552.241.519;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
28265795,Autism Spectrum Disorder,F03.625.164.113
28265411,Adolescent;Anorexia Nervosa;Bulimia Nervosa;Feeding and Eating Disorders;Malnutrition;Refeeding Syndrome,M01.060.057;F03.400.125;F03.400.250;F03.400;C18.654.521;C18.654.521.687
28265130,"Upper Extremity Deep Vein Thrombosis;Radiology, Interventional;Upper Extremity Deep Vein Thrombosis",C14.907.355.830.925.885;H02.403.740.675;C14.907.355.830.925.885
28265120,Adolescent;Adult;Alcoholism;Cohort Studies;Cyclic GMP-Dependent Protein Kinase Type I;Gene-Environment Interaction;Genome-Wide Association Study;Genotype;Humans;Life Change Events;Middle Aged;Mutation;Risk Factors;Young Adult,M01.060.057;M01.060.116;C25.775.100.250;F03.900.100.350;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D08.811.913.696.620.682.700.150.150.500;D12.644.360.200.150.500;D12.776.476.200.150.500;G05.695.337;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;F01.829.458.410;M01.060.116.630;G05.365.590;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28265093,"3' Untranslated Regions;Deuterium Exchange Measurement;Genetic Association Studies;Histone Deacetylases;Humans;Leukocyte Elastase;Mass Spectrometry;Plaque, Atherosclerotic;Polymorphism, Single Nucleotide;Repressor Proteins;Stroke;alpha 1-Antitrypsin;Genetics",D13.444.735.544.875.880;D13.444.735.790.878.880;G05.360.340.024.220.880.880;G05.360.340.024.340.137.910.880;E05.196.344;E05.393.385;D08.811.277.087.520;B01.050.150.900.649.313.988.400.112.400.400;D08.811.277.656.300.760.560.500;D08.811.277.656.959.350.560.500;E05.196.566;C23.300.823;G05.365.795.598;D12.776.260.703;D12.776.930.780;C10.228.140.300.775;C14.907.253.855;D12.644.861.035;D12.776.124.050.070;D12.776.124.790.106.085;D12.776.377.715.085.085;D12.776.395.068;D12.776.872.035;H01.158.273.343
28265073,"3T3 Cells;Animals;CHO Cells;Carrier Proteins;Cricetulus;Cytotoxicity, Immunologic;Humans;Killer Cells, Natural;Membrane Fusion;Membrane Lipids;Mice;Multiprotein Complexes;Munc18 Proteins;Protein Binding;Protein Interaction Domains and Motifs;Qa-SNARE Proteins;SNARE Proteins;T-Lymphocytes;T-Lymphocytes, Cytotoxic;SNARE Proteins;Qa-SNARE Proteins",A11.251.210.100;A11.329.228.100;B01.050;A11.251.210.200;A11.436.155;D12.776.157;B01.050.150.900.649.313.992.635.075.250.250;G12.287;B01.050.150.900.649.313.988.400.112.400.400;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;G04.575;D10.570;B01.050.150.900.649.313.992.635.505.500;D05.500;D12.776.543.990.587;G02.111.679;G03.808;G02.111.570.820.709.275.750.500;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500;D12.776.543.512.249;D12.776.543.990.775;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200;D12.776.543.512.249;D12.776.543.990.775;D12.776.543.512.249.500.500;D12.776.543.990.775.500.500
28265061,"Amyotrophic Lateral Sclerosis;Animals;Axons;Cells, Cultured;Cytoplasmic Granules;DNA-Binding Proteins;Humans;Motor Neurons;Mutation;Rats;Rats, Sprague-Dawley;Ribonucleoproteins;Viscosity;Amyotrophic Lateral Sclerosis;Neurons",C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B01.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A11.251;A11.284.430.214.190.500;A11.284.430.214.190.875.190.190;D12.776.260;B01.050.150.900.649.313.988.400.112.400.400;A08.675.655.500;A11.671.655.500;G05.365.590;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;D12.776.157.725.500;D12.776.664.962.500;G02.930;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;A08.675;A11.671
28264832,"Benin;Burkina Faso;Democratic Republic of the Congo;Developing Countries;Health Services Accessibility;Humans;Mauritania;Retrospective Studies;Sierra Leone;Surgery Department, Hospital;Togo;Uganda;Zambia;Africa",Z01.058.290.190.200;Z01.058.290.190.245;Z01.058.290.100.220;I01.615.500.300;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;Z01.058.290.190.520;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.058.290.190.725;N02.278.216.500.968.750;N04.452.442.422.750;Z01.058.290.190.800;Z01.058.290.120.880;Z01.058.290.175.920;Z01.058
28264090,"Clinical Competence;Cohort Studies;Emergency Medicine;Faculty, Medical;Humans;Internship and Residency;Longitudinal Studies;Multilevel Analysis;Retrospective Studies;Sex Factors;Sexism;United States",I02.399.630.210;N04.761.210;N05.715.175;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;H02.403.250;M01.526.485.375;M01.526.702.250.373;N02.360.375;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;N06.850.520.830.562;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N05.715.350.675;N06.850.490.875;F01.145.813.550.750;F01.145.813.629.750;F01.829.595.750;Z01.107.567.875
28264089,"Ductus Arteriosus, Patent;Humans;Infant;Infant, Extremely Premature;Infant, Newborn;Infant, Premature;Ligation",C14.240.400.340;C14.280.400.340;C16.131.240.400.340;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520.520.500;M01.060.703.520;M01.060.703.520.520;E04.426
28264079,"Back;Diagnosis, Differential;Humans;Infant, Newborn;Skin;Spinal Dysraphism",A01.923.176;E01.171;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;A17.815;C10.500.680.800;C16.131.666.680.800
28263942,Data Mining;Humans;Statistics as Topic;Algorithms;Database;Machine Learning;Patient-Specific Modeling,L01.313.500.750.280.199;L01.470.625;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;G17.035;L01.224.050;V02.300;G17.035.250.500;L01.224.050.375.530;E05.599.395.821;L01.224.160.750
28263866,,
28263447,Adult;Biomarkers;Biomedical Research;Chronic Pain;Enzyme-Linked Immunosorbent Assay;Humans;Interdisciplinary Communication;Matrix Metalloproteinase 9;Pelvic Pain;Research Design;Syndrome;United States;Urinary Tract;Urologic Diseases;Vascular Endothelial Growth Factor A;Lipocalin-2;Vascular Endothelial Growth Factor A;Vascular Endothelial Growth Factor Receptor-1,M01.060.116;D23.101;H01.770.644.145;C23.888.592.612.274;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;D08.811.277.656.300.480.205.360;D08.811.277.656.300.480.252.445;D08.811.277.656.300.480.525.700.350;D08.811.277.656.675.374.205.360;D08.811.277.656.675.374.252.445;D08.811.277.656.675.374.525.700.350;D12.644.276.848.350;D12.776.467.836.350;C23.888.592.612.944;E05.581.500;H01.770.644.728;C23.550.288.500;Z01.107.567.875;A05.810;C12.777;C13.351.968;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;D12.776.124.050.475;D12.776.157.469.325;D12.776.624.664.700.123;D12.644.276.100.800.200;D12.776.467.100.800.200;D23.529.100.800.200;D08.811.913.696.620.682.725.400.950.100;D12.776.543.750.630.750.100;D12.776.543.750.750.400.910.100
28263385,"Aged;Animals;Contrast Media;Disease Models, Animal;Dogs;Fluorescent Dyes;Folate Receptors, GPI-Anchored;Humans;Intraoperative Care;Lung Neoplasms;Lymph Nodes;Middle Aged;Molecular Imaging;Neoplasm Staging;Optical Imaging;Signal-To-Noise Ratio;Spectroscopy, Near-Infrared;Tomography, X-Ray Computed;Lung Neoplasms",M01.060.116.100;B01.050;D27.505.259.500;D27.720.259;C22.232;E05.598.500;E05.599.395.080;B01.050.150.900.649.313.750.250.216.200;D27.720.233.348;D27.720.470.410.505.500;D12.776.157.530.450.074.500.299.500;D12.776.395.550.448.370;D12.776.543.484.500.370;D12.776.543.550.418.370;D12.776.543.585.450.074.500.224.500;D12.776.543.750.301;B01.050.150.900.649.313.988.400.112.400.400;E02.760.731.400;E04.604.249;N02.421.585.722.400;C04.588.894.797.520;C08.381.540;C08.785.520;A10.549.400;A15.382.520.604.412;M01.060.116.630;E01.370.350.557;E05.601.555;E01.789.625;E01.370.350.589;E05.642;E05.318.370.800.875;E05.318.740.872.875;G17.800.500;N05.715.360.325.700.840;N05.715.360.750.725.750;N06.850.520.445.800.875;N06.850.520.830.872.750;E01.370.350.750;E05.196.867.851;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C04.588.894.797.520;C08.381.540;C08.785.520
28262550,"Brain;Humans;Infant, Newborn;Neuroimaging;Stroke;Magnetic Resonance Imaging;Neuroimaging",A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E01.370.350.578;E01.370.376.537;E05.629;C10.228.140.300.775;C14.907.253.855;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629
28262319,"Adolescent;Adrenal Cortex Hormones;Anti-Asthmatic Agents;Appointments and Schedules;Asthma;Child;Child, Preschool;Continuity of Patient Care;Drug Prescriptions;Emergency Service, Hospital;Emergency Treatment;Follow-Up Studies;Humans;Infant;Outcome Assessment (Health Care);Patient Compliance;Quality of Life;Treatment Outcome;United States",M01.060.057;D06.472.040;D27.505.954.796.050;N04.452.095;C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095;M01.060.406;M01.060.406.448;E02.760.169;N02.421.585.169;N04.590.233.727.210;E02.319.307;N02.421.668.778.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.365;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;F01.100.150.750.500.600;F01.145.488.887.500.600;N05.300.150.800.500.600;I01.800;K01.752.400.750;N06.850.505.400.425.837;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875
28262296,"Benchmarking;Cardiac Surgical Procedures;Databases, Factual;Heart Defects, Congenital;Hospital Mortality;Humans;Infant, Newborn;Kaplan-Meier Estimate;Multivariate Analysis;Perioperative Care;Postoperative Complications;Quality of Health Care;Respiration, Artificial;Time Factors;United States",N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;E04.100.376;E04.928.220;L01.313.500.750.300.188.400;L01.470.750.750;C14.240.400;C14.280.400;C16.131.240.400;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E02.760.731;E04.604;N02.421.585.722;C23.550.767;N04.761;N05.715;E02.041.625;E02.365.647.729;E02.880.820;G01.910.857;Z01.107.567.875
28261414,Child;Humans;Internal Medicine;Internship and Residency;Pediatrics;Perception;Teaching Rounds,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;H02.403.670;F02.463.593;I02.358.399.822
28261320,"Algorithms;Anisotropy;Artifacts;Diffusion;Humans;Image Interpretation, Computer-Assisted;Image Processing, Computer-Assisted;Models, Statistical;Normal Distribution;Retina;Retinal Vessels",G17.035;L01.224.050;G01.590.040;G02.050;E05.047;G01.202;G02.196;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;L01.224.308;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E05.318.740.994.500;G17.820.500;N05.715.360.750.750.565;N06.850.520.830.994.500;A09.371.729;A07.015.611
28260794,"Th2 Cells;Macrophages, Alveolar;Pneumonia, Bacterial",A11.118.637.555.567.550.500.400.905;A11.118.637.555.567.569.200.400.905;A11.118.637.555.567.569.500.400.905;A15.145.229.637.555.567.550.500.400.750;A15.145.229.637.555.567.569.200.400.750;A15.145.229.637.555.567.569.500.400.750;A15.382.490.555.567.550.500.400.905;A15.382.490.555.567.569.200.400.905;A15.382.490.555.567.569.500.400.905;A11.329.372.600;A11.627.482.600;A11.733.397.600;A15.382.670.522.600;A15.382.680.397.600;C01.252.620;C08.381.677.540;C08.730.610.540
28260694,"Anti-HIV Agents;Chromatography, Liquid;Drug Monitoring;Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination;HIV Infections;Humans;Pre-Exposure Prophylaxis;Tandem Mass Spectrometry;Treatment Outcome;Young Adult",D27.505.954.122.388.077.088;E05.196.181.400;E01.370.520.200;D02.705.429.906.750;D03.383.742.680.245.500.600.750;D03.633.100.759.138.881.750;D13.570.230.329.525.500;D13.570.685.245.500.600.500;D26.310.423;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;N02.421.726.758.655;N06.850.780.680.655;E05.196.566.880;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815
28259697,"Ambulatory Care;Antipsychotic Agents;Drug Utilization;Emergency Service, Hospital;Hospitalization;Humans;Morbidity;Parkinson Disease;Retrospective Studies;United States;United States Department of Veterans Affairs;Parkinson Disease;Morbidity;Psychotic Disorders",E02.760.106;N02.421.585.106;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;N04.452.706.477;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;I01.409.418.750.700;N03.540.348.500.500.700;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;F03.700.675
28259607,Disease-Free Survival;Humans;Infant;Neuroblastoma,E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550
28259482,"Cardiopulmonary Resuscitation;Child;Clinical Competence;Cooperative Behavior;Emergency Service, Hospital;Feedback;Guideline Adherence;Heart Arrest;Humans;Patient Care Team;Pediatrics;Practice Guidelines as Topic;Problem-Based Learning;Quality Improvement;Retrospective Studies;United States;Video Recording",E02.365.647.110;M01.060.406;I02.399.630.210;N04.761.210;N05.715.175;F01.145.813.115;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;L01.906.394.211;N04.761.337;N05.715.360.395;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;N04.590.715;H02.403.670;N04.761.700.350.650;N05.700.350.650;F02.463.425.720;I02.158.660;I02.903.565;J01.293.754;N04.761.744;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;L01.280.960
28259375,Animals;Atherosclerosis;Biological Transport;Cholesterol;Endothelial Cells;Humans;Macrophages,B01.050;C14.907.137.126.307;G03.143;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;A11.436.275;B01.050.150.900.649.313.988.400.112.400.400;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
28259340,"Adolescent;Anti-Anxiety Agents;Antidepressive Agents;Antipsychotic Agents;Anxiety;Anxiety Disorders;Attention Deficit Disorder with Hyperactivity;Autistic Disorder;Child;Child, Preschool;Depression;Depressive Disorder;Hospitalization;Hospitals, Pediatric;Humans;Mental Disorders;Mental Health;Mental Health Services;Philadelphia;Prevalence;Young Adult;Mental Health;Psychiatry;Psychology",M01.060.057;D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015;D27.505.954.427.700.122;D27.505.696.277.950.040;D27.505.954.427.210.950.040;D27.505.954.427.700.872.331;F01.470.132;F03.080;F03.625.094.150;F03.625.164.113.500;M01.060.406;M01.060.406.448;F01.145.126.350;F03.600.300;E02.760.400;N02.421.585.400;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;F03;F02.418;N01.400.500;F04.408;N02.421.461;Z01.107.567.875.500.550.525;Z01.433.820;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;M01.060.116.815;F02.418;N01.400.500;F04.096.544;H02.403.690;F04.096.628
28259265,"Adolescent;Back Pain;Child;Child, Preschool;Conservative Treatment;Follow-Up Studies;Humans;Radiography;Retrospective Studies;Return to Sport;Severity of Illness Index;Spondylolysis;Treatment Outcome;Young Adult;Adolescent;Radiology;Spondylolysis",M01.060.057;C23.888.592.612.107;M01.060.406;M01.060.406.448;E02.197;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.700;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I03.450.642.845.605;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C05.116.900.938.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;M01.060.057;H02.403.740;C05.116.900.938.500
28258737,"Age Factors;Anti-Inflammatory Agents, Non-Steroidal;Bronchopulmonary Dysplasia;Humans;Indomethacin;Infant, Extremely Premature;Infant, Newborn;Oxygen Inhalation Therapy;Retrospective Studies;Treatment Outcome;Bronchopulmonary Dysplasia;Indomethacin",N05.715.350.075;N06.850.490.250;D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;C08.381.520.750.500;C16.614.521.125;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.473.420;M01.060.703.520.520.500;M01.060.703.520;E02.880.690;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C08.381.520.750.500;C16.614.521.125;D03.633.100.473.420
28258252,Blood-Brain Barrier;Cerebrovascular Circulation;Humans;Infarction;Magnetic Resonance Angiography;Magnetic Resonance Imaging;Spin Labels,A07.035;A08.186.211.035;G09.330.100.159;B01.050.150.900.649.313.988.400.112.400.400;C23.550.513.355;C23.550.717.489;E01.370.350.825.500.500;E01.370.370.050.500;E01.370.350.825.500;D02.389.678
28258242,"Adult;Follow-Up Studies;Heart Defects, Congenital;Heart Transplantation;Humans;Middle Aged;Retrospective Studies;Survival Rate;Time Factors;Treatment Outcome;United States;Young Adult;Heart Transplantation",M01.060.116;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.240.400;C14.280.400;C16.131.240.400;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;M01.060.116.815;E04.100.376.475;E04.928.220.390;E04.936.450.475
28258193,"Blotting, Western;Complement C3b;Deuterium Exchange Measurement;Enzyme-Linked Immunosorbent Assay;Humans;Mass Spectrometry;Protein Structure, Quaternary;Surface Plasmon Resonance",E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;D12.776.124.486.274.250.260;E05.196.344;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;B01.050.150.900.649.313.988.400.112.400.400;E05.196.566;G02.111.570.820.709.550;E05.196.890;E05.601.043.700
28258178,"Adolescent;Adult;Athletes;Child;Consensus;Death, Sudden, Cardiac;Electrocardiography;Heart Diseases;Humans;Mass Screening;Sports Medicine;Washington;Young Adult;Athletes;Death, Sudden, Cardiac;Death, Sudden, Cardiac",M01.060.057;M01.060.116;M01.072;M01.060.406;F01.829.316.068;F02.463.785.373.433;C14.280.383.220;C23.550.260.322.250;E01.370.370.380.240;E01.370.405.240;C14.280;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;H02.403.830;Z01.107.567.875.560.900;Z01.107.567.875.580.900;M01.060.116.815;M01.072;C14.280.383.220;C23.550.260.322.250;C14.280.383.220;C23.550.260.322.250
28257896,"Adrenocorticotropic Hormone;Animals;Habituation, Psychophysiologic;Hypothalamo-Hypophyseal System;Neurons;Orexin Receptor Antagonists;Orexin Receptors;Orexins;Pituitary-Adrenal System;Rats;Rats, Sprague-Dawley;Restraint, Physical;Stress, Psychological",D06.472.699.327.935.531.500;D06.472.699.631.525.600.531.500;D12.644.400.400.935.531.500;D12.644.548.365.935.531.500;D12.644.548.691.525.690.531.500;D12.776.631.650.405.935.531.500;B01.050;F02.463.425.393;F02.830.422;G11.561.312;A06.688.357;A08.186.211.180.497.352.435;A08.186.211.200.317.357.352.435;A08.713.357;A08.675;A11.671;D27.505.519.625.663;D27.505.696.277.350.500.500;D27.505.696.577.663;D27.505.954.427.210.350.500.500;D12.776.543.750.695.023;D12.776.543.750.720.600.074;D12.776.543.750.750.555.074;D12.644.400.360;D12.776.631.650.363;A06.300.691;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;E02.085.700;E05.472.760;F01.145.126.990;F02.830.900
28257716,"Anti-Inflammatory Agents, Non-Steroidal;Bacterial Infections;Barrett Esophagus;Dementia;Evidence-Based Medicine;Fractures, Bone;Gastroesophageal Reflux;Gastrointestinal Neoplasms;Humans;Kidney Diseases;Micronutrients;Myocardial Infarction;Peptic Ulcer Hemorrhage;Practice Guidelines as Topic;Proton Pump Inhibitors;Time Factors",D27.505.696.663.850.014.040.500;D27.505.954.158.030;D27.505.954.329.030;C01.252;C04.834.154;C06.405.117.102;C10.228.140.380;F03.615.400;H02.249.750;H02.403.200.400;C26.404;C06.405.117.119.500.484;C04.588.274.476;C06.301.371;C06.405.249;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;D27.505.696.377.683.500;G07.203.300.681.500;J02.500.681.500;C14.280.647.500;C14.907.585.500;C06.405.227.700;C23.550.414.788.700;N04.761.700.350.650;N05.700.350.650;D27.505.519.389.848;G01.910.857
28257709,"Clone Cells;Hematopoiesis;Humans;Induced Pluripotent Stem Cells;Leukemia, Myeloid, Acute;Myelodysplastic Syndromes",A11.251.353;G04.152.825;G09.188.343;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;C04.557.337.539.275;C15.378.190.625
28257545,Adenoma;Colonic Neoplasms;Colonic Polyps;Colonoscopy;Cross-Sectional Studies;Fellowships and Scholarships;Gastroenterology;Humans;Middle Aged;Quality of Health Care;Retrospective Studies;Texas,C04.557.470.035;C04.588.274.476.411.307.180;C06.301.371.411.307.180;C06.405.249.411.307.180;C06.405.469.158.356.180;C06.405.469.491.307.180;C23.300.825.411.235;E01.370.372.250.250.200;E01.370.388.250.250.250.160;E04.210.240.250.160;E04.502.250.250.250.160;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;N03.219.483.838.276;H02.403.429.405;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N04.761;N05.715;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875.760.750
28257376,Child;Humans;Sepsis,M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C01.539.757;C23.550.470.790.500
28257373,,
28257277,Child;Comprehension;Cross-Over Studies;Humans;Language Tests;Reading;Saccades;Schools;Software;Teaching;Treatment Outcome;Eye Movements;Randomized Controlled Trial;Reading,M01.060.406;F02.463.188.357;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.240;L01.559.423.557;G14.350.500;I02.783;J03.832;L01.224.900;I02.903;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G11.427.410.140;G14.350;V03.175.250.500.500;L01.559.423.557
28257128,,
28256231,"Blood Platelets;Clot Retraction;Elasticity;Erythrocytes;Fibrin;Humans;Models, Biological",A11.118.188;A15.145.229.188;E01.370.225.625.625.160;E05.200.625.625.160;G09.188.390.600.180;G01.374.590;A11.118.290;A11.443.240;A15.145.229.334;D12.776.124.270;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395
28255693,Actins;Animals;Green Fluorescent Proteins;Humans;Immunological Synapses;Jurkat Cells;Mice;T-Lymphocytes;Actins;Cytoskeleton;Immunological Synapses;T-Lymphocytes,D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;B01.050;D12.776.532.265;B01.050.150.900.649.313.988.400.112.400.400;A11.284.149.165.420.548;A15.382.370;A11.251.210.190.495;A11.251.860.180.495;A15.382.490.555.567.569.440;B01.050.150.900.649.313.992.635.505.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D05.750.078.730.250;D12.776.210.500.100;D12.776.220.525.255;A11.284.430.214.190.750;A11.284.149.165.420.548;A15.382.370;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
28255291,Blepharoptosis,C11.338.204
28255241,"Biomarkers;Blood Glucose;Canagliflozin;Diabetes Mellitus, Type 2;Evidence-Based Medicine;Humans;Hypoglycemic Agents;Kidney Tubules;Sodium-Glucose Transporter 2;Sodium-Glucose Transporter 2 Inhibitors;Treatment Outcome;Canagliflozin;Review;Diabetes Mellitus, Type 2",D23.101;D09.947.875.359.448.500;D02.886.778.075;D03.383.903.075;D09.408.348.113;C18.452.394.750.149;C19.246.300;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;A05.810.453.736.560;D12.776.157.530.450.625.437.750;D12.776.157.530.500.750.750;D12.776.157.530.937.700;D12.776.543.585.450.625.562.750;D12.776.543.585.500.750.750;D12.776.543.585.937.825;D27.505.519.936;D27.505.696.422.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D02.886.778.075;D03.383.903.075;D09.408.348.113;V02.600.500;V02.912;C18.452.394.750.149;C19.246.300
28254903,"History, 20th Century;History, 21st Century;Humans;Neoplasms;Pathology, Molecular;Philadelphia;Philadelphia Chromosome;Precision Medicine",K01.400.504.968;K01.400.504.984;B01.050.150.900.649.313.988.400.112.400.400;C04;H01.158.201.636.475.750;H01.158.273.343.595.475.750;H01.181.122.650.475.680;H02.403.650.505;Z01.107.567.875.500.550.525;Z01.433.820;A11.284.187.520.300.325.345.500;A11.284.187.520.300.505.515.500;C23.550.210.870.680;G05.360.162.520.300.325.345.700;G05.360.162.520.300.505.515.700;G05.365.590.175.870.680;E02.574;H02.403.200.700
28253108,"Animals;Autophagy;Carcinoma, Hepatocellular;Cell Cycle Checkpoints;Cell Line, Tumor;Cell Survival;Embolization, Therapeutic;Liver Neoplasms, Experimental;Rats;Rats, Wistar",B01.050;G04.146.399;G04.417.350.091;C04.557.470.200.025.255;C04.588.274.623.160;C06.301.623.160;C06.552.697.160;G04.144.109;A11.251.210.190;A11.251.860.180;G04.346;E02.520.360;E02.926.500;C04.588.274.623.460;C04.619.540;C06.301.623.460;C06.552.697.580;E05.598.500.496.750;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.900
28252468,"Adult;Attitude of Health Personnel;Child;Child Health Services;Education, Continuing;Health Personnel;Humans;Middle Aged;Quality Improvement;Self Efficacy;Surveys and Questionnaires;Teaching;Trauma Centers",M01.060.116;F01.100.050;N05.300.100;M01.060.406;N02.421.143.130;I02.358.212;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;J01.293.754;N04.761.744;F01.752.747.792.700;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;I02.903;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400
28252230,"Adult;Aged;Aged, 80 and over;Depressive Disorder;Humans;Incidence;Middle Aged;Neoplasms;Retrospective Studies;Serotonin Uptake Inhibitors;Survival Analysis;Neoplasms;Survival",M01.060.116;M01.060.116.100;M01.060.116.100.080;F03.600.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;M01.060.116.630;C04;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;D27.505.519.562.437.850;D27.505.519.625.600.850;D27.505.519.625.850.900;D27.505.696.577.600.850;D27.505.696.577.850.900;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;C04;I03.784
28251580,Anemia;Cardiac Output;Hemodilution;Hypotension;Arterial Pressure,C15.378.071;E01.370.370.380.150;G09.330.380.124;E02.514;C14.907.514;G09.330.380.076.347
28250022,Adult;Child;Health Insurance Exchanges;Health Services Accessibility;Humans;Patient Protection and Affordable Care Act;Physicians;United States,M01.060.116;M01.060.406;N03.219.521.576.343.918.500;N04.590.374.350;N05.300.430;B01.050.150.900.649.313.988.400.112.400.400;N03.219.521.576.343.918;N03.706.615.806;M01.526.485.810;N02.360.810;Z01.107.567.875
28249863,"Adult;Anxiety Disorders;Critical Care;Heart Defects, Congenital;Humans;Infant, Newborn;Intensive Care Units, Pediatric;Mothers;Stress, Psychological;United States;Young Adult",M01.060.116;F03.080;E02.760.190;N02.421.585.190;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;N02.278.388.493.390;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;F01.145.126.990;F02.830.900;Z01.107.567.875;M01.060.116.815
28249779,,
28249131,"Conflict of Interest;Financial Support;Humans;Organizations, Nonprofit;Patient Advocacy;Private Sector;Taxes;United States",K01.752.566.479.095;N05.350.225;N03.219.483;B01.050.150.900.649.313.988.400.112.400.400;N03.540.630;I01.880.604.631;N03.706.678;I01.791;N04.452.633.390;N03.219.900;Z01.107.567.875
28248764,"Adolescent;Contrast Media;Duodenal Ulcer;Duodenum;Humans;Peptic Ulcer Perforation;Tomography, X-Ray Computed",M01.060.057;D27.505.259.500;D27.720.259;C06.405.469.275.800.348;C06.405.748.586.349;A03.556.124.684.124;A03.556.875.249;B01.050.150.900.649.313.988.400.112.400.400;C06.405.469.275.800.698;C06.405.748.586.698;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28248582,,
28248553,"Animals;Chronic Disease;Down-Regulation;Endothelium, Vascular;Heterozygote;Homeostasis;Humans;Hypertension, Pulmonary;Hypoxia;Interferon-beta;Lung;Mice, Inbred C57BL;Oncogene Proteins;Pneumonia;Poly I-C;Promoter Regions, Genetic;Proto-Oncogene Protein c-fli-1;Pulmonary Artery;STAT1 Transcription Factor;Transcriptional Regulator ERG;Up-Regulation;Proto-Oncogene Protein c-fli-1;Scleroderma, Systemic",B01.050;C23.550.291.500;G02.111.240;G05.308.200;G07.690.773.937;A07.015.700.500;A10.272.491.355;G05.380.383;G07.410;B01.050.150.900.649.313.988.400.112.400.400;C08.381.423;C23.888.852.079;D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275;A04.411;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.624.664;C08.381.677;C08.730.610;D13.695.578.550.560.600;D13.695.578.550.650.600;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.260.665.400;D12.776.624.664.700.175.400;D12.776.930.720.400;A07.015.114.715;D12.644.360.024.303.500.500;D12.644.360.024.342.100;D12.776.157.057.061.500.500;D12.776.157.057.186.100;D12.776.260.513.249.500;D12.776.476.024.386.500.500;D12.776.476.024.430.100;D12.776.930.354.249.500;D12.776.930.840.100;D12.776.260.755.100;D12.776.930.900.625;G02.111.905;G05.308.850;G07.690.773.998;D12.776.260.665.400;D12.776.624.664.700.175.400;D12.776.930.720.400;C17.300.799;C17.800.784
28248552,"Aged;Aged, 80 and over;Case-Control Studies;Disease Progression;Genotype;Humans;Idiopathic Pulmonary Fibrosis;Lung Transplantation;Middle Aged;Polymorphism, Single Nucleotide;Proportional Hazards Models;Prospective Studies;Receptor for Advanced Glycation End Products;Solubility;United States;Lung Diseases, Interstitial;Pulmonary Fibrosis",M01.060.116.100;M01.060.116.100.080;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C23.550.291.656;G05.380;B01.050.150.900.649.313.988.400.112.400.400;C08.381.483.487.500;C08.381.765.500;E04.928.600.495;E04.936.450.495;M01.060.116.630;G05.365.795.598;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;D12.776.543.750.615;G02.805;Z01.107.567.875;C08.381.483;C08.381.765
28247874,Biomedical Research;Dermatology;Evidence-Based Medicine;Hospital Medicine;Humans;Rare Diseases;Research Design;Skin Diseases;Time Factors;Hospitalists;Rare Diseases;Research,H01.770.644.145;H02.403.225;H02.249.750;H02.403.200.400;H02.403.377;B01.050.150.900.649.313.988.400.112.400.400;C23.550.291.906;E05.581.500;H01.770.644.728;C17.800;G01.910.857;M01.526.485.630.490.400;M01.526.485.740.422.400;M01.526.485.810.580;N02.360.630.490.400;N02.360.740.422.400;N02.360.810.580;C23.550.291.906;H01.770.644
28247223,Head and Neck Neoplasms;Hematologic Neoplasms;Humans;Lymphoma;World Health Organization;Lymphoma;World Health Organization,C04.588.443;C04.588.448;C15.378.400;B01.050.150.900.649.313.988.400.112.400.400;C04.557.386;C15.604.515.569;C20.683.515.761;N03.540.514.718.800;C04.557.386;C15.604.515.569;C20.683.515.761;N03.540.514.718.800
28247082,"Adolescent;Anticoagulants;Catheters;Child;Child, Preschool;Citrates;Heparin;Humans;Membranes, Artificial;Pressure;Renal Dialysis;Retrospective Studies;Thrombosis;Time Factors;Ultrafiltration;Pediatrics",M01.060.057;D27.505.954.502.119;E07.132;M01.060.406;M01.060.406.448;D02.241.081.901.434;D09.698.373.400;B01.050.150.900.649.313.988.400.112.400.400;D25.479;J01.637.051.479;J01.637.087.500;G01.374.715;E02.870.300;E02.912.800;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C14.907.355.830;G01.910.857;E04.292.975;E05.196.454.807;G01.280.807;G02.263.807;H02.403.670
28247064,"Adult;Aged;Aged, 80 and over;Alzheimer Disease;Amyloid beta-Peptides;Apolipoproteins E;Biomarkers;Disease Progression;Endophenotypes;Genetic Loci;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Risk Factors;tau Proteins;Alzheimer Disease;Endophenotypes;Genome-Wide Association Study",M01.060.116;M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;D23.101;C23.550.291.656;G05.695.224;G05.360.340.024.380;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;G05.695.224;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500
28246900,"Adolescent;Child;Contrast Media;Edema;Humans;Magnetic Resonance Imaging;Multimodal Imaging;Ovarian Diseases;Ovary;Radiographic Image Enhancement;Retrospective Studies;Tomography, X-Ray Computed;Ultrasonography;Child;Edema;Magnetic Resonance Imaging;Ovary;Neoplasms",M01.060.057;M01.060.406;D27.505.259.500;D27.720.259;C23.888.277;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.567;C13.351.500.056.630;C19.391.630;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;E01.370.350.600.350.700;E01.370.350.700.700;L01.224.308.380.600;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.370.350.850;M01.060.406;C23.888.277;E01.370.350.825.500;A05.360.319.114.630;A05.360.576.497;A06.300.312.497;C04
28246349,Curriculum;Delivery of Health Care;Forecasting;Health Policy;Hospitalists;Hospitalization;Humans;Internship and Residency;Pediatrics;Specialty Boards;United States;Workforce,I02.158;N04.590.374;N05.300;I01.320;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;M01.526.485.630.490.400;M01.526.485.740.422.400;M01.526.485.810.580;N02.360.630.490.400;N02.360.740.422.400;N02.360.810.580;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;H02.403.670;N03.706.110.120.580;N05.700.200.190.750;Z01.107.567.875;N04.452.525
28246202,"Animals;Animals, Newborn;Autophagy;Blotting, Western;Cardiomegaly;Cells, Cultured;DNA-Binding Proteins;Endosomes;Gene Expression Regulation;HEK293 Cells;Humans;Mechanistic Target of Rapamycin Complex 1;Mechanistic Target of Rapamycin Complex 2;Mice, Knockout;Mice, Transgenic;Microscopy, Confocal;Myocytes, Cardiac;Oxidative Stress;Rats;Signal Transduction;Transcription Factors",B01.050;B01.050.050.282;G04.146.399;G04.417.350.091;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;C14.280.195;C23.300.775.250;A11.251;D12.776.260;A11.284.430.214.190.875.190.880.337;G05.308;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500;D05.500.356;D08.811.913.696.620.682.700.931.750;D12.776.476.925.750;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;E01.370.350.515.395;E05.595.395;A07.541.704.570;A10.690.552.750.570;A11.620.500;G03.673;G07.775.750;B01.050.150.900.649.313.992.635.505.700;G02.111.820;G04.835;D12.776.930
28246194,"Alemtuzumab;Animals;Antibodies, Monoclonal, Humanized;Antigens, CD20;CD3 Complex;Gene Expression;Genetic Vectors;Hematopoietic Stem Cell Transplantation;Humans;Immunotherapy, Adoptive;Interleukin-3 Receptor alpha Subunit;Lentivirus;Leukemia, Myeloid, Acute;Lymphocyte Depletion;Mice;Mice, Inbred NOD;RNA, Antisense;RNA, Messenger;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Remission Induction;Rituximab;T-Lymphocytes;Transplantation, Heterologous;Treatment Outcome;Tumor Necrosis Factor Receptor Superfamily, Member 9;Xenograft Model Antitumor Assays",D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375;B01.050;D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D23.050.301.264.035.120;D23.050.301.264.051.120;D23.101.100.110.120;D23.101.100.150.120;D23.050.301.264.894.095;D23.101.100.894.095;G05.297;G05.360.337;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.776.543.750.705.852.420.340.500;B04.820.650.589;C04.557.337.539.275;E02.095.465.425.450.521;E05.478.610.570;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;D13.150.650;D13.444.600.150.760;D13.444.735.150;D27.720.470.530.600.150.760;D13.444.735.544;D12.776.543.750.705.816.824;D12.776.828.300;E02.860;D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E04.936.764;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;D12.776.543.750.705.852.760.220;E05.337.550.200.900;E05.624.850
28246193,"Animals;Enhancer of Zeste Homolog 2 Protein;Graft vs Host Disease;HSP90 Heat-Shock Proteins;Hematopoiesis;Hematopoietic Stem Cell Transplantation;Histones;Indoles;Isoxazoles;Lysine;Methylation;Mice, Inbred BALB C;Mice, Inbred C57BL;Minor Histocompatibility Antigens;Protein Domains;Protein Stability;Pyridones;Resorcinols;T-Lymphocytes;Transplantation, Homologous",B01.050;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;C20.452;D12.776.580.216.380;G04.152.825;G09.188.343;E02.095.147.500.500.500;E04.936.225.687.500;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;D03.633.100.473;D03.383.129.385;D12.125.068.555;D12.125.095.647;D12.125.142.497;G02.111.035.538;G02.607.094.538;G03.059.538;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D23.050.301.500.600;D23.050.705.552.600;G02.111.570.820.709.275.750;G02.111.570.820.709.610.500;G02.111.700;D03.383.725.791;D02.455.426.559.389.657.852;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E04.936.864
28246187,Animals;Biological Availability;Blood Vessels;Body Patterning;Bone Diseases;Bone Morphogenetic Proteins;Connective Tissue Diseases;Fibrillins;Homeostasis;Humans;Integrins;Signal Transduction;Transforming Growth Factor beta,B01.050;G03.787.151;G07.690.725.129;A07.015;G07.345.500.100;C05.116;D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200;C17.300;D09.400.430.875;D12.776.395.341;D12.776.860.300.400;G07.410;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.408;G02.111.820;G04.835;D12.644.276.374.687;D12.644.276.954.775;D12.776.467.374.687;D12.776.467.942.775;D23.529.374.687;D23.529.942.775
28246053,,
28246000,,
28245999,,
28244983,"Adult;Brain;Depression;Diffusion Magnetic Resonance Imaging;Functional Neuroimaging;Hippocampus;Humans;Magnetic Resonance Imaging;Organ Size;Prefrontal Cortex;Psychological Trauma;Stress Disorders, Post-Traumatic;Veterans;War Exposure",M01.060.116;A08.186.211;F01.145.126.350;E01.370.350.825.500.150;E01.370.350.578.875;E01.370.376.537.625;E05.629.875;A08.186.211.180.405;A08.186.211.200.885.287.500.345;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.600.115.100.660;E05.041.124.715;G07.100.100.660;G07.345.249.690;A08.186.211.200.885.287.500.270.700;F03.950.750.375;F03.950.750.500;M01.930;I01.880.735.950.500.951;N06.850.460.350.600.903
28244929,Adult;Anterior Cruciate Ligament;Anterior Cruciate Ligament Reconstruction;Audiovisual Aids;Checklist;Humans;Internship and Residency;Prospective Studies;Simulation Training,M01.060.116;A02.513.514.100;A02.835.583.512.100;A10.165.669.514.100;E04.555.110.026;E04.680.101.026;J01.897.280.500;L01.178.820.090;N05.715.360.300.179;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I02.903.847
28244925,,
28244576,"Aged;Aged, 80 and over;Arm;Body Composition;Body Mass Index;Cohort Studies;Frail Elderly;Humans;Leg;Mortality;Muscle, Skeletal;Nutrition Surveys;Proportional Hazards Models;Risk;Geriatrics",M01.060.116.100;M01.060.116.100.080;A01.378.800.075;G02.111.130;G03.180;G07.100.049;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.060.116.100.540;B01.050.150.900.649.313.988.400.112.400.400;A01.378.610.500;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;A02.633.567;A10.690.552.500;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;H02.403.355
28244406,,
28243573,Hepacivirus;Liver Transplantation,B04.450.380;B04.820.250.475;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490
28242844,"Biomarkers;Cause of Death;Disease Progression;Fibroblast Growth Factors;Humans;Kaplan-Meier Estimate;Kidney Failure, Chronic;Models, Statistical;Prognosis;Proportional Hazards Models;Renal Insufficiency, Chronic;Risk Assessment;Risk Factors;Survival Analysis;Time Factors;Cardiovascular Diseases;Proportional Hazards Models;Fibroblast Growth Factors;Follow-Up Studies;Renal Insufficiency;Proportional Hazards Models;Renal Insufficiency;Risk;Survival Analysis",D23.101;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;C23.550.291.656;D12.644.276.624;D12.776.467.624;D23.529.624;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C12.777.419.780.750.500;C13.351.968.419.780.750.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;G01.910.857;C14;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;D12.644.276.624;D12.776.467.624;D23.529.624;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C12.777.419.780;C13.351.968.419.780;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C12.777.419.780;C13.351.968.419.780;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
28242633,"Animals;Cyclooxygenase 1;Membrane Proteins;Mice;Mice, Knockout;MicroRNAs;Mitochondria, Heart;Myoblasts;Myocardial Reperfusion Injury;Myocytes, Cardiac;Oxidative Stress;PTEN Phosphohydrolase;Rats;Phosphatidylinositol 3-Kinases;MicroRNAs;Mitochondria;Oxidative Stress;Reperfusion Injury",B01.050;D08.811.600.720.500;D12.776.543;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A11.284.430.214.190.875.564.627.603;A11.284.835.626.627.603;A11.872.620;C14.280.238.615;C14.280.647.625;C14.907.585.625;C14.907.725.600;C23.550.767.877.500;A07.541.704.570;A10.690.552.750.570;A11.620.500;G03.673;G07.775.750;D08.811.277.352.650.850;D12.776.476.590;D12.776.624.776.695;B01.050.150.900.649.313.992.635.505.700;D08.811.913.696.620.500;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;A11.284.430.214.190.875.564;A11.284.835.626;G03.673;G07.775.750;C14.907.725;C23.550.767.877
28242455,"Animals;Anisotropy;Cattle;Extracellular Matrix;Meniscus;Microscopy, Atomic Force;Anisotropy;Extracellular Matrix;Meniscus",B01.050;G01.590.040;G02.050;B01.050.150.900.649.313.500.380.271;A11.284.295.310;A02.165.308.538;A10.165.382.350.163;E01.370.350.515.666.400;E05.595.666.400;G01.590.040;G02.050;A11.284.295.310;A02.165.308.538;A10.165.382.350.163
28242297,"Alzheimer Disease;Amyloid beta-Peptides;Amyloid beta-Protein Precursor;Animals;Animals, Genetically Modified;Antigens, Neoplasm;Caenorhabditis elegans;Disease Models, Animal;Early Growth Response Protein 1;Gene Expression Regulation;Genome-Wide Association Study;Heparin-binding EGF-like Growth Factor;Humans;Membrane Transport Proteins;Mitochondrial ADP, ATP Translocases;NADH Dehydrogenase;Polymorphism, Single Nucleotide;Protein Interaction Maps;RNA Interference;Systems Biology;Temporal Lobe;Alzheimer Disease;Systems Biology",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D12.776.049.407.249;D12.776.543.039;D12.776.645.468.500;D12.776.811.050;B01.050;B01.050.050.136;B05.620.136;D23.050.285;B01.050.500.500.294.400.875.660.250.250;C22.232;E05.598.500;E05.599.395.080;D12.776.260.158.500;D12.776.460.525.500;D12.776.930.213.500;G05.308;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;D12.644.276.382.625;D12.776.467.382.625;D23.529.382.625;B01.050.150.900.649.313.988.400.112.400.400;D12.776.157.530;D12.776.543.585;D12.776.157.530.625.875.500;D12.776.157.530.937.594;D12.776.543.585.450.162.225;D12.776.543.585.475.500;D12.776.543.585.625.875.500;D12.776.543.585.937.688;D12.776.575.750.500;D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500;G05.365.795.598;G03.493.750;G05.308.203.374.790;H01.158.273.180.800;A08.186.211.200.885.287.500.863;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;H01.158.273.180.800
28241909,"Attitude;Blood Cell Count;Blood Transfusion;Child;Hemoglobins;Hospital Costs;Hospitals, Pediatric;Humans;Intensive Care Units, Pediatric;Pennsylvania;Philadelphia;Postoperative Care;Postoperative Period;Practice Patterns, Physicians';Quality Improvement;Risk;Surveys and Questionnaires;Unnecessary Procedures",F01.100;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E02.095.135;M01.060.406;D12.776.124.400;D12.776.422.316.762;N03.219.151.400.687;N03.219.262.500;N05.300.375.500;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493.390;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;Z01.107.567.875.500.550.525;Z01.433.820;E02.760.731.700;E04.604.500;N02.421.585.722.700;E04.614.750;N02.421.585.753.750;N04.590.374.577;N05.300.625;J01.293.754;N04.761.744;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;N02.421.380.450.500;N05.300.150.395.450.500
28241822,"Aged;Blood Pressure;Blood Pressure Monitoring, Ambulatory;Canagliflozin;Diabetes Mellitus, Type 2;Double-Blind Method;Humans;Hypertension;Hypoglycemic Agents;Kidney Tubules, Proximal;Middle Aged;Sodium-Glucose Transporter 2;Sodium-Glucose Transporter 2 Inhibitors;Time Factors;Treatment Outcome;Vascular Stiffness;Blood Pressure Monitoring, Ambulatory;Blood Pressure;Canagliflozin;Arterial Pressure;Blood Pressure;Diabetes Mellitus, Type 2",M01.060.116.100;E01.370.600.875.249;G09.330.380.076;E01.370.370.140.100;E01.370.520.500.100;D02.886.778.075;D03.383.903.075;D09.408.348.113;C18.452.394.750.149;C19.246.300;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;B01.050.150.900.649.313.988.400.112.400.400;C14.907.489;D27.505.696.422;A05.810.453.736.560.570;M01.060.116.630;D12.776.157.530.450.625.437.750;D12.776.157.530.500.750.750;D12.776.157.530.937.700;D12.776.543.585.450.625.562.750;D12.776.543.585.500.750.750;D12.776.543.585.937.825;D27.505.519.936;D27.505.696.422.750;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.940;E01.370.370.140.100;E01.370.520.500.100;E01.370.600.875.249;G09.330.380.076;D02.886.778.075;D03.383.903.075;D09.408.348.113;G09.330.380.076.347;E01.370.600.875.249;G09.330.380.076;C18.452.394.750.149;C19.246.300
29754554,"Adult;Attitude of Health Personnel;Education, Medical;Genomics;Health Knowledge, Attitudes, Practice;Humans;Physicians;Precision Medicine;Surveys and Questionnaires;Taiwan;Taiwan;Attitude;Intention;Physicians",M01.060.116;F01.100.050;N05.300.100;I02.358.399;H01.158.273.180.350;H01.158.273.343.350;F01.100.150.500;N05.300.150.410;B01.050.150.900.649.313.988.400.112.400.400;M01.526.485.810;N02.360.810;E02.574;H02.403.200.700;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.252.474.872;Z01.639.850;Z01.252.474.872;Z01.639.850;F01.100;F01.658.650;F02.463.306;M01.526.485.810;N02.360.810
28241356,Aged;Androgens;Cognition;Double-Blind Method;Executive Function;Gels;Humans;Intention to Treat Analysis;Memory;Memory Disorders;Mental Recall;Reference Values;Testosterone;Time Factors;Treatment Outcome,M01.060.116.100;D27.505.696.399.472.161;F02.463.188;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;F02.463.217;D20.280.320;D26.255.165.320;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.250.250.365.500.500;N05.715.360.330.250.250.365.500.500;N06.850.520.450.250.250.365.500.500;F02.463.425.540;C10.597.606.525;C23.888.592.604.529;F01.700.625;F02.463.425.540.641;E05.978.810;D04.210.500.054.079.429.824;D06.472.334.851.968.984;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28241355,Aged;Androgens;Coronary Angiography;Coronary Artery Disease;Disease Progression;Double-Blind Method;Gels;Hormone Replacement Therapy;Humans;Hypogonadism;Observer Variation;Sample Size;Testosterone;United States;Vascular Calcification,M01.060.116.100;D27.505.696.399.472.161;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;C23.550.291.656;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D20.280.320;D26.255.165.320;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;C19.391.482;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.762;E05.581.500.902;N05.715.360.325.692;N06.850.520.445.762;D04.210.500.054.079.429.824;D06.472.334.851.968.984;Z01.107.567.875;C18.452.174.130.780
28241253,"Anti-Bacterial Agents;Blood Culture;California;Humans;Infant;Infant, Newborn;Infant, Premature;Models, Theoretical;Neonatal Sepsis;Risk Assessment;Risk Factors",D27.505.954.122.085;E01.370.225.875.185;E05.200.875.185;Z01.107.567.875.580.200;Z01.107.567.875.760.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;M01.060.703.520.520;E05.599;C01.539.757.580;C16.614.627;C23.550.470.790.500.470;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28241237,Aged;Androgens;Anemia;Double-Blind Method;Drug Administration Routes;Drug Monitoring;Hemoglobins;Hormone Replacement Therapy;Humans;Testosterone;Treatment Outcome,M01.060.116.100;D27.505.696.399.472.161;C15.378.071;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.267;E01.370.520.200;D12.776.124.400;D12.776.422.316.762;E02.319.452;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.054.079.429.824;D06.472.334.851.968.984;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28241231,"Absorptiometry, Photon;Aged;Androgens;Bone Density;Double-Blind Method;Drug Administration Routes;Drug Monitoring;Hip Fractures;Humans;Lumbar Vertebrae;Spinal Fractures;Testosterone;Tomography, X-Ray Computed;Treatment Outcome",E01.370.350.700.024;E05.196.712.224.187;M01.060.116.100;D27.505.696.399.472.161;G11.427.100;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.267;E01.370.520.200;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;A02.835.232.834.519;C26.117.500.500;C26.404.812;D04.210.500.054.079.429.824;D06.472.334.851.968.984;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28241211,"Adult;Child;Child, Hospitalized;Cohort Studies;Family;Hospitals, Pediatric;Humans;Medical Errors;Prospective Studies;United States",M01.060.116;M01.060.406;M01.643.259;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.829.263;I01.880.853.150;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N02.421.450;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;Z01.107.567.875
28241208,"Adult;Aged;Aged, 80 and over;Cardiovascular Diseases;Genetic Predisposition to Disease;Genome-Wide Association Study;Germ-Line Mutation;Humans;Mendelian Randomization Analysis;Middle Aged;Neoplasms;Polymorphism, Single Nucleotide;Risk Assessment;Telomere;Telomere Homeostasis",M01.060.116;M01.060.116.100;M01.060.116.100.080;C14;C23.550.291.687.500;G05.380.355;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;G05.365.590.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.416.500;M01.060.116.630;C04;G05.365.795.598;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;A11.284.430.106.279.345.190.160.845;G05.360.160.845;G04.144.220.625;G04.161.750.500.500;G05.113.610;G07.345.249.410.750.500.750
28241190,Child;Child Health;Clinical Competence;Humans;Pediatrics;Specialty Boards;United States,M01.060.406;N01.400.225;I02.399.630.210;N04.761.210;N05.715.175;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;N03.706.110.120.580;N05.700.200.190.750;Z01.107.567.875
28241186,"Adult;Aged;Antibodies, Viral;Autopsy;DNA, Viral;Humans;Immunocompromised Host;JC Virus;Middle Aged;Polyomavirus Infections;Seroepidemiologic Studies;Tissue Distribution;Tumor Virus Infections",M01.060.116;M01.060.116.100;D12.776.124.486.485.114.254;D12.776.124.790.651.114.254;D12.776.377.715.548.114.254;E01.370.060;E05.070;I01.198.780.937.120;D13.444.308.568;B01.050.150.900.649.313.988.400.112.400.400;G12.470;B04.280.210.700.615.400;B04.613.204.670.615.400;M01.060.116.630;C02.256.721;E05.318.372.500.950;N05.715.360.330.500.950;N06.850.520.450.500.950;G03.787.917;G07.690.725.949;C02.928
28241164,"Child, Preschool;Craniosynostoses;Cross-Sectional Studies;Humans;Hydrocephalus;Infant;Intracranial Hypertension;Intracranial Pressure;Observer Variation;Prospective Studies;Retina;Sensitivity and Specificity;Tomography, Optical Coherence",M01.060.406.448;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.602;M01.060.703;C10.228.140.631;G11.561.170.505;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;A09.371.729;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500
28240804,Humans;Liver Transplantation;Middle Aged;Tissue and Organ Procurement,B01.050.150.900.649.313.988.400.112.400.400;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;N02.421.911
28240793,"Adolescent;Anemia, Iron-Deficiency;Benzoates;Drug Therapy, Combination;Ferritins;Humans;Hydrazines;Iron;Iron Chelating Agents;Molecular Structure;Platelet Count;Purpura, Thrombocytopenic, Idiopathic;Pyrazoles;Receptors, Fc;Recombinant Fusion Proteins;Thrombopoietin;Young Adult",M01.060.057;C15.378.071.196.300;C18.452.565.100;D02.241.223.100;D02.455.426.559.389.127;E02.319.310;D12.776.157.427.249;D12.776.556.579.249;B01.050.150.900.649.313.988.400.112.400.400;D02.442;D01.268.556.412;D01.268.956.287;D01.552.544.412;D27.505.519.914.500.410;D27.720.832.500.410;G02.111.570;G02.466;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;C15.378.100.802.687.600;C15.378.140.855.925.750.600;C15.378.463.740;C20.111.759;C20.841.600;C23.550.414.950.687.600;C23.888.885.687.687.600;D03.383.129.539;D12.776.543.750.705.871;D12.776.828.300;D12.644.276.374.410.240.750;D12.776.395.240.750;D12.776.467.374.410.240.750;D23.529.374.410.240.750;M01.060.116.815
28240778,"Accidental Falls;Depression;Fear;Hip Fractures;Humans;Longitudinal Studies;Missouri;Prospective Studies;Risk Factors;Stress Disorders, Post-Traumatic;Surveys and Questionnaires;Stress Disorders, Post-Traumatic",N06.850.135.122;F01.145.126.350;F01.470.361;C26.404.061.425;C26.531.750;C26.558.276.425;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;Z01.107.567.875.510.515;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F03.950.750.500;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F03.950.750.500
28240295,"Adolescent;Adult;Attention;Brain;Brain Mapping;Comprehension;Hemodynamics;Humans;Magnetic Resonance Imaging;Neuroimaging;Reproducibility of Results;Spectroscopy, Near-Infrared;Speech;Speech Perception",M01.060.057;M01.060.116;F02.830.104.214;A08.186.211;E01.370.350.578.875.500;E01.370.376.537.625.500;E05.629.875.500;F02.463.188.357;G09.330.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;E01.370.350.578;E01.370.376.537;E05.629;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E01.370.350.750;E05.196.867.851;F01.145.209.908.677;G11.561.812;L01.559.423.676;F02.463.593.071.875
28240214,"Basic Helix-Loop-Helix Transcription Factors;Ectopic Gene Expression;Gene Expression Regulation, Leukemic;Genome, Human;Humans;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Proto-Oncogene Proteins;T-Cell Acute Lymphocytic Leukemia Protein 1;Transcriptional Activation",D12.776.260.103;D12.776.930.125;G05.308.202;G05.308.370.500;G05.360.340.350;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.428.600.620;C15.604.515.560.600.620;C20.683.515.528.600.620;D12.776.624.664.700;D12.776.260.103.829;D12.776.624.664.700.960;D12.776.930.125.829;G05.308.800
28240151,Crime,I01.198.240;I01.880.735.191
28239929,Bias;Confounding Factors (Epidemiology);Epidemiologic Research Design;Humans;Pharmacoepidemiology;Propensity Score;Pharmacoepidemiology,N05.715.350.150;N06.850.490.500;N05.715.350.240;N06.850.490.718;E05.318.370;N05.715.360.325;N06.850.520.445;B01.050.150.900.649.313.988.400.112.400.400;H01.158.703.045;H02.403.720.500.650;H02.628.413;E05.318.740.600.675;N05.715.360.750.625.620;N06.850.520.830.600.650;H01.158.703.045;H02.403.720.500.650;H02.628.413
28239905,"Biomarkers;Child;Child Development;Environmental Exposure;Humans;Lead Poisoning;Likelihood Functions;Longitudinal Studies;Models, Statistical;Pregnancy;Prenatal Exposure Delayed Effects",D23.101;M01.060.406;F01.525.200;G07.345.374.750;N06.850.460.350;B01.050.150.900.649.313.988.400.112.400.400;C25.723.522.750;E05.318.740.500.475;E05.318.740.600.400;E05.599.835.500;N05.715.360.750.530.450;N05.715.360.750.625.450;N06.850.520.830.500.475;N06.850.520.830.600.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E05.318.740.500;E05.599.835;N05.715.360.750.530;N06.850.520.830.500;G08.686.784.769;C13.703.824.500
28239419,"Disease;Regulatory Sequences, Nucleic Acid",C23.550.288;G02.111.570.080.689;G05.360.080.689
28239365,Behavior;Nursing,F01.145;H02.478;N04.452.758.377
28239277,HMGB1 Protein;Rage;Hematologic Neoplasms;Leukemia;Lymphoma,D12.776.260.356.300;D12.776.660.235.400.600.300;D12.776.664.235.400.600.300;F01.470.093.640;C04.588.448;C15.378.400;C04.557.337;C04.557.386;C15.604.515.569;C20.683.515.761
28238740,Aged;Cognition;Cognitive Dysfunction;Educational Status;Humans;Mental Status and Dementia Tests;Nervous System Diseases;Sensitivity and Specificity;Time Factors,M01.060.116.100;F02.463.188;F03.615.250.700;N01.824.196;B01.050.150.900.649.313.988.400.112.400.400;F04.711.513.603;C10;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;G01.910.857
28238711,"Adenosine;Adult;Aged;Aspirin;Atherosclerosis;Dose-Response Relationship, Drug;Double-Blind Method;Fibrinolytic Agents;Humans;International Cooperation;Ischemic Attack, Transient;Middle Aged;Proportional Hazards Models;Stroke;Ticagrelor;Treatment Outcome",D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;M01.060.116;M01.060.116.100;D02.455.426.559.389.657.410.595.176;C14.907.137.126.307;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;D27.505.519.421.750;D27.505.954.411.320;D27.505.954.502.427;B01.050.150.900.649.313.988.400.112.400.400;I01.615.500;C10.228.140.300.150.836;C14.907.253.092.836;M01.060.116.630;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;C10.228.140.300.775;C14.907.253.855;D03.633.100.759.590.138.806;D13.570.583.138.806;D13.570.800.096.815;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28238580,"Aged;Catheter Obstruction;Catheterization, Central Venous;Catheters, Indwelling;Central Venous Catheters;Endovascular Procedures;Humans;Middle Aged;Neoplasms;Prosthesis Design;Retrospective Studies;Risk Factors;Stents;Time Factors;Treatment Outcome;Vascular Diseases;Vascular Patency;Veins",M01.060.116.100;E05.325.095;E07.132.249;E02.148.167;E04.100.814.529.875;E04.502.382.875;E05.157.313;E07.132.500;E07.132.750.500;E04.100.814.529;E04.502.382;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C04;E05.320.550;E07.695.680;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E07.695.750;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.907;G09.330.920;A07.015.908
28237635,Glycated Hemoglobin A;Hispanic Americans;Humans;Hypoglycemic Agents;Life Style;Metformin;Middle Aged;Prediabetic State;Waist Circumference;Weight Loss,D09.400.430.937;D12.776.124.400.405.440;D12.776.395.381;D12.776.422.316.762.380.440;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.422;F01.829.458;D02.078.370.141.450;M01.060.116.630;C18.452.394.750.774;C19.246.774;E01.370.600.115.100.160.560;E05.041.124.160.875;G07.100.100.160.560;C23.888.144.243.963;G07.345.249.314.120.200.963
28237459,"Amylin Receptor Agonists;Animals;Body Weight;Calcitonin;Conditioning, Operant;Eating;Food Preferences;GABA Agents;Gene Expression Regulation;Islet Amyloid Polypeptide;Motivation;Peptide Fragments;Phosphopyruvate Hydratase;RNA, Small Interfering;Rats;Rats, Sprague-Dawley;Receptor Activity-Modifying Proteins;Receptors, Islet Amyloid Polypeptide;Signal Transduction;Ventral Tegmental Area;gamma-Aminobutyric Acid;Calcitonin;Eating;Obesity;Reward",D27.505.519.143;D27.505.696.422.374;B01.050;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D06.472.699.150;D06.472.931.052;D12.644.400.095;D12.644.548.150;D12.776.631.650.095;F02.463.425.179.509;G07.203.650.283;G10.261.330;F01.145.407.516;G07.203.650.353.516;D27.505.519.625.240;D27.505.696.577.240;G05.308;D06.472.699.587.334;D12.644.548.586.234;D12.776.049.407.500;F01.658;F01.752.543.500.750;D12.644.541;D08.811.520.241.300.500;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;D12.776.476.024.414;D12.776.543.725;D12.776.543.750.695.360;G02.111.820;G04.835;A08.186.211.132.659.413.875.820;D02.241.081.114.500.350;D12.125.190.350;D06.472.699.150;D06.472.931.052;D12.644.400.095;D12.644.548.150;D12.776.631.650.095;G07.203.650.283;G10.261.330;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;F02.463.425.770.836
28237426,"Adolescent;Adult;Child;Color Perception;Dependovirus;Follow-Up Studies;Genetic Therapy;Genetic Vectors;Humans;Injections, Intraocular;Leber Congenital Amaurosis;Magnetic Resonance Imaging;Middle Aged;Mutation;Reflex, Pupillary;Retina;Visual Cortex;Visual Pathways;cis-trans-Isomerases",M01.060.057;M01.060.116;M01.060.406;F02.463.593.932.217;B04.280.580.650.170;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;E02.095.301;E05.393.420.301;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;E02.319.267.530.475;C11.270.516;C11.768.364;E01.370.350.825.500;M01.060.116.630;G05.365.590;E01.370.376.550.650.690;E01.370.600.550.650.690;G11.561.731.705;A09.371.729;A08.186.211.200.885.287.500.571.735;A08.186.211.200.885.287.500.814.953;A08.612.220.860;D08.811.399.325
28237248,Animals;Biomedical Research;Brain;Child;Humans;Magnetic Resonance Imaging;Pediatrics;Stroke;Neuroimaging;Stroke,B01.050;H01.770.644.145;A08.186.211;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;H02.403.670;C10.228.140.300.775;C14.907.253.855;E01.370.350.578;E01.370.376.537;E05.629;C10.228.140.300.775;C14.907.253.855
28236946,,
28236575,"3' Untranslated Regions;Animals;Ataxin-3;Cell Line;Disease Models, Animal;Gene Expression;Gene Expression Regulation;Gene Order;Genes, Reporter;Genetic Vectors;Humans;Lentivirus;Machado-Joseph Disease;Mice;Mice, Transgenic;MicroRNAs;Mutation;Neurons;Protein Aggregation, Pathological;RNA Interference;RNA Stability;Machado-Joseph Disease;Genetic Therapy;Lentivirus;MicroRNAs",D13.444.735.544.875.880;D13.444.735.790.878.880;G05.360.340.024.220.880.880;G05.360.340.024.340.137.910.880;B01.050;D08.811.037.250;D12.776.631.069.875;D12.776.660.075.875;A11.251.210;C22.232;E05.598.500;E05.599.395.080;G05.297;G05.308;G05.340;G05.360.340.024.340.435;G05.360.337;B01.050.150.900.649.313.988.400.112.400.400;B04.820.650.589;C10.228.140.252.190.530.530;C10.228.140.252.700.700.500;C10.228.854.787.875.500;C10.574.500.825.700.500;C10.597.350.090.500.530.530;C16.320.400.780.875.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;G05.365.590;A08.675;A11.671;C23.550.770;G02.111.675;G05.308.203.374.790;G02.111.780;C10.228.140.252.190.530.530;C10.228.140.252.700.700.500;C10.228.854.787.875.500;C10.574.500.825.700.500;C10.597.350.090.500.530.530;C16.320.400.780.875.500;E02.095.301;E05.393.420.301;B04.820.650.589;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
28235947,"Autoantigens;Cell Cycle;Cell Line, Tumor;Centromere;Centromere Protein A;Chromatin;Chromosomal Proteins, Non-Histone;DNA;DNA, Satellite;HeLa Cells;Histones;Humans;Nucleosomes",D23.050.422;G04.144;A11.251.210.190;A11.251.860.180;A11.284.430.106.279.345.190.160.165;G05.360.160.165;D12.776.157.687.173;D12.776.260.123;D12.776.660.235.100;D12.776.660.720.173;D12.776.664.235.100;D23.050.422.031;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.660.235;D12.776.664.235;D13.444.308;D13.444.308.480;G02.111.570.080.708.800.150;G05.360.080.708.800.150;G05.360.340.024.220.150;G05.360.340.024.850.150;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;A11.284.430.106.279.345.190.160.180.625;D12.776.664.224.550;G05.360.160.180.625
28235647,"Child;Child, Preschool;Databases, Factual;Hospital Mortality;Humans;Infant;Intensive Care Units, Pediatric;Predictive Value of Tests;Recovery of Function;Risk Assessment;Trauma Centers;Treatment Outcome;United States;Wounds and Injuries",M01.060.406;M01.060.406.448;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N02.278.388.493.390;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;G16.757;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;N02.278.216.500.968.336.500;N02.421.297.195.480;N04.452.442.422.336.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;Z01.107.567.875;C26
28235193,Dengue;Germ Cells;Humans;Membrane Proteins;Zika Virus;Zika Virus Infection,C02.081.270;C02.782.350.250.214;C02.782.417.214;A05.360.490;A11.497;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543;B04.820.250.350.995;C02.081.990;C02.782.350.250.990
28234810,"Adolescent;Attitude of Health Personnel;Child;Child, Preschool;Clinical Competence;Critical Care;Electroencephalography;Heart Arrest;Humans;Infant;Infant, Newborn;Seizures;Sensitivity and Specificity",M01.060.057;F01.100.050;N05.300.100;M01.060.406;M01.060.406.448;I02.399.630.210;N04.761.210;N05.715.175;E02.760.190;N02.421.585.190;E01.370.376.300;E01.370.405.245;C14.280.383;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C10.597.742;C23.888.592.742;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872
28234665,"Antibodies, Monoclonal, Humanized;C-Reactive Protein;Cells, Cultured;Fatal Outcome;Fever;GPI-Linked Proteins;Humans;Hypotension;Immunotherapy, Adoptive;Interferon-gamma;Interleukin-6;Middle Aged;Neoplasm Metastasis;Ovarian Neoplasms;Receptors, Antigen, T-Cell;Receptors, Interleukin-6;Recombinant Fusion Proteins;Single-Chain Antibodies;Syndrome;T-Lymphocytes;Tumor Necrosis Factor Receptor Superfamily, Member 9",D12.776.124.486.485.114.224.060;D12.776.124.790.651.114.224.060;D12.776.377.715.548.114.224.200;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;A11.251;E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325;C23.888.119.344;D12.776.395.550.448;D12.776.543.484.500;D12.776.543.550.418;B01.050.150.900.649.313.988.400.112.400.400;C14.907.514;E02.095.465.425.400.330.050.400;E05.478.550.520.050.400;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224;M01.060.116.630;C04.697.650;C23.550.727.650;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D12.776.543.750.705.816.824;D12.776.543.750.705.852.420.400;D12.776.828.300;D12.644.541.500.650.500.800;D12.776.124.486.485.114.224.785;D12.776.124.486.485.680.650.500.800;D12.776.124.790.651.680.650.500.800;D12.776.377.715.548.680.650.500.795;C23.550.288.500;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.543.750.705.852.760.220
28234650,"Breast Feeding;Evidence-Based Nursing;Food, Fortified;Humans;Infant Nutritional Physiological Phenomena;Infant, Newborn;Infant, Premature;Intensive Care Units, Neonatal;Maternal-Child Nursing;Milk, Human",F01.145.407.199;G07.203.650.195;G07.203.650.220.500.500;G07.203.650.353.199;H02.249.875;H02.478.197;G07.203.300.515;J02.500.515;B01.050.150.900.649.313.988.400.112.400.400;G07.203.650.220.500;M01.060.703.520;M01.060.703.520.520;N02.278.388.493.390.380;H02.478.676.390;N02.421.533.460;A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500
28234345,"Amino Acid Sequence;Animals;Antibodies, Monoclonal;CD47 Antigen;Humans;Leukemia;Mice;Mice, Inbred NOD",G02.111.570.060;L01.453.245.667.060;B01.050;D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224;D12.776.395.550.014;D12.776.543.550.147;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565
28234015,"Alleles;Exons;Genotype;Genotyping Techniques;HLA Antigens;High-Throughput Nucleotide Sequencing;Histocompatibility Testing;Humans;Reproducibility of Results;Sequence Analysis, DNA",G05.360.340.024.340.030;G05.360.340.024.340.137.232;G05.380;E05.393.442;D23.050.301.500.450;D23.050.705.552.450;E05.393.760.319;E01.370.225.812.385;E05.200.812.385;E05.478.594.385;B01.050.150.900.649.313.988.400.112.400.400;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.393.760.700
28233927,Biomarkers;Clinical Trials as Topic;Humans;Parkinson Disease;Parkinson Disease;Biomarkers;Neuroprotection;Systems Biology,D23.101;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;D23.101;G11.561.645;H01.158.273.180.800
28233644,"Anti-Bacterial Agents;Critical Illness;Crowding;Emergency Service, Hospital;Fluid Therapy;Guideline Adherence;Health Services Research;Hospital Mortality;Humans;Middle Aged;Resuscitation;Retrospective Studies;Sepsis;Time-to-Treatment;Triage;United States;Organization and Administration;Crowding;Resuscitation;Sepsis",D27.505.954.122.085;C23.550.291.625;F01.145.875.281;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;E02.319.360;N04.761.337;N05.715.360.395;H01.770.644.145.360;N03.349.380;N05.425;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E02.365.647;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C01.539.757;C23.550.470.790.500;E02.760.928;N02.421.585.928;N02.421.297.900;Z01.107.567.875;N04.452;F01.145.875.281;E02.365.647;C01.539.757;C23.550.470.790.500
28233556,,
28233542,"Histiocytosis, Langerhans-Cell;Humans;Infant, Newborn;Remission, Spontaneous;Histiocytosis, Langerhans-Cell",C08.381.483.375;C15.604.250.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C23.550.291.656.700;G16.767;C08.381.483.375;C15.604.250.400
28233510,Diabetes Complications;Endocrine System Diseases;Humans;Incidence;Metabolic Diseases;Tuberculosis,C19.246.099;C19;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;C18.452;C01.252.410.040.552.846
28233230,Humans;Kidney Calculi;Recurrence;Risk Factors;Ultrasonography;Urolithiasis,B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.600.500;C12.777.967.249.500;C12.777.967.500.503;C13.351.968.419.600.500;C13.351.968.967.249.500;C13.351.968.967.500.503;C23.300.175.850.550;C23.550.291.937;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E01.370.350.850;C12.777.967;C13.351.968.967
28233183,"Animals;DNA, Mitochondrial;Disease Models, Animal;Genetic Therapy;Humans;Mice;Mutation;Optic Atrophy, Hereditary, Leber;Models, Animal;Estrogen Receptor beta;Genetic Therapy;Optic Atrophy, Hereditary, Leber;DNA, Mitochondrial;Mitochondrial Diseases;Oxidative Stress;Retinal Ganglion Cells",B01.050;D13.444.308.283.225;C22.232;E05.598.500;E05.599.395.080;E02.095.301;E05.393.420.301;B01.050.150.900.649.313.988.400.112.400.400;B01.050.150.900.649.313.992.635.505.500;G05.365.590;C10.292.700.225.500.400;C10.574.500.662.400;C11.270.564.400;C11.640.451.451.400;C16.320.290.564.400;C16.320.400.630.400;C18.452.660.670;E05.598;D12.776.826.750.350.262;E02.095.301;E05.393.420.301;C10.292.700.225.500.400;C10.574.500.662.400;C11.270.564.400;C11.640.451.451.400;C16.320.290.564.400;C16.320.400.630.400;C18.452.660.670;D13.444.308.283.225;C18.452.660;G03.673;G07.775.750;A08.675.650.850.875;A09.371.729.831.875;A11.671.650.850.875
28233121,Breast Neoplasms;Humans;Middle Aged;Patient Reported Outcome Measures;Quality of Life;Surveys and Questionnaires;Survival Rate;Survivors;Neoplasms;Quality of Life;Survivorship,C04.588.180;C17.800.090.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.308.980.344.500;N03.349.380.210.750;N04.761.559.590.399.875;N05.425.210.500;N05.715.360.300.800.344.500;N05.715.360.575.575.399.875;N06.850.520.308.980.344.500;I01.800;K01.752.400.750;N06.850.505.400.425.837;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;M01.860;C04;I01.800;K01.752.400.750;N06.850.505.400.425.837;F01.058.144.500
28233046,"Child, Preschool;Europe;Humans;Infant;Infant, Newborn;Pediatrics;Radiology;Shaken Baby Syndrome;Societies, Medical;Sweden",M01.060.406.448;Z01.542;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;H02.403.670;H02.403.740;C10.900.300.087.850;C26.915.300.200.825;N03.540.828.589;Z01.542.816.500
28232951,Fragile X Syndrome;Tuberous Sclerosis;Mechanistic Target of Rapamycin Complex 1,C10.597.606.360.455.500;C16.131.260.830.300;C16.320.180.830.300;C16.320.322.500.500;C16.320.400.525.500;C04.445.810;C04.651.800;C04.700.700;C10.500.507.400.750;C10.562.850;C10.574.500.865;C16.131.666.507.400.750;C16.320.400.880;C16.320.700.700;D05.500.337;D08.811.913.696.620.682.700.931.500;D12.776.476.925.500
28232917,Histology;Therapeutics;Therapeutics,H01.158.100.656;E02;E02
28232608,Glutamine;Humans;Molecular Imaging;Neoplasms;Positron-Emission Tomography;Glioma;Glutamine,D12.125.068.330;D12.125.095.461;D12.125.154.424;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.557;E05.601.555;C04;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;C04.557.465.625.600.380;C04.557.470.670.380;C04.557.580.625.600.380;D12.125.068.330;D12.125.095.461;D12.125.154.424
28232156,"Adenocarcinoma;Adolescent;Adult;Bile Duct Neoplasms;Biomarkers, Tumor;Cholangiocarcinoma;Cytogenetic Analysis;Diagnosis, Differential;Fatal Outcome;Gene Expression Profiling;Genetic Predisposition to Disease;Humans;Immunohistochemistry;Inhibins;Liver Neoplasms;Molecular Diagnostic Techniques;Neuroendocrine Tumors;Phenotype;Polymorphism, Single Nucleotide;Predictive Value of Tests;Terminology as Topic;Treatment Outcome;Cholangiocarcinoma",C04.557.470.200.025;M01.060.057;M01.060.116;C04.588.274.120.250;C06.130.120.120;C06.130.320.120;C06.301.120.250;D23.101.140;C04.557.470.200.025.450;E01.370.225.500.385;E05.200.500.385;E05.242.385;E05.393.285;E01.171;E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325;E05.393.332;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;D06.472.334.968;D06.472.699.337;D12.644.548.387;D12.776.395.439;C04.588.274.623;C06.301.623;C06.552.697;E01.370.225.880;E05.200.880;E05.393.520;C04.557.465.625.650;C04.557.580.625.650;G05.695;G05.365.795.598;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;L01.559.598.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.557.470.200.025.450
28232030,"Adjuvants, Immunologic;Adolescent;B-Lymphocytes;Child;Child, Preschool;Humans;Interleukin-2;Killer Cells, Natural;Leukocyte Count;Platelet Count;T-Lymphocytes;Wiskott-Aldrich Syndrome;Wiskott-Aldrich Syndrome",D27.505.696.477.067;M01.060.057;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;D12.644.276.374.465.021;D12.644.276.374.480.372;D12.776.467.374.465.021;D12.776.467.374.480.372;D23.529.374.465.155;D23.529.374.480.372;A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537;E01.370.225.500.195.107.595;E01.370.225.625.107.595;E05.200.500.195.107.595;E05.200.625.107.595;E05.242.195.107.595;G04.140.107.595;G09.188.105.595;E01.370.225.500.195.107.740;E01.370.225.625.107.700;E01.370.225.625.625.625;E05.200.500.195.107.740;E05.200.625.107.700;E05.200.625.625.625;E05.242.195.107.740;G04.140.107.740;G09.188.105.700;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;C15.378.100.100.970;C15.378.463.960;C15.378.553.546.605.900;C16.320.099.970;C16.320.322.937;C20.673.627.900;C15.378.100.100.970;C15.378.463.960;C15.378.553.546.605.900;C16.320.099.970;C16.320.322.937;C20.673.627.900
28231933,"Adolescent;Adult;Age Factors;Arrhythmias, Cardiac;Child;Death, Sudden, Cardiac;Electrocardiography;Humans;Sports Medicine;Young Adult;Athletes;Electrocardiography",M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;C14.280.067;C23.550.073;M01.060.406;C14.280.383.220;C23.550.260.322.250;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;H02.403.830;M01.060.116.815;M01.072;E01.370.370.380.240;E01.370.405.240
28231929,"Adult;Catheters, Indwelling;Equipment Design;Equipment Failure;Humans;Nephrostomy, Percutaneous;Recurrence;Urinary Bladder, Neurogenic;Wounds, Gunshot",M01.060.116;E07.132.500;E05.320;E05.325;B01.050.150.900.649.313.988.400.112.400.400;E01.370.390.550;E04.579.642;E04.950.774.739.500;E04.950.774.852.642;C23.550.291.937;C10.597.900;C12.777.829.839;C13.351.968.829.760;C23.888.592.900;C26.986.900
28231396,Autism Spectrum Disorder;Body Mass Index;Humans;Mothers;Pregnancy;Pregnancy Complications,F03.625.164.113;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;G08.686.784.769;C13.703
28231254,"Alleles;Animals;Antineoplastic Agents;Benzimidazoles;CRISPR-Cas Systems;Cell Line;Cell Line, Tumor;Cell Proliferation;Clustered Regularly Interspaced Short Palindromic Repeats;Drug Resistance, Neoplasm;Enhancer of Zeste Homolog 2 Protein;HEK293 Cells;Humans;INDEL Mutation;Methyltransferases;Mice;Models, Molecular;Mutagenesis;Neoplasms",G05.360.340.024.340.030;B01.050;D27.505.954.248;D03.633.100.103;G05.308.203.374.394;A11.251.210;A11.251.210.190;A11.251.860.180;G04.161.750;G07.345.249.410.750;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;G07.690.773.984.395;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.500;G05.558.370;D08.811.913.555.500;B01.050.150.900.649.313.992.635.505.500;E05.599.595;G05.558;C04
28230651,"Animals;Cell Culture Techniques;Disease Models, Animal;Dynamins;Hydrazones;Hypoxia;In Vitro Techniques;Mice;Naphthols;Receptors, Opioid, kappa",B01.050;E01.370.225.500.223;E05.200.500.265;E05.242.223;E05.481.500.249;C22.232;E05.598.500;E05.599.395.080;D08.811.277.040.330.200;D12.776.220.600.450.200;D12.776.543.990.400;D02.442.288;C23.888.852.079;E05.481;B01.050.150.900.649.313.992.635.505.500;D02.455.426.559.847.638.638;D04.615.638.638;D12.776.543.750.695.620.400;D12.776.543.750.720.600.610.400;D12.776.543.750.750.555.610.400
28230563,Drainage;Early Ambulation;Humans;Intensive Care Units;Intracranial Pressure;Length of Stay;Middle Aged;Patient Discharge;Physical Therapy Modalities;Prospective Studies;Subarachnoid Hemorrhage,E02.309;E04.237;E02.760.169.063.500.335;E02.831.335;B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;G11.561.170.505;E02.760.400.480;N02.421.585.400.480;M01.060.116.630;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;E02.779;E02.831.535;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C10.228.140.300.535.800;C14.907.253.573.800;C23.550.414.913.850
28230325,"Adult;Biomarkers;Bipolar Disorder;Endophenotypes;Family;Genetic Predisposition to Disease;Humans;Middle Aged;Pedigree;Phosphatidylinositols;Psychiatric Status Rating Scales;Quantitative Trait, Heritable;Risk Factors;Tandem Mass Spectrometry;Genetics;Phosphatidylinositols",M01.060.116;D23.101;F03.084.500;G05.695.224;F01.829.263;I01.880.853.150;C23.550.291.687.500;G05.380.355;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.393.673;D10.570.755.375.760.400.942;F04.711.513.653;G05.420.720;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.196.566.880;H01.158.273.343;D10.570.755.375.760.400.942
28230293,"Adolescent;Alagille Syndrome;Bone Development;Child;Child, Preschool;Down Syndrome;Growth;Growth Charts;Humans;Infant;Infant, Newborn;Nutritional Status",M01.060.057;C06.130.120.135.250.125;C06.552.150.125;C14.240.400.044;C16.131.077.065;C16.131.240.400.044;C16.320.051;G07.345.500.325.377.625.050.500;G11.427.578.050.500;M01.060.406;M01.060.406.448;C10.597.606.360.220;C16.131.077.327;C16.131.260.260;C16.320.180.260;G07.345.249;E05.978.808.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G07.203.650.650;N01.224.425.525
28229472,Biomedical Research;Capital Financing;Global Health;Humans;Vaccines;Public Health;Vaccinology,H01.770.644.145;N03.219.463.085;H02.403.371;N01.400.337;B01.050.150.900.649.313.988.400.112.400.400;D20.215.894;H02.403.720;N01.400.550;N06.850;H02.403.894
28229394,Epilepsy;Exome;Humans;Syndrome;Channelopathies;Electroencephalography;Genetics,C10.228.140.490;G05.360.340.011;B01.050.150.900.649.313.988.400.112.400.400;C23.550.288.500;C23.550.177;E01.370.376.300;E01.370.405.245;H01.158.273.343
28229350,Attitude to Health;Autism Spectrum Disorder;Child;Culture;Genomics;Humans;Microarray Analysis;Parents;Prognosis;Qualitative Research;Surveys and Questionnaires;Autism Spectrum Disorder;Genetic Determinism,F01.100.150;N05.300.150;F03.625.164.113;M01.060.406;I01.076.201.450;I01.880.853.100;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.588.570;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E01.789;H01.770.644.241.850;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;F03.625.164.113;F04.096.276.400
28228583,Animals;Caenorhabditis elegans;Caenorhabditis elegans Proteins;Cyclic GMP-Dependent Protein Kinases;Dopaminergic Neurons;Feeding Behavior;Movement;Reproduction;Sensory Receptor Cells;Serotonergic Neurons;Locomotion,B01.050;B01.050.500.500.294.400.875.660.250.250;D12.776.419.500;D08.811.913.696.620.682.700.150.150;D12.644.360.200.150;D12.776.476.200.150;A08.675.278;A11.671.270;F01.145.113.547;F01.145.407;G07.203.650.353;G07.568;G11.427.410;G08.686.784;A08.675.650.915;A08.800.950;A11.671.650.915;A08.675.895;A11.671.895;G07.568.500;G11.427.410.568
28228501,Adolescent;Age Distribution;Anterior Cruciate Ligament Injuries;Child;Humans;Incidence;Retrospective Studies;Sex Distribution;United States,M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;C26.558.554.213;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;I01.240.800;N01.224.803;N06.850.505.400.850;Z01.107.567.875
28228261,"Adenocarcinoma;Adenocarcinoma of Lung;Animals;Carcinogenesis;Cell Proliferation;Cell Transformation, Neoplastic;Disease Progression;Lung Neoplasms;MAP Kinase Signaling System;Mice;Mitogen-Activated Protein Kinases;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);Signal Transduction;Adenocarcinoma of Lung",C04.557.470.200.025;C04.557.470.200.025.022;C04.588.894.797.520.055;B01.050;C04.697.098;C23.550.727.098;G04.161.750;G07.345.249.410.750;C04.697.098.500;C23.550.727.098.500;C23.550.291.656;C04.588.894.797.520;C08.381.540;C08.785.520;G02.111.820.560;G03.493.560;G04.835.560;B01.050.150.900.649.313.992.635.505.500;D08.811.913.696.620.682.700.567;D12.644.360.450;D12.776.476.450;D08.811.913.696.620.682.700.559.842.374;D12.644.360.400.842.374;D12.776.476.400.842.437;D12.776.624.664.700.204.200;D08.811.277.040.330.300.400.500.600;D12.644.360.525.500.600;D12.776.157.325.515.500.600;D12.776.476.525.500.600;D12.776.624.664.700.200;G02.111.820;G04.835;C04.557.470.200.025.022;C04.588.894.797.520.055
28228257,"Animals;Autoimmunity;Bone Marrow;Bone Marrow Cells;CTLA-4 Antigen;Immunity, Humoral;Immunophenotyping;Mice;Mice, Inbred C57BL;Plasma Cells;T-Lymphocytes, Regulatory;B-Lymphocytes;Bone Marrow;Communicable Diseases;Plasma Cells",B01.050;G12.450.192;A15.382.216;A11.148;A15.378.316;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;G12.450.050.420;E01.370.225.812.447;E05.200.812.447;E05.478.594.450;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725;A11.118.637.555.567.550.500.700;A11.118.637.555.567.569.200.700;A11.118.637.555.567.569.500.700;A15.145.229.637.555.567.550.500.700;A15.145.229.637.555.567.569.200.700;A15.145.229.637.555.567.569.500.700;A15.382.490.555.567.550.500.700;A15.382.490.555.567.569.200.700;A15.382.490.555.567.569.500.700;A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562;A15.382.216;C01.539.221;A11.063.438.725;A11.118.637.555.567.562.725;A15.145.229.637.555.567.562.725;A15.382.032.438.725;A15.382.490.555.567.562.725
28228099,"Accreditation;Attitude of Health Personnel;Clinical Competence;Education, Medical, Graduate;Fatigue;Humans;Internship and Residency;Iowa;Job Satisfaction;Personal Satisfaction;Personnel Staffing and Scheduling;Quality of Health Care;Work Schedule Tolerance;Workload;Education, Medical, Graduate;Internal Medicine;Internship and Residency;Nurse Practitioners;Preoperative Care;Workload",N03.706.110.070;N05.700.200.100;F01.100.050;N05.300.100;I02.399.630.210;N04.761.210;N05.715.175;I02.358.337.350;I02.358.399.350;C23.888.369;B01.050.150.900.649.313.988.400.112.400.400;I02.358.337.350.500;I02.358.399.350.750;Z01.107.567.875.510.370;F02.784.692.425;F01.145.677;I03.946.225;N04.452.677.650;N04.761;N05.715;I03.946.225.375;N04.452.677.650.375;I03.946.225.500;N04.452.677.650.500;I02.358.337.350;I02.358.399.350;H02.403.429;I02.358.337.350.500;I02.358.399.350.750;M01.526.485.650.640;N02.360.650.640;E02.760.795;E04.604.750;N02.421.585.795;I03.946.225.500;N04.452.677.650.500
28225743,Antifibrinolytic Agents;Blood Cell Count;Blood Transfusion;Factor VIIa;Hemorrhage;Humans;Recombinant Proteins;Resuscitation;Tranexamic Acid;Trauma Severity Indices;Wounds and Injuries,D27.505.519.421.500;D27.505.954.502.270.463.091;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;E02.095.135;D08.811.277.656.300.760.300;D08.811.277.656.959.350.300;D12.776.124.125.325.300;D23.119.325.300;C23.550.414;B01.050.150.900.649.313.988.400.112.400.400;D12.776.828;E02.365.647;D02.241.223.268.860;E05.318.308.940.968.875;E05.944;N04.452.859.564.800;N05.715.360.300.715.500.800;N06.850.520.308.940.968.875;C26
28225649,"Cerebral Hemorrhage;Child;Child Abuse;Child, Preschool;Diagnosis, Differential;Diagnostic Imaging;Fractures, Bone;Genital Diseases, Female;Humans;Infant;Infant, Newborn;Skin Diseases;Syndrome;Child Abuse;Physical Abuse;Sex Offenses",C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;M01.060.406.448;E01.171;E01.370.350;C26.404;C13.351.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;C17.800;C23.550.288.500;I01.198.240.856.350.250;I01.880.735.900.350.250;I01.198.240.856.688;I01.880.735.900.744;I01.198.240.748
28225052,"Absorptiometry, Photon;Body Mass Index;Bone Density;Bone Development;Bone and Bones;Calcium, Dietary;Child;Child Development;Follow-Up Studies;Humans",E01.370.350.700.024;E05.196.712.224.187;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;G11.427.100;G07.345.500.325.377.625.050.500;G11.427.578.050.500;A02.835.232;A10.165.265;D01.146.395;M01.060.406;F01.525.200;G07.345.374.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400
28224503,Adult;Condylomata Acuminata;Human papillomavirus 16;Human papillomavirus 18;Humans;Immunocompromised Host;Immunohistochemistry;Middle Aged;Papillomavirus Infections;Retrospective Studies;Staining and Labeling,M01.060.116;C02.256.650.810.217;C02.800.801.220;C02.825.810.110;C02.928.914.217;C17.800.838.790.810.110;B04.280.210.655.050.616;B04.613.204.655.050.616;B04.280.210.655.050.618;B04.613.204.655.050.618;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.116.630;C02.256.650;C02.928.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.225.500.620.670;E01.370.225.750.600.670;E05.200.500.620.670;E05.200.750.600.670
28224063,,
28223503,"Adenine Nucleotide Translocator 1;Adipose Tissue, Brown;Animals;Cell Proliferation;Diabetes Mellitus, Type 2;Diet, High-Fat;Energy Metabolism;Fibroblast Growth Factors;Glucose;Growth Differentiation Factor 15;Humans;Insulin Resistance;Mice;Mitochondria, Muscle;Muscle, Skeletal;Reactive Oxygen Species;Transcriptome;Uncoupling Protein 1;Insulin Resistance;Mitochondria;Muscle, Skeletal",D12.776.157.530.625.875.500.100;D12.776.157.530.937.594.100;D12.776.543.585.450.162.225.100;D12.776.543.585.475.500.100;D12.776.543.585.625.875.500.100;D12.776.543.585.937.688.100;D12.776.575.750.500.100;A10.165.114.322;B01.050;G04.161.750;G07.345.249.410.750;C18.452.394.750.149;C19.246.300;G07.203.650.240.267;G03.295;D12.644.276.624;D12.776.467.624;D23.529.624;D09.947.875.359.448;D12.644.276.374.305;D12.644.276.954.300.915;D12.776.467.374.305;D12.776.467.942.300.915;D23.529.374.305;D23.529.942.300.915;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.968.500;G07.690.773.984.617;B01.050.150.900.649.313.992.635.505.500;A11.284.430.214.190.875.564.627;A11.284.835.626.627;A02.633.567;A10.690.552.500;D01.339.431;D01.650.775;G02.111.873.750;G05.297.700.750;G05.360.920;D12.776.157.530.937.598.500;D12.776.543.585.475.688.500;D12.776.543.585.937.696.500;D12.776.575.750.688.500;C18.452.394.968.500;G07.690.773.984.617;A11.284.430.214.190.875.564;A11.284.835.626;A02.633.567;A10.690.552.500
28223407,"Adolescent;Adult;Aged;Aged, 80 and over;Atherosclerosis;Cohort Studies;Cost of Illness;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Middle Aged;Multifactorial Inheritance;Primary Prevention;Risk Factors;Young Adult;Humans;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Polymorphism, Genetic;Primary Prevention;Vascular Calcification",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;C14.907.137.126.307;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N03.219.151.165;N05.715.360.300.800.438.375.182;N06.850.520.308.980.438.475.046;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;M01.060.116.630;G05.420.590;N02.421.726.758;N06.850.780.680;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815;B01.050.150.900.649.313.988.400.112.400.400;D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370;G05.365.795;N02.421.726.758;N06.850.780.680;C18.452.174.130.780
28223372,"Adult;African Americans;Anxiety;Communication;Family Relations;Home Care Services;Humans;Infant, Newborn;Infant, Premature;Intensive Care Units, Neonatal;Interviews as Topic;Medicaid;Mothers;Patient Discharge;Poverty;Social Support;Trust;United States",M01.060.116;M01.686.508.100.100;M01.686.754.100;F01.470.132;F01.145.209;L01.143;F01.829.263.370;I01.880.853.150.439;N02.421.143.524;N02.421.539.089;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;N02.278.388.493.390.380;E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420;N03.219.521.346.506.564.655;N03.706.615.693;F01.829.263.500.320.200;I01.880.853.150.500.340.270;M01.620.630;E02.760.169.125;E02.760.400.610;N02.421.585.169.125;N02.421.585.400.610;N04.590.233.727.210.125;I01.880.735.634;I01.880.853.996.535;N01.824.600;I01.880.853.500.600;F01.829.401.825;Z01.107.567.875
28222219,"Adolescent;Adult;Anthracyclines;Antineoplastic Agents;Bone Neoplasms;Breast Neoplasms;Child;Chronic Disease;Cohort Studies;Follow-Up Studies;Heart Diseases;Humans;Leukemia, Myeloid, Acute;Longitudinal Studies;Middle Aged;Mortality;Musculoskeletal Diseases;Neoplasm Recurrence, Local;Neoplasms, Second Primary;Orthopedic Procedures;Osteosarcoma;Radiotherapy;Retrospective Studies;Sarcoma, Ewing;Survivors;Thyroid Neoplasms;Young Adult;Sarcoma, Ewing",M01.060.057;M01.060.116;D02.455.426.559.847.562.050;D04.615.562.050;D09.408.051.059;D27.505.954.248;C04.588.149;C05.116.231;C04.588.180;C17.800.090.500;M01.060.406;C23.550.291.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;C14.280;B01.050.150.900.649.313.988.400.112.400.400;C04.557.337.539.275;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;M01.060.116.630;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C05;C04.697.655;C23.550.727.655;C04.692;E02.718;E04.555;C04.557.450.565.575.650;C04.557.450.795.620;E02.815;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.450.565.575.650.800;C04.557.450.795.620.800;M01.860;C04.588.322.894;C04.588.443.915;C19.344.894;C19.874.788;M01.060.116.815;C04.557.450.565.575.650.800;C04.557.450.795.620.800
28222119,"Adolescent;Adult;Child;Child, Preschool;Disease Progression;Humans;Infant;Middle Aged;Mobility Limitation;Motor Activity;Outcome Assessment (Health Care);Pilot Projects;Psychometrics;Severity of Illness Index;Spinal Muscular Atrophies of Childhood;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.116.630;C23.888.550;F01.145.632;G11.427.410.698;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;F04.711.780;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;C10.228.854.468.800;C10.574.500.812;C10.574.562.500.750;C10.668.467.500.750;C16.320.400.765;M01.060.116.815
28221727,"Adolescent;Adult;Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Deoxycytidine;Docetaxel;Follow-Up Studies;Humans;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Retrospective Studies;Sarcoma;Survival Rate;Taxoids;Young Adult;Sarcoma, Ewing;Bevacizumab;Docetaxel;Osteosarcoma;Sarcoma",M01.060.057;M01.060.116;E02.183.750.500;E02.319.077.500;E02.319.310.037;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;D03.383.742.680.245.500;D13.570.230.329;D13.570.685.245.500;D02.455.426.392.368.242.888.389;D02.455.849.291.850.389;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;C04.697.655;C23.550.727.655;E01.789.625;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.557.450.795;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;D02.455.426.392.368.242.888;D02.455.849.291.850;M01.060.116.815;C04.557.450.565.575.650.800;C04.557.450.795.620.800;D12.776.124.486.485.114.224.060.375;D12.776.124.790.651.114.224.060.438;D12.776.377.715.548.114.224.200.438;D02.455.426.392.368.242.888.389;D02.455.849.291.850.389;C04.557.450.565.575.650;C04.557.450.795.620;C04.557.450.795
28220724,"Adolescent;Adult;Child;Communication;Decision Making;Exome;Genetic Research;Health Personnel;Humans;Informed Consent;Informed Consent By Minors;Parents;Patient Participation;Sequence Analysis, DNA;Decision Making;Ethics;Pediatrics;Research",M01.060.057;M01.060.116;M01.060.406;F01.145.209;L01.143;F02.463.785.373;G05.360.340.011;H01.158.273.343.249;H01.770.644.145.350;M01.526.485;N02.360;B01.050.150.900.649.313.988.400.112.400.400;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;I01.880.604.473.650.718.500;I01.880.604.583.427.384;N03.706.437.650.312.500;N03.706.535.489.384;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;E05.393.760.700;F02.463.785.373;K01.752.566.479;N05.350;H02.403.670;H01.770.644
28220710,Acute Kidney Injury;Anti-Glomerular Basement Membrane Disease;Child;Cyclophosphamide;Enzyme Inhibitors;Glucocorticoids;Humans;Immunosuppressive Agents;Kidney;Mycophenolic Acid;Plasmapheresis,C12.777.419.780.050;C13.351.968.419.780.050;C08.381.483.156;C12.777.419.570.363.304;C13.351.968.419.570.363.304;C20.111.190;M01.060.406;D02.455.526.728.650.730.243;D02.705.672.500.243;D27.505.519.389;D06.472.040.543;D27.505.696.399.472.488;B01.050.150.900.649.313.988.400.112.400.400;D27.505.696.477.656;A05.810.453;D02.241.081.193.678;D10.251.618;E02.120.770;E02.912.715
28220462,Cardiovascular Diseases;Clustered Regularly Interspaced Short Palindromic Repeats;Gene Editing;Humans;Mutation;Clustered Regularly Interspaced Short Palindromic Repeats;Cardiovascular Diseases;Gene Editing,C14;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;E05.393.420.270;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;C14;E05.393.420.270
28220358,"Autism Spectrum Disorder;Child Development;Child, Preschool;Developmental Disabilities;Humans;Infant;Logistic Models;Longitudinal Studies;Prevalence;Prospective Studies;Risk Factors;Self-Injurious Behavior;Autism Spectrum Disorder;Infant;Risk Factors;Self-Injurious Behavior",F03.625.164.113;F01.525.200;G07.345.374.750;M01.060.406.448;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.980;F03.625.164.113;M01.060.703;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;F01.145.126.980
28220045,"Animals;Behavior, Animal;Cocaine;Cognition;Epigenesis, Genetic;Epigenomics;Hippocampus;Histones;Memory;Memory Disorders;Neuronal Plasticity;Nucleus Accumbens;Paternal Exposure;Paternal Inheritance;Rats;Rats, Sprague-Dawley;Receptors, N-Methyl-D-Aspartate;Sex Factors",B01.050;F01.145.113;D02.145.074.722.388;D03.132.889.354;D03.605.084.500.722.388;D03.605.869.388;F02.463.188;G05.308.203;H01.158.273.180.350.074;H01.158.273.343.350.042;A08.186.211.180.405;A08.186.211.200.885.287.500.345;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;F02.463.425.540;C10.597.606.525;C23.888.592.604.529;F01.700.625;G11.561.638;A08.186.211.200.885.287.249.487.775.500;N06.850.460.350.700;G05.420.623;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;D12.776.157.530.400.400.500.500;D12.776.543.550.450.500.200.500;D12.776.543.585.400.500.200.500;D12.776.543.750.720.200.450.400.500;N05.715.350.675;N06.850.490.875
28219917,"Aged;Dose-Response Relationship, Drug;Double-Blind Method;Drug Therapy, Combination;Echocardiography, Doppler;Fibrosis;Heart Failure;Heart Ventricles;Humans;Hydralazine;Hypertrophy, Left Ventricular;Isosorbide Dinitrate;Magnetic Resonance Imaging, Cine;Middle Aged;Myocardium;Pilot Projects;Stroke Volume;Vasodilator Agents;Ventricular Function, Left;Ventricular Remodeling;Heart Failure;Hemodynamics;Magnetic Resonance Imaging;Vascular Stiffness;Vasodilator Agents",M01.060.116.100;G07.690.773.875;G07.690.936.500;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E02.319.310;E01.370.350.130.750.220;E01.370.350.850.220.220;E01.370.350.850.850.220;E01.370.370.380.220.220;C23.550.355;C14.280.434;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;D03.383.710.605.500;C14.280.195.400;C23.300.775.250.400;D02.033.800.813.480.500;D09.853.813.480.500;E01.370.350.825.500.510;M01.060.116.630;A02.633.580;A07.541.704;A10.690.552.750;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E01.370.370.380.150.700;G09.330.380.124.882;D27.505.954.411.918;G09.330.955.800;C23.300.985;G09.330.955.975;C14.280.434;G09.330.380;E01.370.350.825.500;G09.330.940;D27.505.954.411.918
28219893,"Animals;Anti-Bacterial Agents;Bacterial Toxins;Clostridium Infections;Clostridium difficile;Intestines;Mice;Mice, Inbred C57BL;Virulence;Whole Genome Sequencing;Anti-Bacterial Agents;Bacterial Infections;Communicable Diseases",B01.050;D27.505.954.122.085;D23.946.123;C01.252.410.222;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;A03.556.124;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G06.930;E05.393.760.700.825;D27.505.954.122.085;C01.252;C01.539.221
28219699,,
28219463,"Adolescent;Adult;Aged;Anti-Bacterial Agents;Child;Child, Preschool;Clindamycin;Humans;Infant;Infant, Newborn;Methicillin;Methicillin-Resistant Staphylococcus aureus;Middle Aged;Pennsylvania;Prevalence;Prospective Studies;Risk Factors;Staphylococcal Infections;Young Adult",M01.060.057;M01.060.116;M01.060.116.100;D27.505.954.122.085;M01.060.406;M01.060.406.448;D03.383.773.532.500.125;D09.408.471.500.125;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;D02.065.589.099.750.500;D02.886.108.750.500;D03.633.100.300.750.500;B03.300.390.400.800.750.100.500;B03.353.500.750.750.100.500;B03.510.100.750.750.100.500;B03.510.400.790.750.100.500;M01.060.116.630;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C01.252.410.868;M01.060.116.815
28218918,"Albuminuria;Alleles;Animals;Apolipoprotein L1;Apolipoproteins;Autophagy;Azotemia;Blotting, Western;Endocytosis;Endosomes;Fluorescent Antibody Technique;Genetic Predisposition to Disease;Genetic Variation;Glomerulosclerosis, Focal Segmental;HEK293 Cells;HeLa Cells;Humans;Immunohistochemistry;In Situ Nick-End Labeling;Kidney Glomerulus;Lipoproteins, HDL;Mice;Mice, Transgenic;Microscopy, Electron;Podocytes;Renal Insufficiency, Chronic",C12.777.934.734.269;C13.351.968.934.734.269;C23.888.942.750.269;G05.360.340.024.340.030;B01.050;D10.532.091.750.500;D12.776.070.400.750.500;D12.776.521.120.750.500;D10.532.091;D12.776.070.400;D12.776.521.120;G04.146.399;G04.417.350.091;C12.777.419.936.231;C13.351.968.419.936.231;C23.550.145;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;G04.417;A11.284.430.214.190.875.190.880.337;E01.370.225.500.607.512.240;E01.370.225.750.551.512.240;E05.200.500.607.512.240;E05.200.750.551.512.240;E05.478.583.375;C23.550.291.687.500;G05.380.355;G05.365;C12.777.419.570.363.660;C13.351.968.419.570.363.640;A11.251.210.172.750;A11.436.334;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;E05.393.475;A05.810.453.324.359;A05.810.453.736.520;D10.532.432;D12.776.521.479;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;E01.370.350.515.402;E05.595.402;A05.810.453.324.359.372.650;A05.810.453.736.520.720;A11.436.720;C12.777.419.780.750;C13.351.968.419.780.750
28218655,"Animals;Biofilms;Genetic Variation;Humans;Immunity, Innate;Paranasal Sinuses;Respiratory Tract Diseases;Taste Buds;Biofilms;Immunity, Innate;Mucociliary Clearance",B01.050;A20.593;G06.120;G05.365;B01.050.150.900.649.313.988.400.112.400.400;G12.450.564;A04.531.621;C08;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779;A20.593;G06.120;G12.450.564;E01.370.386.520;G09.772.555
28218241,"Animals;Chlorides;Dentate Gyrus;Disease Models, Animal;Epilepsy;Glutamine;Mice;Neural Inhibition;Neurons;gamma-Aminobutyric Acid",B01.050;D01.210.450.150;D01.248.497.158.215;A08.186.211.180.405.200;A08.186.211.200.885.287.500.345.200;C22.232;E05.598.500;E05.599.395.080;C10.228.140.490;D12.125.068.330;D12.125.095.461;D12.125.154.424;B01.050.150.900.649.313.992.635.505.500;G07.265.755;G11.561.616;A08.675;A11.671;D02.241.081.114.500.350;D12.125.190.350
28217930,,
28217719,"Myocytes, Cardiac;Epinephrine;Gene Expression;Inflammation",A07.541.704.570;A10.690.552.750.570;A11.620.500;D02.033.100.291.310;D02.092.063.291.310;D02.092.211.215.454;D02.092.311.461;D02.455.426.559.389.657.166.175.461;G05.297;C23.550.470
28216427,"Algorithms;Animals;Axonal Transport;Axons;Confidence Intervals;Kinetics;Microtubule-Associated Proteins;Microtubules;Models, Theoretical;Neurons;Protein Transport;Neurons",G17.035;L01.224.050;B01.050;G03.143.355.040;G04.392.040;G11.561.050;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;E05.318.740.275;N05.715.360.750.220;N06.850.520.830.275;G01.374.661;G02.111.490;D12.776.220.600.450;D12.776.631.560;A11.284.430.214.190.750.602;E05.599;A08.675;A11.671;G03.143.700;A08.675;A11.671
28216256,"Adolescent;Age Factors;Behavioral Symptoms;Cognition;Diagnosis, Differential;Humans;Kleine-Levin Syndrome;Prognosis;Hyperphagia;Disorders of Excessive Somnolence;Kleine-Levin Syndrome",M01.060.057;N05.715.350.075;N06.850.490.250;F01.145.126;F02.463.188;E01.171;B01.050.150.900.649.313.988.400.112.400.400;C10.886.425.800.200.500;F03.870.400.800.200.500;E01.789;C23.888.821.645;C10.886.425.800.200;F03.870.400.800.200;C10.886.425.800.200.500;F03.870.400.800.200.500
28215903,Congresses as Topic;Evidence-Based Medicine;Humans;Laparoscopy;Pancreatectomy;Patient Selection;Postoperative Complications;Risk Factors;Robotic Surgical Procedures;Treatment Outcome,N03.540.199;H02.249.750;H02.403.200.400;B01.050.150.900.649.313.988.400.112.400.400;E01.370.388.250.520;E04.502.250.520;E04.210.752;E05.581.500.653;N04.590.731;C23.550.767;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E02.950.875.500;E04.749.500;L01.313.500.750.100.710.800.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28215790,,
28215787,,
28215779,"Cholangiopancreatography, Endoscopic Retrograde;Humans;Pancreatitis;Risk Factors",E01.370.350.700.715.200.200;E01.370.372.200.200;E01.370.372.250.200;E01.370.388.250.250.160;E04.210.240.160;E04.502.250.250.160;B01.050.150.900.649.313.988.400.112.400.400;C06.689.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28215359,"Disease Management;Humans;Nephrolithiasis;Obesity;Renal Insufficiency, Chronic;Risk Factors",N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28215268,"Child;Child, Preschool;Cohort Studies;Ferritins;Humans;Nocturnal Myoclonus Syndrome;Pregnancy;Premature Birth;Prevalence;Restless Legs Syndrome;Child;Nocturnal Myoclonus Syndrome;Restless Legs Syndrome",M01.060.406;M01.060.406.448;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;D12.776.157.427.249;D12.776.556.579.249;B01.050.150.900.649.313.988.400.112.400.400;C10.886.425.800.600;C10.886.659.618;G08.686.784.769;C13.703.420.491.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C10.803;C10.886.425.800.700;C10.886.659.634;F03.870.400.800.700;F03.870.664.634;M01.060.406;C10.886.425.800.600;C10.886.659.618;C10.803;C10.886.425.800.700;C10.886.659.634;F03.870.400.800.700;F03.870.664.634
28215023,"Adolescent;Adolescent Behavior;Aggression;Anxiety;Behavioral Symptoms;Child;Child Abuse;Child Behavior;Depression;Humans;Hydrocortisone;Hypothalamo-Hypophyseal System;Pituitary-Adrenal System;Psychological Trauma;Saliva;Stress, Psychological;Physical Abuse",M01.060.057;F01.145.022;F01.145.126.125;F01.145.813.045;F01.470.132;F01.145.126;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;F01.145.179;F01.145.126.350;B01.050.150.900.649.313.988.400.112.400.400;D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392;A06.688.357;A08.186.211.180.497.352.435;A08.186.211.200.317.357.352.435;A08.713.357;A06.300.691;F03.950.750.375;A12.200.666;F01.145.126.990;F02.830.900;I01.198.240.856.688;I01.880.735.900.744
28214961,"Body Mass Index;Humans;Obesity;Renal Insufficiency, Chronic;Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C12.777.419.780.750;C13.351.968.419.780.750;C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28213800,Aspergillosis;Aspergillus;Central Nervous System Neoplasms;Humans;Invasive Fungal Infections;Lymphoma;Middle Aged;Respiratory Tract Infections;Aspergillosis;Hoarseness;Larynx,C01.703.080;B01.300.381.081;C04.588.614.250;C10.551.240;B01.050.150.900.649.313.988.400.112.400.400;C01.703.492;C04.557.386;C15.604.515.569;C20.683.515.761;M01.060.116.630;C01.539.739;C08.730;C01.703.080;C08.360.940.490;C08.618.490;C09.400.940.490;C10.597.975.550;C23.888.592.979.550;C23.888.852.490;A04.329
28213501,"Animals;Blotting, Southern;Blotting, Western;DNA Breaks, Double-Stranded;DNA-Binding Proteins;Flow Cytometry;Gene Expression Regulation;Homeodomain Proteins;Lymphoid Progenitor Cells;Mice;Mice, Inbred C57BL;Mice, Knockout;Real-Time Polymerase Chain Reaction;Transcription, Genetic;V(D)J Recombination",B01.050;E05.196.401.114;E05.301.300.087;E05.601.150;E05.196.401.143;E05.301.300.096;E05.478.566.320.200;E05.601.262;E05.601.470.320.200;G05.200.210.220;D12.776.260;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G05.308;D12.776.260.400;A11.148.378.294;A11.872.378.294;A15.378.316.378.550;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;E05.393.620.500.706;G02.111.873;G05.297.700;G05.344.900;G05.728.932
28212919,"Aged;Coronary Angiography;Coronary Thrombosis;Death, Sudden, Cardiac;France;Humans;Microscopy, Electron, Scanning;Middle Aged;Non-ST Elevated Myocardial Infarction;Outcome Assessment (Health Care);Percutaneous Coronary Intervention;Prospective Studies;ST Elevation Myocardial Infarction;Thrombectomy;Time-to-Treatment;ST Elevation Myocardial Infarction;Death, Sudden, Cardiac",M01.060.116.100;E01.370.350.130.625;E01.370.350.700.060.200;E01.370.370.050.200;E01.370.370.380.200;C14.280.647.250.290;C14.907.355.830.220;C14.907.585.250.290;C14.280.383.220;C23.550.260.322.250;Z01.542.286;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.515.402.541;E05.595.402.541;M01.060.116.630;C14.280.647.500.469;C14.907.585.500.656;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E04.100.814.529.968;E04.502.382.968;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C14.280.647.500.875;C14.907.585.500.875;E04.100.814.842;E02.760.928;N02.421.585.928;C14.280.647.500.875;C14.907.585.500.875;C14.280.383.220;C23.550.260.322.250
28212877,"Adolescent;Adult;Child;Child, Preschool;Clinical Trials as Topic;DNA;Electroretinography;Guanylate Cyclase;Humans;Leber Congenital Amaurosis;Middle Aged;Mutation;Receptors, Cell Surface;Retrospective Studies;Rod Cell Outer Segment;Surveys and Questionnaires;Tomography, Optical Coherence;Visual Acuity;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;D13.444.308;E01.370.380.225;E01.370.405.270;D08.811.520.650.600;D12.644.360.350;D12.776.476.350;B01.050.150.900.649.313.988.400.112.400.400;C11.270.516;C11.768.364;M01.060.116.630;G05.365.590;D12.776.543.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;A08.675.650.850.625.670.375.500;A08.675.650.850.625.670.650.650;A08.675.650.915.937.670.375.500;A08.675.650.915.937.670.650.650;A08.800.950.937.670.375.500;A08.800.950.937.670.650.650;A09.371.729.831.625.670.375.500;A09.371.729.831.625.670.650.650;A11.671.650.850.625.670.375.500;A11.671.650.850.625.670.650.650;A11.671.650.915.937.670.375.500;A11.671.650.915.937.670.650.650;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;M01.060.116.815
28212366,Antineoplastic Agents;Child;Drug Discovery;Humans;Neoplasms,D27.505.954.248;M01.060.406;E05.295;H01.158.703.007.675;H01.181.466.675;B01.050.150.900.649.313.988.400.112.400.400;C04
28212163,"Acute Disease;Adolescent;Child;Child, Preschool;Humans;Infant;Infant, Newborn;Logistic Models;Multiple Organ Failure;Odds Ratio;Outcome Assessment (Health Care);Prognosis;Proportional Hazards Models;Respiration, Artificial;Respiratory Insufficiency;Risk Factors",C23.550.291.125;M01.060.057;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C23.550.835.525;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E02.041.625;E02.365.647.729;E02.880.820;C08.618.846;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28212059,"Body Size;Child;Humans;Radiation Dosage;Radiography, Thoracic;Reference Values;Retrospective Studies;Tomography, X-Ray Computed",E01.370.600.115.100.160;E05.041.124.160;G07.100.100.160;G07.345.249.314;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E05.799.513;G01.750.740;N06.850.810.250;E01.370.350.700.730;E05.978.810;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28211987,"Abnormalities, Multiple;Alleles;Child;Chromosome Deletion;Chromosomes, Human, Pair 17;Frameshift Mutation;Genetic Association Studies;Hearing Loss;Humans;Intellectual Disability;Intelligence;Mutation;Neuropsychological Tests;Nuclear Proteins;Phenotype;Verbal Behavior",C16.131.077;G05.360.340.024.340.030;M01.060.406;C23.550.210.050.500.500;G05.365.590.029.530.175;G05.365.590.175.050.500.500;G05.365.590.762.180;G05.558.800.180;G05.700.131.500.500;A11.284.187.520.300.415.425;G05.360.162.520.300.415.425;G05.365.590.265;E05.393.385;C09.218.458.341;C10.597.751.418.341;C23.888.592.763.393.341;B01.050.150.900.649.313.988.400.112.400.400;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539;F01.752.543;G05.365.590;F04.711.513;D12.776.660;G05.695;F01.145.209.908
28211976,"Child;Cleft Palate;Developmental Disabilities;Diseases in Twins;Humans;Matrix Attachment Region Binding Proteins;Point Mutation;Transcription Factors;Twins, Monozygotic",M01.060.406;C05.500.460.185;C05.660.207.540.460.185;C07.320.440.185;C07.465.525.185;C07.650.500.460.185;C07.650.525.185;C16.131.621.207.540.460.185;C16.131.850.500.460.185;C16.131.850.525.185;F03.625.421;C23.550.291.750;B01.050.150.900.649.313.988.400.112.400.400;D12.776.260.532;G05.365.590.675;D12.776.930;M01.438.873.940
28211617,"Child;Child, Preschool;Gene Amplification;Gene Expression Regulation, Neoplastic;Humans;Infant;Infant, Newborn;Mutation;N-Myc Proto-Oncogene Protein;Phosphorylation;Retinoblastoma;Retinoblastoma Binding Proteins;Ubiquitin-Protein Ligases",M01.060.406;M01.060.406.448;G05.308.250;G05.365.590.310;G05.558.315;G05.308.370;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;G05.365.590;D12.776.260.103.500.625;D12.776.260.108.092.625;D12.776.624.664.700.158;D12.776.930.125.500.563;D12.776.930.127.092.625;G02.111.665;G02.607.780;G03.796;C04.557.465.625.600.725;C04.557.470.670.725;C04.557.580.625.600.725;C04.588.364.818.760;C11.270.862;C11.319.475.760;C11.768.717.760;D12.644.360.024.328;D12.776.157.057.158;D12.776.476.024.420;D12.776.660.769;D08.811.464.938.750
28211198,"Aminocaproic Acid;Antifibrinolytic Agents;Blood Loss, Surgical;Child;Child, Preschool;Cooperative Behavior;Craniofacial Abnormalities;Databases, Factual;Humans;Infant;Pediatrics;Reconstructive Surgical Procedures;Registries;Skull;Tranexamic Acid;Aminocaproic Acid;Antifibrinolytic Agents;Craniosynostoses;Safety;Tranexamic Acid",D02.241.081.193.150.075;D12.125.213.075;D27.505.519.421.500;D27.505.954.502.270.463.091;C23.550.414.300;C23.550.505.300;M01.060.406;M01.060.406.448;F01.145.813.115;C05.660.207;C16.131.621.207;L01.313.500.750.300.188.400;L01.470.750.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;H02.403.670;E04.680;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;A02.835.232.781;D02.241.223.268.860;D02.241.081.193.150.075;D12.125.213.075;D27.505.519.421.500;D27.505.954.502.270.463.091;C05.116.099.370.894.232;C05.660.207.240;C05.660.906.364;C16.131.621.207.240;C16.131.621.906.364;N06.850.135.060.075;D02.241.223.268.860
28210840,"Adolescent;Animals;Cardiovascular Diseases;Child;Child Nutritional Physiological Phenomena;Cross-Sectional Studies;Diet Surveys;Energy Intake;Fast Foods;Feeding Behavior;Fruit;Humans;Milk;Nutrition Surveys;Nutritional Status;Obesity;Recommended Dietary Allowances;Renal Insufficiency, Chronic;Sodium, Dietary;Adolescent;Child;Renal Insufficiency, Chronic;Food",M01.060.057;B01.050;C14;M01.060.406;G07.203.650.220;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E05.318.308.980.485.350;N05.715.360.300.800.469.300;N06.850.505.616.300;N06.850.520.308.980.469.350;G07.203.650.240.340;G07.203.300.477;J02.500.477;F01.145.113.547;F01.145.407;G07.203.650.353;A18.024.500;G07.203.300.562;J02.500.562;B01.050.150.900.649.313.988.400.112.400.400;A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469;G07.203.650.650;N01.224.425.525;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;G07.203.650.620.500;I01.655.500.608.400.650.500;I01.880.604.825.608.400.650.500;N03.623.500.608.428.650.500;C12.777.419.780.750;C13.351.968.419.780.750;D01.857.875;M01.060.057;M01.060.406;C12.777.419.780.750;C13.351.968.419.780.750;G07.203.300;J02.500
28210202,Electric Stimulation;Hormesis;Transcranial Direct Current Stimulation,E05.723.402;G07.690.773.875.500;G07.690.936.500.500;E02.331.750;F04.570.200.791;F04.669.224.650
28209774,"Animals;Cognition;Diet, High-Fat;Dietary Supplements;Drug Administration Schedule;Epigenesis, Genetic;Gene Expression Regulation;Mice;Motivation;Pregnancy;Choline;Folic Acid;Vitamin B 12",B01.050;F02.463.188;G07.203.650.240.267;G07.203.300.456;J02.500.456;E02.319.283;G05.308.203;G05.308;B01.050.150.900.649.313.992.635.505.500;F01.658;F01.752.543.500.750;G08.686.784.769;D02.033.100.291.211;D02.092.063.291.211;D02.092.877.883.333;D02.675.276.232;D03.633.100.733.631.400;D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777
28209474,"Adolescent;Central Nervous System Neoplasms;Child;Disorders of Excessive Somnolence;Histamine Antagonists;Humans;Kleine-Levin Syndrome;Narcolepsy;Sleep Apnea, Obstructive;Sleep Deprivation;Sleep Hygiene",M01.060.057;C04.588.614.250;C10.551.240;M01.060.406;C10.886.425.800.200;F03.870.400.800.200;D27.505.519.625.375.425;D27.505.696.577.375.425;B01.050.150.900.649.313.988.400.112.400.400;C10.886.425.800.200.500;F03.870.400.800.200.500;C10.886.425.800.200.750;F03.870.400.800.200.750;C08.618.085.852.850;C10.886.425.800.750.850;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F01.145.488.725;F02.830.855.734
28209451,Air Microbiology;Air Movements;Humans;Observation;Operating Rooms;Particulate Matter;Air Pollution;Infection Control;Operating Rooms;Particulate Matter;General Surgery;Surgical Wound Infection,H01.158.273.540.274.110;N06.850.425.110;G16.500.175.249;G16.500.275.063.725.154;N06.230.300.100.150.185;B01.050.150.900.649.313.988.400.112.400.400;E05.581.249;N02.278.388.700;D20.633;N06.850.460.100;N06.850.780.200.450;N02.278.388.700;D20.633;H02.403.810.300;C01.539.947.692;C23.550.767.925
28209224,"Case-Control Studies;Coronary Artery Disease;Gene Frequency;Genetic Loci;Genetic Pleiotropy;Genome-Wide Association Study;Humans;Odds Ratio;Polymorphism, Single Nucleotide;Cholesterol Ester Transfer Proteins;Genetics;Polymorphism, Single Nucleotide",E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260;G05.330;G05.360.340.024.380;G05.420.556;G05.695.550;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;G05.365.795.598;D09.400.430.750;D12.776.124.197;D12.776.157.165;D12.776.395.199;H01.158.273.343;G05.365.795.598
28209221,"Cholesterol, LDL;Oligonucleotides, Antisense;Apolipoprotein C-II;Apolipoprotein C-III;Triglycerides",D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;D13.150.480;D13.444.600.150.640;D13.695.578.424.480;D27.720.470.530.600.150.640;D10.532.091.400.750;D12.776.070.400.400.750;D12.776.521.120.400.750;D10.532.091.400.875;D12.776.070.400.400.875;D12.776.521.120.400.875;D10.351.801
28208059,"Alzheimer Disease;Amyotrophic Lateral Sclerosis;Bacteriophages;HSP110 Heat-Shock Proteins;HSP40 Heat-Shock Proteins;HSP72 Heat-Shock Proteins;Heat-Shock Proteins;Humans;Parkinson Disease;Protein Aggregation, Pathological;Protein Folding;Saccharomyces cerevisiae;Saccharomyces cerevisiae Proteins",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050;B04.123;D12.776.580.216.375.800;D12.776.580.216.292;D12.776.580.216.375.202;D12.776.580.216;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;C23.550.770;G02.111.675;G01.154.651;G02.111.688;B01.300.107.795.785.800;B01.300.930.705.655;D12.776.354.750
28207639,"Arterial Pressure;Cause of Death;Chi-Square Distribution;Databases, Factual;Decision Support Techniques;Humans;Hypertension, Portal;Hypertension, Pulmonary;Kaplan-Meier Estimate;Liver Diseases;Liver Transplantation;Middle Aged;Multivariate Analysis;Portal Pressure;Predictive Value of Tests;Proportional Hazards Models;Pulmonary Artery;Pulmonary Circulation;Retrospective Studies;Risk Assessment;Risk Factors;Severity of Illness Index;Time Factors;Tissue and Organ Procurement;Treatment Outcome;Vascular Resistance;Waiting Lists",G09.330.380.076.347;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;E05.318.740.994.300;G17.820.300;N05.715.360.750.750.200;N06.850.520.830.994.300;L01.313.500.750.300.188.400;L01.470.750.750;E05.245;L01.313.500.750.190;B01.050.150.900.649.313.988.400.112.400.400;C06.552.494;C08.381.423;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;C06.552;E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;G09.330.380.076.732.650;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;A07.015.114.715;G09.330.100.770;G09.772.593;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;G01.910.857;N02.421.911;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;G09.330.380.921;N04.452.095.738
28207594,"Anesthesiologists;Attitude of Health Personnel;Clinical Competence;Computer-Assisted Instruction;Documentation;Education, Medical, Continuing;Electronic Health Records;Feasibility Studies;Forms and Records Control;Health Information Management;Health Knowledge, Attitudes, Practice;High Fidelity Simulation Training;Humans;Manikins;Task Performance and Analysis",M01.526.485.140.040;M01.526.485.810.040;N02.360.140.040;N02.360.810.040;F01.100.050;N05.300.100;I02.399.630.210;N04.761.210;N05.715.175;I02.903.771.500.208;L01.453.245;I02.358.212.350;I02.358.399.250;E05.318.308.940.968.625.500;E05.318.372.550;E05.337.675;N05.715.360.330.550;N06.850.520.450.550;N04.452.758.708.200.400;L01.399.500;F01.100.150.500;N05.300.150.410;I02.903.847.250;B01.050.150.900.649.313.988.400.112.400.400;J01.897.280.500.545.129.400;L01.178.820.090.545.129.400;F02.784.412.846;F02.784.692.746;F02.808.600
28207194,"Aged;Carcinoma, Squamous Cell;Disease-Free Survival;Humans;Kaplan-Meier Estimate;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Paranasal Sinus Neoplasms;Prognosis;Proportional Hazards Models;Treatment Outcome;Papilloma, Inverted;Recurrence;Neoplasms",M01.060.116.100;C04.557.470.200.400;C04.557.470.700.400;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.998.650;N05.715.360.750.795.650;N06.850.520.830.998.650;M01.060.116.630;C04.697.655;C23.550.727.655;E01.789.625;C04.588.443.665.650.693;C08.460.669.693;C08.460.692.503;C08.785.600.693;C09.603.669.693;C09.603.692.503;C09.647.685.693;E01.789;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C04.557.470.700.600.610;C23.550.291.937;C04
28206689,"Adolescent;Adolescent Behavior;Age of Onset;Child;Disease Progression;Humans;Longitudinal Studies;Memory, Short-Term;Neuropsychological Tests;Philadelphia;Substance-Related Disorders;Adolescent;Delay Discounting;Impulsive Behavior;Substance-Related Disorders",M01.060.057;F01.145.022;N05.715.350.075.100;N06.850.490.250.100;M01.060.406;C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;F02.463.425.540.407;F04.711.513;Z01.107.567.875.500.550.525;Z01.433.820;C25.775;F03.900;M01.060.057;F02.463.785.373.346.700;F01.145.527;C25.775;F03.900
28205551,"Adult;Aged;Biomarkers;Calibration;Cohort Studies;Hispanic Americans;Humans;Middle Aged;Potassium, Dietary;Self Report;Sodium, Dietary;Young Adult",M01.060.116;M01.060.116.100;D23.101;E05.978.155;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;M01.686.754.441;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;D01.745.775;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500;D01.857.875;M01.060.116.815
28205394,"Disease Progression;Humans;Kidney Diseases;Obesity;Prevalence;Renal Insufficiency, Chronic;Obesity",C23.550.291.656;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C12.777.419.780.750;C13.351.968.419.780.750;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28205349,Adult;Child;Humans;Kidney Diseases;Obesity,M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28204757,Adolescent;Adult;Anxiety Disorders;Attention Deficit Disorder with Hyperactivity;Child;Cognitive Dysfunction;Comorbidity;DiGeorge Syndrome;Humans;Middle Aged;Prodromal Symptoms;Psychotic Disorders;Young Adult;DiGeorge Syndrome;Anxiety Disorders;DiGeorge Syndrome,M01.060.057;M01.060.116;F03.080;F03.625.094.150;M01.060.406;F03.615.250.700;N05.715.350.225;N06.850.490.687;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;C23.888.672;E01.599;F03.700.675;M01.060.116.815;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500;F03.080;C05.660.207.103.500;C14.240.400.021.500;C14.280.400.044.500;C15.604.451.249.500;C16.131.077.019.500;C16.131.240.400.021.500;C16.131.260.019.500;C16.131.482.249.500;C16.131.621.207.103.500;C16.320.180.019.500;C19.642.482.500.500
28203772,"Adult;Aged;Anti-Retroviral Agents;Antigens, CD;Antiretroviral Therapy, Highly Active;Apyrase;Biomarkers;Botswana;CD4 Lymphocyte Count;CD8-Positive T-Lymphocytes;Cohort Studies;Coinfection;HIV Infections;Humans;Middle Aged;Prospective Studies;Tuberculosis;Young Adult;HIV;Tuberculosis",M01.060.116;M01.060.116.100;D27.505.954.122.388.077;D23.050.301.264.035;D23.101.100.110;E02.319.310.075;D08.811.277.040.050;D23.101;Z01.058.290.175.230;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C01.539.218;C02.219;C03.202;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;C01.252.410.040.552.846;M01.060.116.815;B04.820.650.589.650.350;C01.252.410.040.552.846
28203687,,
28203624,Minocycline;Sarcoidosis,D02.455.426.559.847.562.900.550;D04.615.562.900.550;C15.604.515.827
28203515,,
28202961,"Autism Spectrum Disorder;Brain;Child, Preschool;Family Health;Humans;Infant;Longitudinal Studies;Neuroimaging;Prognosis;Risk;Social Behavior",F03.625.164.113;A08.186.211;M01.060.406.448;N01.400.300;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.350.578;E01.370.376.537;E05.629;E01.789;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;F01.145.813
28202908,"Animals;Central Nervous System;Cytokines;Down-Regulation;Encephalomyelitis, Autoimmune, Experimental;Gene Knockdown Techniques;Gene Silencing;Inflammation Mediators;Interferon-gamma;Interleukin-17;Macrophages;Mice;Mice, Inbred C57BL;Myelin-Oligodendrocyte Glycoprotein;NF-kappa B;Nanoparticles;Proto-Oncogene Proteins c-rel;RAW 264.7 Cells;RNA, Small Interfering;Th1 Cells;Th17 Cells;Up-Regulation",B01.050;A08.186;D12.644.276.374;D12.776.467.374;D23.529.374;G02.111.240;G05.308.200;G07.690.773.937;C10.114.703.300;C10.228.140.695.562.250;C10.314.350.250;C20.111.258.625.300;E05.598.500.500.500;E05.393.335.500;G05.308.203.374;D23.469;D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350;D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517;A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.395.550.114.500;D12.776.543.550.195.500;D12.776.543.620.550;D12.776.631.580.530;D23.050.422.625;D12.776.260.600;D12.776.660.600;D12.776.930.600;J01.637.512.600;D12.776.260.682;D12.776.624.664.700.192;D12.776.660.767;D12.776.930.730;A11.251.210.172.875;A11.733.397.815;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;A11.118.637.555.567.550.500.400.900;A11.118.637.555.567.569.200.400.900;A11.118.637.555.567.569.500.400.900;A15.145.229.637.555.567.550.500.400.500;A15.145.229.637.555.567.569.200.400.500;A15.145.229.637.555.567.569.500.400.500;A15.382.490.555.567.550.500.400.900;A15.382.490.555.567.569.200.400.900;A15.382.490.555.567.569.500.400.900;A11.118.637.555.567.550.500.400.915;A11.118.637.555.567.569.200.400.915;A11.118.637.555.567.569.500.400.915;A15.145.229.637.555.567.550.500.400.770;A15.145.229.637.555.567.569.200.400.770;A15.145.229.637.555.567.569.500.400.770;A15.382.490.555.567.550.500.400.915;A15.382.490.555.567.569.200.400.915;A15.382.490.555.567.569.500.400.915;G02.111.905;G05.308.850;G07.690.773.998
28202574,"Action Potentials;Adenosine Triphosphate;Animals;Calcium Channels;Cells, Cultured;Ion Channels;Mice;Mice, Inbred C57BL;Sodium;Taste Buds;Taste Buds",G04.580.100;G07.265.675.100;G11.561.570.100;D03.633.100.759.646.138.236;D13.695.667.138.236;D13.695.827.068.236;B01.050;D12.776.157.530.400.150;D12.776.543.550.450.150;D12.776.543.585.400.150;A11.251;D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779;A03.556.500.885.779;A08.675.650.915.500.800;A08.800.950.500.800;A09.846;A11.671.650.915.500.800;A14.549.885.779
28202515,"Adenocarcinoma;Adenocarcinoma of Lung;Animals;Chromatin;Clustered Regularly Interspaced Short Palindromic Repeats;DNA Helicases;HEK293 Cells;Histone-Lysine N-Methyltransferase;Humans;Lung Neoplasms;Mice;Mice, Inbred C57BL;Mutation;Nuclear Proteins;Proto-Oncogene Proteins p21(ras);Transcription Factors;Tumor Suppressor Protein p53;Tumor Suppressor Proteins",C04.557.470.200.025;C04.557.470.200.025.022;C04.588.894.797.520.055;B01.050;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;D08.811.277.040.025.159;D08.811.399.340;A11.251.210.172.750;A11.436.334;D08.811.913.555.500.800.200.500;B01.050.150.900.649.313.988.400.112.400.400;C04.588.894.797.520;C08.381.540;C08.785.520;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;G05.365.590;D12.776.660;D08.811.277.040.330.300.400.500.600;D12.644.360.525.500.600;D12.776.157.325.515.500.600;D12.776.476.525.500.600;D12.776.624.664.700.200;D12.776.930;D12.776.157.687.650;D12.776.260.820;D12.776.624.776.775;D12.776.660.720.650;D12.776.744.845;D12.776.624.776
28202403,"Adult;Age Distribution;Aged;Biopsy, Needle;Cohort Studies;Comorbidity;Databases, Factual;Dermatitis, Atopic;Dermatologic Agents;Humans;Immunohistochemistry;Middle Aged;Prevalence;Prognosis;Risk Assessment;Severity of Illness Index;Sex Distribution;Skin Diseases, Infectious;United Kingdom",M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.116.100;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;N05.715.350.225;N06.850.490.687;L01.313.500.750.300.188.400;L01.470.750.750;C16.320.850.210;C17.800.174.193;C17.800.815.193;C17.800.827.210;C20.543.480.343;D27.505.954.444;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.116.630;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;I01.240.800;N01.224.803;N06.850.505.400.850;C01.539.800;C17.800.838;Z01.542.363
28201856,Adult;Body Mass Index;Child;Health Education;Healthy Lifestyle;Humans;Kidney Diseases;Obesity;Risk Factors,M01.060.116;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;M01.060.406;I02.233.332;N02.421.726.407;F01.829.458.205;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28201738,"Adult;African Continental Ancestry Group;Apolipoprotein C-II;Homozygote;Humans;Hyperlipoproteinemia Type I;Hypertriglyceridemia;Mutation, Missense;Pancreatitis;Recurrence",M01.060.116;M01.686.508.100;D10.532.091.400.750;D12.776.070.400.400.750;D12.776.521.120.400.750;G05.380.554;B01.050.150.900.649.313.988.400.112.400.400;C16.320.565.398.465;C18.452.584.500.500.644.237;C18.452.648.398.465;C18.452.584.500.500.851;G05.365.590.650;C06.689.750;C23.550.291.937
28199983,"Animals;Apoptosis;CRISPR-Cas Systems;CTLA-4 Antigen;Cell Line, Tumor;Cells, Cultured;Gene Editing;Genes, MHC Class I;Humans;Interleukin Receptor Common gamma Subunit;K562 Cells;Mice, Inbred NOD;Mice, Knockout;Mice, SCID;Neoplasms, Experimental;Programmed Cell Death 1 Receptor;Receptors, Antigen, T-Cell;Recombinant Fusion Proteins;Reproducibility of Results;T-Lymphocytes;Transplantation, Heterologous;Clustered Regularly Interspaced Short Palindromic Repeats;T-Lymphocytes;Receptors, Chimeric Antigen",B01.050;G04.146.160;G05.308.203.374.394;D12.776.543.750.705.222.750;D23.050.301.264.894.158;D23.101.100.894.158;A11.251.210.190;A11.251.860.180;A11.251;E05.393.420.270;G05.360.340.024.340.610.595;G05.360.340.024.380.500.595;G12.500.500.595;B01.050.150.900.649.313.988.400.112.400.400;D12.776.543.750.705.852.420.320.875;D12.776.543.750.705.852.420.360.300.500;D12.776.543.750.705.852.420.420.500;D12.776.543.750.705.852.420.500.500;D12.776.543.750.705.852.420.800.750;D12.776.543.750.705.852.420.900.500;A11.251.210.190.510;A11.251.860.180.510;A11.443.240.497.480;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;B01.050.150.900.649.313.992.635.505.500.550.780;C04.619;E05.598.500.496;D12.776.543.750.705.222.875;D23.050.301.264.894.790;D23.101.100.894.790;D12.776.543.750.705.816.824;D12.776.828.300;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;E04.936.764;G02.111.570.080.708.800.325.500;G05.360.080.708.800.325.500;G05.360.340.024.850.069;A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569;D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500
28199838,"Animals;Axon Guidance;Axons;Central Nervous System;DCC Receptor;Dendrites;Drosophila;Drosophila Proteins;Gene Expression Regulation, Developmental;Motor Neurons;Netrin Receptors;Neurogenesis;Receptors, Cell Surface;Netrins;Axon Guidance;Motor Neurons;Transcription Factors",B01.050;G04.152.912.750.500;G07.345.500.325.377.687.750.750;G08.686.784.170.450.500.750.750;G11.561.620.750.500;A08.675.542.145;A11.284.180.075;A11.671.137;A11.671.501.145;A08.186;D12.644.360.075.413;D12.776.476.075.413;D12.776.543.750.003.500;D12.776.624.776.021;A08.675.256;A11.284.180.225;A11.671.240;B01.050.500.131.617.720.500.500.750.310.250;D12.776.093.500.462;G05.308.310;A08.675.655.500;A11.671.655.500;D12.776.543.750.003;G04.152.912;G07.345.500.325.377.687;G08.686.784.170.450.500;G11.561.620;D12.776.543.750;D12.644.276.860.494;D12.776.467.860.494;D12.776.631.600.494;D12.776.860.300.731;D23.125.842;D23.529.850.494;G04.152.912.750.500;G07.345.500.325.377.687.750.750;G08.686.784.170.450.500.750.750;G11.561.620.750.500;A08.675.655.500;A11.671.655.500;D12.776.930
28199780,"CD8-Positive T-Lymphocytes;Cytomegalovirus;Cytomegalovirus Infections;Heart Transplantation;Humans;Immunity, Cellular;Kidney Transplantation;Longitudinal Studies;Flow Cytometry;Communicable Diseases",A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220;B04.280.382.150.150;C02.256.466.245;E04.100.376.475;E04.928.220.390;E04.936.450.475;B01.050.150.900.649.313.988.400.112.400.400;G12.450.050.400;E02.870.500;E04.936.450.485;E04.950.774.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;C01.539.221
28199738,,
28199736,"Adult;Cholesterol, HDL;Cholesterol, LDL;Contraceptives, Oral;Humans;Obesity;Overweight;Polycystic Ovary Syndrome;Risk Reduction Behavior;Weight Loss;Young Adult",M01.060.116;D04.210.500.247.808.197.238;D10.532.432.400;D10.570.938.208.270;D12.776.521.479.470;D04.210.500.247.808.197.244;D10.532.515.500;D10.570.938.208.275;D12.776.521.550.500;D27.505.696.875.360.276.210;D27.505.954.705.360.276.210;B01.050.150.900.649.313.988.400.112.400.400;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.699;E01.370.600.115.100.160.120.699;G07.100.100.160.120.699;C04.182.612.765;C13.351.500.056.630.580.765;C19.391.630.580.765;F01.145.699;C23.888.144.243.963;G07.345.249.314.120.200.963;M01.060.116.815
28199697,"Adenoidectomy;African Americans;Child;Child Behavior;Child, Preschool;European Continental Ancestry Group;Humans;Parents;Prevalence;Sleep;Sleep Apnea, Obstructive;Tonsillectomy;Behavior;Sleep Apnea, Obstructive",E04.580.068;M01.686.508.100.100;M01.686.754.100;M01.060.406;F01.145.179;M01.060.406.448;M01.686.508.400;B01.050.150.900.649.313.988.400.112.400.400;F01.829.263.500.320;I01.880.853.150.500.340;M01.620;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;F02.830.855;G11.561.803;C08.618.085.852.850;C10.886.425.800.750.850;E04.580.848;F01.145;C08.618.085.852.850;C10.886.425.800.750.850
28199477,"Cohort Studies;Communication;Communication Barriers;Cross-Sectional Studies;Humans;Interdisciplinary Communication;Intersectoral Collaboration;Malpractice;Patient Education as Topic;Patient Safety;Patient Satisfaction;Physician-Patient Relations;Postoperative Complications;Quality Assurance, Health Care;Quality Improvement;Retrospective Studies;Risk;Statistics as Topic;Surgeons;Surgical Procedures, Operative",E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F01.145.209;L01.143;L01.143.230;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;F01.829.401.205.249;L01.143.865.500;N04.226;I01.880.604.583.524;N03.706.535.606;I02.233.332.500;N02.421.726.407.680;N06.850.135.060.075.399;F01.100.150.750.625;F01.145.488.887.625;N04.452.822.700;N05.300.150.800.625;N05.715.360.600;F01.829.401.650.675;N05.300.660.625;C23.550.767;N04.761.700;N05.700;J01.293.754;N04.761.744;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.740;H01.548.832;N05.715.360.750;N06.850.520.830;M01.526.485.810.910;N02.360.810.910;E04
28199181,"Sequence Analysis, DNA;Chromatin;Chromosomes;Genes;Humans;Transcription Factors",E05.393.760.700;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;A11.284.187;A11.284.430.106.279.345.190;G05.360.162;G05.360.340.024.340;B01.050.150.900.649.313.988.400.112.400.400;D12.776.930
28198754,"Adolescent;Child;Child, Preschool;Critical Illness;Databases, Factual;Hospital Mortality;Humans;Infant;Infant, Newborn;Intensive Care Units, Pediatric;Intubation, Intratracheal;Length of Stay;Multivariate Analysis;Outcome Assessment (Health Care);Quality Improvement;Respiration, Artificial;Retrospective Studies",M01.060.057;M01.060.406;M01.060.406.448;C23.550.291.625;L01.313.500.750.300.188.400;L01.470.750.750;E05.318.308.985.550.400;N01.224.935.698.400;N06.850.505.400.975.550.400;N06.850.520.308.985.550.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;N02.278.388.493.390;E02.041.500;E02.585.578;E05.497.578;E02.760.400.480;N02.421.585.400.480;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;J01.293.754;N04.761.744;E02.041.625;E02.365.647.729;E02.880.820;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28198723,Humans;Intensive Care Units;Operating Rooms;Patient Handoff;Patient Transfer;Pennsylvania;Prospective Studies;Quality of Health Care;Telemedicine;Time Factors;Video Recording,B01.050.150.900.649.313.988.400.112.400.400;N02.278.388.493;N02.278.388.700;E02.760.169.249;E02.760.400.615;N02.421.585.169.249;N02.421.585.400.615;N04.590.233.727.210.249;N05.715.840.500;E02.760.169.624;E02.760.400.630;N02.421.585.169.624;N02.421.585.400.630;N04.590.233.727.210.624;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;N04.761;N05.715;H02.403.840;L01.178.847.652;N04.590.374.800;G01.910.857;L01.280.960
28198573,"Adolescent;Age Factors;Benchmarking;Cardiac Catheterization;Child;Child, Preschool;Heart Defects, Congenital;Humans;Infant;Patient Safety;Pediatrics;Prospective Studies;Radiation Dosage;Radiation Exposure;Radiography, Interventional;Registries;Risk Assessment;Risk Factors;United States;Pediatrics",M01.060.057;N05.715.350.075;N06.850.490.250;N04.452.500.150;N04.761.685.150;N04.761.700.150;N05.700.150;N05.715.360.650.150;E01.370.370.380.140;E02.148.442;E05.157.250;M01.060.406;M01.060.406.448;C14.240.400;C14.280.400;C16.131.240.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;N06.850.135.060.075.399;H02.403.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.799.513;G01.750.740;N06.850.810.250;G01.750.748;N06.850.460.350.850;E01.370.350.700.725;E04.502.780;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;Z01.107.567.875;H02.403.670
28198005,"Adult;Anticoagulants;Child;Cytochrome P-450 CYP2C9;Cytochrome P450 Family 4;Dose-Response Relationship, Drug;Genotype;Humans;Pharmacogenetics;Practice Guidelines as Topic;Vitamin K Epoxide Reductases;Warfarin",M01.060.116;D27.505.954.502.119;M01.060.406;D08.244.453.491.500.500;D08.811.682.690.708.170.450.500.500;D12.776.422.220.453.491.500.500;D08.244.453.870;D08.811.682.690.708.170.496;D12.776.422.220.453.870;G07.690.773.875;G07.690.936.500;G05.380;B01.050.150.900.649.313.988.400.112.400.400;H01.158.273.343.750;H01.158.703.052;H02.628.479;N04.761.700.350.650;N05.700.350.650;D08.811.682.690.708.961;D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
28197980,Deep Brain Stimulation;Humans;Malignant Hyperthermia;Parkinsonian Disorders,E02.331.300;E04.190;B01.050.150.900.649.313.988.400.112.400.400;C23.550.505.700;C23.550.767.600;C10.228.140.079.862;C10.228.662.600
28197669,Alzheimer Disease;Amyloid beta-Peptides;Animals;Brain;Humans;Microglia;Monocytes;Proteolysis;Neurodegenerative Diseases;Phagocytosis,C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;B01.050;A08.186.211;B01.050.150.900.649.313.988.400.112.400.400;A08.637.400;A11.650.400;A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547;G02.111.720;G03.812;C10.574;G04.417.350;G09.188.665;G12.450.564.809;G12.688
28197542,"Animals;Astrocytes;Cell Death;Cells, Cultured;Cerebral Cortex;Coculture Techniques;DNA Repeat Expansion;Guanine Nucleotide Exchange Factors;HEK293 Cells;Humans;Neurons;Peptides;Proteasome Endopeptidase Complex;Proteasome Inhibitors;Rats, Sprague-Dawley;Spinal Cord;Frontotemporal Dementia;Motor Neurons;Proteasome Endopeptidase Complex",B01.050;A08.637.200;A11.650.200;G04.146;A11.251;A08.186.211.200.885.287.500;E05.481.500.374;G02.111.570.080.708.800.140;G05.360.080.708.800.074;G05.360.340.024.189.220;G05.360.340.024.850.140;G05.365.590.220;G05.558.220;D12.644.360.325.300;D12.776.476.325.300;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;A08.675;A11.671;D12.644;D05.500.562.500;D08.811.277.656.918;D08.811.600.730;D27.505.519.389.745.705;B01.050.150.900.649.313.992.635.505.700.750;A08.186.854;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;A08.675.655.500;A11.671.655.500;D05.500.562.500;D08.811.277.656.918;D08.811.600.730
28197289,"Cardiomyopathy, Hypertrophic",C14.280.238.100;C14.280.484.150.070.160
28197125,"Parkinson Disease;RNA Interference;RNA, Small Interfering;alpha-Synuclein",C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;G05.308.203.374.790;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D12.776.631.860.500;D12.776.637.500
28196848,Accelerometry;Aged;Cohort Studies;Exercise;Geographic Information Systems;Humans;Middle Aged;Residence Characteristics;Self Report,E05.003;M01.060.116.100;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;G11.427.410.698.277;I03.350;L01.313.500.750.300.314;L01.470.750.750.462;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;N01.224.791;N06.850.505.400.800;E05.318.308.980.500;N05.715.360.300.800.500;N06.850.520.308.980.500
28196690,"Apoptosis;Biomarkers;Cell Differentiation;Cell Line;Endoderm;GATA6 Transcription Factor;Gene Expression Profiling;Humans;Induced Pluripotent Stem Cells;Insulin-Secreting Cells;Intercellular Signaling Peptides and Proteins;Models, Biological;Multigene Family;Mutation;Pancreas;Phenotype;Tretinoin;Tretinoin;Stem Cells",G04.146.160;D23.101;G04.152;A11.251.210;A16.504.407;D12.776.260.257.600;D12.776.930.314.600;E05.393.332;B01.050.150.900.649.313.988.400.112.400.400;A11.872.040.500;A11.872.700.500;A03.734.414.131;A06.300.414.087;A06.390.131;A11.382.625.092;A11.436.294.092;D12.644.276;D12.776.467;D23.529;E05.599.395;G05.360.340.024.340.645;G05.365.590;A03.734;G05.695;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780;D02.455.326.271.665.202.495.818.500;D02.455.426.392.368.367.379.249.700.860.500;D02.455.849.131.495.818.800;D23.767.261.700.780;A11.872
28196594,"Animals;Cell Survival;Colorectal Neoplasms;Down-Regulation;Humans;Immune Tolerance;Mice;Mice, Inbred C57BL;Receptor, Interferon alpha-beta;Signal Transduction;T-Lymphocytes, Cytotoxic;Tumor Microenvironment;Colorectal Neoplasms;Immunosuppression;Interferons;Tumor Microenvironment",B01.050;G04.346;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;G02.111.240;G05.308.200;G07.690.773.937;B01.050.150.900.649.313.988.400.112.400.400;G12.535.425;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;D12.776.543.750.705.852.400.500;G02.111.820;G04.835;A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200;G04.366.500;C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180;E02.095.465.425.450;E05.478.610;D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440;G04.366.500
28196591,"Carcinogenesis;Cell Line, Tumor;Humans;Isoenzymes;Protein Kinase C;Ribosomes",C04.697.098;C23.550.727.098;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;D08.811.348;D12.776.800.300;D08.811.913.696.620.682.700.725;A11.284.430.214.190.875.811
28196494,"Animals;Biopsy;Cicatrix;Contrast Media;Disease Models, Animal;Linear Models;Magnetic Resonance Imaging, Cine;Meglumine;Myocardial Infarction;Myocardial Reperfusion;Myocardium;Organometallic Compounds;Predictive Value of Tests;Signal-To-Noise Ratio;Stroke Volume;Sus scrofa;Time Factors;Ventricular Function, Left",B01.050;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;A10.165.450.300;C23.550.355.274;G16.762.891.249;D27.505.259.500;D27.720.259;C22.232;E05.598.500;E05.599.395.080;E05.318.740.500.500;E05.318.740.750.425;E05.599.835.750;N05.715.360.750.530.460;N05.715.360.750.695.460;N06.850.520.830.500.500;N06.850.520.830.750.425;E01.370.350.825.500.510;D02.033.800.813.550;D09.067.342.600;D09.853.813.550;C14.280.647.500;C14.907.585.500;E04.100.700.600;E05.680.730.600;A02.633.580;A07.541.704;A10.690.552.750;D02.691;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.370.800.875;E05.318.740.872.875;G17.800.500;N05.715.360.325.700.840;N05.715.360.750.725.750;N06.850.520.445.800.875;N06.850.520.830.872.750;E01.370.370.380.150.700;G09.330.380.124.882;B01.050.150.900.649.313.500.880.399;G01.910.857;G09.330.955.800
28196478,"Adolescent;Adult;Aged;Choline;DNA;Genetic Testing;Genotype;Humans;INDEL Mutation;Metabolism, Inborn Errors;Methylamines;Middle Aged;Oxygenases;Polymorphism, Single Nucleotide;Sequence Analysis, DNA;Smell",M01.060.057;M01.060.116;M01.060.116.100;D02.033.100.291.211;D02.092.063.291.211;D02.092.877.883.333;D02.675.276.232;D13.444.308;E01.370.225.562;E05.200.562;E05.393.435;N02.421.308.430;N02.421.726.233.221;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590.500;G05.558.370;C16.320.565;C18.452.648;D02.092.668;M01.060.116.630;D08.811.682.690;G05.365.795.598;E05.393.760.700;F02.830.816.643;G11.561.790.643
28196257,"Adult;Aged;Alopecia;Anthracyclines;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Bridged-Ring Compounds;Chemotherapy, Adjuvant;Headache;Humans;Hypothermia, Induced;Medical Illustration;Middle Aged;Neoadjuvant Therapy;Photography;Prospective Studies;Quality of Life;Scalp;Taxoids",M01.060.116;M01.060.116.100;C17.800.329.937.122;C23.300.035;D02.455.426.559.847.562.050;D04.615.562.050;D09.408.051.059;E02.183.750.500;E02.319.077.500;E02.319.310.037;C04.588.180;C17.800.090.500;D02.455.426.100;D04.075;E02.186.170;E02.319.170;C23.888.592.612.441;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;H02.385;J01.897.280.500.480;K01.093.410;L01.178.820.090.480;M01.060.116.630;E02.186.450;E01.370.350.600;E05.712;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;I01.800;K01.752.400.750;N06.850.505.400.425.837;A01.456.810;D02.455.426.392.368.242.888;D02.455.849.291.850
28195984,"Adolescent;Amputation;Arthroplasty, Replacement;Bone Development;Bone Neoplasms;Bone and Bones;Child;Humans;Joint Prosthesis;Reconstructive Surgical Procedures",M01.060.057;E04.555.080;E04.555.110.110;E04.650.110;E04.680.101.110;G07.345.500.325.377.625.050.500;G11.427.578.050.500;C04.588.149;C05.116.231;A02.835.232;A10.165.265;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;E07.695.400;E04.680
28195906,3-Iodobenzylguanidine;Child;Humans;Infant;Lung Neoplasms;Neuroblastoma;Risk,D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;C04.588.894.797.520;C08.381.540;C08.785.520;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800
28194967,"Chromatography, High Pressure Liquid;Enhancer of Zeste Homolog 2 Protein;Epigenomics;HCT116 Cells;Histones;Humans;Polycomb Repressive Complex 2;Protein Processing, Post-Translational;Proteomics;Pyridones;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Spheroids, Cellular",E05.196.181.400.300;D05.500.781.750.250;D08.811.913.555.500.800.200.500.500.500;D12.776.660.235.600.200.250;D12.776.664.235.800.200.250;D12.776.930.780.890.200.250;H01.158.273.180.350.074;H01.158.273.343.350.042;A11.251.210.190.380;A11.251.860.180.380;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;D05.500.781.750;D08.811.913.555.500.800.200.500.500;D12.776.660.235.600.200;D12.776.664.235.800.200;D12.776.930.780.890.200;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;D03.383.725.791;E05.196.566.755;A11.251.800
28194641,Adult;Aged;Exercise;Head and Neck Neoplasms;Humans;Middle Aged;Papillomaviridae;Prognosis;Retrospective Studies;Survivors;Exercise;Head and Neck Neoplasms;Survivorship,M01.060.116;M01.060.116.100;G11.427.410.698.277;I03.350;C04.588.443;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;B04.280.210.655;B04.613.204.655;E01.789;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;M01.860;G11.427.410.698.277;I03.350;C04.588.443;F01.058.144.500
28193798,"Cholesterol;Lipoproteins;Lipoproteins, HDL;Lipoproteins, LDL;Lipoproteins, VLDL;Cholesterol;Diet;Lipoproteins, HDL",D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;D10.532;D12.776.521;D10.532.432;D12.776.521.479;D10.532.515;D12.776.521.550;D10.532.599;D12.776.521.622;D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208;G07.203.650.240;D10.532.432;D12.776.521.479
28193515,"Adolescent;Age Distribution;Anti-Inflammatory Agents;Biological Products;Child;Colitis, Ulcerative;Crohn Disease;Europe;Gastrointestinal Agents;Humans;Immunocompromised Host;Incidence;Infliximab;Lymphohistiocytosis, Hemophagocytic;Neoplasms;North America;Prospective Studies;Registries;Risk Assessment;Risk Factors;SEER Program;Sex Distribution;Time Factors;Treatment Outcome",M01.060.057;I01.240.050;N01.224.033;N06.850.505.400.050;D27.505.954.158;D20.215;M01.060.406;C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249;C06.405.205.731.500;C06.405.469.432.500;Z01.542;D27.505.954.483;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;D12.776.124.486.485.114.224.608;D12.776.124.790.651.114.224.537;D12.776.377.715.548.114.224.642;C15.604.250.410.575;C04;Z01.107.567;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;E05.318.308.970.725;N04.452.859.819.725;N05.715.360.300.715.700.725;N06.850.520.308.970.725;I01.240.800;N01.224.803;N06.850.505.400.850;G01.910.857;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28193509,"Adolescent;Algorithms;Athletes;Cardiomyopathy, Hypertrophic;Child;Cohort Studies;Death, Sudden, Cardiac;Diagnosis, Computer-Assisted;Electrocardiography;Humans;Incidence;Mass Screening;Pilot Projects;Retrospective Studies;United States;Young Adult;Adolescent;Athletes;Electrocardiography;Cardiomyopathy, Hypertrophic;Mass Screening;Death, Sudden, Cardiac",M01.060.057;G17.035;L01.224.050;M01.072;C14.280.238.100;C14.280.484.150.070.160;M01.060.406;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;C14.280.383.220;C23.550.260.322.250;E01.158;L01.313.500.750.100.158;E01.370.370.380.240;E01.370.405.240;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525.375;N01.224.935.597.500;N06.850.505.400.975.525.375;N06.850.520.308.985.525.375;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;E05.318.372.750;E05.337.737;N05.715.360.330.720;N06.850.520.450.720;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;Z01.107.567.875;M01.060.116.815;M01.060.057;M01.072;E01.370.370.380.240;E01.370.405.240;C14.280.238.100;C14.280.484.150.070.160;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;C14.280.383.220;C23.550.260.322.250
28193182,"Algorithms;Exons;Humans;Introns;Models, Genetic;Mutation;Mutation Rate;RNA Splice Sites;Retinoblastoma;Retinoblastoma Binding Proteins;Sequence Analysis, DNA;Ubiquitin-Protein Ligases;Mutation Rate;Retinoblastoma",G17.035;L01.224.050;G05.360.340.024.340.137.232;B01.050.150.900.649.313.988.400.112.400.400;G05.360.340.024.220.400;G05.360.340.024.340.137.515;E05.599.395.397;G05.365.590;G05.045.250.750;G05.365.590.612;G16.075.250.750;D13.444.735.544.550;G02.111.570.080.689.687.490;G05.360.080.689.687.490;G05.360.340.024.340.137.800;C04.557.465.625.600.725;C04.557.470.670.725;C04.557.580.625.600.725;C04.588.364.818.760;C11.270.862;C11.319.475.760;C11.768.717.760;D12.644.360.024.328;D12.776.157.057.158;D12.776.476.024.420;D12.776.660.769;E05.393.760.700;D08.811.464.938.750;G05.045.250.750;G05.365.590.612;G16.075.250.750;C04.557.465.625.600.725;C04.557.470.670.725;C04.557.580.625.600.725;C04.588.364.818.760;C11.270.862;C11.319.475.760;C11.768.717.760
28192815,"Basal Ganglia;Basal Ganglia Cerebrovascular Disease;Developmental Disabilities;Humans;Infant;Infant, Premature;Infant, Premature, Diseases;Ultrasonography",A08.186.211.200.885.287.249;C10.228.140.079.127;C10.228.140.300.100;C14.907.253.061;F03.625.421;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520.520;C16.614.521;E01.370.350.850
28192796,"Adult;Alleles;Eye Proteins;Genes, Dominant;Genetic Association Studies;Genotype;Humans;Mutation;Pedigree;Phenotype;Polymerase Chain Reaction;Prevalence;RNA Splicing;Retinitis Pigmentosa;Spain",M01.060.116;G05.360.340.024.340.030;D12.776.306;G05.360.340.024.340.240;G05.420.320;E05.393.385;G05.380;B01.050.150.900.649.313.988.400.112.400.400;G05.365.590;E05.393.673;G05.695;E05.393.620.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;G02.111.760.700;G03.839.700;G05.308.700.700;C11.270.684;C11.768.585.658.500;C16.320.290.684;Z01.542.846
28192544,Child;Decision Making;Humans;Patient Participation;Trisomy;Trisomy 13 Syndrome,M01.060.406;F02.463.785.373;B01.050.150.900.649.313.988.400.112.400.400;F01.100.150.750.500.620;F01.145.488.887.500.620;N02.421.143.212.300;N03.540.245.360.300;N05.300.150.800.500.620;C23.550.210.050.750;C23.550.210.182.500;G05.365.590.175.050.750;G05.365.590.175.183.500;G05.700.131.750;C10.597.606.360.835;C14.240.400.970;C14.280.400.970;C16.131.077.919;C16.131.240.400.965;C16.131.260.923;C16.320.180.923
28192109,Behavior Therapy;Body Weight Maintenance;Caloric Restriction;Delivery of Health Care;Diet;Directive Counseling;Exercise Therapy;Humans;Internet;Life Style;Mobile Applications;Obesity;Telephone;Weight Reduction Programs;Obesity;Weight Loss,F04.754.137;G07.345.249.314.120.250;E02.642.249.200;G07.203.650.240.340.150;N04.590.374;N05.300;G07.203.650.240;F02.784.176.279;F04.408.413.349;N02.421.461.363.349;E02.760.169.063.500.387;E02.779.483;E02.831.535.483;B01.050.150.900.649.313.988.400.112.400.400;L01.224.230.110.500;F01.829.458;L01.224.900.685;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;L01.178.847.698;I02.233.332.445.650;N02.421.726.407.579.650;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;C23.888.144.243.963;G07.345.249.314.120.200.963
28191886,"Acetylation;Action Potentials;Animals;Arrhythmias, Cardiac;Cardiomyopathies;Echocardiography;Electrocardiography;HEK293 Cells;Heart;Humans;Immunoblotting;Immunoprecipitation;Mass Spectrometry;Membrane Potentials;Mice;Mice, Knockout;Myocardium;Myocytes, Cardiac;NAV1.5 Voltage-Gated Sodium Channel;Patch-Clamp Techniques;Rats;Sirtuin 1",G02.111.012.052;G02.607.063.052;G03.040.052;G04.580.100;G07.265.675.100;G11.561.570.100;B01.050;C14.280.067;C23.550.073;C14.280.238;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E01.370.370.380.240;E01.370.405.240;A11.251.210.172.750;A11.436.334;A07.541;B01.050.150.900.649.313.988.400.112.400.400;E05.478.566.320;E05.601.470.320;E05.196.150.639;E05.478.605;E05.196.566;G01.154.535;G04.580;G07.265.675;G11.561.570;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500.500;B01.050.150.900.649.313.992.635.505.500.550.455;B01.050.150.900.649.313.992.635.505.500.800.500;A02.633.580;A07.541.704;A10.690.552.750;A07.541.704.570;A10.690.552.750.570;A11.620.500;D12.776.157.530.400.875.750.500;D12.776.543.550.450.875.750.500;D12.776.543.585.400.875.750.500;D12.776.631.960.500;E05.200.500.905;E05.242.800;B01.050.150.900.649.313.992.635.505.700;D08.811.277.087.520.200.650.100;D12.776.476.900.100
28191603,,
28191261,"Adult;DNA Methylation;Embryo Culture Techniques;Epigenesis, Genetic;Humans;Long Interspersed Nucleotide Elements;Placenta;Pregnancy;Reproductive Techniques, Assisted;Methylation",M01.060.116;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;E05.481.500.468;G05.308.203;B01.050.150.900.649.313.988.400.112.400.400;G02.111.570.080.708.330.800.400;G05.360.080.708.330.800.400;G05.360.340.024.425.800.400;A16.710;G08.686.784.769;E02.875.800;E05.820.800;G02.111.035.538;G02.607.094.538;G03.059.538
28190606,,
28190457,"Adolescent;Adult;Aged;Biological Specimen Banks;Biomedical Research;Electronic Health Records;Genome, Human;Genomics;Humans;Information Dissemination;Informed Consent;Middle Aged;Privacy;Public Opinion;Socioeconomic Factors;United States;Young Adult;Information Dissemination;Informed Consent",M01.060.057;M01.060.116;M01.060.116.100;N02.278.065;H01.770.644.145;E05.318.308.940.968.625.500;G05.360.340.350;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;L01.143.443;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489;M01.060.116.630;I01.880.604.473.352.500;N03.706.437.352.500;N03.706.615.862;I01.880.630.548;I01.880.853.996;N01.824;Z01.107.567.875;M01.060.116.815;L01.143.443;I01.880.604.473.650.718;I01.880.604.583.427;N03.706.437.650.312;N03.706.535.489
28190445,Blood Coagulation Disorders;Disease Management;Humans;Nervous System Diseases;Hemorrhage;Blood Coagulation Factors;Blood Coagulation Tests;Hemostasis;Cerebral Hemorrhage;Intracranial Hemorrhages;Thrombelastography,C15.378.100;N04.590.607;B01.050.150.900.649.313.988.400.112.400.400;C10;C23.550.414;D12.776.124.125;D23.119;E01.370.225.625.115;E05.200.625.115;G09.188.390;C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100;C10.228.140.300.535;C14.907.253.573;C23.550.414.913;E01.370.225.625.115.830;E05.200.625.115.830
28190301,"Cell Cycle Proteins;Chromosomal Proteins, Non-Histone;De Lange Syndrome;Humans;Phenotype;Behavior;De Lange Syndrome;Intellectual Disability",D12.776.167;D12.776.660.235;D12.776.664.235;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;B01.050.150.900.649.313.988.400.112.400.400;G05.695;F01.145;C10.597.606.360.210;C16.131.077.272;C16.131.260.210;C16.320.180.210;C10.597.606.360;C23.888.592.604.646;F01.700.687;F03.625.539
28189599,"Adult;Cardiopulmonary Resuscitation;Coma;Electric Countershock;Electroencephalography;Evoked Potentials, Somatosensory;Humans;Hypothermia, Induced;Out-of-Hospital Cardiac Arrest;Predictive Value of Tests;Prognosis;Recovery of Function;Withholding Treatment",M01.060.116;E02.365.647.110;C10.597.606.358.800.200;C23.888.592.604.359.800.200;E02.331.350;E01.370.376.300;E01.370.405.245;G07.265.216.500.400;G11.561.200.500.400;B01.050.150.900.649.313.988.400.112.400.400;E02.258.750;C14.280.383.610;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E01.789;G16.757;E02.760.952;N02.421.585.952
28189481,"Adolescent;Child;Cross-Sectional Studies;Humans;Longitudinal Studies;Muscular Dystrophy, Duchenne;Respiratory Function Tests;Respiratory Tract Diseases;Muscular Dystrophy, Duchenne;Vital Capacity",M01.060.057;M01.060.406;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;B01.050.150.900.649.313.988.400.112.400.400;E05.318.372.500.750.500;N05.715.360.330.500.750.500;N06.850.520.450.500.750.500;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.386.700;C08;C05.651.534.500.300;C10.668.491.175.500.300;C16.320.322.562;C16.320.577.300;E01.370.386.700.485.750.900;G09.772.850.970
28189445,"Bronchoscopy;Humans;Infant;Infant, Newborn;Lung;Pulmonary Emphysema;Radionuclide Imaging;Tomography, X-Ray Computed",E01.370.386.105;E01.370.388.250.100;E04.502.250.100;E04.928.600.080;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;A04.411;C08.381.495.389.750;E01.370.350.710;E01.370.384.730;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810
28189290,,
28188565,Bipolar Disorder;Quality of Life,F03.084.500;I01.800;K01.752.400.750;N06.850.505.400.425.837
28188438,"Adolescent;Adult;Child;Child, Preschool;Humans;Kidney;Kidney Diseases;Obesity;Risk Factors;Young Adult",M01.060.057;M01.060.116;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;M01.060.116.815
28188364,"Adult;Arteriovenous Fistula;Contrast Media;Cross-Sectional Studies;Echocardiography;Follow-Up Studies;Humans;Mass Screening;Middle Aged;Pulmonary Artery;Pulmonary Veins;Surveys and Questionnaires;Telangiectasia, Hereditary Hemorrhagic;Telangiectasia, Hereditary Hemorrhagic;Radiology, Interventional;Genetics, Medical",M01.060.116;C14.240.850.750.147;C14.240.850.984.750;C14.907.150.125;C14.907.933.555;C16.131.240.850.750.125;C23.300.575.950.250;D27.505.259.500;D27.720.259;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;E01.370.350.130.750;E01.370.350.850.220;E01.370.370.380.220;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;M01.060.116.630;A07.015.114.715;A07.015.908.713;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;C14.907.454.900;C14.907.823.780;C15.378.463.515.900;C16.131.240.850.968;C14.907.454.900;C14.907.823.780;C15.378.463.515.900;C16.131.240.850.968;H02.403.740.675;H01.158.273.343.385.500;H02.403.350
28188300,"Humans;Infant, Newborn;Quality Control;Risk;Risk Assessment",B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;J01.897.608;E05.318.740.600.800;G17.680.750;N05.715.360.750.625.700;N06.850.520.830.600.800;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715
28188180,"Adult;Aneuploidy;Biological Evolution;Chromosomes, Fungal;Codon, Nonsense;Cryptococcus neoformans;DNA Copy Number Variations;DNA Mismatch Repair;Demography;Genetic Variation;Genetics, Population;Genomics;Host-Pathogen Interactions;Humans;Meningitis, Cryptococcal;Microbial Sensitivity Tests;Phylogeny;Polymorphism, Single Nucleotide;Recurrence;Sequence Analysis, DNA;Cryptococcosis;Genomics",M01.060.116;C23.550.210.050;G05.365.590.175.050;G05.700.131;G05.045;G16.075;A11.284.187.360;A19.311;G05.360.162.360;D13.444.735.544.355.250.235;G05.360.335.355.250.235;G05.365.590.195;B01.300.381.258.366;B01.300.930.316.366;G05.365.795.297.500;G02.111.222.220;G05.219.220;I01.240;N01.224;N06.850.505.400;G05.365;H01.158.273.343.335;H01.158.273.180.350;H01.158.273.343.350;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;C01.703.181.500.500;C01.703.248.290;C10.228.228.198.500.500;C10.228.614.300.500;E01.370.225.875.595;E05.200.875.595;E05.337.550.400;G05.697;G16.075.605;L01.100.697;G05.365.795.598;C23.550.291.937;E05.393.760.700;C01.703.248;H01.158.273.180.350;H01.158.273.343.350
28187045,,
28186544,Disease Progression;Epidemics;Humans;Kidney Diseases;Obesity;Prognosis;Risk Assessment;Risk Factors,C23.550.291.656;N06.850.290.200;B01.050.150.900.649.313.988.400.112.400.400;C12.777.419;C13.351.968.419;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E01.789;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28186374,,
28185620,"Diagnostic Tests, Routine;HIV Infections;Humans;Immunocompromised Host;Radiography, Thoracic;Tomography, X-Ray Computed;Tuberculosis, Pleural;Tuberculosis, Pulmonary",E01.370.395;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;G12.470;E01.370.350.700.730;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;C01.252.410.040.552.846.877;C08.528.928;C08.730.912;C01.252.410.040.552.846.899;C08.381.922;C08.730.939
28185216,"Absorptiometry, Photon;Biopsy;Bone Density;Bone and Bones;Finite Element Analysis;Fractures, Bone;Humans;Osteoporosis;Ultrasonography;Finite Element Analysis;Osteoporosis",E01.370.350.700.024;E05.196.712.224.187;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;G11.427.100;A02.835.232;A10.165.265;E05.355;C26.404;B01.050.150.900.649.313.988.400.112.400.400;C05.116.198.579;C18.452.104.579;E01.370.350.850;E05.355;C05.116.198.579;C18.452.104.579
28184470,"Academic Medical Centers;Adenocarcinoma;Aged;Barrett Esophagus;Biopsy, Needle;Cell Transformation, Neoplastic;Disease Progression;Disease-Free Survival;Esophageal Neoplasms;Esophagectomy;Follow-Up Studies;Humans;Immunohistochemistry;Middle Aged;Precancerous Conditions;Proportional Hazards Models;Registries;Retrospective Studies;Risk Assessment;Statistics, Nonparametric;Survival Analysis",N02.278.020;C04.557.470.200.025;M01.060.116.100;C04.834.154;C06.405.117.102;E01.370.225.500.384.100.119;E01.370.225.998.054.119;E01.370.388.100.100;E04.074.119;E04.665.100;E05.200.500.384.100.119;E05.200.998.054.119;E05.242.384.100.119;C04.697.098.500;C23.550.727.098.500;C23.550.291.656;E01.789.800.190;E05.318.740.998.300;N05.715.360.750.795.300;N06.850.520.830.998.300;C04.588.274.476.205;C04.588.443.353;C06.301.371.205;C06.405.117.430;C06.405.249.205;E04.210.346;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.116.630;C04.834;E05.318.740.500.700;E05.318.740.600.700;E05.318.740.750.725;E05.318.740.998.825;E05.599.835.900;N05.715.360.750.530.650;N05.715.360.750.625.650;N05.715.360.750.695.650;N05.715.360.750.795.825;N06.850.520.830.500.700;N06.850.520.830.600.700;N06.850.520.830.750.725;E05.318.308.970;N04.452.859.819;N05.715.360.300.715.700;N06.850.520.308.970;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998
28184368,Child;Venous Thrombosis;Guideline;Heparin;Pulmonary Embolism;Randomized Controlled Trial,M01.060.406;C14.907.355.830.925;V02.515;D09.698.373.400;C08.381.746;C14.907.355.350.700;V03.175.250.500.500
28184294,Buprenorphine;Heroin;Methadone;Naltrexone;Substance-Related Disorders,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150;D03.132.577.249.562.445;D03.605.497.607.490;D03.633.400.686.607.490;D04.615.723.795.576.445;D02.522.675;D03.132.577.249.706.550;D03.605.497.750.550;D03.633.400.686.750.550;D04.615.723.795.706.550;C25.775;F03.900
28184190,"Adaptation, Psychological;Buspirone;Maternal Deprivation",F01.058;D02.455.426.779.120;D03.383.606.210;D03.383.742.120;D04.711.120;F01.829.263.370.240
28184164,Executive Function;Drug Therapy,F02.463.217;E02.319
28184014,"Adenocarcinoma, Clear Cell;Aminoquinolines;Animals;Antineoplastic Combined Chemotherapy Protocols;Autophagy;Carcinoma, Ovarian Epithelial;Cell Line, Tumor;Humans;Indoles;Mice;Mice, Inbred NOD;Mice, SCID;Neoplasms, Glandular and Epithelial;Ovarian Neoplasms;Polyamines;Pyrroles;Sunitinib;Xenograft Model Antitumor Assays",C04.557.470.200.025.045;D03.633.100.810.050;B01.050;E02.183.750.500;E02.319.077.500;E02.319.310.037;G04.146.399;G04.417.350.091;C04.557.470.200.295;C04.588.322.455.199;C13.351.500.056.630.705.350;C13.351.937.418.685.350;C19.344.410.199;C19.391.630.705.350;A11.251.210.190;A11.251.860.180;B01.050.150.900.649.313.988.400.112.400.400;D03.633.100.473;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.565;B01.050.150.900.649.313.992.635.505.500.400.565;B01.050.150.900.649.313.992.635.505.500.550.780;C04.557.470;C04.588.322.455;C13.351.500.056.630.705;C13.351.937.418.685;C19.344.410;C19.391.630.705;D02.092.782;D03.383.129.578;D03.383.129.578.823;D03.633.100.473.877;E05.337.550.200.900;E05.624.850
28183742,,
28183507,Coronary Artery Disease,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
28183470,"Cardiac Surgical Procedures;Carotid Stenosis;Coronary Artery Bypass;Endarterectomy, Carotid;Humans;Carotid Stenosis;Coronary Artery Bypass",E04.100.376;E04.928.220;C10.228.140.300.200.360;C14.907.137.230;C14.907.253.123.360;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220;E04.100.814.456.250;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.200.360;C14.907.137.230;C14.907.253.123.360;E04.100.376.719.332;E04.100.814.868.750;E04.928.220.520.220
28183375,"Angiotensin-Converting Enzyme Inhibitors;Cardiologists;Clinical Trials as Topic;Electronic Mail;Enalapril;Heart Defects, Congenital;Heart Failure;Heart Ventricles;Humans;Pediatrics;Practice Patterns, Physicians';Surveys and Questionnaires;Translational Medical Research;United States",D27.505.519.389.745.085;M01.526.485.810.128;N02.360.810.128;E05.318.372.250.250;N05.715.360.330.250.250;N06.850.520.450.250.250;L01.178.847.249;L01.559.423.906.377.333;D12.644.456.345.360;C14.240.400;C14.280.400;C16.131.240.400;C14.280.434;A07.541.560;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;N04.590.374.577;N05.300.625;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;H01.770.644.145.675;Z01.107.567.875
28182951,"Animals;Colitis;Disease Models, Animal;Dysbiosis;Escherichia coli;Formates;Gastrointestinal Microbiome;Inflammation;Intestines;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Proteobacteria;Dysbiosis;Gastrointestinal Microbiome;Metagenomics",B01.050;C06.405.205.265;C06.405.469.158.188;C22.232;E05.598.500;E05.599.395.080;C23.550.308;B03.440.450.425.325.300;B03.660.250.150.180.100;D02.241.081.420;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;C23.550.470;A03.556.124;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;B03.660;C23.550.308;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;H01.158.273.343.350.261
28182675,Adolescent;Adult;Age Factors;Antiviral Agents;CD4 Lymphocyte Count;HIV Infections;Humans;Treatment Outcome,M01.060.057;M01.060.116;N05.715.350.075;N06.850.490.250;D27.505.954.122.388;E01.370.225.500.195.107.595.500.150;E01.370.225.625.107.595.500.150;E05.200.500.195.107.595.500.150;E05.200.625.107.595.500.150;E05.242.195.107.595.500.150;G04.140.107.595.500.150;G09.188.105.595.500.150;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28182563,"Animals;Aurora Kinase A;Aurora Kinase B;Aurora Kinases;Azacitidine;Azepines;Cell Line;DNA Methylation;Decitabine;Drug Evaluation, Preclinical;Drug Synergism;Gene Knockdown Techniques;Genes, X-Linked;Green Fluorescent Proteins;High-Throughput Screening Assays;Mice;Mice, Transgenic;Piperazines;Pyrimidines;X Chromosome;X Chromosome Inactivation",B01.050;D08.811.913.696.620.682.700.103.500;D12.776.167.049.500;D08.811.913.696.620.682.700.103.750;D12.776.167.049.750;D08.811.913.696.620.682.700.103;D12.776.167.049;D02.145.150;D03.383.742.680.245.217;D13.570.685.245.217;D13.570.800.286.300;D03.383.066;A11.251.210;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;D02.145.150.500;D03.383.742.680.245.217.500;D13.570.685.245.217.500;D13.570.800.286.300.500;E05.290.750;E05.337.550;G07.690.773.968.477;E05.393.335.500;G05.360.340.024.340.500;G05.420.457;D12.776.532.265;E05.916.680;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D03.383.606;D03.383.742;A11.284.187.865.982;G05.360.162.865.982;G05.308.203.249.970
28182269,"Cost-Benefit Analysis;Delivery of Health Care, Integrated;Forecasting;Humans;Models, Biological;Pharmaceutical Preparations;Precision Medicine",N03.219.151.125;N04.590.374.142;N05.300.262;I01.320;B01.050.150.900.649.313.988.400.112.400.400;E05.599.395;D26;E02.574;H02.403.200.700
28181694,Adolescent;Bone Density;Bone and Bones;Child;Genome-Wide Association Study;Humans;Immunoglobulins;Membrane Proteins;Molecular Sequence Annotation;Quantitative Trait Loci;Sex Characteristics;Spectrin;Young Adult;Genetic Research,M01.060.057;G11.427.100;A02.835.232;A10.165.265;M01.060.406;E05.318.370.392;E05.318.416.249;E05.393.385.500;E05.393.522.500;E05.393.760.640.500;N06.850.520.445.392;N06.850.520.470.500;B01.050.150.900.649.313.988.400.112.400.400;D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548;D12.776.543;E05.393.760.479;L01.453.245.667.580;G05.360.340.024.380.937;G08.686.815;D12.776.220.980;D12.776.543.850;M01.060.116.815;H01.158.273.343.249;H01.770.644.145.350
28180185,,
28179817,"Animals;Humans;Neurodevelopmental Disorders;Placenta;Pregnancy;Prenatal Exposure Delayed Effects;Sex Characteristics;Stress, Physiological;Stress, Psychological;Neurodevelopmental Disorders",B01.050;B01.050.150.900.649.313.988.400.112.400.400;F03.625;A16.710;G08.686.784.769;C13.703.824.500;G08.686.815;G07.775;F01.145.126.990;F02.830.900;F03.625
28179815,"Alzheimer Disease;Dementia;Gender Identity;Humans;Risk Factors;Sex Characteristics;Sex Factors;Apolipoproteins E;Alzheimer Disease;Parkinson Disease;Aging;Dementia;Frontotemporal Dementia;Gender Identity;Genetics;Risk Factors;Sex;Dementia, Vascular",C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.380;F03.615.400;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G08.686.815;N05.715.350.675;N06.850.490.875;D10.532.091.500;D12.776.070.400.500;D12.776.521.120.500;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812;G07.345.124;C10.228.140.380;F03.615.400;C10.228.140.380.266.299;C10.574.950.300.299;C18.452.845.800.300.299;F03.615.400.380.299;F01.393.446.250;F01.752.747.385.200;F01.752.747.722.200;F02.739.794.793.200;H01.158.273.343;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;G08.686.810;C10.228.140.300.400;C10.228.140.300.510.800.500;C10.228.140.380.230;C10.228.140.695.500;C14.907.137.126.372.500;C14.907.253.560.350.500;F03.615.400.350
28179810,Animals;Corticotropin-Releasing Hormone;Dendrites;Humans;Locus Coeruleus;Mental Disorders;Mice;Sex Characteristics;Sex Factors;Signal Transduction;Synaptic Transmission;Amygdala;Arousal;Corticotropin-Releasing Hormone;Locus Coeruleus;Norepinephrine;beta-Arrestins,B01.050;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;A08.675.256;A11.284.180.225;A11.671.240;B01.050.150.900.649.313.988.400.112.400.400;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;F03;B01.050.150.900.649.313.992.635.505.500;G08.686.815;N05.715.350.675;N06.850.490.875;G02.111.820;G04.835;G02.111.820.850;G04.835.850;G07.265.880;G11.561.830;A08.186.211.180.090;A08.186.211.200.885.287.249.152;F02.830.104;G11.561.035;D06.472.699.327.740.140;D12.644.400.400.740.140;D12.644.548.365.740.140;D12.776.631.650.405.740.140;A08.186.211.132.659.473;A08.186.211.132.810.428.600.650.437;D02.033.100.291.502;D02.092.063.480;D02.092.211.215.746;D02.092.311.830;D02.455.426.559.389.657.166.175.830;D12.644.360.024.098.525;D12.776.157.057.005.525;D12.776.476.024.104.525;D12.776.543.090.525
28179566,"Adult;Animals;Cognition;DNA, Bacterial;Dysbiosis;Feces;Gastrointestinal Microbiome;Gastrointestinal Tract;Genes, rRNA;Healthy Volunteers;Humans;Metabolic Diseases;Middle Aged;RNA, Ribosomal, 16S;Rats;Rats, Sprague-Dawley;Sleep Deprivation;Cognition;Microbiota;Sleep Deprivation",M01.060.116;B01.050;F02.463.188;D13.444.308.212;C23.550.308;A12.459;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;A03.556;G05.360.340.024.340.645.750;M01.774.500;M01.955.236;B01.050.150.900.649.313.988.400.112.400.400;C18.452;M01.060.116.630;D13.444.735.686.670;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099;F02.463.188;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C10.886.425.175;C23.888.592.796.772;F02.830.855.671;F03.870.400.099
28179507,"Animals;Animals, Newborn;Antigens, CD;Bacteria;Cell Movement;Colony Count, Microbial;Demography;Dendritic Cells;Disease Resistance;Disease Susceptibility;Humans;Immunity, Mucosal;Infant, Newborn;Interleukins;Intestines;Lung;Lymphocytes;Mice, Inbred C57BL;Pneumonia;Receptors, CCR4;Symbiosis",B01.050;B01.050.050.282;D23.050.301.264.035;D23.101.100.110;B03;G04.198;G07.568.500.180;E01.370.225.875.220;E05.200.875.220;I01.240;N01.224;N06.850.505.400;A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260;C23.550.291.671;G12.450.564.250;G12.450.800.250;G15.630.250;C23.550.291.687;G07.100.250;B01.050.150.900.649.313.988.400.112.400.400;G12.450.573;M01.060.703.520;D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465;A03.556.124;A04.411;A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;C08.381.677;C08.730.610;D12.776.543.750.695.160.150.400;D12.776.543.750.705.852.125.150.400;G06.550.800;G16.840
28179485,"Anti-Bacterial Agents;Blood Cell Count;C-Reactive Protein;Chorioamnionitis;Guideline Adherence;Humans;Infant, Newborn;Neonatal Sepsis;Nurseries, Hospital;Practice Guidelines as Topic;Practice Patterns, Physicians';Pregnancy;Risk Assessment;Surveys and Questionnaires;United States",D27.505.954.122.085;E01.370.225.500.195.107;E01.370.225.625.107;E05.200.500.195.107;E05.200.625.107;E05.242.195.107;G04.140.107;G09.188.105;D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157;C13.703.277.030;C13.703.420.339.260;C13.703.590.268;C16.300.030;N04.761.337;N05.715.360.395;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C01.539.757.580;C16.614.627;C23.550.470.790.500.470;N02.278.388.540;N02.278.617.473;N04.761.700.350.650;N05.700.350.650;N04.590.374.577;N05.300.625;G08.686.784.769;E05.318.740.600.800.715;N04.452.871.715;N05.715.360.750.625.700.690;N06.850.505.715;N06.850.520.830.600.800.715;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980;Z01.107.567.875
28179408,"Cells, Cultured;Chromatin;Chromosomal Proteins, Non-Histone;Fibroblasts;Foreskin;Fuzzy Logic;Gene Expression Regulation, Viral;HeLa Cells;Herpes Simplex;Herpesvirus 1, Human;Histones;Humans;Phosphorylation;Protein Processing, Post-Translational;Proteomics;Viral Proteins",A11.251;A11.284.430.106.279.345.190.160.180;D12.776.664.224;G05.360.160.180;D12.776.660.235;D12.776.664.235;A11.329.228;A05.360.444.492.362;E05.599.250;K01.752.448.250;L01.224.050.375.250;G05.308.385;A11.251.210.190.400;A11.251.860.180.400;A11.436.340;C02.256.466.382;C02.825.320;C17.800.838.790.320;B04.280.382.100.750.390;D12.776.157.687.485;D12.776.660.720.485;D12.776.664.469;B01.050.150.900.649.313.988.400.112.400.400;G02.111.665;G02.607.780;G03.796;G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600;H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738;D12.776.964
28178582,"Hernias, Diaphragmatic, Congenital;Humans;Infant;Infant Mortality;Infant, Newborn;Length of Stay;Survival Analysis;Weight Gain;Hernias, Diaphragmatic, Congenital;Neonatology;Hypertension, Pulmonary;Respiratory Insufficiency",C16.131.433;C23.300.707.500.116;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.308.985.550.475;N01.224.935.698.489;N06.850.505.400.975.550.475;N06.850.520.308.985.550.475;M01.060.703.520;E02.760.400.480;N02.421.585.400.480;E05.318.740.998;N05.715.360.750.795;N06.850.520.830.998;C23.888.144.243.926;G07.345.249.314.120.200.926;C16.131.433;C23.300.707.500.116;H02.403.670.400;C08.381.423;C08.618.846
28178077,"Adrenal Cortex Hormones;Anti-Inflammatory Agents;Case-Control Studies;Child;Child, Preschool;Genetic Markers;Genotype;Gram-Negative Bacterial Infections;Gram-Positive Bacterial Infections;Humans;Infant;Infant, Newborn;Logistic Models;Multiple Organ Failure;Polymorphism, Genetic;Receptors, Glucocorticoid;Shock, Septic;Treatment Outcome",D06.472.040;D27.505.954.158;E05.318.372.500.500;N05.715.360.330.500.500;N06.850.520.450.500.500;M01.060.406;M01.060.406.448;D23.101.387;G05.695.450;G05.380;C01.252.400;C01.252.410;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;C23.550.835.525;G05.365.795;D12.776.826.750.430;C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800
28178076,"Adolescent;Child;Child, Preschool;Critical Illness;Databases, Factual;Hematopoietic Stem Cell Transplantation;Humans;Infant;Logistic Models;Odds Ratio;Prognosis;Respiration, Artificial;Respiratory Distress Syndrome, Adult;Retrospective Studies;Severity of Illness Index;Survival Rate;Transplantation, Homologous;Young Adult",M01.060.057;M01.060.406;M01.060.406.448;C23.550.291.625;L01.313.500.750.300.188.400;L01.470.750.750;E02.095.147.500.500.500;E04.936.225.687.500;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.318.740.600.600;G17.680.500;N05.715.360.750.625.590;N06.850.520.830.600.600;E01.789;E02.041.625;E02.365.647.729;E02.880.820;C08.381.840;C08.618.840;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;E04.936.864;M01.060.116.815
28177962,"Adult;Age Factors;Aged;Biomarkers, Tumor;Biopsy;Child, Preschool;Collagen;DEAD-box RNA Helicases;DNA Mutational Analysis;Humans;Immunohistochemistry;Infant;Inhibins;Kidney Neoplasms;Middle Aged;Mutation;Neoplasms, Complex and Mixed;Neoplasms, Cystic, Mucinous, and Serous;Predictive Value of Tests;Receptors, Estrogen;Ribonuclease III;Stromal Cells",M01.060.116;N05.715.350.075;N06.850.490.250;M01.060.116.100;D23.101.140;E01.370.225.500.384.100;E01.370.225.998.054;E01.370.388.100;E04.074;E05.200.500.384.100;E05.200.998.054;E05.242.384.100;M01.060.406.448;D05.750.078.280;D12.776.860.300.250;D08.811.913.696.445.735.720.249;E05.393.760.700.300;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.607.512;E01.370.225.750.551.512;E05.200.500.607.512;E05.200.750.551.512;E05.478.583;H01.158.100.656.234.512;H01.158.201.344.512;H01.158.201.486.512;H01.181.122.573.512;H01.181.122.605.512;M01.060.703;D06.472.334.968;D06.472.699.337;D12.644.548.387;D12.776.395.439;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;M01.060.116.630;G05.365.590;C04.557.435;C04.557.470.590;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;D12.776.826.750.350;D12.776.930.778.350;D08.811.277.352.700.350.707;A11.329.830
28176387,"Adult;Cohort Studies;Databases, Factual;Heart Failure;Heart Transplantation;Heart Ventricles;Heart-Assist Devices;Humans;Kidney Transplantation;Middle Aged;Renal Insufficiency, Chronic;Retrospective Studies;Survival Rate;Transplants;Treatment Outcome;Heart Failure;Transplants",M01.060.116;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;L01.313.500.750.300.188.400;L01.470.750.750;C14.280.434;E04.100.376.475;E04.928.220.390;E04.936.450.475;A07.541.560;E04.050.430;E07.695.300.300;E07.858.082.374.300;B01.050.150.900.649.313.988.400.112.400.400;E02.870.500;E04.936.450.485;E04.950.774.400;M01.060.116.630;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.308.985.550.900;N01.224.935.698.826;N06.850.505.400.975.550.900;N06.850.520.308.985.550.900;A01.941;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;C14.280.434;A01.941
28176045,"Animals;Biomarkers, Tumor;Cell Proliferation;Fluorescent Dyes;Humans;Ligands;Microscopy, Confocal;Molecular Imaging;Neoplasms;Positron-Emission Tomography;Predictive Value of Tests;Radiopharmaceuticals;Receptors, sigma;Breast Neoplasms;Cell Proliferation;Microscopy, Confocal;Positron-Emission Tomography",B01.050;D23.101.140;G04.161.750;G07.345.249.410.750;D27.720.233.348;D27.720.470.410.505.500;B01.050.150.900.649.313.988.400.112.400.400;D27.720.470.480;E01.370.350.515.395;E05.595.395;E01.370.350.557;E05.601.555;C04;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;D12.776.543.750.695.620.775;D12.776.543.750.720.600.610.775;D12.776.543.750.750.555.610.775;C04.588.180;C17.800.090.500;G04.161.750;G07.345.249.410.750;E01.370.350.515.395;E05.595.395;E01.370.350.350.800.700;E01.370.350.600.350.800.399;E01.370.350.710.800.399;E01.370.350.825.800.399;E01.370.384.730.800.399
28174740,,
28174722,,
28174312,"Blood;Humans;Malaria, Vivax;Nucleic Acid Amplification Techniques;Peru;Plasmodium vivax;Sequence Analysis, DNA",A12.207.152;A15.145;B01.050.150.900.649.313.988.400.112.400.400;C03.752.530.700;E05.393.620;Z01.107.757.702;B01.043.075.380.611.761;E05.393.760.700
28174256,"Animals;Cell Proliferation;Glucose;Glutamine;Humans;Neoplasms;Promoter Regions, Genetic;Proto-Oncogene Proteins c-myc",B01.050;G04.161.750;G07.345.249.410.750;D09.947.875.359.448;D12.125.068.330;D12.125.095.461;D12.125.154.424;B01.050.150.900.649.313.988.400.112.400.400;C04;G02.111.570.080.689.675;G05.360.080.689.675;G05.360.340.024.340.137.750.680;D12.776.260.103.813;D12.776.624.664.700.189;D12.776.660.765;D12.776.930.125.813
28174071,"Aged;Aged, 80 and over;Alzheimer Disease;Atrial Fibrillation;Dementia, Vascular;Heart Failure;Humans;Risk Factors;Alzheimer Disease;Atrial Fibrillation;Dementia;Heart Failure;Neuropathology;Dementia, Vascular",M01.060.116.100;M01.060.116.100.080;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C14.280.067.198;C23.550.073.198;C10.228.140.300.400;C10.228.140.300.510.800.500;C10.228.140.380.230;C10.228.140.695.500;C14.907.137.126.372.500;C14.907.253.560.350.500;F03.615.400.350;C14.280.434;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;C14.280.067.198;C23.550.073.198;C10.228.140.380;F03.615.400;C14.280.434;H01.158.610.184;H02.403.600.250;H02.403.650.375;C10.228.140.300.400;C10.228.140.300.510.800.500;C10.228.140.380.230;C10.228.140.695.500;C14.907.137.126.372.500;C14.907.253.560.350.500;F03.615.400.350
28173888,"Antimicrobial Stewardship;Attitude of Health Personnel;Cross-Sectional Studies;Decision Support Systems, Clinical;Electronic Health Records;Emergency Service, Hospital;Hospitals, Pediatric;Humans;Practice Guidelines as Topic;Program Development;Surveys and Questionnaires",N04.452.706.477.400.500;N04.761.879.300.500;N05.700.900.300.500;F01.100.050;N05.300.100;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;L01.313.500.750.300.190;E05.318.308.940.968.625.500;N02.278.216.500.968.336;N02.421.297.195;N04.452.442.422.336;N02.278.421.556.437;B01.050.150.900.649.313.988.400.112.400.400;N04.761.700.350.650;N05.700.350.650;N04.452.760;E05.318.308.980;N05.715.360.300.800;N06.850.520.308.980
28172488,Antiviral Agents;Cohort Studies;HIV;Hepacivirus;Hepatitis C;Humans,D27.505.954.122.388;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B04.820.650.589.650.350;B04.450.380;B04.820.250.475;C02.440.440;C02.782.350.350;C06.552.380.705.440;B01.050.150.900.649.313.988.400.112.400.400
28171541,"3' Untranslated Regions;Binding Sites;Brain;Databases, Genetic;Gene Expression Regulation;HEK293 Cells;Humans;MicroRNAs;Open Reading Frames;Polymorphism, Single Nucleotide;RNA-Binding Motifs",D13.444.735.544.875.880;D13.444.735.790.878.880;G05.360.340.024.220.880.880;G05.360.340.024.340.137.910.880;G02.111.570.120;A08.186.211;L01.313.500.750.300.188.400.325;L01.470.750.750.325;G05.308;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500;G05.360.335.760.640;G05.360.340.024.340.137.650;G05.365.795.598;G02.111.570.820.709.275.500.869
28170107,Administrative Personnel;Biomedical Research;Disclosure;Feeding and Eating Disorders;Health Policy;Humans;Research Design;Public Policy,M01.526.070;H01.770.644.145;F01.829.401.046;I01.880.604.583.080.134;L01.143.335;F03.400;I01.655.500.608.400;I01.880.604.825.608.400;N03.623.500.608.428;B01.050.150.900.649.313.988.400.112.400.400;E05.581.500;H01.770.644.728;I01.655.500.608;I01.880.604.825.608;N03.623.500.608
28169935,"Area Under Curve;Carbamates;Cyclohexanes;Databases, Factual;Diabetes Mellitus, Type 2;Drug Interactions;Glipizide;Glyburide;Humans;Hypoglycemia;Hypoglycemic Agents;Medical Informatics;Nateglinide;Pharmacoepidemiology;Phenylalanine;Piperidines;Sulfonylurea Compounds",E05.318.740.200;G03.787.101;G07.690.725.064;N06.850.520.830.200;D02.241.081.251;D02.455.426.392.368.367;L01.313.500.750.300.188.400;L01.470.750.750;C18.452.394.750.149;C19.246.300;G07.690.773.968;D02.886.590.795.500;D02.886.590.795.575;D02.948.828.575;B01.050.150.900.649.313.988.400.112.400.400;C18.452.394.984;D27.505.696.422;L01.313.500;D02.455.426.392.368.367.745;D12.125.072.050.685.448;H01.158.703.045;H02.403.720.500.650;H02.628.413;D12.125.072.050.685;D12.125.142.666;D03.383.621;D02.886.590.795;D02.948.828
28169876,"Aged;Amish;Choroid;Florida;Fovea Centralis;Humans;Morbidity;Pennsylvania;Retinal Drusen;Severity of Illness Index;Tomography, Optical Coherence;Visual Acuity;Wet Macular Degeneration",M01.060.116.100;M01.686.754.133;A09.371.894.223;Z01.107.567.875.750.350;A09.371.729.522.436;B01.050.150.900.649.313.988.400.112.400.400;E05.318.308.985.525;N01.224.935.597;N06.850.505.400.975.525;N06.850.520.308.985.525;Z01.107.567.875.075.550;Z01.107.567.875.350.550;Z01.107.567.875.500.550;C11.768.585.585;E05.318.308.980.438.475.456.500;N05.715.360.300.800.438.375.364.500;N06.850.520.308.980.438.475.364.500;E01.370.350.589.249.500;E01.370.350.825.805.500;E05.642.249.500;E01.370.380.850.950;F02.463.593.932.901;G14.940;C11.768.585.439.622
28168983,"Aneurysm, Dissecting;Survival",C14.907.055.050;I03.784
28168404,Humans;Prescription Drug Misuse;Prescription Drug Monitoring Programs;Prescription Drugs,B01.050.150.900.649.313.988.400.112.400.400;E02.319.306.500;E05.337.800.800;N02.421.668.320.600;D26.670
28167947,Heme,D03.383.129.578.840.500.640.587;D03.633.400.909.500.640.587;D04.345.783.500.640.587;D23.767.727.640.587
28167853,"Animals;Antidepressive Agents;Body Weight;Brain-Derived Neurotrophic Factor;Curcumin;Cyclooxygenase 2;Electrophysiology;Hippocampus;Neuronal Plasticity;Rats;Rats, Sprague-Dawley;Stress, Psychological",B01.050;D27.505.954.427.700.122;C23.888.144;E01.370.600.115.100.160.120;E05.041.124.160.750;G07.100.100.160.120;G07.345.249.314.120;D12.644.276.860.100;D12.776.467.860.100;D12.776.631.600.100;D23.529.850.100;D02.455.326.146.485.222.222;D02.455.426.559.389.657.166.200;D02.455.426.559.694.222;D08.811.600.720.750;H01.158.344.528;H01.158.782.236;A08.186.211.180.405;A08.186.211.200.885.287.500.345;G11.561.638;B01.050.150.900.649.313.992.635.505.700;B01.050.150.900.649.313.992.635.505.700.750;F01.145.126.990;F02.830.900
28167750,"ATP Citrate (pro-S)-Lyase;Acetate-CoA Ligase;Acetic Acid;Acetyl Coenzyme A;CRISPR-Cas Systems;Cell Line, Tumor;Cytomegalovirus;Cytomegalovirus Infections;Cytosol;Fibroblasts;Gene Expression Regulation, Enzymologic;Gene Knockout Techniques;Glucose;Glycolysis;Host-Pathogen Interactions;Humans;Lipogenesis;Mitochondria;Primary Cell Culture;Pyruvic Acid;RNA Interference;RNA, Small Interfering;Acetyl Coenzyme A",D08.811.913.050.331;D08.811.464.267.500.200;D02.241.081.018.165;D10.251.400.045.500;D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020;G05.308.203.374.394;A11.251.210.190;A11.251.860.180;B04.280.382.150.150;C02.256.466.245;A11.284.430.214.200;A11.284.430.429.200;A11.284.835.450.200;A11.329.228;G05.308.320;E05.393.335.750;D09.947.875.359.448;G02.111.158.750;G03.191.750;G03.295.436;G03.493.360;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G02.111.528;G03.458.249;A11.284.430.214.190.875.564;A11.284.835.626;E01.370.225.500.223.500;E05.200.500.265.500;E05.242.223.500;E05.481.500.249.500;D02.241.755.812.800;G05.308.203.374.790;D13.150.650.700;D13.444.735.150.700;D13.444.735.790.552.875;D03.633.100.759.646.138.382.300.020;D08.211.211.300.075;D13.695.667.138.382.300.020;D13.695.827.068.382.300.020
28167588,"Adolescent;Botswana;Carrier State;Child;Child, Preschool;HIV Infections;Humans;Infant;Nose;Prevalence;Risk Factors;Staphylococcus aureus",M01.060.057;Z01.058.290.175.230;N06.850.160;M01.060.406;M01.060.406.448;C02.782.815.616.400;C02.800.801.400;C20.673.480;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;A01.456.505.733;A04.531;A09.531;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100
28167344,"Alkaline Phosphatase;Bone Diseases;Calcium;Child;Child, Preschool;Humans;Hypophosphatemia;Infant;Infant Formula;Phosphorus;Rickets",D08.811.277.352.650.035;C05.116;D01.268.552.100;D01.552.539.288;D23.119.100;M01.060.406;M01.060.406.448;B01.050.150.900.649.313.988.400.112.400.400;C18.452.750.400;M01.060.703;G07.203.100.712.249;G07.203.300.525.350.500;G07.203.300.525.500.500;J02.200.712.249;J02.500.525.350.500;J02.500.525.500.500;D01.268.666;C05.116.198.816;C18.452.104.816;C18.452.174.845;C18.654.521.500.133.770.734
28167297,"Animals;Cell Line, Tumor;Cell Transformation, Neoplastic;Cerebellar Neoplasms;Disease Models, Animal;Hedgehog Proteins;Humans;Medulloblastoma;Mice;Mice, Transgenic;NIMA-Interacting Peptidylprolyl Isomerase;Prognosis;Protein Binding;Protein Interaction Mapping;Signal Transduction;Zinc Finger Protein GLI1",B01.050;A11.251.210.190;A11.251.860.180;C04.697.098.500;C23.550.727.098.500;C04.588.614.250.195.411.211;C10.228.140.211.500.200;C10.228.140.252.200;C10.551.240.250.400.300;C22.232;E05.598.500;E05.599.395.080;D12.644.276.671;D12.776.467.671;D23.529.671;B01.050.150.900.649.313.988.400.112.400.400;C04.557.465.625.600.380.515;C04.557.465.625.600.590.500;C04.557.470.670.380.515;C04.557.470.670.590.500;C04.557.580.625.600.380.515;C04.557.580.625.600.590.500;B01.050.150.900.649.313.992.635.505.500;B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800;D08.811.399.325.500.700;E01.789;G02.111.679;G03.808;E05.601.690;G02.111.820;G04.835;D12.776.260.755.850;D12.776.624.664.700.989;D12.776.930.900.700
28167226,"African Americans;Child;Chronic Disease;Cohort Studies;Critical Care;European Continental Ancestry Group;Healthcare Disparities;Humans;Length of Stay;Medicaid;Surgical Procedures, Operative;United States",M01.686.508.100.100;M01.686.754.100;M01.060.406;C23.550.291.500;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;E02.760.190;N02.421.585.190;M01.686.508.400;N04.590.374.380;N05.300.493;B01.050.150.900.649.313.988.400.112.400.400;E02.760.400.480;N02.421.585.400.480;N03.219.521.346.506.564.655;N03.706.615.693;E04;Z01.107.567.875
28166807,Adolescent;Body Mass Index;Breast;Breast Neoplasms;Child;Humans;Ontario;Optical Imaging;Population Surveillance;Puberty;ROC Curve;Sexual Maturation;Spectrum Analysis,M01.060.057;E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175;A01.236;C04.588.180;C17.800.090.500;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;Z01.107.567.176.639;E01.370.350.589;E05.642;E05.318.308.980.438.700;N05.715.360.300.800.438.625;N06.850.520.308.980.438.700;N06.850.780.675;G08.686.760;G08.686.841.374;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;G07.345.750.750;G08.686.841.750;E05.196.867
28166392,"Adolescent;Brain;Child;Child, Preschool;Electroencephalography;Electroencephalography Phase Synchronization;Epilepsy;Humans;Nerve Net;Predictive Value of Tests;Retrospective Studies;Support Vector Machine;Treatment Outcome;Electrocorticography",M01.060.057;A08.186.211;M01.060.406;M01.060.406.448;E01.370.376.300;E01.370.405.245;E01.370.376.300.437;E01.370.405.245.575;G07.265.256;C10.228.140.490;B01.050.150.900.649.313.988.400.112.400.400;A08.511;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;G17.035.250.500.500.500;L01.224.050.375.530.500.500;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;E01.370.376.300.294;E01.370.405.245.431
28166375,"Adolescent;Anxiety;Chronic Disease;Genetic Variation;Humans;Stress, Psychological;Young Adult;Adolescent;Anxiety;Self-Management",M01.060.057;F01.470.132;C23.550.291.500;G05.365;B01.050.150.900.649.313.988.400.112.400.400;F01.145.126.990;F02.830.900;M01.060.116.815;M01.060.057;F01.470.132;N02.421.784.760
28166364,"Brain Waves;Electroencephalography;Humans;Hypoxia-Ischemia, Brain;Infant, Newborn;Multicenter Studies as Topic;Observer Variation;Reproducibility of Results;Retrospective Studies;Statistics, Nonparametric;Electroencephalography;Hypoxia-Ischemia, Brain;Infant, Newborn;Seizures",E01.370.376.300.150;E01.370.405.245.287;G07.265.087;G11.561.127;E01.370.376.300;E01.370.405.245;B01.050.150.900.649.313.988.400.112.400.400;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703.520;E05.318.372.658;N05.715.360.330.643;N06.850.520.450.643;E01.354.753;N02.421.450.600;N05.715.350.150.675;N06.850.490.500.250;E05.318.370.725;E05.337.851;N05.715.360.325.685;N06.850.520.445.725;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;E05.318.740.995;N05.715.360.750.760;N06.850.520.830.995;E01.370.376.300;E01.370.405.245;C10.228.140.300.150.716;C10.228.140.624.500;C14.907.253.092.716;M01.060.703.520;C10.597.742;C23.888.592.742
28166147,"3-Iodobenzylguanidine;Bone Neoplasms;Child, Preschool;Hallux;Humans;Magnetic Resonance Imaging;Neuroblastoma;Radiopharmaceuticals;Single Photon Emission Computed Tomography Computed Tomography",D02.078.370.510;D02.455.426.559.389.454.300;D02.455.526.581.496.300;C04.588.149;C05.116.231;M01.060.406.448;A01.378.610.250.300.792.380;B01.050.150.900.649.313.988.400.112.400.400;E01.370.350.825.500;C04.557.465.625.600.590.650.550;C04.557.470.670.590.650.550;C04.557.580.625.600.590.650.550;D27.505.259.843;D27.505.519.871;D27.720.470.410.650;E01.370.350.350.800.800.750;E01.370.350.350.810.723;E01.370.350.567.750;E01.370.350.600.350.700.810.645;E01.370.350.600.350.800.800.500;E01.370.350.700.700.810.723;E01.370.350.700.810.810.762;E01.370.350.710.800.800.750;E01.370.350.825.800.800.750;E01.370.350.825.810.810.750;E01.370.384.730.800.800.750
28166141,Child;Fluorodeoxyglucose F18;Humans;Leiomyosarcoma;Liver Neoplasms;Positron Emission Tomography Computed Tomography;Radiopharmaceuticals,M01.060.406;D09.254.229.500;B01.050.150.900.649.313.988.400.112.400.400;C04.557.450.590.455;C04.557.450.795.455;C04.588.274.623;C06.301.623;C06.552.697;E01.370.350.350.800.700.500;E01.370.350.350.810.645;E01.370.350.567.500;E01.370.350.600.350.700.810.490;E01.370.350.600.350.800.399.500;E01.370.350.700.700.810.645;E01.370.350.700.810.810.723;E01.370.350.710.800.399.500;E01.370.350.825.800.399.500;E01.370.350.825.810.810.700;E01.370.384.730.800.399.500;D27.505.259.843;D27.505.519.871;D27.720.470.410.650
28165896,,
28165800,Antidotes;Drug Costs;Hospitals;Humans;Poison Control Centers;United States;Antidotes;Drug Costs;Drug Storage;Health Expenditures;Poisoning,D27.505.696.706.037;D27.720.799.037;N03.219.151.400.350;N05.300.375.300;N02.278.421;B01.050.150.900.649.313.988.400.112.400.400;N02.278.726;N02.421.297.695;Z01.107.567.875;D27.505.696.706.037;D27.720.799.037;N03.219.151.400.350;N05.300.375.300;E05.916.350;N03.219.151.450;N05.300.385;C25.723
28165671,"Cannula;Carbon Dioxide;Continuous Positive Airway Pressure;Humans;Infant, Newborn;Infant, Premature;Lung;Nasal Cavity;Tidal Volume;Noninvasive Ventilation;Infant, Premature",E07.132.125;D01.200.200;D01.362.150;D01.650.550.200;E02.041.625.790.259;E02.880.820.790.259;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;M01.060.703.520.520;A04.411;A04.531.449;E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700;E02.041.625.591;E02.880.820.657;M01.060.703.520.520
28165634,"ATP Binding Cassette Transporter, Subfamily B;Anticonvulsants;Calcium Channels, T-Type;Child;Child, Preschool;Cross-Over Studies;Double-Blind Method;Electroencephalography;Epilepsy, Absence;Follow-Up Studies;Humans;Outcome Assessment (Health Care);Pharmacogenetics;Polymorphism, Genetic",D12.776.157.530.100.075;D12.776.157.530.450.074.500.500.250;D12.776.395.550.020.400;D12.776.543.550.192.400;D12.776.543.585.100.200;D12.776.543.585.450.074.500.500.250;D27.505.954.427.080;D12.776.157.530.400.150.720;D12.776.543.550.450.150.720;D12.776.543.585.400.150.720;M01.060.406;M01.060.406.448;E05.318.370.150;N05.715.360.325.150;N06.850.520.445.150;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E01.370.376.300;E01.370.405.245;C10.228.140.490.375.260;C10.228.140.490.493.125;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;H01.770.644.145.431;N04.761.559.590;N05.715.360.575.575;H01.158.273.343.750;H01.158.703.052;H02.628.479;G05.365.795
28165182,"Congenital Hyperinsulinism;Glutamate Dehydrogenase;HEK293 Cells;Humans;Infant, Newborn;Inheritance Patterns;Mutation;Glutamate Dehydrogenase;Hyperinsulinism;Hypoglycemia",C06.689.150;C16.614.200;C18.452.394.968.250;C18.452.394.984.200;D08.811.682.664.500.398;A11.251.210.172.750;A11.436.334;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;G05.420;G05.365.590;D08.811.682.664.500.398;C18.452.394.968;C18.452.394.984
28165116,"Breast Neoplasms;CpG Islands;DNA Methylation;Genomics;Humans;Logistic Models;Models, Genetic;Oligonucleotide Array Sequence Analysis;Sequence Analysis, DNA;Software",C04.588.180;C17.800.090.500;G02.111.570.080.380.160;G05.360.080.380.160;G05.360.340.024.159;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;H01.158.273.180.350;H01.158.273.343.350;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;E05.599.395.397;E05.393.661.640;E05.393.760.640;E05.588.570.660;E05.601.640;E05.393.760.700;L01.224.900
28164853,"Anti-Bacterial Agents;Diarrhea;Dysbiosis;Enterocolitis, Necrotizing;Gastrointestinal Microbiome;Humans;Infant, Newborn;Probiotics;Anti-Bacterial Agents;Clostridium difficile;Microbiota;Enterocolitis, Necrotizing;Probiotics",D27.505.954.122.085;C23.888.821.214;C23.550.308;C06.405.205.596.700;C06.405.469.363.700;G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;G07.203.300.456.500;J02.500.456.500;D27.505.954.122.085;B03.300.390.400.200.250;B03.353.625.375.500.250;B03.510.415.400.200.250;G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500;C06.405.205.596.700;C06.405.469.363.700;G07.203.300.456.500;J02.500.456.500
28162975,"Adult;Aged;Aged, 80 and over;DNA-Binding Proteins;Gene Fusion;Humans;Middle Aged;Mutation;Nuclear Proteins;Paraganglioma;Pheochromocytoma;Pol1 Transcription Initiation Complex Proteins;Proto-Oncogene Proteins c-ret;RNA-Binding Proteins;Transcription Factors;Genomics;Neoplasm Metastasis;Paraganglioma;Pheochromocytoma",M01.060.116;M01.060.116.100;M01.060.116.100.080;D12.776.260;G05.728.385;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G05.365.590;D12.776.660;C04.557.465.625.650.700;C04.557.580.625.650.700;C04.557.465.625.650.700.725;C04.557.580.625.650.700.725;D12.776.260.775.092;D12.776.930.930.092;D08.811.913.696.620.682.725.400.087;D12.776.395.550.200.188.500;D12.776.543.131.500;D12.776.543.750.630.217;D12.776.624.664.700.194;D12.776.157.725;D12.776.664.962;D12.776.930;H01.158.273.180.350;H01.158.273.343.350;C04.697.650;C23.550.727.650;C04.557.465.625.650.700;C04.557.580.625.650.700;C04.557.465.625.650.700.725;C04.557.580.625.650.700.725
28161656,Advisory Committees;Child;Child Abuse;Consensus;Delphi Technique;Health Priorities;Humans;Pediatrics;Prospective Studies;Research;United States;Physical Abuse;Research,N03.706.742.500;M01.060.406;I01.198.240.856.350.250;I01.880.735.900.350.250;F01.829.316.068;F02.463.785.373.433;L01.906.197;N03.349.330;N05.300.400;B01.050.150.900.649.313.988.400.112.400.400;H02.403.670;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;H01.770.644;Z01.107.567.875;I01.198.240.856.688;I01.880.735.900.744;H01.770.644
28160403,"Beckwith-Wiedemann Syndrome;Biomarkers, Tumor;DNA Methylation;Early Detection of Cancer;Hepatoblastoma;Humans;Liver Neoplasms;Mass Screening;Potassium Channels, Voltage-Gated;Ultrasonography;alpha-Fetoproteins;Beckwith-Wiedemann Syndrome;alpha-Fetoproteins;Hepatoblastoma",C16.131.077.133;C16.131.260.080;C16.320.180.080;D23.101.140;G02.111.035.538.161;G02.111.218;G03.059.538.161;G05.206;E01.390.500;C04.557.435.380;B01.050.150.900.649.313.988.400.112.400.400;C04.588.274.623;C06.301.623;C06.552.697;E01.370.500;E05.318.308.980.438.580;N02.421.726.233.443;N05.715.360.300.800.438.500;N06.850.520.308.980.438.580;N06.850.780.500;D12.776.157.530.400.600.900;D12.776.543.550.450.750.900;D12.776.543.585.400.750.900;E01.370.350.850;D12.776.124.790.106.092;D12.776.320.525.500;D12.776.377.228.500;D12.776.377.715.085.092;D23.101.140.050;C16.131.077.133;C16.131.260.080;C16.320.180.080;D12.776.124.790.106.092;D12.776.320.525.500;D12.776.377.228.500;D12.776.377.715.085.092;D23.101.140.050;C04.557.435.380
28160351,Adult;Affect;Antidepressive Agents;Antimanic Agents;Bipolar Disorder;Diagnostic and Statistical Manual of Mental Disorders;Humans;Middle Aged;Periodicity;Prospective Studies;Psychiatric Status Rating Scales;Secondary Prevention;Treatment Outcome;Bipolar Disorder;Depression;Lithium;Bipolar Disorder;Venlafaxine Hydrochloride,M01.060.116;F01.470.047;D27.505.954.427.700.122;D27.505.696.277.950.025;D27.505.954.427.210.950.025;D27.505.954.427.700.872.025;F03.084.500;L01.453.245.945.200;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G01.910.645;G07.180.562;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;F04.711.513.653;E02.897;N02.421.726.825;N06.850.780.750;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;F03.084.500;F01.145.126.350;D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290;F03.084.500;D02.033.415.510.500.901;D02.092.471.683.948;D02.455.426.392.368.367.318.750;D10.289.510.500.901
28159744,"Adolescent;Child;Child, Preschool;Deglutition Disorders;Enteral Nutrition;Failure to Thrive;Fundoplication;Gastroesophageal Reflux;Gastrostomy;Hospitalization;Humans;Infant;Matched-Pair Analysis;Nervous System Diseases;Retreatment;Retrospective Studies",M01.060.057;M01.060.406;M01.060.406.448;C06.405.117.119;C09.775.174;E02.421.360;E02.642.500.360;C23.888.338;E04.210.390;C06.405.117.119.500.484;E04.210.496;E04.579.408;E02.760.400;N02.421.585.400;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;E05.318.370.485;E05.318.740.475;N05.715.360.325.500;N05.715.360.750.500;N06.850.520.445.485;N06.850.520.830.475;C10;E02.887;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825
28159718,Humans;Meniscus;Nanofibers;Polyesters;Tissue Engineering;Tissue Scaffolds;Meniscus,B01.050.150.900.649.313.988.400.112.400.400;A02.165.308.538;A10.165.382.350.163;J01.637.512.300;D05.750.728;D25.720.728;J01.637.051.720.728;E05.481.500.311.500;J01.293.069.249.500;E07.206.627;E07.695.825;A02.165.308.538;A10.165.382.350.163
28159482,"Adolescent;Adult;Child;Humans;Kidney;Obesity;Prevalence;Renal Insufficiency, Chronic;Risk Factors;Renal Insufficiency, Chronic;Kidney Neoplasms;Nephrolithiasis;Obesity",M01.060.057;M01.060.116;M01.060.406;B01.050.150.900.649.313.988.400.112.400.400;A05.810.453;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;C12.777.419.780.750;C13.351.968.419.780.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;C12.777.419.780.750;C13.351.968.419.780.750;C04.588.945.947.535;C12.758.820.750;C12.777.419.473;C13.351.937.820.535;C13.351.968.419.473;C12.777.419.600;C12.777.967.249;C13.351.968.419.600;C13.351.968.967.249;C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
28159440,"Adult;Alcoholism;Cohort Studies;Executive Function;Humans;Middle Aged;Neuropsychological Tests;Personal Satisfaction;Prospective Studies;Recovery of Function;Recurrence;Stress, Psychological;Substance-Related Disorders;Young Adult;Executive Function;Quality of Life;Substance-Related Disorders",M01.060.116;C25.775.100.250;F03.900.100.350;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;F02.463.217;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;F04.711.513;F01.145.677;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;G16.757;C23.550.291.937;F01.145.126.990;F02.830.900;C25.775;F03.900;M01.060.116.815;F02.463.217;I01.800;K01.752.400.750;N06.850.505.400.425.837;C25.775;F03.900
28159380,"Biopsy, Fine-Needle;Chromosome Aberrations;Chromosomes, Human;Ciliary Body;DNA, Neoplasm;Humans;In Situ Hybridization, Fluorescence;Melanoma;Middle Aged;Neoplasm Staging;Retrospective Studies;Uveal Neoplasms",E01.370.225.500.384.100.119.500;E01.370.225.998.054.119.500;E01.370.388.100.100.500;E04.074.119.500;E04.665.100.500;E05.200.500.384.100.119.500;E05.200.998.054.119.500;E05.242.384.100.119.500;C23.550.210;G05.365.590.175;A11.284.187.520.300;G05.360.162.520.300;A09.371.060.160;A09.371.894.280;D13.444.308.425;B01.050.150.900.649.313.988.400.112.400.400;E01.370.225.500.620.670.325.350;E01.370.225.750.600.670.325.350;E05.200.500.620.670.325.350;E05.200.750.600.670.325.350;E05.393.285.350;E05.393.661.475.350;C04.557.465.625.650.510;C04.557.580.625.650.510;C04.557.665.510;M01.060.116.630;E01.789.625;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;C04.588.364.978;C11.319.494;C11.941.855
28158951,"Adolescent;Biomarkers;Brain;Brain Concussion;Child;Child, Preschool;Glasgow Coma Scale;Head Injuries, Closed;Humans;Infant;Infant, Newborn;Predictive Value of Tests;Prospective Studies;Sensitivity and Specificity;Tomography, X-Ray Computed;Ubiquitin Thiolesterase;Young Adult;Adolescent;Biomarkers;Child;Diagnosis;Craniocerebral Trauma;Brain Concussion;Sensitivity and Specificity;Sensitivity and Specificity;Adolescent",M01.060.057;D23.101;A08.186.211;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;M01.060.406;M01.060.406.448;E05.318.308.940.968.875.250;E05.944.500;N04.452.859.564.800.250;N05.715.360.300.715.500.800.325;C10.900.300.350;C26.915.300.450;C26.974.382;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703;M01.060.703.520;E05.318.370.800.650;N05.715.360.325.700.640;N06.850.520.445.800.650;E05.318.372.500.750.625;N05.715.360.330.500.750.650;N06.850.520.450.500.750.650;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E01.370.350.350.810;E01.370.350.600.350.700.810;E01.370.350.700.700.810;E01.370.350.700.810.810;E01.370.350.825.810.810;D08.811.037.500;D08.811.277.352.897.850;D12.776.637.937;M01.060.116.815;M01.060.057;D23.101;M01.060.406;E01;C10.900.300;C26.915.300;C10.228.140.199.444.250;C10.900.300.087.235.250;C10.900.300.350.300;C26.915.300.200.194.250;C26.915.300.450.500;C26.974.382.200;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;E05.318.370.800;E05.318.740.872;G17.800;N05.715.360.325.700;N05.715.360.750.725;N06.850.520.445.800;N06.850.520.830.872;M01.060.057
28158489,,
28158439,"Adolescent;Adult;Antifungal Agents;Candida;Candidiasis;Candidiasis, Cutaneous;Drug Administration Routes;Gestational Age;Humans;Infant, Newborn;Infant, Premature, Diseases;Intensive Care Units, Neonatal;Medical Records;Nystatin;Pregnancy;Skin;Treatment Outcome;Young Adult;Candida;Diagnosis;Therapeutics",M01.060.057;M01.060.116;D27.505.954.122.136;B01.300.107.795.095;B01.300.381.147;B01.300.930.176;C01.703.160;C01.539.800.200.105;C01.703.160.170;C01.703.295.170;C17.800.838.208.170;E02.319.267;G07.345.500.325.235.968;G08.686.320;B01.050.150.900.649.313.988.400.112.400.400;M01.060.703.520;C16.614.521;N02.278.388.493.390.380;E05.318.308.940.968;N04.452.859.564;N05.715.360.300.715.500;N06.850.520.308.940.968;D02.540.505.575;G08.686.784.769;A17.815;E01.789.800;N04.761.559.590.800;N05.715.360.575.575.800;M01.060.116.815;B01.300.107.795.095;B01.300.381.147;B01.300.930.176;E01;E02
28158384,"Adolescent;Adult;Aged;Aged, 80 and over;Arthritis, Psoriatic;Arthritis, Rheumatoid;Cause of Death;Cohort Studies;Humans;Middle Aged;United Kingdom;Young Adult;Epidemiology;Mortality;Arthritis, Psoriatic;Arthritis, Rheumatoid;Suicide",M01.060.057;M01.060.116;M01.060.116.100;M01.060.116.100.080;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;E05.318.308.985.550.250;N01.224.935.698.100;N06.850.505.400.975.550.250;N06.850.520.308.985.550.250;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;Z01.542.363;M01.060.116.815;H02.403.720.500;E05.318.308.985.550;N01.224.935.698;N06.850.505.400.975.550;N06.850.520.308.985.550;C05.116.900.853.625.800.424;C05.550.114.145;C05.550.114.865.800.424;C17.800.859.675.175;C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199;F01.145.126.980.875;I01.880.735.856
28158275,"Animals;Coronaviridae;Coronavirus Infections;Endonucleases;Enzyme-Linked Immunosorbent Assay;Flow Cytometry;Host-Pathogen Interactions;Humans;Immune Evasion;Immunity, Innate;Mice;Mice, Inbred C57BL;Real-Time Polymerase Chain Reaction;Viral Proteins",B01.050;B04.820.504.540;C02.782.600.550.200;D08.811.277.352.355;E05.478.566.350.170;E05.478.566.380.360;E05.478.583.400.170;E05.601.470.350.170;E05.601.470.380.360;E01.370.225.500.363.342;E01.370.225.500.386.350;E05.196.712.516.600.240.350;E05.200.500.363.342;E05.200.500.386.350;E05.242.363.342;E05.242.386.350;G06.462;G16.527.200;B01.050.150.900.649.313.988.400.112.400.400;G06.462.400;G12.413;G16.527.200.700;G12.450.564;B01.050.150.900.649.313.992.635.505.500;B01.050.050.199.520.520.420;B01.050.150.900.649.313.992.635.505.500.400.420;E05.393.620.500.706;D12.776.964
28158196,"Animals;Heart Failure;Heat-Shock Proteins;Humans;Leucine-Rich Repeat Serine-Threonine Protein Kinase-2;Mitochondria;Mitochondrial Proteins;Myocytes, Cardiac;Rats;Transcription Factors;Transcriptome",B01.050;C14.280.434;D12.776.580.216;B01.050.150.900.649.313.988.400.112.400.400;D08.811.913.696.620.682.700.534;D12.776.637.750;A11.284.430.214.190.875.564;A11.284.835.626;D12.776.575;A07.541.704.570;A10.690.552.750.570;A11.620.500;B01.050.150.900.649.313.992.635.505.700;D12.776.930;G02.111.873.750;G05.297.700.750;G05.360.920
28157806,,
28157707,"Animals;Breast Neoplasms;Cell Line, Tumor;Choline Kinase;Cohort Studies;Humans;MCF-7 Cells;Mice;Mice, Nude;Spectroscopy, Near-Infrared;Xenograft Model Antitumor Assays;Breast Neoplasms;Drug Therapy;Choline Kinase",B01.050;C04.588.180;C17.800.090.500;A11.251.210.190;A11.251.860.180;D08.811.913.696.620.155;E05.318.372.500.750;N05.715.360.330.500.750;N06.850.520.450.500.750;B01.050.150.900.649.313.988.400.112.400.400;A11.251.210.190.630;B01.050.150.900.649.313.992.635.505.500;B01.050.150.900.649.313.992.635.505.500.550.500;E01.370.350.750;E05.196.867.851;E05.337.550.200.900;E05.624.850;C04.588.180;C17.800.090.500;E02.319;D08.811.913.696.620.155
28157672,"Adult;Age Distribution;Aged;Aged, 80 and over;Alcohol Drinking;Cardiovascular Diseases;Cross-Sectional Studies;Ethnic Groups;Humans;Logistic Models;Middle Aged;Multivariate Analysis;Nutrition Surveys;Olfaction Disorders;ROC Curve;Risk Factors;Sex Distribution;Socioeconomic Factors;Taste Disorders;United States;Prevalence;Risk Factors",M01.060.116;I01.240.050;N01.224.033;N06.850.505.400.050;M01.060.116.100;M01.060.116.100.080;F01.145.317.269;C14;E05.318.372.500.875;N05.715.360.330.500.875;N06.850.520.450.500.875;M01.686.754;N01.224.317;B01.050.150.900.649.313.988.400.112.400.400;E05.318.740.500.525;E05.318.740.600.800.450;E05.318.740.750.450;E05.599.835.875;N05.715.360.750.530.480;N05.715.360.750.625.700.450;N05.715.360.750.695.470;N06.850.520.830.500.525;N06.850.520.830.600.800.450;N06.850.520.830.750.450;M01.060.116.630;E05.318.740.150.500;N05.715.360.750.125.500;N06.850.520.830.150.500;E05.318.308.980.485;N05.715.360.300.800.469;N06.850.505.616;N06.850.520.308.980.469;C10.597.751.600;C23.888.592.763.550;E05.318.370.800.750;E05.318.740.872.750;N05.715.360.325.700.680;N06.850.520.445.800.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725;I01.240.800;N01.224.803;N06.850.505.400.850;I01.880.853.996;N01.824;C10.597.751.861;C23.888.592.763.861;Z01.107.567.875;E05.318.308.985.525.750;N01.224.935.597.750;N06.850.505.400.975.525.750;N06.850.520.308.985.525.750;E05.318.740.600.800.725;N05.715.350.200.700;N05.715.360.750.625.700.700;N06.850.490.625.750;N06.850.520.830.600.800.725
28157093,Aged;Alzheimer Disease;Amyloid Precursor Protein Secretases;Amyloid beta-Peptides;Apolipoprotein E4;Aspartic Acid Endopeptidases;Biomarkers;Double-Blind Method;Follow-Up Studies;Humans;Middle Aged;Phosphorylation;Protease Inhibitors;tau Proteins;Alzheimer Disease,M01.060.116.100;C10.228.140.380.100;C10.574.945.249;F03.615.400.100;D08.811.277.656.300.032;D12.644.024;D12.776.049.407.249.500;D12.776.543.039.500;D10.532.091.500.750;D12.776.070.400.500.750;D12.776.521.120.500.750;D08.811.277.656.074.500;D08.811.277.656.300.048;D23.101;E05.318.370.300;E05.581.500.300;N05.715.360.325.320;N06.850.520.445.300;E05.318.372.500.750.249;N05.715.360.330.500.750.350;N06.850.520.450.500.750.350;B01.050.150.900.649.313.988.400.112.400.400;M01.060.116.630;G02.111.665;G02.607.780;G03.796;D27.505.519.389.745;D12.776.220.600.450.510;D12.776.631.560.510;C10.228.140.380.100;C10.574.945.249;F03.615.400.100
28156202,"Adolescent;Anthropometry;Biomarkers;Child;Child, Preschool;Diffusion Tensor Imaging;Epiphyses;Humans;Image Interpretation, Computer-Assisted;Musculoskeletal Development;Retrospective Studies;Sex Factors;Signal-To-Noise Ratio",M01.060.057;E01.370.600.024;E05.041;N06.850.505.200.100;D23.101;M01.060.406;M01.060.406.448;E01.370.350.578.750;E01.370.350.825.500.150.500;E01.370.376.537.500;E05.629.750;A02.835.232.251;B01.050.150.900.649.313.988.400.112.400.400;E01.158.600;E01.370.350.350;L01.313.500.750.100.158.600;G07.345.500.325.377.625;G11.427.578;E05.318.372.500.500.500;E05.318.372.500.750.750;N05.715.360.330.500.500.500;N05.715.360.330.500.750.825;N06.850.520.450.500.500.500;N06.850.520.450.500.750.825;N05.715.350.675;N06.850.490.875;E05.318.370.800.875;E05.318.740.872.875;G17.800.500;N05.715.360.325.700.840;N05.715.360.750.725.750;N06.850.520.445.800.875;N06.850.520.830.872.750
28155892,,
